<SEC-DOCUMENT>0001193125-22-215250.txt : 20220809
<SEC-HEADER>0001193125-22-215250.hdr.sgml : 20220809
<ACCEPTANCE-DATETIME>20220808195725
ACCESSION NUMBER:		0001193125-22-215250
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		97
FILED AS OF DATE:		20220809
DATE AS OF CHANGE:		20220808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PROKIDNEY CORP.
		CENTRAL INDEX KEY:			0001850270
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				981586514
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-266683
		FILM NUMBER:		221146034

	BUSINESS ADDRESS:	
		STREET 1:		3929 WESTPOINT BLVD.
		STREET 2:		SUITE G
		CITY:			WINSTON-SALEM
		STATE:			NC
		ZIP:			27103
		BUSINESS PHONE:		336-999-7029

	MAIL ADDRESS:	
		STREET 1:		3929 WESTPOINT BLVD.
		STREET 2:		SUITE G
		CITY:			WINSTON-SALEM
		STATE:			NC
		ZIP:			27103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Social Capital Suvretta Holdings Corp. III
		DATE OF NAME CHANGE:	20210310
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>d373959ds1.htm
<DESCRIPTION>S-1
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:prok="http://www.businesswire.com/20220331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>S-1</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style=""><div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2022To03_31_2022">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2022To03_31_2022">0001850270</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="prok-20220331.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="prok-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="prok-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="prok-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="prok-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references><ix:resources><xbrli:context id="P01_01_2022To03_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P02_25_2021To12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-25</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_02_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-02</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_02_2021To07_02_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-02</xbrli:startDate> <xbrli:endDate>2021-07-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P12_12_2018To12_31_2018" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2018-12-12</xbrli:startDate> <xbrli:endDate>2018-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2018" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2018-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_01_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RestrictionOnTransferOfSponsorSharesMemberPROKBasisAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:FounderMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="prok:BasisAxis" >prok:RestrictionOnTransferOfSponsorSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_DirectorMembersrtTitleOfIndividualAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:DirectorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WorkingCapitalLoansMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >prok:WorkingCapitalLoansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AdvanceFromRelatedPartyLoanMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >prok:AdvanceFromRelatedPartyLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ResearchMemberusgaapTaxCreditCarryforwardAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis" >us-gaap:ResearchMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ConstructionInProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-25</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_25_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-25</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-25</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RestrictionOnTransferOfSponsorSharesMemberPROKBasisAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:FounderMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="prok:BasisAxis" >prok:RestrictionOnTransferOfSponsorSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-25</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_25_2021To12_31_2021_AdministrationAndSupportServicesMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >prok:AdministrationAndSupportServicesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-25</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_25_2021To12_31_2021_AdvanceFromRelatedPartyLoanMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >prok:AdvanceFromRelatedPartyLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:SponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-25</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_25_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-25</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_25_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-25</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_25_2021To12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-25</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-25</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-25</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-25</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_25_2021To12_31_2021_DirectorRestrictedStockUnitAwardAgreementMemberPROKAgreementAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="prok:AgreementAxis" >prok:DirectorRestrictedStockUnitAwardAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-25</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_DirectorRestrictedStockUnitAwardAgreementMemberPROKAgreementAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="prok:AgreementAxis" >prok:DirectorRestrictedStockUnitAwardAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-25</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_25_2021To12_31_2021_DirectorMembersrtTitleOfIndividualAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:DirectorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-25</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-02</xbrli:startDate> <xbrli:endDate>2021-07-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-02</xbrli:startDate> <xbrli:endDate>2021-07-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-02</xbrli:startDate> <xbrli:endDate>2021-07-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_02_2021To07_02_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-02</xbrli:startDate> <xbrli:endDate>2021-07-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_02_2021To07_02_2021_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >prok:PromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-02</xbrli:startDate> <xbrli:endDate>2021-07-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-02</xbrli:startDate> <xbrli:endDate>2021-07-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-02</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-02</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-02</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis" >us-gaap:IPOMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-02</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn07_02_2021_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-07-02</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P03_02_2021To03_02_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:FounderMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-03-02</xbrli:startDate> <xbrli:endDate>2021-03-02</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_29_2021To06_29_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:FounderMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-06-29</xbrli:startDate> <xbrli:endDate>2021-06-29</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_29_2021To06_29_2021_DirectorMembersrtTitleOfIndividualAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:DirectorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-06-29</xbrli:startDate> <xbrli:endDate>2021-06-29</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_29_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:FounderMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-29</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:FounderMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P07_01_2021To09_30_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-07-01</xbrli:startDate> <xbrli:endDate>2021-09-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_25_2021To06_30_2021_FounderSharesMemberusgaapStatementEquityComponentsAxis_IndependentDirectorsMembersrtTitleOfIndividualAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >prok:FounderSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >prok:IndependentDirectorsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-25</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_02_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:SponsorMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-02</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_02_2021_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >prok:PromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-02</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P06_30_2021To06_30_2021_AdministrationAndSupportServicesMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >prok:AdministrationAndSupportServicesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-06-30</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_18_2022_PipeInvestorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:PipeInvestorsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SharePriceThreeMemberPROKSharePriceRangeAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >prok:ProkidneyLpMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis" >prok:RestrictedStockRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="prok:SharePriceRangeAxis" >prok:SharePriceThreeMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SharePriceTwoMemberPROKSharePriceRangeAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >prok:ProkidneyLpMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis" >prok:RestrictedStockRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="prok:SharePriceRangeAxis" >prok:SharePriceTwoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SharePriceOneMemberPROKSharePriceRangeAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >prok:ProkidneyLpMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis" >prok:RestrictedStockRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="prok:SharePriceRangeAxis" >prok:SharePriceOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_18_2022_PipeInvestorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:PipeInvestorsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SharePriceThreeMemberPROKSharePriceRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >prok:ProkidneyLpMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis" >prok:RestrictedStockRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="prok:SharePriceRangeAxis" >prok:SharePriceThreeMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SharePriceTwoMemberPROKSharePriceRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >prok:ProkidneyLpMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis" >prok:RestrictedStockRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="prok:SharePriceRangeAxis" >prok:SharePriceTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SharePriceOneMemberPROKSharePriceRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >prok:ProkidneyLpMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis" >prok:RestrictedStockRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="prok:SharePriceRangeAxis" >prok:SharePriceOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_18_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_18_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >prok:PromissoryNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-18</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_DirectorMembersrtTitleOfIndividualAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:DirectorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RestrictionOnTransferOfSponsorSharesMemberPROKBasisAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:FounderMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="prok:BasisAxis" >prok:RestrictionOnTransferOfSponsorSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis" >us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_AdvanceFromRelatedPartyLoanMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >prok:AdvanceFromRelatedPartyLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WorkingCapitalLoansMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >prok:WorkingCapitalLoansMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CapitalUnitClassB1MemberusgaapCapitalUnitsByClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >prok:CapitalUnitClassB1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ConstructionInProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >prok:PromissoryNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis" >us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_ValuationTechniqueProbabilityWeightedExpectedReturnMethodMemberusgaapValuationTechniqueAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis" >prok:ValuationTechniqueProbabilityWeightedExpectedReturnMethodMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_ClassB1unitsMemberusgaapCapitalUnitsByClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >prok:ClassB1unitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >prok:PromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_18_2022To01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >prok:ProkidneyLpMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis" >prok:RestrictedStockRightsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-18</xbrli:startDate> <xbrli:endDate>2022-01-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_18_2022To01_18_2022_PipeInvestorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:PipeInvestorsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-18</xbrli:startDate> <xbrli:endDate>2022-01-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_18_2022To01_18_2022_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MaximumMembersrtRangeAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-18</xbrli:startDate> <xbrli:endDate>2022-01-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_18_2022To01_18_2022_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-18</xbrli:startDate> <xbrli:endDate>2022-01-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_18_2022To01_18_2022_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-18</xbrli:startDate> <xbrli:endDate>2022-01-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_18_2022To01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >prok:ProkidneyLpMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis" >prok:RestrictedStockRightsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-18</xbrli:startDate> <xbrli:endDate>2022-01-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_18_2022To01_18_2022_PipeInvestorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:PipeInvestorsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-18</xbrli:startDate> <xbrli:endDate>2022-01-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_18_2022To01_18_2022_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-18</xbrli:startDate> <xbrli:endDate>2022-01-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_18_2022To01_18_2022_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-18</xbrli:startDate> <xbrli:endDate>2022-01-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_18_2022To01_18_2022_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-18</xbrli:startDate> <xbrli:endDate>2022-01-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_18_2022To01_18_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >prok:PromissoryNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-18</xbrli:startDate> <xbrli:endDate>2022-01-18</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RestrictionOnTransferOfSponsorSharesMemberPROKBasisAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:FounderMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="prok:BasisAxis" >prok:RestrictionOnTransferOfSponsorSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_AdministrationAndSupportServicesMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >prok:AdministrationAndSupportServicesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_AdvanceFromRelatedPartyLoanMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >prok:AdvanceFromRelatedPartyLoanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_DirectorRestrictedStockUnitAwardAgreementMemberPROKAgreementAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="prok:AgreementAxis" >prok:DirectorRestrictedStockUnitAwardAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_DirectorRestrictedStockUnitAwardAgreementMemberPROKAgreementAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="prok:AgreementAxis" >prok:DirectorRestrictedStockUnitAwardAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_PipeInvestorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SubscriptionAgreementsMemberPROKAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:PipeInvestorsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="prok:AgreementAxis" >prok:SubscriptionAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_AverillMasterFundLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SubscriptionAgreementsMemberPROKAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="prok:AgreementAxis" >prok:SubscriptionAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:AverillMasterFundLtdMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_ScMasterHoldingsLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SubscriptionAgreementsMemberPROKAgreementAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="prok:AgreementAxis" >prok:SubscriptionAgreementsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:ScMasterHoldingsLlcMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_OnTheLatterOfTheFirstAnniversaryMemberusgaapVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >prok:OnTheLatterOfTheFirstAnniversaryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_InFirstAnniversaryOfTheAcquisitionDateMemberusgaapVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >prok:InFirstAnniversaryOfTheAcquisitionDateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_OnEachEnniversaryMemberusgaapVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >prok:OnEachEnniversaryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_EachCalendarQuarterMemberusgaapVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >prok:EachCalendarQuarterMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_OverTheThreeYearPeriodFromTheDateOfGrantMemberusgaapVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >prok:OverTheThreeYearPeriodFromTheDateOfGrantMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_ClassB1unitsMemberusgaapCapitalUnitsByClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >prok:ClassB1unitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis" >us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_ValuationTechniqueProbabilityWeightedExpectedReturnMethodMemberusgaapValuationTechniqueAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis" >prok:ValuationTechniqueProbabilityWeightedExpectedReturnMethodMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis" >us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_AcquiredAssemblyWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >prok:AcquiredAssemblyWorkforceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To03_31_2022_CapitalUnitClassB1MemberusgaapCapitalUnitsByClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >prok:CapitalUnitClassB1Member</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_25_2021To03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-25</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_25_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-25</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_25_2021To03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-25</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_25_2021To03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-25</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_25_2021To03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-25</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P02_25_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-02-25</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn04_20_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >prok:PromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-04-20</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P06_01_2021To06_30_2021_FounderSharesMemberusgaapStatementEquityComponentsAxis_IndependentDirectorsMembersrtTitleOfIndividualAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >prok:FounderSharesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >prok:IndependentDirectorsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-06-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P06_01_2021To06_30_2021_DirectorMembersrtTitleOfIndividualAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis" >srt:DirectorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-06-01</xbrli:startDate> <xbrli:endDate>2021-06-30</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P04_26_2022To04_26_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis" >prok:SponsorMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis" >prok:PromissoryNoteMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-04-26</xbrli:startDate> <xbrli:endDate>2022-04-26</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_OnTheLatterOfTheFirstAnniversaryMemberusgaapVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >prok:OnTheLatterOfTheFirstAnniversaryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_InFirstAnniversaryOfTheAcquisitionDateMemberusgaapVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >prok:InFirstAnniversaryOfTheAcquisitionDateMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_OnEachEnniversaryMemberusgaapVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >prok:OnEachEnniversaryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_EachCalendarQuarterMemberusgaapVestingAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:VestingAxis" >prok:EachCalendarQuarterMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis" >srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_KYsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:KY</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_USsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AcquiredAssemblyWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >prok:AcquiredAssemblyWorkforceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ConstructionInProgressMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:ComputerEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis" >us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_KYsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:KY</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_USsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:US</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AcquiredAssemblyWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >prok:AcquiredAssemblyWorkforceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis" >us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To03_31_2021_AcquiredAssemblyWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis" >prok:AcquiredAssemblyWorkforceMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-03-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_17_2022_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_17_2022_CapitalUnitClassBOneMemberusgaapCapitalUnitsByClassAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >prok:CapitalUnitClassBOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_17_2022_CapitalUnitClassBOneMemberusgaapCapitalUnitsByClassAxis_DeferredProfitSharingMemberusgaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >prok:CapitalUnitClassBOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" >us-gaap:DeferredProfitSharingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_17_2022_ClassB1unitsMemberusgaapCapitalUnitsByClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >prok:ClassB1unitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_17_2022_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-01-17</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_01_2022_CapitalUnitClassBOneMemberusgaapCapitalUnitsByClassAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >prok:CapitalUnitClassBOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_01_2022_CapitalUnitClassBOneMemberusgaapCapitalUnitsByClassAxis_DeferredProfitSharingMemberusgaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >prok:CapitalUnitClassBOneMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis" >us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" >us-gaap:DeferredProfitSharingMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-06-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_20_2016To12_31_2021_KYsrtStatementGeographicalAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis" >country:KY</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2016-01-20</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_09_2019To01_09_2019_RegenAndTwinCityBioLlcMemberusgaapBusinessAcquisitionAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis" >prok:RegenAndTwinCityBioLlcMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2019-01-09</xbrli:startDate> <xbrli:endDate>2019-01-09</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_24_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-24</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_24_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-24</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_24_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-24</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_24_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-24</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn02_24_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-02-24</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis" >us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis" >prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2019_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2019-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2020-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:MemberUnitsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis" >us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001850270</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis" >us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2021-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares" > <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure" > <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Day" > <xbrli:measure>utr:Day</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year" > <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Month" > <xbrli:measure>utr:Month</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share" > <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_segment" > <xbrli:measure>prok:segment</xbrli:measure> </xbrli:unit></ix:resources></ix:header></div><div style="font-size: 13.28px; margin-top: 0pt; margin-bottom: 17pt;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">As filed with the U.S. Securities and Exchange Commission on August 8, 2022 </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="font-weight:bold;display:inline;">Registration <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;333-&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div> </div></div> <div style="font-size: 4pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="line-height: 1pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</div> <div style="line-height: 3pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</div> <div style="margin-top: 4pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">UNITED STATES </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Washington, D.C. 20549 </div></div> <div style="font-size: 3pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="text-align:center"> <div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div> </div> <div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">FORM <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:DocumentType" contextRef="P01_01_2022To03_31_2022">S-1</ix:nonNumeric></div> </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">REGISTRATION STATEMENT </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">UNDER </div></div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">THE SECURITIES ACT OF 1933 </div></div></div> <div style="font-size: 3pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="text-align:center"> <div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div> </div> <div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 24pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2022To03_31_2022">ProKidney Corp.</ix:nonNumeric> </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Exact name of registrant as specified in its charter) </div></div> <div style="font-size: 3pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="text-align:center"> <div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div> </div> <div style="font-size: 3pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P01_01_2022To03_31_2022" format="ixt-sec:edgarprovcountryen">Cayman Islands</ix:nonNumeric></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2836</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">98-1586514</div></div></div></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(State or other jurisdiction of<br/>incorporation or organization)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Primary Standard Industrial<br/>Classification Code Number)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(I.R.S. Employer<br/>Identification Number)</div></div></td> </tr> </table> <div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">2000 Frontis Plaza Blvd., Ste 250 </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Winston-Salem, NC 27103 </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Telephone: (336) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">999-7028</div> </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices) </div></div> <div style="font-size: 3pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="text-align:center"> <div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div> </div> <div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Tim Bertram, Ph.D. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Chief Executive Officer </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">ProKidney Corp. </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">2000 Frontis Plaza Blvd., Ste 250 </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Winston-Salem, NC 27103 </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Telephone: (336) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">999-7028</div> </div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Name, address, including zip code, and telephone number, including area code, of agent for service) </div></div> <div style="font-size: 3pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="text-align:center"> <div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div> </div> <div style="margin-top: 3pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;">Copies to: </div></div></div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Todd C. Girolamo, Esq.</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">ProKidney Corp.</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">2000 Frontis Plaza Blvd., Ste 250</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Winston-Salem, NC 27103</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Telephone: (336) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">999-7028</div></div></div> </td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Megan N. Gates, Esq.</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Jason S. McCaffrey, Esq.</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Matthew T. Simpson, Esq.</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Mintz,&#160;Levin,&#160;Cohn,&#160;Ferris,&#160;Glovsky&#160;and&#160;Popeo, P.C.</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">One Financial Center</div></div> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Boston, Massachusetts 02111</div></div> <div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Telephone: (617) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">542-6000</div></div></div> </td> </tr> </table> <div style="font-size: 3pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="text-align:center"> <div style="line-height: 6pt; margin: 0px auto; border-bottom: 1pt solid rgb(0, 0, 0); width: 21%; text-align: center;">&#160;</div> </div> <div style="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this registration statement. </div> <div style="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box.&#160;&#160;&#9746; </div> <div style="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744; </div> <div style="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744; </div> <div style="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#160;&#9744; </div> <div style="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-</div> accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12b-2</div> of the Exchange Act. </div> <div style="font-size: 3pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:16%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:59%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:20%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:2%"></td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom">Large&#160;accelerated&#160;filer</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#9744;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Accelerated filer</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#9744;</td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2022To03_31_2022" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#9746;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Smaller&#160;reporting&#160;company</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P01_01_2022To03_31_2022" format="ixt:fixed-true">&#9746;</ix:nonNumeric></td> </tr>
<tr style="font-size:1pt">
<td style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td>
<td colspan="2" style="height:6pt">&#160;</td> </tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Emerging growth company</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2022To03_31_2022" format="ixt:fixed-true">&#9746;</ix:nonNumeric></td> </tr> </table> <div style="margin-top:3pt; margin-bottom:0pt; text-indent:4%; font-size:9pt; font-family:Times New Roman">If an emerging growth company, indicate by check <div style="letter-spacing: 0px; top: 0px;;display:inline;">mark </div>if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act.&#160;&#160;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="P01_01_2022To03_31_2022" format="ixt:fixed-false">&#9744;</ix:nonNumeric> </div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 3pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 9pt; letter-spacing: 0px; top: 0px;;display:inline;">The registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section8(a), may determine. </div></div></div></div> <div style="font-size: 10pt; margin-top: 0px; margin-bottom: 0px;">&#160;</div> <div style="line-height: 1pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</div> <div style="line-height: 3pt; margin-top: 0px; margin-bottom: 0px; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Arial Narrow; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="color: rgb(255, 67, 56); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">The information in this preliminary prospectus is not complete and may be changed. The selling securityholders may not sell these securities until the registration statement filed with the Securities and Exchange Commission becomes effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted. </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="color: rgb(255, 67, 56); letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">SUBJECT TO COMPLETION, DATED AUGUST 8, 2022 </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PRELIMINARY PROSPECTUS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 24pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 24pt; letter-spacing: 0px; top: 0px;;display:inline;">PROKIDNEY CORP. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 18pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">Up to 232,530,000 Class&#160;A <div style="letter-spacing: 0px; top: 0px;;display:inline;">Ordinary </div>Shares </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This prospectus relates to the resale from time to time by the selling securityholders named in this prospectus (the &#8220;Selling Securityholders&#8221;) of up to (i) 50,000 Class&#160;A ordinary shares, par value $0.0001 per share (&#8220;Class&#160;A ordinary shares&#8221;) of ProKidney Corp. (formerly known as Social Capital Suvretta Holdings Corp. III, the &#8220;Company&#8221;), collectively held by certain holders of the Company&#8217;s securities (the &#8220;Holders&#8221;) party to that certain Amended and Restated Registration Rights Agreement, dated as of July&#160;11, 2022, by and among the Company, SCS Sponsor III LLC, and the Holders (the &#8220;Amended and Restated Registration Rights Agreement&#8221;), their permitted transferees and certain Additional Holders (as defined in the Amended and Restated Registration Rights Agreement); (ii)&#160;180,000,000 Class&#160;A ordinary shares issued or issuable pursuant to that certain Exchange Agreement, dated as of July&#160;11, 2022, by and among the Company, ProKidney LP, and certain holders of the Company&#8217;s securities party thereto (the &#8220;Exchange Agreement&#8221;); and (iii) 52,480,000 Class&#160;A ordinary shares, purchased by certain investors at a purchase price of $10.00 per share, pursuant to subscription agreements with the Company. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This prospectus provides you with a general description of such securities and the general manner in which the Selling Securityholders may offer or sell the securities. The prospectus supplement may also add, update or change information contained in this prospectus. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We will not receive any proceeds from the sale of Class&#160;A ordinary shares by the Selling Securityholders. However, we will pay the expenses, other than any underwriting discounts and commissions, associated with the sale of securities pursuant to this prospectus. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We are registering the securities for resale pursuant to the Selling Securityholders&#8217; registration rights under certain agreements between us and the Selling Securityholders. Our registration of the securities covered by this prospectus does not mean that either we or the Selling Securityholders will issue, offer or sell, as applicable, any of the securities. The Selling Securityholders may offer and sell the securities covered by this prospectus in a number of different ways and at varying prices. We provide more information about how the Selling Securityholders may sell the shares in the section entitled &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Plan of Distribution</div></div>.&#8221; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">You should read this prospectus and any prospectus <div style="letter-spacing: 0px; top: 0px;;display:inline;">supplement </div>or amendment carefully before you <div style="letter-spacing: 0px; top: 0px;;display:inline;">invest </div>in our securities. </div></div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Class&#160;A ordinary shares are listed on the Nasdaq Capital Market under the symbol &#8220;PROK.&#8221; On August&#160;5, 2022, the closing price of our Class&#160;A ordinary shares was $7.40. </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Investing in our securities involves a high degree of risk. See &#8220;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom373959_5">Risk Factors</a></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#8221; beginning on page 6 of this prospectus and in the other documents that are incorporated by reference in this prospectus. </div></div></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">None of the Securities and Exchange Commission, any state securities commission or any other regulatory body has approved or disapproved of these securities, or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The date of this prospectus is &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; , 2022. </div></div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TABLE OF CONTENTS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 95%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom373959_1">CERTAIN DEFINED TERMS</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">ii</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom373959_2">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">vi</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom373959_3">SUMMARY OF THE PROSPECTUS</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom373959_4">THE OFFERING</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom373959_5">RISK FACTORS</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom373959_6">USE OF PROCEEDS</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom373959_7">MARKET PRICE, TICKER SYMBOL AND DIVIDEND INFORMATION</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">81</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom373959_8">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">82</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom373959_9">NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">88</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom373959_10">BUSINESS OF PROKIDNEY</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">96</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom373959_11">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">141</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom373959_12">DESCRIPTION OF PROKIDNEY SECURITIES</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">152</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom373959_13">SECURITIES ACT RESTRICTIONS ON RESALE OF SECURITIES</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">164</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom373959_14">BENEFICIAL OWNERSHIP OF SECURITIES</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">165</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom373959_15">SELLING SECURITYHOLDERS</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">168</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom373959_16">MANAGEMENT</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">173</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom373959_17">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">192</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><a href="#rom373959_18">CERTAIN MATERIAL U.S. AND <span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NON-U.S.</span> FEDERAL INCOME TAX CONSIDERATIONS</a></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">199</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom373959_19">PLAN OF DISTRIBUTION</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">205</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom373959_20">LEGAL MATTERS</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">207</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom373959_21">EXPERTS</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">208</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom373959_22">WHERE YOU CAN FIND MORE INFORMATION</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">209</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#rom373959_23">INDEX TO FINANCIAL STATEMENTS</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FS-1</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">You should rely only on the information contained in this prospectus. No one has been authorized to provide you with information that is different from that contained in this prospectus. This prospectus is dated as of the date set forth on the cover hereof. You should not assume that the information contained in this prospectus is accurate as of any date other than that date. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For investors outside the United States</div></div>: We have not done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">i </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom373959_1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CERTAIN DEFINED TERMS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In this document: </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Amended and Restated</div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Registration Rights Agreement</div></div>&#8221; means the Amended and Restated Registration Rights Agreement, dated as of July&#160;11, 2022, by and among ProKidney, the Sponsor, certain ProKidney Unitholders and the other parties thereto; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">BLA</div></div>&#8221; means Biologics License Application; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Board</div></div>&#8221; means the board of directors of ProKidney; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combination</div></div>&#8221; refers to the transactions contemplated by the Business Combination Agreement; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business Combination Agreement</div></div>&#8221; means the business combination agreement, dated as of January&#160;18, 2022 by and between SCS and ProKidney LP; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cayman Islands Companies Act</div></div>&#8221; means the Companies Act (as amended) of the Cayman Islands;; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">CBER</div></div>&#8221; means Center for Biologics Evaluation and Research; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">cGMP</div></div>&#8221; means current good manufacturing practices; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Charter</div></div>&#8221; means the second amended and restated memorandum and articles of association of the Company adopted by special resolution on 11 July 2022; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">CKD</div></div>&#8221; means chronic kidney disease; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Closing</div></div>&#8221; means the closing of the Business Combination; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Closing ProKidney Unitholders</div></div>&#8221; means (i)&#160;the ProKidney Unitholders (other than PMEL) and (ii)&#160;the PMEL Post-Combination Unitholders; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">CMS</div></div>&#8221; means the Centers for Medicare&#160;&amp; Medicaid Services; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">eGFR</div></div>&#8221; means the estimated glomerular filtration rate; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EMA</div></div>&#8221; means the European Medicines Agency; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Exchange Act</div></div>&#8221; means the Securities Exchange Act of 1934, as amended; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Exchange Agreement</div></div>&#8221; means the exchange agreement, dated as of July&#160;11, 2022, by and among SCS, ProKidney LP and the Closing ProKidney Unitholders; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">FCA</div></div>&#8221; means the federal False Claims Act; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">FCPA</div></div>&#8221; means the U.S. Foreign Corrupt Practices Act; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">FDA</div></div>&#8221; means the U.S. Food and Drug Administration; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">FTC</div></div>&#8221; means the Federal Trade Commission; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">GAAP</div></div>&#8221; means accounting principles generally accepted in the United States of America; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">GCPs</div></div>&#8221; means Good Clinical Practices; </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ii </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">GP</div></div>&#8221; means ProKidney Corp. GP Limited, which replaced Legacy GP as the general partner of ProKidney LP upon the Closing; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">GP Board</div></div>&#8221; means the board of directors of GP; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">HIPAA</div></div>&#8221; means the Health Insurance Portability and Accountability Act of 1996; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">HITECH</div></div>&#8221; means the Health Information Technology for Economic and Clinical Health Act; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Legacy ProKidney Class</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;A Units</div></div>&#8221; means the units of ProKidney LP designated as &#8220;Class&#160;A Units&#8221; pursuant to the ProKidney Limited Partnership Agreement; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Legacy ProKidney Class</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;B Units</div></div>&#8221; means the units of Prokidney LP designated as &#8220;Class&#160;B Units&#8221; pursuant to the ProKidney Limited Partnership Agreement; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Legacy GP</div></div>&#8221; means ProKidney GP Limited, a private limited company incorporated under the laws of Ireland, which acted as the general partner of ProKidney LP prior to the Closing; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Legacy GP Board</div></div>&#8221; means the board of directors of Legacy GP; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Paired Interest</div></div>&#8221; means one Post-Combination ProKidney Common Unit and one ProKidney Class&#160;B ordinary share, which are together exchangeable for one ProKidney Class&#160;A ordinary share or the cash equivalent thereunder under certain circumstances and subject to certain conditions pursuant to the Exchange Agreement; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">PIPE Investment</div></div>&#8221; means the purchase of SCS Class&#160;A ordinary shares and/or Post-Combination ProKidney Common Units pursuant to the Subscription Agreements; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">PIPE Investment Amount</div></div>&#8221; means the aggregate gross purchase price received by SCS and ProKidney LP in the PIPE Investment; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">PIPE Investors</div></div>&#8221; means those certain investors that participated in the PIPE Investment pursuant to the Subscription Agreements; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">PIPE Shares</div></div>&#8221; means SCS Class&#160;A ordinary shares purchased in the PIPE Investment, or in the case of the ProKidney Related PIPE Investors, the Post-Combination ProKidney Common Units (together with a corresponding number of SCS Class&#160;B ordinary shares, if applicable) purchased in lieu of SCS Class&#160;A ordinary shares in the PIPE Investment; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">PMEL</div></div>&#8221; means ProKidney Management Equity LLC, a Bermuda limited liability company; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">PMEL Existing Holders</div></div>&#8221; means certain persons who, as members of PMEL, held an indirect interest in the Legacy Class&#160;B Units held by PMEL prior to the Closing; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">PMEL Post-Combination Unitholders</div></div>&#8221; means the PMEL Existing Holders, as well as their designees, or one or more holding persons or nominated persons who received Post-Combination ProKidney Common Units or PMEL RCUs on behalf of the PMEL Existing Holders in connection with the Business Combination; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">PMEL RCUs</div></div>&#8221; means the Restricted Common Units of ProKidney designated as &#8220;PMEL RCUs&#8221; pursuant to the Second Amended and Restated ProKidney Limited Partnership Agreement; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Post-Combination ProKidney Common Units</div></div>&#8221;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>means the units of ProKidney designated as &#8220;Common Units&#8221; pursuant to the Second Amended and Restated ProKidney Limited Partnership Agreement; </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">iii </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ProKidney</div></div>&#8221; means (unless otherwise indicated) SCS after the Business Combination, including its name change from Social Capital Suvretta Holdings Corp. III to &#8220;ProKidney Corp.,&#8221; as applicable; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ProKidney Bermuda</div></div>&#8221; means ProKidney LLC, a limited liability company incorporated under the laws of Bermuda in December 2018, which is currently a wholly owned subsidiary of ProKidney; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ProKidney Class</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;A ordinary shares</div></div>&#8221; means ProKidney&#8217;s Class&#160;A ordinary shares, par value $0.0001 per share; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ProKidney Class</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;B ordinary shares</div></div>&#8221; means ProKidney&#8217;s Class&#160;B ordinary shares, par value $0.0001 per share; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ProKidney Class</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;B PMEL RSRs</div></div>&#8221; or &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">PMEL RSRs</div></div>&#8221; means the Restricted Stock Rights of ProKidney designated as &#8220;Class&#160;B PMEL RSRs&#8221; that were issued pursuant to the Business Combination Agreement; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ProKidney Employee Stock Purchase Plan</div></div>&#8221; means the ProKidney Corp. Employee Stock Purchase Plan; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ProKidney Incentive Equity Plan</div></div>&#8221; means the ProKidney Corp. 2022 Incentive Equity Plan; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div></div></div>&#8221; means ProKidney (formerly known as RegenMed (Cayman) Ltd. (d/b/a inRegen)), a clinical-stage cellular therapeutics company incorporated under the Cayman Islands Companies Act focused on the treatment of chronic renal disease and acquired by ProKidney in January 2019; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ProKidney Limited Partnership Agreement</div></div>&#8221; means the First Amended and Restated Limited Partnership Agreement for a Limited Partnership Called ProKidney LP, dated as of January&#160;17, 2022, by and among Tolerantia, LLC, Control Empresarial de Capitales, S.A. de C.V. (formerly Inversora Carso, S.A. de C.V.), PMEL and Legacy GP; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ProKidney LP</div></div>&#8221; means ProKidney LP, a limited partnership organized under the laws of Ireland; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ProKidney ordinary shares</div></div>&#8221; means the ProKidney Class&#160;A ordinary shares and the ProKidney Class&#160;B ordinary shares; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ProKidney Promissory Notes</div></div>&#8221; means the two promissory notes entered into by ProKidney LP on January&#160;18, 2022, concurrently with the execution of the Business Combination Agreement, with certain ProKidney Unitholders pursuant to which such ProKidney Unitholders agreed to fund up to $100,000,000 in the aggregate to support the operational and financing needs of ProKidney LP prior to the Closing; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ProKidney Related PIPE Investors</div></div>&#8221; means certain existing directors, officers and unitholders of ProKidney LP and/or its affiliates that participated in the PIPE Investment; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ProKidney Unitholders</div></div>&#8221; means any person who held units of ProKidney LP immediately prior to the consummation of the Business Combination; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div></div></div>&#8221; means ProKidney, LLC (formerly known as Twin City Bio LLC), a Delaware limited liability company that provides contract development and manufacturing service for pharmaceutical and biotech companies focused on cell-based therapies and that was acquired by ProKidney LP in January 2019; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">REACT</div></div>&#8221; means Renal Autologous Cell Therapy, the lead product candidate of ProKidney; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Common Units</div></div>&#8221;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>means the units of ProKidney LP designated as &#8220;Restricted Common Units&#8221; pursuant to the Second Amended and Restated ProKidney Limited Partnership Agreement; </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">iv </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Rights</div></div>&#8221; means restricted stock rights in respect of ProKidney Class&#160;B ordinary shares; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">RMAT</div></div>&#8221; means regenerative medicine advanced therapy;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8220;Sarbanes-Oxley Act</div></div>&#8221; means the Sarbanes-Oxley Act of 2002, as amended; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">SCS</div></div>&#8221; means Social Capital Suvretta Holdings Corp. III, a Cayman Islands exempted company limited by shares (which, after the Closing, is known as ProKidney Corp.); </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">SCS Class</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;A ordinary shares</div></div>&#8221; means Class&#160;A ordinary shares in the share capital of SCS, par value $0.0001 per share; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">SCS Class&#160;B ordinary shares</div></div>&#8221;&#160;means Class&#160;B ordinary shares in the share capital of SCS, par value $0.0001 per share; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">SEC</div></div>&#8221; means the U.S. Securities and Exchange Commission; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Second Amended and Restated ProKidney Limited Partnership Agreement</div></div>&#8221; means the second amended and restated limited partnership agreement of ProKidney LP, which went into effect upon the completion of the Business Combination; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Securities Act</div></div>&#8221; means the Securities Act of 1933, as amended; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sponsor</div></div>&#8221; means SCS Sponsor III LLC, a Cayman Islands limited liability company; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sponsor Related PIPE Investor</div></div>&#8221; refers to certain existing directors, officers and equityholders of, or investment funds managed by Suvretta Capital Management, LLC, SCS, the Sponsor and/or their respective affiliates that participated in the PIPE Investment (together with their permitted transferees); </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">SRC</div></div>&#8221; means selected renal cell; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Subscription Agreements</div></div>&#8221; means the subscription agreements entered into by and between SCS and certain investors; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tax Receivable Agreement</div></div>&#8221; means the Tax Receivable Agreement, dated as of July&#160;11, 2022, by and among SCS, the TRA party representative (as defined in the Tax Receivable Agreement) and the Closing ProKidney Unitholders; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Third Party PIPE Investment</div></div>&#8221; means any PIPE Investment made by a Third Party PIPE Investor; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Third Party PIPE Investment Amount</div></div>&#8221; means the aggregate gross purchase price received by SCS in the Third Party PIPE Investment; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Third Party PIPE Investor</div></div>&#8221; means any PIPE Investor who is not (i)&#160;a Sponsor Related PIPE Investor or (ii)&#160;a ProKidney Related PIPE Investor; and </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Voting Agreement</div></div>&#8221; means the Deed of Undertaking, dated February&#160;14, 2022, made by Control Empresarial de Capitales, S.A. de C.V. (formerly Inversora Carso, S.A. de C.V.), a Mexican corporation. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">v </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom373959_2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This prospectus includes forward-looking statements regarding, among other things, our plans, strategies and prospects, both business and financial. These statements are based on the beliefs and assumptions of management. Although we believe that our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Generally, statements that are not historical facts, including statements concerning possible or assumed future actions, business strategies, events or results of operations, are forward-looking statements. These statements may be preceded by, followed by or include the words &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;projects,&#8221; &#8220;forecasts,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;seeks,&#8221; &#8220;plans,&#8221; &#8220;scheduled,&#8221; &#8220;anticipates&#8221; or &#8220;intends&#8221; or similar expressions. Forward-looking statements contained in this prospectus include, but are not limited to, statements about: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the anticipated benefits of the Business Combination; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to maintain the listing of our Class&#160;A ordinary shares on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to manage our growth effectively; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the success, cost and timing of our product development activities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the potential attributes and benefits of our product candidates, and if approved, our products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to manufacture REACT, our lead product candidate; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to obtain and maintain regulatory approval for our products, and any related restrictions and limitations of any approved product; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">our ability to identify, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> or acquire additional technology; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to maintain our existing license, manufacturing and supply agreements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our reliance on third parties to conduct, supervise and monitor a certain portion of our research and nonclinical testing and clinical trials for REACT; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to compete with other companies currently marketing or engaged in the biologics market and in the area of treatment of kidney disease, many of which have greater financial and marketing resources than us; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the size and growth potential of the markets for our products, and the ability of each to serve those markets, either alone or in partnership with others; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes in applicable laws or regulations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our estimates regarding expenses, revenue, capital requirements and needs for additional financing; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to raise financing in the future; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our financial performance; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our intellectual property rights; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">security breaches with respect to computer systems; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">economic downturns and political and market conditions beyond our control; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic on our business; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">other factors detailed under the section titled &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk Factors.</div></div>&#8221; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">vi </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These forward-looking statements are based on information available as of the date of this prospectus, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements such as those contained in documents we have filed with the SEC. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. For a discussion of the risks involved in our business and investing in our ordinary shares, see the section titled &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk Factors</div></div>.&#8221; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Should one or more of these risks or uncertainties materialize, or should any of the underlying assumptions prove incorrect, actual results may vary in material respects from those expressed or implied by these forward-looking statements. You should not place undue reliance on these forward-looking statements. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">vii </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"><div style="margin: 1.5% -1.25% 1.5% 1.5%; width: 97%;"><div id="rom373959_3" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SUMMARY OF THE PROSPECTUS </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">This summary highlights selected information included in this prospectus and does not contain all of the information that may be important to you in making an investment decision. This summary is qualified in its entirety by the more detailed information included in this prospectus. Before making your investment decision with respect to our securities, you should carefully read this entire prospectus, including the information under &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and the financial statements included elsewhere in this prospectus. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are a clinical-stage biotechnology business with a transformative proprietary cell therapy platform that is capable of treating multiple chronic diseases of the kidney using a patient&#8217;s own cells. Our approach seeks to redefine the treatment of CKD by restoring kidney function and preventing or delaying the progression of CKD, rather than managing kidney failure. Our lead product candidate, REACT, is designed to stabilize or improve renal, or kidney, function in patients with chronically diseased kidneys. REACT is a product composed of a patient&#8217;s own SRCs, formulated into a product that is reinjected into the kidney by a minimally invasive outpatient procedure that can be repeated if necessary. Because REACT is a personalized treatment composed of a patient&#8217;s own, or autologous, SRCs, there is no need for treatment with immunosuppressive therapies, which are required during a patient&#8217;s lifetime when a patient receives a kidney transplant from another donor, or an allogeneic transplant. We are currently conducting a Phase 3 clinical trial and multiple Phase 2 clinical trials for REACT in patients with moderate to severe CKD caused by diabetes mellitus or congenital anomalies of the kidney and urinary tract. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Developments </div></div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Business Combination Agreement </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company was originally known as Social Capital Suvretta Holdings Corp. III. On July&#160;11, 2022, we consummated the Business Combination pursuant to the terms of the Business Combination Agreement, dated as of January&#160;18, 2022, by and between SCS and ProKidney LP, a limited partnership registered under the laws of Ireland, acting through its general partner ProKidney GP Limited, a private limited company incorporated under the laws of Ireland. In connection with the Business Combination, SCS changed its name to &#8220;ProKidney Corp.&#8221; </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As a consequence of the Business Combination, each SCS Class&#160;B ordinary share that was issued and outstanding as of immediately prior to the effective time of the merger was converted, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-for-one</div></div> basis, into ProKidney Class&#160;A ordinary shares. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, concurrently with the execution of the Business Combination Agreement, on January&#160;18, 2022, SCS entered into the Subscription Agreements, pursuant to which the PIPE Investors purchased, immediately prior to the Closing, an aggregate of 57,480,000 Class&#160;A ordinary shares at a purchase price of $10.00 per share. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the Business Combination, each issued and outstanding Class&#160;B unit (each, a &#8220;ProKidney Class&#160;B Unit&#8221;) in ProKidney LP that had not vested pursuant to the terms of the applicable award agreement was recapitalized into one PMEL RCU, which would, when vested in accordance with the applicable award agreement, automatically convert into a Post-Combination ProKidney Common Unit (and the associated ProKidney Class&#160;B PMEL RSR would vest), and all other issued and outstanding Legacy Class&#160;A Units and Legacy Class&#160;B Units in ProKidney were recapitalized into an aggregate number of Post-Combination ProKidney Common Units equal to (x) 175,000,000 minus (y)&#160;the number of PMEL RCUs issued as described above. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the Closing, (i)&#160;ProKidney LP issued to SCS a number of Post-Combination ProKidney Common Units equal to the number of fully diluted outstanding SCS ordinary shares as of immediately prior to the Closing (but </div></div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"><div style="margin: 1.5% -1.25% 1.5% 1.5%; width: 97%;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">after giving effect to all redemptions of SCS Class&#160;A ordinary shares and the purchase of SCS Class&#160;A ordinary shares and/or Post-Combination ProKidney Common Units pursuant to the PIPE Investment), in exchange for (a) (x)&#160;ProKidney Class&#160;B ordinary shares, which shares have no economic rights but entitle the holders thereof to vote on all matters on which shareholders of ProKidney are entitled to vote generally, and (y)&#160;ProKidney Class&#160;B PMEL RSRs, which convert into ProKidney Class&#160;B ordinary shares upon the vesting of the associated PMEL RCUs, (b)&#160;an amount in cash equal to the aggregate proceeds obtained by SCS in the PIPE Investment and (c)&#160;an amount in cash equal to the aggregate proceeds available for release to SCS from SCS&#8217;s trust account (the &#8220;Trust Account&#8221;) (after giving effect to all redemptions of SCS Class&#160;A ordinary shares and after payment of any deferred underwriting commissions that were held in the Trust Account and payment of certain transaction expenses); (ii) ProKidney distributed to the Closing ProKidney Unitholders the ProKidney Class&#160;B ordinary shares and ProKidney Class&#160;B PMEL RSRs received pursuant to clause (i)(a)&#160;(x) and (y)&#160;above; and (iii)&#160;holders (the &#8220;Earnout Participants&#8221;) of Legacy ProKidney Class&#160;A Units received an aggregate of 17,500,000 Restricted Common Units (the &#8220;Earnout RCUs&#8221;) and 17,500,000 Restricted Stock Rights (the &#8220;Earnout RSRs&#8221;) (collectively, the &#8220;Earnout Rights&#8221;), which Earnout Rights will vest in three equal tranches upon the achievement of certain ProKidney share price milestones or certain change of control events. When vested, the Earnout RCUs will automatically convert into Post-Combination ProKidney Common Units and the associated Earnout RSRs will automatically convert into ProKidney Class&#160;B ordinary shares, respectively. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Exchange Listing </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Class&#160;A ordinary shares are listed for trading on Nasdaq under the symbols &#8220;PROK.&#8221; </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Summary of Risk Factors </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves risks. You should carefully consider the risks described in &#8220;<div style="font-style:italic;display:inline;">Risk Factors</div>&#8221; beginning on page 6 before making a decision to invest in our securities. If any of these risks actually occurs, our business, financial condition and results of operations would likely be materially adversely affected. Some of the risks related to our business and industry are summarized below. </div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have incurred significant net losses since inception and we expect to continue to incur significant net losses for the foreseeable future; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Having completed the Business Combination, we will continue to require substantial additional <div style="display:inline;">capital </div>to finance our operations; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have a limited operating history and have not generated any revenue to date, and may never become profitable; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our business is highly dependent on the success of our lead product candidate, REACT, as well as any other future product candidates that we may advance into clinical development. REACT and our future product candidates will require significant additional clinical development and funding before we may be able to seek regulatory approval for and launch a product commercially; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">REACT is based on a novel technology, which makes it difficult to predict the time and cost of product development and of subsequently obtaining regulatory approval; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinical development involves a lengthy, complex and expensive process, with an uncertain outcome, and the results of nonclinical studies, previous clinical trials, or interim results of ongoing clinical trials of REACT and any of our future product candidates may not be predictive of future results. Further, we may encounter substantial delays in completing the development of REACT and any of our future product candidates; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Negative public opinion and increased regulatory scrutiny of autologous cell therapy using REACT may adversely impact the development or commercial success of our current and future product candidates; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"><div style="margin: 1.5% -1.25% 1.5% 1.5%; width: 97%;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are conducting our first Phase 3 clinical trial and may be unable to successfully complete it or any future clinical trials; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The design or execution of our ongoing and future clinical trials may not support marketing approval; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to our limited resources and access to capital, we must make decisions on the allocation of resources to certain programs and product candidates; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cell therapies are complex and difficult to manufacture, and we could experience manufacturing problems that result in delays in the development or commercialization of REACT, our lead product candidate, or otherwise harm our business; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our autologous cell therapy products are patient-specific, and we need to ensure that the correct product is administered to the correct patient; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Delays in obtaining regulatory approval of the manufacturing process and facility to produce REACT or disruptions in the manufacturing process may delay or disrupt our commercialization efforts; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Managing an autologous ex vivo cell therapy supply chain is highly complex; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unanticipated changes in effective tax rates or adverse outcomes resulting from examination of our income or other tax returns could adversely affect our financial condition and results of operations; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because we are a &#8220;controlled company&#8221; within the meaning of the Nasdaq rules, our shareholders may not have certain corporate governance protections that are available to shareholders of companies that are not controlled companies; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Required payments under the Tax Receivable Agreement may be substantial, and in certain cases, payments under the Tax Receivable Agreement may exceed the actual tax benefits that we realize or may be accelerated; and </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because we are a Cayman Islands exempted company, the rights of our shareholders may be different from the rights of shareholders governed by the laws of U.S. jurisdictions. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Information </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCS was incorporated on February&#160;25, 2021 as a Cayman Islands exempted company. It was formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. As an exempted company, we have received a tax exemption undertaking from the Government of the Cayman Islands to the effect that, in accordance with Section 6 of the Tax Concessions Act (as amended) of the Cayman Islands, for a period of 30 years from the date of the undertaking, no law which is enacted in the Cayman Islands imposing any tax or duty to be levied on profits, income, gains or appreciations, or any tax in the nature of estate duty or inheritance tax, will apply to any property comprised in or any income arising under the company, or to the security holders thereof, in respect of any such property or income. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July 11, 2022, SCS and ProKidney LP completed the Business Combination, and SCS&#8217;s corporate name was changed to &#8220;ProKidney Corp.&#8221; </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The combined structure was organized in an umbrella <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">partnership-C</div> corporation (a so called <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Up-C&#8221;</div> structure). ProKidney Corp. is a holding company, and our direct assets consist of Post-Combination ProKidney Common Units and all of the issued and outstanding equity interests of GP, which became the general partner of ProKidney LP upon the Closing. ProKidney Corp. controls GP, with the rights of management specified in the Second Amended and Restated ProKidney Limited Partnership Agreement. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"><div style="margin: 1.5% -1.25% 1.5% 1.5%; width: 97%;"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Our principal executive offices are located at 2000 Frontis Plaza Blvd., Ste 250, Winston-Salem, North Carolina, and our telephone number is (336) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">999-7028.</div> </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Controlled Company </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Nasdaq Listing Rules, a company of which more than 50% of the voting power for the election of directors is held by an individual, group or another company is a &#8220;controlled company.&#8221; Pursuant to the terms of the Voting Agreement, Tolerantia, LLC (&#8220;Tolerantia&#8221;) effectively controls a majority of the voting power of all of our outstanding ordinary shares with respect to the election, appointment or removal of any director. As a result, we are a &#8220;controlled company&#8221; within the meaning of the Nasdaq Listing Rules. A controlled company may elect not to comply with certain corporate governance standards, including the requirements that (i)&#160;a majority of its board of directors consist of independent directors, (ii)&#160;subject to the exception pursuant to Nasdaq Listing Rule 5605(b)(2), its board of directors have a compensation committee that is composed of at least two members, each of whom is an independent director, with a written charter addressing the committee&#8217;s purpose and responsibilities and (iii)&#160;director nominees must be selected, or recommended for the board&#8217;s selection, either by independent directors constituting a majority of the board&#8217;s independent directors in a vote in which only independent directors participate, or by a nominating and corporate governance committee comprised solely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities. Under the Business Combination Agreement, a majority of the directors on the Board were required to be &#8220;independent&#8221; directors for the purposes of the Nasdaq Listing Rules, but for at least some period following the Business Combination, we may utilize the other exemptions described above. If any of these exemptions are used, you may not have the same protections afforded to shareholders of companies that are subject to all of these corporate governance requirements. If we cease to be a &#8220;controlled company&#8221; and our shares continue to be listed on the Nasdaq, we will be required to comply with these standards and, depending on the Board&#8217;s independence determination with respect to our then-current directors, we may be required to add additional directors to the Board in order to achieve such compliance within the applicable transition period. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Emerging Growth Company </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Section&#160;102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;) exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a registration statement under the Securities Act declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such an election to opt out is irrevocable. We have elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of our financial statements with those of another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We will remain an emerging growth company until the earlier of: (1)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the Closing of SCS&#8217;s initial public offering, (b)&#160;in which we have total annual gross revenue of at least $1.07&#160;billion, or (c)&#160;in which we are deemed to be a large accelerated filer, which means the market value of our common equity that is held by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-affiliates</div> exceeds $700&#160;million as of the end of the prior fiscal year&#8217;s second fiscal quarter; and (2)&#160;the date on which we have issued more than $1.00&#160;billion in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-convertible</div> debt securities during the prior three-year period. References herein to &#8220;emerging growth company&#8221; have the meaning associated with it in the JOBS Act. </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="border: 1pt solid rgb(0, 0, 0); margin-right: 0px; margin-left: 0px; max-width: 100%;"><div style="margin: 1.5% -1.25% 1.5% 1.5%; width: 97%;"><div id="rom373959_4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">THE OFFERING </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top;">
<td style="width: 38%;"><div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2%; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuer </div></div></td>
<td>ProKidney Corp. </td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-bottom: 0pt; margin-left: 2%; margin-top: 1em"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Resale of Class&#160;A ordinary shares </div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr>
<td style="width: 38%;">&#160;</td>
<td style="vertical-align: top; font-size: 0px;;text-align:left;"></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top;">
<td style="width: 38%;"><div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2%; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares offered by the Selling Securityholders (representing the PIPE Shares purchased by certain PIPE Investors, shares issued or issuable pursuant to the vesting of restricted stock units, and shares issued or issuable pursuant to the Exchange Agreement) </div></div></td>
<td>232,530,000 shares </td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top;">
<td style="width: 38%;"><div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2%; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of proceeds </div></div></td>
<td>We will not receive any proceeds from the sale of the Class&#160;A ordinary shares to be offered by the Selling Securityholders. </td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top;">
<td style="width: 38%;"><div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2%; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Lock-up</div> agreements </div></td>
<td>Certain of our shareholders are subject to certain restrictions on transfer until the termination of applicable <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> periods. See &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Plan of Distribution</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#8212;</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Lock-Up</div> Agreements</div></div>&#8221; for further discussion. </td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top;">
<td style="width: 38%;"><div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 2%; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ticker Symbol </div></div></td>
<td>&#8220;PROK&#8221; for the Class&#160;A ordinary shares. </td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="rom373959_5" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RISK FACTORS </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">An investment in our securities involves a high degree of risk. You should carefully consider the risks described below before making an investment decision. Our business, prospects, financial condition, or operating results could be harmed by any of these risks, as well as other risks not known to us or that we consider immaterial as of the date of this prospectus. The trading price of our securities could decline due to any of these risks, and, as a result, you may lose all or part of your investment. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Unless the context otherwise requires, references in this section to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and the &#8220;Company&#8221; refer to ProKidney Corp. and its subsidiaries following the Business Combination and to ProKidney LP and its subsidiaries prior to the Business Combination, as the case may be. </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Our Financial Position and Need for Additional Capital </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We have incurred significant net losses since inception and we expect to continue to incur significant net losses for the foreseeable future. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have incurred significant net losses since our inception.&#160;We continue to incur significant research and development and other expenses related to our ongoing operations. For the three months ended March&#160;31, 2022 and 2021 and for the years ended December&#160;31, 2021 and 2020, we reported a net loss of $67.5&#160;million, $11.6&#160;million, $55.1&#160;million and $26.7&#160;million, respectively. As of March&#160;31, 2022 and December&#160;31, 2021, we had an accumulated deficit of $229.0&#160;million and $161.5&#160;million, respectively. We have devoted substantially all of our resources and efforts to research and development, and we expect that it will be several years, if ever, before we generate revenue from product sales. Even if we receive marketing approval for and commercialize our lead product candidate, Renal Autologous Cell Therapy (&#8220;REACT&#8221;), we expect that we will continue to incur substantial research and development and other expenses to develop and market additional potential product candidates. These conditions raise substantial doubt about our ability to continue as a going concern for a period of at least one year from the date our financial statements are issued, and our independent registered public accounting firm has included an explanatory paragraph relating to our ability to continue as a going concern in its report on our audited financial statements included elsewhere in this prospectus. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our product candidate, REACT, is still in clinical testing. We expect to continue to incur significant losses for the foreseeable future, and we anticipate that our expenses will increase substantially if, and as, we: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">advance the development of REACT and any other future product candidates through clinical development, and, if successful, later-stage clinical trials; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">experience delays or interruptions to any future preclinical studies, our current clinical trials, our receipt of services from our third-party service providers on whom we rely, or our supply chain, including delays due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, other health crises or events or circumstances beyond our control; </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">seek regulatory approvals for any future product candidates that may successfully complete clinical trials; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">commercialize REACT and any future product candidates, if approved; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">increase the amount of research and development activities to discover and develop product candidates and line extensions; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">manufacture the materials needed for clinical trials or, following receipt of necessary regulatory approvals, commercial sales, at our manufacturing facilities; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">establish and validate commercial-scale cGMP manufacturing facilities and partner with Contract Manufacturing Organizations (&#8220;CMOs&#8221;); </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">establish a commercialization infrastructure and scale up internal and external manufacturing and distribution capabilities to commercialize any product candidates for which we may obtain regulatory approval; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">hire additional executives in clinical development, regulatory, manufacturing, quality control, quality assurance, scientific, public / investor relations general and administrative and management personnel; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expand our operational, financial and management systems and increase personnel, including personnel to support our clinical development and manufacturing efforts, general and administrative functions and our operations as a public company; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">establish domestic and global sales, marketing, medical affairs and distribution infrastructure to commercialize any products for which we may obtain marketing approval and intend to commercialize on our own or jointly with third parties; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">maintain, expand and protect our intellectual property portfolio; and </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">invest in or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> other technologies or product candidates. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">To become and remain profitable, we must develop and eventually commercialize products with significant market potential. This will require us to be successful in a range of challenging activities, including completing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> studies and clinical trials, obtaining marketing approval for REACT and any future product candidates, manufacturing, marketing and selling products for which we may obtain marketing approval and satisfying any post-marketing requirements. Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. We may never succeed in any or all of these activities and, even if we do, we may never generate revenue that is significant enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Having completed the Business Combination, we will continue to require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and product development programs, future commercialization efforts or other operations. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Developing biopharmaceutical products, including conducting clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash since inception. We expect our expenses to increase in connection with our ongoing activities, particularly as we conduct our ongoing and planned clinical trials of REACT and any future product candidates that we may develop, seek regulatory approvals for REACT and our future product candidates, and manufacture, launch and commercialize any products for which we receive regulatory approval. We also expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in order to maintain our continuing operations. If we are unable to raise capital when needed or on acceptable terms, we may be forced to delay, reduce or eliminate one or more of our research and product development programs or future commercialization efforts. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2022, we had approximately $29.8&#160;million in cash, cash equivalents and short-term investments. Based on our current operating plan, and having completed the Business Combination and accounting for $574.8&#160;million received in the PIPE Investment, we believe that our cash, cash equivalents and short-term investments will be sufficient to fund our operating expenses and capital expenditure requirements through 2024. However, our future capital requirements and the period for which our existing resources will support our operations may vary significantly from what we expect, and we will in any event require additional capital to complete clinical development of any of our current programs. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our monthly spending levels will vary based on new and ongoing development and corporate activities. Because the length of time and activities associated with development of REACT and any future product candidates is highly uncertain, we are unable to estimate the actual funds we will require for development, marketing and commercialization activities. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the initiation, progress, timing, costs and results of clinical trials for REACT and any future product candidates; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the clinical development plans we establish for these product candidates; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the timelines of our clinical trials and the overall costs to finish the clinical trials due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic; </div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the number and characteristics of product candidates that we develop; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the outcome, timing and cost of meeting regulatory requirements established by the FDA, the EMA and other comparable foreign regulatory authorities; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">whether we are able to enter into and maintain collaboration agreements, including the terms of and timing of payments under any such agreements; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us, REACT or any of our future product candidates; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the effect of competing clinical, technological and market developments; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the costs of maintaining our own commercial-scale cGMP manufacturing facility; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the revenue, if any, received from commercial sales of REACT and any of our future product candidates for which we receive marketing approval; and </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the costs of operating as a public company. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the Business Combination, we currently do not have any committed external source of funds or other support for our development efforts, and we cannot be certain that additional funding will be available on acceptable terms, or at all. Until we can generate sufficient revenue to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution arrangements. If we raise additional funds through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely affect the rights of our shareholders. Further, to the extent that we raise additional capital through the sale of ordinary shares or securities convertible or exchangeable into ordinary shares, your ownership interest will be diluted. In addition, any debt financing may subject us to fixed payment obligations and covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable intellectual property or other rights to REACT and any future product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. We also may be required to seek collaborators for REACT or any of our future product candidates at an earlier stage than otherwise would be desirable or relinquish our rights to REACT and any future product candidates or technologies that we otherwise would seek to develop or </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">8 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">commercialize ourselves. Market volatility resulting from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic or other factors could also adversely impact our ability to access capital as and when needed. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of REACT or any of our future product candidates or one or more of our other research and development initiatives. Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our ordinary shares to decline. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Research and Development of REACT and Our Future Product Candidates </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We have a limited operating history and have not generated any revenue to date, and may never become profitable. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are a clinical-stage biopharmaceutical company with a limited operating history. We were founded in 2018, have no products approved for commercial sale and have not generated any revenue. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, undertaking <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> studies, conducting clinical trials, developing a network of key opinion leaders, and performing research and development of REACT. Our approach to the discovery and development of product candidates is unproven, and we do not know whether we will be able to develop any products of commercial value. REACT and any other product candidates we develop will require substantial additional development and clinical research time and resources before we would be able to apply for or receive regulatory approvals and begin generating revenue from product sales. We have not yet demonstrated the ability to progress any product candidate through later-stage clinical trials leading to successful marketing authorization. We may be unable to obtain regulatory approval, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, achieve market access, and acceptance with insurers and health care providers, or conduct sales and marketing activities necessary for successful product commercialization. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval and become commercially viable. If and when one of our product candidates were to receive regulatory approval, we would need to transition from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition. In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors and risks frequently experienced by early-stage biopharmaceutical companies in rapidly evolving and complex fields. Consequently, we have no meaningful history of operations upon which to evaluate our business, and predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing medical products. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Due to the uncertainties and risks associated with these activities, we are unable to accurately and precisely predict the timing and amount of revenues, the extent of any further losses or if or when we might achieve profitability. We may never succeed in these activities and, even if we succeed in commercializing one or more of our product candidates, we may never generate revenue that is significant enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis and we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates. Our failure to become and remain profitable could decrease the value of our shares and impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The market for biologics and for the treatment of kidney disease is highly competitive. If we fail to effectively compete, our business, financial condition and operating results will suffer. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We face significant competition in the biologics market and in the area of treatment of kidney disease. We face competition from companies that develop and manufacture cell therapies, including major and specialty </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">9 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">pharmaceutical and biotechnology companies, developers of tubular and glomerular cell drug modulators, antifibrosis medications, induced pluripotent cells, other autologous mesenchymal stem cells and mechanical renal assist devices such as implantable and wearable renal dialysis machines, and advances in peritoneal dialysis and home dialysis. Cell-based clinical trials by other companies are underway globally with umbilical, adipose and bone marrow derived mesenchymal stem cells for CKD. Early-phase human induced pluripotent stem cell therapies for kidney diseases are ongoing in Japan. We believe that our principal competitors include developers of SGLT2 inhibitors and Mineral Receptor Agonists (&#8220;MRAs&#8221;), which are small-molecule therapies recently approved to lower risks of CKD progression. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Many of our current competitors may have competitive advantages over us, including significantly greater financial resources and expertise in research and development, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> testing, clinical trials, manufacturing, and marketing than we do. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe that the principal competitive factors in its target markets include: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">accuracy, including sensitivity and specificity, and reproducibility of results; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reputation among customers; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">innovation in offerings or products, if approved; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">efficacy and safety profile; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">cost; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">effectiveness of promotional support; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">intellectual property protection; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the intended patient population; and </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">relative convenience of dosing and administration. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We cannot assure you that our products, if approved, will compete favorably or that we will be successful in the face of increasing competition from new products and technologies introduced by existing competitors or new companies entering our target markets. In addition, we cannot assure you that our competitors do not have or will not develop products or technologies that currently or in the future will enable them to produce competitive products with greater capabilities or at lower costs than ours. Any failure to compete effectively could materially and adversely affect our business, financial condition and operating results. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our business is highly dependent on the success of our lead product candidate, REACT, as well as any other future product candidates that we may advance into clinical development. REACT and our future product candidates will require significant additional clinical development and funding before we may be able to seek regulatory approval for and launch a product commercially. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We currently have no products that are approved for commercial sale and may never be able to develop marketable products. REACT, our lead product candidate, is in Phase 3 clinical development. We cannot offer any assurances or predict with any certainty that such Phase 3 clinical development will be successfully completed, that positive clinical data will be obtained from such Phase 3 clinical development efforts or that regulatory authorities will grant marketing approval for REACT, in any such case on the expected timelines. Furthermore, regulatory approvals for REACT, even if obtained, may limit the type of patients in which REACT may be used for CKD or otherwise require specific warning or labeling language, each of which may reduce the commercial potential of REACT. Even if approved, we might not be successful in commercializing REACT. Should we fail to obtain regulatory approvals for REACT or fail to successfully commercialize REACT upon such regulatory approvals, our business and financial condition could be materially harmed and we may be more heavily dependent on the success of our other therapeutic programs. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">10 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As an organization, we have not previously conducted any later stage or pivotal clinical trials, have limited experience in preparing, submitting and pursuing regulatory filings and have not previously submitted a BLA for any product candidate. Before we can generate any revenue from sales of our lead product candidate, REACT, or any of our future product candidates, we must complete clinical development, regulatory review and approval in one or more jurisdictions. We also need to obtain substantial additional funding to support our continuing operations and pursue our growth strategy. In addition, if REACT or any of our future product candidates is approved, we must ensure access to sufficient commercial manufacturing capacity and conduct significant marketing efforts in connection with any commercial launch. These efforts will require substantial investment, and we may not have the financial resources to continue development of REACT or any of our future product candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may experience setbacks that could delay or prevent regulatory approval of, or our ability to commercialize, REACT and any of our future product candidates, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">negative or inconclusive results from our clinical trials or positive results from the clinical trials of others for product candidates similar to ours leading to their approval, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or to abandon a program; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product-related side effects experienced by patients or subjects in our clinical trials or by individuals using medicines or therapeutics that we, the FDA, other regulators or others view as relevant to the development of REACT or any of our future product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">delays in submitting Investigational New Drug Applications (&#8220;INDS&#8221;) or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">conditions imposed by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials, including our clinical endpoints, and any requirement for additional confirmatory trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">delays in enrolling subjects in clinical trials, including due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, and completion of clinical trials, including under the FDA&#8217;s GCPs, the guidelines from International Conference on Harmonization (&#8220;ICH Guidelines&#8221;), Good Laboratory Practices (&#8220;GLP&#8221;), and current Good Tissue Practices (&#8220;cGTPs&#8221;); </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">inability to maintain compliance with regulatory requirements, including cGMPs, and complying effectively with other procedures; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">high <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">drop-out</div> rates of subjects from clinical trials; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">inadequate supply or quality of REACT or our future product candidates or other materials necessary for the conduct of our clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">greater than anticipated clinical trial costs; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">inability to compete with other therapies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">poor efficacy of REACT or our future product candidates during clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">trial results taking longer than anticipated; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">trials being subjected to fraud or data capture failure or other technical mishaps leading to the invalidation of our trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the results of our trials not supporting application for conditional approval in the European Union, the Asia-Pacific region, and Latin America; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">11 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">delays related to the impact of the spread of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, including the impact of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> on the FDA&#8217;s ability to continue its normal operations; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical development generally or with respect to our technology in particular; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">varying interpretations of data by the FDA and similar foreign regulatory agencies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the completion of Health Technology Assessment (&#8220;HTA&#8221;) procedures with governmental authorities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any policy level&#160;review&#160;of REACT by CMS; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the financing on our other ongoing or future programs; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">evolving scientific discovery and technology of cell-based therapies and bioprocessing; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">obsoleteness of manufacturing automation which could require a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-design</div> of parts or equipment to ensure quality replacement component, the delays of which could cause significant delays in&#160;manufacturing&#160;and loss of sales. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and our manufacturing, marketing, distribution and sales efforts or that of any future collaborator. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our business and operations may be adversely affected by the evolving and ongoing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> global pandemic. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our business and operations may be adversely affected by the effects of the evolving <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> virus, which was declared a global pandemic by the World Health Organization (&#8220;WHO&#8221;). The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic has resulted in travel and other restrictions to reduce the spread of the disease, including public health directives and orders in the United States and the European Union (&#8220;EU&#8221;) that, among other things and for various periods of time, directed individuals to shelter at their places of residence, directed businesses and governmental agencies to cease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-essential</div> operations at physical locations, prohibited certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-essential</div> gatherings and events and ordered cessation of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-essential</div> travel. Future remote work policies and similar government orders or other restrictions on the conduct of business operations related to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic may negatively impact productivity and may disrupt our ongoing research and development activities and our clinical trials and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. Further, such orders also may impact the availability or cost of materials, which would disrupt our supply chain and manufacturing efforts and could affect our ability to conduct ongoing and planned clinical trials and preparatory activities. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Although we have been able to effectively manage our supply chain and manufacturing capabilities despite the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic to date, we may experience related disruptions in the future that could severely impact our clinical trials, including: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">delays or difficulties with patient enrollment in clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">delays, difficulties or a suspension in clinical trial site initiation, including difficulties in recruiting investigators, proceduralists and clinical staff; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">interruptions in our ability to manufacture and deliver the required supply of REACT or future product candidates for clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">diversion of health care resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">potential cancellation or postponement of&#160;elective&#160;procedures&#160;scheduled at our clinical trial sites and reduction in operating hours at a significant number of our clinical trial sites; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">12 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">changes in local regulations as part of a response to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> outbreak that among other things (i)&#160;may interrupt our ability to manufacture REACT and (ii)&#160;may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">interruption of key clinical trial activities, such as clinical trial site monitoring, and the ability or willingness of subjects to travel to trial sites for scheduled visits and laboratory testing due to limitations on travel imposed or recommended by federal or state governments, employers and others; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">limitations in employee resources that would otherwise be focused on the conduct of our clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">refusal of the FDA and other regulatory agencies to accept data from clinical trials in these affected geographies; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">decreases or shifts of government funding from regulatory agencies, university research and education. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The spread of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19,</div> which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> could materially affect our business and the value of our securities. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The global <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic continues to rapidly evolve. The extent to which the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic impacts our business and operations, including our clinical development and regulatory efforts, will depend on future developments that are highly uncertain and cannot be predicted with confidence at the time of this prospectus, such as the ultimate geographic spread of the disease, the duration of the outbreak, the duration and effect of business disruptions and the short-term effects and ultimate effectiveness of the travel restrictions, quarantines, social distancing requirements and business closures in the United States and other countries to contain and treat the disease. Accordingly, we do not yet know the full extent of potential delays or impacts on our business, our clinical and regulatory activities, health care systems or the global economy as a whole. However, these impacts could adversely affect our business, financial condition, results of operations and growth prospects. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, to the extent the ongoing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic adversely affects our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties described in this &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Risk Factors</div></div>&#8221; section. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">REACT is based on a novel technology, which makes it difficult to predict the time and cost of product development and of subsequently obtaining regulatory approval. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The clinical trial requirements of the FDA, the EMA, and other regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty, and intended use and market of the potential products. The regulatory approval process for product candidates such as ours can be more expensive and take longer than for other, better known, or more extensively studied pharmaceutical or other product candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Regulatory requirements in the United States and in other countries governing cell therapy products are evolving and the FDA or other regulatory bodies may change the requirements, or identify different regulatory </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">13 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">pathways, for approval for REACT or any of our future product candidates. For example, the FDA has established the Office of Tissues and Advanced Therapies within CBER to consolidate the review of cell therapy and related products, and has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER in its review when called upon. It is possible that over time new or different divisions may be established or be granted the responsibility for regulating cell therapy products, including regenerative cell-based products, such as ours. Further, additional regulatory involvement from FDA advisory bodies, including the Cardio-Renal Advisory Committee, may delay review or make additional recommendations requiring further investigation. As a result, we may be required to change our regulatory strategy or to modify our applications for regulatory approval, which could delay and impair our ability to complete the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> and clinical development and manufacture of, and obtain regulatory approval for, REACT or any future product candidates. Changes in regulatory authorities and advisory groups, or any new requirements or guidelines they promulgate, may lengthen the regulatory review process, require us to perform additional studies, increase our development and manufacturing costs, lead to changes in regulatory pathways, positions and interpretations, delay or prevent approval and commercialization of REACT or any future product candidates or lead to significant post-approval limitations or restrictions. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have concentrated our research and development efforts on utilizing regenerative renal cell-based therapies. To date, the FDA has approved a relatively small number of cell-based therapies for commercialization and no regenerative renal-based cell therapy has been approved for commercial use by any regulatory authority. The processes and requirements imposed by the FDA or other applicable regulatory authorities may cause delays and additional costs in obtaining approvals for marketing authorization for REACT or any future product candidates. Because our platform is novel, and cell-based therapies are relatively new, regulatory agencies may lack experience in evaluating product candidates like REACT. This novelty may lengthen the regulatory review process, including the time it takes for the FDA to review our IND applications if and when submitted, increase our development costs and delay or prevent commercialization of REACT. Additionally, advancing novel CKD therapies creates significant challenges for us, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">educating medical personnel regarding the potential side-effect profile of REACT and, as the clinical development program progresses, on observed side effects with REACT; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">training medical personnel on the proper use and delivery of REACT; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">enrolling sufficient numbers of subjects in clinical trials; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">continuing to develop a manufacturing process to support the clinical development of REACT. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We must be able to overcome these challenges in order for us to develop, commercialize and manufacture REACT. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As we advance REACT, we will be required to consult with the FDA and other regulatory authorities, and REACT will likely be reviewed by an FDA advisory committee. We also must comply with applicable requirements, and if we fail to do so, we may be required to delay or discontinue development of REACT. Delays or unexpected costs in obtaining, or the failure to obtain, the regulatory approval necessary to bring a potential product to market could impair our ability to generate sufficient product revenues to maintain our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, adverse developments in preclinical studies or clinical trials conducted by others in the field of cell therapy products may cause the FDA, the EMA, and other regulatory bodies to revise the requirements for approval of any product candidates we may develop, and may otherwise negatively affect our ability to develop and commercialize REACT or future product candidates. Similarly, the European Commission may issue new guidelines concerning the development and marketing authorization for cell therapies and require that we comply with these new guidelines, which could require additional studies or clinical trials to support the marketing approval of REACT or any product candidates we may develop in the future or which could make our product candidates unable to successfully obtain approval. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">14 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The regulatory review committees and advisory groups described above and the new guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of these treatment candidates, or lead to significant post-approval limitations or restrictions. As we advance our research programs and develop future product candidates, we will be required to consult with these regulatory and advisory groups and to comply with applicable guidelines. If we fail to do so, we may be required to delay or discontinue development of any product candidates we identify and develop. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical development involves a lengthy, complex and expensive process, with an uncertain outcome, and the results of nonclinical studies, previous clinical trials, or interim results of ongoing clinical trials of REACT and any of our future product candidates may not be predictive of future results. Further, we may encounter substantial delays in completing the development of REACT and any of our future product candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our product candidate, REACT, is in clinical development, and its risk of failure is high.&#160;The clinical trials, manufacturing and marketing of REACT or any of our future product candidates, if approved, will be, subject to extensive and rigorous review and regulation by numerous government authorities in the United States and in other countries where we intend to test and market REACT and any of our future product candidates. Before obtaining regulatory approvals for the commercial sale of REACT or any of our future product candidates, we must demonstrate through lengthy, complex and expensive testing and clinical trials that our product candidates are both safe and effective for use in each target indication. In particular, because REACT is subject to regulation as a biological product, we will need to demonstrate that it is safe, pure and potent for use in its target indication and lacks latent untoward cell effects. REACT and any other product candidate we may develop must demonstrate an adequate risk versus benefit profile in its intended patient population and for its intended use. The process of administration of REACT involves taking a small biopsy of tissue from the kidney. The risks associated with a biopsy include bleeding, pain and hematoma, or bruising. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. In particular, the general approach for FDA approval of a new therapeutic modality can include dispositive data from two well-controlled, Phase&#160;3 clinical trials of the relevant product in the relevant patient population. Our Phase&#160;3 development program may involve one to two thousand patients, have significant costs and take years to complete. A product candidate can fail at any stage of testing, even after observing promising signals of activity in earlier nonclinical studies or clinical trials. The outcome of nonclinical studies and early clinical trials of REACT and our future product candidates may not be predictive of the success of the Phase 3 registrational development program, and interim results of a clinical trial do not necessarily predict final results. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through nonclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence clinical trials are never approved as therapeutic products and there can be no assurance that any of our future clinical trials will ultimately be successful or support further clinical development of REACT or any of our future product candidates. Product candidates and delivery methods for cellular therapeutics and tissue engineered products that appear promising in the early phases of development may fail to reach the market for several reasons, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">nonclinical or preclinical studies or clinical trials may show the product candidates to be less effective than expected (e.g.,&#160;a clinical trial could fail to meet its primary endpoint(s)) or to have unacceptable side effects or toxicities associated with the product or delivery method; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">failure to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful and relevant; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">failure to receive the necessary regulatory approvals; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">15 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">manufacturing costs, formulation issues, pricing or reimbursement issues, mechanism of action, logistical constraints or other factors that make a product candidate uneconomical; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the proprietary rights of others and their competing products and technologies that may prevent one of our product candidates from being commercialized. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, differences in trial design between early-stage clinical trials and later-stage clinical trials make it difficult to extrapolate the results of earlier clinical trials to later clinical trials. Moreover, clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in clinical trials have nonetheless failed to obtain marketing approval of their products. Additionally, our earlier stage trials are open-label studies, where both the subject and investigator know whether the subject is receiving REACT or standard of care therapy. Most typically, open-label clinical trials test only the investigational product candidate and sometimes do so at different dose levels. Open-label clinical trials are subject to various limitations and biases that may exaggerate any therapeutic effect as subjects in open-label clinical trials are aware when they are receiving treatment. In addition, open-label clinical trials may be subject to an &#8220;investigator bias&#8221; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which subjects have received treatment and may interpret the information of the treated group more favorably given this knowledge. Given that our earlier stage trials include an open-label dosing design, while we believe our trials utilize objective assessment measures for measuring our endpoints and therefore are unlikely to be influenced in any manner by subject or investigator bias, it is unknown whether the open-label design may not be predictive of future clinical trial results with this or other product candidates for which we conduct an open-label clinical trial when studied in a controlled environment or with only objective endpoints. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furthermore, the standards that the FDA and comparable foreign regulatory authorities use when regulating REACT require judgment and may change over time, which makes it difficult to predict with certainty how they will be applied. Any analysis we perform of data from nonclinical and clinical activities is subject to validation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We may also encounter unexpected delays or increased costs due to new government regulations. Examples of such regulations include future legislation or administrative action, or changes in FDA policy during the period of product development and FDA regulatory review. Specifically, some countries, such as China, have enacted or are considering enacting restrictions on the import and export of human genetic materials, cells and tissues. Such laws and regulations could impair our ability to import and export human cells and cell-based therapies, which could have a material adverse impact on our business. We cannot predict whether legislative changes will be enacted, whether FDA or foreign regulations, guidance or interpretations will be changed, or what the impact of such changes, if any, may be. The FDA may also require a panel of experts, referred to as an Advisory Committee, to deliberate on the adequacy of the safety and efficacy data to support approval. The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to obtain approval of any product candidates that we develop. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To date, we have not completed any pivotal trials required for the approval of REACT. We may experience delays in conducting any clinical trials, need to be redesigned, recruit and enroll subjects on time or be completed on schedule, or at all. Clinical trials can be delayed suspended or terminated for a variety of reasons, including in connection with: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">delays in sufficiently developing, characterizing, standardizing or controlling a manufacturing process and quality criteria suitable for advanced clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">delays in developing suitable assays for screening patients for eligibility for trials with respect to certain product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">delays in reaching agreement with the FDA, EMA or other regulatory authorities as to the design or implementation of our clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">obtaining additional regulatory authorizations to conduct future clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">16 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reaching agreements on acceptable terms with additional/future clinical trial sites or prospective CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different clinical trial sites; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">obtaining institutional review board (&#8220;IRB&#8221;) or Ethics Committee approval at each additional/future trial site; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">recruiting suitable patients to participate in a clinical trial; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">having subjects complete a clinical trial or return for post-treatment <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up;</div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">inspections of clinical trial sites or operations by applicable regulatory authorities, or the imposition of a clinical hold; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">clinical sites, CROs or other third parties deviating from trial protocol or dropping out of a trial; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">failure to perform in accordance with the applicable regulatory requirements, including FDA&#8217;s GCP requirements, or applicable regulatory requirements in other countries; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">addressing patient safety concerns that arise during the course of a trial, including occurrence of adverse events associated with the product candidate or the delivery procedure that are viewed to outweigh its potential benefits; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">adding a sufficient number of clinical trial sites; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">manufacturing sufficient quantities of a product candidate for use in clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">disruptions in our supply chain, which could result in improper storage, transport or development conditions for our product components, whose treatment is time-sensitive and temperature-sensitive and which are patient-specific; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">interruption of our manufacturing processes, which could lead to our inability to properly administer treatment. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize REACT or any of our future product candidates or significantly increase the cost of such trials, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes in regulatory requirements or guidance, or receive feedback from regulatory authorities that requires us to modify the design of our clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">clinical trials of REACT or our future product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon development programs; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the number of subjects required for clinical trials of REACT or our future product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or subjects may drop out of these clinical trials at a higher rate than we anticipate; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">we or our investigators might have to suspend or terminate clinical trials of REACT or our future product candidates for various reasons, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with regulatory requirements, a finding that REACT or our future product candidates have undesirable side effects or other unexpected characteristics, or a finding that the subjects are being exposed to unacceptable health risks; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the cost of clinical trials of REACT or our future product candidates may be greater than we anticipate and we may not have funds to cover the costs; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the supply or quality of REACT or our future product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">17 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">regulators may revise the requirements for approving REACT or our future product candidates, or such requirements may not be as we anticipate; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any future collaborators that conduct clinical trials may face any of the above issues, and may conduct clinical trials in ways they view as advantageous to them but that are suboptimal for us. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are required to conduct additional clinical trials or other testing of REACT or any of our future product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of REACT or our future product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">incur unplanned costs; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">be delayed in obtaining marketing approval for REACT or any of our future product candidates or not obtain marketing approval at all; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">obtain marketing approval in some countries and not in others; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">obtain marketing approval for indications or patient populations that are not as broad as intended or desired; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">obtain marketing approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings or Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">be subject to additional post-marketing testing requirements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">be subject to changes in the way the product is administered; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">have regulatory authorities withdraw or suspend their approval of the product or to impose restrictions on its distribution after obtaining marketing approval. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the Data Safety Monitoring Board (&#8220;DSMB&#8221;) for such trial or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using REACT or one of our future product candidates, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">REACT, our lead product candidate, will require extensive clinical testing before we are prepared to submit a BLA or MAA for regulatory approval. We cannot predict with any certainty if or when we might complete the clinical development for REACT and submit a BLA or MAA for regulatory approval of REACT or whether any such BLA or MAA will be approved. We may also seek feedback from the FDA, EMA or other regulatory authorities on our clinical development program, and the FDA, EMA or such regulatory authorities may not provide such feedback on a timely basis, or such feedback may not be favorable, which could further delay our development programs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are currently conducting clinical trials in foreign countries, as well as in the United States. If we continue to seek to conduct clinical trials in foreign countries or pursue marketing approvals in foreign jurisdictions, we must comply with numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries and may include all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval from foreign regulatory agencies may differ from that required to obtain FDA approval. Approval by the FDA does not ensure approval by regulatory authorities outside the United States and vice versa. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">18 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Successful completion of clinical trials is a prerequisite to submitting a marketing application to the FDA and similar marketing applications to comparable foreign regulatory authorities, for each product candidate and, consequently, the ultimate approval and commercial marketing of any product candidates. We may experience negative or inconclusive results, which may result in our deciding, or our being required by regulators, to conduct additional clinical studies or trials or abandon some or all of our product development programs, which could have a material adverse effect on our business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Any topline data or interim analyses from our nonclinical studies and clinical trials that may be announced or published from time to time may change as more data becomes available and will remain subject to audit and verification procedures that could result in material changes in the final data. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have disclosed interim analyses of certain ongoing clinical trials and may continue to disclose publicly interim or topline data from its nonclinical studies and clinical trials in the future. These interim updates will be based on a preliminary analysis of then-available data, and the results and related findings and conclusions will be subject to change following a more comprehensive review of the data related to the particular study or trial. We will be required to make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim or topline results that we may report might differ from future results of the same studies or trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Interim and topline data will remain subject to audit and verification procedures that may result in the final data being materially different from the data we previously published. As a result, any interim or topline data should be viewed with caution until the final data are available. Interim data from clinical trials that we may complete will be subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data becomes available. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate and us in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, investors or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the interim or topline data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidate may be harmed, which could harm our business, operating results, prospects or financial condition. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The regulatory approval processes of the FDA, EMA and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable. If we are not able to obtain required regulatory approval for REACT, our lead product candidate, or any of our future product candidates, our business may be materially and adversely affected. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The time required to obtain approval or other marketing authorizations by the FDA, EMA and comparable foreign authorities is unpredictable, and it typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, and the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate, and it is possible that we may never obtain regulatory approval for any product candidates we may seek to develop in the future. Neither we nor any current or future collaborator is permitted to market any biologic product candidates in the United States until we receive regulatory approval of a BLA from the FDA,&#160;and we cannot market it in the European Union until we receive approval from the FDA or approval for a MAA from the EMA, or other required regulatory approval in other </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">19 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">countries. To date, we have had only limited discussions with the regulatory agencies of the United States, the European Union, Argentina, Israel, Canada and Brazil regarding clinical development programs or regulatory approval for any product candidate within such jurisdictions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to obtaining approval to commercialize any biologic product candidate in the United States or abroad, we must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA, EMA or other foreign regulatory agencies, that such product candidates are safe and effective for their intended uses. Results from nonclinical or preclinical studies and clinical trials may be interpreted differently by different regulatory agencies. Even if we believe the nonclinical or clinical data for REACT are promising, such data may be insufficient to support approval by the FDA and other regulatory authorities. The FDA may also require us to conduct additional nonclinical studies or clinical trials for REACT either prior to or after approval, or it may object to elements of our clinical development programs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">REACT could fail to receive regulatory approval for many reasons, including the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the results of our clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the FDA or comparable foreign regulatory authorities may fail to approve our manufacturing processes or facilities of third-party suppliers with which we contract for clinical and commercial supplies; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the approval policies or regulations of the FDA or comparable foreign authorities may significantly change in a manner rendering our clinical data insufficient for approval. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Of the large number of product candidates developed by biologics manufacturers, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. The lengthy approval and marketing authorization process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval and marketing authorization to market REACT or any of our future product candidates, which would significantly harm our business, financial condition, results of operations and prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have invested a significant portion of our time and financial resources in the development of REACT. Our business is dependent on our ability to successfully complete nonclinical and clinical development of, obtain regulatory approval for, and, if approved, successfully commercialize REACT and any future product candidates in a timely manner. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if we eventually complete clinical testing and receive approval of a BLA or foreign marketing application for REACT or any future product candidates, the FDA, EMA or the applicable foreign regulatory agency may grant approval or other marketing authorization contingent on the performance of costly additional clinical trials, including post-marketing clinical trials. The FDA, EMA or the applicable foreign regulatory agency also may approve or authorize for marketing a product candidate for a more limited indication or patient population than we originally request, and the FDA, EMA or applicable foreign regulatory agency may not approve or authorize the labeling that we believe is necessary or desirable for the successful commercialization of a product candidate. Any delay in obtaining, or inability to obtain, applicable regulatory approval or other marketing authorization would delay or prevent commercialization of that product candidate and would materially adversely impact our business and prospects. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">20 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the FDA, EMA and other regulatory authorities may change their policies, issue additional regulations or revise existing regulations, or take other actions, which may prevent or delay approval of our future product candidates on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our nonclinical studies and clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of REACT or our future product candidates, or serious adverse or unacceptable side effects may be identified during the development of REACT or any of our future product candidates, which could prevent, delay or limit the scope of regulatory approval of REACT or any of our future product candidates, limit their commercialization, increase our costs or necessitate the abandonment or limitation of the development of REACT or our future product candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To obtain the requisite regulatory approvals for the commercial sale of REACT and any of our future product candidates, we must demonstrate through lengthy, complex and expensive nonclinical testing and clinical trials that our product candidates are safe, pure and potent for use in each target indication. Nonclinical testing and clinical trials are expensive and time consuming, and their outcomes are inherently uncertain. Failures can occur at any time during the development process. The outcome of nonclinical studies and early clinical trials may not be predictive of the results of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Moreover, nonclinical and clinical data are often susceptible to varying interpretations and analyses. Many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may fail to demonstrate with substantial evidence from adequate and well-controlled trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that REACT is safe and potent for its intended uses. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Possible adverse side effects that could occur with treatment with autologous cell therapy products include thrombocytopenia, chills, anemia, febrile neutropenia, diarrhea, neutropenia, vomiting, hypotension, dyspnea, cytokine release syndrome and neurotoxicity. Side effects may be unrecognized and mismanaged by medical personnel and considered unrelated due to unfamiliarity with REACT. REACT treatment necessitates a renal biopsy to obtain tissue to manufacture the bioactive component and injections to deposit the REACT into the kidney. Each intervention poses the risk of adverse events from renal bleeding that may require hospitalization, blood transfusion or surgical intervention. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A severe bleed was observed in one patient which led to the adoption of a noncutting needle design for the REACT procedure. Since then, no injection-related adverse events have been observed. If, however, any other adverse events, or other unexpected serious adverse events, occur, our clinical trials could be suspended or terminated. If we cannot demonstrate that any adverse events experienced by subjects enrolled in our current and planned clinical trials were not caused by our product candidate, the FDA, EMA or other foreign regulatory authorities could order us to cease further development of, or deny approval of, our product candidate for any or all targeted indications. Even if we are able to demonstrate that any serious adverse events experienced by subjects enrolled in our current and planned clinical trials are not product-related, such occurrences could affect patient recruitment or the ability of enrolled subjects to complete the trial. Moreover, if we elect, or are required, to not initiate, delay, suspend or terminate any future clinical trial of any of our product candidates, the commercial prospects of such product candidates may be harmed and our ability to generate product revenues from any of these product candidates may be delayed or eliminated. Any of these occurrences may harm our ability to develop other product candidates, and may harm our business, financial condition and prospects significantly. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furthermore, if REACT or any of our future product candidates is associated with undesirable effects in nonclinical studies or clinical trials or have characteristics that are unexpected, we may decide or be required to </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">21 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">perform additional nonclinical studies or to halt or delay further clinical development of our product candidates or to limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe, or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for the product candidate, if approved. The FDA, EMA, Paul-Ehrlich-Institut, an Agency of the German Federal Ministry of Health, Medical Products Agency, the government agency in Sweden, Brazilian Health Regulatory Agency, an IRB, or an independent ethics committee (&#8220;IEC&#8221;) may also require that we suspend, discontinue, or limit our clinical trials based on safety information, or that we conduct additional animal or human studies regarding the safety and efficacy of our product candidates which we have not planned or anticipated. Such findings could further result in regulatory authorities failing to provide marketing authorization for our product candidates or limiting the scope of the approved indication, if approved. Many product candidates that initially showed promise in early stage testing have later been found to cause side effects that prevented further development of the product candidate. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, if REACT or any of our future product candidates receives marketing approval, and we or others identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">regulatory authorities may suspend, withdraw or limit approvals of such product, or seek an injunction against its manufacture or distribution; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">regulatory authorities may require additional warnings on the label; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients or other requirements subject to a REMS; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may be required to change the way the product is administered or conduct additional nonclinical studies or clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we could be sued and held liable for harm caused to patients; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may decide to remove the product from the market; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may not be able to achieve or maintain third-party payor coverage and adequate reimbursement; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may be subject to fines, injunctions or the imposition of civil or criminal penalties; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our reputation and physician or patient acceptance of our products may suffer. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There can be no assurance that we will resolve any issues related to any product-related adverse events to the satisfaction of the FDA or foreign regulatory agencies in a timely manner or at all. Moreover, any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Negative public opinion and increased regulatory scrutiny of autologous cell therapy using REACT may adversely impact the development or commercial success of our current and future product candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The clinical and commercial success of REACT will depend in part on public acceptance of the use of autologous cell therapy for treatment of kidney disease. Any adverse public attitudes about the use of REACT may adversely impact our ability to enroll clinical trials. Moreover, our success will depend upon physicians prescribing, and their patients being willing to receive, treatments that involve the use of product candidates we may develop in lieu of, or in addition to, existing treatments with which they are already familiar and for which greater clinical data may be available. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of REACT or any of our future product candidates or demand for any products once approved. Adverse events in our or others&#8217; </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">22 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">clinical trials, even if not ultimately attributable to our product candidates, and the resulting publicity could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of REACT or our future product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates, all of which would have a negative impact on our business and operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We are conducting our first Phase 3 clinical trial and may be unable to successfully complete it or any future clinical trials. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The conduct of a Phase 3 clinical trial is a complicated process. Although members of our management team have conducted Phase 3 clinical trials in the past while employed at other companies, we as a company are currently conducting our first Phase 3 trial, and as a result may require more time and incur greater costs than we anticipate. Failure to include the correct treatment regimen, complete, or delays in, our Phase 3 clinical trial could prevent us from or delay us in commencing future clinical trials for REACT, obtaining regulatory approval of and commercializing REACT, which would adversely impact our financial performance. In addition, some of our competitors are currently conducting clinical trials for product candidates that treat the same indications as REACT, and patients who are otherwise eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Successful and timely completion of clinical trials will require that we enroll a sufficient number of patients. Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors, including the size and nature of the patient population and competition for patients eligible for our clinical trials with competitors which may have ongoing clinical trials for product candidates that are under development to treat the same indications as one or more of our product candidates, or approved products for the conditions for which we are developing our product candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinical trials may be subject to delays as a result of patient enrollment taking longer than anticipated or greater than anticipated subject withdrawal. We may not be able to initiate or continue clinical trials for REACT or our future product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or foreign regulatory authorities. We cannot predict how successful we will be at enrolling subjects in future clinical trials. The enrollment of patients depends on many factors, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the patient eligibility and exclusion criteria defined in the protocol; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the size and demographics of the patient population required for analysis of the clinical trial&#8217;s primary endpoints and the process for identifying patients; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">potential disruptions caused by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, including difficulties in initiating clinical sites, enrolling and retaining subjects, diversion of health care resources away from clinical trials, travel or quarantine policies that may be implemented, and other factors; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the proximity of subjects to clinical trial sites; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the design of the trial; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the availability of competing commercially available therapies and other competing product candidates&#8217; clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">23 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to obtain and maintain clinical trial subject informed consents; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the risk that subjects enrolled in clinical trials will drop out of the trials before completion. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For example, we are initially developing REACT for the treatment of CKD due to diabetes or congenital anomalies of kidney and urinary tract. In the United States, CKD is estimated to affect over 38&#160;million adults. We may encounter difficulties enrolling subjects in our clinical trials of REACT due, in part, to the stringent inclusion criteria for subjects, the novelty of the treatment modality and the fact that it involves a physically invasive procedure. In addition, our clinical trials may compete with other clinical trials for product candidates that are in the same therapeutic areas as REACT, and this competition may reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which may reduce the number of patients who are available for our clinical trials in such clinical trial site. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our inability to enroll a sufficient number of patients for clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our future clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of REACT or any of our future product candidates. Furthermore, we expect to rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and we will have limited influence over their performance. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Furthermore, due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> period of at least 24 months and the requirement for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-site</div> visits, subjects may drop out of our clinical trials at a higher rate than we anticipate or may elect to participate in alternative clinical trials sponsored by our competitors with product candidates that treat the same indications as REACT and any future product candidates. Even if we are able to enroll a sufficient number of subjects for our clinical trials, we may have difficulty maintaining enrollment of such subjects in our clinical trials. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The design or execution of our ongoing and future clinical trials may not support marketing approval. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The design or execution of a clinical trial can determine whether its results will support marketing approval, and flaws in the design or execution of a clinical trial may not become apparent until the clinical trial is well advanced. Additionally, in some instances, there can be significant variability in safety or efficacy results between different trials with the same product candidate due to numerous factors, including differences in trial protocols, size and type of the patient populations, variable adherence by investigators and subject to protocol requirements and the rate of dropout among clinical trial subjects. We do not know whether any clinical trials we conduct will demonstrate consistent or adequate efficacy and safety to obtain marketing approval to market REACT or any of our future product candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, the FDA and comparable foreign regulatory authorities have substantial discretion in the approval process and in determining when or whether marketing approval will be obtained for REACT or any of our future product candidates. REACT may not be approved even if it achieves its primary endpoints in our Phase&#160;3 clinical trials or registrational trials. The FDA or comparable foreign regulatory authorities may disagree with our trial designs and our interpretation of data from nonclinical studies or clinical trials. In addition, any of these regulatory authorities may change requirements for the approval of a product candidate even after reviewing and providing comments or advice on a protocol for a pivotal Phase&#160;3 or registrational clinical trial. In addition, any of these regulatory authorities may also approve a product candidate for fewer or more limited indications than we request or may grant approval contingent on the performance of costly post-marketing clinical trials. The FDA or comparable foreign regulatory authorities may not approve the labeling claims that we believe would be necessary or desirable for the successful commercialization of REACT or any of our future product candidates, if approved. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">24 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We have obtained RMAT Designation from the FDA for REACT, but this may not lead to a faster development or regulatory review process, and such designation does not increase the likelihood that any of our product candidates will receive marketing approval in the United States and the FDA may withdraw such designation. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We intend to evaluate regulatory strategies that could enable us to take advantage of expedited development pathways for REACT, including the RMAT designation that we have already received, although we cannot be certain that REACT will qualify for any additional expedited development pathways or that regulatory authorities will grant, or allow us to maintain, the relevant designations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RMAT designation is intended to expedite the development and review of product candidates that are designed to treat serious or life-threatening diseases and unmet need when &#8220;preliminary clinical evidence indicates that a product candidate may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development.&#8221; The designation of REACT with expedited designation provides potential benefits that include: more frequent meetings with FDA to discuss the development plan for the product candidate and ensure collection of appropriate data needed to support approval; more frequent written correspondence from FDA about such things as the design of the proposed clinical trials and use of biomarkers; intensive guidance on an efficient cell therapy program, beginning as early as Phase&#160;1; organizational commitment involving senior managers; and eligibility for rolling review and priority review if supported by clinical data at the time of the submission of the BLA. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cell and gene therapies, therapeutic tissue engineered products, human cell and tissue products, and combination products using any such therapies or products that are intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition are eligible for designation by the FDA as RMATs. The RMAT designation is intended to facilitate efficient development and expedite review of regenerative medicine therapies by offering eligibility for priority review or accelerated approval, as well as early interactions with FDA to discuss any potential surrogate or intermediate endpoint to be used to support accelerated approval. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We applied for RMAT designation for REACT, which was granted by the FDA on October&#160;28, 2021. As contemplated by the RMAT designation and as directed by the FDA, we requested a comprehensive, multidisciplinary Type B meeting with the FDA to review the status of preclinical and clinical development and manufacturing of REACT, and to discuss the planned clinical program intended to support approval of the product candidate. The FDA provided detailed written responses to our questions included in the meeting request, and the Type B meeting was held in March 2022. As a result of that meeting, we will continue to advance the USA clinical development program with the benefit of enhanced clarity as to the FDA&#8217;s expectations and requirements for a registrational program, including the design of the trials needed for approval, manufacturing assays, and comparability studies. The FDA&#8217;s input is more fully set forth under the heading &#8220;Phase 3 Clinical Development <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(REGEN-006</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-016)&#8221;</div> in the section titled &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Business of ProKidney.</div></div>&#8221; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even though we obtained RMAT designation in October 2021, such a designation does not change the standards for product approval, and there is no assurance that this designation will result in expedited review or approval or that the approved indication will not be narrower than the indication covered by RMAT designation. Thus, even though RMAT designation was granted for REACT, we may not experience a faster development process, review or marketing approval compared to conventional FDA procedures. The FDA may withdraw RMAT designation if it believes that the product no longer meets the qualifying criteria. It is also possible that the FDA could provide further input on our trial design, in which case our timelines to completion of the clinical development of REACT could be delayed. Our business may be harmed if we are unable to avail ourselves of these or any other expedited development and regulatory pathways. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">25 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because we have limited financial and management resources, we must focus on development programs and product candidates that we identify for specific indications. As such, we are only focused on the development of REACT for the treatment of CKD. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications for these product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We have conducted and may in the future continue to conduct additional clinical trials for REACT outside the United States, and the FDA and similar foreign regulatory authorities may not accept data from such trials conducted in locations outside of their jurisdiction. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We have conducted additional clinical trials for REACT in the Asia-Pacific region, European Union, and Latin America, and may in the future continue to conduct clinical trials outside the United States, including in South America, Australia, New Zealand, or other foreign jurisdictions. The acceptance of data from clinical trials conducted outside the United States by the FDA may be subject to certain conditions or may be rejected. In cases where data from clinical trials conducted outside the United States are intended to serve as the sole basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless: (i)&#160;the data are applicable to the United States population and United States medical practice; (ii)&#160;the trials were performed by clinical investigators of recognized competence; and (iii)&#160;the data may be considered valid without the need for an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-site</div> inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-site</div> inspection or other appropriate means. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory bodies have similar approval requirements. In addition, such foreign clinical trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any similar foreign regulatory authority will accept data from clinical trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any similar foreign regulatory authority does not accept such data, it would result in the need for additional clinical trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in REACT not receiving approval or clearance for commercialization in the applicable jurisdiction. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may not be successful in our efforts to identify or discover additional product candidates in the future. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our inability to design such product candidates with the pharmacological properties that we desire or attractive pharmacokinetics; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our inability to design and develop a suitable manufacturing process; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be medicines that will receive marketing approval and achieve market acceptance. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">26 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research programs to identify new product candidates require substantial technical, financial and human resources. If we are unable to identify suitable compounds for clinical development, we will not be able to obtain product revenue in future periods, which likely would result in significant harm to our financial position and adversely impact our share price. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Due to our limited resources and access to capital, we must make decisions on the allocation of resources to certain programs and product candidates; these decisions may prove to be wrong and may adversely affect our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have limited financial and human resources and intend to initially focus on research programs and product candidates for a limited set of indications. As a result, we may forgo or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success. In addition, we may seek to accelerate our development timelines, including by initiating certain clinical trials of REACT or our future product candidates before earlier-stage studies have been completed. This approach may cause us to commit significant resources to prepare for and conduct later-stage trials for one or more product candidates that subsequently fail earlier-stage clinical testing. Therefore, our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities or expend resources on product candidates that are not viable. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There can be no assurance that we will ever be able to identify additional therapeutic opportunities for REACT or our future product candidates or to develop suitable potential product candidates through internal research programs, which could materially adversely affect our future growth and prospects. We may focus our efforts and resources on potential product candidates or other potential programs that ultimately prove to be unsuccessful. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our products may be delayed or never achieved. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, we may estimate the timing of the accomplishment of various scientific, clinical, regulatory, manufacturing and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of clinical trials and the submission of regulatory filings, including IND submissions. From time to time, we may publicly announce the expected timing of some of these milestones. All of these milestones are, and will be, based on a variety of assumptions. The actual timing of these milestones can vary significantly compared to our estimates, in some cases for reasons beyond our control. We may experience numerous unforeseen events during, or as a result of, any future clinical trials that we conduct that could delay or prevent our ability to receive marketing approval or commercialize REACT or any of our future product candidates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to the Manufacturing of REACT and Our Future Product Candidates </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cell therapies are complex and difficult to manufacture, and we could experience manufacturing problems that result in delays in the development or commercialization of REACT, our lead product candidate, or otherwise harm our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The manufacture of cell therapy products is technically complex and necessitates substantial expertise and capital investment. Production difficulties caused by unforeseen events may delay the availability of material for our clinical trials. Further, we are not aware of any other cell therapy that has been manufactured for a market of the anticipated size for REACT. If REACT is approved for commercial sale, as to which no assurance can be given, we may be unable to meet market demand for the product in a timely manner due to the complex processes that are involved in its manufacturing. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, all entities involved in the preparation of therapeutics for clinical trials or commercial sale are subject to extensive cGMP, state and federal regulations, as well as foreign requirements when applicable. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">27 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with cGMP regulations. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of adventitious agents or other contaminants, or to inadvertent changes in the properties or stability of REACT that may not be detectable in final product testing. We must supply all necessary documentation in support of a BLA or MAA on a timely basis. Our facilities and quality systems, including those of any third parties we contract with to manufacture any critical component of the final product, must pass <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a&#160;pre-approval&#160;inspection</div> for compliance with the applicable regulations as a condition of regulatory approval of REACT or any of our other potential products. In addition, the FDA and other regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the preparation of REACT or our other potential products or the associated quality systems for compliance with the regulations applicable to the activities being conducted at such facilities, and they could put a hold on one or more of our clinical trials if our facilities, or those of our contracted third parties, do not pass such audits or inspections. If such facilities do not pass <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a&#160;pre-approval&#160;plant</div> inspection, FDA approval of the products will not be granted. Any failure to adhere to or document compliance with such regulatory requirements could lead to a delay or interruption in the availability of REACT for clinical trials or enforcement action from the FDA, EMA or foreign regulatory authorities. If we or our suppliers were to fail to comply with the requirements of the FDA, EMA or other regulatory authority, it could result in regulatory actions or sanctions being imposed on us, including the issuance of FDA Form 483 notices of inspectional observations, warning letters or untitled letters, clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of REACT. Our potential future dependence upon others for the manufacture of REACT may also adversely affect our future profit margins and our ability to commercialize REACT or any future product candidates that receive regulatory approval on a timely and competitive basis. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Biological products are inherently difficult to manufacture. REACT is manufactured using technically complex processes requiring specialized equipment and facilities, highly specific raw materials, autologous cells collected from patients, and reagents, and the process involves various production constraints. Even though we aim to have backup supplies of raw materials and reagents whenever possible, we cannot be certain they will be sufficient if our primary sources are unavailable. A shortage of a critical raw material or reagent, or a technical issue during manufacturing may lead to delays in clinical development or commercialization plans. Any changes in the manufacturing of components of the raw materials we use could result in unanticipated or unfavorable effects in our manufacturing processes, resulting in delays. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Delays or failures in the manufacture of cell therapies can result in a patient being unable to receive their cell therapy or a requirement to re-manufacture which itself then causes delays in manufacture for other patients. Any delay or failure or inability to manufacture on a timely basis can adversely affect a patient&#8217;s outcomes and delay the timelines for our clinical trials. Such delays or failure or inability to manufacture can result from: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a failure in the manufacturing process itself, for example by an error in manufacturing equipment or reagent failure, failure in any step of the manufacturing process, failure to maintain a cGMP environment or failure in quality systems applicable to manufacture, sterility failures, or contamination during process; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product loss or failure due to logistical issues associated with the collection of a patient&#8217;s autologous cells or other samples, shipping that material to analytical laboratories, and shipping the final cell therapy back to the location using cold chain distribution where it will be administered to the patient, manufacturing issues associated with the differences in patient starting materials, inconsistency in cell growth and variability in product characteristics; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a lack of reliability or reproducibility in the manufacturing process itself, leading to variability in end manufacture of the cell therapy, which may lead to regulatory authorities placing a hold on a clinical </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">28 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">trial or requesting further information on the process, which could in turn result in delays to the clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">product loss or failure due to logistical issues including issues associated with the differences between patients&#8217; autologous cells or characteristics, interruptions to process, contamination, failure to supply patient apheresis material within required timescales (for example, as a result of an import or export <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">hold-up)</div> or supplier error; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">inability to have enough manufacturing slots to manufacture cell therapies for patients as and when those patients require manufacture; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">inability to procure starting materials or to manufacture starting materials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">interruptions in our supply chain, which may require us to find an alternative manufacturer or supplier for one or more components that we need in the manufacture of REACT, which would in turn require such manufacturer or supplier to be qualified through a BLA and/or MAA supplement, could lead the regulatory agencies to require additional studies if a new manufacturer is relied upon for commercial production, and may involve substantial costs and delays related to switching manufacturers; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">loss of or close-down of any manufacturing facility used in the manufacture of our cell therapies, or the inability to find alternative manufacturing capability in a timely fashion; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">loss or contamination of patient starting material, requiring the starting material to be obtained again from the patient or the manufacturing process to be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-started;</div> and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a requirement to modify or make changes to any manufacturing process, which may also require comparability testing that delays our ability to make the required modifications or perform any required comparability testing in a timely fashion, require further regulatory approval or require successful tech transfer to CMOs to continue manufacturing. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These factors could cause the delay of clinical trials, regulatory submissions, required approvals or commercialization of REACT, cause us to incur higher costs and prevent us from commercializing REACT successfully, if approved. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our current costs of manufacturing REACT for use in our ongoing Phase 2 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RMCL-002</div> study are approximately $100,000 per patient. We anticipate that these costs will be lower for our Phase 3 trials and that the costs will continue to decrease by up to 50% from the costs of manufacturing REACT for our Phase 2 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RMCL-002</div> study as we manufacture REACT at commercial scale with implementation of automation, bioprocess developments, formulation improvements and streamlining of the supply chain. We expect to utilize automation in all aspects of manufacturing ranging from tissue processing, cell expansion and renal cell selection to formulation and filling of the final product. We will also extend automation to other manufacturing activities, including warehouse operations and supply chain. In addition, we intend to improve bioprocess development to further reduce manufacturing costs of the commercial REACT product, assuming receipt of necessary regulatory approvals. Culture media represents the highest cost in REACT processing, and we are exploring reduced culture media usage via bioprocess and automation improvements. Further, our final commercial REACT product is planned to be a cryopreserved formulation, which is projected to reduce manufacturing costs compared to our fresh REACT formulation. We expect to leverage bulk purchasing to actively negotiate pricing of materials to further drive cost reductions. However, there can be no assurance that the manufacturing costs for our Phase 3 trials when we manufacture REACT at commercial scale will actually be lower than for our ongoing Phase 2 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RMCL-002</div> study. A number of factors may contribute to an inability to achieve these cost reductions, including any failures to achieve the automation efficiencies that we anticipate, cost overruns or inefficiencies in the supply chain, and any failure to improve the formulation or bioprocessing of REACT in a manner that results in lower costs. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">29 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We have our own manufacturing capabilities, which may result in increased costs being incurred by us. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our manufacturing facility for REACT is within our Winston-Salem facility in North Carolina, and this facility currently manufactures SRCs for use in our clinical trials. Regulatory authorities, in particular the FDA, might not continue to approve our ability to manufacture SRCs or other cell therapies at the Winston-Salem facility. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to successfully manufacture our own cell therapies at the Winston-Salem facility within a reasonable period of time and within currently projected costs is dependent on a number of factors, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to recruit the required employees at a suitable level and experience and within required timescales and to maintain employment of such required employees; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to obtain regulatory approval for the facility and for the manufacture of cell therapies at the facility and to satisfy regulatory authorities on an ongoing basis; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to manufacture cell therapies reliably and reproducibly and to timescales sufficient to support required patient administration; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to manufacture cell therapies in compliance with the applicable regulatory requirements, including requirements applicable in both the United States and the European Union, including cGMP, enforced by the FDA and state regulatory authorities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to develop internal quality controls and processes sufficient to enable manufacture and supply of cell therapies at our Winston-Salem facility; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to establish comparability with currently used manufacturing processes and for such comparability data to be accepted by the appropriate regulatory authorities; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to fund ongoing development, including equipment requirements necessary for successful manufacture of cell therapies at our facility. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any delay or failure in manufacture at our facility could result in delays to the supply of cell therapies for our clinical trials. Should we become unable to produce cell therapies for use in our clinical trials or be unable to produce cell therapies at the required level, then we will be unable to support such clinical trials until alternative manufacturing capability is secured. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our autologous cell therapy products are patient-specific, and we need to ensure that the correct product is administered to the correct patient. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Administration of autologous cell therapies is patient-specific and personalized medicine. The process requires careful handling of patient-specific products and fail-safe tracking to ensure that the tracking process is without error and that patient samples are tracked from patient collection, through manufacturing and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-administration</div> to the same patient. While such mechanisms are in place, should the tracking process fail, whether at our own facility, a third-party facility or at any point in the manufacturing and supply process, a patient could receive another patient&#8217;s SRCs, resulting in significant toxicity and potentially patient fatality. We will need to invest in enhanced systems, such as bar coding, to further ensure fail-safe tracking. There is always a risk of a failure in any such system. Inability to develop or adopt an acceptable fail-safe tracking methodology and handling regime may delay or prevent us from receiving regulatory approval and/or result in significant toxicity and potentially patient fatality if a patient receives another patient&#8217;s SRCs. This risk may be increased where autologous cell therapies are used in clinical trials that we do not control or sponsor and, should an error be made in the administration of our autologous cell therapies in such clinical trials, this could affect the steps required in our own clinical trials and manufacturing process requiring the addition of further tracking mechanisms to ensure fail-safe tracking. The tracking systems required to further ensure safe patient administration may also require enhanced procedures and administration to satisfy other regulatory requirements, for example, data protection requirements in Europe. The need to ensure tracking systems are adequate and to </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">30 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">comply with these additional regulatory requirements may result in delay to the start of clinical trials or the need to obtain additional regulatory licenses or consents prior to starting such trials. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Delays in obtaining regulatory approval of the manufacturing process and facility to produce REACT or disruptions in the manufacturing process may delay or disrupt our commercialization efforts. Very few cGMP cell therapy manufacturing facilities in the United States have received approval from the FDA for the manufacture of an approved cell therapy product. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Before we can begin to commercially manufacture REACT or any of our future product candidates, we must obtain regulatory approval from the FDA for our manufacturing processes and for the facility in which manufacturing is performed. A manufacturing authorization must also be obtained from the appropriate EU regulatory authorities prior to commercialization in the European Union. Very few cGMP cell therapy manufacturing facilities in the United States have received approval from the FDA for the manufacture of an approved cell therapy product and, therefore, the timeframe required for us to obtain regulatory approval for our product candidates is uncertain. In addition, we must pass a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approval</div> inspection of the manufacturing facility, including any facilities that produce any component of REACT, by the FDA and other relevant regulatory&#160;authorities before REACT or any of our future cell therapy product candidates can obtain marketing approval. In response to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, on March&#160;10, 2020, the FDA announced its intention to postpone most inspections of foreign manufacturing facilities while local, national and international conditions warrant. On March&#160;18, 2020, the FDA announced its intention to temporarily postpone routine surveillance inspections of domestic manufacturing facilities. Subsequently, on&#160;July&#160;10,&#160;2020, the&#160;FDA&#160;announced its intention to resume certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-site&#160;inspections</div> of domestic manufacturing facilities subject to a risk-based&#160;prioritization system. The FDA intends to use this risk-based&#160;assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Additionally, on April&#160;15, 2021, the FDA issued a guidance document in which the FDA described its plans to conduct voluntary remote interactive evaluations of certain therapeutic manufacturing facilities and clinical research sites. According to the guidance, the FDA intends to request such remote interactive evaluations in situations where an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-person&#160;inspection</div> would not be prioritized or deemed mission-critical, or where direct inspection is otherwise limited by travel restrictions, but where the FDA determines that remote evaluation would still be appropriate. However, on December&#160;29, 2021, the FDA announced that due to the rapid spread of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> omicron variant, certain inspections, such as domestic and foreign preapproval, surveillance, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">for-cause</div> inspections that are not deemed mission-critical, would be postponed through January&#160;19, 2022, and that the agency would reassess plans to resume foreign inspections. Should the FDA determine that an inspection is necessary for approval of a new drug application (&#8220;NDA&#8221;) and an inspection cannot be completed during the review cycle due to restrictions on travel, and the FDA does not determine a remote interactive evaluation to be adequate, the FDA has stated that it generally intends to issue a complete response letter or defer action on the application until an inspection can be completed. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19&#160;pandemic</div> and may experience delays in their regulatory activities. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, upon completion of this offering and in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to obtain approval, we will need to ensure that all of our processes, quality systems, methods, equipment, policies and procedures are compliant with cGMP and other applicable regulations, and perform extensive audits of vendors, contract laboratories, and suppliers. If any of our vendors, contract laboratories, or suppliers is found to be out of compliance with cGMP or other applicable regulations relating to REACT, we may experience delays or disruptions in manufacturing while we work with such third parties to remedy the violation or while we work to identify suitable replacement vendors. The cGMP requirements govern, among </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">31 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">other things, quality control of the manufacturing process and documentation policies and procedures. In complying with cGMP regulations, we will be obligated to spend time, money and effort in production, record keeping and quality control to assure that the product meets applicable specifications and other requirements. If we fail to comply with these requirements, we may be subject to regulatory enforcement actions or other legal sanctions and may not be permitted to sell any products that we may develop. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any problems in our manufacturing process or facilities could make us a less attractive collaborator for potential partners, including larger pharmaceutical companies and academic research institutions, which could limit our access to additional attractive development programs. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We do not have experience as a company managing a complex supply chain or satisfying manufacturing-related regulatory requirements. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA, the EMA and other foreign regulatory authorities may require us to submit samples of any lot of any approved product together with the protocols showing the results of applicable lot release tests at any time. Under some circumstances, the FDA, the EMA or other foreign regulatory authorities may require that we not distribute a product lot until the relevant agency authorizes its release. Slight deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in a cell therapy product that could lead to lot failures or product recalls. Lot failures or product recalls could cause us to delay product launches or clinical trials, which could be costly to us and otherwise harm our business, financial condition, results of operations and prospects. Problems in our manufacturing processes could restrict our ability to meet market demand for our products. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Managing an autologous&#160;ex vivo&#160;cell therapy supply chain is highly complex.&#160;We must identify, engage, and coordinate with treatment centers where patients&#8217; cellular source material must be collected, prepared and transported to the manufacturing facility and the cryopreserved therapeutic product must be returned to the treatment center for administration to the patient using controlled temperature shipping containers. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Once collected from the patient, the cellular source material must be prepared and stored according to specified procedures. While we intend to standardize the processes at treatment centers, if there is a deviation of the processes, the cellular source material from a patient could be adversely impacted and potentially result in manufacturing failures. The patient&#8217;s cellular materials must be transported to the manufacturing facility using a shipping container that maintains the material at a sufficiently cold temperature and must typically be delivered and processed within four days of collection. While we intend to use reputable couriers and agents for the transport of such materials, if the shipping container is opened or damaged such that the appropriate storage/shipping temperature is not maintained, the cellular source material may be adversely impacted and it may not be feasible to manufacture a cell therapy product for the patient. Similarly, if a shipment is delayed due to adverse weather, misrouting, being held up at a customs point, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> impacts or other events, the cellular source material may not be delivered within a time window that will allow for its use for the successful manufacture of a cell therapy product. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Similarly, the patient&#8217;s autologous cell therapy product must be returned to the clinical site for administration to the patient using a specialized shipping container that maintains the material at a very low temperature. While we intend to use reputable couriers and agents for the transport of our products, if the shipping container is opened or damaged such that the very low temperature is not maintained, the cell therapy product may be adversely impacted and it may not be feasible to administer it to the patient or, if administered, it could cause harm to the patient. Similarly, if a shipment is delayed due to adverse weather, misrouting, being held up at a customs point, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> impacts or other events, and is not delivered to the clinical site within the time period that the very low temperature is maintained, the cell therapy product may be adversely affected and be unable to be administered or, if administered, could cause harm to the patient. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may be delayed or unable to identify, engage, successfully coordinate with or qualify treatment centers in the regions we are targeting as part of our commercial launch strategy, which could delay or prevent patients </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">32 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">from receiving cell therapy treatments, if approved.&#160;For example, due to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19-related</div></div> travel restrictions, some <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-person</div> visits to qualify certain potential treatment centers were postponed or required to take place remotely.&#160;If our treatment centers fail to perform satisfactorily, we may suffer reputational, operational, and business harm. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any of the above events, should they happen, could adversely affect our development timelines and our business, financial condition, results of operations and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We depend on third-party suppliers for materials that are necessary for the conduct of clinical trials of REACT, our lead product candidate, and the loss of these third-party suppliers or their inability to supply us with sufficient quantities of adequate materials, or to do so at acceptable quality levels and on a timely basis, could harm our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Manufacturing REACT, our lead product candidate, requires many reagents, which are substances used in our manufacturing processes to bring about chemical or biological reactions, and other specialty materials and equipment, some of which are manufactured or supplied by small companies with limited resources and experience to support commercial biologics production. We currently depend on a limited number of vendors for certain materials and equipment used in the manufacture of REACT. Some of these suppliers may not have the capacity to support clinical trials and commercial products manufactured under cGMP by biopharmaceutical firms or may otherwise be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ill-equipped</div> to support our needs. We also do not have supply contracts with many of these suppliers and may not be able to obtain supply contracts with them on acceptable terms or at all. Accordingly, we may experience delays or interruption in receiving key materials and equipment to support clinical or commercial manufacturing. Any significant delay or interruption in the supply of components or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-assemblies,</div> or our inability to obtain substitute components, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-assemblies</div> or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand of our customers and harm our business. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For some of these reagents, equipment, and materials, we rely and may in the future rely on sole source vendors or a limited number of vendors. The supply of the reagents and other specialty materials and equipment that are necessary to produce REACT could be reduced or interrupted at any time. In such case, identifying and engaging an alternative supplier could result in delay, and we may not be able to find other acceptable suppliers on acceptable terms, or at all. Switching suppliers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. If we change suppliers for commercial production, applicable regulatory agencies may require us to conduct additional studies or trials. If key suppliers are lost, or if the supply of the materials is diminished or discontinued, we may not be able to develop, manufacture and market REACT in a timely and competitive manner, or at all. An inability to continue to source products from any of these suppliers, which could be due to a number of issues, including regulatory actions or requirements affecting the supplier, adverse financial or other strategic developments experienced by a supplier, labor disputes or shortages, unexpected demands or quality issues, could adversely affect our ability to satisfy demand for REACT, which could adversely and materially affect our product sales and operating results or our ability to conduct clinical trials, either of which could significantly harm our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As we continue to develop and scale our manufacturing process, we expect that we will need to obtain rights to and supplies of certain materials and equipment to be used as part of that process. We may not be able to obtain rights to such materials or equipment on commercially reasonable terms, or at all, and if we are unable to alter our process in a commercially viable manner to avoid the use of such materials or equipment or find a suitable substitute, it would have a material adverse effect on our business. Even if we are able to alter our process so as to use other materials or equipment, such a change may lead to a delay in our clinical development and/or commercialization plans. If such a change occurs for product candidate that is already in clinical development, the change may require us to perform both<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;ex vivo</div></div>&#160;comparability studies and to collect additional data from subjects prior to undertaking more advanced clinical trials. These factors could cause the delay of nonclinical studies or clinical trials, regulatory submissions, required approvals or commercialization of REACT </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">33 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">or future product candidates that we develop, cause us to incur higher costs and prevent us from commercializing our product candidates successfully. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Any microbial contamination in the manufacturing process for our cell-based product, shortages of raw materials or failure of any of our key suppliers to deliver necessary components could result in delays in our clinical development or marketing schedules. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Given the nature of cell product manufacturing, there is a risk of microbial contamination. Any microbial contamination could adversely affect our ability to produce, release or administer our cell therapies on schedule and could, therefore, harm our results of operations and cause reputational damage. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some of the raw materials required in our manufacturing processes are derived from biologic sources. Such raw materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of REACT could adversely impact or disrupt the commercial manufacturing or the production of clinical material, which could adversely affect our development timelines and our business, financial condition, results of operations and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">REACT requires cryopreservation with specific storage, handling and administration at the clinical sites. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">REACT requires cryopreservation and must be stored at very low temperatures in specialized freezers or specialized shipping containers until immediately prior to use. For administration, the cryopreserved product container must be carefully removed from storage, rapidly thawed under controlled temperature conditions in an area proximal to the patient&#8217;s bedside and immediately administered to the patient. The handling, thawing and administration of the cryopreserved cell therapy product must be performed according to specific instructions, typically using specific disposables, and some steps must be completed within specific time periods. Failure to correctly handle the product, follow the instructions for thawing and administration and or failure to administer the product within the specified period post-thaw could negatively impact the efficacy and or safety of the product. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As product candidates progress through clinical trials to marketing approval and commercialization, various aspects of the development program, such as manufacturing methods and the product&#8217;s formulation, may be altered along the way in an effort to optimize yield, manufacturing batch size, minimize costs and achieve consistent quality and results. These changes carry the risk that they will not achieve their intended objectives. Any of these changes could cause REACT or any of our future product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of our ongoing or planned clinical trials, require us to perform bridging clinical trials or repeat one or more clinical trials, increase clinical trial costs, delay any potential approval of REACT or any of our future product candidates and jeopardize our ability to commercialize REACT or any of our future product candidates and generate revenue. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, there are risks associated with process development and large-scale manufacturing for clinical trials or commercial distribution including, among others, cost overruns, potential problems with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">process&#160;scale-up,&#160;process</div> reproducibility, stability issues, compliance with cGMP, lot consistency and timely availability of raw materials. Even if we obtain marketing approval for any of our product candidates, there is no assurance that we will be able to manufacture the approved product to specifications acceptable to the FDA or other comparable foreign regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential commercial launch of the product or to meet potential future demand. Additionally, the manufacturing processes for biological products is more complex and expensive than with small-molecule </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">34 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">products, and additional manufacturing suppliers may be needed to manufacture clinical trial supplies for these development programs. If we are unable to produce sufficient quantities for clinical trials or for commercialization, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our current operations are concentrated in a number of locations, including a single manufacturing facility in North Carolina. We or the third parties upon whom we depend may be adversely affected by earthquakes, wildfires or other natural disasters, as well as epidemics, pandemics and other incidents, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics or pandemics, power shortage, telecommunication failure or other natural or manmade accidents or incidents that result in us being unable to fully utilize our facilities may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of REACT or any of our future product candidates or interruption of our business operations. Earthquakes, wildfires or other natural disasters could further disrupt our operations, and have a material and adverse effect on our business, financial condition, results of operations and prospects. If a natural disaster, power outage or other event prevented us from using all or a significant portion of our manufacturing facilities, or otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place, including use of contract manufacturers and inherent risks associated therewith with respect to technology transfer and quality issues, may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption may have a material and adverse effect on our business, financial condition, results of operations and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to the Commercialization of REACT and Our Future Product Candidates </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Even if REACT or a future product candidate we develop receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if REACT or any other product candidates we develop receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors, such as Medicare and Medicaid programs and managed care organizations, and others in the medical community. In addition, the availability of coverage by third-party payors may be affected by existing and future health care reform measures designed to reduce the cost of health care. If the product candidates we develop do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The degree of market acceptance of any product candidate, if approved for commercial sale, will depend on a number of factors, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the efficacy and potential advantages of our current or future product candidates compared to alternative treatments; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product labeling or product insert requirements of the FDA, EMA or other foreign regulatory authorities, including any limitations or warnings contained in a product&#8217;s approved labeling, including any black box warning or REMS; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">35 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the clinical indications for which our current or future product candidates are approved; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">availability of alternative treatments already approved or commercially launched in the future; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the ability to offer our products, if approved, for sale at competitive prices; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">convenience and ease of administration compared to alternative treatments; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies, including where there may be a perception that our therapies, if approved, involve an increased risk of adverse events; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the recommendations with respect to our product candidates in guidelines published by various scientific organizations applicable to us and our product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the strength of marketing and distribution support; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any restrictions on the use of our products together with other medications; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to hire and retain a sales force in the United States; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the ability to obtain sufficient third-party coverage and adequate reimbursement for our products, including necessary reimbursement codes; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the prevalence and severity of any side effects; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the ability to obtain Current Procedural Terminology (&#8220;CPT&#8221;) Codes and Resource-Based Relative Value Scale for appropriate provider reimbursement; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the ability to obtain designated International Classification of Diseases <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;ICD-10&#8221;)</div> codes from the WHO for disease designation; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">willingness of provider proceduralists to perform invasive kidney procedures that may cause increased medical liability from procedural-related or cell based adverse events; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the ability to provide advanced procedural training for delivery of product candidates. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales of cell-based products also depend on the willingness of physicians to prescribe the treatment, which is likely to be based on a determination by these physicians that the products are safe, therapeutically effective and cost effective. In addition, the inclusion or exclusion of products from treatment guidelines established by various physician groups and the viewpoints of influential physicians can affect the willingness of other physicians to prescribe the treatment. We cannot predict whether physicians, physicians&#8217; organizations, hospitals, other health care providers, government agencies or private insurers will determine that our products are safe, therapeutically effective and cost effective as compared with competing treatments. If any product candidate is approved but does not achieve an adequate level of acceptance by such parties, we may not generate or derive sufficient revenue from that product candidate and may not become or remain profitable. If government and other third-party payors do not provide coverage and adequate reimbursement levels for any products we commercialize, market acceptance and commercial success would be reduced. REACT is percutaneously injected into the kidney and requires additional proceduralist technical training with possible ongoing maintenance of certification. Facilities where REACT is delivered may require additional cell-based licensing by state, federal or laboratory certification agencies and require equipment with appropriate technology and inventories. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may have to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell any products for which we obtain regulatory approval, we may not be able to generate product revenue. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have no internal sales, marketing or distribution capabilities, nor have we commercialized a product. If REACT or any of our future product candidates ultimately receives regulatory approval, we expect to establish a </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">36 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize each such product in major markets, which will be expensive and time consuming. We have no prior experience as a company in the marketing, sale and distribution of biopharmaceutical products and there are significant risks involved in building and managing a sales organization. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Factors that may inhibit our efforts to market our products on our own include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the inability of sales personnel to obtain access to physicians in order to educate physicians about our product candidates, including product administration and product delivery, once approved; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">unforeseen costs and expenses associated with creating an independent sales and marketing organization. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may also choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute any products that we develop and for which we receive regulatory approval ourselves. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we are not successful in commercializing our products, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The affected populations for REACT or any of our future product candidates may be smaller than we or third parties currently project, which may affect the addressable markets for REACT or our future product candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our projections of the number of people who have the diseases we are seeking to treat, as well as the subset of people with these diseases who have the potential to benefit from treatment with REACT or any of our future product candidates, are estimates based on our knowledge and understanding of these diseases. These estimates may prove to be incorrect, and new studies, medications, or medical practices may further reduce the estimated incidence or prevalence of this disease. The number of patients in the United States, the European Union and elsewhere may turn out to be lower than expected, may not be otherwise amenable to treatment with REACT or any of our future product candidates or patients may become increasingly difficult to identify and access, all of which would adversely affect our business, financial condition, results of operations and prospects. Further, even if we obtain approval for REACT or any of our future product candidates, the FDA or other regulators may limit their approved indications to more narrow uses or subpopulations within the populations for which we are targeting development of REACT or any of our future product candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The total addressable market opportunity for REACT or any of our future product candidates will ultimately depend upon a number of factors including the diagnosis and treatment criteria included in the final label, if </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">37 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">approved for sale in specified indications, acceptance by the medical community, patient access and product pricing and reimbursement. Incidence and prevalence estimates are frequently based on information and assumptions that are not exact and may not be appropriate, and the methodology is forward-looking and speculative. The process we have used in developing an estimated incidence and prevalence range for the indications we are targeting has involved collating limited data from multiple sources. Accordingly, the incidence and prevalence estimates included in this prospectus should be viewed with caution. Further, the data and statistical information used in this prospectus, including estimates derived from them, may differ from information and estimates made by our competitors or from current or future studies conducted by independent sources. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Obtaining and maintaining regulatory approval of REACT or any of our future product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of REACT or future product candidates in other jurisdictions. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Obtaining and maintaining regulatory approval of REACT or any of our future product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, similar foreign regulatory authorities must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval and licensure procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining similar foreign regulatory approvals and compliance with similar foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of REACT or any of our future product candidates will be harmed. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Off-label</div> use or misuse of our products may harm our reputation in the marketplace, result in injuries that lead to costly product liability suits, and/or subject us to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with any product. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">If we have any product candidate approved, our product labeling, advertising, and promotion will be subject to regulatory requirements and continuing regulatory review. In the United States, the FDA and the FTC strictly regulate the promotional claims that may be made about pharmaceutical products to ensure that any claims about such products are consistent with regulatory approvals, not misleading or false, and adequately substantiated by clinical data. The promotion of a medicine or biologic product in a manner that is false, misleading, unsubstantiated, or for unapproved (or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label)</div> uses may result in enforcement letters, inquiries and investigations and civil and criminal sanctions by the FDA, FTC, and other regulatory authorities. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses, we may become subject to significant liability. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses, and a company that is found to have improperly </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">38 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">promoted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses may be subject to significant sanctions and may result in false claims litigation under federal and state statutes, which can lead to consent decrees, civil monetary penalties, restitution, criminal fines and imprisonment, and exclusion from participation in Medicare, Medicaid and other federal and state health care programs. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> promotion. The government has also required that companies enter into consent decrees and/or imposed permanent injunctions under which specified promotional conduct is changed or curtailed. Any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> use of REACT or any of our future product candidates could harm our reputation in the marketplace among physicians and patients. There may also be increased risk of injury to patients if physicians attempt to use our products for these uses for which they are not approved, which could lead to product liability suits that might require significant financial and management resources and that could harm our reputation. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, advertising and promotion of any product candidate that obtains approval outside of the United States will be heavily scrutinized by comparable foreign regulatory authorities and stakeholders. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">REACT and our future product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated, and our operating results will suffer if we fail to compete effectively. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if we are successful in achieving regulatory approval to commercialize a product candidate ahead of our competitors, REACT or any of our future product candidates may face competition from biosimilar products. In the United States, REACT is expected to be regulated by the FDA as a biological product, and we intend to seek approval for REACT pursuant to the BLA pathway. The Biologics Price Competition and Innovation Act of 2009 (the &#8220;BPCIA&#8221;) created an abbreviated pathway for FDA approval of biosimilar and interchangeable biological products based on a previously licensed reference product. Under the BPCIA, an application for a biosimilar biological product cannot be approved by the FDA until 12 years after the original reference biological product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for REACT. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We believe that any of our current or future product candidates approved as a biological product under a BLA should qualify for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-year</div> period of exclusivity available to reference biological products. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference biological products pursuant to its interpretation of the exclusivity provisions of the BPCIA for competing products, potentially creating the opportunity for generic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-on</div> biosimilar competition sooner than anticipated. Moreover, the extent to which a biosimilar product, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-biological</div> products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing, including whether a future competitor seeks an interchangeability designation for a biosimilar of one of our products. Under the BPCIA as well as state pharmacy laws, only interchangeable biosimilar products are considered substitutable for the reference biological product without the intervention of the health care provider who prescribed the original biological product. However, as with all prescribing decisions made in the context of a patient-provider relationship and a patient&#8217;s specific medical needs, health care providers are not restricted from prescribing biosimilar products in an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> manner. In addition, a competitor could decide to forego the abbreviated approval pathway available for biosimilar products and to submit a full BLA for product licensure after completing its own nonclinical studies and clinical trials. In such a situation, any exclusivity to which we may be eligible under the BPCIA would not prevent the competitor from marketing its biological product as soon as it is approved. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In Europe, the European Commission has granted marketing authorizations for several biosimilar products pursuant to a set of general and product class-specific guidelines for biosimilar approvals issued over the past few years. In addition, companies may be developing biosimilar products in other countries that could compete with our products, if approved. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">39 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If competitors are able to obtain marketing approval for biosimilars referencing our product candidates, if approved, our future products may become subject to competition from such biosimilars, whether or not they are designated as interchangeable, with the attendant competitive pressure and potential adverse consequences. Such competitive products may be able to immediately compete with us in each indication for which our product candidates may have received approval. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Competitor companies or hospitals may be able to take advantage of EU rules permitting sales of unlicensed medicines for individual patients to sell competing products without a marketing authorization. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The EU medicines rules allow individual member states to permit the supply of a medicinal product without a marketing authorization to fulfill special needs, where the product is supplied in response to a bona fide unsolicited order, formulated in accordance with the specifications of a health care professional and for use by an individual patient under his direct personal responsibility.&#160;This may in certain countries also apply to products manufactured in a country outside the European Union and imported to treat specific patients or small groups of patients.&#160;In addition, designated advanced therapy medicinal products (&#8220;ATMPs&#8221;) do not need a marketing authorization if they are prepared on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-routine</div> basis and are used within the same EU member state in a hospital in accordance with a medical prescription for an individual patient. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These exemptions could allow our competitors to make sales in the EU without having obtained a marketing authorization and without undergoing the expense of clinical trials, especially if those competitors have cell processing facilities in the relevant EU member state.&#160;Similarly, certain hospitals may be able to compete with us on the basis of these rules.&#160;Because any such sales would be made without a marketing authorization, there would be no need for the competitor company or hospital to refer to the clinical data in our marketing authorization dossiers, and so any data exclusivity protection that we may obtain for our products would not prevent such competing sales. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Coverage and reimbursement may be limited or unavailable in certain market segments for REACT or our future product candidates, if approved, which could make it difficult for us to sell any product candidates profitably. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In the United States and in other countries, patients who are prescribed treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. In the United States, sales of any products for which we may receive regulatory marketing approval will depend, in part, on the availability of coverage and reimbursement from third-party payors. Third-party payors include government authorities such as Medicare, Medicaid, TRICARE, and the Veterans Administration, managed care providers, private health insurers, and other organizations. Coverage and adequate reimbursement from governmental health care programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Even if any of our products obtains regulatory approval, patients are unlikely to use such products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost. We cannot be sure that coverage and reimbursement will be available for, or accurately estimate the potential revenue from, any of our products, if approved, or assure that coverage and reimbursement will be available for any product that we may develop. REACT, due to the novel cell therapy and new indication for CKD, may require formulation of CPT codes with resource-based relative value unit appropriation and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ICD-10</div> designation. Each are obtained through different processes and may lead to reimbursement delays of unknown lengths of times. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government authorities and other third-party payors decide which treatments they will cover and the amount of reimbursement. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#8217;s determination that use of a product is: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a covered benefit under its health plan; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">40 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%; font-size: 0px;"></td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">safe, effective and medically necessary; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">appropriate for the specific patient; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">supported by peer-reviewed medical journals; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">included in clinical practice guidelines; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">cost-effective; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">neither experimental nor investigational. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to commercialize successfully any of our products for which we obtain regulatory approval will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from third-party payors, including government health care programs and private health insurers. Moreover, a payor&#8217;s decision to provide coverage for a biopharmaceutical product does not imply that an adequate reimbursement rate will be approved. If coverage and adequate reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize REACT or any of our future product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for our products can differ significantly from payor to payor. As a result, obtaining coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our products on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">payor-by-payor</div></div> basis, with no assurance that coverage and adequate reimbursement will be obtained. Even if we obtain coverage for a given product, the resulting reimbursement payment rates might not be adequate for us to achieve or sustain profitability or may require <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payments</div> that patients find unacceptably high. Additionally, third-party payors may not cover, or provide adequate reimbursement for, long-term <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> evaluations required following the use of product candidates, once approved. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for REACT or any of our future product candidates, if approved. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes to current laws and state and federal health care reform measures that may be adopted in the future may result in additional reductions in Medicare and other health care funding and otherwise affect the prices we may obtain for any product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If product liability lawsuits are brought against us, we may incur substantial financial or other liabilities and may be required to limit commercialization of REACT or our future product candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We face an inherent risk of product liability as a result of testing REACT or any of our future product candidates in clinical trials and will face an even greater risk if we commercialize any products. For example, we may be sued if REACT or any of our future product candidates causes or is perceived to cause injury or are found to be otherwise unsuitable during clinical trials, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of REACT or any of our future product candidates. Even a successful defense of these claims would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">inability to bring a product candidate to the market; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">decreased demand for our products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">41 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">injury to our reputation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">withdrawal of clinical trial subjects and inability to continue clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">initiation of investigations by regulators; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">significant costs to defend the related litigation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reduced resources of our management to pursue our business strategy; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">substantial monetary awards to trial subjects; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product recalls, withdrawals or labeling, marketing or promotional restrictions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">loss of revenue; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">exhaustion of any available insurance and our capital resources; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the inability to commercialize any products that we may develop; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">decline in our share price. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop. We will need to obtain additional insurance for clinical trials as REACT continues clinical development and as additional product candidates enter the clinic. However, we may be unable to obtain, or may obtain on unfavorable terms, clinical trial insurance in amounts adequate to cover any liabilities from any of our clinical trials. Our insurance policies may also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we or any contract manufacturers and suppliers we engage, now or in the future, fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could substantially harm our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We and any CMOs and suppliers we engage, now or in the future, are subject to numerous federal, state and local environmental, health, and safety laws, regulations, and permitting requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment and disposal of hazardous and regulated materials and wastes; the emission and discharge of hazardous materials into the ground, air and water; and employee health and safety. Our operations involve the use of hazardous materials, including chemicals and biological materials. Our operations also produce hazardous waste. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. Under certain environmental laws, we could be held responsible for costs relating to any contamination at our current or past facilities and at third-party facilities. We also could incur significant costs associated with civil or criminal fines and penalties. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our research, product development and manufacturing efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty, and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">42 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended, which could substantially harm our business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Our Reliance on Third Parties </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We rely on third parties to conduct, supervise and monitor a certain portion of our research and nonclinical testing and clinical trials for REACT, and if those third parties do not successfully carry out their contractual duties, comply with regulatory requirements or otherwise perform satisfactorily, we may not be able to obtain regulatory approval or commercialize REACT, or such approval or commercialization may be delayed, and our business may be substantially harmed. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We depend, or may depend in the future, upon third parties to conduct certain aspects of our nonclinical studies and clinical trials, and to monitor and manage data, under agreements with universities, medical institutions, CROs, strategic collaborators and others. We expect to have to negotiate budgets and contracts with such third parties, which may result in delays to our development timelines and increased costs. We expect to continue to rely on third parties, including clinical CROs, medical institutions and clinical investigators, to conduct those clinical trials. If any of our relationships with these third-party CROs or others terminate, we may not be able to enter into arrangements with alternative CROs or other third parties or to do so on commercially reasonable terms, if at all. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO begins work. As a result, delays may occur, which can materially impact our ability to meet our desired development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. Further, the performance of our CROs and other third parties conducting our trials may also be interrupted by the ongoing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, including due to travel restrictions, quarantine policies, heightened exposure of CRO or clinical site or other vendor staff who are health care providers to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> or prioritization of resources toward the pandemic. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Any third parties conducting aspects of our nonclinical studies or clinical trials will not be our employees and, except for remedies that may be available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our nonclinical studies and clinical trials. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the nonclinical or clinical data they obtain is compromised due to the failure to adhere to our protocols or regulatory requirements or for other reasons, or if due to federal or state orders or absenteeism due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic they are unable to meet their contractual and regulatory obligations, our product development timelines, including clinical development timelines, may be extended, delayed or terminated, and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize REACT. As a result, our financial results and the commercial prospects for REACT would be harmed, our costs could increase and our ability to generate revenue could be delayed. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We will rely especially heavily on third parties over the course of our clinical trials and will have limited control over the clinical investigators and limited visibility into their <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> activities, including with respect to their compliance with the approved clinical trial protocol. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical development. Regulatory authorities enforce these GCP requirements through periodic inspections of </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">43 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">trial sponsors, clinical investigators and clinical trial sites. If we or any of these third parties fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to suspend or terminate these trials or perform additional nonclinical studies or clinical trials before approving our marketing applications. We cannot be certain that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the GCP requirements. In addition, our clinical trials must be conducted with biologic product produced under cGMP, and likely cGTP regulations and will require a large number of test subjects. Our failure or any failure by our contracted third parties, including CROs, to comply with these regulations or to recruit a sufficient number of subjects may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or health care privacy and security laws. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We also are required to register certain ongoing clinical trials and post the results of certain completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within specified timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval for REACT or any of our future product candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We also expect to rely on other third parties to store and distribute product supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of REACT or any of our future product candidates or commercialization of REACT or any of our future product candidates, producing additional losses and depriving us of potential revenue. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We rely on third parties for materials, including tissue samples, required for our research and development activities, and if we are unable to reach agreements with these third parties our research and development activities would be delayed.<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px"> </div> </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We rely on third parties, primarily hospitals, health clinics and academic institutions, for the provision of tissue samples and other materials required in our research and development activities. Obtaining these materials requires various approvals as well as reaching a commercial agreement on acceptable terms with the hospital or other provider of the materials. While we currently have agreements in place with the institutions from which we receive our tissue samples, we do not have any exclusive arrangements with such sources and there is no guarantee that we will be able to maintain or renew such agreements on commercially reasonable terms, if at all. If we were unable to maintain or renew such agreements we would be forced to seek new arrangements with new hospitals, clinics or health institutions. If so, we may not be able to reach agreements with alternative partners or do so on terms acceptable to us. If we are unable to enter into such agreements, our research and development activities will be delayed and our ability to implement a key part of our development strategy will be compromised. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may in the future seek to enter into collaborations with third parties for the development and commercialization of REACT and/or our future product candidates, and our future collaborations will be important to our business. If we are unable to enter into collaborations, or if these collaborations are not successful, our business could be adversely affected. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A part of our strategy is to consider partnerships in indications and geographies where we believe partners can add significant commercial and/or development capabilities. Further, we have limited capabilities for product </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">44 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">development and do not yet have any capability for commercialization. Accordingly, we have entered into and may in the future enter into collaborations with other companies to provide us with important technologies and funding for our programs and technology. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any future collaborations we enter into may pose a number of risks, including the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">collaborators have significant discretion in determining the efforts and resources that they will apply; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">collaborators may not perform their obligations as expected; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs or license arrangements based on clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors, such as a strategic transaction that may divert resources or create competing priorities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products and product candidates if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of REACT or our future product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">collaborators may fail to comply with applicable regulatory requirements regarding the development, manufacture, distribution or marketing of a product candidate or product; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">collaborators with marketing and distribution rights to REACT or one or more of our future product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">collaborators may not provide us with timely and accurate information regarding development progress and activity under any future license agreement, which could adversely impact our ability to report progress to our investors and otherwise plan development of REACT or our future product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or terminations of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">if a collaborator of ours is involved in a business combination, the collaborator might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">collaborations may be terminated by the collaborator, and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">45 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If any future collaborations we enter into do not result in the successful discovery, development and commercialization of product candidates or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under such collaboration. All of the risks relating to product development, regulatory approval and commercialization described in this prospectus also apply to the activities of our collaborators. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, if one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our perception in the business and financial communities could be adversely affected. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We face significant competition in seeking appropriate collaborators for REACT and future product candidates, and the negotiation process is time-consuming and complex. In order for us to successfully establish a collaboration for REACT or any of our future product candidates, potential collaborators must view these product candidates as economically valuable in markets they determine to be attractive in light of the terms that we are seeking and other available products for licensing by other companies. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large biopharmaceutical companies that have resulted in a reduced number of potential future collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms, or at all. If we fail to enter into future collaborations or do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop REACT or future product candidates, bring them to market and generate revenue from sales of such products or continue to develop our technology, and our business may be materially and adversely affected. Even if we are successful in our efforts to establish new strategic collaborations, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such strategic collaborations if, for example, development or approval of a product candidate is delayed or sales of an approved product are disappointing. Any delay in entering into new strategic collaboration agreements related to REACT or our future product candidates could delay their development and commercialization and reduce their competitiveness even if it reaches the market. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Legal and Regulatory Compliance Matters </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our relationships with customers, health care providers, physicians, prescribers, purchasers, third-party payors, charitable organizations and patients will be subject to applicable anti-kickback, fraud and abuse and other health care laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although we do not currently have any products on the market, upon commercialization of REACT or any of our future product candidates, if approved, we will be subject to additional health care statutory and regulatory requirements and oversight by federal and state governments in the United States as well as foreign governments in the jurisdictions in which we conduct our business. Health care providers, including physicians, in the United States and elsewhere play a primary role in the recommendation and prescription of biopharmaceutical products. Arrangements with third-party payors and customers can expose biopharmaceutical manufacturers to broadly applicable fraud and abuse and other health care laws and regulations, including, without limitation, the federal Anti-Kickback Statute (the &#8220;AKS&#8221;) and the FCA, which may constrain the business or financial arrangements and relationships through which such companies sell, market and distribute biopharmaceutical products. In </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">46 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">particular, the research of REACT or any of our future product candidates, as well as the promotion, sales and marketing of health care items and services, as well as certain business arrangements in the health care industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The health care laws that may affect us include: the federal fraud and abuse laws, including the AKS; false claims and civil monetary penalties laws, including the FCA and Civil Monetary Penalties Law; federal data privacy and security laws, including HIPAA, as amended by HITECH; and the federal Physician Payments Sunshine Act related to ownership and investment interests and payments and/or other transfers of value made to or held by physicians (including doctors, dentists, optometrists, podiatrists, and chiropractors) and teaching hospitals and, beginning in 2022, information regarding payments and transfers of value provided to other health care professionals, such as physician assistants and nurse practitioners among others, during the previous year. In addition, many states have similar laws and regulations that may differ from each other and federal law in significant ways, thus complicating compliance efforts. Moreover, several states require biopharmaceutical companies to comply with the biopharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require manufacturers to report information related to payments and other transfers of value to physicians and other health care providers or marketing expenditures. Additionally, some state and local laws require the registration of biopharmaceutical sales representatives in the jurisdiction. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of health care reform, especially in light of the lack of applicable precedent and regulations. Ensuring business arrangements comply with applicable health care laws, as well as responding to possible investigations by government authorities, can be time- and resource-consuming and can divert a company&#8217;s attention from other aspects of its business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other health care laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, reputational harm, possible exclusion from participation in federal and state funded health care programs, contractual damages and the curtailment or restricting of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with these laws. Further, if any of the physicians or other health care providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded health care programs. Any action for violation of these laws, even if successfully defended, could cause a biopharmaceutical manufacturer to incur significant legal expenses and divert management&#8217;s attention from the operation of the business. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Prohibitions or restrictions on sales or withdrawal of future marketed products could materially affect business in an adverse way. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Even if we receive regulatory approval of any product candidates, we will be subject to ongoing regulatory oversight and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with REACT or any of our future product candidates. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If REACT or any of our future product candidates is approved, activities such as the manufacturing, labeling, packaging, storage, advertising, promotion, sampling, and record keeping for the products will be </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">47 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP and cGTP regulations. Biopharmaceutical manufacturers and any CMOs responsible for any product manufacturing processes are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP and cGTP regulations and any applicable foreign equivalents. As such, we and any CMOs we may employ in the future will be subject to continual review and inspections to assess compliance with cGMP and cGTP and adherence to commitments made in any BLA, other marketing application, and previous responses to inspection observations. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production and quality control. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA or a comparable foreign regulatory authority may also impose requirements for costly post-marketing nonclinical studies or clinical trials (often called Phase 4 trials) and post-marketing surveillance to monitor the safety or efficacy of the product. If we or a regulatory authority discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, production problems or issues with the facility where the product is manufactured or processed, such as product contamination or significant noncompliance with applicable cGMP regulations, a regulator may impose restrictions on that product, the manufacturing facility or us. If we or our third-party providers fail to comply fully with applicable regulations, then we may be required to initiate a recall or withdrawal of our products. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Later discovery of previously unknown problems with REACT or any of our future product candidates, including adverse events of unanticipated severity or frequency, or with our manufacturing processes, or failure to comply with regulatory requirements, may result in the following, among other things: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">restrictions on the manufacturing of the product, the approved manufacturers or the manufacturing process; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">restrictions on the labeling or marketing of a product; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">restrictions on product distribution or use; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">requirements to conduct post-marketing studies or clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">withdrawal of the product from the market; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product recalls; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">warning or untitled letters from the FDA or comparable notice of violations from foreign regulatory authorities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">refusal of the FDA or other applicable regulatory authority to approve pending applications or supplements to approved applications; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">fines, restitution or disgorgement of profits or revenues; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">suspension or withdrawal of marketing approvals; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">suspension of any of our ongoing clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product seizure or detention or refusal to permit the import or export of products; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">consent decrees, injunctions or the imposition of civil or criminal penalties. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, regulatory authorities&#8217; policies (such as those of the FDA or EMA) may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of REACT or any of our future product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are otherwise not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">48 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-compliance</div> with EU requirements regarding safety monitoring or pharmacovigilance can also result in significant financial penalties. Similarly, failure to comply with the European Union&#8217;s requirements regarding the protection of personal information can also lead to significant penalties and sanctions. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA&#8217;s policies may change and additional government regulations may be enacted that could prevent, limit or delay marketing approval of REACT or any of our future product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Changes in health care policies, laws and regulations, including legislative measures aimed at reducing health care costs, may impact our ability to obtain approval for, or commercialize REACT or any of our future product candidates, if approved. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed reforms of the health care system made in an effort to contain costs, improve quality and expand access to care. In the United States, there have been and continue to be a number of health care-related legislative initiatives, as well as executive, judicial and Congressional challenges to existing health care laws that have significantly affected, and could continue to significantly affect, the health care industry. For example, on June&#160;17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, together with subsequent amendments and regulations (collectively, the &#8220;ACA&#8221;), is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January&#160;28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, which began on February&#160;15, 2021 and remained open through August&#160;15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to health care, including, among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. In addition, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to medicines pricing, reduce the cost of prescription medicines under government payor programs and review the relationship between pricing and manufacturer patient programs. We expect that additional U.S. federal health care reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for health care products and services, which could result in reduced demand for REACT or any of our future product candidates or additional pricing pressures. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">49 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Disruptions at the FDA and other agencies may also slow the time necessary for new products to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical employees and stop critical activities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Separately, the FDA has announced its commitment to achieving timely reviews of applications for medical products during the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic in line with its user fee performance goals; however, the FDA may not be able to continue its current pace and review timelines could be extended, including where a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approval</div> inspection or an inspection of clinical sites is required and due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and travel restrictions FDA is unable to complete such required inspections during the review period. In response to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and the subsequent waves of infection due to variants of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">SARS-CoV-2,</div></div> the FDA postponed most routine inspections of foreign and domestic manufacturing facilities but continued to conduct mission-critical according to a risk-based prioritization system. During this period, the FDA issued a guidance document describing the FDA&#8217;s plans to conduct voluntary remote interactive assessments of certain drug manufacturing facilities and clinical research sites in situations where an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-person</div> inspection would not be prioritized or deemed mission-critical, or where direct inspection is otherwise limited by travel restrictions, but where the FDA determines that remote evaluation would still be appropriate. After a significant decline in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> cases across the United States in the beginning of 2022, the FDA resumed domestic surveillance inspections on February&#160;7, 2022 and is conducting inspections of foreign manufacturing facilities for which the foreign country has provided clearance and is within the CDC&#8217;s Level&#160;1 or 2 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> travel recommendation. Despite the resumption of normal inspection activities, the FDA continues to employ remote assessments as a tool for evaluating regulatory compliance of foreign and domestic facilities. However, if another rapid rise in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> cases occurs, the FDA may decide to postpone foreign and domestic inspections again. In such a situation, should the FDA require an inspection for approval of an NDA or BLA, but one cannot be completed during the review cycle due to travel restrictions, and the agency decides a remote interactive evaluation would be inadequate, the FDA has previously stated its general intent to issue a complete response letter or defer action on such applications until an inspection can be completed. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and may experience delays in their regulatory activities. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">EU medicine marketing and reimbursement regulations may materially affect our ability to market and receive coverage for our products in the European member states. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We intend to seek approval to market REACT in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for REACT, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in the European Union, the pricing of medicines and cell based therapeutics is subject to governmental control and other market regulations which could put pressure on the pricing and usage of REACT. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. In addition, market acceptance and sales of REACT will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for REACT and may be affected by existing and future health care reform measures. Additionally, the international regulatory landscape related to reimbursement is uncertain, and likely will continue to evolve before we are able to commercialize REACT. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Much like the federal AKS prohibition in the United States, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the European Union. The provision of benefits or advantages to </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">50 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">physicians is governed by the national anti-bribery laws of EU Member States, and in respect of the United Kingdom (which is no longer a member of the European Union), the UK Bribery Act 2010. Infringement of these laws could result in substantial fines and imprisonment. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments made to physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, in most foreign countries, including the European Economic Area (the &#8220;EEA&#8221;), the proposed pricing for a medicine must be approved before it may be lawfully marketed. The requirements governing medicine pricing and reimbursement vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Reference pricing used by various EU member states and parallel distribution, or arbitrage between <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">low-priced</div> and high-priced member states, can further reduce prices. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. In some countries, we may be required to conduct a clinical study or other studies that compare the cost-effectiveness of any of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. In addition, these regulations are evolving and subject to change, possibly before we are able to commercialize REACT. There can be no assurance that any country that has price controls or reimbursement limitations for biopharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and generally prices tend to be significantly lower. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales and the potential profitability of any of our product candidates in those countries would be negatively affected. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may incur substantial costs in our efforts to comply with evolving global data protection laws and regulations, and any failure or perceived failure by us to comply with such laws and regulations may harm our business and operations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The global data protection landscape is rapidly evolving, and we may be or become subject to or affected by numerous federal, state and foreign laws and regulations, as well as regulatory guidance, governing the collection, use, disclosure, transfer, security and processing of personal data, such as information that we collect about subjects and health care providers in connection with clinical trials. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, which may create uncertainty in our business, affect our or our service providers&#8217; ability to operate in certain jurisdictions or to collect, store, transfer use and share personal data, result in liability or impose additional compliance or other costs on us. Any failure or perceived failure by us to comply with federal, state, or foreign laws or self-regulatory standards could result in negative publicity, diversion of management time and effort and proceedings against us by governmental entities or others. Recently, California passed the California Consumer Privacy Act of 2018 (the &#8220;CCPA&#8221;), which went into effect in January 2020 and provides new data privacy rights for consumers and new operational requirements for companies, which may increase our compliance costs and potential liability. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. While there is currently an exception for protected health </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">51 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">information that is subject to HIPAA and clinical trial regulations, as currently written, the CCPA may impact certain of our business activities. The CCPA may lead to similar laws in other U.S. states or at a national level, which could increase our potential liability and adversely affect our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition to our operations in the United States, which may be subject to health care and other laws relating to the privacy and security of health information and other personal information, we are conducting, and we may conduct in the future, clinical trials in EEA and may become subject to additional European data privacy laws, regulations and guidelines. The General Data Protection Regulation, (EU) 2016/679 (&#8220;GDPR&#8221;) became effective on May&#160;25, 2018, and deals with the collection, use, storage, disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals in the EEA. The GDPR imposes a broad range of strict requirements on companies subject to the GDPR, including requirements relating to having legal bases for processing personal information relating to identifiable individuals and transferring such information outside the EEA, including to the United States, providing details to those individuals regarding the processing of their personal health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, keeping personal information secure, having data processing agreements with third parties who process personal information, responding to individuals&#8217; requests to exercise their rights in respect of their personal information, reporting security breaches involving personal data to the competent national data protection authority and affected individuals, appointing data protection officers, conducting data protection impact assessments, and record-keeping. The GDPR increases substantially the penalties to which we could be subject in the event of any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance,</div> including fines of up to &#8364;10,000,000 or up to 2% of our total worldwide annual turnover for certain comparatively minor offenses, or up to &#8364;20,000,000 or up to 4% of our total worldwide annual turnover, whichever is greater, for more serious offenses. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR includes restrictions on cross-border data transfers. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, national laws of member states of the European Union are in the process of being adapted to the requirements under the GDPR, thereby implementing national laws which may partially deviate from the GDPR and impose different obligations from country to country, so that we do not expect to operate in a uniform legal landscape in the EEA. Also, as it relates to processing and transfer of genetic data, the GDPR specifically allows national laws to impose additional and more specific requirements or restrictions, and European laws have historically differed quite substantially in this field, leading to additional uncertainty. The United Kingdom&#8217;s decision to leave the European Union, often referred to as Brexit, has created uncertainty with regard to data protection regulation in the United Kingdom. In particular, it is unclear how data transfers to and from the United Kingdom will be regulated now that the United Kingdom has left the European Union. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are conducting clinical trials in the EEA, and the GDPR increases our responsibility and liability in relation to personal data that we process where such processing is subject to the GDPR, and we are required to have in place additional mechanisms and safeguards to ensure compliance with the GDPR, including as implemented by individual countries. Compliance with the GDPR is a rigorous and time-intensive process that increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our European activities. We expect that we will continue to face uncertainty as to whether our efforts to comply with any obligations under European privacy laws will be sufficient. If we are investigated by a European data protection authority, we may face fines and other penalties. Any such investigation or charges by European data protection authorities could have a negative effect on our existing business and on our ability to attract and retain new clients or biopharmaceutical partners. We may also experience hesitation, reluctance, or refusal by European or multi-national vendors or biopharmaceutical partners to continue to use our products due to the potential risk exposure as a result of the current (and, in particular, future) data protection obligations imposed on them by certain data protection authorities in interpretation of current law, including the GDPR. Such vendors or biopharmaceutical partners may also view any alternative approaches to compliance as being too costly, too </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">52 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">burdensome, too legally uncertain, or otherwise objectionable and therefore decide not to do business with us. Any of the forgoing could materially harm our business, prospects, financial condition and results of operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Legal, political and economic uncertainty relating to our international operations could negatively impact or restrict our operations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the result of a referendum in 2016, Brexit took effect on January&#160;31, 2020. Pursuant to the formal withdrawal arrangements agreed to by the United Kingdom and the European Union, as of January&#160;1, 2021, the United Kingdom is no longer subject to the transition period during which EU rules continued to apply (the &#8220;Transition Period&#8221;). Negotiations between the United Kingdom and the European Union are expected to continue in relation to the customs and trading relationship between the United Kingdom and the European Union following the expiry of the Transition Period. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Since a significant proportion of the regulatory framework in the United Kingdom is applicable to our business, and REACT, our lead product candidate, is derived from EU directives and regulations, Brexit, following the Transition Period, could materially impact the regulatory regime with respect to the development, manufacture, importation, approval and commercialization of REACT in the United Kingdom or the European Union. For example, as a result of the uncertainty surrounding Brexit, the EMA relocated to Amsterdam from London. Following the Transition Period, the United Kingdom will no longer be covered by the centralized procedures for obtaining <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">EU-wide</div> marketing authorizations from the EMA, and unless a specific agreement is entered into, a separate process for authorization of cell-based products will be required in the United Kingdom, the potential process for which is currently unclear. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, would prevent us from commercializing REACT in the United Kingdom or the European Union and limit our ability to generate revenue and achieve and sustain profitability. In addition, we may be required to pay taxes or duties or be subjected to other hurdles in connection with the importation of REACT into the European Union, or we may incur expenses in establishing a manufacturing facility in the European Union in order to circumvent such hurdles. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom or the European Union for REACT, or incur significant additional expenses to operate our business, which could significantly and materially harm or delay our ability to generate revenues or achieve profitability of our business. Any further changes in international trade, tariff and import/export regulations as a result of Brexit or otherwise may impose unexpected duty costs or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">other&#160;non-tariff&#160;barriers</div> on us. These developments, or the perception that any of them could occur, may significantly reduce global trade and, in particular, trade between the impacted nations and the United Kingdom. It is also possible that Brexit may negatively affect our ability to attract and retain employees, particularly those from the European Union. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. The FCPA prohibits any U.S. individual or business entity from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the biopharmaceutical industry, because in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals and health care providers in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> nationals, of information products classified for national security purposes, as well as certain products, technology and technical data relating to those products. As we expand our </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">53 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">operations throughout the world, we will be required to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations. We can face serious consequences for violations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Among other matters, U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations (collectively, the &#8220;Trade Laws&#8221;) prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors, and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We plan to engage third parties for clinical trials and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals and we can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our executive officers, directors, security holders and their respective affiliates may have competitive pecuniary interests that conflict with our interests. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have not adopted a policy that expressly prohibits our directors, executive officers, security holders or affiliates from having a direct or indirect pecuniary or financial interest in any investment to be acquired or disposed of by us or in any transaction to which we are a party or have an interest. Nor do we have a policy that expressly prohibits any such persons from engaging for their own account in business activities of the types conducted by us. Accordingly, such persons or entities may have a conflict between their interests and ours. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Charter provides that we renounce, to the maximum extent permitted by law, our interest in any corporate opportunity offered to any director who is not also an employee of the Company or about which any such director acquires knowledge unless such opportunity is expressly offered to such person solely in his or her capacity as a director of the Company and such opportunity is one we are legally and contractually permitted to undertake and would otherwise be reasonable for us to pursue. In addition, our Charter contains provisions to exculpate and indemnify, to the maximum extent permitted by law, such persons in respect of any liability, obligation or duty to our company that may arise as a consequence of such persons becoming aware of any business opportunity or failing to present such business opportunity. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The personal and financial interests of our directors and officers may result in a conflict of interest and may result in a breach of their fiduciary duties to us as a matter of Cayman Islands law and we or our shareholders might have a claim against such individuals for infringing on our shareholders&#8217; rights. See the section titled &#8220;Description of ProKidney Securities&#8212;Certain Differences in Corporate Law&#8212;Shareholders&#8217; Suits&#8221; for further information on the ability to bring such claims. However, we might not ultimately be successful in any claim we may make against them for such reason. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">54 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Because we are incorporated under the laws of the Cayman Islands, you may face difficulties in protecting your interests, and your ability to protect your rights through the U.S. federal courts may be limited. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are an exempted company incorporated under the laws of the Cayman Islands. As a result, it may be difficult for investors to effect service of process within the United States upon our directors or executive officers, or enforce judgments obtained in the United States courts against our directors or officers. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our corporate affairs will be governed by our Charter, the Cayman Islands Companies Act and the common law of the Cayman Islands. We will also be subject to the federal securities laws of the United States. The rights of shareholders to take action against the directors, actions by minority shareholders and the fiduciary responsibilities of our directors to us under Cayman Islands law are to a large extent governed by the common law of the Cayman Islands. The common law of the Cayman Islands is derived in part from comparatively limited judicial precedent in the Cayman Islands as well as from English common law, the decisions of whose courts are of persuasive authority, but are not binding on a court in the Cayman Islands. The rights of our shareholders and the fiduciary responsibilities of our directors under Cayman Islands law are different from what they would be under statutes or judicial precedent in some jurisdictions in the United States. In particular, the Cayman Islands has a different body of corporate and securities laws as compared to the United States, and certain states, such as Delaware, may have more fully developed and judicially interpreted bodies of corporate law. In addition, Cayman Islands companies may not have standing to initiate a shareholder derivative action in a Federal court of the United States. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have been advised by our Cayman Islands legal counsel that the courts of the Cayman Islands are unlikely (i) to recognize or enforce against us judgments of courts of the United States predicated upon the civil liability provisions of the federal securities laws of the United States or any state; and (ii) in original actions brought in the Cayman Islands, to impose liabilities against us predicated upon the civil liability provisions of the federal securities laws of the United States or any state, so far as the liabilities imposed by those provisions are penal in nature. In those circumstances, although there is no statutory enforcement in the Cayman Islands of judgments obtained in the United States, the courts of the Cayman Islands will recognize and enforce a foreign money judgment of a foreign court of competent jurisdiction without retrial on the merits based on the principle that a judgment of a competent foreign court imposes upon the judgment debtor an obligation to pay the sum for which judgment has been given provided certain conditions are met. For a foreign judgment to be enforced in the Cayman Islands, such judgment must be final and conclusive and for a liquidated sum, and must not be in respect of taxes or a fine or penalty, inconsistent with a Cayman Islands judgment in respect of the same matter, impeachable on the grounds of fraud or obtained in a manner, or be of a kind the enforcement of which is, contrary to natural justice or the public policy of the Cayman Islands (awards of punitive or multiple damages may well be held to be contrary to public policy). A Cayman Islands court may stay enforcement proceedings if concurrent proceedings are being brought elsewhere. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result of all of the above, public shareholders may have more difficulty in protecting their interests in the face of actions taken by management, members of the board of directors or controlling shareholders than they would as public shareholders of a United States company. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Our Intellectual Property </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our business will depend in large part on obtaining and maintaining patent, trademark and trade secret protection of our proprietary technologies and REACT, our lead product candidate, its respective components, synthetic intermediates, formulations, combination therapies, methods used to manufacture them and methods of treatment, as well as successfully defending these patents against third-party challenges. Our ability to stop unauthorized third parties from making, using, selling, offering to sell or importing REACT is dependent upon the extent to which we have rights under valid and enforceable patents that cover these activities and whether a </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">55 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">court would issue an injunctive remedy. If we are unable to secure and maintain patent protection for any product or technology we develop, or if the scope of the patent protection secured is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to commercialize any product candidates we may develop may be adversely affected. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The patenting process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. The patenting process is subject to numerous risks and there can be no assurance that we will be successful in obtaining patents for which we have applied. In addition, we may not pursue, obtain, or maintain patent protection in all relevant markets. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or license to third parties and are reliant on our licensors or licensees. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The strength of patents in the biotechnology and biopharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> may fail to result in issued patents with claims that cover REACT or uses thereof in the United States or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our technology, including REACT, or prevent others from designing around the claims in our patents. If the breadth or strength of protection provided by the patent applications we hold with respect to REACT is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, REACT. Further, if we encounter delays in our clinical trials, the period of time during which we could market REACT under patent protection would be reduced. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We cannot be certain that we were the first to file any patent application related to our technology, including REACT, and, if we were not, we may be precluded from obtaining patent protection for our technology, including REACT. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We cannot be certain that we are the first to invent the inventions covered by pending patent applications and, if we are not, we may be subject to priority disputes. Furthermore, for United States applications in which all claims are entitled to a priority date before March&#160;16, 2013, an interference proceeding can be provoked by a third party or instituted by the United States Patent and Trademark Office (the &#8220;USPTO&#8221;) to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. Similarly, for United States applications in which at least one claim is not entitled to a priority date before March&#160;16, 2013, derivation proceedings can be instituted to determine whether the subject matter of a patent claim was derived from a prior inventor&#8217;s disclosure. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may be required to disclaim part or all of the term of certain patents. There may be prior art of which we are not aware that may affect the validity or enforceability of a patent or patent application claim. There also may be prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. No assurance can be given that if challenged, our patents would be declared by a court to be valid or enforceable or that even if found valid and enforceable, would adequately protect REACT, or would be found by a court to be infringed by a competitor&#8217;s technology or product. We may analyze patents or patent applications of our competitors that we believe are relevant to our activities, and consider that we are free to operate in relation to REACT, but our competitors may achieve issued claims, including in patents we consider to be unrelated, which block our efforts or may potentially result in REACT or our activities infringing such claims. The possibility exists that others will develop products which have the same effect as our products on an independent basis which do not infringe our patents or other intellectual property rights, or will design around the claims of patents that may issue that cover our products. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">56 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Recent or future patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. Under the enacted Leahy-Smith America Invents Act (the &#8220;America Invents Act&#8221;) after March 2013, the United States moved from a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;first-to-invent&#8221;</div></div> to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;first-to-file&#8221;</div></div> system. Under a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;first-to-file&#8221;</div></div> system, assuming the other requirements for patentability are met, the first inventor to file&#160;a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. The America Invents Act includes a number of other significant changes to U.S. patent law, including provisions that affect the way patent applications are prosecuted, redefine prior art and establish a new post-grant review system. In addition, the courts have yet to address many of these provisions and the applicability of the America Invents Act and new regulations on specific patents discussed herein, for which issues have not been determined and would need to be reviewed. However, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">others may be able to make or use compounds that are similar to the compositions of REACT but that are not covered by the claims of our patents or those of our licensors; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">we or our licensors, as the case may be, may fail to meet our obligations to the U.S. government in regards to any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patents and patent applications invented or developed using U.S. government funding, leading to the loss of patent rights; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we or our licensors, as the case may be, might not have been the first to file patent applications for these inventions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">others may independently develop similar or alternative technologies or duplicate any of our technologies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">it is possible that our pending patent applications will not result in issued patents; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">it is possible that there are prior public disclosures that could invalidate our or our licensors&#8217; patents, as the case may be, or parts of our or their patents; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">it is possible that others may circumvent our owned or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patents; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims covering our products or technology similar to ours; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the laws of foreign countries may not protect our or our licensors&#8217;, as the case may be, proprietary rights to the same extent as the laws of the United States; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the claims of our owned or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> issued patents or patent applications, if and when issued, may not cover REACT; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">our owned or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> issued patents may not provide us with any competitive advantages, may be narrowed in scope, or be held invalid or unenforceable as a result of legal challenges by third parties; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the inventors of our owned or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patents or patent applications may become involved with competitors, develop products or processes which design around our patents, or become hostile to us or the patents or patent applications on which they are named as inventors; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">it is possible that our owned or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patents or patent applications omit individual(s) that should be listed as inventor(s) or include individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or unenforceable; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">57 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we have engaged in scientific collaborations in the past, and will continue to do so in the future. Such collaborators may develop adjacent or competing products to ours that are outside the scope of our patents; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we may not develop additional proprietary technologies for which we can obtain patent protection; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">it is possible that product candidates or diagnostic tests we develop may be covered by third parties&#8217; patents or other exclusive rights; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">if any of our owned or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patents or applications were made with U.S. government funds, it is possible that the U.S. government may assert certain <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">march-in</div> rights to force us or our licensor to grant a license to third-parties to allow them to practice the claimed invention; or </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the patents of others may have an adverse effect on our business. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may enter into license or other collaboration agreements in the future that may impose certain obligations on us. If we fail to comply with our obligations under such future agreements with third parties, we could lose license rights that may be important to our future business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In connection with our efforts to expand our pipeline of product candidates, we may enter into certain licenses or other collaboration agreements in the future pertaining to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> of rights to additional candidates. Such agreements may impose various diligence, milestone payment, royalty, insurance or other obligations on us. If we fail to comply with these obligations, our licensor or collaboration partners may have the right to terminate the relevant agreement, in which event we would not be able to develop or market the products covered by such licenses or agreements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the scope of rights granted under the license agreement and other interpretation-related issues; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the extent to which REACT, our lead product candidate, or any other product candidate&#8217;s technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the sublicensing of patent and other rights under our collaborative development relationships; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the inventorship and ownership of inventions and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the priority of invention of patented technology. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the agreements under which we may license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations, and prospects. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, we may have limited control over the maintenance and prosecution of these <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patents and patent applications, or any other intellectual property that may be related to our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> intellectual </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">58 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">property. For example, we cannot be certain that such activities by any future licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. We have limited control over the manner in which our licensors initiate an infringement proceeding against a third-party infringer of the intellectual property rights, or defend certain of the intellectual property that is licensed to us. It is possible that the licensors&#8217; infringement proceeding or defense activities may be less vigorous than had we conducted them ourselves. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be negatively impacted, and our business and competitive position would be harmed. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In addition to patent protection, we rely heavily upon <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and trade secret protection, as well as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-disclosure</div> agreements and invention assignment agreements with our employees, consultants and third-parties, to protect our confidential and proprietary information, especially where we do not believe patent protection is appropriate or obtainable. In addition to contractual measures, we try to protect the confidential nature of our proprietary information using physical and technological security measures. Such measures may not, for example, in the case of misappropriation of a trade secret by an employee or third-party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such misconduct may not provide an adequate remedy to protect our interests fully. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, trade secrets may be independently developed by others in a manner that could prevent legal recourse by us. If one or more third parties obtain or are otherwise able to replicate these techniques, an important feature and differentiator of our clinical development strategy will become available to potential competitors. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any such information was independently developed by a competitor, our competitive position could be harmed. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, courts outside the United States are sometimes less willing to protect trade secrets. If we choose to go to court to stop a third-party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual or entity during the course of the party&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary technology by third parties. We also plan to adopt policies and conduct training that provides guidance on our expectations, and our advice for best practices, in protecting our trade secrets. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Third-party claims of intellectual property infringement may be costly and time consuming to defend and could prevent or delay our product discovery, development and commercialization efforts. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our commercial success depends in part on our ability to develop, manufacture, market and sell REACT, our lead product candidate, and use our proprietary technologies without infringing the proprietary rights of third </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">59 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and biopharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, derivation,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;inter partes</div></div>&#160;review, post-grant review, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that REACT and/or proprietary technologies infringe their intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing REACT. As the biotechnology and biopharmaceutical industries expand and more patents are issued, the risk increases that REACT may give rise to claims of infringement of the patent rights of others. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Purple Book Continuity Act, enacted in December 2020 under Title II &#167; 325, directs the FDA for the first time to publicly list certain patent information in the &#8220;Purple Book,&#8221; a database of approved biological products. Specifically, a reference product sponsor (&#8220;RPS&#8221;) is required to provide to FDA the list of patents and corresponding expiry dates (referred to here as the &#8220;initial list&#8221;), not later than 30 days after the RPS has provided the initial list to a 351(k) applicant under section 351(l)(3)(A) or (l)(7) of the Public Health Service Act. Accordingly, the RPS must only provide information on its patents to the FDA for listing in the Purple Book after it engages in the patent dance with a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-on</div> developer or biosimilar. As such, it is not always clear to industry participants, including us, which patents cover various types of medicines, products or their methods of use or manufacture, especially in the earlier stages of product discovery and development. Thus, because of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties may allege they have patent rights encompassing our product candidate, technologies or methods. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If a third party claims that we infringe its intellectual property rights, we may face a number of issues, including, but not limited to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">infringement and other intellectual property claims which, regardless of merit, may be expensive and time-consuming to litigate and may divert our management&#8217;s attention from our core business; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">substantial damages for infringement, which we may have to pay if a court decides that the product or technology at issue infringes on or violates the third-party&#8217;s rights, and, if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent owner&#8217;s attorneys&#8217; fees; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a court prohibiting us from developing, manufacturing, marketing or selling REACT, or from using our proprietary technologies, unless the third-party licenses its product rights to us, which it is not required to do; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">if a license is available from a third-party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant cross-licenses to intellectual property rights for our products and any license that is available may be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive,</div> which could result in our competitors gaining access to the same intellectual property; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">redesigning REACT or processes so they do not infringe, which may not be possible or may require substantial monetary expenditures and time. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our securities. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">60 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">financial condition and prospects. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Third parties may assert that we are employing their proprietary technology without authorization. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">There may be third-party patents of which we are currently unaware with claims to compositions of matter, materials, formulations, methods of manufacture or methods for treatment that encompass the composition, use or manufacture of REACT. There may be currently pending patent applications of which we are currently unaware which may later result in issued patents that REACT or their use or manufacture may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patent were held by a court of competent jurisdiction to cover REACT, intermediates used in the manufacture of REACT or our materials generally, aspects of our formulations or methods of use, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize REACT may be impaired or delayed, which could in turn significantly harm our business. Even if we obtain a license, it may be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive,</div> thereby giving our competitors access to the same technologies licensed to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize REACT. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of REACT. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize REACT, which could harm our business significantly. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Third parties may assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As is common in the biotechnology and biopharmaceutical industries, we employ individuals who were previously employed at universities or other biotechnology or biopharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, and although we try to ensure that our employees and consultants do not use the proprietary information or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">61 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">effect on the price of our securities. This type of litigation or proceeding could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other intellectual property related proceedings could adversely affect our ability to compete in the marketplace. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent which might adversely affect our ability to develop and market our products. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that may be relevant to or necessary for the commercialization of REACT in any jurisdiction. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. We may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact our ability to develop and market REACT. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may not be successful in obtaining or maintaining necessary intellectual property rights to develop any future product candidates on acceptable terms. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">REACT, our current product candidate, may require specific formulations to work effectively and efficiently and these rights may be held by others. We may develop products containing our compounds and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-existing</div> biopharmaceutical compounds. We may be unable to acquire or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all, which would harm our business. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive,</div> thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize REACT. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, or challenging the patent rights of others, which could be expensive, time-consuming and unsuccessful. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Competitors may infringe our patents or the patents of our current or future licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">62 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our patents is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question or for other reasons. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We may choose to challenge the patentability of claims in a third-party&#8217;s U.S. patent by requesting that the USPTO review the patent claims in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">an&#160;ex-parte&#160;re-examination,&#160;inter</div></div> partes&#160;review or post-grant review proceedings. These proceedings are expensive and may consume our time or other resources. We may choose to challenge a third-party&#8217;s patent in patent opposition proceedings in the European Patent Office (the &#8220;EPO&#8221;) or other foreign patent office. The costs of these opposition proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office then we may be exposed to litigation by a third-party alleging that the patent may be infringed by REACT or our proprietary technologies. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, because some patent applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until 18&#160;months after filing, and publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our owned and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> issued patents or our pending applications, or that we or, if applicable, a licensor were the first to invent the technology. Our competitors may have filed, and may in the future file, patent applications covering our products or technology similar to ours. Any such patent application may have priority over our owned and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patent applications or patents, which could require us to obtain rights to issued patents covering such technologies. If another party has filed a U.S. patent application on inventions similar to those owned by or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> to us, we or, in the case of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> technology, the licensor may have to participate in an interference or derivation proceeding declared by the USPTO to determine priority of invention in the United States. If we or one of our licensors is a party to an interference or derivation proceeding involving a U.S. patent application on inventions owned by or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> to us, we may incur substantial costs, divert management&#8217;s time and expend other resources, even if we are successful. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-exclusive</div> license is offered and our competitors gain access to the same technology. Litigation or interference proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our securities. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">63 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with these requirements. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on our owned and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> issued patents and patent applications are or will be due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent application process and following the issuance of a patent. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-payment</div> of fees and failure to properly legalize and submit formal documents. In certain circumstances, even inadvertent noncompliance events may permanently and irrevocably jeopardize patent rights. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Certain patents covering REACT could be found invalid or unenforceable if challenged in court or the USPTO. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">If we or one of our licensors initiate legal proceedings against a third-party to enforce a patent covering REACT, the defendant could counterclaim that the patent covering REACT, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-examination,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">inter partes</div></div> review, post-grant review, and equivalent proceedings in foreign jurisdictions (e.g.,&#160;opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover REACT. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or if we are otherwise unable to adequately protect our rights, we would lose at least part, and perhaps all, of the patent protection on REACT. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and product candidates. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our earliest patents may expire before, or soon after, our first product achieves marketing approval in the United States or foreign jurisdictions. Upon the expiration of our current patents, we may lose the right to exclude others from practicing these inventions. The expiration of these patents could have a similar material adverse effect on our business, results of operations, financial condition and prospects. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Changes in patent law in the United States, changes in the administration&#8217;s interpretation of the law, or changes in the law in other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in either the patent laws or interpretation of the patent laws in the United States or in other jurisdictions could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability are met, prior to March&#160;16, 2013, in the United&#160;States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. On March&#160;16, 2013, under the America Invents Act, enacted in September 2011, the United States transitioned to a first inventor to </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">64 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. A third party that files a patent application in the USPTO on or after March&#160;16, 2013 but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i)&#160;file any patent application related to our product candidates or (ii)&#160;invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The America Invents Act also includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">inter partes</div></div> review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> patent applications and the enforcement or defense of our owned or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensed</div> issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the patent positions of companies in the development and commercialization of biopharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We have limited foreign intellectual property rights and may not be able to protect and enforce our intellectual property rights throughout the world. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Although we have multiple patents in countries outside of the United States, we do not have intellectual property rights in all potential markets outside the United States where CKD is prevalent. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection but where enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from competing. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">65 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">not favor the enforcement of, and may require a compulsory license to, patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products against third parties in violation of our proprietary rights generally. The initiation of proceedings by third parties to challenge the scope or validity of our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Patent terms may be inadequate to protect our competitive position on REACT or our future product candidates for an adequate amount of time, and if we do not obtain protection under the Hatch-Waxman Amendments and similar <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-United</div> States legislation for extending the term of patents covering REACT or our future product candidates, our business may be materially harmed. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years from its earliest claimed U.S. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-provisional</div> filing date. Various extensions such as patent term adjustments and/or extensions, may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering REACT or any of our future product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984, also known as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent extension term of up to five additional years beyond the expiration date as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval, only one patent may be extended. However, we may not be granted the full extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process. Also, we may not be granted any extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced and could have a material adverse effect on our business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Any trademarks we have obtained or may obtain may be infringed or otherwise violated, or successfully challenged, resulting in harm to our business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect to rely on trademarks as one means to distinguish REACT, if approved for marketing, from the products of our competitors. Once we select new trademarks and apply to register them, our trademark applications may not be approved. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome such rejections. Third parties may oppose or attempt to cancel our trademark applications or trademarks, or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">66 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">may infringe or otherwise violate our trademarks and we may not have adequate resources to enforce our trademarks. Any of the foregoing events may have a material adverse effect on our business. Moreover, any name we propose to use with REACT in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to Managing Our Business and Operations </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We expect to expand our clinical development and research and regulatory capabilities, our manufacturing and administrative capacities, and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could adversely affect our operations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of July&#160;31, 2022, we had approximately 77 full-time employees. As our clinical development and commercialization plans and strategies develop, and as we transition into operating as a public company, we will need to expand our managerial, clinical, regulatory, manufacturing, sales, marketing, financial, development and legal capabilities or contract with third parties to provide these capabilities for us. As our operations expand, we expect that we will need to manage additional relationships with various strategic collaborators, suppliers and other third parties. Our future growth would impose significant added responsibilities on members of management, including: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">identifying, recruiting, integrating, maintaining and motivating additional employees; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">managing our development and commercialization efforts effectively, including the clinical and FDA review process for REACT and any other product candidates, while complying with our contractual obligations to contractors and other third parties; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">improving our operational, financial and management controls, reporting systems and procedures. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our ability to continue to develop and, if approved, commercialize REACT will depend, in part, on our ability to effectively manage any future growth. Our management may also have to divert a disproportionate amount of its attention away from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">day-to-day</div></div> activities in order to devote a substantial amount of time to managing these growth activities. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services. There can be no assurance that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality, accuracy or quantity of the services provided is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain, or may be substantially delayed in obtaining, regulatory approval of REACT or any of our future product candidates or otherwise advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize REACT or any other product candidates and, accordingly, may not achieve our research, development and commercialization goals. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">67 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If we lose key management personnel, or if we fail to recruit additional highly skilled personnel, our ability to continue developing REACT or identify and develop new product candidates will be impaired, which could result in loss of markets or market share and could make us less competitive. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to compete in the highly competitive biotechnology and biopharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel, including Tim Bertram, our Chief Executive Officer; Deepak Jain, our Chief Operating Officer; James Coulston, our Chief Financial Officer; and Joseph Stavas, our SVP Clinical Development. The loss of the services of any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements could result in delays in product development and harm our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conduct our operations globally from several locations, including the United States and the Cayman Islands. Competition for skilled personnel in our industry is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we intend to provide equity awards that vest over time, some of which may be in the form of unregistered shares and may dilute the voting and economic rights of our shareholders. The value to employees of such equity awards that vest over time may be significantly affected by movements in our share price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Our key employees are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">at-will</div> employees, which means that any of our employees could leave our employment at any time, with or without notice. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-level</div> and senior scientific and medical personnel. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our employees, independent contractors, consultants, collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with regulatory standards and requirements. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We are exposed to the risk that our employees, independent contractors, consultants, collaborators, principal investigators, CROs, suppliers and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct that violates FDA regulations, including those laws requiring the reporting of true, complete and accurate information to the FDA, manufacturing standards, federal and state health care laws and regulations, and laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, including, without limitation, damages, fines, disgorgement, imprisonment, exclusion from participation in government health care programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with these laws, and the curtailment or restructuring of our operations. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">68 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our internal computer systems, or those of our collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our internal computer systems and those of any future collaborators and other contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of REACT or any of our future product candidates could be delayed. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We could be subject to risks caused by misappropriation, misuse, leakage, falsification or intentional or accidental release or loss of information maintained in the information systems and networks of our company and our vendors, including personal information of our employees and study subjects, and company and vendor confidential data. In addition, outside parties may attempt to penetrate our systems or those of our vendors or fraudulently induce our personnel or the personnel of our vendors to disclose sensitive information in order to gain access to our data and/or systems. We may experience threats to our data and systems, including malicious codes and viruses, phishing and other cyberattack. The number and complexity of these threats continue to increase over time. If a material breach of, or accidental or intentional loss of data from, our information technology systems or those of our vendors occurs, the market perception of the effectiveness of our security measures could be harmed, and our reputation and credibility could be damaged. We could be required to expend significant amounts of money and other resources to repair or replace information systems or networks. In addition, we could be subject to regulatory actions and/or claims made by individuals and groups in private litigation involving privacy issues related to data collection and use practices and other data privacy laws and regulations, including claims for misuse or inappropriate disclosure of data, as well as unfair or deceptive practices. Although we develop and maintain systems and controls designed to prevent these events from occurring, and we have a process to identify and mitigate threats, the development and maintenance of these systems, controls and processes is costly and requires ongoing monitoring and updating as technologies change and efforts to overcome security measures become increasingly sophisticated. Moreover, despite our efforts, the possibility of these events occurring cannot be eliminated entirely. As we outsource more of our information systems to vendors, engage in more electronic transactions with payors and patients, and rely more on cloud-based information systems, the related security risks will increase and we will need to expend additional resources to protect our technology and information systems. In addition, there can be no assurance that our internal information technology systems or those of our third-party contractors, or our consultants&#8217; efforts to implement adequate security and control measures, will be sufficient to protect us against breakdowns, service disruption, data deterioration or loss in the event of a system malfunction, or prevent data from being stolen or corrupted in the event of a cyberattack, security breach, industrial espionage attacks or insider threat attacks which could result in financial, legal, business or reputational harm. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Failure to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We and any potential collaborators may be subject to federal, state and foreign data protection laws and regulations (i.e., laws and regulations that address privacy and data security). In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, state data breach notification laws, state privacy and health information privacy laws and federal and state consumer protection laws (e.g., Section&#160;5 of the Federal Trade Commission Act), that govern the collection, use, disclosure and </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">69 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">protection of health-related and other personal information could apply to our operations or the operations of our collaborators. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA. Depending on the facts and circumstances, we could be subject to civil or criminal penalties if we obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">International data protection laws, including GDPR, may also apply to health-related and other personal information&#160;obtained outside of the United States. The GDPR will increase our responsibility and liability in relation to personal data that we process, and we may be required to put in place additional mechanisms to ensure compliance with the new EU (which also includes the EEA) data protection rules. Further, the Brexit has created more uncertainty with regard to data protection regulation in the United Kingdom. The United Kingdom retained the GDPR in UK law, which sits alongside the amended version of the Data Protection Act 2018. The European Union adopted an adequacy decision so that data can be transferred from the European Union to the United Kingdom. Additionally, there are no new requirements for transfer from the United Kingdom to the European Union. However, going forward, the European Union&#8217;s and United Kingdom&#8217;s data protection rules could diverge, and data transfers may not be possible and/or new arrangements may need to be put in place. In particular, it is unclear to what extent the United Kingdom regime will begin diverging from the GDPR and how data transfers to and from the United Kingdom will be regulated. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, California recently enacted the CCPA, which creates new individual privacy rights for California consumers (as defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA became effective on January&#160;1, 2020, but the California Privacy Rights Act was recently enacted to strengthen elements of the CCPA effective January&#160;1, 2023. In addition, there are a number of other states that have considered similar privacy proposals, with states like Virginia and Colorado enacting their own privacy laws (also scheduled to come into effect in January&#160;1, 2023 and July&#160;1, 2023, respectively). These privacy laws may impact our business activities and exemplify the vulnerability of our business to the evolving regulatory environment related to personal data. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with U.S. and international data protection laws and regulations could result in government enforcement actions (which could include civil or criminal penalties), private litigation and adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Changes in tax law or policy could increase our effective tax rate and tax liability or the taxes payable by holders of our ordinary shares, each of which could have a material adverse effect on our business, financial condition and results of operations. </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We could be adversely affected by changes in applicable tax laws, regulations, or administrative interpretations thereof. For example, the U.S. federal tax legislation commonly referred to as the Tax Cuts and Jobs Act (the &#8220;Tax Act&#8221;), enacted in December 2017, resulted in fundamental changes to the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) including, among many other things, a reduction to the federal corporate income tax rate, a partial limitation on the deductibility of business interest expense, a limitation on the deductibility of certain director and officer compensation expense, limitations on net operating loss carrybacks and carryovers and changes relating to the scope and timing of U.S. taxation on earnings from international business operations. Subsequent legislation, the Coronavirus Aid, Relief, and Economic Security Act (the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">70 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&#8220;CARES Act&#8221;) enacted on March&#160;27, 2020, relaxed certain of the limitations imposed by the Tax Act for certain taxable years, including the limitation on the use and carryback of net operating losses and the limitation on the deductibility of business interest expense. The exact impact of the Tax Act and the CARES Act for future years is difficult to quantify, but these changes could materially affect our investors, the companies in which our clients invest, or us. Legislative proposals in the U.S., if adopted, would increase the corporate income tax rate and capital gains tax rate. In addition, other changes could be enacted in the future to limit further the deductibility of interest, subject carried interests to more onerous taxation or effect other changes that could have a material adverse effect on our business, results of operations and financial condition. Such changes could also include increases in state taxes and other changes to state tax laws to replenish state and local government finances depleted by costs attributable to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and the reduction in tax revenues due to the accompanying economic downturn. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are or may become subject to taxation in more than one tax jurisdiction. As a result, our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Nevertheless, our effective tax rate may be different than experienced in the past due to numerous factors, including passage of newly enacted tax legislation, changes in the mix of our profitability from jurisdiction to jurisdiction, the results of examinations and audits of our tax filings, our inability to secure or sustain acceptable agreements with tax authorities, changes in accounting for income taxes and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations and may result in tax obligations in excess of amounts accrued in our financial statements. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We may be a passive foreign investment company, or &#8220;PFIC,&#8221; which could result in adverse U.S. federal income tax consequences to U.S. investors. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">ProKidney believes that it is likely classified as a PFIC for U.S. federal income tax purposes. If we are a PFIC for any taxable year (or portion thereof) that is included in the holding period of a U.S. Holder of our Class&#160;A ordinary shares, such U.S. Holder may be subject to adverse U.S. federal income tax consequences and may be subject to additional reporting requirements. There can be no assurances with respect to our status as a PFIC for our current taxable year or any subsequent taxable year. Our actual PFIC status for any taxable year, moreover, will not be determinable until after the end of such taxable year. If we determine we are a PFIC for any taxable year (of which there can be no assurance), we will endeavor to provide to a U.S. Holder such information as the IRS may require, including a PFIC Annual Information Statement, upon request, in order to enable a U.S. Holder to make and maintain a &#8220;qualified electing fund&#8221; election. There can be no assurance, however, that ProKidney will timely provide such information. For more information, please see the section entitled &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Certain Material U.S. and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Income</div> Tax Considerations&#8212;U.S. Holders&#8212;PFIC Considerations</div></div>.&#8221; We urge U.S. investors to consult their own tax advisors regarding the possible application of the PFIC rules. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Unanticipated changes in effective tax rates or adverse outcomes resulting from examination of our income or other tax returns could adversely affect our financial condition and results of operations. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We will be subject, directly or indirectly, to income taxes in various jurisdictions, and our tax liabilities will be subject to the allocation of expenses in differing jurisdictions. Our future effective tax rates could be subject to volatility or adversely affected by a number of factors, including: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">changes in the valuation of our deferred tax assets and liabilities; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expected timing and amount of the release of any tax valuation allowances; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">tax effects of share-based compensation; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">71 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs related to intercompany restructurings; </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in tax laws, regulations or interpretations thereof; or </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left;">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left;"><div style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">lower-than-anticipated future earnings in jurisdictions where we have lower statutory tax <div style="display:inline;">rates </div>and higher-than-anticipated future earnings in jurisdictions where we have higher statutory tax rates. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we may be subject to audits of our income, sales and other transaction taxes by taxing authorities. Outcomes from these audits could have an adverse effect on our financial condition and results of operations.<div style="font-style:italic;display:inline;"> </div> </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><div style="font-style:italic;display:inline;">Our principal shareholders have significant influence over us, including over decisions that require the approval of shareholders, and their interests may conflict with the interests of holders of ProKidney Corp. Class&#160;A ordinary shares. </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Voting Agreement provides, with respect to the election, appointment or removal of any director of the <div style="display:inline;">Company</div>, that, until the third anniversary of the Closing, CEC will vote all of its voting shares in the capital of the Company in a manner proportionate to the manner in which all other ProKidney Class&#160;B ordinary shares not held by CEC are voted. As a result, Tolerantia effectively controls approximately 64.7% (accounting for approximately 23.9% held by CEC) of the combined voting power of ProKidney Corp. with respect to the election, appointment or removal of any director. Additionally, Pablo Legorreta, as Chairperson of the Board, is affiliated with and majority owns and controls Tolerantia. As a result, Tolerantia and its affiliates have significant influence over the management and affairs of the Company, and, acting together, effectively control the election, appointment or removal of any director and have indirect control over the approval of significant corporate transactions, including any merger, consolidation or sale of all or substantially all of our assets and the issuance or redemption of equity interests in certain circumstances, to the extent such matters require approval of the Board. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Tolerantia and CEC together control approximately 64.7% of the combined voting power of the Company. The interests of these shareholders may not always coincide with, and in some cases may conflict with, our interests and the interests of our other shareholders, including the holders of ProKidney Class&#160;A ordinary shares. For instance, these shareholders could attempt to delay or prevent a change in control, even if such change in control would benefit our other shareholders, which could deprive our shareholders of an opportunity to receive a premium for their ProKidney Class&#160;A ordinary shares. This concentration of ownership may also affect the prevailing market price of our ProKidney Class&#160;A ordinary shares due to investors&#8217; perceptions that conflicts of interest may exist or arise. As a result, this concentration of ownership may not be in your best interests. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, because these shareholders hold their economic interest in our business through ProKidney LP, rather than through ProKidney Corp., their interests may further conflict with the interests of holders of ProKidney Class&#160;A ordinary shares. For example, such holders may have different tax positions from ProKidney Corp., which could influence their decisions regarding whether and when ProKidney Corp. should dispose of assets or incur new or refinance existing indebtedness, and whether and when ProKidney Corp. should undergo certain changes of control within the meaning of the Tax Receivable Agreement or terminate the Tax Receivable Agreement. In addition, the structuring of future transactions may take into consideration these tax or other considerations even where no similar benefit would accrue to ProKidney Corp. These holders&#8217; significant ownership in ProKidney Corp. and resulting ability, acting together, to effectively control us may discourage someone from making a significant equity investment in ProKidney Corp., or could discourage transactions involving a change in control, including transactions in which a holder of ProKidney Class&#160;A ordinary shares might otherwise receive a premium for their shares over the then-current market price. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">72 </div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Because we are a &#8220;controlled company&#8221; within the meaning of the Nasdaq rules, our shareholders may not have certain corporate governance protections that are available to shareholders of companies that are not controlled companies. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">So long as more than 50% of the voting power for the election of directors is held by an individual, a group or another company, we will qualify as a &#8220;controlled company&#8221; within the meaning of the Nasdaq corporate governance standards. Pursuant to the terms of the Voting Agreement, Tolerantia effectively controls a majority of the voting power of all outstanding ProKidney Corp. ordinary shares with respect to the election, appointment or removal of any director. As a result, we are a &#8220;controlled company&#8221; within the meaning of the Nasdaq corporate governance standards and are not subject to the requirements that would otherwise require us to have: (i)&#160;a majority of our board of directors consist of independent directors, (ii)&#160;subject to the exception pursuant to Nasdaq Listing Rule 5605(b)(2), our board of directors have a compensation committee that is composed of at least two members, each of whom is an independent director, with a written charter addressing the committee&#8217;s purpose and responsibilities and (iii)&#160;director nominees must be selected, or recommended for the board&#8217;s selection, either by independent directors constituting a majority of the board&#8217;s independent directors in a vote in which only independent directors participate, or by a nominating and corporate governance committee comprised solely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities. Pursuant to the requirements under the Business Combination Agreement, a majority of the directors of the Board are &#8220;independent&#8221; directors for the purposes of the Nasdaq Listing Rules, but for at least some period following the Business Combination, we may utilize the other exemptions described above. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tolerantia may have its interest in the Company diluted due to future equity issuances or its own actions in selling shares of the Company, in each case, which could result in a loss of the &#8220;controlled company&#8221; exemption under the Nasdaq listing rules. We would then be required to comply with those provisions of the Nasdaq listing requirements. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Antitakeover provisions contained in our Charter, as well as provisions of Cayman Islands law, could impair a takeover attempt. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Charter contains provisions that may discourage unsolicited takeover proposals that shareholders may consider to be in their best interests. These provisions may make more difficult the removal of management and may discourage transactions that otherwise could involve payment of a premium over prevailing market prices for our securities. These provisions will include, among other things: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">no cumulative voting in the election of directors, which limits the ability of minority shareholders to elect director candidates; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a classified board of directors with three-year staggered terms, which could delay the ability of shareholders to change the membership of a majority of the Board; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the requirement that directors may only be removed from the Board by special resolution; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the right of the Board to elect a director to fill a vacancy of the Board created by the expansion of the Board or the resignation, death, or removal of a director in certain circumstances, which prevents shareholders from being able to fill vacancies on the Board; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a prohibition on shareholders calling an extraordinary general meeting and the requirement that a meeting of shareholders may only be called by members of the Board, which may delay the ability of our shareholders to force consideration of a proposal or to take action, including the removal of directors; and </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the right of the Board to issue and set the voting and other rights of preference shares, which could adversely affect the voting power and other rights of the holders of ordinary shares. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">73 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The JOBS Act permits &#8220;emerging growth companies&#8221; like us to take advantage of certain exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We currently qualify as an &#8220;emerging growth company&#8221; as defined in Section&#160;2(a)(19) of the Securities Act, as modified by the JOBS Act. As such, we take advantage of certain exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies for as long as we continue to be an emerging growth company, including: (i)&#160;the exemption from the auditor attestation requirements with respect to internal control over financial reporting under Section&#160;404 of SOX; (ii)&#160;the exemptions from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">say-on-pay,</div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">say-on-frequency</div></div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">say-on-golden</div></div> parachute voting requirements; and (iii)&#160;reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. As a result, our shareholders may not have access to certain information they deem important. We will remain an emerging growth company until the earliest of (i)&#160;the last day of the fiscal year: (a)&#160;following July&#160;2, 2026, the fifth (5th) anniversary of our IPO; (b)&#160;in which we have total annual gross revenue of at least $1.07&#160;billion; or (c)&#160;in which we are deemed to be a large accelerated filer, which means the market value of our Class&#160;A ordinary shares that is held by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-affiliates</div> equals or exceeds $700&#160;million as of the last business day of our prior second fiscal quarter, and (ii)&#160;the date on which we have issued more than $1.0&#160;billion in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-convertible</div> debt during the prior three-year period. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such an election to opt out is irrevocable. We have elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of our financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Additionally, we are a &#8220;smaller reporting company&#8221; as defined in Item 10(f)(1) of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-K.</div> Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last day of the fiscal year in which (i)&#160;the market value of our ordinary shares that is held by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-affiliates</div> exceeds $250&#160;million as of the last business day of the prior fiscal quarter, or (ii)&#160;our annual revenues equaled or exceeded $100&#160;million during such completed fiscal year, and the market value of our ordinary shares that is held by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-affiliates</div> equals or exceeds $700&#160;million as of the last business day of the prior second fiscal quarter. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We cannot predict if investors will find our Class&#160;A ordinary shares less attractive because we rely on these exemptions. If some investors find our Class&#160;A ordinary shares less attractive as a result, there may be a less active trading market for our Class&#160;A ordinary shares, and our share price may be more volatile. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Our internal controls over financial reporting may not be effective and our independent registered public accounting firm may not be able to certify as to their effectiveness, which could have a significant and adverse effect on our business and reputation. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a public company, we are required to comply with the SEC&#8217;s rules implementing Sections 302 and 404 of SOX, which require management to certify financial and other information in our quarterly and annual reports and provide an annual management report on the effectiveness of internal control over financial reporting. To comply with the requirements of being a public company, we will be required to provide attestation on internal </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">74 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">controls commencing with the annual report for fiscal year ended December&#160;31, 2022, and we may need to undertake various actions, such as implementing additional internal controls and procedures and hiring additional accounting or internal audit staff. The standards required for a public company under Section&#160;404 of SOX are significantly more stringent than those that were previously required of us as a privately held company. Further, as an emerging growth company, our independent registered public accounting firm is not required to formally attest to the effectiveness of our internal controls over financial reporting pursuant to Section&#160;404 until the date we are no longer an emerging growth company. At such time, our independent registered public accounting firm may issue a report that is adverse in the event that it is not satisfied with the level at which our controls are documented, designed or operating. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Testing and maintaining these controls can divert our management&#8217;s attention from other matters that are important to the operation of our business. If we identify material weaknesses in our internal control over financial reporting or are unable to comply with the requirements of Section&#160;404 or assert that our internal control over financial reporting is effective, or if our independent registered public accounting firm is unable to express an opinion as to the effectiveness of our internal controls over financial reporting when we no longer qualify as an emerging growth company, investors may lose confidence in the accuracy and completeness of our financial reports, and the market price of our ordinary shares could be negatively affected, and we could become subject to investigations by the SEC or other regulatory authorities, which could require additional financial and management resources. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks Related to our Organizational Structure </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We are a limited partner of ProKidney LP but may, in certain circumstances, lose the benefit of limited liability. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are a limited partner of ProKidney LP, a limited partnership registered under the laws of Ireland. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Irish LP Act, limited partners of Irish limited partnerships will not be liable for the debts or obligations of the partnership beyond the amount of capital they have contributed. However, the Irish LP Act also provides that such limited liability may be lost if (i)&#160;a limited partner (such as ProKidney Corp.) takes part in the management of the business of the partnership, (ii)&#160;there is a failure to register ProKidney LP as a limited partnership or any change to the registration details of ProKidney LP, including changes to the name of ProKidney LP, the general nature of the business of ProKidney LP, the principal place of business of ProKidney LP, the partners or the name of any partner of ProKidney LP, the term of character of ProKidney LP, the sum contributed by any limited partner or the liability of any partner by reason of his becoming a limited instead of a general partner or a general instead of a limited partner; and (iii)&#160;a limited partner withdraws some or a part of his, her or its capital, in which circumstance he, she or it will be liable for the debts and obligations of the firm up to the amount so withdrawn. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We are a holding company, and our only material asset is our interest in ProKidney LP, and we are accordingly dependent upon distributions made by our subsidiaries to pay taxes, make payments under the Tax Receivable Agreement and pay dividends. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are a holding company with no material assets other than our ownership of Post-Combination ProKidney Common Units. As a result, we have no independent means of generating revenue or cash flow. Our ability to pay taxes, make payments under the Tax Receivable Agreement and pay dividends, if any, will depend on the financial results and cash flows of ProKidney LP and its subsidiaries and the distributions we receive from ProKidney LP. Deterioration in the financial condition, earnings or cash flow of ProKidney LP and its subsidiaries, for any reason, could limit or impair our ability to pay such distributions. Additionally, to the extent that we need funds and ProKidney LP and/or any of its subsidiaries are restricted from making such distributions under applicable law or regulation or under the terms of any financing arrangements, or ProKidney LP is otherwise unable to provide such funds, it could materially adversely affect our liquidity and financial condition. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">75 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Subject to the potential risk of being treated as a publicly traded partnership discussed below, ProKidney LP will continue to be treated as a partnership for U.S. federal income tax purposes and, as such, generally will not be subject to any entity-level U.S. federal income tax. Instead, the taxable income of ProKidney LP will be allocated to holders of Post-Combination ProKidney Common Units, including ProKidney Corp. Accordingly, we may be required to pay income taxes on our allocable share of any net taxable income of ProKidney LP (e.g., U.S. federal income and branch profits tax to the extent such net taxable income is effectively connected to the conduct of a trade or business in the United States). Under the terms of the Second Amended and Restated ProKidney Limited Partnership Agreement, ProKidney LP is obligated to make tax distributions to holders of Post-Combination ProKidney Common Units (including ProKidney Corp.) calculated at certain assumed tax rates. In addition to tax expenses, we will also incur expenses related to our operations, including payment obligations under the Tax Receivable Agreement (and the cost of administering such payment obligations), which could be significant and some of which may be reimbursed by ProKidney LP (excluding payment obligations under the Tax Receivable Agreement). We intend to cause ProKidney LP to make distributions to holders of Post-Combination ProKidney Common Units pro rata, in amounts sufficient to cover all applicable income taxes (calculated at assumed tax rates), relevant operating expenses, payments required to be made by us under the Tax Receivable Agreement and dividends, if any, declared by us. However, as discussed below, ProKidney LP&#8217;s ability to make such distributions may be subject to various limitations and restrictions including, but not limited to, restrictions on distributions that would either violate any contract or agreement to which ProKidney LP is then a party, including debt agreements, or any applicable law, or that would have the effect of rendering ProKidney LP insolvent. If our cash resources are insufficient to meet our obligations under the Tax Receivable Agreement and to fund our obligations, we may be required to incur additional indebtedness to provide the liquidity needed to make such payments, which could materially adversely affect its liquidity and financial condition and subject us to various restrictions imposed by any such lenders. To the extent that we are unable to make payments under the Tax Receivable Agreement for any reason, such payments will be deferred and will accrue interest until paid; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">however</div></div>, that nonpayment for a specified period may constitute a material breach of a material obligation under the Tax Receivable Agreement and therefore accelerate payments due under the Tax Receivable Agreement, which could be substantial. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, although ProKidney LP generally will not be subject to any entity-level U.S. federal income tax, it may be liable under federal tax legislation for adjustments to its tax return, absent an election to the contrary. In the event ProKidney LP&#8217;s calculations of taxable income are incorrect, its members, including ProKidney Corp., in later years may be subject to material liabilities pursuant to this federal legislation and its related guidance. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We anticipate that the distributions we will receive from ProKidney LP may, in certain periods, exceed our actual tax liabilities and obligations to make payments under the Tax Receivable Agreement. The Board, in its sole discretion, may make any determination from time to time with respect to the use of any such excess cash so accumulated, which may include, among other uses, to pay dividends on ProKidney Class&#160;A ordinary shares. We will have no obligation to distribute such cash (or other available cash other than any declared dividend) to our shareholders. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividends on ProKidney Class&#160;A ordinary shares, if any, will be paid at the discretion of the Board, which will consider, among other things, our business, operating results, financial condition, current and expected cash needs, plans for expansion and any legal or contractual limitations on our ability to pay such dividends. Financing arrangements may include restrictive covenants that restrict our ability to pay dividends or make other distributions to our shareholders. Under the Irish LP Act, a limited partner of ProKidney LP may lose its limited liability where such limited partner withdraws some or a part of his, her or its contribution to ProKidney LP, in which circumstance he, she or it will be liable for debts and obligations of ProKidney up to the amount so withdrawn. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney&#8217;s subsidiaries are generally subject to similar legal limitations on their ability to make distributions to ProKidney. If ProKidney does not have sufficient funds to make distributions, our ability to declare and pay cash dividends may also be restricted or impaired. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">76 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">In certain circumstances, ProKidney LP will be required to make distributions to us and the other holders of Post-Combination ProKidney Common Units, and the distributions that ProKidney LP will be required to make may be substantial. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">ProKidney LP will generally be required from time to time to make pro rata distributions in cash to us and the other holders of Post-Combination ProKidney Common Units at certain assumed tax rates in amounts that are intended to be sufficient to cover the taxes on our and the other holders of Post-Combination ProKidney Common Units respective allocable shares of the taxable income of ProKidney LP. As a result of (i)&#160;potential differences in the amount of net taxable income allocable to us and the other holders of Post-Combination ProKidney Common Units, (ii)&#160;the lower tax rate applicable to corporations than individuals, (iii)&#160;our status as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> person and (iv)&#160;the use of an assumed tax rate (the highest effective marginal combined U.S. federal, state and local income tax rate prescribed for an individual or corporate resident of New York, New York) in calculating ProKidney LP&#8217;s distribution obligations, we may receive tax distributions significantly in excess of our tax liabilities and obligations to make payments under the Tax Receivable Agreement. We will determine in its sole discretion the appropriate uses for any excess cash so accumulated, which may include, among other uses, dividends, the payment of obligations under the Tax Receivable Agreement and the payment of other expenses. We will have no obligation to distribute such excess cash (or other available cash other than any declared dividend) to the holders of ProKidney Class&#160;A ordinary shares. No adjustments to the redemption or exchange ratio of Post-Combination ProKidney Common Units for ProKidney Class&#160;A ordinary shares will be made as a result of either (i)&#160;any cash dividend by us or (ii)&#160;any cash that we retain and do not distribute to our shareholders. To the extent that we do not distribute such excess cash as dividends on ProKidney Class&#160;A ordinary shares and instead, for example, holds such cash balances or lends them to ProKidney LP, holders of Post-Combination ProKidney Common Units would benefit from any value attributable to such cash balances as a result of their ownership of ProKidney Class&#160;A ordinary shares following a redemption or exchange of their ProKidney Common Units. </div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Under the Tax Receivable Agreement, we are required to pay 85% of certain tax savings recognized by ProKidney Corp. as a result of the increases in tax basis of ProKidney assets attributable to the exchanges of ProKidney Common Units for ProKidney Class&#160;A ordinary shares and certain other tax benefits, and those payments may be substantial. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Closing ProKidney Unitholders may exchange their Post-Combination ProKidney Common Units for ProKidney Class&#160;A ordinary shares or, subject to certain restrictions, cash, pursuant to the Exchange Agreement, subject to certain conditions and transfer restrictions as set forth therein and in the Second Amended and Restated ProKidney Limited Partnership Agreement. These exchanges are expected to result in increases in our allocable share of the tax basis of the tangible and intangible assets of ProKidney LP. These increases in tax basis may increase (for tax purposes) depreciation and amortization deductions and therefore reduce the amount of income or franchise tax that we would otherwise be required to pay in the future had such exchanges never occurred. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the Business Combination, we entered into the Tax Receivable Agreement, which generally provides for the payment by it of 85% of certain tax savings, if any, that we recognize as a result of these increases in tax basis and certain other tax attributes of ProKidney LP and tax benefits related to entering into the Tax Receivable Agreement. These payments are the obligation of ProKidney Corp. and not of ProKidney LP. The actual increase in our allocable share of ProKidney&#8217;s tax basis in its assets, as well as the amount and timing of any payments under the Tax Receivable Agreement, will vary depending upon a number of factors, including the timing of exchanges, the market price of the Class&#160;A ordinary share at the time of the exchange, the extent to which such exchanges are taxable and the amount and timing of the recognition of our income. Many of the factors that will determine the amount of payments that we will make under the Tax Receivable Agreement are outside of our control and such payments, if any, could be substantial and could have a material adverse effect on our financial condition. Even assuming, among other things, that there are no material changes in relevant tax law, that ProKidney LP&#8217;s enterprise value is equal to the enterprise value that was agreed to in the </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">77 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Business Combination at the time all Post-Combination ProKidney Common Units are exchanged, and that there are significant future redemptions or exchanges of Post-Combination ProKidney Common Units, payments under the Tax Receivable Agreement are not expected to be material because ProKidney LP does not currently (i)&#160;plan to migrate business operations to the United States, or (ii)&#160;otherwise anticipate tax benefits outside of the United States from redemptions or exchanges of Post-Combination ProKidney Common Units that would trigger obligations under the Tax Receivable Agreement based upon the intended operations of ProKidney LP outside the United States. In addition, because ProKidney LP does not currently have business operations in the United States and does not expect to generate significant operating revenues in the near future, if at all, payments under the Tax Receivable Agreement in the near future, if any, are not expected to be material. If, contrary to current intended business operations and strategy, the business operations are migrated to the United States, the business operations outside of the United States change, or there are material changes in relevant tax law, then payments under the Tax Receivable Agreement could be material. Any payments made by us under the Tax Receivable Agreement will generally reduce the amount of overall cash flow that might have otherwise been available to us. To the extent that we are unable to make timely payments under the Tax Receivable Agreement for any reason, the unpaid amounts will be deferred and will accrue interest until paid. Furthermore, our future obligation to make payments under the Tax Receivable Agreement could make it a less attractive target for an acquisition, particularly in the case of an acquirer that cannot use some or all of the tax benefits that may be deemed realized under the Tax Receivable Agreement. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">In certain cases, payments under the Tax Receivable Agreement may exceed the actual tax benefits we realize or may be accelerated. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments under the Tax Receivable Agreement will be based on the tax reporting positions that we determine, and the IRS or any other taxing authorities may challenge all or any part of the tax basis increases, as well as other tax positions that we take, and a court may sustain such a challenge. In the event any tax benefits initially claimed by us are disallowed, the current Closing ProKidney Unitholders will not be required to reimburse us for any excess payments that may previously have been made under the Tax Receivable Agreement, for example, due to adjustments resulting from examinations by taxing authorities. Rather, excess payments made to such holders will be netted against any future cash payments otherwise required to be made by us, if any, after the determination of such excess. However, a challenge to any tax benefits initially claimed by us may not arise for a number of years following the initial time of such payment or, even if challenged early, such excess cash payment may be greater than the amount of future cash payments that we might otherwise be required to make under the terms of the Tax Receivable Agreement and, as a result, there might not be future cash payments from which to net against. As a result, in certain circumstances we could make payments under the Tax Receivable Agreement in excess of our actual income or franchise tax savings, which could materially impair our financial condition. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Moreover, the Tax Receivable Agreement provides that, in the event that (i)&#160;we exercise our early termination rights under the Tax Receivable Agreement, (ii)&#160;the Tax Receivable Agreement is rejected by operation of law in a bankruptcy case, (iii)&#160;certain changes of control of ProKidney Corp. occur (as described in the Tax Receivable Agreement) or (iv)&#160;we are more than three months late in making a payment due under the Tax Receivable Agreement (unless we in good faith determine that we have insufficient funds to make such payment) or otherwise materially breach any of our material obligations under the Tax Receivable Agreement, our obligations under the Tax Receivable Agreement will accelerate, and we will be required to make an immediate <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lump-sum</div> cash payment to the Closing ProKidney Unitholders equal to the present value of all forecasted future payments that would have otherwise been made under the Tax Receivable Agreement, which <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lump-sum</div> payment would be based on certain assumptions, including those relating to our future taxable income. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lump-sum</div> payment to the Closing ProKidney Unitholders could be substantial and could exceed the actual tax benefits that we realize subsequent to such payment because such payment would be calculated assuming, among other things, that we would be able to use the assumed potential tax benefits in future years, and that tax rates applicable to us would be the same as they were in the year of the termination. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">78 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There may be a material negative effect on our liquidity if the payments under the Tax Receivable Agreement exceed the actual income or franchise tax savings that we realize. Furthermore, our obligations to make payments under the Tax Receivable Agreement could also have the effect of delaying, deferring or preventing certain mergers, asset sales, other forms of business combinations or other changes of control. We may need to incur additional indebtedness to finance payments under the Tax Receivable Agreement to the extent our cash resources are insufficient to meet our obligations under the Tax Receivable Agreement as a result of timing discrepancies or otherwise. Such indebtedness may have a material adverse effect on our financial condition. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finally, because we are a holding company with no operations of our own, our ability to make payments under the Tax Receivable Agreement depends on the ability of ProKidney LP to make distributions to us. To the extent that we are unable to make payments under the Tax Receivable Agreement for any reason, such payments will be deferred and will accrue interest until paid, which could negatively impact our results of operations and could also affect our liquidity in periods in which such payments are made. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">If ProKidney LP were to become a publicly traded partnership taxable as a corporation for U.S. federal income tax purposes, we and ProKidney LP might be subject to potentially significant tax inefficiencies, and we would not be able to recover payments previously made by us under the Tax Receivable Agreement even if the corresponding tax benefits were subsequently determined to have been unavailable due to such status. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We intend to operate such that ProKidney LP does not become a publicly traded partnership taxable as a corporation for U.S. federal income tax purposes. A &#8220;publicly traded partnership&#8221; is a partnership the interests of which are traded on an established securities market or are readily tradable on a secondary market or the substantial equivalent thereof. Under certain circumstances, exchanges of Post-Combination ProKidney Common Units pursuant to the Exchange Agreement or other transfers of Post-Combination ProKidney Common Units could cause ProKidney LP to be treated as a publicly traded partnership. Applicable Treasury Regulations provide for certain safe harbors from treatment as a publicly traded partnership, and we intend to operate such that exchanges or other transfers of Post-Combination ProKidney Common Units qualify for one or more such safe harbors. For example, the Exchange Agreement and the Second Amended and Restated ProKidney Limited Partnership Agreement, which were entered into in connection with the consummation of the Business Combination, provide for limitations on the ability of ProKidney Unitholders to transfer their Post-Combination ProKidney Common Units and provide us with the right to cause the imposition of limitations and restrictions (in addition to those already in place) on the ability of ProKidney Unitholders to exchange their Post-Combination ProKidney Common Units, including pursuant to the Exchange Agreement, to the extent we believe it is necessary to ensure that ProKidney LP will continue to be treated as a partnership for U.S. federal income tax purposes. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If ProKidney LP were to become a publicly traded partnership taxable as a corporation for U.S. federal income tax purposes, significant tax inefficiencies might result for us and ProKidney LP. For example, we may not be able to realize tax benefits covered under the Tax Receivable Agreement, and we would not be able to recover any payments previously made by us under the Tax Receivable Agreement, even if the corresponding tax benefits (including any claimed increase in the tax basis of ProKidney&#8217;s assets) were subsequently determined to have been unavailable. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">We are a Cayman Islands exempted company. The rights of our shareholders may be different from the rights of shareholders governed by the laws of U.S. jurisdictions. </div></div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are a Cayman Islands exempted company. Our corporate affairs will continue to be governed by our Charter and by the laws of the Cayman Islands. The rights of shareholders and the responsibilities of members of the Board may be different from the rights of shareholders and responsibilities of directors in companies governed by the laws of U.S. jurisdictions. In the performance of its duties, the board of directors of a solvent Cayman Islands exempted company is required to consider that company&#8217;s best interests, which may differ from the interests of one or more of its individual shareholders. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">79 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="rom373959_6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">USE OF PROCEEDS </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All of the Class&#160;A ordinary shares offered by the Selling Securityholders pursuant to this prospectus will be sold by the Selling Securityholders for their respective accounts. We will not receive any of the proceeds from these sales. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Selling Securityholders will pay any underwriting discounts and commissions and expenses incurred by the Selling Securityholders for brokerage, accounting, tax or legal services or any other expenses incurred by the Selling Securityholders in disposing of the securities. We will bear the costs, fees and expenses incurred in effecting the registration of the securities covered by this prospectus, including all registration and filing fees, Nasdaq listing fees and fees and expenses of our counsel and our independent registered public accounting firm. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">80 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom373959_7" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MARKET PRICE, TICKER SYMBOL AND DIVIDEND INFORMATION </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Market Price and Ticker Symbol </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Class&#160;A ordinary shares are currently listed on Nasdaq under the symbol &#8220;PROK.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The closing price of the Class&#160;A ordinary shares on August 5, 2022, was $7.40. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holders </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of July&#160;31, 2022, there were 61 holders of record of our Class&#160;A ordinary shares and 3 holders of record of our Class&#160;B ordinary shares. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Such numbers do not include beneficial owners holding our securities through nominee names. There is no public market for our Class&#160;B ordinary shares. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend Policy </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have not paid any cash dividends on our Class&#160;A ordinary shares or Class&#160;B ordinary shares to date. The payment of cash dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements and general financial condition. The payment of any cash dividends will be within the discretion of the Board at such time. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">81 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom373959_8" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">In this section, unless the context otherwise requires, the &#8220;combined company&#8221; or &#8220;ProKidney&#8221; refer to ProKidney Corp. (formerly Social Capital Suvretta Holdings Corp. III) and its subsidiaries after the Closing, &#8220;SCS&#8221; refers to SCS prior to the Closing, and &#8220;Legacy ProKidney&#8221; refers to ProKidney LP and its subsidiaries prior to the Closing. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following unaudited pro forma condensed combined financial information for the three months ended March&#160;31, 2022 and for the year ended December&#160;31, 2021 combines the historical statement of operations of SCS and the historical consolidated statement of operations of Legacy ProKidney, giving effect to the Business Combination as if it had occurred on January&#160;1, 2021. The unaudited pro forma condensed combined balance sheet as of March&#160;31, 2022 combines the historical balance sheet of SCS and Legacy ProKidney, giving effect to the Business Combination as if it had occurred on March&#160;31, 2022, and the unaudited pro forma condensed combined balance sheet as of December&#160;31, 2021 combines the historical balance sheet of SCS and Legacy ProKidney, giving effect to the Business Combination as if it had occurred on December&#160;31, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The following unaudited pro forma condensed combined financial information presents the combination of the financial information of SCS and Legacy ProKidney, adjusted to give effect to the Business Combination and other events contemplated by the Business Combination Agreement. The following unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X</div> as amended by the final rule, Release <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">33-10786</div> &#8220;Amendments to Financial Disclosures about Acquired and Disposed Businesses.&#8221; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The unaudited pro forma condensed combined financial information has been prepared to illustrate the effect of the Business Combination and has been prepared for informational purposes only. The unaudited pro forma condensed combined statement of operations is not necessarily indicative of what the actual results of operations would have been had the Business Combination taken place on the date indicated, nor is it indicative of the future consolidated results of operations of the combined company. The pro forma adjustments were based on the information available as of the date of these unaudited pro forma condensed combined financial statements and are subject to change as additional information becomes available and analyses are performed. Actual results may differ materially from the assumptions within the accompanying unaudited pro forma condensed combined financial information. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;11, 2022, SCS and Legacy ProKidney consummated the Business Combination pursuant to the Business Combination Agreement. The historical financial information has been adjusted to give pro forma effect to the following events that are related and/or directly attributable to the Business Combination. The unaudited pro forma condensed combined financial information The following pro forma condensed combined financial statements presented herein reflect the actual redemption of 22,829,769 Class&#160;A ordinary shares in conjunction with the shareholder vote on the Business Combination contemplated by the Business Combination Agreement at the extraordinary general meeting held on July&#160;11, 2022. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following summarizes the pro forma share ownership of the combined company&#8217;s Class&#160;A ordinary shares after giving effect to the Business Combination. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">New&#160;ProKidney<br/>Ordinary&#160;Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Ownership</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Public Shareholders</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,170,231</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">0.9</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">%&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sponsor</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,890,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2.9</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">%&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Third Party PIPE Investors</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">36,840,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">15.2</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">%&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sponsor Related PIPE Investors</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,640,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">6.5</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">%&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney Unitholders (including the ProKidney Related PIPE Investors)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">180,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">74.5</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">%&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Shares Outstanding</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">241,540,231</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">100.00</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">%&#160;</div></div></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">82 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The unaudited pro forma condensed combined financial information is based on and should be read in conjunction with: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the accompanying notes to the unaudited pro forma condensed combined financial information; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the historical unaudited condensed financial statements of SCS as of and for the three months ended March&#160;31, 2022, the historical audited condensed financial statements for SCS as of December&#160;31, 2021 and for the period from February&#160;25, 2021 (date of inception) through December&#160;31, 2021, and the related notes, in each case, included elsewhere in this prospectus; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the historical unaudited consolidated financial statements of Legacy ProKidney as of and for the three months ended March&#160;31, 2022, the historical audited consolidated financial statements of Legacy ProKidney as of and for the year ended December&#160;31, 2021, and the related notes, in each case, included elsewhere in this prospectus; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">other information relating to SCS and Legacy ProKidney contained in this prospectus, including the Business Combination Agreement and the description of certain terms thereof set forth under &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Summary of the Prospectus&#8212;Recent Developments&#8212;Business Combination Agreement</div></div>,&#8221; as well as the disclosures contained in &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</div></div>.&#8221; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">83 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEETS MARCH&#160;31, 2022 </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except share and per share amounts) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 57%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">SCS&#160;Historical</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ProKidney<br/>Historical</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Transaction<br/>Accounting<br/>Adjustments<br/>(Note 3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Proforma<br/>Combined</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">52</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">29,802</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">531,461</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(a</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">561,315</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">543</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">592</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,135</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid clinical</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,855</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,855</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">595</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,249</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">531,461</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">567,305</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held in Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250,034</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(250,034</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(b</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,103</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,103</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Right of use assets, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,673</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,673</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred offering costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,108</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,108</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(c</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">374</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">374</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long term assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">124</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">124</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250,753</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53,507</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">276,319</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">580,579</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,509</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(34</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,502</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">328</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">328</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses and other</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,342</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,117</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,459</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Related party notes payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(20,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(d</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">958</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">958</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advances from related party</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(44</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(e</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,413</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">31,912</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(20,078</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,247</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long term liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred underwriting fee payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(f</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities, net of current portion</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,428</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,428</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax Receivable Agreement liability</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(g</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Temporary equity:</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares subject to possible redemption</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(h</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Redeemable noncontrolling interest</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">422,491</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(i</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">422,491</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney Corp.:</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney Corp. Class&#160;A ordinary shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(j</td>
<td style="vertical-align: bottom; white-space: nowrap;">),(h),(o)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney Corp. Class&#160;B ordinary shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(k</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCS:</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCS Preference shares, $0.0001 par value</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCS Class&#160;A ordinary shares, $0.0001 par value</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCS Class&#160;B ordinary shares, $0.0001 par value</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(o</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney:</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney - Class&#160;A Units</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">186,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(186,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(k</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney - Class&#160;B Units</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">62,663</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(62,663</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(k</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Additional&#160;paid-in&#160;capital</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">131,531</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(k</td>
<td style="vertical-align: bottom; white-space: nowrap;">),(l)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">131,531</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated deficit</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,361</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(228,996</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">249,163</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(k</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,806</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,360</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,167</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">131,606</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">139,413</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities, redeemable noncontrolling interest and equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250,753</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53,507</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">276,319</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">580,579</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">84 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEETS DECEMBER&#160;31, 2021 </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except share and per share amounts) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 54%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">SCS&#160;Historical</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ProKidney<br/>Historical</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Transaction<br/>Accounting<br/>Adjustments<br/>(Note 3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Proforma<br/>Combined</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">440</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,558</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">551,493</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(a</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">572,491</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">505</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">588</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,093</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid clinical</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">945</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,271</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">551,493</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">579,709</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investments held in Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250,008</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(250,008</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(b</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,358</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,358</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Right of Use assets, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,241</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,241</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">428</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">428</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other long term assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">248</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">248</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">251,201</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,298</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">301,485</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">592,984</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,870</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,834</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,704</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">267</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">267</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses and other</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,213</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,213</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advances from related party</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(c</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,880</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,314</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">14,184</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long term liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred underwriting fee payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(d</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities, net of current portion</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,067</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,067</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax Receivable Agreement liability</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(m</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Temporary equity:</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares subject to possible redemption</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250,008</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(250,008</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(e</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Redeemable noncontrolling interest</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">430,480</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(f</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">430,480</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New ProKidney:</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New ProKidney Class&#160;A ordinary shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(g</td>
<td style="vertical-align: bottom; white-space: nowrap;">),(e),(l)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New ProKidney Class&#160;B ordinary shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(h</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCS:</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCS Preference shares, $0.0001 par value</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCS Class&#160;A ordinary shares, $0.0001 par value</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCS Class&#160;B ordinary shares, $0.0001 par value</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">(1)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(l</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney:</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney - Class&#160;A Units</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">186,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(186,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(h</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney - Class&#160;B Units</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,927</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,927</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(h</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Additional&#160;paid-in&#160;capital</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">128,648</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(h</td>
<td style="vertical-align: bottom; white-space: nowrap;">),(i)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">128,648</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated deficit</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,388</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(161,510</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">188,427</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(h</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,529</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,387</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">26,917</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">128,723</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">147,253</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities, redeemable noncontrolling interest and equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">251,201</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40,298</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">301,485</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">592,984</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">85 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENTS OF OPERATIONS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE THREE MONTHS ENDED MARCH&#160;31, 2022 </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except share and per share amounts) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 50%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">SCS&#160;Historical</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ProKidney<br/>Historical</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Transaction<br/>Accounting<br/>Adjustments<br/>(Note 3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Proforma<br/>Combined</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,490</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,490</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operation and formation costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,006</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,006</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37,972</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37,972</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,006</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">66,462</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">70,468</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4,006</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(66,462</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(70,468</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(aa</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,981</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(66,476</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(70,465</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,010</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(bb</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,010</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,981</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(67,486</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(71,475</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss attributable to noncontrolling interest</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(53,264</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(cc</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(53,264</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss available to Class&#160;A ordinary shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,981</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(67,486</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">53,256</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18,211</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average Class&#160;A ordinary shares, basic and diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61,540,231</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per share attributable to Class&#160;A ordinary shares, basic and diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.30</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(dd</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">86 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENTS OF OPERATIONS </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE YEAR ENDED DECEMBER&#160;31, 2021 </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except share and per share amounts) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 50%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">SCS&#160;Historical</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">ProKidney<br/>Historical</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Transaction<br/>Accounting<br/>Adjustments<br/>(Note 3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Proforma<br/>Combined</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46,255</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46,255</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operation and formation costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,333</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,333</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,855</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,855</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,333</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55,110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">57,443</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,333</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(55,110</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(57,443</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(aa</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(55,108</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(57,441</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(bb</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(55,146</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(57,479</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss attributable to noncontrolling interest</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(42,834</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(cc</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(42,834</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss available to Class&#160;A ordinary shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,325</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(55,146</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">42,826</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14,645</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average Class&#160;A ordinary shares, basic and diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61,540,231</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per share attributable to Class&#160;A ordinary shares, basic and diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.24</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(dd</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">87 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom373959_9" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Description of Transaction </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July&#160;11, 2022, SCS and Legacy ProKidney consummated the Business Combination contemplated by the Business Combination Agreement. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Following the Closing, the combined company was organized in an umbrella <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">partnership-C</div> corporation (or &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Up-C</div></div></div>&#8221;) structure, and the combined company&#8217;s direct assets consisted of Post-Combination ProKidney Common Units and all of the issued and outstanding equity interests of GP, which replaced Legacy GP as the general partner of Legacy ProKidney upon the Closing, and substantially all of the operating assets and business of the combined company is held indirectly through Legacy ProKidney, as described further below. ProKidney is domiciled in the Cayman Islands. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Business Combination Agreement, the following transactions occurred: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">prior to the Closing: (i)&#160;Legacy ProKidney amended and restated the ProKidney Limited Partnership Agreement to be in the form of the Second Amended and Restated ProKidney Limited Partnership Agreement, which became effective upon the completion of the Business Combination; (ii)&#160;GP amended and restated its constitution, which became effective upon the completion of the Business Combination; (iii)&#160;SCS obtained the requisite approvals to amend and restate its amended and restated the memorandum and articles of association then in effect to be in the form of the Charter, which became effective upon the completion of the Business Combination; (iv)&#160;(A) each issued and outstanding Legacy ProKidney Class&#160;B Unit that was not vested pursuant to the terms of the applicable award agreement with the PMEL Existing Holder as of such time was recapitalized into one PMEL RCU, which would, when vested in accordance with the applicable award agreement, automatically convert into a Post-Combination ProKidney Common Unit (and the associated Legacy ProKidney Class&#160;B PMEL RSR would vest) and (B)&#160;all other issued and outstanding Legacy ProKidney Class&#160;A Units and ProKidney Class&#160;B Units were recapitalized into an aggregate number of Post-Combination ProKidney Common Units equal to (x) 175,000,000 minus (y)&#160;the number of PMEL RCUs issued pursuant to the foregoing clause (A); (v) Legacy ProKidney completed a restructuring of PMEL; and (vi)&#160;Legacy ProKidney issued 5,000,000 Post-Combination ProKidney Common Units pursuant to certain Subscription Agreements in connection with the election by certain holders to purchase Post-Combination ProKidney Common Units in lieu of SCS Class&#160;A ordinary shares; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at the Closing: (i)&#160;Legacy ProKidney issued to SCS a number of Post-Combination ProKidney Common Units equal to the number of fully diluted outstanding SCS ordinary shares as of immediately prior to the Closing (but after giving effect to all redemptions of SCS Class&#160;A ordinary shares and the purchase of SCS Class&#160;A ordinary shares and/or Post-Combination ProKidney Common Units pursuant to the PIPE Investment), in exchange for (a)&#160;(x) ProKidney Class&#160;B ordinary shares, which shares have no economic rights but entitle the holders thereof to vote on all matters on which shareholders of the combined company are entitled to vote generally, and (y)&#160;ProKidney Class&#160;B PMEL RSRs, which shall convert into ProKidney Class&#160;B ordinary shares upon the vesting of the associated PMEL RCUs (as described above), (b) an amount in cash equal to the aggregate proceeds obtained by SCS in the PIPE Investment and (c)&#160;an amount in cash equal to the aggregate proceeds available for release to SCS from the Trust Account (after giving effect to all redemptions of SCS Class&#160;A ordinary shares and after payment of any deferred underwriting commissions being held in the Trust Account and payment of certain transaction expenses); (ii) Legacy GP resigned as the general partner of Legacy ProKidney and GP was be admitted as the general partner of Legacy ProKidney; (iii)&#160;Legacy ProKidney distributed to the Closing ProKidney Unitholders the ProKidney Class&#160;B ordinary shares and ProKidney Class&#160;B PMEL RSRs received pursuant to clause (i)(a)&#160;(x) and (y) above; and (iv)&#160;the Earnout Participants received the Earnout Rights, which Earnout Rights will vest in three equal tranches upon the achievement of certain ProKidney share price milestones or certain change of control events. When </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">88 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">vested, the Earnout RCUs will automatically convert into Post-Combination ProKidney Common Units and the associated Earnout RSRs will automatically convert into ProKidney Class&#160;B ordinary shares, respectively. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Exchange Agreement as described elsewhere in this prospectus, each Post-Combination ProKidney Common Unit, together with one Class&#160;B ordinary share, is generally exchangeable for one Class&#160;A ordinary share, subject to certain procedures and restrictions. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation and Accounting Policies </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The unaudited pro forma condensed combined financial information has been adjusted to include transaction accounting adjustments related to the Business Combination in accordance with GAAP. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We determined that the Business Combination qualified as a common control transaction and, therefore, was accounted for akin to a reverse recapitalization, with no goodwill or other intangible assets recorded, in accordance with GAAP. Legacy ProKidney is considered the accounting acquirer primarily based on the evaluation of the following facts and circumstances: </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the guidance in ASC 805 for transactions between entities under common control, the assets, liabilities, and noncontrolling interests of Legacy ProKidney and SCS were recognized at their carrying amounts on the date of the Business Combination. Under this method of accounting, SCS was treated as the &#8220;acquired&#8221; company for financial reporting purposes. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of Legacy ProKidney issuing shares for the net assets of SCS, accompanied by a recapitalization. The net assets of SCS were stated at their historical value within the pro formas with no goodwill or other intangible assets recorded. </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The individual controlling Legacy ProKidney prior to the Business Combination also controls the combined company as a result of the Voting Agreement, which provides Tolerantia with the majority of the votes related to the appointment and removal of the majority of the Board; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Legacy ProKidney unitholders prior to the Closing comprise a majority of the voting power of the combined company following the Closing; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Senior management of Legacy ProKidney prior to the Closing comprise the senior management of the combined company following the Closing; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The operations of Legacy ProKidney prior to the Closing comprise the ongoing operations of the combined company following the Closing. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Upon completion of the Business Combination, GP became the sole general partner of Legacy ProKidney. Giving effect to the redemption of 22,829,769 Class&#160;A ordinary shares, ProKidney has the sole voting interest in Legacy ProKidney through its ownership of GP. As a result, ProKidney consolidated the financial results of Legacy ProKidney and reports a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest related to the Post-Combination ProKidney Units held by Legacy ProKidney&#8217;s investors prior to the Closing on ProKidney&#8217;s consolidated balance sheet. The computation of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-controlling</div> interest following the Closing, based upon the various redemption scenarios shown, is as follows: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Percentage</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest in ProKidney LP held by the Issuer</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">61,540,231</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Noncontrolling interest in the Issuer</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">180,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">241,540,231</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Proposed Accounting Treatment of the Earnout Rights </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As discussed in this Note 1, the Earnout Participants received 17,500,000 Earnout Rights upon Closing. Upon satisfaction, during the five-year period after the Closing, of certain volume weighted average price </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">89 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">(&#8220;VWAP&#8221;) thresholds, or a change in control with a per share price exceeding the VWAP thresholds within a five-year period immediately following the Closing, the Earnout Rights will automatically vest and convert into Post-Combination ProKidney Common Units and ProKidney Class&#160;B ordinary shares. As the Business Combination was accounted for as a reverse recapitalization, the issuance of the Earnout Rights to the Legacy ProKidney unitholders was accounted for as an equity transaction. Since the Earnout Rights were payable to the Legacy ProKidney unitholders (i.e., the accounting acquirer in the business combination), the accounting for the Earnout Rights arrangement did not fall under Accounting Standards Codification (&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">ASC</div></div>&#8221;) Topic 805, Business Combinations nor Topic 718, Stock Compensation. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The accounting for the Earnout Rights was also evaluated under ASC Topic 480, Distinguishing Liabilities from Equity, to determine if the arrangement should be classified as a liability. As part of that preliminary analysis, it was determined that the Earnout Rights did not meet the criteria to be accounted for as a liability. Additionally, the Earnout Rights were evaluated under ASC Topic 815, Derivatives. As part of that preliminary analysis, it was determined that the Earnout Rights met the definition of a derivative; however, they meet the scope exception criteria as they were clearly and closely related to the entity&#8217;s own shares, and met the criteria for equity treatment. Therefore, an adjustment to recognize the Earnout Rights would have no net impact on any financial statement line item as it would simultaneously increase and decrease additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital. Thus, no adjustment has been applied to the unaudited pro forma combined financial information related to the Earnout Rights. </div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to Unaudited Pro Forma Condensed Combined Financial Information </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The unaudited pro forma condensed combined financial information has been prepared in accordance with Article 11 of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-X.</div> The adjustments in the unaudited pro forma condensed combined financial information have been identified and presented to provide relevant information necessary for an illustrative understanding of the combined company upon consummation of the Business Combination in accordance with GAAP. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The unaudited pro forma condensed combined financial information has been presented for illustrative purposes only and is not necessarily indicative of the operating results and financial position that would have been achieved had the Business Combination occurred on the dates indicated. The unaudited pro forma condensed combined financial information does not purport to project the future operating results or financial position of ProKidney following the completion of the Business Combination. The unaudited pro forma adjustments represent management&#8217;s estimates based on information available as of the date of this unaudited pro forma condensed combined financial information and are subject to change as additional information becomes available and analyses are performed. SCS and Legacy ProKidney did not have any historical relationship prior to the transactions. Accordingly, no pro forma adjustments were required to eliminate activities between the companies. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The unaudited pro forma condensed combined financial statements give effect to the redemption of 22,829,769 Class&#160;A ordinary shares. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">90 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">3.</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction Adjustments </div></div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Adjustments to Unaudited Pro Forma Condensed Combined Balance Sheet as of March&#160;31, 2022 </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents pro forma adjustments to cash and cash equivalents to reflect the following: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands)</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCS cash held in Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250,034</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment of deferred underwriting fees</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PIPE Financing</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">574,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment to redeeming Public Stockholders</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(228,329</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment of other transaction costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(37,300</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of related party notes payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(20,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of related party advance</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(44</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Excess cash to balance sheet from Business Combination</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">531,461</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reflects the liquidation and reclassification of investments held in the Trust Account to cash and cash equivalents. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reflects the payment of $7.7&#160;million of underwriters&#8217; fees deferred by SCS and which were paid at the Closing. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reflects the gross proceeds of $574.8&#160;million from the issuance and sale of 57.5&#160;million ProKidney Class&#160;A ordinary shares at $10.00 per share pursuant to the Subscription Agreements entered into with PIPE Investors in connection with the PIPE Investment. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents the payments made to the holders of SCS Class&#160;A ordinary shares in connection with the redemption of 22,829,769 SCS Class&#160;A ordinary shares. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(5)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents transaction costs of $37.3&#160;million incurred by Legacy ProKidney prior to, or concurrent with, the Closing that were cash settled upon Closing in accordance with the Business Combination Agreement. Of that amount, approximately $17.5&#160;million related to investment transaction fees; $11.9&#160;million related to equity financing fees associated with the PIPE Investment, and the remaining $7.9&#160;million related to direct and incremental costs such as legal, tax, accounting, third-party advisory and other miscellaneous fees. This amount excluded the $7.7&#160;million of deferred underwriting fees related to the SCS initial public offering as described in note (2)&#160;above, any amounts relating to the ProKidney Promissory Notes, which were repaid at the Closing, and other SCS transaction costs. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(6)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents repayment of amounts drawn on ProKidney Promissory Notes. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(7)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of related party advance. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reflects the liquidation and reclassification of investments held in the Trust Account to cash and cash equivalents. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(c)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents reclassification of Legacy ProKidney deferred offering costs incurred through March&#160;31, 2022 to additional paid in capital as an offset to the proceeds from the transaction. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(d)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reflects repayment of amounts drawn on the ProKidney Promissory Notes. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(e)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of related party advance. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(f)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reflects the payment of $7.7&#160;million of underwriters&#8217; fees deferred by SCS for which payment is due upon the Closing. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(g)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon the completion of the Business Combination, the combined company became a party to the Tax Receivable Agreement. Under the terms of the Tax Receivable Agreement, the combined company is required to pay to certain parties to the agreement 85% of the tax savings that it is deemed to realize in certain circumstances as a result of certain tax attributes that exist following the Transaction and that are created thereafter, including as a result of payments made under the Tax Receivable Agreement. The combined company does not expect to record net deferred tax assets related to the tax basis adjustments associated with the exchange of Paired Interests as those deferred tax assets are not more </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">91 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">likely than not expected to be realized in accordance with ASC 740&#8212;Income Taxes. Accordingly, the combined company has not recorded a liability related to the Tax Receivable Agreement as of December&#160;31, 2021, as the liability is not considered to be probable in accordance with ASC 450&#8212;Contingencies. </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(h)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reflects the reclassification of SCS Class&#160;A ordinary shares, giving effect to the redemption of 22,829,769 SCS Class&#160;A ordinary shares. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(i)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As discussed in Note 1 to these unaudited pro forma condensed consolidated financial statements, the combined company will consolidate ProKidney, but does not own 100% of the economic interest in ProKidney. The noncontrolling interest reflecting actual redemptions is 74.5%. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(j)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reflects the gross proceeds of $574.8&#160;million, net of an adjustment for the associated par value, from the issuance and sale of 57.5&#160;million ProKidney Class&#160;A ordinary shares at $10.00 per share pursuant to the Subscription Agreements entered into with PIPE Investors in connection with the PIPE Investment. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(k)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents the recapitalization of the Legacy ProKidney Class&#160;A and Class&#160;B Units upon issuance of ProKidney Class&#160;B ordinary shares and Class&#160;B PMEL RSRs to Closing ProKidney Unitholders. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(l)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents pro forma adjustments to additional paid in capital to reflect the following: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 81%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands)</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PIPE Financing</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(j</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">574,743</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reclassification of ordinary shares subject to redemption to permanent equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(h</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,705</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of Class&#160;B ordinary shares to existing ProKidney owners</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(k</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction related fees</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(m</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(37,300</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of Earnout Shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(n</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reclassification of ProKidney deferred offering costs to equity upon close</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(c</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,108</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Noncontrolling interest</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(i</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(422,491</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted additional paid in capital</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">131,531</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(m)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents transaction costs of $37.3&#160;million incurred by Legacy ProKidney prior to, or concurrent with, the Closing that were cash settled upon Closing in accordance with the Business Combination Agreement. Of that amount, approximately $17.5&#160;million related to investment transaction fees; $11.9&#160;million related to equity financing fees associated with the PIPE financing and the remaining $7.9&#160;million related to direct and incremental costs such as legal, tax, accounting, third-party advisory and other miscellaneous fees. This amount excluded the $7.7&#160;million of deferred underwriting fees related to the SCS initial public offering as described in note (2)&#160;above, any amounts relating to the ProKidney Promissory Notes, which were repaid at the Closing, and other SCS transaction costs. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(n)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Represents the issuance of 17,500,000 Earnout Rights to Earnout Participants upon Closing. As discussed in Note 2 to the unaudited condensed consolidated financial statements, the adjustment to recognize the Earnout Rights would have no net impact on any financial statement line item as it would simultaneously increase and decrease additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(o)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents the exchange of SCS Class&#160;A ordinary shares, SCS Class&#160;B ordinary shares and related director restricted stock units held by the Sponsor and an independent director of SCS for ProKidney Class&#160;A ordinary shares. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Adjustments to Unaudited Pro Forma Condensed Combined Statement of Operations for the Three Months Ended March&#160;31, 2022 </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(aa)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents the adjustment to eliminate interest income related to the investment held in Trust Account. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(bb)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Does not reflect a pro forma adjustment to income tax expense as Legacy ProKidney has historically been in a net loss position. Legacy ProKidney files as a partnership for federal and state income tax </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">92 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">purposes. As such, each partner is responsible for reporting income or loss to the extent required by federal and state income tax regulations, based upon their respective share of Legacy ProKidney income and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">expenses.&#160;ProKidney-US&#160;is</div> a limited liability company and has elected to be treated as a C corporation, therefore, a provision for federal and state taxes has been recorded. Income tax expense of the combined company may differ from historical results due to the change in structure of ProKidney. </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(cc)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents the adjustment for the net loss attributable to noncontrolling interest. The noncontrolling interest, giving effect to redemptions, is 74.5%. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(dd)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents the loss per share calculated using the historical weighted average shares outstanding, and the issuance of additional shares in connection with the Business Combination, assuming the shares were outstanding since January&#160;1, 2021. As the Business Combination and related equity transactions are being reflected as if they had occurred at the beginning of the period presented, the calculation of weighted average shares outstanding for basic and diluted net income per share assumes that the shares issuable relating to the Business Combination were outstanding for the entirety of the period presented. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Adjustments to Unaudited Pro Forma Condensed Combined Balance Sheet as of December&#160;31, 2021 </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents pro forma adjustments to cash and cash equivalents to reflect the following: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands)</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCS cash held in Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250,008</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment of deferred underwriting fees</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,700</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PIPE Financing</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">574,800</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment to redeeming Public Shareholders</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(228,305</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment of other transaction costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(37,300</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of related party advance</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(6</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Excess cash to balance sheet from Business Combination</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">551,493</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reflects the liquidation and reclassification of investments held in the Trust Account to cash and cash equivalents. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reflects the payment of $7.7&#160;million of underwriters&#8217; fees deferred by SCS and which were paid at the Closing. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reflects the gross proceeds of $574.8&#160;million from the issuance and sale of 57.5&#160;million ProKidney Class&#160;A ordinary shares at $10.00 per share pursuant to the Subscription Agreements entered into with PIPE Investors in connection with the PIPE Investment. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents the payments made to the holders of SCS Class&#160;A ordinary shares in connection with the redemption of 22,829,769 SCS Class&#160;A ordinary shares. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(5)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents transaction costs of $37.3 million incurred by Legacy ProKidney prior to, or concurrent with, the Closing that were cash settled upon Closing in accordance with the Business Combination Agreement. Of that amount, approximately $17.5 million related to investment transaction fees; $11.9 million related to equity financing fees associated with the PIPE financing and the remaining $7.9 million related to direct and incremental costs such as legal, tax, accounting, third-party advisory and other miscellaneous fees. This amount excludes the $7.7 million of deferred underwriting fees related to the SCS initial public offering as described in note (2) above, any amounts relating to the ProKidney Promissory Notes, which were repaid at the Closing, and other SCS transaction costs. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(6)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of related party advance. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reflects the liquidation and reclassification of investments held in the Trust Account to cash and cash equivalents. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(c)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of related party advance. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">93 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(d)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reflects the payment of $7.7&#160;million of underwriters&#8217; fees deferred by SCS and which were paid at the Closing. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(e)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reflects the reclassification of SCS Class&#160;A ordinary shares, giving effect to the redemption of 22,829,769 SCS Class&#160;A ordinary shares. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(f)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As discussed in Note 1 to these unaudited pro forma condensed consolidated financial statements, the combined company will consolidate ProKidney but does not own 100% of the economic interest in Legacy ProKidney. The noncontrolling interest reflecting actual redemptions is 74.5%. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(g)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reflects the gross proceeds of $574.8&#160;million, net of an adjustment for the associated par value, from the issuance and sale of 57.5&#160;million ProKidney Class&#160;A ordinary shares at $10.00 per share pursuant to the Subscription Agreements entered into with PIPE Investors in connection with the PIPE Investment. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(h)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents the recapitalization of the Legacy ProKidney Class&#160;A and Class&#160;B Units upon issuance of ProKidney Class&#160;B ordinary shares and Class&#160;B PMEL RSRs to Closing ProKidney Unitholders. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(i)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents pro forma adjustments to additional paid in capital to reflect the following: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 82%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands)</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Note</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PIPE Financing</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(g</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">574,743</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reclassification of ordinary shares subject to redemption to permanent equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(e</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,703</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of Class&#160;B ordinary shares to existing ProKidney owners</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(h</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(18</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction related fees</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(j</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(37,300</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issuance of Earnout Shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(k</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Noncontrolling interest</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(f</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(430,480</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjusted additional paid in capital</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">128,648</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(j)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents transaction costs of $37.3&#160;million incurred by Legacy ProKidney prior to, or concurrent with, the Closing that were cash settled upon Closing in accordance with the Business Combination Agreement. Of that amount, approximately $17.5&#160;million related to investment transaction fees; $11.9&#160;million related to equity financing fees associated with the PIPE financing and the remaining $7.9&#160;million related to direct and incremental costs such as legal, tax, accounting, third-party advisory and other miscellaneous fees. This amount excluded the $7.7&#160;million of deferred underwriting fees related to the SCS initial public offering as described in note (2)&#160;above, any amounts relating to the ProKidney Promissory Notes, which were repaid at the Closing, and other SCS transaction costs. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(k)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Represents the issuance of 17,500,000 Earnout Rights to Earnout Participants upon Closing. As discussed in Note 2 to the unaudited condensed consolidated financial statements, the adjustment to recognize the Earnout Rights would have no net impact on any financial statement line item as it would simultaneously increase and decrease additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(l)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents the exchange of SCS Class&#160;A ordinary shares, SCS Class&#160;B ordinary shares and related director restricted stock units held by the Sponsor and an independent director of SCS for ProKidney Class&#160;A ordinary shares. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(m)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Upon the completion of the Business Combination, the combined company became a party to the Tax Receivable Agreement. Under the terms of the Tax Receivable Agreement, the combined company is required to pay to certain parties to the agreement 85% of the tax savings that it is deemed to realize in certain circumstances as a result of certain tax attributes that exist following the Transaction and that are created thereafter, including as a result of payments made under the Tax Receivable Agreement. The combined company does not expect to record net deferred tax assets related to the tax basis adjustments associated with the exchange of Paired Interests as those deferred tax assets are not more likely than not expected to be realized in accordance with ASC 740&#8212;Income Taxes. Accordingly, the combined company has not recorded a liability related to the Tax Receivable Agreement as of December&#160;31, 2021, as the liability is not considered to be probable in accordance with ASC 450&#8212;Contingencies. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">94 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Adjustments to Unaudited Pro Forma Condensed Combined Statement of Operations for the Year Ended December&#160;31, 2021 </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(aa)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents the adjustment to eliminate interest income related to the investment held in Trust Account.</div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(bb)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Does not reflect a pro forma adjustment to income tax expense as Legacy ProKidney has historically been in a net loss position. Legacy ProKidney files as a partnership for federal and state income tax purposes. As such, each partner is responsible for reporting income or loss to the extent required by federal and state income tax regulations, based upon their respective share of Legacy ProKidney income and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">expenses.&#160;ProKidney-US&#160;is</div> a limited liability company and has elected to be treated as a C corporation, therefore, a provision for federal and state taxes has been recorded. Income tax expense of the combined company may differ from historical results due to the change in structure of ProKidney. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(cc)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents the adjustment for the net loss attributable to noncontrolling interest. The noncontrolling interest, giving effect to actual redemptions, is 74.5%. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(dd)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents the loss per share calculated using the historical weighted average shares outstanding, and the issuance of additional shares in connection with the Business Combination, assuming the shares were outstanding since January&#160;1, 2021. As the Business Combination and related equity transactions are being reflected as if they had occurred at the beginning of the period presented, the calculation of weighted average shares outstanding for basic and diluted net income per share assumes that the shares issuable relating to the Business Combination were outstanding for the entirety of the period presented. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">95 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom373959_10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BUSINESS OF PROKIDNEY </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The following discussion reflects the business of ProKidney and its subsidiaries. In this section, unless context suggests otherwise, &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; generally refer to ProKidney LP and its subsidiaries prior to the Business Combination, and to ProKidney Corp. and its subsidiaries following the Business Combination. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Overview </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient&#8217;s own cells isolated from the patient intended for treatment. Our approach seeks to redefine the treatment of chronic kidney disease (&#8220;CKD&#8221;), shifting the emphasis away from management of kidney failure, to the restoration or improvement of kidney function to stop or delay progression of CKD. Our lead product candidate, which we refer to as REACT, is designed to stabilize or improve kidney function in a CKD patient&#8217;s diseased kidneys. REACT is a product that includes SRCs prepared from a patient&#8217;s own, autologous, renal cells. SRCs are formulated into a product for reinjection into the patient&#8217;s kidney using a minimally invasive outpatient procedure that can be repeated if necessary. Because REACT is a personalized treatment composed of cells prepared from a patient&#8217;s kidney, there is no need for treatment with immunosuppressive therapies, which are required during a patient&#8217;s lifetime when a patient receives a kidney transplant from another, allogeneic donor. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We are currently conducting a Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease. We are also conducting a Phase 1 clinical trial for REACT in subjects with congenital anomalies of the kidney and urinary tract (&#8220;CAKUT&#8221;). REACT has been well tolerated by subjects with moderate to severe diabetic kidney disease in Phase 1 and 2 clinical testing to date. It has also been shown to stabilize renal function in subjects based on measurements of iohexol renal clearance and urinary <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">albumin-to-creatinine</div></div> ratio (&#8220;UACR&#8221;). REACT has received Regenerative Medicine Advanced Therapy (&#8220;RMAT&#8221;) designation from the FDA. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our patented technology includes multiple breakthroughs in the manufacturing and medical delivery of cellular therapy products. While it has long been held that the body contains cells with regenerative power, our technology is able to prepare key progenitor cells, SRCs, from expanded patient kidney cells for reinjection into patients and restore their lost kidney function due to chronic diseases. Our process begins when a small biopsy of a patient&#8217;s diseased kidney is sent to our cGMP manufacturing facility. We are able to process cells taken from the biopsy and select those with a regenerative capacity. The selected cells, SRCs, are formulated into a personalized product for reinjection into the damaged kidney. To date, clinical studies suggest that REACT can positively impact renal function by stabilizing eGFR or attenuating the rate of eGFR decline in patients with type 2 diabetic CKD. Other improvements observed with REACT treatment include stabilization in UACR, increased kidney cortical thickness, and improved hemoglobin levels, suggestive of a reduced risk of anemia. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We are initially pursuing the development of REACT for use in moderate to severe CKD patients in the United States with diabetes as the primary cause and may include hypertension as potential label expansion indication. We estimate that approximately <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">38-39&#160;million</div> adults, representing approximately 15% of the U.S. adult population, currently suffer from CKD, of which approximately <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">17-18&#160;million</div> patients have stage 3 or 4 CKD, and approximately 13.4&#160;million patients have stage 3 or 4 CKD that is caused by diabetes (approximately 8.3 million) or hypertension (approximately 5.1 million). With respect to those patients with CKD caused primarily by diabetes, we estimate that approximately <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-5&#160;million</div> patients would be eligible to be treated with REACT. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">96 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Pipeline </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are leveraging our cell therapy technology to develop product candidates designed to stop or delay renal failure in CKD from diabetes and CAKUT. The following table summarizes our current pipeline: </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Multiple Potential Therapeutic Targets for Treatment of CKD </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g373959g97s11.jpg" style="width: 605px; height: 165px;"/></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">*</div></div></td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Plan to launch an additional phase 3 trial <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-016</div> in the first quarter of 2023.</div></div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Biopsy tissue of a patient&#8217;s diseased kidney is obtained, and from that sample we prepare and select for SRCs, progenitor cells, by enzymatically dissociating tissue, expanding the dissociated cells and separating the expanded cells via density gradient centrifugation. Clinical studies suggest that REACT can positively impact renal function by stabilizing eGFR or attenuating the rate of eGFR decline in type 2 diabetic CKD patients. We have developed a cryopreserved version of REACT that allows for long-term product preservation to be used in our Phase 3 trials of REACT (called <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-006</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-016),</div> and our Phase 2 trial of REACT (called <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-007),</div> treating diabetes patients with CKD. In addition to the cryopreserved formulation of REACT, we are using a gelatin-based hydrogel formulation in our ongoing Phase 2 trials (called <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RMCL-002</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-003)</div> and Phase 1 trial (called <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-004).</div> We have two preclinical programs (called REACT/Gen and REACT/Universal) where we plan to use genetically modified bioactive renal cell populations to provide regenerative effects to a diseased kidney. The preclinical programs aim to effectively obtain &#8220;universal donor&#8221; immune-privileged renal cell populations, where gene editing is used to generate &#8220;allogeneic&#8221; renal cell populations, to be administered to patients without immunosuppression. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Team and Corporate History </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have an experienced internal research and development team focused on utilizing our deep understanding of kidney disease pathways to discover and develop novel cell-based therapies with a multi-modal mechanism targeting various pathways. Since our founding, we have expanded our team to incorporate additional expertise as needed to pursue our goal of becoming a fully integrated biopharmaceutical company. We have assembled key management team members with expertise in kidney disease, cell therapy, development, regulatory affairs, medical affairs, operations, quality, and manufacturing. Our Chief Executive Officer, Tim Bertram, has more than 38 years of pharmaceutical development expertise and has led innovations in cellular therapeutics for over 18 years. Our Chief Operating Officer, Deepak Jain, Ph.D., has over 36 years of experience in the development of biologics, tissue engineered and cell therapy products. Our technology is being developed based on work that has been conducted for the past 20 years at different institutions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney Bermuda was formed in December 2018 as a Bermuda limited liability company and was founded by a group of investors in the pharmaceutical industry. ProKidney Bermuda was initially capitalized with $75&#160;million. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In January 2019, ProKidney Bermuda acquired all of the equity interests in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US.</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> was duly incorporated under the Cayman Islands Companies Act on </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">97 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">December&#160;21, 2015 as an exempted company. In 2020, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY&#8217;s</div> name was changed from RegenMed (Cayman) Ltd. to ProKidney, and ProKidney US&#8217; name was changed from Twin City Bio LLC to ProKidney, LLC. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> is a Delaware limited liability company formed on December&#160;18, 2015. On August&#160;5, 2021, ProKidney LP was organized as a limited partnership under the Irish LP Act, and, as applicable, the Partnership Act 1890, of Ireland, with ProKidney Bermuda becoming a wholly owned subsidiary of ProKidney LP. References to &#8220;ProKidney&#8221; or the &#8220;Company&#8221; generally refer to ProKidney LP after this reorganization and to ProKidney Corp. following the Closing. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">ProKidney Bermuda acquired the equity interests in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> to develop its renal advanced cell therapy, which has the potential to stabilize or improve renal function in patients with chronic kidney disease or delay or eliminate the need for dialysis and organ transplantation. ProKidney acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> to provide contractual development and manufacturing services to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY,</div> which is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US&#8217;s</div> only customer. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Strategy </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our goal is to become a fully integrated biopharmaceutical company pioneering treatments for CKD. Key components of our business strategy include the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Obtain regulatory approval for and successfully commercialize REACT, initially as a treatment for patients with chronic kidney disease caused by diabetes. </div></div></div></div>We intend to continue to pursue the clinical development of REACT through a world-wide Phase 3 clinical development program that has been reviewed by both the EMA and the FDA. We activated the first site for our first Phase 3 clinical trial, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-006,</div> in the fourth quarter of 2021 with the first Informed Consent Form signed and the first subject randomized into the trial in the first quarter of 2022. Our second Phase 3 trial, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-016,</div> is planned to randomize, or &#8220;launch,&#8221; in the first quarter of 2023 outside the United States. A long term follow up trial, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-008,</div> is expected to launch in late 2023, for subjects who received REACT as part of our trials <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-006,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-007</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-016.</div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expand the clinical development of REACT for the treatment of additional indications, including CKD caused by Congenital Anomalies of the Kidney and Urinary Tract and hypertension. </div></div></div></div>CAKUT is the cause of more than 50% of pediatric cases of renal failure, with long-term complications of CKD which may progress into adulthood. We are currently enrolling patients in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-004,</div> a Phase 1 clinical trial that is designed to assess the ability of REACT to prevent, stop, or delay the negative effects of CAKUT. We aim to complete the enrollment and obtain additional interim data by the end of 2022. Results from interim data may not be indicative of results from future data as patient enrollment continues and more patient data becomes available and will be viewed with caution until the final data are available. Hypertension related CKD is the second most common cause of CKD in adults. Future trials may address CKD in this population. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Discover and develop additional product candidates for the treatment of kidney diseases utilizing our cell therapy approach. </div></div></div></div>Our team has extensive experience in discovery research, deep expertise in kidney disease and a strong record of publication in high-impact peer reviewed journals. The team is focused on understanding additional disease pathways associated with kidney disease, identifying key targets for intervention and generating product candidates against these targets. We may also <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-license</div> from or collaborate with third parties to develop product candidates that, based on our understanding of kidney diseases and pathways, we believe are promising therapeutics. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Maintain and continually refine our sophisticated internal expertise in manufacturing our products</div></div></div></div>. We have developed and built a cGMP manufacturing facility in which we manufacture REACT for clinical trials, which we intend to continue to develop for purposes of the eventual commercial manufacturing process, assuming receipt of necessary regulatory approvals. Our current cGMP manufacturing facility is capable of manufacturing product for our Phase 3 clinical trials and could serve as our commercial launch facility. We anticipate construction of automated manufacturing facilities to meet demand for REACT upon commercialization. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">98 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Kidney Disease Overview </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CKD is highly prevalent in the United States and European Union. Based on available U.S. data from the 2018 National Health and Nutritional Examination Survey, we expect the aggregate CKD population in the United States to reach approximately 74.4&#160;million in 2020, approximately 82.2&#160;million in 2030 and approximately 90.9&#160;million in 2040. The estimated aggregate CKD population in the European Union can reach approximately 93% of the expected CKD population in the United States. We believe that the prevalence in the United States is approximately 15% of the adult population. The most common causes of CKD among adults are diabetes, hypertension, and glomerular disease, and in the pediatric population, CAKUT. In the United States, it is believed that approximately 18&#160;million patients per year suffer stage 3 or 4 from CKD. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Approach: Working to Restore Kidney Function through Autologous Cell Therapy </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Autologous cell therapy refers to the prevention or treatment of human disease by the administration of a person&#8217;s own cells that have been selected, multiplied and formulated for delivery outside the body. We believe that our technology has the potential to restore kidney function by using a patient&#8217;s own SRCs to restore natural healing processes. By contrast, organ transplantation from other donors, or allogeneic transplants, can be associated with surgical complications, organ rejection and failure. Further, organ transplantation patients live with the adverse effects of immunosuppressive therapies and ongoing therapeutic maintenance that are required in order to reduce the risk of rejection of transplanted organs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our kidney restoration process begins when a small biopsy of the diseased kidney is sent to our laboratory. We are able to identify the patient&#8217;s own healthy progenitor cells and formulate them into a personalized product that can be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-injected</div> into the damaged kidney for repair and restoration of function. Due to one severe bleed that occurred during an early REACT injection procedure, we changed to a noncutting needle design for the REACT procedure, and there have been no injection-related serious adverse events since then. Based on preclinical studies, when the manufactured REACT product candidate is injected into the diseased kidney, the progenitor cells it comprises rapidly distribute throughout the kidney and integrate into the damaged nephrons and interstitium. To date, clinical studies suggest that treatment with REACT in patients with type 2 diabetes and CKD can positively impact renal function by stabilizing eGFR or attenuating the rate of eGFR decline. Other improvements observed with REACT treatment include stabilization and/or reduction in UACR, increased kidney cortical thickness, and improved hemoglobin levels, suggestive of a reduced risk of anemia. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">REACT, an autologous homologous cell admixture, is made from expanded autologous SRCs, obtained from each individual subject&#8217;s kidney biopsy. To manufacture REACT, biopsy tissue from each enrolled subject will be sent to ProKidney, in whose facilities renal cells will be expanded and SRCs selected. SRCs are then formulated into the cryopreserved or gelatin-based hydrogel product at a concentration of 100 x 106 cells/mL, and shipped to the clinical site. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">99 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g373959g99d44.jpg" style="width: 588px; height: 342px;"/></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Product Candidates </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">REACT is currently in a Phase 3 development program, as well as ongoing Phase 2 clinical trials, for the treatment of moderate to severe diabetic kidney disease and a Phase 1 clinical trial for REACT in patients with CAKUT. These trials are being or will be conducted at over 150 clinical sites throughout the United States, Europe, Asia and Latin America. REACT has been well tolerated in clinical trials to date involving patients with moderate to severe diabetic kidney disease. For example, in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RMCL-002</div> Phase 2 clinical trial, the interim analysis as of September 2021 demonstrates there is a statistically significant improvement in a measurement of kidney function, referred to as eGFR, between treatment arms in the trial, measured at six months after the second injection of REACT <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(p-value=0.032),</div> nine months after the second injection of REACT <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(p-value=0.018),</div> and 12 months after the second injection of REACT <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(p-value=0.019).</div> The procedure appeared to be well tolerated, consistent with renal biopsy. Adverse events reported are generally associated with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-morbidities</div> of Type 2 diabetes. The ongoing clinical development program utilizes a newly developed percutaneous injection method into the kidney that is conducted using conscious sedation in an outpatient <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">same-day</div> procedure. We cannot assure you that the improvements in eGFR that we have observed as of September 2021 in our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RMCL-002</div> Phase 2 clinical trial will be observed in any future clinical trials. Likewise, promising results in interim analyses or other preliminary analyses may not ensure that the clinical trial as a whole will be successful. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Background and Unmet Need </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Chronic Kidney Disease (CKD) </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">CKD is characterized by progressive nephropathy that, without therapeutic intervention, will worsen until the subject reaches end stage renal disease (&#8220;ESRD&#8221;). CKD patients suffer from reduced kidney function, demonstrated by decreased eGFR, or evidence of kidney damage, such as increased excretion of urinary albumin as shown in physician office laboratory testing. The global prevalence of CKD is estimated at 10% with ranges of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-16%</div> in various high populations. CKD is associated with considerable morbidity, such as diabetes mellitus, and is often accompanied by adverse outcomes due to underlying disease states and/or risk factors such as renovascular disease, hypertension and diabetes, causing an increased risk of mortality. 97% of patients with moderate to severe CKD have asymptomatic Stage 3 disease, but even this stage of CKD is associated with a </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">100 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-</div> to four-fold rise in cardiovascular disease risk, along with a significant increase in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">all-cause</div> mortality. Only a small proportion of CKD patients progress to ESRD (i.e., Stage 5 disease), but the increasing life expectancy of humans has led to growing numbers of patients with chronic diseases and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-stage</div> organ failure. Even with costly treatments, subjects with ESRD experience substantial morbidity and mortality. To survive, ESRD subjects require renal replacement therapy through peritoneal dialysis, hemodialysis or kidney transplantation. Preventing or delaying the onset of adverse outcomes of CKD via early intervention is the primary strategy for CKD management. Nevertheless, early treatments have been less than optimal, resulting in a significant unmet medical need for improved interventional strategies to manage CKD and delay the regression to ESRD. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The major causes of CKD in adults are diabetes and hypertension. Nearly half of all CKD cases arise from diabetes, with or without hypertension. The incidence of CKD continues to increase, primarily due to the increased worldwide incidence of type 2 diabetes and metabolic syndrome. Staging and grading of kidney function are most often quantified by estimated glomerular filtration rate, which is defined as the volume of plasma from which a given substance is completely cleared by glomerular filtration per unit time. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease provided guidelines intended to aid general practitioners and nephrologists in the evaluation, classification, and management of CKD in both adults and children. As set forth below, Figure 1 categorizes the risk of ESRD from &#8220;low&#8221; to &#8220;very high&#8221; based on both eGFR measurements, ranging from &gt;90 mL/min/1.73m2 to &lt;30 mL/min/1.73m2, and albuminuria classifications ranging from &lt;30 mg/g to &gt;300 mg/g. When the kidneys cease to function entirely, which constitutes ESRD, renal replacement therapy in the form of dialysis or transplantation is generally required. </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Summary of Classification Estimates for CKD </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g373959g10a01.jpg" style="width: 457px; height: 353px;"/></div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">All-cause</div> mortality rates were shown to increase as GFR declined; mortality rates were highest at Stages <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">4-5</div> of CKD. Populations defined as having an eGFR &lt;60 mL/min/1.73m2 consistently exhibited a higher mortality rate than comparator groups where there was no evidence of CKD. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Treatment of patients with CKD is focused on slowing progression and preparing for kidney failure or replacement. For many patients, CKD occurs as part of a complex comorbidity cluster, especially with cardiovascular disease and type 2 diabetes. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">101 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increased risk of cardiovascular disease can be a complication of CKD or an independent comorbidity associated with type 2 diabetes. The goals in the treatment of CKD are to lower cardiovascular risk and prevent or slow the progression of kidney failure via administration of angiotensin converting enzyme inhibitors and/or angiotensin receptor blockers to decrease proteinuria and control hypertension, insulin and anti-diabetic agents for glycemic control (e.g., reduced serum hemoglobin A1c), and statin therapy to counter dyslipidemia. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">When a patient reaches ESRD, renal replacement therapy in the form of kidney dialysis or transplantation is generally required. The vast majority of Stage 5 CKD patients in the United States and certain other developed countries receive hemodialysis. Dialysis replaces about <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-15%</div> of kidney function, depending on the intensity and frequency of use; dialysis also helps to restore fluid and electrolyte balance when kidneys fail. However, the life expectancy of an ESRD patient initiating hemodialysis is &lt; 10 years. Additionally, hemodialysis has been associated with multiple, serious complications as well as interference with quality of life, due to the need for frequent dialysis and vascular access maintenance. Although kidney transplantation remains the most effective form of therapy for CKD currently, there is a chronic shortage of organs. If a patient can secure a kidney for transplantation, long-term immunosuppressive therapy is required to prevent rejection. Use of these regimens results in a higher incidence of infection and, over the long term, some types of cancer. And while xenotransplantation might be a promising alternative approach to bridge the gap between the supply and demand of human organs, tissues, and cells, immunological barriers are also limiting factors in clinical xenotransplantation. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">While patients continue to lose kidney function on existing therapies, the cost of CKD treatment is high and the rates of CKD and ESRD along with the associated expenditures are expected to continue to rise. As a large source of healthcare expenditure in the United States, the Medicare spend on beneficiaries with CKD is $80&#160;billion. Medicare spend on beneficiaries with ESRD can reach $50&#160;billion, with $93,000 Medicare annual cost per patient for dialysis. Additionally, the estimated ESRD cost per patient with commercial insurance, assuming a five-year dialysis period, is up to $2&#160;million. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 0pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="color: red; letter-spacing: 0px; top: 0px;;display:inline;">
<img alt="" src="g373959g10b02.jpg" style="width: 499px; height: 397px;"/></div> </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">102 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based on ProKidney management estimates and analysis </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We estimate that there are approximately 4 to 5&#160;million REACT eligible patients. Assuming that we obtain requisite regulatory approvals and that the REACT market penetration rate is 1% in the United States alone, the expected size of the overall market in the United States for REACT could reach up to $16&#160;billion based on the average cost of recently launched novel targeted therapies. Taken together, there is a critical medical and market need for improved therapies for CKD which could stop or dramatically slow the progression of disease and significantly delay the need for renal transplantation. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Congenital Anomalies of the Kidney and Urinary Tract (CAKUT) </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CAKUT is a group of abnormalities affecting the kidneys or other structures of the urinary tract. CAKUT results from abnormal development of the urinary tract system and is present at birth (i.e., it is congenital), although the abnormality may not become apparent until later in life. CAKUT is the most common kind of congenital birth defect, affecting roughly 1 in 500 babies born. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Individuals with CAKUT have one or more kidney or urinary tract abnormalities. The parts of the urinary tract that may be affected include the bladder, the tubes that carry urine from each kidney to the bladder (the ureters), and the tube that carries urine from the bladder out of the body (the urethra). For paired structures, like the kidneys and ureters, one or both may be affected. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are various types of CAKUT. Many different developmental abnormalities are classified as CAKUT, including underdevelopment or absence of a kidney and nephrons, a kidney formed of fluid-filled sacs called cysts, buildup of urine in the kidneys, an extra ureter leading to the kidney, a blockage in a ureter where it joins the kidney, an abnormally wide ureter, backflow of urine from the bladder into the ureter, and an abnormal membrane in the prostatic urethra that blocks the flow of urine out of the bladder. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The causes of CAKUT are complex, and much remains to be uncovered about the genetic and environmental regulators of kidney and outflow tract development. It is likely that a combination of genetic and environmental factors contribute to the formation of kidney and urinary tract abnormalities. The genetic factors involved in most cases of CAKUT are unknown. Syndromic CAKUT is caused by changes in the genes associated with the particular syndrome. Variations in these same genes can also underlie some cases of isolated CAKUT. In addition, environmental factors may influence development of CAKUT. The risk of CAKUT is higher in babies whose mothers had diabetes, took certain medications that are harmful to the kidneys, such as some <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">anti-seizure</div> medicines, or lacked certain vitamins and minerals, such as folate and iron, during pregnancy. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Most cases of CAKUT are diagnosed from antenatal ultrasound imaging, and the remaining cases of CAKUT are usually only diagnosed after an infant or child develops a urinary tract infection, prompting ultrasound and/or other imaging studies to examine the kidneys and outflow tracts. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CAKUT is often one of several features of a condition that affects multiple body systems, and it varies in severity. The abnormalities can result in recurrent urinary tract infections or a buildup of urine in the urinary tract, which may damage the kidneys or other structures. Severe CAKUT can lead to life-threatening kidney failure and ESRD. Children with severe CAKUT may require dialysis and transplantation as infants, and they may experience long-term effects on their ability to lead independent lives as adults. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There is currently a need for greater understanding of the pathogenesis of CAKUT, as well as an unmet need for means for providing proper treatment of those affected by this condition. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Clinical Development </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our completed clinical trials and currently ongoing clinical trials of REACT are summarized below; the name of the product candidate tested in the trials was changed from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Neo-Kidney</div> Augment (&#8220;NKA&#8221;) to REACT after completion of some of the trials. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">103 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The summary below also includes interim results which are based on a preliminary analysis of then- available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular trial. In particular, we have announced interim results from our ongoing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RMCL-002</div> Phase 2 clinical trial and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-004</div> Phase 1 clinical trial and plan to evaluate interim results from our ongoing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-006</div> Phase 3 clinical trial in early 2025 and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-016</div> Phase 3 clinical trial in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-2025.</div> Interim results from clinical trials that we may complete are not necessarily indicative of results from future data and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or topline results also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Diabetic Kidney Disease (DKD) </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Phase 1 Clinical Development <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(TNG-CL010</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TNG-CL011)</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TNG-CL010</div> was an open-label safety and delivery optimization study of REACT (formerly known as NKA) in subjects with CKD conducted in Sweden. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TNG-CL010</div> commenced in April 2013 and terminated in December 2014. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TNG-CL011</div> was also an open-label safety and delivery optimization study of REACT in subjects with type 2 diabetes and CKD conducted in the United States. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TNG-CL011</div> commenced with first subject enrolled in February 2014 and terminated in December 2014. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The primary objective of these trials was to assess the safety and delivery of REACT injected into one kidney. Six subjects from Sweden <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(TNG-CL010)</div> and one from the United States with Diabetes Type 2 CKD, ranging in age from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">53-70</div> years, eGFR levels between <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">19-34</div> (average 25 +/- 2, Cystatin C) and iohexol clearance of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">15-39,</div> average 26 +/- 3, were enrolled. One subject with Type 2 DKD was enrolled in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">TNG-CL011.</div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The results from the Phase 1 trials indicated that REACT was well tolerated when administered to the kidney, with no adverse events from the autologous SRC. When the decline of renal function <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-</div> and post- injection were compared, the subjects receiving REACT in this Phase 1 trial had an imputed delay in dialysis of approximately 1.5 years beyond the standard of care because of slowing in the rate of reduction in eGFR from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-injection</div> baseline. Cortical thickness increased in the injected kidney from an average of 14 mm at time of injection to approximately 16 mm after one year. Renal function was stabilized following the REACT injection by iohexol clearance and based on the subjects&#8217; ACRs. Subjects with a baseline anemia (n = 3 of 7) showed improved hemoglobin levels after REACT injection, and the remaining subjects maintained normal levels during the study. Antihypertensive medication was reduced in three of six subjects during the first six months following injection with REACT. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Phase 2 Clinical Development <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(RMCL-001,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RMCL-002,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-003,</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-007)</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RMCL-001:</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RMCL-001</div> was a Phase 2, open-label safety and efficacy study of REACT in subjects with type 2 diabetes and CKD. The study commenced in May 2016 and was ended in May 2017. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The primary objective of this study was to assess the safety and efficacy of a second REACT injection using a minimally invasive percutaneous procedure that was done under conscious sedation as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">same-day</div> outpatient procedure. A single subject with an eGFR of 14ml/min/1.73m2 was enrolled from the Phase 1 study <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(TNG-CL011)</div> described above. The second dose of REACT was manufactured from cryopreserved renal cells obtained from the Phase 1 renal biopsy. The subject was administered a dose of 3x106 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cells/g-KWest.</div> The subject&#8217;s eGFR increased to approximately 20 ml/min/1.73m2 for a period of eight months, after which the subject experienced a precipitous drop in renal function and began hemodialysis. The study was terminated by the sponsor of the clinical trial after this subject went onto dialysis and resources diverted to study <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RMCL-002.</div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">104 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RMCL-002:</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RMCL-002</div> is an ongoing Phase 2, prospective, randomized, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">double-arm,</div> deferred treatment, open-label, repeat dose, safety and efficacy study of REACT in subjects with type 2 diabetes and CKD. The first subject was enrolled in this study in February 2017, and subjects are now undergoing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up.</div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The primary objective of this study is to assess the safety and efficacy of up to two REACT injections given six months (up to four weeks after target date) apart in Type 2 Diabetic Disease patients with eGFRs between 20 and 50 ml/min/1.73m2, with both doses delivered into the biopsied kidney using an outpatient, minimally invasive, percutaneous approach under conscious sedation in less than 90 minutes. Patients will receive two doses of REACT of 3x106 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">cells/g-KWest.</div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Patients were randomized (1:1) to the active treatment group and the deferred treatment group (i.e., the control group) following renal biopsy. Subjects in the active treatment group receive their first REACT injection as soon as the REACT product is manufactured and shipped to the clinical site. After six months (up to four weeks after target date), a second injection is given, as appropriate. In contrast, subjects in the deferred treatment group will undergo a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-month</div> period of observation after renal biopsy. The deferred treatment group allows assessment of the rate of change in kidney function and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-morbidities</div> in a nonexposed group compared to the active treated arm. During this time, they will receive contemporaneous, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">standard-of-care</div></div> therapy for CKD while undergoing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> evaluations every three months, similar to subjects in the active treatment group. After 12 months, subjects from the deferred treatment group will receive a series of up to two REACT injections given six months (+/- four weeks of the target date) apart, as appropriate. Consequently, the study design includes a randomized control group receiving <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">standard-of-care</div></div> treatment for the first 12 months and a randomized, active treatment group receiving up to two REACT injections and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> evaluations during the same period of time. In addition, each subject&#8217;s baseline rate of renal decline, based on adequate historical and clinical data obtained 18 months prior to REACT injection, will serve as a comparator for monitoring the rate of progression of renal insufficiency over time. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate number of subjects enrolled for the Phase 2 clinical trial was 83. Upon withdrawal and/or replacement of 2 subjects, 81 subjects were enrolled as of December 2020, of which 39 subjects were enrolled into the active treatment group and 42 subjects were enrolled into the deferred treatment group. As of March&#160;31, 2022, 39 subjects enrolled in the active group received their first injection, and 34 have received their second. No further injections will occur in the active group. 33 subjects in the deferred group have crossed over into the active group, with 33 subjects having received their first injection and 21 having received their second injection as of March&#160;31, 2022. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The rate of progression of renal function for the active treatment group, assessed via <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-randomized</div> serial measurements of eGFR over 24 months after the last REACT injection, will be compared against that of the deferred treatment group. In addition, each subject&#8217;s baseline rate of eGFR decline, derived from historical and clinical data, will be compared against the individual subject&#8217;s rate of eGFR decline through 24 months following the final REACT injection. The rate of progression of renal function of subjects, if any, who received a single REACT injection may be compared against that of subjects who received two REACT injections. Patients will be followed through 24 months after their last REACT injection in part 1 of the trial. An open label extension portion of the study (part 2) was added in February 2021 to follow all subjects for an additional 3 years. Visits will be conducted at <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-month</div> intervals to give a total of 5 years (part 1 + part 2) of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> after the last REACT injection. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Subjects in this trial will complete the Kidney Disease Quality of Life (&#8220;KDQOL&#8221;) survey, which is a subjective kidney-specific measure of health-related quality of life, and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">EQ-5D-5L</div></div> survey, which is a health- related quality of life questionnaire. Scores from the active treatment group will be compared against scores from the deferred treatment group. Subjects from the deferred treatment group will comprise the control group for the analysis of KDQOL scores. In addition, each subject&#8217;s baseline score will be compared against his or her </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">105 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">KDQOL scores obtained over the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">24-month</div> period after the last REACT injection. KDQOL scores from subjects who received a single REACT injection may be compared against scores from subjects who received two injections. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Results as of the September 2021 interim analysis demonstrate that renal function has stabilized or improved in the subjects who have received a full course (2 injections) of REACT and has steadily declined in the deferred treatment group. The overall mean total slope for the active treatment group is a positive (+5.0 ml/ min/1.73m2/year), whereas the overall mean total slope for the deferred treatment group is a decline <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(-3.9</div> ml/ min/1.73m2/year). This shows an effect difference of +8.9 ml/min/1.73m2/year in annualized change in renal function between the active treatment group and the deferred treatment group. Each slope is calculated using a simple linear regression between the average eGFR measurements on the first injection day and three, six, nine and 12 months following the last injection day, where the averages are assumed to be equally spaced. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The interim analysis as of September 2021 demonstrates there is a statistically significant difference in the average eGFR between treatment arms (subjects who received a full course of REACT compared to the standard of care) at six months post 2nd injection <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(p-value=0.032),</div> nine months post 2nd injection <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(p-value=0.018)</div> and 12 months post 2nd injection <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(p-value=0.019).</div> The outpatient kidney biopsy and REACT injections procedures are minimally invasive and well tolerated and complications are commensurate with standard of care and published cohort trials and meta-analysis studies. Other adverse events reported are commonly associated with the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-morbidities</div> of Type 2 diabetes and similar to those seen in other small molecule CKD trials. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We aim to have all deferred subjects dosed in 2022, obtain additional interim data and complete all active subjects <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> in November 2023, complete all deferred subjects <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> in 2024, and expect the clinical study report to be available in early 2025. Results from interim data may not be indicative of results from future data. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-003:</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-003</div> is a Phase 2, prospective open-label, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">single-arm,</div> safety and tolerability study of REACT in subjects with type 2 diabetes and CKD. This study commenced in March 2018 with first subject enrolled. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The primary objective of this study is to assess the safety and efficacy of up to two REACT injections given six months (up to four weeks after target date) apart in Type 2 Diabetic Kidney Disease patients with eGFRs between 14 and 20 ml/min/1.73m2 and delivered into the biopsied kidney using a minimally invasive percutaneous approach that can be delivered under conscious sedation in less than 90 minutes. Subjects have an eGFR of between 14&#8212;20 ml/min/1.73m2. Subjects receive up to two doses of REACT of 3x106 cells/ <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">g-KWest.</div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This study has completed enrollment and dosing has commenced for all 10 subjects, with nine subjects having received both doses. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We completed the enrollment of 10 subjects in February 2020. As of March&#160;31, 2022, seven subjects had initiated dialysis, one of which died due to complications related to COVID. An additional subject died due to cardiovascular complications. For the seven subjects that initiated dialysis (baseline average eGFR of 17.5 ml/ min/1.73m2), the time between the first REACT injection and the initiation of dialysis averaged 76 weeks, ranging from 34 weeks to 121 weeks. Of the 10 subjects, two responding and receiving a second dose of REACT had a positive annualized eGFR slope of +1.1 ml/min/1.73m2/year, while the other eight subjects are continuing to progress with an average decline in annualized eGFR of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">-3.9</div> ml/min/1.73m2/year. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We aim to continue to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> until late 2022 and expect the clinical study report to be available in 2023. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-007: </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-007</div> is an ongoing Phase 2, prospective, randomized, open-label, repeat dose, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">double-arm,</div> controlled safety and efficacy study of REACT in subjects with type 1 or 2 diabetes and CKD. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">106 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The primary objective of this study is to assess the safety and efficacy of up to two REACT injections given three months apart (up to 60 days after target date) in Type 1 and 2 Diabetic Kidney Disease with eGFRs between 20 and 50 ml/min/1.73m2) and delivered into biopsied and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-biopsied</div> contralateral kidneys using a minimally invasive percutaneous approach, as compared to a single REACT injection followed by monitoring and a potential second injection delivered into the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-biopsied</div> contralateral kidney using a minimally invasive percutaneous approach triggered by a 20% decrease in eGFR and/or a 30% increase in UACR, that is delivered within 60 days of trigger being met. In previous Phase 2 studies, we injected the same kidney twice to demonstrate the safety and efficacy of REACT using a minimally invasive injection procedure. Based on an observed favorable safety profile in previous studies, we are proceeding with the injection of REACT into both kidneys in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-007,</div> which we expect will result in increased therapeutic effect as compared to injecting a single kidney, as the systemic effects of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Type-2</div> diabetes mellitus impact both kidneys. By injecting both kidneys, patients have maximal exposure to REACT cells, with the potential to impact a greater proportion of renal mass. Further, the number of glomeruli (the filtering units of the kidney) that are amenable to regenerative therapy is effectively doubled when injecting both kidneys, thereby allowing both kidneys to initiate healing and repair to improve function. The main goal of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-007</div> is to evaluate whether REACT injections in both kidneys as opposed to two injections in the same kidney will: (a)&#160;increase the improvement of kidney function over and above the mean eGFR improvement observed in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-002,</div> or (b)&#160;increase the number of patients in which kidney function stabilizes or improves as compared to the number of patients in which this was observed in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-002,</div> or both. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Subjects will receive up to two doses of REACT of 3x106 cells/ <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">g-KWest.</div> The study will enroll subjects between the ages of 30 and 80 with an eGFR &gt;20 and &#8804;50 mL/min/1.73m2. Subjects will be randomized (1:1) before renal biopsy into two cohorts. Cohort 1 will receive the two REACT injections three months apart. Cohort 2 will receive the first REACT injection, and a trigger, as described below, must be met to qualify for the second REACT injection &gt; 3 months after the first dose. This will allow a comparison of the effects of a specified amount of time between dosing, as compared to a biologic trigger between dosing. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Each of the subjects in cohort 1 will receive the first REACT injection as soon as the REACT product is manufactured and shipped to the clinical site. After three months, subjects will receive a second injection, as appropriate. Subjects in cohort 2 will also receive one REACT injection as soon as the REACT product is manufactured and shipped to the clinical site. For cohort 2, a second REACT injection will only be administered if a subject meets one or more clinical surrogate marker criteria. The second REACT injection will be administered to subjects in cohort 2 no less than three months after the first injection, within 30 days (up to four weeks after target date) of meeting the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-dose</div> trigger. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-dose</div> triggers include (1)&#160;a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> sustained decline in eGFR by at least 20% from baseline and (2)&#160;an increase in the baseline UACR of at least 30% greater than 30mg/gram, measured thirty days after the baseline measurement is taken. For all subjects who receive a second injection, the second injection will be administered in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-biopsied</div> contralateral kidney. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">During this time, subjects in cohort 2 will receive contemporaneous, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">standard-of-care</div></div> therapy for CKD while undergoing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> evaluations at one, 14 (up to 7 days after target date) and 28 days (up to 7 days after target date) following the first injection, and then at three months (up to 10 days after target date) following the first injection, similar to subjects in cohort 1. All subjects will continue with long-term <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> visits at three- month intervals for a period of 24 months following the last injection. In addition, each subject&#8217;s baseline rate of renal decline, based on adequate historical, clinical data obtained 24 months prior to the first REACT injection, will serve as a comparator for monitoring the rate of progression of renal insufficiency over time. The primary efficacy endpoint of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-007</div> is improvement in the rate of renal function decline as indicated by the change from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-injection</div> baseline value in total (acute + chronic) slope of eGFR over 24 months. The primary safety endpoint is treatment-emergent adverse events through 24 months following the last REACT injection. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-007</div> is an unblinded study in which cohort 1 patients will receive the same treatment regimen as the patients in our Phase 3 program that are randomized to the active arms. Therefore, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-007</div> may provide some insights regarding the magnitude of clinical benefit that could be observed in our Phase 3 program. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">107 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">We commenced enrollment for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-007</div> in the third quarter of 2021 and has expanded target enrollment from 30 to up to 50 subjects, as a result of strong investigator interest. As of June&#160;1, 2022, 24 subjects were enrolled with 12 subjects randomized to cohort 1 and 12 subjects randomized to cohort 2. As of that date, four subjects in cohort 1 had received their first dose of REACT<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#8482;</div>, two of whom received a second dose into the contralateral kidney, and five subjects in cohort 2 received their first dose of REACT. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We anticipate initial evaluation data from this study from a limited number of patients in the first half of 2023, with topline data expected in 2025. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Phase 3 Clinical Development <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(REGEN-006</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-016):</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We applied for RMAT designation for REACT, which was granted by the FDA on October&#160;28, 2021. As contemplated by the RMAT designation and as directed by the FDA, we requested a comprehensive, multidisciplinary Type B meeting with the FDA to review the status of preclinical and clinical development and manufacturing of REACT, and to discuss the planned clinical program intended to support approval of the product candidate. The FDA provided detailed written responses to our questions included in the meeting request, and the Type B meeting was held in March 2022. As a result of that meeting, we made some modifications to the Phase 3 trial designs, including the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">increased the planned sample size from 500 to 600 subjects in both <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-006</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-016;</div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">removed the increase in UACR of at least 30% and of at least 30 mg/g, using the random urine microalbumin/urine creatinine ratio sustained for 90 days, from the primary composite endpoint for both <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-006</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-016;</div> and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">added a sham control arm and single blind component to the design of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-016.</div> </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We will continue to advance the USA clinical development program with the benefit of enhanced clarity as to the FDA&#8217;s expectations and requirements for a registrational program, including the design of the trials needed for approval, manufacturing assays, and comparability studies, as set forth below. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-006: </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-006</div> is a Phase 3, randomized, single-blinded, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bi-lateral</div> kidney dose, sham control arm, controlled efficacy study of REACT in subjects with type 2 diabetes and CKD Stages <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3a-4</div> with moderate to severe albuminuria. Albuminuria refers to the presence of an excess of the protein albumin in urine, which is a sign of kidney disease. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The primary objective of this study is to assess the efficacy of up to two REACT injections given three months apart and delivered into biopsied and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-biopsied</div> contralateral kidneys using a minimally invasive percutaneous approach. The total planned enrollment is 600 subjects. Subjects in the treatment group will receive two doses of REACT of 3x106 cells/ <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">g-KWest.</div> The study will enroll subjects between the ages of 30 and 80 years of age with an eGFR <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&gt;2</div>0 and <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&lt;5</div>0 mL/min/1.73m2. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The primary composite endpoint is the time from first injection to the earliest of: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">at least 40% reduction in eGFR, using the 2009 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CKD-EPI</div> serum creatinine equation, sustained for 30 days; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">eGFR &lt;15 mL/min/1.73m&#178; using the 2009 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CKD-EPI</div> serum creatinine equation, sustained for 30 days and/or chronic dialysis, and/or renal transplant; or </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">renal or cardiovascular death. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subjects will be randomized (1:1) to the treatment group and the &#8220;masked&#8221; sham control group prior to renal biopsy. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">108 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Each of the subjects in the treatment group will receive the first REACT injection 12 weeks following renal biopsy. After three months, a second injection will be given, as appropriate, into the contralateral kidney. In contrast, subjects in the control group will receive two sham injections, the first of which will be administered 12 weeks following sham biopsy, and the second of which will be administered three months after the first sham injection. During this time, subjects in the control (sham) group will receive contemporaneous, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">standard-of-care</div></div> therapy for CKD while undergoing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> evaluations at one, 14 and 28 days (+7 days) following the first injection, and then at three months (+10 days) following the first injection, similar to subjects in the treatment group. All subjects will continue in the study until they experience a qualifying event under the primary composite endpoint or reach the end of the study. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Subjects will complete the KDQOL and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">EQ-5D-5L</div></div> surveys. Scores from the treatment group will be compared against scores from the control group. In addition, each subject&#8217;s baseline score will be compared against his or her KDQOL scores obtained over the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">24-month</div> period after the last REACT injection. Additionally, KDQOL scores from subjects who received a single REACT injection may be compared against scores from subjects who received two injections. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This study began enrollment in the first quarter of 2022. As of March&#160;31, 2022, 20 subjects had signed informed consent forms, and two were awaiting treatment assignment. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We aim to evaluate interim data for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-006</div> in early 2025. Results from interim data may not be indicative of results from future data. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-016:</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-016</div> is a planned Phase 3, randomized, single-blinded, sham control arm, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">bi-lateral</div> kidney dose, controlled efficacy study of REACT in subjects with type 2 diabetes and CKD Stages <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3a-4</div> with moderate to severe albuminuria. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The primary objective of this study is to assess the efficacy of up to two REACT injections given three months apart and delivered into biopsied and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-biopsied</div> contralateral kidneys using a minimally invasive percutaneous approach. The total planned enrollment is 600 subjects. Subjects in the treatment group will receive two doses of REACT of 3x106 cells/ <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">g-KWest.</div> The study will enroll subjects between the ages of 30 and 80 years of age with an eGFR <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&gt;2</div>0 and <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">&lt;5</div>0 mL/min/1.73m2. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subjects will be randomized (1:1) to the treatment group and the &#8220;masked&#8221; sham control group prior to renal biopsy. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Each of the subjects in the treatment group will receive the first REACT injection 12 weeks following renal biopsy. After three months, a second injection will be given, as appropriate, into the contralateral kidney. In contrast, subjects in the control group will receive two sham injections, the first of which will be administered 12 weeks following sham biopsy, and the second of which will be administered three months after the first sham injection. During this time, subjects in the control group will receive contemporaneous, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">standard-of-care</div></div> therapy for CKD while undergoing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> evaluations at the same time intervals as subjects in the treatment group. All subjects will continue in the study until they experience a qualifying event under the primary composite endpoint or reach the end of the study. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The primary composite endpoint is the time from first injection to the earliest of: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">at least 40% reduction in eGFR, using the 2009 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CKD-EPI</div> serum creatinine equation, sustained for 30&#160;days; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">eGFR &lt;15 mL/min/1.73m&#178; using the 2009 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">CKD-EPI</div> serum creatinine equation, sustained for 30 days and/or chronic dialysis, and/or renal transplant; or </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">renal or cardiovascular death. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">109 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Subjects will complete the KDQOL and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">EQ-5D-5L</div></div> surveys. Scores from the treatment group will be compared against scores from the control group. In addition, each subject&#8217;s baseline score will be compared against his or her KDQOL scores obtained over the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">24-month</div> period after the last REACT injection. Additionally, KDQOL scores from subjects who received a single REACT injection may be compared against scores from subjects who received two injections. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Enrollment for this study is planned to begin in the first quarter of 2023. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We aim to evaluate data for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-016</div> in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-2025,</div> with the potential for conditional FDA approval anticipated in 2026. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Congenital Anomalies of the Kidney and Urinary Tract (CAKUT) </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Phase 1 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(REGEN-004):</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-004</div> is a Phase 1, prospective, open-label, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">single-arm,</div> safety, tolerability, and early efficacy study of REACT in subjects with CKD from CAKUT. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The primary objective of this study is to assess the safety and efficacy of up to two REACT injections given six months (up to four weeks after target date) apart and delivered into the biopsied kidney using a minimally invasive percutaneous approach that can be delivered under conscious sedation in less than 90 minutes in patients with Chronic Kidney Disease with eGFRs between 14 and 50 ml/min/1.73m2 due to Congenital Anomalies of the Kidneys and Urinary Tract. The planned enrollment is 15 subjects. Subjects will receive two doses of REACT of 3x106 cells/ <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">g-KWest.</div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2021, five subjects were enrolled, all had received their first injection, and four subjects had received both injections. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Early interim results as of August 2021 demonstrated that in three of the five subjects currently enrolled, renal function had improved to an annualized eGFR slope of 3.38 ml/min/1.73m2/year compared to their <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-dose</div> slope of negative <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">-4.19</div> ml/min/1.73m2/year. No adverse events have been associated with REACT. The minimally invasive percutaneous procedure has a well-tolerated safety profile consistent with renal biopsy. No adverse events have been reported to date. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We aim to complete the enrollment by the end of 2022 and obtain additional interim data in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mid-2022.</div> Results from interim data may not be indicative of results from future data. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Planned Studies </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Phase 2 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(REGEN-017)</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-017</div> is a planned Phase 2 study of REACT in subjects with diabetes and CKD who were previously enrolled in the sham control arm of either <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-006</div> or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-016.</div> Subjects will be enrolled in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-017,</div> either when a Phase 3 event is triggered or following completion of study visits in Phase 3 protocols. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Each of the subjects will receive the first REACT injection 12 weeks following renal biopsy. After three months, a second injection will be given, as appropriate, into the contralateral kidney. Subjects will continue for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> observation visits for a duration of 12 months following their second REACT injection before continuing into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-008.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Phase 4 Clinical Development <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(REGEN-008)</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-008</div> is a Phase 4, prospective, open-label, observational extension study of REACT in subjects with diabetes and CKD who were previously enrolled and treated with cryopreserved REACT in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-006,</div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">110 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-007,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-016</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-017</div> studies. The total planned enrollment is approximately 600 subjects with no control arm. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The primary objective of this study is to evaluate the long term safety of up to two REACT injections given three months apart and delivered percutaneously into biopsied and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-biopsied</div> contralateral kidneys on renal function in participants with diabetes and CKD. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Subjects who had participated in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-006,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-007,</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-016</div> with exposure to REACT will continue for long-term <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> observation visits every three months (+ 10 days) alternating between clinic and telephone visits after enrollment for a duration of five years following their completion in the previous studies. Visits will include physical examinations, laboratory draws, documentation of vitals and assessment of any concomitant medical changes. Once a year, subjects will also be asked to complete KDQOL and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">EQ-5D-5L</div></div> surveys. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We aim to continue <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-008</div> long-term <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> to 2030. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Phase 4 Clinical Development <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(REGEN-009)</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-009</div> will be a prospective, open-label, observational extension study of REACT in subjects with CAKUT who were previously enrolled and treated with REACT in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-004,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-005</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-011</div> studies. We plan to launch the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-009</div> in late 2022. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The primary objective of this study is to assess the long-term safety and efficacy (including durability) of REACT on renal function in subjects with CAKUT. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Subjects who participate in a CAKUT trial will continue for long-term <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up</div> observation visits every three months after enrollment for a duration of five years following their completion in the previous studies. Visits will include physical examinations, laboratory draws, documentation of vitals, and assessment of any concomitant medical changes. Once a year, subjects will also be asked to complete KDQOL and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">EQ-5D-5L</div></div> surveys. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Competition </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The biotechnology and pharmaceutical industries are characterized by rapid technological advancement, significant competition, and an emphasis on intellectual property. We face potential competition from many different sources, including major and specialty pharmaceutical and biotechnology companies, including developers of tubular and glomerular cell drug modulators, e.g., SGLT2 inhibitors, antifibrosis medications, e.g., Mineralocorticoid Receptor Antagonists&#8212;MRAs, induced pluripotent cells, other autologous mesenchymal stem cells and mechanical renal assist devices such as implantable and wearable renal dialysis machines, and advances in peritoneal dialysis and home dialysis. Cell-based clinical trials by other companies are underway globally with umbilical, adipose and bone marrow derived mesenchymal stem cells for CKD. Early-phase human induced pluripotent stem cell therapies for kidney diseases are ongoing in Japan. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any product candidates that we successfully develop and commercialize will compete with current therapies and new therapies that may become available in the future. We believe that the key competitive factors affecting the success of any of our product candidates will include efficacy, safety profile, dosing, cost, effectiveness of promotional support and intellectual property protection. With respect specifically to REACT, we expect the key competitive factors affecting its success, if approved, will include the intended patient population, the relative convenience of dosing and administration, and efficacy. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Many other companies working on medications for controlling chronic kidney disease, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">111 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">development, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> testing, clinical trials, manufacturing, and marketing than we do. We believe that our principal competitors include developers of SGLT2 inhibitors, including canagliflozin (marketed as Invokana<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> by companies including Janssen Pharmaceuticals, Inc.), dapagliflozin (marketed under the brand names Farxiga<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> and Forxiga<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> by companies including AstraZeneca plc and Bristol-Myers Squibb Company), empagliflozin (marketed as Jardiance<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> by companies including Boehringer Ingelheim and Eli Lilly and Company) and finerenone (marketed as Kerendia<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#174;</div> by companies including Bayer AG), and MRAs, which are small-molecule therapies recently approved to lower risks of CKD progression. Future collaborations and merger and acquisitions may result in further resource concentration among a smaller number of competitors. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our commercial potential could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market or make our development more complicated. These competitors may also vie for a similar pool of qualified scientific and management talent, sites and patient populations for clinical trials, as well as for technologies complementary to, or necessary for, our programs. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Supply and Manufacturing </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">With support from high level manufacturing and regulatory expertise, our internal manufacturing capabilities have enabled us to progress rapidly through our clinical trials. We believe that our current manufacturing capacities enable us to provide sufficient quantities of clinical trial material to supply the clinical trials. As we continue to develop our product candidates, we may need to expand our manufacturing capacities. The manufacturing facilities located in Winston Salem, North Carolina and the quality systems are fully compliant with cGMP and meet EU and FDA regulations. It usually takes approximately 12 weeks to produce the clinical REACT products. As of the date hereof, our manufacturing team, facilities, and bioprocess capacity have produced over 200 cell therapies. During our clinical trials, we have had a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">greater-than-95%</div> success rate in creating a REACT product from a patient&#8217;s biopsy material. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our facility design and quality systems have been audited by European Qualified Persons (QP) and certified as compliant with EU cGMP requirements for phase 2/3 manufacturing. Our bioprocesses have been reviewed by the FDA and EMA and validation activities are ongoing in anticipation of being commercial-ready for the potential launch of REACT. We plan to build additional manufacturing capacity to meet the expanding demand. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our commercial strategy focuses on process automation to scale up to meet the projected market for REACT, if we obtain the necessary regulatory approvals. We are collaborating with engineering companies such as DEKA Research&#160;&amp; Development Corp. to develop automated manufacturing processes for the potential commercial production of REACT, including a REACT launch facility after we complete the Phase 3 patient enrollment and dosing in 2026, and two commercial manufacturing facilities after we launch REACT. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Our current costs of manufacturing REACT for use in our ongoing Phase 2 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RMCL-002</div> study are approximately $100,000 per patient. We anticipate that these costs will be lower for our Phase 3 trials and that the costs will continue to decrease by up to 50% from the costs of manufacturing REACT for our Phase 2 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RMCL-002</div> study as we manufacture REACT at commercial scale with implementation of automation, bioprocess developments, formulation improvements, and streamlining of the supply chain. We expect to utilize automation in all aspects of manufacturing ranging from tissue processing, cell expansion and renal cell selection to formulation and filling of the final product. We will also extend automation to other manufacturing activities, including warehouse operations and supply chain. In addition, we intend to improve bioprocess development to further reduce manufacturing costs of the commercial REACT product, assuming receipt of necessary regulatory approvals. Culture media represents the highest cost in REACT processing, and we are exploring reduced culture media usage via bioprocess and automation improvements. Further, our final commercial REACT product is </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">112 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">planned to be a cryopreserved formulation, which is projected to reduce manufacturing costs compared to our fresh REACT formulation. We expect to leverage bulk purchasing to actively negotiate pricing of materials to further drive cost reductions. However, there can be no assurance that the manufacturing costs for our Phase 3 trials when we manufacture REACT at commercial scale will actually be lower than for our ongoing Phase 2 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RMCL-002</div> study. A number of factors may contribute to an inability to achieve these cost reductions, including any failures to achieve the automation efficiencies that we anticipate, cost overruns or inefficiencies in the supply chain and any failure to improve the formulation or bioprocessing of REACT in a manner that results in lower costs. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Key Agreements </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Master Services Agreement, dated February&#160;15, 2021, by and between George Clinical PTY Limited and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> entered into a Master Services Agreement dated February&#160;15, 2021 (the &#8220;George Clinical MSA&#8221;) with George Clinical PTY Limited (&#8220;George Clinical&#8221;), upon which George Clinical agreed to provide <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> with certain clinical research services pursuant to work orders, including the setup and management of an Endpoint Adjudication Committee for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY&#8217;s</div> protocol <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-006</div> and verification process for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY&#8217;s</div> protocol <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-007,</div> as well as a Data Safety Monitoring Board and a Steering Board Committee for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY&#8217;s</div> development programs. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> and George Clinical agreed to indemnify each other against certain third-party claims. The George Clinical MSA will continue until February&#160;15, 2026, unless terminated earlier by either party. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> may terminate the George Clinical MSA upon 30 days&#8217; prior written notice to George Clinical for any reason. Either party may terminate the George Clinical MSA (i)&#160;for material breach by the other party if, upon 30 days&#8217; prior written notice by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-breaching</div> party, the breach has not been cured, or (ii)&#160;upon the insolvency or declaration of bankruptcy of the other party. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> may terminate any work order immediately if (i)&#160;the relevant study is terminated, or (ii)&#160;George Clinical breaches a material term of the George Clinical MSA or does not perform the services to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY&#8217;s</div> reasonable satisfaction and does not remedy the breach or perform satisfactorily within 30 days of receiving a notice from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> specifying the nature of the breach or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-performance.</div> George Clinical may terminate any work order upon written notice if it believes on reasonable grounds that continued performance of the services poses an unacceptable risk to patient safety or may violate regulatory or scientific standards. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research, Development, Engineering Services and License Memorandum and Agreement, dated January&#160;16,&#160;2022, by and between <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> and DEKA Products Limited Partnership </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> entered into a Research, Development, Engineering Services and License Memorandum and Agreement dated January&#160;16, 2022 (the &#8220;RDELA&#8221;) with DEKA Products Limited Partnership and its general partner DEKA Research&#160;&amp; Development Corp. (collectively, &#8220;DEKA&#8221;) under which DEKA will work with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> to develop certain technology to enhance the Company&#8217;s manufacturing and delivery capabilities for REACT. Under the RDELA, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> pays DEKA for its work on these research and development projects on a cost-plus model. DEKA owns the resulting IP and grants <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> an exclusive, royalty-free, world-wide license to the resulting IP for purposes related to the provisions of cell therapy for the treatment of renal insufficiency. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under the terms of the RDELA, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> agrees to indemnify DEKA for claims arising out of the use of the technology licensed to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> (including losses related to IP infringement claims and personal injury or products liability claims) and DEKA agrees to indemnify <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> for claims arising out of the use of the technologies developed and licensed to third parties. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The term of the RDELA extends through the commercial life of any licensed technology developed thereunder subject to termination for breach and for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY&#8217;s</div> convenience. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">113 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The initial payment for DEKA&#8217;s work under the RDELA was made through the issuance of 2,750,000 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B-1</div> Units of ProKidney Management Equity LLC. All subsequent payments have been and will be made by ProKidney- KY in cash. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Master Services Agreement, dated April&#160;20, 2020, by and between IQVIA RDS Inc. and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> entered into a Master Services Agreement dated April&#160;20, 2020 (the &#8220;IQVIA MSA&#8221;) with IQVIA RDS, Inc. (&#8220;IQVIA&#8221;), under which IQVIA agreed to provide services for individual studies or projects of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> pursuant to work orders covering strategic planning, expert consultation, clinical trial services, statistical programming and analysis, data processing, data management, regulatory services, project management, pharmacovigilance, central laboratory services, clinical pharmacology services, electrocardiogram services and other services. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> and IQVIA agreed to indemnify each other against certain third-party claims. The IQVIA MSA has an initial term of five years, or until terminated by either party, and will automatically renew each year for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> periods, unless either party notifies the other party in writing at least 90 days prior to the renewal date that the notifying party wishes to terminate the IQVIA MSA. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> may terminate the IQVIA MSA without cause upon 60 days&#8217; prior written notice to IQVIA. Either party may terminate the IQVIA MSA, or any work order thereunder, (i)&#160;for material breach by the other party if, upon 30 days&#8217; prior written notice by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-breaching</div> party, the breach has not been cured, or (ii)&#160;upon the insolvency or declaration of bankruptcy of the other party. IQVIA may suspend services under if IQVIA reasonably determines that IQVIA&#8217;s performance under the IQVIA MSA, or a work order thereunder, would constitute a potential or actual violation of regulatory, scientific, or ethical standards. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Master Agreement for Clinical Trials Services, dated April&#160;2, 2020, by and between <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> and Frenova,&#160;LLC </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> entered into a Master Agreement for Clinical Trials Services, dated April&#160;2, 2020 (the &#8220;Frenova MSA&#8221;) with Frenova, LLC d/b/a Frenova Renal Research (&#8220;Frenova&#8221;), under which Frenova agreed to provide <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> with certain services related to the implementation and management of clinical development programs pursuant to statements of work (&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">SOWs</div></div>&#8221;) encompassing such services for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY&#8217;s</div> protocols <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RMCL-002,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-006</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-007.</div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Frenova MSA has an initial term of five years, or until terminated by either party, and will automatically renew each year for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> periods, unless either party notifies the other party in writing at least 60 days prior to the renewal date that the notifying party wishes to terminate the Frenova MSA. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> may terminate the Frenova MSA or any SOW thereunder upon 60 days&#8217; prior written notice to Frenova for any reason. Frenova may terminate the Frenova MSA for material breach under the Frenova MSA by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> if, upon 60 days&#8217; prior written notice, the breach has not been cured. Additionally, Frenova may terminate any SOW upon 30 days&#8217; prior written notice if <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(i)&#160;ProKidney-KY</div> cancels or materially delays the requested services; (ii)&#160;unanticipated material changes to the project assumptions cannot be addressed to both parties&#8217; satisfaction; (iii)&#160;changes to the study protocol cause enrollment targets to become commercially unreasonable; or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(iv)&#160;ProKidney-KY</div> is unable to make timely payments to Frenova resulting in Frenova lacking funds to process payments to the trial sites. Either party may terminate the Frenova MSA or any SOW thereunder (i)&#160;upon the insolvency or declaration of bankruptcy of the other party, (ii)&#160;if the other party is excluded, suspended, sanctioned or otherwise restricted from participating in federal health care programs, or (iii)&#160;the performance of the service would constitute a potential or actual violation of legal, regulatory, scientific, or ethical standards. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> and Frenova also agreed to indemnify each other against certain third-party claims. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Master Services Agreement, dated May&#160;1, 2019, by and between PPD Development, LP and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> entered into a Master Services Agreement dated May&#160;1, 2019 (the &#8220;PPD MSA&#8221;) with PPD Development, L.P. (&#8220;PPD&#8221;), under which PPD agreed to perform clinical development services in connection </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">114 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY&#8217;s</div> clinical research programs, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> agreed to pay PPD in accordance with rates for such services, as set forth in the project addenda. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The PPD MSA has an initial term of five years and may be extended by mutual written agreement of the parties. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> may terminate any project addendum under the PPD MSA without cause upon 30 days&#8217; prior written notice. Either party may terminate any project addendum under the PPD MSA upon the other party&#8217;s breach of the PPD MSA or project addendum upon 30 days&#8217; prior written notice, provided that the breach is not cured within such <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> period. Either party may terminate the PPD MSA or any project addendum thereunder upon the occurrence of certain insolvency events. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> and PPD also agreed to indemnify each other against certain third-party claims. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Master Services Agreement, dated August&#160;14, 2015, by and between CTI Clinical Trial Services Inc. and RegenMedTX, LLC </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">RegenMedTX, LLC (&#8220;RegenMedTX&#8221;), a subsidiary of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY,</div> entered into a Master Services Agreement dated August&#160;14, 2015 (the &#8220;CTI MSA&#8221;) with CTI Clinical Trial Services, Inc. &amp; CTI Clinical Consulting Services, Inc. (&#8220;CTI&#8221;), under which CTI agreed to provide RegenMedTX with certain clinical research or design and development services in connection with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY&#8217;s</div> clinical trials pursuant to work orders. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">RegenMedTX will own all materials, documents and information obtained by, developed by or provided to CTI by or on behalf of RegenMedTX as a part of CTI&#8217;s services or any work order thereunder. The CTI MSA will continue unless terminated by the parties. Either party may terminate the CTI MSA or a work order for any reason upon 90 days&#8217; prior written notice to the other party or for material breach by the other party upon 30 days&#8217; written notice, provided that the material breach has not been cured within the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> period. RegenMedTX may immediately terminate the CTI MSA, or a work order thereunder, if (i)&#160;the FDA withdraws authorization and approval to conduct a study or (ii)&#160;RegenMedTX reasonably determines that for medical, clinical or patient safety reasons, a study should terminate immediately. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Laboratory Service Agreements with LabCorp </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Laboratory Service Agreement, dated August&#160;16, 2016, by and among Covance Central Laboratory Services LP, Covance Central Laboratory Services SA` RL and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August 2016, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> entered into a Laboratory Service Agreement with Covance Central Laboratory Services LP and Covance Central Laboratory Services SA` RL (now known as Labcorp, as described further below) (the &#8220;2016 LSA&#8221;), under which Labcorp agreed to perform certain services for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY&#8217;s</div> protocol <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">RMCL-002.</div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The initial term of the 2016 LSA was 42 months, subject to automatic renewal for successive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-year</div> periods unless a party provides the other party with written notice of its intention to not renew at least 60 days prior to the commencement of a renewal term. Either party may terminate the 2016 LSA upon written notice to the other party, effective immediately, if (i)&#160;the other party commits a material breach of any term of the 2016 LSA and fails to remedy such breach within a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> period, (ii)&#160;the other party repeatedly breaches any term of the 2016 LSA, (iii)&#160;anyone commences bankruptcy proceedings against the other party, which proceedings are not dismissed within 60 days, (iv)&#160;a court of competent jurisdiction appoints a custodian for the other party or substantially all of its assets, (v)&#160;the other party fails to pay its debts as they fall due, or (vi)&#160;any event occurs or proceeding is initiated having a similar effect to the events mentioned above. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> may terminate the 2016 LSA for any reason upon 90 days&#8217; prior written notice to Labcorp. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> granted Labcorp an unrestricted, royalty-free license to aggregate and use any system data produced by or for Labcorp as part of the services with other system data owned or licensed by Labcorp provided Labcorp does not identify such data as belonging to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY.</div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">115 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Laboratory Service Agreement, dated August&#160;1, 2017, by and among Covance Central Laboratory Services LP, Covance Central Laboratory Services SA` RL and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In August 2017, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> entered into a Laboratory Service Agreement with Labcorp (the &#8220;2017 LSA&#8221;). Under the terms of the 2017 LSA, Labcorp agreed to perform certain services for ProKidney&#8217;s protocol <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-003.</div> The 2017 LSA has substantially similar terms and termination provisions to the 2016 LSA. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Laboratory Service Agreement, dated June&#160;21, 2019, by and among Covance Central Laboratory Services LP, Covance Central Laboratory Services SA` RL and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In June 2019, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> entered into a Laboratory Service Agreement with Labcorp (the &#8220;2019 LSA&#8221;). Under the terms of the 2019 LSA, Labcorp agreed to perform certain services for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY&#8217;s</div> protocol <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-004.</div> The 2019 LSA has an initial term of 50 months and will renew automatically for successive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-</div> year periods unless a party provides the other party with written notice of its intention to not renew at least 60 days prior to the commencement of a renewal term. The parties may terminate the 2019 LSA under terms that are substantially similar to the termination provisions of the 2016 LSA and 2017 LSA. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Laboratory Service Agreement, dated September&#160;16, 2021, by and among Labcorp Central Laboratory Services LP, Labcorp Central Laboratory Services SA` RL and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> and Labcorp Central Laboratory Services LP (formerly known as Covance Central Laboratory Services LP) and Labcorp Central Laboratory Services SA` RL (formerly known as Covance Central Laboratory Services SA` RL) (Collectively, &#8220;Labcorp&#8221;) entered into a Laboratory Service Agreement dated September&#160;16, 2021 (the &#8220;Labcorp LSA&#8221;), under which Labcorp agreed to perform certain services for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY&#8217;s</div> protocol <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-006.</div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The term of the Labcorp LSA will continue until the conclusion of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-006</div> study. Either party may terminate the Labcorp LSA under terms that are substantially similar to the termination provisions of the 2016 LSA, the 2017 LSA and the 2019 LSA, as well as pursuant to certain insolvency events. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> and Labcorp also agreed to indemnify each other against certain third-party claims. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> granted Labcorp an unrestricted, royalty-free license to aggregate and use any system data produced by or for Labcorp as part of the services with other system data owned or licensed by Labcorp provided Labcorp does not identify such data as belonging to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY.</div> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intellectual Property </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our success depends in part on our ability to obtain and maintain proprietary protection for our product candidates, technology and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> to operate without infringing the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our proprietary technology, inventions, improvements, and product candidates that are important to the development and implementation of our business. For example, we have or are pursuing patents covering the composition of matter for each of our product candidates and we generally pursue patent protection covering <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">methods-of-use</div></div> for each clinical trial. We also rely on trade secrets, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how,</div> continuing technological innovation and potential <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-licensing</div> opportunities to develop and maintain our proprietary position. Additionally, we expect to benefit, where appropriate, from statutory frameworks in the United States, Europe and other countries that provide a period of clinical data exclusivity to compensate for the time required for regulatory approval of our products. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We continually assess and refine our intellectual property strategy as we develop new technologies and product candidates. We plan to file additional patent applications based on our intellectual property strategies where appropriate, including where we seek to adapt to competition or to improve business opportunities. Further, we plan to file patent applications, as we consider appropriate under the circumstances, to protect new technologies that we develop. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">116 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">To cover our proprietary technologies, proprietary cell-based REACT product and related methods, such as methods of use, we have filed patent applications representing 15 patent families. As of July&#160;31, 2022, our patent estate, which is solely owned, included 286 total issued patents or pending patent applications with nine issued U.S. patents, nine pending U.S. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-provisional</div> patent applications, five pending U.S. provisional patent applications, two pending Patent Cooperation Treaty (PCT) applications, 168 issued foreign patents and 93 pending foreign patent applications in various foreign jurisdictions. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Specifically, our patent family with claims directed to cells formulated in REACT, implantable constructs, and methods of using the same to, for example, improve kidney function or treat kidney disease, includes 30 issued patents and 10 pending patent applications. Patents in this family have been issued in nine jurisdictions, including the United States (three issued patents), Europe (two issued patents, each separately validated in seven countries), China, Japan, and South Korea. Issued patents and any further patents that may be issued from this family&#8217;s 10 pending applications are expected to expire in 2029 absent any patent term adjustments or extensions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We also own two patent families directed to our REACT formulations and methods of preparing the formulations. Across these families, we have 13 issued patents in multiple jurisdictions, including the United States, China, Japan, South Korea, and Canada. We also have 13 patent applications that are pending in multiple jurisdictions, including the United States, Europe, China, Japan, Hong Kong, South Korea, Canada, Mexico, and Australia. Patents across these two patent families, including any patents that may be issued from the pending applications, are expected to expire between 2031 and 2038, depending upon their respective filing dates and absent any patent term adjustments or extensions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, we own two patent families with claims directed to quality control methods for ensuring that renal cells for formulation in REACT, prepared by our proprietary methods, have phenotypic and functional profiles indicative of therapeutic activity. Within the first patent family, we have 58 issued patents in various jurisdictions, including the United States (two issued patents), Europe (two issued patents, one of which has been validated in 21 countries and the other has been validated in 20 countries), China, Japan (two issued patents), South Korea (two issued patents), Hong Kong, Australia (two issued patents), and New Zealand (two issued patents) and are expected to expire in 2033 absent any patent term adjustments or extensions. We also have nine patent applications that are pending in multiple jurisdictions, including the United States, Europe, Australia, China, and South Korea, and are expected to expire in 2033 absent any patent term adjustments or extensions. Our second patent family includes a PCT stage application. Any patents that issue from a national or regional stage application filed from this PCT application are expected to expire in 2041 absent any patent term adjustments or extensions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We further own three patent families directed to methods of improving kidney function and/or in treating kidney disease, e.g., diabetic kidney disease or kidney disease resulting from a congenital anomaly. Across these families, we have three issued patents, including one U.S. patent and 28 pending patent applications filed in 15 jurisdictions, including the United States, Europe, Hong Kong, China, Korea, Japan, Australia, Brazil, Mexico, Israel, Canada, and Mexico. Our issued U.S. patent is expected to expire in 2037 absent any patent term adjustments or extensions. Patents across all three patent families, if issued, are expected to expire between 2036 and 2042, depending upon their respective filing dates and absent any patent term adjustments or extensions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, we plan to file additional applications on aspects of our innovations that may have patent terms that extend beyond these dates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The term of individual patents depends upon the laws of the countries in which they are obtained. In the countries in which we currently file, the patent term is 20 years from the earliest date of filing of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-provisional</div> patent application, which serves as a priority application. However, the term of a U.S. patent may be extended to compensate for the time required to obtain regulatory approval to sell a medicine (a patent term extension) or by delays encountered during patent prosecution that are caused by the USPTO (referred to as </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">117 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">patent term adjustment). For example, the Hatch-Waxman Act permits a patent term extension for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> medicines of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the medicine is under regulatory review and diligence during the review process. Patent term extensions cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent covering an approved medicine or its method of use may be extended. A similar kind of patent extension, referred to as a Supplementary Protection Certificate, is available in Europe. Legal frameworks are also available in certain other jurisdictions to extend the term of a patent. We currently intend to seek patent term extensions on any of our issued patents in any jurisdiction where we have a qualifying patent and the extension is available; however there is no guarantee that the applicable regulatory authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. Further, even if our patent is extended, the patent, including the extended portion of the patent, may be held invalid or unenforceable by a court of final jurisdiction in the United States or a foreign country. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As with other biotechnology and pharmaceutical companies, our ability to obtain and maintain a proprietary position on our product candidates and technologies will depend on our success in obtaining effective patent claims on these pending patents and enforcing those claims if granted. However, our pending patent applications, and any patent applications that we may in the future file or license from third parties, may not result in the issuance of patents. We also cannot predict the breadth of claims that may be allowed or enforced in our patents. Furthermore, our competitors may be able to independently develop and commercialize products with similar mechanisms of action and duplicate our methods of treatments or strategies without infringing our patents. Because of the extensive time required for clinical development and regulatory review of a therapeutic product we may develop, it is possible that, before any of our products can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of any such patent. Moreover, even our issued patents do not guarantee us the right to practice our technology in relation to the commercialization of our clinical candidates. The area of patent and other intellectual property rights in pharmaceuticals is an evolving one with many risks and uncertainties, and third parties may have blocking patents that could be used to prevent us from commercializing our clinical candidates. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The biotechnology and pharmaceutical industries are characterized by extensive litigation regarding patents and other intellectual property rights. Our ability to obtain and maintain our proprietary position for our product candidates and technology will depend on our success in enforcing the claims that have been granted or may grant. However, any of our patents, including patents that we may rely on to protect our market for approved therapeutics, may be held invalid or unenforceable by a court of final jurisdiction. Alternatively, we may decide that it is in our interest to settle a litigation in a manner that affects the term or enforceability of our patent. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish our ability to protect our inventions and enforce our intellectual property rights. Accordingly, we cannot predict the breadth or enforceability of claims that have been or may be granted in our patents or in third-party patents. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trade secrets </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In addition to patents, we rely upon unpatented trade secrets and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality agreements with our commercial partners, collaborators, employees, and consultants, and invention assignment agreements with our employees. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third party. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our commercial partners, collaborators, employees, and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> and inventions. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">118 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Government regulation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the United States, biological products, including cell-based regenerative therapy products, are subject to regulation under the Federal Food, Drug, and Cosmetic Act (the &#8220;FD&amp;C Act&#8221;), the Public Health Service Act (the &#8220;PHS Act&#8221;) and other federal, state, local and foreign statutes and regulations. Both the FD&amp;C Act and the PHS Act and their corresponding regulations govern, among other things, the research, development, clinical trial, testing, manufacturing, safety, efficacy, labeling, packaging, storage, record keeping, distribution, reporting, advertising and other promotional practices involving biological products. Each clinical trial protocol for a cell- based therapy product must be reviewed by the FDA. FDA approval must be obtained before the marketing of any biological product. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources and we may not be able to obtain the required regulatory approvals. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ethical, social and legal concerns about gene or cell-based therapies, genetic testing and genetic research could result in additional laws and regulations restricting or prohibiting the processes we may use. Federal and state legislatures, agencies, congressional committees and foreign governments have expressed interest in further regulating biotechnology. More restrictive laws and regulations or interpretations of existing laws or regulations, or claims that our product candidates are unsafe or pose a hazard, could prevent us from commercializing any products. New government requirements may be established that could delay or prevent regulatory approval of our product candidates under development. It is impossible to predict whether legislative changes will be enacted, regulations, policies or guidance changed, or interpretations by agencies or courts changed, or what the impact of such changes, if any, may be. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S. biological products development process </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The process required by the FDA before a biological product may be marketed in the United States generally involves the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">completion of nonclinical laboratory tests and animal studies according to GLP, and applicable requirements for the humane use of laboratory animals or other applicable regulations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">submission to the FDA of an application for an IND which must become effective before human clinical trials may begin; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">approval of the protocol and related documentation by an IRB, or ethics committee at each clinical trial site before each clinical trial may be initiated; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">performance of adequate and well-controlled human clinical trials according to applicable IND regulations, good clinical practices, or GCPs and other clinical-trial related regulation, to evaluate the safety and efficacy of the investigational biological product for each proposed indication; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">submission to the FDA of a BLA for marketing approval that includes sufficient evidence of establishing the safety, purity, and potency of the proposed biological product for each proposed indication, including from results of nonclinical testing and clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced to assess compliance with cGMP to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s identity, strength, quality and purity and, if applicable, compliance with the FDA&#8217;s cGTPs for the use of human cellular and tissue products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">potential FDA audit of the nonclinical study and clinical trial sites to assure compliance with GLP and GCP and the integrity of the clinical data submitted in support of the BLA; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">review of the product candidate by an FDA advisory committee, where appropriate or if applicable; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">payment of user fees for FDA review of the BLA (unless a fee waiver applies); and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FDA review and approval, or licensure, of the BLA. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">119 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preclinical Studies </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Before testing any biological product candidate, including a cell-based regenerative therapy product, in humans, the product candidate enters the preclinical testing stage. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations of a product candidate&#8217;s biological characteristics, chemistry, toxicity, stability and formulation, as well as animal studies to assess the potential safety and activity of the product candidate. The sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before human clinical trials may begin. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The conduct of the preclinical tests must comply with federal regulations and requirements including GLP. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after an IND for an investigational drug candidate is submitted to the FDA and human clinical trials have been initiated. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Human clinical trials in support of a BLA </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">All clinical trials must be conducted under the supervision of qualified investigators. Clinical trials are conducted under protocols detailing the objectives of the study, the parameters to be used in monitoring the safety and effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND. Study subjects must sign an informed consent form before participating in a clinical trial. There are also requirements governing the reporting of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">on-going</div> clinical trials and clinical trial results to public registries. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">An IND is an exemption from the FD&amp;C Act that allows an unapproved product candidate to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA authorization to administer such investigational product to humans. Such authorization must be secured prior to interstate shipment and administration of any biologic product candidate that is not the subject of an approved BLA. In support of a request for an IND, applicants must submit a protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, must be submitted to the FDA as part of an IND. The FDA requires a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-day</div> waiting period after the filing of each IND before clinical trials may begin. This waiting period is designed to allow the FDA to review the IND to determine whether human research subjects will be exposed to unreasonable health risks. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following commencement of a clinical trial, the FDA may also place a clinical hold or partial clinical hold on that trial. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. No more than 30 days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after the FDA has notified the sponsor that the investigation may proceed. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A sponsor may choose, but is not required, to conduct a foreign clinical trial under an IND. When a foreign clinical trial is conducted under an IND, all FDA IND requirements must be met unless waived. When a foreign clinical trial is not conducted under an IND, the sponsor must ensure that the study complies with certain </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">120 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">regulatory requirements of the FDA in order to use the study as support for an IND or application for marketing approval or licensing. In particular, such studies must be conducted in accordance with GCP, including review and approval by an IEC and informed consent from subjects and must meet other clinical trial requirements, such as sufficient patient population size and statistical powering. The FDA must be able to validate the data through an onsite inspection, if deemed necessary by the FDA. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">An IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a DSMB. This group provides authorization as to whether or not a trial may move forward at designated check points based on access that only the group maintains to available data from the study. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Information about certain clinical trials, including details of the protocol and eventually study results, also must be submitted within specific timeframes to the National Institutes of Health for public dissemination on the ClinicalTrials.gov data registry. Information related to the product, patient population, phase of investigation, study sites and investigators and other aspects of the clinical trial is made public as part of the registration of the clinical trial. Sponsors are also obligated to disclose the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed in some cases for up to two years after the date of completion of the trial. Failure to timely register a covered clinical study or to submit study results as provided for in the law can give rise to civil monetary penalties and also prevent the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliant</div> party from receiving future grant funds from the federal government. The National Institutes of Health&#8217;s (NIH) Final Rule on ClinicalTrials.gov registration and reporting requirements became effective in 2017, and both NIH and FDA have recently begun enforcing those requirements against <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliant</div> clinical trial sponsors. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinical trials typically are conducted in three sequential phases that may overlap or be combined: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Phase 1</div></div>. The product candidate is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some product candidates for severe or life-threatening diseases, especially when the product candidate may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Phase 2</div></div>. The product candidate is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product candidate for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Phase 3</div></div>. Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the product candidate and provide, if appropriate, an adequate basis for approval and product labeling. These trials may include comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">follow-up.</div> In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of a BLA. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">121 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA, the NIH and the investigators for serious and unexpected adverse events, any findings from other studies, tests in laboratory animals or <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in vitro </div></div>testing that suggest a significant risk for human subjects, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of such information. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Human cell-based products administered directly into kidney tissue are a new category of therapeutics. Because this is a relatively new and expanding area of novel therapeutic interventions, there can be no assurance as to the length of the study period, the number of patients the FDA will require to be enrolled in the studies in order to establish the safety, purity and potency of human cell-based therapy products, or that the data generated in these studies will be acceptable to the FDA to support marketing approval. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the physical characteristics of the biological product as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHS Act emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S. review and approval processes </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">After the completion of clinical trials of a biological product candidate, FDA approval of a BLA must be obtained before commercial marketing of the biological product. The BLA must include results of product development, laboratory and animal studies, human studies, information on the manufacture and composition of the product, proposed labeling and other relevant information. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety, purity, potency and efficacy of the investigational product for its proposed indication or indications to the satisfaction of the FDA. The testing and approval processes require substantial time and effort and there can be no assurance that the FDA will accept the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Prescription Drug User Fee Act, as amended (&#8220;PDUFA&#8221;), each BLA must be accompanied by a significant user fee (for example, for fiscal year 2022, this application fee exceeds $3.1 million). The FDA adjusts the PDUFA user fees on an annual basis. PDUFA also imposes an annual program fee for registered biologic product manufacturers, currently more than $300,000 per program. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Within 60 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the FDA accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">122 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-depth</div> substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe, pure, potent and effective for its proposed indication or indications and whether the product is being manufactured in accordance with cGMP to ensure the continued safety, purity and potency of such product. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the performance goals and policies implemented by the FDA under PDUFA, for original BLAs, the FDA targets ten months from the filing date in which to complete its initial review of a standard application and respond to the applicant, and six months from the filing date for an application with priority review. The FDA does not always meet its PDUFA goal dates, and the review process is often significantly extended due to FDA requests for additional information or clarification. The review process and the PDUFA goal date may be extended by the FDA for three additional months to consider new information or in the case of a clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Before approving a BLA, the FDA typically will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. For a cell-based therapy product, the FDA also will not approve the product if the manufacturer is not in compliance with the cGTPs. These are FDA regulations that govern the methods used in, and the facilities and controls used for, the manufacture of human cells, tissues, and cellular and tissue-based products (&#8220;HCT/ Ps&#8221;), which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the cGTP requirements is to ensure that cell and tissue-based products are manufactured in a manner designed to prevent the introduction, transmission and spread of communicable disease. FDA regulations also require tissue establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through appropriate screening and testing. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND study requirements and GCP requirements. To assure cGMP, cGTP and GCP compliance, an applicant must incur significant expenditure of time, money and effort in the areas of training, record keeping, production and quality control. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Additionally, the FDA may refer any BLA, including applications for novel biologic candidates which present difficult questions of safety or efficacy, to an advisory committee. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendation of an advisory committee, but it considers such recommendations when making final decisions on approval. The FDA likely will <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-analyze</div> the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process. The FDA also may require submission of a REMS if it determines that a REMS is necessary to ensure that the benefits of the medicine outweigh its risks and to assure the safe use of the medicine or biological product. The REMS could include medication guides, physician communication plans, assessment plans and/or elements to assure safe use, such as restricted distribution methods, patient registries or other risk minimization tools. The FDA determines the requirement for a REMS, as well as the specific REMS provisions, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">case-by-case</div></div> basis. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve a BLA without a REMS, if required. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Pediatric Research Equity Act (&#8220;PREA&#8221;), a BLA or supplement to a BLA for a novel product (e.g., new active ingredient, new indication, etc.) must contain data to assess the safety and effectiveness of the biological product candidate for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers. The PREA requires a sponsor who is planning to submit a marketing application for a product that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration to submit an initial Pediatric Study Plan </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">123 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">(&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">PSP</div></div>&#8221;), within sixty days of an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">end-of-Phase</div></div> 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 clinical trial. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including trial objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies, early phase clinical trials or other clinical development programs. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA reviews a BLA to determine, among other things whether the product is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The approval process is lengthy and often difficult, and the FDA may refuse to approve a BLA if the applicable regulatory criteria are not satisfied or may require additional clinical or other data and information. On the basis of the FDA&#8217;s evaluation of the BLA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue either an approval letter or a Complete Response Letter (&#8220;CRL&#8221;). An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A CRL indicates that the review cycle of the application is complete and the application will not be approved in its present form. A CRL generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. The CRL may require additional clinical or other data, additional pivotal Phase 3 clinical trial(s) and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a CRL is issued, the applicant may choose to either resubmit the BLA addressing all of the deficiencies identified in the letter, or withdraw the application. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in response to an issued CRL in either two or six months depending on the type of information included. Even with the submission of this additional information, however, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If a product receives regulatory approval from the FDA, the approval is limited to the conditions of use (e.g., patient population, indication) described in the application. Further, depending on the specific risk(s) to be addressed, the FDA may require that contraindications, warnings or precautions be included in the product labeling, require that post-approval trials, including Phase 4 clinical trials, be conducted to further assess a product&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing trials or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fast Track, RMAT and Priority Review Designations </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA has various programs, including Fast Track designation, RMAT designation and priority review, that are intended to expedite or simplify the process for the development or FDA review of medicines and biologics that are intended for the treatment of serious or life-threatening diseases or conditions. These programs do not change the standards for approval but may help expedite the development or approval process. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To be eligible for fast-track designation, the FDA must determine, based on the request of a sponsor, that a new medicine or biological product is intended to treat a serious or life-threatening condition and demonstrates the potential to address an unmet medical need by providing a therapy where none exists or a therapy that may be </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">124 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">potentially superior to existing therapy based on efficacy or safety factors. Fast track designation provides opportunities for more frequent interactions with the FDA review team to expedite development and review of the product. The FDA may also review sections of the NDA or BLA for a fast track product on a rolling basis before the complete application is submitted, if the sponsor and the FDA agree on a schedule for the submission of the application sections and the sponsor pays any required user fees upon submission of the first section of the NDA or BLA. In addition, fast track designation may be withdrawn by the sponsor or rescinded by the FDA if the designation is no longer supported by data emerging from the clinical trial process. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of the 21st Century Cures Act (the &#8220;Cures Act&#8221;), enacted in December 2016, Congress amended the FD&amp;C Act to facilitate an efficient development program for, and expedite review of regenerative medicine advanced therapies, or RMATs, which include cell and gene therapies, therapeutic tissue engineered products, human cell and tissue products, and combination products using any such therapies or products. REACT has received RMAT designation from the FDA. RMAT designation does not include HCT/Ps regulated solely under section 361 of the PHS Act and 21 Code of Federal Regulations Part 1271. This program is intended to facilitate efficient development and expedite review of regenerative medicine therapies that are intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition. A sponsor may request that FDA designate a medicine as a RMAT concurrently with or at any time after submission of an IND. The FDA has 60 calendar days to determine whether the medicine meets the criteria, including whether there is preliminary clinical evidence indicating that the medicine has the potential to address unmet medical needs for a serious or life- threatening disease or condition. A BLA for a regenerative medicine therapy that has received RMAT designation may be eligible for priority review or accelerated approval through use of surrogate or intermediate endpoints reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites. Benefits of RMAT designation also include early interactions with FDA to discuss any potential surrogate or intermediate endpoint to be used to support accelerated approval. A regenerative medicine therapy with RMAT designation that is granted accelerated approval and is subject to post-approval requirements may fulfill such requirements through the submission of clinical evidence from clinical trials, patient registries, or other sources of real-world evidence, such as electronic health records; the collection of larger confirmatory data sets; or post-approval monitoring of all patients treated with such therapy prior to its approval. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Finally, the FDA may designate a product for priority review if it is a medicine or biologic that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines at the time that the marketing application is submitted, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">case-by-case</div></div> basis, whether the proposed medicine represents a significant improvement in treatment, prevention or diagnosis of disease when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA&#8217;s goal for taking action on a marketing application from ten months to six months for an original BLA or for a New Molecular Entity NDA from the date of filing. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Furthermore, fast track designation, RMAT therapy designation and priority review do not change the standards for approval and may not ultimately expedite the development or approval process. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accelerated approval pathway </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval from the FDA and may be approved on the basis of adequate and well-controlled clinical trials establishing that the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">125 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval for such a medicine or biologic when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality (&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">IMM</div></div>&#8221;), and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a medicine receiving accelerated approval perform post- marketing clinical trials to verify and describe the predicted effect on IMM or other clinical endpoint, and the product may be subject to expedited withdrawal procedures. Drugs and biologics granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a medicine, such as an effect on IMM. The FDA has limited experience with accelerated approvals based on intermediate clinical endpoints, but has indicated that such endpoints generally may support accelerated approval when the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate long-term clinical benefit of a medicine. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a medicine, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. For example, accelerated approval has been used extensively in the development and approval of medicines for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large clinical trials to demonstrate a clinical or survival benefit. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accelerated approval pathway is usually contingent on a sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the medicine&#8217;s clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or to confirm the predicted clinical benefit of the product during post-marketing studies, would allow the FDA to withdraw approval of the medicine. All promotional materials for product candidates being considered and approved under the accelerated approval program are subject to prior review by the FDA. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Post-approval requirements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maintaining substantial compliance with applicable federal, state, and local statutes and regulations requires the expenditure of substantial time and financial resources. Following approval of a new product, the manufacturer and the approved product are subject to pervasive and continuing regulation by the FDA, including, among other things, monitoring and recordkeeping activities, reporting of adverse experiences with the product, product sampling and distribution restrictions, complying with promotion and advertising requirements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FDA regulations require that products be manufactured in specific approved facilities and in accordance with cGMP. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports and returned or salvaged products. We must comply with applicable requirements in the cGMP and cGTP regulations, including quality control and quality assurance and maintenance of records and documentation. Entities involved in the manufacture and distribution of approved biologics and HCT/Ps are required to register their establishments with the FDA and certain state agencies, as well as applicable foreign counterparts, and are </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">126 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">subject to periodic unannounced inspections by such governmental authorities for compliance with cGMP, cGTP and other laws. Accordingly, we must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. Future inspections by governmental authorities may identify compliance issues at our facilities that may disrupt production or distribution or require substantial resources to correct. In addition, the discovery of conditions that violate these rules, including failure to conform to cGMP or cGTP, could result in enforcement actions, and the discovery of problems with a product after approval may result in restrictions on a product, manufacturer or holder of an approved BLA, including voluntary recall and regulatory sanctions as described below. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other post-approval requirements applicable to biological products, include reporting of cGMP deviations that may affect the identity, potency, purity and overall safety of a distributed product, record-keeping requirements, reporting of adverse effects, reporting updated safety and efficacy information, and complying with electronic record and signature requirements. After a BLA is approved, the product also may be subject to official lot release. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot. The FDA also may perform certain confirmatory tests on lots of some products, such as viral vaccines, before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological products. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We also must comply with the FDA&#8217;s advertising and promotion requirements, such as those related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">direct-to-consumer</div></div> advertising, industry-sponsored scientific and educational activities, and promotional activities involving the internet, as well as the prohibition on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling (known as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;off-label</div> use&#8221;). Although physicians may prescribe legally available products for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses, manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses, and a company that is found to have improperly promoted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> uses may be subject to significant liability. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">If there are any modifications to the product, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new BLA or a BLA supplement, which may require the applicant to develop additional data or conduct additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-clinical</div> studies and clinical trials. The FDA may also place other conditions on approvals including the requirement for a REMS to assure the safe use of the product. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-compliance</div> with regulatory standards or if problems occur following initial marketing. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Once an approval or clearance of a medicine is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information, imposition of post-market or clinical trials to assess new safety risks, or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">fines, warning letters or other enforcement-related letters or clinical holds on post-approval clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">127 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">refusal of the FDA to approve pending NDAs/BLAs or supplements to approved NDAs/BLAs, or suspension or revocation of product approvals; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">product seizure or detention, or refusal to permit the import or export of products; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">injunctions or the imposition of civil or criminal penalties; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">consent decrees, corporate integrity agreements, debarment, or exclusion from federal health care programs; or mandated modification of promotional materials and labeling and the issuance of corrective information. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of medicine and medicine samples at the federal level, and sets minimum standards for the registration and regulation of pharmaceutical distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. Furthermore, the Drug Supply Chain Security Act (&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">DSCSA</div></div>&#8221;) was enacted with the aim of building an electronic system to identify and trace certain prescription medicines distributed in the United States, including most biological products. The DSCSA mandates <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">phased-in</div> and resource-intensive obligations for pharmaceutical manufacturers, wholesale distributors, and dispensers over a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-year</div> period that is expected to culminate in November 2023. From time to time, new legislation and regulations may be implemented that could significantly change the statutory provisions governing the approval, manufacturing and marketing of products regulated by the FDA. It is impossible to predict whether further legislative or regulatory changes will be enacted, or FDA regulations, guidance or interpretations changed or what the impact of such changes, if any, may be. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S. patent term restoration and marketing exclusivity </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Depending upon the timing, duration and specifics of the FDA approval of the use of our product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-half</div> the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application. Only one patent applicable to an approved biological product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. In addition, a patent can only be extended once and only for a single product. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may intend to apply for restoration of patent term for one of our patents, if and as applicable, to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A biological product may also obtain pediatric market exclusivity in the United States. Pediatric exclusivity is a type of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-patent</div> marketing exclusivity available in the United States and, if granted, it provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity or listed patents. This <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">six-month</div> exclusivity may be granted if an NDA sponsor submits pediatric data that fairly respond to a Written Request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot approve another application. The issuance of a Written Request does not require the sponsor to undertake the described studies. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">128 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Reference product exclusivity for biological products </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In March 2010, the ACA was enacted in the United States and included the BPCIA. The BPCIA amended the PHSA to create an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-licensed</div> reference biological product. To date, the FDA has approved a number of biosimilars, and numerous biosimilars have been approved in Europe. The FDA has also issued several guidance documents outlining its approach to reviewing and approving biosimilars and interchangeable biosimilars. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A biosimilar product is defined as one that is highly similar to a reference product notwithstanding minor differences in clinically inactive components and for which there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity and potency of the product. An interchangeable product is a biosimilar product that can be expected to produce the same clinical results as the reference product in any given patient and, for products administered multiple times to an individual, that the product and the reference product may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product without such alternation or switch. Upon licensure by the FDA, an interchangeable biosimilar may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product. The FDA approved the first interchangeable biosimilars, including an interchangeable monoclonal antibody biosimilar, in 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The biosimilar applicant must demonstrate that the product is biosimilar based on data from (1)&#160;analytical studies showing that the biosimilar product is highly similar to the reference product; (2)&#160;animal studies (including toxicity); and (3)&#160;one or more clinical studies to demonstrate safety, purity and potency in one or more appropriate conditions of use for which the reference product is approved. In addition, the applicant must show that the biosimilar and reference products have the same mechanism of action for the conditions of use on the label, route of administration, dosage and strength, and the production facility must meet standards designed to assure product safety, purity and potency. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A reference biological product is granted 12 years of data exclusivity from the time of first licensure of the product, and the first approved interchangeable biologic product will be granted an exclusivity period of up to one year after it is first commercially marketed. If pediatric studies are performed and accepted by the FDA as responsive to a Written Request, the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-year</div> exclusivity period will be extended for an additional six months. In addition, the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four years after the date of first licensure of the reference product. &#8220;First licensure&#8221; typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of licensure of (and a new period of exclusivity is not available for) a supplement for the reference product for a subsequent application filed by the same sponsor or manufacturer of the reference product (or licensor, predecessor in interest or other related entity) for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery device or strength or for a modification to the structure of the biological product that does not result in a change in safety, purity or potency. Therefore, one must determine whether a new product includes a modification to the structure of a previously licensed product that results in a change in safety, purity or potency to assess whether the licensure of the new product is a first licensure that triggers its own period of exclusivity. Whether a subsequent application, if approved, warrants exclusivity as the &#8220;first licensure&#8221; of a biological product is determined on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">case-by-case</div></div> basis with data submitted by the sponsor. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The BPCIA is complex and is still being interpreted and implemented by the FDA. In addition, recent government proposals have sought to reduce the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-year</div> reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation and meaning of the BPCIA is subject to significant uncertainty. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">129 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Additional regulation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Furthermore, some countries have enacted or are considering enacting legal restrictions on the import or export of human genetic materials, cells or tissues. For example, in China, the Ministry of Science and Technology (&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">MOST</div></div>&#8221;) and the former Ministry of Health in June 1998 jointly established the Interim Measures for the Administration of Human Genetic Resources in China. In July 2015, the MOST issued the Service Guide for the Examination and Approval of Sampling, Collecting, Trading, Exporting Human Genetic Resources, which provides that foreign entities that collect and use patients&#8217; human genetic resources in clinical trials shall be required to file for an advance approval with the Human Genetic Resources Administration Office (&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">HGRAO</div></div>&#8221;) through its online system. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2017, the MOST issued the Circular on Optimizing the Administrative Examination and Approval of Human Genetic Resources, which simplified the approval process for collecting and using human genetic resources for the purpose of seeking marketing authorization of medicines in China. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In May 2019, the State Council of China issued the Regulation on the Administration of Human Genetic Resources (the &#8220;HGR Regulation&#8221;), which stipulates the approval requirements pertinent to research collaborations between Chinese and foreign-owned entities. Pursuant to this new rule, a new filing system (as opposed to the advance approval approach originally in place) is put in place for international clinical trials using Chinese patients&#8217; biospecimens at clinical study sites without involving the export of such biospecimens outside of China. A notification filing that specifies the type, quantity and usage of the biospecimens, among others, with the HGRAO is required before conducting such clinical trials. The collection, use, and outbound transfer of Chinese patients&#8217; biospecimens in international collaboration for basic scientific research involving export are still subject to the advance approval of the HGRAO. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In October 2020, the Standing Committee of the National People&#8217;s Congress promulgated the China Biosecurity Law, which became effective on April&#160;15, 2021. The China Biosecurity Law reaffirms the regulatory requirements stipulated by the HGR Regulation while potentially increasing the administrative fines significantly in cases in which foreign entities are alleged to have collected, preserved or exported Chinese human genetic resources. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S. Foreign Corrupt Practices Act </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FCPA, to which we are subject, prohibits corporations and individuals from engaging in certain activities to obtain or retain business or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize the payment of anything of value to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Government regulation outside of the United States </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions governing, among other things, research and development, clinical trials, testing, manufacturing, safety, efficacy, </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">130 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">labeling, packaging, storage, record keeping, distribution, reporting, advertising and other promotional practices involving biological products as well as authorization and approval of our products. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki. If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension of clinical trials, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">European Union clinical trials regulation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Whether or not we obtain FDA approval for a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. In the European Union, for example, a Clinical Trial Application (&#8220;CTA&#8221;) must be submitted for each clinical trial to each country&#8217;s National Competent Authority (&#8220;NCA&#8221;) and at least one IEC, much like the FDA and an IRB, respectively. Once the CTA is approved in accordance with a country&#8217;s requirements, the corresponding clinical trial may proceed. Under the current regime (the EU Clinical Trials Directive 2001/20/EC and corresponding national laws) all suspected unexpected serious adverse reactions to the investigated medicine that occur during the clinical trial have to be reported to the NCA and ECs of the Member State where they occurred. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under the Clinical Trials Regulation (EU) No 536/2014, which came into effect on January&#160;31, 2022, there is a centralized application procedure where one EU Member State&#8217;s competent authority takes the lead in reviewing part I of the application, which contains scientific and medicinal product documentation, and the other national authorities only have limited involvement. Part II, which contains the national and patient-level documentation, is assessed individually by each EU Member State. Any substantial changes to the trial protocol or other information submitted with the CTA must be notified to or approved by the relevant competent authorities and ethics committees. Medicines used in clinical trials must be manufactured in accordance with good manufacturing practices. Other national and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">EU-wide</div> regulatory requirements may also apply. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Medicinal product review and approval in the EEA </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In the EEA (comprised of the EU Member States plus Norway, Iceland and Liechtenstein), medicinal products, including ATMPs, are subject to extensive <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-</div> and post-market regulation by regulatory authorities at both the EEA and national levels. Regulated in accordance with Regulation (EC) No 1394/2007 (the &#8220;ATMP Regulation&#8221;), ATMPs comprise gene therapy products, somatic cell therapy products and tissue engineered products. The CAT (as defined below) designated REACT as a tissue engineered product. Gene therapy products deliver genes into the body that lead to a therapeutic, prophylactic or diagnostic effect. We anticipate that REACT will be regulated as an ATMP in the EEA. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To obtain regulatory approval of an ATMP under EEA regulatory systems, we must submit a marketing authorization application (&#8220;MAA&#8221;) under the centralized procedure administered by the EMA. The application used to submit the BLA in the United States is similar to the required application process in the European Union, with the exception of, among other things, certain specific requirements set out in the ATMP Regulation, for example certain additional product characteristic information that must be included in the MAA. The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid across all of the EEA. As provided for in the ATMP Regulation, the scientific evaluation of MAAs for ATMPs is primarily performed by a specialized scientific committee called the Committee for Advanced Therapies (the &#8220;CAT&#8221;). The CAT prepares a draft opinion on the quality, safety and efficacy of the ATMP which is the subject </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">131 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of the MAA, which is sent for final approval to the Committee for Medicinal Products for Human Use (the &#8220;CHMP&#8221;). The CHMP recommendation is then sent to the European Commission, which adopts a decision binding in all EEA Member States. The maximum timeframe for the evaluation of a MAA for an ATMP is 210 days from receipt of a valid MAA, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CAT and/or CHMP. Clock stops may extend the timeframe of evaluation of a MAA considerably beyond 210 days. Where the CHMP gives a positive opinion, the EMA provides the opinion together with supporting documentation to the European Commission, which makes and issues the final decision to grant a marketing authorization within 67 days of receipt of the EMA&#8217;s recommendation. Accelerated assessment may be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and, in particular, from the viewpoint of therapeutic innovation. If the CHMP accepts such a request, the timeframe of 210 days for assessment will be reduced to 150 days (excluding clock stops), but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that the application is no longer appropriate to conduct an accelerated assessment. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Now that the United Kingdom (which comprises Great Britain and Northern Ireland) has left the European Union, Great Britain will no longer be covered by centralized marketing authorizations (under the Northern Ireland Protocol, centralized marketing authorizations will continue to be recognized in Northern Ireland). All medicinal products with a current centralized marketing authorization were automatically converted to Great Britain marketing authorizations on January, 1 2021. For a period of two years from January&#160;1, 2021, the Medicines and Healthcare products Regulatory Agency (the &#8220;MHRA&#8221;), the United Kingdom medicines regulator, may rely on a decision taken by the European Commission on the approval of a new marketing authorization in the centralized procedure, in order to more quickly grant a new Great Britain marketing authorization. A separate application will, however, still be required. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Data and marketing exclusivity </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The EEA also provides opportunities for market exclusivity. Upon receiving marketing authorization in the EEA, innovative medicinal products generally receive eight years of data exclusivity and an additional two years of market exclusivity. If granted, data exclusivity prevents generic or biosimilar applicants from referencing the innovator&#8217;s preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization during a period of eight years from the date on which the reference product was first authorized in the EEA. During the additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">two-year</div> period of market exclusivity, a generic or biosimilar marketing authorization can be submitted, and the innovator&#8217;s data may be referenced, but no generic or biosimilar product can be marketed until the expiration of the market exclusivity period. The overall <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ten-year</div> period will be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to authorization, is held to bring a significant clinical benefit in comparison with existing therapies. Even if an innovative medicinal product gains the prescribed period of data exclusivity, another company may market another version of the product if such company obtained marketing authorization based on a MAA with a complete independent data package of pharmaceutical tests, preclinical tests and clinical trials. There is, however, no guarantee that a product will be considered by the European Union&#8217;s regulatory authorities to be an innovative medicinal product, and products may therefore not qualify for data exclusivity. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Post-approval controls </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following approval, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of the medicinal product. These include the following: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The holder of a marketing authorization must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance, who is responsible for oversight of that </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">132 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of periodic safety update reports (&#8220;PSURs&#8221;). </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All new MAAs must include a risk management plan (&#8220;RMP&#8221;), describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. The regulatory authorities may also impose specific obligations as a condition of the marketing authorization. Such risk-minimization measures or post-authorization obligations may include additional safety monitoring, more frequent submission of PSURs, or the conduct of additional clinical trials or post-authorization safety studies. RMPs and PSURs are routinely available to third parties requesting access, subject to limited redactions. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">All advertising and promotional activities for the product must be consistent with the approved Summary of Product Characteristics (&#8220;SmPC&#8221;), and therefore all <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-label</div> promotion is prohibited. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Direct-to-consumer</div></div> advertising of prescription medicines is also prohibited in the European Union. Although general requirements for advertising and promotion of medicinal products are established under EU directives, the details are governed by regulations in each EU Member State and can differ from one country to another. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Failure to comply with European Union and EU Member State laws that apply to the conduct of clinical trials, manufacturing approval, marketing authorization of medicinal products and marketing of such products (both before and after grant of the marketing authorization), manufacturing of pharmaceutical products, statutory health insurance, bribery and anti-corruption or with other applicable regulatory requirements may result in administrative, civil or criminal penalties. Such penalties could include delays or refusal to authorize the conduct of clinical trials or to grant the marketing authorization, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the marketing authorization, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Brexit and the Regulatory Framework in the United Kingdom </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2016, the electorate in the United Kingdom voted in favor of leaving the European Union (commonly referred to as &#8220;Brexit&#8221;). Thereafter, in March 2017, the country formally notified the European Union of its intention to withdraw pursuant to Article 50 of the Lisbon Treaty. The United Kingdom formally left the European Union on January&#160;31, 2020. A transition period began on February&#160;1, 2020, during which EU pharmaceutical law remained applicable to the United Kingdom. This transition period ended on December&#160;31, 2020. Since the regulatory framework in the United Kingdom covering quality, safety and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales and distribution of pharmaceutical products is derived from EU Directives and Regulations, Brexit could materially impact the future regulatory regime which applies to products and the approval of product candidates in the United Kingdom as United Kingdom legislation now has the potential to diverge from EU legislation. It remains to be seen how Brexit will impact regulatory requirements for product candidates and products in the United Kingdom in the long-term. The MHRA, the United Kingdom medicines and medical devices regulator, has recently published detailed guidance for industry and organizations to follow from January&#160;1, 2021 now that the transition period is over, which will be updated as the United Kingdom&#8217;s regulatory position on medicinal products evolves over time. On June&#160;28, 2021, the European Commission issued a decision that the United Kingdom ensures an adequate level of protection for personal data transferred under the GDPR from the European Union to the United Kingdom. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other health care laws and compliance requirements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If our product candidates are approved in the United States, we will have to comply with various U.S. federal and state laws, rules and regulations pertaining to health care fraud and abuse, including anti-kickback laws and false claims laws, rules and regulations. Violations of the fraud and abuse laws are punishable by </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">133 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">criminal and civil sanctions, including, in some instances, exclusion from participation in federal and state health care programs, including Medicare and Medicaid. These laws include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the AKS, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order, arrangement or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal health care program, such as the Medicare and Medicaid programs; a person or entity does not need to have actual knowledge of the AKS or specific intent to violate it to have committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the FCA or federal civil money penalties statute; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the federal civil and criminal false claims laws and civil monetary penalty laws, including the FCA, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, false or fraudulent claims for payment to, or approval by Medicare, Medicaid, or other federal health care programs, knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim or an obligation to pay or transmit money to the federal government, or knowingly concealing or knowingly and improperly avoiding or decreasing or concealing an obligation to pay money to the federal government. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payers if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Civil Monetary Penalties Law (beneficiary inducement law), which prohibits, among other things, the offering or giving of remuneration, which includes, without limitation, any transfer of items or services for free or for less than fair market value (with limited exceptions), to a Medicare or Medicaid beneficiary that the person knows or should know is likely to influence the beneficiary&#8217;s selection of a particular supplier of items or services reimbursable by a federal or state governmental program; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HIPAA, which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any health care benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any health care benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious, or fraudulent statements or representations in connection with the delivery of, or payment for, health care benefits, items or services relating to health care matters; similar to the AKS, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the federal transparency requirements under the ACA, including the provision commonly referred to as the Physician Payments Sunshine Act, and its implementing regulations, which requires applicable manufacturers of medicines, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to the U.S. Department of Health and Human Services (&#8220;DHHS&#8221;) information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, anesthesiologist assistants, certified nurse midwives and teaching hospitals, as well as ownership and investment interests held by the providers described above and their immediate family; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the FCPA and other anti-corruption laws and regulations pertaining to our financial relationships and interactions with foreign government officials, which prohibit U.S. companies and their employees, officers, and representatives from paying, offering to pay, promising, or authorizing the payment of </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">134 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">anything of value to any foreign government official (including, potentially, healthcare professionals in countries in which we operate or may sell our products), government staff member, political party, or political candidate to obtain or retain business or to otherwise seek favorable treatment. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In November 2020, the DHHS finalized significant changes to the regulations implementing the AKS, as well as the civil monetary penalty rules regarding beneficiary inducements, with the goal of offering the healthcare industry more flexibility and reducing the regulatory burden associated with those fraud and abuse laws, particularly with respect to value-based arrangements among industry participants. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Additionally, we are subject to state and foreign equivalents of each of the health care laws and regulations described above, among others, some of which may be broader in scope and may apply regardless of the payor. Many U.S. states have adopted laws similar to the AKS and FCA, and may apply to our business practices, including, but not limited to, research, distribution, sales or marketing arrangements and claims involving health care items or services reimbursed by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-governmental</div> payors, including private insurers. In addition, some states have passed laws that require pharmaceutical companies to comply with the April 2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and/or the Pharmaceutical Research and Manufacturers of America&#8217;s Code on Interactions with Health Care Professionals. Several states also impose other marketing restrictions or require pharmaceutical companies to make marketing or price disclosures to the state. There are ambiguities as to what is required to comply with these state requirements and if we fail to comply with an applicable state law requirement, we could be subject to penalties. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Violations of fraud and abuse laws may be punishable by criminal and/or civil sanctions, including penalties, fines, imprisonment and/or exclusion or suspension from federal and state health care programs such as Medicare and Medicaid and debarment from contracting with the U.S. government. In addition, private individuals have the ability to bring actions on behalf of the U.S. government under the FCA as well as under the false claims laws of several states. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Law enforcement authorities are increasingly focused on enforcing health care fraud and abuse laws, and it is possible that some of our practices may be challenged under these laws. Efforts to ensure that our current and future business arrangements with third parties, and our business generally, will comply with applicable health care laws and regulations will involve substantial costs. If our operations, including our arrangements with physicians and other health care providers are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, the curtailment or restructuring of our operations, exclusion from participation in federal and state health care programs (such as Medicare and Medicaid), and imprisonment, any of which could adversely affect our ability to operate our business and our financial results. The approval and commercialization of any of our product candidates outside the United States will also subject us to foreign equivalents of the health care laws mentioned above, among other foreign laws. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If any of the physicians or other health care providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded health care programs, which may also adversely affect our business. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The risk of our being found in violation of these laws is increased by the fact that many of these laws have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">135 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. The shifting compliance environment and the need to build and maintain a robust system to comply with multiple jurisdictions with different compliance and reporting requirements increases the possibility that a health care company may violate one or more of the requirements. Efforts to ensure that our business arrangements with third parties will comply with applicable health care laws and regulations will involve substantial cost. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Data Privacy and Security </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are federal, state and foreign laws governing the privacy and security of health information and personal information, many of which differ from each other in significant ways and apply simultaneously, thus complicating compliance efforts. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HIPAA, as amended by HITECH, and its implementing regulations, strengthens and expands requirements relating to the privacy, security, and transmission of individually identifiable health information; and requires notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">HITECH strengthened and expanded HIPAA and increased penalties for violations. Under HITECH, regulated entities are subject to enforcement by the federal government and by state Attorneys General, who were given authority to enforce HIPAA under HITECH. Some state laws impose privacy protections more stringent than HIPAA and data security requirements applicable to information beyond health care information (for example, the CCPA). These state laws create an additional level of enforcement and may require additional reporting in the event of breach. Most of the health care providers in the United States with whom we collaborate to develop and test our products must comply with HIPAA and applicable state law. We may not be directly subject to these laws, however, we must structure our activities in compliance with these laws to ensure that we can access and use health information to support our research, development and other activities. Our failure to comply with these privacy and security laws or a breach of health information or personal data could prompt enforcement against our health care provider partners, create third party liability for our company and/or cause significant financial or reputational harm to our company. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may also be subject to additional privacy restrictions. The collection, use, storage, disclosure, transfer, or other processing of personal data regarding individuals in the EEA, including personal health data, is subject to the GDPR, which became effective on May&#160;25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the European Union, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20&#160;million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR includes restrictions on cross-border data transfers. Compliance with the GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices, and despite those efforts, there is a risk that we may be subject to fines and penalties, litigation, and reputational harm in connection with our European activities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Health care reform </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. For example, in </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">136 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">December 2016, the Cures Act was signed into law. The Cures Act, among other things, was intended to modernize the regulation of pharmaceuticals and devices and to spur innovation, but its ultimate implementation is uncertain. Legislative proposals continue to be discussed in the U.S. Congress as potentially leading to a future &#8220;Cures 2.0&#8221; bill that is expected to have bipartisan support. In addition, in August 2017, the FDA Reauthorization Act was signed into law, which reauthorized the FDA&#8217;s user fee programs and included additional medicine and biological product provisions. The next legislative reauthorization must be completed in 2022, which has the potential to make further changes to FDA authorities or policies pertaining to biopharmaceutical products. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we otherwise may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, the containment of healthcare costs has become a priority of federal and state governments and the prices of therapeutics have been a focus in this effort. The U.S. government, state legislatures and foreign governments also have shown significant interest in implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement, and requirements for substitution of generic and biosimilar products for branded prescription medicines and biologics, respectively. In recent years, the U.S. Congress has considered reductions in Medicare reimbursement levels for medicines and biologics administered by physicians. CMS, the agency that administers the Medicare and Medicaid programs, also has authority to revise reimbursement rates and to implement coverage restrictions for some medicines and biologics. Cost reduction initiatives and changes in coverage implemented through legislation or regulation could decrease utilization of and reimbursement for any approved products we may market in the future. While Medicare regulations apply only to pharmaceutical benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from federal legislation or regulation may result in a similar reduction in payments from private payors. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The ACA, as amended by the Health Care and Education Affordability Reconciliation Act, was enacted in 2010 and substantially changed the way healthcare is financed by both governmental and private insurers in the United States, and significantly impacted the pharmaceutical industry. The ACA was intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against healthcare fraud and abuse, add new transparency requirements for healthcare and health insurance industries, impose new taxes and fees on pharmaceutical manufacturers, and impose additional health policy reforms. With regard to biopharmaceutical products, the ACA, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for therapeutics that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees on manufacturers of certain branded prescription medicines, created a new Medicare Part D coverage gap discount program, and expanded the 340B drug discount program. As another example, the 2021 Consolidated Appropriations Act signed into law on December&#160;27, 2020 incorporated extensive healthcare provisions and amendments to existing laws, including a requirement that all manufacturers of medicines and biological products covered under Medicare Part B report the product&#8217;s average sales price, to the DHHS beginning on January&#160;1, 2022, subject to enforcement via civil money penalties. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There have been executive, judicial and Congressional challenges to certain aspects of the ACA since its enactment, and it is possible that there will be additional challenges and amendments to the ACA in the future. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Other legislative changes have been proposed and adopted since passage of the ACA that affect health care expenditures. These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and will remain in effect through 2030 unless additional Congressional action is taken. However, due to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic relief legislation and subsequent legislation, the 2% Medicare sequester reductions were suspended from May&#160;1, 2020 through </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">137 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">June&#160;30, 2021 (a 1% sequester applied from April&#160;1, 2022 through June&#160;30, 2022), and the sequester was extended in order to offset the added expense of the 2020 suspension. Further legislative and regulatory changes under the ACA remain possible, although the new administration under President Biden has signaled that it plans to build on the ACA and expand the number of people who are eligible for health insurance subsidies under it. President Biden indicated that he intends to use executive orders to undo changes to the ACA made by the former administration and would advocate for legislation to build on the ACA. It is unknown what form any such changes or any law would take, and how or whether it may affect the biopharmaceutical industry as a whole or our business in the future. We expect that changes or additions to the ACA, the Medicare and Medicaid programs, changes allowing the federal government to directly negotiate medicine prices, and changes stemming from other healthcare reform measures, especially with regard to healthcare access, financing or other legislation in individual states, could have a material adverse effect on the healthcare industry in the United States. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In recent years, there has been heightened governmental scrutiny over the manner in which biopharmaceutical manufacturers set prices for their marketed products. Such scrutiny has resulted in several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to medicine pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of medicines under Medicare, and reform government program reimbursement methodologies for pharmaceutical products. Congress and the executive branch have each indicated that it will continue to seek new legislative and/or administrative measures to control the costs of medicines, making this area subject to ongoing uncertainty. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the state level in the United States, legislatures have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and marketing cost disclosure and transparency measures, and in some cases, designed to encourage importation from other countries and bulk purchasing. In December 2020, the U.S. Supreme Court held unanimously that federal law does not preempt the states&#8217; ability to regulate pharmaceutical benefit managers and other members of the healthcare and pharmaceutical supply chain, an important decision that may lead to further and more aggressive efforts by states in this area. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. We expect that additional federal, state, and foreign healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in limited coverage and reimbursement and reduced demand for our products, once approved, or additional pricing pressures. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Coverage and reimbursement </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Significant uncertainty exists as to the coverage and reimbursement status of any cell-based regenerative therapies for which we may obtain regulatory approval. In the United States and markets in other countries, sales of any cell-based therapies for which we receive regulatory approval for commercial sale will depend, in part, on the availability of coverage and reimbursement from payors. Payors include government authorities, managed care providers, private health insurers and other organizations. Patients who are prescribed treatments for their conditions and providers who prescribe such treatments generally rely on these third-party payors to reimburse all or part of the treatment and other associated health care costs. The process for determining whether a payor will provide coverage for a medicine, device or biologic product may be separate from the process for setting the reimbursement rate that the payor will pay for the product. Payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FDA-approved</div> products for a particular indication. A decision by a payor not to cover our cell-based therapies could reduce physician utilization of our products, if they are approved, and have a material adverse effect on our sales, results of operations and financial condition. Moreover, a payor&#8217;s decision to provide coverage for a product does not imply that an adequate </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">138 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development and manufacturing costs. Further, due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic, millions of individuals have lost or may lose employer-based insurance coverage, which may adversely affect our ability to commercialize our products in certain jurisdictions. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, coverage and reimbursement for products can differ significantly from payor to payor. One payor&#8217;s decision to cover a particular medical product or service does not ensure that other payors will also provide coverage for the medical product or service, or will provide coverage at an adequate reimbursement rate. In the United States, the principal decisions about reimbursement for new medicines are typically made by CMS. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Additionally, the coverage determination process will require us to provide scientific and clinical support for the use of our products to each payor separately and will be a time-consuming process. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain and maintain coverage and reimbursement for any product, we may need to conduct expensive evidence generation studies in order to demonstrate the medical necessity and cost-effectiveness of such a product, in addition to the costs required to obtain regulatory approvals. If payors do not consider a product to be cost-effective compared to current standards of care, they may not cover the product as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to cover its costs or make a profit. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outside of the United States, the pricing of pharmaceutical products is subject to governmental control in many countries. For example, in the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed with the government authority. Furthermore, some countries may require the completion of additional studies that compare the effectiveness and/or cost-effectiveness of a particular therapy to current standards of care as part of so-called health technology assessments in order to obtain reimbursement or pricing approval. Additionally, there may be a need for activities to secure reimbursement for procedures associated with products administered in a hospital setting under the diagnosis-related group system, whereby a billing code may not exist or may be currently insufficient to cover the cost of the procedure. In other instances, countries may monitor and control product volumes and issue guidance to physicians to limit prescriptions in the form of treatment policies. Efforts to control prices and utilization of pharmaceutical products and medical devices will likely continue as countries attempt to manage health care expenditures. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Human Capital Resources </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of July&#160;31, 2022, ProKidney had 77 full-time employees. This included 26 in research and development, 41 in manufacturing, operations, quality control and quality assurance, and 10 in general and administrative functions. We have no collective bargaining agreements with our employees, and we have not experienced any work stoppages. We consider our relations with our employees to be good. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Facilities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our headquarters are located in Winston-Salem, North Carolina, where we lease approximately 38,400 square feet of office, manufacturing and research space, under a lease that expires on September&#160;30, 2026. We have leased approximately 2,700 square feet of additional office space in Winston-Salem, which we plan to use as our new principal executive offices. This lease commenced in April 2022 and is expected to expire in April 2027. There is an additional office located in Raleigh, North Carolina where we lease approximately 2,200 square feet, under a lease that expires February&#160;28, 2025. There was an amendment to the original lease for the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">139 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Raleigh office. The amended lease is for approximately 5,700 square feet that will expire on January&#160;31, 2027. Further, there has been an additional amendment to the original lease for the Raleigh office, which increases the total space to approximately 7,900 square feet and will expire on July&#160;31, 2027. We believe our facilities are adequate for our current needs and that suitable additional substitute space would be available if needed. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal Proceedings </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">140 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom373959_11" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">AND RESULTS OF OPERATIONS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The following discussion and analysis of the financial condition and results of operations should be read together with the financial statements and the related notes to those statements included elsewhere in this prospectus. The discussion and analysis should also be read together with the pro forma financial information as of and for the three months ended March&#160;31, 2022 and as of and for the year ended December&#160;31, 2021 included in this prospectus. See &#8220;Unaudited Pro Forma Condensed Financial Information.&#8221; Some of the information contained in this discussion and analysis or set forth elsewhere in this prospectus, including information with respect to our plans and strategy for our business, includes forward- looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the section entitled &#8220;Risk Factors,&#8221; our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. In this section, unless the context otherwise requires, references to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; the &#8220;Company&#8221; and &#8220;ProKidney&#8221; refer to ProKidney LP and its subsidiaries prior to the Closing and to ProKidney Corp. and its subsidiaries after the Closing, and &#8220;SCS&#8221; refers to SCS prior to the Closing. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Overview </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are a clinical-stage biotechnology business with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient&#8217;s own cells isolated from the patient intended for treatment. Our approach seeks to redefine the treatment of CKD, shifting the emphasis away from management of kidney failure, to the restoration or improvement of kidney function to stop or delay progression of CKD. Our lead product candidate, which we refer to as REACT, is designed to stabilize or improve kidney function in a CKD patient&#8217;s diseased kidneys. REACT is a product that includes SRCs prepared from a patient&#8217;s own, autologous, renal cells. SRCs are formulated into a product for reinjection into the patient&#8217;s kidney using a minimally invasive outpatient procedure that can be repeated if necessary. Because REACT is a personalized treatment composed of cells prepared from a patient&#8217;s kidney, there is no need for treatment with immunosuppressive therapies, which are required during a patient&#8217;s lifetime when a patient receives a kidney transplant from another, allogeneic donor. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are currently conducting a Phase 3 development program and multiple Phase 2 clinical trials for REACT in subjects with moderate to severe diabetic kidney disease. We are also conducting a Phase 1 clinical trial for REACT in subjects with CAKUT. REACT has been well tolerated by subjects with moderate to severe diabetic kidney disease in Phase 1 and 2 clinical testing to date. It has also been shown to stabilize renal function in subjects based on measurements of iohexol renal clearance and UACR. REACT has received RMAT designation from the FDA. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">ProKidney Bermuda was incorporated under the laws of Bermuda in December 2018, and it was initially capitalized with $75.0&#160;million to finance the purchase of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US,</div> and to fund the clinical development of REACT. In December 2014, Tengion, whose assets were purchased in March 2015 by RegenMedTX, LLC, a predecessor to ProKidney, commenced a Chapter 7 Case by filing a voluntary petition for relief under the provisions of chapter 7 of title 11 of the United States Code, 11 U.S.C. &#167;&#167; 101 et seq. in the Bankruptcy Court. As a result of the filing of the Chapter 7 Case, a Chapter 7 trustee was appointed by the Bankruptcy Court to assume control of Tengion. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On August&#160;5, 2021, ProKidney LP was formed as a limited partnership under the laws of Ireland, with ProKidney Bermuda becoming a wholly owned subsidiary of ProKidney LP. Since inception, ProKidney and its subsidiaries have devoted substantially all of their resources to raising capital, organizing and staffing, business and scientific planning, conducting discovery and research activities, acquiring or discovering product candidates, establishing and protecting their intellectual property portfolio, developing and progressing REACT and preparing for clinical trials, establishing arrangements with third parties for the manufacture of component </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">141 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">materials, and providing general and administrative support for these operations. We do not have any product candidates approved for sale and have not generated any revenue from product sales. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On July 11, 2022, SCS and ProKidney LP completed the Business Combination, and SCS&#8217;s corporate name was changed to &#8220;ProKidney Corp.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The combined company was organized in an umbrella <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">partnership-C</div> corporation (a so called <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Up-C&#8221;</div> structure). ProKidney Corp. is a holding company, and our direct assets consist of Post-Combination ProKidney Common Units and all of the issued and outstanding equity interests of GP, which became the general partner of ProKidney LP upon the Closing. ProKidney Corp. controls GP, with the rights of management specified in the Second Amended and Restated ProKidney Limited Partnership Agreement. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">From inception through March&#160;31, 2022, ProKidney and its subsidiaries funded their operations primarily through capital contributions and promissory notes issued to certain ProKidney unitholders and have received aggregate net proceeds from these transactions of $186.5&#160;million and $35.0&#160;million, respectively. The $35.0&#160;million received under the promissory notes was repaid at the Closing. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We incurred significant operating losses since inception, including net losses of $67.5&#160;million and $11.6&#160;million for the three months ended March&#160;31, 2022 and 2021, respectively, and $55.1&#160;million and $26.7&#160;million for the years ended December&#160;31, 2021 and 2020, respectively. As of March&#160;31, 2022 and December&#160;31, 2021, we had an accumulated deficit of $229.0&#160;million and $161.5&#160;million, respectively. We expect to continue to incur significant and increasing expenses and operating losses for the foreseeable future, particularly if and as we continue to invest in our research and development activities, expand our product pipeline, hire additional personnel, invest in and grow our business, maintain, expand and protect our intellectual property portfolio, and seek regulatory approvals for and commercialize any approved product candidates. In addition, we expect to incur additional costs associated with operating as a public company, including significant legal, audit, accounting, regulatory, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-related,</div> director and officer insurance, investor relations and other expenses that we did not incur as a private company. As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the public or private sale of equity, government or private party grants, debt financings or other capital sources, including potential collaborations with other companies or other strategic transactions. If we are unable to obtain additional funding, we could be forced to delay, reduce or eliminate some, or all, of our research and development programs, product portfolio expansion or any commercialization efforts, which could adversely affect our business prospects, or we may be unable to continue operations. If we raise funds through strategic collaborations or other similar arrangements with third parties, we may have to relinquish valuable rights to our platform technology, future revenue streams, research programs or product candidates or may have to grant licenses on terms that may not be favorable to us and/or may reduce the value of our units. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic or other events. Because of the numerous risks and uncertainties associated with product development, we cannot predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2022, we had cash and cash equivalents of $29.8&#160;million. Additionally, we have remaining availability of $65.0&#160;million under the ProKidney Promissory Notes. We expect that, having completed the Business Combination and accounting for $574.8&#160;million received in the PIPE Investment, our cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements through 2024. We have based this estimate on assumptions that may prove to be wrong and we could exhaust our capital resources sooner than we expect. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">142 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Business Combination </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Business Combination will be accounted for as a common control transaction in accordance with GAAP. Under the guidance in ASC 805, SCS will be treated as the &#8220;acquired&#8221; company for financial reporting purposes. Accordingly, the Business Combination will be reflected as the equivalent of ProKidney issuing shares for the net assets of SCS, accompanied by a recapitalization whereby no goodwill or other intangible assets are recorded. Operations following the Business Combination are those of ProKidney Corp. The Business Combination will have a significant impact on our future reported financial position and results as a consequence of the reverse capitalization. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Business Combination resulted in gross proceeds of approximately $596,537,000. This amount reflects a contribution of $21,737,000 of cash held in SCS&#8217;s trust account, net of redemptions, and a $574,800,000 concurrent private placement of Class&#160;A ordinary shares of the combined company, priced at $10.00 per share (the &#8220;PIPE Placement&#8221;). At the Closing, these proceeds were used to repay the outstanding balance of $35,000,000 under the Company&#8217;s two promissory note agreements with certain holders of its Class&#160;A Units (the &#8220;Promissory Notes&#8221;) and related accrued interest. Additionally, the proceeds were used to pay those expenses previously incurred by SCS related to the business combination of approximately $21,029,000 as well as advisory and placement fees of approximately $29,389,000 incurred in connection with the PIPE Placement. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">Business Impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> Pandemic </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The global <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic continues to rapidly evolve, and we will continue to monitor the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> situation closely. To date, our financial condition and operations have not been significantly impacted by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. However, we cannot, at this time, predict the specific extent, duration or full impact that the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic will have on our financial condition and operations, including our ongoing and planned clinical trials. The extent of the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> on our business, operations and clinical development timelines and plans remains uncertain and will depend on certain developments, including the duration and spread of the outbreak and its impact on our clinical trial enrollment, trial sites, contract research organizations (&#8220;CROs&#8221;), and other third parties with whom we do business, as well as its impact on regulatory authorities and our key scientific and management personnel. To the extent possible, we are conducting business as usual, with necessary or advisable modifications to employee travel as some of our employees are working remotely. We will continue to actively monitor the rapidly evolving situation related to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> and may take further actions that alter our operations, including those that may be required by federal, state or local authorities, or that we determine are in the best interests of our employees and other third parties with whom we do business. The development of our product candidates could be disrupted and materially adversely affected in the future by the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic. Our planned clinical trials also could be delayed due to government orders and site policies on account of the pandemic, and some patients may be unwilling or unable to travel to study sites, enroll in our trials or be unable to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services, which would delay our ability to conduct clinical trials or release clinical trial results and could delay our ability to obtain regulatory approval and commercialize REACT or any future product candidates. Furthermore, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> could affect our employees or the employees of research sites and service providers on whom we rely, including CROs, as well as those of companies with which we do business, including our suppliers, thereby disrupting our business operations. Quarantines and travel restrictions imposed by governments in the jurisdictions in which we and the companies with which we do business operate could materially impact the ability of employees to access clinical sites, laboratories, manufacturing sites and offices. These and other events resulting from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic could disrupt, delay, or otherwise adversely impact our business. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial Operations Overview </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Revenue </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have not generated any revenue since inception, and we do not expect to generate any revenue from the sale of products in the near future, if at all. If our development efforts for REACT or any other product </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">143 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">candidates are successful and result in marketing approval, or if we enter into collaboration or license agreements with third parties, we may generate revenue in the future from a combination of product sales or payments from such agreements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Expenses </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and Development Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development expenses consist primarily of costs incurred in connection with our research and development activities, including the development of REACT. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development costs include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">external research and development expenses incurred under agreements with CROs and other scientific development services; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">costs of other outside consultants, including their fees and related travel expenses; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">costs related to compliance with quality and regulatory requirements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">costs of laboratory supplies and acquiring and developing clinical trial materials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">payments made under third-party licensing agreements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">personnel-related expenses, including salaries, bonuses, benefits and share-based compensation expenses, for individuals involved in research and development activities; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent, insurance and other internal operating costs. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expense research and development costs as incurred. We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our consolidated balance sheets as prepaid clinical or as a component of total accrued expenses and other. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized, even when there is no alternative future use for the research and development. The capitalized amounts are recorded as prepaid clinical and are expensed as the related goods are delivered or the services are performed. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development activities are central to our business model. We expect that our research and development expenses will increase significantly for the foreseeable future as REACT moves into later stages of clinical development. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The successful development of REACT and any product candidates we may develop in the future is highly uncertain. Therefore, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development and commercialization of any of our product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from the sale of REACT or potential future product candidates, if approved. This is due to the numerous risks and uncertainties associated with developing product candidates, many of which are outside of our control, including the uncertainty of: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the timing and progress of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> and clinical development activities; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the number and scope of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> and clinical programs we decide to pursue; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to maintain our current research and development programs and to establish new ones; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">establishing an appropriate safety profile; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the number of sites and patients including clinical trials; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">144 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the countries in which the clinical trials are conducted; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">per patient trial costs; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">successful patient enrollment in, and the initiation of, clinical trials, as well as drop out or discontinuation rates, particularly in light of the current <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic environment; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the successful completion of clinical trials with safety, tolerability and efficacy profiles that are satisfactory to the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and comparable foreign regulatory authorities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the number of trials required for regulatory approval; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the timing, receipt and terms of any regulatory approvals from applicable regulatory authorities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">our ability to establish new licensing or collaboration arrangements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the performance of our future collaborators, if any; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">significant and changing government regulation and regulatory guidance; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the impact of any business interruptions to our operations or to those of the third parties with whom we work, particularly in light of the current <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic environment; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">obtaining, maintaining, defending and enforcing patient claims or other intellectual property rights; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the potential benefits of REACT over other therapies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">launching commercial sales of REACT, if approved, whether alone or in collaboration with others; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">maintaining a continued acceptable safety profile of REACT, should it obtain regulatory approval. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any changes in the outcome of any of these variables could mean a significant change in the costs and timing associated with the development of our product candidates. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we would be required to expend significant additional financial resources and time on the completion of clinical development. We may never obtain regulatory approval for any of our product candidates. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">General and Administrative Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">General and administrative expenses consist primarily of personnel-related costs, including salaries, bonuses, benefits and equity-based compensation expenses for individuals involved in our executive, finance, corporate and administrative functions, as well as expenses for outside professional services, including legal, audit, accounting and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-related</div> services and other consulting fees, facility-related expenses, which include depreciation costs and other allocated expenses for rent and maintenance of facilities, insurance costs, recruiting costs, travel expenses and other general administrative expenses. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We expect that our general and administrative expenses will increase significantly for the foreseeable future as our business expands and we hire additional personnel to support our operations. We also anticipate increased expenses associated with being a public company, including costs for legal, audit, accounting, investor and public relations, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-related</div> services, director and officer insurance, and regulatory costs related to compliance with the rules and regulations of the SEC as well as listing standards applicable to companies listed on a national securities exchange. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">145 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Income (Expense) </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income consists of interest income earned on cash and cash equivalents held in financial institutions. We expect our interest income to increase following the completion of this merger as we invest the net proceeds from this merger pending their use in our operations. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Tax (Expense) Benefit </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense reflects federal and state taxes on income earned by our subsidiary that is organized as a C corporation for U.S. income tax purposes. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Results of Operations </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Comparison of Three Months Ended March&#160;31, 2022 and 2021 </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes our results of operations for the three months ended March&#160;31, 2022 and 2021 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,490</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,859</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">18,631</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">37,972</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,744</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">36,228</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">66,462</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,603</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">54,859</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(66,462</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,603</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(54,859</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(14</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss before taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(66,476</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,603</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(54,873</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense (benefit)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,010</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,004</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(67,486</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,609</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(55,877</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and development expenses</div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The increase in research and development expenses of approximately $18.6&#160;million was primarily driven by a $14.1&#160;million increase in cost related to equity-based payments for services rendered by a third-party in prior periods, as the cost of those payments was adjusted to the fair value of the awards issued upon their grant date in the three months ended March&#160;31, 2022. Additionally, equity-based compensation costs increased approximately $3.3&#160;million for the three months ended March&#160;31, 2022, due to additional awards granted to employees during the period. Further, cash based compensation costs increased by $0.8&#160;million, driven primarily by the hiring of additional personnel. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">General and administrative expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The increase in general and administrative expenses of approximately $36.2&#160;million was primarily driven by a $30.0&#160;million increase in equity-based compensation for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B-1</div> Units sold at less than their fair value to employees and other service providers of the Company. Additionally, there was a $5.1&#160;million increase in equity-based compensation expense which was driven by a modification to the existing awards as well as the grant of additional awards during the three months ended March&#160;31, 2022. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income tax expense </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The increase in income tax expense of approximately $1.0&#160;million was driven primarily by the impact of a provision of the Tax Act which became effective for tax years beginning after December&#160;31, 2021. This </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">146 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">provision requires specified research and development expenses to be capitalized and amortized ratably over a five-year period and is the primary driver of the income tax expense recognized during the three months ended March&#160;31, 2022. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Comparison of Years Ended December&#160;31, 2021 and 2020 </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes our results of operations for the years ended December&#160;31, 2021 and 2020 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 4%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Change</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46,255</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21,042</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,213</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,855</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,982</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,873</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">55,110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,024</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28,086</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(55,110</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(27,024</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(28,086</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">43</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(41</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss before taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(55,108</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(26,981</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(28,127</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense (benefit)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(232</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">270</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(55,146</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(26,749</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(28,397</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Research and development expenses</div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Research and development expenses increased primarily due to the startup costs incurred in 2021 in connection with the launch of our Phase 3 clinical study <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-006</div> in 2022. As a Phase 3 trial, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-006</div> is planned to be much larger in scope than the clinical trials ongoing in 2020. In addition to the impact of spending on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-006,</div> we also began enrollment in our Phase 2 study <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-007</div> in the latter part of 2021. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">General and administrative expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The increase in general and administrative expenses of approximately $2.9&#160;million was primarily driven by services performed in anticipation of a going-public transaction and our reorganization pursuant to our organization as an Irish limited partnership. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Liquidity and Capital Resources </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Sources of liquidity </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since inception, we have not recognized any revenue and have incurred operating losses and negative cash flows from our operations. We have not yet commercialized any product and we do not expect to generate revenue from sales of any products for several years, if at all. From inception through March&#160;31, 2022, we have funded our operations primarily through capital contributions and the ProKidney Promissory Notes and have received aggregate net proceeds from these transactions of $186.5&#160;million and $20.0&#160;million, respectively. The $20.0&#160;million received under the promissory notes was repaid at the Closing. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect that the net proceeds from the Business Combination, together with our cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements through 2024. We </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">147 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">have based this estimate on assumptions that may prove to be wrong and we could exhaust our capital resources sooner than we expect. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We expect our expenses to increase substantially if, and as, we: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">initiate and continue research and clinical development of our product candidates, including in particular our clinical trials for REACT; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">incur third-party manufacturing costs to support our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-clinical</div> studies and clinical trials of our product candidate and, if approved, its commercialization; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">seek to identify and develop additional product candidates; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">make investment in developing internal manufacturing capabilities; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">seek regulatory and marketing approvals for our product candidates. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In addition, we expect to incur additional costs associated with operating as a public company, including significant legal, audit, accounting, investor and public relations, regulatory, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-related,</div> director and officer insurance premiums and other expenses that we did not incur as a private company. Developing pharmaceutical products, including conducting clinical trials, is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval for any product candidates or generate revenue from the sale of any product candidate for which we may obtain marketing approval. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of product that we do not expect to be commercially available for at least several years, if ever. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the public or private sale of equity, government or private party grants, debt financings or other capital sources, including potential collaborations with other companies or other strategic transactions. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our shareholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our unitholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable to obtain additional funding, we could be forced to delay, reduce or eliminate some or all of our research and development programs, product portfolio expansion or any commercialization efforts, which could adversely affect our business prospects, or we may be unable to continue operations. If we raise funds through strategic collaborations or other similar arrangements with third parties, we may have to relinquish valuable rights to our technology, future revenue streams, research programs or product candidates or may have to grant licenses on terms that may not be favorable to us and/or may reduce the value of our units. Our ability to raise additional funds may be adversely impacted by potential worsening global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic or otherwise. Because of the numerous risks and uncertainties associated with product development, we cannot predict the timing or amount of increased expenses, and there is no assurance that we will ever be profitable or generate positive cash flow from operating activities. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">148 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash Flows </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash Flows for the Three Months Ended March&#160;31, 2022 and 2021 </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides information regarding our cash flows for the three months ended March&#160;31, 2022 and 2021 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/>March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(15,459</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(7,256</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(839</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,389</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,542</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,993</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net change in cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,244</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,348</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash Flows for the Years Ended December&#160;31, 2021 and 2020 </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides information regarding our cash flows for the years ended December&#160;31, 2021 and 2020 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year Ended<br/>December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(50,299</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(25,181</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,191</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,456</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">71,470</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,989</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net change in cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,980</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10,648</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Operating Activities</div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Net cash used in operating activities was approximately $15.5&#160;million for the three months ended March&#160;31, 2022, reflecting a net loss of approximately $67.5&#160;million and uses driven by changes in working capital of approximately $1.4&#160;million. Such uses were partially offset by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charges of $53.4&#160;million. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charges primarily consisted of equity-based compensation expense of $52.7&#160;million and depreciation and amortization expense of $0.7&#160;million. The changes in working capital primarily relate to the timing of payments made to our vendors for services performed. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Net cash used in operating activities was approximately $7.3&#160;million for the three months ended March&#160;31, 2021, reflecting a net loss of $11.6&#160;million, partially offset by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charges of $0.5&#160;million and a net change of $3.8&#160;million in our net working capital. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charges primarily consisted of depreciation and amortization of $0.4&#160;million and equity-based compensation expense of $0.2&#160;million. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The approximately $8.2&#160;million increase in cash used in operating activities for the three months ended March&#160;31, 2022 compared to the three months ended March&#160;31, 2021 was primarily driven by the increased use of cash related to the timing of payments to our vendors and the net loss incurred during the period, after adjusting for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charges. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Net cash used in operating activities was approximately $50.3&#160;million for the year ended December&#160;31, 2021, reflecting a net loss of approximately $55.1&#160;million, partially offset by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charges of $2.7&#160;million, and changes in working capital of $2.2&#160;million. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charges primarily consisted of depreciation and amortization expense of $2.0&#160;million and equity-based compensation expense of $0.7&#160;million. The changes in working capital primarily relate to the timing of payments made to our vendors for services performed. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">149 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net cash used in operating activities was approximately $25.2&#160;million for the year ended December&#160;31, 2020, reflecting a net loss of $26.7&#160;million, partially offset by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charges of $1.7&#160;million and a net change of $0.1&#160;million in our net operating assets. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charges primarily consisted of depreciation and amortization of $1.0&#160;million and equity-based compensation expense of $0.7&#160;million. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The approximately $25.1&#160;million increase in cash used in operating activities for the year ended December&#160;31, 2021 compared to the year ended December&#160;31, 2020 was primarily due to a $28.4&#160;million increase in our net loss which was driven by increased spending related to the planned launch of our Phase 3 clinical study, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">REGEN-006.</div> The impact of the increased net loss was offset by higher <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> charges for depreciation, amortization and equity compensation as well as changes in net working capital. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investing Activities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities were approximately $0.8&#160;million and $1.4&#160;million for the three months ended March&#160;31, 2022 and 2021, respectively, which was due to purchases of equipment and facility expansion. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities were approximately $5.2&#160;million and $5.5&#160;million for the years ended December&#160;31, 2021 and 2020, respectively, which was due to purchases of equipment and facility expansion. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; margin-left: 4%;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Financing Activities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Net cash provided by financing activities was $25.5&#160;million and $20.0&#160;million for the three months ended March&#160;31, 2022 and 2021, respectively, which was due to the borrowing of funds under the ProKidney Promissory Notes and sales of our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B-1</div> Units in the 2022 period and due to proceeds received from the issuance of our Class&#160;A Units in the 2021 period. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities was $71.5&#160;million and $20.0&#160;million for the years ended December&#160;31, 2021 and 2020, respectively, which was due to proceeds received from the issuance of our Class&#160;A Units. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Critical Accounting Policies and Significant Judgments and Estimates </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements. Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our significant accounting policies are described in Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this prospectus. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recent Accounting Pronouncements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our audited consolidated financial statements included in this prospectus. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">150 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Off-Balance</div> Sheet Arrangements </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">We did not have during the periods presented, and we do not currently have, any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">off-balance</div> sheet arrangements, as defined in the rules and regulations of the SEC. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">JOBS Act Accounting Election </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are an emerging growth company, as defined in the JOBS Act. The JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards applicable to public companies, allowing them to delay the adoption of those standards until those standards would otherwise apply to private companies. We have elected to use this extended transition period under the JOBS Act. As a result, our consolidated financial statements may not be comparable to the financial statements of companies that are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make our ordinary shares less attractive to investors. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">151 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom373959_12" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DESCRIPTION OF PROKIDNEY SECURITIES </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The following summary of the material terms of our securities is not intended to be a complete summary of the rights and preferences of such securities and is qualified by reference to our Charter, which is incorporated by reference as an exhibit to the registration statement of which this prospectus is a part. We urge you to read our Charter described herein in its entirety for a complete description of the rights and preferences of our securities. Unless the context requires otherwise, all references to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; the &#8220;Company&#8221; and &#8220;ProKidney&#8221; in this section refer solely to ProKidney Corp. and not to our subsidiaries. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Authorized and Outstanding Shares </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are authorized to issue 1,005,000,000 shares, consisting of (x) 500,000,000 Class&#160;A ordinary shares, par value $0.0001 per share, (y) 500,000,000 Class&#160;B ordinary shares, par value $0.0001 per share and (z) 5,000,000 preference shares, par value $0.0001 per share. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A Ordinary Shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Voting Rights </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each holder of Class&#160;A ordinary shares is entitled to one vote for each Class&#160;A ordinary shares held of record by such holder on all matters on which shareholders generally are entitled to vote. The holders of the Class&#160;A ordinary shares do not have cumulative voting rights in the appointment of directors. Generally, all matters to be voted on by shareholders must be approved by a resolution passed by the holders of not less than a simple majority of ordinary shares entitled to vote in person or represented by proxy, with Class&#160;A shareholders and Class&#160;B shareholders voting together as a single class. Notwithstanding the foregoing, the holders of the outstanding Class&#160;A ordinary shares are entitled to vote separately upon any amendment to the Charter (including by merger, consolidation, reorganization or similar event) that would alter or change the powers, preferences or special rights of such Class&#160;A ordinary shares in a manner that has an adverse effect upon such rights. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dividend Rights </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subject to preferences that may be applicable to any outstanding preference shares, the holders of Class&#160;A ordinary shares are entitled to receive ratably such dividends, if any, as may be declared from time to time by the Board out of funds legally available therefor. All dividends are subject to certain restrictions under Cayman Islands law, namely that we may only pay dividends out of profits or share premium account, and provided always that, in no circumstances may a dividend be paid if this would result in us being unable to pay our debts as they fall due in the ordinary course of business. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rights upon Liquidation, Dissolution and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Winding-Up</div> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the event of any voluntary or involuntary liquidation, dissolution or winding up of our affairs, the holders of our Class&#160;A ordinary shares are entitled to share ratably in all assets remaining after payment of our debts and other liabilities, subject to prior distribution rights of preference shares or any class or series of shares having a preference over our Class&#160;A ordinary shares, then outstanding, if any. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preemptive or Other Rights </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The holders of our Class&#160;A ordinary shares have no preemptive or conversion rights or other subscription rights (other than in connection with certain issuances of common units under the Second Amended and Restated ProKidney Limited Partnership Agreement). There are no redemption or sinking fund provisions applicable to our Class&#160;A ordinary shares. The rights, preferences and privileges of holders of our Class&#160;A ordinary shares will be subject to those of the holders of any preference shares we may issue in the future. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">152 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B Ordinary Shares </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Voting Rights </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each holder of our Class&#160;B ordinary shares is entitled to one vote for each Class&#160;B ordinary share held of record by such holder on all matters on which shareholders generally are entitled to vote. The holders of our Class&#160;B ordinary shares do not have cumulative voting rights in the election of directors. Generally, all matters to be voted on by shareholders must be approved by a majority of the votes entitled to be cast by all shareholders present in person or represented by proxy, with Class&#160;A shareholders and Class&#160;B shareholders voting together as a single class. Notwithstanding the foregoing, the holders of our outstanding Class&#160;B ordinary shares are entitled to vote separately upon any amendment to the Charter (including by merger, consolidation, reorganization or similar event) that would alter or change the powers, preferences or special rights of such Class&#160;B ordinary shares in a manner that has an adverse effect upon such rights. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Dividend Rights </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The holders of our Class&#160;B ordinary shares will not participate in any dividends declared by our board of directors. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rights upon Liquidation, Dissolution and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Winding-Up</div> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the event of any voluntary or involuntary liquidation, dissolution or winding up of our affairs, the holders of our Class&#160;B ordinary shares are entitled to a ratable amount equal to the capital paid up on such Class&#160;B ordinary shares of all assets remaining after payment of our debts and other liabilities, subject to prior distribution rights of preference shares or any class or series of shares having a preference over our Class&#160;B ordinary shares, then outstanding, if any. Our Class&#160;B ordinary shares shall not carry any other right to participate in our profits or assets. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preemptive or Other Rights </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The holders of our Class&#160;B ordinary shares do not have preemptive, subscription, redemption or conversion rights. There will be no redemption or sinking fund provisions applicable to our Class&#160;B ordinary shares. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Issuance and Forfeiture of Class&#160;B Ordinary Shares </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the event that any of our outstanding Class&#160;B ordinary shares cease to be held directly or indirectly by a holder of an equal amount of Post-Combination ProKidney Common Units, such share will automatically be transferred to us for no consideration and thereupon will be retired. We will not issue additional Class&#160;B ordinary shares other than in connection with the valid issuance or transfer of Post-Combination ProKidney Common Units in accordance with our governing documents. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preference Shares </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Charter provides that the Board has the authority, without further action by the holders of our ordinary shares, to establish one or more series of preference shares where issue of such series of preference shares is considered by the Board not to have an adverse effect upon rights attached to our Class&#160;A ordinary shares and Class&#160;B ordinary shares. Preference shares may be issued from time to time in one or more series of any number of shares, provided that the aggregate number of shares issued shall not exceed the total number of preference shares authorized, and with such powers, including voting powers, if any, and the designations, preferences and relative, participating, optional or other special rights, if any, and any qualifications, limitations or restrictions thereof, all as shall be stated and expressed in the resolution or resolutions providing for the designation and issue of such preference shares from time to time adopted by the Board pursuant to authority so to do which is </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">153 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expressly vested in the Board. The powers, including voting powers, if any, preferences and relative, participating, optional and other special rights of each series of preference shares, and the qualifications, limitations or restrictions thereof, if any, may differ from those of any and all other series at any time outstanding. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The issuance of preference shares may have the effect of delaying, deferring or preventing a change in control of ProKidney without further action by the shareholders. Additionally, the issuance of preference shares may adversely affect the holders of our ordinary shares by restricting dividends on our Class&#160;A ordinary shares, diluting the voting power of our Class&#160;A ordinary shares and Class&#160;B ordinary shares or subordinating the liquidation rights of our Class&#160;A ordinary shares and Class&#160;B ordinary shares. As a result of these or other factors, the issuance of preference shares could have an adverse impact on the market price of our Class&#160;A ordinary shares. At present, we have no plans to issue any preference shares. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Register of Members </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under Cayman Islands law, the Company must keep a register of members and there will be entered therein: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the names and addresses of the members, a statement of the shares held by each member, and of the amount paid or agreed to be considered as paid, on the shares of each member and the voting rights of shares; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the date on which the name of any person was entered on the register as a member; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the date on which any person ceased to be a member. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under Cayman Islands law, the register of members of our company is prima facie evidence of the matters set out therein (i.e., the register of members will raise a presumption of fact on the matters referred to above unless rebutted) and a member registered in the register of members will be deemed as a matter of Cayman Islands law to have legal title to the shares as set against its name in the register of members. Upon the closing of this offering, the register of members will be immediately updated to reflect the issue of shares by us. Once our register of members has been updated, the shareholders recorded in the register of members will be deemed to have legal title to the shares set against their name. However, there are certain limited circumstances where an application may be made to a Cayman Islands court for a determination on whether the register of members reflects the correct legal position. Further, the Cayman Islands court has the power to order that the register of members maintained by a company should be rectified where it considers that the register of members does not reflect the correct legal position. If an application for an order for rectification of the register of members were made in respect of our ordinary shares, then the validity of such shares may be subject to re-examination by a Cayman Islands court. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Earnout Rights </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Earnout Participants received an additional aggregate amount of 17,500,000 Earnout RCUs and 17,500,000 Earnout RSRs which will convert, in the case of Earnout RCUs, into Post-Combination ProKidney Common Units and, in the case of Earnout RSRs, into our Class&#160;B ordinary shares to vest in three equal tranches upon our ordinary shares satisfying certain VWAP thresholds of $15.00, $20.00, $25.00, respectively, for any 20 trading days within any 30 consecutive trading day period commencing on or after the Closing and ending on or prior to the fifth anniversary of the Closing;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;provided</div></div>&#160;that (i)&#160;if one or all of the VWAP thresholds has not been achieved prior to the end of the five-year period following the Closing and (ii)&#160;we consummate a transaction that results in a change of control with a per share price exceeding the VWAP thresholds, then the applicable share price trigger that has not been satisfied will be deemed to have been satisfied, and, at the closing of such transaction, we shall issue the applicable portion of the Class&#160;B ordinary shares issuable upon the vesting of the Earnout Rights as if such share price trigger has been achieved. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">154 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Earnout RCUs </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We issued to the Earnout Participants the Earnout RCUs, denoted as Series 1 RCUs, Series 2 RCUs and Series 3 RCUs, in each case, equal to the earnout series amount for such Earnout Participant. Upon the achievement of certain of our share price milestones, the Earnout RCUs held by such participant will be converted into Post-Combination ProKidney Common Units. Any Earnout RCUs that have not vested by the fifth anniversary of the Closing will be forfeited and cancelled for no consideration. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Earnout RSRs </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We issued to Earnout Participants the Earnout RSRs, denoted as Class&#160;B Series 1 RSRs, Class&#160;B Series 2 RSRs and Class&#160;B Series 3 RSRs, in each case, equal to the earnout series amount for such Earnout Participant. Upon the achievement of certain of our share price milestones, such Earnout RSRs held by such Earnout Participant will be converted into our Class&#160;B ordinary shares. Any such Earnout RSRs that have not vested by the fifth anniversary of the Closing will be forfeited and cancelled for no consideration. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PMEL Post-Combination Issuance </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the Business Combination, PMEL Post-Combination Unitholders received an additional aggregate amount of each of PMEL RCUs and PMEL RSRs equal to the amount of such unitholder&#8217;s pro rata interest in the unvested Legacy ProKidney Class&#160;B Units held by PMEL prior to the Closing, which will convert, in the case of PMEL RCUs, into Post-Combination ProKidney Common Units and, in the case of PMEL RSRs, into our Class&#160;B ordinary shares when vested in accordance with the terms of the applicable award agreement. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">PMEL RCUs </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the Closing, we issued to PMEL Post-Combination Unitholders a number of PMEL RCUs equal to the amount of such unitholder&#8217;s pro rata interest in the unvested Legacy ProKidney Class&#160;B Units held by PMEL prior to the Closing. Upon the vesting of a PMEL RCU in accordance with the terms of the applicable award agreement, if any, such RCUs held by such PMEL Post-Combination Unitholder will be converted into Post-Combination ProKidney Common Units. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">PMEL RSRs </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the Closing, we issued to PMEL Post-Combination Unitholders a number of PMEL RSRs equal to the amount of such unitholder&#8217;s pro rata interest in the unvested Legacy Class&#160;B Units held by PMEL prior to the Closing. Upon the vesting of a PMEL RCU in accordance with the terms of the applicable award agreement, if any, such PMEL RSRs held by such PMEL Post-Combination Unitholder will be converted into our Class&#160;B ordinary shares. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividends </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The payment of any cash dividends is within the discretion of the Board. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Second Amended and Restated ProKidney Limited Partnership Agreement provides that pro rata cash distributions be made to holders of Post-Combination ProKidney Common Units at certain assumed tax rates, which we refer to as &#8220;tax distributions.&#8221; </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any financing arrangements that we enter into in the future may include restrictive covenants that limit our ability to pay dividends. All dividends are subject to certain restrictions under Cayman Islands law, namely that we may only pay dividends out of profits or share premium account, and provided always that, in no circumstances may a dividend be paid if this would result in the Company being unable to pay its debts as they fall due in the ordinary course of business. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">155 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our subsidiaries are generally subject to similar legal limitations on their ability to make distributions to ProKidney. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Registration Rights </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the Closing, we entered into the Amended and Restated Registration Rights Agreement with the Sponsor and certain Holders. Under the Amended and Restated Registration Rights Agreement, Class&#160;A ordinary shares held by the Holders party thereto (as well as their permitted transferees) and by parties to the Exchange Agreement are entitled to registration rights. The Amended and Restated Registration Rights Agreement provides for us to, within 30 days after the Closing Date, submit or file with the SEC a shelf registration statement registering the resale of our ordinary shares held by the Holders and use our commercially reasonable efforts to have such registration statement declared effective as soon as practicable after the submission or filing thereof, but in no event later than (a)&#160;90 days following the submission or filing deadline, if the SEC notifies us that it will &#8220;review&#8221; the Registration Statement and (b)&#160;the 10th business day after the date we are notified (orally or in writing, whichever is earlier) by the SEC that the registration statement will not be &#8220;reviewed&#8221; or will not be subject to further review. In addition, the Holders have certain &#8220;piggy-back&#8221; registration rights. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Lock-Up&#160;Restrictions</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">At the closing of the Business Combination, we, the Sponsor and certain Closing ProKidney Unitholders entered into the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Lock-Up&#160;Agreement.</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">The&#160;Lock-Up&#160;Agreement</div> contains certain restrictions on transfer with respect to the Sponsor and the ProKidney Unitholders party thereto. Such restrictions begin at the Closing and end on the earlier of (i)&#160;the date that is 180 days after the Closing and (ii)(a) for 33% of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;Lock-Up&#160;Shares</div> (other than the Earnout Shares and the Private Placement Shares)(as each such term is defined in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Lock-Up</div> Agreement), the date on which the last reported sale price of our Class&#160;A ordinary share equals or exceeds $12.50 per share for any 20 trading days within <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">any&#160;30-trading&#160;day</div> period commencing at least 30 days after the Closing and (b)&#160;for an additional 50% of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;Lock-Up&#160;Shares</div> (other than the Earnout Shares and the Private Placement Shares), the date on which the last reported sale price of our Class&#160;A ordinary share equals or exceeds $15.00 per share for any 20 trading days within <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">any&#160;30-trading&#160;day</div> period commencing at least 30 days after the Closing. Notwithstanding the above, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(i)&#160;the&#160;lock-up&#160;period</div> for any Earnout Shares will expire not earlier than 180 days after such Earnout Shares are issued; (ii) 50% of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;Lock-Up&#160;Shares</div> held by certain Closing ProKidney Unitholders and their affiliates will remain locked up until the earlier of four years following the Closing and the date that we receive notice of any regulatory market authorization, including full or conditional authorization, to market REACT (but, in any event, not earlier than 180 days following the Closing or (in the case of Earnout Shares) the date of issuance); and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(iii)&#160;the&#160;lock-up&#160;period</div> for the Private Placement Shares will expire 30 days after the Closing. The restrictions on transfer set forth in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Lock-Up</div> Agreement are subject to customary exceptions. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transfer Agent </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The transfer agent for our ordinary shares is Continental Stock Transfer&#160;&amp; Trust Company. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock Exchange Listing </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Class&#160;A ordinary shares is listed for traing on Nasdaq under the symbol &#8220;PROK.&#8221; </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain Anti-Takeover Provisions of the Charter </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Charter contains provisions that could have the effect of rendering more difficult, delaying, or preventing an acquisition deemed undesirable by the Board. These provisions could also make it difficult for shareholders to take certain actions, including appointing directors who are not nominated by the members of the Board or taking other corporate actions, including effecting changes in our management. For instance, our </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">156 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Charter does not provide for cumulative voting in the appointment of directors and does provide for a classified board of directors with three-year staggered terms, which could delay the ability of shareholders to change the membership of a majority of the Board. The Board is empowered to appoint a director to fill a vacancy created by the expansion of the Board or the resignation, death, or removal of a director in certain circumstances; and our advance notice provisions in our Charter requires that shareholders must comply with certain procedures in order to nominate candidates to the Board or to propose matters to be acted upon at a shareholders&#8217; meeting. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our authorized but unissued ordinary shares and preference shares are available for future issuances without shareholder approval and could be utilized for a variety of corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved ordinary shares and preference shares could render more difficult or discourage an attempt to obtain control of ProKidney by means of a proxy contest, tender offer, merger or otherwise. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain Differences in Corporate Law </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cayman Islands companies are governed by the Cayman Islands Companies Act. The Cayman Islands Companies Act is modeled on English Law but does not follow recent English Law statutory enactments, and differs from laws applicable to United States corporations and their shareholders. Set forth below is a summary of the material differences between the provisions of the Cayman Islands Companies Act applicable to us and the laws applicable to companies incorporated in the United States and their shareholders. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Mergers and Similar Arrangements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In certain circumstances, the Cayman Islands Companies Act allows for mergers or consolidations between two Cayman Islands companies, or between a Cayman Islands exempted company and a company incorporated in another jurisdiction (<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>&#160;that is facilitated by the laws of that other jurisdiction). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Where the merger or consolidation is between two Cayman Islands companies, the directors of each company must approve a written plan of merger or consolidation containing certain prescribed information. That plan or merger or consolidation must then be authorized by either (a)&#160;a special resolution (usually a majority of 66 2/3% in value of the voting shares voted at a shareholder meeting) of the shareholders of each company; or (b)&#160;such other authorization, if any, as may be specified in such constituent company&#8217;s memorandum and articles of association. No shareholder resolution is required for a merger between a parent company (i.e., a company that owns at least 90% of the issued shares of each class in a subsidiary company) and its subsidiary company. The consent of each holder of a fixed or floating security interest of a constituent company must be obtained, unless the court waives such requirement. If the Cayman Islands Registrar of Companies is satisfied that the requirements of the Cayman Islands Companies Act (which includes certain other formalities) have been complied with, the Registrar of Companies will register the plan of merger or consolidation. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Where the merger or consolidation involves a foreign company, the procedure is similar, save that with respect to the foreign company, the directors of the Cayman Islands exempted company are required to make a declaration to the effect that, having made due enquiry, they are of the opinion that the requirements set out below have been met: (i)&#160;that the merger or consolidation is permitted or not prohibited by the constitutional documents of the foreign company and by the laws of the jurisdiction in which the foreign company is incorporated, and that those laws and any requirements of those constitutional documents have been or will be complied with; (ii)&#160;that no petition or other similar proceeding has been filed and remains outstanding or order made or resolution adopted to wind up or liquidate the foreign company in any jurisdictions; (iii)&#160;that no receiver, trustee, administrator or other similar person has been appointed in any jurisdiction and is acting in respect of the foreign company, its affairs or its property or any part thereof; and (iv)&#160;that no scheme, order, compromise or other similar arrangement has been entered into or made in any jurisdiction whereby the rights of creditors of the foreign company are and continue to be suspended or restricted. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">157 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Where the surviving company is the Cayman Islands exempted company, the directors of the Cayman Islands exempted company are further required to make a declaration to the effect that, having made due enquiry, they are of the opinion that the requirements set out below have been met: (i)&#160;that the foreign company is able to pay its debts as they fall due and that the merger or consolidation is bona fide and not intended to defraud unsecured creditors of the foreign company; (ii)&#160;that in respect of the transfer of any security interest granted by the foreign company to the surviving or consolidated company (a)&#160;consent or approval to the transfer has been obtained, released or waived; (b)&#160;the transfer is permitted by and has been approved in accordance with the constitutional documents of the foreign company; and (c)&#160;the laws of the jurisdiction of the foreign company with respect to the transfer have been or will be complied with; (iii)&#160;that the foreign company will, upon the merger or consolidation becoming effective, cease to be incorporated, registered or exist under the laws of the relevant foreign jurisdiction; and (iv)&#160;that there is no other reason why it would be against the public interest to permit the merger or consolidation. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Where the above procedures are adopted, the Cayman Islands Companies Act provides for a right of dissenting shareholders to be paid a payment of the fair value of their shares upon their dissenting to the merger or consolidation if they follow a prescribed procedure. In essence, that procedure is as follows: (a)&#160;the shareholder must give their written objection to the merger or consolidation to the constituent company before the vote on the merger or consolidation, including a statement that the shareholder proposes to demand payment for their shares if the merger or consolidation is authorized by the vote; (b)&#160;within 20 days following the date on which the merger or consolidation is approved by the shareholders, the constituent company must give written notice to each shareholder who made a written objection; (c)&#160;a shareholder must within 20 days following receipt of such notice from the constituent company, give the constituent company a written notice of their intention to dissent including, among other details, a demand for payment of the fair value of their shares; (d)&#160;within seven days following the date of the expiration of the period set out in paragraph (b)&#160;above or seven days following the date on which the plan of merger or consolidation is filed, whichever is later, the constituent company, the surviving company or the consolidated company must make a written offer to each dissenting shareholder to purchase their shares at a price that the company determines is the fair value and if the company and the shareholder agree the price within 30 days following the date on which the offer was made, the company must pay the shareholder such amount; and (e)&#160;if the company and the shareholder fail to agree a price within such 30 day period, within 20 days following the date on which such 30 day period expires, the company (and any dissenting shareholder) must file a petition with the Cayman Islands Grand Court to determine the fair value and such petition must be accompanied by a list of the names and addresses of the dissenting shareholders with whom agreements as to the fair value of their shares have not been reached by the company. At the hearing of that petition, the court has the power to determine the fair value of the shares together with a fair rate of interest, if any, to be paid by the company upon the amount determined to be the fair value. Any dissenting shareholder whose name appears on the list filed by the company may participate fully in all proceedings until the determination of fair value is reached. These rights of a dissenting shareholder are not available in certain circumstances, for example, to dissenters holding shares of any class in respect of which an open market exists on a recognized stock exchange or recognized interdealer quotation system at the relevant date and the consideration paid for such shares meets certain requirements under the Cayman Islands Companies Act or where the consideration for such shares to be contributed are shares of any company listed on a national securities exchange or shares of the surviving or consolidated company. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Moreover, Cayman Islands law has separate statutory provisions that facilitate the reconstruction or amalgamation of companies in certain circumstances, schemes of arrangement will generally be more suited for complex mergers or other transactions involving widely held companies, commonly referred to in the Cayman Islands as a &#8220;scheme of arrangement&#8221; which may be tantamount to a merger. In the event that a merger was sought pursuant to a scheme of arrangement (the procedures for which are more rigorous and take longer to complete than the procedures typically required to consummate a merger in the United States), the arrangement in question must be approved by a majority in number of each class of shareholders and creditors with whom the arrangement is to be made and who must in addition represent three-fourths in value of each such class of shareholders or creditors, as the case may be, that are present and voting either in person or by proxy at a </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">158 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">meeting, or meeting summoned for that purpose. The convening of the meetings and subsequently the terms of the arrangement must be sanctioned by the Grand Court of the Cayman Islands. While a dissenting shareholder would have the right to express to the court the view that the transaction should not be approved, the court can be expected to approve the arrangement if it satisfies itself that: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">we are not proposing to act illegally or beyond the scope of our corporate authority and the statutory provisions as to majority vote have been complied with; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the shareholders have been fairly represented at the meeting in question; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the arrangement is such as a businessman would reasonably approve; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the arrangement is not one that would more properly be sanctioned under some other provision of the Cayman Islands Companies Act or that would amount to a &#8220;fraud on the minority.&#8221; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If a scheme of arrangement or takeover offer (as described below) is approved, any dissenting shareholder would have no rights comparable to appraisal rights (providing rights to receive payment in cash for the judicially determined value of the shares), which would otherwise ordinarily be available to dissenting shareholders of United States corporations. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Squeeze-out&#160;Provisions </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">When a takeover offer is made and accepted by holders of 90% of the shares to whom the offer relates within four months, the offeror may, within a&#160;two-month&#160;period, require the holders of the remaining shares to transfer such shares on the terms of the offer. An objection can be made to the Grand Court of the Cayman Islands, but this is unlikely to succeed unless there is evidence of fraud, bad faith, collusion or inequitable treatment of the shareholders. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Further, transactions similar to a merger, reconstruction and/or an amalgamation may in some circumstances be achieved through means other than these statutory provisions, such as a share capital exchange, asset acquisition or control, or through contractual arrangements of an operating business. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Shareholders&#8217; Suits </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our Cayman Islands counsel is not aware of any reported class action having been brought in a Cayman Islands court. Derivative actions have been brought in the Cayman Islands courts, and the Cayman Islands courts have confirmed the availability for such actions. In most cases, we will be the proper plaintiff in any claim based on a breach of duty owed to us, and a claim against (for example) our officers or directors usually may not be brought by a shareholder. However, based both on Cayman Islands authorities and on English authorities, which would in all likelihood be of persuasive authority and be applied by a court in the Cayman Islands, exceptions to the foregoing principle apply in circumstances in which: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a company is acting, or proposing to act, illegally or beyond the scope of its authority; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the act complained of, although not beyond the scope of the authority, could be effected if duly authorized by more than the number of votes which have actually been obtained; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">those who control the company are perpetrating a &#8220;fraud on the minority.&#8221; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A shareholder may have a direct right of action against us where the individual rights of that shareholder have been infringed or are about to be infringed. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Enforcement of Civil Liabilities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Cayman Islands has a different body of corporate and securities laws as compared to the United States and provides less protection to investors. Additionally, Cayman Islands companies may not have standing to sue before the Federal courts of the United States. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">159 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have been advised by our Cayman Islands legal counsel that the courts of the Cayman Islands are unlikely (i)&#160;to recognize or enforce against us judgments of courts of the United States predicated upon the civil liability provisions of the federal securities laws of the United States or any state; and (ii)&#160;in original actions brought in the Cayman Islands, to impose liabilities against us predicated upon the civil liability provisions of the federal securities laws of the United States or any state, so far as the liabilities imposed by those provisions are penal in nature. In those circumstances, although there is no statutory enforcement in the Cayman Islands of judgments obtained in the United States, the courts of the Cayman Islands will recognize and enforce a foreign money judgment of a foreign court of competent jurisdiction without retrial on the merits based on the principle that a judgment of a competent foreign court imposes upon the judgment debtor an obligation to pay the sum for which judgment has been given provided certain conditions are met. For a foreign judgment to be enforced in the Cayman Islands, such judgment must be final and conclusive and for a liquidated sum, and must not be in respect of taxes or a fine or penalty, inconsistent with a Cayman Islands judgment in respect of the same matter, impeachable on the grounds of fraud or obtained in a manner, and or be of a kind the enforcement of which is, contrary to natural justice or the public policy of the Cayman Islands (awards of punitive or multiple damages may well be held to be contrary to public policy). A Cayman Islands court may stay enforcement proceedings if concurrent proceedings are being brought elsewhere. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Special Considerations for Exempted Companies </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are an exempted company with limited liability (meaning our public shareholders have no liability, as members of the company, for liabilities of the company over and above the amount paid for their shares) under the Cayman Islands Companies Act. The Cayman Islands Companies Act distinguishes between ordinary resident companies and exempted companies. Any company that is registered in the Cayman Islands but conducts business mainly outside of the Cayman Islands may apply to be registered as an exempted company. The requirements for an exempted company are essentially the same as for an ordinary company except for the exemptions and privileges listed below: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">annual reporting requirements are minimal and consist mainly of a statement that the company has conducted its operations mainly outside of the Cayman Islands and has complied with the provisions of the Cayman Islands Companies Act; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">an exempted company&#8217;s register of members is not open to inspection; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">an exempted company does not have to hold an annual shareholder meeting; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">an exempted company may issue negotiable or bearer shares or shares with no par value; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">an exempted company may obtain an undertaking against the imposition of any future taxation (such undertakings are usually given for 30 years in the first instance); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">an exempted company may register by way of continuation in another jurisdiction and be deregistered in the Cayman Islands; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">an exempted company may register as a limited duration company; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">an exempted company may register as a segregated portfolio company. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Anti-Money Laundering, Counter-Terrorist Financing, Prevention of Proliferation Financing and Financial Sanctions Compliance &#8211; Cayman Islands </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to comply with legislation or regulations aimed at the prevention of money laundering, terrorist financing, proliferation financing and compliance with financial sanctions, we are required to adopt and maintain certain procedures, and may require purchasers to provide evidence to verify their identity and source of funds. Where permitted, and subject to certain conditions, we may also delegate the maintenance of our anti-money laundering, terrorist financing, prevention of proliferation financing and financial sanctions compliance procedures (including the acquisition of due diligence information) to a suitable person. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">160 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We reserve the right to request such information as is necessary to verify the identity of a purchaser. In some cases the directors may be satisfied that no further information is required since an exemption applies under the Anti-Money Laundering Regulations (as amended) of the Cayman Islands (the &#8220;Regulations&#8221;). Depending on the circumstances of each application, a detailed verification of identity might not be required where: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the purchaser is a relevant financial business required to comply with the Regulations or is a majority-owned subsidiary of such a business; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">b)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">assessed as having a low degree of risk of money laundering and terrorist financing in accordance with the Regulations (each a &#8220;Low Risk Country&#8221;) or is a majority-owned subsidiary of such subscriber; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">c)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the purchaser is a central or local government organization, statutory body or agency of government in the Cayman Islands or a Low Risk Country; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">d)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the purchaser is a company that is listed on a recognized stock exchange and subject to disclosure requirements which impose requirements to ensure adequate transparency of beneficial ownership, or is a majority-owned subsidiary of such a company; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">e)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the purchaser is a pension fund for a professional association, trade union or is acting on behalf of employees of an entity referred to in&#160;sub-paragraphs&#160;(a)&#160;to (d); or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">f)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the application is made through a nominee or the applicant is relying on an introduction from an introducer, which nominee or introducer, as applicable, falls within one of&#160;sub-paragraphs&#160;(a)&#160;to (e). In this situation the company may rely on a written assurance from the nominee or the introducer (as applicable) which confirms (i)&#160;that the requisite identification and verification procedures on the applicant for business and (for introducers only) its beneficial owners have been carried out; (ii)&#160;the nature and intended purpose of the business relationship; (iii)&#160;that the nominee or the introducer has identified the source of funds of the applicant for business; (iv) (for introducers only) that the introducer is supervised or monitored by an overseas regulatory authority and has measures in place to comply with customer due diligence and record keeping requirements; and (v)&#160;that the nominee or introducer shall make available on request and without delay copies of any identification and verification data or information and relevant documents. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the purposes of these exceptions, recognition of a financial institution, regulatory authority or jurisdiction will be determined in accordance with the Regulations by reference to the Equivalent Jurisdiction definition. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the event of delay or failure on the part of the subscriber in producing any information required for verification purposes, we may refuse to accept the application, in which case any funds received will be returned without interest to the account from which they were originally debited. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We also reserve the right to refuse to make any payment to a shareholder if our directors or officers suspect or are advised that the payment to such shareholder might result in a breach of applicable anti-money laundering, counter-terrorist financing, prevention of proliferation financing and financial sanctions or other laws or regulations by any person in any relevant jurisdiction, or if such refusal is considered necessary or appropriate to ensure our compliance with any such laws or regulations in any applicable jurisdiction. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If any person resident in the Cayman Islands knows or suspects, or has reasonable grounds for knowing or suspecting, that another person is engaged in criminal conduct, is involved with terrorism or terrorist property or proliferation financing or is the target of a financial sanction and the information for that knowledge or suspicion came to their attention in the course of business in the regulated sector or other trade, profession, business or employment, the person will be required to report such knowledge or suspicion to (i)&#160;the Financial Reporting Authority of the Cayman Islands, pursuant to the Proceeds of Crime Act (as amended) of the Cayman Islands if the disclosure relates to criminal conduct, money laundering or proliferation financing or is the target of a financial sanction or (ii)&#160;a police officer of the rank of constable or higher, or the Financial Reporting Authority, </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">161 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">pursuant to the Terrorism Act (as amended) of the Cayman Islands, if the disclosure relates to involvement with terrorism or terrorist financing and property. Such a report will not be treated as a breach of confidence or of any restriction upon the disclosure of information imposed by any enactment or otherwise. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Data Protection &#8211; Cayman Islands </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have certain duties under the Data Protection Act (as amended) of the Cayman Islands (the &#8220;DPA&#8221;) based on internationally accepted principles of data privacy. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Privacy Notice </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Introduction </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This privacy notice puts our shareholders on notice that through your investment in the Company you will provide us with certain personal information which constitutes personal data within the meaning of the DPA (&#8220;personal data&#8221;). In the following discussion, the &#8220;company&#8221; refers to us and our affiliates and/or delegates, except where the context requires otherwise. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Investor Data </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We will collect, use, disclose, retain and secure personal data to the extent reasonably required only and within the parameters that could be reasonably expected during the normal course of business. We will only process, disclose, transfer or retain personal data to the extent legitimately required to conduct our activities of on an ongoing basis or to comply with legal and regulatory obligations to which we are subject. We will only transfer personal data in accordance with the requirements of the DPA, and will apply appropriate technical and organizational information security measures designed to protect against unauthorized or unlawful processing of the personal data and against the accidental loss, destruction or damage to the personal data. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In our use of this personal data, we will be characterized as a &#8220;data controller&#8221; for the purposes of the DPA, while our affiliates and service providers who may receive this personal data from us in the conduct of our activities may either act as our &#8220;data processors&#8221; for the purposes of the DPA or may process personal information for their own lawful purposes in connection with services provided to us. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We may also obtain personal data from other public sources. Personal data includes, without limitation, the following information relating to a shareholder and/or any individuals connected with a shareholder as an investor: name, residential address, email address, contact details, corporate contact information, signature, nationality, place of birth, date of birth, tax identification, credit history, correspondence records, passport number, bank account details, source of funds details and details relating to the shareholder&#8217;s investment activity. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Who this Affects </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If you are a natural person, this will affect you directly. If you are a corporate investor (including, for these purposes, legal arrangements such as trusts or exempted limited partnerships) that provides us with personal data on individuals connected to you for any reason in relation your investment in the company, this will be relevant for those individuals and you should transmit the content of this Privacy Notice to such individuals or otherwise advise them of its content. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">How the Company May Use a Shareholder&#8217;s Personal Data </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The company, as the data controller, may collect, store and use personal data for lawful purposes, including, in particular: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">where this is necessary for the performance of our rights and obligations under any purchase agreements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">162 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">where this is necessary for compliance with a legal and regulatory obligation to which we are subject (such as compliance with anti-money laundering, counter-terrorist financing, prevention of proliferation financing, financial sanctions and FATCA/CRS requirements); and/or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">where this is necessary for the purposes of our legitimate interests and such interests are not overridden by your interests, fundamental rights or freedoms. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Should we wish to use personal data for other specific purposes (including, if applicable, any purpose that requires your consent), we will contact you. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Why We May Transfer Your Personal Data </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In certain circumstances we may be legally obliged to share personal data and other information with respect to your shareholding with the relevant regulatory authorities such as the Cayman Islands Monetary Authority or the Tax Information Authority. They, in turn, may exchange this information with foreign authorities, including tax authorities. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We anticipates disclosing personal data to persons who provide services to us and their respective affiliates (which may include certain entities located outside the United States, the Cayman Islands or the European Economic Area), who will process your personal data on our behalf. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Data Protection Measures We Take </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any transfer of personal data by us or our duly authorized affiliates and/or delegates outside of the Cayman Islands shall be in accordance with the requirements of the DPA. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We and our duly authorized affiliates and/or delegates shall apply appropriate technical and organizational information security measures designed to protect against unauthorized or unlawful processing of personal data, and against accidental loss or destruction of, or damage to, personal data. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We shall notify you of any personal data breach that is reasonably likely to result in a risk to your interests, fundamental rights or freedoms or those data subjects to whom the relevant personal data relates. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Rights of Individual Data Subjects </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Individual data subjects have certain data protection rights, including the right to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">be informed about the purposes for which your personal data are processed; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">access your personal data; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">stop direct marketing; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">restrict the processing of your personal data; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">have incomplete or inaccurate personal data corrected; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ask us to stop processing your personal data; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">be informed of a personal data breach (unless the breach is unlikely to be prejudicial to you); </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">complain to the Data Protection Ombudsman; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">require us to delete your personal data in some limited circumstances. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">163 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom373959_13" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SECURITIES ACT RESTRICTIONS ON RESALE OF SECURITIES </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rule 144 </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Pursuant to Rule 144 under the Securities Act (&#8220;Rule 144&#8221;), a person who has beneficially owned restricted Class&#160;A ordinary shares of ProKidney for at least six months would be entitled to sell their securities; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided </div></div>that (i)&#160;such person is not deemed to have been one of our affiliates at the time of, or at any time during the three months preceding, a sale and (ii)&#160;we are subject to the Exchange Act periodic reporting requirements for at least three months before the sale and have filed all required reports under Section&#160;13 or 15(d) of the Exchange Act during the 12 months (or such shorter period as we were required to file reports) preceding the sale. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Persons who have beneficially owned restricted ordinary shares for at least six months but who are our affiliates at the time of, or at any time during the three months preceding a sale, would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1% of the total number of ordinary shares then outstanding; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the average weekly reported trading volume of ordinary shares during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Sales by our affiliates under Rule 144 are also limited by manner of sale provisions and notice requirements and by the availability of current public information about us. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restrictions on the Use of Rule 144 by Shell Companies or Former Shell Companies </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Rule 144 is not available for the resale of securities initially issued by shell companies (other than business- combination related shell companies) or issuers that have been at any time previously a shell company. However, Rule 144 also includes an important exception to this prohibition if the following conditions are met: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the issuer of the securities that was formerly a shell company has ceased to be a shell company; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the issuer of the securities is subject to the reporting requirements of Section&#160;13 or 15(d) of the </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exchange Act; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">the issuer of the securities has filed all Exchange Act reports and material required to be filed, as applicable, during the preceding 12 months (or such shorter period that the issuer was required to file such reports and materials) other than Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div> reports; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at least one year has elapsed from the time that the issuer filed current Form 10 type information with the SEC reflecting its status as an entity that is not a shell company. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the Closing, we are no longer a shell company, and so, once the conditions listed above are satisfied, Rule 144 will become available for the resale of the above-noted restricted securities. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">164 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom373959_14" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BENEFICIAL OWNERSHIP OF SECURITIES </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth information known to the Company regarding the beneficial ownership of the Company&#8217;s ordinary shares as of July 31, 2022 by: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each person known to the Company to be the beneficial owner of more than 5% of the outstanding Company ordinary shares; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each of Company&#8217;s executive officers and directors; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">all executive officers and directors of the Company as a group. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable within 60 days. Except as described in the footnotes below and subject to applicable community property laws and similar laws, we believe that each person listed below has sole voting and investment power with respect to such shares. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The beneficial ownership of the Company ordinary shares is based on 61,540,231 Class&#160;A ordinary shares and 170,723,961 Class&#160;B ordinary shares issued and outstanding as of July&#160;31, 2022. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unless otherwise indicated, we believe that all persons named in the table below have sole voting and investment power with respect to all ordinary shares beneficially owned by them. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 73%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name and Address of Beneficial Owner(1)</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A<br/>Ordinary<br/>Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B<br/>Ordinary<br/>Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">% of<br/>Total<br/>Voting<br/>Power</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Directors and Named Executive Officers</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tim Bertram, Ph.D.(2)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,696,468</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pablo Legorreta(3)(11)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">94,677,968</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">William F. Doyle(4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,350,469</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;;text-align:right;"></td>
<td style="vertical-align: bottom; white-space: nowrap;">*&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jennifer Fox</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jos&#233; Ignacio Jim&#233;nez Santos</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Alan M. Lotvin(5)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,350,469</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;;text-align:right;"></td>
<td style="vertical-align: bottom; white-space: nowrap;">*&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">John M. Maraganore, Ph.D.(6)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">450,156</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;;text-align:right;"></td>
<td style="vertical-align: bottom; white-space: nowrap;">*&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Brian J.G. Pereira, M.D(7)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,350,469</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;;text-align:right;"></td>
<td style="vertical-align: bottom; white-space: nowrap;">*&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Uma Sinha, Ph.D.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;;text-align:right;"></td>
<td style="vertical-align: bottom; white-space: nowrap;">*&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deepak Jain, Ph.D.(8)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">937,836</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;;text-align:right;"></td>
<td style="vertical-align: bottom; white-space: nowrap;">*&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Joseph Stavas, M.D., MPH(9)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">735,391</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; font-size: 0px;;text-align:right;"></td>
<td style="vertical-align: bottom; white-space: nowrap;">*&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">All Directors and Executive Officers as a Group (14 persons)</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">103,453,062</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">44.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Greater-than-Five Percent Holders:</div></div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tolerantia, LLC(3)(11)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">94,677,968</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Control Empresarial de Capitales, S.A. de C.V. (formerly Inversora Carso, S.A. de C.V.)(10)(11)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63,118,645</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chamath Palihapitiya(12)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">13,273,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SC PIPE Holdings LLC(12)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Banco Invex, S.A., Instituci&#243;n de Banca M&#250;ltiple, Invex Grupo Financiero, as Trustee of Trust I14165(14)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">IHCI Investments LP(15)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jupiter CAN LP(16)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Morgan Stanley Investment Management Inc.(17)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Averill Master Fund, Ltd.(18)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,140,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indicated beneficial ownership of less than 1%. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">165 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unless otherwise noted, the business address of each of the following entities or individuals is c/o ProKidney Corp., 2000 Frontis Plaza Blvd., Ste 250, Winston-Salem, North Carolina, 27103. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents 2,696,468 Class&#160;B ordinary shares issued as consideration in the Business Combination and does not include 2,248,469 Class&#160;B ordinary shares issuable upon the vesting of PMEL RCUs. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents 94,677,968 Class B ordinary shares held by Tolerantia, LLC (&#8220;Tolerantia&#8221;), a Delaware limited liability company, which is an affiliate controlled and majority-owned by Mr. Pablo Legorreta. Mr. Legorreta controls the voting and disposition of the shares held by Tolerantia. Mr.&#160;Legorreta disclaims beneficial ownership of the shares held by Tolerantia except to the extent of his indirect pecuniary interest therein. The business address of Tolerantia is 110, East 59th Street, Suite 3300, New York, New York, 10022. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents 1,350,469 Class&#160;B ordinary shares issued as consideration in the Business Combination and does not include 163,857 Class&#160;B ordinary shares issuable upon the vesting of PMEL RCUs. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(5)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents 1,350,469 Class&#160;B ordinary shares issued as consideration in the Business Combination and does not include 163,857 Class&#160;B ordinary shares issuable upon the vesting of PMEL RCUs. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(6)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents 450,156 Class&#160;B ordinary shares issued as consideration in the Business Combination and does not include 163,857 Class&#160;B ordinary shares issuable upon the vesting of PMEL RCUs. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(7)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents 1,350,469 Class&#160;B ordinary shares issued as consideration in the Business Combination and does not include 163,857 Class&#160;B ordinary shares issuable upon the vesting of PMEL RCUs. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(8)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents 937,836 Class&#160;B ordinary shares issued as consideration in the Business Combination and does not include 630,103 Class&#160;B ordinary shares issuable upon the vesting of PMEL RCUs. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(9)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents 735,391 Class&#160;B ordinary shares issued as consideration in the Business Combination and does not include 315,650 Class&#160;B ordinary shares issuable upon the vesting of PMEL RCUs. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(10)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information in the table and footnote is based upon information provided to us by the direct shareholder, Control Empresarial de Capitales S.A. de C.V., acting as successor of Inversora Carso S.A. de C.V. by virtue of a merger (&#8220;CEC&#8221;). Represents 63,118,645 Class&#160;B ordinary shares held by CEC. Members of the Slim family, directly or indirectly, own all of the issued and outstanding voting equity securities of CEC. Therefore, the Slim family may be deemed to beneficially own indirectly the Class&#160;B ordinary shares held by CEC. CEC is a sociedad an&#243;nima de capital variable organized under the laws of the United Mexican States (&#8220;Mexico&#8221;). The Slim family has an address of Paseo de las Palmas 736, Colonia Lomas de Chapultepec, 11000 Ciudad de Mexico, Mexico and Control Empresarial has an address of Paseo de las Palmas 781, Piso 3, Colonia Lomas de Chapultepec, Seccion III, Migual Hidalgo, Ciudad de Mexico, Mexico, 11000. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(11)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Voting Agreement provides that from the Closing until the third anniversary of the Closing, CEC shall vote all ordinary shares beneficially held by it in a manner proportionate to the manner in which all other Class&#160;B ordinary shares not held by CEC, including the Class&#160;B ordinary shares beneficially held by Tolerantia, are voted, with respect to the election, appointment, or removal of any director to the Board. As a result, Tolerantia may be deemed to share beneficial ownership of CEC&#8217;s ordinary shares. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(12)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The business address of each of Chamath Palihapitiya and SC PIPE Holdings LLC is c/o SC Master Holdings, LLC 506 Santa Cruz Avenue, Suite 300. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(13)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Consists of 9,500,000 Class&#160;A ordinary shares held of record by SC PIPE Holdings LLC and 3,773,000 Class&#160;A ordinary shares held of record by SC Master Holdings, LLC. Mr.&#160;Palihapitiya may be deemed to beneficially own (within the meaning of Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">13d-3</div> under the Exchange Act) securities held by SC PIPE Holdings LLC and/or SC Master Holdings, LLC by virtue of his control over such entities. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(14)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Consists of 5,000,000 Class&#160;A ordinary shares held of record by Banco Invex, S.A., Instituci&#243;n de Banca M&#250;ltiple, Invex Grupo Financiero, acting solely and exclusively in its capacity as trustee of the trustee of Trust I14165 (the &#8220;Trust&#8221;), whose record holders are the Trust Beneficiaries (as defined below), issued in connection with, and, upon the closing of, the PIPE Placement. Each of (i)&#160;Bertha Paula Michel Gonzalez, (ii)&#160;Maria Magdalena Michel Gonzalez and (iii)&#160;Maximino Jose Michel Gonzalez (collectively, the &#8220;Trust Beneficiaries&#8221;), has voting and dispositive power over, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> of the total number of Class&#160;A ordinary shares held by the Trust. The address of the Trust is Boulevard Manuel Avila Camacho No.&#160;40, Piso 7, Lomas De Chapultepec, Ciudad De M&#233;xico 11000. The address of each of the Trust Beneficiaries is Bosque De Radiatas <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-602,</div> Bosques De Las Lomas, Cuajimalpa 05120, Mexico. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">166 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(15)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 5,000,000 Class&#160;A ordinary shares held of record by IHCI Investments LP issued in connection with, and, upon the closing of, the PIPE Placement. The address of IHCI Investments LP is 1188 Union, Montreal QC H3B 0E5, Canada. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(16)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 5,000,000 Class&#160;A ordinary shares held of record by Jupiter CAN LP issued in connection with, and, upon the closing of, the PIPE Placement. The address of Jupiter CAN LP is 5930 Royal Lane, Suite E, #117, Dallas TX 75230-3896. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(17)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Morgan Stanley Investment Management Inc. is the adviser or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-adviser,</div> as the case may be, of each of (i)&#160;Brighthouse Funds Trust I: Morgan Stanley Discovery Portfolio, holding 497,653 Class&#160;A ordinary shares, (ii)&#160;ERAFP Actions Mid Cap USA I holding 12,443 Class&#160;A ordinary shares, (iii)&#160;Growth Trust holding 245,905 Class&#160;A ordinary shares, (iv)&#160;Inception Trust holding, 166,790 Class&#160;A ordinary shares, (v)&#160;Johnson&#160;&amp; Johnson Pension and Savings Master Trust (JJ9L) holding 15,421 Class&#160;A ordinary shares, (vi)&#160;Johnson&#160;&amp; Johnson Pension and Savings Master Trust (JJ9LDB) holding 136,426 Class&#160;A ordinary shares, (vii)&#160;Kinstead Global Equity Pool holding 16,039 Class&#160;A ordinary shares, (viii)&#160;Lawrencium Atoll Investments Ltd. holding 34,707 Class&#160;A ordinary shares, (ix)&#160;Master Trust for Defined Contribution Plans of American Airlines, Inc. and Affiliates holding 109,253 Class&#160;A ordinary shares, (x)&#160;Morgan Stanley Funds (UK)&#8212;Global Insight Fund holding 7,231 Class&#160;A ordinary shares, (xi)&#160;Morgan Stanley Insight Fund holding 1,421,688 Class&#160;A ordinary shares, (xii)&#160;Morgan Stanley Institutional Fund Trust&#8212;Discovery Portfolio holding 800,384 Class&#160;A ordinary shares, (xiii)&#160;Morgan Stanley Institutional Fund, Inc.&#8212;Inception Portfolio holding 332,167 Class&#160;A ordinary shares, (xiv)&#160;Morgan Stanley Institutional Fund, Inc.&#8212;Counterpoint Global Portfolio holding 3,802 Class&#160;A ordinary shares, (xv)&#160;Morgan Stanley Institutional Fund, Inc.&#8212;Global Endurance Portfolio holding 19,748 Class&#160;A ordinary shares, (xvi)&#160;Morgan Stanley Institutional Fund, Inc.&#8212;Global Insight Portfolio holding 67,622 Class&#160;A ordinary shares, (xvii)&#160;Morgan Stanley Institutional Fund, Inc.&#8212;Growth Portfolio holding 3,865,953 Class&#160;A ordinary shares, (xviii)&#160;Morgan Stanley Investment Funds&#8212;Counterpoint Global Fund holding 1,657 Class&#160;A ordinary shares, (xiv)&#160;Morgan Stanley Investment Funds&#8212;Global Endurance Fund holding 34,186 Class&#160;A ordinary shares, (xx)&#160;Morgan Stanley Investment Funds&#8212;Global Insight Fund holding 293,852 Class&#160;A ordinary shares, (xxi)&#160;Morgan Stanley Investment Funds&#8212;US Growth Fund holding 1,549,102 Class&#160;A ordinary shares, (xxii)&#160;Morgan Stanley Investment Funds&#8212;US Insight Fund holding 46,844 Class&#160;A ordinary shares, (xxiii)&#160;Morgan Stanley Variable Insurance Fund, Inc.&#8212;Discovery Portfolio holding 79,084 Class&#160;A ordinary shares, (xxiv)&#160;Morgan Stanley Variable Insurance Fund, Inc.&#8212;Growth Portfolio holding 242,043 Class&#160;A ordinary shares (collectively, the &#8220;MS Accounts&#8221;) and holds voting and dispositive power with respect to shares of record held by each of the MS Accounts. Each of the MS accounts received their respective Class&#160;A ordinary shares in connection with the issuance of, and, upon the closing of, the PIPE Placement. The address of Morgan Stanley Investment Management Inc., acting as adviser or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-adviser,</div> as the case may be, of each of the MS Accounts is 522 Fifth Avenue, New York, NY 10036. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(18)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 3,140,000 Class&#160;A ordinary shares held of record by Averill Master Fund, Ltd. issued in connection with, and, upon the closing of, the PIPE Placement. The address of Averill Master Fund, Ltd. is 540 Madison Avenue, 7th Floor, New York, NY 10022. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">167 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom373959_15" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SELLING SECURITYHOLDERS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This prospectus relates to the possible resale by the Selling Securityholders of up to 232,530,000 Class&#160;A ordinary shares. The Selling Securityholders may from time to time offer and sell any or all of the Class&#160;A ordinary shares set forth below pursuant to this prospectus and any accompanying prospectus supplement. When we refer to the &#8220;Selling Securityholders&#8221; in this prospectus, we mean the persons listed in the table below, and the pledgees, donees, transferees, assignees, successors, designees and others who later come to hold any of the Selling Securityholders&#8217; interest in the Class&#160;A ordinary shares other than through a public sale. We cannot advise you as to whether the Selling Securityholders will in fact sell any or all of such Class&#160;A ordinary shares. In addition, the Selling Securityholders may sell, transfer or otherwise dispose of, at any time and from time to time, Class&#160;A ordinary shares in transactions exempt from the registration requirements of the Securities Act after the date of this prospectus. For purposes of this table, we have assumed that the Selling Securityholders will have sold all of the securities covered by this prospectus upon the completion of the offering. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table is prepared based on information provided to us by the Selling Securityholders. It sets forth the name and address of the Selling Securityholders, the aggregate number of Class&#160;A ordinary shares and Class B ordinary shares or restricted stock rights underlying Class B ordinary shares (issuable upon the vesting of the restricted stock rights), which Class B ordinary shares are exchangeable, pursuant to the Exchange Agreement, to for Class&#160;A ordinary Shares that the Selling Securityholders may offer pursuant to this prospectus, and the beneficial ownership of the Selling Securityholders both before and after the offering. We have based the percentage ownership prior to this offering on a total of 232,314,192 shares outstanding, which includes 61,540,231 Class&#160;A ordinary shares and 170,723,961 Class&#160;B ordinary shares outstanding, in each case as of July&#160;31, 2022. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have determined beneficial ownership in accordance with the rules of the SEC and the information is not necessarily indicative of beneficial ownership for any other purpose. Unless otherwise indicated below, to our knowledge, the persons and entities named in the tables have sole voting and sole investment power with respect to all securities that they beneficially own, subject to community property laws where applicable. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Selling Securityholder information for each additional Selling Securityholder, if any, will be set forth by prospectus supplement to the extent required prior to the time of any offer or sale of such Selling Securityholder&#8217;s shares pursuant to this prospectus. Any prospectus supplement may add, update, substitute, or change the information contained in this prospectus, including the identity of each Selling Securityholder and the number of shares registered on its behalf. A Selling Securityholder may sell or otherwise transfer all, some or none of such shares in this offering. See &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Plan of Distribution</div></div>.&#8221; </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 51%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name of Selling Securityholder</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Class&#160;A<br/>Ordinary<br/>Shares</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Class&#160;B<br/>Ordinary<br/>Shares (or<br/>Securities<br/>Convertible<br/>into&#160;Class&#160;B<br/>Ordinary<br/>Shares)</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Percentage<br/>Voting<br/>Power</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Number&#160;of<br/>Ordinary<br/>Shares<br/>Offered</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Number&#160;of&#160;Ordinary<br/>Shares&#160;Beneficially<br/>Owned&#160;After&#160;the<br/>Offered&#160;Shares&#160;are<br/>Sold</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Percentage<br/>Voting<br/>Power</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Anna-Maria and Stephen Kellen Foundation, Inc.(1)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Averill Master Fund, Ltd.(2)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,140,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,140,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Banco Invex, S.A., Instituci&#243;n de Banca M&#250;ltiple, Invex Grupo Financiero, as Trustee of Trust I14165(3)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Brighthouse Funds Trust I: Morgan Stanley Discover y Portfolio(4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">497,653</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">497,653</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Brown University(5)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Carlos X. Del Rio(6)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">27,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Control Empresarial de Capitales, S.A. de C.V. (formerly Inversora Carso, S.A. de C.V.)(7)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">63,118,645</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">27.2</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">%&#160;</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">63,118,645</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">168 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 49%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name of Selling Securityholder</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Class&#160;A<br/>Ordinary<br/>Shares</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Class&#160;B<br/>Ordinary<br/>Shares (or<br/>Securities<br/>Convertible<br/>into&#160;Class&#160;B<br/>Ordinary<br/>Shares)</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Percentage<br/>Voting<br/>Power</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Number&#160;of<br/>Ordinary<br/>Shares<br/>Offered</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Number&#160;of&#160;Ordinary<br/>Shares&#160;Beneficially<br/>Owned&#160;After&#160;the<br/>Offered&#160;Shares&#160;are<br/>Sold</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Percentage<br/>Voting<br/>Power</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">CP WY REMAINDER INTEREST TRUST U/A/D DATED DECEMBER 22, 2021(8)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">1.3</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">%&#160;</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">David Spiegel(9)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Denise and Michael Kellen Foundation, Inc.(10)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">DJG Associated, LLC(11)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">600,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">600,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Donald P. Spencer and Vickie Riccardo JTWROS(12)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">ERAFP Actions Mid Cap USA I(4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,443</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,443</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Fourteen Plus Twelve Partners, LLC(13)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">George W. Siguler Family Trust (14)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">125,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">125,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Growth Trust(4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">245,905</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">245,905</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Hill Family Alternative Investments LLC(15)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Hottinger AG(16)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">IHCI Investments LP(17)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Inception Trust(4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">166,790</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">166,790</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Johnson &amp; Johnson Pension and Savings Master Trust (JJ9L)(4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,421</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,421</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Johnson &amp; Johnson Pension and Savings Master Trust (JJ9LDB)(4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">136,426</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">*</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">136,426</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Juan Maria Pedro David Michel(18)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">800,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">800,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Jupiter CAN(19)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Kinstead Global Equity Pool(4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,039</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">16,039</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">KJB Associated LLC(20)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Lawrencium Atoll Investments Ltd.(4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34,707</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34,707</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Leman Management Nominees Limited(21)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Luis Felipe Mancera de Arrigunaga(22)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Marina Kellen French Foundation(23)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Master Trust for Defined Contribution Plans of American Airlines, Inc. and Affiliates(4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">109,253</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">*</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">109,253</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Max Pierre David Michel(24)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">800,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">800,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">MGG Strategic SICAF SIF, for and on behalf of its compartment, MGG Strategic(25)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">*</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Mikel Andoni Arriola Pe&#241;alosa (26)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Monique Berthe Michele Madeleine David Michel(27)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">800,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">800,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Morgan Stanley Funds (UK)&#8212;Global Insight Fund(4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,231</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,231</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Morgan Stanley Insight Fund(4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,421,688</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,421,688</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Morgan Stanley Institutional Fund Trust&#8212;Discovery Portfolio(4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">800,384</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">*</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">800,384</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Morgan Stanley Institutional Fund, Inc.&#8212;Counterpoint Global Portfolio(4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,802</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">*</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,802</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Morgan Stanley Institutional Fund, Inc.&#8212;Global Endurance Portfolio(4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,748</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">*</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19,748</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Morgan Stanley Institutional Fund, Inc.&#8212;Global Insight Portfolio(4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67,622</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">*</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">67,622</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Morgan Stanley Institutional Fund, Inc.&#8212;Growth Portfolio(4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,865,953</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.7</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,865,953</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Morgan Stanley Institutional Fund, Inc.&#8212;Inception Portfolio(4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">332,167</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">332,167</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Morgan Stanley Investment Funds&#8212;Counterpoint Global Fund(4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,657</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">*</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,657</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Morgan Stanley Investment Funds&#8212;Global Endurance Fund(4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34,186</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">34,186</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Morgan Stanley Investment Funds&#8212;Global Insight Fund(4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">293,852</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">293,852</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Morgan Stanley Investment Funds&#8212;US Growth Fund(4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,549,102</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,549,102</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">169 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 51%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name of Selling Securityholder</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Class&#160;A<br/>Ordinary<br/>Shares</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Class&#160;B<br/>Ordinary<br/>Shares (or<br/>Securities<br/>Convertible<br/>into&#160;Class&#160;B<br/>Ordinary<br/>Shares)</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Percentage<br/>Voting<br/>Power</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Number&#160;of<br/>Ordinary<br/>Shares<br/>Offered</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Number&#160;of&#160;Ordinary<br/>Shares&#160;Beneficially<br/>Owned&#160;After&#160;the<br/>Offered&#160;Shares&#160;are<br/>Sold</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;">Percentage<br/>Voting<br/>Power</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Morgan Stanley Investment Funds&#8212;US Insight Fund(4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46,844</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">46,844</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Morgan Stanley Variable Insurance Fund, Inc.&#8212;Discovery Portfolio(4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">79,084</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">*</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">79,084</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Morgan Stanley Variable Insurance Fund, Inc.&#8212;Growth Portfolio(4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">242,043</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">*</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">242,043</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Nogra Group SICAF-SIF, for and on behalf of its compartment, Nogra Group SICAF&#8212;SIF&#8212;GG Strategic (the Investor)(28)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">*</div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,200,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Pamela Mallon Siguler Family Trust(29)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">125,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">125,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Paul Mower(30)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney Management Equity LLC(31)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,203,387</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5.6</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22,203,387</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">iPrime Participations LLC(32)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">300,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">300,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Regina Mancera Bustamante(33)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">100,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Ricardo Jos&#233; Garza Bustamante(34)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">50,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">SC PIPE Holdings LLC(35)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Stephen M. Kellen 2004 Trust FBO Annabelle Garrett(36)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Stephen M. Kellen 2004 Trust FBO Andrew Gundlach(37)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Stephen M. Kellen 2004 Trust FBO Caroline L. Kellen(38)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Stephen M. Kellen 2004 Trust FBO Christopher N. Kellen(39)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">75,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Sukumar Nagendran(40)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Tensleep Group LLC(41)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Tolerantia, LLC(42)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">94,677,968</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">94,677,968</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">WECMA Family, LLC(43)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Uma Sinha, Ph.D.(44)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">**</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Less than 1%. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 1,000,000 Class&#160;A ordinary shares. The address of Anna-Maria and Stephen Kellen Foundation, Inc. is 1345 Avenue of the Americas, 47th Floor, New York, NY 10105. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 3,140,000 Class&#160;A ordinary shares. The address of Averill Master Fund, Ltd. is 540 Madison Avenue, 7th Floor, New York, NY 10022. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Consists of 5,000,000 Class&#160;A ordinary shares held of record by Banco Invex, S.A., Instituci&#243;n de Banca M&#250;ltiple, Invex Grupo Financiero, acting solely and exclusively in its capacity as trustee of the trustee of Trust I14165 (the &#8220;Trust&#8221;), whose record holders are the Trust Beneficiaries (as defined below). Each of (i)&#160;Bertha Paula Michel Gonzalez, (ii)&#160;Maria Magdalena Michel Gonzalez and (iii)&#160;Maximino Jose Michel Gonzalez (collectively, the &#8220;Trust Beneficiaries&#8221;), has voting and dispositive power over, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-third</div> of the total number of Class&#160;A ordinary shares held by the Trust. The address of the Trust is Boulevard Manuel Avila Camacho No.&#160;40, Piso 7, Lomas De Chapultepec, Ciudad De M&#233;xico 11000. The address of each of the Trust Beneficiaries is Bosque De Radiatas <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-602,</div> Bosques De Las Lomas, Cuajimalpa 05120, Mexico. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Morgan Stanley Investment Management Inc. is the adviser or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-adviser,</div> as the case may be, of each of (i)&#160;Brighthouse Funds Trust I: Morgan Stanley Discovery Portfolio, holding 497,653 Class&#160;A ordinary shares, (ii)&#160;ERAFP Actions Mid Cap USA I holding 12,443 Class&#160;A ordinary shares, (iii)&#160;Growth Trust holding 245,905 Class&#160;A ordinary shares, (iv)&#160;Inception Trust holding, 166,790 Class&#160;A ordinary shares, (v)&#160;Johnson&#160;&amp; Johnson Pension and Savings Master Trust (JJ9L) holding 15,421 Class&#160;A ordinary shares, (vi)&#160;Johnson&#160;&amp; Johnson Pension and Savings Master Trust (JJ9LDB) holding 136,426 Class&#160;A ordinary shares, (vii)&#160;Kinstead Global Equity Pool holding 16,039 Class&#160;A ordinary shares, (viii)&#160;Lawrencium Atoll Investments Ltd. holding 34,707 Class&#160;A ordinary shares, (ix)&#160;Master Trust for Defined Contribution Plans of American Airlines, Inc. and Affiliates holding 109,253 Class&#160;A ordinary shares, (x)&#160;Morgan Stanley Funds (UK)&#8212;Global Insight Fund holding 7,231 Class&#160;A ordinary shares, (xi)&#160;Morgan Stanley Insight Fund holding 1,421,688 Class&#160;A ordinary shares, (xii)&#160;Morgan Stanley Institutional Fund Trust&#8212;Discovery Portfolio holding 800,384 Class&#160;A ordinary shares, (xiii)&#160;Morgan Stanley Institutional Fund, Inc.&#8212;Inception Portfolio holding 332,167 Class&#160;A ordinary shares, (xiv)&#160;Morgan Stanley Institutional Fund, Inc.&#8212;Counterpoint Global Portfolio holding 3,802 Class&#160;A ordinary shares, (xv)&#160;Morgan Stanley Institutional Fund, Inc.&#8212;Global Endurance Portfolio holding 19,748 Class&#160;A ordinary shares, (xvi)&#160;Morgan Stanley Institutional Fund, Inc.&#8212;Global Insight Portfolio holding 67,622 Class&#160;A ordinary shares, (xvii)&#160;Morgan Stanley Institutional Fund, </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">170 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; font-size: 0px;"></td>
<td style="vertical-align: top;;text-align:left;">Inc.&#8212;Growth Portfolio holding 3,865,953 Class&#160;A ordinary shares, (xviii)&#160;Morgan Stanley Investment Funds&#8212;Counterpoint Global Fund holding 1,657 Class&#160;A ordinary shares, (xiv)&#160;Morgan Stanley Investment Funds&#8212;Global Endurance Fund holding 34,186 Class&#160;A ordinary shares, (xx)&#160;Morgan Stanley Investment Funds&#8212;Global Insight Fund holding 293,852 Class&#160;A ordinary shares, (xxi)&#160;Morgan Stanley Investment Funds&#8212;US Growth Fund holding 1,549,102 Class&#160;A ordinary shares, (xxii)&#160;Morgan Stanley Investment Funds&#8212;US Insight Fund holding 46,844 Class&#160;A ordinary shares, (xxiii)&#160;Morgan Stanley Variable Insurance Fund, Inc.&#8212;Discovery Portfolio holding 79,084 Class&#160;A ordinary shares, (xxiv)&#160;Morgan Stanley Variable Insurance Fund, Inc.&#8212;Growth Portfolio holding 242,043 Class&#160;A ordinary shares (collectively, the &#8220;MS Accounts&#8221;) and holds voting and dispositive power with respect to shares of record held by each of the MS Accounts. The address of Morgan Stanley Investment Management Inc., acting as adviser or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-adviser,</div> as the case may be, of each of the MS Accounts is 522 Fifth Avenue, New York, NY 10036. </td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(5)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 1,000,000 Class&#160;A ordinary shares. The address of Brown University is 121 South Main Street, 9th floor, Providence RI, 02903. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(6)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 27,500 Class&#160;A ordinary shares. The address of Carlos X. Del Rio is Monte Everest 440, Col. Lomas de Chapultepec, Ciudad de M&#233;xico, 11000, Mexico. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(7)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Information in the table and footnote is based upon information provided to us by the direct shareholder, Control Empresarial de Capitales S.A. de C.V., acting as successor of Inversora Carso S.A. de C.V. by virtue of a merger (&#8220;CEC&#8221;). Consists of 63,118,645 Class&#160;B ordinary shares held by CEC, which may be exchanged, together with a corresponding number of Post-Combination ProKidney Common Units, pursuant to the Exchange Agreement, for 63,118,645 Class&#160;A ordinary shares. Members of the Slim family, directly or indirectly, own all of the issued and outstanding voting equity securities of CEC. Therefore, the Slim family may be deemed to beneficially own indirectly the Class&#160;B ordinary shares held by CEC. CEC is a sociedad an&#243;nima de capital variable organized under the laws of the United Mexican States (&#8220;Mexico&#8221;). The Slim family has an address of Paseo de las Palmas 736, Colonia Lomas de Chapultepec, 11000 Ciudad de Mexico, Mexico and Control Empresarial has an address of Paseo de las Palmas 781, Piso 3, Colonia Lomas de Chapultepec, Seccion III, Migual Hidalgo, Ciudad de Mexico, Mexico, 11000. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(8)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 3,000,000 Class&#160;A ordinary shares. The address of CP WY REMAINDER INTEREST TRUST U/A/D DATED DECEMBER&#160;22, 2021 is 506 Santa Cruz Avenue, Suite 300 Menlo Park, California 94025. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(9)</td>
<td style="vertical-align:top;text-align:left;"> <div style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">Consists of 10,000 Class&#160;A ordinary shares. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(10)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 100,000 Class&#160;A ordinary shares. The address of Denise and Michael Kellen Foundation, Inc. is 1345 <div style="display:inline;">Avenue </div>of the Americas, 47th Floor, New York, NY 10105. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(11)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 600,000 Class&#160;A ordinary shares. The address of DJG Associated, LLC is 62 Vineyard Lane, Greenwich, CT 06831. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(12)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 50,000 Class&#160;A ordinary shares. The address of Donald P. Spencer and Vickie Riccardo JTWROS is 370 Palmetto Road, St. Augustine, FL 32080. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(13)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 200,000 Class&#160;A ordinary shares. The address of Fourteen Plus Twelve Partners, LLC is 62 Vineyard Lane, Greenwich, CT 06831. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(14)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 125,000 Class&#160;A ordinary shares. The address of George W. Siguler Family Trust is 893 Ponte Vedra Blvd, Ponte Vedra Beach, FL 32082. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(15)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 500,000 Class&#160;A ordinary shares. The address of Hill Family Alternative Investments LLC is 834 Fifth Avenue, 10B, New York, NY 10065. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(16)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 100,000 Class&#160;A ordinary shares. The address of Hottinger AG is 60 Rue du Stand, Geneva 1204, Switzerland. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(17)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 5,000,000 Class&#160;A ordinary shares. The address of IHCI Investments LP is 1188 Union, Montreal QC H3B 0E5, Canada. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(18)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Consists of 800,000 Class&#160;A ordinary shares. The address of Juan Mar&#237;a Pedro David Michel is Bosque de Radiatas <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-602,</div> Bosques de las Lomas, Cuajimalpa 05120, Mexico. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(19)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 5,000,000 Class&#160;A ordinary shares. The address of Jupiter CAN LP is 5930 Royal Lane, Suite E, #117, Dallas, TX 75230. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(20)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 200,000 Class&#160;A ordinary shares. The address of KJB Associated LLC is 860 United Nations Plz Apt #33D, New York, NY 10017. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(21)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 2,000,000 Class&#160;A ordinary shares. The address of Leman Management Nominees Limited is Wessex House 2nd Floor, 45 Reid Street, Hamilton HM 12, Bermuda. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(22)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 80,000 Class&#160;A ordinary shares. The address of Luis Felipe Mancera de Arrigunaga is Colina 52 Lomas de Bezarcs 11910, Mexico City, Mexico. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(23)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 100,000 Class&#160;A ordinary shares. The address of Marina Kellen French Foundation is 1345 Avenue of the Americas, 47th Floor, New York, NY 10105. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(24)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Consists of 800,000 Class&#160;A ordinary shares. The address of Max Pierre David Michel is Bosque de Radiatas <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-602-103,</div></div> Bosques de las Lomas, Cuajimalpa 05120, Mexico. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(25)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 1,000,000 Class&#160;A ordinary shares. The address of MGG Strategic SICAF SIF, for and on behalf of its compartment, MGG Strategic is 18 Avenue de la Porte Neuve, Luxembourg 2227, Luxembourg. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(26)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Consists of 15,000 Class&#160;A ordinary shares. The address of Mikel Andoni Arriola Pe&#241;alosa is Av. Paseo de la Reforma 2693, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">401-C,</div> Lomas de Bezares, Miguel Hidalgo, Mexico City 11910, Mexico. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(27)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Consists of 800,000 Class&#160;A ordinary shares. The address of Monique Berthe Michele Madeleine David Michel is Bosque de Radiatas <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">6-602-103,</div></div> Bosques de las Lomas, Cuajimalpa 05120, Mexico. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(28)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 1,200,000 Class&#160;A ordinary shares. The address of GG 1978 SICAF SIF, for and on behalf of its compartment, GG Strategic (the Investor) is 18 Avenue de la Porte Neuve, Luxembourg 2227, Luxembourg. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(29)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 125,000 Class&#160;A ordinary shares. The address of Pamela Mallon Siguler Family Trust is 893 Ponte Vedra Blvd, Ponte Vedra Beach, FL 32082. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(30)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 7,500 Class&#160;A ordinary shares. The address of Paul Mower is 614 Lakota Lane (PO Box 4112), Jackson, WY 83001. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">171 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(31)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of (i) 12,927,348 13,045,190 Class B ordinary shares, (ii) 117,842 Class B ordinary shares issuable upon the vesting of PMEL RCUs within 60 days of July 31, 2022 and (iii) 9,158,197 PMEL RCUs held by ProKidney Management Equity LLC on behalf of individual unitholders. Upon vesting of the PMEL RCUS, the aggregate of 22,203,387 Class B ordinary shares may be exchanged, together with a corresponding number of Post-Combination ProKidney Common Units, pursuant to the Exchange Agreement, for a total of 22,203,387 Class&#160;A ordinary shares. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(32)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 300,000 Class&#160;A ordinary shares. The address of Prime Participations LLC is 110 East 59th Street, 33rd Fl, New York, NY 10022. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(33)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 100,000 Class&#160;A ordinary shares. The address of Regina Mancera Bustamante is Bosque de Tulipanes 14, Col. Bosques de las Lomas, Cuajimalpa 05120, Mexico. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(34)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 50,000 Class&#160;A ordinary shares. The address of Ricardo Jos&#233; Garza Bustamante is Av de Los Poetas 100, RCA 901, Col. Cumbres de Santa Fe, Mexico City 05600, Mexico. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(35)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">The business address of SC PIPE Holdings LLC is c/o SC Master Holdings, LLC 506 Santa Cruz Avenue, Suite 300. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(36)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 75,000 Class&#160;A ordinary shares. The address of Stephen M. Kellen 2004 Trust FBO Annabelle Garrett is 1345 Avenue of the Americas, 47th Floor, New York, NY 10105. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(37)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 75,000 Class&#160;A ordinary shares. The address of Stephen M. Kellen 2004 Trust FBO Andrew Gundlach is 1345 Avenue of the Americas, 47th Floor, New York, NY 10105. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(38)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 75,000 Class&#160;A ordinary shares. The address of Stephen M. Kellen 2004 Trust FBO Caroline L. Kellen is 1345 Avenue of the Americas, 47th Floor, New York, NY 10105. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(39)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 75,000 Class&#160;A ordinary shares. The address Stephen M. Kellen 2004 Trust FBO Christopher N. Kellen is 1345 Avenue of the Americas, 47th Floor, New York, NY 10105. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(40)</td>
<td style="vertical-align:top;text-align:left;"> <div style=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:left">Consists of 10,000 Class&#160;A ordinary shares. </div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(41)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 10,000 Class&#160;A ordinary shares. The address of Tensleep <div style="display:inline;">Group </div>LLC is 140 S. Cache St. (PO Box 4112), Jackson, WY 83001. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(42)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 94,677,968 Class&#160;B ordinary shares held by Tolerantia, which may be exchanged, together with a corresponding number of Post-Combination ProKidney Common Units, pursuant to the Exchange Agreement, for 94,677,968 Class&#160;A ordinary shares. Tolerantia is an affiliate controlled and majority-owned by Mr.&#160;Pablo Legorreta. Mr.&#160;Legorreta controls the voting and disposition of the shares held by Tolerantia. Mr.&#160;Legorreta disclaims beneficial ownership of the shares held by Tolerantia except to the extent of his indirect pecuniary interest therein. The business address of Tolerantia is 110, East 59th Street, Suite 3300, New York, New York, 10022. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(43)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 250,000 Class&#160;A ordinary shares. The address of WECMA Family, LLC is 893 Ponte Vedra Blvd, Ponte Vedra Beach, FL 32082. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(44)</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Consists of 30,000 Class&#160;A ordinary shares. The address of Uma Sinha, Ph.D. is c/o ProKidney Corp., 2000 Frontis Plaza Blvd., Ste 250, Winston-Salem, North Carolina, 27103. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">172 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="rom373959_16" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MANAGEMENT </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney Executive Officers and Directors </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table provides certain information concerning the persons who serve as directors and executive officers of ProKidney following the consummation of the Business Combination and their ages as of July 31, 2022 and positions following the Business Combination: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 33%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 57%; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Age</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Position</div></div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Executive Officers:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tim Bertram, Ph.D.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">66</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chief Executive Officer and Director</div></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">James Coulston, CPA</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">46</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Chief Financial Officer</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deepak Jain, Ph.D.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">68</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Chief Operating Officer</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Darin J. Weber, Ph.D.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">54</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Senior Vice President of Regulatory Development</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Todd C. Girolamo</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">57</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Chief Legal Officer</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Libbie P. McKenzie, M.D.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">49</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Chief Medical Officer</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Employee</div> Directors:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pablo Legorreta</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">58</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Chairman of the Board, Director</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">William F. Doyle</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">60</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Director</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Alan M. Lotvin, M.D.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">60</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Director</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Brian J.G. Pereira, M.D.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">63</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Director</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Uma Sinha, Ph.D.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">65</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Director</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">John M. Maraganore, Ph.D.</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">59</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Director</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jos&#233; Ignacio Jimenez Santos</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">47</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Director</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jennifer Fox</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">51</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">Director</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information about the Executive Officers and Directors </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Executive Officers </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">James Coulston, CPA </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Mr.&#160;Coulston has served as our Chief Financial Officer since the Closing, having served as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US&#8217;s</div> Chief Financial Officer since January 2022. Prior to that, Mr.&#160;Coulston served as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US&#8217;s</div> Senior Vice President, Finance from January 2021 to December 2021 and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US&#8217;s</div> Vice President, Finance from February 2019 to December 2020. Before joining ProKidney, from August 2015 to January 2019, Mr.&#160;Coulston served as the Executive Director, Finance of Banner Life Sciences LLC, a privately held clinical-stage pharmaceutical company combining a proven history of formulation expertise with proprietary technologies to create specialty pharmaceuticals that solve real unmet clinical needs, where Mr.&#160;Coulston oversaw the financial, human resources, and IT activities. From 2007 to 2015, Mr.&#160;Coulston held finance roles of increasing responsibility at Targacept Inc. (Nasdaq: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">&#8482;</div> before it merged with and into Catalyst Biosciences, Inc. (Nasdaq: CBIO), a clinical-stage biopharmaceutical company focused on creating and developing novel medicines to address serious medical conditions, including Senior Director, Finance and Controller. Mr.&#160;Coulston earned his B.S. and master degree in Accounting from North Carolina State University and is a Certified Public Accountant in the state of North Carolina. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Deepak Jain, Ph.D. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Dr.&#160;Jain has served as our Chief Operating Officer since the Closing, having served as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US&#8217;s</div> Chief Operating Officer since March 2016. Dr.&#160;Jain brings over 36 years of experience in the development of tissue-engineered and cell therapy products. Previously, Dr.&#160;Jain held management roles of increasing responsibility at Johnson&#160;&amp; Johnson (NYSE: JNJ) and Merck (NYSE: MRK) and was involved in the </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">173 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">development of four marketed products including Johnson&#160;&amp; Johnson&#8217;s erythropoietin-based drug Eprex (epoetin alfa). Dr.&#160;Jain has served as Chairman of the American Society for Testing and Materials Task Group on Preservation of Cells and Tissue Engineered Medical Product&#8217;s with Cells, and has served as Chairman of the USP Tissue and Tissue-based Products Ad hoc Advisory Panel and was member of the USP Biologics and Biotechnology Cell, Gene and Tissue Therapy Expert Committee. Dr.&#160;Jain received his B. Tech and M. Tech in Chemical Engineering and his Ph.D. in Biochemical Engineering from the Indian Institute of Technology in Delhi, India. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Darin J. Weber, Ph.D. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Dr.&#160;Weber has served as our Senior Vice President of Regulatory Development since the Closing, having served as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US&#8217;s</div> Senior Vice President of Regulatory Development since September 2020, where he is responsible for leading the development and implementation of ProKidney&#8217;s regulatory strategy in all markets, worldwide, and interfacing with regulatory authorities. Dr.&#160;Weber has over 25 years of experience in cellular and tissue-based regenerative medicine products, with previous roles as Senior Vice President of Regulatory and Quality at Medeor Therapeutics, from February 2016 to December 2019; Executive Vice President of Global Regulatory Affairs and Quality Management at Mesoblast, from June 2011 to February 2016; Senior Consultant for Cell and Gene Therapies at Biologics Consulting Group from February 2004 to May 2011, and positions of increasing responsibility at the FDA&#8217;s CBER, including as Chief of Cellular Therapies Branch in the Office of Cellular, Tissues and Gene Therapies, (now known as the Office of Tissues and Advanced Therapies) from September 1996 to January 2004. He is a long-serving member of United States Pharmacopeia (USP) expert committees for human tissues and advanced therapies. Dr.&#160;Weber received his B.S. in Molecular Biology from The Evergreen State College and a Ph.D. in Biochemistry and Biophysics from Oregon State University. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Todd C. Girolamo </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Mr.&#160;Girolamo has served as our Chief Legal Officer since July 2022. Mr.&#160;Girolamo joined ProKidney as General Counsel in March 2022. Prior to that, he spent 11 years at Caladrius Biosciences, Inc. (Nasdaq: CLBS), where he served as Chief Legal Officer, Senior Vice President of Corporate Development and Corporate Secretary. He began his legal career at Cahill Gordon&#160;&amp; Reindel in 1990 and later at Reid&#160;&amp; Priest, practicing in the areas of securities law, intellectual property, employment law and general commercial litigation. After private practice, Mr.&#160;Girolamo spent 12 years on Wall Street in institutional equities as a series 24, 7 and 63 licensed principal at Oppenheimer&#160;&amp; Co., CIBC World Markets, Leerink Swann (now SVB Securities LLC) and Summer Street Research Partners where he specialized in equity research, sales, and trading of biotechnology, pharmaceuticals and medical technology market sectors. Mr.&#160;Girolamo then served as an analyst and portfolio manager at Lion&#8217;s Path Capital managing a long-short portfolio of biopharma and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">med-tech</div> equities. Mr.&#160;Girolamo received an A.B. with honors from Harvard College, a J.D. from the University of Pennsylvania Law School and an MBA from Columbia Business School. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Libbie P. McKenzie, M.D. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Dr.&#160;McKenzie has served as our Chief Medical Officer since the Closing, having served as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US&#8217;s</div> Chief Medical Officer since April 2022. Prior to that, she held roles of increasing responsibility at IQVIA / Quintiles since June 2007. Most recently, Dr.&#160;McKenzie served as Vice President, Medical, Global Head of Lifecycle Safety Project Leadership and Strategic Solutions from November 2019 to March 2022, and as Vice President, Medical, Global Head of Marketed Product Safety and Medical Information from March 2015 to November 2018, and as Executive Director, Medical, Global Head of Safety Aggregate Reporting and Analytics from January 2013 to March 2015, and as Executive Director, Medical, Global Head of Medical Safety from January 2009 to January 2013, and as Associate Medical Director from June 2007 to January 2009. Prior to joining IQVIA / Quintiles, Dr.&#160;McKenzie was Medical Director and Medical Safety Officer at Ashfield / Drug Safety Alliance from October 2005 to May 2007. Dr.&#160;McKenzie has expertise in clinical, pharmacovigilance and regulatory affairs, with over fifteen years of industry experience. In addition to her corporate roles, Dr.&#160;McKenzie </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">174 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">was Dialysis Unit Medical Director at NaphCare in Raleigh, NC, from 2006 to 2020, making her intimately familiar with the challenges faced by patients undergoing dialysis. She holds a B.S. in Biology and Psychology from Duke University and an M.D. from Duke University School of Medicine. She completed a residency in internal medicine and a fellowship in nephrology at Duke University Medical Center. Dr.&#160;McKenzie is a Fellow of the American Society of Nephrology and an Associate of the American College of Physicians. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Directors </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tim Bertram, Ph.D. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Dr.&#160;Bertram has served on the Board, as our Chief Executive Officer, and as a director on the GP Board since the Closing. Dr.&#160;Bertram has served as Chief Executive Officer of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> since January 2019. and served on the Legacy GP Board from January 2022 until the Closing. Dr.&#160;Bertram has also served as a member of the board of directors of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;ProKidney-KY</div> Board&#8221;) since January 2022. Since February 2017, Dr.&#160;Bertram has served on the board of directors of NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells. Dr.&#160;Bertram served as Chief Scientific Officer of Tengion Inc. from 2004 to 2014 after serving as President of Research and Development, where he brought four cell-based therapeutic products from discovery through Phase 2 clinical development. Dr.&#160;Bertram was also involved in the development and registration of eight medical products while serving as a senior executive at Pfizer Inc. (NYSE: PFE), SmithKline Beecham Pharmaceuticals, and The Procter&#160;&amp; Gamble Company (NYSE: PG) from 1985 to 2004. He was a faculty member at the University of Illinois, and a visiting scientist at the National Institutes of Health. Tengion Inc. filed a voluntary Chapter 7 bankruptcy petition in December 2014. Dr.&#160;Bertram received his D.V.M. in Biology and Veterinary Medicine and his Ph.D. in Cellular Pathology from Iowa State University and was board certified in Veterinary Pathology in 1984. Dr.&#160;Bertram&#8217;s qualifications to serve on the Board include his leadership experience in the healthcare industry, as well as his knowledge of ProKidney&#8217;s business. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Pablo Legorreta </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Mr.&#160;Legorreta has served as Chairman of the Board and a director on the GP Board since the Closing. Mr.&#160;Legorreta served on the Legacy GP Board from August 2021 until the Closing, as a director of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> Board since January 2019, and as a manager of ProKidney Bermuda since January 2019. Mr.&#160;Legorreta is the founder and has served as Chief Executive Officer of Royalty Pharma plc (Nasdaq: RPRX), a rapidly growing biopharma company and one of the largest dedicated life sciences investors in the world, since September 1996. Mr.&#160;Legorreta has also served as the Chairman of the board of directors of Royalty Pharma plc since April 2020. Mr.&#160;Legorreta has over 25 years of experience building and managing Royalty Pharma plc. Additionally, Mr.&#160;Legorreta is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-founder</div> of Pharmakon Advisors, LP, a leading provider of debt capital to the life sciences industry, where he has served as a managing member, since April 2009. Mr.&#160;Legorreta has served as a director of Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, since November 2019. Additionally, Mr.&#160;Legorreta is a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-founder</div> of Pharmakon Advisors, LP, a leading provider of debt capital to the life sciences industry, where he has served as a managing member since April 2009. Mr.&#160;Legorreta has served on the Board of Governors of the New York Academy of Sciences since January 2015, the Board of Trustees of Rockefeller University since March 2017, and the Board of Trustees and Compensation, Research and Innovation and Development Committees of the Hospital for Special Surgery since January 2015. Mr.&#160;Legorreta has also served on the boards of Brown University; Pasteur Foundation (French: Institut Pasteur), a French <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-profit</div> private foundation dedicated to the study of biology, micro-organisms, diseases, and vaccines; Open Medical Institute, an international initiative for medical professionals, which through education and research, aims to improve healthcare on a global scale; and The Park Avenue Armory, a nonprofit cultural institution within the historic Seventh Regiment Armory. Mr.&#160;Legorreta is the founder and Chairman of Alianza Me&#180;dica para la Salud, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-profit</div> organization dedicated to enhancing the quality of health care in Latin America by providing doctors </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">175 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">and healthcare providers with continued education opportunities. Since its foundation in December 2010, AMSA has provided over 500 scholarships to Mexican and Latin American doctors and healthcare providers to study abroad. Mr.&#160;Legorreta is also a founding member of Mount Sinai&#8217;s new Institute for Health Equity Research, which is created in May 2020 in part as a response to the health inequities made apparent by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19.</div> Mr.&#160;Legorreta received his B.A. degree in Industrial Engineering from Universidad Iberoamericana in Mexico City. We believe that Mr.&#160;Legorreta&#8217;s experience in investing in pharmaceutical royalties and managing a growing life sciences investment company, as well as significant background in investment banking and debt financing provide him with the qualifications and skills to serve as the Chairman and a member of the Board. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">William F. Doyle </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Mr.&#160;Doyle has served on the Board and on the GP Board since the Closing. Mr.&#160;Doyle was a member of the Legacy GP Board from January 2022 until the Closing and has served on the ProKidney <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KY-Board</div> since January 2022. Mr.&#160;Doyle is a recognized expert in medical devices commercialization with over 20 years&#8217; experience in the advanced technology and healthcare industries as an entrepreneur, executive, management consultant and investor. He has served as Executive Chairman of NovoCure Limited (Nasdaq: NVCR), a commercial-stage oncology company which is currently developing Tumor Treating Fields, a new therapy for solid tumor cancers (&#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">NovoCure</div></div>&#8221;), since May 2016 and a member of the board of directors of NovoCure since Feburary, 2004. Mr.&#160;Doyle has been a managing director of WFD Ventures LLC, a private venture capital firm he <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-founded,</div> since June 2002. Prior to that, Mr.&#160;Doyle was a member of Johnson&#160;&amp; Johnson&#8217;s Medical Devices and Diagnostics Group Operating Committee and was the Vice President, Licensing and Acquisitions from 1994 to 1999. While at Johnson&#160;&amp; Johnson, Mr.&#160;Doyle was also the Worldwide President of Biosense-Webster, Inc. and a member of the board of directors of Johnson&#160;&amp; Johnson Development Corporation, Johnson&#160;&amp; Johnson&#8217;s venture capital subsidiary. Mr.&#160;Doyle has served as a member of the board of directors of Elanco Animal Health, Inc. (NYSE: ELAN), a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole, since October 2020 and a member of the board of directors of Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, since November 2017. Previously, Mr.&#160;Doyle served as a member of the board of directors of OptiNose, Inc. (Nasdaq: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, from June 2004 to October 2020, and Zoetis, Inc. (NYSE: ZTS), a leading animal health company, dedicated to supporting its customers and their businesses, from February 2015 to March 2016. Mr.&#160;Doyle earned his B.S. in Materials Science and Engineering from Massachusetts Institute of Technology and his M.B.A. from Harvard Business School. We believe Mr.&#160;Doyle is qualified to serve on the Board due to his business and investment experience and his extensive knowledge of ProKidney and the healthcare industry. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jennifer Fox </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Jennifer Fox has served on the Board and on the GP Board since July 2022. Ms.&#160;Fox has served as the Chief Financial Officer of Nuvation Bio Inc. since October 2020. Prior to this role, Ms.&#160;Fox served as Managing Director, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Head</div> of North America Healthcare Corporate and Investment Banking Group at Citigroup from June 2015 to October 2020. From February 2006 to June 2015, Ms.&#160;Fox served as Managing Director at Deutsche Bank, most recently also as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Co-Head</div> of Life Sciences Investment Banking Group. Prior to that, Ms.&#160;Fox served as Senior Managing Director Healthcare Investment Banking at Bear Stearns, Vice President Healthcare Investment Banking at Bank of America and Financial Analyst, Investment Banking Analyst, Associate, Vice President, Health Care Investment Banking at Prudential Vector Healthcare Group and Prudential Securities Incorporated. Ms.&#160;Fox received B.S. degrees in Finance and Marketing from Manhattan College. We believe that Ms.&#160;Fox is qualified to serve on the Board because she has over 25 years of experience in the healthcare investment banking industry and has been a lead advisor to life sciences companies on over 200 financing and strategic transactions. </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">176 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Jos&#233; Ignacio Jim&#233;nez Santos </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Mr.&#160;Jim&#233;nez Santos has served on the Board and on the GP Board since the Closing and was a member of the Legacy GP Board from August 2021 until the Closing. Mr.&#160;Jim&#233;nez Santos has served as the Chief Executive Officer of Afore Inbursa since August 2015 and the Chief Investment Officer of Grupo Financiero Inbursa, SAB de C.V., a public company registered on the Mexican Stock Exchange, since August 2013. Mr.&#160;Jim&#233;nez Santos served on the board of directors of Procesar SA de C.V., a private company that provides data processing services, from May 2019 to May 2022. Mr.&#160;Jim&#233;nez Santos also serves on the board of directors of Glycosyn, a private biotechnology company developing products based on unique bioactive sugars found in human milk. Mr.&#160;Jim&#233;nez Santos received his bachelor&#8217;s degree in economics and finance from the Instituto Tecnol&#243;gico Autonomo de M&#233;xico. We believe that Mr.&#160;Jim&#233;nez Santos&#8217; combined experience in finance, international investments and the biotechnology industry provide him with the qualifications and skills to serve as a member of the Board. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Alan M. Lotvin, M.D. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Dr.&#160;Lotvin has served on the Board and on the GP Board since the Closing. Dr.&#160;Lotvin was a member of the Legacy GP Board from January 2022 until the Closing and has served on the ProKidney <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KY-Board</div> since January 2022. Dr.&#160;Lotvin has served as the Executive Vice President at CVS Health Corp (NYSE: CVS), a leading health solutions company, since November 2012, and the President of CVS Caremark since March 2020. Prior to that, Dr.&#160;Lotvin served as the Executive Vice President&#8212;Transformation at CVS Health Corporation from June 2018 to February 2020 and the Executive Vice President&#8212;Specialty Pharmacy at CVS Caremark from November 2012 to May 2018. Dr.&#160;Lotvin has extensive experience in the pharmacy benefit management (&#8220;PBM&#8221;) and specialty pharmacy industries. Before joining CVS Health Corp, Dr.&#160;Lotvin was the President and Chief Executive Officer of ICORE Healthcare, a Magellan Health Services company, and prior to that, Dr.&#160;Lotvin held senior positions in the PBM industry. Dr.&#160;Lotvin earned his B.S. in Biochemistry from Stony Brook University, his M.D. in Medicine from SUNY Downstate Health Sciences University, and his M.A. in Medical Informatics from Columbia University Graduate School of Arts and Sciences. We believe Dr.&#160;Lotvin is qualified to serve on the Board due to his extensive knowledge of ProKidney and the healthcare industry. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">John M. Maraganore, Ph.D. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Dr.&#160;Maraganore has served on the Board and on the GP Board since the Closing. Dr.&#160;Maraganore was a member of Legacy GP Board from May 2022 until the Closing and has been a member of the ProKidney <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">KY-Board</div> since May 2022. Dr.&#160;Maraganore is the owner of JMM Consulting, LLC and is a venture partner at ARCH Venture Partners, a venture advisor at Atlas Venture, an executive advisor at RTW Investments and a senior advisor at Blackstone Life Sciences, each of which are investment funds. Previously, Dr.&#160;Maraganore served as the founding chief executive officer and as a director of Alnylam Pharmaceuticals, Inc. (&#8220;Alnylam&#8221;) (Nasdaq: ALNY), a publicly traded biopharmaceutical company, from 2002 until the end of 2021. From 2002 to 2007, Dr.&#160;Maraganore also served as president of Alnylam. From 1997 to 2002, Dr.&#160;Maraganore served in a number of leadership roles including as senior vice president, strategic product development with Millennium Pharmaceuticals, Inc., a biopharmaceutical company (now Takeda Oncology) (&#8220;Millennium&#8221;). Before Millennium, he served as director of molecular biology and director of market and business development at Biogen. Prior to Biogen, Dr.&#160;Maraganore was a scientist at ZymoGenetics, Inc., a biotechnology company, and The Upjohn Company, a pharmaceutical manufacturing company. Dr.&#160;Maraganore currently serves on the board of directors of publicly traded biotechnology companies Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), Beam Therapeutics Inc. (Nasdaq: BEAM) and Kymera Therapeutics, Inc. (Nasdaq: KYMR), and on the board of directors of private biotechnology companies, including Hemab Therapeutics ApS, TranSend Therapeutics, Inc., Versanis Bio, Inc. and Aerium Therapeutics, Inc. Dr.&#160;Maraganore was formerly a director of bluebird bio, Inc. (Nasdaq: BLUE). In addition, he was formerly a venture partner at Third Rock Ventures, L.P., and was formerly chairman of the board of directors of Regulus Therapeutics, Inc. (Nasdaq: RGLS), a publicly traded biotechnology company. Dr.&#160;Maraganore serves as a strategic advisor and investor to Brii Biosciences, a private </div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">177 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">biotechnology company, and also serves in an advisory role with Pictet&#160;&amp; Cie, an investment firm. He also serves as a strategic advisor for a number of private and public biotechnology companies. He is the former Chair and current member of the Executive Committee, the Emerging Companies Section Governing Board and the Health Section Governing Board of the Biotechnology Innovation Organization (BIO), where he serves as Chair Emeritus. Dr.&#160;Maraganore holds an M.S. and a Ph.D. in Biochemistry and Molecular Biology from the University of Chicago and a B.S. in Biological Sciences also from the University of Chicago. We believe that Dr.&#160;Maraganore is qualified to serve on the Board because he has over 35 years of experience in the biotechnology industry, bringing to the Board critical scientific, research and development, international and general management expertise. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Brian J. G. Pereira, M.D. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Dr.&#160;Pereira has served on the Board and on the GP Board since the Closing and was a member of the Legacy GP Board from January 2022 until the Closing. Dr.&#160;Pereira has served as the Chief Executive Officer at Visterra Inc., a clinical-stage biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with kidney diseases and other <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">hard-to-treat</div></div> diseases and a subsidiary of Otsuka America Inc., a global healthcare company listed on Tokyo Stock Exchange, since July 2013. Dr.&#160;Pereira has also served on the board of directors of Visterra Inc. since July, 2013. Dr.&#160;Pereira is a nationally recognized expert on kidney disease and nephrology, is the former Editor of the widely read textbook &#8220;Chronic Kidney Disease, Dialysis and Transplantation,&#8221; and has over 200 scientific papers to his credit. He currently serves on the board of directors of Africa Healthcare Network, Ltd, a dialysis provider, as the Chairman of the Board, the board of directors of KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need, the board of directors of Cullinan Pearl Corp, a privately held biotechnology company and a subsidiary of Cullinan Oncology, Inc. (Nasdaq: CGEM), an oncology company. He was the former Executive Chairman of the board of directors of Abeona Therapeutics Inc. (Nasdaq: ABEO), a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Dr.&#160;Pereira is a graduate of St. John&#8217;s Medical College, Bangalore, India and has an MBA from the Kellogg Business School, Northwestern University. Dr.&#160;Pereira obtained his D.M. in Nephrology and M.D. in Internal Medicine from Post Graduate Institute, Chandigarh, India. We believe Dr.&#160;Pereira&#8217;s qualifications to serve on the Board include his extensive experience with pharmaceutical companies, and his years of experience providing services to pharmaceutical and biotechnology organizations, including evaluating business plans involving clinical trials. </div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Uma Sinha, Ph.D. </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dr.&#160;Sinha has served on the Board and on the GP Board since the Closing. Dr.&#160;Sinha was a member of the SCS Board from September 2021 until the Closing. In April, 2016, Dr.&#160;Sinha was appointed the Chief Scientific Officer of BridgeBio Pharma, Inc. (&#8220;BridgeBio&#8221;) and serves as the Chief Scientific Officer of other BridgeBio subsidiaries, including Eidos Therapeutics. Prior to that, Dr.&#160;Sinha served as Chief Scientific Officer of Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, from 2014 to 2015 and as Senior Vice President of research from 2013 to 2014. She was Vice President, head of biology at Portola Pharmaceuticals, Inc., a clinical-stage biotechnology company, from 2010 to 2012 and was the Vice President of translational biology from 2004 to 2010. Previously, Dr.&#160;Sinha held senior research positions at Millennium Pharmaceuticals, Inc., a biopharmaceutical company, and COR Therapeutics, Inc., a biopharmaceutical company. Dr.&#160;Sinha received her Ph.D. in biochemistry from the University of Georgia and her B.Sc. with honors in chemistry from Presidency College. We believe Dr.&#160;Sinha&#8217;s qualifications to serve on the Board include her significant scientific experience in the biopharmaceutical industry. </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Family Relationships </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are no family relationships among any of ProKidney&#8217;s directors or executive officers. </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">178 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Governance </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Composition of the Board of Directors </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney&#8217;s business and affairs is organized under the direction of the Board. Mr.&#160;Legorreta serves as the Chairperson of the Board. The primary responsibilities of Board are to provide oversight, strategic guidance, counseling and direction to ProKidney&#8217;s management. The Board meets on a regular basis and additionally as required. </div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with the terms of the Charter, the Board may establish the authorized number of directors from time to time by resolution. The Board consists of nine members and is divided into three classes with staggered three-year terms. At each annual general meeting of shareholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual general meeting following election. ProKidney&#8217;s directors is divided among the three classes as follows: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Class&#160;I directors are William F. Doyle, Alan M. Lotvin, M.D., Brian J. G. Pereira, M.D., and their terms will expire at the annual general meeting of shareholders to be held in 2023; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Class&#160;II directors are Jennifer Fox, John M. Maraganore, Ph.D. and Jos&#233; Ignacio Jim&#233;nez Santos, and their terms will expire at the annual general meeting of shareholders to be held in 2024; and </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Class&#160;III directors are Tim Bertram, Ph.D., Pablo Legorreta and Uma Sinha, Ph.D., and their terms will expire at the annual general meeting of shareholders to be held in 2025. </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The division of the Board into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Board Leadership Structure </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney believes that all members of the Board should have a voice in the affairs and the management of ProKidney. The Board believes that ProKidney&#8217;s shareholders are best served at this time by having Mr.&#160;Legorreta, who plays an integral part of the board of director leadership structure and a critical aspect of effective corporate governance, serves as the Chairperson. The active involvement of the independent directors, combined with the qualifications and significant responsibilities of ProKidney&#8217;s Chairperson, provide balance and promote strong oversight of ProKidney&#8217;s management and affairs. ProKidney intends to evaluate its Board leadership structure on a periodic basis, commencing with the first meeting of the Board following the Closing, which evaluations will include, among other things, whether it is appropriate to appoint a lead independent director. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Controlled Company Exemption </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the terms of the Voting Agreement, Tolerantia effectively controls a majority of the voting power of all outstanding ProKidney ordinary shares with respect to the election, appointment or removal of any ProKidney director. As a result, ProKidney is a &#8220;controlled company&#8221; within the meaning of the Nasdaq Listing Rules. Under the Nasdaq Listing Rules, a company of which more than 50% of the voting power for the election of directors is held by an individual, group or another company is a &#8220;controlled company&#8221; and may elect not to comply with certain corporate governance standards, including the requirements that (i)&#160;a majority of its board of directors consist of independent directors, (ii)&#160;subject to the exception pursuant to Nasdaq Listing Rule 5605(b)(2), its board of directors have a compensation committee that is composed of at least two members, each of whom is an independent director, with a written charter addressing the committee&#8217;s purpose and responsibilities and (iii)&#160;director nominees must be selected, or recommended for the board&#8217;s selection, either by independent directors constituting a majority of the board&#8217;s independent directors in a vote in which only independent directors participate, or by a nominating and corporate governance committee comprised solely of independent directors with a written charter addressing the committee&#8217;s purpose and responsibilities. Under the </div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">179 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Business Combination Agreement, immediately following the Closing, a majority of the directors of the Board were required to be &#8220;independent&#8221; directors for the purposes of the Nasdaq Listing Rules, but for at least some period following the Business Combination, ProKidney could utilize the other exemptions described above. If any of these exemptions are used, you may not have the same protections afforded to shareholders of companies that are subject to all of these corporate governance requirements. If ProKidney ceases to be a &#8220;controlled company&#8221; and its shares continue to be listed on the Nasdaq, ProKidney will be required to comply with these standards and, depending on the Board&#8217;s independence determination with respect to its then-current directors, ProKidney may be required to add additional directors to its board in order to achieve such compliance within the applicable transition period. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Director Independence </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">An &#8220;independent director&#8221; is defined generally as a person who has no material relationship with the listed company (either directly or as a partner, shareholder or officer of an organization that has a relationship with the company). The Board has determined that each of William F. Doyle, Alan M. Lotvin, M.D., Brian J. G. Pereira, M.D., John M. Maraganore, Ph.D., Uma Sinha, Ph.D, Jos&#233; Ignacio Jim&#233;nez Santos and Jennifer Fox is an independent director under applicable SEC and Nasdaq rules. The independent directors have regularly scheduled meetings at which only independent directors are present. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Role of the Board in Risk Oversight </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">One of the key functions of the Board is to oversee ProKidney&#8217;s risk management process. The Board does not have a standing risk management committee, but rather administers this oversight function directly through the Board as a whole, as well as through various standing committees of the Board that address risks inherent in their respective areas of oversight. In particular, the Board is responsible for monitoring and assessing strategic risk exposure and ProKidney&#8217;s audit committee has the responsibility to consider and discuss ProKidney&#8217;s major financial risk exposures and the steps its management will take to monitor and control such exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. The audit committee also monitors compliance with legal and regulatory requirements. ProKidney&#8217;s compensation committee also assesses and monitors whether ProKidney&#8217;s compensation plans, policies and programs comply with applicable legal and regulatory requirements. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Committees of the Board of Directors </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The standing committees of Board consist of an audit committee, a compensation committee and a nominating and corporate governance committee. The Board may establish other committees as it deems necessary or appropriate from time to time. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Audit Committee </div></div></div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Our audit committee consists of William F. Doyle, who serves as the chairperson, Brian J. G. Pereira, M.D., Jennifer Fox and Alan M. Lotvin, M.D. Each member of the audit committee qualifies as an independent director under the Nasdaq Listing Rules and the independence requirements of Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10A-3</div> under the Exchange Act. The Board has determined that Mr.&#160;Doyle qualifies as an &#8220;audit committee financial expert&#8221; as such term is defined in Item 407(d)(5) of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-K</div> and possesses financial sophistication, as defined under the rules of the Nasdaq. </div><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The primary purpose of the audit committee is to discharge the responsibilities of the Board with respect to corporate accounting and financial reporting processes, systems of internal control and financial statement audits, and to oversee ProKidney&#8217;s independent registered public accounting firm. Specific responsibilities of the audit committee include: </div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">helping the Board oversee corporate accounting and financial reporting processes; </div></div></td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">180 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc"></a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">managing the selection, engagement, qualifications, independence and performance of a qualified firm to serve as the independent registered public accounting firm to audit ProKidney&#8217;s consolidated financial statements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">discussing the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and the independent accountants, ProKidney&#8217;s interim and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">year-end</div> operating results; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">developing procedures for employees to submit concerns anonymously about questionable accounting or audit matters; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewing related person transactions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">obtaining and reviewing a report by the independent registered public accounting firm at least annually that describes ProKidney&#8217;s internal quality control procedures, any material issues with such procedures, and any steps taken to deal with such issues when required by applicable law; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">approving or, as permitted, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-approving,</div> audit and permissible <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-audit</div> services to be performed by the independent registered public accounting firm. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Board has adopted a written charter for the audit committee, which is available on ProKidney&#8217;s website at <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">https://www.prokidney.com</div> under Investors&#8212;Corporate Governance&#8212;Governance Overview. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation Committee </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our compensation committee consists of Alan M. Lotvin, M.D., who serves as the chairperson, William F. Doyle, John M. Maraganore, Ph.D. and Uma Sinha, Ph.D. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The primary purpose of the compensation committee is to discharge the responsibilities of the Board in overseeing the compensation policies, plans and programs and to review and determine the compensation to be paid to executive officers, directors and other senior management, as appropriate. Specific responsibilities of the compensation committee include: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewing and approving the compensation of the chief executive officer, other executive officers and senior management; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewing and recommending to the Board the compensation of directors; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">administering the ProKidney Incentive Equity Plan and other benefit programs; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">reviewing, adopting, amending and terminating incentive compensation and equity plans, severance agreements, profit sharing plans, bonus plans, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">change-of-control</div></div> protections and any other compensatory arrangements for the executive officers and other senior management; and </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reviewing and establishing general policies relating to compensation and benefits of the employees, including the overall compensation philosophy. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Board has adopted a written charter for the compensation committee, which is available on ProKidney&#8217;s website at <div style="text-decoration: underline; letter-spacing: 0px; top: 0px;;display:inline;">https://www.prokidney.com</div> under Investors&#8212;Corporate Governance&#8212;Governance Overview. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Nominating and Corporate Governance Committee </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our nominating and corporate governance committee consists of John M. Maraganore, Ph.D., who serves as the chairperson, Brian J.G. Pereira, M.D., Uma Sinha, Ph.D., and Jos&#233; Ignacio Jim&#233;nez Santos. The purpose of the nominating and corporate governance committee is to assist the Board in discharging its responsibilities relating to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">identifying and evaluating candidates, including the nomination of incumbent directors for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-election</div> and nominees recommended by shareholders, to serve on the ProKidney Board; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">181 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">considering and making recommendations to the Board regarding the composition and chairmanship of the committees of the ProKidney Board; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">developing and making recommendations to the Board regarding corporate governance guidelines and matters, including in relation to corporate social responsibility; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">overseeing periodic evaluations of the performance of the Board, including its individual directors and committees. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Board has adopted a written charter for the nominating and corporate governance committee, which is available on ProKidney&#8217;s website at https://www.prokidney.com under Investors&#8212;Corporate Governance&#8212;Governance Overview. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Code of Ethics </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">ProKidney has adopted a code of business conduct that applies to all of its directors, officers and employees, including its principal executive officer, principal financial officer and principal accounting officer, which is available on ProKidney&#8217;s website at https://www.prokidney.com under Investors&#8212;Corporate Governance&#8212;Governance Overview. ProKidney&#8217;s code of business conduct is a &#8220;code of ethics&#8221; as defined in Item 406(b) of Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-K.</div> ProKidney will make any legally required disclosures regarding amendments to, or waivers of, provisions of its code of ethics on its Internet website. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation of Directors and Executive Officers </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Overview </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney&#8217;s executive compensation program is designed to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">attract, retain and motivate senior management leaders who are capable of advancing ProKidney&#8217;s mission and strategy and, ultimately, creating and maintaining its long-term equity value. Such leaders must engage in a collaborative approach and possess the ability to execute its business strategy in an industry characterized by competitiveness and growth; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">reward senior management in a manner aligned with ProKidney&#8217;s financial performance; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">align senior management&#8217;s interests with ProKidney&#8217;s equity owners&#8217; long-term interests through equity participation and ownership. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decisions with respect to the compensation of ProKidney&#8217;s executive officers, including its named executive officers, are made by the compensation committee of the Board. Compensation for ProKidney&#8217;s executive officers has the following components: base salary, cash bonus opportunities, long-term incentive compensation, broad-based employee benefits, and severance benefits. Base salaries, broad-based employee benefits, supplemental executive perquisites and severance benefits are designed to attract and retain senior management talent. ProKidney also uses cash bonuses and long-term equity awards to promote performance-based pay that aligns the interests of its named executive officers with the long-term interests of its equity owners and to enhance executive retention. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">See the section entitled &#8220;Executive and Director Compensation&#8221; below for additional information regarding the compensation paid to ProKidney&#8217;s named executive officers and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Base Salary </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The base salaries for ProKidney&#8217;s named executive officers were in effect prior to the Business Combination and are subject to adjustments made by the compensation committee, including in connection with ProKidney&#8217;s annual review of its named executive officers&#8217; base salaries. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">182 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Annual Bonuses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney uses annual cash incentive bonuses for the named executive officers to motivate their achievement of short-term performance goals and tie a portion of their cash compensation to performance. Near the beginning of each year, the compensation committee will select the performance targets, target amounts, target award opportunities and other terms and conditions of annual cash bonuses for the named executive officers, subject to the terms of their employment agreements. Following the end of each year, the compensation committee will determine the extent to which the performance targets were achieved and the amount of the award that is payable to the named executive officers. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-Based Awards </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney uses share-based awards to promote its interests by providing the executives with the opportunity to acquire equity interests as an incentive for their remaining in its service and aligning the executives&#8217; interests with those of ProKidney. Share-based awards will be awarded under the ProKidney Incentive Equity Plan. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Compensation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney maintains various broad-based employee benefit plans, including medical, dental, vision, life and disability insurance and 401(k) plans, paid vacation, sick leave and holidays and employee assistance program benefits in which the named executive officers will participate. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Director Compensation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney plans to adopt a director compensation program that is designed to align compensation with the Company&#8217;s business objectives and the creation of shareholder value, while enabling ProKidney to attract, retain, incentivize and reward directors who contribute to the long-term success of ProKidney. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">183 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EXECUTIVE AND DIRECTOR COMPENSATION </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The following discusses the material components of the executive compensation program for the named executive officers of ProKidney (the &#8220;NEOs&#8221;) who are identified in the 2021 Summary Compensation Table below. This discussion may contain forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. In this section, unless context requires otherwise, references to &#8220;we,&#8221; &#8220;us&#8221; &#8220;our,&#8221; &#8220;ProKidney&#8221; or &#8220;the Company&#8221; generally refer to ProKidney Corp. and its subsidiaries following the Closing and to ProKidney LP and its subsidiaries prior to the Closing. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Summary Compensation Table </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have opted to comply with the executive compensation disclosure rules applicable to emerging growth companies, as ProKidney is an emerging growth company. The scaled disclosure rules are those applicable to &#8220;smaller reporting companies,&#8221; as such term is defined in the rules promulgated under the Securities Act, which require compensation disclosure for ProKidney&#8217;s principal executive officer(s), its two most highly compensated executive officers other than the principal executive officer whose total compensation for 2021 exceeded $100,000 and who were serving as executive officers as of December&#160;31, 2021 and up to two additional individuals for whom disclosure would have been required for the fact that they were not serving as executive officers as of December&#160;31, 2021. We refer to these individuals as &#8220;named executive officers&#8221; or &#8220;NEOs.&#8221; For the year ended December&#160;31, 2021, ProKidney&#8217;s NEOs were: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tim Bertram, Ph.D., Chief Executive Officer; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deepak Jain, Ph.D., Chief Operating Officer; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Joseph Stavas, M.D., MPH, Senior Vice President of Clinical Development. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth certain information with respect to compensation for the year ended December&#160;31, 2021 earned by, awarded to or paid to ProKidney&#8217;s NEOs. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 48%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Name and Principal Position</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Salary ($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Bonus&#160;($)<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.6px">(1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Non-</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Incentive<br/>Equity<br/>Plan ($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">All Other<br/>Compensation<br/>($)<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.6px">(2)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total ($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tim Bertram, Ph.D.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">$</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">489,258</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">$</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">360,000</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">$</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">$</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">24,503</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">$</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">873,761</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Chief Executive Officer</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deepak Jain, Ph.D.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">$</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">401,694</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">$</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">216,000</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">$</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">$</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">14,522</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">$</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">632,216</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Chief Operating Officer</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Joseph Stavas, M.D., MPH</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">2021</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">$</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">530,110</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">$</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">145,000</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">$</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">$</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">14,522</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; white-space: nowrap;">$</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:right;">689,632</td>
<td style="vertical-align: top; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Senior Vice President of Clinical Development</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Reflects bonuses actually paid for the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-month</div> period from January&#160;1, 2021 to December&#160;31, 2021, and excludes payments made in 2021 for 2020 bonuses, for each executive officer. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Reflects the amounts of all other compensation paid to the named individuals for the year ended December&#160;31, 2021, which comprise of (1)&#160;the matching contributions to the 401(k) plan; (2)&#160;allowance paid to Dr.&#160;Bertram, and (3)&#160;insurance premiums with respect to a group life insurance policy, a group short- term disability policy, a group long-term disability policy, an accidental death and dismemberment policy, and flexible spending accounts paid on behalf of each of Dr.&#160;Bertram, Dr.&#160;Jain and Dr.&#160;Stavas. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">184 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Narrative Disclosure to Summary Compensation Table </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Employment Agreements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Below are descriptions of the employment agreements with each of our NEOs setting forth the terms and conditions of such executive&#8217;s employment with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY,</div> respectively. It is expected that each of our NEOs will enter into a new employment agreement with the Company that sets forth new terms and conditions of such executive&#8217;s employment with the Company which reflect the Company&#8217;s executive compensation philosophy as a new public company. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tim Bertram, Ph.D. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On September&#160;17, 2019, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> entered into an employment agreement with Dr.&#160;Bertram, pursuant to which Dr.&#160;Bertram was employed as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY&#8217;s</div> Chief Executive Officer, effective as of January&#160;7, 2019. The agreement entitles Dr.&#160;Bertram to an initial base salary of $237,885 and eligibility for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY&#8217;s</div> annual discretionary bonus program. Dr.&#160;Bertram is also eligible to participate in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY&#8217;s</div> benefit plans and programs, including its retirement plan and medical insurance coverage. Under the terms of this agreement, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> or Dr.&#160;Bertram may terminate Dr.&#160;Bertram&#8217;s employment at any time for any or no reason upon three months&#8217; written notice. In the event that Dr.&#160;Bertram is terminated without Cause (as defined in the agreement and including due to disability or death), Dr.&#160;Bertram is entitled to receive any earned but unpaid base salary, payment for any unused vacation days, and any benefits to which he may be entitled under applicable law or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY&#8217;s</div> employee benefit plans. Unless previously terminated or extended, Dr.&#160;Bertram&#8217;s employment will automatically cease at the end of the month in which he attains 70 years of age. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On the same day, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> entered into an employment agreement with Dr.&#160;Bertram, pursuant to which Dr.&#160;Bertram assumed the role of Chief Executive Officer of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US,</div> effective as of January&#160;7, 2019. The agreement entitles Dr.&#160;Bertram to an initial base salary of $237,885 and eligibility in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US&#8217;s</div> annual discretionary bonus program. Dr.&#160;Bertram is also eligible to participate in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US&#8217;s</div> benefit plans and programs, including its 401K plan. The agreement further provides that PMEL would grant Dr.&#160;Bertram a profits interest, which would indirectly represent 4.5% of the future profits of ProKidney LP measured as of the date of the agreement and as further discussed below, on September&#160;30, 2019, PMEL granted Dr.&#160;Bertram 3,698,631 Profits Interests. Under the terms of this agreement, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> or Dr.&#160;Bertram may terminate his employment at any time for any or no reason upon written notice at any time. In the event that Dr.&#160;Bertram is terminated for any or no reason (including due to disability or death), Dr.&#160;Bertram is entitled to receive any earned but unpaid base salary, payment for any unused vacation days, and any benefits to which he may be entitled under applicable law or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US&#8217;s</div> employee benefit plans. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Deepak Jain, Ph.D. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> entered into an employment agreement with Dr.&#160;Jain on September&#160;17, 2019, pursuant to which Dr.&#160;Jain assumed the role of Chief Operating Officer of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> effective as of January&#160;7, 2019. The agreement entitles Dr.&#160;Jain to an initial base salary of $378,525 and eligibility in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US&#8217;s</div> annual discretionary bonus program. Dr.&#160;Jain is also eligible to participate in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US&#8217;s</div> benefit plans and programs, including its 401K plan. The agreement further provides that PMEL would grant Dr.&#160;Jain a profits interest, which would indirectly represent 1.5% of the future profits of ProKidney LP measured as of the date of Dr.&#160;Jain&#8217;s employment agreement and, as further discussed below, on September&#160;30, 2019, PMEL granted Dr.&#160;Jain 1,232,877 Profits Interests. Under the terms of this agreement, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> or Dr.&#160;Jain may terminate his employment at any time for any or no reason upon written notice at any time. In the event that Dr.&#160;Jain is terminated for any or no reason (including due to disability or death), Dr.&#160;Jain is entitled to receive any earned but unpaid base salary, payment for any unused vacation days, and any benefits to which he may be entitled under applicable law or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US&#8217;s</div> employee benefit plans. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">185 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Joseph Stavas, M.D., MPH </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> entered into an employment agreement with Dr.&#160;Stavas on September&#160;17, 2019, pursuant to which Dr.&#160;Stavas assumed the role of Senior Vice President of Clinical Development of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> beginning October 1, 2019. The agreement entitles Dr.&#160;Stavas to an initial base salary of $500,000 and eligibility in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US&#8217;s</div> annual discretionary bonus program. Dr.&#160;Stavas is also eligible to participate in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US&#8217;s</div> benefit plans and programs, including its 401K plan. The agreement further provides that PMEL would grant Dr.&#160;Stavas a profits interest, which would indirectly represent 1.5% of the future profits of ProKidney measured as of the date of Dr.&#160;Stavas&#8217;s employment agreement and, as further discussed below, on November&#160;1, 2019, PMEL granted Dr.&#160;Stavas 1,232,877 Profits Interests. Under the terms of this agreement, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> or Dr.&#160;Stavas may terminate his employment at any time for any or no reason upon written notice at any time. In the event that Dr.&#160;Stavas is terminated for any or no reason (including due to disability or death), Dr.&#160;Stavas is entitled to receive any earned but unpaid base salary, payment for any unused vacation days, and any benefits to which he may be entitled under applicable law or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US&#8217;s</div> employee benefit plans. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2021 Base Salaries </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Each NEO&#8217;s base salary was a fixed component of annual compensation for performing specific duties and functions, and was established by the Legacy GP Board taking into account each individual&#8217;s role, responsibilities, skills and expertise. Base salaries are reviewed annually, typically in connection with our annual performance review process, and, going forward, will be approved by the compensation committee and adjusted from time to time to realign salaries with market levels after taking into account individual responsibilities, performance and experience. During 2021, the annual base salaries for Dr.&#160;Bertram, Dr.&#160;Jain and Dr.&#160;Stavas, were $489,258, $401,694 and $530,110, respectively. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2021 Bonuses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the fiscal year ended December&#160;31, 2021, each of ProKidney&#8217;s NEOs was eligible to earn an annual bonus based on the achievement of certain predetermined corporate performance objectives. During 2021, the annual bonuses awarded to Dr.&#160;Bertram, Dr.&#160;Jain, and Dr.&#160;Stavas, were $360,000, $216,000, and $145,000, respectively. The annual bonus earned by each NEO with respect to the fiscal year ended December&#160;31, 2021 is reported under the &#8220;Bonus&#8221; column in the Summary Compensation Table above and were determined by the Legacy GP Board on a discretionary basis based on ProKidney&#8217;s overall performance for the year, as well as each individual&#8217;s performance, subject to each NEO&#8217;s continued employment through the payment date. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding Equity Awards at December&#160;31, 2021 </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The outstanding equity incentive awards held by the NEOs as of December&#160;31, 2021, prior to the Business Combination, consisted of Profits Interests issued in 2019 (as detailed in the table below) (the &#8220;2019 Profits Interests&#8221;). No Profits Interests were granted to the NEOs in 2020 or 2021. On January&#160;17, 2022, PMEL issued Profits Interests, some of which were granted subject to vesting and some of which were purchased fully-vested, to employees, directors and other service providers, including to each of the NEOs and certain independent directors of the Legacy GP Board and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> Board, under the ProKidney Limited Partnership Agreement and the related Limited Liability Company Agreement of PMEL then in effect (the &#8220;2022 Profits Interests&#8221;). Dr.&#160;Bertram, Dr.&#160;Jain and Dr.&#160;Stavas were issued 2,337,045, 680,913 and 50,000 2022 Profits Interests, respectively, and, each of Mr.&#160;Doyle, Dr.&#160;Lotvin and Dr.&#160;Pereira were issued 1,848,352 2022 Profits Interests. In addition, on June 1, 2022, Mr.&#160;Maraganore was issued 200,000 Profits Interests. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The purpose of awarding the Profits Interests was to promote the interests of ProKidney by attracting and retaining key employees, managers, independent contractors or other service providers of ProKidney and its subsidiaries and to enable such individuals to acquire an equity interest in and participate in the long-term growth and financial success of ProKidney. The Profit Interests represented an indirect partnership interest in ProKidney </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">186 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LP and generally entitled the holder to receive distributions from PMEL (which PMEL received from ProKidney LP once a specified threshold equity value of ProKidney was reached, in each case as provided in the ProKidney Limited Partnership Agreement and the related Limited Liability Company Agreement of PMEL then in effect). Under these agreements, the Closing qualified as an &#8220;Extraordinary Event,&#8221; pursuant to which the holders of Profits Interests were also entitled to receive disproportionate distributions in ProKidney until each of their threshold equity value had been reduced to zero in order to &#8220;catch up&#8221; each such holder&#8217;s distributions to its pro rata share of aggregate cumulative distributions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney measured compensation expense for Profits Interests based on estimated fair values at the time of grant and estimates the fair value of Profits Interests using generally accepted valuation procedures. ProKidney recognized compensation expense, on a straight-line basis, for the portion of the Profit Interests value that was expected to vest over the requisite period of service provided by the recipient of the Profits Interests. ProKidney also recorded forfeitures of Profits Interest as they occurred. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In general, awards of Profits Interests were 25% vested on the first anniversary of the recipient&#8217;s employment, in the case of Dr.&#160;Bertram and Dr.&#160;Jain, and the first anniversary of the date of award of the Profits Interests, in the case of Dr.&#160;Stavas, with the remainder of each award to vest in increments of 6.25% each calendar quarter following the first anniversary of the grant date, subject generally to the holder&#8217;s continuous employment with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> or its affiliates on each vesting date. The 2022 Profits Interests generally vest in increments of 25% on each anniversary following the grant date, subject generally to the holder&#8217;s continuous employment with <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> or its affiliates on each vesting date. With respect to those 2022 Profits Interests that are subject to vesting conditions, in the event that an NEO&#8217;s employment is terminated without Cause (as defined in the NEO&#8217;s employment agreement) prior to January&#160;17, 2023, the tranche of 2022 Profits Interests that would have vested on January&#160;17, 2023 will immediately vest subject to, among other things, the NEO signing and not revoking a release of claims. All of the 2022 Profits Interests issued to Dr.&#160;Stavas were purchased fully vested, and a portion of the 2022 Profits Interests issued to Dr.&#160;Bertram and Dr.&#160;Jain were purchased fully vested, in each case, subject to certain transfer restrictions as provided in the applicable award agreement and the Limited Liability Company Agreement of PMEL. A portion of the 2022 Profits Interests granted to the independent directors of the Legacy GP Board (who have since gone on to serve as members of the GP Board) and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> Board vest in increments of 33.33% on each anniversary following the grant date, subject generally to the director&#8217;s continuous service on the board on each vesting date. A portion of the 2022 Profits Interests issued to such directors were purchased fully vested, subject to certain transfer restrictions as provided in the applicable award agreement and the Limited Liability Company Agreement of PMEL. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the number of outstanding Profits Interests held by each of the NEOs as of December&#160;31, 2021. Such NEOs do not hold any outstanding equity awards other than the Profits Interests. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 47%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="18" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Equity Awards<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.6px">(1)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Name</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Grant Date</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Profits</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Interest&#160;that</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Have&#160;Vested</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(#)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Market&#160;Value</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">of Profits</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Interest Units</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">that Have</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Vested</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Profits</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Interest&#160;that</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Have Not</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Vested</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(#)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Market&#160;Value</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">of Profits</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Interest Units</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">that Have</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Not Vested</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">($)<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:6.6px">(3)</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tim Bertram, Ph.D.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9/30/2019</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(2)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,773,973</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">998,630</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">924,658</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">332,877</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deepak Jain, Ph.D.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9/30/2019</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(3)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">924,657</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">332,877</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">308,220</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">110,959</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Joseph Stavas, M.D., MPH</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11/1/2019</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">(</div><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">4)</div>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">693,493</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">249,657</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">539,384</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">194,178</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">There was no public market for the Profits Interests. For purposes of this disclosure, the equity value of the Profits Interests was determined using contemporaneous valuations using methodologies consistent with the <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation</div></div>, as of December&#160;31, 2021. As of December&#160;31, 2021, the weighted average grant date fair value of the Profits Interests granted was $0.36 per Class&#160;B Unit. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">187 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents 3,698,631 Profits Interests granted on September&#160;30, 2019, with the first 25% of such Profits Interests vested on January&#160;7, 2020, and the remaining 75% vested in increments of 6.25% each calendar quarter thereafter, subject to continued employment of the NEO on each vesting date. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents 1,232,877 Profits Interests granted on September&#160;30, 2019, with the first 25% of such Profits Interests vested on January&#160;7, 2020, and the remaining 75% vested in increments of 6.25% each calendar quarter thereafter, subject to continued employment of the NEO on each vesting date. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Represents 1,232,877 Profits Interests granted on November&#160;1, 2019, with the first 25% of such Profits Interests vested on November&#160;1, 2020, and the remaining 75% vested in increments of 6.25% each calendar quarter thereafter, subject to continued employment of the NEO on each vesting date. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Actions Taken in Connection with this Business Combination </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Effective as of January&#160;17, 2022, the ProKidney Limited Partnership Agreement was amended to provide that, if, as a result of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">De-SPAC</div> Transaction or Qualified IPO (each as defined in the ProKidney Limited Partnership Agreement), a Profits Interest holder was allocated aggregate cumulative distributions in an amount at least equal to his or her pro rata share of the applicable threshold equity value, then such holder&#8217;s Profits Interests would immediately and automatically be converted into ProKidney Class&#160;B Units. In connection with and by virtue of the Business Combination and immediately prior to the Closing, ProKidney converted all outstanding Profits Interests into Class&#160;B Units of ProKidney (the &#8220;Converted Profits Interests&#8221;) in accordance with the foregoing. As contemplated by and pursuant to the terms of the Business Combination Agreement and the Second Amended and Restated ProKidney Limited Partnership Agreement, each Converted Profits Interest that was not vested pursuant to the terms of the applicable award agreement with the applicable holder as of immediately prior to the Closing was recapitalized into a PMEL RCU and each Converted Profits Interest that was vested pursuant to the terms of the applicable award agreement with the applicable holder as of immediately prior to the Closing was recapitalized into a Post-Combination ProKidney Common Unit. Each PMEL RCU will remain subject to vesting and forfeiture terms provided under the applicable existing award agreement with the holder and each Post-Combination ProKidney Common Unit will remain subject to the forfeiture terms of the applicable existing award agreement. Pursuant to the terms of the Second Amended and Restated ProKidney Limited Partnership Agreement and our Charter, upon the vesting of a PMEL RCU, such PMEL RCU and the corresponding ProKidney Class&#160;B PMEL RSR will automatically vest and each PMEL RCU will immediately and automatically convert, in accordance with the terms of the Second Amended and Restated ProKidney Limited Partnership Agreement, into one Post-Combination ProKidney Common Unit and, as promptly as reasonably practicable following such vesting event, the Company will settle such ProKidney Class&#160;B PMEL RSR by issuing to the holder thereof one ProKidney Class&#160;B ordinary share. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney Incentive Equity Plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In connection with the Business Combination, the SCS Board adopted, and the SCS shareholders approved, the ProKidney Incentive Equity Plan, under which New ProKidney employees, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors, individual consultants, advisors and other service providers are eligible to receive awards based on the compensation committee&#8217;s determination, in its sole discretion, that an award to such individual will further the ProKidney Incentive Equity Plan&#8217;s stated purpose of promoting the long-term success of ProKidney by motivating employees and other individuals to perform at the highest level and contributing significantly to the success of ProKidney, thereby furthering the best interests of ProKidney and its shareholders. The ProKidney Incentive Equity Plan is administered by the compensation committee and is the primary means by which ProKidney will provide equity-based compensation to its employees and other servie providers. As of the date hereof, no grants have been made or awarded under the ProKidney Incentive Equity Plan. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The ProKidney Incentive Equity Plan provides for the issuance of 23,226,419 ProKidney Class&#160;A ordinary shares, which equals 10% of the number of ProKidney Class&#160;A ordinary shares outstanding immediately after the completion of the Business Combination on a fully diluted basis. In addition, the ProKidney Incentive Equity Plan provides for an annual increase on the first day of each fiscal year during the period beginning with fiscal </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">188 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">year 2023 and ending on the second day of fiscal year 2032 equal to the lesser of (a)&#160;5% of the number of outstanding ProKidney Class&#160;A ordinary shares on the last day of the immediately preceding fiscal year on a fully diluted basis, and (b)&#160;an amount determined by the compensation committee. The number of ProKidney Class&#160;A ordinary shares that may be subject to incentive stock options granted under the ProKidney Incentive Equity Plan is 75,567,000. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the event of a change in control, as defined in the ProKidney Incentive Equity Plan, the compensation committee may take certain actions with respect to outstanding awards, including the continuation or assumption of awards, substitution or replacement of awards by a successor entity, acceleration of vesting and lapse of restrictions, determination of the attainment of performance conditions for performance awards or cancellation of awards in consideration of a payment. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney Employee Stock Purchase Plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection with the completion of the Business Combination, the SCS Board adopted, and the SCS shareholders approved, the ProKidney Employee Stock Purchase Plan. The ProKidney Employee Stock Purchase Plan is administered by the compensation committee and provides our employees and employees of participating subsidiaries with an opportunity to acquire a proprietary interest in ProKidney through the purchase of Class&#160;A ordinary shares. Initially, the ProKidney Employee Stock Purchase Plan is not intended to qualify as an &#8220;employee stock purchase plan&#8221; under Section&#160;423 of the Code. However, from and after such date as the compensation committee determines that the ProKidney Employee Stock Purchase Plan is able to satisfy the requirements under Section&#160;423 of the Code, the ProKidney Employee Stock Purchase Plan will be intended to qualify as an &#8220;employee stock purchase plan&#8221; under Section&#160;423 and the ProKidney Employee Stock Purchase Plan will be interpreted in a manner that is consistent with that intent. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The maximum number of our ProKidney Class&#160;A ordinary shares that may be issued pursuant to rights granted under the ProKidney Employee Stock Purchase Plan is 4,645,284 ProKidney Class&#160;A ordinary shares, which equals 2% of the number of ProKidney Class&#160;A ordinary shares outstanding immediately after the Closing on a fully diluted basis. The number of ProKidney ordinary shares reserved for issuance under the ProKidney Employee Stock Purchase Plan will automatically increase on the first day of each calendar year during the term of the ProKidney Employee Stock Purchase Plan, commencing on January&#160;1, 2023 through January&#160;1, 2032, by the least of (i)&#160;5,037,800 ProKidney Class&#160;A ordinary shares, (ii)&#160;1% of the total number of ProKidney Class&#160;A ordinary shares outstanding on a fully diluted basis on December&#160;31 of the immediately preceding calendar year or (iii)&#160;such smaller number of our ProKidney Class&#160;A ordinary shares as determined by the Board. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other Compensation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">All of ProKidney&#8217;s NEOs are eligible to participate in its employee benefit plans, including its medical, dental, vision, life and disability insurance plans, in each case on the same basis as all of ProKidney&#8217;s other employees. ProKidney generally provides perquisites or personal benefits to its NEOs in limited circumstances. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">401(k) Plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">ProKidney maintains a 401(k) plan for its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> employees. The 401(k) plan is intended to qualify under Section&#160;401(k) of the Code, so that contributions to the 401(k) plan by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> employees or by ProKidney, and the investment earnings thereon, are not taxable to the employees until withdrawn from the 401(k) plan, and so that contributions by ProKidney, if any, will be deductible by ProKidney when made. Full- time employees are eligible to participate in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> plan. Under the 401(k) plan, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> employees may elect to reduce their current compensation by up to the statutorily prescribed annual limit and to have the amount of such reduction contributed to the 401(k) plan. The 401(k) plan permits ProKidney to make contributions up to the limits allowed by law on behalf of all eligible <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> employees. As of December&#160;31, 2021, ProKidney matched 50% of participating <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> employees&#8217; contribution up to 8% of salary to the ProKidney 401(k) plan. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">189 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Defined Contribution Plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">ProKidney maintains a defined contribution plan for its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> employees within the Cayman Islands as required by the National Pensions Act (2012 Revision). The plan is administered by an approved provider. All of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY&#8217;s</div> employees between the ages of 18 and 65 are eligible to participate in the plan, other than domestic helpers or employees who have been working in the Cayman Islands for a continuous period of less than 9 months. Under the plan, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> employees may contribute on earnings up to CI$87,000 (approximately US$107,000, above which level earnings are not pensionable), which contributions are matched by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY.</div> The basic contribution rate (and the maximum mandatory contribution for employees) is 5%, but <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> may choose to contribute in excess of this percentage and reduce the employee contribution commensurately. As of December&#160;31, 2021, ProKidney contributed 7% of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> employees salaries to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> defined contribution plan. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Board Compensation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In the year ended December&#160;31, 2021, no member of the Legacy GP Board received cash, equity or other compensation for service on the Legacy GP Board. In January 2022, Legacy GP and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> each entered into separate letter agreements with each of Mr.&#160;Doyle, Dr.&#160;Lotvin and Dr.&#160;Pereira (collectively, the &#8220;Director Agreements&#8221;) that provided for Mr.&#160;Doyle, Dr.&#160;Lotvin and Dr.&#160;Pereira to serve on the Legacy GP Board and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> Board, effective as of January&#160;15, 2022. The Director Agreements with Legacy GP provided that each of Mr.&#160;Doyle, Dr.&#160;Lotvin and Dr.&#160;Pereira would be paid, as compensation for their services as a member of the board of directors of Legacy GP, a $50,000 annual retainer (payable in arrears on a quarterly basis). The Director Agreements provided that PMEL would issue, subject to the terms of the Director Agreement and the Limited Liability Company Agreement of PMEL, 1,848,352 2022 Profits Interests in the aggregate to each such director, some of which were granted subject to vesting and some of which were purchased fully vested. In addition, on June 1, 2022, Mr.&#160;Maraganore was issued 200,000 Profits Interests. Dr.&#160;Bertram did not receive additional compensation for his services as a member of Legacy GP Board. Effective as of the Closing, Legacy GP resigned as the general partner of ProKidney LP, and each of the directors of Legacy GP has served on the GP Board. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney intends to develop a board of directors&#8217; compensation program that is designed to align compensation with ProKidney&#8217;s business objectives and the creation of shareholder value, while enabling ProKidney to attract, retain, incentivize and reward directors who contribute to the long-term success of ProKidney. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">ProKidney&#8217;s compensation committee will determine the annual compensation to be paid to the members of the Board. Directors&#8217; fees after the Business Combination have yet to be determined, but are expected to consist of two components: a cash payment and the issuance of equity or equity-based awards under the ProKidney Incentive Equity Plan. Pursuant to the Director Agreements with Legacy GP, it is anticipated that the following <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employee</div> directors &#8211; Alan M. Lotvin, M.D., Brian J.G. Pereria, M.D., William F. Doyle and John&#160;M.&#160;Maraganore, Ph.D. &#8211; will hold at least five times his annual retainer in the form of ProKidney equity within five years of the completion of the Business Combination. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Limitations on Liability and Indemnification Matters </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Charter provides that, subject to certain limitations, ProKidney shall indemnify its directors and officers, including former directors and officers (each an &#8220;indemnified person&#8221;) against any liability, action, proceeding, claim, demand, costs, damages or expenses, including legal expenses, whatsoever which they or any of them may incur as a result of any act or failure to act in carrying out their functions other than such liability (if any) that they may incur by reason of their own actual fraud, wilful neglect or wilful default. No person shall be found to have committed actual fraud, wilful neglect or wilful default under the Charter unless or until a court of competent jurisdiction shall have made a finding to that effect. The termination of any proceedings by any judgment, order, settlement, conviction or the entering of a <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">nolle prosequi </div></div>does not, by itself, create a presumption that the liability was incurred by reason of their own actual fraud, wilful neglect or wilful default. </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">190 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney entered into agreements with its officers and directors to provide contractual indemnification in addition to the indemnification provided for in the Charter. The Charter also permits ProKidney to purchase and maintain insurance on behalf of any officer or director of ProKidney against any liability which, by virtue of any rule of law, would otherwise attach to such person in respect of any negligence, default, breach of duty or breach of trust of which such person may be guilty in relation to ProKidney, whether or not ProKidney has or would have had the power to indemnify the person against the liability as provided in the Charter. ProKidney purchased a policy of directors&#8217; and officers&#8217; liability insurance that insures its officers and directors against the cost of defense, settlement or payment of a judgment in some circumstances and insures ProKidney against its obligations to indemnify its officers and directors. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These provisions may discourage shareholders from bringing a lawsuit against ProKidney&#8217;s directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against officers and directors, even though such an action, if successful, might otherwise benefit ProKidney and its shareholders. Furthermore, a shareholder&#8217;s investment may be adversely affected to the extent ProKidney pays the costs of settlement and damage awards against officers and directors pursuant to these indemnification provisions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We believe that these provisions, and the insurance and the indemnity agreements, are necessary to attract and retain talented and experienced officers and directors. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">191 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom373959_17" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">In this section, unless the context otherwise requires, references to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and the &#8220;Company&#8221; refer to ProKidney Corp. and its subsidiaries after the Closing;&#8220;ProKidney&#8221; refers to ProKidney LP and its subsidiaries prior to the Closing and to ProKidney Corp. following the Closing; and &#8220;SCS&#8221; refers to SCS prior to the Closing. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCS Related Party Transaction </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Founder Shares </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;2, 2021, the Sponsor paid $25,000 to cover certain offering and formation costs of SCS in consideration for which the Sponsor received 5,750,000 SCS Class&#160;B ordinary shares (the &#8220;Founder Shares&#8221;). On June&#160;29, 2021, SCS effected a share capitalization with respect to its SCS Class&#160;B ordinary shares of 575,000 shares thereof, resulting in the Sponsor holding an aggregate of 6,325,000 Founder Shares. The Founder Shares included an aggregate of up to 825,000 shares that were subject to forfeiture depending on the extent to which the underwriters&#8217; over-allotment option was exercised. As a result of the underwriters&#8217; election to partially exercise their over-allotment option, a total of 750,000 Founder Shares were no longer subject to forfeiture and 75,000 Founder Shares were forfeited, resulting in an aggregate of 6,250,000 Founder Shares then outstanding. In June 2021, the Sponsor transferred 30,000 Founder Shares to Marc Semigran, M.D., an independent director of SCS. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Sponsor and the SCS&#8217;s directors and officers agreed, subject to limited exceptions, not to transfer, assign or sell any of their Founder Shares until the earlier of: (A)&#160;one year after the completion of the Business Combination and (B)&#160;commencing at least 150 days after the Business Combination, the day on which the last reported sale price of the Class&#160;A ordinary shares has equaled or exceeded $12.00 per share (as adjusted for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">share&#160;sub-divisions,&#160;share</div> dividends, rights issuances, consolidations, reorganizations, recapitalizations and other similar transactions) for any 20 trading days within <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">any&#160;30-trading&#160;day</div> period. At the Closing, the Founder Shares became ProKidney Class&#160;A ordinary shares, and ProKidney, the Sponsor and certain Closing ProKidney Unitholders entered into new <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> agreements as described under &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Lock-Up</div> Agreements</div></div>.&#8221; </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Registration Rights </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCS, the Sponsor and certain other security holders entered into a registration rights agreement on June&#160;29, 2021 (the &#8220;SCS Registration Rights Agreement&#8221;). The SCS Registration Rights Agreement granted these holders certain demand and &#8220;piggy back&#8221; registration rights with SCS obligated to bear the expenses incurred in connection with the filing of any such registration statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">At the Closing, ProKidney entered into the Amended and Restated Registration Rights Agreement, which replaced the SCS Registration Rights Agreement. See &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Amended and Restated</div></div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Registration Rights Agreement</div></div>&#8221; below. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Subscription Agreements with SCS Related PIPE Investors </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrently with the execution of the Business Combination Agreement, SCS entered into Subscription Agreements with the certain sponsor-related PIPE Investors (&#8220;the Sponsor Related PIPE Investors&#8221;) pursuant to which the Sponsor Related PIPE Investors subscribed for SCS Class&#160;A ordinary shares. The Sponsor Related PIPE Investors funded $156,400,000 of the PIPE Investment, for which they will received 15,640,000 SCS Class&#160;A ordinary shares. Specifically, (i)&#160;SC Master Holdings, LLC, an entity affiliated with Mr.&#160;Chamath Palihapitiya, SCS&#8217;s Chief Executive Officer and Chairman of its board of directors, subscribed for 12,500,000 SCS Class&#160;A ordinary shares and (ii)&#160;Averill Master Fund, Ltd., an entity affiliated with Mr.&#160;Kishan Mehta, director and President of SCS&#8217;s, subscribed for 3,140,000 SCS Class&#160;A ordinary shares. The PIPE Investment was consummated concurrently with the Closing, and the SCS Class&#160;A ordinary shares purchased by the PIPE Investors became ProKidney Class&#160;A ordinary shares. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">192 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Administrative Services Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SCS entered into an agreement, pursuant to which it paid an affiliate of the Sponsor $10,000 per month, commencing on June&#160;30, 2021 and remaining in effect until the Closing, for office space, administrative and support services. For the period from February&#160;25, 2021 (inception) through the Closing, SCS paid $120,000 for these services. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">SCS Promissory Notes&#8212;Related Party </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On March&#160;2, 2021, SCS issued an unsecured promissory note to the Sponsor (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Pre-IPO</div> SCS Promissory Note&#8221;), pursuant to which SCS could borrow up to an aggregate principal amount of $300,000. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-IPO</div> SCS Promissory Note <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">was&#160;non-interest&#160;bearing</div> and payable on the earlier of December&#160;31, 2021 and the completion of the initial public offering. The outstanding balance under the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-IPO</div> SCS Promissory Note of $300,000 was repaid at the closing of the initial public offering on July&#160;2, 2021. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On April&#160;20, 2022, SCS issued the SCS Promissory Note to the Sponsor, pursuant to which SCS could borrow up to an aggregate principal amount of $1,500,000. The SCS Promissory Note was <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing, unsecured and payable upon the earlier of July&#160;2, 2023 and the Closing. The SCS Promissory Note was subject to customary events of default. On April&#160;26, 2022, SCS drew $250,000 under the SCS Promissory Note. At the Closing, SCS repaid the balance under the SCS Promissory Note. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney Related Party Transactions </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Consulting Services Agreement between <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> and Nefro Health </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On January&#160;1, 2020, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> (formerly known as inRegen) entered into a consulting services agreement with Nefro Health (&#8220;Nefro&#8221;), an Irish partnership controlled and majority-owned by Mr.&#160;Pablo Legorreta, a director of Legacy GP and a holder of over 5% of ProKidney Class&#160;A Units, pursuant to which Nefro provides consulting services for the research and development of ProKidney&#8217;s product candidates, including the conduct of clinical trials in North America and the European Union, the design and manufacturing of ProKidney&#8217;s product candidates as well as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-commercialization</div> activities, which are primarily performed by Mr.&#160;Pablo Legorreta. Under the agreement, Nefro receives $25,000 per quarter and is reimbursed for any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> expenses incurred in connection with activities Nefro conducted under the agreement. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> has paid Nefro an aggregate of $100,000 and $100,000, respectively, for the years ended December&#160;31, 2020 and December&#160;31, 2021. The initial term of the consulting services agreement continued through December&#160;31, 2020 and was renewed pursuant to the provision allowing for automatic renewals for additional periods of one year each unless terminated by either party by providing written notice to the other party at least ninety (90)&#160;days prior to the scheduled termination date. Either party may terminate this agreement upon the occurrence of a material breach by the other party in the performance of its obligations under the agreement or in respect of any provision, representation, warranty or covenant if such breach has not been cured within thirty (30)&#160;days after receiving written notice from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-breaching</div> party. Additionally, either of the parties may terminate the consulting services agreement for any reason upon giving thirty (30)&#160;days&#8217; advance notice of such termination to the other party. In the event of such termination, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> will be obligated to pay Nefro any earned but unpaid consulting fee as of the termination date. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Consulting Services Agreement between <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> and Nefro Health </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On January&#160;1, 2020, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> (formerly known as Twin City Bio, LLC) entered into a consulting services agreement with Nefro, pursuant to which Nefro provides consulting services for the research and development of ProKidney&#8217;s product candidates, including the conduct of clinical trials in North America and the European Union, the design and manufacturing of ProKidney&#8217;s product candidates as well as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-commercialization</div> activities, which are primarily performed by Mr.&#160;Pablo Legorreta, a director of Legacy </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">193 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">GP. Under the agreement, Nefro receives $25,000 per quarter and is reimbursed for any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">out-of-pocket</div></div> expenses incurred in connection with activities Nefro conducted under the agreement. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> has paid Nefro an aggregate of $100,000 and $100,000, respectively, for the years ended December&#160;31, 2020 and December&#160;31, 2021. The initial term of the consulting services agreement continued through December&#160;31, 2020 and was renewed pursuant to the provision allowing for automatic renewals for additional periods of one year each unless terminated by either party by providing written notice to the other party at least ninety (90)&#160;days prior to the scheduled termination date. Either party may terminate this agreement upon the occurrence of a material breach by the other party in the performance of its obligations under the agreement or in respect of any provision, representation, warranty or covenant if such breach has not been cured within thirty (30)&#160;days after receiving written notice from the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-breaching</div> party. Additionally, either of the parties may terminate the consulting services agreement for any reason upon giving thirty (30)&#160;days&#8217; advance notice of such termination to the other party. In the event of such termination, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> will be obligated to pay Nefro any earned but unpaid consulting fee as of the termination date. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contributions to ProKidney Bermuda and ProKidney by Pablo Legorreta and entities controlled by Pablo Legorreta </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Limited Liability Company Agreement of ProKidney Bermuda by and between ProKidney Bermuda and Mr.&#160;Pablo Legorreta, dated as of December&#160;12, 2018 (as amended, the &#8220;ProKidney Bermuda Agreement&#8221;), ProKidney Bermuda issued Mr.&#160;Pablo Legorreta 45,000,000 Class&#160;A Units (as defined in the ProKidney Bermuda Agreement) in exchange for a capital contribution of $45,000,000. Mr.&#160;Legorreta was admitted as the sole member of ProKidney Bermuda. The ProKidney Bermuda Agreement was amended and restated on December&#160;31, 2018 to admit an additional member that contributed to ProKidney Bermuda an aggregate of $30,000,000 as consideration for 30,000,000 Class&#160;A Units of ProKidney Bermuda. On or around October&#160;23, 2019, ProKidney Bermuda issued additional Class&#160;A Units to its members, including Mr.&#160;Legorreta, in accordance with the terms and conditions of the ProKidney Bermuda Agreement, in exchange for an aggregate of $20,000,000 in capital contributions (the &#8220;2019 Contribution&#8221;). Mr.&#160;Legorreta made a capital contribution of $12,000,000 to ProKidney Bermuda in exchange for 12,000,000 Class&#160;A Units in the 2019 Contribution. Given the effect of the 2019 Contribution, Mr.&#160;Legorreta held an aggregate of 57,000,000 Class&#160;A Units of ProKidney Bermuda. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Effective as of January&#160;1, 2020, Mr.&#160;Legorreta transferred 100% of his equity interests in ProKidney Bermuda to Nefro pursuant to a certain contribution, assignment and assumption agreement by and between Mr.&#160;Legorreta and Nefro, and in accordance with the terms of the ProKidney Bermuda Agreement. As a result, Mr.&#160;Legorreta ceased to be a member of ProKidney Bermuda, and Nefro became a substituted member of ProKidney Bermuda. On or around August&#160;12, 2020, ProKidney Bermuda issued additional Class&#160;A Units to its members, including Nefro, in accordance with the terms and conditions of the ProKidney Bermuda Agreement, in exchange for an aggregate of $20,000,000 in capital contributions (the &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">2020 Contribution</div></div>&#8221;). Nefro made a capital contribution of $15,000,000 to ProKidney Bermuda in exchange for 15,000,000 Class&#160;A Units in the 2020 Contribution. As a result of the 2020 Contribution, Nefro held an aggregate of 72,000,000 Class&#160;A Units of ProKidney Bermuda. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective as of February&#160;1, 2021, Nefro transferred 100% of its equity interests in ProKidney Bermuda to Tolerantia, a Delaware limited liability company and a wholly owned subsidiary of Nefro, pursuant to a certain contribution, assignment and assumption agreement by and between Mr.&#160;Legorreta and Nefro, dated as of Febraury 1, 2020, and in accordance with the terms of the ProKidney Bermuda Agreement. As a result, Nefro ceased to be a member of ProKidney Bermuda, and Tolerantia became a substituted member of ProKidney Bermuda. Between February 2021 and May 2021, ProKidney Bermuda issued additional Class&#160;A Units to its members, including Tolerantia, in accordance with the terms and conditions of the ProKidney Bermuda Agreement, in exchange for an aggregate of $30,000,000 in capital contributions (the &#8220;First 2021 Contribution&#8221;). Tolerantia made a capital contribution in an aggregate amount of $15,000,000 to ProKidney Bermuda in exchange for 15,000,000 Class&#160;A Units in the First 2021 Contribution. Given the effect of the First 2021 </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">194 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Contribution, Tolerantia held an aggregate of 87,000,000 Class&#160;A Units of ProKidney Bermuda. On June&#160;29, 2021, ProKidney Bermuda issued additional Class&#160;A Units to its members, including Tolerantia, in accordance with the terms and conditions of the ProKidney Bermuda Agreement, in exchange for an aggregate of $11,500,000 in capital contributions (the &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Second 2021 Contribution</div></div>&#8221;). Tolerantia made a capital contribution of $6,900,000 to ProKidney Bermuda in exchange for 6,900,000 Class&#160;A Units in the Second 2021 Contribution. Given the effect of the Second 2021 Contribution, Tolerantia held an aggregate of 93,900,000 Class&#160;A Units of ProKidney Bermuda. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On August&#160;5, 2021, ProKidney was formed as a limited partnership under the laws of Ireland. The members of ProKidney Bermuda, including Tolerantia, contributed all of their holdings in ProKidney Bermuda as a contribution <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in specie </div></div>to ProKidney. As a result, ProKidney Bermuda became a wholly owned subsidiary of ProKidney and Tolerantia became one of the partners of ProKidney, holding an aggregate of 93,900,000 Legacy Class&#160;A Units. On October&#160;15, 2021, ProKidney issued additional Legacy Class&#160;A Units to its partners, including Tolerantia, in accordance with the terms and conditions of the ProKidney Limited Partnership Agreement, in exchange for an aggregate contribution of $30,000,000 (the &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Third 2021 Contribution</div></div>&#8221;). Tolerantia, as one of the partners of ProKidney, made a contribution of $18,000,000 to ProKidney in exchange for 18,000,000 Legacy Class&#160;A Units pursuant to the ProKidney Limited Partnership Agreement. Given the effect of the Third 2021 Contribution, Tolerantia held an aggregate of 111,900,000 Class&#160;A Units of ProKidney. At the Closing, the ProKidney Class&#160;A Units held by Tolerantia were recapitalized into Post-Combination ProKidney Common Units and ProKidney Class&#160;B ordinary shares pursuant to the terms of the Business Combination Agreement. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Contributions to ProKidney Bermuda and ProKidney by CEC and entities controlled by CEC </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On December&#160;12, 2018, ProKidney Bermuda entered into the ProKidney Bermuda Agreement with Mr.&#160;Pablo Legorreta, which was amended and restated on December&#160;31, 2018 to admit Inversora Carso, S.A. de C.V., a Mexican corporation (&#8220;INCA&#8221;), as an additional member. INCA contributed to ProKidney Bermuda an aggregate of $30,000,000 as consideration for 30,000,000 Class&#160;A Units of ProKidney Bermuda. In the 2019 Contribution, INCA made an additional capital contribution of $8,000,000 to ProKidney Bermuda in exchange for 8,000,000 Class&#160;A Units. Given the effect of the 2019 Contribution, INCA held an aggregate of 38,000,000 Class&#160;A Units of ProKidney Bermuda. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;30, 2020, INCA merged with and into CEC, with CEC surviving the merger. In accordance with the terms of the ProKidney Bermuda Agreement, INCA ceased to be a member of ProKidney Bermuda and CEC became a substituted member of ProKidney Bermuda. In the 2020 Contribution, CEC made another capital contribution of $5,000,000 to ProKidney Bermuda in exchange for 5,000,000 Class&#160;A Units. As a result of the 2020 Contribution, CEC held an aggregate of 43,000,000 Class&#160;A Units of ProKidney Bermuda. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the First 2021 Contribution, CEC made a capital contribution in an aggregate amount of $15,000,000 to ProKidney Bermuda in exchange for 15,000,000 Class&#160;A Units. Given the effect of the First 2021 Contribution, CEC held an aggregate of 58,000,000 Class&#160;A Units of ProKidney Bermuda. In the Second 2021 Contribution, CEC made a capital contribution of $4,600,000 to ProKidney Bermuda in exchange for 4,600,000 Class&#160;A Units. Given the effect of the Second 2021 Contribution, CEC held an aggregate of 62,600,000 Class&#160;A Units of ProKidney Bermuda. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On August&#160;5, 2021, ProKidney was formed as a limited partnership under the laws of Ireland. The members of ProKidney Bermuda, including CEC, contributed all of their holdings in ProKidney Bermuda as a contribution <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">in specie </div></div>to ProKidney. As a result, ProKidney Bermuda became a wholly owned subsidiary of ProKidney, and CEC became one of the partners of ProKidney, holding an aggregate of 62,600,000 Legacy Class&#160;A Units. In the Third 2021 Contribution, CEC, as one of the partners of ProKidney, made a capital contribution of $12,000,000 to ProKidney in exchange for 12,000,000 Legacy Class&#160;A Units pursuant to the ProKidney Limited Partnership Agreement. Given the effect of the Third 2021 Contribution, CEC held an aggregate of 74,600,000 Class&#160;A Units </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">195 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of ProKidney. At the Closing, the ProKidney Class&#160;A Units held by CEC were recapitalized into Post-Combination ProKidney Common Units and ProKidney Class&#160;B ordinary shares pursuant to the terms of the Business Combination Agreement. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Promissory Notes with Tolerantia and CEC </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;18, 2022, in connection with the Business Combination Agreement, ProKidney entered into promissory note agreements with (a)&#160;Tolerantia, pursuant to which ProKidney may borrow up to an aggregate principal amount of $60,000,000, and (b)&#160;CEC, pursuant to which ProKidney may borrow up to an aggregate principal amount of $40,000,000 (collectively, the &#8220;ProKidney Promissory Notes&#8221;). The ProKidney Promissory Notes bear interest at a rate of 3% per annum and are payable on the earlier of the Closing Date and January&#160;17, 2023. Pursuant to the ProKidney Promissory Notes, on March&#160;24, 2022, ProKidney submitted a drawdown request to each of Tolerantia and CEC for $12,000,000 and $8,000,000, respectively, and on March&#160;25, 2022, each of Tolerantia and CEC delivered the requested amount to ProKidney. In June 2022, ProKidney submitted a drawdown request to each of Tolerantia and CEC for $9,000,000 and $6,000,000, respectively, and each of Tolerantia and CEC delivered the requested amounts to ProKidney. At the Closing, ProKidney repaid the amounts outstanding under the ProKidney Promissory Notes. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Subscription Agreements with ProKidney Related PIPE Investors </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrently with the execution of the Business Combination Agreement, ProKidney entered into Subscription Agreements with the ProKidney Related PIPE Investors, pursuant to which the ProKidney Related PIPE Investors have subscribed for SCS Class&#160;A ordinary shares. The ProKidney Related PIPE Investors funded $50,000,000 of the PIPE Investment, for which they received 5,000,000 Post-Combination ProKidney Common Units in lieu of SCS Class&#160;A ordinary shares. Specifically, (i)&#160;Tolerantia, a member of ProKidney affiliated with Mr.&#160;Pablo Legorreta, subscribed for 3,000,000 SCS Class&#160;A ordinary shares and elected to purchase 3,000,000 Post-Combination ProKidney Common Units in lieu thereof, and (ii)&#160;CEC, an entity affiliated with Mr.&#160;Carlos Slim, subscribed for 2,000,000 SCS Class&#160;A ordinary shares and elected purchase 2,000,000 Post-Combination ProKidney Common Units in lieu thereof. The PIPE Investment was consummated substantially concurrently with the Closing. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">V</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">oting Agreement by CEC</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On February&#160;14, 2022, CEC executed the Voting Agreement, pursuant to which CEC agreed, (1)&#160;subject to the constitution of Legacy GP, from February&#160;14, 2022 until the Closing, to vote all of its voting shares in the capital of Legacy GP to exercise its rights of nomination and approval under the constitution of Legacy GP as directed by Tolerantia, solely with respect to (a)&#160;the appointment of any director to Legacy GP Board; and (b)&#160;the removal of any director from the Legacy GP Board; and (2)&#160;subject to the organizational documents of ProKidney, from the Closing until the third anniversary of the Closing, to vote all of its voting shares in the capital of ProKidney in a manner proportionate to the manner in which all other ProKidney Class&#160;B ordinary shares not held by CEC are voted, solely with respect to (a)&#160;the election of any director to the Board at any meeting of shareholders at which directors are to be elected; (b)&#160;the appointment of any director to fill any vacancy created by the failure of any director to complete a term on the Board; and (c)&#160;any removal of a director from the Board. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Tax Receivable Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the Closing, ProKidney entered into the Tax Receivable Agreement, pursuant to which, among other things, ProKidney is required to pay the Closing ProKidney Unitholders party thereto 85% of certain tax savings recognized by ProKidney, as a result of the increases in tax basis attributable to exchanges by the Closing ProKidney Unitholders of Post-Combination ProKidney Common Units for ProKidney Class&#160;A ordinary shares or, subject to certain restrictions, cash, pursuant to the Exchange Agreement and certain other tax attributes of ProKidney and tax benefits related to entering into the Tax Receivable Agreement. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">196 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Exchange Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">At the Closing, ProKidney entered into the Exchange Agreement with certain Closing ProKidney Unitholders pursuant to which, subject to the procedures and restrictions therein, from and after the waiver or expiration of any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">contractual&#160;lock-up&#160;period</div> (including pursuant to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;Lock-Up&#160;Agreements,</div> described below), the holders of Post-Combination ProKidney Common Units (or certain permitted transferees thereof) acquired the right from time to time at and after 180 days following the Closing to exchange their Post-Combination ProKidney Common Units and an equal number of ProKidney Class&#160;B ordinary shares (referred to herein as &#8220;Paired Interests&#8221;) on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">a&#160;one-for-one&#160;basis</div></div> for ProKidney Class&#160;A ordinary shares (the &#8220;Exchange&#8221;); provided, that, subject to certain exceptions, ProKidney, at its sole election, subject to certain restrictions, may, other than in the case of certain secondary offerings, instead settle all or a portion of the Exchange in cash based on a volume weighted average price of a ProKidney Class&#160;A ordinary share. The Exchange Agreement provides that, as a general matter, a holder of Post-Combination ProKidney Common Units do not have the right to exchange Post-Combination ProKidney Common Units if ProKidney determines that such exchange would be prohibited by law or regulation or would violate other agreements with ProKidney and its subsidiaries to which the holder of Post-Combination ProKidney Common Units may be subject, including the Second Amended and Restated ProKidney Limited Partnership Agreement and the Exchange Agreement. Additionally, the Exchange Agreement contains restrictions on redemptions and exchanges intended to prevent ProKidney from being treated as a &#8220;publicly traded partnership&#8221; for U.S. federal income tax purposes. These restrictions are modeled on certain safe harbors provided for under applicable U.S. federal income tax law. ProKidney may impose additional restrictions on exchanges that it determines to be necessary or advisable so that ProKidney is not treated as a &#8220;publicly traded partnership&#8221; for U.S. federal income tax purposes. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Amended and Restated Registration Rights Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the Closing, ProKidney entered into the Amended and Restated Registration Rights Agreement with the Sponsor and certain Closing ProKidney Unitholders. The Amended and Restated Registration Rights Agreement replaced the SCS Registration Rights Agreement. Under the Amended and Restated Registration Rights Agreement, Class&#160;A ordinary shares held by the Holders party thereto (as well as their permitted transferees) and by parties to the Exchange Agreement are entitled to registration rights. The Amended and Restated Registration Rights Agreement provides for ProKidney to, within 30 days after the Closing Date, submit or file with the SEC a shelf registration statement registering the resale of the ProKidney ordinary shares held by the Holders and use its commercially reasonable efforts to have such registration statement declared effective as soon as practicable after the submission or filing thereof, but in no event later than (a)&#160;90 days following the submission or filing deadline, if the SEC notifies ProKidney that it will &#8220;review&#8221; the Registration Statement and (b)&#160;the tenth (10th) business day after the date ProKidney is notified (orally or in writing, whichever is earlier) by the SEC that the registration statement will not be &#8220;reviewed&#8221; or will not be subject to further review. In addition, the Holders have certain &#8220;piggy-back&#8221; registration rights. ProKidney will bear the expenses incurred in connection with the filing of any registration statements filed pursuant to the terms of the Amended and Restated Registration Rights Agreement. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Lock-Up&#160;Agreement</div> </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">At the closing of the Business Combination, ProKidney, the Sponsor and certain Closing ProKidney Unitholders entered into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> agreements (collectively referred to herein as the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Lock-Up&#160;Agreement&#8221;).</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">The&#160;Lock-Up&#160;Agreement</div> contains certain restrictions on transfer with respect to the Sponsor and the ProKidney Unitholders party thereto. Such restrictions begin at the Closing and end on the earlier of (i)&#160;the date that is 180 days after the Closing and (ii)(a) for 33% of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;Lock-Up&#160;Shares</div> (other than the Earnout Shares and the Private Placement Shares)(as each such term is defined in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Lock-Up</div> Agreement), the date on which the last reported sale price of a ProKidney Class&#160;A ordinary share equals or exceeds $12.50 per share for any 20 trading days within <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">any&#160;30-trading&#160;day</div> period commencing at least 30 days after the Closing and (b)&#160;for an additional 50% of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;Lock-Up&#160;Shares</div> (other than the Earnout Shares and the Private Placement Shares), the date on which the last </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">197 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">reported sale price of a ProKidney Class&#160;A ordinary share equals or exceeds $15.00 per share for any 20 trading days within <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">any&#160;30-trading&#160;day</div> period commencing at least 30 days after the Closing. Notwithstanding the above, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(i)&#160;the&#160;lock-up&#160;period</div> for any Earnout Shares will expire not earlier than 180 days after such Earnout Shares are issued; (ii) 50% of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">the&#160;Lock-Up&#160;Shares</div> held by certain Closing ProKidney Unitholders and their affiliates will remain locked up until the earlier of four years following the Closing and the date that ProKidney receives notice of any regulatory market authorization, including full or conditional authorization, to market REACT (but, in any event, not earlier than 180 days following the Closing or (in the case of Earnout Shares) the date of issuance); and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(iii)&#160;the&#160;lock-up&#160;period</div> for the Private Placement Shares will expire 30 days after the Closing. The restrictions on transfer set forth in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Lock-Up</div> Agreement are subject to customary exceptions. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Executive Officer and Director Compensation Arrangements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Please see the section entitled &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Executive Compensation</div></div>&#8221; for information regarding compensation arrangements with the executive officers and directors of ProKidney, which include, among other things, employment, termination of employment and change in control arrangements, equity awards and certain other benefits. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Indemnification Agreements with Officers and Directors and Directors&#8217; and Officers&#8217; Liability Insurance </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Second Amended and Restated ProKidney Limited Partnership Agreement provides for indemnification for, among others, its partners and its partners&#8217; directors, officers and employees to the fullest extent permitted by applicable law. In connection with this Business Combination, ProKidney entered into indemnification agreements with each of ProKidney&#8217;s executive officers and directors. The indemnification agreements and Charter require that ProKidney indemnify its directors to the fullest extent not prohibited by Cayman Islands law. ProKidney also maintains a general liability insurance policy, which covers certain liabilities of its directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Policies and Procedures for Related Person Transactions </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Upon consummation of the Business Combination, ProKidney adopted a written related person transaction policy that sets forth the following policies and procedures for the review and approval or ratification of related person transactions. A &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Person Transaction</div></div>&#8221; is a transaction, arrangement or relationship in which ProKidney or any of its subsidiaries was, is or will be a participant, the amount of which involved exceeds the lesser of $120,000 per year or 1% of the average of ProKidney&#8217;s total assets for the last two completed fiscal years, and in which any Related Person had, has or will have a direct or indirect material interest. A &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Person</div></div>&#8221; means: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any person who is, or at any time during the applicable period was, one of ProKidney&#8217;s officers or one of ProKidney&#8217;s directors; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">any person who is known by ProKidney to be the beneficial owner of more than five percent (5%) of its voting shares; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">any immediate family member of any of the foregoing persons, which means any child, stepchild, parent, stepparent, spouse, sibling, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mother-in-law,</div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">father-in-law,</div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">daughter-in-law,</div></div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">brother-in-law</div></div> or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sister-in-law</div></div> of a director, executive officer or a beneficial owner of more than five percent (5%) of its voting shares, and any person (other than a tenant or employee) sharing the household of such director, executive officer or beneficial owner of more than five percent (5%) of its voting shares. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney has policies and procedures designed to minimize potential conflicts of interest arising from any dealings it may have with its affiliates and to provide appropriate procedures for the disclosure of any real or potential conflicts of interest that may exist from time to time. Specifically, pursuant to its charter, the audit committee has the responsibility to review related party transactions. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">198 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom373959_18" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">CERTAIN MATERIAL U.S. AND <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NON-U.S.</div> INCOME TAX CONSIDERATIONS<div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">8</div> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following is a discussion of certain material U.S. federal income tax consequences of the acquisition, ownership and disposition of shares of Class&#160;A ordinary shares. This discussion is limited to certain U.S. federal income tax considerations to beneficial owners of the Class&#160;A ordinary shares who are initial purchasers of such ordinary shares pursuant to this offering and hold the Class&#160;A ordinary shares as a capital asset within the meaning of Section&#160;1221 of the Code. This discussion assumes that any distributions made by ProKidney on the Class&#160;A ordinary shares and any consideration received by a holder in consideration for the sale or other disposition of the Class&#160;A ordinary shares will be in U.S. dollars. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This summary is based upon U.S. federal income tax laws as of the date of this prospectus, which is subject to change or differing interpretations, possibly with retroactive effect. This discussion is a summary only and does not describe all of the tax consequences that may be relevant to you in light of your particular circumstances, including but not limited to the alternative minimum tax, the Medicare tax on certain net investment income and the different consequences that may apply if you are subject to special rules that apply to certain types of investors, including but not limited to: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">financial institutions or financial services entities; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">broker-dealers; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">governments or agencies or instrumentalities thereof; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">regulated investment companies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">real estate investment trusts; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expatriates or former long-term residents of the United States; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">persons that actually or constructively own five percent or more (by vote or value) of our shares; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">persons that acquired our Class&#160;A ordinary shares pursuant to an exercise of employee share options, in connection with employee share incentive plans or otherwise as compensation; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">insurance companies; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">dealers or traders subject to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-to-market</div></div> method of accounting with respect to our Class&#160;A ordinary shares; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">persons holding our Class&#160;A ordinary shares as part of a &#8220;straddle,&#8221; constructive sale, hedge, conversion or other integrated or similar transaction; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Holders (as defined below) whose functional currency is not the U.S. dollar; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">partnerships (or entities or arrangements classified as partnerships or other pass-through entities for U.S. federal income tax purposes) and any beneficial owners of such partnerships; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">tax-exempt</div> entities; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">controlled foreign corporations; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">passive foreign investment companies. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If a partnership (including an entity or arrangement treated as a partnership or other pass-thru entity for U.S. federal income tax purposes) holds our Class&#160;A ordinary shares, the tax treatment of a partner, member or other beneficial owner in such partnership will generally depend upon the status of the partner, member or other beneficial owner, the activities of the partnership and certain determinations made at the partner, member or other beneficial owner level. If you are a partner, member or other beneficial owner of a partnership holding our Class&#160;A ordinary shares you are urged to consult your tax advisor regarding the tax consequences of the acquisition, ownership and disposition of our Class&#160;A ordinary shares. </div></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;"><div style="font-size: 75%; vertical-align: top;;display:inline;;font-size:8.3px">8</div>&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">NTD: <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-U.S.</div> tax disclosures to be provided by local counsel. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">199 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">This discussion is based on the Code, and administrative pronouncements, judicial decisions and final, temporary and proposed Treasury regulations as of the date hereof, which are subject to change, possibly on a retroactive basis, and changes to any of which subsequent to the date of this prospectus may affect the tax consequences described herein. This discussion does not address any aspect of state, local or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> taxation, or any U.S. federal taxes other than income taxes (such as gift and estate taxes). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have not sought, and do not expect to seek, a ruling from the U.S. Internal Revenue Service (the &#8220;IRS&#8221;) as to any U.S. federal income tax consequence described herein. The IRS may disagree with the discussion herein, and its determination may be upheld by a court. Moreover, there can be no assurance that future legislation, regulations, administrative rulings or court decisions will not adversely affect the accuracy of the statements in this discussion. You are urged to consult your tax advisor with respect to the application of U.S. federal tax laws to your particular situation, as well as any tax consequences arising under the laws of any state, local or foreign jurisdiction. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">THIS DISCUSSION IS ONLY A SUMMARY OF CERTAIN U.S. FEDERAL INCOME TAX CONSIDERATIONS ASSOCIATED WITH THE ACQUISITION, OWNERSHIP AND DISPOSITION OF OUR CLASS A ORDINARY SHARES. EACH PROSPECTIVE INVESTOR IN OUR CLASS A ORDINARY SHARES IS URGED TO CONSULT ITS OWN TAX ADVISOR WITH RESPECT TO THE PARTICULAR TAX CONSEQUENCES TO SUCH INVESTOR OF THE ACQUISITION, OWNERSHIP AND DISPOSITION OF OUR CLASS A ORDINARY SHARES, INCLUDING THE APPLICABILITY AND EFFECT OF ANY U.S. FEDERAL <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NON-INCOME,</div> STATE, LOCAL, AND <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NON-U.S.</div> TAX LAWS. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">U.S. Holders </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This section applies to you if you are a &#8220;U.S. Holder.&#8221; A U.S. Holder is a beneficial owner of our Class&#160;A ordinary shares who or that is, for U.S. federal income tax purposes: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">an individual who is a citizen or resident of the United States; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a corporation (or other entity taxable as a corporation) organized in or under the laws of the United States, any state thereof or the District of Columbia; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">an estate the income of which is includible in gross income for U.S. federal income tax purposes regardless of its source; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 10%;">&#160;</td>
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">a trust, if (i)&#160;a court within the United States is able to exercise primary supervision over the administration of the trust and one or more United States persons (as defined in the Code) have authority to control all substantial decisions of the trust or (ii)&#160;it has a valid election in effect under Treasury Regulations to be treated as a United States person. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">You should consult your own tax advisors about the consequences of the acquisition, ownership and disposition of the Class&#160;A ordinary shares, including the relevance to your particular situation of the considerations discussed below and any consequences arising under <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.,</div> state, local or other tax laws. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Taxation of Distributions </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Subject to the discussion below under &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">PFIC Considerations</div></div>,&#8221; if we pay distributions in cash or other property (other than certain distributions of our shares or rights to acquire our shares) to U.S. Holders of shares of our Class&#160;A ordinary shares, such distributions generally will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles, which will generally be includible in your taxable income as ordinary dividend income on the day on which you receive the dividend and will not be eligible for the dividends-received deduction allowed to U.S. corporations under the Code. Distributions in excess of current and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce (but not below zero) the U.S. Holder&#8217;s adjusted tax basis in our Class&#160;A ordinary shares. Any remaining excess will be treated as gain </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">200 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">realized on the sale or other disposition of the Class&#160;A ordinary shares. Because we believe it is likely that ProKidney will be a PFIC for its current taxable year (as discussed below under &#8220;&#8212;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">PFIC Considerations&#8212;PFIC Status of ProKidney</div></div>&#8221;) dividends ProKidney pays to a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-corporate</div> U.S. Holder generally will not constitute &#8220;qualified dividends&#8221; that would be taxable at a reduced rate. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Class&#160;A Ordinary Shares </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Subject to the discussion below under &#8220;<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">PFIC Considerations</div></div>,&#8221; upon a sale or other taxable disposition of our Class&#160;A ordinary shares, a U.S. Holder generally will recognize capital gain or loss in an amount equal to the difference between the amount realized and the U.S. Holder&#8217;s adjusted tax basis in the Class&#160;A ordinary shares. Any such capital gain or loss generally will be long-term capital gain or loss if the U.S. Holder&#8217;s holding period for the Class&#160;A ordinary shares so disposed of exceeds one year. Long-term capital gains recognized by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-corporate</div> U.S. Holders may be eligible to be taxed at reduced rates. The deductibility of capital losses is subject to limitations. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Generally, the amount of gain or loss recognized by a U.S. Holder is an amount equal to the difference between (i)&#160;the sum of the amount of cash and the fair market value of any property received in such disposition and (ii)&#160;the U.S. Holder&#8217;s adjusted tax basis in its ordinary shares so disposed of. A U.S. Holder&#8217;s adjusted tax basis in its ordinary shares generally will equal the U.S. Holder&#8217;s acquisition cost less any prior distributions treated as a return of capital. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">PFIC Considerations </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Definition of a PFIC </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">A foreign (i.e., <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.)</div> corporation will be classified as a PFIC for U.S. federal income tax purposes if either (i)&#160;at least 75% of its gross income in a taxable year, including its pro rata share of the gross income of any corporation in which it is considered to own at least 25% of the shares by value, is passive income or (ii)&#160;at least 50% of its assets in a taxable year (generally determined based on fair market value and averaged quarterly over the year), including its pro rata share of the assets of any corporation in which it is considered to own at least 25% of the shares by value, are held for the production of, or produce, passive income. Passive income generally includes dividends, interest, rents and royalties (other than rents or royalties derived from the active conduct of a trade or business) and gains from the disposition of passive assets. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">PFIC Status of ProKidney </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Based upon the composition of its income and assets, and upon a review of its financial statements, ProKidney believes that it likely was a PFIC for its most recent taxable year ended on December&#160;31, 2021 and will likely be considered a PFIC for its current taxable year. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In the event that we are classified as a PFIC in any year during which a U.S. Holder holds our Class&#160;A ordinary shares and the U.S. Holder has not timely made (a)&#160;a QEF Election (as defined below) for the first taxable year in which the U.S. Holder owned such Class&#160;A ordinary shares or in which ProKidney was a PFIC, whichever is later (or a QEF Election along with a purging election), or (b)&#160;a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-to-market</div></div> election (as defined below) with respect to such Class&#160;A ordinary shares, then the tax on any gain recognized by such U.S. Holder would be imposed based on a complex set of computational rules designed to offset the tax deferral with respect to the undistributed earnings of ProKidney. Under these rules: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the U.S. Holder&#8217;s gain will be allocated ratably over the U.S. Holder&#8217;s holding period for such U.S. Holder&#8217;s Class&#160;A ordinary shares; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the amount of gain allocated to the U.S. Holder&#8217;s taxable year in which the U.S. Holder recognized the gain, or to the period in the U.S. Holder&#8217;s holding period before the first day of the first taxable year in which ProKidney was a PFIC, will be taxed as ordinary income; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">201 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the amount of gain allocated to other taxable years (or portions thereof) of the U.S. Holder and included in such U.S. Holder&#8217;s holding period would be taxed at the highest tax rate in effect for that year and applicable to the U.S. Holder; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">an additional tax equal to the interest charge generally applicable to underpayments of tax will be imposed on the U.S. Holder in respect of the tax attributable to each such other taxable year of such U.S. Holder. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ALL U.S. HOLDERS ARE URGED TO CONSULT THEIR TAX ADVISORS REGARDING THE EFFECTS OF THE PFIC RULES ON THE EXERCISE OF REDEMPTION RIGHTS. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">QEF Election and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Mark-to-Market</div></div> Election </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The impact of the PFIC rules on a U.S. Holder of Class&#160;A ordinary shares will depend on whether the U.S. Holder has made a timely and effective election to treat ProKidney as a &#8220;qualified electing fund&#8221; under Section&#160;1295 of the Code for the taxable year that is the first year in the U.S. Holder&#8217;s holding period of Class&#160;A ordinary shares during which ProKidney qualified as a PFIC (a &#8220;QEF Election&#8221;) or, if in a later taxable year, the U.S. Holder made a QEF Election along with a purging election. A purging election creates a deemed sale of the U.S. Holder&#8217;s Class&#160;A ordinary shares at their then fair market value and requires the U.S. Holder to recognize gain pursuant to the purging election subject to the special PFIC tax and interest charge rules described above. As a result of any such purging election, the U.S. Holder would have a new basis and holding period in its Class&#160;A ordinary shares. U.S. Holders are urged to consult their tax advisors as to the application of the rules governing purging elections to their particular circumstances. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">A U.S. Holder&#8217;s ability to make a QEF Election (or a QEF Election along with a purging election) with respect to ProKidney is contingent upon, among other things, the provision by ProKidney of a &#8220;PFIC Annual Information Statement&#8221; (within the meaning of the applicable Treasury Regulations) to such U.S. Holder. ProKidney provided PFIC Annual Information Statements to U.S. Holders of ProKidney Class&#160;A ordinary shares, upon request, with respect to its taxable year that ended on December&#160;31, 2021 and will endeavor to continue to provide to a U.S. Holder such information upon request. There is no assurance, however, that ProKidney will continue to timely provide such information. A U.S. Holder that made a QEF Election (or a QEF Election along with a purging election) may be referred to as an &#8220;Electing Shareholder&#8221; and a U.S. Holder that did not make a QEF Election may be referred to as a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Non-Electing</div> Shareholder.&#8221; </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The impact of the PFIC rules on a U.S. Holder of Class&#160;A ordinary shares may also depend on whether the U.S. Holder has made an election under Section&#160;1296 of the Code. U.S. Holders who hold (actually or constructively) stock of a foreign corporation that is classified as a PFIC may annually elect to mark such stock to its market value if such stock is &#8220;marketable stock&#8221; (within the meaning of the applicable Treasury Regulations), generally, stock that is regularly traded on a national securities exchange that is registered with the SEC, including Nasdaq, or on a foreign exchange or market that the IRS determines has rules sufficient to ensure that the market price represents a legitimate and sound fair market value (a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;mark-to-market</div></div> election&#8221;). No assurance can be given that the Class&#160;A ordinary shares are considered to be marketable stock for purposes of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-to-market</div></div> election or whether the other requirements of this election are satisfied. If such an election is available and has been made, such U.S. Holders will generally not be subject to the special taxation rules discussed herein. U.S. Holders are urged to consult their tax advisors regarding the availability and tax consequences of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">mark-to-market</div></div> election with respect to Class&#160;A ordinary shares under their particular circumstances. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">THE RULES DEALING WITH PFICS ARE VERY COMPLEX AND ARE IMPACTED BY VARIOUS FACTORS IN ADDITION TO THOSE DESCRIBED ABOVE. ALL U.S. HOLDERS ARE URGED TO CONSULT THEIR TAX ADVISORS REGARDING THE CONSEQUENCES TO THEM OF THE PFIC RULES, INCLUDING, WITHOUT LIMITATION, WHETHER A QEF ELECTION (OR A QEF ELECTION ALONG WITH A PURGING ELECTION), A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">MARK-TO-MARKET</div></div> ELECTION OR ANY OTHER ELECTION IS AVAILABLE. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">202 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Foreign Financial Asset Reporting </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Certain U.S. Holders who are individuals that own &#8220;specified foreign financial assets&#8221; with an aggregate value in excess of $50,000 are generally required to file an information statement along with their tax returns, currently on IRS Form 8938, with respect to such assets. &#8220;Specified foreign financial assets&#8221; include any financial accounts held at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> financial institution, as well as securities issued by a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-U.S.</div> issuer (which would include the Class&#160;A ordinary shares) that are not held in accounts maintained by financial institutions. Higher reporting thresholds apply to certain individuals living abroad and to certain married individuals. Regulations extend this reporting requirement to certain entities that are treated as formed or availed of to hold direct or indirect interests in specified foreign financial assets based on certain objective criteria. U.S. Holders that fail to report the required information could be subject to substantial penalties. In addition, the statute of limitations for assessment of tax would be suspended, in whole or part. Prospective investors should consult their own tax advisors concerning the application of these rules to their investment in the Class&#160;A ordinary shares, including the application of the rules to their particular circumstances. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Information Reporting Requirements and Backup Withholding </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information returns will be filed with the IRS in connection with payments of dividends on and the proceeds from a sale or other disposition of Class&#160;A ordinary shares and backup withholding may also apply. Backup withholding will not apply, however, to a U.S. Holder who furnishes a correct taxpayer identification number and makes other required certifications, or who is otherwise exempt from backup withholding and establishes such exempt status. Backup withholding is not an additional tax. The amount of any backup withholding from a payment to a U.S. Holder will generally be allowed as a credit against such U.S. Holder&#8217;s U.S. federal income tax liability and may entitle such U.S. Holder to a refund, provided that the required information is furnished by such U.S. Holder to the IRS in a timely manner. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;">EACH PROSPECTIVE INVESTOR IN OUR CLASS A ORDINARY SHARES IS URGED TO CONSULT ITS OWN TAX ADVISOR WITH RESPECT TO THE PARTICULAR TAX CONSEQUENCES TO SUCH INVESTOR OF THE ACQUISITION, OWNERSHIP AND DISPOSITION OF OUR CLASS A ORDINARY SHARES, INCLUDING THE APPLICABILITY AND EFFECT OF ANY U.S. FEDERAL <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NON-INCOME,</div> STATE, LOCAL, AND <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">NON-U.S.</div> TAX LAWS. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cayman Islands Tax Considerations </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following is a discussion on certain Cayman Islands income tax consequences of an investment in the securities of the Company. The discussion is a general summary of present law, which is subject to prospective and retroactive change. It is not intended as tax advice, does not consider any investor&#8217;s particular circumstances, and does not consider tax consequences other than those arising under Cayman Islands law. Payments of dividends and capital in respect of our securities will not be subject to taxation in the Cayman Islands and no withholding will be required on the payment of a dividend or capital to any holder of the securities nor will gains derived from the disposal of the securities be subject to Cayman Islands income or corporation tax. The Cayman Islands currently have no income, corporation or capital gains tax and no estate duty, inheritance tax or gift tax. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No stamp duty is payable in respect of the issue of the warrants. An instrument of transfer in respect of a warrant is stampable if executed in or brought into the Cayman Islands. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No stamp duty is payable in respect of the issue of our Class A ordinary shares or on an instrument of transfer in respect of such shares. An instrument of transfer in respect of Class A ordinary shares is stampable if executed in or brought into the Cayman Islands. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">203 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has been incorporated under the laws of the Cayman Islands as an exempted company with limited liability and, as such, has obtained an undertaking from the Government of the Cayman Islands in the following form: </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Tax Concessions Act </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(as amended) </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Undertaking as to Tax Concessions </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with the provision of Section 6 of The Tax Concessions Act (as amended), the following undertaking is hereby given to ProKidney Corp. (the &#8220;Company&#8221;): </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">1.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">That no law which is hereafter enacted in the Islands imposing any tax to be levied on profits, income, gains or appreciations shall apply to the Company or its operations; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">2.</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, that no tax to be levied on profits, income, gains or appreciations or which is in the nature of estate duty or inheritance tax shall be payable: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">2.1</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On or in respect of the shares, debentures or other obligations of the Company; or </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">2.2</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by way of the withholding in whole or part, of any relevant payment as defined in Section 6(3) of the Tax Concessions Act (as amended). </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These concessions shall be for a period of 30 years from the date hereof. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">204 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom373959_19" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PLAN OF DISTRIBUTION </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We are registering the resale by the Selling Securityholders of up to 232,530,000 our Class&#160;A ordinary shares. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Selling Securityholders may offer and sell, from time to time, their Class&#160;A ordinary shares covered by this prospectus. The Selling Securityholders will act independently of us in making decisions with respect to the timing, manner and size of each sale. Such sales may be made on one or more exchanges or in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">over-the-counter</div></div> market or otherwise, at prices and under terms then prevailing or at prices related to the then current market price or in negotiated transactions. The Selling Securityholders may sell their securities by one or more of, or a combination of, the following methods: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">purchases by a broker-dealer as principal and resale by such broker-dealer for its own account pursuant to this prospectus; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ordinary brokerage transactions and transactions in which the broker solicits purchasers; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">block trades in which the broker-dealer so engaged will attempt to sell the shares as agent but may position and resell a portion of the block as principal to facilitate the transaction; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">an <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">over-the-counter</div></div> distribution in accordance with the rules of the Nasdaq; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">through trading plans entered into by a Selling Securityholder pursuant to Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10b5-1</div> under the Exchange Act that are in place at the time of an offering pursuant to this prospectus and any applicable prospectus supplement hereto that provide for periodic sales of their securities on the basis of parameters described in such trading plans; </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">short sales; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">distribution to employees, members, limited partners or stockholders of the Selling Securityholders; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">through the writing or settlement of options or other hedging transaction, whether through an options exchange or otherwise; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">by pledge to secured debts and other obligations; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">delayed delivery arrangements; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">to or through underwriters or agents; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in &#8220;at the market&#8221; offerings, as defined in Rule 415 under the Securities Act, at negotiated prices, at prices prevailing at the time of sale or at prices related to such prevailing market prices, including sales made directly on a national securities exchange or sales made through a market maker other than on an exchange or other similar offerings through sales agents; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in privately negotiated transactions; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">in options transactions; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">through a combination of any of the above methods of sale, as described below, or any other method permitted pursuant to applicable law. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, any securities that qualify for sale pursuant to Rule 144 may be sold under Rule 144 rather than pursuant to this prospectus. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the extent required, this prospectus may be amended or supplemented from time to time to describe a specific plan of distribution. In connection with distributions of the securities or otherwise, the Selling Securityholders may enter into hedging transactions with broker-dealers or other financial institutions. In </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">205 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">connection with such transactions, broker-dealers or other financial institutions may engage in short sales of the securities in the course of hedging the positions they assume with Selling Securityholders. The Selling Securityholders may also sell the securities short and redeliver the securities to close out such short positions. The Selling Securityholders may also enter into option or other transactions with broker-dealers or other financial institutions which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). The Selling Securityholders may also pledge securities to a broker-dealer or other financial institution, and, upon a default, such broker- dealer or other financial institution, may effect sales of the pledged securities pursuant to this prospectus (as supplemented or amended to reflect such transaction). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In effecting sales, broker-dealers or agents engaged by the Selling Securityholders may arrange for other broker-dealers to participate. Broker-dealers or agents may receive commissions, discounts or concessions from the Selling Securityholders in amounts to be negotiated immediately prior to the sale. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In offering the securities covered by this prospectus, the Selling Securityholders and any broker-dealers who execute sales for the Selling Securityholders may be deemed to be &#8220;underwriters&#8221; within the meaning of the Securities Act in connection with such sales. Any profits realized by the Selling Securityholders and the compensation of any broker-dealer may be deemed to be underwriting discounts and commissions. Certain of our shareholders have entered into <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">lock-up</div> agreements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to comply with the securities laws of certain states, if applicable, the securities must be sold in such jurisdictions only through registered or licensed brokers or dealers. In addition, in certain states the securities may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We will make copies of this prospectus available to the Selling Securityholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The Selling Securityholders may indemnify any broker-dealer that participates in transactions involving the sale of the securities against certain liabilities, including liabilities arising under the Securities Act. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the time a particular offer of securities is made, if required, a prospectus supplement will be distributed that will set forth the number of securities being offered and the terms of the offering, including the name of any underwriter, dealer or agent, the purchase price paid by any underwriter, any discount, commission and other item constituting compensation, any discount, commission or concession allowed or reallowed or paid to any dealer, and the proposed selling price to the public. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have agreed to indemnify certain of the Selling Securityholders against certain liabilities, including certain liabilities under the Securities Act, the Exchange Act or other federal or state law. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have agreed with certain Selling Securityholders pursuant to the Amended and Restated Registration Rights Agreement to use our commercially reasonable efforts to keep the registration statement of which this prospectus constitutes a part effective until such time as all securities covered by this prospectus have been sold or otherwise cease to be registrable securities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Amended and Restated Registration Rights Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At the Closing, ProKidney, the Sponsor and certain Closing ProKidney Unitholders entered into the Amended and Restated Registration Rights Agreement, pursuant to which, among other things, the Sponsor, Closing Company Unitholders and their affiliates and permitted transferees were granted certain registration rights with respect to their respective Class&#160;A ordinary shares on the terms and subject to the conditions therein. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">206 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom373959_20" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LEGAL MATTERS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Walkers (Cayman) LLP has passed upon the validity of the Class&#160;A ordinary shares and Class&#160;B ordinary shares offered by this prospectus and matters of Cayman Islands law. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">207 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom373959_21" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">EXPERTS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The financial statements of SCS as of December&#160;31, 2021 and for the period from February&#160;25, 2021 (inception) through December&#160;31, 2021 included in this prospectus have been audited by Marcum LLP, independent registered public accounting firm, as set forth in their report thereon, appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consolidated financial statements of ProKidney LP at December 31, 2021 and 2020, and for each of the two years in the period ended December 31, 2021, appearing in this Prospectus and Registration Statement have been audited by Ernst &amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon (which contains an explanatory paragraph describing conditions that raise substantial doubt about the Company&#8217;s ability to continue as a going concern as described in Note 2 to the consolidated financial statements) appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">208 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="rom373959_22" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">WHERE YOU CAN FIND MORE INFORMATION </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We have filed a registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-1,</div> including exhibits, under the Securities Act of 1933, as amended, with respect to the ordinary shares offered by this prospectus. This prospectus does not contain all of the information included in the registration statement. For further information pertaining to us and our securities, you should refer to the registration statement and our exhibits. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In addition, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public on a website maintained by the SEC located at www.sec.gov. We also maintain a website at www.prokidney.com. Through our website, we make available, free of charge, annual, quarterly and current reports, proxy statements and other information as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. The information contained on, or that may be accessed through, our website is not part of, and is not incorporated into, this prospectus. </div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">209 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="toc373959_42" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div id="rom373959_23" style="letter-spacing: 0px; top: 0px;;display:inline;"></div>INDEX TO CONSOLIDATED FINANCIAL INFORMATION </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 93%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">PAGE</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Audited Consolidated Financial Statements for Social Capital Suvretta Holdings Corp. III</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fincov373959_1">Report of Independent Registered Public Accounting Firm</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FS-2</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fincov373959_2">Balance Sheets as of December&#160;31, 2021</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FS-3</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fincov373959_3">Statements of Operations for the period from February&#160;25, 2021 (inception) through December&#160;31,&#160;2021</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FS-4</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fincov373959_4">Statement of Changes in Temporary Equity and Permanent Deficit for the period from February&#160;25,&#160;2021 (inception) through December&#160;31, 2021</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FS-5</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fincov373959_5">Statements of Cash Flows for the period from February&#160;25, 2021 (inception) through December&#160;31,&#160;2021</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FS-6</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fincov373959_6">Notes to Financial Statements</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FS-7</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unaudited Consolidated Financial Statements for Social Capital Suvretta Holdings Corp. III</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fincov373959_7">Condensed Balance Sheets at March&#160;31, 2022 (Unaudited) and December&#160;31, 2021</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FS-20</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fincov373959_8">Condensed Statements of Operations for the three months ended March&#160;31, 2022 and for the period from February&#160;25, 2021 (inception) through March&#160;31, 2021 (Unaudited)</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FS-21</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fincov373959_9">Condensed Statements of Changes in Temporary Equity and Permanent Deficit for the three months ended March&#160;31, 2022 and for the period from February&#160;25, 2021 (inception) through March&#160;31, 2021 (Unaudited)</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FS-22</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fincov373959_10">Condensed Statements of Cash Flows for the three months ended March&#160;31, 2022 and for the period from February&#160;25, 2021 (inception) through March&#160;31, 2021 (Unaudited)</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FS-23</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fincov373959_11">Notes to Condensed Financial Statements (Unaudited)</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FS-24</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Audited Consolidated Financial Statements for ProKidney LP and Subsidiaries</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fincov373959_12">Report of Independent Auditors</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FS-39</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fincov373959_13">ProKidney LP and Subsidiaries Consolidated Balance Sheets at December&#160;31, 2020 and December&#160;31, 2021</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FS-40</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fincov373959_14">ProKidney LP and Subsidiaries Consolidated Statements of Operations and Comprehensive Loss for the years ended December&#160;31, 2020 and December&#160;31, 2021</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FS-41</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fincov373959_15">ProKidney LP and Subsidiaries Consolidated Statements of Changes in Members&#8217; Equity for the years ended December&#160;31, 2020 and December&#160;31, 2021</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FS-42</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fincov373959_16">ProKidney LP and Subsidiaries Consolidated Statement of Cash Flows for the years ended December&#160;31, 2020 and December&#160;31, 2021</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FS-43</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fincov373959_17">ProKidney and Subsidiaries Notes to Consolidated Financial Statements</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FS-44</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 3.75pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unaudited Consolidated Financial Statements for ProKidney LP and Subsidiaries</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fincov373959_18">ProKidney LP and Subsidiaries Consolidated Balance Sheets at March&#160;31, 2022 and December&#160;31, 2021</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FS-56</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fincov373959_19">ProKidney LP and Subsidiaries Consolidated Statements of Operations and Comprehensive Loss for the three months ended March&#160;31, 2022 and 2021 (Unaudited)</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FS-57</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fincov373959_20">ProKidney LP and Subsidiaries Consolidated Statements of Changes in Members&#8217; Equity for the three months ended March&#160;31, 2022 and 2021 (Unaudited)</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FS-58</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fincov373959_21">ProKidney LP and Subsidiaries Consolidated Statement of Cash Flows for the three months ended March&#160;31, 2022 and 2021 (Unaudited)</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FS-59</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><a href="#fincov373959_22">Notes to Condensed Financial Statements (Unaudited)</a></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">FS-60</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-1 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fincov373959_1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the Shareholders and Board of Directors of </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Social Capital Suvretta Holdings Corp. III </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opinion on the Financial Statements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have audited the accompanying balance sheet of Social Capital Suvretta Holdings Corp. III (the &#8220;Company&#8221;) as of December&#160;31, 2021, the related statements of operations, changes in temporary equity and permanent deficit and cash flows for the period from February&#160;25, 2021 (inception) through December&#160;31, 2021, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2021, and the results of its operations and its cash flows for the period from February&#160;25, 2021 (inception) through December&#160;31, 2021, in conformity with accounting principles generally accepted in the United States of America. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Explanatory Paragraph&#8212;Going Concern </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company&#8217;s business plan is dependent on the completion of a business combination and the Company&#8217;s cash and working capital as of December&#160;31, 2021 are not sufficient to complete its planned activities. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans with regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis for Opinion </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (the &#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Marcum LLP </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marcum LLP </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">We have served as the Company&#8217;s auditor since 2021<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">.</div></div> </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">New York, NY </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;23, 2022 </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-2 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fincov373959_2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. III </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">BALANCE SHEET </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">DECEMBER&#160;31, 2021 </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 87%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ASSETS</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current Assets</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">440,488</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">504,189</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Current Assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">944,677</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; line-height: 115%; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Non-current prepaid insurance</div> </div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:PrepaidInsuranceNonCurrent" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">247,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable Securities held in Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,008,324</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TOTAL ASSETS</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">251,200,501</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LIABILITIES, TEMPORARY EQUITY AND PERMANENT DEFICIT</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr>
<td style="padding: 0in 0in 0in 0.02in;;vertical-align:top;"> <div style="margin: 0in 0in 0.0001pt 0.26in; line-height: normal; font-family: Calibri, &quot;sans-serif&quot;; font-size: 10pt;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expense</div></div> </td>
<td style="padding:0in 0in 0in 0in;vertical-align:bottom;"> <div style="margin: 0in 0in 0.0001pt; line-height: normal; font-family: Calibri, &quot;sans-serif&quot;; font-size: 10pt;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></div> </td>
<td style="padding:0in 0in 0in 0in;vertical-align:bottom;"> <div style="margin: 0in 0in 0.0001pt; line-height: normal; font-family: Calibri, &quot;sans-serif&quot;; font-size: 10pt;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="padding:0in 0in 0in 0in;vertical-align:bottom;"> <div style="margin: 0in 0in 0.0001pt; text-align: right; line-height: normal; font-family: Calibri, &quot;sans-serif&quot;; font-size: 10pt;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="prok:AccruedExpensesCurrent" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,864,796</ix:nonFraction></div></div> </td>
<td style="padding:0in 0in 0in 0in;vertical-align:bottom;"> <div style="margin: 0in 0in 0.0001pt; line-height: normal; font-family: Calibri, &quot;sans-serif&quot;; font-size: 10pt;"><div style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, &quot;serif&quot;; white-space: pre-wrap; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advances from related party</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Current Liabilities</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,879,796</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred underwriting fee payable</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="prok:DeferredUnderwritingCommissions" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">7,700,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TOTAL LIABILITIES</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">9,579,796</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and Contingencies (Note 6)</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Temporary Equity</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares subject to possible redemption, <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">25,000,000</ix:nonFraction> shares at redemption value</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,008,324</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Permanent Deficit</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preference shares, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction> par value; <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>&#160;shares issued and&#160;outstanding</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction> par value; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">640,000</ix:nonFraction></ix:nonFraction> shares issued and outstanding (excluding <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">25,000,000</ix:nonFraction> shares subject to possible redemption)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">64</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B ordinary shares, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction> par value; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">50,000,000</ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,250,000</ix:nonFraction></ix:nonFraction> shares issued and outstanding</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">625</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated deficit</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,388,308</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Permanent Deficit</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,387,619</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TOTAL LIABILITIES, TEMPORARY EQUITY AND PERMANENT DEFICIT</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">251,200,501</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of the financial statements. </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-3 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div id="fincov373959_3" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. III </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">STATEMENT OF OPERATIONS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE PERIOD FROM FEBRUARY&#160;25, 2021 (INCEPTION) THROUGH DECEMBER&#160;31, 2021 </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 88%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 90%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating and formation costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,332,953</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">2,332,953</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest earned on marketable securities held in Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">8,324</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">2,324,629</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average shares outstanding, Class&#160;A ordinary shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">15,101,877</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share, Class&#160;A ordinary shares</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.11</ix:nonFraction></ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average shares outstanding, Class&#160;B ordinary shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,852,751</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share, Class&#160;B ordinary shares</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.11</ix:nonFraction></ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of the financial statements. </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-4 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fincov373959_4" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. III </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">STATEMENT OF CHANGES IN TEMPORARY EQUITY AND PERMANENT DEFICIT </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE PERIOD FROM FEBRUARY&#160;25, 2021 (INCEPTION) THROUGH DECEMBER&#160;31, 2021</div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 32%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Temporary Equity</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A Ordinary<br/>Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B Ordinary<br/>Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div><br/>Capital</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>Deficit</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>Permanent<br/>Deficit</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 7pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;">Balance&#8212;February 25, 2021 (inception)</div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn02_24_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn02_24_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn02_24_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn02_24_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn02_24_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn02_24_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn02_24_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; white-space: nowrap; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Issuance of Class&#160;B ordinary shares to Sponsor</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,325,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">633</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="P02_25_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">24,367</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; white-space: nowrap; line-height: normal;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Sale of <ix:nonFraction name="prok:TemporaryEquityStockIssuedDuringThePeriodShares" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">25,000,000</ix:nonFraction> Public Shares, net of<div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt; font-size: 8.5pt;;display:inline;">&#160;</div>underwriting <br/>discounts and offering expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="prok:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" contextRef="P02_25_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">25,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" contextRef="P02_25_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">237,520,334</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">Remeasurement of </div>Class&#160;A ordinary shares to redemption value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="prok:RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity" contextRef="P02_25_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">12,487,990</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="prok:RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity" contextRef="P02_25_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">6,424,311</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="prok:RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity" contextRef="P02_25_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">6,063,679</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="prok:RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">12,487,990</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Sale of <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P02_25_2021To12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">640,000</ix:nonFraction> Private Placement Shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">640,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">64</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P02_25_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">6,399,936</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;">&#8212;&#160;&#160;</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">6,400,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeiture of Founder Shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal">75,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="P02_25_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; line-height: 8.5pt; font-size: 8.5pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;&#160;&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_25_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">2,324,629</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">2,324,629</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">)&#160;</div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 8.5pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;">Balance<div style="text-indent: 0px; letter-spacing: 0px; top: 0px; line-height: 8.5pt; font-size: 8.5pt;;display:inline;">&#8212;</div>December 31, 2021</div></div></div></div> </td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">25,000,000</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,008,324</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">640,000</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">64</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,250,000</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">625</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></div></div><div style="line-height: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;">&#160;&#160;</div></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,388,308</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;">)&#160;</div></div></div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;">$</div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;;text-align:right;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,387,619</ix:nonFraction></div></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 8.5pt; font-size: 8.5pt;"><div style="font-size: 8.5pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px; line-height: 8.5pt;;display:inline;"><div style="line-height: 8.5pt; font-size: 8.5pt;;font-weight:bold;display:inline;">)&#160;</div></div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of the financial statements. </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-5 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em; text-align: left;;font-weight: bold;"></div> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fincov373959_5" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. III </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">STATEMENT OF CASH FLOWS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE PERIOD FROM FEBRUARY&#160;25, 2021 (INCEPTION) THROUGH DECEMBER&#160;31, 2021 </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 86%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flows from Operating Activities:</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">2,324,629</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net loss to net cash used in operating activities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Formation costs paid by Sponsor in exchange for issuance of Founder Shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:FormationCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest earned on marketable securities held in Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">8,324</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in operating assets and liabilities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">751,689</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;">Accounts payable </div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses<br/></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="text-align: right; line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,864,796</ix:nonFraction></div><br/></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"> <div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div> </td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">1,209,846</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flows from Investing Activities:</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment of cash into Trust Account</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireInvestments" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in investing activities</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">250,000,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flows from Financing Activities:</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from sale of Public Shares, net of underwriting discounts paid</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">245,600,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from sale of Private Placement Shares</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">6,400,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advances&#160;from related party</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">97,319</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of advances from related party</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="prok:RepaymentOfAdvancesFromRelatedParty" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">87,319</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from promissory note<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div>related party</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">300,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Repayment of promissory note&#8212;related party</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">(<ix:nonFraction name="prok:RepaymentOfPromissoryNoteRelatedParty" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">300,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">)&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment of offering costs</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">359,666</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">251,650,334</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Change in Cash</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">440,488</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div>Beginning of period&#160;(inception)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn02_24_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div>End of period</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">440,488</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Cash</div> Investing and Financing Activities:</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering costs paid by Sponsor in exchange for issuance of Founder Shares</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">20,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(255, 255, 255); padding-bottom: 1.25pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0px; margin-bottom: 0px; margin-left: 3em; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); padding-bottom: 1.25pt;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 2.5pt double black;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); border-bottom: 2.5pt double black;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div> </td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 1.25pt;"> <div style="margin-top: 0px; margin-bottom: 0px; line-height: 1pt;">&#160;</div> </td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Remeasurement</div>&#160;of Class A ordinary share subject to possible redemption</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="prok:RemeasurementOfClassAOrdinarySharesToRedemptionValue" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">12,487,990</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred underwriting fee payable</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="prok:DeferredUnderwritingFeesAccruedButNotPaid" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">7,700,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The accompanying notes are an integral part of the financial statements. </div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-6 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <ix:nonNumeric name="us-gaap:NatureOfOperations" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_53608075"><div id="fincov373959_6" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 1. DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN </div></div></div></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Social Capital Suvretta Holdings Corp. III (the &#8220;Company&#8221;) is a blank check company incorporated as a Cayman Islands exempted company on February&#160;25, 2021. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (a &#8220;Business Combination&#8221;). </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of December&#160;31, 2021, the Company had not commenced&#160;any operations. All activity for the period from <ix:nonNumeric name="dei:EntityIncorporationDateOfIncorporation" contextRef="P02_25_2021To12_31_2021" format="ixt:date-monthname-day-year-en">February 25, 2021</ix:nonNumeric> (inception) through December&#160;31, 2021 relates to the Company&#8217;s formation, the initial public offering (the &#8220;Initial Public Offering&#8221;), described below, and, subsequent to the Initial Public Offering, identifying a target company for a Business Combination and activities in connection with the proposed acquisition of ProKidney LP (see Note 9). The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company generates <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> income in the form of interest income from the marketable securities held in the Trust Account (as defined below). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The registration statements for the Company&#8217;s Initial Public Offering became effective on June&#160;29, 2021 and June&#160;30, 2021. On July&#160;2, 2021, the Company consummated the Initial Public Offering of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000,000</ix:nonFraction> Class&#160;A ordinary shares (the &#8220;Public Shares&#8221;), which includes the partial exercise by the underwriters of their over-allotment option in the amount of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,000,000</ix:nonFraction> Public Shares, at $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction> per Public Share, generating gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,000,000</ix:nonFraction>, which is described in </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">Note 3. The fair value attributable to the unexercised portion of the over-allotment option was deemed to be immaterial to the financial statements.</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">Substantially concurrently with the closing of the Initial Public Offering<div style="letter-spacing: 0px; top: 0px;;display:inline;">, </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Company consummated the sale of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">640,000</ix:nonFraction> Class&#160;A ordinary shares (the &#8220;Private Placement Shares&#8221;) at a price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction> per Private Placement Share in a private placement to SCS Sponsor III LLC, a Cayman Islands limited liability company (the &#8220;Sponsor&#8221;), generating gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">6,400,000</ix:nonFraction>, which is described in Note 4. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs amounted to $<ix:nonFraction name="prok:TransactionCostsIncurredInConnectionWithInitialPublicOffering" contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">12,479,666</ix:nonFraction>, consisting of $<ix:nonFraction name="prok:UnderwritingFee" contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">4,400,000</ix:nonFraction> of underwriting fees, $<ix:nonFraction name="prok:DeferredUnderwritingFees" contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">7,700,000</ix:nonFraction> of deferred underwriting fees and $<ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">379,666</ix:nonFraction> of other offering costs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In connection with the closing of the Initial Public Offering on July&#160;2, 2021, an amount of $<ix:nonFraction name="us-gaap:CommonStockHeldInTrust" contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,000,000</ix:nonFraction> ($<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction> per Public Share) from the net proceeds of the sale of the Public Shares in the Initial Public Offering and the sale of the Private Placement Shares was placed in a trust account (the &#8220;Trust Account&#8221;), and invested in U.S. government treasury bills with a maturity of 185 days or less or in money market funds investing solely in U.S. Treasuries and meeting certain conditions of Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2a-7</div> of the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;). Except with respect to interest earned on the funds held in the Trust Account that may be released to the Company to pay its taxes, if any, the funds held in the Trust Account will not be released from the Trust Account until the earliest of: (a)&#160;the completion of a Business Combination, and then only in connection with those Public Shares that such shareholder properly elected to redeem, subject to certain limitations; (b)&#160;the redemption of any Public Shares properly submitted in connection with a shareholder vote to amend the Company&#8217;s Amended and Restated Memorandum and Articles of Association (i)&#160;to modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with the Business Combination or to redeem <ix:nonFraction name="prok:PercentageOfPublicSharesRedemption" contextRef="P07_02_2021To07_02_2021" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">% of the Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (ii)&#160;with respect to any other material provisions relating to shareholders&#8217; rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-Business</div> Combination activity; and (c)&#160;the redemption of the Public Shares if the Company has not completed a Business Combination within the Combination Period or during any applicable extension period. The proceeds deposited in the Trust Account could become subject to the claims of the Company&#8217;s creditors, if any, which could have priority over the claims of the holders of the Public Shares (the &#8220;Public Shareholders&#8221;). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Shares, although substantially </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">all of </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-7 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><ix:continuation id="TextSelection_53608075" continuedAt="TextSelectionAppend_53608075_1"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the net proceeds are intended to be applied generally toward consummating a Business Combination. The Company must complete one or more Business Combinations having an aggregate fair market value of </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at least <ix:nonFraction name="prok:ProspectiveAssetsOfAcquireeAsAPercentageOfFairValueOfAssetsInTheTrustAccount" contextRef="PAsOn07_02_2021_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">80</ix:nonFraction>% of the value of the assets held in the Trust Account (excluding any deferred underwriting commissions and taxes payable on the income earned on the Trust Account) at the time of the Company signing a definitive agreement in connection with the Business Combination. However, the Company will only complete a Business Combination if the post-Business Combination company owns or acquires <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn07_02_2021_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to complete a Business Combination successfully. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company will provide the Public Shareholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of the Business Combination, either (a)&#160;in connection with a general meeting called to approve the Business Combination or (b)&#160;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company. The Public Shareholders will be entitled to redeem all or a portion of their Public Shares at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, calculated as of two business days prior to the consummation of the Business Combination, including interest (which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares, subject to the limitations described below. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with the Company&#8217;s Amended and Restated Memorandum and Articles of Association, in no event will the Company redeem the Public Shares in an amount that would cause the Company&#8217;s net tangible assets to be less than $<ix:nonFraction name="us-gaap:MinimumNetWorthRequiredForCompliance" contextRef="PAsOn07_02_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000,001</ix:nonFraction> following such redemptions. Redemptions of the Public Shares may also be subject to a higher net tangible asset test or cash requirement pursuant to an agreement relating to the Business Combination.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If a shareholder vote is not required in connection with a Business Combination and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (the &#8220;SEC&#8221;), and file tender offer documents with the SEC prior to completing a Business Combination. If, however, shareholder approval of the transaction is required by applicable law or stock exchange listing requirement, or the Company decides to obtain shareholder approval for business or other reasons, the Company will conduct the redemptions in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules and will file proxy materials with the SEC. If the Company seeks shareholder approval in connection with a Business Combination, the Company will complete such Business Combination only if the Company receives an ordinary resolution under Cayman Islands law, which requires the affirmative vote of holders of a majority of ordinary shares who attend and vote at a general meeting of the Company. The Public Shareholders may elect to redeem their Public Shares without voting and, if they do vote, irrespective of whether they vote for or against a Business Combination. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notwithstanding the foregoing redemption rights, if the Company seeks shareholder approval of the Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, the Company&#8217;s Amended and Restated Memorandum and Articles of Association provide that a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &#8220;group&#8221; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), will be restricted from redeeming its Public Shares with respect to more than an aggregate of <ix:nonFraction name="prok:PercentageOfPublicSharesThatCanBeTransferredWithoutAnyRestriction" contextRef="PAsOn07_02_2021" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">15</ix:nonFraction></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the Public Shares without the Company&#8217;s prior written consent. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsor and the Company&#8217;s directors and officers have agreed to waive: (a)&#160;their redemption rights with respect to any Founder Shares, Private Placement Shares and Public Shares held by them, as applicable, in connection with the completion of a Business Combination; (b)&#160;their redemption rights with respect to any Founder Shares, Private Placement Shares and Public Shares held by them in connection with a shareholder vote </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-8 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><ix:continuation id="TextSelectionAppend_53608075_1" continuedAt="TextSelectionAppend_53608075_2"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">to amend the Company&#8217;s Amended and Restated Memorandum and Articles of Association (i)&#160;to modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with the Business Combination or to </div></div>redeem <ix:nonFraction name="prok:PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated" contextRef="PAsOn07_02_2021" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">% of the Public Shares if the Company does not complete a Business Combination within the Combination Period, or (ii)&#160;with respect to any other material provisions relating to shareholders&#8217; rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-Business</div> Combination activity; and (c)&#160;their rights to liquidating distributions from the Trust Account with respect to any Founder Shares and Private Placement Shares they hold if the Company fails to complete a Business Combination within the Combination Period or during any applicable extension period (although such persons will be entitled to liquidating distributions from the Trust Account with respect to any Public Shares they hold if the Company fails to complete a Business Combination within the prescribed time frame). If the Company submits the Business Combination to the Public Shareholders for a vote, the Sponsor and the Company&#8217;s directors and officers have also agreed to vote any Founder Shares, Private Placement Shares and Public Shares held by them in favor of the Business Combination. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will have until July&#160;</div></div>2, 2023 to complete a Business Combination (the &#8220;Combination Period&#8221;), or such longer period as a result of a shareholder vote to amend such time period pursuant to the Company&#8217;s Amended and Restated Memorandum and Articles of Association. However, if the Company has not completed a Business Combination within such Combination Period or during any applicable extension period, the Company will: (a)&#160;cease all operations except for the purpose of winding up; (b)&#160;as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less up to $<ix:nonFraction name="us-gaap:LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities" contextRef="PAsOn07_02_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction> of interest to pay dissolution expenses and which interest shall be net of taxes payable) divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish the Public Shareholders&#8217; rights as shareholders (including the right to receive further liquidating distributions, if any); and (c)&#160;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#8217;s remaining shareholders and its board of directors, liquidate and dissolve, subject in each case to the Company&#8217;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company&#8217;s independent auditors) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1) $<ix:nonFraction name="prok:PerShareValueOfRestrictedAssets" contextRef="PAsOn07_02_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>per Public Share or (2)&#160;such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, due to reductions in the value of the trust assets, in each case net of the interest which may be withdrawn to pay taxes, except as to any claims by a third party that executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company&#8217;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company has not independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and believes that the Sponsor&#8217;s only assets are securities of the Company and, therefore, the Sponsor may not be able to satisfy those obligations. The Company has not asked the Sponsor to reserve for such obligations. None of the Company&#8217;s directors or officers will indemnify the Company for claims by third parties, including, without limitation, claims by vendors and prospective target businesses. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks and Uncertainties </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Management continues to evaluate the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and has concluded that while it is reasonably possible that the pandemic could have a negative effect on the Company&#8217;s business, financial position, results of operations and/or the search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-9 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div></div></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_53608075_2"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Going Concern </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, the Company had $<ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">440,488</ix:nonFraction> in its operating bank accounts and working capital deficit of $<ix:nonFraction name="prok:WorkingCapital" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">935,119</ix:nonFraction>. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Until the consummation of a Business Combination, the Company will be using the funds not held in the Trust Account for identifying and evaluating prospective acquisition candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to acquire, and structuring, negotiating and consummating the Business Combination. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may need to raise additional capital through loans or additional investments from its Sponsor, shareholders, officers, directors, or third parties. The Company&#8217;s officers, directors and Sponsor may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet the Company&#8217;s working capital needs. Accordingly, the Company may not be able to obtain additional financing. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern for a reasonable period of time, which is considered to be one year from the issuance date of the financial statements. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_53608082"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </div></div></div> <ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the SEC. </div></div></ix:nonNumeric> <ix:nonNumeric name="prok:EmergingGrowthCompanyStatusPolicyTextBlock" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</div></ix:nonNumeric> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-10 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%);;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><ix:continuation id="TextSelection_53608082" continuedAt="TextSelectionAppend_53608082_1"> <ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Significant accounting estimates include the determination of the fair value of Class&#160;A ordinary shares subject to possible redemption and the fair value of Founder Shares transferred to directors. Accordingly, the actual results could differ significantly from those estimates. </div></div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did<ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"> no</ix:nonFraction>t have any cash equivalents as of December&#160;31, 2021.</div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Marketable Securities Held in Trust Account </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2021, substantially all of the assets held in the Trust Account were held in money market funds which are invested primarily in U.S. Treasury securities. </div></div></ix:nonNumeric> <ix:nonNumeric name="prok:TemporaryEquityPolicyTextBlock" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class&#160;A Ordinary Shares Subject to Possible Redemption </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its Class&#160;A ordinary shares subject to possible redemption in accordance with the guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 480, &#8220;Distinguishing Liabilities from Equity.&#8221; Class&#160;A ordinary shares subject to mandatory redemption are classified as a liability instrument and are measured at redemption value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders&#8217; equity. The Company&#8217;s Class&#160;A ordinary shares feature certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events. Accordingly, Class&#160;A ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the permanent deficit section of the Company&#8217;s balance sheet. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying value of redeemable ordinary shares are affected by charges against additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital (to the extent available) and accumulated deficit. </div> <ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2021, the Class&#160;A ordinary shares subject to possible redemption reflected in the balance sheet are reconciled in the following table: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-size: 0px;">
<td style="width: 77%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-size: 0px;">
<td style="width: 83%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares issuance costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="prok:TemporaryEquityIssaunceCosts" contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">12,479,666</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Increase of carrying value to redemption value</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:IncreaseOfOrdinarySharesToRedemptionValueTemporaryEquity" contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">12,487,990</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares subject to possible redemption</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,008,324</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> </ix:nonNumeric> </ix:nonNumeric> </ix:continuation>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 1px;">
<td></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-11 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%);;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><ix:continuation id="TextSelectionAppend_53608082_1" continuedAt="TextSelectionAppend_53608082_2"> <ix:nonNumeric name="prok:DeferredOfferingCostsPolicyTextBlock" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Offering Costs </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div>complies with the requirements of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASC&#160;340-</div></div></div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-S99-1.&#160;Offering&#160;costs</div></div></div> consisted of legal, accounting, underwriting fees and other costs incurred through the Initial Public Offering that were directly related to the Initial Public Offering. The Company incurred offering costs amounting to $<ix:nonFraction name="prok:TransactionCostsIncurredInConnectionWithInitialPublicOffering" contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">12,479,666</ix:nonFraction> as a result of the Initial Public Offering, consisting of $<ix:nonFraction name="prok:UnderwritingFee" contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">4,400,000</ix:nonFraction> of underwriting commissions, $<ix:nonFraction name="prok:DeferredUnderwritingFees" contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">7,700,000</ix:nonFraction> of deferred underwriting commissions, and $<ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">379,666</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>of other offering costs. The offering costs were charged to temporary equity and additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital upon the completion of the Initial Public Offering. Immediately thereafter, temporary equity was remeasured and an adjustment was recognized through additional paid in capital and accumulated deficit to adjust temporary equity to the redemption value. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_53608513"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-Based Payment Arrangements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for stock awards in accordance with ASC 718, &#8220;Compensation&#8212;Stock Compensation,&#8221; which requires that all equity awards be accounted for at their &#8220;fair value.&#8221; Fair value is measured on the grant date and is equal to the underlying value of the stock. </div><br/></div></ix:nonNumeric> </ix:continuation></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_53608082_2" continuedAt="TextSelectionAppend_53608082_3"><ix:continuation id="TextSelection_53608513"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Costs equal to these fair values are recognized ratably over the requisite service period based on the number of awards that are expected to vest, in the period of grant for awards that vest immediately and have no future service condition, or in the period the awards vest immediately after meeting a performance condition becomes probable (i.e., the occurrence of a Business Combination). For awards that vest over time, cumulative adjustments in later periods are recorded to the extent actual forfeitures differ from the Company&#8217;s initial estimates; previously recognized compensation cost is reversed if the service or performance conditions are not satisfied and the award is forfeited.</div></div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes under ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> to be sustained upon examination by taxing authorities. The Company&#8217;s management has determined that the Cayman Islands is the Company&#8217;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were<ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"> no</ix:nonFraction> unrecognized tax benefits and <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">amounts accrued for interest and penalties as of December&#160;31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is considered to be an exempted Cayman Islands company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#8217;s tax provision was zero for the period presented. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_53608275"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Loss Per Ordinary Share </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per ordinary share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding during the period. The Company has two classes of shares, which are referred to as Class&#160;A </div></div></div></ix:nonNumeric> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-12 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%);;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><ix:continuation id="TextSelectionAppend_53608082_3" continuedAt="TextSelectionAppend_53608082_4"><ix:continuation id="TextSelection_53608275"> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ordinary shares and Class&#160;B ordinary shares. Losses are shared pro rata between the two classes of shares. Charges associated with the redeemable Class&#160;A ordinary shares are excluded from net loss per ordinary share as the redemption value approximates fair value. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted net loss per ordinary share is the same as basic net loss per ordinary share for the periods presented. </div></div> <ix:nonNumeric name="us-gaap:TemporaryEquityTableTextBlock" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Period from</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">February&#160;25, 2021 (Inception)<br/>Through December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per ordinary share</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net loss</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">1,675,346</ix:nonFraction></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div><br/></td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom;"><div style="line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div><br/></div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">649,283</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div><br/></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average shares outstanding</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">15,101,877</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,852,751</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-indent: 0px;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per ordinary share</div></div></td>
<td style="vertical-align: bottom;;text-indent: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div><br/></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px; text-align: right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.11</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom;;text-indent: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div><br/></div></td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-indent: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div><br/></div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px; text-align: right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.11</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:center;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div><br/></div></td></tr></table> </ix:nonNumeric> </ix:continuation> <ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution which, at times may exceed the Federal Depository Insurance Corporation coverage limit of $<ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,000</ix:nonFraction>. The Company has not experienced losses on these accounts. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature.</div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Standards </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2020, the FASB issued ASU No. 2020-06, &#8220;Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity&#8221; (&#8220;ASU 2020-06&#8221;), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. We adopted ASU 2020-06 effective as of January 1, 2021. The adoption of ASU 2020-06 did not have an impact on our financial statements. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s financial statements. </div></div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-13 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%);;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><ix:continuation id="TextSelectionAppend_53608082_4"> <ix:nonNumeric name="prok:AccruedExpensesPolicyTextBlock" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accrued Expense </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses </div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">includes $<ix:nonFraction name="prok:AccruedLegalExpense" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,506,528</ix:nonFraction> of accrued legal expense, $<ix:nonFraction name="prok:AccruedPrintingExpense" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000</ix:nonFraction> of accrued printing expense, $<ix:nonFraction name="prok:AccruedDueDiligenceExpense" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">282,500</ix:nonFraction> of accrued due diligence expense, $<ix:nonFraction name="prok:AccruedRegulatoryFilingFee" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">70,000</ix:nonFraction> of accrued regulatory filing fee and $<ix:nonFraction name="prok:AccruedAccountingExpense" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">770</ix:nonFraction> of accrued accounting expense.</div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div></ix:nonNumeric> </ix:continuation> <ix:nonNumeric name="prok:InitialPublicOfferingDisclosureTextBlock" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 3. INITIAL PUBLIC OFFERING </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Initial Public Offering, the Company sold <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">25,000,000</ix:nonFraction> Public Shares, which includes a partial exercise by the underwriters of their over-allotment option in the amount of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">3,000,000</ix:nonFraction> Public Shares, at a price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></ix:nonFraction> per Public Share. Unlike some other initial public offerings of special purpose acquisition companies, investors in the Initial Public Offering did not receive any warrants (which would typically become exercisable following completion of the Business </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">Combination). The fair value attributable to the unexercised portion of the over-allotment option was deemed to be immaterial to the financial statements.</div></div></div></ix:nonNumeric> <ix:nonNumeric name="prok:PrivatePlacementDisclosureTextBlock" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 4. PRIVATE PLACEMENT </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Substantially concurrently </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">with the closing of the Initial Public Offering, the Sponsor purchased <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">640,000</ix:nonFraction> Private Placement Shares at a price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></ix:nonFraction> per Private Placement Share, for an aggregate purchase price of&#160;$<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">6,400,000</ix:nonFraction>. Each Private Placement Share is identical to the Class&#160;A ordinary shares sold in the Initial Public Offering, subject to certain limited exceptions as described in Note 7. A portion of the proceeds from the sale of the Private Placement Shares was added to the net proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period or during any applicable extension period, the proceeds from the sale of the Private Placement Shares held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Shares will be worthless. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_53608790"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 5. RELATED PARTY TRANSACTIONS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Founder Shares </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On March&#160;2, 2021, the Sponsor paid $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="P03_02_2021To03_02_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction> to cover certain offering and formation costs of the Company in consideration for which the Sponsor received <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P03_02_2021To03_02_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,750,000</ix:nonFraction> Class&#160;B ordinary shares (the &#8220;Founder Shares&#8221;). On June&#160;29, 2021, the Company effected a share capitalization with respect to its Class&#160;B ordinary shares of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P06_29_2021To06_29_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">575,000</ix:nonFraction> shares thereof, resulting in the Company&#8217;s initial shareholders holding an aggregate of <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn06_29_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,325,000</ix:nonFraction> Founder Shares. All share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> amounts have been retroactively restated to reflect the share capitalization. The Founder Shares included an aggregate of up to&#160;<ix:nonFraction name="us-gaap:CommonStockOtherSharesOutstanding" contextRef="PAsOn06_30_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">825,000</ix:nonFraction> shares that were subject to forfeiture depending on the extent to which the underwriters&#8217; over-allotment option was exercised. As a result of the underwriters&#8217; election to partially exercise their over-allotment option, a total of <ix:nonFraction name="prok:SharesNoLongerSubjectToForfeiture" contextRef="PAsOn06_30_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">750,000</ix:nonFraction> Founder Shares are no longer subject to forfeiture and <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="P07_01_2021To09_30_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">75,000</ix:nonFraction> Founder Shares were forfeited, resulting in an aggregate of&#160;<ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn06_30_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,250,000</ix:nonFraction> Founder Shares outstanding. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2021, the Sponsor transferred <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P02_25_2021To06_30_2021_FounderSharesMemberusgaapStatementEquityComponentsAxis_IndependentDirectorsMembersrtTitleOfIndividualAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction> Founder Shares to Marc Semigran, an independent director of the Company. The sale of the Founders Shares to the Company&#8217;s director is in the scope of FASB ASC Topic 718, &#8220;Compensation-Stock Compensation&#8221; (&#8220;ASC 718&#8221;).&#160;Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date. The fair value of the <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P06_29_2021To06_29_2021_DirectorMembersrtTitleOfIndividualAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction> shares granted to the Company&#8217;s director was $<ix:nonFraction name="prok:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue" contextRef="P02_25_2021To12_31_2021_DirectorMembersrtTitleOfIndividualAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">214,160</ix:nonFraction> or approximately $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2021_DirectorMembersrtTitleOfIndividualAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">7.14</ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">per share. The Founders Shares were effectively sold subject to a performance condition (i.e., the occurrence of a Business Combination). Compensation expense related to the Founders Shares is recognized only when the performance condition is probable of occurrence. As of December&#160;31, 2021, the Company determined that a Business Combination is not considered probable, and, therefore, no stock-based compensation expense has been recognized. Stock-based compensation would be recognized at the date a Business Combination is considered probable (i.e., upon consummation of a Business Combination) in an amount equal to the number of Founders Shares times the grant date fair value per share (unless subsequently modified) less the amount initially received for the purchase of the Founders Shares. </div></div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-14 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%);;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><ix:continuation id="TextSelection_53608790" continuedAt="TextSelectionAppend_53608790_1"> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsor and the Company&#8217;s directors and officers have agreed, subject to limited exceptions, not to transfer, assign or sell any of their Founder Shares until the earlier of: (A)&#160;one year after the completion of a Business Combination and (B)&#160;subsequent to a Business Combination, (x)&#160;if the last reported sale price of the Class&#160;A ordinary shares equals or exceeds </div></div>$<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RestrictionOnTransferOfSponsorSharesMemberPROKBasisAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">12.00</ix:nonFraction> per share (as adjusted for share <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-divisions,</div> share dividends, rights issuances, consolidations, reorganizations, recapitalizations and other similar transactions) for any <ix:nonNumeric name="prok:NumberOfTradingDaysForDeterminingTheSharePrice" contextRef="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RestrictionOnTransferOfSponsorSharesMemberPROKBasisAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" format="ixt-sec:durday">20</ix:nonNumeric> trading days within any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="prok:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" contextRef="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RestrictionOnTransferOfSponsorSharesMemberPROKBasisAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" format="ixt-sec:durday">30</ix:nonNumeric>-trading</div> day period commencing at least <ix:nonNumeric name="prok:WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered" contextRef="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RestrictionOnTransferOfSponsorSharesMemberPROKBasisAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" format="ixt-sec:durday">150</ix:nonNumeric> days after a Business Combination, or (y)&#160;the date on which the Company completes a liquidation, merger, amalgamation, share exchange, reorganization or other similar transaction that results in all of the Public Shareholders having the right to exchange their Class&#160;A ordinary shares for cash, securities or other property.</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Administrative Services Agreement </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company entered into an agreement in which it will pay an affiliate of the Sponsor $<ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P06_30_2021To06_30_2021_AdministrationAndSupportServicesMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000</ix:nonFraction> per month, commencing on June&#160;30, 2021, for office space, administrative and support services. Upon completion of a Business Combination or its liquidation, the Company will cease paying these monthly fees. For the period from February&#160;25, 2021 (inception) through December&#160;31, 2021, the Company incurred&#160;$<ix:nonFraction name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" contextRef="P02_25_2021To12_31_2021_AdministrationAndSupportServicesMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">60,000</ix:nonFraction> in fees for these services, of which such amount was recognized in Operating and Formation Costs in the accompanying statement of operations. </div><br/></div> </ix:continuation></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_53608790_1"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Advances from Related Party </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, the Sponsor had advanced the Company $<ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="PAsOn12_31_2021_AdvanceFromRelatedPartyLoanMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">97,319</ix:nonFraction> for working capital purposes, inclusive of the administrative services agreement noted above, of which $<ix:nonFraction name="prok:RepaymentOfAdvancesFromRelatedParty" contextRef="P02_25_2021To12_31_2021_AdvanceFromRelatedPartyLoanMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">87,319</ix:nonFraction> was repaid during the period ended December&#160;31, 2021. As of December&#160;31, 2021, the outstanding balance was $<ix:nonFraction name="prok:AdvancesPayableToRelatedPartyCurrent" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000</ix:nonFraction>. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Promissory Note&#8212;Related Party </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On March&#160;2, 2021, the Sponsor issued an unsecured promissory note to the Company (the &#8220;Promissory Note&#8221;), pursuant to which the Company could borrow up to an aggregate principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_02_2021_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">300,000</ix:nonFraction>. The Promissory Note was <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable on the earlier of December&#160;31, 2021 and the completion of the Initial Public Offering. The outstanding balance under the Promissory Note of $<ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="P07_02_2021To07_02_2021_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">300,000</ix:nonFraction> was repaid at the closing of the Initial Public Offering on July&#160;2, 2021. Borrowings are no longer available under the Promissory Note. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Party Loans </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to fund working capital deficiencies or finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor or certain of the Company&#8217;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#8220;Working Capital Loans&#8221;). If the Company completes a Business Combination, it may repay such loaned amounts out of the proceeds of the Trust Account. In the event that the Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay such loaned amounts but no proceeds from the Trust Account would be used to repay such loaned amounts. As of December&#160;31, 2021, there were <ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WorkingCapitalLoansMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> outstanding amounts under the Working Capital Loans. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_53608757"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 6. COMMITMENTS AND CONTINGENCIES </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Registration Rights </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to a registration rights agreement entered into on June&#160;29, 2021, the holders of the Founder Shares, Private Placement Shares and any Private Placement Shares that may be issued on conversion of Working Capital Loans (and any Class&#160;A ordinary shares issuable upon the conversion of the Founder Shares) are entitled </div></div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-15 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%);;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><ix:continuation id="TextSelection_53608757"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">to registration rights requiring the Company to register such securities for resale (in the case of the Founder Shares, only after conversion to the Class&#160;A ordinary shares). The holders of these securities will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent to the completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. The Company will bear the expenses incurred in connection with the filing of any such registration statements. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Underwriting Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The underwriters are entitled to a deferred underwriting commission of $<ix:nonFraction name="prok:DeferredUnderwritingFees" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">7,700,000</ix:nonFraction> in the aggregate. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Unit Award </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September 2021, pursuant to a Director Restricted Stock Unit Award Agreement, dated September&#160;24, 2021, between the Company and Uma Sinha, Ph.D., the Company agreed to </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> grant&#160;</div></div><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P02_25_2021To12_31_2021_DirectorRestrictedStockUnitAwardAgreementMemberPROKAgreementAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;restricted stock units (&#8220;RSUs&#8221;) to Dr.&#160;Sinha, which grant is contingent on both the consummation of a Business Combination and a shareholder approved equity plan. The RSUs will vest upon the consummation of such Business Combination and represent&#160;</div><ix:nonFraction name="prok:NumberOfSharesOfCommonStockCommittedToSettleOnADateFollowingTheYearBusinessCombinationOccurs" contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_DirectorRestrictedStockUnitAwardAgreementMemberPROKAgreementAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;Class&#160;A ordinary shares of the Company that will settle on a date determined in the sole discretion of the Company that shall occur between the vesting date and March&#160;</div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> of the year following the year in which vesting occurs.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The RSUs to be granted by the Company are in the scope of ASC 718.&#160;Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date. The RSUs to be granted are subject to a performance condition (i.e., the occurrence of a Business Combination). Compensation expense related to the RSUs is recognized only when the performance condition is probable of occurrence under the applicable accounting literature in this circumstance. As of December&#160;31, 2021, the Company did not have a shareholder approved equity plan and also determined that a Business Combination is not considered probable, therefore, no stock-based compensation expense has been recognized. Stock-based compensation would be recognized at the date a Business Combination is considered probable (i.e., upon consummation of a Business Combination) in an amount equal to the number of RSUs times the grant date fair value per share (unless subsequently modified).</div></div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_53608771"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 7. TEMPORARY EQUITY AND PERMANENT DEFICIT </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="null;text-indent: 0px;;font-style:italic;display:inline;">Preference Shares</div></div></div></div></div>&#8212;The Company is authorized to issue <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction> preference shares, with a par value of $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction> per share. The Company&#8217;s board of directors will be authorized to fix the voting rights, if any, designations, powers, preferences, the relative, participating, optional or other special rights and any qualifications, limitations and restrictions thereof, applicable to the shares of each series. The Company&#8217;s board of directors will be able to, without shareholder approval, issue preference shares with voting and other rights that could adversely affect the voting power and other rights of the holders of the Company&#8217;s ordinary shares and could have anti-takeover effects. At December&#160;31, 2021, there were <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> preference shares issued or outstanding. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;A Ordinary Shares</div></div></div></div>&#8212;The Company is authorized to issue <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction> Class&#160;A ordinary shares, with a par value of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction> per share. At December&#160;31, 2021, there were <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">640,000</ix:nonFraction></ix:nonFraction> Class&#160;A ordinary shares issued and outstanding, excluding <ix:nonFraction name="us-gaap:CommonStockOtherSharesOutstanding" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">25,000,000</ix:nonFraction> Class&#160;A ordinary shares subject to possible redemption which are presented as temporary equity. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;B Ordinary Shares</div></div></div></div>&#8212;The Company is authorized to issue <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">50,000,000</ix:nonFraction> Class&#160;B ordinary shares, with a par value of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction> per share. At December&#160;31, 2021, there were <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,250,000</ix:nonFraction></ix:nonFraction> Class&#160;B ordinary shares issued and <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">outstanding. </div></div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-16 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%);;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><ix:continuation id="TextSelection_53608771"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holders of record</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;of Class&#160;A ordinary shares and Class&#160;B ordinary shares are entitled to one vote for each share held on all matters to be voted on by shareholders and vote together as a single class, except as required by law; provided that prior to a Business Combination, holders of Class&#160;B ordinary shares will have the right to appoint all of the Company&#8217;s directors and remove members of its board of directors for any reason, and holders of Class&#160;A ordinary shares will not be entitled to vote on the appointment of directors during such time. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Class&#160;B ordinary shares will automatically convert into Class&#160;A ordinary shares at the time of the Business Combination, or earlier at the option of the holder, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-for-one</div></div> basis, subject to adjustment for share <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-divisions,</div> share dividends, rights issuances, consolidations, reorganizations, recapitalizations and the like. Additionally, in the event that additional (in excess of the amounts issued in the Initial Public Offering) Class&#160;A ordinary shares, or equity-linked securities, are issued or deemed issued in connection with the closing of the Business Combination, the ratio at which the Class&#160;B ordinary shares will convert into Class&#160;A ordinary shares will be adjusted (unless the holders of a majority of the issued and outstanding Class&#160;B ordinary shares agree to waive such anti-dilution adjustment with respect to any such issuance or deemed issuance) so that the number of Class&#160;A ordinary shares issuable upon conversion of all Class&#160;B ordinary shares will equal, in the aggregate, <ix:nonFraction name="prok:PercentOfFoundersSharesToCompanysIssuedAndOutstandingOrdinaryShares" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">20</ix:nonFraction>% of the sum of the total number of Class&#160;A ordinary shares outstanding after such conversion (after giving effect to any redemptions of Class&#160;A ordinary shares by Public Shareholders, and excluding the Private Placement Shares), including any Class&#160;A ordinary shares issued or deemed issued, or issuable upon the conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with the Business Combination, excluding any Class&#160;A ordinary shares or equity-linked securities exercisable for or convertible into Class&#160;A ordinary shares issued, or to be issued, to any seller in the Business Combination and any private placement shares issued to the Sponsor or its affiliates upon conversion of Working Capital Loans; provided that such conversion of Class&#160;B ordinary shares will never occur on a less than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-for-one-basis.</div></div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Private Placement Shares</div></div></div></div>&#8212;The Private Placement Shares are not transferable, assignable, or salable until 30 days after the completion of a Business Combination (except, among other limited exceptions, to the Company&#8217;s directors and officers and other persons or entities affiliated with the Sponsor). Holders of the Private Placement Shares are entitled to certain registration rights. If the Company does not complete a Business Combination within the Combination Period or during any applicable extension period, the proceeds from the sale of the Private Placement Shares held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Shares will be worthless. </div> </ix:continuation> <ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_53608773"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 8. FAIR VALUE MEASUREMENTS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company follows the guidance in ASC Topic 820 for its financial assets and liabilities that are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measured</div> and reported at fair value at each reporting period, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> assets and liabilities that are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measured</div> and reported at fair value at least annually. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s financial assets and liabilities reflects management&#8217;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top;">
<td style="width: 20%; font-size: 10pt;"><div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 11%; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1: </div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. </div></td></tr></table> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-17 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%);;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><div style="margin-top: 0px; margin-bottom: 0px;"></div><br/><ix:continuation id="TextSelection_53608773" continuedAt="TextSelectionAppend_53608773_1">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="vertical-align: top;">
<td style="width: 20%; font-size: 10pt;"><div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 11%; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2: </div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">Observable inputs other than Level&#160;1 inputs. Examples of Level&#160;2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. </div></td></tr></table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="vertical-align: top;">
<td style="width: 20%; font-size: 10pt;"><div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 11%; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3: </div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability. </div></td></tr></table> </ix:continuation></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 11%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 88%; font-family: &quot;Times New Roman&quot;;"></td></tr></table><ix:continuation id="TextSelectionAppend_53608773_1"> <ix:nonNumeric name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">following table presents information about the Company&#8217;s assets that are measured at fair value on a recurring basis at December&#160;31, 2021, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 8%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities held in Trust Account</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:MarketableSecuritiesHeldToMaturityFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,008,324</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> </ix:nonNumeric> </ix:continuation> <ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_53608348"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 9. SUBSEQUENT EVENTS </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, other than as described below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements, except as follows: </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Proposed ProKidney Business Combination </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">18, 2022, the Company entered into a Business Combination Agreement (the &#8220;ProKidney Business Combination Agreement&#8221;) with ProKidney LP, a limited partnership registered under the laws of Ireland (&#8220;ProKidney&#8221;), acting through its general partner ProKidney GP Limited, a private limited company incorporated under the laws of Ireland (&#8220;Legacy GP&#8221;). </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The ProKidney Business Combination Agreement provides that, among other things and upon the terms and subject to the conditions thereof, prior to or at the closing of the ProKidney Business Combination Agreement (the &#8220;Closing&#8221;), the following transactions will occur (together with the other transactions contemplated by the ProKidney Business Combination Agreement, the &#8220;ProKidney Business Combination&#8221;): (1) ProKidney will issue to the Company a number of common units of ProKidney (&#8220;Post-Combination ProKidney Common Units&#8221;) equal to the number of fully diluted outstanding ordinary shares of the Company as of immediately prior to the Closing (but after giving effect to all redemptions of Public Shares and the purchase of Class A ordinary shares pursuant to one or more subscription agreements (the &#8220;PIPE Investment&#8221;)), in exchange for (a) (x) new Class B ordinary shares (&#8220;New ProKidney Class B ordinary shares&#8221;), which shares will have no economic rights but will entitle the holders thereof to vote on all matters on which shareholders of the Company are entitled to vote generally, and (y) restricted stock rights in respect of New ProKidney Class B ordinary shares (&#8220;New ProKidney Class B PMEL RSRs&#8221;), which restricted stock rights shall convert into New ProKidney Class B ordinary shares upon the vesting of the associated restricted common unit of ProKidney, (b) an amount in cash equal to the aggregate proceeds obtained by the Company in the PIPE Investment and (c) an amount in cash equal to the aggregate proceeds available for release to the Company from the Trust Account (after giving effect to all redemptions of Public Shares and after payment of any deferred underwriting commissions being held in the Trust Account and payment of certain transaction expenses); (2) Legacy GP will resign as the general partner of ProKidney and a private limited company incorporated under the laws of Ireland (&#8220;New GP&#8221;) will be admitted as the general partner of ProKidney; (3) ProKidney will distribute to the ProKidney unitholders the New ProKidney Class B ordinary shares and New ProKidney Class B PMEL RSRs received pursuant to clause (i)(a) (x) and (y) above; and (4)&#160;certain holders of ProKidney units will receive an aggregate of <ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="P01_18_2022To01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">17,500,000</ix:nonFraction> restricted common units of ProKidney (&#8220;Earnout RCUs&#8221;) and <ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="P01_18_2022To01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">17,500,000</ix:nonFraction> </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">restricted stock rights of the Company (&#8220;Earnout RSRs&#8221; and, together with the Earnout RCUs, the &#8220;Earnout Rights&#8221;), which Earnout Rights will vest in three equal </div></div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-18 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%);;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><ix:continuation id="TextSelection_53608348"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">tranches upon the trading price of a Class&#160;A ordinary share reaching </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">$<ix:nonFraction name="us-gaap:BusinessAcquisitionSharePrice" contextRef="PAsOn01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SharePriceOneMemberPROKSharePriceRangeAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">15.00</ix:nonFraction>/share, $<ix:nonFraction name="us-gaap:BusinessAcquisitionSharePrice" contextRef="PAsOn01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SharePriceTwoMemberPROKSharePriceRangeAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">20.00</ix:nonFraction>/share and $<ix:nonFraction name="us-gaap:BusinessAcquisitionSharePrice" contextRef="PAsOn01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SharePriceThreeMemberPROKSharePriceRangeAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">25.00</ix:nonFraction>/share, respectively, on the terms set forth in the ProKidney Business Combination Agreement, or upon certain change of control events. When vested, the Earnout RCUs will automatically convert into Post-Combination ProKidney Common Units and the associated Earnout RSRs will automatically convert into New ProKidney Class B ordinary shares, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January 18, 2022, the Company entered into subscription agreements (the &#8220;Subscription Agreements&#8221;) with certain investors (&#8220;PIPE Investors&#8221;) pursuant to which the PIPE Investors have subscribed for an aggregate of <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P01_18_2022To01_18_2022_PipeInvestorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">57,500,000</ix:nonFraction> Class A ordinary shares for a price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn01_18_2022_PipeInvestorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction> per share for an aggregate purchase price of $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P01_18_2022To01_18_2022_PipeInvestorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">575,000,000</ix:nonFraction>, of which (1) $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P01_18_2022To01_18_2022_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">156,400,000</ix:nonFraction> is committed by certain existing directors, officers and equityholders of, or investment funds managed by Suvretta Capital Management, LLC, the Company, the Sponsor and/or their respective affiliates participating in the PIPE Investment, and (2) at least $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P01_18_2022To01_18_2022_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">50,000,000</ix:nonFraction> (which may, at the election of such investors, be increased to up to $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P01_18_2022To01_18_2022_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MaximumMembersrtRangeAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">100,000,000</ix:nonFraction>) is committed by certain existing directors, officers and unitholders of ProKidney and/or its affiliates participating in the PIPE Investment (the &#8220;ProKidney Related PIPE Investors&#8221;); provided that the ProKidney Related PIPE Investors may elect instead to purchase Post-Combination ProKidney Common Units, together with a corresponding number of Class B ordinary shares, in lieu of Class A ordinary shares. The Subscription Agreements are subject to certain conditions, including that there shall not be in force any injunction or order enjoining or prohibiting the issuance and sale of the shares under the Subscription Agreements; the terms of the ProKidney Business Combination Agreement shall not have been amended, and the minimum cash condition therein shall not have been waived, in a manner that is materially adverse to the investor party to the Subscription Agreement; and the representation and warranties of the parties to the Subscription Agreement shall be accurate (subject to agreed materiality thresholds). </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the Closing, the combined company will be organized in an umbrella partnership-C corporation (a so called &#8220;Up-C&#8221;) structure, and the Company&#8217;s direct assets will consist of ProKidney Common Units and equity interests of New GP, and substantially all of the operating assets and business of the Company will be held indirectly through ProKidney. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consummation of the proposed ProKidney Business Combination is subject to certain conditions as further described in the ProKidney Business Combination Agreement. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Legal Proceedings </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain purported shareholders of the Company sent demand letters (the &#8220;Demands&#8221;) alleging deficiencies and/or omissions in the ProKidney Disclosure Statement filed by the Company with the SEC on February&#160;14, 2022. The Demands seek additional disclosures to remedy these purported deficiencies. We believe that the allegations in the Demands are meritless. </div></div></div> </ix:continuation> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Promissory Note: Unaudited </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On April&#160;20, 2022, the Company issued an unsecured promissory note (the &#8220;Promissory Note&#8221;) to the Sponsor pursuant to which the Company may borrow up to an aggregate principal amount of $1,500,000. The Promissory Note is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing, unsecured and payable upon the earlier of July&#160;2, 2023 and the effective date of the Company&#8217;s Business Combination. The Promissory Note is subject to customary events of default which could, subject to certain conditions, cause the Promissory Note to become immediately due and payable. On April&#160;26, 2022, the Company drew $250,000 under the Promissory Note. </div></div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-19 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div></div></div></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><br/></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fincov373959_7" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. III </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONDENSED BALANCE SHEETS </div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div><br/></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Unaudited)</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ASSETS</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">51,889</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">440,488</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">543,088</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">504,189</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Current Assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">594,977</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">944,677</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current</div> prepaid insurance</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:PrepaidInsuranceNonCurrent" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">123,750</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:PrepaidInsuranceNonCurrent" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">247,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities held in Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,033,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsHeldInTrustNoncurrent" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,008,324</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TOTAL ASSETS</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,752,227</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">251,200,501</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LIABILITIES, TEMPORARY EQUITY AND PERMANENT DEFICIT</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">26,735</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:AccruedExpensesCurrent" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,342,189</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:AccruedExpensesCurrent" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,864,796</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Advances from related party</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">43,623</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrent" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Total current liabilities</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,412,547</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,879,796</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred underwriting fee payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:DeferredUnderwritingCommissions" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">7,700,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:DeferredUnderwritingCommissions" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">7,700,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Liabilities</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">13,112,547</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">9,579,796</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and Contingencies (Note 6)</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Temporary Equity</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares subject to possible redemption, <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">25,000,000</ix:nonFraction></ix:nonFraction> shares at redemption value as of March&#160;31, 2022 and December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,008,324</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Permanent Deficit</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Preference shares, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;shares issued and&#160;outstanding as of March&#160;31, 2022 and December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">640,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding (excluding <ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">25,000,000</ix:nonFraction></ix:nonFraction> shares subject to possible redemption) as of March&#160;31, 2022 and December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">64</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">64</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B ordinary shares, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">50,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,250,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2022 and December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">625</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">625</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction>&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated deficit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">12,361,009</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,388,308</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Permanent Deficit</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">12,360,320</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,387,619</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TOTAL LIABILITIES, TEMPORARY EQUITY AND PERMANENT DEFICIT</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,752,227</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">251,200,501</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of the unaudited condensed financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-20 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"></div> </div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fincov373959_8" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. III </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONDENSED STATEMENTS OF OPERATIONS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(UNAUDITED) </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Three<br/>Months<br/>Ended<br/>March&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the<br/>Period from<br/>February&#160;25,<br/>2021<br/>(Inception)<br/>Through<br/>March&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating and formation costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">4,006,201</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P02_25_2021To03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,182</ix:nonFraction> </td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss from operations</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">4,006,201</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P02_25_2021To03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">5,182</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest earned on marketable securities held in Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">25,176</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P02_25_2021To03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">3,981,025</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_25_2021To03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">5,182</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average shares outstanding, Class&#160;A ordinary shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">25,640,000</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P02_25_2021To03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:fixed-zero"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P02_25_2021To03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share, Class&#160;A ordinary shares</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal">0.12</ix:nonFraction></ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P02_25_2021To03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:fixed-zero"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P02_25_2021To03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average shares outstanding, Class&#160;B ordinary shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,250,000</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P02_25_2021To03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P02_25_2021To03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,500,000</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per share, Class&#160;B ordinary shares</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal">0.12</ix:nonFraction></ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P02_25_2021To03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P02_25_2021To03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0</ix:nonFraction></ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of the unaudited condensed financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-21 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div id="fincov373959_9" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. III </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONDENSED STATEMENTS OF CHANGES IN TEMPORARY EQUITY AND PERMANENT DEFICIT </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(UNAUDITED) </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE THREE MONTHS ENDED MARCH&#160;31, 2022 </div></div></div></div> <div style="font-size: 12pt; text-align: left;;font-weight:bold;display:inline;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 30%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Temporary Equity</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div><br/>Capital</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>Deficit</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>Permanent<br/>Deficit</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; width: 30%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance&#8212;January&#160;1, 2022</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">25,000,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,008,324</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">640,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">64</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,250,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">625</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,388,308</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,387,619</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap; width: 30%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Remeasurement for Class&#160;A ordinary shares to <br/>redemption amount</div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="prok:RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity" contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">8,324</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity" contextRef="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,324</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,324</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; width: 30%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">3,981,025</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">3,981,025</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 30%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; width: 30%;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance&#8212;March&#160;31, 2022</div></div> </td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">25,000,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,000,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">640,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">64</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,250,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">625</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">12,361,009</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">12,360,320</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; width: 30%;">&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom; width: 1%;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 24pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FOR THE PERIOD FROM FEBRUARY&#160;25, 2021 (INCEPTION) THROUGH MARCH&#160;31, </div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2021 </div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 9pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 43%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Temporary&#160;Equity</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary&#160;Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Ordinary Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Additional<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Paid-in</div><br/>Capital</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>Deficit</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>Permanent<br/>Equity</div></div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance&#8212;February&#160;25, 2021 (inception)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn02_24_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn02_24_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn02_24_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn02_24_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn02_24_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Issuance of Class&#160;B ordinary shares to<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>Sponsor</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160; &#160;&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P02_25_2021To03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,325,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="P02_25_2021To03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">633</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="P02_25_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">24,367</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="P02_25_2021To03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; white-space: nowrap;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_25_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">5,182</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">) </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_25_2021To03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">5,182</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 9pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance&#8212;March&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,325,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">633</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">24,367</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">5,182</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;">) </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">19,818</ix:nonFraction>&#160;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of the unaudited condensed financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-22 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"></div> </div> <div> <div style="font-size: 13.28px; margin-top: 0pt; margin-bottom: 0pt;;font-weight: bold;"></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fincov373959_10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. III </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">CONDENSED STATEMENTS OF CASH FLOWS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(UNAUDITED)</div></div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Three<br/>Months<br/>Ended<br/>March&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the<br/>Period from<br/>February&#160;25,<br/>2021<br/>(Inception)<br/>Through<br/>March&#160;31,</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flows from Operating Activities:</div></div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">3,981,025</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_25_2021To03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">5,182</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net loss to net cash used in operating activities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Formation costs paid by Sponsor in exchange for issuance of Founder Shares</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:FormationCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares" contextRef="P02_25_2021To03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest earned on marketable securities held in Trust Account</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">25,176</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in operating assets and liabilities:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpense" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">84,851</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr>
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;">Advances&#160;from related party</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="prok:IncreaseDecreaseOfAdvanceFromRelatedParty" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">33,623</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;">Accrued expenses and accounts payable</div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,499,128</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P02_25_2021To03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">44</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); padding-bottom: 0.375pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash used in operating activities</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black; border-top: 0.75pt solid black;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); border-bottom: 0.75pt solid black; border-top: 0.75pt solid black;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">388,599</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;">) </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt; border-bottom: 0.75pt solid black;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt; border-bottom: 0.75pt solid black;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P02_25_2021To03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">138</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255); padding-bottom: 0.375pt;">) </td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash Flows from Financing Activities:</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from promissory note<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div>related party</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="P02_25_2021To03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">255</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.26in; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payment of offering costs</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P02_25_2021To03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">117</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);"> <div style="margin-left: 0.26in;">&#160;</div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.52in; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash provided by financing activities</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; width: 8%; padding: 0pt 5pt 0pt 0pt; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P02_25_2021To03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">138</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net Change in Cash</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">388,599</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 9%; padding: 0pt 5pt 0pt 0pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212; </div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div>Beginning of period&#160;(inception)</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">440,488</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash<div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">&#8212;</div>End of period</div></div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">51,889</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255); width: 6%; padding: 0pt 5pt 0pt 0pt;;text-align:right;"><div style="letter-spacing: 0px; top: 0px; white-space: nowrap;;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Cash</div> Investing and Financing Activities:</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering costs paid by Sponsor in exchange for issuance of Founder Shares</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="us-gaap:StockIssued1" contextRef="P02_25_2021To03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">20,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(255, 255, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Remeasurement&#160;of Class&#160;A ordinary shares subject to possible redemption</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td>
<td style="white-space: nowrap; vertical-align: bottom;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; background-color: rgb(204, 238, 255);"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Offering costs included in accrued offering costs</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">$</td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;"><ix:nonFraction name="prok:OfferingCostsIncludedInAccruedOfferingCosts" contextRef="P02_25_2021To03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">&#160;</td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="background-color: rgb(255, 255, 255);">&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px; text-indent: 0px;"></div> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying notes are an integral part of the unaudited condensed financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-23 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"></div> </div> <div><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div id="fincov373959_11" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. III </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTES TO CONDENSED FINANCIAL STATEMENTS </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">MARCH&#160;31, 2022 </div></div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Unaudited) </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <ix:nonNumeric name="us-gaap:NatureOfOperations" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_53608076"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 1. DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN </div></div></div></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Social Capital Suvretta Holdings Corp. III (the &#8220;Company&#8221;) is a blank check company incorporated as a Cayman Islands exempted company on&#160;February 25, 2021. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (a &#8220;Business Combination&#8221;). The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of Marc</div></div>h&#160;31, 2022, the Company had not commenced&#160;any operations. All activity for the period from <ix:nonNumeric name="dei:EntityIncorporationDateOfIncorporation" contextRef="P01_01_2022To03_31_2022" format="ixt:date-monthname-day-year-en">February 25, 2021</ix:nonNumeric> (inception) through March&#160;31, 2022 relates to the Company&#8217;s formation, the initial public offering (the &#8220;Initial Public Offering&#8221;), described below, and, subsequent to the Initial Public Offering, identifying a target company for a Business Combination and activities in connection with the proposed acquisition of ProKidney LP (see Note 6). The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company generates <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> income in the form of interest income from the marketable securities held in the Trust Account (as defined below). </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The registration </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">statements for the Company&#8217;s Initial Public Offering became effective on June&#160;29, 2021 and June&#160;30, 2021. On July&#160;2, 2021, the Company consummated the Initial Public Offering of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000,000</ix:nonFraction> Class&#160;A ordinary shares (the &#8220;Public Shares&#8221;), which includes the partial exercise by the underwriters of their over-allotment option in the amount of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,000,000</ix:nonFraction> Public Shares, at $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction> per Public Share, generating gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,000,000</ix:nonFraction>, which is described in Note 3. The fair value attributable to the unexercised portion of the over-allotment option was deemed to be immaterial to the condensed financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Substantially </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">concurrently with the closing of the Initial Public Offering, the Company consummated the sale of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">640,000</ix:nonFraction> Class&#160;A ordinary shares (the &#8220;Private Placement Shares&#8221;) at a price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction> per Private Placement Share in a private placement to SCS Sponsor III LLC, a Cayman Islands limited liability company (the &#8220;Sponsor&#8221;), generating gross proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">6,400,000</ix:nonFraction>, which is described in Note 4. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">costs amounted to $<ix:nonFraction name="prok:TransactionCostsIncurredInConnectionWithInitialPublicOffering" contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">12,479,666</ix:nonFraction>, consisting of $<ix:nonFraction name="prok:UnderwritingFee" contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">4,400,000</ix:nonFraction> of underwriting fees, $<ix:nonFraction name="prok:DeferredUnderwritingFees" contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">7,700,000</ix:nonFraction> of deferred underwriting fees and $<ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">379,666</ix:nonFraction> of other offering costs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection </div></div>with the closing of the Initial Public Offering on July&#160;2, 2021, an amount of $<ix:nonFraction name="us-gaap:CommonStockHeldInTrust" contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,000,000</ix:nonFraction> ($<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction> per Public Share) from the net proceeds of the sale of the Public Shares in the Initial Public Offering and the sale of the Private Placement Shares was placed in a trust account (the &#8220;Trust Account&#8221;), and invested in U.S. government treasury bills with a maturity of 185 days or less or in money market funds investing solely in U.S. Treasuries and meeting certain conditions of Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2a-7</div> of the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;). Except with respect to interest earned on the funds held in the Trust Account that may be released to the Company to pay its taxes, if any, the funds held in the Trust Account will not be released from the Trust Account until the earliest of: (a)&#160;the completion of a Business Combination, and then only in connection with those Public Shares that such shareholder properly elected to redeem, subject to certain limitations; (b)&#160;the redemption of any Public Shares properly submitted in connection with a shareholder vote to amend the Company&#8217;s Amended and Restated Memorandum and Articles of Association (i)&#160;to modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with the Business Combination or to redeem <ix:nonFraction name="prok:PercentageOfPublicSharesRedemption" contextRef="P07_02_2021To07_02_2021" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">% of the Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (ii)&#160;with respect to any other material provisions relating to shareholders&#8217; rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-Business</div> Combination activity; and (c)&#160;the redemption of the Public Shares if the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-24 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%);;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><ix:continuation id="TextSelection_53608076" continuedAt="TextSelectionAppend_53608076_1"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company has not completed a Business Combination within the Combination Period or during any applicable extension period. The proceeds deposited in the Trust Account could become subject to the claims of the Company&#8217;s creditors, if any, which could have priority over the claims of the holders of the Public Shares (the &#8220;Public Shareholders&#8221;). </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Shares, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. The Company must complete one or more Business Combinations having an aggregate fair market value of at least <ix:nonFraction name="prok:ProspectiveAssetsOfAcquireeAsAPercentageOfFairValueOfAssetsInTheTrustAccount" contextRef="PAsOn07_02_2021_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">80</ix:nonFraction>% of the value of the assets held in the Trust Account (excluding any deferred underwriting commissions and taxes payable on the income earned on the Trust Account) at the time of the Company signing a definitive agreement in connection with the Business Combination. However, the Company will only complete a Business Combination if the post-Business Combination company owns or acquires <ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="PAsOn07_02_2021_MinimumMembersrtRangeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to complete a Business Combination successfully. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div>will provide the Public Shareholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of the Business Combination, either (a)&#160;in connection with a general meeting called to approve the Business Combination or (b)&#160;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company. The Public Shareholders will be entitled to redeem all or a portion of their Public Shares at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, calculated as of two business days prior to the consummation of the Business Combination, including interest (which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares, subject to the limitations described <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">below. </div></div></div><br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">with the Company&#8217;s Amended and Restated Memorandum and Articles of Association, in no event will the Company redeem the Public Shares in an amount that would cause the Company&#8217;s net tangible assets to be less than $<ix:nonFraction name="us-gaap:MinimumNetWorthRequiredForCompliance" contextRef="PAsOn07_02_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000,001</ix:nonFraction> following such redemptions. Redemptions of the Public Shares may also be subject to a higher net tangible asset test or cash requirement pursuant to an agreement relating to the Business Combination. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If a shareholder vote is not required in connection with a Business Combination and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (the &#8220;SEC&#8221;), and file tender offer documents with the SEC prior to completing a Business Combination. If, however, shareholder approval of the transaction is required by applicable law or stock exchange listing requirement, or the Company decides to obtain shareholder approval for business or other reasons, the Company will conduct the redemptions in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules and will file proxy materials with the SEC. If the Company seeks shareholder approval in connection with a Business Combination, the Company will complete such Business Combination only if the Company receives an ordinary resolution under Cayman Islands law, which requires the affirmative vote of holders of a majority of ordinary shares who attend and vote at a general meeting of the Company. The Public Shareholders may elect to redeem their Public Shares without voting and, if they do vote, irrespective of whether they vote for or against a Business Combination. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notwithstanding the foregoing redemption rights, if the Company seeks shareholder approval of the Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, the Company&#8217;s Amended and Restated Memorandum and Articles of Association provide that a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &#8220;group&#8221; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-25 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%);;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><ix:continuation id="TextSelectionAppend_53608076_1" continuedAt="TextSelectionAppend_53608076_2"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Exchange Act&#8221;)), will be restricted from redeeming its Public Shares with respect to more than an aggregate </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of <ix:nonFraction name="prok:PercentageOfPublicSharesThatCanBeTransferredWithoutAnyRestriction" contextRef="PAsOn07_02_2021" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">15</ix:nonFraction>% of the Public Shares without the Company&#8217;s prior written consent. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsor and </div></div>the Company&#8217;s directors and officers have agreed to waive: (a)&#160;their redemption rights with respect to any Founder Shares, Private Placement Shares and Public Shares held by them, as applicable, in connection with the completion of a Business Combination; (b)&#160;their redemption rights with respect to any Founder Shares, Private Placement Shares and Public Shares held by them in connection with a shareholder vote to amend the Company&#8217;s Amended and Restated Memorandum and Articles of Association (i)&#160;to modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with the Business Combination or to redeem <ix:nonFraction name="prok:PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated" contextRef="PAsOn07_02_2021" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">100</ix:nonFraction>% of the Public Shares if the Company does not complete a Business Combination within the Combination Period, or (ii)&#160;with respect to any other material provisions relating to shareholders&#8217; rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-Business</div> Combination activity; and (c)&#160;their rights to liquidating distributions from the Trust Account with respect to any Founder Shares and Private Placement Shares they hold if the Company fails to complete a Business Combination within the Combination Period or during any applicable extension period (although such persons will be entitled to liquidating distributions from the Trust Account with respect to any Public Shares they hold if the Company fails to complete a Business Combination within the prescribed time frame). If the Company submits the Business Combination to the Public Shareholders for a vote, the Sponsor and the Company&#8217;s directors and officers have also agreed to vote any Founder Shares, Private Placement Shares and Public Shares held by them in favor of the Business Combination. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div>will have until July&#160;2, 2023 to complete a Business Combination (the &#8220;Combination Period&#8221;), or such longer period as a result of a shareholder vote to amend such time period pursuant to the Company&#8217;s Amended and Restated Memorandum and Articles of Association. However, if the Company has not completed a Business Combination within such Combination Period or during any applicable extension period, the Company will: (a)&#160;cease all operations except for the purpose of winding up; (b)&#160;as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less up to $<ix:nonFraction name="us-gaap:LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities" contextRef="PAsOn07_02_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">100,000</ix:nonFraction> of interest to pay dissolution expenses and which interest shall be net of taxes payable) divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish the Public Shareholders&#8217; rights as shareholders (including the right to receive further liquidating distributions, if any); and (c)&#160;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#8217;s remaining shareholders and its board of directors, liquidate and dissolve, subject in each case to the Company&#8217;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsor </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">has agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company&#8217;s independent auditors) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1) $<ix:nonFraction name="prok:PerShareValueOfRestrictedAssets" contextRef="PAsOn07_02_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction> per Public Share or (2)&#160;such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, due to reductions in the value of the trust assets, in each case net of the interest which may be withdrawn to pay taxes, except as to any claims by a third party that executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company&#8217;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company has not independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and believes that the Sponsor&#8217;s only assets are securities of the Company and, therefore, the Sponsor may not be able to satisfy those obligations. The Company has not asked the Sponsor to reserve for such obligations. None of the Company&#8217;s directors or officers will indemnify the Company for claims by third parties, including, without limitation, claims by vendors and prospective target </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">businesses.</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><br/></div> </ix:continuation> </div></div> </div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-26 </div></div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><br/></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div></div></div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_53608076_2" continuedAt="TextSelectionAppend_53608076_3"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Proposed ProKidney Business Combination</div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;18, 2022, the Company entered into a Business Combination Agreement (the &#8220;ProKidney Business Combination Agreement&#8221;) with ProKidney LP, a limited partnership registered under the laws of Ireland (&#8220;ProKidney&#8221;), acting through its general partner ProKidney GP Limited, a private limited company incorporated under the laws of Ireland (&#8220;Legacy GP&#8221;). </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The ProKidney </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Business Combination Agreement provides that, among other things and upon the terms and subject to the conditions thereof, prior to or at the closing of the ProKidney Business Combination Agreement (the &#8220;Closing&#8221;), the following transactions will occur (together with the other transactions contemplated by the ProKidney Business Combination Agreement, the &#8220;ProKidney Business Combination&#8221;): (1) ProKidney will issue to the Company a number of common units of ProKidney (&#8220;Post-Combination ProKidney Common Units&#8221;) equal to the number of fully diluted outstanding ordinary shares of the Company as of immediately prior to the Closing (but after giving effect to all redemptions of Public Shares and the purchase of Class&#160;A ordinary shares pursuant to one or more subscription agreements (the &#8220;PIPE Investment&#8221;)), in exchange for (a)&#160;(x) new Class&#160;B ordinary shares (&#8220;New ProKidney Class&#160;B ordinary shares&#8221;), which shares will have no economic rights but will entitle the holders thereof to vote on all matters on which shareholders of the Company are entitled to vote generally, and (y)&#160;restricted stock rights in respect of New ProKidney Class&#160;B ordinary shares (&#8220;New ProKidney Class&#160;B PMEL RSRs&#8221;), which restricted stock rights shall convert into New ProKidney Class&#160;B ordinary shares upon the vesting of the associated restricted common unit of ProKidney, (b)&#160;an amount in cash equal to the aggregate proceeds obtained by the Company in the PIPE Investment and (c)&#160;an amount in cash equal to the aggregate proceeds available for release to the Company from the Trust Account (after giving effect to all redemptions of Public Shares and after payment of any deferred underwriting commissions being held in the Trust Account and payment of certain transaction expenses); (2) Legacy GP will resign as the general partner of ProKidney and a private limited company incorporated under the laws of Ireland (&#8220;New GP&#8221;) will be admitted as the general partner of ProKidney; (3)&#160;ProKidney will distribute to the ProKidney unitholders the New ProKidney Class&#160;B ordinary shares and New ProKidney Class&#160;B PMEL RSRs received pursuant to clause (i)(a)&#160;(x) and (y) above; and (4)&#160;certain holders of ProKidney units will receive an aggregate of <ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="P01_18_2022To01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">17,500,000</ix:nonFraction> restricted common units of ProKidney (&#8220;Earnout RCUs&#8221;) and <ix:nonFraction name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" contextRef="P01_18_2022To01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">17,500,000</ix:nonFraction> restricted stock rights of the Company (&#8220;Earnout RSRs&#8221; and, together with the Earnout RCUs, the &#8220;Earnout Rights&#8221;), which Earnout Rights will vest in three equal tranches upon the trading price of a Class&#160;A ordinary share reaching $<ix:nonFraction name="us-gaap:BusinessAcquisitionSharePrice" contextRef="PAsOn01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SharePriceOneMemberPROKSharePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">15.00</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;per </div>share, $<ix:nonFraction name="us-gaap:BusinessAcquisitionSharePrice" contextRef="PAsOn01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SharePriceTwoMemberPROKSharePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">20.00</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;per </div>share and $<ix:nonFraction name="us-gaap:BusinessAcquisitionSharePrice" contextRef="PAsOn01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SharePriceThreeMemberPROKSharePriceRangeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">25.00</ix:nonFraction><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;per </div>share, respectively, on the terms set forth in the ProKidney Business Combination Agreement, or upon certain change of control events. When vested, the Earnout RCUs will automatically convert into Post-Combination ProKidney Common Units and the associated Earnout RSRs will automatically convert into New ProKidney Class&#160;B ordinary shares, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;18, 2022, the Company entered into subscription agreements (the &#8220;Subscription Agreements&#8221;) with certain investors (&#8220;PIPE Investors&#8221;) pursuant to which the PIPE Investors have subscribed for an aggregate of <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P01_18_2022To01_18_2022_PipeInvestorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">57,500,000</ix:nonFraction> Class&#160;A ordinary shares for a price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn01_18_2022_PipeInvestorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction> per share for an aggregate purchase price of $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P01_18_2022To01_18_2022_PipeInvestorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">575,000,000</ix:nonFraction>, of which (1) $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P01_18_2022To01_18_2022_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">156,400,000</ix:nonFraction> is committed by certain existing directors, officers and equityholders of, or investment funds managed by Suvretta Capital Management, LLC, the Company, the Sponsor and/or their respective affiliates participating in the PIPE Investment (collectively, the &#8220;Sponsor Related PIPE Investors&#8221;), and (2)&#160;at least $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P01_18_2022To01_18_2022_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">50,000,000</ix:nonFraction> (which may, at the election of such investors, be increased to up to $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P01_18_2022To01_18_2022_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MaximumMembersrtRangeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">100,000,000</ix:nonFraction>) is committed by certain existing directors, officers and unitholders of ProKidney and/or its affiliates participating in the PIPE Investment (the &#8220;ProKidney Related PIPE Investors&#8221;); provided that the ProKidney Related PIPE Investors may elect instead to purchase Post-Combination ProKidney Common Units, together with a corresponding number of Class&#160;B ordinary shares, in lieu of Class&#160;A ordinary shares. The Subscription Agreements are subject to certain conditions, including that there shall not be in force any injunction or order enjoining or prohibiting the issuance and sale of the shares under the Subscription Agreements; the terms of the ProKidney Business Combination Agreement shall not have been amended, and the minimum cash condition therein shall not have been waived, in a manner that is materially adverse to the investor party to the Subscription Agreement; and the representation and warranties of the parties to the Subscription Agreement shall be accurate (subject to agreed materiality </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">thresholds). </div></div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-27 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%);;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><ix:continuation id="TextSelectionAppend_53608076_3"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Following the Closing, the combined company will be organized in an umbrella <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">partner</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ship-C</div> corporation (a so called <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Up-C&#8221;)</div> structure, and the Company&#8217;s direct assets will consist of ProKidney Common Units and equity interests of New GP, and substantially all of the operating assets and business of the Company will be held indirectly through ProKidney. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consummation of the proposed ProKidney Business Combination is subject to certain conditions as further described in the ProKidney Business Combination Agreement. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks and Uncertainties </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management </div></div>continues to evaluate the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and has concluded that while it is reasonably possible that the pandemic could have a negative effect on the Company&#8217;s business, financial position, results of operations and/or the search for a target company, the specific impact is not readily determinable as of the date of these condensed financial statements. The condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Going Concern </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31, 2022, the Company had $<ix:nonFraction name="us-gaap:Cash" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">51,889</ix:nonFraction> in its operating bank account and working capital deficit of $<ix:nonFraction name="prok:WorkingCapital" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">4,817,570</ix:nonFraction>. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Until the consummation of a Business Combination, the Company will be using the funds not held in the Trust Account for identifying and evaluating prospective acquisition candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to acquire, and structuring, negotiating and consummating the Business Combination. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may need to raise additional capital through loans or additional investments from its Sponsor, shareholders, officers, directors, or third parties. The Company&#8217;s officers, directors and Sponsor may, but are not obligated to (other than pursuant to the Promissory Note (as defined in Note 9)), loan the Company additional funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet the Company&#8217;s working capital needs. Accordingly, the Company may not be able to obtain such additional financing. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern for a reasonable period of time, which is considered to be one year from the issuance date of the condensed financial statements. These condensed financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We have performed an assessment of going concern considerations in accordance with Financial Accounting Standard Board&#8217;s Accounting Standards Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2014-15,</div> &#8220;Disclosures of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern.&#8221; We have until July&#160;2, 2023 to consummate a Business Combination, which date may be extended pursuant to its Amended and Restated Memorandum and Articles of Association. It is uncertain that the Company will be able to consummate a Business Combination by July&#160;2, 2023. If a Business Combination is not consummated by this date and such date is not extended pursuant to the Company&#8217;s Amended and Restated Memorandum and Articles of Association, there will be a mandatory liquidation and subsequent dissolution of the Company. Management has determined that the mandatory liquidation, should a Business Combination not occur within the required time period, and potential subsequent dissolution raises substantial doubt about the Company&#8217;s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after July&#160;2, 2023. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-28 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%);;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_53608083"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </div></div></div></div> <ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The </div>accompanying unaudited condensed financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and in accordance with the instructions to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;10-Q</div> and Article&#160;8 of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Regulation&#160;S-X</div> of the SEC. Certain information or footnote disclosures normally included in condensed financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements contained in the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the period ended December&#160;31, 2021 filed with the SEC on March&#160;24, 2022. The interim results for the three months ended March&#160;31, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022 or for any future periods. </div></ix:nonNumeric> <ix:nonNumeric name="prok:EmergingGrowthCompanyStatusPolicyTextBlock" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s condensed financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. <br/></div></ix:nonNumeric> </ix:nonNumeric> </div></div></div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_53608083" continuedAt="TextSelectionAppend_53608083_1"> <ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_53608333"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates</div></div></div></div><br/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div></div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-29 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <ix:continuation id="TextSelectionAppend_53608083_1" continuedAt="TextSelectionAppend_53608083_2"><ix:continuation id="TextSelection_53608333"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Significant accounting estimates include the determination of the fair value of Class&#160;A ordinary shares subject to possible redemption and the fair value of Founder Shares transferred to directors. Accordingly, the actual results could differ significantly from those estimates.</div></div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of March&#160;31, 2022 and December&#160;31, 2021. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Marketable Securities Held in Trust Account </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At March&#160;31, 2022 and December&#160;31, 2021, substantially all of the assets held in the Trust Account were held in a money market fund which is invested primarily in U.S. Treasury securities. </div></div></ix:nonNumeric> <ix:nonNumeric name="prok:TemporaryEquityPolicyTextBlock" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class&#160;A Ordinary Shares Subject to Possible Redemption </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its Class&#160;A ordinary shares subject to possible redemption in accordance with the guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 480, &#8220;Distinguishing Liabilities from Equity.&#8221; Class&#160;A ordinary shares subject to mandatory redemption are classified as a liability instrument and are measured at redemption value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) are classified as temporary equity. At all other times, ordinary shares are classified as permanent deficit. The Company&#8217;s Class&#160;A ordinary shares feature certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events. Accordingly, Class&#160;A ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the permanent deficit section of the Company&#8217;s condensed balance sheets. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying value of redeemable ordinary shares are affected by charges against additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital (to the extent available) and accumulated deficit. </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At March&#160;31, 2022 and December&#160;31, 2021, the Class&#160;A ordinary shares subject to possible redemption reflected in the condensed balance sheets are reconciled in the following </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">table: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-size: 0px;">
<td style="width: 77%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares issuance costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="prok:TemporaryEquityIssaunceCosts" contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">12,479,666</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity" contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">12,487,990</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Class&#160;A ordinary shares subject to possible redemption, December&#160;31, <br/>2021</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,008,324</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr>
<td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"><br/></div></div> </td>
<td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;">&#160;</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Remeasurement of carrying value to redemption value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="prok:RemeasurementOfCarryingValueToRedemptionValue" contextRef="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">8,324</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares subject to possible redemption, March&#160;31, 2022</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,000,000</ix:nonFraction></div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr>
<td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"><br/></div></div> </td>
<td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;">&#160;</div></div></div> </td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> </ix:nonNumeric></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-30 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <ix:continuation id="TextSelectionAppend_53608083_2" continuedAt="TextSelectionAppend_53608083_3"> <ix:nonNumeric name="prok:DeferredOfferingCostsPolicyTextBlock" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Offering Costs </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div>complies with the requirements of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASC&#160;340-10-S99-1.&#160;Offering&#160;costs</div></div></div> consisted of legal, accounting, underwriting fees and other costs incurred through the Initial Public Offering that were directly related to the Initial Public Offering. The Company incurred offering costs amounting to $<ix:nonFraction name="prok:TransactionCostsIncurredInConnectionWithInitialPublicOffering" contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">12,479,666</ix:nonFraction> as a result of the Initial Public Offering, consisting of $<ix:nonFraction name="prok:UnderwritingFee" contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">4,400,000</ix:nonFraction> of underwriting commissions, $<ix:nonFraction name="prok:DeferredUnderwritingFees" contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">7,700,000</ix:nonFraction> of deferred underwriting commissions, and $<ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">379,666</ix:nonFraction>&#160;of other offering costs. <div style="letter-spacing: 0px; top: 0px;;display:inline;">As the shares sold in the IPO are redeemable, the offering costs were charged to temporary equity and additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital upon the completion of the Initial Public Offering. Immediately thereafter, temporary equity was remeasured and an adjustment was recognized through additional paid in capital and accumulated deficit to adjust temporary equity to the redemption value. </div><br/></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-Based Payment Arrangements </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">accounts for stock awards in accordance with ASC 718, &#8220;Compensation&#8212;Stock Compensation,&#8221; which requires that all equity awards be accounted for at their &#8220;fair value.&#8221; Fair value is measured on the grant date and is equal to the underlying value of the stock. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Costs equal </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">to these fair values are recognized ratably over the requisite service period based on the number of awards that are expected to vest, in the period of grant for awards that vest immediately and have no future service condition, or in the period the awards vest immediately after meeting a performance condition becomes probable (i.e., the occurrence of a Business Combination). For awards that vest over time, cumulative adjustments in later periods are recorded to the extent actual forfeitures differ from the Company&#8217;s initial estimates; previously recognized compensation cost is reversed if the service or performance conditions are not satisfied and the award is&#160;forfeited. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes under ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the condensed financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s condensed financial statements and prescribes a recognition threshold and measurement process for condensed financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> to be sustained upon examination by taxing authorities. The Company&#8217;s management has determined that the Cayman Islands is the Company&#8217;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of March&#160;31, 2022 and December&#160;31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has been subject to income tax examinations by major taxing authorities since inception. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is considered to be an exempted Cayman Islands company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#8217;s tax provision was zero for the periods presented. </div></div></div></ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_53608274"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Loss per Ordinary Share </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per ordinary share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding during the period. The Company has two classes of ordinary shares, which are referred to as </div></div></div></ix:nonNumeric></ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-31 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <ix:continuation id="TextSelectionAppend_53608083_3" continuedAt="TextSelectionAppend_53608083_4"><ix:continuation id="TextSelection_53608274"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares and Class&#160;B ordinary shares. Losses are shared pro rata between the two classes of shares. Charges associated with the redeemable Class&#160;A ordinary shares are excluded from net loss per ordinary share as the redemption value approximates fair value. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31, 2022 and 2021, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted net loss per ordinary share is the same as basic net loss per ordinary share for the periods presented. </div></div> <ix:nonNumeric name="us-gaap:TemporaryEquityTableTextBlock" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/>March&#160;31, 2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Period from<br/>February&#160;25, 2021<br/>(Inception) Through</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per ordinary share</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">3,200,799</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">780,226</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_25_2021To03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P02_25_2021To03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">5,182</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average shares outstanding</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">25,640,000</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,250,000</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P02_25_2021To03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P02_25_2021To03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P02_25_2021To03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P02_25_2021To03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,500,000</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per ordinary share</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.12</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.12</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P02_25_2021To03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P02_25_2021To03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero">&#8212;</ix:nonFraction></ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P02_25_2021To03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P02_25_2021To03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.00</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> </ix:nonNumeric></ix:continuation> <ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:rgba(255, 255, 255, .0);;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution which, at times may exceed the Federal Depository Insurance Corporation coverage limit of $<ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,000</ix:nonFraction>. The Company has not experienced losses on these </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:rgba(255, 255, 255, .0);;display:inline;">accounts. </div></div></div><br/></div></ix:nonNumeric></ix:continuation> </div> </div> </div> <div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_53608083_4" continuedAt="TextSelectionAppend_53608083_5"> <ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; (&#8220;ASC 820&#8221;), approximates the carrying amounts represented in the accompanying condensed balance sheet, primarily due to their short-term nature. </div></div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Standards </div></div></div><br/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2020, the FASB issued ASU No. 2020-06, &#8220;Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity&#8221; (&#8220;ASU 2020-06&#8221;), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. The Company adopted ASU 2020-06 effective as of January 1, 2021. The adoption of ASU 2020-06 did not have an impact on the Company&#8217;s condensed financial statements. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s condensed financial statements.</div></div></div></ix:nonNumeric></ix:continuation> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-32 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <ix:continuation id="TextSelectionAppend_53608083_5"> <ix:nonNumeric name="prok:AccruedExpensesPolicyTextBlock" contextRef="P01_01_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accrued Expenses </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At March&#160;31, 2022, accrued expenses includes $<ix:nonFraction name="prok:AccruedLegalExpense" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">4,095,414</ix:nonFraction> of&#160;legal expense, $<ix:nonFraction name="prok:AccruedPrintingExpense" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">283,348</ix:nonFraction> of printing expense, $<ix:nonFraction name="prok:AccruedDueDiligenceExpense" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">529,688</ix:nonFraction> of due diligence expense, $<ix:nonFraction name="prok:AccruedRegulatoryFilingFee" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">363,740</ix:nonFraction> of professional fee expense and $<ix:nonFraction name="prok:AccruedAccountingExpense" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">70,000</ix:nonFraction> of&#160;regulatory fee expe<div style="background-color:rgba(255, 255, 255, .0);;display:inline;">nse</div></div><div style="background-color:rgba(255, 255, 255, .0);;display:inline;">, of which $<ix:nonFraction name="prok:BusinessCombinationAccruedLegalExpense" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,500,000</ix:nonFraction> of legal expense, $<ix:nonFraction name="prok:BusinessCombinationAccruedConsultingExpense" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">247,188</ix:nonFraction> of consulting expense and $<ix:nonFraction name="prok:BusinessCombinationAccruedOtherTransactionalRelatedExpenses" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">534,906</ix:nonFraction> of other transactional related expenses incurred in connection with the Business Combination with ProKidney.</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2021, accrued expenses includes $<ix:nonFraction name="prok:AccruedLegalExpense" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,506,528</ix:nonFraction>&#160;of legal expense, $<ix:nonFraction name="prok:AccruedPrintingExpense" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000</ix:nonFraction>&#160;of printing expense, $<ix:nonFraction name="prok:AccruedDueDiligenceExpense" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">282,500</ix:nonFraction>&#160;of due diligence expense, $<ix:nonFraction name="prok:AccruedRegulatoryFilingFee" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">70,000</ix:nonFraction>&#160;of regulatory filing fee and $<ix:nonFraction name="prok:AccruedAccountingExpense" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">770</ix:nonFraction>&#160;of accounting expense. </div></div></ix:nonNumeric></ix:continuation> <ix:nonNumeric name="prok:InitialPublicOfferingDisclosureTextBlock" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 3. INITIAL PUBLIC OFFERING </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Initial Public Offering, the Company sold <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">25,000,000</ix:nonFraction> Public Shares, which includes a partial exercise by the underwriters of their over-allotment option in the amount of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">3,000,000</ix:nonFraction> Public Shares, at a price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></ix:nonFraction> per Public Share. Unlike some other initial public offerings of special purpose acquisition companies, investors in the Initial Public Offering did not receive any warrants (which would typically become exercisable following completion of the Business Combination). The fair value attributable to the unexercised portion of the over-allotment option was deemed to be immaterial to the condensed financial statements. </div></div></ix:nonNumeric> <ix:nonNumeric name="prok:PrivatePlacementDisclosureTextBlock" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 4. PRIVATE PLACEMENT </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Substantially concurrently with the closing of the Initial Public Offering, the Sponsor purchased <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">640,000</ix:nonFraction> Private Placement Shares at a price of $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">10.00</ix:nonFraction></ix:nonFraction> per Private Placement Share, for an aggregate purchase price of&#160;$<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">6,400,000</ix:nonFraction>. Each Private Placement Share is identical to the Class&#160;A ordinary shares sold in the Initial Public Offering, subject to certain limited exceptions as described in Note 7. A portion of the proceeds from the sale of the Private Placement Shares was added to the net proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period or during any applicable extension period, the proceeds from the sale of the Private Placement Shares held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Shares will be worthless. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_53608789"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 5. RELATED PARTY TRANSACTIONS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Founder Shares </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On March&#160;2, 2021, the Sponsor paid $<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="P03_02_2021To03_02_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">25,000</ix:nonFraction> to cover certain offering and formation costs of the Company in consideration for which the Sponsor received <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="P03_02_2021To03_02_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,750,000</ix:nonFraction> Class&#160;B ordinary shares (the &#8220;Founder Shares&#8221;). On June&#160;29, 2021, the Company effected a share capitalization with respect to its Class&#160;B ordinary shares of <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P06_29_2021To06_29_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">575,000</ix:nonFraction> shares thereof, resulting in the Company&#8217;s initial shareholders holding an aggregate of <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn06_29_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,325,000</ix:nonFraction> Founder Shares. All share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> amounts have been retroactively restated to reflect the share capitalization. The Founder Shares included an aggregate of up to&#160;<ix:nonFraction name="us-gaap:CommonStockOtherSharesOutstanding" contextRef="PAsOn06_30_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">825,000</ix:nonFraction> shares that were subject to forfeiture depending on the extent to which the underwriters&#8217; over-allotment option was exercised. As a result of the underwriters&#8217; election to partially exercise their over-allotment option, a total of <ix:nonFraction name="prok:SharesNoLongerSubjectToForfeiture" contextRef="PAsOn06_30_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">750,000</ix:nonFraction> Founder Shares are no longer subject to forfeiture and <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" contextRef="P07_01_2021To09_30_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">75,000</ix:nonFraction> Founder Shares were forfeited, resulting in an aggregate of&#160;<ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn06_30_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,250,000</ix:nonFraction> Founder Shares outstanding. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2021, the Sponsor transferred <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P06_01_2021To06_30_2021_FounderSharesMemberusgaapStatementEquityComponentsAxis_IndependentDirectorsMembersrtTitleOfIndividualAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction> Founder Shares to Marc Semigran, an independent director of the Company. The sale of the Founders Shares to the Company&#8217;s director is in the scope of FASB ASC Topic 718, &#8220;Compensation-Stock Compensation&#8221; (&#8220;ASC 718&#8221;).&#160;Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date. The fair value of the <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P06_01_2021To06_30_2021_DirectorMembersrtTitleOfIndividualAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction> shares granted to the Company&#8217;s director was $<ix:nonFraction name="prok:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue" contextRef="P06_01_2021To06_30_2021_DirectorMembersrtTitleOfIndividualAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">214,160</ix:nonFraction> or approximately $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn03_31_2022_DirectorMembersrtTitleOfIndividualAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">7.14</ix:nonFraction> per share. The Founders Shares were effectively sold subject to a performance condition (i.e., the occurrence of a Business Combination). </div><br/></div></ix:nonNumeric> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-33 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <ix:continuation id="TextSelection_53608789" continuedAt="TextSelectionAppend_53608789_1"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation expense related to the Founders Shares is recognized only when the performance condition is probable of occurrence under the applicable accounting literature in this circumstance. As of March&#160;31, 2022, the Company determined that a Business Combination is not considered probable, and, therefore, no stock-based compensation expense has been recognized. Stock-based compensation would be recognized at the date a Business Combination is considered probable (i.e., upon consummation of a Business Combination) in an amount equal to the number of Founders Shares times the grant date fair value per share (unless subsequently modified) less the amount initially received for the purchase of the Founders Shares. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The Sponsor and the Company&#8217;s&#160;directors and officers have agreed, subject to limited exceptions, not to transfer, assign or sell any of their Founder Shares until the earlier of: (A)&#160;one year after the completion of a Business Combination and (B)&#160;subsequent to a Business Combination, (x)&#160;if the last reported sale price of the Class&#160;A ordinary shares equals or exceeds $<ix:nonFraction name="us-gaap:SharePrice" contextRef="PAsOn03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RestrictionOnTransferOfSponsorSharesMemberPROKBasisAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">12.00</ix:nonFraction> per share (as adjusted for share <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-divisions,</div> share dividends, rights issuances, consolidations, reorganizations, recapitalizations and other similar transactions) for any <ix:nonNumeric name="prok:NumberOfTradingDaysForDeterminingTheSharePrice" contextRef="P01_01_2022To03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RestrictionOnTransferOfSponsorSharesMemberPROKBasisAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" format="ixt-sec:durday">20</ix:nonNumeric> trading days within any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="prok:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" contextRef="P01_01_2022To03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RestrictionOnTransferOfSponsorSharesMemberPROKBasisAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" format="ixt-sec:durday">30</ix:nonNumeric>-trading</div> day period commencing at least <ix:nonNumeric name="prok:WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered" contextRef="P01_01_2022To03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RestrictionOnTransferOfSponsorSharesMemberPROKBasisAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" format="ixt-sec:durday">150</ix:nonNumeric> days after a Business Combination, or (y)&#160;the date on which the Company completes a liquidation, merger, amalgamation, share exchange, reorganization or other similar transaction that results in all of the Public Shareholders having the right to exchange their Class&#160;A ordinary shares for cash, securities or other property. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Administrative Services Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company entered into an agreement in which it will pay an affiliate of the Sponsor $<ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="P06_30_2021To06_30_2021_AdministrationAndSupportServicesMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000</ix:nonFraction> per month, commencing on June&#160;30, 2021, for office space, administrative and support services. Upon completion of a Business Combination or its liquidation, the Company will cease paying these monthly fees. For the three months ended March&#160;31, 2022, the Company incurred&#160;$<ix:nonFraction name="us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" contextRef="P01_01_2022To03_31_2022_AdministrationAndSupportServicesMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction> in fees for these services, of which is included in due to related party in the accompanying condensed balance sheet. For the period from February&#160;25, 2021 (inception) through March&#160;31, 2021, the Company did not incur any fees for these services. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Due to&#160;Related Party </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2022, an affiliate of the Sponsor had advanced the Company $<ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="PAsOn03_31_2022_AdvanceFromRelatedPartyLoanMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">33,623</ix:nonFraction> for working capital purposes, of which $<ix:nonFraction name="prok:RepaymentOfAdvancesFromRelatedParty" contextRef="P01_01_2022To03_31_2022_AdvanceFromRelatedPartyLoanMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">0</ix:nonFraction> was repaid during the three months ended March&#160;31, 2022. As of March&#160;31, 2022, and December&#160;31, 2021, the outstanding balance under the advances amounted to $<ix:nonFraction name="prok:AdvancesPayableToRelatedPartyCurrent" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">43,623</ix:nonFraction> and $<ix:nonFraction name="prok:AdvancesPayableToRelatedPartyCurrent" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000</ix:nonFraction> respectively. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Promissory Note&#8212;Related Party </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On March&#160;2, 2021, the Company issued an unsecured promissory note to the Sponsor (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Pre-IPO</div> Sponsor Promissory Note&#8221;), pursuant to which the Company could borrow up to an aggregate principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn03_02_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">300,000</ix:nonFraction>. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-IPO</div> Sponsor Promissory Note was <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable on the earlier of December&#160;31, 2021 and the completion of the Initial Public Offering. The outstanding balance under the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-IPO</div> Sponsor Promissory Note of $<ix:nonFraction name="us-gaap:RepaymentsOfRelatedPartyDebt" contextRef="P07_02_2021To07_02_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">300,000</ix:nonFraction> was repaid at the closing of the Initial Public Offering on July&#160;2, 2021. Borrowings are no longer available under the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-IPO</div> Sponsor Promissory Note. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Party Loans </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to fund working capital deficiencies or finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor or certain of the Company&#8217;s officers and directors may, but are not obligated to (other than pursuant to the Promissory Note (see Note 9)), loan the Company additional funds as may be required (&#8220;Working Capital Loans&#8221;). If the Company completes a Business Combination, it may repay such loaned amounts out of the proceeds of the Trust Account. In the event that the Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay such loaned amounts but no proceeds from the Trust Account would be used to repay such loaned amounts. As of March&#160;31, 2022 and December&#160;31, 2021, there were <ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WorkingCapitalLoansMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WorkingCapitalLoansMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> outstanding amounts under the Working Capital Loans.</div></div> </ix:continuation> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-34 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div> </div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <ix:continuation id="TextSelectionAppend_53608789_1"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Subscription Agreements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrently with the execution of the ProKidney Business Combination Agreement, the Company entered into Subscription Agreements with the Sponsor Related PIPE Investors, pursuant to which the Sponsor Related PIPE Investors have subscribed for Class&#160;A ordinary shares. The Sponsor Related PIPE Investors are expected to fund $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_PipeInvestorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SubscriptionAgreementsMemberPROKAgreementAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">156,400,000</ix:nonFraction> of the PIPE Investment, for which they will receive <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_PipeInvestorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SubscriptionAgreementsMemberPROKAgreementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">15,640,000</ix:nonFraction> Class&#160;A ordinary shares. Specifically, (i)&#160;SC Master Holdings, LLC, an entity affiliated with Mr.&#160;Palihapitiya, subscribed for <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_ScMasterHoldingsLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SubscriptionAgreementsMemberPROKAgreementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">12,500,000</ix:nonFraction> Class&#160;A ordinary shares and (ii)&#160;Averill Master Fund, Ltd., an entity affiliated with Mr.&#160;Mehta, subscribed for <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P01_01_2022To03_31_2022_AverillMasterFundLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SubscriptionAgreementsMemberPROKAgreementAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">3,140,000</ix:nonFraction> Class&#160;A ordinary shares. The PIPE Investment will be consummated substantially concurrently with the Closing. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_53608756"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 6. COMMITMENTS&#160;AND CONTINGENCIES </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Registration Rights </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to a registration rights agreement entered into on June&#160;29, 2021, the holders of the Founder Shares, Private Placement Shares and any Private Placement Shares that may be issued on conversion of Working Capital Loans (and any Class&#160;A ordinary shares issuable upon the conversion of the Founder Shares) are entitled to registration rights requiring the Company to register such securities for resale (in the case of the Founder Shares, only after conversion to the Class&#160;A ordinary shares). The holders of these securities will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent to the completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. The Company will bear the expenses incurred in connection with the filing of any such registration statements. At the closing of the ProKidney Business Combination, the Company will enter into the Registration Rights Agreement, with the Sponsor, the Company&#8217;s directors and the Closing ProKidney unitholders, which will replace the existing registration rights agreement. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain purported shareholders of the Company sent demand letters (the &#8220;Demands&#8221;) alleging deficiencies and/or omissions in the ProKidney Disclosure Statement filed by the Company with the SEC on February 14, 2022. The Demands seek additional disclosures to remedy these purported deficiencies. We believe that the allegations in the Demands are meritless. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Underwriting Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The underwriters are entitled to a deferred underwriting commission of $<ix:nonFraction name="prok:DeferredUnderwritingFees" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">7,700,000</ix:nonFraction> in the aggregate. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Unit Award </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September 2021, pursuant to a Director Restricted Stock Unit Award Agreement, dated September&#160;24, 2021, between the Company and Uma Sinha, Ph.D., the Company agreed to </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">grant&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2022To03_31_2022_DirectorRestrictedStockUnitAwardAgreementMemberPROKAgreementAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction>&#160;restricted stock units (&#8220;RSUs&#8221;) to Dr.&#160;Sinha, which grant is contingent on both the consummation of a Business Combination and a shareholder approved equity plan. The RSUs will vest upon the consummation of such Business Combination and represent&#160;<ix:nonFraction name="prok:NumberOfSharesOfCommonStockCommittedToSettleOnADateFollowingTheYearBusinessCombinationOccurs" contextRef="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_DirectorRestrictedStockUnitAwardAgreementMemberPROKAgreementAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">30,000</ix:nonFraction>&#160;Class&#160;A ordinary shares of the Company that will settle on a date determined in the sole discretion of the Company that shall occur between the vesting date and March&#160;15 of the year following the year in which vesting occurs.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The RSUs granted by the Company are in the scope of ASC 718. Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date. The RSUs granted are subject to a performance condition (i.e., the occurrence of a Business Combination). Compensation expense related to the RSUs is recognized only when the performance condition is probable of occurrence under</div></div></div></ix:nonNumeric> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-35 </div></div></div> </div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><br/></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> <div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_53608756"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">the</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="font-size: 10pt; letter-spacing: 0px; text-align: center; top: 0px;;display:inline;">applicable accounting literature in this circumstance. As of March&#160;31, 2022, the Company did not have a shareholder approved equity plan and also determined that a Business Combination is not considered probable, and, therefore, no stock-based compensation expense has been recognized. Stock-based compensation would be recognized at the date a Business Combination is considered probable (i.e., upon consummation of a Business Combination) in an amount equal to the number of RSUs times the grant date fair value per share (unless subsequently modified).</div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_53608770"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 7. TEMPORARY EQUITY AND PERMANENT DEFICIT </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preference Shares</div></div></div></div>&#8212;The Company is authorized to issue <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">5,000,000</ix:nonFraction></ix:nonFraction> preference shares, with a par value of $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> per share. The Company&#8217;s board of directors will be authorized to fix the voting rights, if any, designations, powers, preferences, the relative, participating, optional or other special rights and any qualifications, limitations and restrictions thereof, applicable to the shares of each series. The Company&#8217;s board of directors will be able to, without shareholder approval, issue preference shares with voting and other rights that could adversely affect the voting power and other rights of the holders of the Company&#8217;s ordinary shares and could have anti-takeover effects. At March&#160;31, 2022 and December&#160;31, 2021, there were <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> preference shares issued or outstanding. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;A Ordinary Shares</div></div></div></div>&#8212;The Company is authorized to issue <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">500,000,000</ix:nonFraction></ix:nonFraction> Class&#160;A ordinary shares, with a par value of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> per share. At March&#160;31, 2022 and December&#160;31, 2021, there were <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">640,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> Class&#160;A ordinary shares issued and outstanding, excluding <ix:nonFraction name="us-gaap:CommonStockOtherSharesOutstanding" contextRef="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">25,000,000</ix:nonFraction> Class&#160;A ordinary shares subject to possible redemption which are presented as temporary equity. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;B Ordinary Shares</div></div></div></div>&#8212;The Company is authorized to issue <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">50,000,000</ix:nonFraction></ix:nonFraction> Class&#160;B ordinary shares, with a par value of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> per share. At March&#160;31, 2022 and December&#160;31, 2021, there were <ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,250,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> Class&#160;B ordinary shares issued and outstanding. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holders of record of Class&#160;A ordinary shares and Class&#160;B ordinary shares are entitled to one vote for each share held on all matters to be voted on by shareholders and vote together as a single class, except as required by law; provided that prior to a Business Combination, holders of Class&#160;B ordinary shares will have the right to appoint all of the Company&#8217;s directors and remove members of its board of directors for any reason, and holders of Class&#160;A ordinary shares will not be entitled to vote on the appointment of directors during such time. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Class&#160;B ordinary shares will automatically convert into Class&#160;A ordinary shares at the time of the Business Combination, or earlier at the option of the holder, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-for-one</div></div> basis, subject to adjustment for share <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-divisions,</div> share dividends, rights issuances, consolidations, reorganizations, recapitalizations and the like. Additionally, in the event that additional (in excess of the amounts issued in the Initial Public Offering) Class&#160;A ordinary shares, or equity-linked securities, are issued or deemed issued in connection with the closing of the Business Combination, the ratio at which the Class&#160;B ordinary shares will convert into Class&#160;A ordinary shares will be adjusted (unless the holders of a majority of the issued and outstanding Class&#160;B ordinary shares agree to waive such anti-dilution adjustment with respect to any such issuance or deemed issuance) so that the number of Class&#160;A ordinary shares issuable upon conversion of all Class&#160;B ordinary shares will equal, in the aggregate, <ix:nonFraction name="prok:PercentOfFoundersSharesToCompanysIssuedAndOutstandingOrdinaryShares" contextRef="PAsOn03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">20</ix:nonFraction>% of the sum of the total number of Class&#160;A ordinary shares outstanding after such conversion (after giving effect to any redemptions of Class&#160;A ordinary shares by Public Shareholders, and excluding the Private Placement Shares), including any Class&#160;A ordinary shares issued or deemed issued, or issuable upon the conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with the Business Combination, excluding any Class&#160;A ordinary shares or equity-linked securities exercisable for or convertible into Class&#160;A ordinary shares issued, or to be issued, to any seller in the Business Combination and any private placement shares issued to the Sponsor or its affiliates upon conversion of Working Capital Loans; provided that such conversion of Class&#160;B ordinary shares will never occur on a less than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-for-one-basis.</div></div></div></div></ix:nonNumeric> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 10pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-36 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%);;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><br/></div><ix:continuation id="TextSelection_53608770"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Private </div></div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Placement Shares</div></div></div></div>&#8212;The Private Placement Shares are not transferable, assignable, or salable until 30 days after the completion of a Business Combination (except, among other limited exceptions, to the Company&#8217;s directors and officers and other persons or entities affiliated with the Sponsor). Holders of the Private Placement Shares are entitled to certain registration rights. If the Company does not complete a Business Combination within the Combination Period or during any applicable extension period, the proceeds from the sale of the Private Placement Shares held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Shares will be worthless. </div> </ix:continuation> <ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 8. FAIR VALUE MEASUREMENTS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company follows the guidance in ASC Topic 820 for its financial assets and liabilities that are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measured</div> and reported at fair value at each reporting period, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> assets and liabilities that are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measured</div> and reported at fair value at least annually. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s financial assets and liabilities reflects management&#8217;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">liabilities: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 8%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td style="width: 89%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Observable inputs other than Level&#160;1 inputs. Examples of Level&#160;2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Unobservable inputs based on the Company&#8217;s assessment of the assumptions that market participants would use in pricing the asset or liability.</div></td></tr></table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">The</div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">following table presents information about the Company&#8217;s assets that are measured at fair value on a recurring basis at March&#160;31, 2022 and December&#160;31, 2021, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: </div><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 8%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td></tr></table> <ix:nonNumeric name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31, 2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities held in Trust Account</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:MarketableSecuritiesHeldToMaturityFairValueDisclosure" contextRef="PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,033,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:MarketableSecuritiesHeldToMaturityFairValueDisclosure" contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,008,324</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> </ix:nonNumeric> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis" escape="true" continuedAt="TextSelection_53608349"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 9. SUBSEQUENT EVENTS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed financial statements were issued. Based upon this review, other than as described below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the condensed financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On April&#160;20, 2022, the Company issued an unsecured promissory <div style="letter-spacing: 0px; top: 0px;;display:inline;">note </div>(the &#8220;Promissory Note&#8221;) to the Sponsor pursuant to which the Company may borrow up to an aggregate principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn04_20_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,500,000</ix:nonFraction>.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><br/></div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-37 </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"></div></div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><ix:continuation id="TextSelection_53608349"> <div style="letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Promissory Note is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing, unsecured and payable upon the earlier of July&#160;2, 2023 and the effective date of the Company&#8217;s Business Combination. The Promissory Note is subject to customary events of default which could, subject to certain conditions, cause the Promissory Notes to become immediately due and payable. On April&#160;26, 2022, the Company drew $<ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P04_26_2022To04_26_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">250,000</ix:nonFraction> under the Promissory Note. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-38 </div></div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div></div></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><br/></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fincov373959_12" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Report of Independent Registered Public Accounting Firm </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To the Members and the Board of Directors of ProKidney LP </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Opinion on the Financial Statements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have audited the accompanying consolidated balance sheets of ProKidney LP (the Company) as of December&#160;31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, statements of changes in members&#8217; equity and cash flows for the years then ended and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Substantial Doubt About the Company&#8217;s Ability to Continue as a Going Concern </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has suffered recurring losses from operations, has a net capital deficiency, and has stated that substantial doubt exists about the Company&#8217;s ability to continue as a going concern. Management&#8217;s evaluation of the events and conditions and management&#8217;s plans regarding these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Our opinion is not modified with respect to this matter. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Adoption of ASC 842, </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Leases</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As discussed in Note 5 to the consolidated financial statements, the Company changed its method of accounting for leases in the year ended December&#160;31, 2020 due to the adoption of ASC 842, Leases. Our opinion is not modified with respect to this matter. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis for Opinion </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Ernst&#160;&amp; Young LLP </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">We have served as the Company&#8217;s auditor since 2019. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Raleigh, North Carolina </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">April&#160;11, 2022 </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-39 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a><br/></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fincov373959_13" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney LP and Subsidiaries </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Balance Sheets </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,558</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,578</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">588</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">202</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid clinical</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:PrepaidClinicalCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:PrepaidClinicalCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">753</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">52</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,271</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,585</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,358</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,914</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Right of use assets, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:RightOfUseAssetsOperatingAndFinanceLease" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,241</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:RightOfUseAssetsOperatingAndFinanceLease" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,559</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">428</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">642</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">40,298</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities and Equity</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:CurrentAccountsPayable" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,834</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:CurrentAccountsPayable" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">781</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:OperatingAndFinanceLeaseLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">267</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:OperatingAndFinanceLeaseLiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">225</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses and other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:AccruedExpensesAndOther" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,213</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:AccruedExpensesAndOther" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,496</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,314</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,502</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities, net of current portion</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,067</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,334</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commitments and contingencies</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" xsi:nil="true"></ix:nonFraction></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Members&#8217; equity:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A Units (<ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountUnitsIssued" contextRef="PAsOn12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding" contextRef="PAsOn12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">186,500,000</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountUnitsIssued" contextRef="PAsOn12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding" contextRef="PAsOn12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">115,000,000</ix:nonFraction></ix:nonFraction> issued and outstanding as of December&#160;31, 2021 and 2020, respectively)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LimitedPartnersContributedCapital" contextRef="PAsOn12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">186,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LimitedPartnersContributedCapital" contextRef="PAsOn12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">115,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B Units (<ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountUnitsIssued" contextRef="PAsOn12_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountUnitsIssued" contextRef="PAsOn12_31_2020_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding" contextRef="PAsOn12_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding" contextRef="PAsOn12_31_2020_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">7,767,122</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued and outstanding as of December&#160;31, 2021 and 2020)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LimitedPartnersContributedCapital" contextRef="PAsOn12_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,927</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LimitedPartnersContributedCapital" contextRef="PAsOn12_31_2020_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,228</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated deficit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">161,510</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">106,364</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total members&#8217; equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapital" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,917</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapital" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,864</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities and equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">40,298</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,700</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(The accompanying notes are an integral part of the consolidated financial statements.) </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-40 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><br/></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fincov373959_14" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney LP and Subsidiaries </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Operations and Comprehensive Loss </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except for share and per share data) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">46,255</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,042</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,855</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,982</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">55,110</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,024</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">55,110</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">27,024</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest income</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeNonoperating" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InvestmentIncomeNonoperating" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">43</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss before income taxes</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">55,108</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">26,981</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense (benefit)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">38</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">232</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net and comprehensive loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">55,146</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">26,749</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average Class&#160;A Units outstanding:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2021To12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2021To12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">150,706,849</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2020To12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2020To12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">104,986,301</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per Class&#160;A Unit:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2021To12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2021To12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.37</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2020To12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2020To12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.25</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(The accompanying notes are an integral part of the consolidated financial statements.) </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-41 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><br/></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fincov373959_15" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney LP and Subsidiaries </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Changes in Members&#8217; Equity </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except for share data) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 52%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>Members&#8217;<br/>Equity</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Profits<br/>Interests</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of January&#160;1, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:PartnersCapitalOutstanding" contextRef="PAsOn12_31_2019_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">95,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapital" contextRef="PAsOn12_31_2019_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">95,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapital" contextRef="PAsOn12_31_2019_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">498</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PartnersCapital" contextRef="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">79,615</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapital" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,883</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Capital contribution</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapitalAccountUnitsContributed" contextRef="P01_01_2020To12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapitalAccountContributions" contextRef="P01_01_2020To12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapitalAccountContributions" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="P01_01_2020To12_31_2020_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">730</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">730</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">26,749</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">26,749</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:PartnersCapitalOutstanding" contextRef="PAsOn12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">115,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapital" contextRef="PAsOn12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">115,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapital" contextRef="PAsOn12_31_2020_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,228</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PartnersCapital" contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">106,364</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapital" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,864</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Capital contribution</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2021To12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="-3" scale="3" format="ixt:num-dot-decimal">71,500,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2021To12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">71,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">71,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="P01_01_2021To12_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">699</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">699</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">55,146</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">55,146</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:PartnersCapitalOutstanding" contextRef="PAsOn12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">186,500,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapital" contextRef="PAsOn12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">186,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapital" contextRef="PAsOn12_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,927</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PartnersCapital" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">161,510</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapital" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,917</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(The accompanying notes are an integral part of the consolidated financial statements.) </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-42 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><br/></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fincov373959_16" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney LP and Subsidiaries </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Consolidated Statements of Cash Flows </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 80%;"></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 3%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2020&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from operating activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">55,146</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">26,749</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net loss to net cash flows</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,984</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">964</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity-based compensation</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">699</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">730</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in operating assets and liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,704</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">809</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,868</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">683</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash flows used in operating activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">50,299</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">25,181</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows used in investing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Proceeds from sale of equipment</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase of equipment and facility expansion</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,192</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,456</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash flows used in investing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,191</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,456</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from financing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments on finance leases</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash contribution</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">71,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash flows from financing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">71,470</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,989</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net change in cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,980</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">10,648</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, beginning of period</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,578</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,226</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, end of period</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,558</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,578</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Supplemental disclosure of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> investing activities:</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equipment and facility expansion included in accounts payable and accrued expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,295</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,840</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(The accompanying notes are an integral part of the consolidated financial statements.) </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-43 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><br/></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fincov373959_17" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney and Subsidiaries </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Consolidated Financial Statements </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Years Ended December&#160;31, 2021 and 2020 </div></div></div> <ix:nonNumeric name="us-gaap:NatureOfOperations" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 1: The Company </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">ProKidney LLC was formed as a Bermuda limited liability company on <ix:nonNumeric name="dei:EntityIncorporationDateOfIncorporation" contextRef="P12_12_2018To12_31_2018" format="ixt:date-monthname-day-year-en">December 12, 2018</ix:nonNumeric> and funded with $<ix:nonFraction name="prok:InitialCapital" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">75,000,000</ix:nonFraction> on December&#160;31, 2018. On January&#160;9, 2019 (the &#8220;Acquisition Date&#8221;), ProKidney LLC acquired all of the equity interests in inRegen and Twin City Bio LLC (&#8220;TC Bio&#8221;) for $<ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="P01_09_2019To01_09_2019_RegenAndTwinCityBioLlcMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">62,000,000</ix:nonFraction>. inRegen was duly incorporated under the Cayman Islands Companies Act (as amended) on December&#160;21, 2015 as an exempted company. During 2020, inRegen&#8217;s name was changed to ProKidney (and is referred to herein as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;ProKidney-KY&#8221;),</div> and TC Bio&#8217;s name was changed to ProKidney, LLC (and is referred to herein as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;ProKidney-US&#8221;).</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> was formed as a limited liability company under the laws of Delaware on December&#160;18, 2015. In August 2021, ProKidney LP was organized as a limited partnership under the laws and regulations of Ireland, with ProKidney LLC becoming a wholly owned subsidiary of ProKidney LP (and is referred to herein as &#8220;ProKidney&#8221;). Following this reorganization on August&#160;5, 2021 and for the purposes of these financial statements, the term &#8220;ProKidney,&#8221; as used herein, refers to ProKidney LP following this reorganization, and the financial information presented herein is that of ProKidney LP and its wholly owned subsidiaries. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">ProKidney acquired the equity interests in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> to develop its Renal Advanced Cell Therapy, which has the potential to stabilize or improve renal function in patients with chronic kidney disease or delay or eliminate the need for dialysis and organ transplantation. ProKidney acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> to provide contractual development and manufacturing services to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY,</div> which is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US&#8217;s</div> only customer. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because ProKidney is a limited partnership, the debts, obligations and liabilities of the Company (as defined below), whether arising in contract, tort or otherwise, are solely the debts, obligations and liabilities of the Company, and no holder of equity interests in ProKidney (&#8220;members&#8217; equity&#8221;) is obligated personally for any such debt, obligation or liability of the Company solely by reason of being a holder of members&#8217; equity. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_53608081"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 2: Significant Accounting Policies </div></div></div> <ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The consolidated financial statements reflect the operations of ProKidney and its wholly-owned subsidiaries consisting of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> (together, the &#8220;Company&#8221;). All intercompany transactions and accounts have been eliminated. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). These consolidated financial statements are presented in U.S. Dollars. </div></div></ix:nonNumeric> <ix:nonNumeric name="prok:GoingConcernPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_53608969"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Going Concern </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company performed an analysis of its ability to continue as a going concern. As of December&#160;31, 2021, the Company had an accumulated deficit of $<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">161,510,000</ix:nonFraction>. The Company has generated losses from operations for each year since its inception including losses from operations of $<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">55,146,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">26,749,000</ix:nonFraction> for the years ended December&#160;31, 2021 and 2020, respectively. The Company intends to continue to conduct significant </div></div></ix:nonNumeric> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-44 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%);;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><ix:continuation id="TextSelection_53608081" continuedAt="TextSelectionAppend_53608081_1"><ix:continuation id="TextSelection_53608969"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">additional research, development, and clinical study activities which, together with expenses incurred for general and administrative expenses, are expected to result in continuing operating losses for the foreseeable future. The amount of future losses and when, if ever, the Company will achieve profitability are uncertain. The Company&#8217;s ability to achieve profitability will depend, among other things, on successfully completing clinical studies, obtaining requisite regulatory approvals, establishing appropriate pricing for its product with payers, and raising sufficient funds to finance the Company&#8217;s activities. No assurance can be given that the Company&#8217;s clinical development efforts will be successful, that regulatory approvals will be obtained, or that the Company will be able to achieve appropriate pricing and market access or that profitability, if achieved, can be sustained. These matters raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company believes that, based on its current business plan, its existing cash and cash equivalents of $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">20,558,000</ix:nonFraction> at December&#160;31, 2021 will not be sufficient to fund its obligations for the next <ix:nonNumeric name="prok:UnsufficientToFundItsObligationsTerm" contextRef="P01_01_2021To12_31_2021" format="ixt-sec:durmonth">12</ix:nonNumeric> months. The consolidated financial statements do not include any adjustments related to the outcome of this uncertainty. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to execute our operating plan depends on our ability to obtain additional funding through equity offerings, debt financings or potential licensing and collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to us. Even if we raise additional capital, we may also be required to modify, delay or abandon some of our plans which could have a material adverse effect on our business, operating results and financial condition and our ability to achieve our intended business objectives. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of consolidated financial statements, in accordance with GAAP, requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the amounts of expenses during the reported periods. Certain estimates in these consolidated financial statements have been made in connection with the calculation of research and development expenses, equity-based compensation expense and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections, which management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all highly liquid investments with an original maturity of 90 days or less on the date of purchase to be cash equivalents. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concentrations of Credit Risk </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company&#8217;s cash and equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. </div></div></ix:nonNumeric> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-45 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><br/></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_53608081_1" continuedAt="TextSelectionAppend_53608081_2"> <ix:nonNumeric name="prok:AccruedExpensesPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued Expenses </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses which have been presented on the consolidated balance sheets as of December&#160;31, 2021 and 2020 consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,832</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,085</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinical study related costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:AccruedClinicalStudyRelatedCostsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,031</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:AccruedClinicalStudyRelatedCostsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,154</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Facility expansion costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:AccruedFacilityExpansionCostsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:AccruedFacilityExpansionCostsCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,709</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued legal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">964</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Manufacturing improvement costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:AccruedManufacturingImprovementCosts" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,164</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:AccruedManufacturingImprovementCosts" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:OtherAccruedExpenses" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">203</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:OtherAccruedExpenses" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">548</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued expenses and other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,213</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,496</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development Costs </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries, benefits, third party license fees, and external costs of outside vendors engaged to conduct manufacturing and preclinical development activities and clinical trials. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records accruals based on estimates of services received, efforts expended, and amounts owed pursuant to contracts with numerous contract research organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company&#8217;s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the company&#8217;s estimate of the degree of completion of the event or events specified in the specific clinical study. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Statement of Operations and Comprehensive Loss as the Company receives the related goods or services. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Costs incurred in obtaining technology licenses are charged to research and development expense as purchased <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development if the technology licensed has not reached technological feasibility and has no alternative future use. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_53608973"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed Assets </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets are stated at cost, less accumulated depreciation. Generally, expenditures for maintenance and repairs are charged to expense and major improvements or replacements are capitalized. The Company computes depreciation and amortization using the straight-line method over the estimated useful life of the asset. Leasehold improvements are amortized over the lesser of, the life of the lease or the estimated useful life of the leasehold improvement. <ix:nonNumeric name="prok:DisclosureInTabularFormOfUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_53609337">The estimated useful lives are as follows:</ix:nonNumeric> </div></div> <ix:continuation id="TextSelection_53609337"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 51%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 46%; font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment and software</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2021To12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis" format="ixt-sec:duryear">3</ix:nonNumeric>-</div><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2021To12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" format="ixt-sec:durwordsen"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5</div> years</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2021To12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis" format="ixt-sec:duryear">5</ix:nonNumeric>-</div><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2021To12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" format="ixt-sec:durwordsen"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">7</div> years</ix:nonNumeric></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="P01_01_2021To12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">remainder of lease term</ix:nonNumeric></td></tr></table> </ix:continuation></ix:nonNumeric> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-46 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%);;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><ix:continuation id="TextSelectionAppend_53608081_2" continuedAt="TextSelectionAppend_53608081_3"><ix:continuation id="TextSelection_53608973"> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 10%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,180</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,011</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment and software</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">569</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">130</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,517</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">76</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Construction in progress</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">351</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2020_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,854</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: accumulated depreciation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,259</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,157</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total fixed assets, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,358</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,914</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation expense for the years ended December&#160;31, 2021 and 2020 was $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,451,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">606,000</ix:nonFraction>, respectively. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:IntangibleAssetsFiniteLivedPolicy" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible Assets </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets are comprised of acquired assembled workforce, which are accounted for in accordance with ASC 350&#8212;Intangibles&#8212;Goodwill and Other. The acquired assembled workforce is amortized on a straight-line basis over the useful life of <ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="P01_01_2021To12_31_2021_AcquiredAssemblyWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" format="ixt-sec:durwordsen">five years</ix:nonNumeric>. <ix:nonNumeric name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_53609332">The following table summarizes information related to the Company&#8217;s assembled workforce intangible asset (in thousands):</ix:nonNumeric> </div></div> <ix:continuation id="TextSelection_53609332"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross carrying amount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,073</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,073</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">645</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">431</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net carrying amount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">428</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">642</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:continuation> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated amortization expense for each of the years 2022 through 2023 is $<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">215,000</ix:nonFraction></ix:nonFraction> and $<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000</ix:nonFraction> for 2024. Amortization expense relating to the assembled workforce intangible asset was $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2021To12_31_2021_AcquiredAssemblyWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">214,000</ix:nonFraction> for the year ended December&#160;31, 2021 and $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2020To12_31_2020_AcquiredAssemblyWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">215,000</ix:nonFraction> for the year ended December&#160;31, 2020. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairment of Long-Lived Assets </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-lived assets such as fixed assets and intangible assets subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. <ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">No </ix:nonFraction></ix:nonFraction>impairment charges have been recorded for the years ended December&#160;31, 2021 or 2020. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_53608316"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company was organized as a limited liability company, is now a limited partnership and is classified as a partnership for U.S. income tax purposes, and as such, only records a provision for federal and state income taxes on its subsidiaries organized as C corporations or which have elected to be treated as corporations for U.S. federal income tax purposes. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> is a limited liability company and has elected to be treated as a C&#160;corporation. Therefore, a provision for federal and state taxes has been recorded. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> has been granted, by the Government in Council of the Cayman Islands, tax concessions under an undertaking certificate exempting it from any tax levied on profits, income, gains or appreciations in relation to its operations or in the nature of estate duty or inheritance tax for a period of <ix:nonNumeric name="prok:PeriodForWhichTheProfitsEarnedAreExemptFromTax" contextRef="P01_20_2016To12_31_2021_KYsrtStatementGeographicalAxis" format="ixt-sec:durwordsen">twenty years</ix:nonNumeric> from January&#160;20, 2016. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> elected to be treated as an entity disregarded from its owner for U.S. tax purposes, and as a result, it has not recorded an income tax provision. </div></ix:nonNumeric> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-47 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><br/></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_53608081_3" continuedAt="TextSelectionAppend_53608081_4"><ix:continuation id="TextSelection_53608316"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company uses the liability method in accounting for income taxes as required by ASC Topic 740&#160;&#8212; Income Taxes, under which deferred tax assets and liabilities are recorded for the future tax consequences attributable to the differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that such assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, available taxes in the carryback periods, projected future taxable income and tax planning strategies in making this assessment. Accordingly, the Company has provided a full valuation allowance to offset the net deferred tax assets at December&#160;31, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest and penalties related to income taxes are included in the benefit (provision) for income taxes in the Company&#8217;s Consolidated Statements of Operations. The Company has not incurred any significant interest or penalties related to income taxes in any of the periods presented. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 9%;"></td>
<td style="width: 2%; vertical-align: bottom;"></td>
<td style="width: 89%;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Level&#160;1&#160;&#8211;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Unadjusted quoted prices in active markets for identical assets or liabilities</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Level&#160;2&#160;&#8211;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable through correlation with market data</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Level&#160;3&#160;&#8211;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Unobservable inputs that are supported by little or no market data, which require the reporting entity to develop its own assumptions</td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The carrying values of cash equivalents, accounts payable, and accrued liabilities approximate fair value due to the short-term nature of these instruments. There are no <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities included in cash and cash equivalents as of December&#160;31, 2021 and 2020. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leases </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company determines if an arrangement is a lease at inception. Balances recognized related to the Company&#8217;s operating and finance leases are included in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets, net and lease liabilities in the Consolidated Balance Sheets. Right of use assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Lease terms may include options to extend or terminate the lease if it is reasonably certain that the Company will exercise the option. As most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. The right of use asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company has elected a practical expedient to not separate its lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components and instead account for them as a single lease component. Leases with a term of 12 months or less are not recorded on the balance sheet. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Lease payments for short-term leases are recorded to operating expense on a straight-line basis and variable lease payments are recorded in the period in which the obligation for those payments is incurred. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-48 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%);;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><ix:continuation id="TextSelectionAppend_53608081_4"> <ix:nonNumeric name="prok:ContingentLiabilitiesPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent Liabilities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records reserves for contingent liabilities when it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements, and the amount of the loss can be reasonably estimated. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity-Based Compensation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Deed for the Establishment of a Limited Partnership of ProKidney LP, dated as of August&#160;5, 2021 (the &#8220;Limited Partnership Agreement&#8221;) which replaced the Amended and Restated Limited Liability Company Agreement of ProKidney LLC as the governing document of the parent entity in the Company, allows for the issuance of Profits Interests (as defined in the Limited Partnership Agreement) to employees, directors, other service providers of the Company and others denominated in the form of one or more Class&#160;B Units (as defined in the Limited Partnership Agreement). The Company measures compensation expense for Profits Interests based on estimated fair values at the time of grant. The Company estimates the fair value of Profits Interests using generally accepted valuation procedures. The Company recognizes compensation expense, on a straight-line basis, for the portion of the Profits Interests&#8217; value that is expected to vest over the requisite service period. The Company records forfeitures of Profits Interests as they occur. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Defined Contribution Plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company sponsors a 401(k) plan for its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> employees and a defined contribution plan for its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> employees. Full-time employees are eligible to participate in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> plan. The Company matches 50% of participating <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> employees&#8217; contributions up to 8% of salary. The costs of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> plan were $<ix:nonFraction name="prok:DefinedContributionPlanCosts" contextRef="P01_01_2021To12_31_2021_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">161,000</ix:nonFraction> and $<ix:nonFraction name="prok:DefinedContributionPlanCosts" contextRef="P01_01_2020To12_31_2020_USsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">119,000</ix:nonFraction> for the years ended December&#160;31, 2021 and 2020, respectively. The Company contributes <ix:nonFraction name="prok:DefinedContributionPlanPercent" contextRef="P01_01_2021To12_31_2021_KYsrtStatementGeographicalAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="prok:DefinedContributionPlanPercent" contextRef="P01_01_2020To12_31_2020_KYsrtStatementGeographicalAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">7</ix:nonFraction></ix:nonFraction>% of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> employee salaries to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> defined contribution plan. The costs of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> plan were $<ix:nonFraction name="prok:DefinedContributionPlanCosts" contextRef="P01_01_2021To12_31_2021_KYsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">8,000</ix:nonFraction> and $<ix:nonFraction name="prok:DefinedContributionPlanCosts" contextRef="P01_01_2020To12_31_2020_KYsrtStatementGeographicalAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">20,000</ix:nonFraction> for the years ended December&#160;31, 2021 and 2020, respectively. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company operates in only <ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_segment" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> segment. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recently Adopted Accounting Pronouncements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In February 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-02,</div> Leases (Topic 842), which requires lessees to recognize a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset and a liability on the balance sheet for all leases, with the exception of short-term leases. The lease liability will be equal to the present value of lease payments, and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset will be based on the lease liability, subject to adjustment such as for initial direct costs. Leases will continue to be classified as either operating or finance leases in the income statement. The guidance is effective for annual periods beginning after December&#160;15, 2021, with early adoption permitted. The Company early adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-02,</div> Leases (Topic 842), as of January&#160;1, 2021. For additional detail, see Note 4, Leases. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:SubsequentEventsPolicyPolicyTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsequent Events </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has evaluated subsequent events through April&#160;11, 2022, which is the date the consolidated financial statements were available to be issued. See additional information in Notes 5 and 8. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_53608885"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 3: Income Taxes </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company&#8217;s subsidiary, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US,</div> is treated as a C corporation, and therefore a provision for federal and state taxes has been recorded. </div></ix:nonNumeric> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-49 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><br/></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_53608885" continuedAt="TextSelectionAppend_53608885_1"> <ix:nonNumeric name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The provision for income tax expense consisted of the following for the year ended December&#160;31, 2021 and 2020 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"></td>
<td style="width: 14%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 14%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">72</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">242</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">34</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current income tax expense (benefit)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">38</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">232</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred income tax expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense (benefit)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">38</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">232</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The difference between the statutory rate for federal income tax and the effective income tax rate was as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 12%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes at statutory rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">21.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">21.0</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State taxes, net of federal benefit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LLC flow-through structure</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="prok:EffectiveIncomeTaxRateReconciliationLlcFlowThroughStructure" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">21.4</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="prok:EffectiveIncomeTaxRateReconciliationLlcFlowThroughStructure" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">21.5</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal Credits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">1.8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">2.3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provision to return adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">1.3</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">1.1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">0.2</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective income tax rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal">0.1</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.9</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Components of the Company&#8217;s deferred tax assets and liabilities included in the consolidated balance sheet consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued bonus</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">376</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">243</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">108</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal credit carryforwards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:DeferredTaxAssetsFederalCreditCarryForwards" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">939</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:DeferredTaxAssetsFederalCreditCarryForwards" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">331</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:DeferredTaxAssetsLeases" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:DeferredTaxAssetsLeases" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Start-up</div> costs</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:DeferredTaxAssetsStartUpCosts" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">39</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:DeferredTaxAssetsStartUpCosts" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">48</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets before valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,382</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">730</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,237</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">560</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">145</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">170</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">90</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">148</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">47</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">22</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">145</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">170</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net deferred tax asset</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-50 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><ix:continuation id="TextSelectionAppend_53608885_1"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, available taxes in the carryback periods, projected future taxable income and tax planning strategies in making this assessment. Accordingly, the Company has provided a valuation allowance of $<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,237,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">560,000</ix:nonFraction> respectively for December&#160;31, 2021 and 2020, to offset the net deferred tax assets. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has $<ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2021_ResearchMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,118,000</ix:nonFraction> in Research Credit Carryforwards that begin to expire in 2040. </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of the beginning and ending amount of total unrecognized tax benefits for the years ended December&#160;31, 2021 and 2020 consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 13%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrecognized tax benefits (gross):</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Benefits at the beginning of the year</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2019" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase related to prior year tax positions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">94</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decrease related to prior year tax positions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase related to current year tax positions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">86</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Benefits at the end of the year</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">180</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" contextRef="PAsOn12_31_2021_ResearchMemberusgaapTaxCreditCarryforwardAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">no </ix:nonFraction>net unrecognized tax benefits as of December&#160;31, 2021 which, if recognized, would affect our effective tax rate. We expect none of the gross unrecognized tax benefits will decrease within the next year. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In March 2020, the World Health Organization declared coronavirus <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(COVID-19)</div> a global pandemic. This contagious disease outbreak, which continued to spread, and the related adverse public health developments, have adversely affected work forces, economies and financial markets globally. As a result, governments around the world have enacted legislation to provide aid and stimulate economies. In the U.S., The Coronavirus, Aid, Relief and Economics Security Act (&#8220;CARES Act&#8221;), was enacted on March&#160;27, 2020, The Consolidated Appropriations Act, 2021 was enacted on December&#160;27, 2020, and the American Rescue Plan Act of 2021 was enacted on March&#160;11, 2021. All of these acts included both income tax and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-income</div> tax provisions to assist companies. No provisions in these acts had a material impact on the income tax provision or any other area of the Company&#8217;s financial statements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax years 2018 through 2021 remain subject to examination by federal and state authorities. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_53609019"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 4: Leases </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In February 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02:</div> Leases (Topic 842). This ASU requires a lessee to recognize a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset and a lease liability on its balance sheet for most operating leases. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02</div> is effective for annual and interim periods beginning after December&#160;15, 2018, including interim periods within those fiscal years. In July 2018, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-11,</div> Leases (Topic 842): Targeted Improvements, which provides companies with an additional optional transition method to apply the new standard to leases in effect at the adoption date through a cumulative effect adjustment. The Company adopted the new lease standard as of January&#160;1, 2021 using the modified retrospective transition method. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company elected the package of practical expedients referenced in ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02,</div> which permits companies to retain original lease identification and classification without reassessing initial direct costs for existing leases. The Company also elected the practical expedient that exempts leases with an initial lease term of <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="PAsOn12_31_2021" format="ixt-sec:durmonth">12</ix:nonNumeric> months or less, as well as the practical expedient that allows companies to select, by class of underlying asset, </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-51 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div></div></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><br/></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_53609019"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">not to separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components. Adoption of this standard resulted in the recognition of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset and a lease liability on the Company&#8217;s January&#160;1, 2021 Consolidated Balance Sheet of $<ix:nonFraction name="prok:RightOfUseAssetsOperatingAndFinanceLease" contextRef="PAsOn01_01_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,560,000</ix:nonFraction> and $<ix:nonFraction name="prok:OperatingAndFinanceLeaseLiabilitiesCurrent" contextRef="PAsOn01_01_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,559,000</ix:nonFraction> respectively. There was no material impact on the Company&#8217;s Consolidated Statement of Comprehensive Loss. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has operating leases for real estate (primarily office space) and certain equipment with various expiration dates. The Company also has one finance lease for certain equipment. Rent expense was $<ix:nonFraction name="prok:OperatingLeaseRentExpenses" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">434,000</ix:nonFraction> and $<ix:nonFraction name="prok:OperatingLeaseRentExpenses" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">314,000</ix:nonFraction>, for the years ended December&#160;31, 2021 and 2020, respectively. </div></div> <ix:nonNumeric name="prok:LesseeOperatingAndFinanceLeaseTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the classification of operating and finance lease assets and obligations in the Company&#8217;s Consolidated Balance Sheets as of December&#160;31, 2021 and December&#160;31, 2020 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating leases:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Right of use assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,139</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,415</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities, current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">235</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">195</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities, noncurrent</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">985</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,219</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,220</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,414</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr>
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finance leases:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Right of use assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">102</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">145</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finance lease liabilities, current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finance lease liabilities, noncurrent</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">82</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">115</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total finance lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">114</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">145</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <ix:nonNumeric name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturities of lease liabilities for the Company&#8217;s operating and finance leases are as follows for the year ending December&#160;31, 2021 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Finance</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">326</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">366</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">332</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">372</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">341</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">381</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">282</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">289</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">180</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">180</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueAfterYearFive" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,461</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">127</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,588</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">241</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">13</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">254</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,220</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">114</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:OperatingAndFinanceLeaseLiability" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,334</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average remaining lease term for operating leases is <ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2021" format="ixt-sec:duryear">4.4</ix:nonNumeric> years, and <ix:nonNumeric name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2021" format="ixt-sec:duryear">3.3</ix:nonNumeric> years for the finance lease. The weighted average discount rate is <ix:nonFraction name="prok:OperatingAndFinanceLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2021" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">8.5</ix:nonFraction>%. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:MembersEquityNotesDisclosureTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_53608835"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 5: Members&#8217; Equity </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ownership interests in the Company are represented by two classes of units, Class&#160;A Units and Class&#160;B Units. The terms of the units are governed by the LLC Agreement. As of December&#160;31, 2021, there were <ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountUnitsAuthorized" contextRef="PAsOn12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">190,000,000</ix:nonFraction> Class&#160;A and <ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountUnitsAuthorized" contextRef="PAsOn12_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction> Class&#160;B Units authorized. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-52 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><ix:continuation id="TextSelection_53608835"> <ix:nonNumeric name="prok:MembersEquityTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holders of Class&#160;A Units have voting rights and rights to profits and losses of the Company and distributions from the Company. The following is a summary of the activity of the Class&#160;A Units: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 79%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Units outstanding January&#160;1, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding" contextRef="PAsOn12_31_2019_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">95,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issued 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapitalAccountUnitsContributed" contextRef="P01_01_2020To12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Units outstanding December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding" contextRef="PAsOn12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">115,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issued 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapitalAccountUnitsContributed" contextRef="P01_01_2021To12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">71,500,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Units outstanding December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding" contextRef="PAsOn12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">186,500,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Class&#160;B Units are reserved for issuance of Profits Interests and do not have voting rights. The Profits Interests are designed so that the holders of Profits Interests only participate in a qualified distribution event and only if its valuation threshold is attained in such a distribution event as set forth in the Limited Partnership Agreement; provided, however, that the Limited Partnership Agreement (as amended and restated on January&#160;17, 2022 as contemplated by Note 8 below) provides that certain qualified distribution events will result in the holders of Profits Interests receiving disproportionate distributions from ProKidney until each such holder&#8217;s threshold value has been reduced to zero in order to &#8220;catch up&#8221; such holder&#8217;s distributions to its pro rata share of aggregate cumulative distributions, and once sufficient distributions to a holder of Profits Interests have been made in accordance with the foregoing, the associated Class&#160;B Units will automatically be converted into Class&#160;A Units. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 6: Net Loss per Share </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic loss per share (&#8220;EPS&#8221;) was computed by dividing net loss by the number of weighted average units of Class&#160;A Units outstanding during the period. Diluted EPS was calculated to give effect to potentially issuable dilutive units of common units using the treasury method. For all periods presented, the vested Profits Interests have been excluded from the diluted EPS calculation as their effect would be anti-dilutive. <ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_53608867">The following table sets forth the calculation of basic and diluted earnings per share for the periods indicated based on the weighted average number of common shares outstanding:</ix:nonNumeric> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_53608867">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss available to Class&#160;A Unit holders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">55,146</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">26,749</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average Class&#160;A Units outstanding, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2021To12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2021To12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">150,706,849</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2020To12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2020To12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">104,986,301</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per Class&#160;A Unit</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per Class&#160;A Unit, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2021To12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2021To12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.37</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2020To12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2020To12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.25</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table> </ix:continuation></ix:nonNumeric> <ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true" continuedAt="TextSelection_53608998"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 7: Equity Based Compensation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The issuance of Profits Interests to employees, directors, and other service providers of the Company (&#8220;Plan Participants&#8221;) is administered at the discretion of ProKidney GP Limited, the general partner of ProKidney (the &#8220;General Partner&#8221;). Profits Interests allow the Plan Participants to participate in the residual profits of the Company after the distribution of proceeds reach a minimum threshold value. The threshold value is the amount of proceeds that must be distributed to the holders of Class&#160;A Units before the Plan Participants can participate in a distribution. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-53 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><br/></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_53608998" continuedAt="TextSelectionAppend_53608998_1"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Limited Partnership Agreement, the General Partner determines the terms and conditions of the Profits Interests issued. The threshold value assigned to each grant shall not be less than the fair market value of the Company on the date of grant. Profits Interests awards vest at a rate of <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P01_01_2021To12_31_2021_OnTheLatterOfTheFirstAnniversaryMemberusgaapVestingAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction>% on the latter of the first anniversary of employment and the first anniversary of the Acquisition Date with the remaining <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P01_01_2021To12_31_2021_InFirstAnniversaryOfTheAcquisitionDateMemberusgaapVestingAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">75</ix:nonFraction>% to vest in increments of <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P01_01_2021To12_31_2021_OnEachEnniversaryMemberusgaapVestingAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction>% on each anniversary following the first anniversary date or in increments of <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P01_01_2021To12_31_2021_EachCalendarQuarterMemberusgaapVestingAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">6.25</ix:nonFraction>% each calendar quarter following the first anniversary date. The Profits Interests are subject to a repurchase option should the plan participant no longer be employed by the Company. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Limited Partnership Agreement (prior to its amendment and restatement on January&#160;17, 2022), there are <ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountUnitsAuthorized" contextRef="PAsOn01_17_2022_ClassB1unitsMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction> Class&#160;B Units authorized for issuance. </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the activity related to the Company&#8217;s Profits Interest awards for the year ended December&#160;31, 2021: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/>Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average&#160;Grant<br/>Date&#160;Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Awards outstanding at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="PAsOn12_31_2020" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">4,402,398</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.36</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">1,941,781</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.36</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Awards outstanding at December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">2,460,617</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.36</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="PAsOn12_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction> Class&#160;B Units were granted to employees during the year ended December&#160;31, 2021. As of December&#160;31, 2021, <ix:nonFraction name="prok:NumberOfCommonUnitsUnissuedOfLimitedLiabilityCompany" contextRef="PAsOn12_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">2,232,878</ix:nonFraction> Class&#160;B Units remained unissued. Given that these instruments meet the criteria for being considered profits interest, the Company has recognized no tax benefit related to these awards. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the years ended December&#160;31, 2021 and 2020, respectively, the Company recognized equity-based compensation expense of $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">699,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">730,000</ix:nonFraction>. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, the unrecognized compensation expense was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">868,000</ix:nonFraction>. The current weighted average remaining period over which the unrecognized compensation expense is expected to be recognized is <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2021To12_31_2021" format="ixt-sec:duryear">1.4</ix:nonNumeric>&#160;years. The weighted average grant date fair value of the Profits Interests granted during the year ended December&#160;31, 2020 was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.36</ix:nonFraction> per Class&#160;B unit. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Estimate </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is privately held with no active public market for its equity instruments. Therefore, for financial reporting purposes, management may periodically determine the estimated per share fair value of the Company&#8217;s equity shares (including Profits Interests) using contemporaneous valuations. These contemporaneous valuations are done using methodologies consistent with the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, also known as the Practice Aid. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The valuation approach utilized the Option Pricing Method (OPM), where the fair value of the total equity of the Company within each scenario is first estimated using a back-solve method wherein the equity value is derived from a recent transaction in the Company&#8217;s own securities, and then the total equity value is allocated to the various components of the capital structure, including the Profits Interests, using an OPM or a waterfall approach based on the specific rights of each of the equity classes. The OPM uses the fair value of the total equity of the Company within a scenario as a starting point and incorporates assumptions made regarding the expected returns and volatilities that are consistent with the expectations of market participants, and distribution of equity values is produced which cover the range of events that an informed market participant might expect. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-54 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%);;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><ix:continuation id="TextSelectionAppend_53608998_1"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This process creates a range of equity values both between and within scenarios. The fair value measurement is sensitive to changes in the unobservable inputs. Changes in those inputs might result in a higher or lower fair value measurement. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In performing these valuations, management considered all objective and subjective factors that they believed to be relevant, including management&#8217;s best estimate of the Company business condition, prospects, and operating performance at each valuation date. Within the valuations performed, a range of factors, assumptions, and methodologies were used. The significant factors included trends within the industry, the prices at which the Company sold Class&#160;A Units, the rights and preferences of the Class&#160;A Units relative to the Class&#160;B Units at the time of each measurement date, the results of operations, financial position, status of research and development efforts, stage of development and business strategy, the lack of an active public market for the units, and the likelihood of achieving an exit event in light of prevailing market conditions. </div></div> <ix:nonNumeric name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following reflects the key assumptions used in the OPM valuation: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total equity value (in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MembersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">78,100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility of total equity</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">80</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Discount for lack of market</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected time to exit event</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2021To12_31_2021" format="ixt-sec:duryear">3</ix:nonNumeric> years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> </ix:nonNumeric> </ix:continuation> <ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2021To12_31_2021" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 8: Subsequent Events </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On January&#160;17, 2022, the Company amended and restated its Limited Partnership Agreement (the &#8220;Amended and Restated Limited Partnership Agreement&#8221;) in part to authorize the issuance of up to <ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountUnitsAuthorized" contextRef="PAsOn01_17_2022_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">50,000,000</ix:nonFraction> Class&#160;B Units (including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B-1</div> Units). Upon authorization of these units, the Company issued Profits Interests to certain Plan Participants in the form of <ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountUnitsIssued" contextRef="PAsOn01_17_2022_CapitalUnitClassBOneMemberusgaapCapitalUnitsByClassAxis_DeferredProfitSharingMemberusgaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">8,498,488</ix:nonFraction> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B-1</div> Units. Additionally, the Company issued <ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountUnitsIssued" contextRef="PAsOn01_17_2022_CapitalUnitClassBOneMemberusgaapCapitalUnitsByClassAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">8,848,901</ix:nonFraction> of its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B-1</div> Units for total value received by the Company (or its subsidiaries) of $<ix:nonFraction name="us-gaap:CapitalUnits" contextRef="PAsOn01_17_2022_CapitalUnitClassBOneMemberusgaapCapitalUnitsByClassAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,052,000</ix:nonFraction>. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Amended and Restated Limited Partnership Agreement provides that certain qualified distribution events will result in holders of Profits Interests receiving disproportionate distributions from ProKidney until each such holder&#8217;s valuation threshold has been reduced to zero in order to &#8220;catch up&#8221; such holder&#8217;s distributions to its pro rata share of aggregate cumulative distributions, and once sufficient distributions to a holder of Profits Interests have been made in accordance with the foregoing, the associated Class&#160;B Units will automatically be converted into Class&#160;A Units. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On January&#160;18, 2022, the Company executed a definitive business combination agreement (the &#8220;Business Combination Agreement&#8221;), with Social Capital Suvretta Holdings Corp. III (&#8220;SCS&#8221;). Under the terms of the Business Combination Agreement, the Company will become a subsidiary of SCS and will be organized in an umbrella partnership corporation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;Up-C&#8221;)</div> structure, which provides potential future tax benefits for SCS when the equity holders ultimately exchange their pass-through interests for Class&#160;A ordinary shares in SCS. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;18, 2022, in connection with the Business Combination Agreement, the Company entered into two promissory note agreements with certain of its existing holders. Through such promissory notes, the existing holders may fund up to $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="PAsOn01_18_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">100,000,000</ix:nonFraction> to support the operational financing needs of the Company prior to the closing of the Business Combination. The Company has borrowed $<ix:nonFraction name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" contextRef="PAsOn12_31_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction> against these promissory notes subsequent to December&#160;31, 2021. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-55 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div></div></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><br/></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fincov373959_18" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney LP and Subsidiaries </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Condensed Consolidated Balance Sheets </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 78%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Unaudited)</div></div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td colspan="2" style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">29,802</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,558</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">592</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">588</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid clinical</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:PrepaidClinicalCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,855</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:PrepaidClinicalCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,100</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,249</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,271</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,103</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,358</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Right of use assets, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:RightOfUseAssetsOperatingAndFinanceLease" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,673</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:RightOfUseAssetsOperatingAndFinanceLease" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,241</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred offering costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:DeferredOfferingCost" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,108</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:DeferredOfferingCost" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets, net</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">374</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">428</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">53,507</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">40,298</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities and Equity</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,509</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,834</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:OperatingAndFinanceLeaseLiabilitiesCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">328</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:OperatingAndFinanceLeaseLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">267</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses and other</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:AccruedExpensesAndOther" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,117</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:AccruedExpensesAndOther" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,213</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TaxesPayableCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">958</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:TaxesPayableCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Related party notes payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:NotesPayableRelatedPartiesClassifiedCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">31,912</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,314</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities, net of current portion</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,428</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,067</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Members&#8217; equity:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A Units (<ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountUnitsIssued" contextRef="PAsOn03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountUnitsIssued" contextRef="PAsOn12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding" contextRef="PAsOn03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding" contextRef="PAsOn12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">186,500,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued and outstanding as of March&#160;31, 2022 and December&#160;31, 2021)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LimitedPartnersContributedCapital" contextRef="PAsOn03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">186,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LimitedPartnersContributedCapital" contextRef="PAsOn12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">186,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B Units (<ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding" contextRef="PAsOn03_31_2022_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountUnitsIssued" contextRef="PAsOn03_31_2022_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">17,354,894</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding" contextRef="PAsOn12_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountUnitsIssued" contextRef="PAsOn12_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">7,767,122</ix:nonFraction></ix:nonFraction> issued and outstanding as of March&#160;31, 2022 and December&#160;31, 2021, respectively)</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LimitedPartnersContributedCapital" contextRef="PAsOn03_31_2022_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">62,663</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LimitedPartnersContributedCapital" contextRef="PAsOn12_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,927</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated deficit</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">228,996</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">161,510</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total members&#8217; equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapital" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,167</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapital" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,917</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total liabilities and equity</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">53,507</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">40,298</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(The accompanying notes are an integral part of the consolidated financial statements.) </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-56 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><br/></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fincov373959_19" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney LP and Subsidiaries </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except for share and per share data) </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 74%;"></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">28,490</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,859</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,972</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,744</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">66,462</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,603</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">66,462</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">11,603</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">14</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss before income taxes</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">66,476</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">11,603</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,010</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net and comprehensive loss</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">67,486</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">11,609</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average Class&#160;A Units outstanding:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">186,500,000</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2021To03_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2021To03_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">122,111,111</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per Class&#160;A Unit:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.36</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2021To03_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2021To03_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.10</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><div style="clear: both; max-height: 0px;"></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(The accompanying notes are an integral part of the consolidated financial statements.) </div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-57 </div></div></div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div></div></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><br/></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fincov373959_20" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney LP and Subsidiaries </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unaudited Condensed Consolidated Statements of Changes in Members&#8217; Equity </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands, except for share data) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 42%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td colspan="20" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">For the three months ended March&#160;31, 2022</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;a</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total&#160;Members&#8217;<br/>Equity</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amounts</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Profits&#160;Interests</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:PartnersCapitalOutstanding" contextRef="PAsOn12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">186,500,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapital" contextRef="PAsOn12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">186,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapital" contextRef="PAsOn12_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,927</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PartnersCapital" contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">161,510</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapital" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,917</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Capital contribution</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapitalAccountContributions" contextRef="P01_01_2022To03_31_2022_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,550</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapitalAccountContributions" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,550</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity-based payments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="P01_01_2022To03_31_2022_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">55,186</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">55,186</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">67,486</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">67,486</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of March&#160;31, 2022</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:PartnersCapitalOutstanding" contextRef="PAsOn03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">186,500,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapital" contextRef="PAsOn03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">186,500</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapital" contextRef="PAsOn03_31_2022_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">62,663</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PartnersCapital" contextRef="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">228,996</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapital" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,167</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 43%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td colspan="20" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">For the three months ended March&#160;31, 2021</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated<br/>Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total&#160;Members&#8217;<br/>Equity</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Units</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amounts</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Profits&#160;Interests</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of December&#160;31, 2020</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:PartnersCapitalOutstanding" contextRef="PAsOn12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">115,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapital" contextRef="PAsOn12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">115,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapital" contextRef="PAsOn12_31_2020_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,228</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PartnersCapital" contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">106,364</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapital" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,864</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Capital contribution</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2021To03_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2021To03_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity-based payments</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="P01_01_2021To03_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">175</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">175</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">11,609</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">11,609</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Balance as of March&#160;31, 2021</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:PartnersCapitalOutstanding" contextRef="PAsOn03_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">135,000,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapital" contextRef="PAsOn03_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">135,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapital" contextRef="PAsOn03_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,403</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PartnersCapital" contextRef="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">117,973</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PartnersCapital" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,430</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(The accompanying notes are an integral part of the consolidated financial statements.) </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-58 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><br/></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="fincov373959_21" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney LP and Subsidiaries </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unaudited Condensed Consolidated Statements of Cash Flows </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(in thousands) </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from operating activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">67,486</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">11,609</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Adjustments to reconcile net loss to net cash flows</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation and amortization</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">710</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">361</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity-based compensation expense</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">52,684</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">175</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Changes in operating assets and liabilities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other assets</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,843</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">249</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts payable and accrued expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,519</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,568</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">957</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash flows used in operating activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">15,459</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">7,256</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows used in investing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Purchase of equipment and facility expansion</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">839</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,389</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash flows used in investing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">839</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,389</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash flows from financing activities</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Payments on finance leases</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Borrowings under related party notes payable</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromRelatedPartyDebt" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash contribution</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,550</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net cash flows provided by financing activities</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,542</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 0.75pt solid black;;text-align:right;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,993</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net change in cash and cash equivalents</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,244</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,348</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, beginning of period</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,558</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,577</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash, end of period</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">29,802</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,925</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;">Supplemental disclosure of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> investing activities:</div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Right of use assets obtained in exchange for lease obligations</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:RightOfUseAssetsObtainedInExchangeForLeaseObligations" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">496</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equipment and facility expansion included in accounts payable and accrued expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">501</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">910</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear: both; max-height: 0px;"></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">(The accompanying notes are an integral part of the consolidated financial statements.) </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-59 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div> </div> </div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><br/></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div id="fincov373959_22" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney LP and Subsidiaries </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notes to Unaudited Consolidated Financial Statements </div></div></div><div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Three Months Ended March&#160;31, 2022 and 2021 </div></div></div> <ix:nonNumeric name="us-gaap:NatureOfOperations" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 1: The Company </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">ProKidney LLC was formed as a Bermuda limited liability company on <ix:nonNumeric name="dei:EntityIncorporationDateOfIncorporation" contextRef="P12_12_2018To12_31_2018" format="ixt:date-monthname-day-year-en">December 12, 2018</ix:nonNumeric> and funded with $<ix:nonFraction name="prok:InitialCapital" contextRef="PAsOn12_31_2018" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">75,000,000</ix:nonFraction> on December&#160;31, 2018. On January&#160;9, 2019 (the &#8220;Acquisition Date&#8221;), ProKidney LLC acquired all of the equity interests in inRegen and Twin City Bio LLC (&#8220;TC Bio&#8221;) for $<ix:nonFraction name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="P01_09_2019To01_09_2019_RegenAndTwinCityBioLlcMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">62,000,000</ix:nonFraction>. inRegen was duly incorporated under the Cayman Islands Companies Act (as amended) on December&#160;21, 2015 as an exempted company. During 2020, inRegen&#8217;s name was changed to ProKidney (and is referred to herein as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;ProKidney-KY&#8221;),</div> and TC Bio&#8217;s name was changed to ProKidney, LLC (and is referred to herein as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;ProKidney-US&#8221;).</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> was formed as a limited liability company under the laws of Delaware on December&#160;18, 2015. In August 2021, ProKidney LP was organized as a limited partnership under the laws and regulations of Ireland, with ProKidney LLC becoming a wholly owned subsidiary of ProKidney LP (and is referred to herein as &#8220;ProKidney&#8221;). Following this reorganization on August&#160;5, 2021, and for the purposes of these financial statements, the term &#8220;ProKidney&#8221; as used herein, refers to ProKidney LP following this reorganization, and the financial information presented herein is that of ProKidney LP and its wholly owned subsidiaries. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">ProKidney acquired the equity interests in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> to develop its Renal Advanced Cell Therapy, which has the potential to stabilize or improve renal function in patients with chronic kidney disease or delay or eliminate the need for dialysis and organ transplantation. ProKidney acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> to provide contractual development and manufacturing services to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY,</div> which is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US&#8217;s</div> only customer. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because ProKidney is a limited partnership, the debts, obligations and liabilities of the Company (as defined below), whether arising in contract, tort or otherwise, are solely the debts, obligations and liabilities of the Company, and no holder of equity interests in ProKidney (&#8220;members&#8217; equity&#8221;) is obligated personally for any such debt, obligation or liability of the Company solely by reason of being a holder of members&#8217; equity. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On January&#160;18, 2022, the Company executed a definitive business combination agreement (the &#8220;Business Combination Agreement&#8221;), with Social Capital Suvretta Holdings Corp. III (&#8220;SCS&#8221;). Under the terms of the Business Combination Agreement, the Company will become a subsidiary of SCS and will be organized in an umbrella partnership corporation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;Up-C&#8221;)</div> structure, which provides potential future tax benefits for SCS when the equity holders ultimately exchange their pass-through interests for Class&#160;A ordinary shares in SCS. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true" continuedAt="TextSelection_53608084"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 2: Significant Accounting Policies </div></div></div> <ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The condensed consolidated financial statements reflect the operations of ProKidney and its wholly-owned subsidiaries consisting of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> (together, the &#8220;Company&#8221;). All intercompany transactions and accounts have been eliminated. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair presentation of the Company&#8217;s financial information. These interim results and cash flows for any interim period are not necessarily indicative of the results to be expected for the full year. Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States of America (GAAP) as found in the Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB). These unaudited consolidated financial statements are presented in U.S. Dollars. </div></div></ix:nonNumeric> </ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-60 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%);;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><ix:continuation id="TextSelection_53608084" continuedAt="TextSelectionAppend_53608084_1"> <ix:nonNumeric name="prok:GoingConcernPolicyTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Going Concern </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company performed an analysis of its ability to continue as a going concern. As of March&#160;31, 2022, the Company had an accumulated deficit of $<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">228,996,000</ix:nonFraction>. The Company has generated losses from operations for each year since its inception. The Company intends to continue to conduct significant additional research, development, and clinical study activities which, together with expenses incurred for general and administrative expenses, are expected to result in continuing operating losses for the foreseeable future. The amount of future losses and when, if ever, the Company will achieve profitability are uncertain. The Company&#8217;s ability to achieve profitability will depend, among other things, on successfully completing clinical studies, obtaining requisite regulatory approvals, establishing appropriate pricing for its product with payers, and raising sufficient funds to finance the Company&#8217;s activities. No assurance can be given that the Company&#8217;s clinical development efforts will be successful, that regulatory approvals will be obtained, or that the Company will be able to achieve appropriate pricing and market access or that profitability, if achieved, can be sustained. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These matters raise substantial doubt about the Company&#8217;s ability to continue as a going concern. As of March&#160;31, 2022, the Company has cash and cash equivalents of $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">29,802,000</ix:nonFraction>, and remaining availability of $<ix:nonFraction name="us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount" contextRef="PAsOn03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">80,000,000</ix:nonFraction> under its two promissory note agreements with certain holders of its Class&#160;A Units (the &#8220;Promissory Notes&#8221;). The Company believes that these sources of liquidity will not be sufficient to fund its obligations for the next twelve months. The condensed consolidated financial statements do not include any adjustments related to the outcome of this uncertainty. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to execute our operating plan depends on our ability to obtain additional funding through equity offerings, debt financings or potential licensing and collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to us. Even if we raise additional capital, we may also be required to modify, delay or abandon some of our plans which could have a material adverse effect on our business, operating results and financial condition and our ability to achieve our intended business objectives. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of condensed consolidated financial statements, in accordance with GAAP, requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of expenses during the reported periods. Certain estimates in these condensed consolidated financial statements have been made in connection with the calculation of research and development expenses, equity-based compensation expense and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections, which management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all highly liquid investments with an original maturity of 90 days or less on the date of purchase to be cash equivalents. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concentrations of Credit Risk </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company&#8217;s cash and equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. </div></div></ix:nonNumeric> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-61 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><br/></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_53608084_1" continuedAt="TextSelectionAppend_53608084_2"> <ix:nonNumeric name="prok:AccruedExpensesPolicyTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued Expenses </div></div></div> <ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses as presented in the Condensed Consolidated Balance Sheets as of March&#160;31, 2022 and December&#160;31, 2021 consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">818</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,832</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinical study related costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:AccruedClinicalStudyRelatedCostsCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">653</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:AccruedClinicalStudyRelatedCostsCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,031</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued legal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,095</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">964</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Manufacturing improvement costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:AccruedManufacturingImprovementCosts" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,137</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:AccruedManufacturingImprovementCosts" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,164</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">414</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">222</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued expenses and other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,117</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,213</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> </ix:nonNumeric> <ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development Costs </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries, benefits, third party license fees, and external costs of outside vendors engaged to conduct manufacturing and preclinical development activities and clinical trials. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records accruals based on estimates of services received, efforts expended, and amounts owed pursuant to contracts with numerous contract research organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company&#8217;s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company&#8217;s estimate of the degree of completion of the event or events specified in the specific clinical study. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Condensed Consolidated Statement of Operations and Comprehensive Loss as the Company receives the related goods or services. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Costs incurred in obtaining technology licenses are charged to research and development expense as purchased <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development if the technology licensed has not reached technological feasibility and has no alternative future use. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true" continuedAt="TextSelection_53608974"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed Assets </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets are stated at cost, less accumulated depreciation. Generally, expenditures for maintenance and repairs are charged to expense and major improvements or replacements are capitalized. The Company computes depreciation and amortization using the straight-line method over the estimated useful life of the asset. Leasehold improvements are amortized over the lesser of, the life of the lease or the estimated useful life of the leasehold improvement. <ix:nonNumeric name="prok:DisclosureInTabularFormOfUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true" continuedAt="TextSelection_53609336">The estimated useful lives are as follows:</ix:nonNumeric> </div></div> <ix:continuation id="TextSelection_53609336"> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment and software</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2022To03_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis" format="ixt-sec:duryear">3</ix:nonNumeric>-<ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2022To03_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" format="ixt-sec:duryear">5</ix:nonNumeric></div> years</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2022To03_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis" format="ixt-sec:duryear">5</ix:nonNumeric>-<ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="P01_01_2022To03_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis" format="ixt-sec:duryear">7</ix:nonNumeric></div> years</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="P01_01_2022To03_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">remainder of lease term</ix:nonNumeric></td></tr></table> </ix:continuation></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </ix:continuation> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-62 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> </div></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_53608974"><ix:continuation id="TextSelectionAppend_53608084_2" continuedAt="TextSelectionAppend_53608084_3"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets consisted of the following (in thousands): </div></div></div><div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn03_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,220</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,180</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment and software</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn03_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">589</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">569</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn03_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,520</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,517</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Construction in progress</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn03_31_2022_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">631</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2021_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">351</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: accumulated depreciation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,857</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,259</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total fixed assets, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,103</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,358</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table></ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation expense for the three months ended March&#160;31, 2022 and 2021 was $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">593,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:Depreciation" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">176,000</ix:nonFraction>, respectively. </div></div> </ix:continuation></ix:continuation><ix:continuation id="TextSelectionAppend_53608084_3" continuedAt="TextSelectionAppend_53608084_4"> <ix:nonNumeric name="us-gaap:IntangibleAssetsFiniteLivedPolicy" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible Assets </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets are comprised of acquired assembled workforce, which are accounted for in accordance with ASC 350&#8212;Intangibles&#8212;Goodwill and Other. The acquired assembled workforce is amortized on a straight-line basis over the useful life of <ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="P01_01_2022To03_31_2022_AcquiredAssemblyWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" format="ixt-sec:durwordsen">five years</ix:nonNumeric>. <ix:nonNumeric name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true" continuedAt="TextSelection_53609331">The following table summarizes information related to the Company&#8217;s assembled workforce intangible asset (in thousands):</ix:nonNumeric> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_53609331">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross carrying amount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,073</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,073</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">699</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">645</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net carrying amount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">374</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">428</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:continuation> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated amortization expense for the remaining nine months of 2022 is $<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">154,000</ix:nonFraction>, $<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">215,000</ix:nonFraction> for the year ended December&#160;31, 2023 and $<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,000</ix:nonFraction> for the year ended December&#160;31, 2024. Amortization expense relating to the assembled workforce intangible asset was $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2021To03_31_2021_AcquiredAssemblyWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="P01_01_2022To03_31_2022_AcquiredAssemblyWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">54,000</ix:nonFraction></ix:nonFraction> for each of the three months ended March&#160;31, 2022 and 2021. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairment of Long-Lived Assets </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-lived assets such as fixed assets and intangible assets subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. <ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction> impairment charges have been recorded for the three months ended March&#160;31, 2022 or 2021. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true" continuedAt="TextSelection_53608315"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company was organized as a limited liability company, is now a limited partnership and is classified as a partnership for U.S. income tax purposes, and as such, only records a provision for federal and state income taxes on its subsidiaries organized as C corporations or which have elected to be treated as corporations for U.S. federal income tax purposes. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> is a limited liability company and has elected to be treated as a C corporation. Therefore, a provision for federal and state taxes has been recorded. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> has been granted, by the Government in Council of the Cayman Islands, tax concessions under an undertaking certificate exempting it from any tax levied on profits, income, gains or appreciations in relation to its operations or in the nature of estate duty or inheritance tax for a period of <ix:nonNumeric name="prok:PeriodForWhichTheProfitsEarnedAreExemptFromTax" contextRef="P01_20_2016To12_31_2021_KYsrtStatementGeographicalAxis" format="ixt-sec:durwordsen">twenty years</ix:nonNumeric> from January&#160;20, 2016. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> elected to be treated as an entity disregarded from its owner for U.S. tax purposes, and as a result, it has not recorded an income tax provision. <br/></div></ix:nonNumeric> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-63 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><ix:continuation id="TextSelectionAppend_53608084_4" continuedAt="TextSelectionAppend_53608084_5"><ix:continuation id="TextSelection_53608315"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company uses the liability method in accounting for income taxes as required by ASC Topic 740 &#8212; Income Taxes, under which deferred tax assets and liabilities are recorded for the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that such assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, available taxes in the carryback periods, projected future taxable income and tax planning strategies in making this assessment. Accordingly, the Company has provided a full valuation allowance to offset the net deferred tax assets at March&#160;31, 2022 and December&#160;31, 2021. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest and penalties related to income taxes are included in the benefit (provision) for income taxes in the Company&#8217;s Condensed Consolidated Statements of Operations and Comprehensive Loss. The Company has not incurred any significant interest or penalties related to income taxes in any of the periods presented. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">three-level</div> fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three&#160;levels of inputs used to measure fair value are as follows: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1 &#8211; Unadjusted quoted prices in active markets for identical assets or liabilities </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2 &#8211; Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable through correlation with market data </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3 &#8211; Unobservable inputs that are supported by little or no market data, which require the reporting entity to develop its own assumptions </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The carrying values of cash equivalents, accounts payable, and accrued liabilities approximate fair value due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">short-term</div> nature of these instruments. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leases </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company determines if an arrangement is a lease at inception.&#160;Balances recognized related to the Company&#8217;s operating and finance leases are included in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets, net and lease liabilities in the Condensed Consolidated Balance Sheets.&#160;Right of use assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date.&#160;Lease terms may include options to extend or terminate the lease if it is reasonably certain that the Company will exercise the option.&#160;As most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments.&#160;The right of use asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred.&#160;The Company has elected a practical expedient to not separate its lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components and instead account for them as a single lease component. Leases with a term of 12 months or less are not recorded on the balance sheet. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.&#160;Lease payments for short-term leases are recorded to operating expense on a straight-line basis and variable lease payments are recorded in the period in which the obligation for those payments is incurred. </div></div></ix:nonNumeric> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-64 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"></div></div></div><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><br/></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelectionAppend_53608084_5"> <ix:nonNumeric name="prok:ContingentLiabilitiesPolicyTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent Liabilities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records reserves for contingent liabilities when it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements, and the amount of the loss can be reasonably estimated. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity-Based Compensation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Deed for the Establishment of a Limited Partnership of ProKidney LP, dated as of August&#160;5, 2021 (the &#8220;Limited Partnership Agreement&#8221;) which replaced the Amended and Restated Limited Liability Company Agreement of ProKidney LLC as the governing document of the parent entity in the Company, allows for the issuance of Profits Interests (as defined in the Limited Partnership Agreement) to employees, directors, other service providers of the Company and others denominated in the form of one or more Class&#160;B Units (as defined in the Limited Partnership Agreement). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On January&#160;17, 2022, the Company amended and restated its Limited Partnership Agreement (the &#8220;Amended and Restated Limited Partnership Agreement&#8221;) in part to authorize the issuance of up to <ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountUnitsAuthorized" contextRef="PAsOn01_17_2022_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">50,000,000</ix:nonFraction> Class&#160;B Units (including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B-1</div> Units). The Amended and Restated Limited Partnership Agreement provides that certain qualified distribution events will result in holders of Profits Interests receiving disproportionate distributions from ProKidney until each such holder&#8217;s valuation threshold has been reduced to zero in order to &#8220;catch up&#8221; such holder&#8217;s distributions to its pro rata share of aggregate cumulative distributions, and once sufficient distributions to a holder of Profits Interests have been made in accordance with the foregoing, the associated Class&#160;B Units will automatically be converted into Class&#160;A Units. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures compensation expense for Profits Interests based on estimated fair values at the time of grant. The Company estimates the fair value of Profits Interests using generally accepted valuation procedures. The Company recognizes compensation expense, on a straight-line basis, for the portion of the Profits Interests&#8217; value that is expected to vest over the requisite service period. The Company records forfeitures of Profits Interests as they occur. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company operates in only <ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_segment" decimals="0" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> segment. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recently Adopted Accounting Pronouncements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In February 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-02,</div> Leases (Topic 842), which requires lessees to recognize a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset and a liability on the balance sheet for all leases, with the exception of short-term leases. The lease liability will be equal to the present value of lease payments, and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset will be based on the lease liability, subject to adjustment such as for initial direct costs. Leases will continue to be classified as either operating or finance leases in the income statement. The guidance is effective for annual periods beginning after December&#160;15, 2021, with early adoption permitted. The Company early adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-02,</div> Leases (Topic 842), as of January&#160;1, 2021. For additional detail, see Note 4, Leases. </div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:SubsequentEventsPolicyPolicyTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsequent Events </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has evaluated subsequent events through June 10, 2022, which is the date the consolidated financial statements were available to be issued. See additional information in Note 9. </div></div></ix:nonNumeric> </ix:continuation> <ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true" continuedAt="TextSelection_53608886"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 3: Income Taxes </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company&#8217;s subsidiary, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US,</div> is treated as a C corporation, and therefore a provision for federal and state taxes has been recorded. The Company&#8217;s income tax provision for the three months ended March&#160;31, 2022 and 2021 were $<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,010,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">6,000</ix:nonFraction>, respectively. </div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-65 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%);;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><ix:continuation id="TextSelection_53608886"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, available taxes in the carryback periods, projected future taxable income and tax planning strategies in making this assessment. The difference between the Company&#8217;s effective tax rate of (<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">1.5</ix:nonFraction>)% for the three months ended March&#160;31, 2022 and the U.S. statutory rate of <ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">21</ix:nonFraction>% is primarily attributable to the Company and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> being treated as partnerships for income tax purposes. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For tax years beginning after December&#160;31, 2021, the Tax Cuts and Jobs Act of 2017 (the &#8220;TCJA&#8221;) requires specified research and development expenses to be capitalized and amortized ratably over a <ix:nonNumeric name="prok:DeferredExpenseCapitalizedResearchAndDevelopmentCostsTerm" contextRef="P01_01_2022To03_31_2022" format="ixt-sec:durwordsen">five-year</ix:nonNumeric> period. The adoption of this provision of the TCJA is the primary driver of income tax expense recognized during the three months ended March&#160;31, 2022. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are no net unrecognized tax benefits as of March&#160;31, 2022 which, if recognized, would affect our effective tax rate. We expect none of the gross unrecognized tax benefits will decrease within the next year. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There have been no significant changes in the Company&#8217;s uncertain tax positions during the three months ended March&#160;31, 2022. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true" continuedAt="TextSelection_53609018"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 4: Leases </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In February 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02:</div> Leases (Topic 842). This ASU requires a lessee to recognize a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset and a lease liability on its balance sheet for most operating leases. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02</div> is effective for annual and interim periods beginning after December&#160;15, 2018, including interim periods within those fiscal years. In July 2018, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-11,</div> Leases (Topic 842): Targeted Improvements, which provides companies with an additional optional transition method to apply the new standard to leases in effect at the adoption date through a cumulative effect adjustment. The Company adopted the new lease standard as of January&#160;1, 2021 using the modified retrospective transition method. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company elected the package of practical expedients referenced in ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02,</div> which permits companies to retain original lease identification and classification without reassessing initial direct costs for existing leases. The Company also elected the practical expedient that exempts leases with an initial lease term of <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="PAsOn03_31_2022" format="ixt-sec:durwordsen">twelve months</ix:nonNumeric> or less, as well as the practical expedient that allows companies to select, by class of underlying asset, not to separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components. Adoption of this standard resulted in the recognition of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset and a lease liability on the Company&#8217;s January&#160;1, 2021 Consolidated Balance Sheet of $<ix:nonFraction name="prok:RightOfUseAssetsOperatingAndFinanceLease" contextRef="PAsOn01_01_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,560,000</ix:nonFraction> and $<ix:nonFraction name="prok:OperatingAndFinanceLeaseLiabilitiesCurrent" contextRef="PAsOn01_01_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,559,000</ix:nonFraction> respectively. There was no material impact on the Company&#8217;s Condensed Consolidated Statement of Operations and Comprehensive Loss. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has operating leases for real estate (primarily office space) and certain equipment with various expiration dates. The Company also has one finance lease for certain equipment.&#160;&#160;&#160;&#160;Rent expense was $<ix:nonFraction name="prok:OperatingLeaseRentExpenses" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">89,000</ix:nonFraction> and $<ix:nonFraction name="prok:OperatingLeaseRentExpenses" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">81,000</ix:nonFraction>, for the three months ended March&#160;31, 2022 and 2021, respectively. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></ix:nonNumeric> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-66 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><br/></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_53609018"> <ix:nonNumeric name="prok:LesseeOperatingAndFinanceLeaseTableTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the classification of operating and finance lease assets and obligations in the Company&#8217;s Condensed Consolidated Balance Sheets as of March&#160;31, 2022 and December&#160;31, 2021 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating leases:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Right of use assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,579</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,139</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities, current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">295</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">235</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities, noncurrent</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,354</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">985</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,649</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,220</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr>
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finance leases:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Right of use assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">94</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseRightOfUseAsset" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">102</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finance lease liabilities, current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">33</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">32</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finance lease liabilities, noncurrent</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">74</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">82</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total finance lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">107</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="PAsOn12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">114</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <ix:nonNumeric name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturities of lease liabilities for the Company&#8217;s operating and finance leases are as follows for the year ending March&#160;31, 2022 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 5%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating<br/>Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Finance<br/>Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022 (remaining nine months)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">315</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">345</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">428</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">468</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">440</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">40</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">480</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">440</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">7</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">447</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">355</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">355</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero">&#8212;</ix:nonFraction>&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueAfterYearFive" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,993</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiabilityPaymentsDue" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">117</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,110</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">344</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">10</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">354</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,649</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:FinanceLeaseLiability" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">107</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="prok:OperatingAndFinanceLeaseLiability" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,756</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average remaining lease term for operating leases is <ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn03_31_2022" format="ixt-sec:duryear">4.5</ix:nonNumeric> years, and <ix:nonNumeric name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn03_31_2022" format="ixt-sec:duryear">3.0</ix:nonNumeric> years for the finance lease. The weighted average discount rate is <ix:nonFraction name="prok:OperatingAndFinanceLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn03_31_2022" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">8.5</ix:nonFraction>%. </div></div> </ix:continuation> <ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 5: Related Party Debt </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;18, 2022, in connection with the Business Combination Agreement, the Company entered into the Promissory Notes. Through such promissory notes, the holders may fund up to $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn01_18_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">100,000,000</ix:nonFraction> to support the operational financing needs of the Company prior to the closing of the Business Combination. These notes bear interest at a rate of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn01_18_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">3</ix:nonFraction>% per annum and are due upon the earliest of either (i)&#160;the date on which the Business Combination closes or (ii)&#160;<ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="P01_18_2022To01_18_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis" format="ixt:date-monthname-day-year-en">January 17, 2023</ix:nonNumeric>. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Drawdowns on the Promissory Notes may be made in multiples of $<ix:nonFraction name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" contextRef="PAsOn03_31_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000</ix:nonFraction> unless otherwise agreed upon. Once an amount is drawn down under the Promissory Notes, it is no longer available for future drawdown requests even if prepaid. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three months ended March&#160;31, 2022, the Company borrowed $<ix:nonFraction name="us-gaap:DebtInstrumentFeeAmount" contextRef="PAsOn03_31_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">20,000,000</ix:nonFraction> under this agreement, leaving remaining availability of $<ix:nonFraction name="us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount" contextRef="PAsOn03_31_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">80,000,000</ix:nonFraction> as of March&#160;31, 2022. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-67 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%); letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div> <ix:nonNumeric name="us-gaap:MembersEquityNotesDisclosureTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 6: Members&#8217; Equity </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Ownership interests in the Company are represented by two classes of units, Class&#160;A units and Class&#160;B units. The terms of the units are governed by the LLC Agreement. As of March&#160;31, 2022, there are <ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountUnitsAuthorized" contextRef="PAsOn03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">190,000,000</ix:nonFraction> Class&#160;A and <ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountUnitsAuthorized" contextRef="PAsOn03_31_2022_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">50,000,000</ix:nonFraction> Class&#160;B Units authorized (including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B-1</div> Units). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holders of Class&#160;A units have voting rights and rights to profits and losses of the Company and distributions from the Company. No Class&#160;A units were issued during the three months ended March&#160;31, 2022. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">During the three months ended March&#160;31, 2022, the Company issued <ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountUnitsIssued" contextRef="PAsOn03_31_2022_CapitalUnitClassB1MemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">6,098,901</ix:nonFraction> of its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B-1</div> Units for total cash proceeds of $<ix:nonFraction name="prok:ProceedsFromLimitedPartnersCapitalAccountUnits" contextRef="P01_01_2022To03_31_2022_CapitalUnitClassB1MemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,550,000</ix:nonFraction>. As these awards were issued for a price below their estimated fair value to employees, board members and other service providers, the provisions of ASC Topic 718 &#8211; Stock Compensation apply. Refer to Note 8 for further details. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Class&#160;B Units are reserved for issuance of Profits Interests and do not have voting rights. The Profits Interests are designed so that the holders of Profits Interests only participate in a qualified distribution event and only if its valuation threshold is attained in such a distribution event as set forth in the Limited Partnership Agreement; provided, however, that the Limited Partnership Agreement, as amended and restated in January 2022, provides that certain qualified distribution events will result in the holders of Profits Interests receiving disproportionate distributions from ProKidney until each such holder&#8217;s threshold value has been reduced to zero in order to &#8220;catch up&#8221; such holder&#8217;s distributions to its pro rata share of aggregate cumulative distributions, and once sufficient distributions to a holder of Profits Interests have been made in accordance with the foregoing, the associated Class&#160;B Units will automatically be converted into Class&#160;A Units. </div></div></ix:nonNumeric> <ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 7: Net Loss per Share </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic loss per share (&#8220;EPS&#8221;) was computed by dividing net loss by the number of weighted average units of Class&#160;A Units outstanding during the period. Diluted EPS was calculated to give effect to potentially issuable dilutive units of common units using the treasury method. For all periods presented, the vested Profits Interests have been excluded from the diluted EPS calculation as their effect would be anti-dilutive. <ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true" continuedAt="TextSelection_53608868">The following table sets forth the calculation of basic and diluted earnings per share for the periods indicated based on the weighted average number of common shares outstanding:</ix:nonNumeric> </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <ix:continuation id="TextSelection_53608868">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss available to Class&#160;A Unit holders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">67,486</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To03_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">11,609</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average Class&#160;A Units outstanding, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2022To03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2022To03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">186,500,000</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2021To03_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2021To03_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">122,111,111</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per Class&#160;A Unit</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per Class&#160;A Unit, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2022To03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2022To03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.36</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2021To03_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2021To03_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal">0.10</ix:nonFraction></ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table> </ix:continuation></ix:nonNumeric> <ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true" continuedAt="TextSelection_53608999"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 8: Equity Based Compensation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Profits Interests Awards </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The issuance of Profits Interests to employees, directors, and other service providers of the Company (&#8220;Plan Participants&#8221;) is administered at the discretion of ProKidney GP Limited, the general partner of ProKidney (the &#8220;General Partner&#8221;). Profits Interests allow the Plan Participants to participate in the residual profits of the Company after the distribution of proceeds reach a minimum threshold value. The threshold value is the amount of proceeds that must be distributed to the holders of Class&#160;A Units before the Plan Participants can participate in a distribution. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-68 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><br/></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div></div></div> <div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><ix:continuation id="TextSelection_53608999" continuedAt="TextSelectionAppend_53608999_1"> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Limited Partnership Agreement, the General Partner determines the terms and conditions of the Profits Interests issued. The threshold value assigned to each grant shall not be less than the fair market value of the Company on the date of grant. Profits Interests awards vest at a rate of <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P01_01_2022To03_31_2022_OnTheLatterOfTheFirstAnniversaryMemberusgaapVestingAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction>% on the latter of the first anniversary of employment and the first anniversary of the Acquisition Date with the remaining <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P01_01_2022To03_31_2022_InFirstAnniversaryOfTheAcquisitionDateMemberusgaapVestingAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">75</ix:nonFraction>% to vest in increments of <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P01_01_2022To03_31_2022_OnEachEnniversaryMemberusgaapVestingAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">25</ix:nonFraction>% on each anniversary following the first anniversary date, ratably over a three or four-year period from the date of grant, in annual installments of <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P01_01_2022To03_31_2022_OverTheThreeYearPeriodFromTheDateOfGrantMemberusgaapVestingAxis" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal">33.3</ix:nonFraction>% over the three-year period from the date of grant, or in increments of <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P01_01_2022To03_31_2022_EachCalendarQuarterMemberusgaapVestingAxis" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal">6.25</ix:nonFraction>% each calendar quarter following the first anniversary date. The Profits Interests are subject to a repurchase option should the plan participant no longer be employed by the Company. </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The following table summarizes the activity for the three months ended March&#160;31, 2022, related to the Company&#8217;s Class&#160;B and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Units granted as equity awards to its employees, board members and service providers: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 9%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/>Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average&#160;Grant<br/>Date&#160;Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested awards outstanding at January&#160;1, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="PAsOn12_31_2021" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">2,460,617</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2021" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.36</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">8,498,488</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">6.03</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">449,486</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">0.36</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">29,070</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">6.03</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested awards outstanding at March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="PAsOn03_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">10,480,549</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn03_31_2022" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal">4.94</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of March&#160;31, 2022, the unrecognized compensation expense related to these awards was $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn03_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">50,020,000</ix:nonFraction>. The current weighted average remaining period over which the unrecognized compensation expense is expected to be recognized is <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2022To03_31_2022" format="ixt-sec:duryear">3.6</ix:nonNumeric> years. The weighted average grant date fair value of the Profits Interests granted during the three months ended March&#160;31, 2022, was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal">6.03</ix:nonFraction> per <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B-1</div> unit. There were no Profits Interests granted during the three months ended March&#160;31, 2021. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2022, there remain <ix:nonFraction name="prok:CommonUnitsUnissued" contextRef="PAsOn03_31_2022_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">22,164,559</ix:nonFraction> Class&#160;B Units available for issuance. Given that these instruments meet the criteria for being considered profits interests, the Company has recognized no tax benefit related to these awards.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Modification to Profits Interest Awards </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;17, 2022, the Limited Partnership Agreement was amended and restated to provide that certain qualified distribution events will result in the holders of Profits Interests receiving disproportionate distributions from ProKidney until each such holder&#8217;s threshold value has been reduced to zero in order to &#8220;catch up&#8221; such holder&#8217;s distributions to its pro rata share of aggregate cumulative distributions, and once sufficient distributions to a holder of Profits Interests have been made in accordance with the foregoing, the associated Class&#160;B Units will automatically be converted into Class&#160;A Units. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This amendment constitutes a modification to the Class&#160;B Units outstanding as of the date of the modification under the provisions of ASC Topic 718. In connection with the modification of its outstanding share-based compensation awards, the Company will recognize total additional compensation expense of $<ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,437,000</ix:nonFraction> related to awards granted to its employees. The portion of this additional compensation expense attributable to vested awards of $<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" contextRef="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,715,000</ix:nonFraction> was recognized immediately upon modification during the three months ended March&#160;31, 2022. </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-69 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%);;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><ix:continuation id="TextSelectionAppend_53608999_1" continuedAt="TextSelectionAppend_53608999_2"> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Issuance of Profits Interests to Service Provider </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">During the three months ended March&#160;31, 2022, the Company issued <ix:nonFraction name="us-gaap:PartnersCapitalAccountUnitsUnitbasedCompensation" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">2,750,000</ix:nonFraction> fully vested <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B-1</div> Units to a third party service provider as payment for research and development services provided in prior periods. The Company had previously recognized expense of $<ix:nonFraction name="us-gaap:PartnersCapitalAccountUnitBasedCompensation" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,502,000</ix:nonFraction> for these services based on the liability related to the services incurred. As the fair value of shares issued to satisfy that obligation was higher than the amount previously expensed, the Company recognized additional research and development expense of $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentInProcess" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">14,080,000</ix:nonFraction> during the three months ended March&#160;31, 2022. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Purchase of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B-1</div> Units </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As discussed further in Note 6, certain of the Company&#8217;s employees, board members and service providers purchased <ix:nonFraction name="us-gaap:CommonUnitIssued" contextRef="PAsOn03_31_2022_ClassB1unitsMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal">6,098,901</ix:nonFraction> of its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B-1</div> Units for total cash proceeds of $<ix:nonFraction name="us-gaap:CommonUnitIssuanceValue" contextRef="PAsOn03_31_2022_ClassB1unitsMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,550,000</ix:nonFraction> during the three months ended March&#160;31, 2022. Since these <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B-1</div> Units were fully vested upon purchase and contain no service requirements, the Company immediately recognized the difference between the purchase price and the estimated fair value for these <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B-1</div> Units of $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To03_31_2022_ClassB1unitsMemberusgaapCapitalUnitsByClassAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">31,226,000</ix:nonFraction> as equity-based compensation expense during the three months ended March&#160;31, 2022. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation Expense </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three months ended March&#160;31, 2022 and 2021, the Company recognized equity-based compensation expense of $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">52,686,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">175,000</ix:nonFraction>, respectively. </div></div> <ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Compensation expense related to the issuance and purchase of Class&#160;B and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Units is included in research and development and general and administrative expense as follows (in thousands): </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 11%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To03_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,367</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To03_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,319</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To03_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">175</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total equity-based compensation expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2022To03_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">52,686</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2021To03_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">175</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> </ix:nonNumeric> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Estimate </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is privately held with no active public market for its equity instruments. Therefore, for financial reporting purposes, management may periodically determine the estimated per share fair value of the Company&#8217;s equity shares (including Profits Interests) using contemporaneous valuations. These contemporaneous valuations are done using methodologies consistent with the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, also known as the Practice Aid. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the Profits Interest Awards granted during the three months ended March&#160;31, 2022, the valuation approach utilized a hybrid method which consists of a combination of an Option Pricing Method (OPM) and a Probability Weighted Expected Return Method (PWERM) approach. Weighting allocations were assigned to the OPM and PWERM methods based upon the expected likelihood of possible future liquidity events, including the Business Combination. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the OPM approach, the fair value of the total equity of the Company within each scenario was first estimated using a back-solve method wherein the equity value is derived from a recent transaction in the Company&#8217;s own securities, and then the total equity value is allocated to the various components of the capital structure, including the Profits Interests, using an OPM or a waterfall approach based on the specific rights of </div></div> </ix:continuation> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-70 </div></div> </div></div><div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><div style="margin-left: calc(-48.56vw + 48.9%);;display:inline;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div></div><ix:continuation id="TextSelectionAppend_53608999_2"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each of the equity classes. The OPM uses the fair value of the total equity of the Company within a scenario as a starting point and incorporates assumptions made regarding the expected returns and volatilities that are consistent with the expectations of market participants, and distribution of equity values is produced which cover the range of events that an informed market participant might expect. This process creates a range of equity values both between and within scenarios. The fair value measurement is sensitive to changes in the unobservable inputs. Changes in those inputs might result in a higher or lower fair value measurement. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The PWERM approach is a scenario-based analysis that estimates the value per share of common stock based on the probability-weighted present value of expected future equity values for the common stock, under various possible future liquidity event scenarios, including the proposed Business Combination, in light of the rights and preferences of each class and series of stock, including the Profits Interests, discounted for a lack of marketability. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In performing these valuations, management considered all objective and subjective factors that they believed to be relevant, including management&#8217;s best estimate of the Company&#8217;s business condition, prospects, and operating performance at each valuation date. Within the valuations performed, a range of factors, assumptions, and methodologies were used. The significant factors included trends within the industry, the prices at which the Company sold Class&#160;A units, the rights and preferences of the Class&#160;A units relative to the Class&#160;B units at the time of each measurement date, the results of operations, financial position, status of research and development efforts, stage of development and business strategy, the lack of an active public market for the units, and the likelihood of achieving an exit event in light of prevailing market conditions. </div></div> <ix:nonNumeric name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following reflects the key assumptions used in each of the valuation scenarios: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"></td>
<td style="width: 7%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td>
<td style="width: 6%; vertical-align: bottom;"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">OPM</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">PWERM</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total equity value (in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MembersEquity" contextRef="PAsOn03_31_2022_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">280,400</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:MembersEquity" contextRef="PAsOn03_31_2022_ValuationTechniqueProbabilityWeightedExpectedReturnMethodMemberusgaapValuationTechniqueAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,750,000</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility of total equity</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2022To03_31_2022_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">95</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2022To03_31_2022_ValuationTechniqueProbabilityWeightedExpectedReturnMethodMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">60</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Discount for lack of market</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" contextRef="P01_01_2022To03_31_2022_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">30</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" contextRef="P01_01_2022To03_31_2022_ValuationTechniqueProbabilityWeightedExpectedReturnMethodMemberusgaapValuationTechniqueAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal">15</ix:nonFraction></td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected time to exit event</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2022To03_31_2022_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis" format="ixt-sec:duryear">3.7</ix:nonNumeric> years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2022To03_31_2022_ValuationTechniqueProbabilityWeightedExpectedReturnMethodMemberusgaapValuationTechniqueAxis" format="ixt-sec:duryear">0.5</ix:nonNumeric> years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> </ix:nonNumeric> </ix:continuation> <ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2022To03_31_2022" escape="true"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 9: Subsequent Events </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;1, 2022, the Company issued Profits Interests to certain Plan Participants in the form of <ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountUnitsIssued" contextRef="PAsOn06_01_2022_CapitalUnitClassBOneMemberusgaapCapitalUnitsByClassAxis_DeferredProfitSharingMemberusgaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">1,478,590</ix:nonFraction> Class&#160;B-1 Units. Additionally, the Company issued <ix:nonFraction name="us-gaap:LimitedPartnersCapitalAccountUnitsIssued" contextRef="PAsOn06_01_2022_CapitalUnitClassBOneMemberusgaapCapitalUnitsByClassAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal">549,451</ix:nonFraction> of its Class&#160;B-1 Units for total value received by the Company (or its subsidiaries) of $<ix:nonFraction name="us-gaap:CapitalUnits" contextRef="PAsOn06_01_2022_CapitalUnitClassBOneMemberusgaapCapitalUnitsByClassAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">500,000</ix:nonFraction>. </div></div></ix:nonNumeric> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">FS-71 </div></div></div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> </div></div><hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/><div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc" style="null;text-indent: 0px;">Table of Contents</a></div><div style="text-align: center;"><div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> </div></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="line-height: 2pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 3pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 24pt; margin-top: 50pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 24pt; letter-spacing: 0px; top: 0px;;display:inline;">PROKIDNEY CORP. </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 16pt; margin-top: 100pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 16pt; letter-spacing: 0px; top: 0px;;display:inline;">Up to 232,530,000 Class&#160;A Ordinary Shares </div></div></div> <div style="font-size: 100pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 100pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 12pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">PROSPECTUS </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center;"> <div style="margin: 0pt auto 2pt; width: 21%; text-align: center; line-height: 6pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 100pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;, 2022 </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 100pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">You should rely only on the information contained or incorporated by reference in this prospectus. We have not authorized anyone to provide you with different information. You should not assume that the information contained or incorporated by reference in this prospectus is accurate as of any date other than the date of this prospectus. We are not making an offer of these securities in any state where the offer is not permitted. </div></div></div> <div style="font-size: 50pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 50pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 1pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="line-height: 4.5pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 2pt; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">PART II </div></div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">INFORMATION NOT REQUIRED IN PROSPECTUS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;13. Other Expenses of Issuance and Distribution. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the estimated expenses to be borne by the registrant in connection with the issuance and distribution of the ordinary shares being registered hereby. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 76%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 14%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Expense</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated&#160;Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Securities and Exchange Commission registration fee</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">187,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounting fees and expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Legal fees and expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial printing and miscellaneous expenses</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">*</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">187,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="width: 11%; line-height: 8pt; margin-top: 0pt; margin-bottom: 2pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">*</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These fees are calculated based on the securities offered and the number of issuances and accordingly cannot be defined at this time. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;14. Indemnification of Directors and Officers. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cayman Islands law does not limit the extent to which a company&#8217;s memorandum and articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud or the consequences of committing a crime. Our Charter will provide for indemnification of our officers and directors to the maximum extent permitted by law, including for any liability incurred in their capacities as such, except through their own actual fraud, willful default or willful neglect. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is theretofore unenforceable. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;15. Recent Sales of Unregistered Securities. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Founder Shares </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March&#160;2, 2021, the Sponsor paid $25,000 to cover certain offering and formation costs of SCS in consideration for which the Sponsor received 5,750,000 SCS Class&#160;B ordinary shares (the &#8220;Founder Shares&#8221;). On June&#160;29, 2021, SCS effected a share capitalization with respect to its SCS Class&#160;B ordinary shares of 575,000 shares thereof, resulting in the Sponsor holding an aggregate of 6,325,000 Founder Shares. The Founder Shares included an aggregate of up to 825,000 shares that were subject to forfeiture depending on the extent to which the underwriters&#8217; over-allotment option was exercised. As a result of the underwriters&#8217; election to partially exercise their over-allotment option, a total of 750,000 Founder Shares were no longer subject to forfeiture and 75,000 Founder Shares were forfeited, resulting in an aggregate of 6,250,000 Founder Shares then outstanding. In June 2021, the Sponsor transferred 30,000 Founder Shares to Marc Semigran, M.D., an independent director of SCS. The Founder Shares became ProKidney Class&#160;A ordinary shares upon the consummation of the Business Combination. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Such securities were issued in connection with SCS&#8217;s organization pursuant to the exemption from registration contained in Section&#160;4(a)(2) of the Securities Act. The Sponsor is an accredited investor for purposes of Rule&#160;501 of Regulation&#160;D. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-1 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Subscription Agreements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On the Closing Date, SCS consummated the PIPE Investment, pursuant to which SCS offered and sold to the PIPE Investors, under the Subscription Agreements, an aggregate of 57,480,000 SCS Class&#160;A ordinary shares at a price of $10.00 per share for aggregate gross proceeds of $574,800,000. The PIPE Investment closed substantially concurrently with the Business Combination. The SCS Class&#160;A ordinary shares issued to the PIPE Investors became ProKidney Class&#160;A ordinary shares upon consummation of the Business Combination. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The shares issued to the PIPE Investors in the PIPE Investment on the Closing Date were issued pursuant to the exemption from registration under Section&#160;4(a)(2) of the Securities Act and/or Regulation&#160;D promulgated under the Securities Act. The PIPE Investors are accredited investors for purposes of Rule&#160;501 of Regulation D. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;16. Exhibits and Financial Statements. </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(a)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Exhibits</div></div>. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 48%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit<br/>Number</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit&#160;Description</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Filed<br/>Herewith</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Incorporated&#160;by<br/>Reference<br/>herein&#160;from<br/>Form&#160;or&#160;Schedule</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Filing&#160;Date</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">SEC File/<br/>Reg.<br/>Number</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;2.1&#8224;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1850270/000119312522014862/d259568dex21.htm">Business Combination Agreement, dated as of January&#160;18, 2022, by and among ProKidney Corp. (formerly Social Capital Suvretta Holdings Corp. III) and ProKidney LP. </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K/A</div><br/> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;2.1)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">01/21/2022</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-40560</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;3.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1850270/000119312522195148/d285643dex31.htm">Second Amended and Restated Memorandum and Articles of Association of ProKidney Corp. </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div><br/> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;3.1)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">07/15/2022</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-40560</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;&#160;&#160;5.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d373959dex51.htm">Opinion of Walkers (Cayman) LLP </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1850270/000119312522014862/d259568dex101.htm">Form of Subscription Agreement for Institutional Investors, dated as of January&#160;18, 2022, by and between ProKidney Corp. (formerly Social Capital Suvretta Holdings Corp. III) and the subscriber parties thereto. </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K/A</div><br/> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.1)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">01/21/2022</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-40560</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1850270/000119312522014862/d259568dex102.htm">Form of Subscription Agreement for Individual Investors, dated as of January&#160;18, 2022, by and between ProKidney Corp. (formerly Social Capital Suvretta Holdings Corp. III) and the subscriber parties thereto. </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K/A</div><br/> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.2)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">01/21/2022</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-40560</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.3</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1850270/000119312522014862/d259568dex103.htm">Sponsor Support Agreement, dated January&#160;18, 2022, by and among ProKidney Corp. (formerly Social Capital Suvretta Holdings Corp. III), SCS Sponsor III LLC, ProKidney LP and the directors and officers named therein. </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K/A</div><br/> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.3)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">01/21/2022</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-40560</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.4</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1850270/000119312522014862/d259568dex104.htm">ProKidney Unitholder Support Agreement, dated January&#160;18, 2022, by and among ProKidney Corp. (formerly Social Capital Suvretta Holdings Corp. III), ProKidney LP and the persons named therein. </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K/A</div><br/> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">01/21/2022</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-40560</div></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-2 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 47%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit<br/>Number</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit&#160;Description</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Filed<br/>Herewith</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Incorporated&#160;by<br/>Reference<br/>herein&#160;from<br/>Form&#160;or&#160;Schedule</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Filing&#160;Date</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">SEC File/<br/>Reg.<br/>Number</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.5+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1850270/000119312522195148/d285643dex1012.htm">ProKidney Corp. Employee Stock Purchase Plan. </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div><br/> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.12)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">07/15/2022</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-40560</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.6+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1850270/000119312522195148/d285643dex1011.htm">ProKidney Corp. 2022 Incentive Equity Plan. </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div><br/> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.11)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">07/15/2022</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-40560</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.7+</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1850270/000119312522195148/d285643dex1013.htm">Form of Indemnification Agreement. </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div><br/> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.13)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">07/15/2022</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-40560</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.8</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1850270/000119312522195148/d285643dex104.htm">Amended and Restated Registration Rights Agreement, dated as of July&#160;11, 2022, by and among ProKidney Corp. (formerly Social Capital Suvretta Holdings Corp. III), SCS Sponsor III LLC and certain of their securityholders. </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div><br/> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.4)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">07/15/2022</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-40560</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.9</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1850270/000119312522195148/d285643dex103.htm"><span style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Lock-up</span> Agreement, dated July&#160;11, 2022, by and among ProKidney Corp. (formerly Social Capital Suvretta Holdings Corp. III), SCS Sponsor III LLC and certain holders. </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div><br/> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.3)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">07/15/2022</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-40560</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.10</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1850270/000119312522195148/d285643dex105.htm">Second Amended and Restated Limited Partnership Agreement for a Limited Partnership Called ProKidney LP, dated July&#160;11, 2022, by and among ProKidney Corp. (formerly Social Capital Suvretta Holdings Corp. III), ProKidney Corp. GP Limited, ProKidney GP Limited, and the limited partners named therein </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div><br/> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.5)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">07/15/2022</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-40560</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.11</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1850270/000119312522195148/d285643dex101.htm">Tax Receivable Agreement, dated July&#160;11, 2022, by and among ProKidney Corp. (formerly Social Capital Suvretta Holdings Corp. III), TRA Party Representative, and other parties named therein. </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div><br/> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.1)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">07/15/2022</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-40560</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.12</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1850270/000119312522195148/d285643dex102.htm">Exchange Agreement, by and among ProKidney Corp. (formerly Social Capital Suvretta Holdings Corp. III), ProKidney LP, and certain holders named therein. </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">8-K</div><br/> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;10.2)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">07/15/2022</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-40560</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.13</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d373959dex1013.htm">Master Services Agreement, dated February&#160;15, 2021, by and between George Clinical PTY Limited and ProKidney (formerly RegenMed (Cayman) Ltd.) </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.14</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d373959dex1014.htm">Research, Development, Engineering Services and License Memorandum and Agreement, dated January&#160;16, 2022, by and between ProKidney (formerly RegenMed (Cayman) Ltd.) and DEKA Products Limited Partnership </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-3 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 48%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit<br/>Number</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit&#160;Description</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Filed<br/>Herewith</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Incorporated&#160;by<br/>Reference<br/>herein&#160;from<br/>Form&#160;or&#160;Schedule</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Filing&#160;Date</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">SEC File/<br/>Reg.<br/>Number</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.15</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d373959dex1015.htm">Master Services Agreement, dated April&#160;20, 2020, by and between IQVIA RDS Inc. and ProKidney (formerly RegenMed (Cayman) Ltd.) </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.16</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d373959dex1016.htm">Master Agreement for Clinical Trials Services, dated April&#160;2, 2020, by and between ProKidney (formerly RegenMed (Cayman) Ltd.) and Frenova, LLC </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.17</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d373959dex1017.htm">Master Services Agreement, dated May&#160;1, 2019, by and between PPD Development, LP and ProKidney (formerly RegenMed (Cayman) Ltd.) </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.18</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d373959dex1018.htm">Master Services Agreement, dated August&#160;14, 2015, by and between CTI Clinical Trial Services Inc. and RegenMedTX, LLC </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.19</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d373959dex1019.htm">Laboratory Service Agreement, dated August&#160;16, 2016, by and among Covance Central Laboratory Services LP, Covance Central Laboratory Services SA` RL and ProKidney (formerly RegenMed (Cayman) Ltd.) </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.20</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d373959dex1020.htm">Laboratory Service Agreement, dated August&#160;1, 2017, by and among Covance Central Laboratory Services LP, Covance Central Laboratory Services SA` RL and ProKidney (formerly RegenMed (Cayman) Ltd.) </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.21</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d373959dex1021.htm">Laboratory Service Agreement, dated June&#160;21, 2019, by and among Covance Central Laboratory Services LP, Covance Central Laboratory Services SA` RL and ProKidney (formerly RegenMed (Cayman) Ltd.) </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;10.22</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d373959dex1022.htm">Laboratory Service Agreement, dated September&#160;16, 2021, by and among Labcorp Central Laboratory Services LP, Labcorp Central Laboratory Services SA` RL and ProKidney (formerly RegenMed (Cayman) Ltd.) </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;21.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="http://www.sec.gov/Archives/edgar/data/1850270/000119312522195148/d285643dex211.htm">List of Subsidiaries. </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;8-K</div><br/> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">(Exhibit&#160;21.1)</div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;;text-align:center;">07/15/2022</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">001-40560</div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;23.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d373959dex231.htm">Consent of Marcum LLP, independent registered public accounting firm. </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-4 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 10%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 48%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td>
<td style="font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit<br/>Number</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Exhibit&#160;Description</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Filed<br/>Herewith</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Incorporated&#160;by<br/>Reference<br/>herein&#160;from<br/>Form&#160;or&#160;Schedule</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Filing&#160;Date</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">SEC<br/>File/<br/>Reg.<br/>Number</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;23.2</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d373959dex232.htm">Consent of Ernst&#160;&amp; Young LLP, independent registered public accounting firm. </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;23.3</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d373959dex51.htm">Consent of Walkers (Cayman) LLP (included in Exhibit 5.1). </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">&#160;&#160;24.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="#sig">Power of Attorney (included on the signature page hereof) </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.INS</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Instance Document</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.SCH</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Schema Document</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.CAL</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.DEF</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Definition Linkbase Document</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.LAB</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Label Linkbase Document</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">101.PRE</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">104</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Cover Page Interactive Data File (formatted as Inline XBRL)</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; white-space: nowrap;">107.1</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;"><a href="d373959dexfilingfees.htm">Calculation of Registration Fee </a></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">X</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">&#8224;</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-K</div> Item 601(a) (5). The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">@</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain confidential portions of this Exhibit were omitted by means of marking such portions with brackets (&#8220;[***]&#8221;) because the identified confidential portions (i)&#160;are not material and (ii)&#160;would be competitively harmful if publicly disclosed. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 2%; vertical-align: top;;text-align:left;">+</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management contract or compensatory plan or arrangement. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Item&#160;17. Undertakings. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The undersigned registrant hereby undertakes: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(1)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(i)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To include any prospectus required by Section&#160;10(a)(3) of the Securities Act of 1933, as amended; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(ii)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-5 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;">
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 13%;">&#160;</td>
<td style="vertical-align: top;;text-align:left;">in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement; and </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(iii)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(2)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">bona fide</div></div> offering thereof. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(3)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(4)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;">That, for the purpose of determining liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness; <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">provided</div></div>, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">however</div></div>, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. </div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 4%;">&#160;</td>
<td style="width: 5%; vertical-align: top;;text-align:left;">(5)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">That, for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(i)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(ii)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(iii)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 9%;">&#160;</td>
<td style="width: 4%; vertical-align: top;;text-align:left;">(iv)</td>
<td style="vertical-align: top;;text-align:left;"> <div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </div></div> </td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Insofar as indemnification for liabilities arising under the Securities may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-6 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">SIGNATURES </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Winston-Salem, State of North Carolina, on August 8, 2022. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 40%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: auto; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 7%;"></td>
<td style="width: 1%; vertical-align: bottom;"></td>
<td style="width: 92%;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td colspan="3" style="vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">PROKIDNEY CORP.</div></div></td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">By:</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top;"> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Tim Bertram, Ph.D.</div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">Tim Bertram, Ph.D.</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">Chief Executive Officer</td> </tr> </table> <div style="clear:both;max-height:0pt;"></div> </div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-7 </div></div> </div> </div> <div style="margin-top: 1em; margin-bottom: 0em; page-break-before: always;"></div> <hr style="width: 100%; height: 3px; color: rgb(153, 153, 153);"/> <div style="font-size: 13.28px; margin-top: 1.67em; margin-bottom: 1.67em;;font-weight: bold;"><a href="#toc">Table of Contents</a></div> <div style="text-align: center;"> <div style="width: 8.5in; text-align: left; margin-right: auto; margin-left: auto;"> <div id="sig" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">POWER OF ATTORNEY </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Each person whose signature appears below constitutes and appoints each of Tim Bertram and James Coulston, acting alone or together with another <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">attorney-in-fact,</div></div> as his or her true and lawful <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">attorney-in-fact</div></div> and agent, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign any or all further amendments (including post-effective amendments) to this registration statement (and any additional registration statement related hereto permitted by Rule 462(b) promulgated under the Securities Act (and all further amendments, including post-effective amendments, thereto)), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">attorneys-in-fact</div></div> and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">attorney-in-fact</div></div> and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the dated indicated. </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 39%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 1%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 39%; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"></td>
<td style="width: 18%; font-family: &quot;Times New Roman&quot;;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Signature</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Title</div></div></div> </td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: inline-block; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Date</div></div></div> </td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Tim Bertram, Ph.D.</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tim Bertram, Ph.D.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Chief Executive Officer and Director<br/>(Principal Executive Officer)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">August 8, 2022</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ James Coulston, CPA</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">James Coulston, CPA</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Chief Financial Officer (Principal Financial and Accounting Officer)</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">August 8, 2022</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Pablo Legorreta</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pablo Legorreta</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Chairman</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">August 8, 2022</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ William F. Doyle</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">William F. Doyle</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">August 8, 2022</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Jennifer Fox</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jennifer Fox</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">August 8, 2022</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Jos&#233; Ignacio Jimenez</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Jos&#233; Ignacio Jimenez Santos</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">August 8, 2022</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Alan M. Lotvin, M.D.</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Alan M. Lotvin, M.D.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">August 8, 2022</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ John M. Maraganore, Ph.D.</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">John M. Maraganore, Ph.D</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">August 8, 2022</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Brian J.G. Pereira, M.D.</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Brian J.G. Pereira, M.D.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">August 8, 2022</td> </tr>
<tr style="font-size: 1pt;">
<td style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td>
<td colspan="2" style="height: 12pt; font-family: &quot;Times New Roman&quot;; font-size: 0px;"></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">/s/ Uma Sinha, Ph.D.</div></div> <div style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Uma Sinha, Ph.D.</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;;text-align:center;">Director</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: top; white-space: nowrap;;text-align:center;">August 8, 2022</td> </tr> </table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">II-8 </div></div> </div> </div>
</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d373959dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g373959page001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August&nbsp;8, 2022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROKIDNEY CORP. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Walkers Corporate Limited </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">190 Elgin Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">George Town </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Grand Cayman <FONT STYLE="white-space:nowrap">KY1-9008</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cayman Islands</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Addressees </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROKIDNEY CORP. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have been asked to provide this legal
opinion to you with regard to the laws of the Cayman Islands in connection with the registration for resale from time to time by certain selling securityholders (the &#147;<B>Selling Securityholders</B>&#148;) of up to an aggregate of 232,530,000
Class&nbsp;A ordinary shares, par value $0.0001 per share (&#147;<B>Class</B><B></B><B>&nbsp;A ordinary shares</B>&#148;) of ProKidney Corp. (the &#147;<B>Company</B>&#148;), including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">50,000 Class&nbsp;A ordinary shares collectively held by certain holders of the Company&#146;s securities (the
&#147;<B>Holders</B>&#148;) party to that certain Amended and Restated Registration Rights Agreement, dated as of 11&nbsp;July 2022, by and among the Company, SCS Sponsor III LLC, and the Holders, their permitted transferees and certain additional
holders; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">180,000,000 Class&nbsp;A ordinary shares issued or issuable pursuant to that certain Exchange Agreement, dated
as of 11&nbsp;July 2022, by and among the Company, ProKidney LP, and certain holders of the Company&#146;s securities party thereto; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">52,480,000 Class&nbsp;A ordinary shares purchased by certain investors at a purchase price of $10.00 per share,
pursuant to subscription agreements with the Company, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(collectively, the &#147;<B>Resale Shares</B>&#148;), in each case under the
United States Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;) and pursuant to the terms of the Registration Statement (as defined in Schedule 1). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of giving this opinion, we have examined and relied solely upon the originals or copies of the documents listed in Schedule 1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are Cayman Islands Attorneys at Law and express no opinion as to any laws other than the laws of the Cayman Islands in force and as interpreted at the date
of this opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon the foregoing examinations and the assumptions and qualifications set out below and having regard to legal considerations
which we consider relevant, and under the laws of the Cayman Islands, as at the date hereof, we give the following opinions in relation to the matters set out below. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>WALKERS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> Page
 2
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company is an exempted company duly incorporated with limited liability, validly existing under the laws of
the Cayman Islands and in good standing with the Registrar of Companies in the Cayman Islands (the &#147;<B>Registrar</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Resale Shares have been duly authorised for issue to the Selling Securityholders by all necessary corporate
action of the Company, and upon the issue of the Resale Shares (by the entry of the name of the registered owner thereof in the Register of Members of the Company confirming that such Resale Shares have been issued and credited as fully paid),
delivery and payment therefor by the purchaser in accordance with the Memorandum and Articles (as defined in Schedule 1), the Resale Shares will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> (meaning that
no additional sums may be levied in respect of such Resale Shares on the holder thereof by the Company). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing opinions are
given based on the following assumptions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The originals of all documents examined in connection with this opinion are authentic. The signatures, initials
and seals on the Registration Statement and Resolutions (each as defined in Schedule 1) are, or will be, genuine and are, or will be, those of a person or persons stated therein. All documents purporting to be sealed have been, or will be, so
sealed. All copies are complete and conform to their originals. The Registration Statement will conform in every material respect to the latest drafts of the same produced to us prior to the date hereof and, where provided in successive drafts, have
been marked up to indicate all changes thereto. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Memorandum and Articles will be the memorandum and articles of association of the Company in effect at the
time of the issue and sale of the Resale Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company Records (as defined in Schedule 1) are complete and accurate and all matters required by law and
the Memorandum and Articles to be recorded therein are completely and accurately so recorded. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The accuracy and completeness of all factual representations made in the Registration Statement and all other
documents reviewed by us. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company will receive or has received consideration in money or money&#146;s worth for each Resale Share
offered by the Company when issued at the agreed issue price as per the terms of applicable documents relating to the issue of such Resale Shares to the Selling Securityholders, such price in any event not being less than the stated par or nominal
value of each Resale Share. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The preparation and filing of the Registration Statement has been duly authorised by or on behalf of the
Company prior to the issue and sale of the Ordinary Shares. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">There is nothing under any law (other than the laws of the Cayman Islands) which would or might affect any of
the opinions set forth above. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>WALKERS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> Page
 3
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The opinions expressed above are subject to the following qualifications: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We have relied upon the statements and representations of directors, officers and other representatives of the
Company as to factual matters. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Our opinion as to good standing is based solely upon receipt of the Certificate of Good Standing issued by the
Registrar. The Company shall be deemed to be in good standing under section 200A of the Companies Act (as amended) of the Cayman Islands (the &#147;<B>Companies Act</B>&#148;) on the date of issue of the certificate if all fees and penalties under
the Companies Act have been paid and the Registrar has no knowledge that the Company is in default under the Companies Act. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This
opinion is limited to the matters referred to herein and shall not be construed as extending to any other matter or document not referred to herein. This opinion is given solely for your benefit and the benefit of your legal advisers acting in that
capacity in relation to this transaction and may not be relied upon by any other person, other than persons entitled to rely upon it pursuant to the provisions of the Securities Act, without our prior written consent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion shall be construed in accordance with the laws of the Cayman Islands. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to our firm, as Cayman Islands counsel to
the Company, in the Registration Statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yours faithfully </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Walkers (Cayman) LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WALKERS (Cayman) LLP </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>WALKERS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> Page
 4
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>LIST OF DOCUMENTS EXAMINED </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A draft of the Form <FONT STYLE="white-space:nowrap">S-1</FONT> Registration Statement to be filed by the
Company with the United States Securities and Exchange Commission registering the Resale Shares under the Securities Act (as filed, the &#147;<B>Registration Statement</B>&#148;). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Certificate of Incorporation dated 25&nbsp;February 2021, Certificate of Incorporation on Change of Name
dated 11&nbsp;July 2022, Register of Directors and Register of Officers, the Second Amended and Restated Memorandum and Articles of Association of the Company adopted and effective on 11&nbsp;July 2022 (the &#147;<B>Memorandum and
Articles</B>&#148;), in each case, of the Company, copies of which have been provided to us by its registered office in the Cayman Islands (together the &#147;<B>Company Records</B>&#148;). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Cayman Online Registry Information System (CORIS), the Cayman Islands&#146; General Registry&#146;s online
database, searched on August&nbsp;8, 2022. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A copy of a Certificate of Good Standing dated August&nbsp;8, 2022 in respect of the Company issued by the
Registrar (the &#147;<B>Certificate of Good Standing</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A copy of executed written resolutions of the directors of the Company approving various matter, including the
Registration Statement (the &#147;<B>Resolutions</B>&#148;). </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>3
<FILENAME>d373959dex1013.htm
<DESCRIPTION>EX-10.13
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.13</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.13 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g373959g0805082153456.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><SMALL>MASTER</SMALL> <SMALL>SERVICES</SMALL> <SMALL>AGREEMENT</SMALL> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">BETWEEN </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>GEORGE CLINICAL PTY
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN 33 098 184 528 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AND </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>REGENMED (CAYMAN) LTD,
d/b/a PROKIDNEY </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MASTER SERVICES AGREEMENT (MSA) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS AGREEMENT </B>is made on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15&nbsp;February 2021 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BETWEEN: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>GEORGE CLINICAL PTY LTD</B> (ABN 33 098 184 528) of Level&nbsp;5, 1 King Street, Newtown, NSW 2042 AUSTRALIA
(<B>George Clinical</B>); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">RegenMed (Cayman) Ltd., d/b/a PROKIDNEY of 10 Market Street, # 688 Camana Bay, Grand Cayman, <FONT
STYLE="white-space:nowrap">KY1-9006,</FONT> Cayman Islands (<B>ProKidney</B>). </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BACKGROUND: </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">George Clinical is a medical research company that performs clinical research services for other medical
research companies and commercial entities within the pharmaceutical, medical device and biotechnology industries. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ProKidney is a company that is conducting a clinical trial related to renal autologous cell therapy.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ProKidney wishes to engage George Clinical to provide Services in accordance with the terms of this Agreement.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IT IS AGREED AS FOLLOWS: </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEFINITIONS AND INTERPRETATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Definitions </B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">In this Agreement unless the context otherwise requires: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Affiliate </B>means an entity which controls, is controlled by, or is under common control with, a Party, but only so long as such control
exists, and <B>control </B>means the ability to vote 50% or more of the voting securities of any entity or otherwise having the ability to control the polices and direction of an entity; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Applicable Law</B> means all laws, rules and regulations, including any subordinate legislation, applying in the jurisdiction of the Study
and the performance of Services and includes: (i)&nbsp;ICH guidelines; (ii)&nbsp;current Good Clinical Practices, and if applicable, current Good Laboratory Practices; and (iii)&nbsp;applicable industry standards in the pharmaceutical industry when
performing studies used to support regulatory filings. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Background Intellectual Property</B> of a Party means all Intellectual Property
rights owned or controlled by the Party as at the Commencement Date, or independently developed after the Commencement Date, which it makes available for the purpose of carrying out Services for a Research Project, and includes any improvements made
solely by that Party to its Intellectual Property. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Business Day</B> means a day that is not a Saturday, Sunday or public holiday in the
relevant jurisdiction; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Change Order</B><U> </U>means an agreement signed by both Parties substantially in the form of Exhibit C to
amend a Work Order. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Master Services Agreement &#150;ProKidney and George ClinicalPage <B>2 </B>of <B>17</B></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Commencement Date</B> means 15&nbsp;February, 2021. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Confidential Information</B> means information that is by its nature confidential, is designated by a Party as confidential, or the other
Party knows or ought to know is confidential, which is provided by one Party to the other for the purposes of this Agreement and includes all documents, materials, data, works, ideas, <FONT STYLE="white-space:nowrap">know-how,</FONT> trade secrets,
concepts and information, in any form or medium, relating in any way to a Party&#146;s affairs, customers, businesses, products, sales, marketing or promotional information; and includes Confidential Information of a Study&#146;s sponsor or third
parties provided to George Clinical for it to perform Services; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Dispute</B> means a dispute or disagreement arising out of or in
connection with this Agreement or a Work Order; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Fee</B> means the amounts payable to George Clinical for the Services, as described in
the applicable Work Order; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property</B> means all industrial and intellectual property rights, including patents,
copyright, future copyright, trade business, company or domain names, rights in relation to circuit layouts, plant breeders&#146; rights, registered designs, registered and unregistered trademarks, know how, trade secrets and the right to have
confidential information kept confidential, and any and all other rights to intellectual property which may exist anywhere in the world, and any application or right to apply for registration of any of the preceding rights; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Investigator Site</B> means a location where a Study is actually conducted. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Parties</B> means George Clinical and ProKidney and <B>Party</B>, as the context requires, is a reference to either of them;<B> </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Privacy Laws </B>means privacy laws, legislation, codes and/or guidelines that apply to the Services in the applicable jurisdiction; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Representatives</B> means the officers, employees, contractors, agents, authorised representatives and permitted contractors of a Party or
its Affiliates; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Research Project</B> means the research project identified in a Work Order. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Services</B> means the services to be performed by George Clinical on behalf of ProKidney as described in the applicable Work Order. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Study</B> means an investigation of a medicine or device as identified in a Work Order. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Study Drug</B> means the medicine or device being trialled or tested in a Study and includes where relevant any placebo. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Term</B> means the period specified in clause 6. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Termination Date</B> means 15&nbsp;February 2026; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman"><B>Work Order</B> means an agreement substantially in the form of Exhibit A, which specifies Services George Clinical will perform for
ProKidney in respect of a Study. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Interpretation</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">In this Agreement, unless the context requires otherwise: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">headings are for convenience only and do not affect interpretation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the singular includes the plural and vice versa, and any words importing a gender include other genders;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Master Services Agreement &#150;ProKidney and George ClinicalPage <B>3 </B>of <B>17</B></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">other grammatical forms of defined words or expressions have corresponding meanings; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reference to a document, including this Agreement, is to that document as amended, novated, renewed,
substituted or supplemented at any time; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reference to a clause, paragraph, schedule or annexure is a reference to a clause or paragraph of or
schedule, exhibit or annexure to this Agreement and a reference to this Agreement includes any schedules, exhibits and annexures; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reference to any legislation or statutory instrument or regulation includes an amendment or <FONT
STYLE="white-space:nowrap">re-enactment</FONT> to that legislation and includes subordinate legislation in force under it; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reference to a person means an individual, corporation, government or governmental agency, estate, trust,
association or other legal or commercial entity or undertaking. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reference to &#145;writing&#146; includes any means of reproducing words in a tangible and permanently
visible form; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reference to a Party includes that Party&#146;s executors, administrators, successors, substitutes (including
persons taking by novation) and permitted assigns; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(j)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">mentioning anything after &#145;include&#146;, &#145;includes&#146; or &#145;including&#146; does not limit
what else might be included; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(k)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reference to &#145;dollars&#146; or &#145;$&#146; is to Australian currency unless such reference specifies
otherwise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(l)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">an obligation not to do something includes an obligation not to cause and not to permit it to be done;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(m)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">no clause in this Agreement will be construed adversely to a Party on the ground, irrespective of whether or
not it is the only ground, that the Party was responsible for the preparation of the clause; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(n)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a reference to days is to calendar days unless qualified as a Business Day. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>APPOINTMENT AND SCOPE OF ENGAGEMENT </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement contains the standard terms which apply to Services George Clinical provides to ProKidney in
accordance with Work Orders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ProKidney appoints George Clinical to provide Services during the Term in accordance with this Agreement and
applicable Work Orders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">George Clinical agrees to provide Services to ProKidney on a
<FONT STYLE="white-space:nowrap">non-exclusive</FONT> basis, in accordance with this Agreement and applicable Work Orders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">George Clinical is an independent contractor and no relationship of employment, joint venture or agency will
come into existence between George Clinical and ProKidney. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">George Clinical may use an Affiliate to perform Services but it will remain responsible for its obligations
under this Agreement and each applicable Work Order and must ensure that its Affiliate complies with this Agreement and the Work Order. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Neither Party may do any of the following without the other Party&#146;s written consent:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">contract on behalf of or bind the other Party; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">publish an advertisement or other information relating to the other Party; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Master Services Agreement &#150;ProKidney and George ClinicalPage <B>4 </B>of <B>17</B></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">use the other Party&#146;s name or logo. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WORK ORDERS </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Work Order is not effective unless it is signed by both Parties. A template Work Order is provided as Exhibit
A. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ProKidney determines in its sole discretion if and when it requests Services from George Clinical.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Work Orders must be numbered sequentially and specify the following information or identify that such
information is &#147;not applicable&#148; to the Work Order: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">name of the Study and its basic parameters, including sponsor; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Services and scope of work; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">estimated dates for deliverables and completion; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the budget and approval process for reimbursement of expenses, payment of costs and Fees, the schedule of
payments, payment instructions, any prepayments and currency schedules; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">resource allocation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any transfer of obligations specifying sponsor responsibilities George Clinical assumes on ProKidney&#146;s
behalf in relation to the Study, substantially in the form of Attachment C to the template Work Order in Exhibit A; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any other specific Services to be performed by George Clinical. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Work Order is incorporated by reference into this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If ProKidney requests George Clinical to perform &#147;sponsor&#148; responsibilities under a Work Order with
respect to a Study, the Work Order must specify which responsibilities ProKidney transfers to George Clinical in a list substantially in the form of Attachment C of the Template Work Order. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Work Order can only be amended by a Change Order. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In the event of a conflict between the terms of this Agreement and a Work Order, the terms of this Agreement
will control unless expressly superseded in the Work Order. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CHANGE ORDERS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Change Order is not effective unless it is signed by both Parties. A template Change Order is provided as
Exhibit B. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Change Order must: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">be numbered sequentially; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">refer to the Work Order it amends; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">list the changes to the Work Order; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">state the reason for each change, and the impact on responsibilities, budget, timelines, payment schedules and
assumptions (as applicable). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Master Services Agreement &#150;ProKidney and George ClinicalPage <B>5 </B>of <B>17</B></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>STUDY DRUG/ BIOLOGIC &#150; INTENTIONALLY OMITTED </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TERM </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This Agreement commences on the Commencement Date and continues until the Termination Date, unless terminated
earlier under clause 11 (<B>Termination</B>). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a Work Order remains active at the Termination Date, this Agreement continues until the Work Order is either
completed or terminated. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>GEORGE CLINICAL&#146;S OBLIGATIONS, REPRESENTATIONS AND WARRANTIES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">George Clinical must perform its Services in compliance with the requirements of the applicable Study, as set
out in its protocol, this Agreement, the applicable Work Order, Applicable Law and ProKidney&#146;s reasonable instructions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">George Clinical must: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">perform the Services in a competent and efficient manner with all necessary skill, care and diligence expected
in relation to similar services and must comply with Applicable Law, standards, codes and guidelines relating to the Services; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">provide ProKidney with prompt progress reports on the Services if ProKidney requests; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">maintain records, Study subject medical records and other raw data sources relating to the Study in compliance
with Applicable Law for the longer of: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">3 years after the health authority approves the marketing application for the Study Drug;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">3 years after the termination or withdrawal of the health regulatory agency exemption under which the Study was
conducted; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">iii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the period required by Applicable Law; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">notify ProKidney promptly if it identifies a breach by an Investigator Site of any of the activities which
George Clinical monitors as part of the Services. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Though the Services are aimed at monitoring Investigator Site&#146;s regulatory compliance, George Clinical
does not guarantee that compliance or any particular Study results. George Clinical is not liable for regulatory <FONT STYLE="white-space:nowrap">non-compliance</FONT> by Investigator Site or adverse effects associated with the Study or the
Services, except to the extent arising from George Clinical&#146;s breach of this Agreement, violation of law, or willful misconduct or gross negligence. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ProKidney may inspect or audit George Clinical&#146;s records relating to Services with reasonable notice. The
inspection or audit must be during normal business hours, at ProKidney&#146;s cost, and is to assure compliance with this Agreement and the relevant Work Order. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If either Party becomes aware that a regulatory authority intends to audit or inspect it in relation to any
Services, it must notify the other Party in writing, send copies of any correspondence, and inform the other Party of the findings and outcome of the audit or inspection. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">When George Clinical completes a Study, it must deliver all relevant records to ProKidney within 30 days.
George Clinical may keep a copy of records for verification of the Services performed but remains subject to an obligation of confidence under this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Master Services Agreement &#150;ProKidney and George ClinicalPage <B>6 </B>of <B>17</B></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Services include material scientific input and/or leadership, George Clinical must ensure that the
relevant Work Order and agreement with the Sponsor, if applicable, includes rights to scientific attribution and access to data for independent publication for George Clinical. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">George Clinical represents and warrants to ProKidney as follows: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">George Clinical is and will remain a corporation or company duly organized, validly existing and in good
standing under the laws of its jurisdiction of organization. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The execution and delivery of this Agreement by George Clinical has been authorized by all requisite corporate
or company action. This Agreement is and will remain a valid and binding obligation of George Clinical, enforceable in accordance with its terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">George Clinical is under no contractual or other obligation or restriction that is inconsistent with George
Clinical&#146;s execution or performance of this Agreement. George Clinical will not enter into any agreement, either written or oral, that would conflict with George Clinical&#146;s responsibilities under this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">George Clinical has engaged, will engage and will cause its Affiliates involved in rendering Services to
engage, employees and permitted subcontractors including consultants (collectively,<B> Personnel</B>) with the proper skill, training, availability and experience to provide Services. Before providing Services, all Personnel must be subject to
binding written agreements with George Clinical under which they (a)&nbsp;have confidentiality obligations that are consistent with the terms of this Agreement; and (b)&nbsp;assign and effectively vest in George Clinical any and all rights that such
personnel might have in the results of their work without any obligation of ProKidney to pay any royalties or other consideration to such Personnel. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">George Clinical, its Affiliates, their Personnel and each of their respective officers and directors, as
applicable: (i)&nbsp;have not been debarred and will not knowingly use in any capacity in connection with Services any person who has been debarred, pursuant to section 306 of the United States Food, Drug and Cosmetic Act, 21 U.S.C. &#167; 335a;
(ii)&nbsp;are not ineligible to participate in any federal and/or state healthcare programs or federal procurement or <FONT STYLE="white-space:nowrap">non-procurement</FONT> programs (as that term is defined in 42 U.S.C. &#167; <FONT
STYLE="white-space:nowrap">1320a-7b(f));</FONT> (iii) are not disqualified by any government or regulatory authorities from performing specific services; and (iv)&nbsp;have not been convicted of a criminal offense related to the provision of
healthcare items or services. Service Provider will notify ProKidney immediately if George Clinical, its Affiliates, any Personnel, or any of their respective officers or directors, as applicable, is subject to the foregoing, or if any action, suit,
claim, investigation, or proceeding relating to the foregoing is pending, or to the best of George Clinical&#146;s knowledge, is threatened. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PAYMENTS </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Payments</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ProKidney must pay George Clinical the Fee in accordance with the applicable Work Order. The Fee is calculated
by reference to the prices, timelines and payment terms agreed in the Work Order. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Master Services Agreement &#150;ProKidney and George ClinicalPage <B>7 </B>of <B>17</B></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a Work Order provides for prepayments, the Work Order must specify the amount and timing of the prepayment.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">George Clinical will invoice ProKidney monthly. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ProKidney will pay George Clinical within 45 days of receiving a valid tax invoice. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If part of an invoice is disputed, ProKidney will pay the undisputed amounts. The Parties will try to resolve
the disputed amount in good faith and as soon as possible. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If any tax or duty must be withheld on a payment, ProKidney must promptly pay the tax or duty to the
appropriate taxing authority without deducting any amount owed to George Clinical. ProKidney must obtain an official receipt for the tax paid and send it to George Clinical, to be reimbursed. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party must pay all costs of bank transfers within its own country and any taxes relating to their income
and revenue. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless otherwise expressly stated, all amounts, prices, values or other sums payable or to be provided under
this Agreement are exclusive of any value added, general sales or local taxes. Any value added, general sales or local taxes chargeable are to be paid by the ProKidney in addition to the amounts, prices, value or other sums payable under this
Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Currency and inflation adjustments</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The currency for invoices and payments must be agreed in the relevant Work Order. George Clinical may request
ProKidney to make a provision for any currency fluctuations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If George Clinical incurs expenses in a currency differing from the invoice and payment currency (<B>Foreign
Currency</B>), those expenses will be converted in the invoice at the average exchange rates of the month in which the expenses were incurred, as published by Reserve Bank of Australia, unless the applicable Work Order provides otherwise.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Invoices must detail the costs in the invoice and payment currency and include an itemised list per country,
detailing each cost in Foreign Currency and the exchange rate(s) used. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If Services in a Work Order will be performed over multiple calendar years, George Clinical may request
ProKidney to pay an increase in fees to account for inflation. If inflation is already built into the Fee then this must be detailed in the Work Order or Change Order. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Master Services Agreement &#150;ProKidney and George ClinicalPage <B>8 </B>of <B>17</B></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CONFIDENTIALITY </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Obligation of confidence</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Each Party must retain in confidence and must not use any Confidential Information or disclose it to any third party except as expressly
permitted under this Agreement, to perform Services or with the other Party&#146;s written consent. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Terms of this Agreement</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Neither Party may disclose the terms of this Agreement to any third party without the other Party&#146;s written consent. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exceptions</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The obligations of confidence do not apply to Confidential Information that is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the public domain, otherwise than as a result of a breach of obligation of confidence;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">obtained by a Party from a third party who does not have an obligation of confidentiality with respect to such
information; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">disclosed to a Party&#146;s professional advisers who have agreed in writing to keep the Confidential
Information confidential. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Further, a recipient Party may disclose Confidential Information of the Party that provided
the Confidential Information to the extent required by law or order of a judicial or parliamentary body or governmental agency, but only if such recipient Party promptly notifies the providing Party in writing, if legally permissible, provides
reasonable cooperation to the providing Party in its efforts to oppose or obtain confidential treatment of such disclosure (and at such providing Party&#146;s expense) and only discloses that part of the Confidential Information required by law or
order to be disclosed. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Return and destruction of Confidential Information </B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If this Agreement expires or is terminated, each Party must immediately return (or if requested by the other
Party, destroy) all Confidential Information of the other Party that is in its possession, power or control. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">George Clinical may retain a copy of Confidential Information relating to a Study that must be retained under
Applicable Law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Study results and the Study protocol are regarded as ProKidney&#146;s Confidential Information.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party must limit access to Confidential Information of the other Party to its personnel who have a need to
know it to perform Services and must ensure that they comply with the obligations of confidence under this clause as if they were a party to this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party acknowledges that monetary damages are an inadequate remedy for breach of the obligation of
confidence under this clause so a Party may seek equitable relief, including an injunction to protect its Confidential Information from unauthorised use or disclosure, without the need to post any bond and without the need to demonstrate actual
damages. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INTELLECTUAL PROPERTY </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Background Intellectual Property</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">This Agreement, including any Work Order or Change Order, does not affect the ownership of a Party&#146;s Background Intellectual Property.
Background Intellectual Property of each Party remains the sole property of that Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Master Services Agreement &#150;ProKidney and George ClinicalPage <B>9 </B>of <B>17</B></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Study Intellectual Property</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Any Intellectual Property, deliverables, work product and data arising from the Services (collectively,
<B>Deliverables</B>) vests immediately in ProKidney upon its creation. George Clinical hereby assigns, and agrees to assign, to ProKidney all of George Clinical&#146;s right, title and interest in and to all Deliverables. Each Party will do
everything reasonably necessary to effect that assignment, including executing and delivering all requested applications, assignments and other documents, and take such other measures as ProKidney reasonably requests, at ProKidney&#146;s expense, in
order to perfect and enforce ProKidney&#146;s rights in the Deliverables. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">George Clinical must disclose promptly to ProKidney any new Intellectual Property, including inventions which
it creates in the course of performing Services or based on ProKidney&#146;s Confidential Information. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TERMINATION </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination of Agreement</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ProKidney may terminate this Agreement or any Work Order for whatever reason by giving 30 days&#146; notice in
writing to George Clinical. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Party may terminate this Agreement or any applicable Work Order immediately if the other Party:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">becomes insolvent, files for bankruptcy or has a receiver or administrator appointed to it; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">breaches a material term of this Agreement, and does not remedy the breach substantially within 30 days of
receiving a written notice by the <FONT STYLE="white-space:nowrap">non-breaching</FONT> Party specifying the nature of the breach. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party must continue to perform its obligations under this Agreement or a Work Order during the 30 day
remedy period if material breach is alleged. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination of Work Orders</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ProKidney may terminate a Work Order immediately if: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the relevant Study is terminated; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">George Clinical breaches a material term of this Agreement or does not perform Services to ProKidney&#146;s
reasonable satisfaction and does not remedy the breach or perform satisfactorily within 30 days of receiving a notice specifying the nature of the breach or <FONT STYLE="white-space:nowrap">non-performance.</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">George Clinical may terminate a Work Order by written notice stating the effective date (which may be less than
30 days from the notice date) of termination if it believes on reasonable grounds that continued performance of the Services under the Work Order poses an unacceptable risk to patient safety or may violate regulatory or scientific standards of
integrity. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A termination notice must identify each Work Order that is terminated by its number. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Master Services Agreement &#150;ProKidney and George ClinicalPage <B>10 </B>of <B>17</B></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">11.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Consequences on Termination</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If this Agreement or a Work Order expires or is terminated for any reason: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Parties must meet promptly and in good faith to prepare a <FONT STYLE="white-space:nowrap">close-out</FONT>
schedule, budget and timelines. George Clinical must only work as necessary to <FONT STYLE="white-space:nowrap">close-out</FONT> the Services or as required by Applicable Law or as specified in a Work Order; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ProKidney must pay George Clinical for all Services actually performed in accordance with this Agreement and
any applicable Work Order and must reimburse all costs and expenses George Clinical incurred in performing those Services, including <FONT STYLE="white-space:nowrap">non-cancelable</FONT> costs payable to third parties incurred before termination
but paid after the t Termination Date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ProKidney must pay all George Clinical&#146;s actual costs incurred to complete activities associated with the <FONT
STYLE="white-space:nowrap">close-out</FONT> of the Study; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each Party must return to the other any unused supplies of products or other materials in its control within 60
days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the terms of this Agreement continue to apply to each open Work Order until it expires or terminates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">payment may be based on: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#145;tasks completed&#146; and ProKidney must pay the unit rate for each completed task as detailed in the
applicable Work Order; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">milestones, and if some milestones are incomplete, ProKidney must pay George Clinical a pro rata amount for
actual work up to the date of termination, (in addition to paying for completed units or milestones); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="16%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a combination of the two, as detailed in the <FONT STYLE="white-space:nowrap">close-out</FONT> budget prepared
under clause 11.3 (a). </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DISPUTES </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Dispute must be resolved in accordance with this clause. However, nothing in this clause prevents a Party
from obtaining urgent injunctive relief, if necessary to protect Intellectual Property rights or its Confidential Information. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Parties must first attempt to negotiate in good faith to resolve a Dispute. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Dispute is not resolved within 14 days after good faith negotiations commence, either Party may refer
the Dispute to mediation with the International Chamber of Commerce (ICC). The mediation will be conducted in accordance with the ICC Mediation Rules operating at the time the Dispute is referred. The location for such mediation shall be New York,
U.S.A., or, upon mutual written agreement of the Parties, such mediation may be conducted virtually in English. Any information or documents obtained during the mediation must only be used to resolve the Dispute before the ADC.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If the Dispute is not resolved within 21 days of the commencement of mediation, either Party may commence
proceedings in any court of competent jurisdiction. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Unless specifically provided otherwise, each Party must continue to perform its obligations under this
Agreement, despite the existence of a Dispute. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Master Services Agreement &#150;ProKidney and George ClinicalPage <B>11 </B>of <B>17</B></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INDEMNITY </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Mutual indemnities</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party (<B>Indemnifying Party</B>) indemnifies the other Party, its Affiliates and their Representatives
(each an <B>Indemnified Party</B>), against any third party loss, liability, expense or cost (collectively <B>Loss</B>) an Indemnified Party suffers as a direct result of the existence, performance or termination of this Agreement and which is
caused by Indemnifying Party&#146;s breach of this Agreement, or negligence or wilful misconduct of Indemnifying Party, or any person it retains to perform this Agreement. Losses constitute a direct payment obligation of the Indemnifying Party.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The indemnity in paragraph (a)&nbsp;will be reduced proportionally to the extent that the Indemnified
Party&#146;s negligent act, omission or willful misconduct contributed to the Loss. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Indemnified Party must give the Indemnifying Party prompt written notice of any claim likely to lead to a
claim for indemnity and must fully cooperate with the Indemnifying Party and its legal representatives in the investigation and management of any claim. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indemnifying Party has the right to manage the defence and settlement of a claim but must obtain Indemnified
Party&#146;s written consent to settle the claim. Alternatively, Indemnified Party may elect to control defence of the claim itself at its own expense but if it does so, Indemnifying Party has no obligation to indemnify or defend Indemnified Party
in relation to that claim. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Neither Party may withhold its approval of the settlement of a claim unreasonably. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indemnified Party must take all reasonable steps to mitigate its Loss. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ProKidney&#146;s indemnity to George Clinical </B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Solely in connection with a Work Order under which George Clinical will supervise the conduct of a Study and
that expressly requires indemnification, ProKidney indemnifies George Clinical, its Affiliates and their Representatives against any Loss any of them suffers as a direct result of claims brought by third parties arising from or in connection with
the administration or use of a Study Drug, any clinical intervention or procedure provided for or required by the Study protocol or a <B>Local Indemnity</B> (as defined in paragraph (g). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The indemnity in paragraph (a)&nbsp;will be reduced proportionally to the extent that George Clinical&#146;s
negligent act, omission or wilful misconduct or breach of this Agreement or the Study protocol contributed to the Loss. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">George Clinical must give ProKidney prompt notice of any circumstances likely to lead to a claim for indemnity
and must fully cooperate with ProKidney and its legal representatives in the investigation and management of any claim. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">ProKidney may manage the defence and settlement of a claim but must obtain George Clinical&#146;s consent to
settle the claim. Alternatively, George Clinical may elect to assume control of the defence of the claim itself at its own expense but if it does, ProKidney has no obligation to indemnify or defend George Clinical in relation to that claim.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Neither Party may withhold its approval of the settlement of a claim unreasonably. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Master Services Agreement &#150;ProKidney and George ClinicalPage <B>12 </B>of <B>17</B></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">George Clinical must take all reasonable steps to mitigate its Loss. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A <B>Local Indemnity</B> means an indemnity George Clinical must provide to Investigator Sites or human
research ethics review committees against claims arising from a Study on standard terms and conditions applicable in the relevant jurisdiction. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(h)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">For avoidance of doubt, ProKidney&#146;s indemnity covers all Work Orders and Change Orders executed under this
Agreement. George Clinical may request additional indemnity in associated Work Orders depending on the nature of the Services and study sponsor relationship. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INSURANCE </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party must maintain appropriate insurance policies required by Applicable Law or reasonable professional
practice with reputable insurers to cover its obligations to the other Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Party will provide the other Party with certificates of insurance or other evidence of its insurance, if
requested in writing. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">14.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Party must not knowingly do anything that might invalidate any insurance policy held by the other Party.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>FORCE MAJEURE </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Party will not be liable for failure or delay in performing its obligations (except for payment obligations)
under this Agreement, or any Work Order, for the period and to the extent that its failure or delay is due to a Force Majeure Event. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Party relying on this clause must: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">promptly notify the other Party in writing of the circumstances and effect of the Force Majeure Event; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">take all steps reasonably necessary to mitigate the effects of the Force Majeure Event. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If a Force Majeure Event continues for more than 3 months, the other Party may immediately terminate this
Agreement and applicable Work Orders by written notice. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">15.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">In this clause, <B>Force Majeure Event</B> means an event, which is out of the reasonable control of a Party
and not caused by its own act or omission, including acts of God, natural events, fire, flood, hurricane, earthquake, explosion, volcanic eruption, war, embargo, events of terrorism, industrial action, strike (other than a strike involving the
affected Party&#146;s labor force), riot, crime and act of government or regulatory agency. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>LIMITATION OF LIABILITY </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Despite any other clause in this Agreement, no Party is liable (including without limitation, in contract,
negligence or tort) for any loss of profits, opportunities or goodwill or any type of indirect or consequential damages in connection with this Agreement or any Work Order or Services performed by it. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Master Services Agreement &#150;ProKidney and George ClinicalPage <B>13 </B>of <B>17</B></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">16.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Nothing in this Agreement excludes or limits any liability which cannot be excluded under Applicable Law.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PRIVACY </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party must ensure that it collects, stores and discloses any personal information it obtains as a result
of this Agreement in accordance with applicable Privacy Laws. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party must promptly report to the other Party any unauthorised access to, use or disclosure of personal
information and must work with the other Party to remedy the incident. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NON SOLICITATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Neither Party may directly or indirectly solicit, recruit or hire an employee of the other Party.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This clause does not apply if an employee applies for employment in response to a public advertisement that is
not specifically directed to that employee or responds to a general advertisement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">18.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This clause applies during the term of this Agreement and for 12 months after its expiry or termination.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>19.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NOTICES </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">19.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A notice, consent, approval, or other communication in connection with this Agreement (each a N<B>otice</B>)
must be in writing and delivered or sent to the address or email of the recipient as follows (as amended by Notice): </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if to ProKidney: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">ProKidney </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Attn: Ashley Johns
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">8020 Arco Corporate Dr.&nbsp;Ste 118 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Raleigh, NC 27617 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Email:Ashley.Johns@ProKidney.com </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if to George Clinical: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">George Clinical Pty Ltd </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Level&nbsp;5, 1 King Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Newtown NSW 2042, AUSTRALIA </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Email: contracts@georgeclinical.com </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Marked for the attention of: CEO </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">19.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Notice takes effect from the time received and is taken to be received by the recipient:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if delivered by hand, on the day of delivery; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if sent by post, on the third (seventh, if sent to another country) Business Day after the date of posting;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Master Services Agreement &#150;ProKidney and George ClinicalPage <B>14 </B>of <B>17</B></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">if sent by email, on the day that the recipient acknowledges receipt by return email;
However, if received after 5:00pm or on a day that is not a Business Day, it is be taken to be received at 9:00am on the next Business Day </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">19.3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Although the Parties may correspond via <FONT STYLE="white-space:nowrap">e-mail</FONT> for operational
purposes, no formal notice required by this Agreement may be given or made via email. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>20.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MISCELLANEOUS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>20.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Entire Agreement </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">This Agreement, together with each Work Order and Change Order relating to a Study, contains the entire agreement between the Parties and
supersedes all communications, negotiations, arrangements and agreements, whether oral or in writing, in respect of that Study. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>20.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Inconsistency </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If, for a particular Study, there is any inconsistency between this Agreement and its Work Order and any Change Order, the clauses of this
Agreement prevail, unless expressly provided otherwise in the Work Order or Change Order. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>20.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Amendment </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">This Agreement may only be amended by a written document signed by both Parties. An amendment to a Work Order must comply with clause 4. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>20.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Waiver </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">No right under this Agreement is waived except by notice in writing signed by the Party waiving the right. A failure or delay to exercise any
right, power or remedy under this Agreement will not operate as a waiver. Likewise, a single or partial exercise of any right, power or remedy will not preclude any other or future exercise of that or any other right, power or remedy. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>20.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Assignment and Subcontracting </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">A Party must not assign, <FONT STYLE="white-space:nowrap">sub-contract,</FONT> or transfer its rights or
obligations under this Agreement or a Work Order without the prior written consent of the other Party or if it is to an Affiliate under clause 2.5. Such consent should not be unreasonably withheld. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If George Clinical subcontracts an obligation under this Agreement or any Work Order George Clinical remains
responsible and liable for Services performed by its subcontractors. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>20.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Governing Law </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The laws applicable in the state of New York, U.S.A., govern this Agreement, without regard to conflicts of laws provisions. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>20.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Severability </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Any clause of this Agreement which is prohibited or unenforceable is ineffective to the extent of the prohibition or unenforceability, but the
validity or enforceability of the remaining clauses of this Agreement will not be affected. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Master Services Agreement &#150;ProKidney and George ClinicalPage <B>15 </B>of <B>17</B></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>20.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Counterparts </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">This Agreement may be executed in a number of counterparts and all counterparts taken together are regarded as one instrument. A Party may sign
any one counterpart. This Agreement may be delivered by email and the Parties may rely on an electronic signature as though it were an original signature. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>20.9</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Warranty of authority </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">If this Agreement, or a Work Order or Change Order, is signed by a person for and on behalf of a Party (<B>signee</B>), that Party represents
and warrants that the signee has authority to enter into and sign this Agreement, or a Work Order or Change Order, on its behalf and constitutes a valid execution on behalf of that Party. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>20.10</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Survival </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">Clauses 9 (<B>Confidentiality</B>), 10 (<B>Intellectual Property</B>), 11.3 (<B>Consequences on Termination</B>), 12 (<B>Disputes</B>), 13
(<B>Indemnity)</B>, 14 (<B>Insurance</B>), 16 (<B>Limitation of Liability)</B>, 18 (<B>Non Solicitation</B>) and any operational clauses giving effect to these, survive expiry and termination of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EXECUTED</B> as an <B>Agreement</B> between the Parties: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Executed for and on behalf of <B>GEORGE CLINICAL PTY LIMITED </B>(ABN 33 098 184 528) by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jacqueline Thorn</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Sean Hart</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Jacqueline Thorn</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">Sean Hart</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Please print</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Please print</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">16&nbsp;February 2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">16&nbsp;February 2021</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Master Services Agreement &#150;ProKidney and George ClinicalPage <B>16 </B>of <B>17</B></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="8%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Executed for and on behalf of RegenMed (Cayman) Ltd., d/b/a PROKIDNEY<B> </B>by:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Ashley H. Johns</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Chelsey J. Hehl</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">VP Clinical Ops</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Sr. Clinical Operations Manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">Ashley H. Johns</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">Chelsey J. Hehl</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Please print</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Please print</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Date: 17&nbsp;February 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>Date: 17&nbsp;February 2021</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000">Master Services Agreement &#150;ProKidney and George ClinicalPage <B>17 </B>of <B>17</B></TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>4
<FILENAME>d373959dex1014.htm
<DESCRIPTION>EX-10.14
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.14</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.14 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESEARCH, DEVELOPMENT, ENGINEERING SERVICES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND LICENSE MEMORANDUM AND AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THIS
<B>RESEARCH, DEVELOPMENT, ENGINEERING SERVICES AND LICENSE</B> <B>MEMORANDUM AND AGREEMENT </B>(&#147;Agreement&#148;) is made by and among <B>ProKidney, a Cayman Islands exempted limited company (&#147;ProKidney Cayman&#148;), a wholly-owned
subsidiary of ProKidney LP, an Irish limited partnership (&#147;ProKidney Ireland&#148;) </B>(hereinafter collectively &#147;PROKIDNEY&#148;) and DEKA PRODUCTS LIMITED PARTNERSHIP, a New Hampshire limited partnership with its principal offices at
340 Commercial Street, Manchester, New Hampshire 03101, and its general partner, DEKA RESEARCH&nbsp;&amp; DEVELOPMENT CORP., a New Hampshire corporation of the same address (hereinafter collectively &#147;DEKA&#148;). PROKIDNEY and DEKA shall be
referred to individually as &#147;Party&#148; and collectively as &#147;Parties.&#148; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WITNESSETH: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, DEKA has expertise in the design, development, and testing of sophisticated mobility technology and DEKA has previously
developed and owns and, as a result of the Development Program (as defined herein), has come to develop and own and may further come to develop and own certain patent rights, copyrights, trade secrets, and/or confidential <FONT
STYLE="white-space:nowrap">know-how</FONT> relating to the ProKidney Field (as defined herein); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, PROKIDNEY desired and
continues to desire that DEKA undertake the Development Program (as defined herein) to attempt to develop Licensed Technology (as defined herein), for use within the ProKidney Field, and PROKIDNEY is willing to remunerate DEKA for such work on the
Development Program; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, DEKA desired and continues to desire that the Licensed Technology, if successfully developed, be
made available for use within the ProKidney Field, on the terms stated herein; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, PROKIDNEY wished to and continues to
wish to have developed and made available such Licensed Technology, for use within the ProKidney Field, and for PROKIDNEY to obtain an exclusive, worldwide right and license to Commercialize (as defined herein) the Licensed Technology within the
ProKidney Field; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, PROKIDNEY and DEKA reached an agreement on August&nbsp;30, 2021 (the &#147;<B>Effective Date</B>&#148;)
for DEKA to undertake components of the Development Program to attempt to develop Licensed Technology for use within the ProKidney Field so that PROKIDNEY could develop and make available such Licensed Technology, for use within the ProKidney Field,
and for DEKA to grant PROKIDNEY an exclusive, worldwide right and license to Commercialize the Licensed Technology within the ProKidney Field, in return for DEKA being remunerated utilizing DEKA&#146;s Standard Reimbursement Formula (as defined
herein), but with amounts so due by PROKIDNEY to DEKA to be settled through the issuance of up to a certain number of <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> Units of ProKidney Ireland (or through the issuance of an equivalent number
of <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> Profits Units of ProKidney Management Equity LLC (&#147;<B>PMEL</B>&#148;), which units represent an equivalent interest) (collectively, the &#147;<B>Class</B><B></B><B><FONT
STYLE="white-space:nowrap">&nbsp;B-1</FONT> Units</B>&#148;) to DEKA (with such <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> Units to be valued as at the date the amounts become due by PROKIDNEY to DEKA), and, once the obligation to
procure the issuance of all such <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> Units has fallen due, thereafter by cash payment by PROKIDNEY to DEKA; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the number of <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> Units
available to be issued to DEKA was subject to agreement among PROKIDNEY and its two (indirect) founding investors, and this number was agreed by the founding investors to be 2,750,000 <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> Units; and
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, PROKIDNEY and DEKA now wish to memorialize the agreements set forth above in this Agreement and set out further and more
detailed terms of such agreements in this Agreement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the promises and mutual covenants
herein contained, the Parties hereto confirm the terms agreed and further agree such more detailed terms as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 1
DEFINITIONS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where capitalized and used in this Agreement, the following terms shall have the ascribed meanings: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1 The term &#147;Affiliate&#148; shall mean any company or other legal entity, other than PROKIDNEY or DEKA, in whatever country organized,
now or hereafter controlling, controlled by, or under common control with PROKIDNEY or DEKA, as applicable, for the period during which such control exists. The term &#147;control&#148; means the possession, direct or indirect, of the power (whether
or not exercised) to direct or cause the direction of the management and policies of an entity, whether through the ownership of voting securities, by contract, or otherwise, and the term &#147;entity&#148; includes an individual, corporation or
other entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2 The term &#147;Business Day&#148; means a day except a Saturday, a Sunday or other day on which banks in the State of
Delaware are authorized or required by a legal requirement to be closed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3 The term &#147;Commercial Introduction&#148; shall mean,
with respect to Licensed Technology, the date that Licensed Technology are first made available in commercially reasonable quantities by PROKIDNEY, or PROKIDNEY uses such Licensed Technology within its operations, directly or by or through an
Affiliate, in commercially reasonable quantities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.4 The term &#147;Confidential Information&#148; shall mean all information,
including, without limitation, all data, samples, designs, reports, technologies, software, materials, and other information, and all copies thereof, made or disclosed for or in contemplation of the Development Program by a Party, its employees, or
its contractors (the &#147;Disclosing Party&#148;) to another Party, its employees or contractors (the &#147;Receiving Party&#148;), excluding any information that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">a) at the time of the disclosure was known to the Receiving Party, as shown by written records, and was not previously subject to any
obligation of confidentiality; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">b) was generally available to the public or was otherwise part of the public domain at the time of its
disclosure without breach of a prior obligation of confidentiality; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">c) becomes generally available to the public or otherwise part of the public domain after
its disclosure other than through a breach of a confidentiality agreement (including, but not limited to, an act or omission in breach of this Agreement); or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">d) becomes known to the Receiving Party by disclosure of a third party, as shown by written records, without an obligation of confidentiality;
or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">e) is hereafter independently developed by personnel of the Receiving Party that have not been exposed to the Confidential Information
of the Disclosing Party, PROVIDED that the burden of proving such independent development shall be on the Receiving Party; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">f) is, or
relates, to Intellectual Property that is owned by the Receiving Party pursuant to the terms of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.5 The term
&#147;PROKIDNEY Intellectual Property&#148; shall mean, collectively, any Intellectual Property in existence prior to the commencement of the Development Program, which PROKIDNEY owns, controls, or to which PROKIDNEY is empowered to grant a license.
&#147;PROKIDNEY Intellectual Property&#148; shall also include any Intellectual Property developed by PROKIDNEY outside of the Development Program during the term of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.6 The term &#147;DEKA Intellectual Property&#148; shall mean, collectively, any Intellectual Property: (a)&nbsp;in existence as of the
Effective Date and incorporated by DEKA into any Licensed Technology or (b)&nbsp;resulting from the performance of the Development Program, which DEKA owns, controls, or is empowered to grant a license to during the Term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.7 The term &#147;Development Contractor&#148; shall mean any person or entity performing services under the Development Program. For the
avoidance of doubt, the Advanced Regenerative Manufacturing Institute, which is also providing services to PROKIDNEY, shall not be considered as a Development Contractor to the Development Program, unless otherwise agreed by the Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.8 The term &#147;Development Program&#148; shall mean all of DEKA&#146;s efforts relating to the Licensed Technology for use in the
ProKidney Field, including, but not limited, to the development, regulatory approval, design control, continuing engineering, manufacture, and improvement of Licensed Technology, both prior to and after the Effective Date, to attempt to achieve the
Development Purpose (as defined in Section&nbsp;2.1). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.9 The term &#147;Exclusive Rights and License&#148; shall mean the rights and
licenses granted by DEKA to PROKIDNEY under Section&nbsp;8.1 hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.10 The term &#147;Improvements&#148; shall mean any modification
or enhancement of any Licensed Technology that allows the Licensed Technology, or any portion thereof, to perform the same, substantially similar, or an enhanced purpose in a better, more useful, or more economical way, or which permits a better or
more economical means of manufacture or testing of the Licensed Technology, or any portion thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.11 The term &#147;Intellectual
Property&#148; shall mean, collectively, any copyright, trade secret, devices, designs, materials, <FONT STYLE="white-space:nowrap">know-how,</FONT> technology, information, invention, patent or patent application (including all continuations, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuations-in-part,</FONT></FONT> divisions, renewals, and any other patent or patent application claiming priority thereof, all patents which may be granted thereon, all reissues,
reexaminations and extensions thereof, and all foreign counterparts of any of the forgoing), methods, data, testing results, software or algorithms. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.12 The term &#147;Intellectual Property Losses&#148; shall mean any and all damages,
liabilities, claims, costs, charges, judgments, settlements and expenses (including attorney&#146;s fees) or other losses to the extent resulting from, arising out of, or incurred in connection with, or otherwise with respect to any claim by a
third-party asserting, arising from or premised upon any Intellectual Property-related right pursuant to Section&nbsp;11.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.13 The term
&#147;ProKidney Field&#148; shall mean the use of Licensed Technology for any purposes relating to the provision of cell therapy for treatment of renal insufficiency (including, but not limited to, collecting cells from kidneys, injecting and/or
inserting cells into kidneys, and manufacturing, monitoring, and testing of cells for injection and/or insertion of cells into kidneys). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.14 The term &#147;Licensed Technology&#148; shall mean any technology resulting from the Development Program, including but not limited to:
(a)&nbsp;an injection device, (b)&nbsp;an automated cell digester, (c)&nbsp;a cell stack manipulator, and (d)&nbsp;any other technology development project that is made part of the Development Program pursuant to the Development Plan (as may be as
may be amended from time to time by a signed writing between the Parties). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 2 DEVELOPMENT AND PRODUCT SUPPORT OBLIGATIONS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 <U>Development Purpose</U>. The purpose of the Development Program is to achieve as expeditiously as practicable, the development
and testing of Licensed Technology in accordance with the Development Plan agreed upon by the Steering Committee (and as may be amended from time to time) (the &#147;Development Purpose&#148;). PROKIDNEY and DEKA shall undertake the Development
Program to attempt to achieve the Development Purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Joint Steering Committee</U>. To manage the Development Program and attempt
to achieve the Development Purpose, PROKIDNEY and DEKA will form a joint steering committee (&#147;Steering Committee&#148;) as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">a) <U>Membership; Voting; Meetings</U>. The Steering Committee shall consist of four (4)&nbsp;members in total, with two representatives
designated by PROKIDNEY (and reasonably acceptable to DEKA) and two representatives designated by DEKA (and reasonably acceptable to PROKIDNEY). Such Steering Committee shall act by unanimous agreement of all such members, provided, however, that
any modifications to the Development Plan shall be subject to the signed approval of the Parties. A Party may change any of its representatives at any time upon written notice to the other Party. The Steering Committee shall meet, either in person
or by telephone, approximately once each calendar quarter (unless otherwise agreed by the Steering Committee). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">b) <U>Purpose</U>. The
Steering Committee shall be responsible for establishing and reviewing the progress of the Development Program toward achieving the Development Purpose. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">c) <U>Conflict Resolution</U>. The Steering Committee shall attempt in good faith to resolve
any conflict arising within the Steering Committee, PROVIDED that, in the event that a dispute cannot be resolved promptly by the Steering Committee, the dispute may be referred to Dean Kamen (or his successor, as appointed by DEKA)
(&#147;Mr.&nbsp;Kamen&#148;), and Tim Bertram (or such person&#146;s successor, as appointed by PROKIDNEY) (&#147;Mr.&nbsp;Bertram&#148;), for resolution. If Mr.&nbsp;Kamen and Mr.&nbsp;Bertram are not able to resolve the matter through good faith
negotiations within thirty (30) Business Days of first being presented, then either Party may pursue mediation pursuant to Section&nbsp;14.4. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 <U>Development Plan</U>. DEKA shall lead the Development Program and, unless otherwise agreed by the Steering Committee (pursuant to the
procedures set forth in Section&nbsp;2.2), DEKA shall be primarily responsible for all activities relating to the Development Program. The Development Program shall be governed by a development plan (&#147;Development Plan&#148;) attached hereto as
<U>Exhibit A</U> (as may be amended from time to time by a signed writing between the Parties), which sets forth a mutually agreed scope of work generally consistent with this Agreement, including a
<FONT STYLE="white-space:nowrap">non-binding</FONT> cost estimate, desired deliverables, and the roles and responsibilities of DEKA and PROKIDNEY. In the event of any inconsistencies between the Development Plan and this Agreement, the terms and
conditions of this Agreement shall control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 <U>DEKA Development Program Efforts</U>. Subject to the terms of this Agreement, DEKA
shall perform the obligations assigned to it under the Development Plan and this Agreement, which shall include without limitation: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">a)
developing prototypes of Licensed Technology for testing as described in the Development Plan; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">b) conduct preparations and engineering
support for trials, as needed, of Licensed Technology; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">c) cooperate with PROKIDNEY to implement an appropriate regulatory strategy for
Licensed Technology; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">d) maintain the design history file, provide design control in compliance with DEKA&#146;s quality system (unless
otherwise mutually agreed by the Steering Committee), and provide continuing engineering for Licensed Technology; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">e) collaborate with
PROKIDNEY to develop an appropriate plan for the manufacture and manufacturing supply chain for the Licensed Technology; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">f) take such
other efforts within the scope of this Agreement as set forth in the Development Plan or as otherwise agreed to by the Steering Committee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DEKA shall
ensure that all Development Contractors engaged by DEKA to perform aspects of the Development Program comply with the terms and conditions of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.5 <U>PROKIDNEY&#146;s Development Program Efforts</U>. Subject to the terms of this Agreement, PROKIDNEY shall perform the efforts assigned
to it under the Development Plan (or as otherwise agreed by the Steering Committee) to achieve the Development Purpose. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.6 <U>No Transfer of Development Program Materials</U>. As part of the Development Program,
prototypes, tooling, fixtures, test equipment, and other materials may be utilized (&#147;Development Program Materials&#148;). Subject to the terms of this Agreement, DEKA shall own all Development Program Materials developed by DEKA or its
Development Contractors in conjunction with the Development Program. All such Development Program Materials provided by DEKA to PROKIDNEY for analysis, testing, and/or other activities related to the Development Program shall remain the property of
DEKA. For the avoidance of doubt, to the extent that any DEKA Intellectual Property is incorporated into any such Development Program Materials (or necessary to utilize any such Development Program Materials), such DEKA Intellectual Property shall
be included in the Exclusive Rights and License. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.7 <U>Disclaimer</U>. Anything in this Agreement to the contrary notwithstanding, DEKA
does not extend or make any guarantees, warranties or representations regarding the successful development, testing or commercial viability of any Licensed Technology. PROKIDNEY and DEKA acknowledge that each Party is actively involved in other,
unrelated development programs of equal priority, but each Party agrees to use its Commercially Reasonable Efforts to achieve the Development Purpose. PROKIDNEY and DEKA acknowledge that any cost and time estimates provided are <FONT
STYLE="white-space:nowrap">non-binding</FONT> estimates made in good faith based upon the Development Program. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 3 FUNDING OF
RESEARCH AND DEVELOPMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 <U>Reimbursement</U>. PROKIDNEY shall reimburse DEKA on a cost plus system for DEKA&#146;s efforts (and
the efforts of DEKA&#146;s Development Contractors) under the Development Program as described below in this Section&nbsp;3.1. DEKA will bill its services at all direct labor incurred plus one hundred sixty percent (160%) labor overhead, plus direct
material, plus zero percent (0%) general and administration, plus ten percent (10%) fee; that is, according to the following formula: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">((L
x 2.6) + M) x 1.1 = reimbursement </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">where &#147;L&#148; equals direct labor and &#147;M&#148; equals <FONT STYLE="white-space:nowrap">non-labor</FONT>
direct project costs (such as materials, Development Contractors, consultants, and other direct costs) (&#147;DEKA&#146;s Standard Reimbursement Formula&#148;), PROVIDED that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">a) PROKIDNEY shall be obliged to settle this reimbursement, initially, through procuring that ProKidney Ireland or PMEL, as determined by
PROKIDNEY, issues up to 2,750,000 <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> Units to recipients as directed by DEKA and identified to PROKIDNEY on or prior to the date of this agreement (the &#147;DEKA Recipients&#148;), each of whom
shall enter into the form of subscription agreement attached as Exhibit B hereto in connection with such issuance of <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> Units (the &#147;Subscription Agreement&#148;), with such <FONT
STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> Units to be valued for these purposes as at the day the reimbursement falls due to be settled by PROKIDNEY as determined in accordance with the following sentence. The Parties agree that this
obligation has fully vested on PROKIDNEY by virtue of work carried out by DEKA up to December&nbsp;31, 2021 as follows: the total value of the work carried out by DEKA to December 31, 2021 amounts to $4,163,992.23 and the value of 2,750,000 <FONT
STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> Units as of December&nbsp;31, 2021 amounts to $2,502,500.00. PROKIDNEY hereby acknowledges its present and fully vested obligation to procure the issuance, by ProKidney Ireland or PMEL, as applicable,
of these 2,750,000 <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> Units to the DEKA Recipients. The <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> Units issued to the DEKA Recipients in accordance with this Section shall be subject
to the provisions of the Subscription Agreements and the governing documents (including applicable transfer restrictions) of ProKidney Ireland or PMEL, as applicable. The parties agree that, as of December 31, 2021, the total cash payment due by
PROKIDNEY to DEKA equals $1,661,492.23; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">b) PROKIDNEY shall thereafter settle all further amounts due under this Section&nbsp;3.1
through cash payment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 <U>Taxes</U>. DEKA is responsible for the payment and remittance of all applicable federal, state or local
taxes or foreign taxes resulting from payments received from PROKIDNEY, including payments of <FONT STYLE="white-space:nowrap">Class&nbsp;B-1</FONT> Units and cash pursuant to Section&nbsp;3.1 of this Agreement. DEKA acknowledges and agrees that
DEKA is obligated to report as income all payments received from PROKIDNEY pursuant to this Agreement. DEKA agrees to and acknowledges the obligation to pay all self-employment and other taxes on such income. DEKA shall pay all applicable
unemployment and disability insurance required by the applicable jurisdictions in which DEKA conducts business. DEKA agrees to indemnify, defend and hold PROKIDNEY harmless from any liability for, or assessment of, any claims or penalties or
interest with respect to such taxes, labor or employment requirements, including any liability for, or assessment of, taxes imposed on PROKIDNEY by the relevant taxing authorities with respect to any payments made to DEKA pursuant to this Agreement
or any liability related to the withholding of such taxes. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 4 RESEARCH REPORTS AND ACCOUNTING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 <U>Monthly Reporting and Reimbursement</U>. DEKA shall furnish to PROKIDNEY during the Term written monthly reports (&#147;Monthly
Report&#148;) within approximately fifteen (15)&nbsp;days following the start of each month, containing an accounting of the reimbursement due for the preceding month. PROKIDNEY shall reimburse DEKA for all undisputed amounts within thirty (30) days
of receipt of each Monthly Report. Should PROKIDNEY wish to dispute any amount set forth in a Monthly Report, PROKIDNEY shall notify DEKA in writing, within thirty (30)&nbsp;days of receipt of such Monthly Report, of such disputed amount and
PROKIDNEY and DEKA shall use their respective reasonable efforts to amicably resolve the dispute. In the event that PROKIDNEY and DEKA do not amicably resolve a dispute within thirty (30)&nbsp;days of such written notification of dispute, the
Parties shall follow the dispute resolution procedures set forth in Section 14.4 herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 <U>Audits of Books and Records</U>. DEKA
shall keep full, true and accurate books and records which account for the services rendered by DEKA under the Development Program, which account for the payments due to DEKA under this Section&nbsp;4. Such books and records shall be maintained
until the fifth (5<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) anniversary of the termination of this Agreement or the completion of the final Milestone on any Project (as described in Exhibit A) unless a longer timeframe for records
maintenance is provided in an SOW or the Development Plan. PROKIDNEY, at its own expense, shall have the right during normal business hours on ten (10)&nbsp;days&#146; prior written notice to DEKA and not more than once in any calendar year to have
a nationally recognized independent public accounting firm selected by PROKIDNEY and acceptable to DEKA examine the relevant books and records of DEKA for the two (2)&nbsp;preceding years for the purpose of verifying the payments under this
Section&nbsp;4 for those two (2)&nbsp;years (PROVIDED that payments for such years have not been the subject of a prior audit). Such accounting firm shall not work on a contingency fee basis, shall execute and deliver to DEKA a standard
confidentiality agreement and shall not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disclose to PROKIDNEY any information relating to DEKA&#146;s business, except whether DEKA&#146;s invoices are correct or incorrect, and if incorrect, the specific details concerning any
discrepancies and the amounts of the payment due under this Section&nbsp;4. If such examination reveals a discrepancy, and neither party disputes such conclusion, PROKIDNEY shall pay to DEKA any additional amount owed to DEKA, or DEKA shall refund
to PROKIDNEY any excess payments made by PROKIDNEY, as appropriate. In the event of a dispute, the provisions of Section&nbsp;14.4 shall apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3 <U>Inspections</U>. During the term of this Agreement and for five (5)&nbsp;years thereafter, PROKIDNEY&#146;s authorized
representative(s) and governmental regulatory authorities, shall be permitted to inspect and audit Service Provider&#146;s premises, records, processes, software, and systems used by Service Provider in connection with this Agreement, for quality
assurance purposes. Any such PROKIDNEY audit will be conducted at PROKIDNEY&#146;s sole expense, during DEKA&#146;s regular business hours and upon reasonable prior notice to DEKA. In the event an audit reveals DEKA&#146;s noncompliance, DEKA shall
immediately implement appropriate corrective action at DEKA&#146;s expense. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 5 COMMERCIALIZATION AND MANUFACTURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1 <U>Support of the Development Program</U>. DEKA and PROKIDNEY shall use Commercially Reasonable Efforts to support the Development Program
and to attempt to achieve the Development Purpose as soon as practicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 <U>Manufacturing</U>. Upon the request of PROKIDNEY, DEKA
(or a DEKA Affiliate) shall provide support for establishing the manufacturing supply chain for, and making arrangements for the production of, Licensed Technology as part of the Development Program, by DEKA (or a DEKA Affiliate) or by one or more
third party contract manufacturers, as mutually agreed by the Parties. Any Licensed Technology manufactured by DEKA (or a DEKA Affiliate) shall be supplied pursuant to a supply agreement(s) between DEKA, PROKIDNEY, and any other entity or entities
providing contract manufacturing services, which supply agreement(s) shall be negotiated in good faith no later than six (6)&nbsp;months prior to the anticipated Commercial Introduction. If the Parties agree to the use of one or more contract
manufacturers for some or all of the manufacturing supply chain and/or production, such support shall include helping to identify such contract manufacturer and assisting with the transfer of the Licensed Technology, and associated <FONT
STYLE="white-space:nowrap">know-how,</FONT> necessary to implement a manufacturing supply chain and production, as appropriate. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION
6 PROPRIETARY INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1 <U>Treatment of Confidential Information</U>. All Confidential Information of a Disclosing Party
disclosed to a Receiving Party shall be treated by the Receiving Party as confidential throughout the Term and for so long thereafter as the information remains Confidential Information. The Receiving Party shall: (i)&nbsp;treat and safeguard such
Confidential Information in the same manner as its own proprietary information of a similar type, which in no event shall be less than reasonable care; (ii)&nbsp;limit access to only those employees and contractors who need to know for purposes of
this Agreement; (iii)&nbsp;assure that such persons and entities are under the same obligations of confidentiality as are included in this Agreement; and (iv)&nbsp;assure </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that such persons do not use such Confidential Information except as necessary to perform its obligations under this Agreement, and use such Confidential Information consistent with Section 7. If
this Agreement is terminated for any reason, the Receiving Party, upon request of the Disclosing Party, shall return all Confidential Information in its possession or certify that all Confidential Information in its possession has been destroyed
within thirty (30)&nbsp;days of such request, except that the Receiving Party shall be permitted to maintain, at its own cost and expense, one archival copy of any Confidential Information necessary to support its regulatory compliance. Such
archival copy shall be maintained subject to the confidentiality requirements of this Agreement and shall only be used for the satisfaction of the regulatory obligations of the Receiving Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2 <U>Disclosures Required by Law</U>. The Receiving Party shall not be liable to the Disclosing Party for disclosure of any Confidential
Information received hereunder if such disclosure is made pursuant to a governmental or judicial mandate, PROVIDED that the Receiving Party shall have given the Disclosing Party prompt notice of such mandate prior to the submission of such
Confidential Information, and FURTHER PROVIDED that the Receiving Party shall have cooperated with any efforts by the Disclosing Party to intervene in such proceedings or otherwise prevent such disclosure. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 7 OWNERSHIP OF LICENSED SUBJECT MATTER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1 <U>DEKA Intellectual Property</U>. Subject to the Exclusive Rights and License, and except as expressly set forth in Sections 7.2, DEKA
shall own title to any and all Intellectual Property created, developed and/or invented as a result of, or in conjunction with, the Development Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2 <U>PROKIDNEY Intellectual Property</U>. PROKIDNEY shall own title to any and all Intellectual Property created, developed and/or invented
solely by PROKIDNEY independent of any assistance from DEKA as a result of PROKIDNEY&#146;s own development efforts separate and apart from the Development Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.3 <U>Cooperation</U>. To the extent the Parties are able to do so, the Parties shall provide each other with reasonable opportunity to
advise the other and shall cooperate with each other in the prosecution of all patent applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.4 <U>Party Employee Agreements</U>.
Each of the Parties represent and warrant that it and its employees have entered into agreements wherein its employees agreed to assign their rights in and to all inventions, as well as all patents and patent applications directed to such
inventions, resulting from their employment with such Party to that Party. DEKA will enforce the same so that DEKA can perfect its title to the DEKA Intellectual Property and PROKIDNEY can perfect its title to the Intellectual Property PROKIDNEY is
entitled to own under this Agreement. Furthermore, each of the Parties represents and warrants that it has caused or will cause all additional employees, or personnel performing work pursuant to the Development Program, to execute similar agreements
with respect to the rights in and to all inventions, as well as all patents and patent applications directed to such inventions, resulting from their association with such Party and will enforce such agreements so that the Party can perfect its
title to the Intellectual Property it is entitled to own under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 8 EXCLUSIVE RIGHTS AND LICENSE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.1 <U>Exclusive Rights and License</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">a) <U>Exclusive License</U>. DEKA hereby grants to PROKIDNEY a worldwide, exclusive, royalty-free, perpetual, irrevocable (except as set forth
in Section&nbsp;12) license to practice the DEKA Intellectual Property to make, have made, use, offer for sale, sell and import the Licensed Technology and Improvements thereto, all solely within the ProKidney Field. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">b) <U>DEKA Development License</U>. DEKA hereby grants PROKIDNEY an exclusive, worldwide, royalty-free, perpetual (except as set forth in
Section&nbsp;12) license to use the DEKA Intellectual Property solely for the purpose of developing, in collaboration with DEKA, the Licensed Technology for commercial use in the ProKidney Field. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">c) <U>Sublicense Rights</U>. Subject to the terms of this Agreement, PROKIDNEY shall have the right to grant a sublicense to the rights and
license granted under this Section&nbsp;8.1(a) &#150; (b) (&#147;Exclusive Rights and License&#148;) for use within the ProKidney Field to any ProKidney Affiliate and, subject to DEKA&#146;s prior written approval (not to be unreasonably withheld or
delayed), to any third party. DEKA shall provide a response to PROKIDNEY&#146;s notice of intent to sublicense to any third party within ninety (90)&nbsp;days, unless otherwise agreed by the Parties. Any sublicense granted by PROKIDNEY must be
consistent herewith and PROKIDNEY shall remain responsible for performance of PROKIDNEY&#146;s obligations hereunder. Any sublicense under this Section&nbsp;8.1(c) must be subject to a confidentiality agreement no less restrictive than the
confidentiality provisions contained in Section&nbsp;6 herein prior to the grant of such sublicense or transmission of any Confidential Information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">d) <U>PROKIDNEY Improvements</U>. ProKidney shall own all title to any and all Improvements to the Licensed Technology conceived, created,
reduced to practice, developed and/or invented solely by ProKidney independent of any assistance from DEKA as a result of PROKIDNEY&#146;s own development efforts separate and apart from the Development Program. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.2. <U>DEKA Rights to Licensed Patents</U>. For the avoidance of doubt, DEKA reserves all rights to the DEKA Intellectual Property, except as
specifically granted in Sections 7 and 8, including, without limitation, the right to utilize (by licensing others and otherwise) the DEKA Intellectual Property outside of the ProKidney Field during the Term. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.3. <U>Section 365(n) of the Bankruptcy Code</U>. All licenses granted under this Agreement are deemed to be, for purposes of
Section&nbsp;365(n) of the Bankruptcy Code, licenses of rights to &#147;intellectual property&#148; as defined in Section&nbsp;101 of such Code. ProKidney, as licensee, may fully exercise all of its rights and elections under the Bankruptcy Code.
The parties further agree that, if a Party elects to retain its rights as a licensee under any Bankruptcy Code, such party will be entitled to complete access to any technology licensed to it hereunder and all embodiments of such technology. Such
embodiments of the technology will be delivered to the licensee party not later than: (a)&nbsp;the commencement of bankruptcy proceedings against the licensor, upon written request, unless the licensor elects to perform its obligations under the
Agreement, or (b)&nbsp;if not delivered under the foregoing clause (a), upon the rejection of this Agreement by or on behalf of the licensor, upon written request. Any agreements supplemental hereto will be deemed to be &#147;agreements
supplementary to&#148; this Agreement for purposes of Section&nbsp;365(n) of the Bankruptcy Code. As used herein, &#147;Bankruptcy Code&#148; means the U.S. Bankruptcy Code and any foreign equivalent thereto in any country having jurisdiction over a
Party or its assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 9 RESERVED </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Section reserved. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 10 PATENT
FILINGS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.1 <U>Disclosure of Patent Filings</U>. DEKA shall promptly disclose to PROKIDNEY, and PROKIDNEY shall promptly disclose to
DEKA, all inventions arising out of the Development Program, including patents and patent applications and any other intellectual property protections. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.2 <U>DEKA Patent Filing.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">a) <U>In the United States</U>. For inventions that DEKA owns pursuant to Section 7.1 herein, DEKA may elect to file and prosecute patent
applications directed to any such inventions and such applications shall be filed, prosecuted, and maintained in DEKA&#146;s name at DEKA&#146;s expense utilizing patent counsel selected by DEKA. Should DEKA elect not to file a certain patent
application despite the written request by PROKIDNEY, PROKIDNEY may elect to file, prosecute, and maintain such patent application in DEKA&#146;s name and at PROKIDNEY&#146;s expense utilizing patent counsel selected by PROKIDNEY and reasonably
acceptable to DEKA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">b) <U>Outside the United States</U>. PROKIDNEY shall notify DEKA when PROKIDNEY desires that DEKA file for patent
protection in respect to DEKA Intellectual Property in any country other than the United States. Such applications shall be filed, prosecuted, and maintained by DEKA in DEKA&#146;s name utilizing patent counsel selected by DEKA and reasonably
acceptable to PROKIDNEY. PROKIDNEY shall reimburse DEKA for reasonable mutually agreed outside patent counsel and other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection
with preparing, filing, and maintaining such patents and patent applications on a quarterly basis, provided, however, that if DEKA has executed a license with a third party who will make use of the patent in such country outside of the PROKIDNEY
Field, PROKIDNEY shall only be required to pay its pro rata portion of such fees and expenses. DEKA and PROKIDNEY shall work cooperatively to estimate the patent expenses to be paid on a quarterly basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.3 <U>Cooperation</U>. With respect to all patent applications referred to above, and to the extent the Parties are able to do so, the
Parties shall provide each other with reasonable opportunity to advise the other and shall cooperate with each other at its own expense in the prosecution of all such patent applications, such cooperation not to include retention, payment of costs
or expenses, and reimbursement of counsel and similar activities unless mutually agreed by the Parties. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 11 INFRINGEMENT AND
INDEMNIFICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.1 <U>DEKA Enforcement Actions</U>. Each Party shall promptly notify the other in writing if the Party becomes
aware of any actually or reasonably suspected infringement or misappropriation by a third party of any DEKA or PROKIDNEY Intellectual Property including, without limitation, with such written notice any evidence available to it of such infringement
or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
misappropriation by such third party. As between the Parties to this Agreement, PROKIDNEY shall have the right, but not the obligation, to bring an Enforcement Action against such third party for
infringement of any DEKA Intellectual Property solely within the ProKidney Field and join DEKA as a party plaintiff, PROVIDED that PROKIDNEY shall bear all expenses of such Enforcement Action. DEKA shall reasonably cooperate with PROKIDNEY in such
Enforcement Action, including, without limitation, by providing PROKIDNEY with reasonable access to materials and witnesses. DEKA shall have the right to consult with PROKIDNEY and to participate in and be represented by independent counsel in such
Enforcement Action. Neither Party shall settle any such litigation, if such settlement would have a material adverse effect on the DEKA Intellectual Property or the PROKIDNEY Intellectual Property, unless the other Party gives prior, written
consent, which consent shall be timely and not be unreasonably withheld. Any damages or other monies awarded or received in settlement of an Enforcement Action brought by PROKIDNEY shall be first applied to reimburse PROKIDNEY&#146;s reasonable
unreimbursed expenses. Any remainder relating to infringement or misappropriation within the ProKidney Field shall then be paid to PROKIDNEY, except that PROKIDNEY shall reimburse DEKA for its reasonable attorneys&#146; fees. For infringement of any
DEKA Intellectual Property both within and outside of the ProKidney Field, DEKA and PROKIDNEY will reasonably cooperate with any relevant DEKA licensees to determine an appropriate sharing of responsibilities and expenses for any Enforcement Action.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.2 <U>Third Party Infringement Claims</U><I><U>.</U></I><I> </I>In the event PROKIDNEY is charged with infringement of any Intellectual
Property-related right by a third-party based on the sale, lease, use, or manufacture of Licensed Technology, each Party shall immediately notify the other Parties of such claim in writing. PROKIDNEY shall have the exclusive to right to defend
against such claim and DEKA will reasonably cooperate with PROKIDNEY, including, without limitation, by providing PROKIDNEY with reasonable access to materials and witnesses, in any such action and shall have the right to consult with PROKIDNEY and
be represented by its own counsel. PROKIDNEY shall cover all costs of defending against such claim and PROKIDNEY shall have no remedy against DEKA for any Intellectual Property Losses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.3 <U>Freedom to Operate Analyses</U>. Upon reasonable request of PROKIDNEY, DEKA shall provide reasonable assistance by conducting with
PROKIDNEY appropriate analyses of freedom to operate with respect to Licensed Technology, including (i)&nbsp;sharing lists of identified patents and patent applications that may constitute prior art references to one or more aspects of the Licensed
Technology, (ii)&nbsp;providing input regarding the initial prioritization of such potential prior art references, (iii)&nbsp;contributing technical and legal input regarding such potential prior art references, and (iv)&nbsp;conducting regular
coordination teleconferences and/or in person meetings between DEKA&#146;s counsel and, as needed, technical personnel, and PROKIDNEY&#146;s counsel regarding the substance and progress of the freedom to operate analysis. DEKA and PROKIDNEY shall
execute promptly a community of interest agreement to facilitate the cooperation between DEKA and PROKIDNEY regarding intellectual property matters relating to the Licensed Technology. If it determined that a license to a third party&#146;s
intellectual property may be required to practice the Licensed Technology, PROKIDNEY shall be solely responsible for obtaining such third party license. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 12 TERMINATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.1 <U>Term</U>. The term of this Agreement (&#147;Term&#148;) shall extend from the Effective Date through the commercial life of any
Licensed Technology, unless sooner terminated by a Party pursuant to this Section&nbsp;12. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.2 <U>Termination for Breach</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">a) Upon any material breach of, or default under, this Agreement by DEKA, PROKIDNEY may terminate this Agreement: upon ninety
(90)&nbsp;days&#146; written notice to DEKA. Said notice shall become automatically effective at the end of such period unless, during such period, DEKA shall cure such breach or default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">b) In the event of <FONT STYLE="white-space:nowrap">non-payment,</FONT> DEKA may upon sixty (60)&nbsp;days&#146; written notice to PROKIDNEY,
terminate this Agreement. Said notice shall become automatically effective at the end of such period unless, during such period, PROKIDNEY shall cure such breach or default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">c) In the event PROKIDNEY fails to proceed for a period of one hundred- eighty (180)&nbsp;days to undertake its obligations under the
Development Program as reasonably necessary to achieve the Development Purpose, DEKA may send a notice of termination to PROKIDNEY, and termination shall automatically become effective thirty (30)&nbsp;days following PROKIDNEY&#146;s receipt of such
notice, unless PROKIDNEY has cured such breach. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">d) DEKA&#146;s rights of termination under Sections 12.2 (b) and (c), above are
DEKA&#146;s sole rights of termination under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.3 <U>Termination for Convenience</U>. PROKIDNEY shall have the right to
terminate this Agreement on ninety (90)&nbsp;days&#146; advance written notice to DEKA. During such ninety (90)&nbsp;day period, PROKIDNEY shall cooperate in good faith with DEKA to wind down the Development Program and PROKIDNEY shall continue to
reimburse DEKA pursuant to Sections 3 and 4, but the monthly reimbursements due to DEKA during the ninety (90)&nbsp;day period shall not exceed the average monthly reimbursement rate for the prior three (3)&nbsp;months. Upon DEKA&#146;s receipt of
such notice, the termination shall be irrevocable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.4 <U>Return of Rights to DEKA</U>. If this Agreement is terminated for any reason
while work is ongoing on any Project, then, with respect to such Project: a) the Exclusive Rights and License under Section&nbsp;8.1 related only to any then-uncompleted Milestones shall terminate, and b) any and all rights in and to all Licensed
Technology developed under such Milestones shall be returned to DEKA. All other Exclusive Rights and License under Section&nbsp;8.1 and rights in and to all Licensed Technology shall continue in perpetuity. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 13 NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.1 <U>Notices</U>. All notices given under this Agreement shall be in writing and shall be given, if to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to DEKA, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">DEKA Research&nbsp;&amp; Development Corp. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">340 Commercial Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manchester, NH 030101 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: President </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">With a copy to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Maureen K. Toohey </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Toohey Law Group LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">340 Commercial Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manchester, NH 030101 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to PROKIDNEY, to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">PROKIDNEY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">329 Westpoint Blvd., Suite G </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Winston Salem, NC 27103 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attn: Deepak Jain </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">With a copy to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">PROKIDNEY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">329 Westpoint Blvd., Suite G </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Winston Salem, NC 27103 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attn: Tim Bertram </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each such
notice or other communication shall for all purposes of this Agreement be treated as effective or as having been given: (a)&nbsp;upon delivery, if personally delivered; (b)&nbsp;one (1) Business Day after
<FONT STYLE="white-space:nowrap">pre-paid</FONT> deposit for next Business Day delivery with a commercial courier service (<I>e.g.</I>, FedEx); or (c)&nbsp;five (5) Business Days after deposit, postage
<FONT STYLE="white-space:nowrap">pre-paid,</FONT> with first class airmail (which airmail must be certified or registered). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 14
GENERAL </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.1 <U>Use of Name</U>. Except in furtherance of the obligations owing under, and as contemplated by, this Agreement, no
Party to this Agreement shall employ or use the name of the other Party in any promotional materials, advertising, or other publicly communicated materials without the prior written permission of such other Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.2 <U>Indemnification by PROKIDNEY</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">a) PROKIDNEY shall indemnify, defend and hold harmless DEKA, its partners, shareholders, members, directors, managers, officers, and
employees, from and against any and all demands, claims, actions, suits, proceedings, liabilities, obligations, damages, losses, costs and expenses (including without limitation reasonable attorneys&#146; fees and disbursements) arising out of the
following: any claim of a third party (including, without limitation, by any person or entity in connection with the use of Licensed Technology tested or Commercialized by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PROKIDNEY or an Authorized Sublicensee under this Agreement , and any other third party) alleging damages
caused by any such Licensed Technology, or any component thereof, alleging product liability, negligence, personal injury, property damage, or any other cause of action of any nature seeking to impose liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">b) In the event of any claim under Section&nbsp;14.2(a), DEKA shall promptly notify PROKIDNEY of such claim, PROVIDED that failure to provide
such notice shall not release PROKIDNEY from any of its indemnification obligations hereunder unless PROKIDNEY is materially prejudiced by the delay in notification. PROKIDNEY will undertake the defense of any such claim by counsel of
PROKIDNEY&#146;s choosing and shall have control of the defense of, and have the right to compromise, any such claim. DEKA will provide PROKIDNEY with all information reasonably requested by PROKIDNEY, and will cooperate with PROKIDNEY in defending
such claim. DEKA&#146;s reasonable actual costs in connection therewith will be reimbursed by PROKIDNEY. DEKA, at its sole option, may participate in such defense through separate counsel of its own choosing and at its own cost. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">c) <U>Failure to Assume Defense</U>. In the event, PROKIDNEY, within a reasonable time after notice of any such claim, fails to undertake the
defense of such claim, DEKA, upon further notice to PROKIDNEY, shall have the right to undertake the defense, compromise or settlement of such claim, subject to PROKIDNEY&#146;s right (and continuing obligation) to assume the defense of such claim,
and subject to the DEKA&#146;s right to obtain reimbursement to which it is due from PROKIDNEY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">d) <U>No Dispute Resolution
Procedures</U>. The provisions of Section&nbsp;14.4 hereof regarding dispute resolution shall not apply to disputes with third parties arising out of this Section&nbsp;14.2, but shall apply in determining the respective obligations of PROKIDNEY and
DEKA to one another under this Section&nbsp;14.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.3 <U>Indemnification by DEKA</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">a) DEKA shall indemnify, defend and hold harmless PROKIDNEY, its partners, shareholders, members, directors, managers, officers, and
employees, from and against any and all demands, claims, actions, suits, proceedings, liabilities, obligations, damages, losses, costs and expenses (including without limitation reasonable attorneys&#146; fees and disbursements) arising out of any
claim by a third party alleging damages caused solely by the use of any Licensed Technology by DEKA, or any licensee of DEKA, outside of the ProKidney Field. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">b) In the event of any claim under Section&nbsp;14.3(a), PROKIDNEY shall promptly notify DEKA of such claim, PROVIDED that failure to provide
such notice shall not release DEKA from any of its indemnification obligations hereunder unless DEKA is materially prejudiced by the delay in notification. DEKA will undertake the defense of any such claim by counsel of DEKA&#146;s choosing and
shall have control of the defense of, and have the right to compromise, any such claim. PROKIDNEY will provide DEKA with all information reasonably requested by DEKA, and will cooperate with DEKA in defending such claim. PROKIDNEY&#146;s reasonable
actual costs in connection therewith will be reimbursed by DEKA. PROKIDNEY, at its sole option, may participate in such defense through separate counsel of its own choosing and at its own cost. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">c) <U>Failure to Assume Defense</U>. In the event, DEKA, within a reasonable time after
notice of any such claim, fails to undertake the defense of such claim, PROKIDNEY, upon further notice to DEKA, shall have the right to undertake the defense, compromise or settlement of such claim, subject to DEKA&#146;s right (and continuing
obligation) to assume the defense of such claim, and subject to the PROKIDNEY&#146;s right to obtain reimbursement to which it is due from DEKA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">d) <U>No Dispute Resolution Procedures</U>. The provisions of Section&nbsp;14.4 hereof regarding dispute resolution shall not apply to
disputes with third parties arising out of this Section&nbsp;14.3, but shall apply in determining the respective obligations of PROKIDNEY and DEKA to one another under this Section&nbsp;14.3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.4 <U>Mediation</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">a) The
Parties will attempt to settle any claim or controversy arising out of this Agreement through consultation and negotiation in good faith and a spirit of mutual cooperation for at least forty-five (45)&nbsp;days after such claim or controversy was
brought to the attention of the other Party. If such attempts fail, then the dispute will be mediated pursuant to mutually agreeable rules of mediation by a mutually acceptable mediator, having knowledge of commercial matters as contained in this
Agreement, to be chosen by the Parties within forty-five (45)&nbsp;days after written notice by one of the Parties demanding mediation. If the Parties are unable to agree on a mutually acceptable mediator, then the Parties agree that the mediator
shall be selected by the American Arbitration Association. Neither Party may unreasonably withhold consent to the selection of a mediator, and the Parties will share the costs of the mediation equally. By mutual agreement the Parties may replace
mediation with some other form of alternative dispute resolution, such as neutral fact finding or a mini-trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">b) Any dispute which the
Parties cannot resolve through negotiation, mediation or other form of ADR within six months of the date of the initial demand may then be submitted to a court of proper jurisdiction for resolution. The use of any ADR procedures will not be
construed under the doctrines of laches, waiver or estoppel to affect adversely the rights of either party to pursue its legal remedies. Nothing in this Section will prevent either party from resorting to judicial proceedings if (i)&nbsp;good faith
efforts to resolve the dispute under these procedures have been unsuccessful or (ii)&nbsp;interim relief from a court is necessary to prevent serious and irreparable injury to a Party or to others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.5 <U>Independent Contractor</U>. For all purposes related to this Agreement, each Party shall be deemed an independent contractor of the
other Party, and nothing in this Agreement shall be deemed to create a relationship of employment or agency, constitute DEKA and PROKIDNEY as partners or joint venturers, or authorize one Party to bind the other to any third party under contract or
otherwise, without the express written authorization of the other Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.6 <U>No Further Warranties</U>. Each Party hereto
acknowledges and agrees: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">a) that no representation or promise not expressly contained in this Agreement has been made by the other Party
hereto or by any of its agents, employees, representatives or attorneys concerning the subject matter of this Agreement; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">b) that this Agreement is not being entered into on the basis of or in reliance on any
promise or representation, express or implied, covering the subject matter hereof other than those which are set forth expressly in this Agreement ; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">c) that each Party has had the opportunity to be represented by counsel of its own choice in this matter, including without limitation during
the negotiations which preceded the execution of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.7 <U>DEKA Representations and Warranties</U>. DEKA represents and
warrants that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">a) DEKA Products Limited Partnership is a limited partnership duly organized, validly existing, and in good standing under
the laws of New Hampshire; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">b) DEKA Research&nbsp;&amp; Development Corp. is a corporation duly organized, validly existing, and in good
standing under the laws of New Hampshire; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">c) DEKA has the full right and power to enter into, and perform its obligations under, this
Agreement, and that, to the best of its knowledge, there are no outstanding agreements, assignments or encumbrances in existence inconsistent with the provisions of this Agreement; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">d) DEKA is the legal owner of the DEKA Intellectual Property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">e) DEKA represents, warrants and covenants that it is not, and it is not currently using, and will not in the future use, to perform the
services hereunder, the services of any person or entity, excluded or debarred pursuant to the Generic Drug Enforcement Act of 1992, 21 U.S.C. &#167;335a, as amended, or any similar state law or regulation, excluded by the Office of Inspector
General pursuant to 42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7,</FONT> et seq., or any state agency from participation in any Federal or state health care program or otherwise disqualified or restricted by the U.S. Food and Drug
Administration pursuant to 21 C.F.R. 312.70 or any other regulatory authority (a &#147;Debarred Person&#148;). DEKA further represents, warrants and covenants that, during the term of this Agreement, DEKA will not hire or employ to provide Services
under this Agreement any person or entity listed on the General Services Administration&#146;s List of Parties Excluded from Federal Programs or on the U.S. Department of Health and Human Services Office of Inspector General&#146;s List of Excluded
Individuals/Entities (each an &#147;Excluded Person&#148;). DEKA shall immediately notify PROKIDNEY in writing if it becomes aware that any person or entity (including DEKA) who is performing services hereunder is or becomes a Debarred Person or
Excluded Person, or to its knowledge, if any action, suit, claim, investigation, or other legal or administrative proceeding is pending or threatened, that would make any person or entity (including DEKA) performing services hereunder a Debarred
Person or Excluded Person, and DEKA shall ensure that such person or entity does not perform services under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.8
<U>PROKIDNEY Representations and Warranties</U>. PROKIDNEY represents and warrants that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">a) PROKIDNEY is duly organized, validly existing,
and in good standing under the laws of the Cayman Islands; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">b) PROKIDNEY has the full right and power to enter into, and perform its obligations under,
this Agreement, and that, to the best of its knowledge, there are no outstanding agreements, assignments or encumbrances in existence inconsistent with the provisions of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.9 <U>Limitation of Liability Regarding Representations and Warranties</U>. A Party shall have no liability for any breach of any
representation or warranty herein, including but not limited to any representations and warranties set forth in Sections 14.6 and 14.7, that exceeds one million U.S. dollars ($USD 1,000,000) in the aggregate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.10 <U>Force Majeure</U>. No Party shall be liable for any failure to perform as required by this Agreement to the extent such failure to
perform is caused by any reason beyond the Party&#146;s control, or by reason of any of the following: labor disturbances or disputes, accidents, civil disorders, acts of aggression, acts of God, disease, or similar occurrences. This section shall
not apply to any obligation to make any payment to the other Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.11 <U>Compliance with Anti-Corruption Laws.</U> In connection with
this Agreement, the Parties have complied and will comply with all applicable local, national, and international laws, regulations, and industry codes dealing with government procurement, conflicts of interest, corruption or bribery, including
without limitation, if applicable, the U.S. Foreign Corrupt Practices Act of 1977, as amended, and any laws enacted to implement the Organization of Economic Cooperation and Development Convention on Combating Bribery of Foreign Officials in
International Business Transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.12 <U>Assignment</U>. Neither this Agreement nor any rights hereunder may be assigned or
otherwise transferred by a Party without the prior written consent of the other Party, which consent shall not be unreasonably conditioned, withheld, or delayed, except that PROKIDNEY may assign this Agreement and its rights hereunder to a purchaser
of all or substantially all of the assets of PROKIDNEY regardless of the form of the transaction. Subject to the foregoing, this Agreement will be binding upon and inure to the benefit of the Parties and their respective successors and permitted
assigns. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.13 <U>Severability</U>. If any part of this Agreement is held (by final judicial decree) void, invalid or unenforceable, such
ruling shall not affect the validity or enforceability of the remainder of this Agreement, but such part shall be deemed modified to the extent necessary, in the opinion of the judicial authority, to render such term or condition enforceable, and
the rights and obligations of the Parties shall be construed and enforced accordingly, preserving to the fullest permissible extent the intent and agreements of the Parties as set forth in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.14 <U>Entire Agreement</U>. This Agreement contains the entire agreement between the Parties relating to the subject matter hereof. No
amendments or modifications to this Agreement shall be effective unless made in writing and signed by an authorized representative of each Party. Further, the Parties agree that the Recitals and the Attachments attached hereto are specifically
incorporated into the Agreement by reference herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.15 <U>Governing Law</U>. This Agreement shall be governed by and construed in accordance
with the laws of the State of Delaware, without giving effect to any choice of law provision or rule that would cause the application of the laws of any other jurisdiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.16 <U>No Public Announcements</U>. No Party, except as required by law, shall originate any publicity, news release or public announcement,
written or oral, whether to the public or press, stockholders or otherwise, relating to this Agreement, including without limitation its existence, the subject matter to which it relates, or any of its terms, to any amendment hereto or performance
hereunder, without the express written permission of the other Party, which permission will not be unreasonably withheld. The Parties expressly agree that PROKIDNEY may disclose the existence of this Agreement, the subject matter to which it
relates, its terms, amendments or either Party&#146;s performance hereunder, in each case to the extent such disclosure is required by the Securities Exchange Act of 1934 or any other law (&#147;Required Disclosure&#148;), which may include, without
limitation, PROKIDNEY&#146;s filing of this Agreement, or some portion thereof, with the Securities and Exchange Commission pursuant to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or other Exchange Act report. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.17 <U>Compliance with Export Laws</U>. This Agreement is subject to any law, regulation, order or other restriction on the export or <FONT
STYLE="white-space:nowrap">re-export</FONT> of technology licensed under this Agreement as may be imposed from time to time by the governments of the United States, or any other country, or any agency thereof. No Party shall knowingly export or <FONT
STYLE="white-space:nowrap">re-export</FONT> or cause to be exported or <FONT STYLE="white-space:nowrap">re-</FONT> exported, directly or indirectly, any technology licensed under this Agreement from any other Party to any country for which the
United States or any other government, or any agency thereof, requires an export license or other government approval at the time of such export without first obtaining any required license or approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.18 <U>Amendments; Waivers</U>. No provision of this Agreement may be waived except by an instrument in writing executed by the Party
against whom the waiver is to be effective. No provision of this Agreement may be amended or otherwise modified except by an instrument in writing executed by or on behalf of the Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.19 <U>Counterparts</U>. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and
all of which together shall be deemed to be one and the same instrument. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.20 <U>Headings</U>. The headings contained in this Agreement
are for convenience only and shall not affect the meaning or interpretation of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>***Signature Page Follows*** </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties hereto have executed this Agreement by their duly authorized
officers or representatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">DEKA PRODUCTS LIMITED PARTNERSHIP</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">By DEKA Research&nbsp;&amp; Development Corp., its sole general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Dean Kamen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Dean Kamen, President</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">DEKA RESEARCH&nbsp;&amp; DEVELOPMENT CORP.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Dean Kamen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Dean Kamen, President</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: January 16, 2022 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">PROKIDNEY</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Pablo Legorreta</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pablo Legorreta</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Signature Page to DEKA
PROKIDNEY RDEL Agreement </I></P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>5
<FILENAME>d373959dex1015.htm
<DESCRIPTION>EX-10.15
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.15</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.15 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MASTER SERVICES AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Master Services Agreement (&#147;Agreement&#148;) is made effective as of April&nbsp;20, 2020 (&#147;Effective Date&#148;) by and between
inRegen, a Cayman Islands company, which has a place of business at 10 Market St., #688 Camana Bay, Grand Cayman <FONT STYLE="white-space:nowrap">KY1-9006</FONT> Cayman Islands (&#147;Customer&#148;) and IQVIA RDS Inc. a North Carolina corporation
having its principal place of business at 4820 Emperor Boulevard, Durham, NC 27703 USA, IQVIA Ltd. a company organized under the laws of England and Wales having its principal place of business at 3 Forbury Place, 23 Forbury Road, Reading, United
Kingdom, RG1 3JH, and IQVIA RDS East Asia Ltd. a company organized under the laws of Singapore having its principal place of business at 79 Anson Road, <FONT STYLE="white-space:nowrap">#19-01,</FONT> Singapore 079906 (collectively
&#147;IQVIA&#148;). When signed by the parties, this Agreement will set forth the terms and conditions under which IQVIA agrees to provide certain services to Customer as set forth herein. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Recitals: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. Customer is
in the business of developing, manufacturing and/or distributing pharmaceutical products and/or biotechnology products. IQVIA is in the business of providing clinical trial services, research, and other services for the pharmaceutical, medical
device and biotechnology industries. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. Customer and IQVIA desire to enter into this Agreement to provide the terms and conditions upon
which Customer or its affiliates may engage IQVIA or its affiliates from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">time-to-time</FONT></FONT> to provide services for individual studies or projects by executing individual Work
Orders (as defined below) specifying the details of the services. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Agreement: </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Agreement and Work Orders. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Scope of Agreement.</U> As a master form of contract, this Agreement allows the parties to contract for
multiple projects through the issuance of multiple Work Orders (as discussed in Section&nbsp;1.3 below), without having to <FONT STYLE="white-space:nowrap">re-negotiate</FONT> the basic terms and conditions contained herein. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Nature of Services.</U> The services covered by this Agreement may include strategic planning, expert
consultation, clinical trial services, statistical programming and analysis, data processing, data management, regulatory, project management, pharmacovigilance, central laboratory services, clinical pharmacology services, electrocardiogram (ECG)
services, the IQVIA Technology services (as defined in Section&nbsp;5.3), and other services requested by Customer, and agreed to by IQVIA as set forth in the relevant Work Order (collectively, the &#147;Services&#148;). IQVIA and Customer, where
appropriate or required by law, shall cooperate in the completion of a Transfer of Obligations Form in conjunction with the relevant Work Order. Any responsibilities not specifically transferred in the Transfer of Obligations Form shall remain the
regulatory responsibility of Customer. The Transfer of Obligations Form will be filed with the Food and Drug Administration (&#147;FDA&#148;) by Customer where appropriate, or as required by law or regulation. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Work Orders.</U> The specific details of the Services for each project under this Agreement (each a
&#147;Project&#148;) shall be set forth in a work order signed by the parties (a &#147;Work Order&#148;). A form Work Order is attached hereto as Exhibit A. Each Work Order will include, as appropriate, the scope of work, time line, and budget and
payment schedule. Each Work Order shall be subject to all of the terms and conditions of this Agreement, in addition to the specific details set forth in the Work Order. To the extent any terms or provisions of a Work Order conflict with the terms
and provisions of this Agreement, the terms and provisions of this Agreement shall control, except to the extent that the applicable Work Order expressly and specifically states an intent to supersede this Agreement on a specific matter. All
exhibits hereto shall be deemed to be incorporated herein by reference. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Change Orders.</U> Any change in the details of a Work Order or the assumptions upon which the Work Order is
based, that requires changes in the budget and/or time lines, shall require a written amendment to the Work Order (a &#147;Change Order&#148;) executed by both parties. IQVIA reserves the right to postpone effecting material changes in the
Project&#146;s scope until such time as the parties agree to and execute the corresponding Change Order. For any Change Order that affects the scope of the regulatory obligations that have been transferred to IQVIA, IQVIA and Customer shall execute
a corresponding amendment to the Transfer of Obligations Form. Customer shall file such amendment with the FDA as required by law or regulation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Relationship with Affiliates.</U> IQVIA may use the services of its affiliates as subcontractors to fulfill
IQVIA&#146; s obligations under this Agreement or any Work Order, provided that (a)&nbsp;the affiliate shall be bound in writing by confidentiality and intellectual property provisions at least as restrictive as those contained herein and
(b)&nbsp;the IQVIA entity that is the party to the Work Order shall remain responsible for all such Services performed by its affiliates. Any affiliate of IQVIA or Customer may enter into a Work Order under this Agreement. The terms, conditions and
rights in this Agreement shall be incorporated into the Work Order. The term &#147;affiliate&#148; shall mean all entities controlling, controlled by or under common control with IQVIA or Customer, as the case may be. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Payment of Fees and Expenses. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Project Budget.</U> Customer will pay IQVIA the fees, expenses and pass-through costs in accordance with the
budget and payment schedule contained in each Work Order. Depending on the estimated cash flow of the Project and the payment terms, Customer agrees that a prepayment may be needed for IQVIA to maintain cash neutrality over the term of the Project.
For Projects extending over more than one calendar year, the budget may include an annual cost adjustment. </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">The parties
hereby authorize the IQVIA entity that is party to each Work Order to invoice, collect, and receive, in the applicable affiliate&#146;s name and on behalf of such affiliate, for all Services rendered by such affiliate pursuant to this Agreement and
all other amounts payable to such affiliate under each Work Order. Unless the applicable affiliate and IQVIA otherwise agree to a different form and timing of remittance, IQVIA shall remit to the applicable affiliate the portion of the payments
collected or received from Customer on behalf of the affiliate for its provision of Services pursuant to this Agreement and undertaking of the related functions, activities and risks associated with the performance of Services. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Invoices.</U> IQVIA will invoice Customer in accordance with the budget and payment schedule in each Work
Order for IQVIA&#146;s fees, and monthly for its expenses and pass-through costs incurred in performing the Services. All invoice payments shall be made to IQVIA within thirty (30)&nbsp;days of the invoice date if an invoice is delivered
electronically, or from the date of receipt if Customer requests a paper invoice, except for prepayment and investigator invoices as required in a Work Order, which are due and payable upon receipt. Expenses and pass-through costs will be supported
by a detailed summary sheet. If any portion of an invoice is disputed, then Customer shall pay the undisputed amounts as set forth above and the parties shall use good faith efforts to reconcile the disputed amount as soon as practicable. IQVIA
reserves the right to impose, and Customer agrees to pay if imposed by IQVIA, interest from thirty (30)&nbsp;days after the due date of the invoice in an amount equal to one percent (1%) per month (or the maximum lesser amount permitted by law) of
all undisputed amounts owing hereunder. If Customer requires a purchase order (&#147;PO&#148;) related to an IQVIA invoice, then Customer will provide the PO prior to invoicing by IQVIA. If no PO is provided, IQVIA will invoice Customer without the
PO. If resubmission of an invoice is required based on Customer&#146;s PO requirement or based upon Customer request, IQVIA&#146;s <FONT STYLE="white-space:nowrap">re-submission</FONT> of that invoice will not change the due date for payment based
on the original invoice. Any provisions contained within a PO that modify, conflict with or contradict any term or provision of this Agreement shall be deemed to be null and void. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Taxes.</U> Customer shall pay all sales and use taxes, including all applicable goods and services tax,
value added tax, local taxes, applicable duties, electronic delivery taxes, excise taxes, levies and import fees (collectively, &#147;Taxes&#148;) that are imposed by legislation in connection with the provision of Services and that are not
recoverable by IQVIA. All fees set forth in a Work Order are exclusive of Taxes. Where Taxes are paid by IQVIA, IQVIA will provide an invoice showing the Taxes included. Where any Taxes are paid directly to a tax authority or government by Customer,
Customer shall not deduct this amount from any amount due to IQVIA. The requirements of this provision shall not apply to any employment-related taxes, duties, income taxes or withholding and shall only apply to Taxes applicable to the Services.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Foreign Currency Exchange.</U> The currency to be used for invoicing and payment shall be the currency
stated in the budget or table attached to the applicable Work Order (the &#147;Contract Currency&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Pass-Through Costs.</U> If IQVIA incurs pass-through costs in a currency other than the Contract Currency,
then Customer shall reimburse IQVIA for IQVIA&#146;s actual costs in the Contract Currency based on the Oanda foreign currency exchange rate (<U>Oanda.com</U>) for the applicable currencies on the last business day of the month immediately preceding
the month in which such pass-through costs are paid by IQVIA. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>IQVIA&#146; s Fees.</U> If any Work Order involves the performance of Services by IQVIA or its affiliates in
any country that uses a currency other than the Contract Currency, the Budget for those Services will be based on the local rates in the currency used by IQVIA for pricing in that country (the
<FONT STYLE="white-space:nowrap">&#147;Non-Contract</FONT> Currency&#148;), but converted to and reflected in the Contract Currency based on the Oanda foreign currency exchange rate (<U>Oanda.com</U>) for the applicable currencies on the last
business day of the month immediately preceding the month in which such fees are invoiced to Customer by IQVIA. If the portion of the fees based on <FONT STYLE="white-space:nowrap">Non-Contract</FONT> Currencies exceeds the equivalent of US
$3,000,000 (based on the assumptions in the Budget) in any Work Order, inclusive of executed Change Orders, IQVIA will perform an annual reconciliation (at the anniversary of the effective date of the applicable Work Order each year during the term
&#151; the &#147;Contract Anniversary&#148;) of the fees billed in the 12 months prior to the Contract Anniversary compared to the fees that would have been billed based on the application of the Oanda quarterly weighted average Contract Currency
exchange rates to <FONT STYLE="white-space:nowrap">Non-Contract</FONT> Currency fees. The reconciliation will be performed on the final invoice if the term of the applicable Work Order is less than 12 months. If the reconciliation establishes a
difference of more than 3%, plus or minus, the amount exceeding 3% will be charged or credited to Customer. By way of example only, if the amount of fees billed in <FONT STYLE="white-space:nowrap">Non-Contract</FONT> Currencies is $1,000,000 in the
12 months prior to the annual reconciliation, and the annual reconciliation determines that the amount that would have been billed during this same time period utilizing the quarterly foreign currency exchange rates equals $950,000, then the
difference equals $50,000, or 5%. Under this example, IQVIA would credit to Customer the amount of $20,000 ($50,000&#151;(3% x $1,000,000)). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Information Requests.</U> If Customer has failed to make any undisputed payments hereunder, and does not
cure such failure within five (5)&nbsp;business days of its receipt of written notice thereof, IQVIA may request that Customer share financial details (such as audited financials, if available) that reasonably demonstrate Customer&#146;s continuing
ability to meet its payment obligations under this Agreement and associated Work Orders (each, an &#147;Information Request&#148;). If Customer declines to provide such financial data within thirty (30)&nbsp;days, then IQVIA may, at its discretion,
notify Customer and deliver an invoice to the Customer, which the Customer agrees to pay upon request, for an additional deposit for a value of up to two (2)&nbsp;months estimated fees and expenses under the applicable Work Order following the date
of notification, with this deposit to be held until the end of the Project and then reconciled against final invoices for the Project. Additionally, Customer shall promptly notify IQVIA upon becoming insolvent or commencing bankruptcy proceedings.
Any information shared with IQVIA pursuant to an Information Request will be subject to IQVIA&#146;s obligations of confidentiality set forth in Section&nbsp;4.1. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Term and Termination. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Term.</U> This Agreement shall commence on the Effective Date and shall continue for a period of five
(5)&nbsp;years, or until terminated by either party in accordance with this Section 3. The Agreement will automatically renew each year thereafter for a period of one year, unless either party notifies the other party in writing at least ninety
(90)&nbsp;days prior to the renewal date that the notifying party does not want to renew the Agreement. If this Agreement expires but a Work Order hereunder has not been completed or terminated, the terms of this Agreement will continue to apply to
such Work Order as if the Agreement had not expired until such Work Order is completed or terminated. Termination of this Agreement shall terminate all Work Orders. Termination of Work Order shall not result in termination of this Agreement.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination without Cause.</U> Customer may terminate this Agreement or any Work Order without cause at any
time during the term of the Agreement on sixty (60)&nbsp;days&#146; prior written notice to IQVIA. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Termination for Cause.</U> Either party may terminate this Agreement or any Work Order (and to the extent
IQVIA is providing Local or Legal Representation Services, it may terminate the provision of such Services) for material breach upon thirty (30)&nbsp;days&#146; written notice specifying the nature of the breach, if such breach has not been
substantially cured within the thirty (30)&nbsp;day period, provided, however, in the event Customer fails to timely pay any undisputed amounts, IQVIA may at its discretion upon providing five (5)&nbsp;business days prior written notice thereof,
cease extension of credit privileges to Customer; suspend Services (including data transmission) except to the extent that any suspension would reasonably be expected to cause harm to any subject in a clinical trial; and/or withhold payment of
refunds to Customer until such undisputed amounts are paid. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Standards.</U> If IQVIA reasonably determines that its continued performance of the Services contemplated by
one or more Work Orders would constitute a potential or actual violation of regulatory, scientific or ethical standards of integrity, then IQVIA may, in the case of any actual violation, suspend Services under the applicable Work Order(s) (and to
the extent IQVIA is providing Local or Legal Representation Services, it may suspend the provision of such Services) by giving written notice stating the effective date (which may be less than thirty (30)&nbsp;days from the notice date) of such
suspension. The parties shall then cooperate to negotiate a Change Order for the applicable Work Order to correct such potential or actual violation, upon which IQVIA shall resume the Services. If the parties fail to execute a Change Order within
forty-five (45)&nbsp;days following the suspension of Services, either party may terminate the Work Order. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Bankruptcy.</U> Either party may terminate this Agreement or any Work Orders immediately upon provision of
written notice if the other party becomes insolvent or files for bankruptcy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Identification of Work Order.</U> Any written termination notice shall identify the specific Work Order or
Work Orders that are being terminated. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Payment.</U> Customer shall pay IQVIA for all Services performed and reimburse IQVIA for all costs and
expenses incurred in accordance with this Agreement and any applicable Work Order, even if the parties&#146; original payment schedule spreads out payments for certain services or defers payments for certain services until the end of the Project,
with payments to include all <FONT STYLE="white-space:nowrap">non-cancelable</FONT> and <FONT STYLE="white-space:nowrap">non-avoidable</FONT> costs incurred prior to termination but paid after the termination date. If payments are unit or milestone
based, and the Agreement or a Work Order is terminated after costs have been incurred toward achieving portions of one or more incomplete units or milestones, Customer will pay IQVIA on a <FONT STYLE="white-space:nowrap">pro-rated</FONT> basis for
actual work performed toward those incomplete units or milestones up to the date of termination, in addition to paying for completed units or milestones. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Closeout.</U> Upon termination of a Work Order, the parties shall promptly meet to prepare a <FONT
STYLE="white-space:nowrap">close-out</FONT> schedule, and IQVIA shall cease performing all work not necessary for the orderly <FONT STYLE="white-space:nowrap">close-out</FONT> of the Services or required by laws or regulations. Customer shall pay
for all actual costs, including time spent by IQVIA personnel (at the agreed upon rates), incurred to complete activities reasonably necessary for the termination and <FONT STYLE="white-space:nowrap">close-out</FONT> of affected Projects, including
the fulfillment of any regulatory requirements. In addition, if the termination is by Customer without cause, or by IQVIA for cause, Customer shall also pay IQVIA for any IQVIA personnel exclusively assigned to the affected Projects at the rates set
forth in the Work Order (provided that such personnel&#146;s time is not already being billed for <FONT STYLE="white-space:nowrap">close-out</FONT> Services) from the date of termination until such personnel have been assigned to another project, or
until forty-five (45)&nbsp;days from the date of termination, whichever comes first. IQVIA shall make all reasonable efforts to promptly <FONT STYLE="white-space:nowrap">re-assign</FONT> such personnel. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Confidentiality. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Confidential Information.</U> Customer and its affiliates possess certain confidential and proprietary data
and information, including without limitation Customer Technology (as defined in Section&nbsp;5.1 below) and Customer Property (as defined in Section&nbsp;5.2 below) (&#147;Customer Confidential Information&#148;), and IQVIA and its affiliates
possess certain confidential and proprietary information pertaining to its operations, methods and pricing, including without limitation IQVIA Property (as defined in Section&nbsp;5.2 below)(&#147;IQVIA Confidential Information&#148;) (Customer
Confidential Information and IQVIA Confidential Information, including the terms of this Agreement and any Work Order, are each referred to herein as &#147;Confidential Information&#148;). &#147;Confidential Information&#148; does not include
information that is (a)&nbsp;already in the receiving party&#146;s possession at the time of disclosure, as evidenced by the receiving party&#146;s prior written records; (b)&nbsp;part of or becomes part of the public domain through no fault of the
receiving party; (c)&nbsp;received from a third party authorized to provide it; or (d)&nbsp;independently developed by the receiving party, as evidenced by the receiving party&#146;s contemporaneous written records. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Obligations.</U> The Confidential Information shall be used by the receiving party, its affiliates and their
employees only for purposes of performing the receiving party&#146;s obligations hereunder. Each party shall keep confidential all Confidential Information received from the other party or its affiliates, and will not disclose or publish
Confidential Information to third parties without the other party&#146;s prior written consent, provided, however, that IQVIA may disclose limited Confidential Information to third parties performing on behalf of IQVIA or Customer in connection with
this Agreement who have a need to know such Confidential Information, provided that such third party is not a </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">competitor of Customer and is bound by confidentiality obligations substantially similar to those set forth herein. Upon the disclosing party&#146;s request or upon completion of the Services, the receiving party shall
promptly cease all use of the disclosing party&#146;s Confidential Information and return it to the disclosing party or, at the disclosing party&#146;s option, certify to the destruction of all Confidential Information; provided, however, that the
receiving party may retain one copy of the disclosing party&#146;s Confidential Information for archival purposes only and Customer may retain IQVIA Confidential Information that is incorporated into any work product and deliverables. These
obligations of confidentiality and nondisclosure shall remain in effect for a period of five (5)&nbsp;years after the completion or termination of this Agreement or the applicable Work Order, whichever is later. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Permitted Disclosures.</U> The receiving party may disclose the disclosing party&#146;s Confidential
Information to the extent required pursuant to any judicial or administrative process or order; provided that the receiving party shall, as soon as practicable and where not prohibited, prior to any such disclosure, give the disclosing party
sufficient notice and reasonable assistance to contest such requirement or order should it wish to do so. The receiving party agrees to reasonably cooperate with the disclosing party, at disclosing party&#146;s expense, in seeking any protective
order or other remedy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Publicity.</U> Neither party will use the other party&#146;s name in connection with any publication or
promotion without the other party&#146;s prior express written consent. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Equitable Relief.</U> The parties recognize that any threatened breach or breach of this
Section&nbsp;4&nbsp;may cause irreparable harm that may be inadequately compensable in damages and that, in addition to other remedies that may be available at law or equity, a party is entitled to seek injunctive relief for such threatened or
actual breach, and the entry of such injunctive relief, shall not preclude a party from seeking any damages or other relief to which it may be entitled under law. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Ownership and Inventions. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Customer Property.</U> Excluding IQVIA Property (as defined below), all data and information provided by
IQVIA to Customer as deliverables under this Agreement, and any inventions that are conceived of as the direct result of Services performed by IQVIA under this Agreement, and all intellectual property rights thereto, shall be the sole property of
Customer (&#147;Customer Property&#148;). IQVIA hereby assigns title and interest in all Customer Property to Customer. At Customer&#146;s request and expense, IQVIA shall, and shall cause its affiliates and employees to, execute all documents and
take all actions that Customer reasonably deems necessary to perfect Customer&#146;s ownership of the Customer Property. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>IQVIA Property.</U> IQVIA Property is defined as data, data models, databases, inventions, processes, <FONT
STYLE="white-space:nowrap">know-how,</FONT> copyrights, trade secrets, analytical methods, procedures and techniques, manuals, personnel data, pricing, financial information, technical expertise, software, and other intellectual property rights that
are owned by IQVIA or its affiliates prior to the Effective Date. IQVIA Property shall include property that is independently developed by or for IQVIA and its affiliates without incorporation of Customer&#146;s Confidential Information or
Intellectual Property; and any improvements, modifications and enhancements made to the foregoing during the term of this Agreement that do not incorporate any Customer Confidential Information or Intellectual Property. IQVIA and its affiliates own
all right title and interest in and to the IQVIA Property. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>IQVIA Technology.</U> IQVIA Property shall also include its proprietary systems, platforms and applications
(collectively, the &#147;IQVIA Technology&#148;). To the extent that IQVIA provides Services using the IQVIA Technology, Customer grants to IQVIA all rights necessary to use and manage the data entered into the IQVIA Technology solely for the
benefit of Customer and in accordance with this Agreement and applicable laws. If permitted in the applicable Work Order, pursuant to the terms and conditions of this Agreement and that Work Order, Customer shall have the <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> right, during the term specified in that Work Order, to use the IQVIA Technology. Upon expiration or termination of the applicable Work Order, Customer shall promptly cease use of the IQVIA Technology.
Customer shall have no right to use the IQVIA Technology for any purpose other than specifically allowed under this Agreement. IQVIA makes no representations or warranties as to the accuracy of the data entered into the IQVIA Technology provided to
IQVIA or entered by Customer or third parties. IQVIA does not warrant that use of the IQVIA Technology will be uninterrupted or error free, nor does IQVIA make any warranty as to the results to be obtained from the use of the IQVIA Technology.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">5.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Except as otherwise stated in this Agreement or any Work Order, THE IQVIA TECHNOLOGY, THE SERVICES AND THE
DELIVERABLES DELIVERED HEREUNDER ARE PROVIDED AND DISTRIBUTED ON AN &#147;AS IS&#148; BASIS WITHOUT WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF TITLE,
<FONT STYLE="white-space:nowrap">NON-INFRINGEMENT,</FONT> MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Records and Materials. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Maintenance of Records.</U> IQVIA shall maintain and retain records relating to the Services and Projects as
provided in each Work Order and per IQVIA SOPs. IQVIA shall ensure that records are protected from destruction or damage and are maintained within IQVIA&#146;s control during the Term of each Work Order unless agreed upon otherwise in a Post-Study
Archiving Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">6.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Return of Customer Materials.</U> At the completion of the Services under a Work Order or upon termination
of this Agreement, IQVIA will deliver to Customer all materials, information and all other data owned by Customer, regardless of the method of storage or retrieval, in such form as is then currently in the possession of IQVIA or as specified in a
Work Order. IQVIA, however, reserves the right to retain, at its own cost and subject to the confidentiality provisions herein, one (1)&nbsp;copy of information as necessary to satisfy regulatory requirements or to resolve disputes regarding the
Services. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Relationship of the Parties. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Independent Contractor.</U> The parties hereto are independent contractors and nothing contained in this
Agreement shall be construed to place them in the relationship of partners, principal and agent, employer/employee or joint venturers. Neither party shall have the power nor right to bind or obligate the other party, and neither party shall hold
itself out as having such authority. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Local Representative.</U> If Customer desires to conduct a trial in one or more countries that require a
local sponsor or representative (the &#147;Local Representative&#148;): (a) to indemnify sites for harm caused by the trial drug, or (b)&nbsp;otherwise assume primary responsibility for: (i)&nbsp;the trial drug, (ii)&nbsp;acting as the importer of
record for any trial drug, devices or other goods, or (iii)&nbsp;the trial in general, including without limitation any procedures required by the protocol, Customer may request that IQVIA serve as Local Representative in such countries and IQVIA
will confirm in writing whether or not it agrees that one or more of its affiliates will act as Local Representative for Customer for a particular project or trial (&#147;Local Representation Services&#148;). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">7.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Legal Representative in European Union.</U> If Customer is not based in the European Union (&#147;EU&#148;)
and services will be performed in the EU, Customer may request that IQVIA serve as its legal representative in the EU and IQVIA will confirm in writing whether or not it agrees that one or more of its affiliates will act as Legal Representative for
Customer for a particular project or trial. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Regulatory Compliance. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>General.</U> IQVIA agrees that its Services will be conducted in compliance with all applicable laws, rules
and regulations, with the standard of care customary in the contract research organization industry. IQVIA&#146;s standard operating procedures will be used in performance of the Services, unless otherwise specifically stated in the applicable Work
Order. Customer further represents that it will reasonably cooperate with IQVIA in taking any actions necessary to comply with the regulatory obligations that have been transferred to IQVIA pursuant to a Transfer of Obligations Form.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Debarment.</U> IQVIA represents that it is not and has never been, and neither its employees nor its
affiliates&#146; employees, nor any subcontractor who will be rendering Services hereunder is currently, (a)&nbsp;debarred or voluntarily excluded or convicted of a crime for which a person can be debarred under 21 U.S.C. &#167; 335(a), as amended,
or any equivalent thereof, in any country in which any portion of the Services are conducted, nor (b)&nbsp;to IQVIA&#146;s knowledge, threatened to be debarred or voluntarily excluded or indicted for a crime or otherwise engaged in conduct for which
a person can be debarred under &#167; 335(a), or subject to any governmental sanction that would prevent the rendering of Services hereunder in any jurisdiction in which the study is to be conducted, nor (c)&nbsp;excluded from participation in any
federally-funded health-care program. In the event that, during the Term, IQVIA becomes so debarred or excluded, IQVIA shall promptly notify Customer and, upon receipt of such notice, Customer shall have the right to terminate this Agreement
immediately. In the event that, during the Term, IQVIA becomes aware of the debarment or exclusion any person or entity providing Services under this Agreement, IQVIA shall notify Customer promptly and cease activities with such person or entity in
connection with the Services. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Data Protection.</U> Both parties shall at all times abide by all applicable privacy laws and regulations,
and this Agreement, including the Data Processing Agreement attached in Exhibit B. In addition, IQVIA shall at all times abide by its privacy policies and Customer&#146;s instructions when processing personal data under this Agreement. If the
Services will involve the collection or processing of personal data (as defined by applicable data protection legislation) within the European Union (&#147;EU&#148;), then Customer shall serve as the controller of such personal data, as defined by
the General Data Protection Regulation (Regulation (EU) 2016/679 Regulation of the European Parliament and the Council on the Protection of individuals with regard to the processing of personal data and on the free movement of such data)
(&#147;GDPR&#148;), and IQVIA shall act only under the instructions of the Customer in regard to such personal data. If Customer is not based in the EU, Customer must appoint a third party to act as its local data protection representative or
arrange for a <FONT STYLE="white-space:nowrap">co-controller</FONT> established in the EU for data protection purposes in order to comply with GDPR as IQVIA does not provide this service. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">8.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Pharmacovigilance Databases and Systems.</U> In the event a project does not utilize IQVIA&#146; s
Pharmacovigilance Databases and System, Customer shall be responsible for verifying such systems and databases are of an adequate standard and compliant with applicable law. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Audits and Regulatory Inspections. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Customer Audits.</U> During the term of this Agreement, IQVIA will permit Customer&#146;s representatives
(provided that (a)&nbsp;such representatives are not competitors of IQVIA; and (b)&nbsp;prior to any audit Customer shall procure that its <FONT STYLE="white-space:nowrap">non-employee</FONT> representative enter into a confidentiality agreement
with IQVIA on terms at least as stringent as the confidentiality terms herein) to examine or audit the work performed hereunder and the facilities at which the work is conducted upon reasonable advance notice during regular business hours to
determine that the Project assignment is being conducted in accordance with the agreed task and that the facilities utilized are adequate. Customer agrees that it shall not disclose to any third party any information ascertained by Customer in
connection with any such audit or examination, except to the extent required by law or regulation. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Regulatory Inspections.</U> Each party acknowledges that the other party may respond independently to any
regulatory correspondence or inquiry in which such party or its affiliates is named. Each party, however, shall notify the other party promptly of any FDA or other governmental or regulatory inspection or inquiry concerning any study or Project of
Customer for which IQVIA is providing Services. During any such inspection or inquiry, the parties agree to make reasonable efforts to disclose only the information required to be disclosed. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">9.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Audit and Inspection Costs.</U> Except as provided below, Customer shall reimburse IQVIA for its time and
expenses (including reasonable attorney fees and the costs of responding to findings) associated with any inspection, audit or investigation relating to the Services instigated by Customer or by a governmental authority, unless and to the extent
such inspection, audit or investigation reveals that IQVIA breached this Agreement or any applicable law or regulation; provided, however, during the term of this Agreement Customer shall have the right to audit IQVIA once per year for up to five
(5)&nbsp;days and to conduct reasonable follow up to an audit revealing IQVIA&#146;s breach of this Agreement or any applicable law or regulation, each at IQVIA&#146; s cost (excluding expenses). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Investigators. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Agreements with Investigators.</U> If the applicable Work Order provides that IQVIA will enter into
agreements with investigators or investigative sites (collectively, &#147;Investigators&#148;), IQVIA will use its local Clinical Trial Agreement forms (&#147;CTAs&#148;) unless an industry-standard form is required in the country in question or a
site-specific form is required by a site that has been selected. If no local CTA, site-specific or industry-standard form exists for the country or Investigator as applicable, IQVIA will use its global CTA. Any applicable Local CTAs,
industry-standard forms, site-specific forms, and the Global CTA will be made available for inspection and approval by the Customer. IQVIA and Customer will mutually agree upon CTA negotiation guidelines (the &#147;CTA Guidelines&#148;) in order to
allow IQVIA to negotiate CTAs on the Customer&#146;s behalf. If an Investigator insists upon any material changes to any provisions that are not allowed under or addressed by the CTA Guidelines, IQVIA shall submit the proposed change to Customer,
and Customer shall review, comment on and/or approve such proposed changes within ten (10)&nbsp;working days. IQVIA&#146;s responsibilities with respect to Investigators shall be limited to those responsibilities specifically set forth in this
Agreement or the applicable Work Order. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">10.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Payment to Investigators.</U> If IQVIA will be paying Investigators on behalf of Customer: (a)&nbsp;IQVIA
will only pay Investigators from <FONT STYLE="white-space:nowrap">pre-payments</FONT> received from Customer, (b)&nbsp;IQVIA will not be responsible for delays in a study or Project to the extent that such delays are caused by Customer&#146;s
failure to make such <FONT STYLE="white-space:nowrap">pre-payment,</FONT> and (c)&nbsp;such payments to Investigators will be separate from payments to IQVIA for its Services. When Customer must publicly report to certain government or regulatory
authorities, information regarding payments or transfers of value made to certain healthcare professionals by or on behalf of Customer to comply with applicable law, IQVIA will prepare and submit financial reports to Customer on a quarterly basis in
a mutually agreeable format. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Anti-Bribery. </B>Each party undertakes to the other party that: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">it will not, and will procure that each of its affiliates and each of their respective employees, directors,
officers, subcontractors and agents will not, (i)&nbsp;offer, promise or give an advantage to another person, or (ii)&nbsp;request, agree to receive or accept a financial or other advantage in violation of any anticorruption laws, rules, regulations
and decrees applicable to the respective party (collectively, &#147;Legislation&#148;), including the United States Foreign Corrupt Practices Act, as amended, the United Kingdom Bribery Act 2010 and any implementing legislation under the OECD
Convention Against the Bribery of Foreign Government Officials in International Business Transactions. It is each party&#146;s responsibility to be familiar with, and comply with, the provisions of the applicable Legislation; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">from time to time, at the reasonable request of the other party, it will confirm in writing that it has
complied with its undertakings under Section&nbsp;11(a) above and will provide any information reasonably requested by the other party in support of such compliance. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Limitation of Liability. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Consequential Damages.</U> Except for breach of Section&nbsp;4 (Confidentiality), neither IQVIA, Customer,
their affiliates nor any of their respective directors, officers, employees, subcontractors or agents shall have any liability (including without limitation, contract, negligence and tort liability) for any loss of profits, opportunities or goodwill
or any type of indirect or consequential damages in connection with this Agreement or any Work Order or the Services performed by IQVIA. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Direct Damages Cap.</U> Except for breach of Section&nbsp;4 (Confidentiality), or in connection with the
obligations under Section&nbsp;13 (Indemnification) to the extent any claim involves the gross negligence, willful misconduct, or in connection with Third Party Claims for which the third party is not a governmental or regulatory agency, in no event
shall the collective, aggregate liability (including without limitation, contract, negligence and tort liability) of IQVIA or its affiliates, directors, officers, employees, subcontractors or agents under this Agreement exceed the amount of fees
actually received by IQVIA from Customer under the applicable Work Order. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">12.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Damages.</U> For purposes of this Section&nbsp;12, the following, additionally and without limitation, will
be deemed to be direct damages and not consequential damages: (a)&nbsp;court costs and reasonable attorneys&#146;, accounting and other consulting fees and expenses, (b)&nbsp;necessary and appropriate investigatory and third party forensics provider
fees and expenses for the purpose of determining if data was subject to unauthorized access or misappropriation, governmental and regulatory fines, penalties, assessments and/or settlements, (c)&nbsp;the reasonable costs of providing notice to
government or regulatory agencies, media, the public and/or affected individuals whose personal information was misappropriated, provided that any notice is legally required to be provided, (d)&nbsp;the reasonable costs of remediation (including the
cost of twelve (12)&nbsp;months of credit monitoring for individuals whose personal information was misappropriated, call center support and identity theft protection). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Customer Indemnification.</U> Customer shall indemnify, defend and hold harmless IQVIA and its affiliates,
and its and their directors, officers, employees and agents (each, an &#147;IQVIA Indemnified Party&#148;), from and against any and all losses, damages, liabilities, fines, reasonable attorney fees, court costs, and expenses (collectively
&#147;Losses&#148;), resulting or arising from any third-party claims, actions, proceedings, investigations (including subpoenas or other legal process) or litigation (&#147;Third-Party Claims&#148;) arising from this Agreement, any Work Order, or
the Services contemplated herein (including, without limitation, any Losses arising from or in connection with the provision of Local Representation Services and/or any device, product or potential product to which this Agreement or any Work Order
relates), except to the extent such Losses result directly from (a)&nbsp;the gross negligence or intentional misconduct of IQVIA or any IQVIA Indemnified Party or (b)&nbsp;breach of its obligations under this Agreement by IQVIA.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>IQVIA Indemnification.</U> IQVIA shall indemnify, defend and hold harmless Customer and its affiliates, and
its and their directors, officers and employees (each, a &#147;Customer Indemnified Party&#148;), from and against any and all Losses, resulting or arising from any Third-Party Claims arising from this Agreement, any Work Order, or the Services
contemplated herein, to the extent such Losses result directly from (a)&nbsp;the gross negligence or intentional misconduct of IQVIA or any IQVIA Indemnified Party or (b)&nbsp;breach of its obligations under this Agreement by IQVIA.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">13.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Indemnification Procedure.</U> A party seeking indemnification or reimbursement hereunder shall give the
other party prompt notice of any such claim or lawsuit (including a copy thereof) served upon it and shall fully cooperate with the indemnifying party and its legal representatives in the investigation of any matter the subject of indemnification.
The party seeking indemnification shall not unreasonably withhold its approval of the settlement of any claim, liability, or action covered by Section&nbsp;13.1 or Section&nbsp;13.2, as applicable, will cooperate with counsel of the indemnifying or
reimbursing party, and reserves the right to engage its own counsel at the indemnified party&#146;s expense. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Cooperation; Disclosure of Hazards. </B>Customer shall forward to IQVIA in a timely manner all documents,
materials and information in Customer&#146;s possession or control necessary for IQVIA to conduct the Services. IQVIA shall not be liable to Customer nor be deemed to have breached this Agreement for errors, delays or other consequences arising from
Customer&#146;s failure to timely provide documents, materials or information or to otherwise cooperate with IQVIA in order for IQVIA to timely and properly perform its obligations, and any such failure by Customer shall automatically extend any
timelines affected by a time period reasonably commensurate to take into account such failure, unless Customer agrees in writing to pay any additional costs that would be required to meet the original timeline. Customer shall provide IQVIA with all
information available to Customer regarding known or potential hazards associated with the use of any substances supplied to IQVIA by Customer, and Customer shall comply with all current legislation and regulations concerning the shipment of
substances by the land, sea or air. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Force Majeure. </B>In the event either party shall be delayed or hindered in or prevented from the
performance of any act required hereunder by reasons of strike, lockouts, labor troubles (except for strikes, lockouts, labor troubles involving the affected party&#146;s labor force), inability to procure materials or services, failure of power or
restrictive government or judicial orders, or decrees, riots, insurrection, war, Acts of God, inclement weather or other reason or cause beyond that party&#146;s control, then performance of such act (except for the payment of money owed) shall be
excused for the period of such delay. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Notices and Deliveries. </B>Any notice required or permitted to be given hereunder by either party shall be
made in writing and via email if an email address is provided below. Notice shall be deemed given on the date received if delivered personally, by a reputable overnight delivery service, or three (3)&nbsp;days after the date postmarked if sent by
regular, registered or certified mail, return receipt requested, postage prepaid to the following addresses: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.50em; font-size:10pt; font-family:Times New Roman">If to IQVIA:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">If to Customer:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.50em; font-size:10pt; font-family:Times New Roman">IQVIA RDS Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.50em; font-size:10pt; font-family:Times New Roman">Office of the General Counsel</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.50em; font-size:10pt; font-family:Times New Roman">P.O. Bo 13979</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.50em; font-size:10pt; font-family:Times New Roman">Research
Triangle Park, NC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.50em; font-size:10pt; font-family:Times New Roman">27709-3979</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.50em; font-size:10pt; font-family:Times New Roman">Attention: General Counsel</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.50em; font-size:10pt; font-family:Times New Roman"><U>Email: officeofgeneralcounsel@iqvia.com</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">inRegen</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">do Twin City Bio, LLC <BR>3929
WestPoint BLVD <BR>Suite G</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Winston-Salem, NC 27103 <BR>Attention: CEO</P></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Insurance. </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Customer.</U> During the term of this Agreement and for three (3)&nbsp;years after the expiration or earlier
termination of this Agreement or any Work Order hereunder, whichever is later, Customer shall maintain insurance coverage to cover its obligations under this Agreement and any Work Orders hereunder as follows: (a)&nbsp;clinical trials and/or product
liability by Customer in an amount of at least US $5,000,000 and (b)&nbsp;general liability in amounts of at least US $1,000,000; provided, however, in the event IQVIA is acting as Local Representative hereunder Customer shall maintain clinical
trials and/or product liability by Customer in an amount of at least US $10,000,000 and general liability in amounts of at least US $3,000,000. The Parties acknowledge that clinical trial coverage amounts available and/or required locally may be
less than the limits set forth above, and in such case Customer may meet the full requirements above through a global policy in addition to any local coverage. Customer represents and warrants that it will (a)&nbsp;maintain product
liability/clinical trials insurance that does not contain any conditions or exclusions in the policy that would not normally be included in insurance of this type, and (b)&nbsp;include IQVIA as an additional insured on all applicable clinical trials
and/or product liability policies. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>IQVIA.</U> During the term of this Agreement and for four (4)&nbsp;years after the expiration or earlier
termination of this Agreement or any Work Order hereunder, whichever is later, IQVIA shall maintain insurance coverage to cover its obligations under this Agreement and any Work Orders hereunder as follows: (a)&nbsp;professional liability insurance
coverage in an amount of at least US $5,000,000 and (b)&nbsp;general liability in amounts of at least US$1,000,000. IQVIA represents and warrants that it will make Customer an additional insured on IQVIA&#146;s general liability policy.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">17.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>General Requirements.</U> All insurance coverage under this Section&nbsp;17 must be issued by an insurance
company that is rated at least <FONT STYLE="white-space:nowrap">A-,</FONT> VII by A.M. Best. All insurance amounts under this Section&nbsp;17&nbsp;may be obtained by full, individual primary policy amount; a primary amount of less than minimum
requirement enhanced by a blanket excess umbrella policy; or a combination of either. Each party shall provide the other party with a certificate of insurance upon request. Each party shall provide the other party with at least thirty (30)&nbsp;days
prior written notice of any cancellation or expiration of the above-required insurance or any material change to such insurance that causes it to no longer comply with the provisions above. In no event shall the obligations set out in this
Section&nbsp;17 in any way limit or reduce any of either party&#146;s other obligations under this Agreement, including, without limitation, either party&#146;s indemnification obligations set out in Section&nbsp;13. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Binding Agreement and Assignment. </B>This Agreement shall be binding upon and inure to the benefit of
Customer and IQVIA and their respective successors and permitted assigns. Neither party may assign any of its rights or obligations under this Agreement to any party without the express, written consent of the other party, except in event of a
merger or acquisition of substantially all of the assets of the assignor to an assignee with the financial resources to be able to perform the obligations under this Agreement. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>19.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Choice of Law, Waiver and Enforceability. </B>This Agreement shall be construed, governed, interpreted, and
applied in accordance with the laws of the State of New York, exclusive of its conflicts of law provisions. The failure to enforce any right or provision herein shall not constitute a waiver of that right or provision. Any waiver of a breach of a
provision shall not constitute a waiver of any subsequent breach of that provision. If any provisions herein are found to be unenforceable on the grounds that they are overly broad or in conflict with applicable laws, it is the intent of the parties
that such provisions be replaced, reformed or narrowed so that their original business purpose can be accomplished to the extent permitted by law, and that the remaining provisions shall not in any way be affected or impaired thereby.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>20.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Survival. </B>The rights and obligations of Customer and IQVIA, which by intent or meaning have validity
beyond such termination (including, but not limited to, rights with respect to inventions, confidentiality, discoveries and improvements, indemnification, insurance, data protection and liability limitations) shall survive the termination of this
Agreement or any Work Order. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>21.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Entire Agreement, Headings and Modification. </B>This Agreement, as amended from time to time, together with
the applicable Work Orders, contains the entire understandings of the parties with respect to the subject matter herein, and supersedes all previous agreements (oral and written), negotiations and discussions. The descriptive headings of the
sections of this Agreement are inserted for convenience only and shall not control or affect the meaning or construction of any provision hereof. Any modifications to the provisions herein must be in writing and signed by the parties.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>22.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Counterparts. </B>This Agreement, a Work Order, Change Order or amendment may be executed by electronic
means (including <B>.PDF) </B>and in any number of counterparts, each of which when executed and delivered, shall constitute an original, but all of which together shall constitute one agreement binding on all parties, notwithstanding that all
parties are not signatories to the same counterpart. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, this Agreement has been executed by the parties hereto through their
duly authorized officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ACKNOWLEDGED, ACCEPTED AND AGREED TO: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><B>IQVIA RDS Inc.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B><I>inRegen</I></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">By: /s/ Stan Patterson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">By: /s/ Timothy A. Bertram</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Print Name: Stan Patterson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Print Name: Timothy A. Bertram</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Title: VP, Commercial Operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Title: CEO</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Date: 4/30/2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Date: 29&nbsp;April 2020</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><B>IQVIA Ltd.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">By: /s/ Nicola Kerr</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Print Name: Nicola Kerr</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Title: VP, GBO</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Date: 4/30/2020</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman"><B>IQVIA RDS East Asia Ltd.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">By: /s/ Roy Toh</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Print Name: Roy Toh</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Title: Vice President</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Date: 5/3/2020</P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>6
<FILENAME>d373959dex1016.htm
<DESCRIPTION>EX-10.16
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.16</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.16 </B></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g373959dsp18.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Master Agreement for </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Clinical Trials Services </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">This Master Agreement for Clinical Trials Management Services (the &#147;<B>Agreement</B>&#148;) is made and entered into on April 2<SUP
STYLE="font-size:75%; vertical-align:top">nd</SUP>, 2020, (the &#147;<B>Effective Date</B>&#148;), </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">by and between </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">inRegen, a Cayman Islands company, with offices at </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 Market Street #688 Camana Bay </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Grand Cayman Islands, <FONT STYLE="white-space:nowrap">KY1-9006</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(hereinafter referred to as &#147;<B>Sponsor</B>&#148;) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">and </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Frenova, LLC d/b/a Frenova
Renal Research, 920 Winter Street, </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Waltham, Massachusetts 02451-1457 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(hereinafter referred to as &#147;<B>Frenova</B>&#148;). </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Each is sometimes referred to as &#147;Party&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sponsor is engaged in the business of developing and marketing cell-based products and desires to engage Frenova to perform services in connection with
certain clinical trials under development by or under control of Sponsor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frenova, among other things, is engaged in the business of providing certain
services related to the implementation and management of clinical development programs for the pharmaceutical, biotechnology and medical device industries, which may include certain contract research organization related services. This Agreement
sets forth terms under which Sponsor will engage Frenova to provide such services and is comprised of the following Articles: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Definitions </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Services and Standards </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Financial Terms and Conditions </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Term and Termination </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidentiality and Proprietary Rights </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Representations and Warranties </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Indemnification and Insurance </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Miscellaneous Clauses </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By signing below, each Party agrees to the terms of this Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Frenova, LLC</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>inRegen</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Franklin W. Maddux</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Timothy A. Bertram</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Name: Franklin W. Maddux, MD, FACP</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Name: Timothy A. Bertram</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Title: Global Chief Medical Officer</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Title: CEO inRegen/TCBIO</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Date: April&nbsp;2, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>Date: 02 April 2020</B></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g373959dsp18.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.0</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>RECITALS AND DEFINITIONS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>1.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Definitions </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Affiliates</U>: With respect to either Party, an Affiliate is an entity that is controlled by, controls or
is under common control with such Party. A person, corporation or other entity will be regarded as in control of another corporation or entity if such first person, corporation or other entity owns or directly or indirectly controls more than fifty
percent (50%) of the voting stock or other ownership interest of the other corporation or entity, or if such first person, corporation or other entity possesses, directly or indirectly, the power to direct or cause the direction of the management
and policies of the other corporation or other entity or the power to elect or appoint fifty percent (50%) or more of the members of the governing body of the other corporation or other entity. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Amendment</U>: A written specification of changes to a Statement of Work signed by each Party&#146;s
authorized representatives. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Case Report Form (&#147;CRF&#148;)</U>: The printed, optical, or electronic document designed to record all
the Protocol required information to be reported to Sponsor on each Study Subject. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Facility</U>: The location at which the clinical trial is actually conducted (e.g., end stage renal disease
facility or, if applicable, for certain studies this may reference a medical practice) under the supervision of an Investigator. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Frenova Project Manager</U>: The Frenova representative assigned to lead the Frenova project team, act as
the principal liaison between Frenova and Sponsor, and provide general oversight in the delivery of Services with regard to a specific Statement of Work. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Good Clinical Practice (&#147;GCP&#148;)</U>: The standard defined in the ICH Harmonised Tripartite
Guideline For Good Clinical Practice E6(R1) Current Step 4 version dated 10&nbsp;June 1996 (including the Post Step 4 corrections) and applicable EU regulations, e.g. EU Directive 2001/20/EC and Regulation (EU) No.&nbsp;536/2014 and DIN ISO 14155
and the Federal Food, Drug and Cosmetic Act, 21 U.S.C. &#167;&#167; 301 et seq., 21 C.F.R. Parts 11, 50, 54, 56, and 312; the Good Clinical Practices adopted as guidance by the U.S. Food and Drug Administration; or comparable state, federal or local
law. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g373959dsp18.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.1.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>HIPAA</U>: means the United States Health Insurance Portability and Accountability Act of 1996 as amended by
the Health Information Technology for Economic and Clinical Health (HITECH) Act, enacted as part of the American Recovery and Reinvestment Act of 2009 and its applicable regulations. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.1.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Institutional Review Board (&#147;IRB&#148;)</U>: Any board, committee, or other group formally designated
by an institution to review, to approve the initiation of, and to conduct periodic review of, biomedical research involving human subjects constituted in accordance with and in compliance with 21 C.F.R. Part 56, EU Directive 2001/20/EC Art. 2 k) and
Regulation (EU) No.&nbsp;536/2014 Art. 2 (11). The primary purpose of such review is to assure the protection of the rights and welfare of human subjects. An IRB may also be referred to as an independent ethics committee or ethics committee.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.1.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Invention</U>: Inventions or discoveries, whether patentable or not, which are conceived or first actually
reduced to practice in the performance of the Study or the Services including any related patent, trade secret, copyright or other proprietary right. For the purpose of clarity, conception of an invention shall be dictated by inventorship in
accordance with United States patent law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.1.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Investigator</U>: A person responsible for the conduct of the clinical trial at a Facility. If a trial is
conducted by a team of individuals at a Trial Site, the Investigator is the responsible leader of the team and may be called the Principal Investigator. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.1.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Investigator Budget</U>: A subset of the Pass-Through Budget which sets forth the estimated costs related to
the services to be provided by the Investigator in conducting the Study as set forth in the Statement of Work. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.1.12</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Key Personnel</U>: The Frenova Project Manager and other key Frenova personnel assigned to the Services as
set forth in a Statement of Work. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.1.13</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Pass-Through Budget</U>: The estimated costs of Pass-Through expenses for goods and materials incurred by
Frenova on behalf of Sponsor, in connection with the performance of the Services as set forth in a Statement of Work. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.1.14</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Payment Schedule</U>: The schedule of payments due to be made for Services delivered and Pass-Through
expenses incurred, as set forth in a Statement of Work. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g373959dsp18.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.1.15</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Project Specifications</U>: The specific Services to be provided, statement of assumptions used in preparing
the Services Budget, Pass-Through Budget, and assignment of project-related responsibilities between the Parties as set forth in a Statement of Work. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.1.16</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Protocol</U>: A written document that describes a Study and sets forth specific activities to be performed
in accordance with 21 C.F.R. Section&nbsp;312.23(a)(6), 21 C.F.R. 812.25(b), EU Directive 2001/20/EC Art. 2 h) or Regulation (EU) No.&nbsp;536/2014 Art. 2 (22), as may be amended from time to time. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.1.17</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Services:</U> The services to be provided by Frenova, its Affiliates and its Subcontractors (if applicable)
under this Agreement as specifically outlined in a Statement of Work, Amendment or winding down plan. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.1.18</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Services Budget</U>: The estimated cost of the Services, based upon the Project Specifications as set forth
in a Statement of Work. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.1.19</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Statement of Work</U>: A written specification of Services to be performed by Frenova under this Agreement,
including the Project Specifications, Contact Information, Services Budget, Pass-Through Budget, Investigator Budget and Payment Schedule. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.1.20</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Study</U>: A clinical trial performed at one or more Trial Sites under the supervision of one or more
Investigator(s) pursuant to a study Protocol. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.1.21</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Study Agent</U>: The drug(s), biologic(s) or device(s), if any, that are the subject of the Study as
specified in the Protocol. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.1.22</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Study Subject:</U> individuals who are screened for a Study and/or are participating in a Study.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.1.23</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Subcontractor</U>: An individual or company engaged by Frenova to conduct some elements of a Statement of
Work, such as clinical laboratories, patient recruitment services, interactive voice recognition systems and other services, which shall exclude reference to contract employees as set forth in Section&nbsp;2.3.3. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">1.1.24</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Trial Site(s)</U>: Any public or private entity or agency specifically identified related to or pursuant to
Statement of Work which performs clinical research, and is engaged to perform a Study by Frenova or Sponsor and the location(s) where trial-related activities are actually conducted. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g373959dsp18.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.0</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SERVICES AND STANDARDS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parties will agree on all Services to be provided and the performance of those Services will be authorized in writing through the execution of a Statement
of Work. Frenova will not begin work on any Services without an executed Statement of Work or other written document authorizing commencement of the Services, except with respect to an agreed upon letter of agreement which may executed between the
parties to permit Frenova to perform preliminary work involving a Study as the specific Statement of Work for such Study is being negotiated and finalized and signed by the Parties. Statements of Work may be entered into by Frenova or any of its
Affiliates, which by execution of such a Statement of Work, will agree to be bound to the terms of this Agreement. Each and every Statement of Work is subject to the agreement of both Parties and each Party reserves the right to decline to enter any
Statement of Work. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Statements of Work </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frenova will provide Services as specified in one or more Statements of Work. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Project Specifications</U>. The Statement of Work will include Project Specifications, which may include
items such as a description of the Study Protocol, Trial Sites, Facilities, subjects, CRFs, reports and Services to be provided by Frenova, including potential Facilities, potential Trial Sites and potential Investigators. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Services Budget</U>. Each Statement of Work will include a Services Budget and will include the costs
related to the Services to be provided. Frenova will not exceed the total cost outlined in the Services Budget without the prior written approval of Sponsor, unless specifically authorized by an Amendment, as set out in Section&nbsp;2.2 below.
Sponsor agrees that the Services Budget presented in each Statement of Work is an estimate based upon the Project Specifications. Any changes to the Project Specifications, including without limitation, a request by Sponsor for compression of the
timelines or extensions of the timelines for any reason, may result in changes to the Statement of Work, which will be documented in accordance with Section&nbsp;2.2 below. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Pass-Through Budget</U>. Each Statement of Work may include a Pass-Through Budget, which will contain an
estimate of anticipated Pass-Through expenses to be incurred on Sponsor&#146;s behalf in connection with performance of the Services. Sponsor agrees that the Pass-Through Budget contains an estimate based on the Project Specifications, and
information supplied by third party suppliers, and that such costs cannot be predicted with complete certainty at the outset of a Study. Sponsor will reimburse all of Frenova&#146;s actual direct costs for Pass-Through expenses incurred in
performance of the Services, in accordance with Article 3 below. Frenova will notify Sponsor in writing of any increases or decreases in the Pass-Through Budget upon receipt of such information from third party suppliers or other sources, as the
case may be, and such information will be included in an Amendment to the applicable Statement of Work. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g373959dsp18.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Investigator Budget</U>. While a subset of the Pass-Through Budget, each Statement of Work may include an
Investigator Budget including the costs related to the services to be provided by the Investigator in conducting the Study which will be the basis of the budget attached to the clinical trial agreements to be executed with Investigators. Sponsor
agrees that the Investigator Budget generally contains a per procedure fee structure based on the specific Study protocol schedule of events, prorated according to Study Subject participation, and that such costs may be subject to change in the
event of changes to the Study protocol. Sponsor will reimburse all of Frenova&#146;s actual direct costs for the expenses incurred by the Investigator in performance of the Study, in accordance with Article 3 below. Frenova will notify Sponsor in
writing of any increases or decreases in the Investigator Budget upon receipt of such information from Investigators or other sources, as the case may be, and such information will be included in an Amendment to the applicable Statement of Work.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Payment Schedule.</U> Each Statement of Work will contain a Payment Schedule, which will specify the manner
and timing of all payments for Services and pass-through expenses described in the Statement of Work. Any changes to the Project Specifications, and corresponding changes to the Services Budget or Pass-Through Budget, will be reflected in a
corresponding change in the Payment Schedule. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Contact Information and Designation of Key Personnel</U>. Each Statement of Work will identify the Key
Personnel as the Parties may agree are to be included and their contact information. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.1.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Territory-Specific Requirements</U>. A Statement of Work may contain terms and conditions supplemental to or
different from the terms and conditions set forth in this Agreement, as are necessary for territory-specific matters. In such case, the Statement of Work shall explicitly state that it will govern with respect to such terms and such
territory-specific terms shall take precedence over this Agreement with respect to such terms in such territory. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Amendments </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any changes to a Statement of Work, including but not limited to changes to the Project Specifications, Services Budget, Pass-Through Budget or Investigator
Budget, will be agreed upon by the Parties and documented in an Amendment to the Statement of Work. Sponsor agrees that Frenova will not perform any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-scope</FONT></FONT> work
described in an Amendment until it is approved in writing by both Parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g373959dsp18.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Unanticipated Changes</U>. Sponsor agrees that changes in costs resulting from, for example, changes to
Project Specifications due to modifications to the Study Protocol, delays in receipt of Study Agent from Sponsor, changes in amounts charged by third party suppliers or poor subject enrollment due to changes in clinical practices, cannot be
reasonably anticipated in advance. Upon identification by either Party of changes to the Project assumptions or other unanticipated changes to the Project Specifications, the Parties will prepare an Amendment to accommodate increases or decreases to
the Project Budget (including the Services Budget and Pass-Through Budget, or Payment Schedule that are reasonably associated with any such adjustments. Such unanticipated changes may include, but are not limited to, any of the following:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.2.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">delays in receiving from Sponsor technical information or Sponsor&#146;s acceptance of documents submitted by
Frenova in the performance of its duties under this Agreement or any Statement of Work, or any other delay on the part of Sponsor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.2.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">delay in receipt of regulatory approval from a regulatory agency, IRB or Ethics Committee;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.2.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">delay in performance by a Subcontractor not selected by Frenova; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.2.1.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">delay in shipment of Study Agent, clinical samples and/or clinical supplies to Trial Sites;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.2.1.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">delay due to changes in standard of care imposed by law, regulation or changes in medical practice affecting
participating Trial Sites; or Facilities<U>;</U> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.2.1.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">commencement of a new clinical trial with the same target patient population as the Study which is undertaken
by Frenova on behalf of Sponsor; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.2.1.7</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">delay by reason of force majeure as defined herein; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.2.1.8</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sponsor requested changes to the Services or Protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.2.1.9</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">delays due to questions received by either Party from regulatory agencies or ethics committees regarding
submission materials that relate to characteristics of the Study Agent or Protocol design; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.2.1.10</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">delays due to any changes in applicable law or regulatory environment; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">2.2.1.11</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">changes for any other reason agreed upon in writing by Sponsor. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g373959dsp18.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Project Staffing </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In performing the Services, Frenova will reasonably allocate personnel who are adequately trained, qualified and experienced to conduct the work as specified
in a Statement of Work. Sponsor will have the right, before executing a Statement of Work to review the qualifications of any Key Personnel and raise any concerns which Sponsor may have in that regard and, if such concerns cannot be sufficiently
addressed to both parties satisfaction, then such Statement of Work shall not be executed by the parties. In the event that Sponsor has concerns regarding the performance of any Key Personnel, Sponsor shall raise such concerns to Frenova, and the
parties shall in good faith seek to resolve such concerns. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Key Personnel</U>. Frenova will assign a Frenova Project Manager and/or other employees whose participation
in a project is expected for the duration of the project, who will serve as Key Personnel. Frenova will use reasonable efforts to seek the continuity of Key Personnel&#146;s participation in a project for the duration of the project. Frenova will
provide thirty (30)&nbsp;days&#146; notice to Sponsor, whenever practical, of any changes to the Key Personnel. Frenova will provide project-specific training to replacement Key Personnel at its own expense. Sponsor will have the right to review the
qualifications of any Key Personnel replacements and raise any reasonable concerns which Sponsor may have in that regard and, both parties shall seek in good faith to address such concerns.<U> </U> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Project Team</U>. Frenova will assign <FONT STYLE="white-space:nowrap">non-Key</FONT> Personnel at its sole
discretion, as needed to perform the Services in accordance with the Statement of Work. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Use of Contract Employees</U>. Frenova may, at its own discretion, assign some elements of the Services to
contract employees. Frenova agrees that any contract employees used to perform the Services will be adequately qualified, experienced and trained as required to perform the Services in the same manner as Frenova qualifies and trains its own
employees. Frenova will remain responsible for satisfactory performance of all Services performed by contract employees. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Use of Subcontractors </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frenova may use Subcontractors to conduct some elements of a Statement of Work. Frenova will notify Sponsor in advance of its use of Subcontractors. In the
event that Sponsor objects, for reasonable cause, to any such Frenova Subcontractors, Frenova will replace the Subcontractor within a mutually agreeable timeframe. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Sponsor-Selected Subcontractors.</U> In the event that Sponsor requires Frenova to use a specific
Subcontractor that is not otherwise agreeable to Frenova, Frenova will not be responsible for the performance of the Subcontractor, and Sponsor will manage the performance of the Subcontractor and be responsible for any delays or changes to the
Project Budget that result from the performance of the Subcontractor. Frenova will notify Sponsor promptly of any performance issues arising out of the use of any such Subcontractors. If Sponsor engages a Subcontractor, but requires that Frenova
manage or oversee the performance of the Subcontractor, then Sponsor will supply Frenova with a copy of the relevant contract with the Subcontractor. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g373959dsp18.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Frenova-Selected Subcontractors</U>. For Subcontractors selected and contracted directly by Frenova, Frenova
will manage the performance of the Subcontractor in coordination with Frenova. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Engagement of Trial Sites and Investigators </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If required in the terms of a Statement of Work, Frenova will coordinate execution of contracts with Trial Sites and Principal Investigators for the
performance of each Study (which may include, by example, clinical trial agreements and facility use agreements) using templates mutually agreeable to Frenova and Sponsor. Unless otherwise agreed upon in any Statement of Work, if an Investigator or
other relevant party insists upon any material changes to any provisions of the applicable template agreement(s), then Frenova shall submit the proposed material change to Sponsor, and Sponsor shall promptly review, comment on, reject and/or approve
such proposed changes. Each such contract will include terms, to the extent applicable, pertaining to Confidentiality, Proprietary Rights, Inspections and any other pertinent matters as the Parties may decide, which shall be no less restrictive than
those of this Agreement without the consent of Sponsor. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Applicable Standards </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frenova shall perform Services pursuant to this Agreement any Statement of Work in compliance with the specifications of that Statement of Work, GCP and
applicable United States, EU laws and regulations, and/or laws of regulations of the specific territories where Services are being performed. The Statement of Work shall specify to what extent Frenova or Sponsor shall provide standard operation
procedures in the performance of the Services. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Sponsor-Provided Systems </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.7.1 In the event that Sponsor requires Frenova to use Sponsor&#146;s information systems and associated processes pursuant to a Statement of
Work, Sponsor will be responsible for all costs associated with installation and operation of the systems, including costs for hardware and software licenses, and for training of Frenova personnel assigned to the project in the use of Sponsor
system(s). Sponsor shall allow Frenova to access the EDC System (defined below) to review and approve Trial Site visit activity for the purpose of processing payments to the Trial Sites. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.7.2 Sponsor acknowledges that Frenova shall contract with and/or license from an electronic data capture vendor (&#147;EDC Vendor&#148;)
such that Sponsor may utilize the EDC Vendor software applications to serve as Sponsor&#146;s electronic data capture system for any particular Study. Sponsor&#146;s rights to use such EDC Vendor software, including, but not limited to, any
derivative works, modifications, updates and enhancements thereto, and/or services (&#147;EDC System&#148;) for purposes of electronic data capture are subject to Sponsor&#146;s compliance with the following terms and conditions: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g373959dsp18.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Only Sponsor&#146;s employees and contractors conducting or performing services directly related to the Study
pursuant to a Statement of Work and/or clinical trial agreement executed thereto (the &#147;Authorized Users&#148;) may access the EDC System on behalf of Sponsor. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sponsor shall use the EDC System only for lawful purposes and in accordance with this Agreement, the Statement
of Work (including clinical trial agreements executed thereto), consistent with industry standards, and for purposes related to a Study. Any data that Sponsor plans to collect in the EDC System that is the proprietary information of Fresenius
Medical Care Holdings, Inc. and any of its Affiliates, shall be subject to approval by Frenova, which shall not be unreasonably withheld. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sponsor acknowledges that the EDC System is proprietary to the EDC Vendor, and such EDC Vendor owns all right,
title and interest in the EDC System, including, but not limited to, any derivative works, modifications, updates and enhancements. The Authorized Users shall protect and treat the EDC System and materials as confidential using the same care as
required under the Agreement with respect to Sponsor&#146;s Confidential Information, but no less than reasonable care. Sponsor understands and agrees that the EDC System may only be used by Sponsor and its Authorized Users in accordance with the
terms set forth above and that Sponsor will not (1)&nbsp;modify, copy or create derivative works based on the EDC System, or (2)&nbsp;reverse engineer, disassemble or decompile the EDC System or any portion thereof in any manner. Sponsor agrees to
execute any additional documentation as Frenova&#146;s and/or EDC Vendor&#146;s request setting forth any such additional obligations or use restrictions as may be required for Authorized Users to access and/or utilize the EDC System.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sponsor acknowledges that errors may exist or occur in any software program. Frenova makes no warranty or
representation that the EDC System shall operate uninterrupted or be error-free and assumes no responsibility for obsolescence of the EDC System. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.7.3 Frenova shall in good faith seek to enforce on behalf of Sponsor, at Sponsor&#146;s expense, warranties which Frenova may hold pursuant
to Frenova&#146;s license and/or contractual arrangement with the EDC Vendor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise stated in this Agreement, the EDC SYSTEM, THE SERVICES
PROVIDED IN CONNECTION WITH THE EDC SYSTEM, AND THE DELIVERABLES DELIVERED THROUGH USE OF THE EDC SYSTEM ARE PROVIDED AND DISTRIBUTED ON AN &#147;AS IS&#148; BASIS WITHOUT WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED
TO WARRANTIES OF TITLE, <FONT STYLE="white-space:nowrap">NON-INFRINGEMENT,</FONT> MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.7.4 EDC Vendor shall provide to Sponsor at the completion of the Study a download of the Study data contained in the EDC System for such
Study. Frenova shall in good faith seek to facilitate the execution of additional documentation as to the nature, timing, and extent of such download of Study data by and among Frenova, EDC Vendor and Sponsor as may be reasonably requested. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g373959dsp18.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.7.5 To the extent that Frenova utilizes, or Sponsor otherwise requires the use of,
additional software services or an additional software vendor in additional that provided by the EDC Vendor, then the provisions with respect to the use and scope of services to be provided pursuant to such software services or software vendor shall
be addressed in the applicable Statement of Work. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Inspections </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.8.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Inspection by Sponsor</U>:<B> </B>During the term of this Agreement, Frenova will permit representatives of
Sponsor who are not competitors of Frenova in the dialysis services business to examine, at Sponsor&#146;s cost, at a reasonable time during normal business hours and subject to at least ten (10)&nbsp;business days prior written notice to Frenova:
(i)&nbsp;the facilities where the Services are being, will be or have been conducted; (ii)&nbsp;documentation directly related to the conduct of the Study as necessary for Sponsor to confirm that the Services are being or will be or have been
conducted in conformance with applicable specific Statements of Work, this Agreement and in compliance with applicable laws and regulations. Frenova may exclude from any such inspection any of its proprietary or confidential information that is not
otherwise required to be provided to Sponsor in connection with this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.8.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Inspection by Regulatory Authorities</U>:<B> </B>Sponsor acknowledges that Frenova may respond independently
to any correspondence, inquiry or inspection request from a regulatory authority in which Frenova or its Affiliates is named if it is not practicable to inform and work cooperate with Sponsor in such regard. To the extent any such request is related
to a Study, Frenova shall: (i)&nbsp;notify Sponsor promptly of any regulatory authority inspection or inquiry, including, but not limited to, inspections of Trial Sites, Facilities<U>,</U> subcontractors or laboratories; (ii)&nbsp;forward to Sponsor
copies of any correspondence from any regulatory authority relating to such inspection or inquiry, including, but not limited to, FDA Form 483 notices, and FDA refusal to file, rejection or warning letters; (iii)&nbsp;notify Sponsor of the results
of any such inspection or inquiry, including requested or required improvements, changes or modifications to Frenova&#146;s operations; and (iv)&nbsp;notify Sponsor of any actions taken in response to or anticipation of such an inspection or
inquiry. Where reasonably practicable, Frenova will give Sponsor the opportunity to have a representative present during an inspection by a regulatory authority. Sponsor, however, acknowledges that it may not direct the manner in which Frenova
fulfills its obligations to permit inspection by regulatory authorities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g373959dsp18.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">2.8.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Inspections of Trial Site(s) by Frenova</U>: To the extent required pursuant to the Statement of Work and/or
in connection with Frenova&#146;s provision of Services as specified in this Agreement and any associated Statement of Work, Frenova may conduct monitoring visits and/or inspections of participating Trial Sites, and Facilities. Based on
Frenova&#146;s observations during such Trial Site or Facility visits and inspections, Frenova may decide: (i)&nbsp;that enrollment should be suspended at the Trial Site or Facility; (ii)&nbsp;that a Trial Site&#146;s or Facility&#146;s <FONT
STYLE="white-space:nowrap">non-compliance</FONT> needs to be reported to Sponsor and/or regulatory authorities; and/or (iii)&nbsp;Trial Site&#146;s or Facility&#146;s participation in a Study needs to be terminated. Upon such a determination,
Frenova will present to Sponsor a basis for its decision. If Sponsor disagrees with the basis for Frenova&#146;s decision, Frenova will assign its contract with the Trial Site or Facility to Sponsor and Sponsor agrees to accept such assignment and
to be responsible for all contractual duties and obligations to the Trial Site and/or Facility. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.9</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Steering Committee </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Both Parties hereby may, upon mutual agreement, establish a joint review committee (&#147;Joint Review Committee&#148;) which shall be responsible for
reviewing and discussing operational, clinical quality, implementation of current and potential clinical trials. If established, each Party shall appoint two representatives (or more, upon mutual agreement) to the Joint Review Committee, which
representatives shall include appropriate leadership for both Parties. The Joint Review Committee shall convene quarterly at mutually agreeable dates and times. Agendas for the Joint Review Committee meetings can include, but not be limited to,
discussions of issues related to operations, quality, strategy, and future opportunities. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.10</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Participation in Protocol Review </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because of Frenova expertise in the conduct and administration of clinical trials involving patients with end stage renal disease or other patients with kidney
disease, Sponsor may include as part of the Statement of Work Frenova&#146; review, consultation and advisement on the Protocol for improving implementation and administration to the target subject population and potentially Study design, as
applicable. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.11</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Potential Trial Sites/Investigators Generally </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frenova as part of the Services pursuant to a Statement of Work, may routinely provide to Sponsor a list of potential Trial Sites and potential Investigators
(including potential Facilities). Consistent with Section&nbsp;5, such potential Trial Site(s) and potential Investigators and potential Facilities are deemed Confidential Information of Frenova. Sponsor hereby agrees that it shall not knowingly
seek to directly contract with any potential Trial Site or any potential Investigator that are contractually obligated to facilitate Frenova&#146;s involvement for any clinical trial that he/she would conduct for Sponsor at least in part at a
facility owned or operated by Frenova or its Affiliates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g373959dsp18.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.0</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>FINANCIAL TERMS AND CONDITIONS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parties agree that the fees and other reimbursements that Frenova will receive for performing the Services hereunder will be outlined in each Statement of
Work and are subject to the following terms and conditions. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Compensation for Services </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Services provided, Sponsor will pay Frenova in accordance with the terms in this section of the Agreement and each applicable Statement of Work. The timing
and frequency of payments will be governed by the Payment Schedule detailed in each Statement of Work. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Services Budget </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All fees for Services shall be paid in the amounts and at the times indicated in the Payment Schedule. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Pass-Through Budget </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to provide funding for Pass-Through expenses, exclusive of Trial Site/Investigator payments described below, Sponsor will make an advance payment to
Frenova of an amount to be specified in each Statement of Work. Frenova will submit to Sponsor detailed monthly invoices for amounts incurred during the relevant billing period. The advance payment will be retained by Frenova until the completion of
the Services, at which time a reconciliation of expenses will be done to ensure that Sponsor pays for only those expenses actually incurred. The advance payment will then be applied to the final invoice, if unpaid, and any remaining advance payment
will be refunded to Sponsor within thirty (30)&nbsp;days from the date of the final reconciliation. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Trial Site/Investigator Payments and Reconciliation </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to provide for timely payments to Trial Sites/Investigators, Sponsor will make an initial advance payment to Frenova of an amount to be determined in
each Statement of Work. The Statement of Work shall specify, as the parties may mutually agree, any additional advance payments shall be made from Sponsor to Frenova and the process of invoicing and reconciliation of such advance payments, to the
extent applicable. In the event Frenova has any remaining advance payment upon the completion of Services, Frenova shall apply such advanced payment to the final invoice, if unpaid, and any remaining advance payment will be refunded to Sponsor
within thirty (30)&nbsp;days from the date of the final reconciliation. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Invoices </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.5.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Invoices for Services and Pass-Through expenses will be submitted in accordance with the Payment Schedule
associated with the relevant Statement of Work and will be prepared monthly, or as frequently as necessary. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g373959dsp18.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.5.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All invoices under this Agreement will be forwarded to the Sponsor representative designated in the relevant
Statement of Work. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">3.5.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">All payments under this Agreement will be remitted to the Frenova Affiliate named in the Statement of Work, to
the address and in the manner set forth in the Payment Schedule of the applicable Statement of Work. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Payment Terms </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sponsor agrees to pay for Services and Pass-Through expenses in accordance with the Payment Schedule outlined in each Statement of Work or associated
Amendment. Sponsor will pay for all Services, Pass-Through expenses and other correctly invoiced items within forty-five (45)&nbsp;days of receipt of invoice. All payments will be made in the currency noted in the Payment Schedule of the Statement
of Work. All fees for Services and Pass-Through expenses are exclusive of VAT (including <FONT STYLE="white-space:nowrap">non-refundable</FONT> VAT) and other local taxes (excluding taxes based on Frenova&#146;s income), which Sponsor will pay when
applicable. All Frenova invoices are payable within forty-five (45)&nbsp;days of receipt by Sponsor. Undisputed payments from Sponsor which are received 30 days past due will incur a 1.0% penalty per month calculated daily and compounded monthly or,
if lower, the highest rate permitted under applicable law. Sponsor will use reasonable efforts to inform Frenova in writing of any claimed errors on the invoice or invoice items being disputed within fifteen (15)&nbsp;business days of Sponsor&#146;s
receipt of the invoices and the basis of such dispute (&#147;disputed items&#148;) (payment of undisputed items shall be required consistent with this Section). Sponsor acknowledges and agrees that any discrepancies identified through verification
of Study documentation that may result in an adjustment to payment must be resolved in a timely and satisfactory manner The parties shall in good faith seek to resolve any disputed items within thirty (30)&nbsp;days of any such items being deemed
&#147;disputed&#148; as set forth above. If the parties cannot resolve such disputed items within such time frame, then a party may pursue all of its rights in law and equity with respect to such disputed items.&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Final Payments </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any final payments specified in a Statement of Work will be invoiced upon completion of the Services and delivery to Sponsor of any final Study databases,
reports or other deliverables as specified in the Statement of Work. If a final payment is specified in a Statement of Work, it will be due within forty-five (45)&nbsp;days of Sponsor&#146;s receipt of invoice unless Sponsor notifies Frenova in
writing of any deficiencies in the Services. Frenova will correct any such deficiencies within thirty (30)&nbsp;days of notice and will resubmit the final invoice to Sponsor immediately upon final shipment of the corrected project deliverable(s).
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Currency Management </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parties agree that all amounts to be paid to Frenova for Services rendered and all Pass-Through expenses, including Trial Site/Investigator payments, shall
be paid in U. S. Dollars unless otherwise set forth in an applicable Statement of Work. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g373959dsp18.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.0</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TERM AND TERMINATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>4.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Term </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless earlier terminated according to Section&nbsp;4.2, 4.3, or 4.4 below, this Agreement will remain in effect for an initial term of five (5)&nbsp;years
from the Effective Date, and thereafter will renew automatically for successive terms of one (1)&nbsp;year unless either Party notifies the other Party of termination of the Agreement no later than sixty (60)&nbsp;days prior to renewal hereof. In
the event of <FONT STYLE="white-space:nowrap">non-renewal</FONT> by either Party, the term of this Agreement applicable under any outstanding Statement of Work will continue until completion of the Services described in such Statement of Work or
appropriate termination of the Statement of Work. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination by Sponsor </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sponsor may terminate this Agreement or any Statement of Work upon sixty (60)&nbsp;days prior written notice to
Frenova for any reason. Sponsor will pay Frenova for all Services properly rendered and Pass-Through expenses, including Trial Site/Investigator/Facility expenses incurred pursuant to this Agreement or any terminated Statement of Work. Sponsor will
also pay for Services and Pass-Through expenses, including Trial Site/Investigator/Facility expenses, necessary to conduct an orderly winding down of the administration of this Agreement, or any terminated Statement of Work, which amount will not
exceed the remaining unpaid balance of the Project Budget of the Statement of Work, unless special circumstances warrant otherwise. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">As soon as practicable following receipt of notice of termination under this Section&nbsp;4.2, Frenova will
submit an itemized accounting of Pass-Through expenses and costs incurred, costs anticipated, and payments received in order to determine a balance to be paid by either Party to the other. Such balance will be paid by Sponsor or Frenova within
thirty (30)&nbsp;days of completion of work. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination by Frenova </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Failure of Sponsor to comply with any<B> </B>of the material terms or conditions of this Agreement or to
respond to Frenova&#146;s inquiries or requests for information will entitle Frenova to give written notice of default of this Agreement or a Statement of Work via certified/return receipt mail or overnight courier to ensure receipt by Sponsor. If
Sponsor does not cure the default within sixty (60)&nbsp;days of receipt of notice (or for such reasonable amount of time thereafter, if the default is not susceptible of cure within sixty (60)&nbsp;days), this Agreement or the affected Statement of
Work may be terminated by Frenova, which will </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g373959dsp18.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
cease performance of Services. The cessation of Services in accordance with this Section will not be a default of performance obligations by Frenova, nor will it be a breach of this Agreement or
any Statement of Work. Sponsor will pay to Frenova all amounts due and owing for Services performed, Pass-Through expenses (including Trial Site/Investigator expenses) incurred, costs associated with winding up activities described in
Section&nbsp;4.2 above, as well as any late fees which may be due, pursuant to Section&nbsp;3.6 above. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Additionally, Frenova may terminate any Statement of Work upon thirty (30)&nbsp;days prior written notice if:
(i)&nbsp;Sponsor cancels or materially delays the requested Services; (ii)&nbsp;unanticipated material changes to the project assumptions or project specifications cannot be addressed to both Parties&#146; satisfaction through an Amendment;
(iii)&nbsp;changes to the Study Protocol cause enrollment targets to become commercially unreasonable; (iv)&nbsp;Sponsor is unable to make timely payments to Frenova resulting in Frenova lacking funds to process payments to Trial Sites.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Termination for Other Reasons </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">If in the reasonable assessment of Frenova or Sponsor, the continued performance of the Services contemplated
by this Agreement or any Statement of Work could constitute a potential or actual violation of legal, regulatory, ethical or scientific standards and/or patient safety and welfare is jeopardized, then either Party may terminate this Agreement or any
Statement of Work by giving written notice stating the effective date of such termination and notice period, if any. The parties shall use all reasonable efforts to rectify the alleged violation prior to the end of the notice period, if any.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">4.4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Either Party may terminate this Agreement and all Statements of Work hereunder, effective immediately upon
written notice to the other Party, if the other Party: (i)&nbsp;files a voluntary petition in bankruptcy or has an involuntary bankruptcy petition filed against it, which is not dismissed within thirty (30)&nbsp;days after its institution,
(ii)&nbsp;is adjudged as bankrupt, (iii)&nbsp;becomes insolvent, (iv)&nbsp;has a receiver, trustee, conservator or liquidator appointed for all or a substantial part of its assets, (v)&nbsp;ceases to do business, (vi)&nbsp;commences any dissolution,
liquidation or winding up, (vii)&nbsp;makes an assignment of its assets for the benefit of its creditors, (viii)&nbsp;is excluded, suspended, sanctioned or otherwise restricted from participating in federal health care programs, including but not
limited to, Medicare or Medicaid, or is (ix)&nbsp;is convicted of a felony. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g373959dsp18.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Survival </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Expiration or termination of this Agreement will not relieve the Parties of any obligation accruing prior to such expiration or termination. In addition, the
following sections: Financial Terms and Conditions, Term and Termination, Confidentiality and Proprietary Rights, Representations and Warranties, Indemnification and Insurance, <FONT STYLE="white-space:nowrap">Non-Solicitation</FONT> of Employees,
Governing Law, as well as any other sections which by their nature should survive, will survive expiration or termination of this Agreement indefinitely, or for the period of time noted in the specific clause. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.0</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CONFIDENTIALITY AND PROPRIETARY RIGHTS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.1</B> During the term of this Agreement and thereafter, the Parties and their Representatives (as defined below) shall neither disclose
nor use for any purpose except as expressly provided in this Agreement below, Confidential Information (as defined below) that is provided by Sponsor or Frenova (including without limitation their affiliates, customers, and licensors), directly or
indirectly, pursuant to this Agreement, whether oral or in written form, or other tangible medium, and whether or not marked confidential. &#147;Confidential Information&#148; means all Sponsor or Frenova (including without limitation their
Affiliates, customers and licensors) information and data, including, but not limited to, technical data, trade secrets, <FONT STYLE="white-space:nowrap">know-how,</FONT> ideas, research, prototypes, samples, formulas, compounds, methods, plans,
specifications, characteristics, raw material data, software, inventions, discoveries, processes, designs, drawings, schematics whether or not patentable, and information concerning Sponsor&#146;s or Frenova&#146;s financial condition, product
plans, services, customers, potential customers, potential Trial Site lists and potential Investigator lists, distribution systems, suppliers, markets, business, technology, marketing plans, sales, manufacturing, purchasing and accounting methods,
strategy, budgets, contracts, grants, costs, profits, employees and consultants, plans for future development, and other information of a similar nature. For the sake of clarity, the potential Trial Site list(s), potential Investigator&#146;s
list(s), and potential Facility list(s) developed by Frenova, including but not limited to the identity and contact information for potential Investigators, is confidential and proprietary and, subject to 5.3, shall be deemed as Frenova Confidential
Information. Notwithstanding any provision herein to the contrary, the medical records of any Study Subject used in the care and treatment of such patient shall be owned by the medical provider(s), as applicable, and their applicable Affiliates, and
in no event will this Section&nbsp;5 be construed to place restrictions on the use of and disclosure of such medical information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.2</B> In consideration of any access the Parties may have to Sponsor&#146;s or Frenova&#146;s Confidential Information hereunder, during
the term of this Agreement and thereafter, the Parties shall: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">in the case of Frenova, not use such Confidential Information except in the performance of Study related
Services in accordance with the applicable Statement of Work; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">hold the Confidential Information in strict confidence and shall protect such Confidential Information from
disclosure and shall use the same degree of care to avoid disclosure of such Confidential Information as the parties employ with respect to their own confidential information of like importance, but in no event less than a reasonable amount of care;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g373959dsp18.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not, without the express written permission of Sponsor or Frenova, as applicable, divulge any such Confidential
Information to others, except to persons who are (i)&nbsp;employees of the Parties or their Affiliates used in accordance with Section&nbsp;8.8 or represent a Party or their Affiliate used in accordance with Section&nbsp;8.8 in a professional
capacity; (ii)&nbsp;are bound by obligations of confidentiality and nonuse at least as restrictive as those set forth herein; and (iii)&nbsp;who have a bona fide need to know Confidential Information in connection with the Study related Services
(collectively, &#147;<B>Representatives</B>&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not use for its own benefit or the benefit of its Representatives or any person or entity, other than the Party
owning the information, any such Confidential Information; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.2.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">not copy, create derivative works of or reverse engineer any such Confidential Information, except such
duplication as is necessary in the performance of the Study related Services, or in the case of Sponsor, for the use of the Services. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.3</B> Confidential Information shall not include information that the receiving Party can show: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">was already in their possession without obligation to keep it confidential as evidenced by its written records
prepared or received prior to the disclosure; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is lawfully disclosed to them by a third party, provided such information was not obtained by such third party
directly or indirectly from either Sponsor or Frenova (including without limitation their Affiliates, customers and licensors) on a confidential basis as evidenced by its written records; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is independently developed by them (including without limitation their Affiliates) without access to or use of
the Confidential Information as evidenced by its written records prepared contemporaneously with the development; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.3.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">is generally known to the public without violation hereof. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g373959dsp18.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.4</B> A Party may make disclosures of the other Party&#146;s Confidential Information as
required by law or regulation or by an order of a governmental agency, legislative body or court of competent jurisdiction, provided that the Party required to disclose such information: (i) provides the other Party, as applicable, with prompt
written notice of such requirement, (ii)&nbsp;cooperates with the other Party, as applicable, in connection with such Party&#146;s actions to obtain a protective order and/or confidential treatment for such Confidential Information, and
(iii)&nbsp;limits such disclosure of Confidential Information to the fullest extent permitted under applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.5</B>
Notwithstanding any language to the contrary in this Agreement, the Parties shall be responsible for any disclosure or use of the other Party&#146;s Confidential Information or other prohibited activity involving the other Party&#146;s Confidential
Information by any of their respective Representatives, person or entity to which the other Party&#146;s Confidential Information is disclosed. Each Party shall notify the other in writing immediately upon becoming aware of the occurrence of any
unauthorized release of the other Party&#146;s Confidential Information or other breach of this Agreement. The Parties each acknowledge and agree that due to the unique nature of the Confidential Information there is no adequate remedy at law for
any breach of its or its Representatives&#146; obligations hereunder and that any breach would result in irreparable harm to Sponsor or Frenova, as applicable. Therefore, upon any such breach, Sponsor or Frenova, as applicable, shall be entitled to
obtain appropriate equitable relief in addition to its remedies at law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.6</B> Nothing contained in this Agreement shall be construed
as granting or conveying to Sponsor or Frenova, or their Representatives, by implication, license, estoppel or otherwise, any right, title or interest in or to the Confidential Information. None of the Confidential Information which may be disclosed
hereunder shall constitute any representation, warranty, assurance, guarantee, or inducement by Sponsor or Frenova as to the <FONT STYLE="white-space:nowrap">non-infringement</FONT> of patents, trademarks, copyrights or any intellectual property
rights or other rights of third parties. All Confidential Information and other written data provided by Sponsor or Frenova hereunder shall be and remain the property of Sponsor or Frenova, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.7</B> In the event Sponsor shall come into contact with any Subject&#146;s medical records, Sponsor shall hold in confidence the identity
of such Subject and shall comply with all applicable law(s) and contractual obligations regarding the confidentiality of such Subject&#146;s records. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.8</B> Sponsor and Frenova each agree to hold the terms of this Agreement in confidence. Notwithstanding anything in this Agreement to the
contrary, Frenova may, however, disclose such Confidential Information to potential Principal Investigator(s) or Principal Investigator(s) and/or their designees, provided that such parties have agreed to protect the confidential nature of the
information disclosed to them. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.9</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Return or Destruction of Information </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon a Party&#146;s written request, Sponsor or Frenova shall promptly deliver to the other or to destroy if so requested, as applicable, all originals,
copies, and summaries of documents, materials, and other tangible manifestations of Confidential Information and any other property of Sponsor or Frenova, as applicable, that the Party shall have in its possession or under their control, in whatever
media; provided, however, that each Party shall be entitled to retain in confidence under this Agreement, including without limitation (i)&nbsp;one (1) archived copy of the other Party&#146;s Confidential Information and all materials created by
such Party and containing the other Party&#146;s Confidential Information, including without limitation notes and memoranda, solely for the purpose of administering a Party&#146;s obligations under this Agreement; and (ii)&nbsp;Confidential
Information contained in such Party&#146;s electronic <FONT STYLE="white-space:nowrap">back-up</FONT> files that are created and maintained in the normal course of business pursuant to such Party&#146;s standard protocol for preserving its
electronic backup records. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g373959dsp18.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.10</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Proprietary Rights </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.10.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The entire right, title and interest in and to any Invention that is related to an indication, use, formulation
or dosage, or to the manufacture, of the Study Agent shall be the property of Sponsor (&#147;<B>Sponsor Inventions</B>&#148;). Frenova hereby assigns and agrees to assign all Sponsor Inventions to Sponsor. Any Inventions that are related to dialysis
devices and processes (including disposables related thereto) shall be owned by Frenova or its designee (&#147;<B>Frenova Inventions</B>&#148;). Sponsor hereby assigns and agrees to assign all Frenova Inventions to Frenova. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.10.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The parties hereto acknowledge and agree that the inventions and technologies of Sponsor and Frenova or their
respective Affiliates that <FONT STYLE="white-space:nowrap">pre-exist</FONT> this Agreement or are made or conceived independently of a Study and the Services are their separate property, respectively, and are not affected by this Agreement and no
Party hereto shall have any claims to or rights in such <FONT STYLE="white-space:nowrap">pre-existing</FONT> or independently made or conceived inventions and technologies. The Sponsor and Frenova shall not be deemed to transfer or grant to another
Party hereto any rights except insofar as necessary to permit the parties to conduct Study related Services, and as expressly provided in this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.10.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Subject to Section&nbsp;5.10.1 above, title to any other Inventions made or conceived (i)&nbsp;solely by
Sponsor employees or consultants shall be solely owned by Sponsor; (ii)&nbsp;solely by Frenova employees or consultants shall be solely owned by Frenova; and (iii)&nbsp;jointly by Sponsor employees or consultants and/or Frenova employees or
consultants shall be jointly owned by the respective employers (&#147;<B>Joint Inventions</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.10.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Parties understand and agree that Frenova is in the business of providing dialysis care through its
clinics. As such, the Parties agree that with respect to data and results arising out of the performance of the Study related Services, Frenova retains a right to use the Study data in connection with the treatment of patients. Frenova agrees to
hold the Study data in confidence and to maintain the Study data as Confidential Information as defined by this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.10.5</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Each Party hereto agrees to assist the other Party hereto in their efforts to establish and perfect its rights
acquired under this Section&nbsp;5.10, and to execute any documents reasonably necessary to do the same. The Party requesting such assistance shall reimburse the other Party for reasonable expenses incurred in satisfying the obligations under the
immediately preceding sentence. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g373959dsp18.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">5.10.6</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">With respect to Joint Inventions, Frenova and Sponsor shall each own a
<FONT STYLE="white-space:nowrap">one-half</FONT> undivided interest in the Joint Inventions and, subject to the terms of this Agreement, can sell, license or otherwise transfer its rights to the Joint Inventions without a duty of accounting to the
other Party. Each Party hereby grants to the other Party all permissions, consents and waivers with respect to, and all licenses under, such Joint Inventions, throughout the world, necessary to provide the other Party with such rights of practice,
use and other exploitation, and will execute documents as necessary to accomplish the foregoing. In addition, the Parties shall cooperate in good faith in connection with (i)&nbsp;preparing, filing and prosecuting patent applications (including
reissue, continuing, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">continuation-in-part,</FONT></FONT> provisional, divisional, and substitute applications and any foreign counterparts thereof); (ii) maintaining any resulting
patents; (iii)&nbsp;managing any interference or opposition proceedings relating to the foregoing; and (iv)&nbsp;bringing, pursuing and settling infringement claims against third parties. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.11</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Publicity </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as may be required by law, a Party shall not use the other Party&#146;s name or any of the name of any of the other Party&#146;s Affiliates, in any
press release, publicity, advertising, or other disclosure without the named party&#146;s prior written consent. Furthermore, no Party to this Agreement shall use the names, trade names, trademarks, service marks, logos or other brand-source indicia
(&#147;Trademarks&#148;) of any other Party in any advertising, promotional or sales literature or in any publicity without the prior written approval of the Party whose Trademarks are to be used. Further, either Party may make such public
disclosures as it determines, based on advice of counsel, are reasonably necessary to comply with laws or regulations. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.12</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Publications </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frenova shall not publish any articles or make any presentations relating to the Services, Sponsor Confidential Information or referring to data generated
pursuant to any Statement of Work issued hereunder, without the prior written consent of Sponsor. Sponsor shall not publish any articles or make any presentations including Frenova Confidential Information, without the prior written consent of
Frenova. Nothing in this Section&nbsp;5.12 will prevent Sponsor from publishing any results of any Study. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g373959dsp18.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.0</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>REPRESENTATIONS AND WARRANTIES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Acknowledgements </B></P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sponsor acknowledges and agrees that there can be no assurance, representation or warranty by Frenova that a Study Agent which is the subject of research in
any Study to which the Services are related, either during the term of this Agreement or thereafter, will be successfully developed or, if so developed, will receive the required approval by the United States Food and Drug Administration
(&#147;<B>FDA</B>&#148;) or other regulatory authority. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Representations and Warranties of Sponsor </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">6.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sponsor represents and warrants to Frenova as of the Effective Date that, to Sponsor&#146;s knowledge,
performance of obligations required of Frenova hereunder will not infringe or violate the intellectual property rights of any third party including but not limited to trademark, trade secrets, copyright, patent, proprietary information rights.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">6.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sponsor represents and warrants that neither any assignment nor task requested by Sponsor nor the conduct
thereof as provided in this Agreement would necessarily violate any applicable law or regulation. Sponsor shall notify Frenova immediately upon learning of any potential violation of this Agreement or of applicable law pertaining to the Study.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">6.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sponsor represents and warrants that it has the right, title and interest in the Study Agent which is the
subject of research covered by this Agreement or any Statement of Work (whether such right, title and interest is held solely by Sponsor or jointly with others) and that it has the legal right, authority and power to enter into this Agreement, and
to perform any clinical trial which is the subject of a Statement of Work issued hereunder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">6.2.4</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sponsor represents and warrants it will provide Frenova with copies of any monitoring visit <FONT
STYLE="white-space:nowrap">follow-up</FONT> letters sent to the Trial Sites, provided that Frenova agrees to limit their use of these monitoring visit <FONT STYLE="white-space:nowrap">follow-up</FONT> letters to the provision of the Services.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Representations and Warranties of Frenova </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">6.3.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Frenova represents and warrants that the personnel assigned to perform Services rendered under this Agreement
will be capable professionally, and that it will perform its obligations hereunder in accordance with all applicable federal, international, state or local law or regulation, the terms of this Agreement and any Statement of Work issued hereunder.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g373959dsp18.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">6.3.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Frenova further represents and warrants that it will make available to Sponsor or to the responsible regulatory
authority relevant records, programs, and data as may be reasonably requested by Sponsor for purposes related to filing and prosecution of Sponsor&#146;s related applications for any regulatory approvals. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">6.3.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Frenova&#146;s sole obligation for material breach of a representation and warranty set out in this Section
will be, at Sponsor&#146;s option, to correct or <FONT STYLE="white-space:nowrap">re-perform,</FONT> or refund all amounts paid for that portion of the Services that fails to materially conform thereto. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Debarment Certification </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">6.4.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Frenova certifies that it has not been debarred under Section&nbsp;306 of the Federal Food, Drug, and Cosmetic
Act, 21 U.S.C. <B>&#167;</B>335a(a) or (b)&nbsp;or any equivalent local law or regulation. In the event that Frenova becomes debarred, Frenova agrees to notify Sponsor immediately. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">6.4.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Frenova certifies that no individual or entity providing Services hereunder has been or will be debarred under
Section&nbsp;306 of the Federal Food, Drug and Cosmetic Act, 21 U.S.C &#167;335a (a)&nbsp;or (b) or any equivalent local law or regulation. In the event that Frenova becomes aware of or receives notice of the debarment of any individual or entity
providing Services hereunder, Frenova agrees to notify Sponsor immediately. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Suspension or Exclusion from Federal Health Care Programs </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each Party represents and warrants that it has not been and will not be excluded, suspended, sanctioned or otherwise restricted from participating in federal
health care programs in the U.S., including but not limited to, Medicare or Medicaid.&nbsp;&nbsp;&nbsp;&nbsp;In the event that a Party becomes aware of or receives notice of its exclusion, suspension, sanction or restriction from participating in
federal health care programs in the U.S., such Party shall notify the other Party immediately. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Other Warranties </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parties&#146; warranties and representations contained in this Agreement are in lieu of all other warranties expressed or implied. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.0</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INDEMNIFICATION AND INSURANCE </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification by Sponsor </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.1.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sponsor will indemnify, defend and hold harmless Frenova, its Affiliates, and their officers, directors,
agents, employees, and independent contractors (each an &#147;<B>Indemnitee</B>&#148;) against any and all losses, damages, liabilities, costs and expenses, settlement payments, judgments, fines, fees, penalties or other charges, including
reasonable </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g373959dsp18.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
attorneys and professional fees (collectively &#147;Losses&#148;) resulting from any claims, causes of action or suits, proceeding, arbitration, pending or threatened, and in each case by a third
party (each a &#147;<B>Claim</B>&#148;) against Indemnitees arising out of the authorized use or disclosure of Sponsor&#146;s Confidential Information by the Indemnitee or their respective Representatives, the Study, the Services and other work
conducted under this Agreement, in each case subject to Section&nbsp;7.1.3. Frenova will promptly notify Sponsor upon receipt of notice of any Claim (provided that the failure to give such notice will not relieve Sponsor of its obligations under
this Section except to the extent, if at all, it is prejudiced thereby) and will permit Sponsor&#146;s attorneys and personnel, at Sponsor&#146;s discretion and cost, to handle and control the defense of any such Claim. Frenova may participate in
the defense using its own independent counsel, at Frenova&#146;s expense, without relieving Sponsor of its obligations under this Section. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.1.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Under no circumstances, however, will Sponsor accept liability, settle or otherwise compromise any Claims
without prior written consent of Frenova, which will not be unreasonably withheld. Frenova will fully cooperate and aid in any such defense. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.1.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sponsor will not be obligated to indemnify, defend, or hold harmless Frenova against any Claim to the extent
that such Claim arose as a result of Frenova&#146;s negligence, intentional misconduct or breach of this Agreement or any Statement of Work hereunder. If Sponsor incurs reasonable defense costs that it is not responsible for pursuant to this
Section&nbsp;7.1.3, Frenova will repay to Sponsor all such costs. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification by Frenova </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.2.1</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Frenova will indemnify, defend and hold harmless Sponsor and its employees, officers, and directors against any
and all Losses, resulting from any Claim arising from the authorized use or disclosure of Frenova&#146;s Confidential Information by Sponsor or their respective Representatives, Frenova&#146;s negligence, intentional misconduct, or breach of this
Agreement or any Statement of Work hereunder. Sponsor will promptly notify Frenova upon receipt of notice of any Claim for which it intends to seek indemnification hereunder, provided that the failure to give such notice will not relieve Frenova of
its obligations under this Section except to the extent, if at all, it is prejudiced thereby. Sponsor will permit Frenova&#146;s attorneys and personnel, at Frenova&#146;s discretion and cost, to handle and control the defense of any such Claim.
Sponsor may participate in the defense using its own independent counsel, at Sponsor&#146;s expense, without relieving Frenova of its obligations under this Section. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g373959dsp18.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.2.2</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Under no circumstances, however, will Frenova accept liability, settle or otherwise compromise any Claims
subject to indemnification under this Section without prior written consent of Sponsor, which will not be unreasonably withheld. Sponsor will fully cooperate and aid in any such defense. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">7.2.3</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Frenova will not be obligated to indemnify, defend or hold harmless Sponsor against any Claim to the extent
that such claim arose as a result of Sponsor&#146;s negligence, intentional misconduct or breach of this Agreement or any Statement of Work hereunder. If Frenova incurs reasonable defense costs that it is not responsible for pursuant to this
Section&nbsp;7.2.3, Sponsor will repay to Frenova all such costs. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Limits of Liability </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frenova&#146;s liability for direct damages hereunder will not exceed the total fees for Services payable by Sponsor to Frenova under the applicable Statement
of Work. Except for any breach of provisions related to Confidential Information in Section&nbsp;5, in no event will a Party be liable to the other Party for any indirect, incidental, special, consequential, punitive, exemplary damages of any kind
(including without limitation, lost profits, lost savings, loss of data, loss of business opportunities) arising out of or related to this Agreement, any Statement of Work, or the transactions contemplated by this Agreement, however caused, under
any theory of liability, even if any or all of the Parties have been advised of the possibility of such damages. Nothing in this Section&nbsp;7.3 will limit a Party&#146;s liability pursuant to Sections 7.1 or 7.2. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Insurance </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sponsor represents and warrants that it maintains a policy or program of insurance or at levels sufficient to support the Sponsor&#146;s Indemnification and
obligations and duties assumed under this Agreement. This includes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">General liability insurance for bodily injury, including death, and property damage; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Workers&#146; compensation insurance in the amount required by the law of the state in which the
Institution&#146;s employees are located; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Clinical trial insurance policy or similar systems for compensation for any damage suffered by a subject
resulting from participation in a clinical trial conducted in the EU. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sponsor shall provide to Frenova, upon request, evidence of its
insurance of the types specified in this Section or self-insurance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frenova represents and warrants that it maintains a policy or program of insurance or
self-insurance at levels sufficient to support the Frenova&#146;s Indemnification and obligations and duties assumed under this Agreement. For Services performed within the United States of America, this includes: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">General liability insurance for bodily injury, including death, and property damage; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g373959dsp18.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Workers&#146; compensation insurance in the amount required by the law of the state in which the
Institution&#146;s employees are located; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Professional liability insurance. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For Services performed outside of the United States of America, this includes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="7%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">General and Product liability insurance for bodily injury, including death, and property damage.
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frenova shall provide to Sponsor, upon request, evidence of its insurance of the types specified in this Section or self-insurance. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.0</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MISCELLANEOUS CLAUSES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Independent contractor relationship </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frenova and Sponsor are independent contractors. Nothing in this Agreement will be construed to create the relationship of partners, joint venturers, or
employer and employee between Frenova and Sponsor or Frenova&#146;s employees. Neither Party, nor its employees, or independent contractors will have authority to act on behalf of or bind the other Party in any manner whatsoever unless otherwise
authorized in this Agreement or a specific Statement of Work or in a separate writing signed by both Parties. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Nonsolicitation of Employees </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither Party, during the term of this Agreement and for twelve (12)&nbsp;months thereafter, will, without the prior written consent of the other Party,
directly or indirectly solicit for employment or contract, attempt to employ or contract with or assist any other entity in employing, contracting with or soliciting for employment or contract any employee or executive who is at that time
employed/contracted by the other Party or an Affiliate used in accordance with Section&nbsp;8.8 and who had been employed/contracted by the other Party or an Affiliate used in accordance with Section&nbsp;8.8 in connection with one or more
Statements of Work issued hereunder. Provided, however, that the foregoing provision will not prevent either Party from conducting solicitation via a general advertisement for employment that is not specifically directed to any such employee or from
employing any such person who responds to such solicitation. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Notices </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise provided, all communications and notices required under this Agreement will be mailed by first class mail or sent via nationally
recognized overnight courier to the addresses set forth below, or to such other addresses as the Parties from time to time specify in writing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g373959dsp18.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><U>If to Sponsor:</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>If to Frenova:</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">inRegen</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Twin City Bio LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3929 WestPoint BLVD</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite G</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Winston-Salem, NC 27103</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attn: Tim Bertram</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frenova, LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">920 Winter Street</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Waltham, MA 02451</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: Business Operations</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">with a copy to:</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Frenova, LLC</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o FMCNA</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">920 Winter Street</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Waltham, MA 02451</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: Corporate Law
Department</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Anti-Bribery; Anti-Corruption </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As stated in the Fresenius Medical Care Code of Ethics and Business Conduct, Frenova upholds the values of quality, honesty and integrity, innovation and
improvement, respect and dignity, as well as lawful conduct, especially with regard to anti-bribery and anti-corruption. Frenova upholds these values in its own operations, as well as in its relationships with business partners. Frenova&#146;s
continued success and reputation depends on a common commitment to act accordingly. Together with Frenova, Sponsor is committed to uphold these fundamental values by adherence to applicable laws and regulations. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Force Majeure </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the performance of this Agreement by Frenova or Sponsor is prevented, restricted, interfered with or delayed (either totally or in part) by reason of any
cause beyond the control of the Parties (including, but not limited to, acts of God, explosion, disease, weather, war, insurrection, terrorism, civil strike, riots or extensive power failure), the Party so affected will, upon giving notice to the
other Party as soon as is practical, be excused from such performance to the extent of such prevention, restriction, interference or delay, provided that the affected Party will use reasonable efforts to avoid or remove such causes of <FONT
STYLE="white-space:nowrap">non-performance</FONT> and will continue performance whenever such causes are removed. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Governing Law </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Agreement will be governed in all respects by the laws of New York, United States of America or the laws of Germany, as applicable to where the Services
are performed, without regard to its conflict of laws principles. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Severability </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any of the provisions or a portion of any provision of this Agreement is held to be unenforceable or invalid by a court of competent jurisdiction, the
validity and enforceability of the enforceable portion of any such provision and/or the remaining provisions will not be affected thereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g373959dsp18.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Assignment </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither Party may assign this Agreement without the prior written consent of the other Party, which consent will not be unreasonably withheld; provided,
however, that either Party may assign this Agreement without consent to a successor in interest to substantially all of the business of that Party to which the subject matter of this Agreement relates upon delivery to the other Party of notice of
such assignment. Additionally, Frenova may use the services of its corporate Affiliates to fulfill its obligations under this Agreement and any Statement of Work provided that Frenova shall also remain fully responsible for such obligations
regardless of whether Frenova or one of its Affiliates has signed the Statement of Work. Frenova shall ensure that any Affiliate so used shall be acts according to all of the terms and conditions applicable to Frenova under this Agreement or any
Statement of Work, and the Affiliate shall be entitled to all rights and protections afforded Frenova under this Agreement and any Statement of Work. Any such Affiliate of Frenova may execute a Statement of Work directly. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.9</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Waiver </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No waiver of any term, provision or condition of this Agreement whether by conduct or otherwise in any one or more instances will be deemed to be construed as
a further or continuing waiver of such term, provision or condition or of any other term, provision or condition of this Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.10</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Entire Agreement; Incorporation by Reference; Conflict </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement and all Statements of Work (including any Protocols and Study Specifications) contains the full understanding of the Parties
with respect to the Services and supersedes all existing agreements and all other oral, written or other communications between the Parties concerning the subject matter hereof. This Agreement will not be modified in any way except in writing and
signed by a duly authorized representative of Sponsor and an authorized officer of Frenova. In the event of a conflict between the terms and conditions this Agreement or those of any Statement of Work, the terms of this Agreement will take
precedence and control unless the provisions of a Statement of Work expressly provide otherwise. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.11</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>English Language </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parties hereto confirm that this Agreement as well as any other documents relating hereto, including notices, have been and shall be drawn up in the
English language only. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.12</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Counterparts; Facsimile Signatures </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Agreement may be executed in any number of counterparts with the same effect as if all the parties had signed the same document. Such executions may be
transmitted to the parties by facsimile, or in graphical-image form by email or other electronic transmission (collectively, &#147;facsimile evidenced signature&#148;), is to be deemed for all purposes to have been executed and delivered by that
party to the other party and such facsimile evidenced signature shall have the full force and effect of an original signature. All fully executed counterparts, whether original or facsimile evidenced signature or a combination of both, shall be
construed together and shall constitute one and the same agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g373959dsp18.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.13</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Dispute Resolution </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event a dispute relating to this Agreement or any Statement of Work arises between the Parties, the Parties will use all reasonable efforts to resolve
the dispute through direct discussions for a period of thirty (30)&nbsp;business days. The senior management of each Party is committed to respond to any such dispute. Should such effort to amicably settle the dispute fail, the Parties may proceed
to file an action in court. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.13</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>No Requirement for Referrals; Fair Market Value. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parties agree that the benefits to the parties hereunder do not require, are not payment for and are not in any way contingent upon the referral of
patients or business or any other arrangement between the Parties. The Parties represent that the compensation negotiated and agreed upon is fair market value for the services rendered based upon arm&#146;s length bargaining. Furthermore, the
parties represent that the compensation is not and has not been determined in a manner that takes into account the volume or value of any referrals or business otherwise generated between the Parties for which payment may be made in whole or in part
under Medicare or any other federal health care program. The parties further represent that nothing contained in this Agreement and no amount paid hereunder is intended or shall be construed as an inducement for the Parties to refer or admit any
patients to, or order any goods or services from any Parties, or any of their respective Affiliates. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.14</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><FONT STYLE="white-space:nowrap">Non-Exclusivity;</FONT> Other Interests. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Parties acknowledge and agree that this Agreement is <FONT STYLE="white-space:nowrap">non-exclusive.</FONT> Additionally, nothing in this Agreement shall
limit, restrict or prevent each Party from pursuing, developing, engaging, or providing products or services that are or may be competitive with the products or services of the other Party including, but not limited, providing products or services
to a competitor; provided, however, that the confidentiality obligations hereunder remain in full force and effect with respect to each Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>7
<FILENAME>d373959dex1017.htm
<DESCRIPTION>EX-10.17
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.17</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.17 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MASTER SERVICES AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>T<SMALL>HIS</SMALL> M<SMALL>ASTER</SMALL> S<SMALL>ERVICES</SMALL> A<SMALL>GREEMENT</SMALL></B><SMALL></SMALL> (the
<B><I>&#147;Agreement&#148;</I></B>) is effective as of May&nbsp;1, 2019 (the <B><I>&#147;Effective Date&#148;</I></B>) by and between <B>PPD DEVELOPMENT, L.P.</B>, a Delaware limited partnership, with its principal executive offices located at 929
North Front Street, Wilmington, North Carolina (<B><I>&#147;PPD&#148;</I></B>) and <B>inRegen</B>, a Cayman Islands exempted company with its principal executive offices located at 10 Market St., #688 Camana Bay, Grand Cayman <FONT
STYLE="white-space:nowrap">KY1-9006</FONT> Cayman Islands (<B><I>&#147;Sponsor&#148;</I></B>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Sponsor is engaged in the
development, manufacture, distribution and sale of pharmaceutical products; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, PPD is a clinical research organization engaged
in the business of managing clinical research programs and providing clinical development and other related services; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS,
Sponsor may wish to retain the services of PPD from time to time to perform clinical development services in connection with certain clinical research programs Sponsor is conducting (individually, a <B><I>&#147;Project&#148;</I></B>), in which case
the terms and conditions for each such Project shall be set forth in a project addendum to be attached to this Agreement and incorporated herein by reference (individually, a <B><I>&#147;Project Addendum&#148; </I></B>and collectively, the
<B><I>&#147;Project Addenda&#148;</I></B>); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, PPD is willing to provide such services to Sponsor in accordance with the terms
and conditions of this Agreement and the attached Project Addenda. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, for good and valuable consideration contained herein,
the exchange, receipt and sufficiency of which are acknowledged, the parties agree as follows: </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>S<SMALL>ERVICES</SMALL></U><SMALL></SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1 <U>Services to be Provided by PPD</U>. PPD hereby agrees to provide to Sponsor the services identified and described in the Services
section of each Project Addendum attached to this Agreement (the <B><I>&#147;Services&#148;</I></B>). PPD shall perform the Services for each Project set forth in the applicable Project Addendum in compliance with (i)&nbsp;the protocol for the
Project (<B><I>&#147;Protocol&#148;</I></B>), which may be attached to and made a part of the applicable Project Addendum, as amended or updated from time to time, (ii)&nbsp;the terms and conditions of this Agreement, (iii)&nbsp;the terms and
conditions of the applicable Project Addendum, (iv)&nbsp;PPD&#146;s standard operating procedures (<B><I>&#147;SOPs&#148;</I></B>), which will be available for Sponsor&#146;s review upon written request, and (v)&nbsp;all applicable laws, rules and
regulations. Sponsor agrees that PPD is responsible only for those Services set forth on a properly executed Project Addendum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.2
<U>Project Addendum</U>. In the event that the parties hereto shall reach agreement with respect to the provision of Services for a Project, PPD, or a PPD Affiliate, and Sponsor, or an affiliate of Sponsor, shall execute a Project Addendum
evidencing such Services. Each Project Addendum shall be attached to this Agreement and incorporated into and made a part of this Agreement by reference, and each such Project Addendum and this Agreement shall constitute the entire agreement for the
applicable Project. To the extent any terms set forth in a Project Addendum conflict with the terms set forth in this Agreement, the terms of the Project Addendum shall control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.3 <U>Sponsor Cooperation</U>. Sponsor will, and will cause its affiliates and their respective representatives, agents, employees and
contractors (collectively referred to as &#147;<B><I>Sponsor&#146;s Representatives</I></B>&#148;) to, cooperate with PPD and its Affiliates in providing accurate and up to date information, taking action and executing documents, as appropriate, to
perform the Services or regulatory obligations delegated to PPD under a Project Addendum or achieve the objectives of this Agreement and any Project Addendum executed under this Agreement. Sponsor acknowledges and agrees that PPD&#146;s performance
under this Agreement is dependent on Sponsor&#146;s and Sponsor&#146;s Representatives&#146; timely and effective cooperation with PPD and its Affiliates. Accordingly, Sponsor acknowledges that any delay by
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="100%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">Page 1</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">PPD PROPRIETARY AND CONFIDENTIAL </P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sponsor or Sponsor&#146;s Representatives may result in PPD being released from an obligation or schedule
deadline or in Sponsor having to pay extra fees in order for PPD to meet a specific obligation or deadline despite the delay. In the event of any such delays, the study timelines will be revised accordingly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.4 <U>Compliance with Law</U>. Sponsor shall comply with all Applicable Laws in its performance of its obligations under, and subject matter
of, this Agreement. PPD will comply with all Applicable Laws in the performance of the Services and its obligations under this Agreement </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.5 <U>Operating Guideline, Safety Plan or Safety and Medical Management</U> <U>Plan.</U> Notwithstanding anything to the contrary herein, in
the event PPD and Sponsor agree upon operating guidelines, safety plans or safety and medical management plans (each shall be referred as a &#147;<B><I>Project- Specific Plan</I></B>&#148;), the parties shall comply with the terms and conditions of
any such Project-Specific Plan. In the event of any conflict between the terms and conditions of a Project-Specific Plan and the relevant Project Addendum, the terms and conditions of the Project-Specific Plan shall control. Sponsor shall be
responsible for any additional costs associated with compliance with the Project-Specific Plan, which will be captured in Contract Modification to the relevant Project Addendum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.6 <U>Patient Enrollment</U>. The parties agree that enrollment numbers are good faith estimates and that various factors outside of
PPD&#146;s control can affect the rate of enrollment. PPD shall exercise all reasonable efforts to meet such enrollment estimates but cannot guarantee that enrollment numbers or enrollment timelines will be met. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.7 <U>Final Protocol</U>. PPD shall not be liable or responsible for the final review, approval, adoption, and content of the Protocol, and,
accordingly, Sponsor shall be solely liable and responsible in this regard. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.8 <U>Definitions</U>. &#147;<B><I>Affiliate</I></B>&#148;
means an entity which that controls, is controlled by or is under common control with a party or, with respect to PPD, PPD&#146;s parent company Pharmaceutical Product Development, LLC. &#147;<B><I>Applicable Laws</I></B>&#148; means any applicable
federal, national (U.S. or foreign), supranational, state, provincial, territorial, local, municipal, regulatory, self-regulatory or similar statute, constitution, resolution, law, ordinance, regulation, rule or code, administrative order or
requirement, judgment, decree or other restriction enacted, adopted, issued, implemented or promulgated or otherwise put into effect by or under the authority of any governmental entity or common law. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>C<SMALL>OMPENSATION</SMALL> <SMALL>AND</SMALL> P<SMALL>AYMENT</SMALL></U><SMALL></SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 <U>Charges for Services</U>. Sponsor shall pay PPD for all Services performed under this Agreement and any
Project Addendum (<B><I>&#147;Direct Fees&#148;</I></B>) in accordance with the rates for such Services set forth in such Project Addendum, CNF or Contract Modification thereto. Upon signature of a Project Addendum, PPD shall invoice Sponsor an
initial amount equal to twelve percent (12%) of the total Direct Fees budget for that Project. Each Project Addendum will detail the payment schedule, inclusive of said advance, through which PPD shall be compensated for Services performed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Charges for Pass Through Costs</U>. Sponsor shall also reimburse PPD for all <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred in connection with the performance of the Services with respect to a Project, including, without limitation, investigator grants and fees, travel expenses, shipping and postage
costs, copying and printing fees, copyright fees, third party drug storage and distribution fees, required Institutional Review Board or similar board or committee fees, and other &#147;pass through&#148; expenses, each as set forth in the Project
Addendum or <FONT STYLE="white-space:nowrap">pre-approved</FONT> in writing by Sponsor and incurred in connection with performing the Services (collectively, the <B><I>&#147;Pass Through Costs&#148;</I></B>). Upon signature of a Project Addendum,
PPD shall invoice Sponsor a mutually <FONT STYLE="white-space:nowrap">pre-agreed</FONT> initial amount of the total estimated Pass Through Costs, exclusive of investigator fees, which are addressed separately in Section&nbsp;2.3 below. This initial
payment will be used to offset PPD&#146;s payment of Pass Through Costs on Sponsor&#146;s behalf. After this initial payment, PPD will invoice Sponsor monthly in arrears reflecting all actual Pass Through Costs incurred by PPD. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">PPD PROPRIETARY AND CONFIDENTIAL </P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Where PPD incurs Pass Through Costs in a currency other than the currency as stated in the
contract (&#147;Contract Currency&#148;), PPD shall, for Sponsor invoicing and payment purposes, convert such costs to the Contract Currency based on an average exchange rate between the local currency and the Contract Currency for the month in
which such costs were incurred. This average exchange rate will be based on the monthly average of the daily exchange rates as published in the Wall Street Journal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 <U>Charges for Investigator Fees</U>. At the beginning of each study Sponsor shall advance PPD a
<FONT STYLE="white-space:nowrap">pre-agreed</FONT> amount of the total investigator fee budget for the sole purpose of paying investigator fees. PPD will then invoice Sponsor monthly for reimbursement for all payments made to investigators during
the invoice period using funds received in the advance payment, and Sponsor agrees to pay such invoices in accordance with the terms of this Section&nbsp;2. For Sponsor invoicing and payment purposes, PPD shall convert all investigator fees that are
to be paid in a currency other than the Contract Currency to the Contract Currency based on the average exchange rate between the currencies for the month prior to the month the invoice is raised. PPD shall have no obligation to pay vendor costs, or
investigator payments to any vendor or investigator site for conduct of services related to a Project until PPD has received payment of such Pass-Through Costs from Sponsor. Notwithstanding anything to the contrary contained herein, Sponsor
acknowledges and agrees that certain vendor contracts, including without limitation, contracts for investigator meetings, comparator drug purchase and patient recruitment services, must be advanced and paid up front by Sponsor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.4 <U>Payment Terms</U>. Sponsor shall pay (meaning PPD shall receive cleared funds into its account(s)) each invoice within forty-five
(45)&nbsp;days of receipt of said invoice. In the event Sponsor disputes an invoice, or any portion of an invoice, such a dispute should be made, in writing <FONT STYLE="white-space:nowrap">(e-mail</FONT> is sufficient) within forty-five
(45)&nbsp;days of receipt of said invoice, together with documentation supporting Sponsor&#146;s dispute. Notwithstanding the foregoing, all undisputed invoices and all undisputed portions of any invoice shall continue to be payable forty-five
(45)&nbsp;days from receipt of said invoice. PPD and Sponsor shall use commercially reasonable efforts to resolve the dispute in good faith and as expeditiously as reasonably possible. Upon resolution of any such dispute, Sponsor shall make the
agreed upon payment within fifteen (15) days of such resolution. If payment is not received within the timeframes set forth in this Section&nbsp;2.4, in addition to any other rights and remedies available to PPD, such amounts shall be considered
late and will be subject to interest at the rate of one per cent (1.0%) per month (or the maximum amount permitted by applicable law if less than 1.0% per month) from the due date of the applicable invoice and lasting until the date of actual and
full payment of the outstanding amounts. Furthermore, in the event any undisputed amounts remain unpaid for ten (10)&nbsp;business days after Sponsor&#146;s receipt of written notice from PPD of such amount, PPD shall have the right, in its sole
discretion, to (i)&nbsp;suspend performance of the Services until PPD receives full payment of all outstanding and undisputed amounts. In no event will PPD have the right to withhold safety reports or patient data from Sponsor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.6 <U>Purchase Orders</U>. In the event Sponsor utilizes a purchase ordering system with its suppliers, Sponsor shall provide PPD the
applicable purchase order number (&#147;<B><I>PO</I></B>&#148;) for the Project on or before the date on which the Project Addendum or any amendment, is executed (whichever is earlier in time). Should Sponsor fail to provide the PO within the above
timeframe, PPD may invoice for Services performed and Pass Through Costs incurred. Sponsor will pay such invoices in accordance with the payment terms set forth in this Agreement irrespective of whether the invoice includes the Project PO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.7 <U>Payment after Termination</U>. Upon termination of any Project Addendum or this Agreement, Sponsor shall pay PPD: (i)&nbsp;all Direct
Fees for all Services performed; (ii)&nbsp;all Pass Through Costs incurred; (iii) any other costs or expenses payable by Sponsor pursuant to the terms of this Agreement or the Project Addendum, including any costs specified for wind down activities;
and (iv)&nbsp;all future <FONT STYLE="white-space:nowrap">non-cancelable</FONT> obligations incurred (where such obligations were created as a result of a Project being authorized by Sponsor). If no sums are outstanding from Sponsor to PPD, any
funds held by PPD, determined to be unearned (taking into account any wind down activities), shall be returned to Sponsor within sixty (60)&nbsp;days following completion of the final reconciliation Project budget. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.9 <U><FONT STYLE="white-space:nowrap">Pre-Execution</FONT> Services</U>. In the event Sponsor requests in writing PPD to begin providing the
Services for a Project prior to the execution by Sponsor of a Project Addendum, Sponsor agrees that PPD shall be compensated for Services performed pursuant to such written request in accordance with the payment terms contained herein and the PPD
Proposal for Services. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">PPD PROPRIETARY AND CONFIDENTIAL </P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.10 <U>Taxes</U>. All fees stated in this Agreement or any Project Addendum are exclusive of
Value Added Tax (&#147;<B><I>VAT</I></B>&#148;) or similar taxes. If any VAT or similar taxes are due, these will be payable by Sponsor in addition to the fees paid to PPD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.11 <U>Payments</U>. Unless otherwise set forth in a Project Addendum, all payments to PPD under this Agreement or any Project Addendum shall
be made as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">payment wired to:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">JPMorgan Chase</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Acct: 500002360</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">R/T Number: 021000021 (ACH&nbsp;&amp; Wire)</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>SWIFT/BIC: CHASUS33</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Beneficiary: PPD Development, L.P.</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any changes to the payee information set forth above require a writing signed by PPD&#146;s treasurer or chief financial
officer. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>T<SMALL>ERM</SMALL> <SMALL>AND</SMALL> T<SMALL>ERMINATION</SMALL></U><SMALL></SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 <U>Term</U>. The term of this Agreement shall commence on the Effective Date and shall continue for a period of
five (5)&nbsp;years unless extended by mutual written agreement by the parties. Each Project Addendum shall be effective upon the date set forth in such Project Addendum and shall terminate upon (i)&nbsp;the completion of the Services to be provided
thereunder, and (ii)&nbsp;PPD&#146;s receipt of all Direct Fees, Pass Through Costs, and any other payments due to PPD related to the Services provided thereunder, unless earlier terminated pursuant to the terms of this Agreement or the Project
Addendum, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 <U>Early Termination.</U> Any Project Addendum may be terminated without cause by Sponsor upon thirty
(30)&nbsp;days prior written notice. PPD or Sponsor may terminate any Project Addendum in the event of the other party&#146;s breach of Agreement or Project Addendum upon thirty (30)&nbsp;days prior written notice, provided that such breach is not
cured within such thirty (30)&nbsp;day period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.3 <U>Insolvency</U>. Either party hereto may terminate this Agreement or any Project
Addendum hereunder immediately upon the occurrence of an &#147;Insolvency Event&#148; with respect to the other party. For purposes of this Agreement, <B><I>&#147;Insolvency Event&#148; </I></B>shall mean (1)&nbsp;a party, a party&#146;s parent
organisation or any of the party&#146;s subsidiaries shall commence a voluntary proceeding seeking liquidation, reorganization or other relief with respect to itself or its debts under any bankruptcy, insolvency or other similar law or seeking the
appointment of a trustee, receiver, liquidator, custodian or other similar official of it or any substantial part of its property, or shall consent to any such relief or to the appointment of or taking possession by any such official in an
involuntary case or other proceeding commenced against it, or shall make a general assignment for the benefit of creditors, or ceases to be solvent, or suspends business, or shall fail generally to pay its debts as they become due, or shall take any
action to authorize any of the foregoing; (2)&nbsp;an involuntary case or other proceeding shall be commenced against a party, a party&#146;s parent organisation or any of the party&#146;s subsidiaries seeking liquidation, reorganization or other
relief with respect to it or its debts under bankruptcy, insolvency or other similar law or seeking the appointment of a trustee, receiver, liquidator, custodian or other similar official of it or any substantial part of its property, and such
involuntary case or other proceeding shall remain undismissed and unstayed for a period of sixty (60)&nbsp;days; or (3)&nbsp;an order for relief shall be entered against a party, a party&#146;s parent organisation or any of the party&#146;s
subsidiaries under the federal bankruptcy laws now or hereafter in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.4 <U>Effect of Termination</U>. The termination of this
Agreement by either party shall not automatically terminate all Project Addenda, unless otherwise agreed in writing. In the event of termination or expiration of this Agreement, the terms and conditions of this Agreement shall continue to apply to
all Project Addenda still in effect after such termination or expiration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">PPD PROPRIETARY AND CONFIDENTIAL </P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.5 <U>Wind Down</U>. Upon the termination of this Agreement or a Project Addendum, PPD shall
reasonably cooperate with Sponsor to provide for an orderly wind-down or transfer of the Services provided by PPD hereunder, which, shall include the prompt provision of all data and results belonging to Sponsor of any Project to Sponsor in a
mutually acceptable format. Costs associated with such wind-down or transfer activities shall be billed to Sponsor on a time and materials basis, based on the then-current PPD rates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.6 <U>Provisions Surviving Termination</U>. The expiration, termination or cancellation of this Agreement will not extinguish the rights of
either party that accrue prior to expiration, termination or cancellation or any obligations that extend beyond expiration, termination or cancellation, either by their inherent nature or by their express terms, including, without limitation, the
obligations contained in Sections 2 (Compensation and Payment), 3.4 (Effect of Termination), 3.5 (Wind Down), 3.6 (Provisions Surviving Termination), 5 (Confidentiality), 6 (Data Privacy), 7 (Intellectual Property), 8 (Indemnification), 9
(Limitation of Liability), 10 (Insurance) 11.2 (Record Maintenance after Expiration or Termination), 13.2 (Publicity), 13.5 (Notices), 13.6 (Governing Law), 13.7 (Severability), 13.10 (Assignment), 13.11 (Subcontracting), 13.12 (Arbitration), 13.13
(Construction) and 13.18 (Clinical Trial Supply), hereof and herein shall survive termination of this Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>P<SMALL>ERSONNEL</SMALL></U><SMALL></SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 <U>Project Management</U>. The Services with respect to each Project shall be performed by PPD under the direction of the person identified
as the operational lead in the applicable Project Addendum or such other person acceptable to Sponsor as PPD may from time to time designate as the Project Manager, such Sponsor acceptance of the designated Project Manager not to be unreasonably
withheld or delayed in all instances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 <U>Covenant Not to Interfere</U>. During the term of a Project Addendum, neither party will
knowingly solicit for employment any employee of the other party who is conducting the Project under that Project Addendum. As used in this section &#147;<B><I>solicit</I></B>&#148; means the initiation by a party or its agent of a contact with any
of the other party&#146;s then current employees who are conducting the Project under that Project Addendum for the purpose of offering employment to such employees, but shall not include the circumstance where any such employee initiates a contact
with the other party for the purpose of obtaining employment whether in response to a general advertisement of employment or where such contact is initiated by a third party who was not instructed to contact such employee by the hiring party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3 <U>Personnel Retention</U>. In the event of delays in the performance of the Project, i.e., after PPD is authorized to commence work,
which are beyond the control of PPD or caused by or are the responsibility of Sponsor, and where Sponsor desires for PPD to keep PPD Project personnel assigned to the Project, in addition to any other sums payable to PPD hereunder, Sponsor shall pay
a personnel fee calculated on an <FONT STYLE="white-space:nowrap">FTE-day</FONT> basis rate agreed upon by both parties. Said personnel fees shall be invoiced by PPD on a monthly basis and shall be due and payable by Sponsor within forty-five
(45)&nbsp;days of receipt of invoice. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>C<SMALL>ONFIDENTIALITY</SMALL></U><SMALL></SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1 <U>Sponsor Confidential Information</U>. PPD shall treat all of Sponsor&#146;s information, including information generated by or as a
result of the Services or otherwise provided to PPD by or on behalf of Sponsor (<B><I>&#147;Sponsor Confidential Information&#148;</I></B>) as the confidential and exclusive property of Sponsor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 <U>PPD Confidential Information</U>. Sponsor shall treat all information of PPD or any of PPD&#146;s Affiliates including, without
limitation, any PPD bids or proposals, standard operating procedures, third party confidential information, personnel information, all PPD Property (as defined below) (<B><I>&#147;PPD Confidential Information&#148;</I></B>) as the confidential and
exclusive property of PPD. Further, with the exception of Sponsor Confidential Information, any information disclosed, obtained, or observed by Sponsor or any affiliate of Sponsor during an audit of PPD or an Affiliate of PPD, or the facilities of
either shall be deemed to be PPD Confidential Information. Sponsor Confidential Information and PPD Confidential Information shall collectively be referred to as &#147;<B><I>Confidential Information</I></B>.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">PPD PROPRIETARY AND CONFIDENTIAL </P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3 <U>Use of Confidential Information</U>. Each party shall use the other&#146;s
Confidential Information solely for the purposes contemplated by this Agreement and for no other purpose without the prior written consent of the other party. Neither party shall publish, disseminate or otherwise disclose Confidential Information of
the other to any third party without first obtaining the written consent of such other party; provided however that (i)&nbsp;each party may disseminate or otherwise disclose the other&#146;s Confidential Information within its organization to only
those Affiliates, employees, agents, representatives and advisors (collectively &#147;<B><I>Associates</I></B>&#148;) and Subcontractors who have a need to know; and (ii)&nbsp;PPD may disclose Sponsor&#146;s Confidential Information to investigator
sites performing Services in respect of the applicable Project to the extent reasonably required to perform the Services or the Project. Furthermore, each party shall ensure that its Associates and Subcontractors are aware of this Agreement and
bound by terms of confidentiality no less stringent than those stated herein. In addition, prior to providing any Confidential Information to a permitted third party other than an Associate, the receiving party will ensure that such third parties
are bound to written obligations of confidentiality that are not less stringent than those contained herein. Each Party will remain responsible for the acts or omissions of its Associates and Subcontractors in connection with the Confidential
Information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4 <U>Exceptions to Confidential Information</U>. The above provisions of confidentiality shall not apply to that part of
disclosing party&#146;s Confidential Information which the receiving party is able to demonstrate by documentary evidence: (i)&nbsp;was in the receiving party&#146;s possession prior to receipt from the disclosing party or is independently developed
by or for the receiving party, as shown by the receiving party&#146;s contemporaneous written records; (ii)&nbsp;was in the public domain at the time of receipt from disclosing party; (iii)&nbsp;subsequently becomes a part of the public domain
through no fault of the receiving party, its affiliates or its Associates and Subcontractors; or (iv)&nbsp;is lawfully received by the receiving party from a third party having a right of further disclosure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5 <U>Disclosure Required by Law</U>. The receiving party may disclose Confidential Information to the extent required pursuant to any
judicial action, order of the court or other governmental agency; provided, however, that the receiving party shall make all reasonable efforts to notify the disclosing party prior to the disclosure of Confidential Information and allow the
disclosing party the opportunity to contest and avoid such disclosure, and further provided that the receiving party shall disclose only that portion of such Confidential Information that it is legally required to disclose. To the extent permitted
by law the receiving party will request any disclosures made under this section be maintained confidential by the court or agency involved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.6 <U>Return of Information</U>. Upon termination or expiration of this Agreement and subject to the terms of Section&nbsp;11.2 or at the
disclosing party&#146;s earlier written request, the receiving party shall return, and shall cause its affiliates and Associates and Subcontractors to return, all documentary, electronic or other tangible forms of Confidential Information provided
by the disclosing party including, without limitation, any and all copies thereof, or, at the disclosing party&#146;s request, destroy all or such parts of the disclosing party&#146;s Confidential Information as the disclosing party shall direct.
Notwithstanding the foregoing, the receiving party may retain copies of such of the disclosing party&#146;s Confidential Information as is reasonably necessary for regulatory purposes and one copy for legal archival purposes, subject to the ongoing
obligations of <FONT STYLE="white-space:nowrap">non-</FONT> use and confidentiality. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.7 <U>Remedy</U>. Each party agrees that its
obligations hereunder are necessary and reasonable in order to protect the other party and the other party&#146;s business, and expressly agrees that monetary damages would be inadequate to compensate the other party for any breach of the terms of
this Agreement or a Project Addendum. Accordingly, each party agrees and acknowledges that any such violation or threatened violation will cause irreparable injury to the other party, and that, in addition to any other remedies that may be available
in law, in equity or otherwise, the other party shall be entitled to seek injunctive relief against the threatened breach of this Agreement or a Project Addendum or the continuation of any such breach, without the necessity of proving actual
damages. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.8 <U>Survival</U>. The obligations contained herein shall survive for a period of ten (10)&nbsp;years from the date of the
disclosure of the Confidential Information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">PPD PROPRIETARY AND CONFIDENTIAL </P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>D<SMALL>ATA</SMALL> P<SMALL>RIVACY</SMALL></U><SMALL></SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.1 <U>Definitions</U>. &#147;Data Protection and Privacy Laws&#148; means all applicable laws, regulations and regulatory requirement and
guidance relating to data protection and privacy globally, including: (a)&nbsp;the U.S. Health Insurance Portability and Accountability Act of 1996 (&#147;HIPAA&#148;) Privacy and Security Rules, 45 C.F.R. Parts
<FONT STYLE="white-space:nowrap">160-164;</FONT> (b) any other U.S. state or federal laws or regulations governing the privacy or security of personal data; (c)&nbsp;the EU Data Protection Directive 95/46/EC (&#147;the Directive&#148;), superseded
by the General Data Protection Regulation (&#147;Regulation&#148;) on 25&nbsp;May 2018, or any related legislation of any member state in the European Economic Area (&#147;EEA&#148;); or (d)&nbsp;any other law now in force or that may in future come
into force governing the Processing of Personal Data applicable to any party to this Agreement, and including those relating to security breaches, identity theft, and unauthorized disclosures of Personal Data. &#147;Personal Data&#148;,
&#147;Process/Processing&#148;, &#147;Controller&#148;, &#147;Processor&#148; and &#147;Data Subject&#148; shall have the same meaning as under the Regulation and shall also include these terms, or corresponding terms, as defined under any other
Data Protection and Privacy Laws. In particular, &#147;Personal Data&#148; shall also include &#147;personal information&#148;, &#147;health information&#148;, and &#147;protected health information&#148; as defined by Data Protection and Privacy
Laws, including HIPAA. &#147;Data Subject&#148; shall also include a &#147;person&#148; or &#147;individual&#148; as defined by Data Protection and Privacy Laws, including an &#147;individual&#148; as defined by HIPAA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.2 <U>Compliance</U>. Each party warrants to the other that it will Process Personal Data in compliance with all Data Protection and Privacy
Laws, as well as applicable regulatory guidance, including the International Conference on Harmonisation Guideline for Good Clinical Practice <FONT STYLE="white-space:nowrap">(ICH-GCP)</FONT> and Good Laboratory Practice (GLP). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.3 <U>Respective Roles of the Parties</U>. Sponsor and PPD acknowledge that Sponsor is the Controller and PPD is the Processor with respect
to the Processing of Personal Data on behalf of the Sponsor pursuant to Services provided by PPD under this Agreement. In the event that the Services are performed by any PPD Affiliate then such PPD Affiliate shall be a <FONT
STYLE="white-space:nowrap">sub-Processor.</FONT> Where Sponsor is the Controller, PPD shall Process the Personal Data only in accordance with instructions from Sponsor, unless restricted in doing so by a law to which PPD is subject. In such case,
PPD shall inform the Sponsor of this legal restriction before the Processing begins, unless prevented from doing so by law. (The instructions referred to in this paragraph may be specific instructions or instructions of a general nature as set out
in this Agreement, a Project Addendum, Protocol, SOP or Project-Specific Plan or as otherwise documented by Sponsor to PPD during the term of this Agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.4 <U>Representative</U>. If Sponsor needs to appoint a representative to comply with Data Protection and Privacy Laws in any EU Member State
pursuant to Article 4 of the Directive or Article 27 of the Regulation, and PPD is willing to provide such services to Sponsor, Sponsor and PPD may enter into a mutually acceptable agreement for such representative purposes. Unless and until such an
agreement is entered into, PPD shall not be deemed to be a representative under any Data Protection and Privacy Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.5 <U>Data
Processing Obligations</U>. PPD shall implement appropriate technical and organisational measures to protect Personal Data as required by <FONT STYLE="white-space:nowrap">ICH-GCP</FONT> and/or GLP and Data Protection and Privacy Laws, and in
particular shall implement measures to assist Sponsor in meeting its information security obligations under Articles 32 to 36 of the Regulation. PPD shall in particular ensure that persons authorized to Process Personal Data have committed
themselves to confidentiality or are under an appropriate statutory obligation of confidentiality. PPD shall make available to Sponsor all information necessary to demonstrate compliance with its data protection obligations pursuant to this
Agreement and any Project Addendum and contribute to audits conducted by Sponsor or another auditor mandated by Sponsor, subject to the provisions of Section&nbsp;11.3 of this Agreement regarding audits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.6 <U>Privacy and Security Incidents</U>. If PPD becomes aware of any unauthorized access, acquisition, use, disclosure, loss, destruction,
or alteration of Personal Data resulting in a compromise of the confidentiality, integrity, or availability of the Personal Data, and a risk of harm to the Data Subjects (&#147;Security Breach&#148;), then it shall notify Sponsor without undue
delay, and in any event within two (2) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">PPD PROPRIETARY AND CONFIDENTIAL </P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">business days, and, if requested, assist Sponsor in meeting its obligations to notify Data Subjects,
regulatory authorities or other required parties. Such required notifications shall be at Sponsor&#146;s sole cost and expense, except to the extent PPD or its Associate or Subcontractor was responsible for such Security Breach. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.7 <U>Data Protection Requests.</U> PPD shall promptly notify Sponsor in writing if, in the context of the Services, it receives any
communication from a Data Subject (in particular where the Data Subject wishes to exercise their data protection rights), a privacy supervisory authority or other regulatory authority in each case in respect of data protection, and provide Sponsor
with cooperation and assistance in relation to any such communication. PPD shall be entitled to charge Sponsor for such assistance at a mutually agreed upon hourly rate, unless the communication relates to a breach or violation by PPD or a PPD
Affiliate of its obligations under this Section&nbsp;6. However, PPD and Sponsor recognize that any fees charged to the requesting party must comply with Data Protection and Privacy Laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.8 <U>Processors and Data Transfers</U>. In providing Services, it may be necessary to <FONT STYLE="white-space:nowrap">sub-contract</FONT>
certain Personal Data Processing tasks to one or more third party <FONT STYLE="white-space:nowrap">sub-Processors.</FONT> An <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">up-to-date</FONT></FONT> list of appointed <FONT
STYLE="white-space:nowrap">sub-Processors</FONT> is available from the Sponsor&#146;s PPD business contact. It may also be necessary to transfer Personal Data to PPD Affiliates based outside the EEA (member states of the European Union plus, Norway,
Iceland&nbsp;&amp; Liechtenstein) and Switzerland or <FONT STYLE="white-space:nowrap">sub-contract</FONT> certain tasks to one or more third party <FONT STYLE="white-space:nowrap">sub-Processors,</FONT> including cloud-based service providers, whose
servers may be located outside the EEA and Switzerland. Transfers of Personal Data to PPD Affiliates and <FONT STYLE="white-space:nowrap">sub-Processors</FONT> outside the EEA and Switzerland shall be variously protected by EU Standard Contractual
Clauses &#147;Controller to Processor&#148; 2010, or otherwise proceed on the basis of Data Subject consent. For the avoidance of doubt, Sponsor consents to the transfer of Personal Data to PPD&#146;s Affiliates and
<FONT STYLE="white-space:nowrap">sub-Processors,</FONT> including those outside the EEA and Switzerland using the above transfer mechanisms, where such transfers are necessary to perform the Services in accordance with this Agreement, any Project
Addendum, Protocol, SOP or Project- Specific Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.9 <U>Termination Obligations</U>. On any termination or expiry of this Agreement or
when instructed by Sponsor in writing, PPD shall cease all operations on Personal Data and shall promptly, at Sponsor&#146;s direction, cost and expense, return and/or irretrievably delete all Personal Data Processed by PPD under this Agreement and
in a format agreed by the Parties and instruct its subcontractors to do the same. Should PPD be prevented by its national law or local regulator from destroying or returning all or part of such data, the data shall be kept confidential and not be
actively processed for any purpose, and shall be deleted promptly upon the expiration or such legal or regulatory obligation. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>I<SMALL>NTELLECTUAL</SMALL> P<SMALL>ROPERTY</SMALL></U><SMALL></SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.1 <U>No License</U>. Neither anything contained herein, nor the delivery of any information to a party hereto, shall be deemed to grant the
receiving party any right or license under any patent or patent application or to any <FONT STYLE="white-space:nowrap">know-how,</FONT> technology or invention of the disclosing party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.2 <U>Sponsor Property</U>. Subject to Section&nbsp;7.3 below, PPD hereby assigns to Sponsor all rights PPD, PPD Affiliates or its Associates
and Subcontractors may have in any invention, technology, know- how or other intellectual property relating to the drug or therapeutic product, which is the subject of the Project, or Protocol and which is either: (i)&nbsp;the result of PPD&#146;s
provision of the Services and is contracted as part of the Services; (ii)&nbsp;incorporates, references, requires the use of, or is a derivative work of Sponsor&#146;s Confidential Information; or (ii)&nbsp;specifically set forth as a deliverable
under a Project Addendum (&#147;Sponsor Property&#148;). PPD shall assist Sponsor, at Sponsor&#146;s sole cost and expense, in obtaining or extending protection therefor. PPD warrants that it has and will continue to have agreements with its
Associates and Subcontractors to effect the terms of this Section&nbsp;7.2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.3 <U>PPD Property</U>. PPD and PPD Affiliates possess, and
in the future may possess certain processes, technology, <FONT STYLE="white-space:nowrap">know-how,</FONT> methodologies trade secrets, improvements, and other intellectual property, which has been independently developed without the benefit of any
information provided by Sponsor or in connection with the Services, does not incorporate, require the use of, or constitute derivative </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">PPD PROPRIETARY AND CONFIDENTIAL </P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">works of any Sponsor Confidential Information (collectively, &#147;PPD Inventions&#148;). Sponsor and PPD
agree that (i)&nbsp;any PPD Inventions; (ii)&nbsp;any literature reviews and analyses based on publicly available databases conducted by PPD in the performing the Services; and (iii)&nbsp;revisions, improvements, upgrades, or enhancements to each of
(i)-(ii) set forth in this section (collectively, &#147;PPD Property&#148;) shall, in each case, be the sole and exclusive property of PPD. PPD hereby grants to Sponsor a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> royalty-free,
worldwide, irrevocable (except in the event Sponsor breaches its licensing obligations herein), nontransferable (except in connection with the transfer of the product to which the Services or deliverable relate, and in no event to a competitor of
PPD), sublicensable (except to a competitor of PPD), perpetual license to use and exploit any PPD Property that is incorporated in any deliverable or other material provided by PPD pursuant to this Agreement, but only to the extent necessary for
Sponsor to use of the deliverables or the Services. In the event that Sponsor transfers its license or sublicenses as permitted in this Section&nbsp;7.3, Sponsor agrees that it will (i)&nbsp;first have written confidentiality agreements in place
with such third party in accordance with Section&nbsp;5 above, (ii)&nbsp;have such third parties bound to licensing obligations that are no less stringent than the terms of this Section&nbsp;7.3, with no further right to sublicense, and
(iii)&nbsp;remain liable and responsible to PPD for any third party&#146;s breach of the confidentiality and licensing terms required herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.4 <U>Third Party Materials</U>. In the event any Third Party Materials (as hereinafter defined) are used by PPD or its Affiliates to perform
the Services, Sponsor acknowledges and agrees that any such Third Party Materials are the sole and exclusive property of the applicable third party providing such Third Party Materials. Sponsor shall obtain no right, title or interest in any Third
Party Materials except as expressly provided herein. To the extent that a deliverable contains any Third Party Materials, PPD shall secure for Sponsor a fully paid up, royalty-free, <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license (PPD
will use commercially reasonable efforts to secure a license that is sublicensable and transferable in connection with any license or transfer of the drug product to which the Services Relate) to use such Third Party Materials solely to the extent
necessary to use such deliverable, provided that in no event may Sponsor use, offer, sell, commercialize or otherwise dispose of such Third Party Materials separate from such deliverable or on a stand-alone basis. &#147;Third Party Materials&#148;
means any data or other materials obtained by PPD or its Associates and Subcontractors from third parties or proprietary databases maintained by third parties, scales, or copies of published articles. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>I<SMALL>NDEMNIFICATION</SMALL></U><SMALL></SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.1 <U>Sponsor Indemnity</U>. Sponsor shall indemnify, defend, and hold harmless PPD and its Associates (<I>&#147;</I><B><I>PPD
Indemnitees</I></B><I>&#148;</I>) from and against any and all damages, liabilities, losses, fines, penalties, settlement amounts, costs and expenses of any kind or nature whatsoever, including, without limitation, reasonable attorneys&#146; fees,
expert witness fees, court costs, and amounts (collectively, &#147;<B>Losses</B>&#148;) incurred by PPD Indemnitees as a result of any third party claim, demand, action, proceeding, investigation or hearing (collectively, a
<B><I>&#147;Claim&#148;</I></B>) to the extent arising from this Agreement or any Services provided by PPD Indemnitees hereunder, including but not limited to, Project related services provided by PPD at the request of Sponsor yet prior to
finalization of the relevant Project Addendum; provided however, that Sponsor shall have no obligation of indemnity hereunder with respect to any Claim to the extent such Claim arises from the negligence, intentional misconduct or breach of this
Agreement on the part of PPD or its Associates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.2 <U>PPD Indemnity</U>. PPD shall indemnify, defend and hold harmless Sponsor and its
Associates (&#147;Sponsor Indemnitees&#148;) from and against any and all Losses incurred by Sponsor Indemnitees as a result of any Claim to the extent arising from the negligence, intentional misconduct, or breach of Agreement of PPD, PPD
Affiliates or its Associates; provided however, that PPD shall have no obligation of indemnity hereunder with respect to any Claim which arose from the negligence, intentional misconduct or material breach of this Agreement on the part of Sponsor or
its Associates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.3 <U>Indemnification Procedure</U>. Each indemnified party shall give the indemnifying party prompt notice of any Claim
for which indemnification is sought hereunder. The indemnifying party shall have the right to control the defense and settlement of a Claim, at its sole expense, provided the indemnifying party shall act reasonably and in good faith with respect to
all matters relating to the settlement or disposition of the Claim, and the indemnified party shall reasonably cooperate in the investigation, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">PPD PROPRIETARY AND CONFIDENTIAL </P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">defense and settlement of such Claim at the indemnifying party&#146;s expense. Neither party will enter into
any settlement agreement that attributes fault or negligence to the other party, requires any payment by the other party, or restricts the future actions or activities of the other party, without the other party&#146;s prior written consent, which
shall not be unreasonably withheld. Any indemnified party shall have the right to participate in, but not control, the defense and settlement of a Claim and to employ separate legal counsel of its own choice; provided, however, that such employment
shall be at the indemnified party&#146;s own expense, unless the indemnifying party has failed to assume the defense and employ counsel (in which case the indemnified party shall control the defense and settlement of such Claim). </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>L<SMALL>IMITATION</SMALL> <SMALL>OF</SMALL> L<SMALL>IABILITY</SMALL></U><SMALL></SMALL>.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.1 EXCEPT FOR LIABILITY ARISING FROM A PARTY&#146;S BREACH OF SECTIONS 5, OR 6 OR A PARTY&#146;S OBLIGATION OF
INDEMNIFICATION UNDER SECTION 8, NEITHER PARTY SHALL BE LIABLE FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL OR INDIRECT DAMAGES ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT (OR THE TERMINATION HEREOF) OR ANY PROJECT ADDENDUM, INCLUDING, WITHOUT
LIMITATION, LOSS OF PROFITS OR ANTICIPATED SALES, EVEN IF THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.2 TO
THE FULLEST EXTENT PERMITTED BY LAW, AND EXCEPT FOR PPD&#146;S LIABILITY FOR: (I)&nbsp;ITS BREACH OF SECTIONS 5 OR 6; (II) ITS INDEMNIFICATION OBLIGATIONS UNDER SECTION 8.2; OR (III)&nbsp;GROSS NEGLIGENCE, WILLFUL MISCONDUCT OR FRAUD, THE TOTAL
LIABILITY, IN THE AGGREGATE, OF PPD, PPD ASSOCIATES, AND ANY OF THEM, TO SPONSOR AND ANYONE CLAIMING BY OR THROUGH SPONSOR, FOR ANY AND ALL CLAIMS, LOSSES, COSTS OR DAMAGES, INCLUDING WITHOUT LIMITATION, ATTORNEYS&#146; FEES AND COSTS AND
EXPERT-WITNESS FEES AND COSTS OF ANY NATURE WHATSOEVER OR CLAIMS EXPENSES RESULTING FROM OR IN ANY WAY RELATED TO THIS AGREEMENT OR ANY PROJECT ADDENDUM FROM ANY CAUSE OR CAUSES SHALL NOT EXCEED ONE MILLION U.S. DOLLARS ($1,000,000) OR THREE TIMES
THE TOTAL DIRECT FEES, WHICHEVER IS GREATER, RECEIVED BY PPD UNDER THE APPLICABLE PROJECT ADDENDUM, WHICH IS THE SUBJECT OF THE CLAIM. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.3 TO THE FULLEST EXTENT PERMITTED BY LAW, THE TOTAL LIABILITY, IN THE AGGREGATE, OF EACH PARTY, ITS ASSOCIATES, AND ANY OF THEM, TO THE
OTHER PARTY AND ANYONE CLAIMING BY OR THROUGH THE OTHER PARTY, FOR ANY AND ALL SPECIAL, CONSEQUENTIAL, INCIDENTAL OR INDIRECT DAMAGES UNDER SECTION 9.1 ABOVE, AND RESULTING FROM ITS BREACH OF SECTIONS 5 OR 6 SHALL NOT EXCEED (I)&nbsp;EIGHT MILLION
U.S. DOLLARS ($8,000,000) IF THE DIRECT FEES PAYABLE UNDER THE PROJECT ADDENDUM GIVING RISE TO THE BREACH TOTAL TWO MILLION U.S. DOLLARS ($2,000,000) OR LESS, OR (II)&nbsp;FOUR TIMES (4X) THE TOTAL DIRECTS FEES PAYABLE UNDER THE PROJECT ADDENDUM OR
TWENTY- FIVE MILLION U.S. DOLLARS ($25,000,000), WHICHEVER IS LESS, WHERE SUCH DIRECT FEES ARE GREATER THAN TWO MILLION US DOLLARS ($2,000,000). </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.4 TO THE FULLEST EXTENT PERMITTED BY LAW, THE TOTAL LIABILITY, IN THE AGGREGATE, OF PPD, PPD ASSOCIATES, AND ANY OF THEM, TO SPONSOR AND
ANYONE CLAIMING BY OR THROUGH SPONSOR, FOR ANY AND ALL CLAIMS, LOSSES, COSTS OR DAMAGES, INCLUDING WITHOUT LIMITATION, ATTORNEYS&#146; FEES AND COSTS AND EXPERT- WITNESS FEES AND COSTS OF ANY NATURE WHATSOEVER OR CLAIMS EXPENSES RESULTING FROM ITS
GROSS NEGLIGENCE SHALL NOT EXCEED (I)&nbsp;EIGHT MILLION U.S. DOLLARS ($8,000,000) IF THE DIRECT FEES PAYABLE UNDER THE PROJECT ADDENDUM GIVING RISE TO THE BREACH TOTAL TWO MILLION U.S. DOLLARS ($2,000,000) OR LESS, OR (II)&nbsp;FOUR TIMES (4X) THE
TOTAL DIRECTS FEES PAYABLE UNDER THE PROJECT ADDENDUM OR TWENTY-FIVE MILLION U.S. DOLLARS ($25,000,000), WHICHEVER IS LESS, WHERE SUCH DIRECT FEES ARE GREATER THAN TWO MILLION US DOLLARS ($2,000,000). </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">PPD PROPRIETARY AND CONFIDENTIAL </P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>I<SMALL>NSURANCE</SMALL></U><SMALL></SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.1 Sponsor and PPD will each undertake to purchase and maintain insurance of such types and amounts reasonably adequate to cover any
liabilities arising out of its obligations hereunder. Sponsor further undertakes to purchase and maintain insurance of such types and amounts and coverage reasonably adequate (including but not limited to that required by law) to cover any
liabilities arising in relation to all clinical trials contracted to PPD pursuant to this Agreement. The following sets forth the minimum thresholds of insurance each party will maintain: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.2 <U>PPD Insurance</U>. PPD shall, at its own cost and expense, obtain and thereafter maintain in full force and effect and with properly
licensed and financially secure insurers (AM Best rating of <FONT STYLE="white-space:nowrap">A-VII</FONT> in the United States and reasonably equivalent in countries outside the United States) the following insurance during the term of this
Agreement and for a period of not less than three (3)&nbsp;years following termination of this Agreement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Worker&#146;s Compensation. In amounts as required by applicable law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Automobile Liability Insurance. One Million US Dollars ($1,000,000) per occurrence covering all owned, leased
and hired vehicles; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">General Commercial Liability Insurance. One Million US Dollars ($1,000,000) per occurrence and Three Million US
Dollars ($3,000,000) in the annual aggregate; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Professional Liability Insurance. Five Million US Dollars ($5,000,000) per occurrence and Five Million US
Dollars ($5,000,000) in the annual aggregate. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.3 <U>Sponsor Insurance</U>. Sponsor shall, at its own cost and
expense, obtain and thereafter maintain in full force and effect, and with properly licensed and financially secure insurers (AM Best rating of <FONT STYLE="white-space:nowrap">A-VII</FONT> in the United States and reasonably equivalent in countries
outside the United States) the following insurance during the term of this Agreement and for a period of not less than three (3)&nbsp;years following termination of this Agreement: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Worker&#146;s Compensation. In amounts as required by applicable law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">General Commercial Liability Insurance. One Million US Dollars ($1,000,000) per occurrence and Three Million US
Dollars ($3,000,000) in the annual aggregate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Products Liability Insurance, including coverage for bodily injury suffered in the context of a clinical trial,
with a minimum limit of Ten Million US Dollars ($10,000,000) per occurrence and Ten Million US Dollars ($10,000,000) in the annual aggregate; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Clinical Trials Insurance. In amounts as required by applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.4 Sponsor and PPD will each undertake, upon request, to provide the other party a certificate (or certificates) of insurance setting forth
the liability limits, exclusions and deductibles of the insurance such party is required to carry pursuant to this Agreement. Each party shall obtain the prior written consent of the other party before implementing any material change or
cancellation of the insurance coverage agreed upon herein. Neither party will make any material changes to coverage thresholds that bring such party&#146;s required coverage below the minimum requirements stated in this Agreement. Unapproved
reductions in any coverage threshold is a breach of this Agreement and at the <FONT STYLE="white-space:nowrap">non-breaching</FONT> party&#146;s option, can result in termination of this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">PPD PROPRIETARY AND CONFIDENTIAL </P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>R<SMALL>ECORD</SMALL> S<SMALL>TORAGE</SMALL>, A<SMALL>UDITS</SMALL>, <SMALL>AND</SMALL>
I<SMALL>NSPECTIONS</SMALL></U><SMALL></SMALL>. </B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.1 <U>Record Maintenance during Project</U>. During the term of the
applicable Project Addendum, PPD shall maintain all materials and all other data obtained or generated by PPD in the course of providing the Services thereunder, including all computerized records and files. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.2 <U>Record Maintenance after Expiration or Termination</U>. Subject to the terms of this Section&nbsp;11.2, upon the expiration or
termination of the applicable Project Addendum, the continued retention of all materials and data directly relating to the Protocol and/or applicable drug product and obtained or generated by PPD in the course of providing the Services under the
applicable Project Addendum (collectively, the <B><I>&#147;Records&#148;</I></B>) is the Sponsor&#146;s responsibility. Upon completion of Sponsor&#146;s payment obligations hereunder, PPD shall (at Sponsor&#146;s risk, cost and expense), deliver
the Records to Sponsor at its offices identified herein in such form as is then currently in the possession of PPD. Notwithstanding the foregoing, PPD shall be entitled at its expense to retain copies of the Records reasonably necessary for
regulatory and business purposes and in accordance with PPD&#146;s corporate records retention schedule, all subject to the confidentiality obligations set forth in Section&nbsp;5 above. Upon the expiration of PPD&#146;s retention period, PPD may
dispose of all such copies; provided however that, prior to any such disposal, PPD shall provide Sponsor with ninety (90)&nbsp;days written notice and shall offer Sponsor, at Sponsor&#146;s risk, cost and expense, the opportunity to request that PPD
deliver such copies to Sponsor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.3 <U>Sponsor conducted Services Audits</U>. During the term of the applicable Project Addendum, at
mutually agreeable dates and times and upon reasonable prior written notice to PPD, representatives of Sponsor (who shall not be competitors of PPD) shall be permitted to review, on site at PPD&#146;s facilities, all documents, information, data and
materials in the possession of PPD directly relating to the applicable Project conducted hereunder for the sole purpose of determining the compliance of the Services with the: (i) standard of performance and specifications set forth in the
applicable Project Addendum; and (ii)&nbsp;applicable laws, regulations, guidelines and rules governing the Services. PPD and Sponsor agree to one (1) <FONT STYLE="white-space:nowrap">no-cost</FONT> Services audit per year, to include no more than
three (3)&nbsp;days <FONT STYLE="white-space:nowrap">on-site</FONT> at PPD&#146;s facilities. In instances where an audit is deemed necessary by Sponsor due to a significant quality concern or investigation (For Cause Audit), PPD and Sponsor agree
to <FONT STYLE="white-space:nowrap">no-cost</FONT> audits as needed. All other Services audits shall be charged according to PPD&#146;s personnel billable rates. All Sponsor representatives shall, in advance of such audit, execute a mutually
agreeable confidentiality and <FONT STYLE="white-space:nowrap">non-disclosure</FONT> agreement with PPD. Notwithstanding the foregoing, Sponsor shall not be permitted to review information that is subject to third party confidentiality obligations,
privileged, or not directly related to the performance of the applicable Services. Sponsor and its agents and consultants shall observe all confidentiality obligations concerning all documents, information, data or materials that it comes in contact
with in connection with the audit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.4 <U>Regulatory Inspections</U>. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Inspections of Investigator Sites</U>. Both parties shall promptly notify the other party of any regulatory
inspections of investigator sites of which it becomes aware. Where reasonably practicable and permitted by the relevant regulatory authority, Sponsor will have the right to be present at any inspections which are directly related to the Services.
PPD shall reasonably act to secure the cooperation of investigators with respect to regulatory review. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Inspections of PPD</U>. PPD agrees to promptly notify Sponsor of a regulatory inspection of PPD in which
Sponsor&#146;s project is the scope of the inspection. Sponsor agrees to provide PPD support during the inspection as needed relative to the Services contracted and Project. PPD agrees to provide updates to Sponsor as to the progress of the
inspection relative to the Services and Sponsor project. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Inspection of Sponsor</U>. Sponsor agrees to notify PPD of a regulatory inspection of Sponsor which are
directly related to the Services. PPD agrees to provide Sponsor with support relative to the Services. Sponsor agrees to provide PPD with updates of inspection activities relative to the Services. The parties shall review costs associated with
participation and shall agree to a reasonable rate of compensation in advance of the performance of any regulatory services. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">PPD PROPRIETARY AND CONFIDENTIAL </P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.5 <U>Suspected Scientific Misconduct</U>. Both parties agree to notify the other party of
instances of suspected scientific misconduct as it relates to the Services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.6
<U><FONT STYLE="white-space:nowrap">Non-Compliance</FONT> of Clinical Investigators and Related Parties</U>. Notwithstanding anything to the contrary herein, in the event PPD or Sponsor identify continued
<FONT STYLE="white-space:nowrap">non-compliance</FONT> on the part of the clinical investigator/institution or related supporting staff, Sponsor agrees to support all actions required by PPD procedures/actions to secure compliance. Should the
decision be made to terminate or suspend the trial as a result of serious and persistent <FONT STYLE="white-space:nowrap">non-compliance</FONT> by these parties, Sponsor agrees to report the clinical investigator according to applicable regulatory
requirement and authorizes PPD to report in the absence of such appropriate Sponsor action. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>D<SMALL>EBARMENT</SMALL></U><SMALL></SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PPD represents that, consistent with Section&nbsp;306(a) and Section&nbsp;306(b) of the Federal Food, Drug and Cosmetic Act (21 U.S.C. &#167; 335a (a)&nbsp;and
335a (b)), neither it nor any of its Associates and Subcontractors engaged in the performance of Services hereunder, is debarred and PPD will not knowingly hire any debarred individual to perform Services. PPD further warrants that neither it nor
any of its Associates and Subcontractors engaged in the performance of Services hereunder, will use in any capacity in connection with the Services, any person who to its knowledge is the subject of a conviction described in 42 U.S.C. &#167; <FONT
STYLE="white-space:nowrap">1320a-7(a)</FONT> for which a person can be debarred, suspended, or excluded. PPD will Sponsor in writing promptly if it is debarred or it becomes aware of the fact that any of its Associates and Subcontractors performing
Services is debarred or is the subject of a conviction described in 42 U.S.C. &#167; <FONT STYLE="white-space:nowrap">1320a-7(a),</FONT> or if it is aware of any action, suit, claim, investigation or legal or administrative proceeding is pending,
relating to the debarment, suspension, exclusion or conviction of PPD or its Associates and Subcontractors providing Services hereunder. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B><U>M<SMALL>ISCELLANEOUS</SMALL></U><SMALL></SMALL>. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.1 <U>Independent Contractor Relationship</U>. The parties hereto are independent contractors, and nothing contained in this Agreement is
intended, and shall not be construed, to place the parties in the relationship of partners, principal and agent, employer/employee or joint venturer. Neither party shall have any right, power or authority to bind or obligate the other, nor shall
either hold itself out as having such right, power or authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.2 <U>Publicity</U>. Neither party shall mention or otherwise use the
name, insignia, symbol, trademark, trade name or logotype of the other party (or any abbreviation or adaptation thereof) in any publication, press release, promotional material or other form of publicity without the prior written approval of the
other party in each instance. The restrictions imposed by this Section shall not prohibit a party from making any disclosure identifying the other party that is required by any Applicable Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.3 <U>Publication</U>. PPD may not publish any articles or make any presentations relating to the Services provided to Sponsor hereunder
with respect to a Project or referring to data, information or materials generated as part of the Services without the prior written consent of Sponsor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.4 <U>Force Majeure</U>. If either party shall be delayed, hindered, or prevented from the performance of any act required hereunder by
reason of strike, lockouts, labor troubles, restrictive governmental or judicial orders or decrees, riots, insurrection, war, acts of God, inclement weather, or other cause beyond such party&#146;s reasonable control (each, a
<B><I>&#147;Disability&#148;</I></B>), then performance of such act shall be excused for the length of time necessary to cure such Disability and resume performance. A party shall not be liable for any delays resulting from a Disability, and any
affected timelines may be extended for a period at least equal to that of the Disability. The party incurring the Disability shall provide notice to the other of the commencement and termination of the Disability and reasonably cooperate with the
unaffected party to mitigate any potential delay. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">PPD PROPRIETARY AND CONFIDENTIAL </P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.5 <U>Notices</U>. Any notice required or permitted to be given hereunder by either party
hereto shall be in writing and shall be deemed effectively given or delivered: (i)&nbsp;on the date delivered if delivered personally, (ii)&nbsp;on the first business day after the date sent if sent by recognized overnight courier, (iii)&nbsp;on the
date transmitted if sent via facsimile (with confirmation of receipt generated by the transmitting machine), or (iv)&nbsp;on the second business day after the date deposited if mailed by certified mail, return receipt requested, postage prepaid. All
notices to each party shall be sent to the address for said party set forth in the applicable Project Addendum. If no address is provided in the Project Addendum, then notices shall be sent to the following address: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="72%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">If to PPD:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PPD Development, L.P.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">929 North Front
Street</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wilmington, North Carolina 28401</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: CEO</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Tel: (910) <FONT STYLE="white-space:nowrap">251-0081</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fax: (910) <FONT STYLE="white-space:nowrap">558-5820</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">If to Sponsor:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">inRegen</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Twin City Bio LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3929 WestPoint
BLVD</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Suite G</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Winston-Salem, NC 27103</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attn: Tim
Bertram</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A party desiring to change its address for notice must give notice of the change to the other party hereto in the form and
manner provided in this Section&nbsp;13.5. Upon the failure of a party to notify the other Party of any change to or discontinuance of an address, any notices sent to the original or discontinued address shall be deemed to have been effectively
given. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.6 <U>Governing Law</U>. This Agreement and the rights and obligations of the parties hereunder shall be governed by and
construed in accordance with the laws of the State of New York without reference to its conflicts of laws provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.7
<U>Severability</U>. If any provision of this Agreement or any Project Addendum is held to be illegal, invalid or unenforceable under any present or future law, and if the rights or obligations of any party hereto under this Agreement or such
Project Addendum will not be materially or adversely affected thereby, (a) such provision will be fully severable, (b)&nbsp;this Agreement or such Project Addendum will be construed and enforced as if such illegal, invalid or unenforceable provision
had never compromised a part hereof, (c) the remaining provisions of this Agreement or such Project Addendum will remain in full force and effect and will not be affected by the illegal, invalid or unenforceable provision or by its severance
herefrom, and (d) in lieu of such illegal, invalid or unenforceable provision, there will be added automatically as a part of this Agreement or such Project Addendum, a legal, valid and enforceable provision as similar in terms as to such illegal,
invalid or unenforceable provision as may be possible and reasonably acceptable to the parties herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.8 <U>Waiver</U>. Any term or
condition of this Agreement or a Project Addendum may be waived at any time by the party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the
party waiving such term or condition. No waiver by any party hereto of any term or condition of this Agreement or a Project Addendum, in any one or more instances, shall be deemed to be or construed as a waiver of the same or any other term or
condition of this Agreement or such Project Addendum on any future occasion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.9 <U>Amendments</U>. No amendment, change or modification
to this Agreement or any Project Addendum shall be effective unless in writing and executed by the parties hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">PPD PROPRIETARY AND CONFIDENTIAL </P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.10 <U>Assignment</U>. This Agreement and any Project Addendum may not be assigned by
either party without the prior written consent of the other party; provided, however, that a party hereto may assign this Agreement or a Project Addendum hereunder to (i)&nbsp;a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">successor-in-interest</FONT></FONT> to the party&#146;s business or (ii) an Affiliate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.11 <U>Subcontracting</U>. In the event that PPD subcontracts all or part of the Services under a Project Addendum to a third party
Subcontractor, PPD shall be responsible and retain primary liability for the performance of all obligations of Subcontractors (as defined below). When used in this Agreement, the term &#147;Subcontractor&#148; shall mean and refer to any third party
selected, managed and contracted by PPD or to whom PPD has subcontracted or delegated PPD&#146;s obligation to perform any portion of the Services hereunder, but shall exclude (i)&nbsp;investigators and investigative site personnel involved in the
performance of a Project; (ii)&nbsp;a third party serving as a member on a data and safety monitoring board or data monitoring committee hereunder; and (iii)&nbsp;third party providers used by PPD at the written request of Sponsor despite the fact
that PPD has the ability to perform the subcontracted service either itself or through a PPD Affiliate. Regarding Sponsor-requested subcontractors, PPD shall be liable to Sponsor only to the extent that PPD was negligent in fulfilling any
contracting, validation, management and/or oversight responsibilities in respect to such third-party. Sponsor shall have the ability to approve PPD&#146;s use of any subcontractor prior to the assignment of any such Services by PPD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.12 <U>Arbitration</U>. Except for disputes regarding breaches of Section&nbsp;5 and the right to pursue the remedies set forth in
Section&nbsp;5.7 above, the parties may submit any dispute arising hereunder to binding arbitration pursuant to the Commercial Arbitration Rules of the American Arbitration Association (&#147;AAA&#148;). The arbitration shall be conducted in
Winston-Salem, North Carolina. The decision of the arbitrator or arbitration panel shall be final and binding upon the parties hereto and shall be enforceable by any court of competent jurisdiction. By agreeing to arbitration, the parties do not
intend to deprive any competent court of such court&#146;s jurisdiction to issue a <FONT STYLE="white-space:nowrap">pre-arbitral</FONT> injunction, <FONT STYLE="white-space:nowrap">pre-arbitral</FONT> attachment or other order in aid of the
arbitration proceedings and the enforcement of any award or judgment. Without prejudice to such provisional remedies in aid of arbitration as may be available under the jurisdiction of a national court, the court of arbitration shall have full
authority to grant provisional remedies and to award damages for failure of any party to respect the court of arbitration&#146;s order to that effect. The parties will keep the arbitration confidential and that the existence of the arbitration
proceeding and any element of it (including but not limited to any pleadings, briefs or other documents submitted or exchanged, any testimony or other oral submissions, and any awards) shall not be disclosed beyond the tribunal, the AAA, the
parties, their counsel, accountants and auditors, insurers and <FONT STYLE="white-space:nowrap">re-insurers,</FONT> and any person or entity necessary to the conduct of the proceeding. The confidentiality obligations in this Section&nbsp;13.12 shall
not apply (i)&nbsp;if disclosure is required by law, or in judicial or administrative proceedings, or (ii)&nbsp;as far as disclosure is necessary to enforce the rights arising out of the arbitration award. Without otherwise limiting the requirements
imposed by this Section&nbsp;13.12, a party may seek from any court having jurisdiction any interim or provisional relief that may be necessary to protect its interests hereunder, pending the resolution of any dispute in accordance with this
Section&nbsp;13.12. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.13 <U>Construction</U>. Except where the context otherwise requires, wherever used the singular shall include the
plural, the plural the singular, the use of any gender shall be applicable to all genders, the word &#147;or&#148; is used in the inclusive sense, and &#147;including&#148; means including, without limitation. The captions of this Agreement are for
convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The language of this Agreement shall be deemed to be the language
mutually chosen by the parties and no rule of strict construction shall be applied against either party hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.14 <U>MedDRA and
WHODrug Dictionary License.</U> The parties acknowledge that MedDRA and Uppsala Monitoring Centre product licenses are required by all parties who wish to distribute or receive MedDRA or WHODrug dictionary terminology. Each party represents and
warrants that it possesses a current MedDRA and/or Uppsala Monitoring Centre product license. In the event Sponsor requests that PPD perform services which require PPD to distribute MedDRA terminology or WHODrug dictionary to third parties, Sponsor
shall be responsible for ensuring that all such third parties possess the necessary MedDRA and/or Uppsala Monitoring Centre product licenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">PPD PROPRIETARY AND CONFIDENTIAL </P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.15 <U>Counterparts and Electronic Signatures</U>. This Agreement, any Project Addendum
hereunder, and all associated amendments may be executed in counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same instrument. Each party may execute this Agreement, any Project Addendum,
and all amendments by electronic signature (whatever form the electronic signature takes) or in Portable Document Format (or other file format) sent by electronic means. Signatures of authorized signatories of the parties completed by electronic
signature or sent by electronic means in Portable Document Format shall have the same force and effect as manual signatures, shall be valid and binding, and, upon delivery, shall constitute due execution of this Agreement, any Project Addendum, or
any amendments hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.16 <U>Representative</U>. With regard to any Project conducted under this Agreement, Sponsor shall not name
any PPD employee, contractor, or other PPD representative on Line 16 of Form FDA 1571. Sponsor acknowledges and understands that if Sponsor desires that any PPD employee, contractor, or other PPD representative be named as the Senior Medical Officer
in Canada on Line 89 of Form HC/SC 3011 or in any similar capacity for clinical trials conducted in other countries, Sponsor must first submit such a request to PPD in writing for the performance of services pursuant to such naming, including,
without limitation, responsibility for review and evaluation of information relevant to the safety of the study drug. If PPD agrees to perform such services, the parties shall enter into good faith negotiations and enter into either a separate
agreement or written amendment to the applicable Project Addendum prior to PPD initiating the services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.17 <U>Economic Sanctions and
Trade Embargoes</U>. Sponsor represents and warrants that (i)&nbsp;neither Sponsor nor Sponsor&#146;s directors or officers are subject to economic sanctions and trade embargoes; (ii) Sponsor is not 50% or more owned, directly or indirectly, by
individuals or entities that are subject to economic sanctions or trade embargoes; and (iii)&nbsp;Sponsor will not request PPD to provide any services that would cause PPD to violate any economic sanctions or trade embargoes. PPD represents and
warrants that (i)&nbsp;neither PPD nor its Affiliates, nor its or their directors or officers are subject to economic sanctions and trade embargoes; (ii)&nbsp;PPD is not 50% or more owned, directly or indirectly, by individuals or entities that are
subject to economic sanctions or trade embargoes; and (iii)&nbsp;PPD will not violate any economic sanctions or trade embargoes in connection with the Services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.18 <U>Clinical Trial Supply</U>. Sponsor acknowledges that in certain jurisdictions PPD may, at Sponsor&#146;s request, act as importer of
record (&#147;IoR&#148;) for the study by the operation of the laws or regulations or engaged by Sponsor to provide clinical trial supply management services. Where PPD acts as the IoR, clinical trial supply process shall follow PPD&#146;s
guidelines and the Incoterms for the goods arriving into a jurisdiction shall be decided by PPD. If Sponsor uses its own logistics vendors for the study, Sponsor shall make sure its logistics vendors follow PPD&#146;s guidelines and adopt the
Incoterms as designated by PPD. Sponsor shall bear or reimburse PPD for all the costs PPD may incur as IoR including without limitation all applicable customs duties, taxes, and government levies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where PPD recovers import VAT (or other tax) on behalf of Sponsor, fees shall be charged to Sponsor net of such VAT (or such other tax). Notwithstanding the
foregoing, Sponsor agrees that if such import VAT (or other tax) is subsequently determined by a tax authority, during an audit or otherwise, to not be recoverable by PPD, Sponsor agrees that it will indemnify PPD and hold PPD harmless for all
losses, claims and demands (including but not limited to such irrecoverable tax) in connection thereto, except to the extent arising out of PPD&#146;s negligence or willful misconduct or fraud. The indemnity under this clause shall survive the
expiration or early termination of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.19 <U>Entire Agreement</U>. This Agreement constitutes the entire agreement between
the parties and supersedes all prior negotiations, representations or agreements, either written or oral, with respect to the subject matter hereof </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">PPD PROPRIETARY AND CONFIDENTIAL </P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, this Agreement has been executed and delivered by the parties hereto by their duly
authorized officers as of the date of last signature below. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PPD DEVELOPMENT, L.P.</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>BY:
PPD GP, LLC</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>INREGEN</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ITS: GENERAL PARTNER</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ William Sharbaugh</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Timothy A Bertram</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">William Sharbaugh</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Timothy A Bertram</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Operating Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">CEO</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">01-May-2019</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">30 April 2019</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 17 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>8
<FILENAME>d373959dex1018.htm
<DESCRIPTION>EX-10.18
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.18</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.18 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>MASTER SERVICES AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Master Services Agreement (the &#147;Agreement&#148;) is made as of the 14th day of August, 2015 (&#147;Effective Date&#148;) by and
between RegenMedTX, LLC, a Delaware limited liability company (&#147;Sponsor&#148;) with offices located at 3929 Westpoint Blvd., Suite G, Winston-Salem, NC 27103, and CTI Clinical Trial Services, Inc. &amp; CTI Clinical Consulting Services, Inc.,
(&#147;CTI&#148;) with offices located at 10123 Alliance Road, Cincinnati, OH 45242. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Introduction </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sponsor may sponsor and/or conduct one or more clinical research studies from time to time, and CTI is knowledgeable and experienced in the design, management
and conduct of such studies. Sponsor wishes to retain CTI to assist Sponsor in these studies on the terms and conditions set forth in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To
that end, Sponsor and CTI now agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B><U>Services.</U> </B>From time to time, CTI will provide Sponsor certain
clinical research or design and development services pursuant to the terms of this Agreement. Prior to the commencement of such services, CTI and Sponsor shall enter into a Work Order that will describe the specific obligations transferred by
Sponsor to CTI (the &#147;Services&#148;) in the performance of a particular clinical research study sponsored or conducted by Sponsor (each a &#147;Study&#148;). Each Work Order will be a separate agreement, and each Work Order will incorporate the
terms of this Agreement by reference. A sample form of this Work Order is attached to this Agreement as <U>Exhibit A</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CTI represents
to Sponsor that it is not a party to any agreement which would prevent it from fulfilling its obligations under this Agreement and, that during the term, CTI agrees it will not enter into any agreement to provide services which would in any way
prevent it from providing the Services as contemplated under this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CTI will ensure that the Services are carried out by
qualified and experienced staff. CTI covenants that it will render the Services in accordance with its applicable standard operating procedures and to the highest professional standards&middot;and will make all efforts to maintain consistently high
levels of accuracy and expertise. CTI will comply with all applicable laws, rules, regulations and guidelines relating to the conduct of clinical investigations, including, without limitation, 21 C.F.R. Parts 50, 54, 56 and 312, the International
Conference on Harmonization Guidelines for Good Clinical Practices (collectively, &#147;Applicable Law&#148;) and other good clinical practice requirements (collectively, &#147;Applicable Requirements&#148;). The parties agree to comply with the
Health Insurance Portability and Accountability Act (45 C.F.R. Parts 160, 162 and 164, as well as the regulations thereunder) and any state, municipal or local law, ordinance or regulation protecting the privacy of individual health information
(collectively &#147;Privacy Laws and Regulations&#148;). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <B><U>Personnel.</U> </B>CTI shall ensure that appropriately trained and qualified
employees and contractors of CTI deliver the Services outlined in each Work Order. CTI must obtain the prior written consent of Sponsor regarding any contractor which CTI proposes to engage to deliver the Services outlined in any Work Order. CTI
also must obtain the prior written consent of Sponsor with respect to a decision by CTI to utilize any CTI employee that CTI proposes to have a substantive role in the delivery of the Services with respect to any Work Order that is not so engaged as
of the Effective Date. However, such prior written consent shall not be required with respect to those employees whose involvement in the Study is limited to only <FONT STYLE="white-space:nowrap">non-substantive</FONT> activities (e.g., monitors,
etc.). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If CTI contracts with investigators or investigative sites (collectively, &#147;Investigators&#148;), any such contract shall be
on a form mutually acceptable to CTI and Sponsor. If an Investigator requests any material changes to such form, CTI shall submit the proposed change to Sponsor, and Sponsor shall promptly review, comment on and/or approve such proposed changes. The
parties acknowledge and agree that Investigators shall not be considered the employees, agents, or subcontractors of CTI or Sponsor, and that Investigators shall exercise their own independent medical judgment with respect to the applicable Study.
CTI&#146;s responsibilities with respect to Investigators shall be limited to those responsibilities specifically set forth in this Agreement and any applicable Work Order. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If CTI will be paying Investigators on behalf of Sponsor, the parties will agree to a schedule of amounts to be paid to Investigators. Sponsor
acknowledges and agrees CTI will only pay Investigators from advances or <FONT STYLE="white-space:nowrap">pre-payments</FONT> received from Sponsor for Investigators&#146; services, and that CTI will not make payments to Investigators prior to
receipt of sufficient funds from Sponsor. Sponsor acknowledges and agrees that CTI will not be responsible for delays in a Study to the extent that such delays are caused by Sponsor&#146;s failure to make adequate
<FONT STYLE="white-space:nowrap">pre-payment</FONT> for Investigators&#146; services. Sponsor further acknowledges and agrees that payments for Investigator&#146;s services are pass&nbsp;-through payments to third parties and are separate from
payments for CTI Services. Sponsor agrees that it will not withhold Investigator payments except to the extent that it has reasonable questions about the services performed by a particular Investigator. CTI shall have Investigators complete and
return to Sponsor such financial disclosure forms as may be required to comply with Applicable Regulations pertaining to financial disclosures of clinical investigators. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties agree that any payments to Investigators are not intended to encourage, and are not being given in exchange for any explicit or
implicit agreement to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(i) order, purchase, prescribe or recommend any Sponsor product; or (ii)&nbsp;influence or provide favorable formulary status for
any Sponsor product. Payments have not been determined in a manner that would take into account the volume or value of referrals or business, if any, generated between Sponsor and any investigator,
<FONT STYLE="white-space:nowrap">sub-investigator</FONT> or their practice. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By entering into this Agreement, each party attests that it understands what is required of it for the Study
under Applicable Law and Applicable Requirements, and commits to complying with such law and requirements. CTI hereby certifies to Sponsor that it is not, has not been, or has not used, nor will it use the services of any person, debarred under 21
U.S.C. 335a, as amended, or disqualified by any regulatory authority, or otherwise found by any regulatory authority to have violated any Applicable Law or Applicable Requirements concerning the conduct of clinical investigations or excluded from
participation in any state or federal healthcare program (collectively, &#147;Debarred&#148; or &#147;Debarment&#148;) in any capacity in connection with any of the services or work provided hereunder. In the event that during the term of this
Agreement, CTI or any of its Investigators or any of their employees or agents (i)&nbsp;becomes Debarred or (ii)&nbsp;receives notice of an action or threat of an action with respect to its Debarment, CTI shall notify Sponsor immediately. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <B><U>Transfer of Obligations.</U> </B>The specific obligations transferred by Sponsor to CTI in any particular Study will be detailed in
the relevant Work Order. Sponsor will retain those responsibilities not specifically listed in that Work Order. Sponsor shall at all times be the &#147;Sponsor&#148; of each Study pursuant to the terms of the U.S. Food, Drug and Cosmetic Act, as
from time to time amended (the &#147;Act&#148;). Sponsor will maintain all direct communication, whether oral, electronic or hard copy, with the U.S. Food and Drug Administration (the &#147;FDA&#148;) at all times with respect to the Study, and CTI
will only engage in limited preliminary communications with the FDA regarding the Study and shall give prompt notice of such communications to Sponsor. Sponsor will cooperate with CTI in taking any action that CTI reasonably believes is necessary to
comply with the regulatory obligations that have been transferred to CTI. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each party acknowledges that the other party may respond
independently to any regulatory correspondence or inquiry in which such party or its affiliates is named and which does not relate to the Services provided under this Agreement. Each party however, shall: (a)&nbsp;notify the other party promptly of
any FDA or other U.S. or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> governmental or regulatory inspection or inquiry relating to the Services provided by CTI under this Agreement including, but not limited to, inspections of investigational
sites; (b) forward to the other party copies (within five (5)&nbsp;business days) of any correspondence from any regulatory or governmental agency relating to a Study, including, but not limited to, Form
<FONT STYLE="white-space:nowrap">FD-483</FONT> notices, and FDA refusal to file, rejection or warning letters, even if they do not specifically mention the other party; (c)&nbsp;give the other party the opportunity to review and comment upon any
response to a regulatory authority relative to the Services or a Study under this agreement before such response is submitted, such review and comment to be conducted promptly and without delay; and (d) obtain the written consent of the other party,
which will not unreasonably be withheld, before referring to the other party or any of its affiliates in any regulatory correspondence relative to the Services or a Study under this Agreement. Where reasonably practicable, each party will be given
the opportunity to have a representative present during a FDA or regulatory inspection. Each party however, acknowledges that it may not direct the manner in which the other party fulfills its obligations to permit inspection by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">governmental entities. Notwithstanding the foregoing, CTI will promptly notify Sponsor of any FDA or other
U.S. or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> governmental or regulatory inspection or inquiry with respect to CTI not relating to the Services or the Study but which is reasonably likely to have an impact on CTI&#146;s perfonnance of the
Services and/or its other obligations under this Agreement and, to the extent legally permissible, discuss with Sponsor such potential impact. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each party agrees that, during an inspection by the FDA or other regulatory authority concerning any Study for which CTI is providing the
Services, it will not disclose information and materials that are not required to be disclosed to such authority, without the prior written consent of the other party, which shall not unreasonably be withheld. Such information and materials
includes, but are not limited to (i)&nbsp;financial data and pricing data (including, but not limited to, the Budget (as defined below)); (ii) sales data (other than shipment data); and (iii)&nbsp;personnel data (other than data as to qualification
of technical and professional persons performing functions subject to regulatory requirements). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the tenn of this Agreement, CTI
will permit Sponsor&#146;s representatives (unless such representatives are competitors of CTI) to examine and review, without any additional cost to Sponsor, the work performed hereunder and any facilities at which the work is conducted, upon
reasonable advance notice and at mutually agreeable times during regular business hours to detennine that the Services are being perfonned in accordance with this Agreement and the Work Orders. In the event of a more formal audit, unless the costs
of governmental or Sponsor audits are specifically included in the Budget, or a governmental &#147;for cause&#148; audit is conducted as a result of CTI activities, Sponsor shall reimburse CTI for its time and expenses, including reasonable attorney
fees, associated with such audits, including the costs of responding to the findings of any such audit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <B><U>Scope of Work and
Payment.</U> </B>The Work Order for each Study will include a scope of work statement that details CTI&#146;s Services for that Study. The Work Order will also include a budget and payment schedule for CTI&#146;s Services for each Study, and Sponsor
will pay CTI for the Services accordingly (&#147;Budget&#148;). The aggregate fees and expenses set forth in that schedule will not change or be modified unless authorized by both parties in writing. CTI will invoice Sponsor in accordance with the
relevant Work Order. Each invoice will describe the Services performed, and any expenses billed will be supported by appropriate documentation. Sponsor will pay all uncontested amounts reflected on each invoice within thirty (30)&nbsp;days of the
date thereof. If all or any portion of an invoice is contested, Sponsor will provide written notice and a summary of the contested items to CTI within ten (10)&nbsp;days of Sponsor&#146;s receipt of invoice. The parties shall work in good faith
toward resolution of such items. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Sponsor requests CTI to perform services beyond those set out in the Work Order, CTI
shall proceed as follows: consistent with the desire of both parties not to disrupt the ongoing progress of any Study, CTI shall (i)&nbsp;submit a proposed budget and payment schedule for such <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-scope</FONT></FONT> work and obtain Sponsor&#146;s written approval of that schedule before commencing that work, or (ii)&nbsp;obtain written authorization from Sponsor to proceed with such work prior to a final
agreement on the proposed schedule. In either case, both parties will make good faith efforts to negotiate and agree upon a revised schedule as soon as possible and practicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <B><U>Term and Termination.</U> </B>This Agreement and any Work Order will begin as of its stated Effective Date and will continue unless
terminated under this Section&nbsp;5. This Agreement or any Work Order may be terminated for any reason by any party upon ninety (90)&nbsp;days prior written notice to the other party. Further, this Agreement or any relevant Work Order may be
terminated immediately by written notice from Sponsor, in the following circumstances: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The FDA withdraws authorization and approval to conduct a Study; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sponsor reasonably determines that for medical, clinical or patient safety reasons, a Study should terminate
immediately. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, either party may terminate this Agreement or any Work Order for material breach upon thirty
(30)&nbsp;days written notice specifying the nature of the breach, if such breach has not been substantially cured within the thirty (30)&nbsp;day period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For any termination of this Agreement or any Work Order, both parties recognize that such an event will require discussion, cooperation and
coordination between them to ensure patient safety, compliance with all applicable regulations and continuity of treatment (if appropriate). To that end, upon any termination of this Agreement or any Work Order, CTI will cooperate with Sponsor to
provide for an orderly cessation of CTI Services. Additionally, unless otherwise stipulated by Sponsor, CTI will perform such Services as are reasonably necessary for an orderly termination and shall transfer to Sponsor all Study data, reports, and
all related Study documents prepared but not yet submitted to Sponsor after receiving full payment from Sponsor for all services and work related to such Study data, reports and Study documents. Similarly, upon any termination of this Agreement or
any Work Order, Sponsor shall promptly pay CTI for Services performed under this Agreement or such Work Order prior to the effective date of termination or in connection with the process of an orderly termination; provided, however, that the total
of such payments shall not exceed the total amount remaining under the Budget unless agreed to by Sponsor and CTI in writing. Sponsor&#146;s final payment to CTI will include reimbursement to CTI for all
<FONT STYLE="white-space:nowrap">non-cancelable</FONT> obligations and all pass-through expenses incurred prior to the effective date of termination or in connection with the process of an orderly termination. In the orderly cessation of activities,
CTI will use its best efforts, consistent with good clinical practice, to minimize costs to be incurred by Sponsor for the Services. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <B><U>Confidentiality</U>. </B>For this Agreement and its Work Orders, all materials,
documents and information concerning a Study, including, without limitation, the protocol, case report forms, clinical data and other proprietary data provided to or developed by CTI for use in a Study, shall be considered &#147;Confidential
Information.&#148; All Confidential Infonnation, except CTI Intellectual Property as defined in Section&nbsp;7.D. below (&#147;Records&#148;), will be the exclusive property of Sponsor. CTI will maintain Confidential Information in confidence and
shall not disclose it unless that disclosure is required for CTI&#146;s performance of its obligations under this Agreement or a Work Order. Unless otherwise agreed in a Work Order, CTI&#146;s confidentiality obligations shall survive for seven
(7)&nbsp;years after the expiration or termination of the relevant Work Order. CTI is responsible for ensuring that all of its employees and contractors understand and maintain the confidentiality of such Confidential Information under this
Agreement or its Work Orders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under this Agreement and its Work Orders, Confidential Information shall not include: (a)&nbsp;information
which is known to CTI prior to disclosure by Sponsor; (b)&nbsp;information which is or becomes public through no improper act of CTI; (c)&nbsp;information which becomes available to CTI from a source other than Sponsor; or (d)&nbsp;information
developed by or for CTI independent of the disclosure of Confidential Information by Sponsor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties may disclose Confidential
Infonnation to the extent such disclosure is required to comply with applicable governmental regulations or to the extent ordered by a court exercising its right of authority over the disclosing party (subject to entry of an appropriate protective
order), provided that if a party is required by such law, regulation or order to make any such disclosure of Confidential Infonnation, such party shall give reasonable notice to the other party of such disclosure requirement and will use its
reasonable efforts to secure confidential treatment of such Confidential Information required to be disclosed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CTI shall maintain all
Records in a safe and secure manner and in compliance with all Applicable Laws and Applicable Requirements. CTI shall store all Records in compliance with the appropriate record retention regulations. Thereafter, prior to disposal of any Records,
CTI shall give Sponsor not less than sixty (60)&nbsp;days written notice, and, if Sponsor so requests prior to such disposal, CTI shall transfer such Records to Sponsor at Sponsor&#146;s cost and expense. CTI shall make any and all Records available
for inspection or duplication by Sponsor&#146;s authorized representatives during normal business hours at mutually agreed upon times. At any time and at Sponsor&#146;s cost and expense, Sponsor may request that CTI (i)&nbsp;deliver any or all
Records to Sponsor or to a location specified by Sponsor, or (ii)&nbsp;dispose of Records as directed by Sponsor, unless such Records are required by Applicable Laws and Applicable Requirements to be stored or maintained. CTI shall be entitled to
retain one (1)&nbsp;copy of any Confidential Information necessary for determining its ongoing obligations pursuant to this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <B><U>Intellectual Property.</U></B> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Ownership.</U> All materials, documents and information obtained by, developed by or provided to CTI by or
on behalf of Sponsor as part of CTI&#146;s Services under this Agreement or any Work Order will be the exclusive property of Sponsor. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Inventions.</U> CTI will disclose to Sponsor any and all inventions or discoveries that incorporate
Confidential Information and that are made by CTI as part of its Services under this Agreement or any Work Order (&#147;Intellectual Property&#148;). Further, CTI will assign all rights it may have in any such Intellectual Property to Sponsor.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Assistance</U>. CTI will cooperate with Sponsor in executing any and all applications, assignments or other
instruments reasonably necessary to apply for and obtain a patent in the United States or any foreign country, or to otherwise protect Sponsor&#146;s interest in such Intellectual Property. Sponsor shall compensate CTI for its time and reasonable
expenses required by this assistance. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">D.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notwithstanding subsection A, B, and C above, all computer programs, software, applications, databases,
proposals and other documentation generally used or developed by CTI, and any improvement, alteration or enhancement to these (unless specifically requested <B>and </B>paid for by Sponsor as part of CTI&#146;s Services under this Agreement and any
Work Order), are the exclusive and confidential property of CTI or the third parties from whom CTI has secured the right of use (&#147;CTI Intellectual Property&#148;). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <B><U>Indemnification</U>.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">CTI will hold harmless and indemnify Sponsor, its employees, agents, representatives and assigns from and against all claims, costs,
complaints, or lawsuits that arise as a result of the negligence or malfeasance of CTI or its employees, agents, representatives, and assigns in its performance under this Agreement or any Work Order. This CTI indemnification does not apply to any
loss, damage, cost or expense to the extent such loss, damage, cost or expense is caused by or attributable to the negligence or malfeasance of Sponsor or any of its employees, agents, representatives or assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sponsor will hold harmless and indemnify CTI, its employees, agents, representatives and assigns from and against all claims, costs,
complaints, or lawsuits that arise as a result of (i)&nbsp;the negligence or malfeasance of Sponsor or its employees, agents, representatives and assigns, or (ii)&nbsp;personal injury or death alleged to have been caused by or attributed to any
Study substance provided by Sponsor and dispensed or administered in the Study pursuant to the provisions of the Study Protocol. CTI will promptly notify Sponsor of any such claim, complaint or lawsuit. Sponsor has the right, in its sole discretion,
to defend, and/or settle any such claim, complaint, or lawsuit at its own expense and by its own counsel. CTI will cooperate fully in the investigation and defense of any such claim, complaint or lawsuit. This Sponsor indemnification does not apply
to any loss, damage, cost or expense to the extent such loss, damage, cost or expense is caused by or attributable to the negligence or malfeasance of CTI or any of its employees, agents, representatives or assigns. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <B><U>Independent Contractor Relationship.</U> </B>The parties to this Agreement and its
Work Orders are independent contractors. Neither party can offer or agree to incur or assume any obligations or commitments in the name of or on behalf of the other, except as specifically stated in this Agreement or in a Work Order. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <B><U>Miscellaneous</U>.</B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Delegation and Subcontracts</U>. CTI may delegate part of its Services under a Work Order to its affiliated
companies or other subcontractors as it may require, and with written notice to Sponsor of that delegation. However, CTI remains principally responsible to Sponsor for the performance of all its Services and obligations under this Agreement, whether
delegated, subcontracted or otherwise. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Non-Solicitation</U>. During the term of this Master Agreement and for a period of twelve (12)&nbsp;months
thereafter, neither Sponsor nor CTI shall recruit or otherwise induce any employee to terminate his/her.employment or violate any agreement with, or duty to, Sponsor or CTI. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Force Majeure.</U> Either party shall be excused from performing its obligations under this Agreement or any
Work Order if their performance is delayed or prevented by a cause beyond that party&#146;s control, including, but not limited to, acts of God, fire, explosion, weather, disease, war, insurrection, civil strife, riots, government action, or power
failure. Performance will be excused only to the extent of and during the reasonable continuance of such disability. Any deadline or time for performance specified in a Work Order which falls due during or subsequent to the occurrence of any
<I>force majeure </I>under this section will be extended for a period of time equal to the period of such disability. CTI will promptly notify Sponsor if, by reason of any <I>force majeure, </I>CTI is unable to meet any deadline or time for
performance specified in a Work Order. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">D.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Binding Agreement.</U> This Agreement is binding on and inures to the benefit of its parties and their
respective legal representatives, successors and assigns. However, neither party can transfer or assign this Agreement without the prior written consent of the other party. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">E.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Amendments.</U> This Agreement may be modified or amended only by a writing executed by the parties hereof.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">F.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Notices. All notices shall be in writing and shall be personally delivered or sent by certified mail, return
receipt requested to the parties at the addresses each party will furnish to the other. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">G.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Waiver.</U> The waiver or breach of any term or condition of this Agreement does not constitute a waiver of
any other of its terms or conditions or any subsequent breach of the same term or condition. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">H.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Entire Agreement.</U> This Agreement and its Work Orders are the entire agreement between its parties as to
its subject matter. There are no representations, warranties, covenants or undertakings as to that subject roarer other than those expressly set forth in this Agreement and its Work Orders. This 11greement and Work Orders supersede all prior
agreements between the parties as to its subject matter. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">I.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Severability.</U> The invalidity or unenforceability of any Agreement or Work Order provision shall in no
way affect the validity or enforceability of any other provision. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">J.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Governing Law.</U> The laws of the State of Delaware (without regard to any provision or rule applying the
law of another state or jurisdiction) shall govern this Agreement and its Work Orders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">K.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Counterparts.</U> This Agreement and its Work Orders may be executed in two (2)&nbsp;counterparts and by
facsimile or electronic means, each of which shall be considered an original, but are one and the same document. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature page follows] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As witness to this Agreement, the authorized representatives of its parties have signed this Agreement below
as of its Effective Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">CTI Clinical Trial Services, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Timothy J. Schroeder</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U></U>Date: 14&nbsp;August 2015</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Timothy J. Schroeder</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">CEO</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">RegenMedTX, LLC</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Timothy A. Bertram</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Timothy A. Bertram</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Executive Officer and Managing Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Date: 17&nbsp;August 2015</TD></TR>
</TABLE> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Master
Services Agreement] </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>9
<FILENAME>d373959dex1019.htm
<DESCRIPTION>EX-10.19
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.19</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.19 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This Laboratory Service Agreement</B> (&#148;<B>Agreement&#148;)</B> is made effective on 26&nbsp;August 2016 by and between </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COVANCE CENTRAL LABORATORY SERVICES LP</B><B> </B>an Indiana limited partnership, with its principal place
of business at 8211 SciCor Drive, Indianapolis, Indiana 46214, USA; and <B>COVANCE CENTRAL LABORATORY SERVICES S</B><B>&Agrave;</B><B>RL</B>, with its principal place of business at Rue Moise-Marchines 7, 1217 Meyrin, Geneva Switzerland
(collectively &#147;<B>Covance</B>&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>RegenMed (Cayman) Ltd., </B>10 Market Street, No.&nbsp;774 Camana Bay, Grand Cayman <FONT
STYLE="white-space:nowrap">KY1-9006,</FONT> Cayman Islands (&#147;<B>Sponsor</B>&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(each a<B>
</B>&#147;<B>Party</B>&#148;<B> </B>and collectively the &#147;<B>Parties</B>&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEREAS </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Covance is engaged in the business of providing laboratory testing, data management, protocol management and
information management services for pharmaceutical clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sponsor desires for Covance to perform such services for one or more clinical trials, all in accordance with
and subject to the terms and conditions of this Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IT IS AGREED </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEFINITIONS </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In this Agreement, the following words and expressions shall have the following meanings:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;</B><B>Affiliate</B>&#148; means any entity controlling, controlled by, or in common control with a Party. For
the purposes of this definition, &#147;<B>Control</B>&#148; shall mean ownership or control, directly or indirectly of more than fifty percent (50%) of the common voting stock or ordinary shares in the entity or the right to appoint fifty percent
(50%) or more of the directors of that entity. With respect to Covance, the term Affiliate shall include Laboratory Corporation of America Holdings and any business entity that is controlled by or is under common control with Laboratory Corporation
of America Holdings. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Anti-Corruption Laws</B>&#148; means any anti-bribery and anti-corruption laws, rules, regulations
applicable to either Party (each as amended from time to time) including the United States Anti-Kickback Law, United States Foreign Corrupt Practices Act, the UK Bribery Act 2010 and the OECD Convention Against the Bribery of Foreign Government
Officials in International Business Transactions, together with any applicable implementing legislation including any applicable local law addressing bribery or corruption. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Applicable Law</B>&#148; means applicable federal, state and local laws, rules, regulations, including the regulations of the FDA and
Data Protection Laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Background IP</B>&#148; means all <FONT STYLE="white-space:nowrap">pre-existing</FONT> intellectual
property belonging to or licensed to a Party or other intellectual property created outside the scope of the Services. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Claim</B>&#148; means any third party claims, demands, assessments, actions, suits,
proceedings, or settlements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Confidential Information</B>&#148; means any and all
<FONT STYLE="white-space:nowrap">non-public</FONT> information or materials and derivatives thereof, in any and all forms, howsoever disclosed or obtained, including business plans, financial information, client lists, and requirements, techniques,
designs, methods, processes and procedures, which: (i)&nbsp;is identified by a suitable legend or other marking as being confidential (or similar designation) in a prominent position or (ii)&nbsp;is described as being confidential at the time of
disclosure or (iii)&nbsp;the disclosing Party regards or should reasonably be expected to regard as proprietary and confidential given the nature of the information and the circumstances of disclosure. Confidential Information shall not include
information (a)&nbsp;that is or becomes publicly disclosed except to the extent such disclosure results from a violation hereof or any improper action or inaction by Recipient or any agent or representative of Recipient; (b)&nbsp;that was in
Recipient&#146;s possession prior to Recipient&#146;s receipt of such material from Disclosing Party, as demonstrated by documentary evidence that itself was in Recipient&#146;s possession at the time of Disclosing Party&#146;s disclosure of such
Confidential Information to Recipient; (c)&nbsp;that is lawfully acquired by Recipient from a third party not obligated to keep such information confidential; or (d)&nbsp;that is developed by the Recipient without the use of or reliance on the
Disclosing Party&#146;s Confidential Information, as demonstrated by Recipient&#146;s written records. Information will not be deemed to be within the foregoing exceptions merely because such information is embraced by more general information that
is within the foregoing exceptions. In addition, any combination of features will not be deemed to be within the foregoing exceptions merely because individual features are within the exceptions, but only if the combination itself and its principle
of operation are within the exceptions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Covance Property</B>&#148; means inventions, proprietary processes, software (including
codes) data, technology, <FONT STYLE="white-space:nowrap">know-how</FONT> and other intellectual property that have been independently developed or discovered by Covance or its Affiliates without the use of Sponsor&#146;s Confidential Information,
including those that relate to the proprietary innovative testing procedures, laboratory testing data collection or data management procedures, procedural manuals, delta flags, nucleic acid based vectors, analytical procedures and approaches that
are not specific for use with the Sponsor&#146;s Background IP even if such are developed in the performance of the Services or are captured in documents pertaining to the Services (i.e. laboratory notebooks), techniques, skills, models, <FONT
STYLE="white-space:nowrap">non-product</FONT> specific components of questionnaires, management tools and any other materials, employed, developed or acquired by Covance or its Affiliates. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>&#147;Data Protection Laws&#148;</B> mean all applicable privacy, data protection or similar laws and regulations anywhere in the World, as
the same may be amended from time to time, including to the extent applicable to the respective Services, the Data Protection Directive (95/46/EC), the Personal Data Protection Act 2012 of Singapore and any applicable implementing legislation or any
amendment thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Deliverables</B>&#148; means as applicable to the Services, Results, or any other
deliverable specified in this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Disclosing Party</B>&#148; means the Party disclosing or making available its
Confidential Information to the other Party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>FDA</B>&#148; means the United States Food and Drug Administration or any other
government body or agency that succeeds it. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Force Majeure Event</B>&#148; means circumstances or causes beyond the reasonable
control of a Party, including war, threat of war or warlike conditions, blockade, embargo, fire, explosion, lightning, storm, drought, flood, earthquake or other natural disaster, pandemic or epidemic, power failure, acts of terrorism, riot, civil
unrest, insurrection, acts of government or other international bodies, political subdivision and any other events which by their nature could not have been foreseen by the Parties, or, if it could have been foreseen were unavoidable by a reasonable
prudent business. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>HBS Donor</B>&#148; means an individual, living or deceased, from whom the HBS was obtained. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Human Biological Samples</B>&#148; or &#147;<B>HBS</B>&#148; means any human biological material, including, without limitation, human
bodily parts and organs in whole or <FONT STYLE="white-space:nowrap">sub-samples,</FONT> any tissue, skin, bone, muscle, connective tissue, blood, cerebrospinal fluid, cells, gametes, or <FONT STYLE="white-space:nowrap">sub-cellular</FONT>
structures such as DNA, or any derivative or product of such human biological materials including stem cells, cell lines, bodily fluids, blood derivatives and urine. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>IEC/IRB</B>&#148; means an independent ethics committee or institutional review board. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Informed Consent</B>&#148; means an IEC/IRB approved informed consent form signed by the HBS Donor authorizing the Use of their HBS.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Invention</B>&#148; means any patentable invention or other registerable intellectual property rights discovered, conceived of or
made by Covance or its Affiliates specifically as result of the Services for the Sponsor and relating to the Test Materials. Covance Property is not included in Inventions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Loss</B>&#148; means any loss, cost, damage or expense (including reasonable legal expenses). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Project</B>&#148; means a Study, project or assignment between Covance and Sponsor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Protocol</B>&#148; means the document which specifies the laboratory testing procedures as written by Sponsor as applicable for the
performance of a Study and is provided to Covance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Recipient</B>&#148; means the Party receiving or having access to the
Confidential Information from the other Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Regulatory Authority</B>&#148; means any national or state (in the case of the US),
or local agency, authority, department, inspectorate, minister, ministry official, parliament or public or statutory person (whether autonomous or not) of any government of any country having jurisdiction over either any of the activities
contemplated by this Agreement or the Parties. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Regulatory Requirements</B>&#148;<B> </B>means all laws, statutes, acts, rules,
regulations, guidelines, codes, orders, directives or other legally binding requirements of any Regulatory Authority and industry standards or codes of conduct applicable to the Services. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Results</B>&#148; mean materials, data, Inventions, documents and information produced, conceived or developed by Covance specifically
as a result of the Services and related to the Test Materials. Covance Property is not included in Results. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Services</B>&#148;
means the services provided by Covance to the Sponsor as more particularly described in this Agreement and the SOW. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>SOW</B>&#148;
means the scope of work mutually agreed to in writing by the Parties, which will be attached hereto as an exhibit and will be governed by and is hereby made a part of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sponsor Information</B>&#148; means Test Materials, data, specification, or other materials or information supplied by the Sponsor to
Covance in connection with the Services. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Study</B>&#148; means a clinical trial or scientific evaluation of the Test Materials on
the terms and conditions of the Protocol. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Subcontractor</B>&#148; means a third party approved, reviewed and contracted by
Covance for Services within the scope of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>System Data</B>&#148; means control data from laboratory tests or
transactional, volume and performance data related to the Services, which does not contain any personally identifiable information or Sponsor Confidential Information. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Test Materials</B>&#148; means compounds, materials or other substances as described in the Protocol to be tested or used in the
performance of the Services and provided to Covance by the Sponsor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Use</B>&#148; (in the context of Section&nbsp;13) means
collection, storage, transfer (including import and export), use and return or disposal of HBS including by commercial organizations. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;<B>Vendor</B>&#148; means third-party service providers other than a Subcontractor for which Covance may hold the contract with such
service provider at Sponsor&#146;s written request for the convenience or benefit of the Sponsor in connection with Services under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In this Agreement, unless the context otherwise requires, references to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Schedule and Section headings are inserted for convenience only and do not affect the construction or
interpretation of this Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a particular law or statutory provision is a reference to it as it is in force for the time being taking
account of any amendment, extension, or <FONT STYLE="white-space:nowrap">re-enactment</FONT> and includes any subordinate legislation for the time being in force made under it; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>writing</B> or <B>written</B> includes faxes and <FONT STYLE="white-space:nowrap">e-mail;</FONT>
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a person includes a corporate or unincorporated body; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any gender includes all genders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>including</B>, <B>include</B>, <B>in particular</B> or any similar expression shall be construed as
illustrative and shall not limit the sense of the words preceding those terms; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">words in the singular include the plural and vice versa. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>If this Agreement is translated, the English language text shall prevail. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SERVICES </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance through itself and/or its Affiliates hereby agrees to perform Services for Sponsor&#146;s
protocol RMCL-CL002, &#147;A Phase 2, Prospective, Randomized, Double Arm, Deferred Treatment, Open Label, Repeat Dose, Safety and Efficacy Study of Autologous <FONT STYLE="white-space:nowrap">Neo-Kidney</FONT> Augment (NKA) in Subjects with Type 2
Diabetes and Chronic Kidney Disease&#148; as amended from time to time, a copy of which is attached hereto as Exhibit A. Such Services shall be performed pursuant to the terms and conditions contained herein. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Any changes or modifications to the Protocol and/or Services provided by Covance, or any Sponsor request
for additional Services may commence upon Covance&#146;s receipt of Sponsors written approval of the revised SOW. Upon Sponsor&#146;s SOW signature, Covance shall provide such Services to the Sponsor and the Sponsor shall pay for costs associated
with such Services at its current standard rates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Should a kit be lost through no fault of Covance, or should a kit expire at the investigator site,
Covance will supply replacement kits for those that are lost, expired, or otherwise rendered unusable, at an amount equal to the price listed in the Budget per kit for the same kit/visit that is being replaced. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>After performing Services, Covance will store the remaining Study specimens for the length of time and
under storage conditions as described in the applicable SOW. The remaining specimens may subsequently be shipped to Sponsor or another party as specified in the SOW or if not specified in the SOW, held as otherwise instructed by the Sponsor. In no
event shall Covance&#146;s liability for any breach or default with regard to storage of an archival specimen exceed the fee it has been paid for storage of that specimen for the previous twelve (12)&nbsp;months. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TERM AND TERMINATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The term of this Agreement shall be for <B>forty two (42)</B><B></B><B>&nbsp;months</B> commencing on
the date hereof or the conclusion of the study, whichever is earlier, and shall renew automatically for successive one (1)&nbsp;year periods unless a Party provides the other Party with written notice of its intention to not renew and extend this
Agreement at least sixty (60)&nbsp;days prior to the commencement of any such renewal term. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Either Party may terminate this Agreement with immediate effect by notice in writing in the event that:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the other Party commits a material breach of any term of this Agreement which breach is irremediable or (if
such breach is remediable) fails to remedy that breach within a period of thirty (30)&nbsp;days after being notified in writing to do so; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the other Party repeatedly breaches any of the terms of this Agreement in such a manner as to reasonably
justify the opinion that its conduct is inconsistent with it having the intention or ability to give effect to the terms of this Agreement; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">anyone commences an involuntary case against such other Party under title 11 of the United States Code or the
corresponding provisions of any successor laws and either the case is not dismissed by midnight at the end of the sixtieth (60<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) day after commencement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a court of competent jurisdiction appoints a custodian (as that term is defined in title 11 of the United
States Code or the corresponding provisions of any successor laws) for such other Party or all or substantially all of its assets, or such other Party makes an assignment of all or substantially all of its assets to a custodian;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the other Party fails generally to pay its debts as they become due (unless those debts are subject to a
good-faith dispute as to liability or amount) or acknowledges in writing that it is unable to do so; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any event occurs, or proceeding is initiated, in any jurisdiction to which it is subject that has an effect
equivalent or substantially similar to any of the events mentioned above. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Sponsor may terminate this Agreement for any reason upon ninety (90)&nbsp;days prior written notice to
Covance. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In the event of such termination, Covance shall be entitled to full payment for work performed on the
Study through the date work on such Study is concluded, including, without limitation, all fees and other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by Covance for such Study.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The termination of this Agreement shall not relieve either Party of its obligations to the other with
respect to: (a)&nbsp;maintaining the confidentiality of Confidential Information; (b)&nbsp;obtaining consents for the use of names; (c)&nbsp;ownership of and assignment of inventions; (d)&nbsp;indemnification; (d) limitation
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
of liability; (e)&nbsp;compensation for Services performed; (f)&nbsp;publications; and (g)&nbsp;retention of records. The provisions of this Section together with any other section which is
necessary for the interpretation or enforcement of this Agreement shall survive the expiry or termination of this Agreement howsoever arising. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>REGULATORY COMPLIANCE </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance will perform its Services in accordance with good laboratory practices and the applicable terms
of this Agreement. All of Covance&#146;s tests, assays and other activities undertaken under this Agreement shall comply in all material respects with College of American Pathologists (<B>CAP</B>) rules. Covance represents that it has and shall
maintain Clinical Laboratory Improvement Act (<B>CLIA</B>) certification. This Agreement shall contain all the conditions under which Covance will provide clinical laboratory Services. Covance makes no express or implied commitments or warranties
concerning the performance of the Study except as set forth in this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In the event that compliance with any regulatory requirements necessitates a change in this Agreement,
Covance will submit to Sponsor a revised technical and cost proposal for Sponsor&#146;s acceptance prior to performing Services. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In the event of a conflict in government regulations, the Parties will discuss and designate which
regulations shall be followed by Covance in its performance of the Services. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>FEES, BILLING AND TAXES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Fees for the Project are set forth in the attached Budget. Sponsor acknowledges that SOW finalization,
changes and/or modifications to the Project may result in a revised budget, which must be mutually agreed upon and the Agreement amended accordingly. The Budget contains all of the applicable discounts for Services that will be provided for that
Project. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Upon execution, Covance will assess a fee equal to twenty percent (20%) of the value of the contract
Budget (&#147;<B>Project Initiation Fee&#148;</B>). The Project Initiation Fee covers those value-added services rendered but unbilled, including developing the Scope of Work, quality control and loading of project databases, project management and
shipping of kits. Sponsor will pay the Project Initiation Fee within thirty (30)&nbsp;days after receipt of invoice. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Each month, Covance will invoice Sponsor for all fees due and documented expenses incurred while
providing Services during the previous month documentation for all expenses included on such invoice. Payment is due thirty (30)&nbsp;days from the date of the invoice. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Project Initiation Fee will be retained until the first invoice has been paid. Covance will issue a
credit on each month&#146;s invoices equal to <FONT STYLE="white-space:nowrap">one-sixth</FONT> (1/6) of the Project Initiation Fee. Should the Study be terminated before the Project Initiation Fee is exhausted and assuming all prior invoices have
been paid, Covance will apply Project Initiation Fee funds to the final invoice and refund any remaining Project Initiation Fee funds to Sponsor within thirty (30)&nbsp;days of termination. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>For budgeting purposes, Covance creates the Budget using local unit pricing. The local unit pricing is
then converted to the billing currency, as requested by Sponsor, using the Reuters exchange rate for the month the Budget is first created. Unless specified otherwise, this exchange rate remains unchanged during the course of the Study to simplify
budget comparisons and enable Sponsor to track changes to the Study unrelated to changes in currency exchange rates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>For invoicing purposes, expenses are billed based on the contracted local unit prices. Each month, at
the time of invoice creation, the local unit prices are converted to the billing currency using the Reuters exchange rate for the month in which the expenses were incurred. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance will hold prices unchanged for twelve (12)&nbsp;months from Project start up. Thereafter, a
Project is subject to a fee increase every twelve (12)&nbsp;months from Project <FONT STYLE="white-space:nowrap">start-up.</FONT> Any such increase shall not exceed the annual inflation rate during the previous twelve (12)&nbsp;month period, as
measured by the increase in the U.S. Consumer Price Index. Fee increases apply only to Services not yet performed and invoiced on the Study. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Should the Sponsor disagree with the accuracy of an invoice, the Sponsor shall notify Covance of such
inaccuracy within thirty (30)&nbsp;working days of receipt of the invoice. The Sponsor agrees to pay the amounts for any items not in dispute. The Sponsor agrees not to unreasonably withhold payment. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.9</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>If Sponsor requests a material change to the Project at any time which would affect the Services,
Covance will revise fees to reflect the change in the SOW and Budget. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.10</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Upon written notification by Sponsor that the Study has been concluded or upon completion of all
Services required by Covance under this Agreement, Covance will issue a final invoice for Services rendered to identify amounts due to Covance or refund due to Sponsor. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.11</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Fees payable under this Agreement shall not include local, state, federal or foreign sales or use taxes,
excise taxes, goods and services tax, value added tax or consumption taxes, as applicable. Any applicable taxes will be billed to and paid by Sponsor without deduction to amounts owed to Covance. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SITE VISITS </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Sponsor or its representative (which shall not be a competitor of Covance) may visit Covance&#146;s
premises where the Services are being performed at reasonable times, on reasonable notice and with reasonable frequency during normal business hours to observe the progress of the Services. Covance will assist the Sponsor in scheduling such visits.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Sponsor acknowledges that the Sponsor&#146;s representatives granted access to Covance facilities
during any such visits may have access to confidential and proprietary information of Covance. The Sponsor agrees that all such confidential and proprietary information of Covance obtained or observed by the Sponsor during such visits shall remain
the sole property of Covance and the Sponsor shall treat such information as Confidential Information in accordance with Section&nbsp;8 of this Agreement </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>REGULATORY INSPECTIONS AND AUDITS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In the event of a Party receiving a notice from a Regulatory Authority which directly relates to the
Services, the Party receiving such notice shall promptly notify the other Party or forward to the other Party a copy of such notice (or extract thereof). Each Party will cooperate with the other in responding to such notice before referring to the
other Party in any regulatory correspondence or disclosing any Confidential Information to a Regulatory Authority. However, each Party acknowledges that it may not direct the manner in which the other Party fulfils its obligations to permit
inspection by Regulatory Authorities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance shall cooperate with any inspection or audit by a Regulatory Authority and shall notify the
Sponsor promptly of any request by a Regulatory Authority. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance agrees that, during an inspection or audit by a Regulatory Authority concerning the Services, it
will not disclose information and materials that are not required to be disclosed to such Regulatory Authority, without the prior written consent of the Sponsor. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>If any inspections or audits conducted pursuant to this Section&nbsp;7 that result in a finding that
Covance has failed to comply with the terms of this Agreement, Covance shall promptly take such measures at its own cost and expense as are necessary to correct such defaults. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>It is agreed that where any audit of Covance concerns or relates to referral laboratory testing or
shipping methods of Covance, the Sponsor or its representative (which shall not be a competitor of Covance) may only confirm or not if Covance is properly billing such costs. The Sponsor expressly agrees that Sponsor&#146;s representatives may not
directly or indirectly provide any details of the charges to the Sponsor, such as the actual amount of the referral laboratory testing or shipping costs incurred by Covance. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CONFIDENTIAL INFORMATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Each Party agrees that all Confidential Information of the Disclosing Party is and shall be the sole
property of the Disclosing Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Without prejudice to any Covance Property, all Results, information, data and records developed by
Covance or its Affiliates in the performance of the Services shall be the Confidential Information of the Sponsor. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Each Party agrees to hold the Confidential Information of the other Party in confidence and in a manner
consistent with the way in which it maintains the confidentiality of its own proprietary information, being at least a reasonable standard of care. Each Party shall disclose the Confidential Information only on a need to know basis, to its
employees, officers, directors, representatives and third party investigators, in each case who are legally bound to treat the Confidential Information in the manner set forth in this Section&nbsp;8. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Recipient agrees that, except as necessary to fulfil its obligations under this Agreement, it will not
use any of the Confidential Information of the Disclosing Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Notwithstanding the <FONT STYLE="white-space:nowrap">non-disclosure</FONT> obligations herein, Recipient
shall not be in breach of this Section&nbsp;8 if it discloses Confidential Information to the extent such disclosure is required by Applicable Law or a court or administrative subpoena or order; provided, however, that (a)&nbsp;any such disclosure
shall not otherwise relieve Recipient of its continuing confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> obligations hereunder with respect to all of the Confidential Information, including the information disclosed by it to the
court or agency under this Section&nbsp;8 and (b)&nbsp;Recipient shall give Disclosing Party reasonable advance notice of any such disclosure and cooperate reasonably with Disclosing Party (and at Disclosing Party&#146;s expense) in Disclosing
Party&#146;s efforts to object to such disclosure and to obtain the court&#146;s or administrative agency&#146;s agreement to maintain the confidentiality of the Confidential Information to be disclosed by Recipient under this Section&nbsp;8.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The obligations in this Section&nbsp;8 shall remain in full force and effect for a period of <B>seven
(7)</B><B></B><B>&nbsp;years</B> following termination of this Agreement except with respect to Confidential Information which is considered a trade secret under Applicable Law, which shall remain confidential as long as such Confidential
Information retains its status as a trade secret. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Misuse or disclosure of the Confidential Information by Recipient may cause irreparable harm to
Disclosing Party not adequately compensable by money damages. In the event of actual or threatened breach or violation of this Section&nbsp;8, the disclosing Party shall have the right to seek injunctive relief in any court of competent
jurisdiction, without the need to post any bond and without the need to demonstrate actual damages. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INTELLECTUAL PROPERTY RIGHTS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>All Background IP is and shall remain the exclusive property of the Party owning it and except as
expressly provided in this Agreement, no Party shall acquire any rights in or to the Background IP of the other Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.2</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Sponsor acknowledges that Covance Property is owned or licensed by Covance or its Affiliates.
Strategic insight and proposed Project design and scope provided in any quotation by Covance shall remain the property of Covance and may be used by the Sponsor only to assess whether it wishes to pursue such work with Covance.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Sponsor will have title to the Deliverables and all intellectual property rights therein. Subject to
RMCL&#146;s payment of amounts due to Covance hereunder, Covance assigns all rights in and to the Deliverables to the Sponsor, except that one (1)&nbsp;copy of the Results may be retained by Covance solely for regulatory or legal compliance
purposes. The Sponsor hereby grants Covance an unrestricted, royalty-free license to aggregate and use System Data produced by or for Covance as part of the Services with other System Data owned or licensed by Covance only if Sponsor is not
identifiable through Covance&#146;s aggregation and use. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance shall promptly disclose to the Sponsor (or its nominee) all Inventions. Covance assigns and
agrees to assign to the Sponsor (or its nominee) all rights, title and interest in and to such Invention and shall do all acts that are reasonably necessary to vest the Invention in the name of the Sponsor (or its nominee), at Sponsor&#146;s
expense. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>REMEDIES AND LIMITATION OF LIABILITY </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In the event of a material error by Covance that prevents proper performance under this Agreement or
which renders the Services in whole or in part unacceptable to a Regulatory Authority to which the Sponsor intends to submit the Results, Covance&#146;s sole obligation to Sponsor (other than the obligations set forth in Section&nbsp;11) shall be
for Covance, at Sponsor&#146;s election, to either: (a)&nbsp;repeat the defective part of the Services at Covance&#146;s own cost; or (b)&nbsp;refund to the Sponsor the amount paid for the defective part of the Services. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Except for liability resulting from any breach of Sections 8 or 9 or liability pursuant to
Section&nbsp;11, Covance&#146;s total liability to the Sponsor, whether in contract, tort (including negligence) or otherwise, shall in no circumstances exceed the total price paid by the Sponsor for the Services that are the subject of this
Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Nothing in this Agreement excludes or limits the liability of either Party where liability cannot be
excluded or restricted as a matter of law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.4</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Except for liability resulting from any breach of Sections 8 or 9 or liability pursuant to
Section&nbsp;11, Covance will not be liable to the Sponsor for any Loss in respect of any: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">loss of profit, opportunity, business, or goodwill (in each case whether direct or indirect); or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any indirect, consequential, punitive, exemplary or special damages or losses, arising under or in connection
with this Agreement, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">and each type of loss arising under this Section&nbsp;10.4 shall be severable in accordance with
Section&nbsp;22 of this Agreement. To the extent that Covance agrees to perform Services for Sponsor Affiliates, Covance shall only be liable to the entity named in this Agreement and not for multiple claims by Sponsor Affiliates.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance shall not be liable for any failure, error or delay in performing the Services if such failure,
error or delay is directly caused by Sponsor, but Covance will cooperate with Sponsor to minimize any such delay and to correct any such failure or error. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance shall have no liability to Sponsor for loss, damage, delay or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">non-delivery/non-collection</FONT></FONT> of any samples or shipment dispatched by Covance to Sponsor or to any third party designated by Sponsor in connection with the Services that are caused by the acts or omissions of
any third party delivery services or carrier (&#147;<B>Carrier&#148;</B>). Notwithstanding the foregoing, to the extent permitted by law, Covance shall have the benefit of any right or remedy permitted under international or domestic law and any
sums recoverable from a Carrier shall be paid to the Sponsor. For the avoidance of doubt, a Carrier is not considered a Subcontractor for the purposes of this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INDEMNITIES </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Sponsor shall defend, indemnify, and hold harmless Covance and its respective Affiliates and their
respective officers, directors, employees and agents (<B>Covance Group</B>) from any Loss resulting from any Claim arising from or related to: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">personal injury to a participant in the Study directly or indirectly caused by the Test Material;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Covance&#146;s proper execution and/or the proper performance of its obligations under this Agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Sponsor&#146;s use of the Results or Deliverables or its use or marketing of any substance tested in
association with the Study by Covance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the negligence or intentional misconduct of the Sponsor; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Test Material&#146;s harmful or otherwise unsafe effect, including, without limitation, a product liability
claim based upon the Sponsor&#146;s or Sponsor&#146;s representatives&#146; use, consumption, sale, distribution or marketing of the Sponsor&#146;s products tested under this Agreement; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the infringement, unlawful disclosure or misappropriation of copyright, patent, trade secret or other
intellectual property of a third party by reason of Covance&#146;s use of the Sponsor Information in accordance with the terms of this Agreement, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">provided that if such Loss or Claim arises in whole or in part from Covance&#146;s negligence or intentional misconduct, then the amount of
such Loss that Sponsor shall indemnify the appropriate person or entity within the Covance Group pursuant to this Section&nbsp;11 shall be reduced by an amount in proportion to the percentage of Covance&#146;s responsibilities for such Loss as
determined by a court of competent jurisdiction in a final and <FONT STYLE="white-space:nowrap">non-appealable</FONT> decision or in a binding settlement between the Parties. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance shall defend, indemnify and hold harmless the Sponsor and its Affiliates and their respective
officers, directors and employees (the &#147;<B>Sponsor Group&#148;</B>) from any Loss resulting from any Claim arising from a breach of this Agreement by Covance, or the negligence or intentional misconduct of Covance, <U>provided</U> that if such
Losses or Claims arise in whole, or in part, from the Sponsors Group&#146;s negligence or intentional misconduct, then the amount of such Losses that Covance shall be responsible for pursuant to this Section&nbsp;11 shall be reduced by an amount in
proportion to the percentage of the Sponsor Group&#146;s responsibilities for such Losses as determined by a court of competent jurisdiction in a final and <FONT STYLE="white-space:nowrap">non-appealable</FONT> decision or in a binding settlement
between the Parties. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>An indemnitee entitled to indemnification under Section&nbsp;11 (the &#147;<B>Indemnified
Party&#148;</B>) shall give written notice to the other Party (&#147;<B>Indemnifying Party&#148;</B>) of a claim or other circumstances likely to give rise to a request for indemnification, promptly after the Indemnified Party becomes aware of the
same. The Indemnifying Party shall be afforded the opportunity to undertake the defense of, and, subject to Section&nbsp;11.5, to settle by compromise, or otherwise, any claim for which indemnification is available under this Section.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.4</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>If the Indemnifying Party assumes the defense of any claim, the Indemnified Party may participate in
such defense with legal counsel of its selection and at its expense. If the Indemnifying Party fails to promptly assume the defense of a claim by the Indemnified Party under this Section&nbsp;11.4, the Indemnified Party may thereupon undertake the
defense on behalf of, at the risk and expense of the Indemnifying Party with all reasonable costs and expenses of such defense to be paid by the Indemnifying Party. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In the event that the Indemnifying Party assumes the defense of any claim, no compromise or settlement
of any such claim may be made without the prior written consent of the Indemnified Party, which consent shall not be unreasonably withheld or delayed. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INSURANCE </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>12.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance shall secure and maintain in full force and effect through the performance of the Services the
necessary insurance coverage in amounts appropriate to the conduct of Covance&#146;s business. Certificates evidencing such insurance will be made available for examination upon written request by Sponsor. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>12.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Sponsor hereby warrants and represents that it maintains and shall maintain adequate clinical trial and
product liability insurance coverage consistent with industry standards and in compliance with all Applicable Laws. Certificates evidencing such insurance will be made available for examination upon written request by either Covance or Sponsor.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>HUMAN BIOLOGICAL SAMPLES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>13.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Where the Sponsor supplies HBS to Covance, the Sponsor represents and warrants that:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all HBS supplied under this Agreement are or have been procured and reviewed by ethics committee and supplied
to Covance in full compliance with any and all Applicable Laws and Regulatory Requirements relating to the Use of HBS providing protection for human subjects in the country of origin; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the HBS Donor has given Informed Consent; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all HBS supplied to Covance: (i)&nbsp;may be Used for the Services; (ii)&nbsp;may be used to provide data in
support of commercial product development; and (iii)&nbsp;were procured without inappropriate financial benefit to the HBS Donor. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>13.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Sponsor shall: (a)&nbsp;upon request, provide a copy of the relevant Informed Consent template; and
(b)&nbsp;ensure any HBS shall be <FONT STYLE="white-space:nowrap">de-identified</FONT> or &#145;coded&#146; according to applicable Regulatory Requirements to protect the identity and confidentiality of the HBS Donor. Full date of birth shall only
be collected if medically relevant to the Services (unless legally restricted in the country of operation). In the event of a withdrawal of, or a material variation to the Informed Consent (including any material changes that may affect the Services
provided by Covance) the Sponsor shall promptly notify all relevant Covance entities of such changes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>13.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance agrees to Use the HBS in accordance with all applicable Regulatory Requirements.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>13.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Upon Sponsor&#146;s request, Covance shall retain, return or destroy all HBS in accordance with the
Informed Consent, the Sponsor&#146;s instructions or any other specific requirements under Applicable Law and Regulatory Requirements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>13.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Sponsor acknowledges that where Covance enters into a material transfer agreement
(&#147;<B>MTA&#148;</B>) with the provider of any HBS, Covance shall act in accordance with the terms of the MTA and the disposition of the relevant HBS shall be as prescribed in the MTA. In the event of a conflict between the terms of the MTA, this
Agreement, any Work Order and any instructions provided by the Sponsor, the terms of the MTA shall prevail. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DATA PROTECTION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>14.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Where Covance processes any personal data on behalf of the Sponsor, Covance shall process such personal
data in accordance with all applicable Data Protection Laws in the territories in which the Services are performed (&#147;<B>Protected Data</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>14.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>If Covance processes any Protected Data on behalf of the Sponsor, Covance and the Sponsor each agree and
acknowledge that the Sponsor shall be the data controller and Covance shall be the data processor with respect to the processing of such Protected Data. Covance shall only process such Protected Data on behalf and upon the reasonable instructions of
the Sponsor for purposes notified to it by the Sponsor for which consent from the relevant data subjects has been obtained in accordance with all applicable Regulatory Requirements. Covance shall follow such procedures, policies and reasonable
instructions as may be agreed by the Parties from time to time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>14.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance shall take reasonable technical and organizational measures that are necessary to protect
against the unauthorized or unlawful processing of or the unauthorized or unlawful disclosure of such personal data. Covance shall promptly notify the Sponsor in the event of a security breach involving any personal data which Covance is processing
on behalf of the Sponsor. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>14.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Sponsor warrants that it has complied with any and all notification and information requirements
under the applicable Data Protection Laws. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SUBCONTRACTORS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>15.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Notwithstanding Section&nbsp;18, certain tasks, as may be agreed during the development of and specified
in the Protocol, may be subcontracted by Covance to Subcontractors approved by Covance or subcontracted, or assigned and transferred to its Affiliates. Covance shall be responsible for the acts and performance of Subcontractors and Affiliates.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>15.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance shall not be responsible for the performance of third party Vendors. Liability of Covance to the
Sponsor with respect to such Vendors shall be limited to the extent Covance is negligent in the performance of its obligations under this Agreement. Covance shall provide to the Sponsor any amounts that Covance may recover from such Vendors as a
result of any error or service failure on the part of the Vendors in connection with this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>FORCE MAJEURE </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>16.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Neither Party shall be in breach of this Agreement nor liable for delay in performing, or failure to
perform, any of its obligations under this Agreement, if such delay or failure result from a Force Majeure Event. In such circumstances, any time specified for completion of performance in the Protocol falling due during or subsequent to the
occurrence of a Force Majeure Event shall be automatically extended for a period of time equal to such event. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>16.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Should any part of the Services be rendered invalid as a result of a Force Majeure Event, Covance shall,
upon written request from the Sponsor, and at the Sponsor&#146;s sole cost and expense, repeat the affected part of the Services. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>16.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>If a Force Majeure Event prevents a Party from performing pursuant to this Agreement for a period of 180
days or more, the unaffected Party may terminate this Agreement upon written notice to the affected Party. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INDEPENDENT CONTRACTOR </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>17.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Parties agree that in performing the Services, Covance (including its employees, agents,
subcontractors or other representatives) is acting as an independent contractor to Sponsor. The Parties further agree that Covance and its employees, agents, subcontractors or other representatives are not employees, agents or partners of Sponsor,
and nothing in this Agreement and no actions of Sponsor in engaging Covance shall render Covance or any of its employees, agents, subcontractors or other representatives the employees, agents or partners of Sponsor. Neither Covance nor any of its
employees, agents, subcontractors or other representatives will have power or authority to bind Sponsor. Neither the relationship between Covance and Sponsor nor any provision of this Agreement shall be construed to authorize Covance to take (or
fail to take) any action or make (or fail to make) any decision, representation or commitment binding upon Sponsor or any of its affiliate companies. Sponsor shall at all times be free to engage other third parties to perform services in addition to
or in lieu of those services being provided by the Covance. Subject to the provisions of this Agreement, Covance shall be free to devote such time that they do not spend providing Services under this Agreement to such person, firms or corporations
as they may choose. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>17.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Nothing contained herein shall be construed (i)&nbsp;to create any association, partnership, joint
venture, or relationship of principal and agent, or master and servant between the Parties or any of their affiliates or subsidiaries, employees and subcontractors, (ii)&nbsp;to provide any Party with the right, power or authority, either express or
implied, to create any duty or obligation on behalf of another Party, (iii)&nbsp;to impose liability upon one Party for the act or failure to act of another Party, or (iv)&nbsp;to confer any right for Covance (or any of its employees, agents,
subcontractors or other representatives) to participate in or be eligible to participate in any pension or welfare benefit plans, programs or arrangements of Sponsor or of its affiliate companies pertaining to any pension, stock, bonus, profit
sharing or similar benefits or any employee health, life assurance, workers compensation insurance, disability, severance or any other benefit of any kind whatsoever which is associated with or customarily paid in connection with or in relation to
an employment contractor. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ASSIGNMENT </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>18.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Either Party may assign, transfer or subcontract any or all of its rights and obligations under this
Agreement to its Affiliates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>18.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Notwithstanding Section&nbsp;18.1 and except in connection with an internal reorganization of the
relevant Party&#146;s corporate structure, this Agreement shall not be assigned or transferred in whole or in part by either Party without the prior written consent of the other, which consent shall not be unreasonably withheld or delayed.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>19.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NOTICES </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>19.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>All notices required to be given under this Agreement shall be in writing and shall be deemed to have
been duly given if delivered personally or mailed first class, registered or certified mail, return receipt requested, postage paid: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">If to Sponsor to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">RegenMed
(Cayman) Ltd. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">10 Market St. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">#774 Camana Bay, Grand Cayman </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">KY <FONT STYLE="white-space:nowrap">1-90006</FONT> Cayman Islands </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;Attention: ________________________ </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">With a copy by email to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">If to
Covance to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Covance Central Laboratory Services LP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">8211 SciCor Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Indianapolis, Indiana 46214-2985 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">UNITED STATES </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: VP,
Finance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">or at such other place as either Party shall hereafter furnish to the other Party in
writing. Notices shall be deemed given on the date of personal delivery or deposit in the mail as specified above. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>19.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>For the purposes of this Section&nbsp;19, in relation to the purposes of any legal proceeding,
&#147;<B>writing</B>&#148; shall not include email. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>20.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WAIVER </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">No waiver of any term, provision, or condition of this Agreement whether by conduct or otherwise in any one or more instances shall be deemed
to be or construed as a further or continuing waiver or estoppel of any such term, provision, or condition or of any other term, provision, or condition of this Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>21.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>VARIATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">No provision of this Agreement may be amended, modified, varied, discharged, or terminated except by the express written agreement of both
Parties and signed by an authorized representative of each Party. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>22.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SEVERABILITY </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">If any court or competent authority finds that any provision of this Agreement (or part of any provision) is invalid, illegal or unenforceable,
that provision or part-provision shall, to the extent required, be deemed to be deleted, and the validity and enforceability of the other provisions of this Agreement shall not be affected. If any invalid, unenforceable or illegal provision of this
Agreement would be valid, enforceable and legal if some part of it were deleted, the provision shall apply with the minimum modification necessary to make it legal, valid and enforceable. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>23.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PUBLICITY AND PUBLICATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>23.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Neither Party will use the name, trademark or the name of any representative of the other, or the
existence of this Agreement for any promotional or advertising purposes, or any other publication, without the prior written consent of the other. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>23.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Neither Party will state or imply that the other Party endorses or approves any service, material,
product or compound of the other Party without the prior written consent of the other. Such restrictions shall not apply to internal communications and publications to a Party&#146;s Affiliates. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>23.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Sponsor shall provide Covance with a <FONT STYLE="white-space:nowrap">pre-publication</FONT> copy of any
report, manuscript, publication or form of marketing material recognizing Covance&#146;s participation in the Services or otherwise identifying Covance, for approval (which approval shall not be unreasonably withheld or delayed) in each case at
least thirty (30)&nbsp;days before its submission for publication. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>24.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ENTIRE AGREEMENT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">This Agreement represents the entire understanding between the Parties with respect to the subject matter hereof as of the Effective Date, and
this Agreement supersedes all prior agreements, negotiations, understandings, representations, statements and writings between the Parties relating thereto, except that any written agreement entered into prior to the Effective Date with respect to a
Study in process prior to the Effective Date shall remain effective and shall continue to govern such existing Study. The Parties agree that neither has relied upon prior representations made before executing this Agreement. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>25.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>LEGAL TESTIMONY </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Covance agrees to provide testimony or records regarding the Services for the Sponsor in any legal or administrative proceeding, provided that
the Sponsor shall reimburse Covance for its out of pocket costs plus a reasonable hourly fee for the involvement of its employees or representatives in such proceedings. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>26.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>THIRD PARTY RIGHTS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Except as expressly set forth in this Agreement in respect of Covance Affiliates, nothing in this Agreement is intended to confer any rights,
benefits or remedies of any kind whatsoever, and a person who is not a party to this Agreement shall have no right to enforce any of its terms. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>27.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ANTI-BRIBERY </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>27.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Both Parties agree that each has not and will not, either directly or indirectly, engage in bribery, or
offer, or promise, or authorize to pay or make any improper payment of any monies or financial or other advantage, including cash, loan, gift, travel, entertainment, hospitality, facilitation payment, kickback, political or philanthropic
contribution, anything of value, or any other perceived benefit to improperly obtain or retain a business advantage in violation of any Anti-Corruption Laws and further, each Party agrees that they shall not take any action that would cause the
other Party to be in violation of such Anti-Corruption Laws. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>27.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Any breach of Section&nbsp;27.1 by a Party shall allow the other Party to immediately terminate this
Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>28.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TRADE CONTROL </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>28.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Notwithstanding any other provision of this Agreement to the contrary, each Party shall comply with, and
retain responsibility for its compliance with, all applicable export control laws (e.g., the U.S. Export Administration Regulations) and economic sanctions programs (e.g., economic sanctions maintained by the U.S. Treasury Department, as well as
Specially Designated Nationals and Blocked Persons (<B>SDNs</B>)) relating to its respective business, facilities, and the provision of services to third parties (collectively, <B>Trade Control Laws</B>). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>28.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Nothing in this Agreement shall be construed to require Covance to be directly or indirectly involved in
the provision of goods, software, services and/or technical data that may be prohibited by applicable Trade Control Laws, including sanctions currently in place against Cuba, Iran, North Korea, Sudan, Syria and SDNs. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>29.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COUNTERPARTS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">This Agreement may be executed in any number of counterparts, each of which when executed and delivered shall constitute an original to this
Agreement but all of which together shall constitute the same Agreement. Signatures upon this Agreement transmitted by facsimile, electronic mail or other electronic method shall have the same legal and biding effect as wet signatures. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>30.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CHOICE OF LAW AND DISPUTE RESOLUTION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>30.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>This Agreement shall be governed and construed in accordance with the laws of the State of New York,
U.S.A., without regard to conflicts of laws provisions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>30.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Any dispute, controversy, or claim arising out of, relating to, or in connection with this Agreement, or
the breach, termination, or validity thereof, shall be finally settled by arbitration. The arbitration shall be conducted in accordance with the Securities Arbitration Rules (the &#147;Rules&#148;) of the American Arbitration Association
(&#147;AAA&#148;), including the AAA&#146;s Procedures for Large, Complex Commercial Disputes, in effect at the time of the arbitration, except as they may be modified herein or by mutual agreement of the parties. The seat of the arbitration shall
be New York, New York, and it shall be conducted in the English language. The arbitration and this clause shall be governed by Title 9 (Arbitration) of the United States Code. The Parties agree that irreparable damage may occur to a Party in the
event that the other Party may fail or fails to comply with the provisions of Section&nbsp;8. Accordingly and without otherwise limiting the requirement of mandatory arbitration imposed hereunder, a Party may seek from any court having jurisdiction
any interim or provisional relief (without the necessity of posting bond) that may be necessary to protect its interests under Section&nbsp;8, pending the arbitral tribunal&#146;s final determination of the merits of the controversy.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>30.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The arbitration shall be conducted by three arbitrators. The claimant shall appoint an arbitrator in its
request for arbitration. The respondent shall appoint an arbitrator within twenty (20)&nbsp;days of the receipt of the request for arbitration. The two arbitrators shall appoint a third arbitrator, who shall act as chair of the tribunal, within
twenty (20)&nbsp;days after the appointment of the second arbitrator. If any of the three arbitrators is not appointed within the time prescribed above, then the AAA shall appoint that arbitrator from its National Panel of Securities Arbitrators or
its Large, Complex Commercial Case Panel, not including any such members affiliated with the securities industry. The chair of the tribunal shall be a citizen of the United States. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>30.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In addition to the authority conferred on the arbitration tribunal by the Rules, the arbitration
tribunal shall have the authority to order such production of documents, generally consistent with the discovery permitted under the Federal Rules of Civil Procedure, as may reasonably be requested by any party or by the tribunal itself. In
addition, any party may request a reasonable number of depositions of party witnesses. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>30.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Parties agree that the arbitration shall be kept confidential and that the existence of the
proceeding and any element of it (including but not limited to any pleadings, briefs or other documents submitted or exchanged, any testimony or other oral submissions, and any awards) shall not be disclosed beyond the tribunal, the AAA, the
Parties, their counsel, accountants and auditors, insurers and <FONT STYLE="white-space:nowrap">re-insurers,</FONT> and any person or entity necessary to the conduct of the proceeding. The confidentiality obligations in this Section&nbsp;28.5 shall
not apply (i)&nbsp;if disclosure is required by Applicable Law, or in judicial or administrative proceedings, or (ii)&nbsp;as far as disclosure is necessary to enforce the rights arising out of the award. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>30.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The arbitration award shall be final and binding on the Parties. Judgment upon the award may be entered
by any court having jurisdiction thereof or having jurisdiction over the relevant Party or its assets. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>30.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In order to facilitate the comprehensive resolution of related disputes, and upon request of any party
to the arbitration proceeding, the arbitration tribunal may consolidate the arbitration proceeding with any other arbitration proceeding involving any of the Parties hereto relating to this Agreement. The arbitration tribunal shall not consolidate
such arbitrations unless it determines that (i)&nbsp;there are issues of fact or law common to the related proceedings so that a consolidated proceeding would be more efficient than separate proceedings, and (ii)&nbsp;no party would be prejudiced as
a result of such consolidation through undue delay or otherwise. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>30.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Parties agree that any dispute arising from or in connection with this Agreement (including any <FONT
STYLE="white-space:nowrap">non-contractual</FONT> obligations) shall be referred to and finally resolved by arbitration under the Rules of the International Chamber of Commerce which Rules shall be deemed incorporated by reference to the Agreement.
The number of arbitrators shall be three (3), the seat or legal place of arbitration shall be New York and the language used in the arbitration shall be English. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>signature page follows</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties by their duly authorized officers have executed this Agreement on the dates
set forth below, to be effective on the Effective Date set forth on the first page of this Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>RegenMed (Cayman) Ltd.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Alasdair Foster</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Alasdair Foster</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">29&nbsp;August 2016</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>COVANCE CENTRAL LABORATORY SERVICES LP</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>COVANCE CENTRAL LABORATORY SERVICES S&Agrave;RL</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Cheryl Helton</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Cheryl Helton</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">VP, Covance CLS</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8/29/2016</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 of 21 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>10
<FILENAME>d373959dex1020.htm
<DESCRIPTION>EX-10.20
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.20</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.20 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This Laboratory Service Agreement </B>(&#148;<B>Agreement&#148;) </B>is made effective on 1 August 2017 by and between </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COVANCE CENTRAL LABORATORY SERVICES LP </B>an Indiana limited partnership, with its principal place of
business at 8211 SciCor Drive, Indianapolis, Indiana 46214, USA; and <B>COVANCE CENTRAL LABORATORY SERVICES</B> <B>S&Agrave;RL</B>, with its principal place of business at Rue Moise-Marchines 7, 1217 Meyrin, Geneva Switzerland (collectively
&#147;<B>Covance</B>&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>inRegen, </B>10 Market Street, No.&nbsp;774 Camana Bay, Grand Cayman
<FONT STYLE="white-space:nowrap">KY1-9006,</FONT> Cayman Islands (&#147;<B>Sponsor</B>&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(each a
&#147;<B>Party</B>&#148; and collectively the &#147;<B>Parties</B>&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEREAS </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Covance is engaged in the business of providing laboratory testing, data management, protocol management and
information management services for pharmaceutical clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sponsor desires for Covance to perform such services for one or more clinical trials, all in accordance with
and subject to the terms and conditions of this Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IT IS AGREED </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEFINITIONS</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>1.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In this Agreement, the following words and expressions shall have the following meanings:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman"><B>&#147;Affiliate</B>&#148; means any entity controlling, controlled by, or in common control with a Party. For the
purposes of this definition, &#147;<B>Control</B>&#148; shall mean ownership or control, directly or indirectly of more than fifty percent (50%) of the common voting stock or ordinary shares in the entity or the right to appoint fifty percent (50%)
or more of the directors of that entity. With respect to Covance, the term Affiliate shall include Laboratory Corporation of America Holdings and any business entity that is controlled by or is under common control with Laboratory Corporation of
America Holdings. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Anti-Corruption Laws</B>&#148; means any anti-bribery and anti-corruption laws, rules, regulations applicable
to either Party (each as amended from time to time) including the United States Anti-Kickback Law, United States Foreign Corrupt Practices Act, the UK Bribery Act 2010 and the OECD Convention Against the Bribery of Foreign Government Officials in
International Business Transactions, together with any applicable implementing legislation including any applicable local law addressing bribery or corruption. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Applicable Law</B>&#148; means applicable federal, state and local laws, rules, regulations, including the regulations of the FDA and
Data Protection Laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Background IP</B>&#148; means all <FONT STYLE="white-space:nowrap">pre-existing</FONT> intellectual
property belonging to or licensed to a Party or other intellectual property created outside the scope of the Services. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Claim</B>&#148; means any third party claims, demands, assessments, actions, suits, proceedings, or settlements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Confidential Information</B>&#148; means any and all <FONT
STYLE="white-space:nowrap">non-public</FONT> information or materials and derivatives thereof, in any and all forms, howsoever disclosed or obtained, including business plans, financial information, client lists, and requirements, techniques,
designs, methods, processes and procedures, which: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">(i) is identified by a suitable legend or other marking as being confidential (or
similar designation) in a prominent position or (ii)&nbsp;is described as being confidential at the time of disclosure or (iii)&nbsp;the disclosing Party regards or should reasonably be expected to regard as proprietary and confidential given the
nature of the information and the circumstances of disclosure. Confidential Information shall not include information (a)&nbsp;that is or becomes publicly disclosed except to the extent such disclosure results from a violation hereof or any improper
action or inaction by Recipient or any agent or representative of Recipient; (b)&nbsp;that was in Recipient&#146;s possession prior to Recipient&#146;s receipt of such material from Disclosing Party, as demonstrated by documentary evidence that
itself was in Recipient&#146;s possession at the time of Disclosing Party&#146;s disclosure of such Confidential Information to Recipient; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">(c) that is lawfully acquired by Recipient from a third party not obligated to keep such information confidential; or (d)&nbsp;that is
developed by the Recipient without the use of or reliance on the Disclosing Party&#146;s Confidential Information, as demonstrated by Recipient&#146;s written records. Information will not be deemed to be within the foregoing exceptions merely
because such information is embraced by more general information that is within the foregoing exceptions. In addition, any combination of features will not be deemed to be within the foregoing exceptions merely because individual features are within
the exceptions, but only if the combination itself and its principle of operation are within the exceptions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Covance
Property</B>&#148; means inventions, proprietary processes, software (including codes) data, technology, <FONT STYLE="white-space:nowrap">know-how</FONT> and other intellectual property that have been independently developed or discovered by Covance
or its Affiliates without the use of Sponsor&#146;s Confidential Information, including those that relate to the proprietary innovative testing procedures, laboratory testing data collection or data management procedures, procedural manuals, delta
flags, nucleic acid based vectors, analytical procedures and approaches that are not specific for use with the Sponsor&#146;s Background IP even if such are developed in the performance of the Services or are captured in documents pertaining to the
Services (i.e. laboratory notebooks), techniques, skills, models, <FONT STYLE="white-space:nowrap">non-product</FONT> specific components of questionnaires, management tools and any other materials, employed, developed or acquired by Covance or its
Affiliates. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman"><B>&#147;Data Protection Laws&#148; </B>mean all applicable privacy, data protection or similar laws and regulations anywhere
in the World, as the same may be amended from time to time, including to the extent applicable to the respective Services, the Data Protection Directive (95/46/EC), the Personal Data Protection Act 2012 of Singapore and any applicable implementing
legislation or any amendment thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Deliverables</B>&#148; means as applicable to the Services, Results, or any other
deliverable specified in this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Disclosing Party</B>&#148; means the Party disclosing or making available its
Confidential Information to the other Party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>FDA</B>&#148; means the United States Food and Drug Administration or any other
government body or agency that succeeds it. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Force Majeure Event</B>&#148; means circumstances or causes beyond the reasonable
control of a Party, including war, threat of war or warlike conditions, blockade, embargo, fire, explosion, lightning, storm, drought, flood, earthquake or other natural disaster, pandemic or epidemic, power failure, acts of terrorism, riot, civil
unrest, insurrection, acts of government or other international bodies, political subdivision and any other events which by their nature could not have been foreseen by the Parties, or, if it could have been foreseen were unavoidable by a reasonable
prudent business. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>HBS Donor</B>&#148; means an individual, living or deceased, from whom the HBS was obtained. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Human Biological Samples</B>&#148; or &#147;<B>HBS</B>&#148; means any human biological material, including, without limitation,
human bodily parts and organs in whole or <FONT STYLE="white-space:nowrap">sub-samples,</FONT> any tissue, skin, bone, muscle, connective tissue, blood, cerebrospinal fluid, cells, gametes, or <FONT STYLE="white-space:nowrap">sub-cellular</FONT>
structures such as DNA, or any derivative or product of such human biological materials including stem cells, cell lines, bodily fluids, blood derivatives and urine. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>IEC/IRB</B>&#148; means an independent ethics committee or institutional review board. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Informed Consent</B>&#148; means an IEC/IRB approved informed consent form signed by the HBS Donor authorizing the Use of their HBS.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Invention</B>&#148; means any patentable invention or other registerable intellectual property rights discovered, conceived of
or made by Covance or its Affiliates specifically as result of the Services for the Sponsor and relating to the Test Materials. Covance Property is not included in Inventions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Loss</B>&#148; means any loss, cost, damage or expense (including reasonable legal expenses). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Project</B>&#148; means a Study, project or assignment between Covance and Sponsor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Protocol</B>&#148; means the document which specifies the laboratory testing procedures as written by Sponsor as applicable for the
performance of a Study and is provided to Covance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Recipient</B>&#148; means the Party receiving or having access to the
Confidential Information from the other Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Regulatory Authority</B>&#148; means any national or state (in the case of the
US), or local agency, authority, department, inspectorate, minister, ministry official, parliament or public or statutory person (whether autonomous or not) of any government of any country having jurisdiction over either any of the activities
contemplated by this Agreement or the Parties. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Regulatory Requirements</B>&#148; means all laws, statutes, acts, rules,
regulations, guidelines, codes, orders, directives or other legally binding requirements of any Regulatory Authority and industry standards or codes of conduct applicable to the Services. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Results</B>&#148; mean materials, data, Inventions, documents and information produced, conceived or developed by Covance
specifically as a result of the Services and related to the Test Materials. Covance Property is not included in Results. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Services</B>&#148; means the services provided by Covance to the Sponsor as more particularly described in this Agreement and the
SOW. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>SOW</B>&#148; means the scope of work mutually agreed to in writing by the Parties, which will be attached hereto as an
exhibit and will be governed by and is hereby made a part of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sponsor Information</B>&#148; means Test Materials,
data, specification, or other materials or information supplied by the Sponsor to Covance in connection with the Services. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Study</B>&#148; means a clinical trial or scientific evaluation of the Test Materials on the terms and conditions of the Protocol.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Subcontractor</B>&#148; means a third party approved, reviewed and contracted by Covance for Services within the scope of this
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>System Data</B>&#148; means control data from laboratory tests or transactional, volume and performance data related
to the Services, which does not contain any personally identifiable information or Sponsor Confidential Information. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Test
Materials</B>&#148; means compounds, materials or other substances as described in the Protocol to be tested or used in the performance of the Services and provided to Covance by the Sponsor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Use</B>&#148; (in the context of Section&nbsp;13) means collection, storage, transfer (including import and export), use and return
or disposal of HBS including by commercial organizations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Vendor</B>&#148; means third-party service providers other than a
Subcontractor for which Covance may hold the contract with such service provider at Sponsor&#146;s written request for the convenience or benefit of the Sponsor in connection with Services under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>1.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In this Agreement, unless the context otherwise requires, references to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Schedule and Section headings are inserted for convenience only and do not affect the construction or
interpretation of this Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a particular law or statutory provision is a reference to it as it is in force for the time being taking
account of any amendment, extension, or <FONT STYLE="white-space:nowrap">re-enactment</FONT> and includes any subordinate legislation for the time being in force made under it; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>writing </B>or <B>written </B>includes faxes and e-mail; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a person includes a corporate or unincorporated body; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any gender includes all genders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>including</B>, <B>include</B>, <B>in particular </B>or any similar expression shall be construed as
illustrative and shall not limit the sense of the words preceding those terms; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">words in the singular include the plural and vice versa. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>1.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>If this Agreement is translated, the English language text shall prevail. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SERVICES</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>2.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance through itself and/or its Affiliates hereby agrees to perform Services for Sponsor&#146;s
protocol REGEN003, <B>&#147;</B>PHASE II, OPEN-LABEL SAFETY AND TOLERABILITY STUDY OF AN AUTOLOGOUS <FONT STYLE="white-space:nowrap">NEO-KIDNEY</FONT> AUGMENT (NKA) IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE<B>.&#148; </B>as amended
from time to time, a copy of which is attached hereto as Exhibit A. Such Services shall be performed pursuant to the terms and conditions contained herein. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>2.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Any changes or modifications to the Protocol and/or Services provided by Covance, or any Sponsor request
for additional Services may commence upon Covance&#146;s receipt of Sponsors written approval of the revised SOW. Upon Sponsor&#146;s SOW signature, Covance shall provide such Services to the Sponsor and the Sponsor shall pay for costs associated
with such Services at its current standard rates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>2.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Should a kit be lost through no fault of Covance, or should a kit expire at the investigator site,
Covance will supply replacement kits for those that are lost, expired, or otherwise rendered unusable, at an amount equal to the price listed in the Budget per kit for the same kit/visit that is being replaced. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>2.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>After performing Services, Covance will store the remaining Study specimens for the length of time and
under storage conditions as described in the applicable SOW. The remaining specimens may subsequently be shipped to Sponsor or another party as specified in the SOW or if not specified in the SOW, held as otherwise instructed by the Sponsor. In no
event shall Covance&#146;s liability for any breach or default with regard to storage of an archival specimen exceed the fee it has been paid for storage of that specimen for the previous twelve (12)&nbsp;months. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TERM AND TERMINATION</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>3.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The term of this Agreement shall be for <B>forty two (42)</B><B></B><B>&nbsp;months </B>commencing on
the date hereof or the conclusion of the study, whichever is earlier, and shall renew automatically for successive one (1)&nbsp;year periods unless a Party provides the other Party with written notice of its intention to not renew and extend this
Agreement at least sixty (60)&nbsp;days prior to the commencement of any such renewal term. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>3.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Either Party may terminate this Agreement with immediate effect by notice in writing in the event that:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the other Party commits a material breach of any term of this Agreement which breach is irremediable or (if
such breach is remediable) fails to remedy that breach within a period of thirty (30)&nbsp;days after being notified in writing to do so; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the other Party repeatedly breaches any of the terms of this Agreement in such a manner as to reasonably
justify the opinion that its conduct is inconsistent with it having the intention or ability to give effect to the terms of this Agreement; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">anyone commences an involuntary case against such other Party under title 11 of the United States Code or the
corresponding provisions of any successor laws and either the case is not dismissed by midnight at the end of the sixtieth (60<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) day after commencement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a court of competent jurisdiction appoints a custodian (as that term is defined in title 11 of the United
States Code or the corresponding provisions of any successor laws) for such other Party or all or substantially all of its assets, or such other Party makes an assignment of all or substantially all of its assets to a custodian;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the other Party fails generally to pay its debts as they become due (unless those debts are subject to a
good-faith dispute as to liability or amount) or acknowledges in writing that it is unable to do so; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any event occurs, or proceeding is initiated, in any jurisdiction to which it is subject that has an effect
equivalent or substantially similar to any of the events mentioned above. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>3.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Sponsor may terminate this Agreement for any reason upon ninety (90)&nbsp;days prior written notice to
Covance. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>3.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In the event of such termination, Covance shall be entitled to full payment for work performed on the
Study through the date work on such Study is concluded, including, without limitation, all fees and other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by Covance for such Study.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>3.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The termination of this Agreement shall not relieve either Party of its obligations to the other with
respect to: (a)&nbsp;maintaining the confidentiality of Confidential Information; (b)&nbsp;obtaining consents for the use of names; (c)&nbsp;ownership of and assignment of inventions; (d)&nbsp;indemnification; (d) limitation
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
of liability; (e)&nbsp;compensation for Services performed; (f)&nbsp;publications; and (g)&nbsp;retention of records. The provisions of this Section together with any other section which is
necessary for the interpretation or enforcement of this Agreement shall survive the expiry or termination of this Agreement howsoever arising. </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>REGULATORY COMPLIANCE</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>4.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance will perform its Services in accordance with good laboratory practices and the applicable terms
of this Agreement. All of Covance&#146;s tests, assays and other activities undertaken under this Agreement shall comply in all material respects with College of American Pathologists (<B>CAP</B>) rules. Covance represents that it has and shall
maintain Clinical Laboratory Improvement Act (<B>CLIA</B>) certification. This Agreement shall contain all the conditions under which Covance will provide clinical laboratory Services. Covance makes no express or implied commitments or warranties
concerning the performance of the Study except as set forth in this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>4.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In the event that compliance with any regulatory requirements necessitates a change in this Agreement,
Covance will submit to Sponsor a revised technical and cost proposal for Sponsor&#146;s acceptance prior to performing Services. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>4.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In the event of a conflict in government regulations, the Parties will discuss and designate which
regulations shall be followed by Covance in its performance of the Services. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>FEES, BILLING AND TAXES</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Fees for the Project are set forth in the attached Budget. Sponsor acknowledges that SOW finalization,
changes and/or modifications to the Project may result in a revised budget, which must be mutually agreed upon and the Agreement amended accordingly. The Budget contains all of the applicable discounts for Services that will be provided for that
Project. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Upon execution, Covance will assess a fee equal to twenty percent (20%) of the value of the contract
Budget (&#147;<B>Project Initiation Fee&#148;</B>). The Project Initiation Fee covers those value-added services rendered but unbilled, including developing the Scope of Work, quality control and loading of project databases, project management and
shipping of kits. Sponsor will pay the Project Initiation Fee within thirty (30)&nbsp;days after receipt of invoice. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Each month, Covance will invoice Sponsor for all fees due and documented expenses incurred while
providing Services during the previous month documentation for all expenses included on such invoice. Payment is due thirty (30)&nbsp;days from the date of the invoice. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Project Initiation Fee will be retained until the first invoice has been paid. Covance will issue a
credit on each month&#146;s invoices equal to <FONT STYLE="white-space:nowrap">one-sixth</FONT> (1/6) of the Project Initiation Fee. Should the Study be terminated before the Project Initiation Fee is exhausted and assuming all prior invoices have
been paid, Covance will apply Project Initiation Fee funds to the final invoice and refund any remaining Project Initiation Fee funds to Sponsor within thirty (30) days of termination. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>For budgeting purposes, Covance creates the Budget using local unit pricing. The local unit pricing is
then converted to the billing currency, as requested by Sponsor, using the Reuters exchange rate for the month the Budget is first created. Unless specified otherwise, this exchange rate remains unchanged during the course of the Study to simplify
budget comparisons and enable Sponsor to track changes to the Study unrelated to changes in currency exchange rates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>For invoicing purposes, expenses are billed based on the contracted local unit prices. Each month, at
the time of invoice creation, the local unit prices are converted to the billing currency using the Reuters exchange rate for the month in which the expenses were incurred. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance will hold prices unchanged for twelve (12)&nbsp;months from Project start up. Thereafter, a
Project is subject to a fee increase every twelve (12)&nbsp;months from Project <FONT STYLE="white-space:nowrap">start-up.</FONT> Any such increase shall not exceed the annual inflation rate during the previous twelve (12)&nbsp;month period, as
measured by the increase in the U.S. Consumer Price Index. Fee increases apply only to Services not yet performed and invoiced on the Study. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Should the Sponsor disagree with the accuracy of an invoice, the Sponsor shall notify Covance of such
inaccuracy within thirty (30)&nbsp;working days of receipt of the invoice. The Sponsor agrees to pay the amounts for any items not in dispute. The Sponsor agrees not to unreasonably withhold payment. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.9</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>If Sponsor requests a material change to the Project at any time which would affect the Services,
Covance will revise fees to reflect the change in the SOW and Budget. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.10</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Upon written notification by Sponsor that the Study has been concluded or upon completion of all
Services required by Covance under this Agreement, Covance will issue a final invoice for Services rendered to identify amounts due to Covance or refund due to Sponsor. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.11</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Fees payable under this Agreement shall not include local, state, federal or foreign sales or use taxes,
excise taxes, goods and services tax, value added tax or consumption taxes, as applicable. Any applicable taxes will be billed to and paid by Sponsor without deduction to amounts owed to Covance. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SITE VISITS</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>6.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Sponsor or its representative (which shall not be a competitor of Covance) may visit Covance&#146;s
premises where the Services are being performed at reasonable times, on reasonable notice and with reasonable frequency during normal business hours to observe the progress of the Services. Covance will assist the Sponsor in scheduling such visits.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>6.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Sponsor acknowledges that the Sponsor&#146;s representatives granted access to Covance facilities
during any such visits may have access to confidential and proprietary information of Covance. The Sponsor agrees that all such confidential and proprietary information of Covance obtained or observed by the Sponsor during such visits shall remain
the sole property of Covance and the Sponsor shall treat such information as Confidential Information in accordance with Section&nbsp;8 of this Agreement </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>REGULATORY INSPECTIONS AND AUDITS</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>7.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In the event of a Party receiving a notice from a Regulatory Authority which directly relates to the
Services, the Party receiving such notice shall promptly notify the other Party or forward to the other Party a copy of such notice (or extract thereof). Each Party will cooperate with the other in responding to such notice before referring to the
other Party in any regulatory correspondence or disclosing any Confidential Information to a Regulatory Authority. However, each Party acknowledges that it may not direct the manner in which the other Party fulfils its obligations to permit
inspection by Regulatory Authorities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>7.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance shall cooperate with any inspection or audit by a Regulatory Authority and shall notify the
Sponsor promptly of any request by a Regulatory Authority. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>7.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance agrees that, during an inspection or audit by a Regulatory Authority concerning the Services, it
will not disclose information and materials that are not required to be disclosed to such Regulatory Authority, without the prior written consent of the Sponsor. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>7.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>If any inspections or audits conducted pursuant to this Section&nbsp;7 that result in a finding that
Covance has failed to comply with the terms of this Agreement, Covance shall promptly take such measures at its own cost and expense as are necessary to correct such defaults. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>7.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>It is agreed that where any audit of Covance concerns or relates to referral laboratory testing or
shipping methods of Covance, the Sponsor or its representative (which shall not be a competitor of Covance) may only confirm or not if Covance is properly billing such costs. The Sponsor expressly agrees that Sponsor&#146;s representatives may not
directly or indirectly provide any details of the charges to the Sponsor, such as the actual amount of the referral laboratory testing or shipping costs incurred by Covance. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CONFIDENTIAL INFORMATION</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>8.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Each Party agrees that all Confidential Information of the Disclosing Party is and shall be the sole
property of the Disclosing Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>8.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Without prejudice to any Covance Property, all Results, information, data and records developed by
Covance or its Affiliates in the performance of the Services shall be the Confidential Information of the Sponsor. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>8.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Each Party agrees to hold the Confidential Information of the other Party in confidence and in a manner
consistent with the way in which it maintains the confidentiality of its own proprietary information, being at least a reasonable standard of care. Each Party shall disclose the Confidential Information only on a need to know basis, to its
employees, officers, directors, representatives and third party investigators, in each case who are legally bound to treat the Confidential Information in the manner set forth in this Section&nbsp;8. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>8.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Recipient agrees that, except as necessary to fulfil its obligations under this Agreement, it will not
use any of the Confidential Information of the Disclosing Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>8.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Notwithstanding the <FONT STYLE="white-space:nowrap">non-disclosure</FONT> obligations herein, Recipient
shall not be in breach of this Section&nbsp;8 if it discloses Confidential Information to the extent such disclosure is required by Applicable Law or a court or administrative subpoena or order; provided, however, that (a)&nbsp;any such disclosure
shall not otherwise relieve Recipient of its continuing confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> obligations hereunder with respect to all of the Confidential Information, including the information disclosed by it to the
court or agency under this Section&nbsp;8 and (b)&nbsp;Recipient shall give Disclosing Party reasonable advance notice of any such disclosure and cooperate reasonably with Disclosing Party (and at Disclosing Party&#146;s expense) in Disclosing
Party&#146;s efforts to object to such disclosure and to obtain the court&#146;s or administrative agency&#146;s agreement to maintain the confidentiality of the Confidential Information to be disclosed by Recipient under this Section&nbsp;8.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>8.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The obligations in this Section&nbsp;8 shall remain in full force and effect for a period of <B>seven
(7)</B><B></B><B>&nbsp;years </B>following termination of this Agreement except with respect to Confidential Information which is considered a trade secret under Applicable Law, which shall remain confidential as long as such Confidential
Information retains its status as a trade secret. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>8.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Misuse or disclosure of the Confidential Information by Recipient may cause irreparable harm to
Disclosing Party not adequately compensable by money damages. In the event of actual or threatened breach or violation of this Section&nbsp;8, the disclosing Party shall have the right to seek injunctive relief in any court of competent
jurisdiction, without the need to post any bond and without the need to demonstrate actual damages. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INTELLECTUAL PROPERTY RIGHTS</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>9.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>All Background IP is and shall remain the exclusive property of the Party owning it and except as
expressly provided in this Agreement, no Party shall acquire any rights in or to the Background IP of the other Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>9.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Sponsor acknowledges that Covance Property is owned or licensed by Covance or its Affiliates.
Strategic insight and proposed Project design and scope provided in any quotation by Covance shall remain the property of Covance and may be used by the Sponsor only to assess whether it wishes to pursue such work with Covance.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>9.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Sponsor will have title to the Deliverables and all intellectual property rights therein. Subject to
RMCL&#146;s payment of amounts due to Covance hereunder, Covance assigns all rights in and to the Deliverables to the Sponsor, except that one (1)&nbsp;copy of the Results may be retained by Covance solely for regulatory or legal compliance
purposes. The Sponsor hereby grants Covance an unrestricted, royalty-free license to aggregate and use System Data produced by or for Covance as part of the Services with other System Data owned or licensed by Covance only if Sponsor is not
identifiable through Covance&#146;s aggregation and use. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>9.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance shall promptly disclose to the Sponsor (or its nominee) all Inventions. Covance assigns and
agrees to assign to the Sponsor (or its nominee) all rights, title and interest in and to such Invention and shall do all acts that are reasonably necessary to vest the Invention in the name of the Sponsor (or its nominee), at Sponsor&#146;s
expense. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>REMEDIES AND LIMITATION OF LIABILITY</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>10.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In the event of a material error by Covance that prevents proper performance under this Agreement or
which renders the Services in whole or in part unacceptable to a Regulatory Authority to which the Sponsor intends to submit the Results, Covance&#146;s sole obligation to Sponsor (other than the obligations set forth in Section&nbsp;11) shall be
for Covance, at Sponsor&#146;s election, to either: (a)&nbsp;repeat the defective part of the Services at Covance&#146;s own cost; or (b)&nbsp;refund to the Sponsor the amount paid for the defective part of the Services. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>10.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Except for liability resulting from any breach of Sections 8 or 9 or liability pursuant to
Section&nbsp;11, Covance&#146;s total liability to the Sponsor, whether in contract, tort (including negligence) or otherwise, shall in no circumstances exceed the total price paid by the Sponsor for the Services that are the subject of this
Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>10.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Nothing in this Agreement excludes or limits the liability of either Party where liability cannot be
excluded or restricted as a matter of law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>10.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Except for liability resulting from any breach of Sections 8 or 9 or liability pursuant to
Section&nbsp;11, Covance will not be liable to the Sponsor for any Loss in respect of any: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">loss of profit, opportunity, business, or goodwill (in each case whether direct or indirect); or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any indirect, consequential, punitive, exemplary or special damages or losses, arising under or in connection
with this Agreement, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">and each type of loss arising under this Section&nbsp;10.4 shall be severable in accordance with
Section&nbsp;22 of this Agreement. To the extent that Covance agrees to perform Services for Sponsor Affiliates, Covance shall only be liable to the entity named in this Agreement and not for multiple claims by Sponsor Affiliates.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>10.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance shall not be liable for any failure, error or delay in performing the Services if such failure,
error or delay is directly caused by Sponsor, but Covance will cooperate with Sponsor to minimize any such delay and to correct any such failure or error. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>10.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance shall have no liability to Sponsor for loss, damage, delay or
<FONT STYLE="white-space:nowrap">non-</FONT> <FONT STYLE="white-space:nowrap">delivery/non-collection</FONT> of any samples or shipment dispatched by Covance to Sponsor or to any third party designated by Sponsor in connection with the Services that
are caused by the acts or omissions of any third party delivery services or carrier (&#147;<B>Carrier&#148;</B>). Notwithstanding the foregoing, to the extent permitted by law, Covance shall have the benefit of any right or remedy permitted under
international or domestic law and any sums recoverable from a Carrier shall be paid to the Sponsor. For the avoidance of doubt, a Carrier is not considered a Subcontractor for the purposes of this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B><B>INDEMNITIES</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>11.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Sponsor shall defend, indemnify, and hold harmless Covance and its respective Affiliates and their
respective officers, directors, employees and agents (<B>Covance Group</B>) from any Loss resulting from any Claim arising from or related to: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">personal injury to a participant in the Study directly or indirectly caused by the Test Material;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Covance&#146;s proper execution and/or the proper performance of its obligations under this Agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Sponsor&#146;s use of the Results or Deliverables or its use or marketing of any substance tested in
association with the Study by Covance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the negligence or intentional misconduct of the Sponsor; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Test Material&#146;s harmful or otherwise unsafe effect, including, without limitation, a product liability
claim based upon the Sponsor&#146;s or Sponsor&#146;s representatives&#146; use, consumption, sale, distribution or marketing of the Sponsor&#146;s products tested under this Agreement; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the infringement, unlawful disclosure or misappropriation of copyright, patent, trade secret or other
intellectual property of a third party by reason of Covance&#146;s use of the Sponsor Information in accordance with the terms of this Agreement, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">provided that if such Loss or Claim arises in whole or in part from Covance&#146;s negligence or intentional misconduct, then the amount of
such Loss that Sponsor shall indemnify the appropriate person or entity within the Covance Group pursuant to this Section&nbsp;11 shall be reduced by an amount in proportion to the percentage of Covance&#146;s responsibilities for such Loss as
determined by a court of competent jurisdiction in a final and <FONT STYLE="white-space:nowrap">non-appealable</FONT> decision or in a binding settlement between the Parties. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>11.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance shall defend, indemnify and hold harmless the Sponsor and its Affiliates and their respective
officers, directors and employees (the &#147;<B>Sponsor Group&#148;</B>) from any Loss resulting from any Claim arising from a breach of this Agreement by Covance, or the negligence or intentional misconduct of Covance, <U>provided</U> that if such
Losses or Claims arise in whole, or in part, from the Sponsors Group&#146;s negligence or intentional misconduct, then the amount of such Losses that Covance shall be responsible for pursuant to this Section&nbsp;11 shall be reduced by an amount in
proportion to the percentage of the Sponsor Group&#146;s responsibilities for such Losses as determined by a court of competent jurisdiction in a final and <FONT STYLE="white-space:nowrap">non-appealable</FONT> decision or in a binding settlement
between the Parties. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>11.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>An indemnitee entitled to indemnification under Section&nbsp;11 (the &#147;<B>Indemnified
Party&#148;</B>) shall give written notice to the other Party (&#147;<B>Indemnifying Party&#148;</B>) of a claim or other circumstances likely to give rise to a request for indemnification, promptly after the Indemnified Party becomes aware of the
same. The Indemnifying Party shall be afforded the opportunity to undertake the defense of, and, subject to Section&nbsp;11.5, to settle by compromise, or otherwise, any claim for which indemnification is available under this Section.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>11.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>If the Indemnifying Party assumes the defense of any claim, the Indemnified Party may participate in
such defense with legal counsel of its selection and at its expense. If the Indemnifying Party fails to promptly assume the defense of a claim by the Indemnified Party under this Section&nbsp;11.4, the Indemnified Party may thereupon undertake the
defense on behalf of, at the risk and expense of the Indemnifying Party with all reasonable costs and expenses of such defense to be paid by the Indemnifying Party. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>11.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In the event that the Indemnifying Party assumes the defense of any claim, no compromise or settlement
of any such claim may be made without the prior written consent of the Indemnified Party, which consent shall not be unreasonably withheld or delayed. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INSURANCE</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>12.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance shall secure and maintain in full force and effect through the performance of the Services the
necessary insurance coverage in amounts appropriate to the conduct of Covance&#146;s business. Certificates evidencing such insurance will be made available for examination upon written request by Sponsor. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>12.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Sponsor hereby warrants and represents that it maintains and shall maintain adequate clinical trial and
product liability insurance coverage consistent with industry standards and in compliance with all Applicable Laws. Certificates evidencing such insurance will be made available for examination upon written request by either Covance or Sponsor.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>HUMAN BIOLOGICAL SAMPLES</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>13.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Where the Sponsor supplies HBS to Covance, the Sponsor represents and warrants that:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all HBS supplied under this Agreement are or have been procured and reviewed by ethics committee and supplied
to Covance in full compliance with any and all Applicable Laws and Regulatory Requirements relating to the Use of HBS providing protection for human subjects in the country of origin; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the HBS Donor has given Informed Consent; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all HBS supplied to Covance: (i)&nbsp;may be Used for the Services; (ii)&nbsp;may be used to provide data in
support of commercial product development; and (iii)&nbsp;were procured without inappropriate financial benefit to the HBS Donor. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>13.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Sponsor shall: (a)&nbsp;upon request, provide a copy of the relevant Informed Consent template; and
(b)&nbsp;ensure any HBS shall be <FONT STYLE="white-space:nowrap">de-identified</FONT> or &#145;coded&#146; according to applicable Regulatory Requirements to protect the identity and confidentiality of the HBS Donor. Full date of birth shall only
be collected if medically relevant to the Services (unless legally restricted in the country of operation). In the event of a withdrawal of, or a material variation to the Informed Consent (including any material changes that may affect the Services
provided by Covance) the Sponsor shall promptly notify all relevant Covance entities of such changes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>13.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance agrees to Use the HBS in accordance with all applicable Regulatory Requirements.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>13.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Upon Sponsor&#146;s request, Covance shall retain, return or destroy all HBS in accordance with the
Informed Consent, the Sponsor&#146;s instructions or any other specific requirements under Applicable Law and Regulatory Requirements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>13.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Sponsor acknowledges that where Covance enters into a material transfer agreement
(&#147;<B>MTA&#148;</B>) with the provider of any HBS, Covance shall act in accordance with the terms of the MTA and the disposition of the relevant HBS shall be as prescribed in the MTA. In the event of a conflict between the terms of the MTA, this
Agreement, any Work Order and any instructions provided by the Sponsor, the terms of the MTA shall prevail. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DATA PROTECTION</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>14.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Where Covance processes any personal data on behalf of the Sponsor, Covance shall process such personal
data in accordance with all applicable Data Protection Laws in the territories in which the Services are performed (&#147;<B>Protected Data</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>14.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>If Covance processes any Protected Data on behalf of the Sponsor, Covance and the Sponsor each agree and
acknowledge that the Sponsor shall be the data controller and Covance shall be the data processor with respect to the processing of such Protected Data. Covance shall only process such Protected Data on behalf and upon the reasonable instructions of
the Sponsor for purposes notified to it by the Sponsor for which consent from the relevant data subjects has been obtained in accordance with all applicable Regulatory Requirements. Covance shall follow such procedures, policies and reasonable
instructions as may be agreed by the Parties from time to time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>14.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance shall take reasonable technical and organizational measures that are necessary to protect
against the unauthorized or unlawful processing of or the unauthorized or unlawful disclosure of such personal data. Covance shall promptly notify the Sponsor in the event of a security breach involving any personal data which Covance is processing
on behalf of the Sponsor. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>14.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Sponsor warrants that it has complied with any and all notification and information requirements
under the applicable Data Protection Laws. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SUBCONTRACTORS</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>15.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Notwithstanding Section&nbsp;18, certain tasks, as may be agreed during the development of and specified
in the Protocol, may be subcontracted by Covance to Subcontractors approved by Covance or subcontracted, or assigned and transferred to its Affiliates. Covance shall be responsible for the acts and performance of Subcontractors and Affiliates.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>15.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance shall not be responsible for the performance of third party Vendors. Liability of Covance to the
Sponsor with respect to such Vendors shall be limited to the extent Covance is negligent in the performance of its obligations under this Agreement. Covance shall provide to the Sponsor any amounts that Covance may recover from such Vendors as a
result of any error or service failure on the part of the Vendors in connection with this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>FORCE MAJEURE</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>16.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Neither Party shall be in breach of this Agreement nor liable for delay in performing, or failure to
perform, any of its obligations under this Agreement, if such delay or failure result from a Force Majeure Event. In such circumstances, any time specified for completion of performance in the Protocol falling due during or subsequent to the
occurrence of a Force Majeure Event shall be automatically extended for a period of time equal to such event. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>16.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Should any part of the Services be rendered invalid as a result of a Force Majeure Event, Covance shall,
upon written request from the Sponsor, and at the Sponsor&#146;s sole cost and expense, repeat the affected part of the Services. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>16.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>If a Force Majeure Event prevents a Party from performing pursuant to this Agreement for a period of 180
days or more, the unaffected Party may terminate this Agreement upon written notice to the affected Party. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INDEPENDENT CONTRACTOR</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>17.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Parties agree that in performing the Services, Covance (including its employees, agents,
subcontractors or other representatives) is acting as an independent contractor to Sponsor. The Parties further agree that Covance and its employees, agents, subcontractors or other representatives are not employees, agents or partners of Sponsor,
and nothing in this Agreement and no actions of Sponsor in engaging Covance shall render Covance or any of its employees, agents, subcontractors or other representatives the employees, agents or partners of Sponsor. Neither Covance nor any of its
employees, agents, subcontractors or other representatives will have power or authority to bind Sponsor. Neither the relationship between Covance and Sponsor nor any provision of this Agreement shall be construed to authorize Covance to take (or
fail to take) any action or make (or fail to make) any decision, representation or commitment binding upon Sponsor or any of its affiliate companies. Sponsor shall at all times be free to engage other third parties to perform services in addition to
or in lieu of those services being provided by the Covance. Subject to the provisions of this Agreement, Covance shall be free to devote such time that they do not spend providing Services under this Agreement to such person, firms or corporations
as they may choose. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>17.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Nothing contained herein shall be construed (i)&nbsp;to create any association, partnership, joint
venture, or relationship of principal and agent, or master and servant between the Parties or any of their affiliates or subsidiaries, employees and subcontractors, (ii)&nbsp;to provide any Party with the right, power or authority, either express or
implied, to create any duty or obligation on behalf of another Party, (iii)&nbsp;to impose liability upon one Party for the act or failure to act of another Party, or (iv)&nbsp;to confer any right for Covance (or any of its employees, agents,
subcontractors or other representatives) to participate in or be eligible to participate in any pension or welfare benefit plans, programs or arrangements of Sponsor or of its affiliate companies pertaining to any pension, stock, bonus, profit
sharing or similar benefits or any employee health, life assurance, workers compensation insurance, disability, severance or any other benefit of any kind whatsoever which is associated with or customarily paid in connection with or in relation to
an employment contractor. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ASSIGNMENT</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>18.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Either Party may assign, transfer or subcontract any or all of its rights and obligations under this
Agreement to its Affiliates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>18.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Notwithstanding Section&nbsp;18.1 and except in connection with an internal reorganization of the
relevant Party&#146;s corporate structure, this Agreement shall not be assigned or transferred in whole or in part by either Party without the prior written consent of the other, which consent shall not be unreasonably withheld or delayed.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>19.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NOTICES</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>19.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>All notices required to be given under this Agreement shall be in writing and shall be deemed to have
been duly given if delivered personally or mailed first class, registered or certified mail, return receipt requested, postage paid: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:20%; font-size:10pt; font-family:Times New Roman">If to Sponsor to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:20%; font-size:10pt; font-family:Times New Roman">inRegen </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20%; font-size:10pt; font-family:Times New Roman">10 Market St. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20%; font-size:10pt; font-family:Times New Roman">#774 Camana Bay,
Grand Cayman </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20%; font-size:10pt; font-family:Times New Roman">KY <FONT STYLE="white-space:nowrap">1-90006</FONT> Cayman Islands </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:20%; font-size:10pt; font-family:Times New Roman">With a copy by email to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:20%; font-size:10pt; font-family:Times New Roman">If to
Covance to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:20%; font-size:10pt; font-family:Times New Roman">Covance Central Laboratory Services LP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20%; font-size:10pt; font-family:Times New Roman">8211 SciCor Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20%; font-size:10pt; font-family:Times New Roman">Indianapolis, Indiana 46214-2985 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20%; font-size:10pt; font-family:Times New Roman">UNITED STATES </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20%; font-size:10pt; font-family:Times New Roman">Attention: VP,
Finance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">or at such other place as either Party shall hereafter furnish to the other Party in
writing. Notices shall be deemed given on the date of personal delivery or deposit in the mail as specified above. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>19.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>For the purposes of this Section&nbsp;19, in relation to the purposes of any legal proceeding,
&#147;<B>writing</B>&#148; shall not include email. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>20.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WAIVER</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">No waiver of any term, provision, or condition of this Agreement whether by conduct or otherwise in any one or more instances shall be deemed
to be or construed as a further or continuing waiver or estoppel of any such term, provision, or condition or of any other term, provision, or condition of this Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>21.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>VARIATION</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">No provision of this Agreement may be amended, modified, varied, discharged, or terminated except by the express written agreement of both
Parties and signed by an authorized representative of each Party. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>22.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SEVERABILITY</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">If any court or competent authority finds that any provision of this Agreement (or part of any provision) is invalid, illegal or
unenforceable, that provision or part-provision shall, to the extent required, be deemed to be deleted, and the validity and enforceability of the other provisions of this Agreement shall not be affected. If any invalid, unenforceable or illegal
provision of this Agreement would be valid, enforceable and legal if some part of it were deleted, the provision shall apply with the minimum modification necessary to make it legal, valid and enforceable. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>23.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PUBLICITY AND PUBLICATION</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>23.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Neither Party will use the name, trademark or the name of any representative of the other, or the
existence of this Agreement for any promotional or advertising purposes, or any other publication, without the prior written consent of the other. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>23.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Neither Party will state or imply that the other Party endorses or approves any service, material,
product or compound of the other Party without the prior written consent of the other. Such restrictions shall not apply to internal communications and publications to a Party&#146;s Affiliates. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>23.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Sponsor shall provide Covance with a <FONT STYLE="white-space:nowrap">pre-publication</FONT> copy of any
report, manuscript, publication or form of marketing material recognizing Covance&#146;s participation in the Services or otherwise identifying Covance, for approval (which approval shall not be unreasonably withheld or delayed) in each case at
least thirty (30)&nbsp;days before its submission for publication. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>24.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ENTIRE AGREEMENT</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">This Agreement represents the entire understanding between the Parties with respect to the subject matter hereof as of the Effective Date, and
this Agreement supersedes all prior agreements, negotiations, understandings, representations, statements and writings between the Parties relating thereto, except that any written agreement entered into prior to the Effective Date with respect to a
Study in process prior to the Effective Date shall remain effective and shall continue to govern such existing Study. The Parties agree that neither has relied upon prior representations made before executing this Agreement. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>25.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>LEGAL TESTIMONY</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Covance agrees to provide testimony or records regarding the Services for the Sponsor in any legal or administrative proceeding, provided that
the Sponsor shall reimburse Covance for its out of pocket costs plus a reasonable hourly fee for the involvement of its employees or representatives in such proceedings. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>26.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>THIRD PARTY RIGHTS</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Except as expressly set forth in this Agreement in respect of Covance Affiliates, nothing in this Agreement is intended to confer any rights,
benefits or remedies of any kind whatsoever, and a person who is not a party to this Agreement shall have no right to enforce any of its terms. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>27.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ANTI-BRIBERY</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>27.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Both Parties agree that each has not and will not, either directly or indirectly, engage in bribery, or
offer, or promise, or authorize to pay or make any improper payment of any monies or financial or other advantage, including cash, loan, gift, travel, entertainment, hospitality, facilitation payment, kickback, political or philanthropic
contribution, anything of value, or any other perceived benefit to improperly obtain or retain a business advantage in violation of any Anti-Corruption Laws and further, each Party agrees that they shall not take any action that would cause the
other Party to be in violation of such Anti-Corruption Laws. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>27.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Any breach of Section&nbsp;27.1 by a Party shall allow the other Party to immediately terminate this
Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>28.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TRADE CONTROL</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>28.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Notwithstanding any other provision of this Agreement to the contrary, each Party shall comply with, and
retain responsibility for its compliance with, all applicable export control laws (e.g., the U.S. Export Administration Regulations) and economic sanctions programs (e.g., economic sanctions maintained by the U.S. Treasury Department, as well as
Specially Designated Nationals and Blocked Persons (<B>SDNs</B>)) relating to its respective business, facilities, and the provision of services to third parties (collectively, <B>Trade Control Laws</B>). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>28.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Nothing in this Agreement shall be construed to require Covance to be directly or indirectly involved in
the provision of goods, software, services and/or technical data that may be prohibited by applicable Trade Control Laws, including sanctions currently in place against Cuba, Iran, North Korea, Sudan, Syria and SDNs. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>29.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COUNTERPARTS</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">This Agreement may be executed in any number of counterparts, each of which when executed and delivered shall constitute an original to this
Agreement but all of which together shall constitute the same Agreement. Signatures upon this Agreement transmitted by facsimile, electronic mail or other electronic method shall have the same legal and biding effect as wet signatures. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>30.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CHOICE OF LAW AND DISPUTE RESOLUTION</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>30.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>This Agreement shall be governed and construed in accordance with the laws of the State of New York,
U.S.A., without regard to conflicts of laws provisions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>30.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Any dispute, controversy, or claim arising out of, relating to, or in connection with this Agreement, or
the breach, termination, or validity thereof, shall be finally settled by arbitration. The arbitration shall be conducted in accordance with the Securities Arbitration Rules (the &#147;Rules&#148;) of the American Arbitration Association
(&#147;AAA&#148;), including the AAA&#146;s Procedures for Large, Complex Commercial Disputes, in effect at the time of the arbitration, except as they may be modified herein or by mutual agreement of the parties. The seat of the arbitration shall
be New York, New York, and it shall be conducted in the English language. The arbitration and this clause shall be governed by Title 9 (Arbitration) of the United States Code. The Parties agree that irreparable damage may occur to a Party in the
event that the other Party may fail or fails to comply with the provisions of Section&nbsp;8. Accordingly and without otherwise limiting the requirement of mandatory arbitration imposed hereunder, a Party may seek from any court having jurisdiction
any interim or provisional relief (without the necessity of posting bond) that may be necessary to protect its interests under Section&nbsp;8, pending the arbitral tribunal&#146;s final determination of the merits of the controversy.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>30.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The arbitration shall be conducted by three arbitrators. The claimant shall appoint an arbitrator in its
request for arbitration. The respondent shall appoint an arbitrator within twenty (20)&nbsp;days of the receipt of the request for arbitration. The two arbitrators shall appoint a third arbitrator, who shall act as chair of the tribunal, within
twenty (20)&nbsp;days after the appointment of the second arbitrator. If any of the three arbitrators is not appointed within the time prescribed above, then the AAA shall appoint that arbitrator from its National Panel of Securities Arbitrators or
its Large, Complex Commercial Case Panel, not including any such members affiliated with the securities industry. The chair of the tribunal shall be a citizen of the United States. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>30.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In addition to the authority conferred on the arbitration tribunal by the Rules, the arbitration
tribunal shall have the authority to order such production of documents, generally consistent with the discovery permitted under the Federal Rules of Civil Procedure, as may reasonably be requested by any party or by the tribunal itself. In
addition, any party may request a reasonable number of depositions of party witnesses. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>30.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Parties agree that the arbitration shall be kept confidential and that the existence of the
proceeding and any element of it (including but not limited to any pleadings, briefs or other documents submitted or exchanged, any testimony or other oral submissions, and any awards) shall not be disclosed beyond the tribunal, the AAA, the
Parties, their counsel, accountants and auditors, insurers and <FONT STYLE="white-space:nowrap">re-insurers,</FONT> and any person or entity necessary to the conduct of the proceeding. The confidentiality obligations in this Section&nbsp;28.5 shall
not apply (i)&nbsp;if disclosure is required by Applicable Law, or in judicial or administrative proceedings, or (ii)&nbsp;as far as disclosure is necessary to enforce the rights arising out of the award. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>30.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The arbitration award shall be final and binding on the Parties. Judgment upon the award may be entered
by any court having jurisdiction thereof or having jurisdiction over the relevant Party or its assets. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>30.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In order to facilitate the comprehensive resolution of related disputes, and upon request of any party
to the arbitration proceeding, the arbitration tribunal may consolidate the arbitration proceeding with any other arbitration proceeding involving any of the Parties hereto relating to this Agreement. The arbitration tribunal shall not consolidate
such arbitrations unless it determines that (i)&nbsp;there are issues of fact or law common to the related proceedings so that a consolidated proceeding would be more efficient than separate proceedings, and (ii)&nbsp;no party would be prejudiced as
a result of such consolidation through undue delay or otherwise. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>30.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Parties agree that any dispute arising from or in connection with this Agreement (including any <FONT
STYLE="white-space:nowrap">non-contractual</FONT> obligations) shall be referred to and finally resolved by arbitration under the Rules of the International Chamber of Commerce which Rules shall be deemed incorporated by reference to the Agreement.
The number of arbitrators shall be three (3), the seat or legal place of arbitration shall be New York and the language used in the arbitration shall be English. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>signature page follows</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties by their duly authorized officers have executed this Agreement on the dates
set forth below, to be effective on the Effective Date set forth on the first page of this Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>INREGEN</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Alasdair Foster</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Alasdair Foster</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">10th August 2017</TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="85%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>COVANCE&nbsp;CENTRAL&nbsp;LABORATORY&nbsp;SERVICES&nbsp;LP<BR>COVANCE&nbsp;CENTRAL&nbsp;LABORATORY&nbsp;SERVICES&nbsp;
S&Agrave;RL</B></P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Cheryl Helton</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Cheryl Helton</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">VP, Covance Central Laboratories</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">8/12/2017</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 of 21 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.21
<SEQUENCE>11
<FILENAME>d373959dex1021.htm
<DESCRIPTION>EX-10.21
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.21</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.21 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This Laboratory Service Agreement </B>(&#147;<B>Agreement</B>&#148;<B>) </B>is made effective on 21&nbsp;June 2019 by and between </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COVANCE CENTRAL LABORATORY SERVICES LP </B>an Indiana limited partnership, with its principal place of
business at 8211 SciCor Drive, Indianapolis, Indiana 46214, USA; and <B>COVANCE CENTRAL LABORATORY SERVICES</B> <B>S&Agrave;RL</B>, with its principal place of business at Rue Moise-Marchines 7, 1217 Meyrin, Geneva Switzerland (collectively
&#147;<B>Covance</B>&#148;); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>inRegen, </B>10 Market Street, No.&nbsp;774 Camana Bay, Grand Cayman
<FONT STYLE="white-space:nowrap">KY1-9006,</FONT> Cayman Islands (&#147;<B>Sponsor</B>&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman">(each a
&#147;<B>Party</B>&#148; and collectively the &#147;<B>Parties</B>&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WHEREAS </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Covance is engaged in the business of providing laboratory testing, data management, protocol management and
information management services for pharmaceutical clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Sponsor desires for Covance to perform such services for one or more clinical trials, all in accordance with
and subject to the terms and conditions of this Agreement. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IT IS AGREED </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEFINITIONS</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>1.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In this Agreement, the following words and expressions shall have the following meanings:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman"><B>&#147;Affiliate</B>&#148; means any entity controlling, controlled by, or in common control with a Party. For the
purposes of this definition, &#147;<B>Control</B>&#148; shall mean ownership or control, directly or indirectly of more than fifty percent (50%) of the common voting stock or ordinary shares in the entity or the right to appoint fifty percent (50%)
or more of the directors of that entity. With respect to Covance, the term Affiliate shall include Laboratory Corporation of America Holdings and any business entity that is controlled by or is under common control with Laboratory Corporation of
America Holdings. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Anti-Corruption Laws</B>&#148; means any anti-bribery and anti-corruption laws, rules, regulations applicable
to either Party (each as amended from time to time) including the United States Anti-Kickback Law, United States Foreign Corrupt Practices Act, the UK Bribery Act 2010 and the OECD Convention Against the Bribery of Foreign Government Officials in
International Business Transactions, together with any applicable implementing legislation including any applicable local law addressing bribery or corruption. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Applicable Law</B>&#148; means applicable federal, state and local laws, rules, regulations, including the regulations of the FDA and
Data Protection Laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Background IP</B>&#148; means all <FONT STYLE="white-space:nowrap">pre-existing</FONT> intellectual
property belonging to or licensed to a Party or other intellectual property created outside the scope of the Services. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Claim</B>&#148; means any third party claims, demands, assessments, actions,
suits, proceedings, or settlements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Confidential Information</B>&#148; means any and all
<FONT STYLE="white-space:nowrap">non-public</FONT> information or materials and derivatives thereof, in any and all forms, howsoever disclosed or obtained, including business plans, financial information, client lists, and requirements, techniques,
designs, methods, processes and procedures, which: (i) is identified by a suitable legend or other marking as being confidential (or similar designation) in a prominent position or (ii)&nbsp;is described as being confidential at the time of
disclosure or (iii)&nbsp;the disclosing Party regards or should reasonably be expected to regard as proprietary and confidential given the nature of the information and the circumstances of disclosure. Confidential Information shall not include
information (a)&nbsp;that is or becomes publicly disclosed except to the extent such disclosure results from a violation hereof or any improper action or inaction by Recipient or any agent or representative of Recipient; (b)&nbsp;that was in
Recipient&#146;s possession prior to Recipient&#146;s receipt of such material from Disclosing Party, as demonstrated by documentary evidence that itself was in Recipient&#146;s possession at the time of Disclosing Party&#146;s disclosure of such
Confidential Information to Recipient; (c) that is lawfully acquired by Recipient from a third party not obligated to keep such information confidential; or (d)&nbsp;that is developed by the Recipient without the use of or reliance on the Disclosing
Party&#146;s Confidential Information, as demonstrated by Recipient&#146;s written records. Information will not be deemed to be within the foregoing exceptions merely because such information is embraced by more general information that is within
the foregoing exceptions. In addition, any combination of features will not be deemed to be within the foregoing exceptions merely because individual features are within the exceptions, but only if the combination itself and its principle of
operation are within the exceptions. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Covance Property</B>&#148; means inventions, proprietary processes, software (including
codes) data, technology, <FONT STYLE="white-space:nowrap">know-how</FONT> and other intellectual property that have been independently developed or discovered by Covance or its Affiliates without the use of Sponsor&#146;s Confidential Information,
including those that relate to the proprietary innovative testing procedures, laboratory testing data collection or data management procedures, procedural manuals, delta flags, nucleic acid based vectors, analytical procedures and approaches that
are not specific for use with the Sponsor&#146;s Background IP even if such are developed in the performance of the Services or are captured in documents pertaining to the Services (i.e. laboratory notebooks), techniques, skills, models, <FONT
STYLE="white-space:nowrap">non-product</FONT> specific components of questionnaires, management tools and any other materials, employed, developed or acquired by Covance or its Affiliates. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman"><B>&#147;Data Protection Laws&#148; </B>mean all applicable privacy, data protection or similar laws and regulations anywhere in the World, as
the same may be amended from time to time, including to the extent applicable to the respective Services, the Data Protection Directive (95/46/EC), the Personal Data Protection Act 2012 of Singapore and any applicable implementing legislation or any
amendment thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Deliverables</B>&#148; means as applicable to the Services, Results, or any other
deliverable specified in this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Disclosing Party</B>&#148; means the Party disclosing or making available its
Confidential Information to the other Party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>FDA</B>&#148; means the United States Food and Drug Administration or any other
government body or agency that succeeds it. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Force Majeure Event</B>&#148; means circumstances or causes beyond the reasonable
control of a Party, including war, threat of war or warlike conditions, blockade, embargo, fire, explosion, lightning, storm, drought, flood, earthquake or other natural disaster, pandemic or epidemic, power failure, acts of terrorism, riot, civil
unrest, insurrection, acts of government or other international bodies, political subdivision and any other events which by their nature could not have been foreseen by the Parties, or, if it could have been foreseen were unavoidable by a reasonable
prudent business. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>HBS Donor</B>&#148; means an individual, living or deceased, from whom the HBS was obtained. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Human Biological Samples</B>&#148; or &#147;<B>HBS</B>&#148; means any human biological material, including, without limitation,
human bodily parts and organs in whole or <FONT STYLE="white-space:nowrap">sub-samples,</FONT> any tissue, skin, bone, muscle, connective tissue, blood, cerebrospinal fluid, cells, gametes, or <FONT STYLE="white-space:nowrap">sub-cellular</FONT>
structures such as DNA, or any derivative or product of such human biological materials including stem cells, cell lines, bodily fluids, blood derivatives and urine. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>IEC/IRB</B>&#148; means an independent ethics committee or institutional review board. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Informed Consent</B>&#148; means an IEC/IRB approved informed consent form signed by the HBS Donor authorizing the Use of their HBS.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Invention</B>&#148; means any patentable invention or other registerable intellectual property rights discovered, conceived of
or made by Covance or its Affiliates specifically as result of the Services for the Sponsor and relating to the Test Materials. Covance Property is not included in Inventions. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Loss</B>&#148; means any loss, cost, damage or expense (including reasonable legal expenses). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Project</B>&#148; means a Study, project or assignment between Covance and Sponsor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Protocol</B>&#148; means the document which specifies the laboratory testing procedures as written by Sponsor as applicable for the
performance of a Study and is provided to Covance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Recipient</B>&#148; means the Party receiving or having access to the
Confidential Information from the other Party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Regulatory Authority</B>&#148; means any national or state (in the case of the
US), or local agency, authority, department, inspectorate, minister, ministry official, parliament or public or statutory person (whether autonomous or not) of any government of any country having jurisdiction over either any of the activities
contemplated by this Agreement or the Parties. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Regulatory Requirements</B>&#148; means all laws, statutes, acts, rules,
regulations, guidelines, codes, orders, directives or other legally binding requirements of any Regulatory Authority and industry standards or codes of conduct applicable to the Services. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Results</B>&#148; mean materials, data, Inventions, documents and information produced, conceived or developed by Covance
specifically as a result of the Services and related to the Test Materials. Covance Property is not included in Results. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Services</B>&#148; means the services provided by Covance to the Sponsor as more particularly described in this Agreement and the
SOW. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>SOW</B>&#148; means the scope of work mutually agreed to in writing by the Parties, which will be attached hereto as an
exhibit and will be governed by and is hereby made a part of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Sponsor Information</B>&#148; means Test Materials,
data, specification, or other materials or information supplied by the Sponsor to Covance in connection with the Services. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Study</B>&#148; means a clinical trial or scientific evaluation of the Test Materials on the terms and conditions of the Protocol.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Subcontractor</B>&#148; means a third party approved, reviewed and contracted by Covance for Services within the scope of this
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>System Data</B>&#148; means control data from laboratory tests or transactional, volume and performance data related
to the Services, which does not contain any personally identifiable information or Sponsor Confidential Information. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Test
Materials</B>&#148; means compounds, materials or other substances as described in the Protocol to be tested or used in the performance of the Services and provided to Covance by the Sponsor. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Use</B>&#148; (in the context of Section&nbsp;13) means collection, storage, transfer (including import and export), use and return
or disposal of HBS including by commercial organizations. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">&#147;<B>Vendor</B>&#148; means third-party service providers other than a
Subcontractor for which Covance may hold the contract with such service provider at Sponsor&#146;s written request for the convenience or benefit of the Sponsor in connection with Services under this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>1.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In this Agreement, unless the context otherwise requires, references to: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Schedule and Section headings are inserted for convenience only and do not affect the construction or
interpretation of this Agreement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a particular law or statutory provision is a reference to it as it is in force for the time being taking
account of any amendment, extension, or <FONT STYLE="white-space:nowrap">re-enactment</FONT> and includes any subordinate legislation for the time being in force made under it; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>writing </B>or <B>written </B>includes faxes and e-mail; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a person includes a corporate or unincorporated body; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any gender includes all genders; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>including</B>, <B>include</B>, <B>in particular </B>or any similar expression shall be construed as
illustrative and shall not limit the sense of the words preceding those terms; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(g)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">words in the singular include the plural and vice versa. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>1.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>If this Agreement is translated, the English language text shall prevail. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SERVICES</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>2.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance through itself and/or its Affiliates hereby agrees to perform Services for Sponsor&#146;s
protocol REGEN004, &#147;A PHASE 1, OPEN-LABEL SAFETY, TOLERABILITY, AND EARLY EFFICACY STUDY OF A RENAL AUTOLOGOUS CELL THERAPY (REACT) IN PATIENTS WITH CHRONIC KIDNEY DISEASE FROM CONGENITAL ANOMALIES OF THE KIDNEY AND URINARY TRACT (CAKUT)&#148;
as amended from time to time, a copy of which is attached hereto as Exhibit A. Such Services shall be performed pursuant to the terms and conditions contained herein. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>2.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Any changes or modifications to the Protocol and/or Services provided by Covance, or any Sponsor request
for additional Services may commence upon Covance&#146;s receipt of Sponsors written approval of the revised SOW. Upon Sponsor&#146;s SOW signature, Covance shall provide such Services to the Sponsor and the Sponsor shall pay for costs associated
with such Services at its current standard rates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>2.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Should a kit be lost through no fault of Covance, or should a kit expire at the investigator site,
Covance will supply replacement kits for those that are lost, expired, or otherwise rendered unusable, at an amount equal to the price listed in the Budget per kit for the same kit/visit that is being replaced. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>2.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>After performing Services, Covance will store the remaining Study specimens for the length of time and
under storage conditions as described in the applicable SOW. The remaining specimens may subsequently be shipped to Sponsor or another party as specified in the SOW or if not specified in the SOW, held as otherwise instructed by the Sponsor. In no
event shall Covance&#146;s liability for any breach or default with regard to storage of an archival specimen exceed the fee it has been paid for storage of that specimen for the previous twelve (12)&nbsp;months. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TERM AND TERMINATION</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>3.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The term of this Agreement shall be for fifty (50)&nbsp;months, commencing on the date hereof, or the
conclusion of the study, whichever is earlier, and shall renew automatically for successive one (1)&nbsp;year periods unless a Party provides the other Party with written notice of its intention to not renew and extend this Agreement at least sixty
(60)&nbsp;days prior to the commencement of any such renewal term. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>3.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Either Party may terminate this Agreement with immediate effect by notice in writing in the event that:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the other Party commits a material breach of any term of this Agreement which breach is irremediable or (if
such breach is remediable) fails to remedy that breach within a period of thirty (30)&nbsp;days after being notified in writing to do so; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the other Party repeatedly breaches any of the terms of this Agreement in such a manner as to reasonably
justify the opinion that its conduct is inconsistent with it having the intention or ability to give effect to the terms of this Agreement; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">anyone commences an involuntary case against such other Party under title 11 of the United States Code or the
corresponding provisions of any successor laws and either the case is not dismissed by midnight at the end of the sixtieth (60<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) day after commencement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a court of competent jurisdiction appoints a custodian (as that term is defined in title 11 of the United
States Code or the corresponding provisions of any successor laws) for such other Party or all or substantially all of its assets, or such other Party makes an assignment of all or substantially all of its assets to a custodian;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the other Party fails generally to pay its debts as they become due (unless those debts are subject to a
good-faith dispute as to liability or amount) or acknowledges in writing that it is unable to do so; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any event occurs, or proceeding is initiated, in any jurisdiction to which it is subject that has an effect
equivalent or substantially similar to any of the events mentioned above. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>3.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Sponsor may terminate this Agreement for any reason upon ninety (90)&nbsp;days prior written notice to
Covance. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>3.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In the event of such termination, Covance shall be entitled to full payment for work performed on the
Study through the date work on such Study is concluded, including, without limitation, all fees and other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by Covance for such Study.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>3.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The termination of this Agreement shall not relieve either Party of its obligations to the other with
respect to: (a)&nbsp;maintaining the confidentiality of Confidential Information; (b)&nbsp;obtaining consents for the use of names; (c)&nbsp;ownership of and assignment of inventions; (d)&nbsp;indemnification; (d) limitation </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">of liability; (e)&nbsp;compensation for Services performed; (f)&nbsp;publications; and
(g)&nbsp;retention of records. The provisions of this Section together with any other section which is necessary for the interpretation or enforcement of this Agreement shall survive the expiry or termination of this Agreement howsoever arising.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>REGULATORY COMPLIANCE</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>4.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance will perform its Services in accordance with good laboratory practices and the applicable terms
of this Agreement. All of Covance&#146;s tests, assays and other activities undertaken under this Agreement shall comply in all material respects with College of American Pathologists (<B>CAP</B>) rules. Covance represents that it has and shall
maintain Clinical Laboratory Improvement Act (<B>CLIA</B>) certification. This Agreement shall contain all the conditions under which Covance will provide clinical laboratory Services. Covance makes no express or implied commitments or warranties
concerning the performance of the Study except as set forth in this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>4.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In the event that compliance with any regulatory requirements necessitates a change in this Agreement,
Covance will submit to Sponsor a revised technical and cost proposal for Sponsor&#146;s acceptance prior to performing Services. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>4.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In the event of a conflict in government regulations, the Parties will discuss and designate which
regulations shall be followed by Covance in its performance of the Services. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>FEES, BILLING AND TAXES</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Fees for the Project are set forth in the attached Budget. Sponsor acknowledges that SOW finalization,
changes and/or modifications to the Project may result in a revised budget, which must be mutually agreed upon and the Agreement amended accordingly. The Budget contains all of the applicable discounts for Services that will be provided for that
Project. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Upon execution, Covance will assess a fee equal to twenty percent (20%) of the value of the contract
Budget (&#147;<B>Project Initiation Fee&#148;</B>). The Project Initiation Fee covers those value-added services rendered but unbilled, including developing the Scope of Work, quality control and loading of project databases, project management and
shipping of kits. Sponsor will pay the Project Initiation Fee within thirty (30)&nbsp;days after receipt of invoice. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Each month, Covance will invoice Sponsor for all fees due and documented expenses incurred while
providing Services during the previous month documentation for all expenses included on such invoice. Payment is due thirty (30)&nbsp;days from the date of the invoice. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Project Initiation Fee will be retained until the first invoice has been paid. Covance will issue a
credit on each month&#146;s invoices equal to <FONT STYLE="white-space:nowrap">one-sixth</FONT> (1/6) of the Project Initiation Fee. Should the Study be terminated before the Project Initiation Fee is exhausted and assuming all prior invoices have
been paid, Covance will apply Project Initiation Fee funds to the final invoice and refund any remaining Project Initiation Fee funds to Sponsor within thirty (30) days of termination. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>For budgeting purposes, Covance creates the Budget using local unit pricing. The local unit pricing is
then converted to the billing currency, as requested by Sponsor, using the Reuters exchange rate for the month the Budget is first created. Unless specified otherwise, this exchange rate remains unchanged during the course of the Study to simplify
budget comparisons and enable Sponsor to track changes to the Study unrelated to changes in currency exchange rates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>For invoicing purposes, expenses are billed based on the contracted local unit prices. Each month, at
the time of invoice creation, the local unit prices are converted to the billing currency using the Reuters exchange rate for the month in which the expenses were incurred. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance will hold prices unchanged for twelve (12)&nbsp;months from Project start up. Thereafter, a
Project is subject to a fee increase every twelve (12)&nbsp;months from Project <FONT STYLE="white-space:nowrap">start-up.</FONT> Any such increase shall not exceed the annual inflation rate during the previous twelve (12)&nbsp;month period, as
measured by the increase in the U.S. Consumer Price Index. Fee increases apply only to Services not yet performed and invoiced on the Study. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Should the Sponsor disagree with the accuracy of an invoice, the Sponsor shall notify Covance of such
inaccuracy within thirty (30)&nbsp;working days of receipt of the invoice. The Sponsor agrees to pay the amounts for any items not in dispute. The Sponsor agrees not to unreasonably withhold payment. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.9</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>If Sponsor requests a material change to the Project at any time which would affect the Services,
Covance will revise fees to reflect the change in the SOW and Budget. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.10</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Upon written notification by Sponsor that the Study has been concluded or upon completion of all
Services required by Covance under this Agreement, Covance will issue a final invoice for Services rendered to identify amounts due to Covance or refund due to Sponsor. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>5.11</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Fees payable under this Agreement shall not include local, state, federal or foreign sales or use taxes,
excise taxes, goods and services tax, value added tax or consumption taxes, as applicable. Any applicable taxes will be billed to and paid by Sponsor without deduction to amounts owed to Covance. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SITE VISITS</B> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>6.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Sponsor or its representative (which shall not be a competitor of Covance) may visit Covance&#146;s
premises where the Services are being performed at reasonable times, on reasonable notice and with reasonable frequency during normal business hours to observe the progress of the Services. Covance will assist the Sponsor in scheduling such visits.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>6.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Sponsor acknowledges that the Sponsor&#146;s representatives granted access to Covance facilities
during any such visits may have access to confidential and proprietary information of Covance. The Sponsor agrees that all such confidential and proprietary information of Covance obtained or observed by the Sponsor during such visits shall remain
the sole property of Covance and the Sponsor shall treat such information as Confidential Information in accordance with Section&nbsp;8 of this Agreement </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>REGULATORY INSPECTIONS AND AUDITS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>7.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In the event of a Party receiving a notice from a Regulatory Authority which directly relates to the
Services, the Party receiving such notice shall promptly notify the other Party or forward to the other Party a copy of such notice (or extract thereof). Each Party will cooperate with the other in responding to such notice before referring to the
other Party in any regulatory correspondence or disclosing any Confidential Information to a Regulatory Authority. However, each Party acknowledges that it may not direct the manner in which the other Party fulfils its obligations to permit
inspection by Regulatory Authorities. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>7.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance shall cooperate with any inspection or audit by a Regulatory Authority and shall notify the
Sponsor promptly of any request by a Regulatory Authority. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>7.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance agrees that, during an inspection or audit by a Regulatory Authority concerning the Services, it
will not disclose information and materials that are not required to be disclosed to such Regulatory Authority, without the prior written consent of the Sponsor. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>7.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>If any inspections or audits conducted pursuant to this Section&nbsp;7 that result in a finding that
Covance has failed to comply with the terms of this Agreement, Covance shall promptly take such measures at its own cost and expense as are necessary to correct such defaults. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>7.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>It is agreed that where any audit of Covance concerns or relates to referral laboratory testing or
shipping methods of Covance, the Sponsor or its representative (which shall not be a competitor of Covance) may only confirm or not if Covance is properly billing such costs. The Sponsor expressly agrees that Sponsor&#146;s representatives may not
directly or indirectly provide any details of the charges to the Sponsor, such as the actual amount of the referral laboratory testing or shipping costs incurred by Covance. </P></TD></TR></TABLE>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CONFIDENTIAL INFORMATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>8.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Each Party agrees that all Confidential Information of the Disclosing Party is and shall be the sole
property of the Disclosing Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>8.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Without prejudice to any Covance Property, all Results, information, data and records developed by
Covance or its Affiliates in the performance of the Services shall be the Confidential Information of the Sponsor. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>8.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Each Party agrees to hold the Confidential Information of the other Party in confidence and in a manner
consistent with the way in which it maintains the confidentiality of its own proprietary information, being at least a reasonable standard of care. Each Party shall disclose the Confidential Information only on a need to know basis, to its
employees, officers, directors, representatives and third party investigators, in each case who are legally bound to treat the Confidential Information in the manner set forth in this Section&nbsp;8. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>8.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Recipient agrees that, except as necessary to fulfil its obligations under this Agreement, it will not
use any of the Confidential Information of the Disclosing Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>8.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Notwithstanding the <FONT STYLE="white-space:nowrap">non-disclosure</FONT> obligations herein, Recipient
shall not be in breach of this Section&nbsp;8 if it discloses Confidential Information to the extent such disclosure is required by Applicable Law or a court or administrative subpoena or order; provided, however, that (a)&nbsp;any such disclosure
shall not otherwise relieve Recipient of its continuing confidentiality and <FONT STYLE="white-space:nowrap">non-use</FONT> obligations hereunder with respect to all of the Confidential Information, including the information disclosed by it to the
court or agency under this Section&nbsp;8 and (b)&nbsp;Recipient shall give Disclosing Party reasonable advance notice of any such disclosure and cooperate reasonably with Disclosing Party (and at Disclosing Party&#146;s expense) in Disclosing
Party&#146;s efforts to object to such disclosure and to obtain the court&#146;s or administrative agency&#146;s agreement to maintain the confidentiality of the Confidential Information to be disclosed by Recipient under this Section&nbsp;8.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>8.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The obligations in this Section&nbsp;8 shall remain in full force and effect for a period of <B>seven
(7)</B><B></B><B>&nbsp;years </B>following termination of this Agreement except with respect to Confidential Information which is considered a trade secret under Applicable Law, which shall remain confidential as long as such Confidential
Information retains its status as a trade secret. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>8.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Misuse or disclosure of the Confidential Information by Recipient may cause irreparable harm to
Disclosing Party not adequately compensable by money damages. In the event of actual or threatened breach or violation of this Section&nbsp;8, the disclosing Party shall have the right to seek injunctive relief in any court of competent
jurisdiction, without the need to post any bond and without the need to demonstrate actual damages. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INTELLECTUAL PROPERTY RIGHTS</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>9.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>All Background IP is and shall remain the exclusive property of the Party owning it and except as
expressly provided in this Agreement, no Party shall acquire any rights in or to the Background IP of the other Party. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>9.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Sponsor acknowledges that Covance Property is owned or licensed by Covance or its Affiliates.
Strategic insight and proposed Project design and scope provided in any quotation by Covance shall remain the property of Covance and may be used by the Sponsor only to assess whether it wishes to pursue such work with Covance.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>9.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Sponsor will have title to the Deliverables and all intellectual property rights therein. Subject to
RMCL&#146;s payment of amounts due to Covance hereunder, Covance assigns all rights in and to the Deliverables to the Sponsor, except that one (1)&nbsp;copy of the Results may be retained by Covance solely for regulatory or legal compliance
purposes. The Sponsor hereby grants Covance an unrestricted, royalty-free license to aggregate and use System Data produced by or for Covance as part of the Services with other System Data owned or licensed by Covance only if Sponsor is not
identifiable through Covance&#146;s aggregation and use. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>9.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance shall promptly disclose to the Sponsor (or its nominee) all Inventions. Covance assigns and
agrees to assign to the Sponsor (or its nominee) all rights, title and interest in and to such Invention and shall do all acts that are reasonably necessary to vest the Invention in the name of the Sponsor (or its nominee), at Sponsor&#146;s
expense. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>REMEDIES AND LIMITATION OF LIABILITY</B> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>10.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In the event of a material error by Covance that prevents proper performance under this Agreement or
which renders the Services in whole or in part unacceptable to a Regulatory Authority to which the Sponsor intends to submit the Results, Covance&#146;s sole obligation to Sponsor (other than the obligations set forth in Section&nbsp;11) shall be
for Covance, at Sponsor&#146;s election, to either: (a)&nbsp;repeat the defective part of the Services at Covance&#146;s own cost; or (b)&nbsp;refund to the Sponsor the amount paid for the defective part of the Services. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>10.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Except for liability resulting from any breach of Sections 8 or 9 or liability pursuant to
Section&nbsp;11, Covance&#146;s total liability to the Sponsor, whether in contract, tort (including negligence) or otherwise, shall in no circumstances exceed the total price paid by the Sponsor for the Services that are the subject of this
Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>10.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Nothing in this Agreement excludes or limits the liability of either Party where liability cannot be
excluded or restricted as a matter of law. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>10.4</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Except for liability resulting from any breach of Sections 8 or 9 or liability pursuant to
Section&nbsp;11, Covance will not be liable to the Sponsor for any Loss in respect of any: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">loss of profit, opportunity, business, or goodwill (in each case whether direct or indirect); or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">any indirect, consequential, punitive, exemplary or special damages or losses, arising under or in connection
with this Agreement, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">and each type of loss arising under this Section&nbsp;10.4 shall be severable in accordance with
Section&nbsp;22 of this Agreement. To the extent that Covance agrees to perform Services for Sponsor Affiliates, Covance shall only be liable to the entity named in this Agreement and not for multiple claims by Sponsor Affiliates.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>10.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance shall not be liable for any failure, error or delay in performing the Services if such failure,
error or delay is directly caused by Sponsor, but Covance will cooperate with Sponsor to minimize any such delay and to correct any such failure or error. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>10.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance shall have no liability to Sponsor for loss, damage, delay or
<FONT STYLE="white-space:nowrap">non-</FONT> <FONT STYLE="white-space:nowrap">delivery/non-collection</FONT> of any samples or shipment dispatched by Covance to Sponsor or to any third party designated by Sponsor in connection with the Services that
are caused by the acts or omissions of any third party delivery services or carrier (&#147;<B>Carrier&#148;</B>). Notwithstanding the foregoing, to the extent permitted by law, Covance shall have the benefit of any right or remedy permitted under
international or domestic law and any sums recoverable from a Carrier shall be paid to the Sponsor. For the avoidance of doubt, a Carrier is not considered a Subcontractor for the purposes of this Agreement. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INDEMNITIES </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>11.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Sponsor shall defend, indemnify, and hold harmless Covance and its respective Affiliates and their
respective officers, directors, employees and agents (<B>Covance Group</B>) from any Loss resulting from any Claim arising from or related to: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">personal injury to a participant in the Study directly or indirectly caused by the Test Material;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Covance&#146;s proper execution and/or the proper performance of its obligations under this Agreement;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Sponsor&#146;s use of the Results or Deliverables or its use or marketing of any substance tested in
association with the Study by Covance; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the negligence or intentional misconduct of the Sponsor; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(e)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Test Material&#146;s harmful or otherwise unsafe effect, including, without limitation, a product liability
claim based upon the Sponsor&#146;s or Sponsor&#146;s representatives&#146; use, consumption, sale, distribution or marketing of the Sponsor&#146;s products tested under this Agreement; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(f)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the infringement, unlawful disclosure or misappropriation of copyright, patent, trade secret or other
intellectual property of a third party by reason of Covance&#146;s use of the Sponsor Information in accordance with the terms of this Agreement, </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">provided that if such Loss or Claim arises in whole or in part from Covance&#146;s negligence or intentional misconduct, then the amount of
such Loss that Sponsor shall indemnify the appropriate person or entity within the Covance Group pursuant to this Section&nbsp;11 shall be reduced by an amount in proportion to the percentage of Covance&#146;s responsibilities for such Loss as
determined by a court of competent jurisdiction in a final and <FONT STYLE="white-space:nowrap">non-appealable</FONT> decision or in a binding settlement between the Parties. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>11.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance shall defend, indemnify and hold harmless the Sponsor and its Affiliates and their respective
officers, directors and employees (the &#147;<B>Sponsor Group&#148;</B>) from any Loss resulting from any Claim arising from a breach of this Agreement by Covance, or the negligence or intentional misconduct of Covance, <U>provided</U> that if such
Losses or Claims arise in whole, or in part, from the Sponsors Group&#146;s negligence or intentional misconduct, then the amount of such Losses that Covance shall be responsible for pursuant to this Section&nbsp;11 shall be reduced by an amount in
proportion to the percentage of the Sponsor Group&#146;s responsibilities for such Losses as determined by a court of competent jurisdiction in a final and <FONT STYLE="white-space:nowrap">non-appealable</FONT> decision or in a binding settlement
between the Parties. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>11.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>An indemnitee entitled to indemnification under Section&nbsp;11 (the &#147;<B>Indemnified
Party&#148;</B>) shall give written notice to the other Party (&#147;<B>Indemnifying Party&#148;</B>) of a claim or other circumstances likely to give rise to a request for indemnification, promptly after the Indemnified Party becomes aware of the
same. The Indemnifying Party shall be afforded the opportunity to undertake the defense of, and, subject to Section&nbsp;11.5, to settle by compromise, or otherwise, any claim for which indemnification is available under this Section.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>11.4</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>If the Indemnifying Party assumes the defense of any claim, the Indemnified Party may participate in
such defense with legal counsel of its selection and at its expense. If the Indemnifying Party fails to promptly assume the defense of a claim by the Indemnified Party under this Section&nbsp;11.4, the Indemnified Party may thereupon undertake the
defense on behalf of, at the risk and expense of the Indemnifying Party with all reasonable costs and expenses of such defense to be paid by the Indemnifying Party. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>11.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In the event that the Indemnifying Party assumes the defense of any claim, no compromise or settlement
of any such claim may be made without the prior written consent of the Indemnified Party, which consent shall not be unreasonably withheld or delayed. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INSURANCE </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>12.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance shall secure and maintain in full force and effect through the performance of the Services the
necessary insurance coverage in amounts appropriate to the conduct of Covance&#146;s business. Certificates evidencing such insurance will be made available for examination upon written request by Sponsor. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>12.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Sponsor hereby warrants and represents that it maintains and shall maintain adequate clinical trial and
product liability insurance coverage consistent with industry standards and in compliance with all Applicable Laws. Certificates evidencing such insurance will be made available for examination upon written request by either Covance or Sponsor.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>HUMAN BIOLOGICAL SAMPLES </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>13.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Where the Sponsor supplies HBS to Covance, the Sponsor represents and warrants that:
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all HBS supplied under this Agreement are or have been procured and reviewed by ethics committee and supplied
to Covance in full compliance with any and all Applicable Laws and Regulatory Requirements relating to the Use of HBS providing protection for human subjects in the country of origin; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the HBS Donor has given Informed Consent; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">all HBS supplied to Covance: (i)&nbsp;may be Used for the Services; (ii)&nbsp;may be used to provide data in
support of commercial product development; and (iii)&nbsp;were procured without inappropriate financial benefit to the HBS Donor. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>13.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Sponsor shall: (a)&nbsp;upon request, provide a copy of the relevant Informed Consent template; and
(b)&nbsp;ensure any HBS shall be <FONT STYLE="white-space:nowrap">de-identified</FONT> or &#145;coded&#146; according to applicable Regulatory Requirements to protect the identity and confidentiality of the HBS Donor. Full date of birth shall only
be collected if medically relevant to the Services (unless legally restricted in the country of operation). In the event of a withdrawal of, or a material variation to the Informed Consent (including any material changes that may affect the Services
provided by Covance) the Sponsor shall promptly notify all relevant Covance entities of such changes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>13.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance agrees to Use the HBS in accordance with all applicable Regulatory Requirements.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>13.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Upon Sponsor&#146;s request, Covance shall retain, return or destroy all HBS in accordance with the
Informed Consent, the Sponsor&#146;s instructions or any other specific requirements under Applicable Law and Regulatory Requirements. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>13.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Sponsor acknowledges that where Covance enters into a material transfer agreement
(&#147;<B>MTA&#148;</B>) with the provider of any HBS, Covance shall act in accordance with the terms of the MTA and the disposition of the relevant HBS shall be as prescribed in the MTA. In the event of a conflict between the terms of the MTA, this
Agreement, any Work Order and any instructions provided by the Sponsor, the terms of the MTA shall prevail. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DATA PROTECTION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>14.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Where Covance processes any personal data on behalf of the Sponsor, Covance shall process such personal
data in accordance with all applicable Data Protection Laws in the territories in which the Services are performed (&#147;<B>Protected Data</B>&#148;). </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>14.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>If Covance processes any Protected Data on behalf of the Sponsor, Covance and the Sponsor each agree and
acknowledge that the Sponsor shall be the data controller and Covance shall be the data processor with respect to the processing of such Protected Data. Covance shall only process such Protected Data on behalf and upon the reasonable instructions of
the Sponsor for purposes notified to it by the Sponsor for which consent from the relevant data subjects has been obtained in accordance with all applicable Regulatory Requirements. Covance shall follow such procedures, policies and reasonable
instructions as may be agreed by the Parties from time to time. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>14.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance shall take reasonable technical and organizational measures that are necessary to protect
against the unauthorized or unlawful processing of or the unauthorized or unlawful disclosure of such personal data. Covance shall promptly notify the Sponsor in the event of a security breach involving any personal data which Covance is processing
on behalf of the Sponsor. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>14.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Sponsor warrants that it has complied with any and all notification and information requirements
under the applicable Data Protection Laws. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SUBCONTRACTORS </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>15.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Notwithstanding Section&nbsp;18, certain tasks, as may be agreed during the development of and specified
in the Protocol, may be subcontracted by Covance to Subcontractors approved by Covance or subcontracted, or assigned and transferred to its Affiliates. Covance shall be responsible for the acts and performance of Subcontractors and Affiliates.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>15.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Covance shall not be responsible for the performance of third party Vendors. Liability of Covance to the
Sponsor with respect to such Vendors shall be limited to the extent Covance is negligent in the performance of its obligations under this Agreement. Covance shall provide to the Sponsor any amounts that Covance may recover from such Vendors as a
result of any error or service failure on the part of the Vendors in connection with this Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>FORCE MAJEURE </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>16.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Neither Party shall be in breach of this Agreement nor liable for delay in performing, or failure to
perform, any of its obligations under this Agreement, if such delay or failure result from a Force Majeure Event. In such circumstances, any time specified for completion of performance in the Protocol falling due during or subsequent to the
occurrence of a Force Majeure Event shall be automatically extended for a period of time equal to such event. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>16.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Should any part of the Services be rendered invalid as a result of a Force Majeure Event, Covance shall,
upon written request from the Sponsor, and at the Sponsor&#146;s sole cost and expense, repeat the affected part of the Services. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>16.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>If a Force Majeure Event prevents a Party from performing pursuant to this Agreement for a period of 180
days or more, the unaffected Party may terminate this Agreement upon written notice to the affected Party. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INDEPENDENT CONTRACTOR </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>17.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Parties agree that in performing the Services, Covance (including its employees, agents,
subcontractors or other representatives) is acting as an independent contractor to Sponsor. The Parties further agree that Covance and its employees, agents, subcontractors or other representatives are not employees, agents or partners of Sponsor,
and nothing in this Agreement and no actions of Sponsor in engaging Covance shall render Covance or any of its employees, agents, subcontractors or other representatives the employees, agents or partners of Sponsor. Neither Covance nor any of its
employees, agents, subcontractors or other representatives will have power or authority to bind Sponsor. Neither the relationship between Covance and Sponsor nor any provision of this Agreement shall be construed to authorize Covance to take (or
fail to take) any action or make (or fail to make) any decision, representation or commitment binding upon Sponsor or any of its affiliate companies. Sponsor shall at all times be free to engage other third parties to perform services in addition to
or in lieu of those services being provided by the Covance. Subject to the provisions of this Agreement, Covance shall be free to devote such time that they do not spend providing Services under this Agreement to such person, firms or corporations
as they may choose. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>17.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Nothing contained herein shall be construed (i)&nbsp;to create any association, partnership, joint
venture, or relationship of principal and agent, or master and servant between the Parties or any of their affiliates or subsidiaries, employees and subcontractors, (ii)&nbsp;to provide any Party with the right, power or authority, either express or
implied, to create any duty or obligation on behalf of another Party, (iii)&nbsp;to impose liability upon one Party for the act or failure to act of another Party, or (iv)&nbsp;to confer any right for Covance (or any of its employees, agents,
subcontractors or other representatives) to participate in or be eligible to participate in any pension or welfare benefit plans, programs or arrangements of Sponsor or of its affiliate companies pertaining to any pension, stock, bonus, profit
sharing or similar benefits or any employee health, life assurance, workers compensation insurance, disability, severance or any other benefit of any kind whatsoever which is associated with or customarily paid in connection with or in relation to
an employment contractor. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>18.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ASSIGNMENT </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>18.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Either Party may assign, transfer or subcontract any or all of its rights and obligations under this
Agreement to its Affiliates. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>18.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Notwithstanding Section&nbsp;18.1 and except in connection with an internal reorganization of the
relevant Party&#146;s corporate structure, this Agreement shall not be assigned or transferred in whole or in part by either Party without the prior written consent of the other, which consent shall not be unreasonably withheld or delayed.
</P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>19.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NOTICES </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>19.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>All notices required to be given under this Agreement shall be in writing and shall be deemed to have
been duly given if delivered personally or mailed first class, registered or certified mail, return receipt requested, postage paid: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">If to Sponsor to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">inRegen </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">10 Market St. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">#774 Camana Bay,
Grand Cayman </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">KY <FONT STYLE="white-space:nowrap">1-90006</FONT> Cayman Islands </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">If to Covance to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Covance
Central Laboratory Services LP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">8211 SciCor Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Indianapolis, Indiana 46214-2985 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">UNITED STATES </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">Attention: VP,
Finance </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">or at such other place as either Party shall hereafter furnish to the other Party in writing. Notices shall be deemed given on
the date of personal delivery or deposit in the mail as specified above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>19.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>For the purposes of this Section&nbsp;19, in relation to the purposes of any legal proceeding,
&#147;<B>writing</B>&#148; shall not include email. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>20.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WAIVER </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">No waiver of any term, provision, or condition of this Agreement whether by conduct or otherwise in any one or more instances shall be deemed
to be or construed as a further or continuing waiver or estoppel of any such term, provision, or condition or of any other term, provision, or condition of this Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>21.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>VARIATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">No provision of this Agreement may be amended, modified, varied, discharged, or terminated except by the express written agreement of both
Parties and signed by an authorized representative of each Party. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>22.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SEVERABILITY </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">If any court or competent authority finds that any provision of this Agreement (or part of any provision) is invalid, illegal or
unenforceable, that provision or part-provision shall, to the extent required, be deemed to be deleted, and the validity and enforceability of the other provisions of this Agreement shall not be affected. If any invalid, unenforceable or illegal
provision of this Agreement would be valid, enforceable and legal if some part of it were deleted, the provision shall apply with the minimum modification necessary to make it legal, valid and enforceable. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>23.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PUBLICITY AND PUBLICATION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>23.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Neither Party will use the name, trademark or the name of any representative of the other, or the
existence of this Agreement for any promotional or advertising purposes, or any other publication, without the prior written consent of the other. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>23.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Neither Party will state or imply that the other Party endorses or approves any service, material,
product or compound of the other Party without the prior written consent of the other. Such restrictions shall not apply to internal communications and publications to a Party&#146;s Affiliates. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>23.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Sponsor shall provide Covance with a <FONT STYLE="white-space:nowrap">pre-publication</FONT> copy of any
report, manuscript, publication or form of marketing material recognizing Covance&#146;s participation in the Services or otherwise identifying Covance, for approval (which approval shall not be unreasonably withheld or delayed) in each case at
least thirty (30)&nbsp;days before its submission for publication. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>24.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ENTIRE AGREEMENT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">This Agreement represents the entire understanding between the Parties with respect to the subject matter hereof as of the Effective Date, and
this Agreement supersedes all prior agreements, negotiations, understandings, representations, statements and writings between the Parties relating thereto, except that any written agreement entered into prior to the Effective Date with respect to a
Study in process prior to the Effective Date shall remain effective and shall continue to govern such existing Study. The Parties agree that neither has relied upon prior representations made before executing this Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>25.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>LEGAL TESTIMONY </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Covance agrees to provide testimony or records regarding the Services for the Sponsor in any legal or administrative proceeding, provided that
the Sponsor shall reimburse Covance for its out of pocket costs plus a reasonable hourly fee for the involvement of its employees or representatives in such proceedings. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>26.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>THIRD PARTY RIGHTS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">Except as expressly set forth in this Agreement in respect of Covance Affiliates, nothing in this Agreement is intended to confer any rights,
benefits or remedies of any kind whatsoever, and a person who is not a party to this Agreement shall have no right to enforce any of its terms. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>27.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ANTI-BRIBERY </B></P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>27.1</B><B></B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Both Parties agree that each has not and will not, either directly or indirectly, engage in bribery, or
offer, or promise, or authorize to pay or make any improper payment of any monies or financial or other advantage, including cash, loan, gift, travel, entertainment, hospitality, facilitation payment, kickback, political or philanthropic
contribution, anything of value, or any other perceived benefit to improperly obtain or retain a business advantage in violation of any Anti-Corruption Laws and further, each Party agrees that they shall not take any action that would cause the
other Party to be in violation of such Anti-Corruption Laws. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>27.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Any breach of Section&nbsp;27.1 by a Party shall allow the other Party to immediately terminate this
Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>28.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TRADE CONTROL </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>28.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Notwithstanding any other provision of this Agreement to the contrary, each Party shall comply with, and
retain responsibility for its compliance with, all applicable export control laws (e.g., the U.S. Export Administration Regulations) and economic sanctions programs (e.g., economic sanctions maintained by the U.S. Treasury Department, as well as
Specially Designated Nationals and Blocked Persons (<B>SDNs</B>)) relating to its respective business, facilities, and the provision of services to third parties (collectively, <B>Trade Control Laws</B>). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>28.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Nothing in this Agreement shall be construed to require Covance to be directly or indirectly involved in
the provision of goods, software, services and/or technical data that may be prohibited by applicable Trade Control Laws, including sanctions currently in place against Cuba, Iran, North Korea, Sudan, Syria and SDNs. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>29.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COUNTERPARTS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:11%; font-size:10pt; font-family:Times New Roman">This Agreement may be executed in any number of counterparts, each of which when executed and delivered shall constitute an original to this
Agreement but all of which together shall constitute the same Agreement. Signatures upon this Agreement transmitted by facsimile, electronic mail or other electronic method shall have the same legal and biding effect as wet signatures. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>30.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CHOICE OF LAW AND DISPUTE RESOLUTION </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>30.1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>This Agreement shall be governed and construed in accordance with the laws of the State of New York,
U.S.A., without regard to conflicts of laws provisions. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>30.2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>Any dispute, controversy, or claim arising out of, relating to, or in connection with this Agreement, or
the breach, termination, or validity thereof, shall be finally settled by arbitration. The arbitration shall be conducted in accordance with the Securities Arbitration Rules (the &#147;Rules&#148;) of the American Arbitration Association
(&#147;AAA&#148;), including the AAA&#146;s Procedures for Large, Complex Commercial Disputes, in effect at the time of the arbitration, except as they may be modified herein or by mutual agreement of the parties. The seat of the arbitration shall
be New York, New York, and it shall be conducted in the English language. The arbitration and this clause shall be governed by Title 9 (Arbitration) of the United States Code. The Parties agree that irreparable damage may occur to a Party in the
event that the other Party may fail or fails to comply with the provisions of Section&nbsp;8. Accordingly, and without otherwise limiting the requirement of mandatory arbitration imposed hereunder, a Party may seek from any court having jurisdiction
any interim or provisional relief (without the necessity of posting bond) that may be necessary to protect its interests under Section&nbsp;8, pending the arbitral tribunal&#146;s final determination of the merits of the controversy.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>30.3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The arbitration shall be conducted by three arbitrators. The claimant shall appoint an arbitrator in its
request for arbitration. The respondent shall appoint an arbitrator within twenty (20)&nbsp;days of the receipt of the request for arbitration. The two arbitrators shall appoint a third arbitrator, who shall act as chair of the tribunal, within
twenty (20)&nbsp;days after the appointment of the second arbitrator. If any of the three arbitrators is not appointed within the time prescribed above, then the AAA shall appoint that arbitrator from its National Panel of Securities Arbitrators or
its Large, Complex Commercial Case Panel, not including any such members affiliated with the securities industry. The chair of the tribunal shall be a citizen of the United States. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>30.4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In addition to the authority conferred on the arbitration tribunal by the Rules, the arbitration
tribunal shall have the authority to order such production of documents, generally consistent with the discovery permitted under the Federal Rules of Civil Procedure, as may reasonably be requested by any party or by the tribunal itself. In
addition, any party may request a reasonable number of depositions of party witnesses. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>30.5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Parties agree that the arbitration shall be kept confidential and that the existence of the
proceeding and any element of it (including but not limited to any pleadings, briefs or other documents submitted or exchanged, any testimony or other oral submissions, and any awards) shall not be disclosed beyond the tribunal, the AAA, the
Parties, their counsel, accountants and auditors, insurers and <FONT STYLE="white-space:nowrap">re-insurers,</FONT> and any person or entity necessary to the conduct of the proceeding. The confidentiality obligations in this Section&nbsp;28.5 shall
not apply (i)&nbsp;if disclosure is required by Applicable Law, or in judicial or administrative proceedings, or (ii)&nbsp;as far as disclosure is necessary to enforce the rights arising out of the award. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>30.6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The arbitration award shall be final and binding on the Parties. Judgment upon the award may be entered
by any court having jurisdiction thereof or having jurisdiction over the relevant Party or its assets. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>30.7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>In order to facilitate the comprehensive resolution of related disputes, and upon request of any party
to the arbitration proceeding, the arbitration tribunal may consolidate the arbitration proceeding with any other arbitration proceeding involving any of the Parties hereto relating to this Agreement. The arbitration tribunal shall not consolidate
such arbitrations unless it determines that (i)&nbsp;there are issues of fact or law common to the related proceedings so that a consolidated proceeding would be more efficient than separate proceedings, and (ii)&nbsp;no party would be prejudiced as
a result of such consolidation through undue delay or otherwise. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><B>30.8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>The Parties agree that any dispute arising from or in connection with this Agreement (including any <FONT
STYLE="white-space:nowrap">non-contractual</FONT> obligations) shall be referred to and finally resolved by arbitration under the Rules of the International Chamber of Commerce, which Rules shall be deemed incorporated by reference to the Agreement.
The number of arbitrators shall be three (3), the seat or legal place of arbitration shall be New York and the language used in the arbitration shall be English. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>signature page follows</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 of 21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties by their duly authorized officers have executed this Agreement on the dates
set forth below, to be effective on the Effective Date set forth on the first page of this Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>INREGEN</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Timothy A Bertram</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Timothy A Bertram</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">CEO</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">26 June 2019</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="20%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COVANCE CENTRAL LABORATORY SERVICES LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Annabel Bower</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Annabel Bower</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Dir, Contract Mgt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">June&nbsp;21, 2019</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="82%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>COVANCE&nbsp;CENTRAL&nbsp;LABORATORY&nbsp;SERVICES&nbsp;S&Agrave;RL</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature:&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Monica Malcarne</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Geneva Site Lead and Senior Director Operations</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">June&nbsp;22, 2019</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 of 21 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.22
<SEQUENCE>12
<FILENAME>d373959dex1022.htm
<DESCRIPTION>EX-10.22
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.22</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.22 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>This Laboratory Service Agreement</B> (&#147;<B>Agreement</B>&#148;<B>)</B> is made effective on the date of the last signature below (&#147;Effective
Date&#148;) by and between </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>LABCORP CENTRAL LABORATORY SERVICES LP</B><B> </B>(formerly known as Covance Central Laboratory Services LP)<B> </B>an
Indiana limited partnership, with its principal place of business at 8211 SciCor Drive, Indianapolis, Indiana 46214, USA; and <B>LABCORP CENTRAL LABORATORY SERVICES S</B><B>&Agrave;</B><B>RL </B>(formerly known as Covance Central Laboratory Services
S&Agrave;RL), with its principal place of business at Rue Moise-Marchines 7, 1217 Meyrin, Geneva Switzerland (collectively &#147;<B>Labcorp</B>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ProKidney</B> with its principal place of business located at 10 Market St., #688 Camana Bay, Grand Cayman <FONT STYLE="white-space:nowrap">KY1-9006</FONT>
Cayman Islands (&#147;<B>Sponsor</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(each a<B> </B>&#147;<B>Party</B>&#148;<B> </B>and collectively the &#147;<B>Parties</B>&#148;). </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IT IS AGREED </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left"><B>1</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DEFINITIONS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.1 In this Agreement, unless the context otherwise requires, the following words and expressions shall have the following meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;</B><B>Affiliate</B>&#148; means any entity controlling, controlled by, or in common control with a Party. For the purposes of this definition,
&#147;<B>Control</B>&#148; shall mean ownership or control, directly or indirectly of more than fifty percent (50%) of the common voting stock or ordinary shares in the entity or the right to appoint fifty percent (50%) or more of the directors of
that entity. With respect to Labcorp, the term Affiliate shall include Laboratory Corporation of America Holdings and any business entity that is controlled by or is under common control with Laboratory Corporation of America Holdings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Anti-Corruption Laws</B>&#148; means any anti-bribery and anti-corruption laws, rules, regulations applicable to either Party (each as amended from
time to time) together with any applicable implementing legislation including any applicable local law addressing bribery or corruption. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Background IP</B>&#148; means all <FONT STYLE="white-space:nowrap">pre-existing</FONT> intellectual property belonging to or licensed to a Party or
other intellectual property created outside the scope of the Services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Claim</B>&#148; means any third party claims, demands, assessments,
actions, suits, proceedings, settlements or investigations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Confidential Information</B>&#148; means any and all
<FONT STYLE="white-space:nowrap">non-public</FONT> information or materials and all derivatives thereof, in any and all forms, howsoever disclosed or obtained, including business plans, financial information, client lists, and requirements,
techniques, designs, methods, processes and procedures, which: (i)&nbsp;is identified by a suitable legend or other marking as being confidential (or similar designation) in a prominent position or (ii)&nbsp;is described as being confidential at the
time of disclosure or (iii)&nbsp;the disclosing Party regards or should reasonably be expected to regard as proprietary and confidential given the nature of the information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Labcorp Property</B>&#148; means inventions, proprietary processes, software (including codes), data, technology,
<FONT STYLE="white-space:nowrap">know-how</FONT> and other intellectual property that have been independently developed or discovered by Labcorp or its Affiliates without the use of Sponsor&#146;s Confidential Information, including those that
relate to the proprietary innovative testing procedures, laboratory testing, data collection or data management, procedural manuals, delta flags, nucleic acid based vectors, analytical procedures and approaches that are not specific for use with the
Sponsor&#146;s Background IP even if such are developed in the performance
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the Services or are captured in documents pertaining to the Services (i.e. laboratory notebooks), techniques, models, <FONT STYLE="white-space:nowrap">non-product</FONT> specific components of
questionnaires, management tools and any other materials, employed, developed or acquired by Labcorp or its Affiliates which are not specifically part of the Services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&#147;Data Protection Laws&#148;</B> mean all applicable privacy, data protection or similar laws and regulations anywhere in the World, as the same may be
amended from time to time, including to the extent applicable to the respective Services and any applicable implementing legislation or any amendment thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Deliverables</B>&#148; means as applicable to the Services, Results, or any other deliverable specified in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Force Majeure Event</B>&#148; means circumstances or causes beyond the reasonable control of a Party, including war, threat of war or warlike
conditions, blockade, embargo, fire, explosion, lightning, storm, drought, flood, earthquake or other natural disaster, pandemic or epidemic, power failure, acts of terrorism, riot, civil unrest, insurrection, acts of government or other
international bodies, political subdivision and any other events which by their nature could not have been foreseen by the Parties, or, if it could have been foreseen were unavoidable by a reasonable prudent business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>HBS Donor</B>&#148; means an individual, living or deceased, from whom the HBS was obtained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Human Biological Samples</B>&#148; or &#147;<B>HBS</B>&#148; means any human biological material, including human bodily parts and organs in whole or
<FONT STYLE="white-space:nowrap">sub-samples,</FONT> any tissue, skin, bone, muscle, connective tissue, blood, cerebrospinal fluid, gametes, or <FONT STYLE="white-space:nowrap">sub-cellular</FONT> structures such as DNA, or any derivative or product
of such human biological materials, cell lines, bodily fluids, blood derivatives and urine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>IEC/IRB</B>&#148; means an independent ethics
committee or institutional review board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Informed Consent</B>&#148; means an IEC/IRB approved informed consent form signed by the HBS Donor
authorizing the Use of their HBS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Invention</B>&#148; means any invention (whether or not patentable), proprietary processes, software
(including codes), data, technology, <FONT STYLE="white-space:nowrap">know-how</FONT> or other intellectual property discovered, conceived or made by Labcorp or its Affiliates specifically as a part of the Services for the Sponsor and directly
relating to the Test Materials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Loss</B>&#148; means any loss, cost, damage or expense (including reasonable legal expenses).
</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 of 9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Project</B>&#148; means a Study, project or assignment between Labcorp and Sponsor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Protocol</B>&#148; means the document which specifies the laboratory testing procedures as written by Sponsor as applicable for the performance of a
Study and is provided to Labcorp. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Regulatory Authority</B>&#148; means any national or state or local agency, authority, department,
inspectorate, minister, ministry official, parliament or public or statutory person of any government of any country having jurisdiction over either any of the activities contemplated by this Agreement or the Parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Regulatory Requirements</B>&#148;<B> </B>means all laws, statutes, acts, rules, regulations, guidelines, codes, orders, directives or other legally
binding requirements of any Regulatory Authority and industry standards or codes of conduct applicable to the Services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Results</B>&#148; mean
materials, data, Inventions, documents and information produced or developed by Labcorp exclusively in the course of the Services and directly related to the Test Materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Services</B>&#148; means the services provided by Labcorp to the Sponsor as more particularly described in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>SOW</B>&#148; means the scope of work, which is the primary Labcorp laboratory specification document and defines all study specific Services to be
provided for a Protocol. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Sponsor Information</B>&#148; means Test Materials, data, specification, or other materials or information supplied by
the Sponsor to Labcorp in connection with the Services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Study</B>&#148; means a clinical trial or scientific evaluation of the Test Materials on
the terms and conditions of the Protocol. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Subcontractor</B>&#148; means a third party approved, reviewed and contracted by Labcorp for Services
within the scope of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>System Data</B>&#148; means control data from laboratory tests or transactional, volume and performance data
related to the Services, which does not contain any personally identifiable information or Sponsor Confidential Information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Test
Materials</B>&#148; means compounds, materials or other substances as described in the Protocol to be tested or used in the performance of the Services and provided to Labcorp by the Sponsor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Use</B>&#148; (in the context of Section&nbsp;13) means collection, storage, transfer (including import and export), use and return or disposal of
HBS including by commercial organizations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;<B>Vendor</B>&#148; means third-party service providers other than a Subcontractor for which Labcorp may
hold the contract with such service provider for the convenience or benefit of the Sponsor in connection with Services under this Agreement and as set forth in the applicable SOW. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.2 In this Agreement, unless the context otherwise requires, references to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) Schedule and Section headings are inserted for convenience only and do not affect the construction or interpretation of this Agreement; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) <B>writing</B> or <B>written</B> includes faxes and <FONT STYLE="white-space:nowrap">e-mail;</FONT> </P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) a particular law or statutory provision is a reference to it as it is in force for the time being taking
account of any amendments, extensions, or <FONT STYLE="white-space:nowrap">re-enactments</FONT> and includes any subordinate legislation for the time being in force made under it; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) a person includes a corporate or unincorporated body; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e)
any gender includes all genders; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f) <B>including</B>, <B>include</B>, <B>in particular</B> or any similar expression shall be construed as illustrative
and shall not limit the sense of the words preceding those terms; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(g) words in the singular include the plural and vice versa. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1.3 If this Agreement is translated, the English language text shall prevail. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left"><B>2</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SERVICES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.1 Labcorp through itself and/or its Affiliates hereby agrees to perform Services for Sponsor&#146;s protocol REGEN006. Such Services shall be performed
pursuant to the terms and conditions contained herein and the terms of the Protocol. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.2 Any changes or modifications to the Protocol and/or Services
provided by Labcorp, or any Sponsor request for additional Services may commence upon Labcorp&#146;s receipt of Sponsor&#146;s written approval of the revised SOW. Upon Sponsor&#146;s SOW signature, Labcorp shall provide such Services to the Sponsor
and the Sponsor shall pay for costs associated with such Services at its current standard rates. Labcorp reserves the right to refuse to perform any Services of Test Materials that are hazardous in nature when performed in accordance with relevant
instructions and specifications, but only where such hazard was not known prior to signing the SOW. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.3 Labcorp shall provide each investigator site with
Project-related materials and documentation, including the relevant Protocol, as well as Project- and visit-specific specimen collection supplies needed to collect and ship specimens. The specimen collection kits shall also have a test requisition
form or other electronic method to capture such data, for the particular Project. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.4 Should a kit be lost through no fault of Labcorp, or should a kit
expire at the investigator site, Labcorp will supply replacement kits for those that are lost, expired, or otherwise rendered unusable, at an amount equal to the price listed in the quote for Services attached hereto (&#147;<B>Budget</B>&#148;) per
kit for the same kit/visit that is being replaced. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.5 After performing Services, Labcorp will store the remaining Study specimens for the length of time
and under storage conditions as described in the applicable SOW. The remaining specimens may subsequently be shipped to Sponsor or another party as specified in the SOW or if not specified in the SOW, held as otherwise instructed by the Sponsor. In
no event shall Labcorp&#146;s liability for any breach or default with regard to storage of an archival specimen exceed the fee it has been paid for storage of that specimen for the previous twelve (12)&nbsp;months. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left"><B>3</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TERM AND TERMINATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.1 The term of this Agreement shall commence on the date hereof and continue until the conclusion of the Study.
</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 of 9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.2 Either Party may terminate this Agreement with immediate effect by notice in writing in the event that the
other Party: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) commits a material breach of any term of this Agreement which breach is irremediable or (if such breach is remediable) fails to remedy
that breach within a period of thirty (30)&nbsp;days after being notified in writing to do so; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) repeatedly breaches any of the terms of this
Agreement in such a manner as to reasonably justify the opinion that its conduct is inconsistent with it having the intention or ability to give effect to the terms of this Agreement; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) suspends, or threatens to suspend, payment of all or substantially all of its debts or is unable to pay all or substantially all of its debts as they fall
due or admits in writing its inability to pay its debts or is deemed by a court of competent jurisdiction to be unable to pay its debts; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) suspends,
or threatens to suspend, or ceases or threatens to cease to carry on, all or substantially the whole of its business; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) presents a petition or has a
petition presented for its <FONT STYLE="white-space:nowrap">winding-up</FONT> or has a receiver or an administrative receiver appointed of all or substantially all of its assets; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f) any event occurs, or proceeding is initiated, in any jurisdiction to which it is subject that has an effect equivalent or similar to any of the events
mentioned above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.3 Sponsor may terminate this Agreement for any reason upon ninety (90)&nbsp;days prior written notice to Labcorp. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.4 In the event of such termination, Labcorp shall be entitled to full payment for work properly performed on the Study through the date work on such Study
is concluded, including, without limitation, all <FONT STYLE="white-space:nowrap">non-cancelable</FONT> fees and other <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses of Labcorp for such Study.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3.5 The termination of this Agreement shall not relieve either Party of its obligations to the other with respect to: (a)&nbsp;maintaining the
confidentiality of Confidential Information; (b)&nbsp;obtaining consents for the use of names; (c)&nbsp;ownership of and assignment of inventions; (d)&nbsp;indemnification; (d) limitation of liability; (e)&nbsp;compensation for Services performed;
(f)&nbsp;publications; and (g)&nbsp;retention of records. The provisions of this Section together with any other section which is necessary for the interpretation or enforcement of this Agreement shall survive the expiry or termination of this
Agreement howsoever arising. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left"><B>4</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>REGULATORY COMPLIANCE </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.1 Labcorp will perform its Services in accordance with the terms of this Agreement, the applicable Protocol, and all Regulatory Requirements applicable to
the Project. All activities undertaken under this Agreement by Labcorp shall comply in all material respects with College of American Pathologists (CAP) rules. Labcorp represents that it has and shall maintain Clinical Laboratory Improvement Act
(CLIA) certification. This Agreement shall contain all the conditions under which Labcorp will provide clinical laboratory Services. Labcorp makes no other express or implied commitments or warranties concerning the performance of the Study. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.2 In the event that compliance with any new Regulatory Requirements necessitates a change in this Agreement, Labcorp will submit to Sponsor a revised
technical and cost proposal for Sponsor&#146;s acceptance prior to performing Services.
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4.3 In the event of a material conflict in applicable Regulatory Requirements, the Sponsor will designate which
regulations shall be followed by Labcorp in its performance of the Services and the Sponsor shall be fully responsible, to the extent permitted by law, for the outcome of such a decision. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left"><B>5</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>FEES, BILLING AND TAXES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.1 Fees for the Project are set forth in the attached Budget. Sponsor acknowledges that SOW finalization, changes and/or modifications to the Project may
result in a revised Budget. The Budget contains all the applicable discounts and Services that will be provided for that Project. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.2 During performance
of Services, Labcorp may be required to provide certain items including but not limited to ancillary supplies, logistics and minor modifications to database design (&#147;<B>Items</B>&#148;). Items may not appear in Sponsor&#146;s Budget and will
require written approval from Sponsor prior to the commencement of work on said items. Total fees for these items will be capped at $150,000. Sponsor agrees to remit payment for Items invoiced in accordance with payment terms provided in
Section&nbsp;5.4. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.3 Upon execution, Labcorp will assess a fee equal to five per cent (5%) of the value of the contract Budget
(<B>Deposit</B>).&nbsp;Sponsor will pay the Deposit within thirty (30)&nbsp;calendar days after receipt of invoice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.4 Each month, Labcorp will invoice
Sponsor for all fees due and expenses incurred while providing Services during the previous month. Payment is due thirty (30)&nbsp;calendar days from invoice receipt. Payments not received within five business days of Labcorp&#146;s notice to
Sponsor of <FONT STYLE="white-space:nowrap">non-payment</FONT> may be subject to a fifteen per cent (15%) per annum late payment fee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.5 Labcorp shall
retain the Deposit until the Study invoices have reached ninety-five percent (95%) of the total Study Budget at which point the Deposit will be applied to monthly invoices. At the end of each Study, Labcorp shall conduct a final account
reconciliation and will refund to Sponsor any remaining amounts of the Deposit within sixty (60)&nbsp;days after the date of the final invoice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.6 For
budgeting purposes, Labcorp creates the Budget using local unit pricing. The local unit pricing is then converted to the billing currency, as requested by Sponsor, using the Reuters exchange rate for the month the Budget is first created. Unless
specified otherwise, this exchange rate remains unchanged during the course of the Study to simplify budget comparisons and enable Sponsor to track changes to the Study unrelated to changes in currency exchange rates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.7 For invoicing purposes, Services are billed based on the contracted local unit prices. Each month, at the time of invoice creation, the local unit prices
are converted to the billing currency using the Reuters exchange rate for the month in which the Services were performed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.8 Labcorp will hold prices
unchanged for twelve (12)&nbsp;months from Project start up. Thereafter, fees may be adjusted annually by Labcorp upon thirty (30)&nbsp;days written notice to Sponsor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.9 Invoices will be provided by Labcorp to: ProKidney Accounts Payable payables@ProKidney.com
</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 of 9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.10 Payment shall be made from Sponsor to Labcorp as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment by Check: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Labcorp Central Laboratory Services, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">P.O. Box 2484 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Burlington, NC 27216 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment by Bank Transfer: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Labcorp Central Laboratory Services,
Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wells Fargo Bank, N.A </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">420 Montgomery, San Francisco,
CA 94104 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Routing Transit Number/ABA: 121000248 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Account
Number: 4244842191 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SWIFT: WFBIUS6S </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.11 If a dispute
arises between the Parties in respect of any part of an invoice, and unless otherwise agreed in a Work Order, Sponsor (i)&nbsp;must pay all undisputed parts of the invoice when due; (ii)&nbsp;must notify Labcorp in writing of the particulars of the
dispute within fifteen (15)&nbsp;business days of receipt of the invoice; and (iii)&nbsp;may withhold payment of the disputed part of the invoice, provided that Sponsor endeavors promptly and in good faith to resolve the dispute pursuant to
Section&nbsp;30. If Sponsor fails to pay the amount of any undisputed invoice or part of an invoice within the time prescribed in Section&nbsp;5.4, five (5)&nbsp;business days after giving Sponsor written notice after providing Sponsor, Labcorp may
charge interest on any such amount at the rate of one and one half percent (1.5%) per month, or the maximum rate allowed by Applicable Law if lower, will accrue from the date the payment was originally due until the date of payment, and
(b)&nbsp;five (5) business days after giving Sponsor written notice that undisputed amounts are due, Labcorp may elect to suspend work on a Study or to withhold Deliverables, reports or other material in respect of a Study for so long as Sponsor
fails to pay such undisputed amounts until such undisputed amounts are paid. If Sponsor requests a material change to the Project at any time which would affect the Services, Labcorp will notify Sponsor of the new proposed budget amount and, if
approved and agreed to by Sponsor, Labcorp will revise fees to reflect the change in the SOW and Budget. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.12 Upon written notification by Sponsor that
the Study has been concluded or upon completion of all Services required by Labcorp under this Agreement, Labcorp will issue a final invoice for Services rendered to identify amounts due to Labcorp or refund due to Sponsor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5.13 Fees payable under this Agreement shall not include local, state, federal or foreign sales or use taxes, excise taxes, goods and services tax,&nbsp;value
added tax or consumption taxes, as applicable. Any applicable taxes will be billed to and paid by Sponsor without deduction&nbsp;to amounts owed to&nbsp;Labcorp. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left"><B>6</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SITE VISITS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.1 The Sponsor or its representative (which shall not be a competitor of Labcorp) may visit Labcorp&#146;s premises where the Services are being performed at
reasonable times, on reasonable notice and with reasonable frequency during normal business hours to observe the progress of the Services. Labcorp will assist the Sponsor in scheduling such visits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6.2 The Sponsor acknowledges that the Sponsor&#146;s representatives granted access to Labcorp facilities during any such visits may have access to
confidential and proprietary information of Labcorp. The Sponsor agrees that all such confidential and proprietary information of Labcorp obtained
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or observed by the Sponsor during such visits shall remain the sole property of Labcorp and the Sponsor shall treat such information as Confidential Information in accordance with Section&nbsp;8
of this Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left"><B>7</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>REGULATORY INSPECTIONS AND AUDITS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.1 In the event of a Party receiving a notice from a Regulatory Authority which directly relates to the Services, the Party receiving such notice shall
promptly notify the other Party or forward to the other Party a copy of such notice (or extract thereof). Each Party will cooperate with the other in responding to such notice before referring to the other Party in any regulatory correspondence or
disclosing any Confidential Information to a Regulatory Authority. However, each Party acknowledges that it may not direct the manner in which the other Party fulfils its obligations to permit inspection by Regulatory Authorities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.2 Labcorp shall cooperate with any inspection or audit by a Regulatory Authority and shall notify the Sponsor promptly of any request by a Regulatory
Authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.3 Labcorp agrees that, during an inspection or audit by a Regulatory Authority concerning the Services, it will not disclose information and
materials that are not required to be disclosed to such Regulatory Authority, without the prior written consent of the Sponsor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.4 If any inspections or
audits conducted pursuant to this Section&nbsp;7 that result in a finding that Labcorp has failed to comply with the terms of this Agreement, Labcorp shall promptly take such measures at its own cost and expense as are necessary to correct such
defaults. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7.5 It is agreed that where any audit of Labcorp concerns or relates to referral laboratory testing or shipping methods of Labcorp, the Sponsor
or its representative (which shall not be a competitor of Labcorp) may only confirm or not if Labcorp is properly billing such costs. The Sponsor expressly agrees that Sponsor&#146;s representatives may not directly or indirectly provide any details
of the charges to the Sponsor, such as the actual amount of the referral laboratory testing or shipping costs incurred by Labcorp. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left"><B>8</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CONFIDENTIAL INFORMATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.1 Each Party agrees that all Confidential Information of the disclosing Party is and shall be the sole property of the disclosing Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.2 Without prejudice to any Labcorp Property, all Results, Inventions, data and records developed by Labcorp or its Affiliates specifically from the
performance of the Services shall be the Confidential Information of the Sponsor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.3 Each Party agrees to hold the Confidential Information of the other
Party in confidence and in a manner consistent with the way in which it maintains the confidentiality of its own proprietary information, being at least a reasonable standard of care. Each Party shall disclose the Confidential Information only on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">need-to-know</FONT></FONT> basis, to its employees, officers, directors, representatives and third-party investigators and who are bound to retain the Confidential Information in
confidence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.4 Each Party agrees that, except as necessary to fulfil its obligations under this Agreement, it will not use or disclose to any third
party any of the Confidential Information. </P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 of 9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.5 The obligations of <FONT STYLE="white-space:nowrap">non-use</FONT> and
<FONT STYLE="white-space:nowrap">non-disclosure</FONT> shall not apply to Confidential Information that the receiving Party can show: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) was, or becomes,
publicly known through no fault of the receiving Party; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) was lawfully obtained from a third party without restriction as to its use or disclosure;
or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) was already in the possession of the receiving Party prior to disclosure as shown by the receiving Party&#146;s written records; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) was independently developed by the receiving Party without the benefit of the Confidential Information as shown by the receiving Party&#146;s
contemporaneous written records; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) is required for Sponsor&#146;s pursuit of registration of a product connected with the Services with a government
agency. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.6 The receiving Party shall be entitled to disclose Confidential Information to the extent required by any law, rule, regulation, order, decree
or subpoena, except that the receiving Party shall, unless restricted by law or where not practicable, promptly notify the other Party of such requirement prior to the disclosure and shall cooperate with the disclosing Party to seek to oppose,
minimize or obtain the confidential treatment of the requested disclosure to the extent of such order. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.7 The obligations in this Section&nbsp;8 shall
remain in full force and effect for a period of <B>seven (7)</B><B></B><B>&nbsp;years</B> following termination of this Agreement except with respect to Confidential Information which is considered a trade secret under applicable law, which shall
remain confidential as long as such Confidential Information retains its status as a trade secret. Labcorp shall not disclose any trade secret to Sponsor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8.8 In the event of actual or threatened breach or violation of this Section&nbsp;8, the disclosing Party shall have the right to seek injunctive relief in
any court of competent jurisdiction. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left"><B>9</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INTELLECTUAL PROPERTY RIGHTS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9.1 All Background IP is and shall remain the exclusive property of the Party owning it and except as expressly provided in this Agreement, no Party shall
acquire any rights in or to the Background IP of the other Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9.2 The Sponsor acknowledges that Labcorp Property is owned or licensed by Labcorp or
its Affiliates. The Parties agree that any improvement, enhancement or modification made, conceived or developed by Labcorp to any Labcorp Property in the performance of the Services which is not (i)&nbsp;specific or related directly to the Test
Materials, or (ii)&nbsp;an Invention, shall be deemed Labcorp Property and shall vest absolutely and exclusively in Labcorp. In addition, subject to Sections 8 and 9 of this Agreement, Labcorp and its Affiliates shall be entitled to use and exploit
any skills, techniques or <FONT STYLE="white-space:nowrap">know-how</FONT> acquired, developed or used in the course of the Services. Strategic insight and proposed Project design and scope provided in any quotation by Labcorp shall remain the
property of Labcorp and may be used by the Sponsor only to assess whether it wishes to pursue such work with Labcorp. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9.3 Without prejudice to Sections
9.1 and 9.2, and upon receipt by Labcorp of payment in full of all amounts due and payable under this Agreement, the Sponsor will have title to the Deliverables and all intellectual property rights arising
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
therefrom. Labcorp agrees to assign such rights to the Sponsor except that one (1)&nbsp;copy of the Results may be retained by Labcorp for regulatory or legal compliance purposes. Labcorp hereby
grants to Sponsor a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> worldwide, transferrable, perpetual, royalty-free license to use any Labcorp Background IP incorporated or included in the Deliverables for the sole purpose of and to the
extent necessary to use, incorporate or explain any Deliverable (without modification), and for obtaining regulatory approvals in connection with such Deliverable. In no event shall Sponsor use or distribute Labcorp Background IP on a stand-alone
basis, separate from the Deliverables. Notwithstanding the foregoing, the Sponsor hereby grants Labcorp an unrestricted, royalty-free license to aggregate and use any System Data produced by or for Labcorp as part of the Services with other System
Data owned or licensed by Labcorp provided that Labcorp shall not identify such data as belonging to the Sponsor and Sponsor is not identifiable through such aggregated data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9.4 Without prejudice to Sections 9.1 and 9.2, Labcorp shall promptly disclose to the Sponsor (or its nominee) all Inventions and hereby assigns and agrees to
assign to the Sponsor (or its nominee) the rights to such Inventions and shall do all acts that are reasonably necessary to vest the Inventions in the name of the Sponsor (or its nominee). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Where an Invention is a laboratory testing method, or other laboratory processes used by Labcorp in the performance of its laboratory testing services, the
Sponsor hereby agrees to grant to Labcorp and its Affiliates a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> <FONT STYLE="white-space:nowrap">non-transferable,</FONT> irrevocable, perpetual, royalty-free, worldwide license to use the
Invention solely to perform its laboratory testing services, in each case subject to Section&nbsp;8. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left"><B>10</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>REMEDIES AND LIMITATION OF LIABILITY </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.1 In the event of a material error by Labcorp that prevents proper performance under this Agreement or which renders the Services in whole or in part
unacceptable to a Regulatory Authority to which the Sponsor intends to submit the Results, Labcorp&#146;s sole obligation to Sponsor shall be for Labcorp, in agreement with the Sponsor, to either: (a)&nbsp;repeat the defective part of the Services
at Labcorp&#146;s own cost; or (b)&nbsp;refund to the Sponsor the amount paid for the defective part of the Services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.2 Labcorp&#146;s total liability
to the Sponsor, whether in contract, tort (including negligence) or otherwise, shall in no circumstances exceed the total price paid by the Sponsor for the Services that are the subject of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.3 Nothing in this Agreement excludes or limits the liability of either Party where liability cannot be excluded or restricted as a matter of law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.4 Except for any liability resulting from any breach of Section&nbsp;8 or indemnification obligation pursuant to Section&nbsp;11, Labcorp will not be
liable to the Sponsor for any Loss in respect of any (a)&nbsp;loss of profit, opportunity, business, or goodwill (in each case whether direct or indirect); or (b)&nbsp;any indirect, consequential, punitive, exemplary or special damages or losses,
arising under or in connection with this Agreement, and each type of loss arising under this Section&nbsp;10.4 shall be severable in accordance with Section&nbsp;22 of this Agreement. To the extent that Labcorp agrees to perform Services for Sponsor
Affiliates, Labcorp shall only be liable to the entity named in this Agreement and not for multiple claims by Sponsor Affiliates.
</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 of 9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.5 Labcorp shall not be liable for any failure, error or delay in performing the Services if such failure,
error or delay is caused by Sponsor, or is a result of an express instruction from Sponsor or a change in Sponsor Information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10.6 Labcorp shall have no
liability to Sponsor for loss, damage, delay or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-delivery/non-collection</FONT></FONT> of any samples or shipment dispatched by Labcorp to Sponsor or to any third party designated
by Sponsor in connection with the Services that are caused by the acts or omissions of any third party delivery services or carrier (&#147;<B>Carrier</B>&#148;). Notwithstanding the foregoing, to the extent permitted by law, Labcorp shall have the
benefit of any right or remedy permitted under international or domestic law and any sums recoverable from a Carrier shall be paid to the Sponsor. For the avoidance of doubt, a Carrier is not considered a Subcontractor for the purposes of this
Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left"><B>11</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INDEMNITIES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.1 The Sponsor shall defend, indemnify, and hold harmless Labcorp and its respective Affiliates and their respective officers, directors, employees and
agents (&#147;<B>Labcorp Group</B>&#148;) from any Loss resulting from any Claim arising from or related to, directly or indirectly: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) personal injury
to a participant in the Study or personal injury to any employee within the Labcorp Group directly or indirectly caused by the Test Material; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b)
Labcorp&#146;s proper execution and/or proper performance of its obligations under this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) the Sponsor&#146;s use of the Results or
Deliverables or its use or marketing of any substance tested in association with the Study by Labcorp; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) the negligence or intentional misconduct of
the Sponsor; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(e) the Test Material&#146;s harmful or otherwise unsafe effects, including, without limitation, a Claim based upon Sponsors or any other
person&#146;s use, consumption, sale, distribution or marketing of any substance tested in association with the Study; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(f) the infringement, unlawful
disclosure or misappropriation of copyright, patent, trade secret or other intellectual property of a third party by reason of the proper performance of the Services using the Sponsor Information, provided that if such Loss or Claim arises in whole
or in part from Labcorp&#146;s negligence or intentional misconduct, then the amount of such Loss that Sponsor shall indemnify the appropriate person or entity within the Labcorp Group pursuant to this Section&nbsp;11 shall be reduced by an amount
in proportion to the percentage of Labcorp&#146;s responsibilities for such Loss as determined by a court of competent jurisdiction in a final and <FONT STYLE="white-space:nowrap">non-appealable</FONT> decision or in a binding settlement between the
Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.2 Labcorp shall defend, indemnify and hold harmless the Sponsor and its Affiliates and their respective officers, directors and employees
(the &#147;<B>Sponsor Group</B>&#148;) from any Loss resulting from any Claim arising from or associated directly with, a breach of this Agreement by Labcorp, or the negligence or intentional misconduct of Labcorp, <U>provided</U> that if such
Losses or Claims arise in whole, or in part, from the Sponsors Group&#146;s negligence or intentional misconduct, then the amount of such Losses that Labcorp shall be responsible for pursuant to this Section&nbsp;11 shall be reduced by an amount in
proportion to the percentage of the Sponsor
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Group&#146;s responsibilities for such Losses as determined by a court of competent jurisdiction in a final and <FONT STYLE="white-space:nowrap">non-appealable</FONT> decision or in a binding
settlement between the Parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.3 An indemnitee entitled to indemnification under Section&nbsp;11 (&#147;<B>Indemnified Party</B>&#148;) shall give
written notice to the other Party (&#147;<B>Indemnifying Party</B>&#148;) of a claim or other circumstances likely to give rise to a request for indemnification, promptly after the Indemnified Party becomes aware of the same. The Indemnifying Party
shall be afforded the opportunity to undertake the defense of, and, subject to Section&nbsp;11.5, to settle by compromise, or otherwise, any claim for which indemnification is available under this Section. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.4 If the Indemnifying Party assumes the defense of any claim, the Indemnified Party may participate in such defense with legal counsel of its selection and
at its expense. If the Indemnifying Party fails to promptly assume the defense of a claim by the Indemnified Party under this Section&nbsp;11, the Indemnified Party may thereupon undertake the defense on behalf of, at the risk and expense of the
Indemnifying Party with all reasonable costs and expenses of such defense to be paid by the Indemnifying Party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11.5 In the event that the Indemnified
Party assumes the defense of any claim, no compromise or settlement of any such claim shall be made without the prior written consent of the Indemnifying Party, which consent shall not be unreasonably withheld or delayed. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left"><B>12</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INSURANCE </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12.1 Labcorp shall secure and maintain in full force and effect through the performance of the Services the necessary insurance coverage in amounts appropriate
to the conduct of Labcorp&#146;s business. Certificates evidencing such insurance will be made available for examination upon written request by Sponsor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12.2 Sponsor hereby represents and warrants that it maintains or shall maintain adequate clinical trial and product liability insurance coverage consistent
with industry standards and in compliance with all applicable laws, rules and regulations. Certificates evidencing such insurance will be made available for examination upon written request by Labcorp. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left"><B>13</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>HUMAN BIOLOGICAL SAMPLES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13.1 Where the Sponsor supplies HBS to Labcorp, the Sponsor represents and warrants that: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(a) all HBS supplied under this Agreement are or have been procured and supplied to Labcorp ethically in full compliance with any and all applicable national
laws, regulations, or codes of practice relating to the Use of HBS providing protection for human subjects in the country of origin; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(b) the HBS Donor
has given Informed Consent; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(c) all HBS will be supplied to Labcorp without any information or data that identifies the HBS Donor; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) all HBS supplied to Labcorp: (i)&nbsp;may be Used for the Services; (ii)&nbsp;may be used to provide data in support of commercial product development;
and (iii)&nbsp;were procured without inappropriate financial benefit to the HBS Donor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13.2 The Sponsor shall: (a)&nbsp;upon request, provide a copy of
the relevant Informed Consent template; (b)&nbsp;upon request, provide adequate evidence that the HBS provided to Labcorp has completed the necessary submissions, approvals and
</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 of 9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
registrations required to be made to any applicable Regulatory Authority and (c)&nbsp;ensure any HBS shall be <FONT STYLE="white-space:nowrap">de-identified</FONT> or &#145;coded&#146; according
to applicable Regulatory Requirements to protect the identity and confidentiality of the HBS Donor. Full date of birth of the HBS Donor shall only be collected if medically relevant to the Services (unless legally restricted in the country of
operation). In the event of a withdrawal of, or a material variation to the Informed Consent that is likely to affect the Services provided by Labcorp, the Sponsor shall promptly notify all relevant Labcorp entities of such changes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13.3 Upon Sponsor&#146;s request, Labcorp shall retain, return or destroy all HBS in accordance with the Informed Consent, the Sponsor&#146;s instructions or
any other specific requirements under applicable national law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13.4 The Sponsor acknowledges that where Labcorp enters into a material transfer agreement
(&#147;<B>MTA</B>&#148;) with the provider of any HBS, Labcorp shall act in accordance with the terms of the MTA and the disposition of the relevant HBS shall be as prescribed in the MTA. In the event of a conflict between the terms of the MTA, this
Agreement and any instructions provided by the Sponsor with regard to handling HBS, the terms of the MTA shall prevail. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left"><B>14</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>DATA PROTECTION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14.1 Where Labcorp processes any personal data on behalf of the Sponsor, Labcorp shall process such personal data in accordance with all applicable Data
Protection Laws in the territories in which the Services are performed (&#147;<B>Protected Data</B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14.2 If Labcorp processes any Protected Data
of Data Subject(s) who are in the European Union (&#147;<B>EU</B>&#148;) on behalf of the Sponsor, Labcorp and the Sponsor each agree and acknowledge that the Sponsor shall be the data controller and Labcorp shall be the data processor, as defined
by the General Data Protection Regulation (Regulation (EU) 2016/679) (&#147;<B>GDPR</B>&#148;), with respect to the processing of such Protected Data. Labcorp shall only process such Protected Data on behalf and upon the reasonable instructions of
the Sponsor for purposes notified to it by the Sponsor under this Agreement, including the Data Processing Agreement annexed to it as Appendix A. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left"><B>15</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SUBCONTRACTORS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15.1 Notwithstanding Section&nbsp;18, certain tasks, as may be agreed during the development of and specified in the Protocol, may be subcontracted by Labcorp
to Subcontractors approved by Labcorp or subcontracted, or assigned and transferred to its Affiliates. Labcorp shall be responsible for the performance of Subcontractors and Affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15.2 Labcorp shall not be responsible for the performance of third-party Vendors. Liability of Labcorp to the Sponsor with respect to such Vendors shall be
limited to the extent Labcorp is negligent in the performance of its obligations under this Agreement. Labcorp shall provide to the Sponsor any amounts that Labcorp may recover from such Vendors as a result of any error or service failure on the
part of the Vendors in connection with this Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left"><B>16</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>FORCE MAJEURE </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16.1 Neither Party shall be in breach of this Agreement nor liable for delay in performing, or failure to perform, any of its obligations under this Agreement,
if such delay or failure result from a Force Majeure Event. In such circumstances, any
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
time specified for completion of performance in the Protocol falling due during or subsequent to the occurrence of a Force Majeure Event shall be automatically extended for a period of time equal
to such event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16.2 Should any part of the Services be rendered invalid as a result of a Force Majeure Event, Labcorp shall, upon written request from
the Sponsor, and at the Sponsor&#146;s sole cost and expense, repeat the affected part of the Services, or if Labcorp is unable to <FONT STYLE="white-space:nowrap">re-perform,</FONT> Sponsor will not be obligated to pay for the affected Services.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left"><B>17</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>INDEPENDENT CONTRACTOR </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Labcorp and/or its Affiliates shall perform their duties as an independent contractor and shall have complete and exclusive control over its employees and
agents. Labcorp will have no authority to bind or commit the Sponsor in any manner whatsoever and will not, at any time, hold itself out to third parties as having authority to enter into or incur any commitments, expenses, liabilities or
obligations or any nature on behalf of the Sponsor, except pursuant to this Agreement. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left"><B>18</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ASSIGNMENT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">18.1 Labcorp may subcontract any or all of its obligations under this Agreement to its Affiliates as indicated in the Budget. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">18.2 Notwithstanding Section&nbsp;18.1 and except in connection with an internal reorganization of the relevant Party&#146;s corporate structure, this
Agreement shall not be assigned in whole or in part by either Party without the prior written consent of the other, which consent shall not be unreasonably withheld or delayed. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left"><B>19</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>NOTICES </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">19.1 All notices required to be given under this Agreement shall be in writing and shall be deemed to have been duly given if delivered personally or mailed
first class, registered or certified mail, return receipt requested, postage paid: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:20pt; font-size:10pt; font-family:Times New Roman">If to Sponsor to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:20pt; font-size:10pt; font-family:Times New Roman">ProKidney </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20pt; font-size:10pt; font-family:Times New Roman">8020 Arco
Corporate Drive, Ste 118 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20pt; font-size:10pt; font-family:Times New Roman">Raleigh, NC 27617 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20pt; font-size:10pt; font-family:Times New Roman">Attention: Ashley Johns, VP, Clinical Operations </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:20pt; font-size:10pt; font-family:Times New Roman">If to Labcorp to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:20pt; font-size:10pt; font-family:Times New Roman">Labcorp
Central Laboratory Services LP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20pt; font-size:10pt; font-family:Times New Roman">8211 SciCor Drive </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20pt; font-size:10pt; font-family:Times New Roman">Indianapolis, Indiana 46214-2985 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:20pt; font-size:10pt; font-family:Times New Roman">UNITED STATES </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:40pt; font-size:10pt; font-family:Times New Roman">Attention: VP,
Finance </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">or at such other place as either Party shall hereafter furnish to the other Party in writing. Notices shall be deemed given on the date of
personal delivery or deposit in the mail as specified above. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">19.2 For the purposes of this Section&nbsp;19, in relation to the purposes of any legal
proceeding, &#147;<B>writing</B>&#148; shall not include email. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left"><B>20</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>WAIVER </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No waiver of any term, provision, or condition of this Agreement whether by conduct or otherwise in any one or more instances shall be deemed to be or
construed as a further or continuing waiver or estoppel of any such term, provision, or condition or of any other term, provision, or condition of this Agreement.
</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 of 9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left"><B>21</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>VARIATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No provision of this Agreement may be amended, modified, varied, discharged, or terminated except by the express written agreement of both Parties and signed
by an authorized representative of each Party. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left"><B>22</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>SEVERABILITY </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any court or competent authority finds that any provision of this Agreement (or part of any provision) is invalid, illegal or unenforceable, that provision
or part-provision shall, to the extent required, be deemed to be deleted, and the validity and enforceability of the other provisions of this Agreement shall not be affected. If any invalid, unenforceable or illegal provision of this Agreement would
be valid, enforceable and legal if some part of it were deleted, the provision shall apply with the minimum modification necessary to make it legal, valid and enforceable. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left"><B>23</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>PUBLICITY AND PUBLICATION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">23.1 Neither Party will use the name, trademark or the name of any representative of the other, or the existence of this Agreement for any promotional or
advertising purposes, or any other publication, without the prior written consent of the other. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">23.2 Neither Party will state or imply that the other
Party endorses or approves any service, material, product or compound of the other Party without the prior written consent of the other. Such restrictions shall not apply to internal communications and publications to a Party&#146;s Affiliates. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">23.3 Sponsor shall provide Labcorp with a <FONT STYLE="white-space:nowrap">pre-publication</FONT> copy of any report, manuscript, publication or form of
marketing material recognizing Labcorp&#146;s participation in the Services or otherwise identifying Labcorp, for approval (which approval shall not be unreasonably withheld or delayed) in each case at least thirty (30)&nbsp;days before its
submission for publication. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left"><B>24</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ENTIRE AGREEMENT </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Agreement represents the entire understanding between the Parties with respect to the subject matter hereof as of the Effective Date, and this Agreement
supersedes all prior agreements, negotiations, understandings, representations, statements and writings between the Parties relating thereto, except that any written agreement entered into prior to the Effective Date with respect to a Study in
process prior to the Effective Date shall remain effective and shall continue to govern such existing Study. The Parties agree that neither has relied upon prior representations made before executing this Agreement. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left"><B>25</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>LEGAL TESTIMONY </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If Labcorp is obliged to provide testimony or records regarding the Services for the Sponsor in any legal or administrative proceeding, then the Sponsor shall
reimburse Labcorp for its out of pocket costs plus a reasonable hourly fee for the involvement of its employees or representatives in such proceedings. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left"><B>26</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>THIRD PARTY RIGHTS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as expressly set forth in this Agreement in respect of Labcorp Affiliates, nothing in this Agreement is intended to confer any rights, benefits or
remedies of any kind whatsoever, and a person who is not a party to this Agreement shall have no right to enforce any of its terms.
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:visible;padding-top:3pt">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left"><B>27</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>ANTI-BRIBERY </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">27.1 Both Parties agree that each has not and will not, either directly or indirectly, engage in bribery, or offer, or promise, or authorize to pay or make any
improper payment of any monies or financial or other advantage, including cash, loan, gift, travel, entertainment, hospitality, facilitation payment, kickback, political or philanthropic contribution, anything of value, or any other perceived
benefit to improperly obtain or retain a business advantage in violation of any Anti-Corruption Laws and further, each Party agrees that they shall not take any action that would cause the other Party to be in violation of such Anti-Corruption
Laws.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">27.2 Any breach of Section&nbsp;27.1 by a Party shall allow the other Party to immediately terminate this Agreement. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left"><B>28</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>TRADE CONTROL </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">28.1 Notwithstanding any other provision of this Agreement to the contrary, each Party shall comply with, and retain responsibility for its compliance with,
all applicable export control laws (e.g., the U.S. Export Administration Regulations) and economic sanctions programs (e.g., economic sanctions maintained by the U.S. Treasury Department, as well as Specially Designated Nationals and Blocked Persons
(&#147;<B>SDNs</B>&#148;)) relating to its respective business, facilities, and the provision of services to third parties (collectively, &#147;<B>Trade Control Laws</B>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">28.2 It shall be in the sole discretion of Labcorp to refrain from being directly or indirectly involved in the provision of goods, software, services and/or
technical data that may be prohibited by applicable Trade Control Laws, including sanctions currently in place against Cuba, Iran, North Korea, Sudan, Syria and SDNs. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left"><B>29</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>COUNTERPARTS </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Agreement may be executed in any number of counterparts, each of which when executed and delivered shall constitute an original to this Agreement but all
of which together shall constitute the same Agreement. Signatures upon this Agreement transmitted by facsimile, electronic mail or other electronic method shall have the same legal and biding effect as wet signatures. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="27" VALIGN="top" ALIGN="left"><B>30</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>CHOICE OF LAW AND JURISDICTION </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">30.1 This Agreement will be governed by the laws of Delaware excluding its conflict of law provisions. The application of the United Nations Convention on
Contracts for the International Sale of Goods is expressly excluded from this Agreement. The Parties irrevocably agree that any dispute or claim arising out of or in connection with this Agreement or its subject matter or formation (including <FONT
STYLE="white-space:nowrap">non-contractual</FONT> disputes or claims) shall be governed by the exclusive jurisdiction of the courts of the state of Delaware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">30.2 The Parties agree that any dispute arising from or in connection with this Agreement (including any
<FONT STYLE="white-space:nowrap">non-contractual</FONT> obligations) shall be referred to and finally resolved by arbitration under the Rules of the New York which Rules shall be deemed incorporated by reference to the Agreement. The number of
arbitrators shall be three (3), the seat or legal place of arbitration shall be New York and the language used in the arbitration shall be English.
</P></div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 of 9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Parties by their duly authorized officers have executed this Agreement on the dates
set forth below, to be effective on the Effective Date set forth on the first page of this Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>PROKIDNEY</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>LABCORP CENTRAL LABORATORY SERVICES LP</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>Signature: /s/ Pablo Legorreta</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Signature: /s/ Kristine Needle</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>Name: Pablo Legorreta</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Name: Kristine Needle</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>Date: September&nbsp;15, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Date: September&nbsp;16, 2021</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>LABCORP CENTRAL LABORATORY SERVICES S&Agrave;RL</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Signature: /s/ Kristine Needle</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Name: Kristine Needle</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Date: September&nbsp;16, 2021</B></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 of 9 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>13
<FILENAME>d373959dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM&#146;S CONSENT </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the inclusion in this Registration Statement of ProKidney Corp. (f/k/a Social Capital Suvretta Holdings Corp. III) on Form <FONT
STYLE="white-space:nowrap">S-1</FONT> of our report dated March&nbsp;23, 2022, which includes an explanatory paragraph as to the Company&#146;s ability to continue as a going concern, with respect to our audits of the financial statements of
ProKidney Corp. (f/k/a Social Capital Suvretta Holdings Corp. III) as of December&nbsp;31, 2021 and for the period from February&nbsp;25, 2021 (inception) through December&nbsp;31, 2021, which report appears in the Prospectus, which is part of this
Registration Statement. We were dismissed as auditors on July&nbsp;15, 2022 and, accordingly, we have not performed any audit or review procedures with respect to any financial statements appearing in such Prospectus for the periods after the date
of our dismissal. We also consent to the reference to our Firm under the heading &#147;Experts&#148; in such Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Marcum <SMALL>LLP</SMALL>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marcum <SMALL>LLP</SMALL> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">August&nbsp;8, 2022 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>14
<FILENAME>d373959dex232.htm
<DESCRIPTION>EX-23.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#147;Experts&#148; and to the use of our report dated April&nbsp;11, 2022, with respect to the
consolidated financial statements of ProKidney LP included in the Registration Statement (Form <FONT STYLE="white-space:nowrap">S-1)</FONT> and related Prospectus of ProKidney Corp. for the registration of up to 232,530,000 shares of its
Class&nbsp;A ordinary shares. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Ernst&nbsp;&amp; Young LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Raleigh, North Carolina</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">August&nbsp;8, 2022</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>15
<FILENAME>d373959dexfilingfees.htm
<DESCRIPTION>EX-FILING FEES
<TEXT>
<HTML><HEAD>
<TITLE>EX-FILING FEES</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 107 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Calculation of Filing Fee Table </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Form Type) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>ProKidney Corp.
</U></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Exact Name of Registrant as Specified in its Charter) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Table 1: Newly Registered Securities </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; padding-left:8pt"><B>Title of Each Class&nbsp;of Security to be Registered</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Amount to be</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Registered(1)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Proposed&nbsp;Maximum</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Offering Price</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>per
Security</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Proposed Maximum</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Aggregate</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Offering
Price</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; padding-right:2pt"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Amount of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:Times New Roman" ALIGN="center"><B>Registration Fee</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="1" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="1" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">Class&nbsp;A ordinary shares, par value $0.0001 per share</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">232,530,000(2)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">$8.68(3)</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-BOTTOM:1px solid #000000">$2,018,360,400.00</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="padding-bottom:1pt ;BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">$187,102.01</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to Rule&nbsp;416 under the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), the
registrant is also registering an indeterminate number of additional Class&nbsp;A common ordinary shares that may become issuable as a result of any stock dividend, stock split, recapitalization or other similar transaction. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Consists of (i) 50,000 Class&nbsp;A ordinary shares, par value $0.0001 per share, of the Registrant,
collectively held by certain holders of the Registrant&#146;s securities (the &#147;Holders&#148;) party to that certain Amended and Restated Registration Rights Agreement, dated as of July&nbsp;11, 2022, by and among the Registrant, SCS Sponsor III
LLC, and the Holders (the &#147;Amended and Restated Registration Rights Agreement&#148;), their permitted transferees and certain Additional Holders (as defined in the Amended and Restated Registration Rights Agreement); (ii) 180,000,000
Class&nbsp;A ordinary shares issued or issuable pursuant to that certain Exchange Agreement, dated as of July&nbsp;11, 2022, by and among the Registrant, ProKidney LP, and certain holders of the Company&#146;s securities party thereto; and (iii)
52,480,000 Class&nbsp;A ordinary shares purchased by certain investors at a purchase price of $10.00 per share, pursuant to subscription agreements with the Registrant. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Pursuant to Rule&nbsp;457(c) under the Securities Act, and solely for the purpose of calculating the
registration fee, the proposed maximum offering price per share is $8.68, which is the average of the high and low prices of the Class&nbsp;A ordinary shares on August&nbsp;3, 2022 on the Nasdaq Capital Market. </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>16
<FILENAME>prok-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 09-August-2022 [04:09:18] {AM}-->
<schema targetNamespace="http://www.businesswire.com/20220331" elementFormDefault="qualified" xmlns:prok="http://www.businesswire.com/20220331" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
<annotation>
<appinfo>
<link:roleType roleURI="http://www.businesswire.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/CondensedBalanceSheet" id="CondensedBalanceSheet">
<link:definition>1002 - Statement - Condensed Balance Sheet</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/CondensedBalanceSheetParenthetical" id="CondensedBalanceSheetParenthetical">
<link:definition>1003 - Statement - Condensed Balance Sheet (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/CondensedStatementsOfOperations" id="CondensedStatementsOfOperations">
<link:definition>1004 - Statement - Condensed Statements of Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit" id="CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit">
<link:definition>1005 - Statement - Condensed Statements of Changes In Temporary Equity And Permanent Deficit</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficitParenthetical" id="CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficitParenthetical">
<link:definition>1006 - Statement - Condensed Statements of Changes In Temporary Equity And Permanent Deficit (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/CondensedStatementOfCashFlows" id="CondensedStatementOfCashFlows">
<link:definition>1007 - Statement - Condensed Statement of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcern" id="DescriptionOfOrganizationBusinessOperationsAndGoingConcern">
<link:definition>1008 - Disclosure - Description Of Organization, Business Operations And Going Concern</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
<link:definition>1009 - Disclosure - Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/InitialPublicOffering" id="InitialPublicOffering">
<link:definition>1010 - Disclosure - Initial Public Offering</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1011 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/PrivatePlacement" id="PrivatePlacement">
<link:definition>1012 - Disclosure - Private Placement</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/Leases" id="Leases">
<link:definition>1013 - Disclosure - Leases</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>1014 - Disclosure - Related Party Transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1015 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/MembersEquity" id="MembersEquity">
<link:definition>1016 - Disclosure - Members' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficit" id="TemporaryEquityAndPermanentDeficit">
<link:definition>1017 - Disclosure - Temporary Equity and Permanent Deficit</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/NetLossPerShare" id="NetLossPerShare">
<link:definition>1018 - Disclosure - Net Loss per Share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/FairValueMeasurements" id="FairValueMeasurements">
<link:definition>1019 - Disclosure - Fair Value Measurements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/EquityBasedCompensation" id="EquityBasedCompensation">
<link:definition>1020 - Disclosure - Equity Based Compensation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>1021 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
<link:definition>1022 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesTables" id="SignificantAccountingPoliciesTables">
<link:definition>1023 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>1024 - Disclosure - Income Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/LeasesTables" id="LeasesTables">
<link:definition>1025 - Disclosure - Leases (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/MembersEquityTables" id="MembersEquityTables">
<link:definition>1026 - Disclosure - Members' Equity (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/NetLossPerShareTables" id="NetLossPerShareTables">
<link:definition>1027 - Disclosure - Net Loss per Share (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
<link:definition>1028 - Disclosure - Fair Value Measurements (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/EquityBasedCompensationTables" id="EquityBasedCompensationTables">
<link:definition>1029 - Disclosure - Equity Based Compensation (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail" id="DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail">
<link:definition>1030 - Disclosure - Description Of Organization, Business Operations And Going Concern - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/TheCompanyAdditionalInformationDetail" id="TheCompanyAdditionalInformationDetail">
<link:definition>1031 - Disclosure - The Company - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" id="SignificantAccountingPoliciesAdditionalInformationDetail">
<link:definition>1032 - Disclosure - Significant Accounting Policies - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfClassAOrdinarySharesReflectedInTheBalanceSheetsDetail" id="SignificantAccountingPoliciesScheduleOfClassAOrdinarySharesReflectedInTheBalanceSheetsDetail">
<link:definition>1033 - Disclosure - Significant Accounting Policies - Schedule of Class A Ordinary Shares Reflected in the Balance Sheets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail" id="SignificantAccountingPoliciesScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail">
<link:definition>1034 - Disclosure - Significant Accounting Policies - Schedule of Calculation of Basic and Diluted Net Income (Loss) per Ordinary Share (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfAccruedExpensesDetail" id="SignificantAccountingPoliciesScheduleOfAccruedExpensesDetail">
<link:definition>1035 - Disclosure - Significant Accounting Policies - Schedule of Accrued Expenses (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail" id="SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail">
<link:definition>1036 - Disclosure - Significant Accounting Policies - Schedule of Estimated Useful Lives (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfFixedAssetsDetail" id="SignificantAccountingPoliciesScheduleOfFixedAssetsDetail">
<link:definition>1037 - Disclosure - Significant Accounting Policies - Schedule of Fixed Assets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfFixedAssetsParentheticalDetail" id="SignificantAccountingPoliciesScheduleOfFixedAssetsParentheticalDetail">
<link:definition>1038 - Disclosure - Significant Accounting Policies - Schedule of Fixed Assets (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetDetail" id="SignificantAccountingPoliciesScheduleOfIntangibleAssetDetail">
<link:definition>1039 - Disclosure - Significant Accounting Policies - Schedule of Intangible Asset (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetParentheticalDetail" id="SignificantAccountingPoliciesScheduleOfIntangibleAssetParentheticalDetail">
<link:definition>1040 - Disclosure - Significant Accounting Policies - Schedule of Intangible Asset (Parenthetical) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/InitialPublicOfferingAdditionalInformationDetail" id="InitialPublicOfferingAdditionalInformationDetail">
<link:definition>1041 - Disclosure - Initial Public Offering - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail" id="IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail">
<link:definition>1042 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail" id="IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail">
<link:definition>1043 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" id="IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail">
<link:definition>1044 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetail" id="IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetail">
<link:definition>1045 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward  (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/IncomeTaxesAdditionalInformationDetail" id="IncomeTaxesAdditionalInformationDetail">
<link:definition>1046 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/PrivatePlacementAdditionalInformationDetail" id="PrivatePlacementAdditionalInformationDetail">
<link:definition>1047 - Disclosure - Private Placement - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/LeasesScheduleOfTheClassificationOfOperatingAndFinanceLeaseAssetsAndObligationsInTheCompanySConsolidatedBalanceSheetsDetail" id="LeasesScheduleOfTheClassificationOfOperatingAndFinanceLeaseAssetsAndObligationsInTheCompanySConsolidatedBalanceSheetsDetail">
<link:definition>1048 - Disclosure - Leases - Schedule of the Classification of Operating and Finance Lease Assets and Obligations in the Company's Consolidated Balance Sheets (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail" id="LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail">
<link:definition>1049 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities for the Company's Operating and Finance Leases (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/LeasesAdditionalInformationDetail" id="LeasesAdditionalInformationDetail">
<link:definition>1050 - Disclosure - Leases - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail" id="RelatedPartyTransactionsAdditionalInformationDetail">
<link:definition>1051 - Disclosure - Related Party Transactions - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/RelatedPartyDebtAdditionalInformationDetail" id="RelatedPartyDebtAdditionalInformationDetail">
<link:definition>1052 - Disclosure - Related Party Debt - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" id="CommitmentsAndContingenciesAdditionalInformationDetail">
<link:definition>1053 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/MembersEquityScheduleOfMembersEquityDetail" id="MembersEquityScheduleOfMembersEquityDetail">
<link:definition>1054 - Disclosure - Members' Equity -Schedule Of  Members Equity (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/MembersEquityAdditionalInformationDetail" id="MembersEquityAdditionalInformationDetail">
<link:definition>1055 - Disclosure - Members' Equity - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficitAdditionalInformationDetail" id="TemporaryEquityAndPermanentDeficitAdditionalInformationDetail">
<link:definition>1056 - Disclosure - Temporary Equity and Permanent Deficit - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/NetLossPerShareScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail" id="NetLossPerShareScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail">
<link:definition>1057 - Disclosure - Net Loss per Share - Schedule of calculation of basic and diluted net income (loss) per ordinary share (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/FairValueMeasurementsSummaryOfAssetsThatAreMeasuredAtFairValueOnARecurringBasisDetail" id="FairValueMeasurementsSummaryOfAssetsThatAreMeasuredAtFairValueOnARecurringBasisDetail">
<link:definition>1058 - Disclosure - Fair Value Measurements - Summary of Assets that are Measured at Fair Value on a Recurring Basis (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/EquityBasedCompensationSummaryOfTheActivityRelatedToCompanySClassBAndB1UnitsGrantedDetail" id="EquityBasedCompensationSummaryOfTheActivityRelatedToCompanySClassBAndB1UnitsGrantedDetail">
<link:definition>1059 - Disclosure - Equity Based Compensation - Summary of the Activity Related to Company's Class B and B-1 Units Granted (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail" id="EquityBasedCompensationAdditionalInformationDetail">
<link:definition>1060 - Disclosure - Equity Based Compensation - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/EquityBasedCompensationSummaryOfKeyAssumptionsUsedInTheOpmValuationDetail" id="EquityBasedCompensationSummaryOfKeyAssumptionsUsedInTheOpmValuationDetail">
<link:definition>1061 - Disclosure - Equity Based Compensation - Summary of Key Assumptions Used in the OPM Valuation (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/EquityBasedCompensationSummaryOfCompensationExpenseDetail" id="EquityBasedCompensationSummaryOfCompensationExpenseDetail">
<link:definition>1062 - Disclosure - Equity Based Compensation - Summary of Compensation Expense (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail" id="SubsequentEventsAdditionalInformationDetail">
<link:definition>1063 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetailAlternate1" id="LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetailAlternate1">
<link:definition>1064 - Statement - Leases - Schedule of Maturities of Lease Liabilities for the Company's Operating and Finance Leases (Detail) Alternate 1</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="prok-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="prok-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="prok-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="prok-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
<import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2022" schemaLocation="https://xbrl.sec.gov/currency/2022/currency-2022.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2022" schemaLocation="https://xbrl.sec.gov/exch/2022/exch-2022.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2022" schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
<import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
<import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
<import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<element name="DeferredOfferingCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_DeferredOfferingCost" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PrepaidInsuranceNonCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_PrepaidInsuranceNonCurrent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PrepaidClinicalCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_PrepaidClinicalCurrent" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RightOfUseAssetsOperatingAndFinanceLease" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_RightOfUseAssetsOperatingAndFinanceLease" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AccruedExpensesAndOther" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_AccruedExpensesAndOther" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedExpensesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_AccruedExpensesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="CurrentAccountsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_CurrentAccountsPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OperatingAndFinanceLeaseLiabilitiesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_OperatingAndFinanceLeaseLiabilitiesCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredUnderwritingCommissions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_DeferredUnderwritingCommissions" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SocialCapitalSuvrettaHoldingsCorp.IiiMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" substitutionGroup="xbrli:item" />
<element name="RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PartnersCapitalOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_PartnersCapitalOutstanding" substitutionGroup="xbrli:item" />
<element name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" substitutionGroup="xbrli:item" />
<element name="TemporaryEquityStockIssuedDuringThePeriodShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_TemporaryEquityStockIssuedDuringThePeriodShares" substitutionGroup="xbrli:item" />
<element name="RepaymentOfAdvancesFromRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_RepaymentOfAdvancesFromRelatedParty" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RepaymentOfPromissoryNoteRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_RepaymentOfPromissoryNoteRelatedParty" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RemeasurementOfClassAOrdinarySharesToRedemptionValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_RemeasurementOfClassAOrdinarySharesToRedemptionValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="DeferredUnderwritingFeesAccruedButNotPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_DeferredUnderwritingFeesAccruedButNotPaid" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OfferingCostsIncludedInAccruedOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_OfferingCostsIncludedInAccruedOfferingCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RightOfUseAssetsObtainedInExchangeForLeaseObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_RightOfUseAssetsObtainedInExchangeForLeaseObligations" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="FormationCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_FormationCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseDecreaseOfAdvanceFromRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_IncreaseDecreaseOfAdvanceFromRelatedParty" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="InitialPublicOfferingDisclosureTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_InitialPublicOfferingDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="PrivatePlacementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_PrivatePlacementAbstract" substitutionGroup="xbrli:item" />
<element name="PrivatePlacementDisclosureTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_PrivatePlacementDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="DeferredOfferingCostsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_DeferredOfferingCostsPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="EmergingGrowthCompanyStatusPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_EmergingGrowthCompanyStatusPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="TemporaryEquityPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_TemporaryEquityPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="AccruedExpensesPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_AccruedExpensesPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="GoingConcernPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_GoingConcernPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ContingentLiabilitiesPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_ContingentLiabilitiesPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="DisclosureInTabularFormOfUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_DisclosureInTabularFormOfUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" substitutionGroup="xbrli:item" />
<element name="LesseeOperatingAndFinanceLeaseTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_LesseeOperatingAndFinanceLeaseTableTextBlock" substitutionGroup="xbrli:item" />
<element name="MembersEquityTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_MembersEquityTableTextBlock" substitutionGroup="xbrli:item" />
<element name="DescriptionOfOrganizationAndBusinessOperationsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_DescriptionOfOrganizationAndBusinessOperationsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="DescriptionOfOrganizationAndBusinessOperationsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_DescriptionOfOrganizationAndBusinessOperationsLineItems" substitutionGroup="xbrli:item" />
<element name="ProspectiveAssetsOfAcquireeAsAPercentageOfFairValueOfAssetsInTheTrustAccount" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_ProspectiveAssetsOfAcquireeAsAPercentageOfFairValueOfAssetsInTheTrustAccount" substitutionGroup="xbrli:item" />
<element name="UnderwritingFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_UnderwritingFee" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredUnderwritingFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_DeferredUnderwritingFees" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfPublicSharesThatCanBeTransferredWithoutAnyRestriction" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_PercentageOfPublicSharesThatCanBeTransferredWithoutAnyRestriction" substitutionGroup="xbrli:item" />
<element name="PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated" substitutionGroup="xbrli:item" />
<element name="PerShareValueOfRestrictedAssets" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_PerShareValueOfRestrictedAssets" substitutionGroup="xbrli:item" />
<element name="TransactionCostsIncurredInConnectionWithInitialPublicOffering" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_TransactionCostsIncurredInConnectionWithInitialPublicOffering" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfPublicSharesRedemption" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_PercentageOfPublicSharesRedemption" substitutionGroup="xbrli:item" />
<element name="WorkingCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_WorkingCapital" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ProkidneyLpMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_ProkidneyLpMember" substitutionGroup="xbrli:item" />
<element name="RestrictedStockRightsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_RestrictedStockRightsMember" substitutionGroup="xbrli:item" />
<element name="PipeInvestorsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_PipeInvestorsMember" substitutionGroup="xbrli:item" />
<element name="ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMember" substitutionGroup="xbrli:item" />
<element name="ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember" substitutionGroup="xbrli:item" />
<element name="SharePriceRangeAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_SharePriceRangeAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="SharePriceRangeDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_SharePriceRangeDomain" substitutionGroup="xbrli:item" />
<element name="SharePriceOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_SharePriceOneMember" substitutionGroup="xbrli:item" />
<element name="SharePriceThreeMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_SharePriceThreeMember" substitutionGroup="xbrli:item" />
<element name="SharePriceTwoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_SharePriceTwoMember" substitutionGroup="xbrli:item" />
<element name="NatureOfOperationsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_NatureOfOperationsTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="RegenAndTwinCityBioLlcMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_RegenAndTwinCityBioLlcMember" substitutionGroup="xbrli:item" />
<element name="NatureOfOperationsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_NatureOfOperationsLineItems" substitutionGroup="xbrli:item" />
<element name="InitialCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_InitialCapital" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_AccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="AccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_AccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
<element name="AccruedPrintingExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_AccruedPrintingExpense" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedDueDiligenceExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_AccruedDueDiligenceExpense" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedRegulatoryFilingFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_AccruedRegulatoryFilingFee" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedLegalExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_AccruedLegalExpense" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BusinessCombinationAccruedLegalExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_BusinessCombinationAccruedLegalExpense" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedAccountingExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_AccruedAccountingExpense" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BusinessCombinationAccruedConsultingExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_BusinessCombinationAccruedConsultingExpense" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PeriodForWhichTheProfitsEarnedAreExemptFromTax" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_PeriodForWhichTheProfitsEarnedAreExemptFromTax" substitutionGroup="xbrli:item" />
<element name="DefinedContributionPlanCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_DefinedContributionPlanCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DefinedContributionPlanPercent" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_DefinedContributionPlanPercent" substitutionGroup="xbrli:item" />
<element name="BusinessCombinationAccruedOtherTransactionalRelatedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_BusinessCombinationAccruedOtherTransactionalRelatedExpenses" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="UnsufficientToFundItsObligationsTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_UnsufficientToFundItsObligationsTerm" substitutionGroup="xbrli:item" />
<element name="AcquiredAssemblyWorkforceMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_AcquiredAssemblyWorkforceMember" substitutionGroup="xbrli:item" />
<element name="PromissoryNoteMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_PromissoryNoteMember" substitutionGroup="xbrli:item" />
<element name="TemporaryEquityIssaunceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_TemporaryEquityIssaunceCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IncreaseOfOrdinarySharesToRedemptionValueTemporaryEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_IncreaseOfOrdinarySharesToRedemptionValueTemporaryEquity" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="RemeasurementOfCarryingValueToRedemptionValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_RemeasurementOfCarryingValueToRedemptionValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="EarningsPerShareBasicAndDilutedTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_EarningsPerShareBasicAndDilutedTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="EarningsPerShareBasicAndDilutedLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_EarningsPerShareBasicAndDilutedLineItems" substitutionGroup="xbrli:item" />
<element name="BasicAndDilutedEarningsPerShareOtherDisclosuresAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_BasicAndDilutedEarningsPerShareOtherDisclosuresAbstract" substitutionGroup="xbrli:item" />
<element name="AccruedClinicalStudyRelatedCostsCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_AccruedClinicalStudyRelatedCostsCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedFacilityExpansionCostsCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_AccruedFacilityExpansionCostsCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OtherAccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_OtherAccruedExpenses" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedManufacturingImprovementCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_AccruedManufacturingImprovementCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="EffectiveIncomeTaxRateReconciliationLlcFlowThroughStructure" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_EffectiveIncomeTaxRateReconciliationLlcFlowThroughStructure" substitutionGroup="xbrli:item" />
<element name="DeferredTaxAssetsFederalCreditCarryForwards" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_DeferredTaxAssetsFederalCreditCarryForwards" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxAssetsLeases" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_DeferredTaxAssetsLeases" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="DeferredTaxAssetsStartUpCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_DeferredTaxAssetsStartUpCosts" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="UnrecognizedTaxBenefitsGrossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_UnrecognizedTaxBenefitsGrossAbstract" substitutionGroup="xbrli:item" />
<element name="IncomeTaxDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_IncomeTaxDisclosureTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="IncomeTaxActAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_IncomeTaxActAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="IncomeTaxActDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_IncomeTaxActDomain" substitutionGroup="xbrli:item" />
<element name="IncomeTaxDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_IncomeTaxDisclosureLineItems" substitutionGroup="xbrli:item" />
<element name="DeferredExpenseCapitalizedResearchAndDevelopmentCostsTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_DeferredExpenseCapitalizedResearchAndDevelopmentCostsTerm" substitutionGroup="xbrli:item" />
<element name="LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueAfterYearFive" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueAfterYearFive" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LesseeOperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OperatingAndFinanceLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_OperatingAndFinanceLeaseLiability" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="OperatingAndFinanceLeaseWeightedAverageDiscountRatePercent" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_OperatingAndFinanceLeaseWeightedAverageDiscountRatePercent" substitutionGroup="xbrli:item" />
<element name="OperatingLeaseRentExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_OperatingLeaseRentExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered" substitutionGroup="xbrli:item" />
<element name="SharesNoLongerSubjectToForfeiture" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_SharesNoLongerSubjectToForfeiture" substitutionGroup="xbrli:item" />
<element name="NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" substitutionGroup="xbrli:item" />
<element name="AdvancesPayableToRelatedPartyCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_AdvancesPayableToRelatedPartyCurrent" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="NumberOfTradingDaysForDeterminingTheSharePrice" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_NumberOfTradingDaysForDeterminingTheSharePrice" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BasisAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_BasisAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="BasisDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_BasisDomain" substitutionGroup="xbrli:item" />
<element name="RestrictionOnTransferOfSponsorSharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_RestrictionOnTransferOfSponsorSharesMember" substitutionGroup="xbrli:item" />
<element name="SponsorMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_SponsorMember" substitutionGroup="xbrli:item" />
<element name="FounderMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_FounderMember" substitutionGroup="xbrli:item" />
<element name="AverillMasterFundLtdMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_AverillMasterFundLtdMember" substitutionGroup="xbrli:item" />
<element name="ScMasterHoldingsLlcMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_ScMasterHoldingsLlcMember" substitutionGroup="xbrli:item" />
<element name="WorkingCapitalLoansMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_WorkingCapitalLoansMember" substitutionGroup="xbrli:item" />
<element name="AdministrationAndSupportServicesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_AdministrationAndSupportServicesMember" substitutionGroup="xbrli:item" />
<element name="AdvanceFromRelatedPartyLoanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_AdvanceFromRelatedPartyLoanMember" substitutionGroup="xbrli:item" />
<element name="FounderSharesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_FounderSharesMember" substitutionGroup="xbrli:item" />
<element name="AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_AgreementAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="AgreementDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_AgreementDomain" substitutionGroup="xbrli:item" />
<element name="SubscriptionAgreementsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_SubscriptionAgreementsMember" substitutionGroup="xbrli:item" />
<element name="IndependentDirectorsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_IndependentDirectorsMember" substitutionGroup="xbrli:item" />
<element name="DirectorRestrictedStockUnitAwardAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_DirectorRestrictedStockUnitAwardAgreementMember" substitutionGroup="xbrli:item" />
<element name="NumberOfSharesOfCommonStockCommittedToSettleOnADateFollowingTheYearBusinessCombinationOccurs" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_NumberOfSharesOfCommonStockCommittedToSettleOnADateFollowingTheYearBusinessCombinationOccurs" substitutionGroup="xbrli:item" />
<element name="MembersEquityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_MembersEquityTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="MembersEquityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_MembersEquityLineItems" substitutionGroup="xbrli:item" />
<element name="ProceedsFromLimitedPartnersCapitalAccountUnits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="prok_ProceedsFromLimitedPartnersCapitalAccountUnits" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CapitalUnitClassB1Member" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_CapitalUnitClassB1Member" substitutionGroup="xbrli:item" />
<element name="PercentOfFoundersSharesToCompanysIssuedAndOutstandingOrdinaryShares" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_PercentOfFoundersSharesToCompanysIssuedAndOutstandingOrdinaryShares" substitutionGroup="xbrli:item" />
<element name="BasicAndDilutedNetIncomeLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_BasicAndDilutedNetIncomeLossPerShareAbstract" substitutionGroup="xbrli:item" />
<element name="MarketableSecuritiesHeldToMaturityFairValueDisclosure" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_MarketableSecuritiesHeldToMaturityFairValueDisclosure" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ClassB1unitsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_ClassB1unitsMember" substitutionGroup="xbrli:item" />
<element name="CommonUnitsUnissued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_CommonUnitsUnissued" substitutionGroup="xbrli:item" />
<element name="NumberOfCommonUnitsUnissuedOfLimitedLiabilityCompany" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="prok_NumberOfCommonUnitsUnissuedOfLimitedLiabilityCompany" substitutionGroup="xbrli:item" />
<element name="OnTheLatterOfTheFirstAnniversaryMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_OnTheLatterOfTheFirstAnniversaryMember" substitutionGroup="xbrli:item" />
<element name="EachCalendarQuarterMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_EachCalendarQuarterMember" substitutionGroup="xbrli:item" />
<element name="InFirstAnniversaryOfTheAcquisitionDateMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_InFirstAnniversaryOfTheAcquisitionDateMember" substitutionGroup="xbrli:item" />
<element name="OnEachEnniversaryMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_OnEachEnniversaryMember" substitutionGroup="xbrli:item" />
<element name="OverTheThreeYearPeriodFromTheDateOfGrantMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_OverTheThreeYearPeriodFromTheDateOfGrantMember" substitutionGroup="xbrli:item" />
<element name="ValuationTechniqueProbabilityWeightedExpectedReturnMethodMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_ValuationTechniqueProbabilityWeightedExpectedReturnMethodMember" substitutionGroup="xbrli:item" />
<element name="EarnoutSharesTrancheAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_EarnoutSharesTrancheAxis" substitutionGroup="xbrldt:dimensionItem" />
<element name="EarnoutSharesTrancheDomain" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_EarnoutSharesTrancheDomain" substitutionGroup="xbrli:item" />
<element name="CapitalUnitClassBOneMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="prok_CapitalUnitClassBOneMember" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>17
<FILENAME>prok-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 09-August-2022 [04:09:18] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#CondensedBalanceSheet" roleURI="http://www.businesswire.com/role/CondensedBalanceSheet" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#CondensedStatementsOfOperations" roleURI="http://www.businesswire.com/role/CondensedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#CondensedStatementOfCashFlows" roleURI="http://www.businesswire.com/role/CondensedStatementOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#SignificantAccountingPoliciesScheduleOfAccruedExpensesDetail" roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfAccruedExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#SignificantAccountingPoliciesScheduleOfFixedAssetsDetail" roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfFixedAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#SignificantAccountingPoliciesScheduleOfIntangibleAssetDetail" roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail" roleURI="http://www.businesswire.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" roleURI="http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail" roleURI="http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetailAlternate1" roleURI="http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetailAlternate1" />
<calculationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" use="optional" order="2" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" use="optional" order="12" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail">
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OperatingAndFinanceLeaseLiability" xlink:label="loc_PROK_OperatingAndFinanceLeaseLiability" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue" xlink:label="loc_PROK_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PROK_OperatingAndFinanceLeaseLiability" xlink:to="loc_PROK_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_PROK_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PROK_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue" xlink:to="loc_PROK_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_PROK_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PROK_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue" xlink:to="loc_PROK_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_PROK_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PROK_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue" xlink:to="loc_PROK_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_PROK_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PROK_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue" xlink:to="loc_PROK_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_PROK_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PROK_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue" xlink:to="loc_PROK_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_PROK_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueAfterYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PROK_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue" xlink:to="loc_PROK_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueAfterYearFive" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_PROK_LesseeOperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_PROK_OperatingAndFinanceLeaseLiability" xlink:to="loc_PROK_LesseeOperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount" use="optional" order="20" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetailAlternate1">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_OperatingLeaseLiability" use="optional" order="22" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetailAlternate1">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_FinanceLeaseLiability" use="optional" order="24" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" use="optional" order="6" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredTaxAssetsNet" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsGross" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredTaxAssetsFederalCreditCarryForwards" xlink:label="loc_PROK_DeferredTaxAssetsFederalCreditCarryForwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_PROK_DeferredTaxAssetsFederalCreditCarryForwards" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredTaxAssetsLeases" xlink:label="loc_PROK_DeferredTaxAssetsLeases" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_PROK_DeferredTaxAssetsLeases" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredTaxAssetsStartUpCosts" xlink:label="loc_PROK_DeferredTaxAssetsStartUpCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_PROK_DeferredTaxAssetsStartUpCosts" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities" use="optional" order="9" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" use="optional" order="12" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfFixedAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="2" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfAccruedExpensesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedClinicalStudyRelatedCostsCurrent" xlink:label="loc_PROK_AccruedClinicalStudyRelatedCostsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_PROK_AccruedClinicalStudyRelatedCostsCurrent" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedFacilityExpansionCostsCurrent" xlink:label="loc_PROK_AccruedFacilityExpansionCostsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_PROK_AccruedFacilityExpansionCostsCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedManufacturingImprovementCosts" xlink:label="loc_PROK_AccruedManufacturingImprovementCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_PROK_AccruedManufacturingImprovementCosts" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OtherAccruedExpenses" xlink:label="loc_PROK_OtherAccruedExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_PROK_OtherAccruedExpenses" use="optional" order="7" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/CondensedBalanceSheet">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_Cash" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PrepaidClinicalCurrent" xlink:label="loc_PROK_PrepaidClinicalCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_PROK_PrepaidClinicalCurrent" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_OtherAssetsCurrent" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredOfferingCost" xlink:label="loc_PROK_DeferredOfferingCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_PROK_DeferredOfferingCost" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PrepaidInsuranceNonCurrent" xlink:label="loc_PROK_PrepaidInsuranceNonCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_PROK_PrepaidInsuranceNonCurrent" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsHeldInTrustNoncurrent" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RightOfUseAssetsOperatingAndFinanceLease" xlink:label="loc_PROK_RightOfUseAssetsOperatingAndFinanceLease" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_PROK_RightOfUseAssetsOperatingAndFinanceLease" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet" use="optional" order="13" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/CondensedBalanceSheet">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredUnderwritingCommissions" xlink:label="loc_PROK_DeferredUnderwritingCommissions" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_PROK_DeferredUnderwritingCommissions" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedExpensesAndOther" xlink:label="loc_PROK_AccruedExpensesAndOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_PROK_AccruedExpensesAndOther" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" use="optional" order="19" weight="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedExpensesCurrent" xlink:label="loc_PROK_AccruedExpensesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_PROK_AccruedExpensesCurrent" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_CurrentAccountsPayable" xlink:label="loc_PROK_CurrentAccountsPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_PROK_CurrentAccountsPayable" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OperatingAndFinanceLeaseLiabilitiesCurrent" xlink:label="loc_PROK_OperatingAndFinanceLeaseLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_PROK_OperatingAndFinanceLeaseLiabilitiesCurrent" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_TaxesPayableCurrent" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapital" xlink:label="loc_us-gaap_PartnersCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_PartnersCapital" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersContributedCapital" xlink:label="loc_us-gaap_LimitedPartnersContributedCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PartnersCapital" xlink:to="loc_us-gaap_LimitedPartnersContributedCapital" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PartnersCapital" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="27" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" use="optional" order="28" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_CommitmentsAndContingencies" use="optional" order="29" weight="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion" xlink:label="loc_PROK_OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_PROK_OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion" use="optional" order="30" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="31" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="32" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="33" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" use="optional" order="34" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/CondensedStatementOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments" use="optional" order="2" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets" use="optional" order="4" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromNotesPayable" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" use="optional" order="8" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RepaymentOfAdvancesFromRelatedParty" xlink:label="loc_PROK_RepaymentOfAdvancesFromRelatedParty" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_PROK_RepaymentOfAdvancesFromRelatedParty" use="optional" order="11" weight="-1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RepaymentOfPromissoryNoteRelatedParty" xlink:label="loc_PROK_RepaymentOfPromissoryNoteRelatedParty" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_PROK_RepaymentOfPromissoryNoteRelatedParty" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments" use="optional" order="13" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_FormationCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares" xlink:label="loc_PROK_FormationCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PROK_FormationCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_InvestmentIncomeInterest" use="optional" order="19" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="21" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" use="optional" order="22" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" use="optional" order="23" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" use="optional" order="24" weight="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_IncreaseDecreaseOfAdvanceFromRelatedParty" xlink:label="loc_PROK_IncreaseDecreaseOfAdvanceFromRelatedParty" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PROK_IncreaseDecreaseOfAdvanceFromRelatedParty" use="optional" order="25" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="26" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" use="optional" order="27" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" use="optional" order="28" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/CondensedStatementOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="29" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments" use="optional" order="30" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" use="optional" order="31" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets" use="optional" order="32" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="33" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" use="optional" order="34" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromNotesPayable" use="optional" order="35" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" use="optional" order="36" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" use="optional" order="37" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" use="optional" order="38" weight="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RepaymentOfAdvancesFromRelatedParty" xlink:label="loc_PROK_RepaymentOfAdvancesFromRelatedParty" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_PROK_RepaymentOfAdvancesFromRelatedParty" use="optional" order="39" weight="-1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RepaymentOfPromissoryNoteRelatedParty" xlink:label="loc_PROK_RepaymentOfPromissoryNoteRelatedParty" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_PROK_RepaymentOfPromissoryNoteRelatedParty" use="optional" order="40" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments" use="optional" order="41" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" use="optional" order="42" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt" use="optional" order="43" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="44" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="45" weight="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_FormationCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares" xlink:label="loc_PROK_FormationCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PROK_FormationCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares" use="optional" order="46" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_InvestmentIncomeInterest" use="optional" order="47" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="48" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="49" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" use="optional" order="50" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" use="optional" order="51" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" use="optional" order="52" weight="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_IncreaseDecreaseOfAdvanceFromRelatedParty" xlink:label="loc_PROK_IncreaseDecreaseOfAdvanceFromRelatedParty" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_PROK_IncreaseDecreaseOfAdvanceFromRelatedParty" use="optional" order="53" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="54" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" use="optional" order="55" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" use="optional" order="56" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/CondensedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_Revenues" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_InterestExpense" use="optional" order="7" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_InvestmentIncomeInterest" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" use="optional" order="10" weight="-1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>18
<FILENAME>prok-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 09-August-2022 [04:09:18] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#CoverPage" roleURI="http://www.businesswire.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#CondensedBalanceSheet" roleURI="http://www.businesswire.com/role/CondensedBalanceSheet" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#CondensedBalanceSheetParenthetical" roleURI="http://www.businesswire.com/role/CondensedBalanceSheetParenthetical" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#CondensedStatementsOfOperations" roleURI="http://www.businesswire.com/role/CondensedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit" roleURI="http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficitParenthetical" roleURI="http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficitParenthetical" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#CondensedStatementOfCashFlows" roleURI="http://www.businesswire.com/role/CondensedStatementOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#DescriptionOfOrganizationBusinessOperationsAndGoingConcern" roleURI="http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcern" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#SignificantAccountingPolicies" roleURI="http://www.businesswire.com/role/SignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#InitialPublicOffering" roleURI="http://www.businesswire.com/role/InitialPublicOffering" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#PrivatePlacement" roleURI="http://www.businesswire.com/role/PrivatePlacement" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#RelatedPartyTransactions" roleURI="http://www.businesswire.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#CommitmentsAndContingencies" roleURI="http://www.businesswire.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#TemporaryEquityAndPermanentDeficit" roleURI="http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficit" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#FairValueMeasurements" roleURI="http://www.businesswire.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#SubsequentEvents" roleURI="http://www.businesswire.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#SignificantAccountingPoliciesTables" roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#FairValueMeasurementsTables" roleURI="http://www.businesswire.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail" roleURI="http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#TheCompanyAdditionalInformationDetail" roleURI="http://www.businesswire.com/role/TheCompanyAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#SignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#SignificantAccountingPoliciesScheduleOfClassAOrdinarySharesReflectedInTheBalanceSheetsDetail" roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfClassAOrdinarySharesReflectedInTheBalanceSheetsDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#SignificantAccountingPoliciesScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail" roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail" roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#SignificantAccountingPoliciesScheduleOfFixedAssetsDetail" roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfFixedAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#SignificantAccountingPoliciesScheduleOfIntangibleAssetParentheticalDetail" roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#InitialPublicOfferingAdditionalInformationDetail" roleURI="http://www.businesswire.com/role/InitialPublicOfferingAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://www.businesswire.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#PrivatePlacementAdditionalInformationDetail" roleURI="http://www.businesswire.com/role/PrivatePlacementAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#LeasesAdditionalInformationDetail" roleURI="http://www.businesswire.com/role/LeasesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#RelatedPartyTransactionsAdditionalInformationDetail" roleURI="http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#RelatedPartyDebtAdditionalInformationDetail" roleURI="http://www.businesswire.com/role/RelatedPartyDebtAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://www.businesswire.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#MembersEquityScheduleOfMembersEquityDetail" roleURI="http://www.businesswire.com/role/MembersEquityScheduleOfMembersEquityDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#MembersEquityAdditionalInformationDetail" roleURI="http://www.businesswire.com/role/MembersEquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#TemporaryEquityAndPermanentDeficitAdditionalInformationDetail" roleURI="http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficitAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#NetLossPerShareScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail" roleURI="http://www.businesswire.com/role/NetLossPerShareScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#FairValueMeasurementsSummaryOfAssetsThatAreMeasuredAtFairValueOnARecurringBasisDetail" roleURI="http://www.businesswire.com/role/FairValueMeasurementsSummaryOfAssetsThatAreMeasuredAtFairValueOnARecurringBasisDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#EquityBasedCompensationSummaryOfTheActivityRelatedToCompanySClassBAndB1UnitsGrantedDetail" roleURI="http://www.businesswire.com/role/EquityBasedCompensationSummaryOfTheActivityRelatedToCompanySClassBAndB1UnitsGrantedDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#EquityBasedCompensationAdditionalInformationDetail" roleURI="http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#EquityBasedCompensationSummaryOfKeyAssumptionsUsedInTheOpmValuationDetail" roleURI="http://www.businesswire.com/role/EquityBasedCompensationSummaryOfKeyAssumptionsUsedInTheOpmValuationDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#EquityBasedCompensationSummaryOfCompensationExpenseDetail" roleURI="http://www.businesswire.com/role/EquityBasedCompensationSummaryOfCompensationExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#SubsequentEventsAdditionalInformationDetail" roleURI="http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#MembersEquity" roleURI="http://www.businesswire.com/role/MembersEquity" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#MembersEquityTables" roleURI="http://www.businesswire.com/role/MembersEquityTables" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#NetLossPerShare" roleURI="http://www.businesswire.com/role/NetLossPerShare" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#NetLossPerShareTables" roleURI="http://www.businesswire.com/role/NetLossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#IncomeTaxes" roleURI="http://www.businesswire.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#IncomeTaxesTables" roleURI="http://www.businesswire.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail" roleURI="http://www.businesswire.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail" roleURI="http://www.businesswire.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" roleURI="http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetail" roleURI="http://www.businesswire.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#EquityBasedCompensation" roleURI="http://www.businesswire.com/role/EquityBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#EquityBasedCompensationTables" roleURI="http://www.businesswire.com/role/EquityBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#Leases" roleURI="http://www.businesswire.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#LeasesTables" roleURI="http://www.businesswire.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#LeasesScheduleOfTheClassificationOfOperatingAndFinanceLeaseAssetsAndObligationsInTheCompanySConsolidatedBalanceSheetsDetail" roleURI="http://www.businesswire.com/role/LeasesScheduleOfTheClassificationOfOperatingAndFinanceLeaseAssetsAndObligationsInTheCompanySConsolidatedBalanceSheetsDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail" roleURI="http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#SignificantAccountingPoliciesScheduleOfAccruedExpensesDetail" roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfAccruedExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#SignificantAccountingPoliciesScheduleOfIntangibleAssetDetail" roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#SignificantAccountingPoliciesScheduleOfFixedAssetsParentheticalDetail" roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfFixedAssetsParentheticalDetail" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_DocumentInformationTable_3" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4" xlink:to="loc_us-gaap_ClassOfStockDomain_5" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_5_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4" xlink:to="loc_us-gaap_ClassOfStockDomain_5_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_DocumentType_9" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_AmendmentFlag_10" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityRegistrantName_14" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityCentralIndexKey_15" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityIncorporationStateCountryCode_18" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityFilerCategory_31" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntitySmallBusiness_33" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityEmergingGrowthCompany_34" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityExTransitionPeriod_35" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/CondensedBalanceSheet">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_45" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_42" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_45" xlink:to="loc_us-gaap_StatementTable_42" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_43" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_42" xlink:to="loc_us-gaap_StatementClassOfStockAxis_43" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_44" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_43" xlink:to="loc_us-gaap_ClassOfStockDomain_44" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_44_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_43" xlink:to="loc_us-gaap_ClassOfStockDomain_44_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_52" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_44" xlink:to="loc_us-gaap_CommonClassBMember_52" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_51" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_44" xlink:to="loc_us-gaap_CommonClassAMember_51" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573372" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_42" xlink:to="loc_dei_LegalEntityAxis_1573372" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573378" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1573372" xlink:to="loc_dei_EntityDomain_1573378" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573378_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1573372" xlink:to="loc_dei_EntityDomain_1573378_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573386" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1573378" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573386" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="loc_us-gaap_CapitalUnitsByClassAxis_1573229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_42" xlink:to="loc_us-gaap_CapitalUnitsByClassAxis_1573229" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_1573230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_1573229" xlink:to="loc_us-gaap_CapitalUnitClassDomain_1573230" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_1573230_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_1573229" xlink:to="loc_us-gaap_CapitalUnitClassDomain_1573230_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassBMember" xlink:label="loc_us-gaap_CapitalUnitClassBMember_1573232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1573230" xlink:to="loc_us-gaap_CapitalUnitClassBMember_1573232" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassAMember" xlink:label="loc_us-gaap_CapitalUnitClassAMember_1573231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1573230" xlink:to="loc_us-gaap_CapitalUnitClassAMember_1573231" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_46" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_45" xlink:to="loc_us-gaap_AssetsAbstract_46" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredOfferingCost" xlink:label="loc_prok_DeferredOfferingCost_56" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_46" xlink:to="loc_prok_DeferredOfferingCost_56" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent_1153783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_46" xlink:to="loc_us-gaap_AssetsHeldInTrustNoncurrent_1153783" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_57" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_46" xlink:to="loc_us-gaap_Assets_57" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PrepaidInsuranceNonCurrent" xlink:label="loc_prok_PrepaidInsuranceNonCurrent_1153781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_46" xlink:to="loc_prok_PrepaidInsuranceNonCurrent_1153781" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_47" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_46" xlink:to="loc_us-gaap_AssetsCurrentAbstract_47" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_53" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_47" xlink:to="loc_us-gaap_Cash_53" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_54" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_47" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_54" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_55" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_47" xlink:to="loc_us-gaap_AssetsCurrent_55" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_1573153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_47" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_1573153" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_1573172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_47" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_1573172" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PrepaidClinicalCurrent" xlink:label="loc_prok_PrepaidClinicalCurrent_1573174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_47" xlink:to="loc_prok_PrepaidClinicalCurrent_1573174" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_1573186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_47" xlink:to="loc_us-gaap_OtherAssetsCurrent_1573186" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1573191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_46" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1573191" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1573188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_46" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1573188" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RightOfUseAssetsOperatingAndFinanceLease" xlink:label="loc_prok_RightOfUseAssetsOperatingAndFinanceLease_1573189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_46" xlink:to="loc_prok_RightOfUseAssetsOperatingAndFinanceLease_1573189" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_48" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_45" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_48" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_1152785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_48" xlink:to="loc_us-gaap_Liabilities_1152785" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_49" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_48" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_49" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_60" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_49" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_60" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedExpensesAndOther" xlink:label="loc_prok_AccruedExpensesAndOther_58" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_49" xlink:to="loc_prok_AccruedExpensesAndOther_58" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_62" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_49" xlink:to="loc_us-gaap_LiabilitiesCurrent_62" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1153786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_49" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1153786" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedExpensesCurrent" xlink:label="loc_prok_AccruedExpensesCurrent_1342206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_49" xlink:to="loc_prok_AccruedExpensesCurrent_1342206" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_CurrentAccountsPayable" xlink:label="loc_prok_CurrentAccountsPayable_1573198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_49" xlink:to="loc_prok_CurrentAccountsPayable_1573198" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OperatingAndFinanceLeaseLiabilitiesCurrent" xlink:label="loc_prok_OperatingAndFinanceLeaseLiabilitiesCurrent_1573201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_49" xlink:to="loc_prok_OperatingAndFinanceLeaseLiabilitiesCurrent_1573201" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_1573738" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_49" xlink:to="loc_us-gaap_TaxesPayableCurrent_1573738" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_1573742" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_49" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_1573742" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_69" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_48" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_69" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_63" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_48" xlink:to="loc_us-gaap_CommitmentsAndContingencies_63" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredUnderwritingCommissions" xlink:label="loc_prok_DeferredUnderwritingCommissions_1153795" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_48" xlink:to="loc_prok_DeferredUnderwritingCommissions_1153795" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_50" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_48" xlink:to="loc_us-gaap_StockholdersEquityAbstract_50" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_66" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_50" xlink:to="loc_us-gaap_AdditionalPaidInCapital_66" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_68" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_50" xlink:to="loc_us-gaap_StockholdersEquity_68" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_64" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_50" xlink:to="loc_us-gaap_PreferredStockValue_64" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_65" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_50" xlink:to="loc_us-gaap_CommonStockValue_65" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1153810" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_48" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1153810" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion" xlink:label="loc_prok_OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion_1573208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_48" xlink:to="loc_prok_OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion_1573208" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MembersEquityAbstract" xlink:label="loc_us-gaap_MembersEquityAbstract_1573215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_48" xlink:to="loc_us-gaap_MembersEquityAbstract_1573215" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersContributedCapital" xlink:label="loc_us-gaap_LimitedPartnersContributedCapital_1573216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MembersEquityAbstract_1573215" xlink:to="loc_us-gaap_LimitedPartnersContributedCapital_1573216" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1573217" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MembersEquityAbstract_1573215" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1573217" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapital" xlink:label="loc_us-gaap_PartnersCapital_1573220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MembersEquityAbstract_1573215" xlink:to="loc_us-gaap_PartnersCapital_1573220" use="optional" order="57" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/CondensedBalanceSheetParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_75" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_80" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_75" xlink:to="loc_us-gaap_PreferredStockSharesIssued_80" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_82" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_75" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_82" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_72" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_75" xlink:to="loc_us-gaap_StatementTable_72" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_73" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_72" xlink:to="loc_us-gaap_StatementClassOfStockAxis_73" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_74" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_73" xlink:to="loc_us-gaap_ClassOfStockDomain_74" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_74_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_73" xlink:to="loc_us-gaap_ClassOfStockDomain_74_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_76" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_74" xlink:to="loc_us-gaap_CommonClassAMember_76" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_77" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_74" xlink:to="loc_us-gaap_CommonClassBMember_77" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573410" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_72" xlink:to="loc_dei_LegalEntityAxis_1573410" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573411" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1573410" xlink:to="loc_dei_EntityDomain_1573411" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573411_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1573410" xlink:to="loc_dei_EntityDomain_1573411_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573412" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1573411" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573412" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="loc_us-gaap_CapitalUnitsByClassAxis_1573253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_72" xlink:to="loc_us-gaap_CapitalUnitsByClassAxis_1573253" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_1573254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_1573253" xlink:to="loc_us-gaap_CapitalUnitClassDomain_1573254" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_1573254_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_1573253" xlink:to="loc_us-gaap_CapitalUnitClassDomain_1573254_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassAMember" xlink:label="loc_us-gaap_CapitalUnitClassAMember_1573255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1573254" xlink:to="loc_us-gaap_CapitalUnitClassAMember_1573255" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassBMember" xlink:label="loc_us-gaap_CapitalUnitClassBMember_1573256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1573254" xlink:to="loc_us-gaap_CapitalUnitClassBMember_1573256" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_84" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_75" xlink:to="loc_us-gaap_CommonStockSharesIssued_84" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_85" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_75" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_85" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_78" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_75" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_78" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_81" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_75" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_81" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding" xlink:label="loc_us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding_1573260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_75" xlink:to="loc_us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding_1573260" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_83" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_75" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_83" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersCapitalAccountUnitsIssued" xlink:label="loc_us-gaap_LimitedPartnersCapitalAccountUnitsIssued_1573258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_75" xlink:to="loc_us-gaap_LimitedPartnersCapitalAccountUnitsIssued_1573258" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_1153834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_75" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_1153834" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_79" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_75" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_79" use="optional" order="26" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/CondensedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1152848" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1152843" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1152848" xlink:to="loc_us-gaap_StatementTable_1152843" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1152844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1152843" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1152844" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1152845" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1152844" xlink:to="loc_us-gaap_ClassOfStockDomain_1152845" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1152845_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1152844" xlink:to="loc_us-gaap_ClassOfStockDomain_1152845_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1152846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1152845" xlink:to="loc_us-gaap_CommonClassAMember_1152846" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_1152847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1152845" xlink:to="loc_us-gaap_CommonClassBMember_1152847" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="loc_us-gaap_CapitalUnitsByClassAxis_1573298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1152843" xlink:to="loc_us-gaap_CapitalUnitsByClassAxis_1573298" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_1573299" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_1573298" xlink:to="loc_us-gaap_CapitalUnitClassDomain_1573299" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_1573299_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_1573298" xlink:to="loc_us-gaap_CapitalUnitClassDomain_1573299_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassAMember" xlink:label="loc_us-gaap_CapitalUnitClassAMember_1573301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1573299" xlink:to="loc_us-gaap_CapitalUnitClassAMember_1573301" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573407" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1152843" xlink:to="loc_dei_LegalEntityAxis_1573407" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573408" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1573407" xlink:to="loc_dei_EntityDomain_1573408" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573408_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1573407" xlink:to="loc_dei_EntityDomain_1573408_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1573408" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573439" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_1153848" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1152848" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_1153848" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_1153849" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_1153848" xlink:to="loc_us-gaap_InvestmentIncomeInterest_1153849" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_1573284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_1153848" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_1573284" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_89" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1152848" xlink:to="loc_us-gaap_OperatingExpenses_89" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_90" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1152848" xlink:to="loc_us-gaap_OperatingIncomeLoss_90" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1573269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1152848" xlink:to="loc_us-gaap_Revenues_1573269" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1573280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1152848" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1573280" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1573282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1573280" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1573282" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1573283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1573280" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1573283" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_91" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1152848" xlink:to="loc_us-gaap_NetIncomeLoss_91" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1573285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1152848" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1573285" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1573286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1152848" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1573286" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1573288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1152848" xlink:to="loc_us-gaap_EarningsPerShareAbstract_1573288" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1573290" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1573288" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1573290" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_1573291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1573288" xlink:to="loc_us-gaap_EarningsPerShareBasic_1573291" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1573293" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1573288" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1573293" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1573289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1573288" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1573289" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_1573752" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1152848" xlink:to="loc_us-gaap_InterestExpense_1573752" use="optional" order="32" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_109" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1154450" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1154450" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_SharesOutstanding_115" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_StockholdersEquity_114" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_1153889" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_1153889" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1153898" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1153898" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_116" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1154939" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1154939" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_1154940" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_1154940" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_1154449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_1154449" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity" xlink:label="loc_prok_RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity_1155778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_prok_RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity_1155778" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapital" xlink:label="loc_us-gaap_PartnersCapital_1573398" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_PartnersCapital_1573398" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PartnersCapitalOutstanding" xlink:label="loc_prok_PartnersCapitalOutstanding_1573588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_prok_PartnersCapitalOutstanding_1573588" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapitalAccountContributions" xlink:label="loc_us-gaap_PartnersCapitalAccountContributions_1573589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_PartnersCapitalAccountContributions_1573589" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapitalAccountUnitsContributed" xlink:label="loc_us-gaap_PartnersCapitalAccountUnitsContributed_1573592" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_PartnersCapitalAccountUnitsContributed_1573592" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_prok_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_1153890" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_prok_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_1153890" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_117" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_StatementTable_104" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_104" xlink:to="loc_dei_LegalEntityAxis_1573440" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573441" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1573440" xlink:to="loc_dei_EntityDomain_1573441" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573441_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1573440" xlink:to="loc_dei_EntityDomain_1573441_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573442" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1573441" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573442" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="loc_us-gaap_CapitalUnitsByClassAxis_1573661" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_104" xlink:to="loc_us-gaap_CapitalUnitsByClassAxis_1573661" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_1573662" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_1573661" xlink:to="loc_us-gaap_CapitalUnitClassDomain_1573662" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_1573662_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_1573661" xlink:to="loc_us-gaap_CapitalUnitClassDomain_1573662_default" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassAMember" xlink:label="loc_us-gaap_CapitalUnitClassAMember_1573663" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1573662" xlink:to="loc_us-gaap_CapitalUnitClassAMember_1573663" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassBMember" xlink:label="loc_us-gaap_CapitalUnitClassBMember_1573666" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1573662" xlink:to="loc_us-gaap_CapitalUnitClassBMember_1573666" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_104" xlink:to="loc_us-gaap_StatementClassOfStockAxis_105" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_105" xlink:to="loc_us-gaap_ClassOfStockDomain_106" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_106_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_105" xlink:to="loc_us-gaap_ClassOfStockDomain_106_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1152849" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_106" xlink:to="loc_us-gaap_CommonClassAMember_1152849" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_106" xlink:to="loc_us-gaap_CommonClassBMember_110" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_104" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_107" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_107" xlink:to="loc_us-gaap_EquityComponentDomain_108" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_108_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_107" xlink:to="loc_us-gaap_EquityComponentDomain_108_default" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_112" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_108" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_112" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MemberUnitsMember" xlink:label="loc_us-gaap_MemberUnitsMember_1573657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_108" xlink:to="loc_us-gaap_MemberUnitsMember_1573657" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_108" xlink:to="loc_us-gaap_RetainedEarningsMember_113" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_108" xlink:to="loc_us-gaap_CommonStockMember_111" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1153897" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1153897" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_NetIncomeLoss_118" use="optional" order="40" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficitParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_126" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_123" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_126" xlink:to="loc_us-gaap_StatementTable_123" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_124" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_123" xlink:to="loc_us-gaap_StatementClassOfStockAxis_124" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_125" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_124" xlink:to="loc_us-gaap_ClassOfStockDomain_125" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_125_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_124" xlink:to="loc_us-gaap_ClassOfStockDomain_125_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1320025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_123" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1320025" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1320026" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1320025" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1320026" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1320026_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1320025" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1320026_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_1320027" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1320026" xlink:to="loc_us-gaap_PrivatePlacementMember_1320027" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573435" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_123" xlink:to="loc_dei_LegalEntityAxis_1573435" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1573435" xlink:to="loc_dei_EntityDomain_1573436" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573436_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1573435" xlink:to="loc_dei_EntityDomain_1573436_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573437" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1573436" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573437" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_TemporaryEquityStockIssuedDuringThePeriodShares" xlink:label="loc_prok_TemporaryEquityStockIssuedDuringThePeriodShares_1154329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_126" xlink:to="loc_prok_TemporaryEquityStockIssuedDuringThePeriodShares_1154329" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1153963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_126" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1153963" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/CondensedStatementOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1573354" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_134" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573354" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_134" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RepaymentOfAdvancesFromRelatedParty" xlink:label="loc_prok_RepaymentOfAdvancesFromRelatedParty_1154177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_134" xlink:to="loc_prok_RepaymentOfAdvancesFromRelatedParty_1154177" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_144" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_134" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_144" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_142" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_134" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_142" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_134" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_141" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_143" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_134" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_143" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RepaymentOfPromissoryNoteRelatedParty" xlink:label="loc_prok_RepaymentOfPromissoryNoteRelatedParty_1155780" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_134" xlink:to="loc_prok_RepaymentOfPromissoryNoteRelatedParty_1155780" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1153985" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_134" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1153985" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1153983" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_134" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1153983" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_1573555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_134" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_1573555" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits_1573556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_134" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits_1573556" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_1573930" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_134" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_1573930" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573354" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_146" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_135" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573354" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_135" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RemeasurementOfClassAOrdinarySharesToRedemptionValue" xlink:label="loc_prok_RemeasurementOfClassAOrdinarySharesToRedemptionValue_1154069" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_135" xlink:to="loc_prok_RemeasurementOfClassAOrdinarySharesToRedemptionValue_1154069" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_1154159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_135" xlink:to="loc_us-gaap_StockIssued1_1154159" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredUnderwritingFeesAccruedButNotPaid" xlink:label="loc_prok_DeferredUnderwritingFeesAccruedButNotPaid_1154951" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_135" xlink:to="loc_prok_DeferredUnderwritingFeesAccruedButNotPaid_1154951" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OfferingCostsIncludedInAccruedOfferingCosts" xlink:label="loc_prok_OfferingCostsIncludedInAccruedOfferingCosts_1572771" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_135" xlink:to="loc_prok_OfferingCostsIncludedInAccruedOfferingCosts_1572771" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_1573542" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_135" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_1573542" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1573543" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_1573542" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1573543" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RightOfUseAssetsObtainedInExchangeForLeaseObligations" xlink:label="loc_prok_RightOfUseAssetsObtainedInExchangeForLeaseObligations_1573932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_1573542" xlink:to="loc_prok_RightOfUseAssetsObtainedInExchangeForLeaseObligations_1573932" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573354" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_131" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_131" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_132" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_FormationCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares" xlink:label="loc_prok_FormationCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares_137" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_132" xlink:to="loc_prok_FormationCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares_137" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_1153973" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_132" xlink:to="loc_us-gaap_InvestmentIncomeInterest_1153973" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1573495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_132" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1573495" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1573496" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_132" xlink:to="loc_us-gaap_ShareBasedCompensation_1573496" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_133" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_131" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_133" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_133" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_139" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_133" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_138" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1153974" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_133" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1153974" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_IncreaseDecreaseOfAdvanceFromRelatedParty" xlink:label="loc_prok_IncreaseDecreaseOfAdvanceFromRelatedParty_1572774" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_133" xlink:to="loc_prok_IncreaseDecreaseOfAdvanceFromRelatedParty_1572774" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1572775" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_133" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1572775" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_1573917" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_133" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_1573917" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1573497" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_133" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1573497" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_136" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_131" xlink:to="loc_us-gaap_NetIncomeLoss_136" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_131" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_140" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1153975" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573354" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1153975" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1153979" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1153975" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1153979" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_1153977" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1153975" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_1153977" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1573519" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1153975" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1573519" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_1573520" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1153975" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_1573520" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1573351" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1573354" xlink:to="loc_us-gaap_StatementTable_1573351" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573382" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1573351" xlink:to="loc_dei_LegalEntityAxis_1573382" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573383" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1573382" xlink:to="loc_dei_EntityDomain_1573383" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573383_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1573382" xlink:to="loc_dei_EntityDomain_1573383_default" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573385" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1573383" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573385" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_prok_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents_1574638" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573354" xlink:to="loc_prok_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents_1574638" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1573532" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573354" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1573532" use="optional" order="49" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcern">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1573277" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573277" xlink:to="loc_us-gaap_NatureOfOperations_152" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1573274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1573277" xlink:to="loc_us-gaap_StatementTable_1573274" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1573274" xlink:to="loc_dei_LegalEntityAxis_1573278" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573279" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1573278" xlink:to="loc_dei_EntityDomain_1573279" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573279_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1573278" xlink:to="loc_dei_EntityDomain_1573279_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573281" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1573279" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573281" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/SignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1573490" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573490" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_155" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1573487" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1573490" xlink:to="loc_us-gaap_StatementTable_1573487" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1573487" xlink:to="loc_dei_LegalEntityAxis_1573491" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573492" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1573491" xlink:to="loc_dei_EntityDomain_1573492" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573492_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1573491" xlink:to="loc_dei_EntityDomain_1573492_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573493" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1573492" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573493" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/InitialPublicOffering">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1573344" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_InitialPublicOfferingDisclosureTextBlock" xlink:label="loc_prok_InitialPublicOfferingDisclosureTextBlock_158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573344" xlink:to="loc_prok_InitialPublicOfferingDisclosureTextBlock_158" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1573341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1573344" xlink:to="loc_us-gaap_StatementTable_1573341" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1573342" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1573341" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1573342" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1573343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1573342" xlink:to="loc_us-gaap_ClassOfStockDomain_1573343" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1573343_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1573342" xlink:to="loc_us-gaap_ClassOfStockDomain_1573343_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573346" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1573341" xlink:to="loc_dei_LegalEntityAxis_1573346" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1573346" xlink:to="loc_dei_EntityDomain_1573347" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573347_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1573346" xlink:to="loc_dei_EntityDomain_1573347_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1573347" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573349" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/PrivatePlacement">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1573362" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1573359" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1573362" xlink:to="loc_us-gaap_StatementTable_1573359" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1573360" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1573359" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1573360" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1573361" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1573360" xlink:to="loc_us-gaap_ClassOfStockDomain_1573361" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1573361_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1573360" xlink:to="loc_us-gaap_ClassOfStockDomain_1573361_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573365" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1573359" xlink:to="loc_dei_LegalEntityAxis_1573365" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573366" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1573365" xlink:to="loc_dei_EntityDomain_1573366" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573366_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1573365" xlink:to="loc_dei_EntityDomain_1573366_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573368" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1573366" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573368" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PrivatePlacementDisclosureTextBlock" xlink:label="loc_prok_PrivatePlacementDisclosureTextBlock_161" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573362" xlink:to="loc_prok_PrivatePlacementDisclosureTextBlock_161" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1573506" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1573503" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1573506" xlink:to="loc_us-gaap_StatementTable_1573503" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1573504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1573503" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1573504" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1573505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1573504" xlink:to="loc_us-gaap_ClassOfStockDomain_1573505" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1573505_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1573504" xlink:to="loc_us-gaap_ClassOfStockDomain_1573505_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1573503" xlink:to="loc_dei_LegalEntityAxis_1573507" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1573507" xlink:to="loc_dei_EntityDomain_1573508" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573508_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1573507" xlink:to="loc_dei_EntityDomain_1573508_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573509" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1573508" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573509" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1573510" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573506" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1573510" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1573377" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1573374" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1573377" xlink:to="loc_us-gaap_StatementTable_1573374" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1573375" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1573374" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1573375" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1573376" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1573375" xlink:to="loc_us-gaap_ClassOfStockDomain_1573376" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1573376_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1573375" xlink:to="loc_us-gaap_ClassOfStockDomain_1573376_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573381" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1573374" xlink:to="loc_dei_LegalEntityAxis_1573381" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573384" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1573381" xlink:to="loc_dei_EntityDomain_1573384" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573384_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1573381" xlink:to="loc_dei_EntityDomain_1573384_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573388" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1573384" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573388" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1573389" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573377" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1573389" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1573420" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1573417" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1573420" xlink:to="loc_us-gaap_StatementTable_1573417" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573423" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1573417" xlink:to="loc_dei_LegalEntityAxis_1573423" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573424" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1573423" xlink:to="loc_dei_EntityDomain_1573424" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573424_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1573423" xlink:to="loc_dei_EntityDomain_1573424_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1573424" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573425" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1573418" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1573417" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1573418" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1573419" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1573418" xlink:to="loc_us-gaap_ClassOfStockDomain_1573419" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1573419_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1573418" xlink:to="loc_us-gaap_ClassOfStockDomain_1573419_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1573426" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573420" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1573426" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1573451" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1573448" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1573451" xlink:to="loc_us-gaap_StatementTable_1573448" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1573449" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1573448" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1573449" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1573450" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1573449" xlink:to="loc_us-gaap_ClassOfStockDomain_1573450" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1573450_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1573449" xlink:to="loc_us-gaap_ClassOfStockDomain_1573450_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573452" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1573448" xlink:to="loc_dei_LegalEntityAxis_1573452" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573453" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1573452" xlink:to="loc_dei_EntityDomain_1573453" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573453_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1573452" xlink:to="loc_dei_EntityDomain_1573453_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573454" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1573453" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573454" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1573455" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573451" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_1573455" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1573397" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573397" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_173" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1573394" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1573397" xlink:to="loc_us-gaap_StatementTable_1573394" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1573395" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1573394" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1573395" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1573396" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1573395" xlink:to="loc_us-gaap_ClassOfStockDomain_1573396" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1573396_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1573395" xlink:to="loc_us-gaap_ClassOfStockDomain_1573396_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573399" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1573394" xlink:to="loc_dei_LegalEntityAxis_1573399" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573401" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1573399" xlink:to="loc_dei_EntityDomain_1573401" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573401_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1573399" xlink:to="loc_dei_EntityDomain_1573401_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573402" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1573401" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573402" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1573526" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredOfferingCostsPolicyTextBlock" xlink:label="loc_prok_DeferredOfferingCostsPolicyTextBlock_180" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_prok_DeferredOfferingCostsPolicyTextBlock_180" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_185" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_181" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_182" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_184" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1179816" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1179816" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_183" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_178" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_UseOfEstimates_178" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_179" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_179" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="loc_prok_EmergingGrowthCompanyStatusPolicyTextBlock_177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_prok_EmergingGrowthCompanyStatusPolicyTextBlock_177" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_TemporaryEquityPolicyTextBlock" xlink:label="loc_prok_TemporaryEquityPolicyTextBlock_1154670" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_prok_TemporaryEquityPolicyTextBlock_1154670" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1154668" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1154668" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedExpensesPolicyTextBlock" xlink:label="loc_prok_AccruedExpensesPolicyTextBlock_1355565" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_prok_AccruedExpensesPolicyTextBlock_1355565" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1573523" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_StatementTable_1573523" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573527" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1573523" xlink:to="loc_dei_LegalEntityAxis_1573527" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573528" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1573527" xlink:to="loc_dei_EntityDomain_1573528" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573528_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1573527" xlink:to="loc_dei_EntityDomain_1573528_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573530" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1573528" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573530" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_GoingConcernPolicyTextBlock" xlink:label="loc_prok_GoingConcernPolicyTextBlock_1573758" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_prok_GoingConcernPolicyTextBlock_1573758" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_176" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1573761" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1573761" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1573763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1573763" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_1573765" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_1573765" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_1573767" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_1573767" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock" xlink:label="loc_us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock_1573772" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock_1573772" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_1573773" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_1573773" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_1573776" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_1573776" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ContingentLiabilitiesPolicyTextBlock" xlink:label="loc_prok_ContingentLiabilitiesPolicyTextBlock_1573790" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_prok_ContingentLiabilitiesPolicyTextBlock_1573790" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1573769" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1573769" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_1573770" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_1573770" use="optional" order="30" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/SignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1573551" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1179814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573551" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1179814" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1573972" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573551" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1573972" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DisclosureInTabularFormOfUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:label="loc_prok_DisclosureInTabularFormOfUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_1573977" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573551" xlink:to="loc_prok_DisclosureInTabularFormOfUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_1573977" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1573978" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573551" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1573978" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock_1317334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573551" xlink:to="loc_us-gaap_TemporaryEquityTableTextBlock_1317334" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1573550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1573551" xlink:to="loc_us-gaap_StatementTable_1573550" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573552" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1573550" xlink:to="loc_dei_LegalEntityAxis_1573552" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1573552" xlink:to="loc_dei_EntityDomain_1573553" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573553_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1573552" xlink:to="loc_dei_EntityDomain_1573553_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1573553" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573554" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1573979" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573551" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1573979" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/FairValueMeasurementsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1573460" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_1573467" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573460" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_1573467" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1573457" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1573460" xlink:to="loc_us-gaap_StatementTable_1573457" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573461" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1573457" xlink:to="loc_dei_LegalEntityAxis_1573461" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573463" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1573461" xlink:to="loc_dei_EntityDomain_1573463" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573463_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1573461" xlink:to="loc_dei_EntityDomain_1573463_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573465" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1573463" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573465" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1573458" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1573457" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1573458" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1573459" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1573458" xlink:to="loc_us-gaap_ClassOfStockDomain_1573459" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1573459_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1573458" xlink:to="loc_us-gaap_ClassOfStockDomain_1573459_default" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DescriptionOfOrganizationAndBusinessOperationsLineItems" xlink:label="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ProspectiveAssetsOfAcquireeAsAPercentageOfFairValueOfAssetsInTheTrustAccount" xlink:label="loc_prok_ProspectiveAssetsOfAcquireeAsAPercentageOfFairValueOfAssetsInTheTrustAccount_214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_prok_ProspectiveAssetsOfAcquireeAsAPercentageOfFairValueOfAssetsInTheTrustAccount_214" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockHeldInTrust" xlink:label="loc_us-gaap_CommonStockHeldInTrust_213" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_us-gaap_CommonStockHeldInTrust_213" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_205" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_212" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_us-gaap_DeferredOfferingCosts_212" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_215" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_215" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_UnderwritingFee" xlink:label="loc_prok_UnderwritingFee_210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_prok_UnderwritingFee_210" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredUnderwritingFees" xlink:label="loc_prok_DeferredUnderwritingFees_211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_prok_DeferredUnderwritingFees_211" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinimumNetWorthRequiredForCompliance" xlink:label="loc_us-gaap_MinimumNetWorthRequiredForCompliance_216" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_us-gaap_MinimumNetWorthRequiredForCompliance_216" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_206" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PercentageOfPublicSharesThatCanBeTransferredWithoutAnyRestriction" xlink:label="loc_prok_PercentageOfPublicSharesThatCanBeTransferredWithoutAnyRestriction_218" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_prok_PercentageOfPublicSharesThatCanBeTransferredWithoutAnyRestriction_218" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DescriptionOfOrganizationAndBusinessOperationsTable" xlink:label="loc_prok_DescriptionOfOrganizationAndBusinessOperationsTable_188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_prok_DescriptionOfOrganizationAndBusinessOperationsTable_188" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsTable_188" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_195" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_195" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_196" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_196_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_195" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_196_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_196" xlink:to="loc_us-gaap_IPOMember_201" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_196" xlink:to="loc_us-gaap_OverAllotmentOptionMember_202" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_196" xlink:to="loc_us-gaap_PrivatePlacementMember_203" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsTable_188" xlink:to="loc_srt_RangeAxis_193" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_193" xlink:to="loc_srt_RangeMember_194" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_194_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_193" xlink:to="loc_srt_RangeMember_194_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_194" xlink:to="loc_srt_MinimumMember_200" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1572769" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_194" xlink:to="loc_srt_MaximumMember_1572769" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsTable_188" xlink:to="loc_us-gaap_StatementClassOfStockAxis_191" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_191" xlink:to="loc_us-gaap_ClassOfStockDomain_192" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_192_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_191" xlink:to="loc_us-gaap_ClassOfStockDomain_192_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_192" xlink:to="loc_us-gaap_CommonClassAMember_199" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1572409" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsTable_188" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1572409" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1572743" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1572409" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1572743" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1572743_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1572409" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1572743_default" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ProkidneyLpMember" xlink:label="loc_prok_ProkidneyLpMember_1572744" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1572743" xlink:to="loc_prok_ProkidneyLpMember_1572744" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1572742" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsTable_188" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1572742" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1572746" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1572742" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1572746" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1572746_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1572742" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1572746_default" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RestrictedStockRightsMember" xlink:label="loc_prok_RestrictedStockRightsMember_1572747" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1572746" xlink:to="loc_prok_RestrictedStockRightsMember_1572747" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1572749" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsTable_188" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1572749" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1572757" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1572749" xlink:to="loc_us-gaap_RelatedPartyDomain_1572757" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1572757_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1572749" xlink:to="loc_us-gaap_RelatedPartyDomain_1572757_default" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PipeInvestorsMember" xlink:label="loc_prok_PipeInvestorsMember_1572759" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1572757" xlink:to="loc_prok_PipeInvestorsMember_1572759" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMember" xlink:label="loc_prok_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMember_1572764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1572757" xlink:to="loc_prok_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMember_1572764" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember" xlink:label="loc_prok_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember_1572773" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1572757" xlink:to="loc_prok_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember_1572773" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SharePriceRangeAxis" xlink:label="loc_prok_SharePriceRangeAxis_1572745" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsTable_188" xlink:to="loc_prok_SharePriceRangeAxis_1572745" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SharePriceRangeDomain" xlink:label="loc_prok_SharePriceRangeDomain_1572750" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_prok_SharePriceRangeAxis_1572745" xlink:to="loc_prok_SharePriceRangeDomain_1572750" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SharePriceRangeDomain" xlink:label="loc_prok_SharePriceRangeDomain_1572750_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_prok_SharePriceRangeAxis_1572745" xlink:to="loc_prok_SharePriceRangeDomain_1572750_default" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SharePriceOneMember" xlink:label="loc_prok_SharePriceOneMember_1572751" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_SharePriceRangeDomain_1572750" xlink:to="loc_prok_SharePriceOneMember_1572751" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SharePriceThreeMember" xlink:label="loc_prok_SharePriceThreeMember_1572753" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_SharePriceRangeDomain_1572750" xlink:to="loc_prok_SharePriceThreeMember_1572753" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SharePriceTwoMember" xlink:label="loc_prok_SharePriceTwoMember_1572752" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_SharePriceRangeDomain_1572750" xlink:to="loc_prok_SharePriceTwoMember_1572752" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_1167786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_us-gaap_Cash_1167786" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated" xlink:label="loc_prok_PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated_219" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_prok_PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated_219" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities" xlink:label="loc_us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities_220" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities_220" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PerShareValueOfRestrictedAssets" xlink:label="loc_prok_PerShareValueOfRestrictedAssets_221" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_prok_PerShareValueOfRestrictedAssets_221" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation_204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_dei_EntityIncorporationDateOfIncorporation_204" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_208" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_208" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_207" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1572741" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1572741" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_1572748" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_1572748" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_TransactionCostsIncurredInConnectionWithInitialPublicOffering" xlink:label="loc_prok_TransactionCostsIncurredInConnectionWithInitialPublicOffering_209" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_prok_TransactionCostsIncurredInConnectionWithInitialPublicOffering_209" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PercentageOfPublicSharesRedemption" xlink:label="loc_prok_PercentageOfPublicSharesRedemption_1061550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_prok_PercentageOfPublicSharesRedemption_1061550" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_WorkingCapital" xlink:label="loc_prok_WorkingCapital_1167789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_prok_WorkingCapital_1167789" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1572754" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1572754" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1572760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1572760" use="optional" order="60" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/TheCompanyAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_NatureOfOperationsLineItems" xlink:label="loc_prok_NatureOfOperationsLineItems_1573209" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_NatureOfOperationsTable" xlink:label="loc_prok_NatureOfOperationsTable_1573197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_prok_NatureOfOperationsLineItems_1573209" xlink:to="loc_prok_NatureOfOperationsTable_1573197" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1573205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_prok_NatureOfOperationsTable_1573197" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1573205" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1573206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1573205" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1573206" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1573206_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1573205" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1573206_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RegenAndTwinCityBioLlcMember" xlink:label="loc_prok_RegenAndTwinCityBioLlcMember_1573207" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1573206" xlink:to="loc_prok_RegenAndTwinCityBioLlcMember_1573207" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_InitialCapital" xlink:label="loc_prok_InitialCapital_1573211" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_NatureOfOperationsLineItems_1573209" xlink:to="loc_prok_InitialCapital_1573211" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1573214" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_NatureOfOperationsLineItems_1573209" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1573214" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation_1573210" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_NatureOfOperationsLineItems_1573209" xlink:to="loc_dei_EntityIncorporationDateOfIncorporation_1573210" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccountingPoliciesLineItems" xlink:label="loc_prok_AccountingPoliciesLineItems_229" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccountingPoliciesTable" xlink:label="loc_prok_AccountingPoliciesTable_224" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_prok_AccountingPoliciesTable_224" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_227" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_prok_AccountingPoliciesTable_224" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_227" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_227" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_228" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_228_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_227" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_228_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_228" xlink:to="loc_us-gaap_IPOMember_232" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1179834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_prok_AccountingPoliciesTable_224" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1179834" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1179835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1179834" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1179835" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1179835_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1179834" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1179835_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_225" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_prok_AccountingPoliciesTable_224" xlink:to="loc_us-gaap_StatementClassOfStockAxis_225" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_226" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_225" xlink:to="loc_us-gaap_ClassOfStockDomain_226" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_226_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_225" xlink:to="loc_us-gaap_ClassOfStockDomain_226_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_226" xlink:to="loc_us-gaap_CommonClassAMember_230" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1574073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_prok_AccountingPoliciesTable_224" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1574073" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1574075" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1574073" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1574075" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1574075_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1574073" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1574075_default" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AcquiredAssemblyWorkforceMember" xlink:label="loc_prok_AcquiredAssemblyWorkforceMember_1574077" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1574075" xlink:to="loc_prok_AcquiredAssemblyWorkforceMember_1574077" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573563" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_prok_AccountingPoliciesTable_224" xlink:to="loc_dei_LegalEntityAxis_1573563" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573564" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1573563" xlink:to="loc_dei_EntityDomain_1573564" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573564_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1573563" xlink:to="loc_dei_EntityDomain_1573564_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573565" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1573564" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573565" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1574056" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_prok_AccountingPoliciesTable_224" xlink:to="loc_srt_StatementGeographicalAxis_1574056" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1574057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1574056" xlink:to="loc_srt_SegmentGeographicalDomain_1574057" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1574057_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1574056" xlink:to="loc_srt_SegmentGeographicalDomain_1574057_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_1574060" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1574057" xlink:to="loc_country_US_1574060" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KY" xlink:label="loc_country_KY_1574058" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1574057" xlink:to="loc_country_KY_1574058" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1574292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_prok_AccountingPoliciesTable_224" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1574292" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1574293" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1574292" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1574293" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1574293_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1574292" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1574293_default" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PromissoryNoteMember" xlink:label="loc_prok_PromissoryNoteMember_1574294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1574293" xlink:to="loc_prok_PromissoryNoteMember_1574294" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="loc_us-gaap_CapitalUnitsByClassAxis_1574296" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_prok_AccountingPoliciesTable_224" xlink:to="loc_us-gaap_CapitalUnitsByClassAxis_1574296" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_1574297" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_1574296" xlink:to="loc_us-gaap_CapitalUnitClassDomain_1574297" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_1574297_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_1574296" xlink:to="loc_us-gaap_CapitalUnitClassDomain_1574297_default" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassAMember" xlink:label="loc_us-gaap_CapitalUnitClassAMember_1574298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1574297" xlink:to="loc_us-gaap_CapitalUnitClassAMember_1574298" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassBMember" xlink:label="loc_us-gaap_CapitalUnitClassBMember_1574299" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1574297" xlink:to="loc_us-gaap_CapitalUnitClassBMember_1574299" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_233" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_237" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_236" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_236" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount_239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_CashFDICInsuredAmount_239" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedPrintingExpense" xlink:label="loc_prok_AccruedPrintingExpense_1355579" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_prok_AccruedPrintingExpense_1355579" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedDueDiligenceExpense" xlink:label="loc_prok_AccruedDueDiligenceExpense_1355590" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_prok_AccruedDueDiligenceExpense_1355590" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedRegulatoryFilingFee" xlink:label="loc_prok_AccruedRegulatoryFilingFee_1355592" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_prok_AccruedRegulatoryFilingFee_1355592" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_UnderwritingFee" xlink:label="loc_prok_UnderwritingFee_1179827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_prok_UnderwritingFee_1179827" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedLegalExpense" xlink:label="loc_prok_AccruedLegalExpense_1355573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_prok_AccruedLegalExpense_1355573" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_BusinessCombinationAccruedLegalExpense" xlink:label="loc_prok_BusinessCombinationAccruedLegalExpense_1572777" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_prok_BusinessCombinationAccruedLegalExpense_1572777" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_1574063" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_1574063" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredUnderwritingFees" xlink:label="loc_prok_DeferredUnderwritingFees_1179828" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_prok_DeferredUnderwritingFees_1179828" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedAccountingExpense" xlink:label="loc_prok_AccruedAccountingExpense_1355604" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_prok_AccruedAccountingExpense_1355604" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_BusinessCombinationAccruedConsultingExpense" xlink:label="loc_prok_BusinessCombinationAccruedConsultingExpense_1572778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_prok_BusinessCombinationAccruedConsultingExpense_1572778" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_DeferredOfferingCosts_235" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_TransactionCostsIncurredInConnectionWithInitialPublicOffering" xlink:label="loc_prok_TransactionCostsIncurredInConnectionWithInitialPublicOffering_1179825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_prok_TransactionCostsIncurredInConnectionWithInitialPublicOffering_1179825" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PeriodForWhichTheProfitsEarnedAreExemptFromTax" xlink:label="loc_prok_PeriodForWhichTheProfitsEarnedAreExemptFromTax_1574064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_prok_PeriodForWhichTheProfitsEarnedAreExemptFromTax_1574064" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1574061" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1574061" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1574062" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_NetIncomeLoss_1574062" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DefinedContributionPlanCosts" xlink:label="loc_prok_DefinedContributionPlanCosts_1574067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_prok_DefinedContributionPlanCosts_1574067" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DefinedContributionPlanPercent" xlink:label="loc_prok_DefinedContributionPlanPercent_1574068" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_prok_DefinedContributionPlanPercent_1574068" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_1574070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_Depreciation_1574070" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_BusinessCombinationAccruedOtherTransactionalRelatedExpenses" xlink:label="loc_prok_BusinessCombinationAccruedOtherTransactionalRelatedExpenses_1572779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_prok_BusinessCombinationAccruedOtherTransactionalRelatedExpenses_1572779" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1574090" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1574090" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_UnsufficientToFundItsObligationsTerm" xlink:label="loc_prok_UnsufficientToFundItsObligationsTerm_1574091" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_prok_UnsufficientToFundItsObligationsTerm_1574091" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1574093" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1574093" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1574094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1574094" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1574095" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1574095" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized" xlink:label="loc_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized_1574357" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized_1574357" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1574096" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1574096" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1574097" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1574097" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_1574291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_1574291" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_1574359" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_NumberOfOperatingSegments_1574359" use="optional" order="67" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfClassAOrdinarySharesReflectedInTheBalanceSheetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems_1317350" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_TemporaryEquityIssaunceCosts" xlink:label="loc_prok_TemporaryEquityIssaunceCosts_1317354" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1317350" xlink:to="loc_prok_TemporaryEquityIssaunceCosts_1317354" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity" xlink:label="loc_prok_RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity_1317356" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1317350" xlink:to="loc_prok_RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity_1317356" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1317352" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1317350" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1317352" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_1317344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1317350" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_1317344" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1317347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_1317344" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1317347" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1317348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1317347" xlink:to="loc_us-gaap_ClassOfStockDomain_1317348" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1317348_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1317347" xlink:to="loc_us-gaap_ClassOfStockDomain_1317348_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1317349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1317348" xlink:to="loc_us-gaap_CommonClassAMember_1317349" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573560" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_1317344" xlink:to="loc_dei_LegalEntityAxis_1573560" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573561" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1573560" xlink:to="loc_dei_EntityDomain_1573561" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573561_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1573560" xlink:to="loc_dei_EntityDomain_1573561_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573562" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1573561" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573562" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1317358" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1317350" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1317358" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_IncreaseOfOrdinarySharesToRedemptionValueTemporaryEquity" xlink:label="loc_prok_IncreaseOfOrdinarySharesToRedemptionValueTemporaryEquity_1353572" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1317350" xlink:to="loc_prok_IncreaseOfOrdinarySharesToRedemptionValueTemporaryEquity_1353572" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RemeasurementOfCarryingValueToRedemptionValue" xlink:label="loc_prok_RemeasurementOfCarryingValueToRedemptionValue_1572770" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1317350" xlink:to="loc_prok_RemeasurementOfCarryingValueToRedemptionValue_1572770" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail">
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_EarningsPerShareBasicAndDilutedLineItems" xlink:label="loc_prok_EarningsPerShareBasicAndDilutedLineItems_1154678" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_1154680" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_EarningsPerShareBasicAndDilutedLineItems_1154678" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_1154680" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1154681" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_1154680" xlink:to="loc_us-gaap_NetIncomeLoss_1154681" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_EarningsPerShareBasicAndDilutedTable" xlink:label="loc_prok_EarningsPerShareBasicAndDilutedTable_1154677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_prok_EarningsPerShareBasicAndDilutedLineItems_1154678" xlink:to="loc_prok_EarningsPerShareBasicAndDilutedTable_1154677" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1154688" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_prok_EarningsPerShareBasicAndDilutedTable_1154677" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1154688" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1154689" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1154688" xlink:to="loc_us-gaap_ClassOfStockDomain_1154689" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1154689_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1154688" xlink:to="loc_us-gaap_ClassOfStockDomain_1154689_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1154690" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1154689" xlink:to="loc_us-gaap_CommonClassAMember_1154690" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_1154691" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1154689" xlink:to="loc_us-gaap_CommonClassBMember_1154691" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573557" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_prok_EarningsPerShareBasicAndDilutedTable_1154677" xlink:to="loc_dei_LegalEntityAxis_1573557" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573558" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1573557" xlink:to="loc_dei_EntityDomain_1573558" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573558_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1573557" xlink:to="loc_dei_EntityDomain_1573558_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573559" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1573558" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573559" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_1154684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_EarningsPerShareBasicAndDilutedLineItems_1154678" xlink:to="loc_us-gaap_EarningsPerShareBasic_1154684" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_BasicAndDilutedEarningsPerShareOtherDisclosuresAbstract" xlink:label="loc_prok_BasicAndDilutedEarningsPerShareOtherDisclosuresAbstract_1154682" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_EarningsPerShareBasicAndDilutedLineItems_1154678" xlink:to="loc_prok_BasicAndDilutedEarningsPerShareOtherDisclosuresAbstract_1154682" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1154683" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_BasicAndDilutedEarningsPerShareOtherDisclosuresAbstract_1154682" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1154683" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1574701" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_BasicAndDilutedEarningsPerShareOtherDisclosuresAbstract_1154682" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1574701" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1574702" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_EarningsPerShareBasicAndDilutedLineItems_1154678" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1574702" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1573997" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1573996" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1573997" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1573996" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1573998" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1573996" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1573998" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1573999" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1573998" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1573999" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1573999_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1573998" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1573999_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1574000" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1573999" xlink:to="loc_us-gaap_ComputerEquipmentMember_1574000" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1574003" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1573999" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1574003" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_1574001" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1573999" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_1574001" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1574004" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1573996" xlink:to="loc_srt_RangeAxis_1574004" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1574005" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1574004" xlink:to="loc_srt_RangeMember_1574005" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1574005_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1574004" xlink:to="loc_srt_RangeMember_1574005_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1574006" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1574005" xlink:to="loc_srt_MaximumMember_1574006" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1574007" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1574005" xlink:to="loc_srt_MinimumMember_1574007" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1574008" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1573997" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1574008" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_1574009" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1573997" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_1574009" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfFixedAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1574013" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1574012" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1574013" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1574012" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1574014" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1574012" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1574014" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1574015" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1574014" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1574015" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1574015_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1574014" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1574015_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_1574016" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1574015" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_1574016" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1574017" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1574015" xlink:to="loc_us-gaap_ComputerEquipmentMember_1574017" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1574018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1574015" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1574018" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_1574019" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1574015" xlink:to="loc_us-gaap_ConstructionInProgressMember_1574019" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1574020" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1574013" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1574020" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1574021" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1574013" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1574021" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1574022" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1574013" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1574022" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1574342" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1574347" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1574342" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1574347" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1574343" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1574342" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1574343" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1574344" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1574342" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1574344" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1574320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1574342" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1574320" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1574339" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1574320" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1574339" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1574340" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1574339" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1574340" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1574340_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1574339" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1574340_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AcquiredAssemblyWorkforceMember" xlink:label="loc_prok_AcquiredAssemblyWorkforceMember_1574341" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1574340" xlink:to="loc_prok_AcquiredAssemblyWorkforceMember_1574341" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1574349" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1574342" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1574349" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1574348" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1574342" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1574348" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/InitialPublicOfferingAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_249" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_249" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_254" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_249" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_242" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_242" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_243" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_243" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_244" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_244_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_243" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_244_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_242" xlink:to="loc_us-gaap_StatementClassOfStockAxis_245" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_245" xlink:to="loc_us-gaap_ClassOfStockDomain_246" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_246_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_245" xlink:to="loc_us-gaap_ClassOfStockDomain_246_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_251" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_246" xlink:to="loc_us-gaap_CommonClassAMember_251" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_247" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_242" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_247" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_247" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_248" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_248_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_247" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_248_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_248" xlink:to="loc_us-gaap_IPOMember_252" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_248" xlink:to="loc_us-gaap_OverAllotmentOptionMember_253" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_249" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_255" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_IncomeTaxDisclosureLineItems" xlink:label="loc_prok_IncomeTaxDisclosureLineItems_1573794" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1573807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_IncomeTaxDisclosureLineItems_1573794" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1573807" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1573801" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_IncomeTaxDisclosureLineItems_1573794" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1573801" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1574098" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_IncomeTaxDisclosureLineItems_1573794" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1574098" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1574099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_IncomeTaxDisclosureLineItems_1573794" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1574099" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1574102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_IncomeTaxDisclosureLineItems_1573794" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1574102" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_1573804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_IncomeTaxDisclosureLineItems_1573794" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_1573804" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_IncomeTaxDisclosureTable" xlink:label="loc_prok_IncomeTaxDisclosureTable_1573783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_prok_IncomeTaxDisclosureLineItems_1573794" xlink:to="loc_prok_IncomeTaxDisclosureTable_1573783" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_IncomeTaxActAxis" xlink:label="loc_prok_IncomeTaxActAxis_1574104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_prok_IncomeTaxDisclosureTable_1573783" xlink:to="loc_prok_IncomeTaxActAxis_1574104" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_IncomeTaxActDomain" xlink:label="loc_prok_IncomeTaxActDomain_1574105" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_prok_IncomeTaxActAxis_1574104" xlink:to="loc_prok_IncomeTaxActDomain_1574105" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_IncomeTaxActDomain" xlink:label="loc_prok_IncomeTaxActDomain_1574105_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_prok_IncomeTaxActAxis_1574104" xlink:to="loc_prok_IncomeTaxActDomain_1574105_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_1573786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_prok_IncomeTaxDisclosureTable_1573783" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_1573786" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1573787" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1573786" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1573787" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1573787_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1573786" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1573787_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_1573788" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1573787" xlink:to="loc_us-gaap_ResearchMember_1573788" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredExpenseCapitalizedResearchAndDevelopmentCostsTerm" xlink:label="loc_prok_DeferredExpenseCapitalizedResearchAndDevelopmentCostsTerm_1574109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_IncomeTaxDisclosureLineItems_1573794" xlink:to="loc_prok_DeferredExpenseCapitalizedResearchAndDevelopmentCostsTerm_1574109" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/PrivatePlacementAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_265" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_265" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_258" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_258" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_259" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_259" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_260" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_260_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_259" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_260_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_258" xlink:to="loc_us-gaap_StatementClassOfStockAxis_261" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_261" xlink:to="loc_us-gaap_ClassOfStockDomain_262" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_262_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_261" xlink:to="loc_us-gaap_ClassOfStockDomain_262_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_267" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_262" xlink:to="loc_us-gaap_CommonClassAMember_267" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_258" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_263" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_263" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_264" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_264_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_263" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_264_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_268" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_264" xlink:to="loc_us-gaap_PrivatePlacementMember_268" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_270" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_265" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_270" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_265" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_271" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_269" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_265" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_269" use="optional" order="15" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/LeasesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_1573956" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OperatingAndFinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_prok_OperatingAndFinanceLeaseWeightedAverageDiscountRatePercent_1573959" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1573956" xlink:to="loc_prok_OperatingAndFinanceLeaseWeightedAverageDiscountRatePercent_1573959" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1573961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1573956" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1573961" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RightOfUseAssetsOperatingAndFinanceLease" xlink:label="loc_prok_RightOfUseAssetsOperatingAndFinanceLease_1573962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1573956" xlink:to="loc_prok_RightOfUseAssetsOperatingAndFinanceLease_1573962" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OperatingAndFinanceLeaseLiabilitiesCurrent" xlink:label="loc_prok_OperatingAndFinanceLeaseLiabilitiesCurrent_1573968" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1573956" xlink:to="loc_prok_OperatingAndFinanceLeaseLiabilitiesCurrent_1573968" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OperatingLeaseRentExpenses" xlink:label="loc_prok_OperatingLeaseRentExpenses_1573974" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1573956" xlink:to="loc_prok_OperatingLeaseRentExpenses_1573974" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1573955" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1573956" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1573955" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1573957" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1573956" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1573957" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_1573958" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1573956" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_1573958" use="optional" order="8" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_285" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_308" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_308" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_297" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_297" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered" xlink:label="loc_prok_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered_305" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_prok_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered_305" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_274" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_275" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_274" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_275" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_275" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_276" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_276_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_275" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_276_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_BasisAxis" xlink:label="loc_prok_BasisAxis_277" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_274" xlink:to="loc_prok_BasisAxis_277" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_BasisDomain" xlink:label="loc_prok_BasisDomain_278" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_prok_BasisAxis_277" xlink:to="loc_prok_BasisDomain_278" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_BasisDomain" xlink:label="loc_prok_BasisDomain_278_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_prok_BasisAxis_277" xlink:to="loc_prok_BasisDomain_278_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RestrictionOnTransferOfSponsorSharesMember" xlink:label="loc_prok_RestrictionOnTransferOfSponsorSharesMember_287" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_BasisDomain_278" xlink:to="loc_prok_RestrictionOnTransferOfSponsorSharesMember_287" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_281" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_274" xlink:to="loc_us-gaap_StatementClassOfStockAxis_281" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_281" xlink:to="loc_us-gaap_ClassOfStockDomain_282" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_282_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_281" xlink:to="loc_us-gaap_ClassOfStockDomain_282_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_282" xlink:to="loc_us-gaap_CommonClassBMember_292" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1572765" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_282" xlink:to="loc_us-gaap_CommonClassAMember_1572765" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_274" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_283" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_283" xlink:to="loc_us-gaap_RelatedPartyDomain_284" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_284_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_283" xlink:to="loc_us-gaap_RelatedPartyDomain_284_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SponsorMember" xlink:label="loc_prok_SponsorMember_294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_284" xlink:to="loc_prok_SponsorMember_294" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_FounderMember" xlink:label="loc_prok_FounderMember_293" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_284" xlink:to="loc_prok_FounderMember_293" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AverillMasterFundLtdMember" xlink:label="loc_prok_AverillMasterFundLtdMember_1572768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_284" xlink:to="loc_prok_AverillMasterFundLtdMember_1572768" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ScMasterHoldingsLlcMember" xlink:label="loc_prok_ScMasterHoldingsLlcMember_1572767" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_284" xlink:to="loc_prok_ScMasterHoldingsLlcMember_1572767" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PipeInvestorsMember" xlink:label="loc_prok_PipeInvestorsMember_1572766" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_284" xlink:to="loc_prok_PipeInvestorsMember_1572766" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_279" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_274" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_279" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_279" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_280" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_280_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_279" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_280_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_WorkingCapitalLoansMember" xlink:label="loc_prok_WorkingCapitalLoansMember_291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_280" xlink:to="loc_prok_WorkingCapitalLoansMember_291" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AdministrationAndSupportServicesMember" xlink:label="loc_prok_AdministrationAndSupportServicesMember_288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_280" xlink:to="loc_prok_AdministrationAndSupportServicesMember_288" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AdvanceFromRelatedPartyLoanMember" xlink:label="loc_prok_AdvanceFromRelatedPartyLoanMember_289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_280" xlink:to="loc_prok_AdvanceFromRelatedPartyLoanMember_289" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PromissoryNoteMember" xlink:label="loc_prok_PromissoryNoteMember_290" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_280" xlink:to="loc_prok_PromissoryNoteMember_290" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1062027" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_274" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1062027" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1062028" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1062027" xlink:to="loc_us-gaap_EquityComponentDomain_1062028" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1062028_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1062027" xlink:to="loc_us-gaap_EquityComponentDomain_1062028_default" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_FounderSharesMember" xlink:label="loc_prok_FounderSharesMember_1062029" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1062028" xlink:to="loc_prok_FounderSharesMember_1062029" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1167798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_274" xlink:to="loc_us-gaap_AwardTypeAxis_1167798" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1167800" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1167798" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1167800" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1167800_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1167798" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1167800_default" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AgreementAxis" xlink:label="loc_prok_AgreementAxis_1572615" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_274" xlink:to="loc_prok_AgreementAxis_1572615" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AgreementDomain" xlink:label="loc_prok_AgreementDomain_1572762" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_prok_AgreementAxis_1572615" xlink:to="loc_prok_AgreementDomain_1572762" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AgreementDomain" xlink:label="loc_prok_AgreementDomain_1572762_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_prok_AgreementAxis_1572615" xlink:to="loc_prok_AgreementDomain_1572762_default" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SubscriptionAgreementsMember" xlink:label="loc_prok_SubscriptionAgreementsMember_1572763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AgreementDomain_1572762" xlink:to="loc_prok_SubscriptionAgreementsMember_1572763" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1062030" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_274" xlink:to="loc_srt_TitleOfIndividualAxis_1062030" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1062031" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_1062030" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1062031" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1062031_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_1062030" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1062031_default" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_IndependentDirectorsMember" xlink:label="loc_prok_IndependentDirectorsMember_1062032" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1062031" xlink:to="loc_prok_IndependentDirectorsMember_1062032" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_1317425" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1062031" xlink:to="loc_srt_DirectorMember_1317425" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573511" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_274" xlink:to="loc_dei_LegalEntityAxis_1573511" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573512" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1573511" xlink:to="loc_dei_EntityDomain_1573512" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573512_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1573511" xlink:to="loc_dei_EntityDomain_1573512_default" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573513" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1573512" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573513" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_1154756" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_1154756" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SharesNoLongerSubjectToForfeiture" xlink:label="loc_prok_SharesNoLongerSubjectToForfeiture_1154722" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_prok_SharesNoLongerSubjectToForfeiture_1154722" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_296" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_296" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RepaymentOfAdvancesFromRelatedParty" xlink:label="loc_prok_RepaymentOfAdvancesFromRelatedParty_1154807" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_prok_RepaymentOfAdvancesFromRelatedParty_1154807" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_295" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_295" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xlink:label="loc_prok_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice_304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_prok_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice_304" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1154727" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1154727" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AdvancesPayableToRelatedPartyCurrent" xlink:label="loc_prok_AdvancesPayableToRelatedPartyCurrent_1154810" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_prok_AdvancesPayableToRelatedPartyCurrent_1154810" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1318969" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1318969" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_309" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_309" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_us-gaap_SharePrice_302" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_298" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_299" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_299" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1572755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1572755" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_NumberOfTradingDaysForDeterminingTheSharePrice" xlink:label="loc_prok_NumberOfTradingDaysForDeterminingTheSharePrice_303" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_prok_NumberOfTradingDaysForDeterminingTheSharePrice_303" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_306" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_307" use="optional" order="68" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue" xlink:label="loc_prok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue_1317434" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_prok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue_1317434" use="optional" order="69" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1572758" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1572758" use="optional" order="70" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/RelatedPartyDebtAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_1574049" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1574039" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1574049" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1574039" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1574045" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1574039" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1574045" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1574046" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1574045" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1574046" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1574046_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1574045" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1574046_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PromissoryNoteMember" xlink:label="loc_prok_PromissoryNoteMember_1574048" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1574046" xlink:to="loc_prok_PromissoryNoteMember_1574048" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1574051" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1574049" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1574051" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_1574053" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1574049" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_1574053" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_1574055" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1574049" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_1574055" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_1574057" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1574049" xlink:to="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_1574057" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_1574593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1574049" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_1574593" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1574052" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1574049" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1574052" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/CommitmentsAndContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_1167823" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_1167806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_1167823" xlink:to="loc_us-gaap_LossContingenciesTable_1167806" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AgreementAxis" xlink:label="loc_prok_AgreementAxis_1167809" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1167806" xlink:to="loc_prok_AgreementAxis_1167809" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AgreementDomain" xlink:label="loc_prok_AgreementDomain_1167810" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_prok_AgreementAxis_1167809" xlink:to="loc_prok_AgreementDomain_1167810" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AgreementDomain" xlink:label="loc_prok_AgreementDomain_1167810_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_prok_AgreementAxis_1167809" xlink:to="loc_prok_AgreementDomain_1167810_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DirectorRestrictedStockUnitAwardAgreementMember" xlink:label="loc_prok_DirectorRestrictedStockUnitAwardAgreementMember_1167812" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_AgreementDomain_1167810" xlink:to="loc_prok_DirectorRestrictedStockUnitAwardAgreementMember_1167812" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1167814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1167806" xlink:to="loc_us-gaap_AwardTypeAxis_1167814" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1167815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1167814" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1167815" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1167815_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1167814" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1167815_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1167817" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1167815" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1167817" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1167818" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1167806" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1167818" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1167819" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1167818" xlink:to="loc_us-gaap_ClassOfStockDomain_1167819" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1167819_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1167818" xlink:to="loc_us-gaap_ClassOfStockDomain_1167819_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1167820" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1167819" xlink:to="loc_us-gaap_CommonClassAMember_1167820" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573428" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_1167806" xlink:to="loc_dei_LegalEntityAxis_1573428" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573429" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1573428" xlink:to="loc_dei_EntityDomain_1573429" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573429_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1573428" xlink:to="loc_dei_EntityDomain_1573429_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573430" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1573429" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573430" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredUnderwritingFees" xlink:label="loc_prok_DeferredUnderwritingFees_316" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1167823" xlink:to="loc_prok_DeferredUnderwritingFees_316" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_NumberOfSharesOfCommonStockCommittedToSettleOnADateFollowingTheYearBusinessCombinationOccurs" xlink:label="loc_prok_NumberOfSharesOfCommonStockCommittedToSettleOnADateFollowingTheYearBusinessCombinationOccurs_1167830" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1167823" xlink:to="loc_prok_NumberOfSharesOfCommonStockCommittedToSettleOnADateFollowingTheYearBusinessCombinationOccurs_1167830" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1167829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_1167823" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1167829" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/MembersEquityScheduleOfMembersEquityDetail">
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_MembersEquityLineItems" xlink:label="loc_prok_MembersEquityLineItems_1573615" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding" xlink:label="loc_us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding_1573616" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_MembersEquityLineItems_1573615" xlink:to="loc_us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding_1573616" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapitalAccountUnitsContributed" xlink:label="loc_us-gaap_PartnersCapitalAccountUnitsContributed_1573617" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_MembersEquityLineItems_1573615" xlink:to="loc_us-gaap_PartnersCapitalAccountUnitsContributed_1573617" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_MembersEquityTable" xlink:label="loc_prok_MembersEquityTable_1573607" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_prok_MembersEquityLineItems_1573615" xlink:to="loc_prok_MembersEquityTable_1573607" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1573608" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_prok_MembersEquityTable_1573607" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1573608" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1573609" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1573608" xlink:to="loc_us-gaap_EquityComponentDomain_1573609" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1573609_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1573608" xlink:to="loc_us-gaap_EquityComponentDomain_1573609_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MemberUnitsMember" xlink:label="loc_us-gaap_MemberUnitsMember_1573610" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1573609" xlink:to="loc_us-gaap_MemberUnitsMember_1573610" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="loc_us-gaap_CapitalUnitsByClassAxis_1573611" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_prok_MembersEquityTable_1573607" xlink:to="loc_us-gaap_CapitalUnitsByClassAxis_1573611" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_1573612" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_1573611" xlink:to="loc_us-gaap_CapitalUnitClassDomain_1573612" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_1573612_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_1573611" xlink:to="loc_us-gaap_CapitalUnitClassDomain_1573612_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassAMember" xlink:label="loc_us-gaap_CapitalUnitClassAMember_1573614" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1573612" xlink:to="loc_us-gaap_CapitalUnitClassAMember_1573614" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/MembersEquityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1573967" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1573964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1573967" xlink:to="loc_us-gaap_StatementTable_1573964" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1573965" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1573964" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1573965" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1573966" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1573965" xlink:to="loc_us-gaap_ClassOfStockDomain_1573966" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1573966_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1573965" xlink:to="loc_us-gaap_ClassOfStockDomain_1573966_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="loc_us-gaap_CapitalUnitsByClassAxis_1573969" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1573964" xlink:to="loc_us-gaap_CapitalUnitsByClassAxis_1573969" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_1573970" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_1573969" xlink:to="loc_us-gaap_CapitalUnitClassDomain_1573970" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_1573970_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_1573969" xlink:to="loc_us-gaap_CapitalUnitClassDomain_1573970_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassAMember" xlink:label="loc_us-gaap_CapitalUnitClassAMember_1573980" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1573970" xlink:to="loc_us-gaap_CapitalUnitClassAMember_1573980" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassBMember" xlink:label="loc_us-gaap_CapitalUnitClassBMember_1573971" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1573970" xlink:to="loc_us-gaap_CapitalUnitClassBMember_1573971" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_CapitalUnitClassB1Member" xlink:label="loc_prok_CapitalUnitClassB1Member_1573973" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1573970" xlink:to="loc_prok_CapitalUnitClassB1Member_1573973" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ProceedsFromLimitedPartnersCapitalAccountUnits" xlink:label="loc_prok_ProceedsFromLimitedPartnersCapitalAccountUnits_1573976" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573967" xlink:to="loc_prok_ProceedsFromLimitedPartnersCapitalAccountUnits_1573976" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized" xlink:label="loc_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized_1574635" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573967" xlink:to="loc_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized_1574635" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersCapitalAccountUnitsIssued" xlink:label="loc_us-gaap_LimitedPartnersCapitalAccountUnitsIssued_1573975" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1573967" xlink:to="loc_us-gaap_LimitedPartnersCapitalAccountUnitsIssued_1573975" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficitAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_322" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_322" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_325" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_326" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_322" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_326" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_329" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_322" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_329" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_322" xlink:to="loc_us-gaap_PreferredStockSharesIssued_327" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_322" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_333" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_322" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_332" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_322" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_328" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_331" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_322" xlink:to="loc_us-gaap_CommonStockSharesIssued_331" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_322" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_330" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PercentOfFoundersSharesToCompanysIssuedAndOutstandingOrdinaryShares" xlink:label="loc_prok_PercentOfFoundersSharesToCompanysIssuedAndOutstandingOrdinaryShares_334" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_322" xlink:to="loc_prok_PercentOfFoundersSharesToCompanysIssuedAndOutstandingOrdinaryShares_334" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_322" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_319" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_320" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_319" xlink:to="loc_us-gaap_StatementClassOfStockAxis_320" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_320" xlink:to="loc_us-gaap_ClassOfStockDomain_321" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_321_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_320" xlink:to="loc_us-gaap_ClassOfStockDomain_321_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_321" xlink:to="loc_us-gaap_CommonClassBMember_324" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_321" xlink:to="loc_us-gaap_CommonClassAMember_323" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573431" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_319" xlink:to="loc_dei_LegalEntityAxis_1573431" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573432" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1573431" xlink:to="loc_dei_EntityDomain_1573432" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573432_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1573431" xlink:to="loc_dei_EntityDomain_1573432_default" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573434" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1573432" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573434" use="optional" order="20" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/NetLossPerShareScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_1573638" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1573634" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1573638" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1573634" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="loc_us-gaap_CapitalUnitsByClassAxis_1573635" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1573634" xlink:to="loc_us-gaap_CapitalUnitsByClassAxis_1573635" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_1573636" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_1573635" xlink:to="loc_us-gaap_CapitalUnitClassDomain_1573636" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_1573636_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_1573635" xlink:to="loc_us-gaap_CapitalUnitClassDomain_1573636_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassAMember" xlink:label="loc_us-gaap_CapitalUnitClassAMember_1573637" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1573636" xlink:to="loc_us-gaap_CapitalUnitClassAMember_1573637" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1573641" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1573638" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1573641" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1573642" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1573641" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1573642" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1573644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1573641" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1573644" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_BasicAndDilutedNetIncomeLossPerShareAbstract" xlink:label="loc_prok_BasicAndDilutedNetIncomeLossPerShareAbstract_1574231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1573638" xlink:to="loc_prok_BasicAndDilutedNetIncomeLossPerShareAbstract_1574231" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_1573664" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_BasicAndDilutedNetIncomeLossPerShareAbstract_1574231" xlink:to="loc_us-gaap_EarningsPerShareBasic_1573664" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1573667" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_BasicAndDilutedNetIncomeLossPerShareAbstract_1574231" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1573667" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_1573639" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1573638" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_1573639" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1573640" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_1573639" xlink:to="loc_us-gaap_NetIncomeLoss_1573640" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/FairValueMeasurementsSummaryOfAssetsThatAreMeasuredAtFairValueOnARecurringBasisDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_1154438" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_1154436" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_1154438" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_1154436" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_MarketableSecuritiesHeldToMaturityFairValueDisclosure" xlink:label="loc_prok_MarketableSecuritiesHeldToMaturityFairValueDisclosure_1154439" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1154436" xlink:to="loc_prok_MarketableSecuritiesHeldToMaturityFairValueDisclosure_1154439" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_1154437" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_1154438" xlink:to="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_1154437" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1154440" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_1154437" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1154440" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1154441" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1154440" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1154441" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1154441_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1154440" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1154441_default" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1154442" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1154441" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1154442" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573468" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_1154437" xlink:to="loc_dei_LegalEntityAxis_1573468" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573469" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1573468" xlink:to="loc_dei_EntityDomain_1573469" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573469_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1573468" xlink:to="loc_dei_EntityDomain_1573469_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573471" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1573469" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573471" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/EquityBasedCompensationSummaryOfTheActivityRelatedToCompanySClassBAndB1UnitsGrantedDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573806" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1573808" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573806" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1573808" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1573814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573806" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1573814" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1573802" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573806" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1573802" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_1573815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573806" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_1573815" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1573809" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573806" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1573809" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1574146" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1574146" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1574148" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1574148" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1574149" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573806" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1574149" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_1574147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573806" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_1574147" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_1574192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_1574192" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1574193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1574193" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonUnitIssued" xlink:label="loc_us-gaap_CommonUnitIssued_1574185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_us-gaap_CommonUnitIssued_1574185" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapitalAccountUnitsUnitbasedCompensation" xlink:label="loc_us-gaap_PartnersCapitalAccountUnitsUnitbasedCompensation_1574189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_us-gaap_PartnersCapitalAccountUnitsUnitbasedCompensation_1574189" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapitalAccountUnitBasedCompensation" xlink:label="loc_us-gaap_PartnersCapitalAccountUnitBasedCompensation_1574190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_us-gaap_PartnersCapitalAccountUnitBasedCompensation_1574190" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_1574191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_1574191" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized" xlink:label="loc_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized_1573844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized_1573844" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1573846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1573846" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_CommonUnitsUnissued" xlink:label="loc_prok_CommonUnitsUnissued_1574197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_prok_CommonUnitsUnissued_1574197" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1573825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1573825" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="loc_us-gaap_CapitalUnitsByClassAxis_1573833" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1573825" xlink:to="loc_us-gaap_CapitalUnitsByClassAxis_1573833" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_1573834" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_1573833" xlink:to="loc_us-gaap_CapitalUnitClassDomain_1573834" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_1573834_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_1573833" xlink:to="loc_us-gaap_CapitalUnitClassDomain_1573834_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassBMember" xlink:label="loc_us-gaap_CapitalUnitClassBMember_1573835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1573834" xlink:to="loc_us-gaap_CapitalUnitClassBMember_1573835" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ClassB1unitsMember" xlink:label="loc_prok_ClassB1unitsMember_1574188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1573834" xlink:to="loc_prok_ClassB1unitsMember_1574188" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1574194" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1573825" xlink:to="loc_us-gaap_AwardTypeAxis_1574194" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1574195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1574194" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1574195" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1574195_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1574194" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1574195_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1574196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1574195" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1574196" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_1573827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1573825" xlink:to="loc_us-gaap_VestingAxis_1573827" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_1573828" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_1573827" xlink:to="loc_us-gaap_VestingDomain_1573828" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_1573828_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_1573827" xlink:to="loc_us-gaap_VestingDomain_1573828_default" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OnTheLatterOfTheFirstAnniversaryMember" xlink:label="loc_prok_OnTheLatterOfTheFirstAnniversaryMember_1573829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_1573828" xlink:to="loc_prok_OnTheLatterOfTheFirstAnniversaryMember_1573829" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_EachCalendarQuarterMember" xlink:label="loc_prok_EachCalendarQuarterMember_1573832" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_1573828" xlink:to="loc_prok_EachCalendarQuarterMember_1573832" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_InFirstAnniversaryOfTheAcquisitionDateMember" xlink:label="loc_prok_InFirstAnniversaryOfTheAcquisitionDateMember_1573830" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_1573828" xlink:to="loc_prok_InFirstAnniversaryOfTheAcquisitionDateMember_1573830" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OnEachEnniversaryMember" xlink:label="loc_prok_OnEachEnniversaryMember_1573831" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_1573828" xlink:to="loc_prok_OnEachEnniversaryMember_1573831" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OverTheThreeYearPeriodFromTheDateOfGrantMember" xlink:label="loc_prok_OverTheThreeYearPeriodFromTheDateOfGrantMember_1574199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_1573828" xlink:to="loc_prok_OverTheThreeYearPeriodFromTheDateOfGrantMember_1574199" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1573838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1573838" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_NumberOfCommonUnitsUnissuedOfLimitedLiabilityCompany" xlink:label="loc_prok_NumberOfCommonUnitsUnissuedOfLimitedLiabilityCompany_1573847" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_prok_NumberOfCommonUnitsUnissuedOfLimitedLiabilityCompany_1573847" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1573848" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1573848" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1573849" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1573849" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1573850" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1573850" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonUnitIssuanceValue" xlink:label="loc_us-gaap_CommonUnitIssuanceValue_1574186" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_us-gaap_CommonUnitIssuanceValue_1574186" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1573851" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1573851" use="optional" order="34" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/EquityBasedCompensationSummaryOfKeyAssumptionsUsedInTheOpmValuationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1574168" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1574167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1574168" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1574167" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_1574175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1574167" xlink:to="loc_us-gaap_ValuationTechniqueAxis_1574175" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_1574176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_1574175" xlink:to="loc_us-gaap_ValuationTechniqueDomain_1574176" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_1574176_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_1574175" xlink:to="loc_us-gaap_ValuationTechniqueDomain_1574176_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ValuationTechniqueProbabilityWeightedExpectedReturnMethodMember" xlink:label="loc_prok_ValuationTechniqueProbabilityWeightedExpectedReturnMethodMember_1574179" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_1574176" xlink:to="loc_prok_ValuationTechniqueProbabilityWeightedExpectedReturnMethodMember_1574179" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_1574177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_1574176" xlink:to="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_1574177" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MembersEquity" xlink:label="loc_us-gaap_MembersEquity_1574170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1574168" xlink:to="loc_us-gaap_MembersEquity_1574170" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1574171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1574168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1574171" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_1574172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1574168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_1574172" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1574173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1574168" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1574173" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/EquityBasedCompensationSummaryOfCompensationExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1574154" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1574159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1574154" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1574159" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1574152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1574154" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1574152" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1574155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1574152" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1574155" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1574156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1574155" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1574156" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1574156_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1574155" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1574156_default" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1574157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1574156" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1574157" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1574158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1574156" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1574158" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1317634" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1317496" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_1317634" xlink:to="loc_us-gaap_SubsequentEventTable_1317496" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1317608" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1317496" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1317608" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1317610" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1317608" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1317610" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1317610_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1317608" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1317610_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_EarnoutSharesTrancheAxis" xlink:label="loc_prok_EarnoutSharesTrancheAxis_1317500" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1317496" xlink:to="loc_prok_EarnoutSharesTrancheAxis_1317500" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_EarnoutSharesTrancheDomain" xlink:label="loc_prok_EarnoutSharesTrancheDomain_1317501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_prok_EarnoutSharesTrancheAxis_1317500" xlink:to="loc_prok_EarnoutSharesTrancheDomain_1317501" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_EarnoutSharesTrancheDomain" xlink:label="loc_prok_EarnoutSharesTrancheDomain_1317501_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_prok_EarnoutSharesTrancheAxis_1317500" xlink:to="loc_prok_EarnoutSharesTrancheDomain_1317501_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1317552" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1317496" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1317552" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1317555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1317552" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1317555" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1317555_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1317552" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1317555_default" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1317556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1317555" xlink:to="loc_us-gaap_SubsequentEventMember_1317556" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AgreementAxis" xlink:label="loc_prok_AgreementAxis_1317598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1317496" xlink:to="loc_prok_AgreementAxis_1317598" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AgreementDomain" xlink:label="loc_prok_AgreementDomain_1317600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_prok_AgreementAxis_1317598" xlink:to="loc_prok_AgreementDomain_1317600" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AgreementDomain" xlink:label="loc_prok_AgreementDomain_1317600_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_prok_AgreementAxis_1317598" xlink:to="loc_prok_AgreementDomain_1317600_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1317521" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1317496" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1317521" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1317522" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1317521" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1317522" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1317522_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1317521" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1317522_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RestrictedStockRightsMember" xlink:label="loc_prok_RestrictedStockRightsMember_1355639" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1317522" xlink:to="loc_prok_RestrictedStockRightsMember_1355639" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SharePriceRangeAxis" xlink:label="loc_prok_SharePriceRangeAxis_1355677" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1317496" xlink:to="loc_prok_SharePriceRangeAxis_1355677" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SharePriceRangeDomain" xlink:label="loc_prok_SharePriceRangeDomain_1355679" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_prok_SharePriceRangeAxis_1355677" xlink:to="loc_prok_SharePriceRangeDomain_1355679" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SharePriceRangeDomain" xlink:label="loc_prok_SharePriceRangeDomain_1355679_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_prok_SharePriceRangeAxis_1355677" xlink:to="loc_prok_SharePriceRangeDomain_1355679_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SharePriceOneMember" xlink:label="loc_prok_SharePriceOneMember_1355684" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_SharePriceRangeDomain_1355679" xlink:to="loc_prok_SharePriceOneMember_1355684" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SharePriceTwoMember" xlink:label="loc_prok_SharePriceTwoMember_1355687" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_SharePriceRangeDomain_1355679" xlink:to="loc_prok_SharePriceTwoMember_1355687" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SharePriceThreeMember" xlink:label="loc_prok_SharePriceThreeMember_1355689" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prok_SharePriceRangeDomain_1355679" xlink:to="loc_prok_SharePriceThreeMember_1355689" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1355642" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1317496" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1355642" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1355644" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1355642" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1355644" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1355644_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1355642" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1355644_default" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ProkidneyLpMember" xlink:label="loc_prok_ProkidneyLpMember_1355646" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1355644" xlink:to="loc_prok_ProkidneyLpMember_1355646" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1355654" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1317496" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1355654" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1355655" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1355654" xlink:to="loc_us-gaap_RelatedPartyDomain_1355655" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1355655_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1355654" xlink:to="loc_us-gaap_RelatedPartyDomain_1355655_default" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PipeInvestorsMember" xlink:label="loc_prok_PipeInvestorsMember_1355659" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1355655" xlink:to="loc_prok_PipeInvestorsMember_1355659" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMember" xlink:label="loc_prok_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMember_1355666" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1355655" xlink:to="loc_prok_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMember_1355666" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember" xlink:label="loc_prok_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember_1355669" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1355655" xlink:to="loc_prok_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember_1355669" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SponsorMember" xlink:label="loc_prok_SponsorMember_1572740" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1355655" xlink:to="loc_prok_SponsorMember_1572740" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1355724" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1317496" xlink:to="loc_srt_RangeAxis_1355724" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1355725" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1355724" xlink:to="loc_srt_RangeMember_1355725" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1355725_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1355724" xlink:to="loc_srt_RangeMember_1355725_default" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1355726" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1355725" xlink:to="loc_srt_MaximumMember_1355726" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1572732" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1317496" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1572732" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1572738" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1572732" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1572738" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1572738_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1572732" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1572738_default" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PromissoryNoteMember" xlink:label="loc_prok_PromissoryNoteMember_1572739" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1572738" xlink:to="loc_prok_PromissoryNoteMember_1572739" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573404" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1317496" xlink:to="loc_dei_LegalEntityAxis_1573404" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573405" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1573404" xlink:to="loc_dei_EntityDomain_1573405" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573405_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1573404" xlink:to="loc_dei_EntityDomain_1573405_default" use="optional" order="46" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573406" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1573405" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573406" use="optional" order="47" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="loc_us-gaap_CapitalUnitsByClassAxis_1573573" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1317496" xlink:to="loc_us-gaap_CapitalUnitsByClassAxis_1573573" use="optional" order="48" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_1573575" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_1573573" xlink:to="loc_us-gaap_CapitalUnitClassDomain_1573575" use="optional" order="49" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_1573575_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_1573573" xlink:to="loc_us-gaap_CapitalUnitClassDomain_1573575_default" use="optional" order="50" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassBMember" xlink:label="loc_us-gaap_CapitalUnitClassBMember_1573577" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1573575" xlink:to="loc_us-gaap_CapitalUnitClassBMember_1573577" use="optional" order="51" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_CapitalUnitClassBOneMember" xlink:label="loc_prok_CapitalUnitClassBOneMember_1573578" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1573575" xlink:to="loc_prok_CapitalUnitClassBOneMember_1573578" use="optional" order="52" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_1574263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1317496" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_1574263" use="optional" order="53" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_1574264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_1574263" xlink:to="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_1574264" use="optional" order="54" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_1574264_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_1574263" xlink:to="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_1574264_default" use="optional" order="55" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredProfitSharingMember" xlink:label="loc_us-gaap_DeferredProfitSharingMember_1574265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_1574264" xlink:to="loc_us-gaap_DeferredProfitSharingMember_1574265" use="optional" order="56" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1572735" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1317634" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1572735" use="optional" order="57" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_1572736" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1317634" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_1572736" use="optional" order="58" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnits" xlink:label="loc_us-gaap_CapitalUnits_1573582" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1317634" xlink:to="loc_us-gaap_CapitalUnits_1573582" use="optional" order="59" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1355701" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1317634" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1355701" use="optional" order="60" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_1355708" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1317634" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_1355708" use="optional" order="61" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1355710" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1317634" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1355710" use="optional" order="62" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1355711" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1317634" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1355711" use="optional" order="63" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1355712" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1317634" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1355712" use="optional" order="64" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1573590" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1317634" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1573590" use="optional" order="65" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersCapitalAccountUnitsIssued" xlink:label="loc_us-gaap_LimitedPartnersCapitalAccountUnitsIssued_1573581" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1317634" xlink:to="loc_us-gaap_LimitedPartnersCapitalAccountUnitsIssued_1573581" use="optional" order="66" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_1573591" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1317634" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_1573591" use="optional" order="67" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized" xlink:label="loc_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized_1573580" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1317634" xlink:to="loc_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized_1573580" use="optional" order="68" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>19
<FILENAME>prok-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 09-August-2022 [04:09:18] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod" xml:lang="en-US">Entity Ex Transition Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonClassBMember" xml:lang="en-US">Common Class B [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonClassBMember" xml:lang="en-US">Class B [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonClassAMember" xml:lang="en-US">Common Class A [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonClassAMember" xml:lang="en-US">Common Class A [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredOfferingCost" xlink:label="loc_prok_DeferredOfferingCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_DeferredOfferingCost" xml:lang="en-US">Deferred Offering Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_DeferredOfferingCost" xml:lang="en-US">Deferred offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_DeferredOfferingCost" xlink:to="lab_prok_DeferredOfferingCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_DeferredOfferingCost" xml:lang="en-US">Deferred offering cost.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsHeldInTrustNoncurrent" xml:lang="en-US">Assets Held-in-trust, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsHeldInTrustNoncurrent" xml:lang="en-US">Marketable Securities held in Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldInTrustNoncurrent" xlink:to="lab_us-gaap_AssetsHeldInTrustNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PrepaidInsuranceNonCurrent" xlink:label="loc_prok_PrepaidInsuranceNonCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_PrepaidInsuranceNonCurrent" xml:lang="en-US">Prepaid Insurance Non Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_prok_PrepaidInsuranceNonCurrent" xml:lang="en-US">Non-current prepaid insurance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_PrepaidInsuranceNonCurrent" xlink:to="lab_prok_PrepaidInsuranceNonCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_PrepaidInsuranceNonCurrent" xml:lang="en-US">Prepaid insurance non current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Cash" xml:lang="en-US">Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xml:lang="en-US">Other Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xml:lang="en-US">Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xml:lang="en-US">Cash equivalents, at carrying value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PrepaidClinicalCurrent" xlink:label="loc_prok_PrepaidClinicalCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_PrepaidClinicalCurrent" xml:lang="en-US">Prepaid Clinical Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_PrepaidClinicalCurrent" xml:lang="en-US">Prepaid clinical</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_PrepaidClinicalCurrent" xlink:to="lab_prok_PrepaidClinicalCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_PrepaidClinicalCurrent" xml:lang="en-US">Prepaid clinical current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Intangible assets, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Net carrying amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Fixed assets, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Total fixed assets, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RightOfUseAssetsOperatingAndFinanceLease" xlink:label="loc_prok_RightOfUseAssetsOperatingAndFinanceLease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_RightOfUseAssetsOperatingAndFinanceLease" xml:lang="en-US">Right Of Use Assets Operating And Finance Lease</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_RightOfUseAssetsOperatingAndFinanceLease" xml:lang="en-US">Right of use assets, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_prok_RightOfUseAssetsOperatingAndFinanceLease" xml:lang="en-US">Right Of Use Assets Operating And Finance Lease</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_RightOfUseAssetsOperatingAndFinanceLease" xlink:to="lab_prok_RightOfUseAssetsOperatingAndFinanceLease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_RightOfUseAssetsOperatingAndFinanceLease" xml:lang="en-US">Right of use assets operating and finance lease.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xml:lang="en-US">Due to Related Parties, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xml:lang="en-US">Advances from related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedExpensesAndOther" xlink:label="loc_prok_AccruedExpensesAndOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_AccruedExpensesAndOther" xml:lang="en-US">Accrued Expenses And Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_prok_AccruedExpensesAndOther" xml:lang="en-US">Accrued expenses and other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_AccruedExpensesAndOther" xlink:to="lab_prok_AccruedExpensesAndOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_AccruedExpensesAndOther" xml:lang="en-US">Accrued expenses and other.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedExpensesCurrent" xlink:label="loc_prok_AccruedExpensesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_AccruedExpensesCurrent" xml:lang="en-US">Accrued Expenses Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_AccruedExpensesCurrent" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_AccruedExpensesCurrent" xlink:to="lab_prok_AccruedExpensesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_AccruedExpensesCurrent" xml:lang="en-US">Accrued expenses current.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_CurrentAccountsPayable" xlink:label="loc_prok_CurrentAccountsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_CurrentAccountsPayable" xml:lang="en-US">Current Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_CurrentAccountsPayable" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_CurrentAccountsPayable" xlink:to="lab_prok_CurrentAccountsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_CurrentAccountsPayable" xml:lang="en-US">Current accounts payable.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OperatingAndFinanceLeaseLiabilitiesCurrent" xlink:label="loc_prok_OperatingAndFinanceLeaseLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_OperatingAndFinanceLeaseLiabilitiesCurrent" xml:lang="en-US">Operating And Finance Lease Liabilities Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_OperatingAndFinanceLeaseLiabilitiesCurrent" xml:lang="en-US">Lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_prok_OperatingAndFinanceLeaseLiabilitiesCurrent" xml:lang="en-US">Operating And Finance Lease Liabilities Current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_OperatingAndFinanceLeaseLiabilitiesCurrent" xlink:to="lab_prok_OperatingAndFinanceLeaseLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_OperatingAndFinanceLeaseLiabilitiesCurrent" xml:lang="en-US">Operating and finance lease liabilities current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxesPayableCurrent" xml:lang="en-US">Taxes Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxesPayableCurrent" xml:lang="en-US">Income taxes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xml:lang="en-US">Notes Payable, Related Parties, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xml:lang="en-US">Related party notes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:to="lab_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies (Note 6)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredUnderwritingCommissions" xlink:label="loc_prok_DeferredUnderwritingCommissions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_DeferredUnderwritingCommissions" xml:lang="en-US">Deferred Underwriting Commissions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_DeferredUnderwritingCommissions" xml:lang="en-US">Deferred underwriting fee payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_DeferredUnderwritingCommissions" xlink:to="lab_prok_DeferredUnderwritingCommissions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_DeferredUnderwritingCommissions" xml:lang="en-US">Deferred underwriting fee payable.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Shareholder's Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional&#160;paid-in&#160;capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total Permanent Deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preference shares, $0.0001 par value; 5,000,000 shares authorized; no&#160;shares issued and&#160;outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stock value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Class A ordinary shares subject to possible redemption</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xml:lang="en-US">Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion" xlink:label="loc_prok_OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion" xml:lang="en-US">Operating And Finance Lease Liabilities Non Current Portion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion" xml:lang="en-US">Lease liabilities, net of current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion" xlink:to="lab_prok_OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion" xml:lang="en-US">Operating and finance lease liabilities non current portion.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MembersEquityAbstract" xlink:label="loc_us-gaap_MembersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MembersEquityAbstract" xml:lang="en-US">Members' Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MembersEquityAbstract" xml:lang="en-US">Members' equity:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MembersEquityAbstract" xlink:to="lab_us-gaap_MembersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersContributedCapital" xlink:label="loc_us-gaap_LimitedPartnersContributedCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LimitedPartnersContributedCapital" xml:lang="en-US">Limited Partners' Contributed Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LimitedPartnersContributedCapital" xml:lang="en-US">Class Units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LimitedPartnersContributedCapital" xlink:to="lab_us-gaap_LimitedPartnersContributedCapital" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained earnings accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapital" xlink:label="loc_us-gaap_PartnersCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PartnersCapital" xml:lang="en-US">Partners' Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PartnersCapital" xml:lang="en-US">Total members' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_PartnersCapital" xml:lang="en-US">Ending Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_PartnersCapital" xml:lang="en-US">Beginning Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PartnersCapital" xlink:to="lab_us-gaap_PartnersCapital" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xml:lang="en-US">Social Capital Suvretta Holdings Corp. III [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:to="lab_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xml:lang="en-US">Social capital suvretta holdings corp. III.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="loc_us-gaap_CapitalUnitsByClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalUnitsByClassAxis" xml:lang="en-US">Capital Units by Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis" xlink:to="lab_us-gaap_CapitalUnitsByClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalUnitClassDomain" xml:lang="en-US">Capital Unit, Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalUnitClassDomain" xlink:to="lab_us-gaap_CapitalUnitClassDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassBMember" xlink:label="loc_us-gaap_CapitalUnitClassBMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalUnitClassBMember" xml:lang="en-US">Capital Unit, Class B [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalUnitClassBMember" xml:lang="en-US">Capital Unit, Class B [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalUnitClassBMember" xlink:to="lab_us-gaap_CapitalUnitClassBMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassAMember" xlink:label="loc_us-gaap_CapitalUnitClassAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalUnitClassAMember" xml:lang="en-US">Capital Unit, Class A [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalUnitClassAMember" xml:lang="en-US">Capital Unit, Class A [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalUnitClassAMember" xlink:to="lab_us-gaap_CapitalUnitClassAMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding" xlink:label="loc_us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding" xml:lang="en-US">Limited Partners' Capital Account, Units Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding" xml:lang="en-US">Limited partners capital account units outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding" xml:lang="en-US">Ending Balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding" xml:lang="en-US">Units outstanding January&#160;1, 2020</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding" xlink:to="lab_us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersCapitalAccountUnitsIssued" xlink:label="loc_us-gaap_LimitedPartnersCapitalAccountUnitsIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LimitedPartnersCapitalAccountUnitsIssued" xml:lang="en-US">Limited Partners' Capital Account, Units Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LimitedPartnersCapitalAccountUnitsIssued" xml:lang="en-US">Limited partners capital account units issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LimitedPartnersCapitalAccountUnitsIssued" xml:lang="en-US">Limited Partners' Capital Account, Units Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LimitedPartnersCapitalAccountUnitsIssued" xlink:to="lab_us-gaap_LimitedPartnersCapitalAccountUnitsIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Temporary Equity, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Temporary Equity, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Beginning balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xml:lang="en-US">Ending Balance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other income:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Investment Income, Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Interest earned on marketable securities held in Trust Account</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Interest earned on marketable securities held in Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating" xml:lang="en-US">Investment Income, Nonoperating</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestmentIncomeNonoperating" xml:lang="en-US">Interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNonoperating" xlink:to="lab_us-gaap_InvestmentIncomeNonoperating" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating and formation costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net income loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Allocation of net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Net loss before income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax expense (benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax expense (benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted average Class A Units outstanding , Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Net loss per ordinary share , Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Net loss per Class A Unit , Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Net loss per ordinary share , Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Net loss per Class A Unit , Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted average Class A Units outstanding , Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestExpense" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xml:lang="en-US">Forfeiture of Founder Shares (share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xml:lang="en-US">Share based compensation shares forfeited during the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Ending Balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Beginning Balance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Sale of 25,000,000 Public Shares, net of underwriting discounts and offering expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Capital contribution(Shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock issued during period new shares issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock issued during period, shares, new issues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Issuance of Class B ordinary shares to Sponsor</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US">Stock shares issued during the period for services value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, Forfeited</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xml:lang="en-US">Equity-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity" xlink:label="loc_prok_RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity" xml:lang="en-US">Remeasurement of Ordinary Shares to Redemption Value Temporary Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_prok_RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity" xml:lang="en-US">Remeasurement of Class A ordinary shares to redemption value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity" xml:lang="en-US">Accretion of carrying value to redemption value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity" xlink:to="lab_prok_RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity" xml:lang="en-US">Remeasurement of Class A ordinary shares to redemption value.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PartnersCapitalOutstanding" xlink:label="loc_prok_PartnersCapitalOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_PartnersCapitalOutstanding" xml:lang="en-US">Partners Capital Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_prok_PartnersCapitalOutstanding" xml:lang="en-US">Ending Balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_prok_PartnersCapitalOutstanding" xml:lang="en-US">Units outstanding January&#160;1, 2020</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_PartnersCapitalOutstanding" xlink:to="lab_prok_PartnersCapitalOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_PartnersCapitalOutstanding" xml:lang="en-US">Partners capital Outstanding.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapitalAccountContributions" xlink:label="loc_us-gaap_PartnersCapitalAccountContributions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PartnersCapitalAccountContributions" xml:lang="en-US">Partners' Capital Account, Contributions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_PartnersCapitalAccountContributions" xml:lang="en-US">Capital contribution(Value)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PartnersCapitalAccountContributions" xlink:to="lab_us-gaap_PartnersCapitalAccountContributions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapitalAccountUnitsContributed" xlink:label="loc_us-gaap_PartnersCapitalAccountUnitsContributed" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PartnersCapitalAccountUnitsContributed" xml:lang="en-US">Partners' Capital Account, Units, Contributed</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_PartnersCapitalAccountUnitsContributed" xml:lang="en-US">Capital contribution(Shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PartnersCapitalAccountUnitsContributed" xml:lang="en-US">Issued 2020</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PartnersCapitalAccountUnitsContributed" xlink:to="lab_us-gaap_PartnersCapitalAccountUnitsContributed" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_prok_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Temporary Equity Stock Issued During Period Shares New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_prok_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Sale of 25,000,000 Public Shares, net of underwriting discounts and offering expenses (shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_prok_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Temporary equity stock issued during period shares new issues.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Issuance of Class B ordinary shares to Sponsor (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US">Stock shares issued during the period for services shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Capital contribution(Value)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MemberUnitsMember" xlink:label="loc_us-gaap_MemberUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MemberUnitsMember" xml:lang="en-US">Member Units [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MemberUnitsMember" xml:lang="en-US">Member Units [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MemberUnitsMember" xlink:to="lab_us-gaap_MemberUnitsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_TemporaryEquityStockIssuedDuringThePeriodShares" xlink:label="loc_prok_TemporaryEquityStockIssuedDuringThePeriodShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_TemporaryEquityStockIssuedDuringThePeriodShares" xml:lang="en-US">Temporary Equity Stock Issued During The Period Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_TemporaryEquityStockIssuedDuringThePeriodShares" xml:lang="en-US">Temporary Equity Stock Issued During The Period Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_TemporaryEquityStockIssuedDuringThePeriodShares" xlink:to="lab_prok_TemporaryEquityStockIssuedDuringThePeriodShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_TemporaryEquityStockIssuedDuringThePeriodShares" xml:lang="en-US">Temporary equity stock issued during the period shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds from sale of Private Placement Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds from private placement issue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash Flows from Financing Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RepaymentOfAdvancesFromRelatedParty" xlink:label="loc_prok_RepaymentOfAdvancesFromRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_RepaymentOfAdvancesFromRelatedParty" xml:lang="en-US">Repayment Of Advances From Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_prok_RepaymentOfAdvancesFromRelatedParty" xml:lang="en-US">Repayment of advances from related party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_RepaymentOfAdvancesFromRelatedParty" xml:lang="en-US">Repayment of advances from related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_RepaymentOfAdvancesFromRelatedParty" xlink:to="lab_prok_RepaymentOfAdvancesFromRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_RepaymentOfAdvancesFromRelatedParty" xml:lang="en-US">Repayment of advances from related party.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash flows from financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xml:lang="en-US">Proceeds from Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromNotesPayable" xml:lang="en-US">Proceeds from promissory note&#8212;related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_us-gaap_ProceedsFromNotesPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xml:lang="en-US">Proceeds from (Repayments of) Related Party Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xml:lang="en-US">Advances from related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payment of offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RepaymentOfPromissoryNoteRelatedParty" xlink:label="loc_prok_RepaymentOfPromissoryNoteRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_RepaymentOfPromissoryNoteRelatedParty" xml:lang="en-US">Repayment of Promissory Note Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_RepaymentOfPromissoryNoteRelatedParty" xml:lang="en-US">Repayment of promissory note&#8212;related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_RepaymentOfPromissoryNoteRelatedParty" xlink:to="lab_prok_RepaymentOfPromissoryNoteRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_RepaymentOfPromissoryNoteRelatedParty" xml:lang="en-US">Repayment of Promissory Note Related Party.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from sale of Public Shares, net of underwriting discounts paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from initial public offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Gross proceeds</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xml:lang="en-US">Finance Lease, Principal Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xml:lang="en-US">Payments on finance leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" xml:lang="en-US">Proceeds from Issuance of Common Limited Partners Units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" xml:lang="en-US">Net cash contribution</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xml:lang="en-US">Proceeds from Related Party Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xml:lang="en-US">Borrowings under related party notes payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt" xml:lang="en-US">Amount drew under the note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="lab_us-gaap_ProceedsFromRelatedPartyDebt" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, end of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, beginning of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Non-Cash Investing and Financing Activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RemeasurementOfClassAOrdinarySharesToRedemptionValue" xlink:label="loc_prok_RemeasurementOfClassAOrdinarySharesToRedemptionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_RemeasurementOfClassAOrdinarySharesToRedemptionValue" xml:lang="en-US">Remeasurement Of Class A Ordinary Shares To Redemption Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_RemeasurementOfClassAOrdinarySharesToRedemptionValue" xml:lang="en-US">Remeasurement of Class A ordinary shares subject to possible redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_RemeasurementOfClassAOrdinarySharesToRedemptionValue" xlink:to="lab_prok_RemeasurementOfClassAOrdinarySharesToRedemptionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_RemeasurementOfClassAOrdinarySharesToRedemptionValue" xml:lang="en-US">Remeasurement of class A ordinary shares to redemption value.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssued1" xml:lang="en-US">Stock Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssued1" xml:lang="en-US">Offering costs paid by Sponsor in exchange for issuance of Founder Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredUnderwritingFeesAccruedButNotPaid" xlink:label="loc_prok_DeferredUnderwritingFeesAccruedButNotPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_DeferredUnderwritingFeesAccruedButNotPaid" xml:lang="en-US">Deferred Underwriting Fees Accrued But Not Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_DeferredUnderwritingFeesAccruedButNotPaid" xml:lang="en-US">Deferred underwriting fee payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_DeferredUnderwritingFeesAccruedButNotPaid" xlink:to="lab_prok_DeferredUnderwritingFeesAccruedButNotPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_DeferredUnderwritingFeesAccruedButNotPaid" xml:lang="en-US">Deferred underwriting fees accrued but not paid.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OfferingCostsIncludedInAccruedOfferingCosts" xlink:label="loc_prok_OfferingCostsIncludedInAccruedOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_OfferingCostsIncludedInAccruedOfferingCosts" xml:lang="en-US">Offering Costs Included In Accrued Offering Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_OfferingCostsIncludedInAccruedOfferingCosts" xml:lang="en-US">Offering costs included in accrued offering costs.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_OfferingCostsIncludedInAccruedOfferingCosts" xlink:to="lab_prok_OfferingCostsIncludedInAccruedOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_OfferingCostsIncludedInAccruedOfferingCosts" xml:lang="en-US">Offering costs included in accrued offering costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract" xml:lang="en-US">Supplemental disclosure of non-cash investing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xml:lang="en-US">Equipment and facility expansion included in accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RightOfUseAssetsObtainedInExchangeForLeaseObligations" xlink:label="loc_prok_RightOfUseAssetsObtainedInExchangeForLeaseObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_RightOfUseAssetsObtainedInExchangeForLeaseObligations" xml:lang="en-US">Right Of Use Assets Obtained In Exchange For Lease Obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_prok_RightOfUseAssetsObtainedInExchangeForLeaseObligations" xml:lang="en-US">Right of use assets obtained in exchange for lease obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_RightOfUseAssetsObtainedInExchangeForLeaseObligations" xlink:to="lab_prok_RightOfUseAssetsObtainedInExchangeForLeaseObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_RightOfUseAssetsObtainedInExchangeForLeaseObligations" xml:lang="en-US">Right of use assets obtained in exchange for lease obligations.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash Flows from Operating Activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_FormationCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares" xlink:label="loc_prok_FormationCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_FormationCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares" xml:lang="en-US">Formation Costs Paid By Sponsor In Exchange For Issuance Of Ordinary Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_FormationCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares" xml:lang="en-US">Formation costs paid by Sponsor in exchange for issuance of Founder Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_FormationCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares" xlink:to="lab_prok_FormationCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_FormationCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares" xml:lang="en-US">Formation costs paid by sponsor in exchange for issuance of ordinary shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Equity-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_IncreaseDecreaseOfAdvanceFromRelatedParty" xlink:label="loc_prok_IncreaseDecreaseOfAdvanceFromRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_IncreaseDecreaseOfAdvanceFromRelatedParty" xml:lang="en-US">Increase Decrease of Advance From Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_prok_IncreaseDecreaseOfAdvanceFromRelatedParty" xml:lang="en-US">Advances from related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_IncreaseDecreaseOfAdvanceFromRelatedParty" xlink:to="lab_prok_IncreaseDecreaseOfAdvanceFromRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_IncreaseDecreaseOfAdvanceFromRelatedParty" xml:lang="en-US">Increase decrease of advance from related party.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xml:lang="en-US">Income taxes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash Flows from Investing Activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash used in investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xml:lang="en-US">Payments to Acquire Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xml:lang="en-US">Investment of cash into Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US">Proceeds from sale of equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xml:lang="en-US">Payments to Acquire Productive Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xml:lang="en-US">Purchase of equipment and facility expansion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_prok_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_prok_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, end of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_prok_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, beginning of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_prok_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, cash equivalent, restricted cash and restricted cash equivalents.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Net change in cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NatureOfOperations" xml:lang="en-US">Nature of Operations [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NatureOfOperations" xml:lang="en-US">Description Of Organization, Business Operations And Going Concern</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_InitialPublicOfferingDisclosureTextBlock" xlink:label="loc_prok_InitialPublicOfferingDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_InitialPublicOfferingDisclosureTextBlock" xml:lang="en-US">Initial Public Offering Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_InitialPublicOfferingDisclosureTextBlock" xml:lang="en-US">Initial Public Offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_InitialPublicOfferingDisclosureTextBlock" xlink:to="lab_prok_InitialPublicOfferingDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_InitialPublicOfferingDisclosureTextBlock" xml:lang="en-US">Initial public offering disclosure [text block].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PrivatePlacementAbstract" xlink:label="loc_prok_PrivatePlacementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_PrivatePlacementAbstract" xml:lang="en-US">Private Placement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_PrivatePlacementAbstract" xlink:to="lab_prok_PrivatePlacementAbstract" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PrivatePlacementDisclosureTextBlock" xlink:label="loc_prok_PrivatePlacementDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_PrivatePlacementDisclosureTextBlock" xml:lang="en-US">Private Placement Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_PrivatePlacementDisclosureTextBlock" xml:lang="en-US">Private Placement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_PrivatePlacementDisclosureTextBlock" xlink:to="lab_prok_PrivatePlacementDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_PrivatePlacementDisclosureTextBlock" xml:lang="en-US">Private placement disclosure [text block].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesAbstract" xml:lang="en-US">Leases [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MembersEquityNotesDisclosureTextBlock" xlink:label="loc_us-gaap_MembersEquityNotesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MembersEquityNotesDisclosureTextBlock" xml:lang="en-US">Members' Equity Notes Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MembersEquityNotesDisclosureTextBlock" xml:lang="en-US">Members' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MembersEquityNotesDisclosureTextBlock" xlink:to="lab_us-gaap_MembersEquityNotesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Temporary Equity and Permanent Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Net Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Equity Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Event [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredOfferingCostsPolicyTextBlock" xlink:label="loc_prok_DeferredOfferingCostsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_DeferredOfferingCostsPolicyTextBlock" xml:lang="en-US">Deferred Offering Costs [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_DeferredOfferingCostsPolicyTextBlock" xml:lang="en-US">Offering Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_DeferredOfferingCostsPolicyTextBlock" xlink:to="lab_prok_DeferredOfferingCostsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_DeferredOfferingCostsPolicyTextBlock" xml:lang="en-US">Deferred offering costs [policy text block].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recently Adopted Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Net Loss Per Ordinary Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Equity-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration of Credit Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="loc_prok_EmergingGrowthCompanyStatusPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_EmergingGrowthCompanyStatusPolicyTextBlock" xml:lang="en-US">Emerging Growth Company Status [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_prok_EmergingGrowthCompanyStatusPolicyTextBlock" xml:lang="en-US">Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:to="lab_prok_EmergingGrowthCompanyStatusPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_EmergingGrowthCompanyStatusPolicyTextBlock" xml:lang="en-US">Emerging growth company status [policy text block].</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_TemporaryEquityPolicyTextBlock" xlink:label="loc_prok_TemporaryEquityPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_TemporaryEquityPolicyTextBlock" xml:lang="en-US">Temporary Equity [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_TemporaryEquityPolicyTextBlock" xml:lang="en-US">Class A Ordinary Shares Subject to Possible Redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_TemporaryEquityPolicyTextBlock" xlink:to="lab_prok_TemporaryEquityPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_TemporaryEquityPolicyTextBlock" xml:lang="en-US">Temporary equity [Policy text block].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xml:lang="en-US">Marketable Securities Held in Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedExpensesPolicyTextBlock" xlink:label="loc_prok_AccruedExpensesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_AccruedExpensesPolicyTextBlock" xml:lang="en-US">Accrued Expenses [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_AccruedExpensesPolicyTextBlock" xml:lang="en-US">Accrued Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_AccruedExpensesPolicyTextBlock" xlink:to="lab_prok_AccruedExpensesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_AccruedExpensesPolicyTextBlock" xml:lang="en-US">Accrued expenses [Policy text block].</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_GoingConcernPolicyTextBlock" xlink:label="loc_prok_GoingConcernPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_GoingConcernPolicyTextBlock" xml:lang="en-US">Going Concern [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_GoingConcernPolicyTextBlock" xml:lang="en-US">Going Concern</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_GoingConcernPolicyTextBlock" xlink:to="lab_prok_GoingConcernPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_GoingConcernPolicyTextBlock" xml:lang="en-US">Going concern [Policy text block].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Fixed Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xml:lang="en-US">Intangible Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xml:lang="en-US">Impairment of Long-Lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock" xlink:label="loc_us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Accounting Policy Election, Measurement Date [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock" xml:lang="en-US">Defined Contribution Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock" xlink:to="lab_us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xml:lang="en-US">Subsequent Events, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SubsequentEventsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ContingentLiabilitiesPolicyTextBlock" xlink:label="loc_prok_ContingentLiabilitiesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_ContingentLiabilitiesPolicyTextBlock" xml:lang="en-US">Contingent Liabilities [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_ContingentLiabilitiesPolicyTextBlock" xml:lang="en-US">Contingent Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_ContingentLiabilitiesPolicyTextBlock" xlink:to="lab_prok_ContingentLiabilitiesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_ContingentLiabilitiesPolicyTextBlock" xml:lang="en-US">Contingent liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of calculation of basic and diluted net income (loss) per ordinary share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DisclosureInTabularFormOfUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:label="loc_prok_DisclosureInTabularFormOfUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_DisclosureInTabularFormOfUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xml:lang="en-US">Disclosure In Tabular Form Of Useful Lives Of Property Plant And Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_DisclosureInTabularFormOfUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xml:lang="en-US">Schedule of estimated useful lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_DisclosureInTabularFormOfUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:to="lab_prok_DisclosureInTabularFormOfUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_DisclosureInTabularFormOfUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xml:lang="en-US">Disclosure in tabular form of useful lives of property plant and equipment [Table Text Block].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Schedule of fixed assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock" xml:lang="en-US">Temporary Equity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock" xml:lang="en-US">Schedule of Class A Ordinary shares reflected in the Balance Sheets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityTableTextBlock" xlink:to="lab_us-gaap_TemporaryEquityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xml:lang="en-US">Schedule of intangible asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_LesseeOperatingAndFinanceLeaseTableTextBlock" xlink:label="loc_prok_LesseeOperatingAndFinanceLeaseTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_LesseeOperatingAndFinanceLeaseTableTextBlock" xml:lang="en-US">Lessee operating and finance lease [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_LesseeOperatingAndFinanceLeaseTableTextBlock" xml:lang="en-US">Schedule of the classification of operating and finance lease assets and obligations in the Company's Consolidated Balance Sheets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_LesseeOperatingAndFinanceLeaseTableTextBlock" xlink:to="lab_prok_LesseeOperatingAndFinanceLeaseTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_LesseeOperatingAndFinanceLeaseTableTextBlock" xml:lang="en-US">Lessee operating and finance lease.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xml:lang="en-US">Contractual Obligation, Fiscal Year Maturity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xml:lang="en-US">Schedule of Maturities of lease liabilities for the Company's operating and finance leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_MembersEquityTableTextBlock" xlink:label="loc_prok_MembersEquityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_MembersEquityTableTextBlock" xml:lang="en-US">Members Equity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_MembersEquityTableTextBlock" xml:lang="en-US">Schedule Of Members Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_MembersEquityTableTextBlock" xlink:to="lab_prok_MembersEquityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_MembersEquityTableTextBlock" xml:lang="en-US">Members equity</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xml:lang="en-US">Summary of Assets that are Measured at Fair Value on a Recurring Basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Summary of Compensation Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xml:lang="en-US">Summary of the activity related to the Company's Class B and B-1 Units granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xml:lang="en-US">Summary of key assumptions used in the OPM valuation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DescriptionOfOrganizationAndBusinessOperationsTable" xlink:label="loc_prok_DescriptionOfOrganizationAndBusinessOperationsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_DescriptionOfOrganizationAndBusinessOperationsTable" xml:lang="en-US">Description Of Organization And Business Operations [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsTable" xlink:to="lab_prok_DescriptionOfOrganizationAndBusinessOperationsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xml:lang="en-US">Over-Allotment Option [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DescriptionOfOrganizationAndBusinessOperationsLineItems" xlink:label="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems" xml:lang="en-US">Description Of Organization And Business Operations [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems" xlink:to="lab_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ProspectiveAssetsOfAcquireeAsAPercentageOfFairValueOfAssetsInTheTrustAccount" xlink:label="loc_prok_ProspectiveAssetsOfAcquireeAsAPercentageOfFairValueOfAssetsInTheTrustAccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_ProspectiveAssetsOfAcquireeAsAPercentageOfFairValueOfAssetsInTheTrustAccount" xml:lang="en-US">Prospective Assets Of Acquiree As A Percentage Of Fair Value Of Assets In The Trust Account</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_ProspectiveAssetsOfAcquireeAsAPercentageOfFairValueOfAssetsInTheTrustAccount" xml:lang="en-US">Prospective assets of acquiree as a percentage of fair value of assets in the trust account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_ProspectiveAssetsOfAcquireeAsAPercentageOfFairValueOfAssetsInTheTrustAccount" xlink:to="lab_prok_ProspectiveAssetsOfAcquireeAsAPercentageOfFairValueOfAssetsInTheTrustAccount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_ProspectiveAssetsOfAcquireeAsAPercentageOfFairValueOfAssetsInTheTrustAccount" xml:lang="en-US">Prospective assets of acquiree as a percentage of fair value of assets in the trust account.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockHeldInTrust" xlink:label="loc_us-gaap_CommonStockHeldInTrust" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockHeldInTrust" xml:lang="en-US">Common Stock Held in Trust</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockHeldInTrust" xml:lang="en-US">Common stock held in trust account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockHeldInTrust" xlink:to="lab_us-gaap_CommonStockHeldInTrust" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredOfferingCosts" xml:lang="en-US">Deferred Offering Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredOfferingCosts" xml:lang="en-US">Deferred offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts" xlink:to="lab_us-gaap_DeferredOfferingCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xml:lang="en-US">Equity method investment ownership percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_UnderwritingFee" xlink:label="loc_prok_UnderwritingFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_UnderwritingFee" xml:lang="en-US">Underwriting Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_UnderwritingFee" xml:lang="en-US">Underwriting fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_UnderwritingFee" xlink:to="lab_prok_UnderwritingFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_UnderwritingFee" xml:lang="en-US">Underwriting fee.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredUnderwritingFees" xlink:label="loc_prok_DeferredUnderwritingFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_DeferredUnderwritingFees" xml:lang="en-US">Deferred Underwriting Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_DeferredUnderwritingFees" xml:lang="en-US">Deferred underwriting fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_DeferredUnderwritingFees" xlink:to="lab_prok_DeferredUnderwritingFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_DeferredUnderwritingFees" xml:lang="en-US">Deferred underwriting fee.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinimumNetWorthRequiredForCompliance" xlink:label="loc_us-gaap_MinimumNetWorthRequiredForCompliance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MinimumNetWorthRequiredForCompliance" xml:lang="en-US">Banking Regulation, Mortgage Banking, Net Worth, Minimum</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MinimumNetWorthRequiredForCompliance" xml:lang="en-US">Minimum net worth to consummate business combination</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumNetWorthRequiredForCompliance" xlink:to="lab_us-gaap_MinimumNetWorthRequiredForCompliance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of stock price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PercentageOfPublicSharesThatCanBeTransferredWithoutAnyRestriction" xlink:label="loc_prok_PercentageOfPublicSharesThatCanBeTransferredWithoutAnyRestriction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_PercentageOfPublicSharesThatCanBeTransferredWithoutAnyRestriction" xml:lang="en-US">Percentage Of Public Shares That Can Be Transferred Without Any Restriction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_PercentageOfPublicSharesThatCanBeTransferredWithoutAnyRestriction" xml:lang="en-US">Percentage of public shares that can be transferred without any restriction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_PercentageOfPublicSharesThatCanBeTransferredWithoutAnyRestriction" xlink:to="lab_prok_PercentageOfPublicSharesThatCanBeTransferredWithoutAnyRestriction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_PercentageOfPublicSharesThatCanBeTransferredWithoutAnyRestriction" xml:lang="en-US">Percentage of public shares that can be transferred without any restriction.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated" xlink:label="loc_prok_PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated" xml:lang="en-US">Percentage Of Public Shares To Be Redeemed In Case Business Combination Is Not Consummated</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated" xml:lang="en-US">Percentage of public shares to be redeemed in case business combination is not consummated</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated" xlink:to="lab_prok_PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated" xml:lang="en-US">Percentage of public shares to be redeemed in case business combination is not consummated.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities" xlink:label="loc_us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities" xml:lang="en-US">Liquidation Basis of Accounting, Accrued Costs to Dispose of Assets and Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities" xml:lang="en-US">Interest to pay dissolution expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities" xlink:to="lab_us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PerShareValueOfRestrictedAssets" xlink:label="loc_prok_PerShareValueOfRestrictedAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_PerShareValueOfRestrictedAssets" xml:lang="en-US">Per Share Value Of Restricted Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_PerShareValueOfRestrictedAssets" xml:lang="en-US">Per share value of restricted assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_PerShareValueOfRestrictedAssets" xlink:to="lab_prok_PerShareValueOfRestrictedAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_PerShareValueOfRestrictedAssets" xml:lang="en-US">Per share value of restricted assets.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationDateOfIncorporation" xml:lang="en-US">Entity Incorporation, Date of Incorporation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_dei_EntityIncorporationDateOfIncorporation" xml:lang="en-US">Incorporation date of entity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationDateOfIncorporation" xlink:to="lab_dei_EntityIncorporationDateOfIncorporation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xml:lang="en-US">Business acquisition, equity interest issued or issuable, number of shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xml:lang="en-US">Business Acquisition, Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xml:lang="en-US">Business acquisition, share price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_TransactionCostsIncurredInConnectionWithInitialPublicOffering" xlink:label="loc_prok_TransactionCostsIncurredInConnectionWithInitialPublicOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_TransactionCostsIncurredInConnectionWithInitialPublicOffering" xml:lang="en-US">Transaction Costs Incurred In Connection With Initial Public Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_TransactionCostsIncurredInConnectionWithInitialPublicOffering" xml:lang="en-US">Transaction costs incurred inconnection with initial public offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_TransactionCostsIncurredInConnectionWithInitialPublicOffering" xlink:to="lab_prok_TransactionCostsIncurredInConnectionWithInitialPublicOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_TransactionCostsIncurredInConnectionWithInitialPublicOffering" xml:lang="en-US">Transaction costs incurred in connection with initial public offering.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PercentageOfPublicSharesRedemption" xlink:label="loc_prok_PercentageOfPublicSharesRedemption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_PercentageOfPublicSharesRedemption" xml:lang="en-US">Percentage Of Public Shares Redemption</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_PercentageOfPublicSharesRedemption" xml:lang="en-US">Percentage of public shares redemption</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_PercentageOfPublicSharesRedemption" xlink:to="lab_prok_PercentageOfPublicSharesRedemption" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_PercentageOfPublicSharesRedemption" xml:lang="en-US">Percentage of public shares redemption.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_WorkingCapital" xlink:label="loc_prok_WorkingCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_WorkingCapital" xml:lang="en-US">Working Capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_WorkingCapital" xlink:to="lab_prok_WorkingCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_WorkingCapital" xml:lang="en-US">Working capital .</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of stock, number of shares issued in transaction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Sale of stock, consideration received on transaction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ProkidneyLpMember" xlink:label="loc_prok_ProkidneyLpMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_ProkidneyLpMember" xml:lang="en-US">ProKidney LP [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_ProkidneyLpMember" xlink:to="lab_prok_ProkidneyLpMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xml:lang="en-US">Equity Interest Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xml:lang="en-US">Equity Interest Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xml:lang="en-US">Equity Interest Issued or Issuable, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:to="lab_us-gaap_EquityInterestIssuedOrIssuableTypeDomain" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RestrictedStockRightsMember" xlink:label="loc_prok_RestrictedStockRightsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_RestrictedStockRightsMember" xml:lang="en-US">Restricted Stock Rights [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_RestrictedStockRightsMember" xlink:to="lab_prok_RestrictedStockRightsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_RestrictedStockRightsMember" xml:lang="en-US">Restricted stock rights[Member].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PipeInvestorsMember" xlink:label="loc_prok_PipeInvestorsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_PipeInvestorsMember" xml:lang="en-US">PIPE Investors [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_PipeInvestorsMember" xlink:to="lab_prok_PipeInvestorsMember" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMember" xlink:label="loc_prok_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMember" xml:lang="en-US">Existing Directors, Officers And Equityholders Of, Or Investment Funds Managed By Suvretta Capital Management, LLC [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMember" xlink:to="lab_prok_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMember" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember" xlink:label="loc_prok_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember" xml:lang="en-US">Existing Directors, Officers And Unitholders Of ProKidney [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember" xlink:to="lab_prok_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SharePriceRangeAxis" xlink:label="loc_prok_SharePriceRangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_SharePriceRangeAxis" xml:lang="en-US">Share Price Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_SharePriceRangeAxis" xlink:to="lab_prok_SharePriceRangeAxis" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SharePriceRangeDomain" xlink:label="loc_prok_SharePriceRangeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_SharePriceRangeDomain" xml:lang="en-US">Share Price Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_SharePriceRangeDomain" xlink:to="lab_prok_SharePriceRangeDomain" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SharePriceOneMember" xlink:label="loc_prok_SharePriceOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_SharePriceOneMember" xml:lang="en-US">Share Price One [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_SharePriceOneMember" xlink:to="lab_prok_SharePriceOneMember" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SharePriceThreeMember" xlink:label="loc_prok_SharePriceThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_SharePriceThreeMember" xml:lang="en-US">Share Price Three [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_SharePriceThreeMember" xlink:to="lab_prok_SharePriceThreeMember" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SharePriceTwoMember" xlink:label="loc_prok_SharePriceTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_SharePriceTwoMember" xml:lang="en-US">Share Price Two [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_SharePriceTwoMember" xlink:to="lab_prok_SharePriceTwoMember" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_NatureOfOperationsTable" xlink:label="loc_prok_NatureOfOperationsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_NatureOfOperationsTable" xml:lang="en-US">Nature Of Operations [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_NatureOfOperationsTable" xlink:to="lab_prok_NatureOfOperationsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_NatureOfOperationsTable" xml:lang="en-US">Nature of operations.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RegenAndTwinCityBioLlcMember" xlink:label="loc_prok_RegenAndTwinCityBioLlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_RegenAndTwinCityBioLlcMember" xml:lang="en-US">Regen And Twin City Bio LLC [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_RegenAndTwinCityBioLlcMember" xlink:to="lab_prok_RegenAndTwinCityBioLlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_RegenAndTwinCityBioLlcMember" xml:lang="en-US">Regen and twin city bio LLC.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_NatureOfOperationsLineItems" xlink:label="loc_prok_NatureOfOperationsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_NatureOfOperationsLineItems" xml:lang="en-US">Nature Of Operations [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_NatureOfOperationsLineItems" xlink:to="lab_prok_NatureOfOperationsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_NatureOfOperationsLineItems" xml:lang="en-US">Nature of operations.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_InitialCapital" xlink:label="loc_prok_InitialCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_InitialCapital" xml:lang="en-US">Initial Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_InitialCapital" xml:lang="en-US">Initial capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_InitialCapital" xlink:to="lab_prok_InitialCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_InitialCapital" xml:lang="en-US">Initial capital.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xml:lang="en-US">Business Combination, Consideration Transferred</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xml:lang="en-US">Business combination consideration transferred</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccountingPoliciesTable" xlink:label="loc_prok_AccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_AccountingPoliciesTable" xml:lang="en-US">Accounting Policies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_AccountingPoliciesTable" xlink:to="lab_prok_AccountingPoliciesTable" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccountingPoliciesLineItems" xlink:label="loc_prok_AccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_AccountingPoliciesLineItems" xml:lang="en-US">Accounting Policies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_AccountingPoliciesLineItems" xlink:to="lab_prok_AccountingPoliciesLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xml:lang="en-US">Unrecognized tax benefits, accrued interests and penalities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized Tax Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized tax benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Benefits at the beginning of the year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Benefits at the end of the year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFDICInsuredAmount" xml:lang="en-US">Cash, FDIC Insured Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashFDICInsuredAmount" xml:lang="en-US">Cash, FDIC insured amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFDICInsuredAmount" xlink:to="lab_us-gaap_CashFDICInsuredAmount" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedPrintingExpense" xlink:label="loc_prok_AccruedPrintingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_AccruedPrintingExpense" xml:lang="en-US">Accrued Printing Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_AccruedPrintingExpense" xml:lang="en-US">Accrued printing expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_AccruedPrintingExpense" xlink:to="lab_prok_AccruedPrintingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_AccruedPrintingExpense" xml:lang="en-US">Accrued printing expense.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedDueDiligenceExpense" xlink:label="loc_prok_AccruedDueDiligenceExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_AccruedDueDiligenceExpense" xml:lang="en-US">Accrued Due Diligence Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_AccruedDueDiligenceExpense" xml:lang="en-US">Accrued due diligence expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_AccruedDueDiligenceExpense" xlink:to="lab_prok_AccruedDueDiligenceExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_AccruedDueDiligenceExpense" xml:lang="en-US">Accrued due diligence expense.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedRegulatoryFilingFee" xlink:label="loc_prok_AccruedRegulatoryFilingFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_AccruedRegulatoryFilingFee" xml:lang="en-US">Accrued Regulatory Filing Fee</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_AccruedRegulatoryFilingFee" xml:lang="en-US">Accrued regulatory filing fee</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_AccruedRegulatoryFilingFee" xlink:to="lab_prok_AccruedRegulatoryFilingFee" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_AccruedRegulatoryFilingFee" xml:lang="en-US">Accrued regulatory filing fee.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedLegalExpense" xlink:label="loc_prok_AccruedLegalExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_AccruedLegalExpense" xml:lang="en-US">Accrued Legal Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_AccruedLegalExpense" xml:lang="en-US">Accrued legal expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_AccruedLegalExpense" xlink:to="lab_prok_AccruedLegalExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_AccruedLegalExpense" xml:lang="en-US">Accrued legal expense.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_BusinessCombinationAccruedLegalExpense" xlink:label="loc_prok_BusinessCombinationAccruedLegalExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_BusinessCombinationAccruedLegalExpense" xml:lang="en-US">Business Combination Accrued legal Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_BusinessCombinationAccruedLegalExpense" xml:lang="en-US">Business combination, accrued legal expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_BusinessCombinationAccruedLegalExpense" xlink:to="lab_prok_BusinessCombinationAccruedLegalExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_BusinessCombinationAccruedLegalExpense" xml:lang="en-US">Business combination accrued legal expense.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xml:lang="en-US">Impairment of long lived assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedAccountingExpense" xlink:label="loc_prok_AccruedAccountingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_AccruedAccountingExpense" xml:lang="en-US">Accrued Accounting Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_AccruedAccountingExpense" xml:lang="en-US">Accrued accounting expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_AccruedAccountingExpense" xlink:to="lab_prok_AccruedAccountingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_AccruedAccountingExpense" xml:lang="en-US">Accrued accounting expense.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_BusinessCombinationAccruedConsultingExpense" xlink:label="loc_prok_BusinessCombinationAccruedConsultingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_BusinessCombinationAccruedConsultingExpense" xml:lang="en-US">Business Combination Accrued Consulting Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_BusinessCombinationAccruedConsultingExpense" xml:lang="en-US">Business combination, accrued consulting expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_BusinessCombinationAccruedConsultingExpense" xlink:to="lab_prok_BusinessCombinationAccruedConsultingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_BusinessCombinationAccruedConsultingExpense" xml:lang="en-US">Business combination accrued consulting expense.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PeriodForWhichTheProfitsEarnedAreExemptFromTax" xlink:label="loc_prok_PeriodForWhichTheProfitsEarnedAreExemptFromTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_PeriodForWhichTheProfitsEarnedAreExemptFromTax" xml:lang="en-US">Period For Which The Profits Earned Are Exempt From Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_PeriodForWhichTheProfitsEarnedAreExemptFromTax" xml:lang="en-US">Periods for which the profits earned are exempt from tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_PeriodForWhichTheProfitsEarnedAreExemptFromTax" xlink:to="lab_prok_PeriodForWhichTheProfitsEarnedAreExemptFromTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_PeriodForWhichTheProfitsEarnedAreExemptFromTax" xml:lang="en-US">Period for which the profits earned are exempt from tax.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DefinedContributionPlanCosts" xlink:label="loc_prok_DefinedContributionPlanCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_DefinedContributionPlanCosts" xml:lang="en-US">Defined Contribution Plan Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_DefinedContributionPlanCosts" xml:lang="en-US">Defined contribution plan costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_DefinedContributionPlanCosts" xlink:to="lab_prok_DefinedContributionPlanCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_DefinedContributionPlanCosts" xml:lang="en-US">Defined contribution plan costs.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DefinedContributionPlanPercent" xlink:label="loc_prok_DefinedContributionPlanPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_DefinedContributionPlanPercent" xml:lang="en-US">Defined Contribution Plan Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_DefinedContributionPlanPercent" xml:lang="en-US">Defined contribution plan employer matching contribution percent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_DefinedContributionPlanPercent" xlink:to="lab_prok_DefinedContributionPlanPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_DefinedContributionPlanPercent" xml:lang="en-US">Defined contribution plan percent.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Depreciation" xml:lang="en-US">Depreciation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_BusinessCombinationAccruedOtherTransactionalRelatedExpenses" xlink:label="loc_prok_BusinessCombinationAccruedOtherTransactionalRelatedExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_BusinessCombinationAccruedOtherTransactionalRelatedExpenses" xml:lang="en-US">Business Combination Accrued Other Transactional Related Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_BusinessCombinationAccruedOtherTransactionalRelatedExpenses" xml:lang="en-US">Business combination, Accrued other transactional related expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_BusinessCombinationAccruedOtherTransactionalRelatedExpenses" xlink:to="lab_prok_BusinessCombinationAccruedOtherTransactionalRelatedExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_BusinessCombinationAccruedOtherTransactionalRelatedExpenses" xml:lang="en-US">Business combination accrued other transactional related expenses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_UnsufficientToFundItsObligationsTerm" xlink:label="loc_prok_UnsufficientToFundItsObligationsTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_UnsufficientToFundItsObligationsTerm" xml:lang="en-US">Unsufficient To Fund Its Obligations Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_UnsufficientToFundItsObligationsTerm" xml:lang="en-US">Unsufficient to fund its obligations term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_UnsufficientToFundItsObligationsTerm" xlink:to="lab_prok_UnsufficientToFundItsObligationsTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_UnsufficientToFundItsObligationsTerm" xml:lang="en-US">Unsufficient to fund its obligations term.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xml:lang="en-US">Finite lived intangible assets useful lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xml:lang="en-US">Finite lived intangible assets amortization expense next twelve months</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xml:lang="en-US">Finite lived intangible assets amortization expense next two years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized" xlink:label="loc_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized" xml:lang="en-US">Limited Partners' Capital Account, Units Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized" xml:lang="en-US">Limited Partners' Capital Account, Units Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized" xml:lang="en-US">Limited Partners' Capital Account, Units Authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized" xlink:to="lab_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xml:lang="en-US">Finite lived intangible assets amortization expense next three years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Amortization of Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US">Finite lived intangible assets amortization expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xml:lang="en-US">Debt Instrument, Unused Borrowing Capacity, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xml:lang="en-US">Debt Instrument, Unused Borrowing Capacity, Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:to="lab_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xml:lang="en-US">Number of Operating Segments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xml:lang="en-US">Number of Operating Segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AcquiredAssemblyWorkforceMember" xlink:label="loc_prok_AcquiredAssemblyWorkforceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_AcquiredAssemblyWorkforceMember" xml:lang="en-US">Acquired Assembly Workforce [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_AcquiredAssemblyWorkforceMember" xlink:to="lab_prok_AcquiredAssemblyWorkforceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_AcquiredAssemblyWorkforceMember" xml:lang="en-US">Acquired Assembly Workforce.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_US" xml:lang="en-US">UNITED STATES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KY" xlink:label="loc_country_KY" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_country_KY" xml:lang="en-US">CAYMAN ISLANDS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_KY" xlink:to="lab_country_KY" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xml:lang="en-US">Related Party Transaction [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xml:lang="en-US">Related Party Transaction [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PromissoryNoteMember" xlink:label="loc_prok_PromissoryNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_PromissoryNoteMember" xml:lang="en-US">Promissory Note [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_PromissoryNoteMember" xlink:to="lab_prok_PromissoryNoteMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityDisclosureAbstract" xml:lang="en-US">Temporary Equity Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityDisclosureAbstract" xml:lang="en-US">Temporary Equity Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract" xlink:to="lab_us-gaap_TemporaryEquityDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="lab_us-gaap_TemporaryEquityByClassOfStockTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xml:lang="en-US">Temporary Equity [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xml:lang="en-US">Temporary Equity [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLineItems" xlink:to="lab_us-gaap_TemporaryEquityLineItems" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_TemporaryEquityIssaunceCosts" xlink:label="loc_prok_TemporaryEquityIssaunceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_TemporaryEquityIssaunceCosts" xml:lang="en-US">Temporary Equity Issaunce Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_TemporaryEquityIssaunceCosts" xml:lang="en-US">Class&#160;A ordinary shares issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_TemporaryEquityIssaunceCosts" xlink:to="lab_prok_TemporaryEquityIssaunceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_TemporaryEquityIssaunceCosts" xml:lang="en-US">Temporary Equity Issaunce Costs.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_IncreaseOfOrdinarySharesToRedemptionValueTemporaryEquity" xlink:label="loc_prok_IncreaseOfOrdinarySharesToRedemptionValueTemporaryEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_IncreaseOfOrdinarySharesToRedemptionValueTemporaryEquity" xml:lang="en-US">Increase of Ordinary Shares to Redemption Value Temporary Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_IncreaseOfOrdinarySharesToRedemptionValueTemporaryEquity" xml:lang="en-US">Increase of carrying value to redemption value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_IncreaseOfOrdinarySharesToRedemptionValueTemporaryEquity" xlink:to="lab_prok_IncreaseOfOrdinarySharesToRedemptionValueTemporaryEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_IncreaseOfOrdinarySharesToRedemptionValueTemporaryEquity" xml:lang="en-US">Increase of ordinary shares to redemption value temporary equity.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RemeasurementOfCarryingValueToRedemptionValue" xlink:label="loc_prok_RemeasurementOfCarryingValueToRedemptionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_RemeasurementOfCarryingValueToRedemptionValue" xml:lang="en-US">Remeasurement Of Carrying Value To Redemption Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_RemeasurementOfCarryingValueToRedemptionValue" xlink:to="lab_prok_RemeasurementOfCarryingValueToRedemptionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_RemeasurementOfCarryingValueToRedemptionValue" xml:lang="en-US">Remeasurement of carrying value to redemption value.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_EarningsPerShareBasicAndDilutedTable" xlink:label="loc_prok_EarningsPerShareBasicAndDilutedTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_EarningsPerShareBasicAndDilutedTable" xml:lang="en-US">Earnings Per Share Basic And Diluted [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_EarningsPerShareBasicAndDilutedTable" xlink:to="lab_prok_EarningsPerShareBasicAndDilutedTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_EarningsPerShareBasicAndDilutedTable" xml:lang="en-US">Earnings per share basic and diluted [Table].</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_EarningsPerShareBasicAndDilutedLineItems" xlink:label="loc_prok_EarningsPerShareBasicAndDilutedLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_EarningsPerShareBasicAndDilutedLineItems" xml:lang="en-US">Earnings Per Share Basic And Diluted [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_EarningsPerShareBasicAndDilutedLineItems" xlink:to="lab_prok_EarningsPerShareBasicAndDilutedLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_EarningsPerShareBasicAndDilutedLineItems" xml:lang="en-US">Earnings per share basic and diluted [Line items].</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xml:lang="en-US">Numerator:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_BasicAndDilutedEarningsPerShareOtherDisclosuresAbstract" xlink:label="loc_prok_BasicAndDilutedEarningsPerShareOtherDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_BasicAndDilutedEarningsPerShareOtherDisclosuresAbstract" xml:lang="en-US">Basic And Diluted Earnings Per Share Other Disclosures [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_BasicAndDilutedEarningsPerShareOtherDisclosuresAbstract" xml:lang="en-US">Denominator:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_BasicAndDilutedEarningsPerShareOtherDisclosuresAbstract" xlink:to="lab_prok_BasicAndDilutedEarningsPerShareOtherDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_BasicAndDilutedEarningsPerShareOtherDisclosuresAbstract" xml:lang="en-US">Basic and diluted earnings per share other disclosures.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Employee-related Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedClinicalStudyRelatedCostsCurrent" xlink:label="loc_prok_AccruedClinicalStudyRelatedCostsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_AccruedClinicalStudyRelatedCostsCurrent" xml:lang="en-US">Accrued Clinical Study Related Costs Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_AccruedClinicalStudyRelatedCostsCurrent" xml:lang="en-US">Clinical study related costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_AccruedClinicalStudyRelatedCostsCurrent" xlink:to="lab_prok_AccruedClinicalStudyRelatedCostsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_AccruedClinicalStudyRelatedCostsCurrent" xml:lang="en-US">Accrued clinical study related costs current.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedFacilityExpansionCostsCurrent" xlink:label="loc_prok_AccruedFacilityExpansionCostsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_AccruedFacilityExpansionCostsCurrent" xml:lang="en-US">Accrued Facility Expansion Costs Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_AccruedFacilityExpansionCostsCurrent" xml:lang="en-US">Facility expansion costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_AccruedFacilityExpansionCostsCurrent" xlink:to="lab_prok_AccruedFacilityExpansionCostsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_AccruedFacilityExpansionCostsCurrent" xml:lang="en-US">Accrued facility expansion costs current.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OtherAccruedExpenses" xlink:label="loc_prok_OtherAccruedExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_OtherAccruedExpenses" xml:lang="en-US">Other Accrued Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_OtherAccruedExpenses" xml:lang="en-US">Other accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_OtherAccruedExpenses" xlink:to="lab_prok_OtherAccruedExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_OtherAccruedExpenses" xml:lang="en-US">Other accrued expenses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued Professional Fees, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued legal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedManufacturingImprovementCosts" xlink:label="loc_prok_AccruedManufacturingImprovementCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_AccruedManufacturingImprovementCosts" xml:lang="en-US">Accrued Manufacturing Improvement Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_AccruedManufacturingImprovementCosts" xml:lang="en-US">Manufacturing improvement costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_AccruedManufacturingImprovementCosts" xlink:to="lab_prok_AccruedManufacturingImprovementCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_AccruedManufacturingImprovementCosts" xml:lang="en-US">Accrued manufacturing improvement costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Total accrued expenses and other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer equipment and software</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember" xlink:to="lab_us-gaap_ComputerEquipmentMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold improvements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less: accumulated depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConstructionInProgressMember" xml:lang="en-US">Construction in Progress [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConstructionInProgressMember" xml:lang="en-US">Construction in progress</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US">Gross carrying amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US">Accumulated amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Current:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Total current income tax expense (benefit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Deferred:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Federal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US">State</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Total deferred income tax expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Federal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">State</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xml:lang="en-US">Provision to return adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Change in valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Income taxes at statutory rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">State taxes, net of federal benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_EffectiveIncomeTaxRateReconciliationLlcFlowThroughStructure" xlink:label="loc_prok_EffectiveIncomeTaxRateReconciliationLlcFlowThroughStructure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_EffectiveIncomeTaxRateReconciliationLlcFlowThroughStructure" xml:lang="en-US">Effective Income Tax Rate Reconciliation LLC Flow Through Structure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_EffectiveIncomeTaxRateReconciliationLlcFlowThroughStructure" xml:lang="en-US">LLC flow-through structure</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_EffectiveIncomeTaxRateReconciliationLlcFlowThroughStructure" xlink:to="lab_prok_EffectiveIncomeTaxRateReconciliationLlcFlowThroughStructure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_EffectiveIncomeTaxRateReconciliationLlcFlowThroughStructure" xml:lang="en-US">Effective income tax rate reconciliation llc flow through structure.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xml:lang="en-US">Federal Credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective income tax rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xml:lang="en-US">Deferred tax assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Bonuses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xml:lang="en-US">Accrued bonus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xml:lang="en-US">Fixed assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredTaxAssetsFederalCreditCarryForwards" xlink:label="loc_prok_DeferredTaxAssetsFederalCreditCarryForwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_DeferredTaxAssetsFederalCreditCarryForwards" xml:lang="en-US">Deferred Tax Assets Federal Credit Carry forwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_prok_DeferredTaxAssetsFederalCreditCarryForwards" xml:lang="en-US">Federal credit carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_DeferredTaxAssetsFederalCreditCarryForwards" xlink:to="lab_prok_DeferredTaxAssetsFederalCreditCarryForwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_DeferredTaxAssetsFederalCreditCarryForwards" xml:lang="en-US">Deferred tax assets federal credit carry forwards.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredTaxAssetsLeases" xlink:label="loc_prok_DeferredTaxAssetsLeases" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_DeferredTaxAssetsLeases" xml:lang="en-US">Deferred Tax Assets Leases</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_prok_DeferredTaxAssetsLeases" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_DeferredTaxAssetsLeases" xlink:to="lab_prok_DeferredTaxAssetsLeases" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_DeferredTaxAssetsLeases" xml:lang="en-US">Deferred tax assets leases.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredTaxAssetsStartUpCosts" xlink:label="loc_prok_DeferredTaxAssetsStartUpCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_DeferredTaxAssetsStartUpCosts" xml:lang="en-US">Deferred Tax Assets Start Up Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_prok_DeferredTaxAssetsStartUpCosts" xml:lang="en-US">Start-up&#160;costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_DeferredTaxAssetsStartUpCosts" xlink:to="lab_prok_DeferredTaxAssetsStartUpCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_DeferredTaxAssetsStartUpCosts" xml:lang="en-US">Deferred tax assets start up costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred tax assets before valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Total deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xml:lang="en-US">Deferred tax liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xml:lang="en-US">Fixed assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xml:lang="en-US">Intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xml:lang="en-US">Deferred Tax Liabilities, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xml:lang="en-US">Total deferred tax liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Deferred Tax Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US">Net deferred tax asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_UnrecognizedTaxBenefitsGrossAbstract" xlink:label="loc_prok_UnrecognizedTaxBenefitsGrossAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_UnrecognizedTaxBenefitsGrossAbstract" xml:lang="en-US">Unrecognized Tax Benefits (Gross) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_prok_UnrecognizedTaxBenefitsGrossAbstract" xml:lang="en-US">Unrecognized tax benefits (gross):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_UnrecognizedTaxBenefitsGrossAbstract" xlink:to="lab_prok_UnrecognizedTaxBenefitsGrossAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_UnrecognizedTaxBenefitsGrossAbstract" xml:lang="en-US">Unrecognized tax benefits (gross).</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xml:lang="en-US">Increase related to current year tax positions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xml:lang="en-US">Increase related to prior year tax positions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xml:lang="en-US">Decrease related to prior year tax positions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_IncomeTaxDisclosureTable" xlink:label="loc_prok_IncomeTaxDisclosureTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_IncomeTaxDisclosureTable" xml:lang="en-US">Income Tax Disclosure [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_IncomeTaxDisclosureTable" xlink:to="lab_prok_IncomeTaxDisclosureTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_IncomeTaxDisclosureTable" xml:lang="en-US">Income tax disclosure.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_IncomeTaxActAxis" xlink:label="loc_prok_IncomeTaxActAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_IncomeTaxActAxis" xml:lang="en-US">Income Tax Act [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_IncomeTaxActAxis" xlink:to="lab_prok_IncomeTaxActAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_IncomeTaxActAxis" xml:lang="en-US">Income tax act.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_IncomeTaxActDomain" xlink:label="loc_prok_IncomeTaxActDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_IncomeTaxActDomain" xml:lang="en-US">Income Tax Act [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_IncomeTaxActDomain" xlink:to="lab_prok_IncomeTaxActDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_IncomeTaxActDomain" xml:lang="en-US">Income tax act.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_IncomeTaxDisclosureLineItems" xlink:label="loc_prok_IncomeTaxDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_IncomeTaxDisclosureLineItems" xml:lang="en-US">Income Tax Disclosure [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_IncomeTaxDisclosureLineItems" xlink:to="lab_prok_IncomeTaxDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_IncomeTaxDisclosureLineItems" xml:lang="en-US">Income tax disclosure.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Statutory income tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredExpenseCapitalizedResearchAndDevelopmentCostsTerm" xlink:label="loc_prok_DeferredExpenseCapitalizedResearchAndDevelopmentCostsTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_DeferredExpenseCapitalizedResearchAndDevelopmentCostsTerm" xml:lang="en-US">Deferred Expense Capitalized Research and Development Costs term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_DeferredExpenseCapitalizedResearchAndDevelopmentCostsTerm" xml:lang="en-US">Deferred Expense Capitalized Research and Development Costs term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_DeferredExpenseCapitalizedResearchAndDevelopmentCostsTerm" xlink:to="lab_prok_DeferredExpenseCapitalizedResearchAndDevelopmentCostsTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_DeferredExpenseCapitalizedResearchAndDevelopmentCostsTerm" xml:lang="en-US">Deferred expense capitalized research and development costs term.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchMember" xml:lang="en-US">Research Tax Credit Carryforward [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xml:lang="en-US">Operating Lease, Liability [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityAbstract" xml:lang="en-US">Operating leases:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating lease liabilities, current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating lease liabilities, noncurrent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Right of use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Total operating lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Total operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityAbstract" xlink:label="loc_us-gaap_FinanceLeaseLiabilityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityAbstract" xml:lang="en-US">Finance Lease, Liability [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityAbstract" xml:lang="en-US">Finance leases:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xml:lang="en-US">Right of use assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xml:lang="en-US">Finance Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xml:lang="en-US">Finance lease liabilities, current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xml:lang="en-US">Finance Lease, Liability, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xml:lang="en-US">Finance lease liabilities, noncurrent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiability" xml:lang="en-US">Finance Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiability" xml:lang="en-US">Total finance lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiability" xml:lang="en-US">Present value of lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2022 (remaining nine months)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US">Thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xml:lang="en-US">Finance Lease, Liability, to be Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xml:lang="en-US">Total lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Less: imputed interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Lessee Operating Lease And Finance Lease Liability Payments Due Next Twelve Months</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2022 (remaining nine months)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Lessee operating lease and finance lease liability payments due next twelve months.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lessee Operating Lease And Finance Lease Liability Payments Due Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lessee operating lease and finance lease liability payments due year two.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">Lessee Operating Lease And Finance Lease Liability Payments Due Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">Lessee operating lease and finance lease liability payments due year five.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US">2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueAfterYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US">Lessee Operating Lease And Finance Lease Liability Payments Due After Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US">Thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueAfterYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US">Lessee operating lease and finance lease liability payments due after year five.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue" xlink:label="loc_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee Operating Lease And Finance Lease Liability Payments Due</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue" xml:lang="en-US">Total lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue" xlink:to="lab_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee operating lease and finance lease liability payments due.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Lessee Operating Lease And Finance Lease Liability Undiscounted Excess Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Less: imputed interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Lessee operating lease and finance lease liability undiscounted excess amount.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OperatingAndFinanceLeaseLiability" xlink:label="loc_prok_OperatingAndFinanceLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_OperatingAndFinanceLeaseLiability" xml:lang="en-US">Operating And Finance Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_prok_OperatingAndFinanceLeaseLiability" xml:lang="en-US">Present value of lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_OperatingAndFinanceLeaseLiability" xlink:to="lab_prok_OperatingAndFinanceLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_OperatingAndFinanceLeaseLiability" xml:lang="en-US">Operating and finance lease liability.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Lessee Operating Lease And Finance Lease Liability Payments Due Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Lessee operating lease and finance lease liability payments due year three.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">Lessee Operating Lease And Finance Lease Liability Payments Due Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US">Lessee operating lease and finance lease liability payments due year four.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US">Thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Total lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Less: imputed interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2022 (remaining nine months)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US">2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xml:lang="en-US">Lessee, Lease, Description [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xml:lang="en-US">Lessee, Lease, Description [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OperatingAndFinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_prok_OperatingAndFinanceLeaseWeightedAverageDiscountRatePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_OperatingAndFinanceLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating And Finance Lease Weighted Average Discount Rate Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_OperatingAndFinanceLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating And Finance Lease Weighted Average Discount Rate, Percent</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_OperatingAndFinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_prok_OperatingAndFinanceLeaseWeightedAverageDiscountRatePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_OperatingAndFinanceLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating and finance lease weighted average discount rate percent.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OperatingLeaseRentExpenses" xlink:label="loc_prok_OperatingLeaseRentExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_OperatingLeaseRentExpenses" xml:lang="en-US">Operating Lease Rent Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_OperatingLeaseRentExpenses" xml:lang="en-US">Operating Lease Rent Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_OperatingLeaseRentExpenses" xlink:to="lab_prok_OperatingLeaseRentExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_OperatingLeaseRentExpenses" xml:lang="en-US">Operating lease rent expenses.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xml:lang="en-US">Repayments of Related Party Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt" xml:lang="en-US">Repayments of related party debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="lab_us-gaap_RepaymentsOfRelatedPartyDebt" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered" xlink:label="loc_prok_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered" xml:lang="en-US">Waiting Period After Which The Share Trading Days Are Considered</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered" xml:lang="en-US">Waiting period after which the share trading days are considered</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered" xlink:to="lab_prok_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered" xml:lang="en-US">Waiting period after which the share trading days are considered.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xml:lang="en-US">Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xml:lang="en-US">Selling general and administrative expenses from transactions with related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SharesNoLongerSubjectToForfeiture" xlink:label="loc_prok_SharesNoLongerSubjectToForfeiture" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_SharesNoLongerSubjectToForfeiture" xml:lang="en-US">Shares No Longer Subject To Forfeiture</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_SharesNoLongerSubjectToForfeiture" xml:lang="en-US">Shares no longer subject to forfeiture</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_SharesNoLongerSubjectToForfeiture" xlink:to="lab_prok_SharesNoLongerSubjectToForfeiture" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_SharesNoLongerSubjectToForfeiture" xml:lang="en-US">Shares no longer subject to forfeiture.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xlink:label="loc_prok_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xml:lang="en-US">Number Of Consecutive Trading Days For Determining The Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xml:lang="en-US">Number of consecutive trading days for determining the share price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xlink:to="lab_prok_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xml:lang="en-US">Number of consecutive trading days for determining the share price.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AdvancesPayableToRelatedPartyCurrent" xlink:label="loc_prok_AdvancesPayableToRelatedPartyCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_AdvancesPayableToRelatedPartyCurrent" xml:lang="en-US">Advances Payable To Related Party Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_AdvancesPayableToRelatedPartyCurrent" xml:lang="en-US">Advances from related party current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_AdvancesPayableToRelatedPartyCurrent" xlink:to="lab_prok_AdvancesPayableToRelatedPartyCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_AdvancesPayableToRelatedPartyCurrent" xml:lang="en-US">Advances payable to related party current.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of shares granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Number of shares , Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt instrument face value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharePrice" xml:lang="en-US">Share price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding" xml:lang="en-US">Common Stock, Other Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockOtherSharesOutstanding" xml:lang="en-US">Common stock, shares, subject to forfeiture</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockOtherSharesOutstanding" xlink:to="lab_us-gaap_CommonStockOtherSharesOutstanding" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_NumberOfTradingDaysForDeterminingTheSharePrice" xlink:label="loc_prok_NumberOfTradingDaysForDeterminingTheSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_NumberOfTradingDaysForDeterminingTheSharePrice" xml:lang="en-US">Number Of Trading Days For Determining The Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_NumberOfTradingDaysForDeterminingTheSharePrice" xml:lang="en-US">Number of trading days for determining the share price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_NumberOfTradingDaysForDeterminingTheSharePrice" xlink:to="lab_prok_NumberOfTradingDaysForDeterminingTheSharePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_NumberOfTradingDaysForDeterminingTheSharePrice" xml:lang="en-US">Number of trading days for determining the share price.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xml:lang="en-US">Related party transaction fees payable per month</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Due to Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Due to related parties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue" xlink:label="loc_prok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Options Granted In Period Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue" xml:lang="en-US">Fair value of shares granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue" xlink:to="lab_prok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Options Granted In Period Fair Value.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_BasisAxis" xlink:label="loc_prok_BasisAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_BasisAxis" xml:lang="en-US">Basis [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_BasisAxis" xlink:to="lab_prok_BasisAxis" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_BasisDomain" xlink:label="loc_prok_BasisDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_BasisDomain" xml:lang="en-US">Basis [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_BasisDomain" xlink:to="lab_prok_BasisDomain" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RestrictionOnTransferOfSponsorSharesMember" xlink:label="loc_prok_RestrictionOnTransferOfSponsorSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_RestrictionOnTransferOfSponsorSharesMember" xml:lang="en-US">Restriction On Transfer Of Sponsor Shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_RestrictionOnTransferOfSponsorSharesMember" xlink:to="lab_prok_RestrictionOnTransferOfSponsorSharesMember" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SponsorMember" xlink:label="loc_prok_SponsorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_SponsorMember" xml:lang="en-US">Sponsor [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_SponsorMember" xlink:to="lab_prok_SponsorMember" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_FounderMember" xlink:label="loc_prok_FounderMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_FounderMember" xml:lang="en-US">Founder [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_FounderMember" xlink:to="lab_prok_FounderMember" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AverillMasterFundLtdMember" xlink:label="loc_prok_AverillMasterFundLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_AverillMasterFundLtdMember" xml:lang="en-US">Averill Master Fund, Ltd [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_AverillMasterFundLtdMember" xml:lang="en-US">Averill Master Fund, Ltd</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_AverillMasterFundLtdMember" xlink:to="lab_prok_AverillMasterFundLtdMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_AverillMasterFundLtdMember" xml:lang="en-US">Averill Master Fund, Ltd.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ScMasterHoldingsLlcMember" xlink:label="loc_prok_ScMasterHoldingsLlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_ScMasterHoldingsLlcMember" xml:lang="en-US">SC Master Holdings, LLC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_ScMasterHoldingsLlcMember" xml:lang="en-US">SC Master Holdings, LLC</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_ScMasterHoldingsLlcMember" xlink:to="lab_prok_ScMasterHoldingsLlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_ScMasterHoldingsLlcMember" xml:lang="en-US">SC master holdings, llc.</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_WorkingCapitalLoansMember" xlink:label="loc_prok_WorkingCapitalLoansMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_WorkingCapitalLoansMember" xml:lang="en-US">Working Capital Loans [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_WorkingCapitalLoansMember" xlink:to="lab_prok_WorkingCapitalLoansMember" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AdministrationAndSupportServicesMember" xlink:label="loc_prok_AdministrationAndSupportServicesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_AdministrationAndSupportServicesMember" xml:lang="en-US">Administration And Support Services [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_AdministrationAndSupportServicesMember" xlink:to="lab_prok_AdministrationAndSupportServicesMember" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AdvanceFromRelatedPartyLoanMember" xlink:label="loc_prok_AdvanceFromRelatedPartyLoanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_AdvanceFromRelatedPartyLoanMember" xml:lang="en-US">Advance From Related Party Loan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_AdvanceFromRelatedPartyLoanMember" xlink:to="lab_prok_AdvanceFromRelatedPartyLoanMember" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_FounderSharesMember" xlink:label="loc_prok_FounderSharesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_FounderSharesMember" xml:lang="en-US">Founder Shares [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_FounderSharesMember" xlink:to="lab_prok_FounderSharesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AgreementAxis" xlink:label="loc_prok_AgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_AgreementAxis" xlink:to="lab_prok_AgreementAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_AgreementAxis" xml:lang="en-US">Agreement .</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AgreementDomain" xlink:label="loc_prok_AgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_AgreementDomain" xml:lang="en-US">Agreement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_AgreementDomain" xml:lang="en-US">Agreement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_AgreementDomain" xlink:to="lab_prok_AgreementDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_AgreementDomain" xml:lang="en-US">Agreement .</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SubscriptionAgreementsMember" xlink:label="loc_prok_SubscriptionAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_SubscriptionAgreementsMember" xml:lang="en-US">Subscription Agreements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_SubscriptionAgreementsMember" xlink:to="lab_prok_SubscriptionAgreementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_SubscriptionAgreementsMember" xml:lang="en-US">Subscription Agreements</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title of Individual [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_IndependentDirectorsMember" xlink:label="loc_prok_IndependentDirectorsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_IndependentDirectorsMember" xml:lang="en-US">Independent Directors [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_IndependentDirectorsMember" xlink:to="lab_prok_IndependentDirectorsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_DirectorMember" xml:lang="en-US">Director [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt Instrument, Maturity Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt Instrument, Maturity Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xml:lang="en-US">Debt Instrument, Fee Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingenciesTable" xml:lang="en-US">Loss Contingencies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DirectorRestrictedStockUnitAwardAgreementMember" xlink:label="loc_prok_DirectorRestrictedStockUnitAwardAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_DirectorRestrictedStockUnitAwardAgreementMember" xml:lang="en-US">Director Restricted Stock Unit Award Agreement [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_DirectorRestrictedStockUnitAwardAgreementMember" xlink:to="lab_prok_DirectorRestrictedStockUnitAwardAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_DirectorRestrictedStockUnitAwardAgreementMember" xml:lang="en-US">Director restricted stock unit award agreement .</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LossContingenciesLineItems" xml:lang="en-US">Loss Contingencies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_NumberOfSharesOfCommonStockCommittedToSettleOnADateFollowingTheYearBusinessCombinationOccurs" xlink:label="loc_prok_NumberOfSharesOfCommonStockCommittedToSettleOnADateFollowingTheYearBusinessCombinationOccurs" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_NumberOfSharesOfCommonStockCommittedToSettleOnADateFollowingTheYearBusinessCombinationOccurs" xml:lang="en-US">Number of Shares Of Common Stock Committed To Settle On A Date Following The Year Business Combination Occurs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_NumberOfSharesOfCommonStockCommittedToSettleOnADateFollowingTheYearBusinessCombinationOccurs" xml:lang="en-US">Number of shares of common stock committed to settle on a date following the year Business combination occurs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_NumberOfSharesOfCommonStockCommittedToSettleOnADateFollowingTheYearBusinessCombinationOccurs" xlink:to="lab_prok_NumberOfSharesOfCommonStockCommittedToSettleOnADateFollowingTheYearBusinessCombinationOccurs" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_NumberOfSharesOfCommonStockCommittedToSettleOnADateFollowingTheYearBusinessCombinationOccurs" xml:lang="en-US">Number of shares of common stock committed to settle on a date following the year Business combination occurs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Number of stock units granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_MembersEquityTable" xlink:label="loc_prok_MembersEquityTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_MembersEquityTable" xml:lang="en-US">Members Equity [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_MembersEquityTable" xlink:to="lab_prok_MembersEquityTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_MembersEquityTable" xml:lang="en-US">Members equity</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_MembersEquityLineItems" xlink:label="loc_prok_MembersEquityLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_MembersEquityLineItems" xml:lang="en-US">Members Equity [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_MembersEquityLineItems" xlink:to="lab_prok_MembersEquityLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_MembersEquityLineItems" xml:lang="en-US">Members equity</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ProceedsFromLimitedPartnersCapitalAccountUnits" xlink:label="loc_prok_ProceedsFromLimitedPartnersCapitalAccountUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_ProceedsFromLimitedPartnersCapitalAccountUnits" xml:lang="en-US">Proceeds from Limited partners capital account units</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_ProceedsFromLimitedPartnersCapitalAccountUnits" xml:lang="en-US">Proceeds from Limited partners capital account units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_ProceedsFromLimitedPartnersCapitalAccountUnits" xlink:to="lab_prok_ProceedsFromLimitedPartnersCapitalAccountUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_ProceedsFromLimitedPartnersCapitalAccountUnits" xml:lang="en-US">Proceeds from limited partners capital account units</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_CapitalUnitClassB1Member" xlink:label="loc_prok_CapitalUnitClassB1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_CapitalUnitClassB1Member" xml:lang="en-US">Capital Unit Class B1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_CapitalUnitClassB1Member" xlink:to="lab_prok_CapitalUnitClassB1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_CapitalUnitClassB1Member" xml:lang="en-US">Capital unit class B-1</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PercentOfFoundersSharesToCompanysIssuedAndOutstandingOrdinaryShares" xlink:label="loc_prok_PercentOfFoundersSharesToCompanysIssuedAndOutstandingOrdinaryShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_PercentOfFoundersSharesToCompanysIssuedAndOutstandingOrdinaryShares" xml:lang="en-US">Percent Of Founders Shares To Companys Issued And Outstanding Ordinary Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_PercentOfFoundersSharesToCompanysIssuedAndOutstandingOrdinaryShares" xml:lang="en-US">Percent of founders shares to company's issued and outstanding ordinary shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_PercentOfFoundersSharesToCompanysIssuedAndOutstandingOrdinaryShares" xlink:to="lab_prok_PercentOfFoundersSharesToCompanysIssuedAndOutstandingOrdinaryShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_PercentOfFoundersSharesToCompanysIssuedAndOutstandingOrdinaryShares" xml:lang="en-US">Percent of founders shares to Company's issued and outstanding ordinary shares.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicLineItems" xml:lang="en-US">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems" xlink:to="lab_us-gaap_EarningsPerShareBasicLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xml:lang="en-US">Denominator</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_BasicAndDilutedNetIncomeLossPerShareAbstract" xlink:label="loc_prok_BasicAndDilutedNetIncomeLossPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_BasicAndDilutedNetIncomeLossPerShareAbstract" xml:lang="en-US">Basic And Diluted Net Income Loss Per Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_BasicAndDilutedNetIncomeLossPerShareAbstract" xml:lang="en-US">Net loss per Class A Unit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_BasicAndDilutedNetIncomeLossPerShareAbstract" xlink:to="lab_prok_BasicAndDilutedNetIncomeLossPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_BasicAndDilutedNetIncomeLossPerShareAbstract" xml:lang="en-US">Basic and diluted net income loss per share.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xml:lang="en-US">Numerator</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTable" xml:lang="en-US">Fair Value Option, Disclosures [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xml:lang="en-US">Fair Value, Option, Quantitative Disclosures [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="lab_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xml:lang="en-US">Assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_MarketableSecuritiesHeldToMaturityFairValueDisclosure" xlink:label="loc_prok_MarketableSecuritiesHeldToMaturityFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_MarketableSecuritiesHeldToMaturityFairValueDisclosure" xml:lang="en-US">Marketable Securities Held To Maturity Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_MarketableSecuritiesHeldToMaturityFairValueDisclosure" xml:lang="en-US">Marketable securities held in Trust Account</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_MarketableSecuritiesHeldToMaturityFairValueDisclosure" xlink:to="lab_prok_MarketableSecuritiesHeldToMaturityFairValueDisclosure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_MarketableSecuritiesHeldToMaturityFairValueDisclosure" xml:lang="en-US">Marketable securities held to maturity fair value disclosure.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xml:lang="en-US">Number of Shares , Ending Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xml:lang="en-US">Number of Shares , Beginning Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value , Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value , Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value ,Vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US">Number of Shares , Vested</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value , Granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">weighted average grant date fair value of the Profits Interests granted during the year</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted Average Grant Date Fair Value , Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xml:lang="en-US">Number of shares , Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ClassB1unitsMember" xlink:label="loc_prok_ClassB1unitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_ClassB1unitsMember" xml:lang="en-US">Class B1Units [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_ClassB1unitsMember" xml:lang="en-US">Class&#160;B-1&#160;Units [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_ClassB1unitsMember" xlink:to="lab_prok_ClassB1unitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_ClassB1unitsMember" xml:lang="en-US">Class&#160;B-1&#160;Units.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xml:lang="en-US">Employee Benefits and Share-Based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xml:lang="en-US">Compensation Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="lab_us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xml:lang="en-US">Compensation expense attributable to vested awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonUnitIssued" xlink:label="loc_us-gaap_CommonUnitIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonUnitIssued" xml:lang="en-US">Common Unit, Issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonUnitIssued" xlink:to="lab_us-gaap_CommonUnitIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapitalAccountUnitsUnitbasedCompensation" xlink:label="loc_us-gaap_PartnersCapitalAccountUnitsUnitbasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PartnersCapitalAccountUnitsUnitbasedCompensation" xml:lang="en-US">Partners' Capital Account, Unit-Based Payment Arrangement, Number of Units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PartnersCapitalAccountUnitsUnitbasedCompensation" xlink:to="lab_us-gaap_PartnersCapitalAccountUnitsUnitbasedCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapitalAccountUnitBasedCompensation" xlink:label="loc_us-gaap_PartnersCapitalAccountUnitBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PartnersCapitalAccountUnitBasedCompensation" xml:lang="en-US">Partners' Capital Account, Unit-Based Payment Arrangement, Amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PartnersCapitalAccountUnitBasedCompensation" xlink:to="lab_us-gaap_PartnersCapitalAccountUnitBasedCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xml:lang="en-US">Research and Development in Process</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US">Number of Shares Available for Grant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_CommonUnitsUnissued" xlink:label="loc_prok_CommonUnitsUnissued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_CommonUnitsUnissued" xml:lang="en-US">Common Units Unissued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_CommonUnitsUnissued" xlink:to="lab_prok_CommonUnitsUnissued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_CommonUnitsUnissued" xml:lang="en-US">Common units unissued.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xml:lang="en-US">Percentage of vesting of award under share-based payment arrangement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_NumberOfCommonUnitsUnissuedOfLimitedLiabilityCompany" xlink:label="loc_prok_NumberOfCommonUnitsUnissuedOfLimitedLiabilityCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_NumberOfCommonUnitsUnissuedOfLimitedLiabilityCompany" xml:lang="en-US">Number of common units unissued of limited liability company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_NumberOfCommonUnitsUnissuedOfLimitedLiabilityCompany" xml:lang="en-US">Number of common units unissued of limited liability company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_NumberOfCommonUnitsUnissuedOfLimitedLiabilityCompany" xlink:to="lab_prok_NumberOfCommonUnitsUnissuedOfLimitedLiabilityCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_NumberOfCommonUnitsUnissuedOfLimitedLiabilityCompany" xml:lang="en-US">Number of common units unissued of limited liability company</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-based Payment Arrangement, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Equity-based compensation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Total equity-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Unrecognized compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonUnitIssuanceValue" xlink:label="loc_us-gaap_CommonUnitIssuanceValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonUnitIssuanceValue" xml:lang="en-US">Common Unit, Issuance Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonUnitIssuanceValue" xlink:to="lab_us-gaap_CommonUnitIssuanceValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">unrecognized compensation expense is expected to be recognized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingAxis" xml:lang="en-US">Vesting [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingDomain" xml:lang="en-US">Vesting [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OnTheLatterOfTheFirstAnniversaryMember" xlink:label="loc_prok_OnTheLatterOfTheFirstAnniversaryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_OnTheLatterOfTheFirstAnniversaryMember" xml:lang="en-US">On The Latter Of The First Anniversary [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_OnTheLatterOfTheFirstAnniversaryMember" xlink:to="lab_prok_OnTheLatterOfTheFirstAnniversaryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_OnTheLatterOfTheFirstAnniversaryMember" xml:lang="en-US">on the latter of the first anniversary</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_EachCalendarQuarterMember" xlink:label="loc_prok_EachCalendarQuarterMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_EachCalendarQuarterMember" xml:lang="en-US">Each Calendar Quarter [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_EachCalendarQuarterMember" xlink:to="lab_prok_EachCalendarQuarterMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_EachCalendarQuarterMember" xml:lang="en-US">each calendar quarter</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_InFirstAnniversaryOfTheAcquisitionDateMember" xlink:label="loc_prok_InFirstAnniversaryOfTheAcquisitionDateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_InFirstAnniversaryOfTheAcquisitionDateMember" xml:lang="en-US">In First Anniversary Of The Acquisition Date [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_InFirstAnniversaryOfTheAcquisitionDateMember" xlink:to="lab_prok_InFirstAnniversaryOfTheAcquisitionDateMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_InFirstAnniversaryOfTheAcquisitionDateMember" xml:lang="en-US">In first anniversary of the acquisition date</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OnEachEnniversaryMember" xlink:label="loc_prok_OnEachEnniversaryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_OnEachEnniversaryMember" xml:lang="en-US">On Each Enniversary [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_OnEachEnniversaryMember" xlink:to="lab_prok_OnEachEnniversaryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_OnEachEnniversaryMember" xml:lang="en-US">on each anniversary</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OverTheThreeYearPeriodFromTheDateOfGrantMember" xlink:label="loc_prok_OverTheThreeYearPeriodFromTheDateOfGrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_OverTheThreeYearPeriodFromTheDateOfGrantMember" xml:lang="en-US">Over The Three Year Period From The Date Of Grant [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_OverTheThreeYearPeriodFromTheDateOfGrantMember" xlink:to="lab_prok_OverTheThreeYearPeriodFromTheDateOfGrantMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_OverTheThreeYearPeriodFromTheDateOfGrantMember" xml:lang="en-US">Over the three - year period from the date of grant</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xml:lang="en-US">Share-Based Payment Arrangement, Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:to="lab_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MembersEquity" xlink:label="loc_us-gaap_MembersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MembersEquity" xml:lang="en-US">Members' Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MembersEquity" xml:lang="en-US">Total equity value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MembersEquity" xlink:to="lab_us-gaap_MembersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility of total equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xml:lang="en-US">Discount for lack of market</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected time to exit event</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xml:lang="en-US">Valuation Approach and Technique [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xml:lang="en-US">Valuation Approach and Technique [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ValuationTechniqueProbabilityWeightedExpectedReturnMethodMember" xlink:label="loc_prok_ValuationTechniqueProbabilityWeightedExpectedReturnMethodMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_ValuationTechniqueProbabilityWeightedExpectedReturnMethodMember" xml:lang="en-US">Valuation Technique, Probability Weighted Expected Return Method [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_ValuationTechniqueProbabilityWeightedExpectedReturnMethodMember" xlink:to="lab_prok_ValuationTechniqueProbabilityWeightedExpectedReturnMethodMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_ValuationTechniqueProbabilityWeightedExpectedReturnMethodMember" xml:lang="en-US">Valuation technique, probability weighted expected return method.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ValuationTechniqueOptionPricingModelMember" xml:lang="en-US">Valuation Technique, Option Pricing Model [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:to="lab_us-gaap_ValuationTechniqueOptionPricingModelMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xml:lang="en-US">Share-Based Payment Arrangement, Recognized Amount [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnits" xlink:label="loc_us-gaap_CapitalUnits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CapitalUnits" xml:lang="en-US">Capital Units, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CapitalUnits" xml:lang="en-US">Capital Units, Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalUnits" xlink:to="lab_us-gaap_CapitalUnits" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xml:lang="en-US">Line of Credit Facility, Current Borrowing Capacity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xml:lang="en-US">Line of Credit Facility, Current Borrowing Capacity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_EarnoutSharesTrancheAxis" xlink:label="loc_prok_EarnoutSharesTrancheAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_EarnoutSharesTrancheAxis" xml:lang="en-US">Earnout Shares Tranche [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_EarnoutSharesTrancheAxis" xml:lang="en-US">Earnout Shares Tranche [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_EarnoutSharesTrancheAxis" xlink:to="lab_prok_EarnoutSharesTrancheAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_EarnoutSharesTrancheAxis" xml:lang="en-US">Earnout Shares Tranche [Axis].</label>
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_EarnoutSharesTrancheDomain" xlink:label="loc_prok_EarnoutSharesTrancheDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_EarnoutSharesTrancheDomain" xml:lang="en-US">Earnout Shares Tranche [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_EarnoutSharesTrancheDomain" xml:lang="en-US">Earnout Shares Tranche [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_EarnoutSharesTrancheDomain" xlink:to="lab_prok_EarnoutSharesTrancheDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_EarnoutSharesTrancheDomain" xml:lang="en-US">Earnout Shares Tranche</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_CapitalUnitClassBOneMember" xlink:label="loc_prok_CapitalUnitClassBOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_prok_CapitalUnitClassBOneMember" xml:lang="en-US">Capital Unit Class B One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_prok_CapitalUnitClassBOneMember" xml:lang="en-US">Capital Unit Class B 1 [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prok_CapitalUnitClassBOneMember" xlink:to="lab_prok_CapitalUnitClassBOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_prok_CapitalUnitClassBOneMember" xml:lang="en-US">Capital unit classB1member.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xml:lang="en-US">Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xml:lang="en-US">Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:to="lab_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredProfitSharingMember" xlink:label="loc_us-gaap_DeferredProfitSharingMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredProfitSharingMember" xml:lang="en-US">Deferred Profit Sharing [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredProfitSharingMember" xlink:to="lab_us-gaap_DeferredProfitSharingMember" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>20
<FILENAME>prok-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 09-August-2022 [04:09:18] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#CoverPage" roleURI="http://www.businesswire.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#CondensedBalanceSheet" roleURI="http://www.businesswire.com/role/CondensedBalanceSheet" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#CondensedBalanceSheetParenthetical" roleURI="http://www.businesswire.com/role/CondensedBalanceSheetParenthetical" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#CondensedStatementsOfOperations" roleURI="http://www.businesswire.com/role/CondensedStatementsOfOperations" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit" roleURI="http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficitParenthetical" roleURI="http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficitParenthetical" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#CondensedStatementOfCashFlows" roleURI="http://www.businesswire.com/role/CondensedStatementOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#DescriptionOfOrganizationBusinessOperationsAndGoingConcern" roleURI="http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcern" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#SignificantAccountingPolicies" roleURI="http://www.businesswire.com/role/SignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#InitialPublicOffering" roleURI="http://www.businesswire.com/role/InitialPublicOffering" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#IncomeTaxes" roleURI="http://www.businesswire.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#PrivatePlacement" roleURI="http://www.businesswire.com/role/PrivatePlacement" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#Leases" roleURI="http://www.businesswire.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#RelatedPartyTransactions" roleURI="http://www.businesswire.com/role/RelatedPartyTransactions" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#CommitmentsAndContingencies" roleURI="http://www.businesswire.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#MembersEquity" roleURI="http://www.businesswire.com/role/MembersEquity" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#TemporaryEquityAndPermanentDeficit" roleURI="http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficit" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#NetLossPerShare" roleURI="http://www.businesswire.com/role/NetLossPerShare" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#FairValueMeasurements" roleURI="http://www.businesswire.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#EquityBasedCompensation" roleURI="http://www.businesswire.com/role/EquityBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#SubsequentEvents" roleURI="http://www.businesswire.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#SignificantAccountingPoliciesPolicies" roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#SignificantAccountingPoliciesTables" roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesTables" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#IncomeTaxesTables" roleURI="http://www.businesswire.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#LeasesTables" roleURI="http://www.businesswire.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#MembersEquityTables" roleURI="http://www.businesswire.com/role/MembersEquityTables" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#NetLossPerShareTables" roleURI="http://www.businesswire.com/role/NetLossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#FairValueMeasurementsTables" roleURI="http://www.businesswire.com/role/FairValueMeasurementsTables" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#EquityBasedCompensationTables" roleURI="http://www.businesswire.com/role/EquityBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail" roleURI="http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#TheCompanyAdditionalInformationDetail" roleURI="http://www.businesswire.com/role/TheCompanyAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#SignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#SignificantAccountingPoliciesScheduleOfClassAOrdinarySharesReflectedInTheBalanceSheetsDetail" roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfClassAOrdinarySharesReflectedInTheBalanceSheetsDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#SignificantAccountingPoliciesScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail" roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#SignificantAccountingPoliciesScheduleOfAccruedExpensesDetail" roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfAccruedExpensesDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail" roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#SignificantAccountingPoliciesScheduleOfFixedAssetsDetail" roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfFixedAssetsDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#SignificantAccountingPoliciesScheduleOfFixedAssetsParentheticalDetail" roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfFixedAssetsParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#SignificantAccountingPoliciesScheduleOfIntangibleAssetDetail" roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#SignificantAccountingPoliciesScheduleOfIntangibleAssetParentheticalDetail" roleURI="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetParentheticalDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#InitialPublicOfferingAdditionalInformationDetail" roleURI="http://www.businesswire.com/role/InitialPublicOfferingAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail" roleURI="http://www.businesswire.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail" roleURI="http://www.businesswire.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" roleURI="http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetail" roleURI="http://www.businesswire.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#IncomeTaxesAdditionalInformationDetail" roleURI="http://www.businesswire.com/role/IncomeTaxesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#PrivatePlacementAdditionalInformationDetail" roleURI="http://www.businesswire.com/role/PrivatePlacementAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#LeasesScheduleOfTheClassificationOfOperatingAndFinanceLeaseAssetsAndObligationsInTheCompanySConsolidatedBalanceSheetsDetail" roleURI="http://www.businesswire.com/role/LeasesScheduleOfTheClassificationOfOperatingAndFinanceLeaseAssetsAndObligationsInTheCompanySConsolidatedBalanceSheetsDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail" roleURI="http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#LeasesAdditionalInformationDetail" roleURI="http://www.businesswire.com/role/LeasesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#RelatedPartyTransactionsAdditionalInformationDetail" roleURI="http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#RelatedPartyDebtAdditionalInformationDetail" roleURI="http://www.businesswire.com/role/RelatedPartyDebtAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#CommitmentsAndContingenciesAdditionalInformationDetail" roleURI="http://www.businesswire.com/role/CommitmentsAndContingenciesAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#MembersEquityScheduleOfMembersEquityDetail" roleURI="http://www.businesswire.com/role/MembersEquityScheduleOfMembersEquityDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#MembersEquityAdditionalInformationDetail" roleURI="http://www.businesswire.com/role/MembersEquityAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#TemporaryEquityAndPermanentDeficitAdditionalInformationDetail" roleURI="http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficitAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#NetLossPerShareScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail" roleURI="http://www.businesswire.com/role/NetLossPerShareScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#FairValueMeasurementsSummaryOfAssetsThatAreMeasuredAtFairValueOnARecurringBasisDetail" roleURI="http://www.businesswire.com/role/FairValueMeasurementsSummaryOfAssetsThatAreMeasuredAtFairValueOnARecurringBasisDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#EquityBasedCompensationSummaryOfTheActivityRelatedToCompanySClassBAndB1UnitsGrantedDetail" roleURI="http://www.businesswire.com/role/EquityBasedCompensationSummaryOfTheActivityRelatedToCompanySClassBAndB1UnitsGrantedDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#EquityBasedCompensationAdditionalInformationDetail" roleURI="http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#EquityBasedCompensationSummaryOfKeyAssumptionsUsedInTheOpmValuationDetail" roleURI="http://www.businesswire.com/role/EquityBasedCompensationSummaryOfKeyAssumptionsUsedInTheOpmValuationDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#EquityBasedCompensationSummaryOfCompensationExpenseDetail" roleURI="http://www.businesswire.com/role/EquityBasedCompensationSummaryOfCompensationExpenseDetail" />
<roleRef xlink:type="simple" xlink:href="prok-20220331.xsd#SubsequentEventsAdditionalInformationDetail" roleURI="http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail" />
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_2" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_2" xlink:to="loc_dei_DocumentInformationTable_3" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4" xlink:to="loc_us-gaap_ClassOfStockDomain_5" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_3" xlink:to="loc_dei_DocumentInformationLineItems_6" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_DocumentType_9" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_AmendmentFlag_10" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityRegistrantName_14" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityCentralIndexKey_15" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityIncorporationStateCountryCode_18" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityFilerCategory_31" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntitySmallBusiness_33" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityEmergingGrowthCompany_34" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_6" xlink:to="loc_dei_EntityExTransitionPeriod_35" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/CondensedBalanceSheet">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_41" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_42" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_41" xlink:to="loc_us-gaap_StatementTable_42" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_43" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_42" xlink:to="loc_us-gaap_StatementClassOfStockAxis_43" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_44" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_43" xlink:to="loc_us-gaap_ClassOfStockDomain_44" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_51" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_44" xlink:to="loc_us-gaap_CommonClassAMember_51" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_52" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_44" xlink:to="loc_us-gaap_CommonClassBMember_52" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="loc_us-gaap_CapitalUnitsByClassAxis_1573229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_42" xlink:to="loc_us-gaap_CapitalUnitsByClassAxis_1573229" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_1573230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_1573229" xlink:to="loc_us-gaap_CapitalUnitClassDomain_1573230" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassAMember" xlink:label="loc_us-gaap_CapitalUnitClassAMember_1573231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1573230" xlink:to="loc_us-gaap_CapitalUnitClassAMember_1573231" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassBMember" xlink:label="loc_us-gaap_CapitalUnitClassBMember_1573232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1573230" xlink:to="loc_us-gaap_CapitalUnitClassBMember_1573232" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_42" xlink:to="loc_dei_LegalEntityAxis_1573372" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1573372" xlink:to="loc_dei_EntityDomain_1573378" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573386" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1573378" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573386" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_45" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_42" xlink:to="loc_us-gaap_StatementLineItems_45" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_46" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_45" xlink:to="loc_us-gaap_AssetsAbstract_46" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_47" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_46" xlink:to="loc_us-gaap_AssetsCurrentAbstract_47" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_53" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_47" xlink:to="loc_us-gaap_Cash_53" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_1573153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_47" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_1573153" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_1573172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_47" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_1573172" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_54" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_47" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_54" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PrepaidClinicalCurrent" xlink:label="loc_prok_PrepaidClinicalCurrent_1573174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_47" xlink:to="loc_prok_PrepaidClinicalCurrent_1573174" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_1573186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_47" xlink:to="loc_us-gaap_OtherAssetsCurrent_1573186" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_55" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_47" xlink:to="loc_us-gaap_AssetsCurrent_55" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredOfferingCost" xlink:label="loc_prok_DeferredOfferingCost_56" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_46" xlink:to="loc_prok_DeferredOfferingCost_56" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PrepaidInsuranceNonCurrent" xlink:label="loc_prok_PrepaidInsuranceNonCurrent_1153781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_46" xlink:to="loc_prok_PrepaidInsuranceNonCurrent_1153781" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsHeldInTrustNoncurrent" xlink:label="loc_us-gaap_AssetsHeldInTrustNoncurrent_1153783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_46" xlink:to="loc_us-gaap_AssetsHeldInTrustNoncurrent_1153783" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1573188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_46" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1573188" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RightOfUseAssetsOperatingAndFinanceLease" xlink:label="loc_prok_RightOfUseAssetsOperatingAndFinanceLease_1573189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_46" xlink:to="loc_prok_RightOfUseAssetsOperatingAndFinanceLease_1573189" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1573191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_46" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1573191" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_57" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_46" xlink:to="loc_us-gaap_Assets_57" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_48" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_45" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_48" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_49" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_48" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_49" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1153786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_49" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1153786" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedExpensesAndOther" xlink:label="loc_prok_AccruedExpensesAndOther_58" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_49" xlink:to="loc_prok_AccruedExpensesAndOther_58" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedExpensesCurrent" xlink:label="loc_prok_AccruedExpensesCurrent_1342206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_49" xlink:to="loc_prok_AccruedExpensesCurrent_1342206" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_60" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_49" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_60" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_CurrentAccountsPayable" xlink:label="loc_prok_CurrentAccountsPayable_1573198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_49" xlink:to="loc_prok_CurrentAccountsPayable_1573198" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OperatingAndFinanceLeaseLiabilitiesCurrent" xlink:label="loc_prok_OperatingAndFinanceLeaseLiabilitiesCurrent_1573201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_49" xlink:to="loc_prok_OperatingAndFinanceLeaseLiabilitiesCurrent_1573201" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_1573738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_49" xlink:to="loc_us-gaap_TaxesPayableCurrent_1573738" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_1573742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_49" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_1573742" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_62" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_49" xlink:to="loc_us-gaap_LiabilitiesCurrent_62" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredUnderwritingCommissions" xlink:label="loc_prok_DeferredUnderwritingCommissions_1153795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_48" xlink:to="loc_prok_DeferredUnderwritingCommissions_1153795" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion" xlink:label="loc_prok_OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion_1573208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_48" xlink:to="loc_prok_OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion_1573208" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_1152785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_48" xlink:to="loc_us-gaap_Liabilities_1152785" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_63" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_48" xlink:to="loc_us-gaap_CommitmentsAndContingencies_63" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1153810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_48" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1153810" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_50" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_48" xlink:to="loc_us-gaap_StockholdersEquityAbstract_50" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_64" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_50" xlink:to="loc_us-gaap_PreferredStockValue_64" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_65" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_50" xlink:to="loc_us-gaap_CommonStockValue_65" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_66" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_50" xlink:to="loc_us-gaap_AdditionalPaidInCapital_66" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_68" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_50" xlink:to="loc_us-gaap_StockholdersEquity_68" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MembersEquityAbstract" xlink:label="loc_us-gaap_MembersEquityAbstract_1573215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_48" xlink:to="loc_us-gaap_MembersEquityAbstract_1573215" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersContributedCapital" xlink:label="loc_us-gaap_LimitedPartnersContributedCapital_1573216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MembersEquityAbstract_1573215" xlink:to="loc_us-gaap_LimitedPartnersContributedCapital_1573216" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1573217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MembersEquityAbstract_1573215" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1573217" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapital" xlink:label="loc_us-gaap_PartnersCapital_1573220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MembersEquityAbstract_1573215" xlink:to="loc_us-gaap_PartnersCapital_1573220" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_69" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_48" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_69" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/CondensedBalanceSheetParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_71" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_72" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_71" xlink:to="loc_us-gaap_StatementTable_72" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_73" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_72" xlink:to="loc_us-gaap_StatementClassOfStockAxis_73" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_74" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_73" xlink:to="loc_us-gaap_ClassOfStockDomain_74" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_76" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_74" xlink:to="loc_us-gaap_CommonClassAMember_76" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_77" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_74" xlink:to="loc_us-gaap_CommonClassBMember_77" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="loc_us-gaap_CapitalUnitsByClassAxis_1573253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_72" xlink:to="loc_us-gaap_CapitalUnitsByClassAxis_1573253" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_1573254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_1573253" xlink:to="loc_us-gaap_CapitalUnitClassDomain_1573254" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassAMember" xlink:label="loc_us-gaap_CapitalUnitClassAMember_1573255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1573254" xlink:to="loc_us-gaap_CapitalUnitClassAMember_1573255" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassBMember" xlink:label="loc_us-gaap_CapitalUnitClassBMember_1573256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1573254" xlink:to="loc_us-gaap_CapitalUnitClassBMember_1573256" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573410" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_72" xlink:to="loc_dei_LegalEntityAxis_1573410" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1573410" xlink:to="loc_dei_EntityDomain_1573411" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573412" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1573411" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573412" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_75" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_72" xlink:to="loc_us-gaap_StatementLineItems_75" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_1153834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_75" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_1153834" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_78" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_75" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_78" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_79" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_75" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_79" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_80" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_75" xlink:to="loc_us-gaap_PreferredStockSharesIssued_80" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_81" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_75" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_81" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_82" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_75" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_82" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_83" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_75" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_83" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_84" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_75" xlink:to="loc_us-gaap_CommonStockSharesIssued_84" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_85" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_75" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_85" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersCapitalAccountUnitsIssued" xlink:label="loc_us-gaap_LimitedPartnersCapitalAccountUnitsIssued_1573258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_75" xlink:to="loc_us-gaap_LimitedPartnersCapitalAccountUnitsIssued_1573258" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding" xlink:label="loc_us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding_1573260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_75" xlink:to="loc_us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding_1573260" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/CondensedStatementsOfOperations">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_88" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1152843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_88" xlink:to="loc_us-gaap_StatementTable_1152843" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1152844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1152843" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1152844" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1152845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1152844" xlink:to="loc_us-gaap_ClassOfStockDomain_1152845" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1152846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1152845" xlink:to="loc_us-gaap_CommonClassAMember_1152846" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_1152847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1152845" xlink:to="loc_us-gaap_CommonClassBMember_1152847" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="loc_us-gaap_CapitalUnitsByClassAxis_1573298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1152843" xlink:to="loc_us-gaap_CapitalUnitsByClassAxis_1573298" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_1573299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_1573298" xlink:to="loc_us-gaap_CapitalUnitClassDomain_1573299" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassAMember" xlink:label="loc_us-gaap_CapitalUnitClassAMember_1573301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1573299" xlink:to="loc_us-gaap_CapitalUnitClassAMember_1573301" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573407" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1152843" xlink:to="loc_dei_LegalEntityAxis_1573407" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1573407" xlink:to="loc_dei_EntityDomain_1573408" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1573408" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573439" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1152848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1152843" xlink:to="loc_us-gaap_StatementLineItems_1152848" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_1573269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1152848" xlink:to="loc_us-gaap_Revenues_1573269" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1573280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1152848" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1573280" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1573282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1573280" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1573282" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1573283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1573280" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1573283" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_89" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1152848" xlink:to="loc_us-gaap_OperatingExpenses_89" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_90" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1152848" xlink:to="loc_us-gaap_OperatingIncomeLoss_90" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_1573752" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1152848" xlink:to="loc_us-gaap_InterestExpense_1573752" use="optional" order="19" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_1153848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1152848" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_1153848" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_1153849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_1153848" xlink:to="loc_us-gaap_InvestmentIncomeInterest_1153849" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="loc_us-gaap_InvestmentIncomeNonoperating_1573284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_1153848" xlink:to="loc_us-gaap_InvestmentIncomeNonoperating_1573284" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1573285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1152848" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1573285" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1573286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1152848" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1573286" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_91" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1152848" xlink:to="loc_us-gaap_NetIncomeLoss_91" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1573288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1152848" xlink:to="loc_us-gaap_EarningsPerShareAbstract_1573288" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1573289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1573288" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1573289" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1573290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1573288" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1573290" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_1573291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1573288" xlink:to="loc_us-gaap_EarningsPerShareBasic_1573291" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1573293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1573288" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1573293" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_103" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_103" xlink:to="loc_us-gaap_StatementTable_104" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_104" xlink:to="loc_us-gaap_StatementClassOfStockAxis_105" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_105" xlink:to="loc_us-gaap_ClassOfStockDomain_106" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1152849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_106" xlink:to="loc_us-gaap_CommonClassAMember_1152849" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_106" xlink:to="loc_us-gaap_CommonClassBMember_110" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_104" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_107" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_107" xlink:to="loc_us-gaap_EquityComponentDomain_108" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_108" xlink:to="loc_us-gaap_CommonStockMember_111" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_112" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_108" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_112" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_108" xlink:to="loc_us-gaap_RetainedEarningsMember_113" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MemberUnitsMember" xlink:label="loc_us-gaap_MemberUnitsMember_1573657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_108" xlink:to="loc_us-gaap_MemberUnitsMember_1573657" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_104" xlink:to="loc_dei_LegalEntityAxis_1573440" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1573440" xlink:to="loc_dei_EntityDomain_1573441" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1573441" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573442" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="loc_us-gaap_CapitalUnitsByClassAxis_1573661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_104" xlink:to="loc_us-gaap_CapitalUnitsByClassAxis_1573661" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_1573662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_1573661" xlink:to="loc_us-gaap_CapitalUnitClassDomain_1573662" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassAMember" xlink:label="loc_us-gaap_CapitalUnitClassAMember_1573663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1573662" xlink:to="loc_us-gaap_CapitalUnitClassAMember_1573663" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassBMember" xlink:label="loc_us-gaap_CapitalUnitClassBMember_1573666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1573662" xlink:to="loc_us-gaap_CapitalUnitClassBMember_1573666" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_104" xlink:to="loc_us-gaap_StatementLineItems_109" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1154946" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1154946" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_1154947" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_1154947" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_StockholdersEquity_114" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_SharesOutstanding_115" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapital" xlink:label="loc_us-gaap_PartnersCapital_1573398" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_PartnersCapital_1573398" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PartnersCapitalOutstanding" xlink:label="loc_prok_PartnersCapitalOutstanding_1573588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_prok_PartnersCapitalOutstanding_1573588" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_116" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_117" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_1153889" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_1153889" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_prok_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_1153890" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_prok_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_1153890" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity" xlink:label="loc_prok_RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity_1155778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_prok_RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity_1155778" use="optional" order="30" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1153897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_1153897" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1153898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1153898" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_1154449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited_1154449" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1154450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1154450" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapitalAccountContributions" xlink:label="loc_us-gaap_PartnersCapitalAccountContributions_1573589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_PartnersCapitalAccountContributions_1573589" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapitalAccountUnitsContributed" xlink:label="loc_us-gaap_PartnersCapitalAccountUnitsContributed_1573592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_PartnersCapitalAccountUnitsContributed_1573592" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_NetIncomeLoss_118" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_StockholdersEquity_119" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_SharesOutstanding_120" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1154939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1154939" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_1154940" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_1154940" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapital" xlink:label="loc_us-gaap_PartnersCapital_1573598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_us-gaap_PartnersCapital_1573598" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PartnersCapitalOutstanding" xlink:label="loc_prok_PartnersCapitalOutstanding_1573599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_109" xlink:to="loc_prok_PartnersCapitalOutstanding_1573599" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficitParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_122" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_123" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_122" xlink:to="loc_us-gaap_StatementTable_123" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_123" xlink:to="loc_us-gaap_StatementClassOfStockAxis_124" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_125" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_124" xlink:to="loc_us-gaap_ClassOfStockDomain_125" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1320025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_123" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1320025" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1320026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1320025" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1320026" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_1320027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1320026" xlink:to="loc_us-gaap_PrivatePlacementMember_1320027" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573435" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_123" xlink:to="loc_dei_LegalEntityAxis_1573435" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1573435" xlink:to="loc_dei_EntityDomain_1573436" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1573436" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573437" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_126" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_123" xlink:to="loc_us-gaap_StatementLineItems_126" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_TemporaryEquityStockIssuedDuringThePeriodShares" xlink:label="loc_prok_TemporaryEquityStockIssuedDuringThePeriodShares_1154329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_126" xlink:to="loc_prok_TemporaryEquityStockIssuedDuringThePeriodShares_1154329" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1153963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_126" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1153963" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/CondensedStatementOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_130" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1573351" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_130" xlink:to="loc_us-gaap_StatementTable_1573351" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573382" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573351" xlink:to="loc_dei_LegalEntityAxis_1573382" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573383" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1573382" xlink:to="loc_dei_EntityDomain_1573383" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573385" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1573383" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573385" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1573354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573351" xlink:to="loc_us-gaap_StatementLineItems_1573354" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573354" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_131" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_136" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_131" xlink:to="loc_us-gaap_NetIncomeLoss_136" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_131" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_132" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_FormationCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares" xlink:label="loc_prok_FormationCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares_137" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_132" xlink:to="loc_prok_FormationCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares_137" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_1153973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_132" xlink:to="loc_us-gaap_InvestmentIncomeInterest_1153973" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1573495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_132" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1573495" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_1573496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_132" xlink:to="loc_us-gaap_ShareBasedCompensation_1573496" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_133" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_131" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_133" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_133" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_138" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1153974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_133" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1153974" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_133" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_139" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_IncreaseDecreaseOfAdvanceFromRelatedParty" xlink:label="loc_prok_IncreaseDecreaseOfAdvanceFromRelatedParty_1572774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_133" xlink:to="loc_prok_IncreaseDecreaseOfAdvanceFromRelatedParty_1572774" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1573497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_133" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_1573497" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1572775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_133" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1572775" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_1573917" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_133" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_1573917" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_131" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_140" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1153975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573354" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1153975" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_1153977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1153975" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_1153977" use="optional" order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1573519" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1153975" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1573519" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_1573520" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1153975" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_1573520" use="optional" order="25" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1153979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1153975" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1153979" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_134" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573354" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_134" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1153983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_134" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1153983" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1153985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_134" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_1153985" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_134" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt_141" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RepaymentOfAdvancesFromRelatedParty" xlink:label="loc_prok_RepaymentOfAdvancesFromRelatedParty_1154177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_134" xlink:to="loc_prok_RepaymentOfAdvancesFromRelatedParty_1154177" use="optional" order="31" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_142" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_134" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_142" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RepaymentOfPromissoryNoteRelatedParty" xlink:label="loc_prok_RepaymentOfPromissoryNoteRelatedParty_1155780" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_134" xlink:to="loc_prok_RepaymentOfPromissoryNoteRelatedParty_1155780" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_143" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_134" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_143" use="optional" order="34" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_1573555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_134" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_1573555" use="optional" order="35" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_1573930" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_134" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_1573930" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits_1573556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_134" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits_1573556" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_144" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_134" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_144" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1573532" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573354" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1573532" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573354" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_146" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_prok_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents_1574648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573354" xlink:to="loc_prok_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents_1574648" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573354" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_147" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_prok_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents_1574638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573354" xlink:to="loc_prok_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents_1574638" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_135" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573354" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_135" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaap_StockIssued1_1154159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_135" xlink:to="loc_us-gaap_StockIssued1_1154159" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RemeasurementOfClassAOrdinarySharesToRedemptionValue" xlink:label="loc_prok_RemeasurementOfClassAOrdinarySharesToRedemptionValue_1154069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_135" xlink:to="loc_prok_RemeasurementOfClassAOrdinarySharesToRedemptionValue_1154069" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredUnderwritingFeesAccruedButNotPaid" xlink:label="loc_prok_DeferredUnderwritingFeesAccruedButNotPaid_1154951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_135" xlink:to="loc_prok_DeferredUnderwritingFeesAccruedButNotPaid_1154951" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OfferingCostsIncludedInAccruedOfferingCosts" xlink:label="loc_prok_OfferingCostsIncludedInAccruedOfferingCosts_1572771" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_135" xlink:to="loc_prok_OfferingCostsIncludedInAccruedOfferingCosts_1572771" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_1573542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_135" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_1573542" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RightOfUseAssetsObtainedInExchangeForLeaseObligations" xlink:label="loc_prok_RightOfUseAssetsObtainedInExchangeForLeaseObligations_1573932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_1573542" xlink:to="loc_prok_RightOfUseAssetsObtainedInExchangeForLeaseObligations_1573932" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1573543" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_1573542" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1573543" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcern">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_151" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1573274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_151" xlink:to="loc_us-gaap_StatementTable_1573274" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573274" xlink:to="loc_dei_LegalEntityAxis_1573278" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1573278" xlink:to="loc_dei_EntityDomain_1573279" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1573279" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573281" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1573277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573274" xlink:to="loc_us-gaap_StatementLineItems_1573277" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573277" xlink:to="loc_us-gaap_NatureOfOperations_152" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/SignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_154" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1573487" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_154" xlink:to="loc_us-gaap_StatementTable_1573487" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573487" xlink:to="loc_dei_LegalEntityAxis_1573491" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573492" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1573491" xlink:to="loc_dei_EntityDomain_1573492" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1573492" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573493" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1573490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573487" xlink:to="loc_us-gaap_StatementLineItems_1573490" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573490" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_155" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/InitialPublicOffering">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_157" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1573341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_157" xlink:to="loc_us-gaap_StatementTable_1573341" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1573342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573341" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1573342" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1573343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1573342" xlink:to="loc_us-gaap_ClassOfStockDomain_1573343" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573346" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573341" xlink:to="loc_dei_LegalEntityAxis_1573346" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1573346" xlink:to="loc_dei_EntityDomain_1573347" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1573347" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573349" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1573344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573341" xlink:to="loc_us-gaap_StatementLineItems_1573344" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_InitialPublicOfferingDisclosureTextBlock" xlink:label="loc_prok_InitialPublicOfferingDisclosureTextBlock_158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573344" xlink:to="loc_prok_InitialPublicOfferingDisclosureTextBlock_158" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1573656" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1573658" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1573656" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1573658" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/PrivatePlacement">
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PrivatePlacementAbstract" xlink:label="loc_prok_PrivatePlacementAbstract_160" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1573359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_PrivatePlacementAbstract_160" xlink:to="loc_us-gaap_StatementTable_1573359" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1573360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573359" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1573360" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1573361" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1573360" xlink:to="loc_us-gaap_ClassOfStockDomain_1573361" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573365" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573359" xlink:to="loc_dei_LegalEntityAxis_1573365" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1573365" xlink:to="loc_dei_EntityDomain_1573366" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573368" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1573366" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573368" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1573362" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573359" xlink:to="loc_us-gaap_StatementLineItems_1573362" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PrivatePlacementDisclosureTextBlock" xlink:label="loc_prok_PrivatePlacementDisclosureTextBlock_161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573362" xlink:to="loc_prok_PrivatePlacementDisclosureTextBlock_161" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/Leases">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1573812" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_1573813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573812" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_1573813" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_163" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1573503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_163" xlink:to="loc_us-gaap_StatementTable_1573503" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1573504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573503" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1573504" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1573505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1573504" xlink:to="loc_us-gaap_ClassOfStockDomain_1573505" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573503" xlink:to="loc_dei_LegalEntityAxis_1573507" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1573507" xlink:to="loc_dei_EntityDomain_1573508" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573509" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1573508" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573509" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1573506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573503" xlink:to="loc_us-gaap_StatementLineItems_1573506" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1573510" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573506" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1573510" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_166" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1573374" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_166" xlink:to="loc_us-gaap_StatementTable_1573374" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1573375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573374" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1573375" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1573376" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1573375" xlink:to="loc_us-gaap_ClassOfStockDomain_1573376" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573381" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573374" xlink:to="loc_dei_LegalEntityAxis_1573381" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1573381" xlink:to="loc_dei_EntityDomain_1573384" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573388" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1573384" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573388" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1573377" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573374" xlink:to="loc_us-gaap_StatementLineItems_1573377" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1573389" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573377" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1573389" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/MembersEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MembersEquityAbstract" xlink:label="loc_us-gaap_MembersEquityAbstract_1573594" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MembersEquityNotesDisclosureTextBlock" xlink:label="loc_us-gaap_MembersEquityNotesDisclosureTextBlock_1573597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MembersEquityAbstract_1573594" xlink:to="loc_us-gaap_MembersEquityNotesDisclosureTextBlock_1573597" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficit">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_169" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1573417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_169" xlink:to="loc_us-gaap_StatementTable_1573417" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573417" xlink:to="loc_dei_LegalEntityAxis_1573423" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1573423" xlink:to="loc_dei_EntityDomain_1573424" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1573424" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573425" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1573418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573417" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1573418" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1573419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1573418" xlink:to="loc_us-gaap_ClassOfStockDomain_1573419" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1573420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573417" xlink:to="loc_us-gaap_StatementLineItems_1573420" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1573426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573420" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1573426" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/NetLossPerShare">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1573625" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1573626" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1573625" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1573626" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1154242" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1573448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1154242" xlink:to="loc_us-gaap_StatementTable_1573448" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1573449" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573448" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1573449" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1573450" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1573449" xlink:to="loc_us-gaap_ClassOfStockDomain_1573450" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573452" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573448" xlink:to="loc_dei_LegalEntityAxis_1573452" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573453" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1573452" xlink:to="loc_dei_EntityDomain_1573453" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573454" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1573453" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573454" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1573451" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573448" xlink:to="loc_us-gaap_StatementLineItems_1573451" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1573455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573451" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_1573455" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/EquityBasedCompensation">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1573784" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1573785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1573784" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1573785" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_172" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1573394" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_172" xlink:to="loc_us-gaap_StatementTable_1573394" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1573395" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573394" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1573395" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1573396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1573395" xlink:to="loc_us-gaap_ClassOfStockDomain_1573396" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573394" xlink:to="loc_dei_LegalEntityAxis_1573399" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573401" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1573399" xlink:to="loc_dei_EntityDomain_1573401" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1573401" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573402" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1573397" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573394" xlink:to="loc_us-gaap_StatementLineItems_1573397" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573397" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_173" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_175" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1573523" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_175" xlink:to="loc_us-gaap_StatementTable_1573523" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573527" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573523" xlink:to="loc_dei_LegalEntityAxis_1573527" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573528" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1573527" xlink:to="loc_dei_EntityDomain_1573528" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573530" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1573528" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573530" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1573526" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573523" xlink:to="loc_us-gaap_StatementLineItems_1573526" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_176" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_GoingConcernPolicyTextBlock" xlink:label="loc_prok_GoingConcernPolicyTextBlock_1573758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_prok_GoingConcernPolicyTextBlock_1573758" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_178" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_UseOfEstimates_178" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_179" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_EmergingGrowthCompanyStatusPolicyTextBlock" xlink:label="loc_prok_EmergingGrowthCompanyStatusPolicyTextBlock_177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_prok_EmergingGrowthCompanyStatusPolicyTextBlock_177" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_183" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedExpensesPolicyTextBlock" xlink:label="loc_prok_AccruedExpensesPolicyTextBlock_1355565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_prok_AccruedExpensesPolicyTextBlock_1355565" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1573761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_1573761" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1573763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1573763" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_1573765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_1573765" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_1573767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_1573767" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_181" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1573769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1573769" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_1573770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_1573770" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ContingentLiabilitiesPolicyTextBlock" xlink:label="loc_prok_ContingentLiabilitiesPolicyTextBlock_1573790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_prok_ContingentLiabilitiesPolicyTextBlock_1573790" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1179816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1179816" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock" xlink:label="loc_us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock_1573772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock_1573772" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_1573773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_1573773" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_TemporaryEquityPolicyTextBlock" xlink:label="loc_prok_TemporaryEquityPolicyTextBlock_1154670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_prok_TemporaryEquityPolicyTextBlock_1154670" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1154668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1154668" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredOfferingCostsPolicyTextBlock" xlink:label="loc_prok_DeferredOfferingCostsPolicyTextBlock_180" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_prok_DeferredOfferingCostsPolicyTextBlock_180" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_182" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_184" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_185" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_1573776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573526" xlink:to="loc_us-gaap_SubsequentEventsPolicyPolicyTextBlock_1573776" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/SignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1154674" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1573550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1154674" xlink:to="loc_us-gaap_StatementTable_1573550" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573550" xlink:to="loc_dei_LegalEntityAxis_1573552" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1573552" xlink:to="loc_dei_EntityDomain_1573553" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1573553" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573554" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1573551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573550" xlink:to="loc_us-gaap_StatementLineItems_1573551" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1179814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573551" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1179814" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock_1317334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573551" xlink:to="loc_us-gaap_TemporaryEquityTableTextBlock_1317334" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1573972" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573551" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1573972" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DisclosureInTabularFormOfUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock" xlink:label="loc_prok_DisclosureInTabularFormOfUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_1573977" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573551" xlink:to="loc_prok_DisclosureInTabularFormOfUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock_1573977" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1573978" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573551" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1573978" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1573979" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573551" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1573979" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1573665" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1573668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1573665" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1573668" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1573669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1573665" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1573669" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1573670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1573665" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1573670" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_1573671" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1573665" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_1573671" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/LeasesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1573840" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_LesseeOperatingAndFinanceLeaseTableTextBlock" xlink:label="loc_prok_LesseeOperatingAndFinanceLeaseTableTextBlock_1573842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573840" xlink:to="loc_prok_LesseeOperatingAndFinanceLeaseTableTextBlock_1573842" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:label="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_1573845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573840" xlink:to="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_1573845" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/MembersEquityTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MembersEquityAbstract" xlink:label="loc_us-gaap_MembersEquityAbstract_1573601" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_MembersEquityTableTextBlock" xlink:label="loc_prok_MembersEquityTableTextBlock_1573603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MembersEquityAbstract_1573601" xlink:to="loc_prok_MembersEquityTableTextBlock_1573603" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/NetLossPerShareTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1573628" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1573629" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1573628" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1573629" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/FairValueMeasurementsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1154309" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1573457" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1154309" xlink:to="loc_us-gaap_StatementTable_1573457" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573457" xlink:to="loc_dei_LegalEntityAxis_1573461" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573463" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1573461" xlink:to="loc_dei_EntityDomain_1573463" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1573463" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573465" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1573458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573457" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1573458" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1573459" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1573458" xlink:to="loc_us-gaap_ClassOfStockDomain_1573459" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1573460" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573457" xlink:to="loc_us-gaap_StatementLineItems_1573460" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_1573467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573460" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_1573467" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/EquityBasedCompensationTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1573791" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_1573792" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1573791" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_1573792" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1574121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1573791" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1574121" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_1574139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1573791" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_1574139" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_187" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DescriptionOfOrganizationAndBusinessOperationsTable" xlink:label="loc_prok_DescriptionOfOrganizationAndBusinessOperationsTable_188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_187" xlink:to="loc_prok_DescriptionOfOrganizationAndBusinessOperationsTable_188" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsTable_188" xlink:to="loc_us-gaap_StatementClassOfStockAxis_191" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_191" xlink:to="loc_us-gaap_ClassOfStockDomain_192" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_192" xlink:to="loc_us-gaap_CommonClassAMember_199" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsTable_188" xlink:to="loc_srt_RangeAxis_193" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_193" xlink:to="loc_srt_RangeMember_194" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_194" xlink:to="loc_srt_MinimumMember_200" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1572769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_194" xlink:to="loc_srt_MaximumMember_1572769" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsTable_188" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_195" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_195" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_196" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_196" xlink:to="loc_us-gaap_IPOMember_201" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_196" xlink:to="loc_us-gaap_OverAllotmentOptionMember_202" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_196" xlink:to="loc_us-gaap_PrivatePlacementMember_203" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1572409" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsTable_188" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1572409" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1572743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1572409" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1572743" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ProkidneyLpMember" xlink:label="loc_prok_ProkidneyLpMember_1572744" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1572743" xlink:to="loc_prok_ProkidneyLpMember_1572744" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SharePriceRangeAxis" xlink:label="loc_prok_SharePriceRangeAxis_1572745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsTable_188" xlink:to="loc_prok_SharePriceRangeAxis_1572745" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SharePriceRangeDomain" xlink:label="loc_prok_SharePriceRangeDomain_1572750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_SharePriceRangeAxis_1572745" xlink:to="loc_prok_SharePriceRangeDomain_1572750" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SharePriceOneMember" xlink:label="loc_prok_SharePriceOneMember_1572751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_SharePriceRangeDomain_1572750" xlink:to="loc_prok_SharePriceOneMember_1572751" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SharePriceTwoMember" xlink:label="loc_prok_SharePriceTwoMember_1572752" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_SharePriceRangeDomain_1572750" xlink:to="loc_prok_SharePriceTwoMember_1572752" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SharePriceThreeMember" xlink:label="loc_prok_SharePriceThreeMember_1572753" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_SharePriceRangeDomain_1572750" xlink:to="loc_prok_SharePriceThreeMember_1572753" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1572742" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsTable_188" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1572742" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1572746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1572742" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1572746" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RestrictedStockRightsMember" xlink:label="loc_prok_RestrictedStockRightsMember_1572747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1572746" xlink:to="loc_prok_RestrictedStockRightsMember_1572747" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1572749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsTable_188" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1572749" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1572757" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1572749" xlink:to="loc_us-gaap_RelatedPartyDomain_1572757" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PipeInvestorsMember" xlink:label="loc_prok_PipeInvestorsMember_1572759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1572757" xlink:to="loc_prok_PipeInvestorsMember_1572759" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMember" xlink:label="loc_prok_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMember_1572764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1572757" xlink:to="loc_prok_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMember_1572764" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember" xlink:label="loc_prok_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember_1572773" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1572757" xlink:to="loc_prok_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember_1572773" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DescriptionOfOrganizationAndBusinessOperationsLineItems" xlink:label="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsTable_188" xlink:to="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation_204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_dei_EntityIncorporationDateOfIncorporation_204" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_205" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_206" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_207" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_208" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_208" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_TransactionCostsIncurredInConnectionWithInitialPublicOffering" xlink:label="loc_prok_TransactionCostsIncurredInConnectionWithInitialPublicOffering_209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_prok_TransactionCostsIncurredInConnectionWithInitialPublicOffering_209" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_UnderwritingFee" xlink:label="loc_prok_UnderwritingFee_210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_prok_UnderwritingFee_210" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredUnderwritingFees" xlink:label="loc_prok_DeferredUnderwritingFees_211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_prok_DeferredUnderwritingFees_211" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_us-gaap_DeferredOfferingCosts_212" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockHeldInTrust" xlink:label="loc_us-gaap_CommonStockHeldInTrust_213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_us-gaap_CommonStockHeldInTrust_213" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ProspectiveAssetsOfAcquireeAsAPercentageOfFairValueOfAssetsInTheTrustAccount" xlink:label="loc_prok_ProspectiveAssetsOfAcquireeAsAPercentageOfFairValueOfAssetsInTheTrustAccount_214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_prok_ProspectiveAssetsOfAcquireeAsAPercentageOfFairValueOfAssetsInTheTrustAccount_214" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_215" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MinimumNetWorthRequiredForCompliance" xlink:label="loc_us-gaap_MinimumNetWorthRequiredForCompliance_216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_us-gaap_MinimumNetWorthRequiredForCompliance_216" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PercentageOfPublicSharesThatCanBeTransferredWithoutAnyRestriction" xlink:label="loc_prok_PercentageOfPublicSharesThatCanBeTransferredWithoutAnyRestriction_218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_prok_PercentageOfPublicSharesThatCanBeTransferredWithoutAnyRestriction_218" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated" xlink:label="loc_prok_PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated_219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_prok_PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated_219" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities" xlink:label="loc_us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities_220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities_220" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PerShareValueOfRestrictedAssets" xlink:label="loc_prok_PerShareValueOfRestrictedAssets_221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_prok_PerShareValueOfRestrictedAssets_221" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PercentageOfPublicSharesRedemption" xlink:label="loc_prok_PercentageOfPublicSharesRedemption_1061550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_prok_PercentageOfPublicSharesRedemption_1061550" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_1167786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_us-gaap_Cash_1167786" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_WorkingCapital" xlink:label="loc_prok_WorkingCapital_1167789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_prok_WorkingCapital_1167789" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1572741" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1572741" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_1572748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_1572748" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1572754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1572754" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1572760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems_197" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1572760" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/TheCompanyAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1573195" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_NatureOfOperationsTable" xlink:label="loc_prok_NatureOfOperationsTable_1573197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1573195" xlink:to="loc_prok_NatureOfOperationsTable_1573197" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1573205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_NatureOfOperationsTable_1573197" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1573205" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1573206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1573205" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1573206" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RegenAndTwinCityBioLlcMember" xlink:label="loc_prok_RegenAndTwinCityBioLlcMember_1573207" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1573206" xlink:to="loc_prok_RegenAndTwinCityBioLlcMember_1573207" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_NatureOfOperationsLineItems" xlink:label="loc_prok_NatureOfOperationsLineItems_1573209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_NatureOfOperationsTable_1573197" xlink:to="loc_prok_NatureOfOperationsLineItems_1573209" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="loc_dei_EntityIncorporationDateOfIncorporation_1573210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_NatureOfOperationsLineItems_1573209" xlink:to="loc_dei_EntityIncorporationDateOfIncorporation_1573210" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_InitialCapital" xlink:label="loc_prok_InitialCapital_1573211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_NatureOfOperationsLineItems_1573209" xlink:to="loc_prok_InitialCapital_1573211" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1573214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_NatureOfOperationsLineItems_1573209" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1573214" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_223" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccountingPoliciesTable" xlink:label="loc_prok_AccountingPoliciesTable_224" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_223" xlink:to="loc_prok_AccountingPoliciesTable_224" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_225" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesTable_224" xlink:to="loc_us-gaap_StatementClassOfStockAxis_225" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_226" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_225" xlink:to="loc_us-gaap_ClassOfStockDomain_226" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_226" xlink:to="loc_us-gaap_CommonClassAMember_230" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesTable_224" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_227" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_227" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_228" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_228" xlink:to="loc_us-gaap_IPOMember_232" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1179834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesTable_224" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1179834" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1179835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1179834" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1179835" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573563" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesTable_224" xlink:to="loc_dei_LegalEntityAxis_1573563" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573564" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1573563" xlink:to="loc_dei_EntityDomain_1573564" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1573564" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573565" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_1574056" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesTable_224" xlink:to="loc_srt_StatementGeographicalAxis_1574056" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_1574057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1574056" xlink:to="loc_srt_SegmentGeographicalDomain_1574057" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_KY" xlink:label="loc_country_KY_1574058" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1574057" xlink:to="loc_country_KY_1574058" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US" xlink:label="loc_country_US_1574060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1574057" xlink:to="loc_country_US_1574060" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1574073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesTable_224" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1574073" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1574075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1574073" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1574075" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AcquiredAssemblyWorkforceMember" xlink:label="loc_prok_AcquiredAssemblyWorkforceMember_1574077" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1574075" xlink:to="loc_prok_AcquiredAssemblyWorkforceMember_1574077" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1574292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesTable_224" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1574292" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1574293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1574292" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1574293" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PromissoryNoteMember" xlink:label="loc_prok_PromissoryNoteMember_1574294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1574293" xlink:to="loc_prok_PromissoryNoteMember_1574294" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="loc_us-gaap_CapitalUnitsByClassAxis_1574296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesTable_224" xlink:to="loc_us-gaap_CapitalUnitsByClassAxis_1574296" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_1574297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_1574296" xlink:to="loc_us-gaap_CapitalUnitClassDomain_1574297" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassAMember" xlink:label="loc_us-gaap_CapitalUnitClassAMember_1574298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1574297" xlink:to="loc_us-gaap_CapitalUnitClassAMember_1574298" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassBMember" xlink:label="loc_us-gaap_CapitalUnitClassBMember_1574299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1574297" xlink:to="loc_us-gaap_CapitalUnitClassBMember_1574299" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccountingPoliciesLineItems" xlink:label="loc_prok_AccountingPoliciesLineItems_229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesTable_224" xlink:to="loc_prok_AccountingPoliciesLineItems_229" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_233" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_DeferredOfferingCosts_235" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_236" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_236" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_237" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount_239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_CashFDICInsuredAmount_239" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_TransactionCostsIncurredInConnectionWithInitialPublicOffering" xlink:label="loc_prok_TransactionCostsIncurredInConnectionWithInitialPublicOffering_1179825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_prok_TransactionCostsIncurredInConnectionWithInitialPublicOffering_1179825" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_UnderwritingFee" xlink:label="loc_prok_UnderwritingFee_1179827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_prok_UnderwritingFee_1179827" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredUnderwritingFees" xlink:label="loc_prok_DeferredUnderwritingFees_1179828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_prok_DeferredUnderwritingFees_1179828" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedLegalExpense" xlink:label="loc_prok_AccruedLegalExpense_1355573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_prok_AccruedLegalExpense_1355573" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedPrintingExpense" xlink:label="loc_prok_AccruedPrintingExpense_1355579" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_prok_AccruedPrintingExpense_1355579" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedDueDiligenceExpense" xlink:label="loc_prok_AccruedDueDiligenceExpense_1355590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_prok_AccruedDueDiligenceExpense_1355590" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedRegulatoryFilingFee" xlink:label="loc_prok_AccruedRegulatoryFilingFee_1355592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_prok_AccruedRegulatoryFilingFee_1355592" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedAccountingExpense" xlink:label="loc_prok_AccruedAccountingExpense_1355604" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_prok_AccruedAccountingExpense_1355604" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_BusinessCombinationAccruedLegalExpense" xlink:label="loc_prok_BusinessCombinationAccruedLegalExpense_1572777" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_prok_BusinessCombinationAccruedLegalExpense_1572777" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_BusinessCombinationAccruedConsultingExpense" xlink:label="loc_prok_BusinessCombinationAccruedConsultingExpense_1572778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_prok_BusinessCombinationAccruedConsultingExpense_1572778" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_BusinessCombinationAccruedOtherTransactionalRelatedExpenses" xlink:label="loc_prok_BusinessCombinationAccruedOtherTransactionalRelatedExpenses_1572779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_prok_BusinessCombinationAccruedOtherTransactionalRelatedExpenses_1572779" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1574061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1574061" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1574062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_NetIncomeLoss_1574062" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_1574063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_1574063" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PeriodForWhichTheProfitsEarnedAreExemptFromTax" xlink:label="loc_prok_PeriodForWhichTheProfitsEarnedAreExemptFromTax_1574064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_prok_PeriodForWhichTheProfitsEarnedAreExemptFromTax_1574064" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DefinedContributionPlanCosts" xlink:label="loc_prok_DefinedContributionPlanCosts_1574067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_prok_DefinedContributionPlanCosts_1574067" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DefinedContributionPlanPercent" xlink:label="loc_prok_DefinedContributionPlanPercent_1574068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_prok_DefinedContributionPlanPercent_1574068" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_1574070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_Depreciation_1574070" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1574090" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1574090" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_UnsufficientToFundItsObligationsTerm" xlink:label="loc_prok_UnsufficientToFundItsObligationsTerm_1574091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_prok_UnsufficientToFundItsObligationsTerm_1574091" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1574093" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1574093" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1574094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1574094" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1574095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1574095" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1574096" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1574096" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1574097" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1574097" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_1574291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_1574291" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized" xlink:label="loc_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized_1574357" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized_1574357" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_1574359" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AccountingPoliciesLineItems_229" xlink:to="loc_us-gaap_NumberOfOperatingSegments_1574359" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfClassAOrdinarySharesReflectedInTheBalanceSheetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityDisclosureAbstract" xlink:label="loc_us-gaap_TemporaryEquityDisclosureAbstract_1317343" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_1317344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityDisclosureAbstract_1317343" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_1317344" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1317347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_1317344" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1317347" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1317348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1317347" xlink:to="loc_us-gaap_ClassOfStockDomain_1317348" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1317349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1317348" xlink:to="loc_us-gaap_CommonClassAMember_1317349" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_1317344" xlink:to="loc_dei_LegalEntityAxis_1573560" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1573560" xlink:to="loc_dei_EntityDomain_1573561" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573562" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1573561" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573562" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems_1317350" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_1317344" xlink:to="loc_us-gaap_TemporaryEquityLineItems_1317350" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1317352" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1317350" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_1317352" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_TemporaryEquityIssaunceCosts" xlink:label="loc_prok_TemporaryEquityIssaunceCosts_1317354" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1317350" xlink:to="loc_prok_TemporaryEquityIssaunceCosts_1317354" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity" xlink:label="loc_prok_RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity_1317356" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1317350" xlink:to="loc_prok_RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity_1317356" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_IncreaseOfOrdinarySharesToRedemptionValueTemporaryEquity" xlink:label="loc_prok_IncreaseOfOrdinarySharesToRedemptionValueTemporaryEquity_1353572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1317350" xlink:to="loc_prok_IncreaseOfOrdinarySharesToRedemptionValueTemporaryEquity_1353572" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1317358" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1317350" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_1317358" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RemeasurementOfCarryingValueToRedemptionValue" xlink:label="loc_prok_RemeasurementOfCarryingValueToRedemptionValue_1572770" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_1317350" xlink:to="loc_prok_RemeasurementOfCarryingValueToRedemptionValue_1572770" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1154676" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_EarningsPerShareBasicAndDilutedTable" xlink:label="loc_prok_EarningsPerShareBasicAndDilutedTable_1154677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1154676" xlink:to="loc_prok_EarningsPerShareBasicAndDilutedTable_1154677" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1154688" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_EarningsPerShareBasicAndDilutedTable_1154677" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1154688" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1154689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1154688" xlink:to="loc_us-gaap_ClassOfStockDomain_1154689" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1154690" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1154689" xlink:to="loc_us-gaap_CommonClassAMember_1154690" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_1154691" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1154689" xlink:to="loc_us-gaap_CommonClassBMember_1154691" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_EarningsPerShareBasicAndDilutedTable_1154677" xlink:to="loc_dei_LegalEntityAxis_1573557" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1573557" xlink:to="loc_dei_EntityDomain_1573558" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1573558" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573559" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_EarningsPerShareBasicAndDilutedLineItems" xlink:label="loc_prok_EarningsPerShareBasicAndDilutedLineItems_1154678" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_EarningsPerShareBasicAndDilutedTable_1154677" xlink:to="loc_prok_EarningsPerShareBasicAndDilutedLineItems_1154678" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_1154680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_EarningsPerShareBasicAndDilutedLineItems_1154678" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_1154680" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1154681" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_1154680" xlink:to="loc_us-gaap_NetIncomeLoss_1154681" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_BasicAndDilutedEarningsPerShareOtherDisclosuresAbstract" xlink:label="loc_prok_BasicAndDilutedEarningsPerShareOtherDisclosuresAbstract_1154682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_EarningsPerShareBasicAndDilutedLineItems_1154678" xlink:to="loc_prok_BasicAndDilutedEarningsPerShareOtherDisclosuresAbstract_1154682" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1154683" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_BasicAndDilutedEarningsPerShareOtherDisclosuresAbstract_1154682" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1154683" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1574701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_BasicAndDilutedEarningsPerShareOtherDisclosuresAbstract_1154682" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1574701" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_1154684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_EarningsPerShareBasicAndDilutedLineItems_1154678" xlink:to="loc_us-gaap_EarningsPerShareBasic_1154684" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1574702" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_EarningsPerShareBasicAndDilutedLineItems_1154678" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1574702" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfAccruedExpensesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1573982" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1573983" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1573982" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1573983" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedClinicalStudyRelatedCostsCurrent" xlink:label="loc_prok_AccruedClinicalStudyRelatedCostsCurrent_1573984" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1573982" xlink:to="loc_prok_AccruedClinicalStudyRelatedCostsCurrent_1573984" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedFacilityExpansionCostsCurrent" xlink:label="loc_prok_AccruedFacilityExpansionCostsCurrent_1573985" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1573982" xlink:to="loc_prok_AccruedFacilityExpansionCostsCurrent_1573985" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_1573986" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1573982" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_1573986" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AccruedManufacturingImprovementCosts" xlink:label="loc_prok_AccruedManufacturingImprovementCosts_1573987" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1573982" xlink:to="loc_prok_AccruedManufacturingImprovementCosts_1573987" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OtherAccruedExpenses" xlink:label="loc_prok_OtherAccruedExpenses_1574631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1573982" xlink:to="loc_prok_OtherAccruedExpenses_1574631" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1573988" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1573982" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1573988" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1573989" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1573982" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1573989" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1573994" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1573996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1573994" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1573996" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1573998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1573996" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1573998" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1573999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1573998" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1573999" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1574000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1573999" xlink:to="loc_us-gaap_ComputerEquipmentMember_1574000" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_1574001" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1573999" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_1574001" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1574003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1573999" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1574003" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1574004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1573996" xlink:to="loc_srt_RangeAxis_1574004" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1574005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1574004" xlink:to="loc_srt_RangeMember_1574005" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1574006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1574005" xlink:to="loc_srt_MaximumMember_1574006" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_1574007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1574005" xlink:to="loc_srt_MinimumMember_1574007" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1573997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1573996" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1573997" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1574008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1573997" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_1574008" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_1574009" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1573997" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_1574009" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfFixedAssetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1574011" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1574012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1574011" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1574012" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1574014" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1574012" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1574014" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1574015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_1574014" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1574015" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_1574016" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1574015" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_1574016" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_1574017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1574015" xlink:to="loc_us-gaap_ComputerEquipmentMember_1574017" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_1574018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1574015" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_1574018" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_1574019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_1574015" xlink:to="loc_us-gaap_ConstructionInProgressMember_1574019" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1574013" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1574012" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1574013" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1574020" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1574013" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1574020" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1574021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1574013" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1574021" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1574022" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1574013" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1574022" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfFixedAssetsParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1574306" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_1574307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1574306" xlink:to="loc_us-gaap_Depreciation_1574307" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1574040" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1574041" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1574040" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1574041" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1574043" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1574040" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1574043" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1574047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1574040" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1574047" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetParentheticalDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1574319" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1574320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1574319" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1574320" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1574339" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1574320" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1574339" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1574340" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1574339" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1574340" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AcquiredAssemblyWorkforceMember" xlink:label="loc_prok_AcquiredAssemblyWorkforceMember_1574341" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1574340" xlink:to="loc_prok_AcquiredAssemblyWorkforceMember_1574341" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1574342" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1574320" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1574342" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1574343" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1574342" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1574343" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1574344" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1574342" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1574344" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1574347" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1574342" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1574347" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1574348" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1574342" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1574348" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1574349" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_1574342" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1574349" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/InitialPublicOfferingAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_241" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_241" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_242" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_242" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_243" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_243" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_244" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_242" xlink:to="loc_us-gaap_StatementClassOfStockAxis_245" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_245" xlink:to="loc_us-gaap_ClassOfStockDomain_246" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_251" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_246" xlink:to="loc_us-gaap_CommonClassAMember_251" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_247" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_242" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_247" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_247" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_248" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_248" xlink:to="loc_us-gaap_IPOMember_252" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_248" xlink:to="loc_us-gaap_OverAllotmentOptionMember_253" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_242" xlink:to="loc_us-gaap_ClassOfStockLineItems_249" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_249" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_254" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_249" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_255" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1573674" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1573675" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1573674" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1573675" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1573676" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1573675" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1573676" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1573677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1573675" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1573677" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1573679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1573675" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_1573679" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_1573680" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1573675" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_1573680" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1573682" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_1573680" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1573682" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1573683" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_1573680" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_1573683" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1573684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_1573680" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1573684" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1573685" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1573674" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1573685" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1573707" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1573708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1573707" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_1573708" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1573709" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1573707" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1573709" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_EffectiveIncomeTaxRateReconciliationLlcFlowThroughStructure" xlink:label="loc_prok_EffectiveIncomeTaxRateReconciliationLlcFlowThroughStructure_1573710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1573707" xlink:to="loc_prok_EffectiveIncomeTaxRateReconciliationLlcFlowThroughStructure_1573710" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_1573711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1573707" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_1573711" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_1573714" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1573707" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_1573714" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1573717" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1573707" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_1573717" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_1573719" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1573707" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_1573719" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1573720" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1573707" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1573720" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1573727" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1573728" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1573727" xlink:to="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1573728" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_1573729" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1573728" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses_1573729" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1573730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1573728" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_1573730" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredTaxAssetsFederalCreditCarryForwards" xlink:label="loc_prok_DeferredTaxAssetsFederalCreditCarryForwards_1573735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1573728" xlink:to="loc_prok_DeferredTaxAssetsFederalCreditCarryForwards_1573735" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredTaxAssetsLeases" xlink:label="loc_prok_DeferredTaxAssetsLeases_1573739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1573728" xlink:to="loc_prok_DeferredTaxAssetsLeases_1573739" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredTaxAssetsStartUpCosts" xlink:label="loc_prok_DeferredTaxAssetsStartUpCosts_1573743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1573728" xlink:to="loc_prok_DeferredTaxAssetsStartUpCosts_1573743" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1573745" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1573728" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1573745" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1573746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1573728" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1573746" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1573747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1573728" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_1573747" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1573748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_1573728" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1573748" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1573749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1573748" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_1573749" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1573750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1573748" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_1573750" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_1573751" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1573748" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_1573751" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_1573753" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_1573748" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_1573753" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1573754" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1573727" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1573754" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1573759" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_UnrecognizedTaxBenefitsGrossAbstract" xlink:label="loc_prok_UnrecognizedTaxBenefitsGrossAbstract_1573766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1573759" xlink:to="loc_prok_UnrecognizedTaxBenefitsGrossAbstract_1573766" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1573774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_UnrecognizedTaxBenefitsGrossAbstract_1573766" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1573774" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1573775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_UnrecognizedTaxBenefitsGrossAbstract_1573766" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1573775" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_1573777" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_UnrecognizedTaxBenefitsGrossAbstract_1573766" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_1573777" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_1573778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_UnrecognizedTaxBenefitsGrossAbstract_1573766" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_1573778" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1573779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_UnrecognizedTaxBenefitsGrossAbstract_1573766" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1573779" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/IncomeTaxesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1573781" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_IncomeTaxDisclosureTable" xlink:label="loc_prok_IncomeTaxDisclosureTable_1573783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1573781" xlink:to="loc_prok_IncomeTaxDisclosureTable_1573783" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_1573786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_IncomeTaxDisclosureTable_1573783" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_1573786" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_1573787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_1573786" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_1573787" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_1573788" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_1573787" xlink:to="loc_us-gaap_ResearchMember_1573788" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_IncomeTaxActAxis" xlink:label="loc_prok_IncomeTaxActAxis_1574104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_IncomeTaxDisclosureTable_1573783" xlink:to="loc_prok_IncomeTaxActAxis_1574104" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_IncomeTaxActDomain" xlink:label="loc_prok_IncomeTaxActDomain_1574105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_IncomeTaxActAxis_1574104" xlink:to="loc_prok_IncomeTaxActDomain_1574105" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_IncomeTaxDisclosureLineItems" xlink:label="loc_prok_IncomeTaxDisclosureLineItems_1573794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_IncomeTaxDisclosureTable_1573783" xlink:to="loc_prok_IncomeTaxDisclosureLineItems_1573794" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1573801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_IncomeTaxDisclosureLineItems_1573794" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1573801" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_1573804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_IncomeTaxDisclosureLineItems_1573794" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_1573804" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1573807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_IncomeTaxDisclosureLineItems_1573794" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1573807" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1574098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_IncomeTaxDisclosureLineItems_1573794" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1574098" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1574099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_IncomeTaxDisclosureLineItems_1573794" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1574099" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1574102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_IncomeTaxDisclosureLineItems_1573794" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1574102" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredExpenseCapitalizedResearchAndDevelopmentCostsTerm" xlink:label="loc_prok_DeferredExpenseCapitalizedResearchAndDevelopmentCostsTerm_1574109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_IncomeTaxDisclosureLineItems_1573794" xlink:to="loc_prok_DeferredExpenseCapitalizedResearchAndDevelopmentCostsTerm_1574109" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/PrivatePlacementAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PrivatePlacementAbstract" xlink:label="loc_prok_PrivatePlacementAbstract_257" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_PrivatePlacementAbstract_257" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_258" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_258" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_259" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_259" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_260" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_258" xlink:to="loc_us-gaap_StatementClassOfStockAxis_261" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_261" xlink:to="loc_us-gaap_ClassOfStockDomain_262" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_262" xlink:to="loc_us-gaap_CommonClassAMember_267" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_258" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_263" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_263" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_264" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_264" xlink:to="loc_us-gaap_PrivatePlacementMember_268" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_258" xlink:to="loc_us-gaap_ClassOfStockLineItems_265" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_269" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_265" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_269" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_270" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_265" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_270" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_265" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_271" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/LeasesScheduleOfTheClassificationOfOperatingAndFinanceLeaseAssetsAndObligationsInTheCompanySConsolidatedBalanceSheetsDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1573863" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilityAbstract_1573864" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573863" xlink:to="loc_us-gaap_OperatingLeaseLiabilityAbstract_1573864" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_1573865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_1573864" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_1573865" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1573867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_1573864" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1573867" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1573869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_1573864" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1573869" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_1573870" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityAbstract_1573864" xlink:to="loc_us-gaap_OperatingLeaseLiability_1573870" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityAbstract" xlink:label="loc_us-gaap_FinanceLeaseLiabilityAbstract_1573871" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573863" xlink:to="loc_us-gaap_FinanceLeaseLiabilityAbstract_1573871" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_1573873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_1573871" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_1573873" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_1573875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_1573871" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_1573875" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1573877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_1573871" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1573877" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability_1573880" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilityAbstract_1573871" xlink:to="loc_us-gaap_FinanceLeaseLiability_1573880" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1573901" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1573905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573901" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1573905" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1573907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573901" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1573907" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1573908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573901" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1573908" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1573909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573901" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1573909" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1573911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573901" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_1573911" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1573913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573901" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1573913" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1573915" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573901" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1573915" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1573916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573901" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1573916" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_1573919" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573901" xlink:to="loc_us-gaap_OperatingLeaseLiability_1573919" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_1573920" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573901" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_1573920" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_1573921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573901" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_1573921" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_1573922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573901" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_1573922" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_1573923" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573901" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_1573923" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_1573924" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573901" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_1573924" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_1573925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573901" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_1573925" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_1573926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573901" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_1573926" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_1573927" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573901" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_1573927" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability_1573928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573901" xlink:to="loc_us-gaap_FinanceLeaseLiability_1573928" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_1573929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573901" xlink:to="loc_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths_1573929" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo_1573931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573901" xlink:to="loc_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo_1573931" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree_1573933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573901" xlink:to="loc_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree_1573933" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour_1573934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573901" xlink:to="loc_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour_1573934" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive_1573936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573901" xlink:to="loc_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive_1573936" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueAfterYearFive_1573941" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573901" xlink:to="loc_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueAfterYearFive_1573941" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue" xlink:label="loc_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue_1573945" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573901" xlink:to="loc_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue_1573945" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount_1573947" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573901" xlink:to="loc_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount_1573947" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OperatingAndFinanceLeaseLiability" xlink:label="loc_prok_OperatingAndFinanceLeaseLiability_1573949" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573901" xlink:to="loc_prok_OperatingAndFinanceLeaseLiability_1573949" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/LeasesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_1573954" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_1573955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1573954" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_1573955" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_1573956" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_1573955" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_1573956" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1573957" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1573956" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1573957" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_1573958" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1573956" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_1573958" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OperatingAndFinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_prok_OperatingAndFinanceLeaseWeightedAverageDiscountRatePercent_1573959" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1573956" xlink:to="loc_prok_OperatingAndFinanceLeaseWeightedAverageDiscountRatePercent_1573959" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1573961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1573956" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_1573961" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RightOfUseAssetsOperatingAndFinanceLease" xlink:label="loc_prok_RightOfUseAssetsOperatingAndFinanceLease_1573962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1573956" xlink:to="loc_prok_RightOfUseAssetsOperatingAndFinanceLease_1573962" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OperatingAndFinanceLeaseLiabilitiesCurrent" xlink:label="loc_prok_OperatingAndFinanceLeaseLiabilitiesCurrent_1573968" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1573956" xlink:to="loc_prok_OperatingAndFinanceLeaseLiabilitiesCurrent_1573968" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OperatingLeaseRentExpenses" xlink:label="loc_prok_OperatingLeaseRentExpenses_1573974" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1573956" xlink:to="loc_prok_OperatingLeaseRentExpenses_1573974" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_273" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_273" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_274" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_274" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_275" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_275" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_276" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_BasisAxis" xlink:label="loc_prok_BasisAxis_277" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_274" xlink:to="loc_prok_BasisAxis_277" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_BasisDomain" xlink:label="loc_prok_BasisDomain_278" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_BasisAxis_277" xlink:to="loc_prok_BasisDomain_278" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RestrictionOnTransferOfSponsorSharesMember" xlink:label="loc_prok_RestrictionOnTransferOfSponsorSharesMember_287" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_BasisDomain_278" xlink:to="loc_prok_RestrictionOnTransferOfSponsorSharesMember_287" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_274" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_279" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_279" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_280" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AdministrationAndSupportServicesMember" xlink:label="loc_prok_AdministrationAndSupportServicesMember_288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_280" xlink:to="loc_prok_AdministrationAndSupportServicesMember_288" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AdvanceFromRelatedPartyLoanMember" xlink:label="loc_prok_AdvanceFromRelatedPartyLoanMember_289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_280" xlink:to="loc_prok_AdvanceFromRelatedPartyLoanMember_289" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PromissoryNoteMember" xlink:label="loc_prok_PromissoryNoteMember_290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_280" xlink:to="loc_prok_PromissoryNoteMember_290" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_WorkingCapitalLoansMember" xlink:label="loc_prok_WorkingCapitalLoansMember_291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_280" xlink:to="loc_prok_WorkingCapitalLoansMember_291" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_281" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_274" xlink:to="loc_us-gaap_StatementClassOfStockAxis_281" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_281" xlink:to="loc_us-gaap_ClassOfStockDomain_282" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_282" xlink:to="loc_us-gaap_CommonClassBMember_292" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1572765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_282" xlink:to="loc_us-gaap_CommonClassAMember_1572765" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_274" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_283" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_283" xlink:to="loc_us-gaap_RelatedPartyDomain_284" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_FounderMember" xlink:label="loc_prok_FounderMember_293" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_284" xlink:to="loc_prok_FounderMember_293" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SponsorMember" xlink:label="loc_prok_SponsorMember_294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_284" xlink:to="loc_prok_SponsorMember_294" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PipeInvestorsMember" xlink:label="loc_prok_PipeInvestorsMember_1572766" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_284" xlink:to="loc_prok_PipeInvestorsMember_1572766" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ScMasterHoldingsLlcMember" xlink:label="loc_prok_ScMasterHoldingsLlcMember_1572767" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_284" xlink:to="loc_prok_ScMasterHoldingsLlcMember_1572767" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AverillMasterFundLtdMember" xlink:label="loc_prok_AverillMasterFundLtdMember_1572768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_284" xlink:to="loc_prok_AverillMasterFundLtdMember_1572768" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1062027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_274" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1062027" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1062028" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1062027" xlink:to="loc_us-gaap_EquityComponentDomain_1062028" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_FounderSharesMember" xlink:label="loc_prok_FounderSharesMember_1062029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1062028" xlink:to="loc_prok_FounderSharesMember_1062029" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1062030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_274" xlink:to="loc_srt_TitleOfIndividualAxis_1062030" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1062031" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_1062030" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1062031" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_IndependentDirectorsMember" xlink:label="loc_prok_IndependentDirectorsMember_1062032" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1062031" xlink:to="loc_prok_IndependentDirectorsMember_1062032" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember" xlink:label="loc_srt_DirectorMember_1317425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1062031" xlink:to="loc_srt_DirectorMember_1317425" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1167798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_274" xlink:to="loc_us-gaap_AwardTypeAxis_1167798" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1167800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1167798" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1167800" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AgreementAxis" xlink:label="loc_prok_AgreementAxis_1572615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_274" xlink:to="loc_prok_AgreementAxis_1572615" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AgreementDomain" xlink:label="loc_prok_AgreementDomain_1572762" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AgreementAxis_1572615" xlink:to="loc_prok_AgreementDomain_1572762" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SubscriptionAgreementsMember" xlink:label="loc_prok_SubscriptionAgreementsMember_1572763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AgreementDomain_1572762" xlink:to="loc_prok_SubscriptionAgreementsMember_1572763" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573511" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_274" xlink:to="loc_dei_LegalEntityAxis_1573511" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573512" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1573511" xlink:to="loc_dei_EntityDomain_1573512" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573513" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1573512" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573513" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_274" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_285" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_295" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_296" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_297" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1318969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1318969" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_298" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_299" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SharesNoLongerSubjectToForfeiture" xlink:label="loc_prok_SharesNoLongerSubjectToForfeiture_1154722" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_prok_SharesNoLongerSubjectToForfeiture_1154722" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1154727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1154727" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_us-gaap_SharePrice_302" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_NumberOfTradingDaysForDeterminingTheSharePrice" xlink:label="loc_prok_NumberOfTradingDaysForDeterminingTheSharePrice_303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_prok_NumberOfTradingDaysForDeterminingTheSharePrice_303" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice" xlink:label="loc_prok_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice_304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_prok_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice_304" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered" xlink:label="loc_prok_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered_305" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_prok_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered_305" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_306" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_1154756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty_1154756" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RepaymentOfAdvancesFromRelatedParty" xlink:label="loc_prok_RepaymentOfAdvancesFromRelatedParty_1154807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_prok_RepaymentOfAdvancesFromRelatedParty_1154807" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AdvancesPayableToRelatedPartyCurrent" xlink:label="loc_prok_AdvancesPayableToRelatedPartyCurrent_1154810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_prok_AdvancesPayableToRelatedPartyCurrent_1154810" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_307" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_308" use="optional" order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_309" use="optional" order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue" xlink:label="loc_prok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue_1317434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_prok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue_1317434" use="optional" order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1572755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1572755" use="optional" order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1572758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_285" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1572758" use="optional" order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/RelatedPartyDebtAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1574038" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1574039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1574038" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1574039" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1574045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1574039" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1574045" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1574046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1574045" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1574046" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PromissoryNoteMember" xlink:label="loc_prok_PromissoryNoteMember_1574048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1574046" xlink:to="loc_prok_PromissoryNoteMember_1574048" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_1574049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1574039" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_1574049" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1574051" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1574049" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1574051" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1574052" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1574049" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1574052" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_1574053" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1574049" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_1574053" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_1574055" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1574049" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_1574055" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount" xlink:label="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_1574057" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1574049" xlink:to="loc_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount_1574057" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_1574593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1574049" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_1574593" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/CommitmentsAndContingenciesAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_314" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_1167806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_314" xlink:to="loc_us-gaap_LossContingenciesTable_1167806" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AgreementAxis" xlink:label="loc_prok_AgreementAxis_1167809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1167806" xlink:to="loc_prok_AgreementAxis_1167809" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AgreementDomain" xlink:label="loc_prok_AgreementDomain_1167810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AgreementAxis_1167809" xlink:to="loc_prok_AgreementDomain_1167810" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DirectorRestrictedStockUnitAwardAgreementMember" xlink:label="loc_prok_DirectorRestrictedStockUnitAwardAgreementMember_1167812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AgreementDomain_1167810" xlink:to="loc_prok_DirectorRestrictedStockUnitAwardAgreementMember_1167812" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1167814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1167806" xlink:to="loc_us-gaap_AwardTypeAxis_1167814" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1167815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1167814" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1167815" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_1167817" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1167815" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_1167817" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1167818" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1167806" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1167818" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1167819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1167818" xlink:to="loc_us-gaap_ClassOfStockDomain_1167819" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1167820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1167819" xlink:to="loc_us-gaap_CommonClassAMember_1167820" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1167806" xlink:to="loc_dei_LegalEntityAxis_1573428" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1573428" xlink:to="loc_dei_EntityDomain_1573429" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1573429" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573430" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_1167823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_1167806" xlink:to="loc_us-gaap_LossContingenciesLineItems_1167823" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_DeferredUnderwritingFees" xlink:label="loc_prok_DeferredUnderwritingFees_316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1167823" xlink:to="loc_prok_DeferredUnderwritingFees_316" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1167829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1167823" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1167829" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_NumberOfSharesOfCommonStockCommittedToSettleOnADateFollowingTheYearBusinessCombinationOccurs" xlink:label="loc_prok_NumberOfSharesOfCommonStockCommittedToSettleOnADateFollowingTheYearBusinessCombinationOccurs_1167830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_1167823" xlink:to="loc_prok_NumberOfSharesOfCommonStockCommittedToSettleOnADateFollowingTheYearBusinessCombinationOccurs_1167830" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/MembersEquityScheduleOfMembersEquityDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MembersEquityAbstract" xlink:label="loc_us-gaap_MembersEquityAbstract_1573606" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_MembersEquityTable" xlink:label="loc_prok_MembersEquityTable_1573607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MembersEquityAbstract_1573606" xlink:to="loc_prok_MembersEquityTable_1573607" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1573608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_MembersEquityTable_1573607" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1573608" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1573609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1573608" xlink:to="loc_us-gaap_EquityComponentDomain_1573609" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MemberUnitsMember" xlink:label="loc_us-gaap_MemberUnitsMember_1573610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1573609" xlink:to="loc_us-gaap_MemberUnitsMember_1573610" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="loc_us-gaap_CapitalUnitsByClassAxis_1573611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_MembersEquityTable_1573607" xlink:to="loc_us-gaap_CapitalUnitsByClassAxis_1573611" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_1573612" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_1573611" xlink:to="loc_us-gaap_CapitalUnitClassDomain_1573612" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassAMember" xlink:label="loc_us-gaap_CapitalUnitClassAMember_1573614" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1573612" xlink:to="loc_us-gaap_CapitalUnitClassAMember_1573614" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_MembersEquityLineItems" xlink:label="loc_prok_MembersEquityLineItems_1573615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_MembersEquityTable_1573607" xlink:to="loc_prok_MembersEquityLineItems_1573615" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding" xlink:label="loc_us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding_1573616" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_MembersEquityLineItems_1573615" xlink:to="loc_us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding_1573616" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapitalAccountUnitsContributed" xlink:label="loc_us-gaap_PartnersCapitalAccountUnitsContributed_1573617" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_MembersEquityLineItems_1573615" xlink:to="loc_us-gaap_PartnersCapitalAccountUnitsContributed_1573617" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding" xlink:label="loc_us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding_1573618" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_MembersEquityLineItems_1573615" xlink:to="loc_us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding_1573618" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/MembersEquityAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MembersEquityAbstract" xlink:label="loc_us-gaap_MembersEquityAbstract_1573621" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1573964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MembersEquityAbstract_1573621" xlink:to="loc_us-gaap_StatementTable_1573964" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1573965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573964" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1573965" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1573966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1573965" xlink:to="loc_us-gaap_ClassOfStockDomain_1573966" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="loc_us-gaap_CapitalUnitsByClassAxis_1573969" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573964" xlink:to="loc_us-gaap_CapitalUnitsByClassAxis_1573969" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_1573970" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_1573969" xlink:to="loc_us-gaap_CapitalUnitClassDomain_1573970" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassBMember" xlink:label="loc_us-gaap_CapitalUnitClassBMember_1573971" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1573970" xlink:to="loc_us-gaap_CapitalUnitClassBMember_1573971" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_CapitalUnitClassB1Member" xlink:label="loc_prok_CapitalUnitClassB1Member_1573973" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1573970" xlink:to="loc_prok_CapitalUnitClassB1Member_1573973" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassAMember" xlink:label="loc_us-gaap_CapitalUnitClassAMember_1573980" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1573970" xlink:to="loc_us-gaap_CapitalUnitClassAMember_1573980" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_1573967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1573964" xlink:to="loc_us-gaap_StatementLineItems_1573967" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized" xlink:label="loc_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized_1574635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573967" xlink:to="loc_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized_1574635" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersCapitalAccountUnitsIssued" xlink:label="loc_us-gaap_LimitedPartnersCapitalAccountUnitsIssued_1573975" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573967" xlink:to="loc_us-gaap_LimitedPartnersCapitalAccountUnitsIssued_1573975" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ProceedsFromLimitedPartnersCapitalAccountUnits" xlink:label="loc_prok_ProceedsFromLimitedPartnersCapitalAccountUnits_1573976" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1573967" xlink:to="loc_prok_ProceedsFromLimitedPartnersCapitalAccountUnits_1573976" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficitAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_318" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_318" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_319" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_320" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_319" xlink:to="loc_us-gaap_StatementClassOfStockAxis_320" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_320" xlink:to="loc_us-gaap_ClassOfStockDomain_321" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_321" xlink:to="loc_us-gaap_CommonClassAMember_323" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_321" xlink:to="loc_us-gaap_CommonClassBMember_324" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573431" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_319" xlink:to="loc_dei_LegalEntityAxis_1573431" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573432" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1573431" xlink:to="loc_dei_EntityDomain_1573432" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573434" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1573432" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573434" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_319" xlink:to="loc_us-gaap_ClassOfStockLineItems_322" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_322" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_325" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_326" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_322" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_326" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_322" xlink:to="loc_us-gaap_PreferredStockSharesIssued_327" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_322" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_328" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_329" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_322" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_329" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_322" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_330" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_331" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_322" xlink:to="loc_us-gaap_CommonStockSharesIssued_331" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_322" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_332" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockOtherSharesOutstanding" xlink:label="loc_us-gaap_CommonStockOtherSharesOutstanding_333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_322" xlink:to="loc_us-gaap_CommonStockOtherSharesOutstanding_333" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PercentOfFoundersSharesToCompanysIssuedAndOutstandingOrdinaryShares" xlink:label="loc_prok_PercentOfFoundersSharesToCompanysIssuedAndOutstandingOrdinaryShares_334" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_322" xlink:to="loc_prok_PercentOfFoundersSharesToCompanysIssuedAndOutstandingOrdinaryShares_334" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/NetLossPerShareScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1573633" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1573634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1573633" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1573634" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="loc_us-gaap_CapitalUnitsByClassAxis_1573635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1573634" xlink:to="loc_us-gaap_CapitalUnitsByClassAxis_1573635" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_1573636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_1573635" xlink:to="loc_us-gaap_CapitalUnitClassDomain_1573636" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassAMember" xlink:label="loc_us-gaap_CapitalUnitClassAMember_1573637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1573636" xlink:to="loc_us-gaap_CapitalUnitClassAMember_1573637" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="loc_us-gaap_EarningsPerShareBasicLineItems_1573638" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_1573634" xlink:to="loc_us-gaap_EarningsPerShareBasicLineItems_1573638" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_1573639" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1573638" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_1573639" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1573640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_1573639" xlink:to="loc_us-gaap_NetIncomeLoss_1573640" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1573641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1573638" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1573641" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1573642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1573641" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1573642" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1573644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1573641" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1573644" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_BasicAndDilutedNetIncomeLossPerShareAbstract" xlink:label="loc_prok_BasicAndDilutedNetIncomeLossPerShareAbstract_1574231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicLineItems_1573638" xlink:to="loc_prok_BasicAndDilutedNetIncomeLossPerShareAbstract_1574231" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_1573664" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_BasicAndDilutedNetIncomeLossPerShareAbstract_1574231" xlink:to="loc_us-gaap_EarningsPerShareBasic_1573664" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1573667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_BasicAndDilutedNetIncomeLossPerShareAbstract_1574231" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1573667" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/FairValueMeasurementsSummaryOfAssetsThatAreMeasuredAtFairValueOnARecurringBasisDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1154347" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_1154437" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1154347" xlink:to="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_1154437" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1154440" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_1154437" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1154440" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1154441" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_1154440" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1154441" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1154442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1154441" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1154442" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_1154437" xlink:to="loc_dei_LegalEntityAxis_1573468" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573469" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1573468" xlink:to="loc_dei_EntityDomain_1573469" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573471" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1573469" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573471" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_1154438" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_1154437" xlink:to="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_1154438" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_1154436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_1154438" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_1154436" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_MarketableSecuritiesHeldToMaturityFairValueDisclosure" xlink:label="loc_prok_MarketableSecuritiesHeldToMaturityFairValueDisclosure_1154439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_1154436" xlink:to="loc_prok_MarketableSecuritiesHeldToMaturityFairValueDisclosure_1154439" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/EquityBasedCompensationSummaryOfTheActivityRelatedToCompanySClassBAndB1UnitsGrantedDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1573800" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1573802" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1573800" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1573802" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1573802" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573806" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1573808" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573806" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1573808" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1573809" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573806" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1573809" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1574146" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1574146" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_1574147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573806" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_1574147" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1573810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573806" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_1573810" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1573814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573806" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1573814" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_1573815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573806" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_1573815" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1574148" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1574148" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1574149" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573806" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1574149" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1573817" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573806" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_1573817" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1573821" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1573825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1573821" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1573825" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_1573827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1573825" xlink:to="loc_us-gaap_VestingAxis_1573827" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_1573828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_1573827" xlink:to="loc_us-gaap_VestingDomain_1573828" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OnTheLatterOfTheFirstAnniversaryMember" xlink:label="loc_prok_OnTheLatterOfTheFirstAnniversaryMember_1573829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_1573828" xlink:to="loc_prok_OnTheLatterOfTheFirstAnniversaryMember_1573829" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_InFirstAnniversaryOfTheAcquisitionDateMember" xlink:label="loc_prok_InFirstAnniversaryOfTheAcquisitionDateMember_1573830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_1573828" xlink:to="loc_prok_InFirstAnniversaryOfTheAcquisitionDateMember_1573830" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OnEachEnniversaryMember" xlink:label="loc_prok_OnEachEnniversaryMember_1573831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_1573828" xlink:to="loc_prok_OnEachEnniversaryMember_1573831" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_EachCalendarQuarterMember" xlink:label="loc_prok_EachCalendarQuarterMember_1573832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_1573828" xlink:to="loc_prok_EachCalendarQuarterMember_1573832" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_OverTheThreeYearPeriodFromTheDateOfGrantMember" xlink:label="loc_prok_OverTheThreeYearPeriodFromTheDateOfGrantMember_1574199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_1573828" xlink:to="loc_prok_OverTheThreeYearPeriodFromTheDateOfGrantMember_1574199" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="loc_us-gaap_CapitalUnitsByClassAxis_1573833" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1573825" xlink:to="loc_us-gaap_CapitalUnitsByClassAxis_1573833" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_1573834" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_1573833" xlink:to="loc_us-gaap_CapitalUnitClassDomain_1573834" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassBMember" xlink:label="loc_us-gaap_CapitalUnitClassBMember_1573835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1573834" xlink:to="loc_us-gaap_CapitalUnitClassBMember_1573835" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ClassB1unitsMember" xlink:label="loc_prok_ClassB1unitsMember_1574188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1573834" xlink:to="loc_prok_ClassB1unitsMember_1574188" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1574194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1573825" xlink:to="loc_us-gaap_AwardTypeAxis_1574194" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1574195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1574194" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1574195" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1574196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1574195" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1574196" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1573825" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1573838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1573838" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized" xlink:label="loc_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized_1573844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized_1573844" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1573846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1573846" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_NumberOfCommonUnitsUnissuedOfLimitedLiabilityCompany" xlink:label="loc_prok_NumberOfCommonUnitsUnissuedOfLimitedLiabilityCompany_1573847" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_prok_NumberOfCommonUnitsUnissuedOfLimitedLiabilityCompany_1573847" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1573848" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1573848" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1573849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1573849" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1573850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1573850" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1573851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1573851" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonUnitIssued" xlink:label="loc_us-gaap_CommonUnitIssued_1574185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_us-gaap_CommonUnitIssued_1574185" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonUnitIssuanceValue" xlink:label="loc_us-gaap_CommonUnitIssuanceValue_1574186" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_us-gaap_CommonUnitIssuanceValue_1574186" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapitalAccountUnitsUnitbasedCompensation" xlink:label="loc_us-gaap_PartnersCapitalAccountUnitsUnitbasedCompensation_1574189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_us-gaap_PartnersCapitalAccountUnitsUnitbasedCompensation_1574189" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PartnersCapitalAccountUnitBasedCompensation" xlink:label="loc_us-gaap_PartnersCapitalAccountUnitBasedCompensation_1574190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_us-gaap_PartnersCapitalAccountUnitBasedCompensation_1574190" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_1574191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_1574191" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_1574192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_us-gaap_EmployeeBenefitsAndShareBasedCompensation_1574192" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1574193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_1574193" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_CommonUnitsUnissued" xlink:label="loc_prok_CommonUnitsUnissued_1574197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1573836" xlink:to="loc_prok_CommonUnitsUnissued_1574197" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/EquityBasedCompensationSummaryOfKeyAssumptionsUsedInTheOpmValuationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract" xlink:label="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_1574166" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1574167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract_1574166" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1574167" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_1574175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1574167" xlink:to="loc_us-gaap_ValuationTechniqueAxis_1574175" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_1574176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_1574175" xlink:to="loc_us-gaap_ValuationTechniqueDomain_1574176" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_1574177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_1574176" xlink:to="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_1574177" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ValuationTechniqueProbabilityWeightedExpectedReturnMethodMember" xlink:label="loc_prok_ValuationTechniqueProbabilityWeightedExpectedReturnMethodMember_1574179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_1574176" xlink:to="loc_prok_ValuationTechniqueProbabilityWeightedExpectedReturnMethodMember_1574179" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1574168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1574167" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1574168" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MembersEquity" xlink:label="loc_us-gaap_MembersEquity_1574170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1574168" xlink:to="loc_us-gaap_MembersEquity_1574170" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1574171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1574168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1574171" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_1574172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1574168" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_1574172" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1574173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1574168" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1574173" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/EquityBasedCompensationSummaryOfCompensationExpenseDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1574151" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1574152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1574151" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1574152" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1574155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1574152" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1574155" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1574156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1574155" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1574156" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1574157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1574156" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1574157" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1574158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1574156" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1574158" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1574154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1574152" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1574154" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1574159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1574154" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1574159" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1317495" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1317496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1317495" xlink:to="loc_us-gaap_SubsequentEventTable_1317496" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1573404" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1317496" xlink:to="loc_dei_LegalEntityAxis_1573404" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1573405" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1573404" xlink:to="loc_dei_EntityDomain_1573405" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember" xlink:label="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573406" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1573405" xlink:to="loc_prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember_1573406" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_EarnoutSharesTrancheAxis" xlink:label="loc_prok_EarnoutSharesTrancheAxis_1317500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1317496" xlink:to="loc_prok_EarnoutSharesTrancheAxis_1317500" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_EarnoutSharesTrancheDomain" xlink:label="loc_prok_EarnoutSharesTrancheDomain_1317501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_EarnoutSharesTrancheAxis_1317500" xlink:to="loc_prok_EarnoutSharesTrancheDomain_1317501" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableByTypeAxis" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1317521" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1317496" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1317521" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityInterestIssuedOrIssuableTypeDomain" xlink:label="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1317522" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis_1317521" xlink:to="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1317522" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_RestrictedStockRightsMember" xlink:label="loc_prok_RestrictedStockRightsMember_1355639" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityInterestIssuedOrIssuableTypeDomain_1317522" xlink:to="loc_prok_RestrictedStockRightsMember_1355639" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1317552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1317496" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1317552" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1317555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1317552" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1317555" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1317556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1317555" xlink:to="loc_us-gaap_SubsequentEventMember_1317556" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AgreementAxis" xlink:label="loc_prok_AgreementAxis_1317598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1317496" xlink:to="loc_prok_AgreementAxis_1317598" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_AgreementDomain" xlink:label="loc_prok_AgreementDomain_1317600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_AgreementAxis_1317598" xlink:to="loc_prok_AgreementDomain_1317600" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1317608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1317496" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1317608" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1317610" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1317608" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1317610" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1355642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1317496" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1355642" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1355644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1355642" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1355644" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ProkidneyLpMember" xlink:label="loc_prok_ProkidneyLpMember_1355646" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1355644" xlink:to="loc_prok_ProkidneyLpMember_1355646" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1355654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1317496" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1355654" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_1355655" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1355654" xlink:to="loc_us-gaap_RelatedPartyDomain_1355655" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PipeInvestorsMember" xlink:label="loc_prok_PipeInvestorsMember_1355659" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1355655" xlink:to="loc_prok_PipeInvestorsMember_1355659" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMember" xlink:label="loc_prok_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMember_1355666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1355655" xlink:to="loc_prok_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMember_1355666" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember" xlink:label="loc_prok_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember_1355669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1355655" xlink:to="loc_prok_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember_1355669" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SponsorMember" xlink:label="loc_prok_SponsorMember_1572740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1355655" xlink:to="loc_prok_SponsorMember_1572740" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SharePriceRangeAxis" xlink:label="loc_prok_SharePriceRangeAxis_1355677" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1317496" xlink:to="loc_prok_SharePriceRangeAxis_1355677" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SharePriceRangeDomain" xlink:label="loc_prok_SharePriceRangeDomain_1355679" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_SharePriceRangeAxis_1355677" xlink:to="loc_prok_SharePriceRangeDomain_1355679" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SharePriceOneMember" xlink:label="loc_prok_SharePriceOneMember_1355684" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_SharePriceRangeDomain_1355679" xlink:to="loc_prok_SharePriceOneMember_1355684" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SharePriceTwoMember" xlink:label="loc_prok_SharePriceTwoMember_1355687" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_SharePriceRangeDomain_1355679" xlink:to="loc_prok_SharePriceTwoMember_1355687" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_SharePriceThreeMember" xlink:label="loc_prok_SharePriceThreeMember_1355689" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prok_SharePriceRangeDomain_1355679" xlink:to="loc_prok_SharePriceThreeMember_1355689" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1355724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1317496" xlink:to="loc_srt_RangeAxis_1355724" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1355725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1355724" xlink:to="loc_srt_RangeMember_1355725" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1355726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1355725" xlink:to="loc_srt_MaximumMember_1355726" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_1572732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1317496" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_1572732" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1572738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_1572732" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1572738" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_PromissoryNoteMember" xlink:label="loc_prok_PromissoryNoteMember_1572739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1572738" xlink:to="loc_prok_PromissoryNoteMember_1572739" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="loc_us-gaap_CapitalUnitsByClassAxis_1573573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1317496" xlink:to="loc_us-gaap_CapitalUnitsByClassAxis_1573573" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_1573575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_1573573" xlink:to="loc_us-gaap_CapitalUnitClassDomain_1573575" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnitClassBMember" xlink:label="loc_us-gaap_CapitalUnitClassBMember_1573577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1573575" xlink:to="loc_us-gaap_CapitalUnitClassBMember_1573577" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="prok-20220331.xsd#prok_CapitalUnitClassBOneMember" xlink:label="loc_prok_CapitalUnitClassBOneMember_1573578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitClassDomain_1573575" xlink:to="loc_prok_CapitalUnitClassBOneMember_1573578" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_1574263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1317496" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_1574263" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain" xlink:label="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_1574264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_1574263" xlink:to="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_1574264" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredProfitSharingMember" xlink:label="loc_us-gaap_DeferredProfitSharingMember_1574265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain_1574264" xlink:to="loc_us-gaap_DeferredProfitSharingMember_1574265" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1317634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1317496" xlink:to="loc_us-gaap_SubsequentEventLineItems_1317634" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1355701" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1317634" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_1355701" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_1355708" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1317634" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_1355708" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1355710" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1317634" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1355710" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_1355711" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1317634" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_1355711" use="optional" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1355712" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1317634" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1355712" use="optional" order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1572735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1317634" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1572735" use="optional" order="50" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_1572736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1317634" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_1572736" use="optional" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized" xlink:label="loc_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized_1573580" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1317634" xlink:to="loc_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized_1573580" use="optional" order="52" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LimitedPartnersCapitalAccountUnitsIssued" xlink:label="loc_us-gaap_LimitedPartnersCapitalAccountUnitsIssued_1573581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1317634" xlink:to="loc_us-gaap_LimitedPartnersCapitalAccountUnitsIssued_1573581" use="optional" order="53" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalUnits" xlink:label="loc_us-gaap_CapitalUnits_1573582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1317634" xlink:to="loc_us-gaap_CapitalUnits_1573582" use="optional" order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1573590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1317634" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1573590" use="optional" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_1573591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1317634" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_1573591" use="optional" order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g373959dsp18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g373959dsp18.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MC:>+]%AN;B/;=0-M?8Q4HV.H(.0"/\\4GH,Z"UM8+.!8+>,1QKT _G[T@)J
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M%C_CUTO_ 'Y/Y"J0F=IX>_Y%S3/^O:/_ -!%2,N7EK'>V4]K,,QS(4;Z$8H
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MEMY03'*A1@#C@C!H S]%\.Z=X?$PT^)T$V-^YRV<9QU^M%P-1E#*5(!!Z@T
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MU% $VH:O%I\B1M;7<[N"V+>!GP!ZD4 26FHV^I:>;JSD+)AAR""K#J"#T(H
MJ>%[F:[\,:?<7$C2S21 L[=2: '^);B:T\,ZE<6\ACFC@9D9>H('6@#"66]T
MB?1I%U>>\^W2)');3E6.&7)9< $8I@=+J6J6FE6ZS73D!FV(JJ69V]% Y)I
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MXT@%MK69/&%_<F%A!):Q*LF.&8%LC]10!MB@ H * "@ H * "@ H * "@ H
G* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g373959g0805082153456.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g373959g0805082153456.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !8 4,# 2(  A$! Q$!_\0
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MA6+S"N-V!C..U7J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+ "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g373959g10a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g373959g10a01.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[2&*4&AO=&]S:&]P(#,N,  X0DE-! 0
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M4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M"G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@
M  EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN=$]U
M='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O
M;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M        1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M     %)S;'15;G1&(U!X;$!8_HT         "G9E8W1O<D1A=&%B;V]L 0
M  !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M            5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C
M0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T
M0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O
M<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))
M30/M       0 )3,S  !  $ E,S,  $  3A"24T$)@      #@
M   _@   .$))300-       $    6CA"24T$&0      !    !XX0DE- _,
M      D           $ .$))32<0       *  $          3A"24T#]0
M    2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M 0!:    !@       0 U     0 M    !@       3A"24T#^       <
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@     ________
M_____________________P/H   X0DE-! @      !     !   "0    D
M    .$))300>       $     #A"24T$&@     #00    8
M 7    '<    !@!G #$ , !A #  ,0    $
M 0             !W    7                       0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   7      4F=H=&QO;F<   '<    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $     SA"24T$#      6\     $   "@    ?
M >   .B    6U  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ ? "@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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MKFOM_P"#95_-K9?U?JPMLKKPJ+0T-<'#*8(!:SZ;2S=[;W;-_P#H_23-Z[U
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MWYGMT]R=F-]6
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M/:3:R91'FXW7V\*PO8R<CN,*P.SJXV07DZQ@QY]LW9R7VF=MDY<JY^67IHB
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M7KU6\4J]CZ]>XQ1=5_:>^&+2W6OQ#X"CP\+RK4KPOT.9YWJ-<5]'AC$^!BF
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M"I+X6-MA%#EQX>N,12M*HY1!<ALJ!OG<^D'@BT#T/L]+[O3[%IU39:083E6
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M;[<Z=]^7;?\ C?+[_IP@HSB(6@G8*23UZ C?H2#T^A!!^[A")0\T1N'$$?\
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M<LQTOP.@/&*0$2M+G]5''K6,J/\ CT]I7CF2"F>T[T]R.LQ+!]3LI?LF:>%
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M!=X#-R2[@TU/58\_CE'>UPE0D8@+:ZR6MKK.UM'N6A0B0AU+LA(2:?-2FC:
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MOHE716#LFNOGF["6]%R-N.^^&ZBL;8KI+,N&TJ:MN(DNO(=,"Z>N-;-9W,5
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M0#;;N1ON-M^$6(I>0KMS#J!U&W4[=!UZG8\WP[C;?KN".$0$'/Y9\#;.(EU
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M(S&\T^QFSR9^5#362'+R75Q7;!URM0VTB&52"X5Q@VA32]TJ2.Y[<&::8>V
MI"E%1VH2=5O&N= "97*A@[&J(E.='C-8'8?,@;#Y=/V;;_N/RXV[LHJBDW->
MOJD:UGR%":'XN3\.4$CG!42 02!OZ ';Z]>G3;?Y;<9RI*J7", /$(B<U\8+
M,2?-"IY'Q<:&.^RG>HG*!6%^]Q "".P8L-P21TW'T^?8CC29AWDM" )AU,C\
MC>PSJ* 4(X$\7RJ H%4*D+8=+H0#N 5<RB.P!*B#L!VW[[>FQXWK*0%9*)1\
MES)0)Y1!=0KD,MVOH ^6JQ*1N=B=]MR-B=OP(Z;^G!<.CT:GA!!5"[(0,[M0
M-TJ:1B+7?496D&CNIFID:GG9!889A=Y=5%!71'YLV]O&83S>/4\6-'0[(>>G
MWKM?&"&&U;!TKD?F >.?:9S++,,,D@2DE[TIF*]=(RD .)*2M@:46]J42J)4
M1XETOB\\8=?IO@N%9WE>5X5K_1ZM3<4N7LET@@Q*W.<?O:W',NQR\RZ>]5N5
MV+X?CM=:W>-RA1,)M[N;"J%Q76U.RE)\G!Q<;??=7>1Y2J%275*K=R\=V*,+
M<*%4%%;A572^K(B_03%)5&84M06XMEE;JT[^6IU;25.% 5N0A2R2D$[I20D@
M;;<>RY0DR@_\N7$\V?6//"RJQ*DD(_4K[H[&Z>N_-W/7H=MMOIUV/U'KVVX(
M0?PL0J5"GA>CVYQ29F06N$=]6IKQ>)T$\[) W 6DA)'7<*VV.P22#S$D*).W
M;ITX AY24ME9.5.'&X&=1D,P CK8E<@YUI'/9C>PF@;#E?6.^WKZGUV[[ ?L
M'&4B;LKEP"ED0!LO&O43,I:YL31\W6SYWCII((!*$[[;'OWZ?7MW_=Q4 -36
MQ/@%0\(A,U4*%$"#C0!G]]&CJRI;4&/*F/<PCQ([TAP@'<I80IYT<NQY0&TJ
M0CE+CBU)2>0%P)$F( &?KP1.<02J5J'4%0:7J]^A%6\"('C0\5\Z!X@%Y789
MYIE"R.:]FGATR"RTG87#C8M6V%E3-8FS)EUDB(EJZ?AP+-5[D<6:Y%][,=E@
MAYOD\.3'V@8TX(&[O$/*00%JI.3TCK$F&4)H [W#E6'Q\A[+>'C+,LSC0S2K
M+\[8D1\SR7!J*WR5J94MU$MN[>B-.37)$ ;^X.@^>I$=LIY$*;<*0#R\>O@S
MSS#VP*4 (9LR:JNG6-,Z2F9,V&8SY)Q2M#&;1WW(^?I\@.AVZ]2/3N-CQM66
MMES1^/'K&G=)%V15\$LPUN1'&V05HZ$DK1W'ZOQ#HD=P.OK_ #=.+BF7NIR
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M1QIH6I!=M2N$)6])4DI4#^@A9Y1R**RGG4#R*3NV.B^I_C;'B=T9@BBCC1_
MTIK6,3B)3)7%$.3C]=(D]_H'4^8ZEQ2G-U?G:UAU2$%(0E/QJ4I/1"5!+A4X
M@A.R@"00V42%2%5)@AI=#HS4B]],64/2C^_/)X[!MZD ?I$H '<DQ @;'J25
M*=Y-NY64C<;]M^,QA;U+)<FE1>WJJA.E<BC,2Y5C?+GG W-2H\WGRN4^ONAV
M/78*2HK',@CLH#8@[[GB]TB!%=5LZ!_!6L;+#O U?#P>.1NYJ?,;3[Q)W+B=
MA[J =P4_-S?MT Z?3U'&HX:3S!TII1LB@*YU?2]X-6I3,KP?GX1VK&UJ183>
M9^4%*D+YA[H2 =_GYNWXC8?=UXV2X9,LH(H &.2+Z?K$[R47N:H6<,X\7$=#
M[8J KE$B3N/@0?=4[%T*YDH'Z1S*7Y6ZG$A'PGJ/EP.%,I4*XH2>- Z4&F30
MWQK3*F=6R1S>)56]*I2DB1(6I3?4*C;@\RDJ;<<3YJ5I2O;E3MMSCE'H>!P9
MC29N?LBM^0I 8FGOTTM>T2KG8^XDM.>:XTH)2IIRM0XVIM*DN!OE<4I(:YP%
ME('ZP2>XZSZO*JI+O"@96T]X(T($3OI7^-GXY4B95I3[)3[Q*Z<_*DPST4I)
M0I82TO<*Y"&]PD#D  &W&<L@L &4\"??77@D8[Q*369TY@>]#SB<6]2>[\H
M^ONAW'?T\P'\.G"; F LJJ M***9(>FL;.] 4*^0(R94/KSE3:525I(D2C\2
M=OT0CKN!M_?-]M_H?GVXU8LA&%,"R2S'.QOS]5B]X"<R6H,T]$><;\5JN>#"
M6#NA42.I"MMBH%IL'=/IO^[?Z<?C)_OD?UIFY\J<.C1Z$H9;E.@#>NN0J'$C
M*'"$.$(<(0X0APA#A"'"$.$(<(0X0APA#A"'"$.$(<(0X0C07VAGB4U0\,VE
MF"Y%I'55EMEN;:JXOI^RS889DFH3S4>]3,6Z]68;BEI3W=_8 QDH9@PI[;ZP
MM2FT.%! 0C2.A]K7K+C%=5XCK)X0KVGU=8L,"PZY0[J%A6GN'OZ@YUA]KJ#!
MI[!>8V$FQP6,W@U'9W4IR_6^F/;&#C"'W[%UT@NFE\S8:(ZI54-(A=QFX\*A
M?/4T-'/MW].;#R+#'/#]G=MC<_&V[&ML9F;X)29&_DJ-*:;5:;CKV$29<J^C
MUC-?>U]- S5YI.,W%HM_W*48D=N3+B^@_1/DL4 A5(*:&KZ5.3)J\7G']M#C
MC5C J+SPZYG26M7>O4>J-:]J)I\J5@KJLIBXE7?DZT_)B2-3I4VSFQ3(B8W'
MCHJF%.OSY26F5+XOS]>?RN0K4=*K=T;H=:Q8;/MMZ^\;KKZHT8R2M8I+?6*#
ME.F[UA2VN<WC&$:9P<ZQ)$"7)DXW&QB9=.S R\VJMRAB8P%KHI%NMMMJ2@FH
M5G=*]:/?6Z;+2?:I8FOPQ:4>(*BTJL;^ZU:U R736HT_3G./X_$J<DPU&0S,
MF;OL]R:%5T],(=5C5C,A0+6MAWL^6J)4KJ(DY]T1D '*G5Z: (%IG&(<2]J'
MJGFN@OB]\1E7IEC-;AND;FG<32*GN)DPV$@YO64,E^XU%?AO*3&KJ5R^][L&
MJD<AKZYR3&G*9?"VX"<D8HZ]0.M8&R'BWKGST,8;UO\ :J^(_P /&+8 J2OP
MU^(BZR;)M3J+(LFT75FC^-8!54&G^&9; RW4BN8EW=CCU/IJG*IF0:E1\?7E
M<F;BE7%5 =JI\Z2((^O&N@K73BS-M:Z"SE/B@C+-1[1+7>O\1])I[-R'P\ZB
MZ?3M?](O#[]EXE&OH&H.1-:C:0X9J!,U@Q&8QD-Y3R\3A3LG?FMU[E<[%1C,
M13GY0/R6%R9(*NEO7EQY 6&M>"+K?4BF3QT[[VQ[^E.K6L^!:LZ/+G8GIYJC
MEF,UN=X/E^-.+@8=B;N.HN[O*L,F3963011QKYJ?)LG&HE=9-(=1"#985SWU
MZ]7B.::67/(BONC-6LOC^U!7I;X5,FTLQW&=,)'BMGYK+J<SU98DY558=B6&
MX)=9_ +6-8]:8^<BS34:MK8D/!*+\H(;;\^5(BR&GWV$(4ME0\JD<Q1.2P!S
MR"@"ZI7*MBEXT<Q'VM7BKU3DY'>Z=8=AM[@> Z!XYJ=E.48KI'FM]BCV1OHU
M&AWS-Q<9+J!A60Z?43ES@#D:H$O%,MFN>;/0E<UJ/#ERXJECDO K^O*RQEQ&
MG2JC](V;\'OM)M7\_P!/_$/F_B,PNJH86B>E.GVK$3W?$;?26YN8.<XW(O&X
M H,RR?*&7: O-,QJ/,VK=IFZ9?,A%0T0VVNC7W_!^@%K1B59%?)&?6^B&EJQ
M9F&^W+Q?,7:1Z/X:\[C4K%E10]2[EC-\:E-X!#R35EK1^ILH5;*JZZWS!$K(
M9E=)$.'"K)L>)*>>?9+<4>>!S7T2/F?-'BH4;7PK[WT,;/\ @1]H%D?C2U.U
M8@'3NMT]T\QO3G2//< CO971Y5F%I6:BS<W29V4+QN7.KJ"Q<@T=2J1ADQIB
M^QN:MV+9N/*?_,O7KX00@.5+\B-!ZUCU(X0APA&'=<D@Z>V>X)_3*[MMO_A+
M/;J!OL/H.GIQV; OUF1 I0H-6C1BD]VNB\:<A4]8^<S4_6WQ+:>:HZAN4M9E
M&:X#,U4H:/"X=;1/.B@52XFY<6%-)DL0_.F8KESJ@T;%E+DBOL8SD:,Z"XTV
MK]!BX^TX<^'N@S2*\NZ"2$(R4.?=1(YI!ASRS"9 =URKJ4JA15<+FC15X_BQ
M\1MXP\<0QC [V)&2VMW,%87J)74MW+LLJP#%F8%;63YL>?7JQB5F5TJ\DSWG
M(]BC$7W(C\-$I]QB';=HE+899WE#_P#31[/HHB'"P@ I1V&\26'%.8IPK;>2
M^,WQ(X1CB)60X%B\RZG3^6I=KL'S.+5NM5N1ZF8]*J+)B?>HE,3\C9P>JNZI
MV,I]YN-D+=7$K;*6F-)D8S[;M&ZHPR/:E"B49@7S&BN.,!A8:ABRDK,6OI=7
M<LK((R%>:Y:ZTND6G^H=&S)G6-IJ9EC=U2SL7N9Z[+'#6OS<=I=XD%FPKX:9
M*5-LSXT=R6\B-[H4JE+*5]&+MF,, ;N$1/\ \H.:G=0]0];K&.[ADD$,'J0A
M%P3X,*N46+OJ/$+K+E.E-=?8W4X=9Y+:ZS4.G=7ESF'YJSAUAB\YMV;:9<WB
MKLZ)DCAHEL/52F56,>NDVD,/&P:BJ<Y-<NV8T^S@G#)F[P %+),H1$9K*+I$
ME&&9T(+!44@@J@<9*5KJ%8X#M?$[XH94^E3-Q'R;6)C^&9<^<.I,E@T]PSF+
M.G&0.8U/C6KEFJ7/JD7=UCTFV;EP>=#;SB(L1YI<1C5]9QD_FR;N!QR5K,MH
MV#"P5=2C!YO,&E/'-8HM#XN/$#576>ZA2XS&H&%4%72/*HJ'$<IQ^C;^U&(L
M617T#5VR;%5O39!-C5-HIZ>_'=*9#Z(S*P6F9@[1M4\\X(,L@ 0&4.IHJ52]
ME5 'A-A8)H**OM3%ZT6[7"U6/7K!IU[8:<PY^2QX,/(9D?'IUO"KDNB)"L)-
M;.=DQF ^LO%N.\5,;$+3YC2PE]T;[>EAI,900IW9B2R*-W5$4&YJB+'/-)*"
M4! H0IUUI=\XY)BE(:>"0MQ2FY"PA) &X2ZH;%7PE7F<G*@;%2COU;2X.-I]
MJ68A%E*@H0Y#FXJ*%1DBOI$P42S%B<R%J3^IHFL>+-9XA_%I5OX_%E1<LN!A
M>79W=Y-,F8C/;@YGB-]:W+>%5EN(-:Y+-=AD*#*L+)$!+,J5&CL-I?\ -D-$
M^5/B[5OH)@!_R2T5  H4/<)O+8QWC#P3*292:(-^8FE:YI2JU%!>>2^,;Q S
M7,;C4-!4V!:S7'':%C%,,S^+-\1&-0['*'+9_#7;"+-&'U'DT=563&[YIYQY
M^Z5*KK,QU0W7,<3&VG"(0&<D A)0@?0)S3@T3NL+(JZN6-,PI!<(M& BI4WC
M7\0]K@TW+W\ Q6/#IZO*KB;/B8CEMHY9JK6\#9C5D2M8O!'@2*F\R^XA74MV
MXF1%Q,<6\X*>2U:18>0V[:D0R*,C*&S'W7JUZI 86$X=SF2JL74U31%"Q8RO
M'/XD(LB/?M8=164*ZKZ=IJL?Q&Y;I:2QB2[6-)6U8-VC$R0O+78T*%#8#\U,
M-^6AZ"+-"FFW,/K.U*=WV030R!NLOD+):*,+9PQ!6K3GW%GX-&R&A?B$URR#
M46BTPS+%F?,RB?FF>"WL(-FQ.I--L<NLBH[.I4B2U#9=M(>3_DM64SCK;'O-
M#/>?##LR.L-]6SXFT3B433!U5990@"Y!=-4YF8DF%+*3*" &'M$DE 1<Z^]1
M'HRPH\S*]@D^>4;!) '*YR?"E>ZDCIVW7MOT<< "U=^[*A)"35)L3P!1FS4"
MKE>=):$*%6I#YBFK-'?M /M*=VV$A?0[$]_OW!W[C;[N,I2 !6@H;<@_41"!
MKJYN=#3YVC6SQ.W>0X]HQF%MC.02,0MF7J)E.2M0K:2*FN>O:MBYER7*&MN[
MFEJ/LU4ENURJ#53)&.PY+ERB'+17*:=YL?:)I"=W#)&=5JA .FJ"QA(!-/NS
M*11 ]U<WN@5:C0^?^!>+7Q!JM,/P''\%?R9BZ&0+I,CS^587SN7MHR?(X/O6
M-9G!J\5%]C&,5]772XMS:XE"N+=NS:%LF$KEG2O/.V8ZE))BZ41E-S(",@N:
MJ&([#A8$H5$* 'VIFIJ-*4=%:+DF^./Q$+M\/]ST,8IJ;+JRQLZ:!D53D4:[
MMFZ]J7$G04%+I?AV5=9U\I[W;[-EF5!,<J5'+[;AUG:=H-,.<JY94&2;HO5P
M*5C'N\%%"9*OGH.0%WBW\F\6GBIF3[S 7L%K*.V:QFGMA>X_C^3,V$*-/&+6
M+F4P69;MHB53L+N)N+38,Z-$Y76G9C5O'FQY#$/9]<VD+[$Q9#[(<LY9<@0>
MJA8R$N$$*AA52:J&4HI.0/!Q&\?AOU?SC6:FS&YRW%8F*C$,M=TZ=8B-S5-S
MLPQ1"XVH,QEV<XAQ_'H]\K[.QWW1IR3,C1W5/2UR$*5QZ&%-BXCSS$V0 2\O
M9 X-J@8D\F-*)4 %09JDH%!>G1V0M?9OE 6D@#<+:(/?;XP>OR/[OQ/&S:0!
MA3%2"92IXA& (S- O$4QD]HRDEQ,*'6XIGRYQZ55>PKX&WI#C#O_ )"._P S
MMMU/'X7$^_-Q)\E;F;MD8]>14?/W >Z*EQC&<.$(<(0X0APA#A"'"$.$(<(0
MX0APA#A"'"$.$(<(1Q/*4E&Z0HG?^* 3V.W0]2"H *"03L20!L2$0HCLK:\M
M8\YO%'[2O1+PQYQ:Z37[.0VNJ3."3<UIJ2+5NHI;-<:LN+6)3/9 4N18,ZPB
M8];O-(<0L%N/^N%$#A\!XNG0Q I=64Y.%8CR\>.!M-?:M>%_6:?0XQJ_@EWB
MV8)U'368!79)BB,CI[*ZK9K=='O\7O7(:X2K"LD2EHFOQ4MR:U*MTK'/OP49
MZ<\HI!Y>F</<6'$A8H&I7M)/9Q9*W?4N:Z86>HL#+F(.098[+T-_*NJO'\:Q
M)S+F5WTB37R8]A.QS!JRQNR7U..0*.KENH6VPA:3&= :W"+>A]+ ";S1R4LZ
MV&98G)(US9U=]FO*\4ESKKJ'A&4V.:0,BR?3+'X$:G<S#1RDP/&CCNE-)E=I
M2IHHT+'H]K%R&EKH='*DS:BL<G(D08K3[RG6Z2"ER5X($0Y-\$BNA%O>5]9Y
ME8VNS;QG^SRIWL3R%C2.AR_.5,R,OP 0M&ZZPN6;C((UXXY;,6)JGY=8X_\
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MGS";+*[>.@-S*);$>:'FG$,<1A;@$U#Z#,^XQ2"H)+W<ZA$.J:IPBT(_C_\
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MWBXKUO(>H7%/3G(@'N:WU! Y'6T A3C00I:M_-*]R.)W.$3O2B6@&B%?-F/
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M&NA.^Y)'\7CEVS]O^TX6"<8]D34+[LH9B1I4*:W9X]GL+LG&[0G0JDR!U_K
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ML^>X_MC7C[MCW[]O3Y?)/VS-]&P_X<4UT/EX&.C!^Z#P\AHO4<JQJ./UU?\
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M5YD^$%"JH! %P0:YOHJ@O$.8*/-S [=!U[=.N_7KVW[?4^G%"%22'+.AYN*
MV-RJEHK%U:UD;CDIL0KT"1)'S[_4==OD>G^C?OZ\% =1D@ 4!33VO$/>!(JH
M0MJ49BN:OD;5B1P[;'IMU!Z[$;@_N[=/Z.+*:E@UM+D5"! BI7.%]X$(A6VK
M\DOT"QL!HCUC9GMUZT/0=S^:M-_O[$>N_;Z#@[;4[ NA<4T=6\'ZG]-]$O\
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ML?KI_62-NI4G8E20H;;?$.+OR%")I49U<#6G)M 4B"295W21D ""G&GG5$B
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MR'1OPZY%B^77#%YDEMEV59[=2HGD>XQ;#.<[>R!RM@*BP*R,(\%J4VA?N]=
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M($H*6RN%:PR.C?EUXIZ.D12I![]?B21T^1._IVV_HW'IQ#-AS+[*)=S7DWA
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M%YI4I^4-X)S,>9VH'7.LR)!W_**T.PZ?[+=[]-_D/GMTW[<>EVQ/*-NQ&#@
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M$B)66\3)K*_B1%U+DQIIVSCK_)YU\V2$JKY$9Y"XR]FR>)L^U2SS$2DU+&5
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MICF,5R&YTY$&)65)B,LUJ)<MB$P4PVU<D=)/Q']N^%BR_0;%&*@[S$FFD"V
M*@Z)JKN4*Q^B^BT^']LG=5Y)0]SGU!JYYQL@1ND^G38_?VZ?0;CY<?Y^&F'*
M$,THGF(J@WO/W\"GU.64[@F9!,2@+HYIF5Z\#'%RG;H5=#^X'H>_;?\ G[<-
MX_E/C\/TBB8G\$W('X!](B$['?8]-_3;Y?,GYGZ]^VW$FF,P(W$J:'Y41A\8
M3*0?8FY@YQ,"?D?QV_H/&!EF11+Z\3X1J(/Y3R'QB! Z=AU/XD_LZ]/GU[>O
M&4IFE7V5"(ZMX->_O$92F:7[TLP"5(RH*FQ;E2)>4#^,/7[AOMN!N=P1]_\
MIR$\P_#X*?$>GC+?T.FOKG$P3MOMUW(/0=@#O^S;AOK, 1+*312 YL%X]+M#
M>W@10HSU\HP=XC$G^#:/ML?[JJ]>P4.WV3=J&_WCOZ[=._'L;()CV;MN%*!-
M.3A354(#BWS4CU3]']&Q,-J&&QG24H2U0%)HRM&BS@/.1L=TE6^_4 \Q((/7
M8=-O7L".G'CRSV( 0 >TU6;,A ;(J9K],Q)93NRS$+*+*:YD([5]ZQ(-_GL"
M.O7J3Z_+?UVW W^>_%,]6E/ C.FG&NJ1KW,//2A]<ZQ#;L"-O7H>P'4#UV/3
MK]?EP,X8@26%6=G6VH<U@FZ@D(0D$JH\SYMTAT5UV([#KV[=3M\S_,#]>+OI
M^0J3?Y,.CT2D-Z=55*5X.P*5ISB"@KLGIL.Q^0W/3?T[_P"<\-\7$G$%%7F/
M+-,H;LLSS$+H" G 'C$P2H@$$;=3V/P]#_,0#OTW/3TVXQ8E?9LBS=:*Q!U&
M8BC#D_,'-P4HC\*C6ACMP@!*B@DDB5%![[[EY*@ #MT4#U'7OZ;<=>R33#:-
ME  .]M.&B%0N\%7+C#=P994,Y)OZ&A%F(!UCSVU6.^IVH!V'^JR\!!/3K.=V
MZ[C[_N^O3C^LL(SR8.QJ)6PL,!POW)0X.@Y7I'TCL23"/9VRI.4[L]=Z8H&L
MI=Z/F;!&_3J.FVX^_MV[].OW]3]-\\P,TQ(-;!1>_0KEF8];N%I/( 24!F"A
M[J=6LU@XEZD^@ZD>H]=QVV)/7IZ^NV^YXPWA92RTM\KNFIB_5_\ S,/+[\I%
M/)?@4K$>G0;@$=2=AM_0.G[?W\9IJ.H]=?@K<'YP;??916GQB/3YIWW/78?A
MZG[]^_;?UWN[,E/$)?UUANRK_.2\-[R*KRN> AS';J!L01OUV[=>RNIZ;#?[
MP>XX=Y(J;KY;K^67PUC9W&&Q&)*/[<OO<?#K'-%V,N(-R")D3;I\WV?YNW?I
M]3QMV::3ZUAM_22,G]:7,(E<FX1P]I84H[.VLG$D)&'B_B<CNYD5#?5<SE'W
M):;;?D%B>W7^YNE^_I7,_P!?V[=./M>P ]Q(=#XE1UC_ #I[;_UIVA_[K'\Y
MLFB^^.Z/.EH. \H<(L.$(<(0X0APA#A"'"$.$(<(0X0APA#A".O*&\=X'?\
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MQ;K0I*]+<H"B%J/V6%[%AQMM_P"VJQ\I24I+:G=TK/FA8"TJ!0'#S!/PC_*
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MW&VY[CKL>QZ?8?V4S33S=J EI>[F*N2)1CG@KT9;F/9^CXEG[7V>7N<!9Q,
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M&=TL85Y]2F7-@S;6/8BQL(T*LJ)$.;#D,SD3 Q7PHC<NM>3(BI8!4]&)<*M
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M2I,.25;=!Y#A22G<I"P G;E6$J'E\I 0@ IV)-(PPJX=Z;P8:L7I0)&,TTP
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MRJ@T01]M^GBBU@^(,K24N(QVE"T*!2M"DPHR5H4" $K3S?$@JYAV"5'C[5L
M_P WE"(147#FN2K2T?Y\]LD'M3;Y@B':L<A"""-XL"*:9A498OSCMCS05 .8
M6'"+#A"'"$.$(<(0X0APA#A"'"$.$(<(0X0CC>/*RZ3L &UG<[[#X3WV!/[
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M,P;>-&EXCCE!E,W(:6TER4%+-K75= WDV.N1I3:9UG-KZU\/EYI+F(VG:3,
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M,3#/,M?7=U"6RKRU!:F0I"PV5<H44[MC?KL"I7*0>*9)'F*<$KX6]SZT[TJ
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M[F(V5Z:-YOK00&V[ 2!]8V<T0]^&&:"1@X(&;+'/';7[U%):>V]]B@'R7_\
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M7AFSE0Z!3^)D[_(9'2;;?CT^_P!!OT_&_M!'_@)"_BG7DR5T;E'UG]A[_3'
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M!TXZL,X>& ))@G4E5 KX^"4CGQ))\0%07*FQ**16[(6+WCOH*/-:ZD_&-DI
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M\=2]FTI0CXB@GX4H2D$'?8#C+ZQC?Q)O#736D.[D54?B?)4B3\A,-_WM4_\
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M#QPG[^L#J?\ .?IP^Q>S_P"!+UF_Q0_EI]*?^-;9_?E_PQ$>$#PO@ #032<
M=@,&QX;?3_ >WT].'V+V?_ EZS_XHO\ +7Z4_P#&=K_O2?X(C_8@^%__ + F
MD_??_4+CW_L.X_#;A]B=G_P)>LW^*'\M?I3_ ,:VS^]+_AB']B!X7ST.@FDY
M^_!L>^[_ '#\CP^Q>S_X$O6?_%#^6OTI_P",[7_>D_P03X0/"X@I4WH#I,A:
M"E2%IP;'DK0M!"D+2M, *2I*@"E0.X(W!WXRE['V&0[TN" 5!59K./Q1A/\
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MO\PX(,KJ[O2$2^4W_(3\^PZGKU/S/4]3P09#I"(EMLD$H3TWVZ#IN "-NVQ
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M_P"7,X1B?NR\/_Z&+?Q__"LC_P"[TO\ _;Q^$0T'_*/^V>*VY^NW_P!O=_\
M,3>$M)N?_>(LU3P]T\17_?9/_%:_\V]PBRTZ?]LL5%G^]I^]?_EJX113G-YF
M.7A%APA#A"'"$.$(<(0X0APA#A"'"$.$(<(0X0APA#A"'"$.$(<(0X0APA#A
M"'"$.$(<(0X0APA#A"'"$.$(<(0X0APA#A"'"$.$(<(0X0APA#A"'"$.$(__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g373959g10b02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g373959g10b02.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[2 &4&AO=&]S:&]P(#,N,  X0DE-! 0
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M4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M"G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@
M  EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN=$]U
M='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O
M;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M        1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M     %)S;'15;G1&(U!X;$!F,I2@        "G9E8W1O<D1A=&%B;V]L 0
M  !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M            5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C
M0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T
M0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O
M<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))
M30/M       0 )3,S  !  $ E,S,  $  3A"24T$)@      #@
M   _@   .$))300-       $    6CA"24T$&0      !    !XX0DE- _,
M      D           $ .$))32<0       *  $          3A"24T#]0
M    2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M 0!:    !@       0 U     0 M    !@       3A"24T#^       <
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@     ________
M_____________________P/H   X0DE-! @      !     !   "0    D
M    .$))300>       $     #A"24T$&@     #00    8
M MX   .;    !@!G #$ , !B #  ,@    $
M 0             #FP   MX                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   MX     4F=H=&QO;F<   .;    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  +>     %)G:'1L;VYG   #FP    -U<FQ415A4     0       &YU;&Q4
M15A4     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F
M875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D
M969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP
M90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L
M;VYG          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E
M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $     SA"24T$#      5:P    $   "@    ?P
M >   .X@   53P 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ ?P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
M  ,  0($!08'" D*"P$  04! 0$! 0$          0 " P0%!@<("0H+$  !
M! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S
M-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($
M! ,$!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T? S)&+A<H*2
M0U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$
MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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M:9#?YL<?F?F*3\/$LL;:^FMUC)VO+07"0]KH=_*;;9_VXAJK1Q?VOP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M8DT\\R80E+*DFFFP #BI%:0JJ LSL$15\IF8D*  ,G+$X YYVQFKG\@$L0
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M75KJX,KNXI9U56MZ\]H5.S$F3(ULH'JYW1(!TIBQ"B<T[<H/.!'(;-1J"O\
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MF*LR22M:W)9[9F)7$09UX #QEPY/TG1#47O;7489Y;N6XL+UX9%O9+:>6W#
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MR![Y\\X_NJD**7<\<8;S_+GFF&PWEVTAE:ZN3*8.R]8;B4R=FP ;</Q\0A(
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MX-Q*9@N.'@$A?B"<)(X 0N"1C!-0FGV$=J]E'8V:6<C%WM5MH5@=R0>-H@G
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MI9ICBB#>; PDJ:3HS:_?/8Z?86\DUG'86KVK/;W,T;7:N5/%,$*#B4*1CRB
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MD*)333#04%)Y#@-,G,YSES#,.?;[[M/;>VW7;".'M7:)>T8X2F!-Q]8!P$J
M&V78;;54-/L%M>PK8V8LR<FV%M (<\1<MU?!P\18EBV,DG))KOJ9I.EJ+:2&
M"CZ<8Z68TTYAB=HIYJ0L[:28;-RCC9$3>0G3RFG3^O-- OG#9Q&<R::81$:[
MBZN;N0S74\UQ*0%,D\CROPKGA4,Y8A1G900.6VPQ=;VUO:1""UMX+:$,6ZN"
M&.).(@ N0BKER  6.6(SON<U!%%74A2D*4A2KH6BGY-822_](VKI/)@"C-/Y
M&/((QI:A_%_^>OVC[:V[/^&_YC?6*RHCB5U:0I5!7.ES0[X.OK94,VF/;)&&
MH#P !$1\D;-H<7$?_/\ _<;V^O:J9_X)_1^SGW>D5B&&X/($=^N,WY1]-3"H
MI"E(4I"E(4I"E(4I"E(4I"E(4I"E(4I#^[UG8#UG:E6;J/:%LC2-:I[=5-="
MCF.ME1B,DNGG%W((7%GN,I<S>G5"/S.A/6R'$SI"%QZ<Y3(<3.3)-(>5--TK
M71]5OH&N;.PN+BW3B#2QHS E#Y? , R%,$-U7'PD$. 0:YMUK6C6$ZVM[J-M
M;7+ 'JI951EXMTX\@B,,""#*T>001D;U]:Z^MGFRM@MPX7&I5)7?;LC;-2IS
MD5(\2+#&DI]D+-2CZ\D!:3BEPG&\V1*0:5RC)3)PD&F+3K^>T:_AM)Y;)$ED
M:Y1<QA+>1X9R6Q@M'+')$Z#)5D<#=' MEU72H+Y=-GO8(KYY(85M&?$S2W*1
MR6Z\+8/XQ)$96 *D2QY.'4M^E 7PM'=1>[M5N;B4I63BQ#,+JC8G9.M4)2@-
M[7[; J099E""8_\ ,I'!,!R*<P0DD/&890&R[TG4K"*.>]LKBVBF8K')+&54
MMS$9./)DP#Y#88X) P#B+75])OYIK>QO[:YG@XNLBAF1VX%*@R( 27C!8 NN
M5!*Y(R ;3;1&T'5MH:JM+1-$T$U5U45UE]2H$!+S5A-'HD1M.MZ1RGYUQ4H%
MB64#TYQ^!/G("6<F2209YC)8W=#TF#5#?M<W3VD%A;1W+R1VYN79';JVX8Q(
MARK+D+DE@VW*M#I#K$NC#3%M[6.\FU.]:RC26X[.JO\ B^K)?@=1Q&8!^)D"
M<)))XMN\I"]M1M=,O-4;0[!1-F6M*\M#.SN"6X;=6#2X*'210 %KG%"D3$-)
MH'EDD$2JI^2>)VD\HA+R\+G3;>2:UM]%GNM2N)Q.9()+&2VD01+&R=5Q28F+
M SE@F>$19_)R:66K7207EUKMI9Z5:VXMNJGCU%+Q':9YDE$W4I^(6)A;JCL?
MQCS%>'R<U7+G?6S[.%4"YW'I-%)1#DS,U7'FNA$J>G76H)C)69O=5/*F3I%;
MB)<X$IS# - 2Y^<"3D3@&I%I6I3+;-%93R"\-P+7$8!N#:_QCJLOY?4_[H<!
M5_2)(!WY=6TF W0EO[=18QP27AXCBV2YWMWF8'A43 Y120Q )P "1RI*^=GJ
M\:ZE>Z.N51]0M%' 9-5+@@>T,Z-A(*+.-F6.1\YLDB=OF+3J)R7&800*"TY\
MY"@T"3!EQN=+U.S[/VJRN81=,$M^.%@TKDJ.K3G^-RZ QLBNO$N5R:RM=5TF
M]-QV2_M9^R M<]7*A$"@,2[DL,HH5BT@/5C!'%D'"C+YV?N$RO\ 4-%W(I"H
M66E9##:E<T;RD!*Q$%%''S*G>8^<@4**8E,H-+6J.;2&DD'&DGF2%F3297FE
MZG8&$7EC<6YN"5MU=#F5\J!&O"#F1BRJ$&7XF4%=Q466JZ3J(G-C?VUR+0!K
MEHY5X84/$>L<DC$1",>LV3"L0Q"FK>/&UW89';>O[F,%P&&M&>W*(M0^(::<
MDBASG5K%$J)G;R$ZHQ( &/;C.6W-JHV:1$H4&>L4"$DP2[/X/ZPMY8V<UE+;
M2:A-U%NTZ,JNZKUT@.!L8H$DFE0_C!$K,JD@9TQTCT-[2_O+?4+>YBTVV>XN
M%CD4OP\21Q! &'$9IY([>$C*//+'&SIQAJ^YOVJK'!;J@KD5-<6DZ3:;@(2#
MF@ES>T\\W=&0LN1Y;"YY2I#5,S OF,;W16"4E*F4%AVQ,1RY))\INC^JQZC>
M:=#:3W4MHY+&*/A4P<1$,^68J([A )(@TB2,"0BOPDC&WZ2:++I=KJDU[!;0
MW.(PLDH++<*N9X" >(R6Y($H52BDJ7=0R@UQ6=\+0V];*<>:TN/2-.-57!)-
M3"]P>4DB9]*,+(.E5MALDYDJI!(4I3FG.!?*0D%J")SE$DIQ0S:4.F:C<S3V
MUM97$MS;*W7PK&1)"RL5"R!@.!BRNBJV&=E*J"P(K<GU;2;6WAN[J_MH;6Y*
MFWGZY&CG!",3"RL1(H61&9D+!%968@$9I;9NO8-_[:E7"[B$,,AU2U2PDHDS
MB+L0:33SL<W$KBEO:J,)Y5I9<J@))2II"^7R9330Q/&WK>DG1KFWMC*96FLX
M;IBRA'C>4N#$4!..#@YMACX#!K6T'5UURSGO$A$*Q7MQ:H$D,JR)#U?#+Q%5
M'XP/G"\2@ $,0:Z]JVG;;O%_*BV?4[@035-.,9;D<L4KDLB5P=)23ESC3[:G
ME&<\Y<R,Y!CH[SG3)Y4I(!++(;*$YDHZ'?#1&UTHPM5N$C X&)ZA@5[6S</"
M+<SE($PW$TK@;*5XL%Z06#=($Z.KY5T;.2Y:7B 03H\(6QX1EC.\,DERQ(14
MBAP.-F;JZPH>_=F+EO[C2U W,HZK*A:9#CEK2RO*58K!.G,E*/4IBY)L+TA)
MD\DARM!,I3$SSR 8:'+DY6O<:3JEI;)=W-A<PVTA0+,\;*F7!*<7$ R%P"5#
M 9 )4D5MV^L:1=W+V=KJ-K/=)QDP1S(SG@V<)Y6).K.>/@XBHW8#?%/7^OE)
M99HI4IKI=;75=W"JA)1E T6@6$-ICR^*RC3YSEKFID-);6E 05SBY;,2=S<Q
MJ<L99)#IU!%FD:6^JW4D/71VUO;6DU[=W$BLX@MK?'6.J*5,CDNH1 1G#%F5
M035>L:K%I%I',8)+JYN;J*RLK2%E62XN9U<H@9@0B+P<4DA5E5<#'$PKI[4W
MCN:^U)5=(7FLXNM8X4TRIJD(JM$\]\]MG9I/FGE/)+K"5O;4*)W;^2)REL4"
M)XI2U*L>9)3B)EVHZ?IT-K#>Z;JT5]&UP]K);30FTOE<*669+<R2,]N04#.
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M'/T??[_0J>:[)7]-;)?\FXX=/][^0/3U8GZO?S?;2G-=DKS^NMDL0Z!EN/\
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M9.X)"J:8SW"8R=6]*4I)!DRR=%++("%9(<G%1*,Q!@%&"]_?W-/?W]^?T['
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M2H  #=\M_P",85 &.7O[_4 .ZIA4TA2D*4A2D*4A2D*5KXVB/HV=B'H_3?\
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M&4_RX^3B"E;!X4I"E:_NR&^P?9^^NMM1]RJTA[^_KW]5*V PI2%*0I2%*^-
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MI;R+Y<\UO<ROE4#<3W-G9SN<GK)+6!WXFC0KD;6_;!9Y"0R/DW!.&BCNHHB
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M4A2D*4A2D*4A2D*4A2D*4A2J:K.:8ND*I-EQRBJ<?#9<AD.46UJII<AD,AD
MR&?QQN:<H?4=/0YPU]:*2.8XKB-<CS@'(\]<_5I6ATO4ID"EXK"\E0."4+1V
M\CJ& ()4D $ @XKSU=_3T.XILP.1#YF49P&GTT/O<=T?L(=&-.  ZR\V'=+%
M]MOR^FOPJ?A0Z1 D"#2=B<?O6\SL=\_O_<Y].?/4]_+T _\ $MNH: "=1Z?U
MSCCC7 ;L[H?@QIOREY_E8?\ 5Z@_"ATBY&WTG?)_BMV<[8_P_P! W.U._A[U
M_,6W7?\ ,Z@?1\U:>_IQ#?$_@QIOZ=X>?^[1;_\ [<?1BI/PH](_D-)V\+6[
M^R_R:=_+U_T+;K_V"C0 _P#-:::"(\<#OB/P8TW;R[S;_P!=%]/[WI^ZCTC^
M0TC?/_FMV/.<_O\ ^OT=]._IZW<RV9#I(48'?_?61T'ITTZX?@QIOREY_E8?
M]7J/W4>D62.HTG/\VNQN=SC]_P#ASQXT[^GK=S39D=0^9S]WV5[\/P8TW].\
M_P K%_J]/W4>D6?X#2=^7[VN^7I[?3OZ>L_\2V9T ?F=3C([OVUNQ[^HZX"'
MX,:;\I>?Y:+_ %?W]M/W4>D7+J-)VV_BMWW\MQ?^SPY;<JSPV":B7O5<5P2K
MD32RD4HE,D$@LR01F%W3R#GEFF9# Z8Y(Y$<B.Z/)OA9T>UT[3-+EMWF9I=0
MD1Q*R-A1;NR@<,:'8YW).PQZ/;/@3Z7:GTCUC6(;^*S1(-,BFC:VBEC=F[4D
M;!S)/-E-SP 8( W)Y#:3'A5?H^D*4A2D*4$0#?"E>::K'5MEJJIPF<$("%0/
M(" JB $!!Q4@(" SY 0'?Y],Z#^X].8=@L?YG;8W7?\ $)Y_9MS\*_FEJ\,W
MQMJI$;D'4;T@\#8QVF7'\D_7C?(\]/ ZMGMDA#J%40.G#_E>C&=_V\[?$/<K
M]]<_J9ARCD'_ #'(QW>'=C/T=^8[JM>X7)'C.=5:?W_S0<AQQ@/..(DD#^\9
M'AG?;V_1O4=1+R*2D9S^0WTY!R/-]=!=6P1T<4 8W95)],>2<=_5@=/2XAXC
MVC[Z&";.T3[8QE&VQ_S3]&#R\*D'5K]L$.-^JI/OWACU^[ CC\'&<@9(WQZ/
MM/=SP3[:""7Y)R#O^0QWSMCR>6_OOEW6;-/SQ1;P_;:?3ISZ_?TXX>>(R/'E
MYQX9\??T5/4S?)R;$?R&Y=Y_)]O+;UT%V;-<.*$=V/FLC/7OG]&<CGJAD>CQ
MW&V^-]Z=3-OB*3NQE&]?\GV<]^?A6>G8\UJ13=ZK9"%2<^?P<.4XRDG%FS!*
M%3TJ B(23#-R0$0#(@  (AKJ$>1?#*<]'-._IN#;(_P'4,[#TX/OGWS_ ,GI
M'7I=JI9'4?@W<C)5@,_&FEG&2!DXW&,Y&];AH_-M?L&D*4A2D*4A2M?&T1]&
MSL1?XW@__P!93C^#[4*5L'A2D*5K^[(;[!]G[ZZVU'W)K6%*V PI01QK"E<>
M7+T_+Y?:&&>?FI7+IZOQ /X85&<^P'VU;2T'SOVC]_U/]];W$#[3]9J:N7$T
MI"E(4I"E(4I"E(4I"E(4I"E(4I"E(4I"E=#53PHIZF*B?TB(MR4L;$[NZ=N-
M5B@*7G-K>H6E(C%P)EHHBU1A,I$ZL$:L4\LXG E4<CFI[(HI)Y8H(@#+-(D4
M88\*F21@J!FPW"I8@%N%L#?!Y5DCVL;I)?32V]BC*][<00+=3P6BGBN)H;9Y
M[5+F6*(.\<#W-LLSJ(VGB#&1=>H;=MQ,!_Z/]-B.-?T[5?DX6?$->@-T?1CH
M5TE(SU>E;C/YPN6YGQ&G;^C[*ZOQU\#/^_GIR/#/P::7G_\ Z/W^DU/J[+BC
M_P#=_IK_ #VK/PV>B?P)Z3'E'I/KO[C_ +O%/CKX&?\ ?STY_P"K32__ !&I
MZNRXG_5_IK_/:L\V^SX!KPW>7?B#T+Z2CFFD^!_V0N-B>6?]C]O'T;G WI\=
M? US_#GISC'/]S72\#&<Y_\ K'R!YR#GNY5'J[;B:?\ H_TWY/#:L 0__P"/
M[OMCH&8?@7TD^3THX.#C4+C;T_[''GW4^.O@:&<]-^G8VSO\&>F9]&!\(^0>
M>Q[@2< '#U=MQ/\ J_TU_GM6;L9S\Y_=^'3?#\"NDOR>E<\#-_<^!.,?%PWP
M"<_>*#6O@:.?_IQTZV__ *9Z9S\/_P"8^02!D9QD;T]7;<3_ *O]-_Y[5O\
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M* X_\>=CAT3XZ./1'[3%O -A%& .0"@8[O#PVK^<_;KSD+RY&!L!/*  /,'
M]7KJ.VU0Y %*C?J';!OG$?7\!WZ#^*>SP?))\T5';[T["[NL@_X3+Z_Y?<>?
M/[K17T!]76PJ9*S>$)2X'R-I:>6W+NY-E6$B+JBRK1J&NIZ/>34", [:?$#)
M4S.]N3&4X(&I86M4D1P.DEFTVE7,5K#=B>3@6.;3LK<PR<8ZN9A%=64\L$3\
M,EQ!#=0O-"K1A@"0WT?175)HM:M);F^ME@07#,-8<RV3?O:4=64GM-1MTGE
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M=D-=PCKKYAS#&V=_9Z._P.=O<TV.#L=\D>.3L",YVSOO]>T $O#&@  #D $
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M()P/$C(R&_+/+.>%@/1DKC/=S[CW;U/)'H_59P YSG7=ID<>@?0,2 3RWR2
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M\3)T6L88)+%]6ANK4S-$H[5*KG76ONL?JHIA% /BN(23/)%<F6%[5(>JF27
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M.F-=P"&H9 !#73&!Z  >/&%1N=L;\@1N,@$;[8P?  ]_?4<!U .&!QC33/4
MS!P#?O >"H[CN!W8.,;;9\P+#N'/F#W2._7?H.,=&HXTW"'7G.@]$*D\]^>Q
MQCPW.-N1'GSG8^%;:NPX_1%W#_B5>?OZH'IA60Y#T>_.O2#"II"E(4I"E(4K
M7QM$8]6SL1?XWL>YE/K\NGKA[^_O^U6P>%*0I6O_ +(;["-G_P"NMM1]RJU_
MW?+$01]!S2M@$32OC<25"A M(2*9D2LY(H*2K)"2U$R1085/(2JE3F_F1XIS
M!E. DS\S-&3D3B$LPQA*K/'(B2&)W1E250K-&S*0L@5P58H2& 8%21@C%9QL
MJ2(SIUJ*ZL\98J)%!!9"PW7C *\0W&<C<5J.6=B=:JAM4GME<#:!JVX2U1<^
ML;DU/<BI+66B67'J577R)A2U&I[[E-.JGNGZW)FI])+3%QF!<AJ"EVV1(Q-Q
M0LS.Q(FV(8TAETN1%(72S&T*)E&D:*_L=3+R3+B7BNKRS+Z@68_& N;@7(8E
M&6V6ZFECU&-B,:BJ!\A3%$4LM0TY.KMR.S\$-I?M':(T9%H88S 45IDEV\ER
MC* @.\1SCHT#H''HQ&8SW^_M'T]_/ K6'+W_ &_6?35N+0?._:/W_4_WUO<!
MR];?6:FKEQ-*Q6VY?H.-I[^(ZY'WKN,=[HM_MET#^EK+^V6N!TJ_VMZ[_15[
M_8/7@ZFW]>0X@.X/?SOU (_55?DZHXZ:"/7\AWAY=WE%2@:>_G7HUTW:Z::Z
MCB%*9SC/1CR:YW<.CR<-T*5(B&<Z" 8]'0 :".!S[P:!I"E1H(<<_;#?D>/V
M] A2I# 9UTW=8AQZO3YLB$*5ZC.P+?.0OAC=X56W'D[TFZ/#?A7_ #GI/]'R
M?Z5)7N_P2_FO5?Y_'_HZ5OBCRFO6:0I2%*0I5F=HY/*KV>[[)9QF M39NYY!
MHR"$LX%G40^%S\B::6>4)N3,/)$91 !P(AB+[6XDM+FVNXN'K;6>&XCXP64R
M02+*G$ 02O$HR,C([ZU[NWCO+6YM)2PBNH)K:0H0'$<\;1N5)# -PL<$@@'&
MQY5X<O!E3XB/YJZ:Y'(*$XAYLH\\>@.'&/0/W4>D?R&E=_*VN<?3>9]^ZO//
MW+.CGRNJ>NZ@SZ=K/'IQGU4"V-/\#G7C^V$^@_8>-.G?H''<_=1Z1_(:5_FU
MQ_KE3^Y9T<^5U3_.X/\ 4JCP8T]Q.= Q_?*?R_2GV_M0_=0Z1]\&DD>'9;G&
M/ _ORH_<MZ-C_=M4&.?[[@\^/_,N=<QMDP9_XUT <<%*?RYT28Z TT#3 :!B
M?W4NDGR.E[G)'9IQS[CB\&1YM_H%/W+>C8 '6ZH,C! N8-P.>?WCG&<$YYD#
M).*>#-@#_E74,[_FA/QUP.$G3T:Y&(_=1Z1G!-OI60>?9KGT;XO>\;9&YS@\
MS4_N6]'-OQVJ;<LW<.Q&P/\ $P=L[;_77'P94_C//.N-P_-*;CGH28QU!NSC
M$/W4>D?^#Z5Z.S7&W_[W[2:C]RWHW\MJF/'M<&.>.?8L>_(T\&-/!D.>=/LE
M..[?^T^'' ^6'[J/2/Y#2O\ -KC_ %RG[EO1OY;5._\ \[@'+GSLNZM\'8/:
M6;Z=J+:,G0F*YQ5LUL93@4F%F8 E;7 R#+R"2QE'\T$!R(\K :9 <?.](.E6
MI])5M$OX[1%LVF:+LL4D1+3JBOQ]9<3%AB).'AX<;Y&^WT?1WHGIG1E[IM/>
M[8WBQ"47,L<H A:0IP%((>'>5\@\1.W+%>A./FJ^HI"E(4I"E4+='YV=Q/\
M 6KOO?<(4KQ&@&F_> 8'&1#IUQGI  \P;H5@>9.1OL,#<=Q.>>=B .\[#S3D
M!X@([M= U'@&=PAID,Y 0SD-(4R#W@GEOL-SW#/(C;(SD$9R-J;@ >O0!P&F
M!#<&G'/HSC>"G( ^?8' VP1R&W?GV9QS$#KNP.@AUCJ(CC&F>(:<>,*@[\L'
M8CSG<DXQMGO&W?WURTS@!QC7KSQZ1$<"/ 0W;L0K+;D#@C?SY[R.9)QGF#W8
MY&H$>D--=> >C<(;@XCP'I5!/B-M]^X>SD1R'>>X^,!C&1Q@<@&@\!\FG'CD
M?-"H&,9.,'(&Q[CZ-N_OR?56X[L- YN[=[^+ANZ.-3HAX>7R_:A68Y9'?D^T
MUZ'H5-(4I"E(4I"E>(*X'L]K?(CGOOJ3 !@,AW96XSP'CO$!$(5@>>Y(.=@,
M;CNSOZMR,@>-4C@,Y\VF=/\ :.0# =([]84P,Y]6V=OVG(&!XGGO0.G/#0-P
M8Z<9$0WC@=,;L8T%4C'//(<N0(WP<;D#?U<L8VJ.&<@.0$-VFHCQTQPWX#>.
MHC"L>[.1N",XVW)SOMCN^D@$FI'3RCG/6. QNU]&<3#H/2J3MZ3G/G.!CEO[
M,X8['QC30 '>&!W[AW>? ?:TQI"HVV /,8//D>7KP/JVQM33H <Z9 >@/)NP
M ?JAUU_L=84]A[L@\L=PVY;=YWW/Y.36VOL./T1=Q.'Z2SS]_5 PJP<AW5Z0
M84I"E(4I"E(4K7QM$8]6SL0]/Z;_ ) #O93:_@\\/?T\_?O[Z5L'A2D*5K^[
M(;[!]G_ZZVU'W*K3Y<?PPI6P&%*"(!J(X#I&%*Z\QV:BC51!KFWE'H4X*UI)
MBU-(:C2C+R@4JBYC0G3IQE]<!QTLA8RZ\K$1D8)R, @$]P)&0">XD;@=XY5(
M!)  ))Y <SCG@=_,<O&OK).)4E%GISBCR#I)3"3B3)#2C2YP":0PLR09I)Y)
MY1":6>6899@$! 1 8R((.""".8.Q'JK$$$9!!'B-Q5N;0?._:/W_ %/]];W&
M(^T_6:FKEQ-*Q6VY?H.-I[^(ZY'WKN,=[HK_ +9= _I:R_MUK@=*O]K6N_T5
M>_V#UX/!SG(9P.-XC@.H>@0'/'.1TUC]55^3@#C<$;GNQWFN.,X  'TZ  Y$
M!'TY](8Z53@^!]E!W9QOWX# :".-<8Z-<".\,AQ#<X\?7]&1]8](H 3C8X\<
M5F1<C9DIND=G2V]\:>K-?42FI'.EVJIF?M=F DE755-/M2F%LB=&YJ'U+-2?
M>XN9WF:HFU$4Z*%"9S9S.YP3\Y\S;:_++TAN=%GM!!$D5[+;S\;L66RDTV+B
ME8QBWQ<OJ(,21RM+%U)BF0/*I7Z>?0(%Z.0:Y;WAEE[18P7-N5CP'OX]4<1P
MH)#/FU.F,D\DJ+'(9E-N76-F-NMH*W5N;;.-"-M".M<+E]0V_IZMZG;*W1L2
M5=3O?BE+?:6;9)V%2I3GG+Z25L]1J0GF^9B7Q$E&:902J O<TB]OKUM1[6EF
M(K2^DL;>6S>=UGDMO(OB>N1,"VNN.Q/#G-S:77)0F=+5["RLH]--K)=F:\LA
M>3P720J]NDKL+49A=LM/ @NE5@"+>:W8GC=TCQ\$!U'J'@/D\FG# Z &8[5<
M7!\#[#0 'KW!@<#D-<Z:>?.<XW<0A3!\#[*]1G8%?G(7P_C5;<^7O2;M_7'A
MOPK_ )STG^CY/])D^\>T5[M\$OYLU4?_ '^,_P#[=1]GMSWYK?%'E->LTA2D
M*4A2K0;0GS@[X?Q07+^\MZA2O%EG 9$1_4Z<-V/)[VHAG7="L&.,Y/=L!ZO?
M;?&=]A4C@>.H\0'.@#UY  WB(9X8UA0X/?N>\'.P/GR .9(SW8WIUXP'' _V
M6>G.! ,[]W3NP"H\^,#OP?Y6?'."!GGR\>6 P/3G(='0 X#?C?KC=TCKJJ<'
MQSD>'@#@<\<]\<O$[[P$H8USG X !'HW!GCKNR/HR$*@*,;YS@X )\.0SW[\
MLGV9%3H/$-W$,#C7(\,YW\ #?OA4['O'+O&#C?)[LYY]P'/G4AC?@,ZXTWXR
M&F U 0 =-<>B%2,<\#.^-N>,C; W! .V^/96[SL+?[/[0O\ !%MO+^O*UU'K
M'>,*D=_V\^0Y^_W#?="II"E(4I"E4+='YV=Q/\!:N^]]PA2O$: Y#CD,<.H-
M1T'HTW](!N %8'?.,Y!\/,#GEYO/W$ [5.F!W" C@<<<Z\,CD.&H<=P8A3;!
MY$$X.._._=DY'=N._D,5'0 B/1G.G";.1$.D-=^\.C"H\ 2?#.=NYLY)'B-^
M?,>&)Z-<#TAC7?C0!'B(YP&HY\H*G/+??;<8/B!MD]Y/(>/J8TX[N/7G.=,;
MAW[^D,Y 5,;=_+O\^<YVQR//GXC.00\..>C@ Z!PTQG0=X[MV<*'NW)SX=P.
M1X;8SL>9Y<J .> <1'( .F0W8''E$<Z[LXP"@(/<.\G8';(WR#[2<[\N6*W'
M=AI^>]=_3&+<-V_?[)D/R#&F-T*R'K\-_?'LV]E>AV%32%*0I2%*0I7B!N#K
M7M;AKK5U28QN'#RM# ^CH' ZYP,*K.YQOORQWXVP?9X'!.<X-4EQ ==1SKC7
M0 SIQW=6,[H5/>#ON<[XWV SMW\O-C/*HZ)1P& '3 "''&_<(;^L-<ZPJ!W*
M< [[8R/-SY$>O/B<U(] "'3@1W"&N[AH(#C=IN#.85//D1C&1OR(^H;@XY#'
M(9S48$>/'.=^H@(!KYM-=!$ U&%1@G;UYY\P0#]&QSMD<Z#UX'4!'7.!'S#@
M-=,Y# =(@(J'SX.X)WS@GU' WVSD8'B03.G'C@--PACKTQUA@==-^15.W?WX
M&W(C'GVQYQ@[[<\G;5V''Z(NX?\ $J\_?U0,/?W]E9#D/17I!A4TA2D*4A2D
M*5KXVB,^K9V(O\;V?<RGA2M@\*4A2M?_ &0WV$;/_P!=;:C[E5K\O]F84K8!
M"E<9_P!3-TXB#L"??[:>_ORK1EM%[!U];SW^VEKA-5I[$,E.UE;MDI:W[XBN
M L:ZANWVO5MJ*GKQDVA4'@L<G!Z;JZ:+;)K?TV0%7.-)V^I<%@24:]KZI=UJ
M;4MH.I'6.HR-;TN_FM$;BM+NPT_5A?302(ZK&+N[9Y9[FYFCGRJPV$2Q1)+-
M-OR7$;/$ [D+IE[;"X>,"XBNKS3GLUZME8LEG;H$ACBB>,RL]Q=SB1GCMX]E
M>Q99ZK+![,MK+35N8S!4E)-;J4M;Z<6G.-.4Z2ZU$[OC=2%/+CT#68J8Z.;'
M)'2[2?W+;2C$+21,G;T2?FDQ>\<B.VC:9[AX+&PM9+F3/'<2VMG!!+*Q8LY#
M21MPM(SRNG"\K&1FKGDAI;F14$:3W=U<1Q+@"..>>25$P"P!X6!8 L Y8!F_
M*:[-H/G?M'[_ *G^^M[C ?:?K-35RXFE8V;8Z<E5LI;1*=07*:0=9VORS2IM
M93"YJ<7A-),'&68!P(1;!/-:S17-O(T,\$B2PRH<-'(C!D=3W,K $>>J;BWA
MNX)K:YC6:WGC>*:)\E9(W!5T8 @E64D'?D:\8<M)4X./SG0]8\UQWXWAIKU!
MPZ,][\+^DY_]-W_^6_97SOX'=&"=M$L",YR8F](_E^?OQX'NS(TC389_.A%I
M_P!ET  [QF][72)_"_I/_CN__P L?N]]_&AZ'=&!G_82PV_]4W< >9?Z-]J#
M25.:?G.BP(_]"(;]=V?1C(#TZ!#\+^D^<_'=_P \_P -W^.X(]H/GJ#T.Z,<
M_B2PP<#/4MYSRXM^>PW!JNIJDJD6Q@9)JMJSN-2B-W;J9:0J=_E;:<;Z@2G(
M7U"PH0<03-*-Z0GJ$+LE;RTY+BC.-2K"S2)YBXTGU[5Y))I9+QWDN1&+F1XX
M6DN!$Z2QB=VC;K1')%%)%Q@F-XT9""B<.X.CVCI'! ME&D-MUO41+).J6_:%
MD68P*) L?6K)(DG5*ID625')26132SNU(WY:+D^R&/3C,E;D,S@[*53BMG1M
M*!*T-22=6L/.43)VQJ0HVQO3\OF4+<B2(DTA2<@HN7:CZ5](H0RPZM=0J\DL
MS+$4C#37$LD]Q*0B+F2>>66:1SEWED=W9G=F-$O1/H[,RM-I%I,R1PP(\HDD
M816\4=O;PJ6D)6."")(8HEQ'%#&D<:(BA1UW>E3?M0AT#_H=<"'5-KIGB.-!
MC/\ "_I/O_LW?[_^N_9[\JK/0_HOWZ)I^PS_  ))Y;?R]^_OVV/G#O1IOVG1
M;L_\5N#AGUW'SXXQ'X7])O\ '=__ )7]E1^!W1C_ !)8<L_P3;#NS^,[_7CO
MKT7]A::T#9:&\,B!*4ED,N2VSSRDRC++/.%+(90F$!$=0E#&=!$ #.Z.7?ZI
MJ.JR)+J-Y/>21(4C>=R[*A/$5'F)WKL:=I.G:5')'IUI#9QS,))$@4JKN%"A
MB"2>+&V<C(YC-;GXT*Z-(4I"E(4JT&T)\X.^'\4%R_O+>H4KQ9!PP&!$ U'/
M4&_=C&--=1#3.85@>>PP3WG/HY\L8QMON1MG-2 <=,8#SXZ1UTT <@ 9TZ,0
MH!W[8P/7CQ.^VP.0!G;PQ0< &=VF@:[\YX8$-VFH>0(4.PSR[@-^9.>[![AC
M<>@4P.H8#&N-,YQN#3</'3''2%1@[C QOC;.<<AMR/?MCOVH.!'&_._.0Z<!
MIC&N[0<A@85)P3CGGGG(\<#;&-^6QR,&FX!'.\=W7O']SY.G0 SPA3D"<\SR
M\_,_H^CQV SW5QTWCG(8'?G'1G(;]==_''1"L=N9SD8//./#.1SWWY]^/"MW
M_86_V?VA>/YTVV_KM:]/1$=X]!^RK!W^G[![:WW1-32%*0I2%*H6Z/SL[B?X
M"U=][[A"E>(T # ;^O@&<".[&OH'3I !"%8$#?GS.>X9P3RQO[#MX@$5RQ@,
MZ9SG(XTZ1'=G&N..N(5.,#.V<YR<;>)/+.-\=^^*C^Q'=C3&\0 0WCKO#HQY
M,#Q5'=OC&0.\X/+/E=W+EYQOO545%0]:4@B8'&J:4?Z=054W2NU-K'AI6MR9
M^;)I"3 7M1RHDHM<DF*4IS .3B:6)1Y!H#R#BQF-Y$AB;:10"R;<2J21DCPR
M& _X0(.-R &4#C!0GAX@ ,M@' ![\$$YVQ@BNN=V!]IXU"0_L[BS'.;2W/K>
M4Y(ST9JUE>2 5M3JFD.DDG-0."::4]&ID 25)(@869-*(",9P[QG9XBJRIGR
MHW:-)@CK@%6ZN6-L'?# XP14X.$;!"R*S(PSAE$CQEE(QE>LC=<[9X<D@X%=
M1Q 0'.F@<1WCD=0TTXZ;\<(FH[P0<[;#O/,Y.XVV[]N>.ZFF=..>C00$-PZ:
M;QUW[\#D0%3O&/Y6?#;!&<';;F=^?/!)(.X[L-.0N]=\,Y_2X;OOF0[^OWQA
M60&//Y^_S5Z'85-(4I"E(4INA2O'#7.S_?)56]8J4UHKBJ$Y]4U">0<52+T8
M4<2<[*S"C2C)4<TLY9D@RSR3R#@91 0SF(XAXCO^CZJ@KN"<^8'EZ=_1W??5
M+!L\7X#=9RY&0T]A[WQ$1W=IZ /O=8!$<2^-,8WQCP]&>[WV\^*^QML)?IM<
MD#E+9*NEHMZQ*M!$Y4.]+6Y6*4\L\$R]).DEE4HCQ+YM2G$993B9IRA$ FR&
M:N%8$<)(.1Q*''IX6!5L<\$%<CR@1D'%E!##?!5@>$D'&#R8;KMWJ05[CR(V
M%NR!<Z-M_1EM'7"4VN9BCD;619I^3%544;:5+3#,B;^8I^5/3:>C+A2F5+*G
M-%K3B3)(I; 5*"""!H>/][W$*2$%M6U:6)G)=ECNM=BN[2Y=B<G@L([F,KEY
MD$S1$$R.E;$<J"X@DDB#-'8Z='+P !6>WT>>UN;55Y@&]D@8-@J_4J[, B!K
M,N-JIT&S _6K8K07?570FN/2U4*:D&UCO(UU5*V!7+::8V/"HI.[M=--]/N;
M*);*Z-2%PE?U*I446M3+UD[5;.Q<VO5 HD)=94;&6DD4B2<E2<K*RJD";!(H
M@SJDCN#5$$07)D/&\R($<;JH62WDCA5<#A90)VE??K&<KDHJ9Q-]3O?C/SG;
MD8'7V'O>1Z=>U/)]O>&89'B/N]/AZ^_:L>$;_3MX^?U'Z^8S0=G>_(9Q9VY/
MD"CWS?G?CM0>K<' ,"$.(>(\*<(WQD9]GL^['+;%;1.Q.6LN30U_:\=*SH.K
M*6;55H'9 F7OS$XM:0]<96E#J)$92A8G*+,4S$)E!TI4LPSS%$F3@&))\ 0>
M59>;'CS\WW_WUZ!(FE(4I"E(4I"E:^=HCZ-C8B_QO?>RG^7R&'O[^YI6P:%*
M0I6O[LAOL(V?OKK;4?<FM84K8#"E(4I"E(4JVEH/G?M'[_J?[ZWN('+UM]9I
M5RXFE8Y;7_T+.T)_%!7OWNKX4KQP!P'CIQQG& QU].[0=-1A6!&_GR-\X!P1
MM@\_'8;;#<U.@YSG?D0'HZ@WX#?G 9X\84V.<YYY(/AYASP.><#/?WU&=1SK
MG @.! ?(&1 >G&!](CB%1G<YWS@@X(/H&2#XXP?:3BFN1'7.0P #KCI$1#4.
M 9Z\Z@(PIODG?.1@ [X\22-QW#/GSN": . R.-VX=,YUT ,Y <^8<[@$<* X
M&?-R.W/T9R#GOY'(V!.)SINR.Z8=X<.C>(9 ?)D &%3G;ED\F/,=WAS(R#Z,
M@&H''2&@[\9QD!P'2.N==^0R(<85!QXC8\\9QD' \3OG?GD9([Z]#G8:?G1W
M?W?/';MV@>QA#"K![XVK<A"E(4I"E(4JT&T)\X.^'\4%R_O+>H4KQ9AN\W6
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M ?O)NR A@>B+>/S>C)Q[[U@1CW]_OJ/^#,8=WA<=M^/8BBX='Y_:C@>/GUQ
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MANPJ-]\>@G."<#)YC;'T#/FQR'@'DT#&0QJ'' ;N@<PK(]P]&PQD8W'?@<O
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ML?J[\_?0 QOR/1GSZ;QU#7..$#OO@>KNY4/F]'I^@;> .<4UZ_P=&[4,:!H
MYUSIK#W'OMR^D\LT]_[OI[L?14 .-_GTSOUR APWCYAT#&(8[O9W>T>O'AGO
M-#ON, >GPS[2!X>([S3(9R.0#> 8Q@0# AG(= A@0_VM]A[/7O[^FIP,;$<\
M9R//OC'G[B?:-KQ65]DKE_ 9V?+V^WY\P!C&FL9)S]7VBH/(??G;]ISD?0*R
M9BVHI"E(4I"E(4K7QM$?1L[$7^-_S_H93\?3"E;!X4I"E:_^R&Y[R-G['_6M
MM1Z.Y-:YB",^W-*V 1-*" "&!U 8>_LI5.*Z/I1>":5=3;"LE1O/?&DE5,[<
MHE2U#RYYQ?DX&II@(>AG,,G[J%!*NY<\TW/\J81'$*H*E0%*=9P%0 4ZUF>7
MA(_),C.[.1@LSN226),DDA@22'"!P22'$854# [,$"J%!SPA5 P%&*B  E#
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M@,  CI%>!X^G;EX=_?OMFLLDG;;;&-M_-C&#DD]QYT' < &; <0P @..K&O
M-^Z QXXW\^2#[1R]S3<YY@;^?F,[^/I/+G5X;*^R9S_@0X.'!>W\0_WAI&2<
M^6-ON]_#PJ#R&_CW\M_#N^VLFHMJ*0I2%*0I2%*U\;1'T;.Q%Y;O?>RG][3=
MTXZ(4K8/"E(4K7]V0WV$;/WUUMJ/N36L*5L!A2D*4A2D*5;2T'SOVC]_U/\
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M4QA@A)*:,P@$#@%U.QC(60<C&S E5<<T) ) ."0#C85'<I[GSP'N;AQGA/\
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M3LUG(]N&5&29]/O[F[432<*2%;RR[(D&!)' SWL@-NG&F+#@0R.P"%KQ8Y>
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M6;"'K6;3WB1A'&PB;0[NYN8V,<S0+-\80Q02E"Z"69$018J(TC(XC(O5K)=
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3O\_.E<XFE(4I"E(4I"E(4K__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g373959g97s11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g373959g97s11.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[12(4&AO=&]S:&]P(#,N,  X0DE-! 0
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M4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M"G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@
M  EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN=$]U
M='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O
M;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M        1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M     %)S;'15;G1&(U!X;$!F==L@        "G9E8W1O<D1A=&%B;V]L 0
M  !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M            5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C
M0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T
M0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O
M<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))
M30/M       0 )3,S  !  $ E,S,  $  3A"24T$)@      #@
M   _@   .$))300-       $    6CA"24T$&0      !    !XX0DE- _,
M      D           $ .$))32<0       *  $          3A"24T#]0
M    2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M 0!:    !@       0 U     0 M    !@       3A"24T#^       <
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@     ________
M_____________________P/H   X0DE-! @      !     !   "0    D
M    .$))300>       $     #A"24T$&@     #00    8
M 34   1M    !@!G #D -P!S #$ ,0    $
M 0             $;0   34                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   34     4F=H=&QO;F<   1M    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $     SA"24T$#      )[@    $   "@    +
M >   %*    )T@ 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ + "@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
M  ,  0($!08'" D*"P$  04! 0$! 0$          0 " P0%!@<("0H+$  !
M! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S
M-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4
MI(6TE<34Y/2E
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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ML/[O_,>>L:'DFVE;$$QOX^K BQV"-!O&[NIJ/\%/_P#6WZO^"IK6O5<&(WB
M+C2\2; [-ZX374P-#?=>-]^@]<F=]B:A!U%C:;2; C:()W1$SNNB:7DBP O
MD$[MG0)A$U3(&TZ[YG43&[2-/@BN2WG[6]_?]Q,/_P"UB":\]7];AM;U*@N
M"/L:HMTB+ 7GKA:,\BK_ (6_\VJF]; ',))M<;-VS4#8;!9IJG98';)@DS-H
M&L2-.B)1-6=D@$S)UT[-.FX&H*)J"2=;:@:6V QJ"-+]8V(FH8VS)V3( ,@'
M8/B-44T\P]H?CU3)#B3:\=-K;+B^LQMV2@U&WHWJYN(W]OV\W]LR:?\ 3Z[U
M!^+6.&/]GHWTIT]ACR&[O:1KLZ"M*OZQ_P#B/XJF-;:$D6O>3:(V[NB3-S;8
MLTTV>PD2-NL@DSO(/3KL1-2#&L2(T.TV .L&8(-]\A$T))_&\7@F !MD$20;
MC?M)KJ"8%K03)FQD1V=N^URN1M_U/DR_MR6T_P"I-V=8$_VBE<#[&K),W^TH
M$ZQJ?AV+0?JG?YC?^+U3>M@==0=HL#<&#,#I)D&(F-^::08G:0(_KLG9.V8@
M;2:3<;S-I,WWZD1M B#<:(FFL C2Q)N0>OI N1IJ8A$U 2-=@)T(DZFY&L W
M,;NE%:-C_P!NJT']M&W_ /UL:=95P?!ZPM(I5>L#(X[]"8V!=T_UC/\ &W\0
MM$=J::GQSIKK JBIV6TUF#354!=(K#0JK&F@!JJ"@!&H::0&H<8I 1$-;7#6
MP-FG3;IG?IK;4+DZGK/XKVI<?P?EZX6+(1%P1W2='EC=Y8+!$6N1HW]+#6ID
MA;P7-:&N2M+,<YQ-V53=OBK(\M(K27>;H72(-M*M\34)#?GTN$J%0/+YHAKV
MMS5'-+#4<Y[<F9I=E<UM,O<TP12(>8:9'H?A:C8RP\D%T-#IRPTYK@6.8 ':
MX%NHA:FNX%^)%LC"R0N$%[&I;U1H+F(YZ8 6H&E.6M*5/3DNI=:F1L+(>$"F
M.BT.+FED)SZ2<WIVDTY,II*T;PAA7/#14!D#G!KH+CL +<[B6N#\P:6!I!+H
M,KDX:J!);!W2-!,DF8$$%L$@YK1(*^!XX(>)QF<UC2;;>E>J1JG]#4+/+H0[
M%*%D5-7)Y(D0UH9&;4M5LBQM6M[DE3T&*4KD50W&% M4)2#J,?A7 .%4B0T@
M.94;9XED@LBX(()@%O.F 4.'K QDDW%G--VR' 7O!!!Z;;1/TOG _P 1#(E1
M8AQ;R[G%OZER8V!W:'8]C2,$5MY,3:7%R2+JV2IZ5,MQFI25$T3DJEA29"X.
M)[*6U=C7JN6X_#$GGEK6Y8+P1F+G5:0@1F#<U,C.0&20 <TM X>J(YLF"2 0
M2(:UU[Q.5X,"_1$$TC=.S]R;)R)-$[I11;$) K;//"9N6J&]76>V@ZNK'6J+
M/:UBY+524\L;PUJ"P/\ +)US:K3'EEFDU4AZ:5:EB&E]%X>T$M) BX =$.$G
MFN8=@((),$!9OIOIG*]I:2)@QI)&R=H(ZPOZR?\ 0_W^HUGW^^'EW_4&V.OQ
MWZ1SX;2G7P9D]?&55]O@O]0[_,/_ !:OW-U^?7TDT1:;<1R<V6 S9Y955")W
M9XI('9M5&IBUA1"UL:E2U-6:E.$"SRO*D4TF%5#2%= U %5(XJ#NF ZI3:X2
MUSVM(F+$@&ZY>2UCG#4-)'L$KQ;#>,Y/%^%#AOO!=5*ZS.YU]XK E[7![<1V
MI0]R"339$@6&M\=8"#E!M#<VUN%)!(G*%"L^F@@BBI:X'A17[WX'/C,50HEM
M.EAWU :E5X :RF2)>ZP),7@ "YL!*\[<0&T:3WRY]5K2&,%R719HW"=IGK*F
M0^$7M'&IE(X,XPVY2=]9(FRR1&C5L[8W+'%P?WRW,;;H@N;ESN0NB<J![NE%
M4CBU2PAH4LI)JE:]%-Z4$9BR-X,K/8RH*E(M<]S"0XD ,;5>7@AI#V9:+R"R
M<Q@"2;#BZ;7.:6OEK0[0#RBP!I!(+3+Q(=$;=DUJLXL+TT<$-RK]5FL;;<:"
MWKFT#(3U1Y.O0FL<;ON=:],D7MB1R4$*7:ADJI.4JFM=20I=TX&I2P2&]GJV
M&#PYQ]+#\XTJE"G4G,0<S\.*L@D2&YM 03E,&]UP<14&'=5YN=M5S((D0VKD
MN =<M[&)N+67Q,_&!?NW%TJ8]?V+MZ6)56^N_-&-&A:6M@F4D86&]\)M]:N2
MN*5;)S4$>7R&/RX3WF+"::YF*"$AC<VEN:LMB-IP.&JT<^&>2_C*--Q)<YC'
M.P]2K68"& N#7,AK_)B9, N4&(JL>15:,N5[QE$.+14:QAN2!(=)%G$BPOE7
M37 \)0_NUM9K-++VP54HF^R5F+I,#]-%;52<2=>.Z)MN"TJ^/I'8!J,CQB!W
M#R=*TVA6ZIBZS@H:?$,6]4^"FMJTZ=>K<XBO1<VF'7%"CQLAQ;;."W46:=\P
M=C"6.?3984Z;P7$2#4J9(+0=A!&MR-@NK%9?")19BC;4W3",2Z73=.?&&)0X
M15F8&!IF[@X7I-X=GF21QJ>)@I&/M*.Z9-!%+3('<EQK8UR9T2"J**5T)L7<
M&/+R6O8QA#G /<Y[F 4/"6M>YK '$T3.9K8S @@2)Z&+:!SFN+A )  #B:AI
M$@%T@<8 ()F"")$QRDOA+8?#5TH:I38V\+*[0\)@4^MBA1;@Q6C<8'9AJOO*
M6NL$TY.)%6UP5RK&JN@VM*I>$E;:A4*A-H. W@M[PQS,10<U_%EI^U +:E=V
M'8Z],6-1NAN&F2 J[%AI(=2J C,".9JVF*CAY6QIZB=)%UWG%-Q!WFB<FL"T
M6%I*<U-[8'>-[8X^IAQ4B<7220VVY,U@*&FFMV: ;4+V[+437)E"I>2F;FJH
MY90M0F$UJ=<X3#4'LQ#L1S1AZE!KG<9E#65*IIU#Y+I+0"6P"2;0="K5JC32
M%*#QK*A +222UA<RTB 3 ,[)TA94_'EYEK5QV<63GJ69QV>1.S$E,C[A"5T0
M.O1)&"$OU,59'-1+:'"AMK02Q6XI7EU0ID/88^Y$U*C5XI"%0\'9H=3KTS3?
M3?79F%0/%!KJC<[@&1,TPTM:29<#$20\*#;.IOS!XINREA;QA#3E!+ICG2";
M0-5KB?PGUIG<Y2,8MQ=%_0(K3R6\*Q<"..M)J>+1.V)%TG<ZIK=7Y,Z"D\W*
MB(VWR$4M,7<IB)K"C>C3RO'K[/!-9L9ZM%KC7;0#9<9>^MQ+1+6ELR"\MG.*
M?.+0%!C&'R65##"\F (:UF<F"9B.:'1E+K K?%''M#VIXM<QR6UMR8RY7;)H
M419*Y'P94?V5R8)/(HJN<"F67.M2%OE"2++"$"M5Y&@M6H))KIK%(["VYC@Z
MHYM9S*U)XHF'QQ@N'L8\ N8T$L+Q(U@=+<W7A306!S'M+Q(!RZ$$MT<8S1 F
M+] ,:-"O":6YFU4:!!:&\!54K/AZ-H3DI8<[.*IPN#:BX=VX2V)FMGEBU>L<
M9"SVRD;2G3)2#13O)C4G55$EKO*$Z5.":M/--:A#,Y<27M %.M2HU"2Y@ #'
M56$DZMS$:+EN,8X@<74$Y8$-))<QSV@ .,DAA'7 5U.?%(F?;66CF<$;*4CK
M?"[3%:&-EO=:5RHBKFO='LI_<I$@;5U!I3C'F6+R%15%UQ[8ZD2 E&Q/Q#2H
M!>6F\XPA;6K,J&1AZ#J[\LMS@!N4-)&CG/8,X!&67-)M.AK@LIN:+U:@IMF\
M$DYB0#^R&N,&#(#3$JKH5?V]%S^'>Y'$4R2&&0^AD=KNIF:WCW%#EIS*S6O<
MY$PEHGMV%]2K*[@.:V.@ZJ"S$1;(G)<!C]#)2>),C(VJ8;#TL52PKFU*F9M
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MJ8'IW8EHTBL971P:58T4G44"J;59R-0-%*@H@^FD32:_%I/)). , 8476%5
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M:X$%I:2""-""+RH0""' $$7!T(Z>A4JEL1PQ(6\EJ1VFLNF:TR9F1)6\B'Q
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M%SS (/)IBU(G4J?W!6&-BMPCS8XI$S@6D6(U5:,XZA12F5)CZBP*/*JJ_6<
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MP#AE=]BXR)!B[3%P#:+@'8K4:TOA,604HM%K^)5NJ0IK=IT-22P\C)K0A:A
MH:;?JD-=,$"M&YQYI5JV@MW3"4Z.#4J4MCLL7H3S4]>)J<$.S%V(P9!XR0<2
MP@BL0ZK)XR[7D9B#8$!S0" NPW&C2E7'D?\ A=^QY,<RQ&\7()!)!6RMLC\*
M0S,R./--J[[MK&W4'%-[2BX6R$R%O)/42I48G1)RK5T%I$WEIU,1+3)P+()H
MDSR22702O/+KX)X'<XN=B,*7'4^&2?V!)FM)GBF3)DY03<*@8T"!2K #0"@;
M>4?,_>=VE2IDWA4%CJVO:BVW$.8Z,S@N=6E5[FL^FIK<G1'6WNRUO*HMG20C
M4/"&HI*\&)RBZG<E"TT./:@9FGL=G@4 M%?!Y7 !P\+%VM((!^UDY7>3)YI<
M8 DI_;I!XNM()(/$FQ-B1S+2-8UM.@BG[JVIX];VR!+*KH6*XA)2_HFXQJ3.
M%=AI4TU%H#GEXD)Q0D,,*:TAM1ST_/#B:I-(K4FGKC?'.JH NBC:CB>"Z#<E
M'%85C9EP;B:9YP#6_MU"8 : 1T"VJX?2Q=0YGT:SB!$\2X6DG8T;23[56/N1
MN*W^MEX@O[S5Q?\ )S6QQ^ ]<PIW?VBD (_USO\ @+ +CP?$>@K?=/[J>Y'X
MK?ZV7B!_O-W$_P G-.4,#?\ MF$!N!_:*<03T/\ CK*>#XCT%;[I_=4^Y&XK
M?ZV7B"[OVFKB\^[]CFG*&!M_;L+:W_R*8G>;/D[-HOUIX/B/05ONG]U6Q>/A
M7XG7*11D]MX=+ZN!)%J;.MYYR&TD^5E$KVRV,5;W%$:80P&4EJT"Y.>B6IJQ
MI.2JR34Y]!9I== 94<?@FM<#B\, :M=UZ]*;UJCFF,^T$1L(@@KM^'KDB*-4
M\Q@M3>;AC01(!T(@]*J;W(W%;_6R\07]YJXO^3FM!C\ /_NX4@7 X^C$[KOU
MZ;;=Y7'@^(]!6^Z?W5O=NK(<<%IY,7,(%P]7Z99$4VNS26O46!D[[32W/J ]
MJ>$U**10IV;_ !7%K5*FY37V03:T*I4E\<"%!]%?%3%<&UFY*N+PQ9+70,4Q
MO.:0X&6U&NLYH(WFY,@1TRCBF.S-HU@8(DT7&Q!!LYA%P2--"K'9VOPD+ KD
M"IJLQ?A.7*%$C5OC29PU*ED;5*9@0QII8H*BBVVZB--YLF)C;%2_&-S2DJ=Z
MFT@Q<)Y@F5UY&IP0]K0[$X4EN3*[PL9@&%Q8,XJAY#"]V67&))&Y=AN,$Q2J
MW+B0:!(ET9K%A F!, 3"IN3\-O&?-9&]RZ6\/W$G(Y/)'-8]/[Z[VDN4N<W9
MU<#ZU*Q<N5'1ZHTY0H.,JKKJJ'&_BTA32%-(;T\=P=28UC,9@PQH#6-;7HM
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MHB .=:(T7#J.)>XN=1K%SC)/%/$D[;- 6MAPC<5H"'_Z9>('H/[3=Q.60_\
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MA9CUBEK V%XZ(UB=(A<>#XCT%;[I_=5AQ^S?'/%8N?"V/AZOLCC:F91FX!Z
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M1)5%9AE=-%-0ASB,?@74:H;C,*2:541Q],DDL($ .N20(]EEW3P]<5&$T*P
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MJ? '!U:>*QM2KE\KBWT7%LD@3E:2V2"!,7!C1>)_"N*I@&IAV4Y%LXJ-DB)
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M_?T@'_O?KU^7GOIXLX3UC$?P^XIRS7@$4J5^EPV3YR>^0W.^X* ]=OKAZ_\
M"_\ +(]^GBSA?6,1_"[BG+-;T5&8F)??_=.F\('A(+G!OZ!0+(CG]\/^!W -
M/%G">L8C^'W%>6:WHJ71Y=_]VS:->C27OD-SON"@7_*#\7G?'Q!MW@.GBSA/
M6,1_#[B#AFN?_#2C?+]YV9NCK!,1JN5/A([GTTF4^@4"$#*:::LC(>5-=-?P
MOS$:0 >F,[9P(3Q9PD@^$8BW^5M_T)RS7O\ 94K1M?T7\KZA<0\)!<X,?6%
M1$.6?2'E]]]7Q9PGI\1_"[B<LU[#BJ4ZQ+[?[AT#^@E1[Y!<W ?6% =NOUP"
M/LW=\8_EU'+Q9PFO'XB=_P!EW$Y8K^AI=K^]^?S0?"07.'G H%TZR'I_PO\
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M'&X!J'0]1_!5NHZQ^*Q5^*-0[ &^X8 !QD>_F.! 0^4,<M)G3H^K_6JBC "
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M(M,)4NS20M)JOEDG$KPE>G[:US"XK T7 AZQS3-S<I=7E+6SJI54V1CSBO\
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M#;YKG.<\N<2YQ!)<XDN))$DDW)WF2=Z]@ :V&@!H@  0! ,  6 B5DR.<\\
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MN*'AFOZ*D;[,\_\ +8==G3L62GPDET::3*0@< $#  !R$AV *J:]@\\XW&D
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MR13,V]90:N4H4"-S;F]F%,E)\9)YV<%XC#/:_"5F4R:#*=0//E/;2>PD9:)
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MGATS^U6P^L>UO(AR''[J; (_+T !P&G+/"?K;_=I=Q.3\'Z!O:_O*1X2.'(
MR-JV+GT5/8<QS\*#R#Y!SS'3EGA/UM_N4NXG)^#] WM?WEE#A(X<.SF5_H4L
M/C <53XPJWL-JJ#AJ ,.HAN--.P9'N#GF<L\)R/[6^(/[-+61_=]*<GX/T#?
M>?WES2<*G#RB4E*D]J8U4:17286"D'%:3X](@(>42K%JA*< " 9H.)K+WQ4
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MKJJ+CL&<9P YY8S@0#K[>G41R 8 -$4@.-\X#/7OQUQN(]>G^EWW'.B* QS
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MD:!$<YQD=M]MLAMZM,K=,HCJ$))WGM*RD-#8)Q.4"00$TH! 4Y6!R8 "&,"
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M">'<QSP_%,=08YS<L9*KJ3Y;S6!Q/&4P79@ P5@T-<6@CT.;@:K2&EM!PJN
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MZ+,2SG<>V'[\NXC.-NF.8!C&<.2N$?4ZWNCYJ^&X3UBG[R>ZCX?!'/Z+,1Z
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MUI<"\?:M;FS@MXLTZ;G51#,I:TEQ!):7 !L!^8#Y6VP,".2S96O0/28YC:I
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MCLA>"1AWL;2<W,"XN ):XB?14PF%IM<6O<_*2 P/:"8J,:ULAA$UFN<]KLL
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ML%<*SS]';4GS5IEL@B=QWY:M4ML5?C7%*O:I-8^UC"JEZ>6$Q-)1$HP2\JY
ME>G4UF;$!#;68D(O0QDTN')(%9^7(Y9<&*N0PXISN>W([8DE$T*J[45RET6O
MC/([;O\ )RER*2JXZVM3)#R$2TMQ<'AN6-,@/;%34TD7ER/<;G$8@>83;:3\
M,LT=5CNAB;6[7,,3720UF+Y!)+0QE6^&)F/AJ40YNI2H;HNTT(,6+&(D8[;B
M6*Y#'X2ZIU<2:2+U'=2<W2:XG;Q):Z1GOUS([<1NADY92HH:\L$V=&VW;G*W
MJ(/S[5%$Q<&IE 4-":/7' R.QB.25]8U3]2[--*Z,+R+J;-74XD'= 6GN39R
M3QR%%01RD5%Y)4^0I1-SG*MMH=4S:\V9A30C=$;PVF*5+08W-S)4"@UEI\F6
MN-7E'*"+SDW\0W%>U-M;Z^,LGJ&.0YZDA3&]6_H3-EP6)DD,S*95]$LJ@\)+
M1SZY#LVP>W,7AGFZ'2*EOF*:<G6R(, U$B(OUCT1-$31$T1-$31$T1:C( ^F
MR?\ :]/3.?TPW;X@SSP&_/J&C-#;V_DLGZCJ_,KP#Q <$D=O)(5<XC<B"&2E
M6268]EFMOG)G>C"@+3T+#"BE*10A<1*$N@\\NM04IH*+\=-2<)BBO]#P=PY4
MP5,4*M/CZ()XN'97TYEQ;)#@YDR0" 028,0!\K%\&LQ+S58_BJA S\W,U\0
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MR,KK-.NE'C#3:A,,,,8W2NLRNL1JK,KKJ6#55554(U555"-50CD1R(ZZ\9J
M@>"U1L SL[!90\#5"9-=IF?V73K.H(^O;,F>#4F% @'Z)\;'-%%>?,+F&U=
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ME0:<BIKII\L@)3%]JIS08II*\<LSRXO](WU:3J6&HFBYX(=5>_,YK3(.1K0
M';G$F+PV8(WP_!+:;P^M4%4-((8&@-)!D9IF1^Z )VG8OTF  HQ32'BAXN*0
M# 4A2&, &!P 8V  Q@-PWU^97V4P/3F'(!Y\P#<<9V$,<PP&=L:(I#U\AQL(
M\@ 1$ '/+XPW#.-/^M/KZLBZ>11UBEC*XQR2M:-[8W9.*5Q;%Y 'IE9/CTF4
MTF459$*RS2J#BC:1I-(.*+.(J+.+IKI$ V*+-'(\QQ2.I8]'&U(SLC:8%"-N
M1%^2((\M6L5'UX'-59RE4<<I5'FF5GJE1YZ@\TPXTRL>8AP&R"=PU!_[&GL,
M*[#UC\#_ $^H78Y[^\=M@SN'//+< V#/4!VUTHIW'Z'?_2CCJ'/;<-NN,[!@
M!#1$Y!U#8<;B._+ ^L< ([\PY!HBC/M$<"(;;AUW'KU$._NW'1%.^P#CN ,;
MCSP'7&<8$<X'OZ:(LI&YY'4?+%YWS_1*<>T-MO6(>K4=H>H_@J-1UC\5PKYU
M\@[L>T0'\(XR(!GV9U?K>HN.<@&:>@8$1QMOC8>60SO\8;@&B*-A$1''>( /
M,>[Y=]N0#SY:(I'<!R [8Y^W8=PSGE@=AP'/IHBD.09[P[]O9@.H8QSR(YZ#
MHB@.GJQCNWQWU!G&^0#KGGRT1;A'Q$41F>?:3 ]>Q9(;Y_E^,<GZ^SYK5FAZ
M_P @N]UPNTT1<#*:JJ*Z:*Q+KJIJ"@P*::AHJ$! *PIJS34-([XJ# XP.VB+
MKNQN/PN9\R1_Q-$]OX?+ZGJ3L;C\,&>WL2/\GC\&BD=)ZK?*?BG8W'X8,^9(
M_P GHGM/PM\/QE.QN/PN9\R1_P 31(Z3\/DG8W'X8-^9(_R>BOM]MOE'P3L;
MC\+F?,D?\313VGX?).QN/PP;\R1_D]$]I^'R3L;C\+F?,D?\31(Z3\/DG8W'
MX7,^9(_XFB1TGJM\I^*^98SG."14@7K2UR%:G.2+$2QK;U*16E4%U$J$RE.<
M362>G/*KK*.)-HK+-+KJHKIJI$0T2.D_#Y?4=<YZ4*^BFFBAVKIHHIIIIII0
MHJ::::0P%--(%@           8  T2.D_#Y;/^Y4]C<?A@WYDC_)Z*J>QN/P
MN9\R1_Q-%/:?A\D[&X_"YGS)'_$T2.D]5OE/Q3L;C\+F?,D?\31(Z3\.W3^G
M0G8W'X7,^9(_XFB1TGX?).QN/PN9\R2?Q-$CI/P^2XTH%U U#0ZU4#74-=8T
MH$0#76(!3X]6"_HJO%II#QAR.  !V ,$CI)[/R"Y=C<?A<SYDC_B:*^W\/DO
MF5,QJT":5JPI92F4DK$X*FMN4 G6)JO'3JB0-)K I2GK^B)/H\4TJKZ*BND=
M]%(Z3\/DOI[&X_"YGS)'_$T2.D_#Y)V-Q^%S/F2/^)HD=)^'RV_]0G8W'X7,
M^9(_XFB1TGX?+9_VG8W'X7,^9(_XFB>T_#Y)V-Q^%S/F23^)HD=)^'R3L;C\
M+F?,D?\ $T2.DGL_()V-Q^&#/F2/Y/YG_G]>B>T_#Y+4W]*OI4E!4Z&5_2].
M1%*EIP'E3<; 7W]0#(\NFM& QK GHW#>+?'V+AY$Z VZ=YW%='754B3JU*U[
MH2)J",UG*J$2<D/&/)  J--"BBG(X_G@$1#Q=PSKK*YQ:&DDSH&R=#)@;(V+
MC, '2 +:R8U&\^WV+H D;#@1]-F(!W ?J@R;AL&,^5^4<YY<]M:<17\RK]V?
MQC=\USQM+86>_NUV]74H&1L&X!.&(<\LN+*& P.,_IP!G/?W^L=.(K^94^[=
M\DXVEM+-)\L#VZZ:*/21A  $)LQX'?\ 7!D =LX_HW/GC([XQGN<17\RI]T?
MDG&4])9-XY_]>N?Z*1DK#L'INQ[[#]463&0]8&^H-Q'\ [WB*WF5?NSW;_6J
M<93WT]_E=7[WU(3TD8?NW8Q$0P/U09>NV P:.^-L]>>=Q )Q%?S*GW9^2<93
MWL][?I^UM/R4A)&'&?3AB#;?#@R9W$,Y_3MAZ!T#\;B*_F5?NSW=/J5!5I>=
M3/4__P!E'I(P8'Z^&/(AOEQ9?5_LHCD,?)IQ%?S*GW9^2O&4CH6>_/X%/2-A
M#G-V/G@?JBR].F/*X$ # >WU;Z<17\RI]T?DIQM/SJ?O_P#MT'Z"D9(P!RF[
M'OC]T&0-P';^B@&,#ZPZB'+3B*_F5/NC\DXVGYU/W_\ VW2GI(PCC,W8L!U\
MXLG?L !Y7EN CRYX'& PXBOYE3[L_+Z_"\92\YGO[]-NT:=O0H])&';,W8L8
M'( XL@=0Z>4QUSOW9SW.(K^94^[/R"<;2CRJ>NN>W_+ZW+,?)&$*Z ].&(?T
M@D!PX,FWZ52&/YKG;  (\]@VSMH*%?S*FI_\;MYZ-NJG&TMCF1TO!_ C>%B"
M2,.<>F['ZQ%Q9!#<=AQY7O'.XY ?9IQ%?S*GW9^2<93.CJ9_U?\ L@25BV^O
MAC]>7%D'NZ>6'/X\YSIQ%?S*GW9^2O&4][-O[>[V[-JX^D;".?KV8@ =A^J+
M+C?IL=TV'?NZ[Z<17\RI]T?DG&TM[-8'/^&MS]0I])& <_7NQ>KZH,@9^0[.
M>?,!VWTXBOYE3[L_).-I;V6UY_\ 6R>DC (C]>S%@>]Q91'?'( -SGXL<PSJ
M\16VLJ_=D?\ ]2IQM/SJ?O\ _LLY<D8?)GXG#$'Z71MYP9-_TZ@,#^FB/T//
M/J[LCJ&C7D<RIK;[,VL>A45*=^<S3SAO'3T3[#=8/21AY^F[%U_=%DW'O_FH
M8SCGSSZQTXBOYE3[L_+K^A<*E,[6'J?_ .R#)&"H?V;,>_\ 9%D]H[>6VW';
M\><CIQ%;S*OW9Z?W?K6-TXVGYU/WO_92$C81'(SABZ;@XLN1SW?IN>O=MRY!
MLXBOYE3[L_)7C*7G,]_KC;]7]D#)&#I-F,1SL N#)M\AHAN/,,9]6G$5_,J?
M=N^7P3C*>]GO?^W5V]2>DC ("'INQCS']<&0!VS_ +, CW]<;:<17\RI]V==
MNSK4XVEYU/W_ /V4A)&+'[-V/.0$?JBR9W  ZG!MCXMP#(]'$5_,J?='Y)QM
M/SJ?O[/>651)&'RYWU\,8@)M89!P9,#N(9#)H!OWX#J("(:@H5X',JZ>C/R^
M6[JIJT_.I[23G&__ !;]NBPC(V$/W[L0Y /W19<XQZS=N@8VR'R!>(K^94^[
M/R3C:6]GO^T;=RY!(V&K8)NQU>,(  4KV7QJA$<<O*Y 1$<!T$!]8:<37CR*
MGW9C\$XRGO9U9O\ V7?4D*JZ::RW2HRBL JIKH3I:@J 0"H*J:J:!IK 0P(#
MD0'.W?K.'>=UV&OU"ZD;AT7.G:@)E@XRY&8W' I4W,,!S\0 Y8P [=.N!0ZW
M.Z[ ]E@DCS1VGYJ03+ V\XF;<OI9,.!R&<9+ ,[\N_IG Z0[SO@$D>:/C\UF
MI3+!2F"+D9@#R0P"5,/]#/$!VH$=LB ]-QSC  $ATCG;#L'1/;\$D;A\?FL(
MIEFX^<:]@P(@F3;]X"(E[CS'(<\@',=6'>=\ DCS1TW/SM\4!.LY XU[!N(I
MDH"'L'R?/?&^.HYTAWG? )(W#X_-.SK,@'G(SF%(!V9*.PASQXG/'J#8=(=Y
MWP"2/-':?FG9EGP@8._+LR4.N! ,EY ,B !TY^O2'>=\![$D;A\?FG9UHB/U
M1-Y<NSI1'EN ?I>,[;[ (<A#.,H=YWP'U^"2-P^/S^:RITRP3R<.1F?+48^E
MDPX :Z<CN6(9W 1#/J$<CJ$&#SMAV"X^MJH(D6&HVG?U_7P6.I,L&H0\Y&#F
MH<?2R;O'.!\GC?; 9 !'.,XU8/G? *2/-':?FH%,LY><3!V^U4O3 8R% [_'
MD<  9SI#O._VCH^HU,621N'Q^:@$RS<!<C W';LR8.@]]'=SV#.P;<P0Z/*O
MU"/P_-)'FCIN?G\U/9UGPC7L.X]F3#SSO_,]\<\C@,]^VD.\[X!)&[XGX?UG
MV("=6.WG"K?8 %,EY8P.1\3.1SCEN'3<=(=YWP"2-WXW_I\>E1V=:(X\XF=X
M"*9.&*0ZB/B8QD VWW$!#J(H/G'L'RW)(\T=I^?5]&V]1F@VA 8!I]1]7:C!
M"NJBB@0#R9/T.**:0QG(YQG?<>@9NF;F=/KH6C--(OT]&^5L6N5VFB*J+[W&
M7V>LE=Z[38QI),NM?;.<7#3QU<ZG,21]&%QIRD=;2<\IVM[.; <"VVM+2NH:
M'$4]9M)@I#J:1I$B_,^V/A/IS<Z:6:B3=8N(($UW9)?5@)?U-RY[65&Z+%H[
M9*7M=+H[^@67+K>%G*I^XMKE1=%B@U3$,8+>JO.,?EL6<7$BM9V\(TV#=1_L
M?';;&57(]T?;RQT%"92)QB$1ED0N' I9-6J])K]7$7)6GB#@OME=.#Q8AE:)
M&7*YC'6%O1NR5+*TZY"1;:=Q:7E9[FRJWLCL]:JCT=LU#KIH%D6O?(I,?)G6
MY<SG]LK<0AB+,LRSH5*^17!B#,UG.1J].F1-,HI<:252UJ,:5I%IR+C]F:KA
M'<^+Q/8E$_QUYM>KN;:BUT+N$ZRF[TM %SG6WPR31-+;<BF*RL&%L4KI"4V+
M96@C#ZB>XZYJP*9#WL\BK%=X58ASN3?^W%N[=PV4G6JMZ5=ZVT@<[BR5DCM[
M[>4<-\1XB%A,8>4]K7=L+N&#5.6-*D@+2LDKD,;0R2=.:AK:6M,E<"*\7SB[
MO4C?;&MC':"T;NAO=<"*6U;G!1>R5HS&.0R+AT?>(-0>M3H[*.I1[4C0L!S
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MTY<\DXN\BE?<^.O9\^O<]P-Q#;_4R+!CG]<Z3_ 2/K^33Q@X-\^K]TY.2<7
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MYZ>TZSJ=>U(&X=@4>B[']IF?/G#\ZTD[S>=IVZ]J0-P[ I]&&3Q?%[(9XHB
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51-$31$T1-$31$T1-$31$T1-$7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g373959g99d44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g373959g99d44.jpg
M_]C_X  02D9)1@ ! 0$ E "4  #_[1CP4&AO=&]S:&]P(#,N,  X0DE-! 0
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M4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M"G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@
M  EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN=$]U
M='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O
M;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M        1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M     %)S;'15;G1&(U!X;$!8^X)         "G9E8W1O<D1A=&%B;V]L 0
M  !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M            5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C
M0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T
M0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O
M<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))
M30/M       0 )3,S  !  $ E,S,  $  3A"24T$)@      #@
M   _@   .$))300-       $    6CA"24T$&0      !    !XX0DE- _,
M      D           $ .$))32<0       *  $          3A"24T#]0
M    2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M 0!:    !@       0 U     0 M    !@       3A"24T#^       <
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@     ________
M_____________________P/H   X0DE-! @      !     !   "0    D
M    .$))300>       $     #A"24T$&@     #00    8
M 60   )D    !@!G #D .0!D #0 -     $
M 0             "9    60                      0
M           0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M      !"=&]M;&]N9P   60     4F=H=&QO;F<   )D    !G-L:6-E<U9L
M3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M        !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC
M94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC
M951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
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M=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M 0$ .$))3004       $     SA"24T$#      .50    $   "@    70
M >   *Y@   ..0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ 70"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
M  ,  0($!08'" D*"P$  04! 0$! 0$          0 " P0%!@<("0H+$  !
M! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S
M-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($
M! ,$!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T? S)&+A<H*2
M0U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$
MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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MR&AQYVLW/]R@>H8S?I9- [:O:-9V_O\ [R7I[?BK7O\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MJ=7K-+?*KZG&.8 P0"6GYAT20"Y?F8 &LKZ=,8GPHTIMYM:7&4'J4#GJZ1U
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M,<84 X^%.+')UE\!\9T/$..V>#ZC@?"KFFU!U%TW%V;JUVFMJN)Y'6D,%,D
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M%NT0&<.Y^8L 3"0]=>YXJY+MG1?T=^YK/A)NW;020NTE2>9UA@I)(<CF2AX
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M22\I!AA.CQ7Q&=9PY%W0BY9U%G4V1>Y2E8"5!;GGMJ*2 0D$@LY1DXR,VVW
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M==KW?LO;L*ZJS93=?M2YVJM1:I*$6'(H]R4&=,I1>;E-OQ)4!XMR&N@!;3N
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M %J.>MK_ !CH[ZM)>LKXZ;]K56-5?T]_B"KNC5\*ZFX1;MW.8..4\H=*=@!
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MI4+EM.H*T+LJEDW#_F%)CYB1N:W^&>&=9?/!-9Q+4<R.'6$&QI@2Z+AM,47
M0""@'D=14ITMTJD?!QX:G:7XH?$/NY,HM?I=AVW>-U6ULG;UPLOLPZ+*N>H1
M*SN'<]JQ)(Q'I-:J;#,&GRF4I$IA,\-J#2BC5O%/B-%_PSPCA.FOHNZ^XDKX
MMJK:N8W4H2^GM7%25<AY24N>4H0\&H\.>'UV>.<1XGJ=.NW82L_]+LW 0;3D
MA:T P.8%2?E;FYU09-;=FL^6C(4#@#"A@C QDCTSC/Z@:^:)!2D GF( !5_N
M($GU,U]&R20&!D)_VCI_:N0'/N/S[ZFIII2FE*:4II2FE*:4II2L4-^:=U1)
M:>DX4P/3@E77VX'<'(P.4\YSSJ7 *9#P)Z_QTG8 U%DE*^8_[@6Z%N[]B?/%
M:P/#X4P$7=2P5A5'W&J*$)[!MB3(>4A &,)RAQ*^G'X<$>FKJ_22DB1YX,'S
MER\_4UO7ASHYHC&YAFS,N2<MB7K<?M/*\VE-H)[,\9[DD@^O?/./R[DGC&"X
M@0#T]/21VGTK0PKS#9Z.3^WU];OZ5:FE*:4II2FE*:4II2FE*:4II2FE*:4I
MI2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4J1Q)4!C\22%)/L1GU].H9
M03Z!1.E0>G6*X8S*600EL(ZB5$!*1SV()2!U'(*NLY4YU=1.1C4DDY)/G0 "
M &\AT83W;[5V=14TTI32E-*4TI32E-*4TI32E-*4TI32E-*5 D#N=0X&3V_>
ME.I.,Y[?O_=W_AHX/NWK2I%.#I)P><@9P.?;G^'OJ% LP;KGI,-O4 OU]1^?
M2NFXVA8'F,C/ /4D8^D@CISE//(5P,Y/Y:R(4< E.P?^7P?5S.:QJ0@ER@*B
M=V]&_AVKG0I "1E*>E1Z<?2GI.!]0XR<'">,9 [8U#*)+N3N<SYS]ZD*0,0.
MC>3=?3&<5S>8C_,-&/0^QJW,GK]Z>8C_ ##3E5T/M_:G.GK]#_%/,1_F&H"5
M=R)AOW;8_P 4YT]?H?XIYB/\PU/*>A]J<Z>OT/\ %.M)X!ZC[#DZ,1D$>E2%
M XGM_P M3K&<8.>>,<\?US[:B@+[$>W[$U,#GT(_/C]-*FA4!QSGV&E0_8[Y
M[?SMZU+YB>H))PH]@>"?R'\_;4$@9[_0.:D%W[1@_FU39&<9Y[X_4#^9&I>E
M0ZTY(SR._!X_7&/TTI4V1^[OI2NH^V5JQY?6A02%<!1R"<$!1Z1T^N4G.1SD
M#1RGYAS/B-NXG?![>M44.;Y2!R[N'=WQY1T8_6(0O 2$D%'TIZB>DI_0XR.?
MJQZX''8^\RWG/7]Z<IQ '0 ,SNVQZ=!YFN1IE#8X2E)*BI12 ,J(Q]1'*CCU
M.2>/;4DDY)-2$@;;OZ_D^IZURC]>Y[_F?X>WVQJ*M4=*4TI32E-*4TI32E-*
M4TI5@-[(P=@K)'"F3D]R0EO /Z'('_755?Z/_+/MV[]?,8HG]7ER^[GVBM16
MW"C2MT-WZ0@=)-3H];2D_A'S+4<JZ1G'401DC]>Y!RC]"A^;;Q/MMY5NL]E9
M@@!HB!AW;#&!EIQ6W/9:47X# 41GR1GWRH''Z\>NJ" 0\$CS,DG]L5H%N9+]
MV\XK('2K4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI3
M2E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI4.I.<9'?!]@?8
MGL#R."<Z5!(&?SUVIU ]OUX.1^8QD?J-0[=?8G["IKC4\V@=2E8 SG 42,<'
M(2"1^9'W[:LE)4S!WQM]2U5*TAW+-F##>0^M4W,O:U("U-2*[!\]"BA4:.M4
MR4E:24J08L-#\@+2H%*D^5U!7! .LJ-/>6_*@ENZ0?8D$^E:Z]9I[?ZKG=P"
MJ/\ ]06]6KPU7Y'>4I-,HE>J*>Z5&GBFLJR>,+J[D%S!X.>@^^/?,G0K)^?Y
M8G!:7PY>9C ]A@5Q!#?*ZGQ!3Y200'[SG85U%W)=CH*H]NQ8PQ@*GUI)7CT)
M8AQ'FU8]@_GMVP0,HTMA(=5WJP"5?4$%W?;![36!6KOF$(!?_>IVZ0"D&6G;
MHV.J)M^N]1<GVW&S_P"139[SGN"7'IZ4$C '+>/MC1-FRQYG?9PG;?(C(.6K
M'<U&M9D7K0,2$J/T(;S&_85-F\'/_N+HPD]TQ:336L=\X,AJ40?8\X[X[C4I
ML6!EW'=\;S)&78?9J"]K _-?MK&X""DD-@%VG8C%<#E-K#Y'G77< P/_ ,*J
M<PD]_P#R(31!^XP?48U?DL=1G'*H='V.9[O4&]>B3'<&6Z$CU..DFI?V+.QT
MJN:YW <@_P#\D$9!],I;"A^8Y^X[Z<MD2&)Z<JI[2U2;]XPY8[N']L?VJ(H3
MN?\ _(+G XY%9D#^6#G^!_=J.:W_ /B2V6:!Y3/YFH"[@GXBO*/>!^]150W<
M'%P7/R1Q^VY7.2.>5*&?MC'W[$2/A$L;:4C<\N/8OGIUH;ET@_YBO<?P?WJ4
M4*01A%QW.D\<_M9U1R.>RT$'[\?EC5N2V0X2GH&#/G_N)EY<= 6J@N702ZU%
M\@%NW0#ZCK3]A51))9NVYDJ].N8RXG' (PXPL'[>H]^^H^';P4 CMO[_ -ON
M]S=NM%Q0^K>CUS(IUPM*!;NZM*(_\]JFR$GUY#L4CJ) &<9 ) ."=!:LS\@#
MQ_.!TGTJ#=U)'_O'_P"+=>A^E3N-7CD%JZSP1@2*13'4C'V:894/7GJ['!],
M458L[)/OV/?V_&E-_63_ )Z!#_-;)GI\ISU.[5$/WX@$BLT20H#&7Z,^T2><
M?^!4!GN!^$ ??4#3VAE)^A/U(^_M4_'U@G^HM*G_ /&H!L^?; 'K1%7OYA14
M_'MN<#CI#3D^ H8'/4M9FY*B1^%("2"2%9&(.GLAI+EV!:7V$$1L[= ]73JM
M2(6JVOND+ ]02#Y-OE@:[*+LNA*C\S:H6D* !@UV*^2D_B(3*BT\@C P"M6<
MDDC',#2H)<+2W_B3[L.\0TXJXUMP1R'L.=(?JS.?=VKE%\^4<S[<N2-S^-$&
M+40![@4R5+=()&?_  \^N!QJBM(0W*0H=>8"=\GN"6]NMTZY)A8N)+N Q40/
M01EI]S7?:W$M-)2B94WJ<MPCI%6IU3I@&<  KFPH[03D$ ]9&0KZN#K&K27Q
MA#CKS( ^JAC>LJ==IY=9$RZ5N(&1ROMNU5#!N*@U,XIU8IL]0[IB3&)"QP#^
M!I:U>OM_(ZQ&U<#NA0;+C%;"=197*;B52T.Y.8#.?05ZP<0KLH?KQ^G..?MW
MU1B-C[5DYDG<>L?>IB0.Y _/^OMJ*EQUS^/Y=\4!!) ()'<9Y'YCTU!(&34T
M!!Y&I!>12HZ4II2FE*:4II2FE*:4JT.[,7SZ4M0 _P# P2<<?4L=CSQP>/S]
M-55^D'_2"#Y8V9RX)]O(51^5;E@"TSD;P^.GX=-93^R/$7=4?IPFL6@VZG)Q
MYSL):$ \$<I2G@G!^G@D8.LJ90IB&_X=LSV8-)KH";*^Z7 ZS[;_ ,&MHFQ$
M\KB1!ZJ91SU# 4% #(XSP<]\X^W:B6^8.,^Q</V<.<9\R:T%PSP02/H?XSMF
MLKM*M32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4T
MI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5QEUM*NE2@DDA(SP"I78 ]
MB3G2E<$F?#AMK>E2&F&F_P ;KJTH;3COE:B!QZ\ZL$J5@$U15Q" ZE!(&7<?
MF:HF7?D!:RW1HD^N+ZB/-AMH;IXXP JHRPS#2.K((0\MS.0 2<:V$:2XH!1#
M SL[.SMON6CWK3N:VTE3(5S$=,3NY!'6>QFO&=EWE44 "33+>:/^!AIVM5#I
M)Y2N3)7%CM.8X)2W,0,#"E)SK81:LH+J 4=G]MH'=X,]*U+FHNK=*'0#T#EB
M' ^8N>K@OL:Z2K5CSE!5<?J%P<^9TU>>_)A^83DJ12$K:I#:?5"1!ZD# #Q
M!&3D0Q4D %1)9BP!P )##]\3&![BB M:E  ?,5%\!VW8RX)__8LY]Z)!A0&P
MU$AQX:4A(Z([2(S)PD =33!+>1Z H< ]"3@Z%; )=FZ/&[X'T+C;<5E2FTGY
MB0HD""D[L6.7R9>3U:NQ@D<E8//"'7&_?L1U8_4>OVU8K21#$P[I!G?:>L]G
M,UB DNX#P 2'#>K-C]FJ<D8 'IQC)SZ')/KR#_ XUB6068X?K5TD#) +AG#]
M?[;[5+J"SL& /5@1C)]/-GW+FM-"&?S( _XGHPZR6Q2G?5<4J/X1U*X2GDGV
M /.K)!?&#/YVZ5+&8QFH^:V0KZSTISU* ^D #J)4K&, =SP!V/?612TIR6]_
MV_/>I2E2L!_S\^G6HI<:62D* Q@*XYQT]:3SR4K&"@CA7(!)U.4N X,='EO.
M,EA&:<IYN4B>G_'G'79Z\RI5JC4CRC4JI3Z=YRDH9,Z9'BI=<4"0VV9#B MS
M@CH22H'&1G5"H)/02Y).?KTW^@+F1;47:6Z2_P#%=B%/@U1A,JGS(DV*M:T)
MDQ)#,EA:VW"TXA#S*E(6IMP%#@2HE"@0O!!U4K2N 2EWD26[C9_^.M/AJ=FG
M8;GK[8.U=D="@2E8400.E/*CU8QTI!R0<GD<92H=TG3E3_O/?)?L3.6\]]S3
MX:^F<?3TW?R!.U2E;87T=14<9/2DJ2!@$=2A]()R>D$@J*5].>A6'*G_ 'JQ
M/=S/W.&,[M0VU .1V[X?&?R'J"G&TA2EJ* @*4HJ20$I3W423@) YZB0",'.
M",SRI)/SJZL51VB'[SU=J@(47@_G3\:N!B=!E0VZA$F1Y4)YH/-2H[K;L=UM
M024*:>;4MMT+2I*T^6I74@]2<IYU7]+LHES.6#3'UEVVJPMD@D[-C;J_]L5R
M09L.?&:F093,R(^A+C$J*ZW(C/M+2%MN,O-%2'&W$*2MM:%%#B%)6E12I)-T
M+#2>A!8[O]^\F>]0I#$SAQ/;/GU#;.\BN<H;5R2D$>A"B2,\X7C(^X'?OZ:O
M\1C!V\ATPT^QZ]6KR).2/J_D' [[^E0\MO)*2!GVPC/).,I3YA[?XEA)! Z=
M#<<,2XR ^#)=B0 S1&\.X:0A#"6\H?SW]SEO*O#FVW09ZE*F46ERU.<J6]3H
M7F=6<Y\X)Z\\@@J'6/\ $L\ 0FX'93$&9(.3N"Y [/GUJJD,/D?_ /7J[[$!
M^I(+[8:NFBU($4 4V77*0<@I33*]56&$9'80G);U/^^/E.?\6>-74+1+$(9\
M$9EC!  &7G:-ZA*[B064H%C(,XW+E]AB/.:[+;5W1EI5#NIQUM (\JLTB!+*
M^^$JD0/V7(2"0/J*WB >02#FALV%3\KEX&.S8$;N.CFKIU&H2".;FW!4 3G<
MN3UPYPPKLBXKQAX^9I%.JF"2XNF5%<=:DC)ZDQ:B&VT'IQ]"93I)!/4,X&,Z
M>S/S'_X[G =N_6-YK(-9?!_2-RSG'1GP_0!WWS7H1MP(#(Z:K3JM1B%=.9<!
MYR+GCD2XB'H:$@]\/%.<\ZPG1K,I(8^C>Y^XK91KD,"ITN'8@J/T#_7]ZJF!
M<E#J20854A2E$#*6GVRK)].CJZL\]L9^VM=5JXDD%)#/TV_,UMHU%I8#+#L[
M=NM>P'6R 0K@]B<@9YX_,8YU1CTK)S)Z_G?IZU,E:%?A4DX]CJ';_@G[5:IM
M*4TI32E-0<'R-*M_N''+E&=5TA20V48X')R0 .^/UU);D+L"W\!AM^0^V&X[
M@[-/H_\ :M+NYK:J5XAK.EE/TU2E5JG*)QTK<0 I+9)X) Y&1CGOP=6MN;:B
M^003N6V_N)WKIV@3:2Q+,3). S]YAN\]*V ;!3/^7BI!'T+]3GG)&.3_ .D@
M]\#([G)H,D=GZ=I)C[=*T;N%>8[Y/;\&^#6<"3E*3[I!_>-28)H) /4"IM*F
MFE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:
M4II2FE*:4II2FE*:4II2FE*:4J13B$GI4><9QW..?;MV/)P/OJ'#@;G^_P#%
M*\^H5BFTME4B?*;C-)'XG#@J/HAM/XG7#Z(;"U*.0 2#BZ4*46 S_#UB7>1;
M?F)@/ Z50\BYZM4UK51(:(,18"452IMJ#BPH#ZF:></*&<@!XLI.,J R,;2=
M.D)>YDDB"X[&"._[S%:%S6+)/(!R_P#=!?<%+/#;UYJ:!'DJ2_69$BLR4J*^
MN<M2HR%YX\B @_*I2D<#S4NE('TJP!K8!2EN5+L8<,\G)[SU[S6NHBX"5J/.
MK(DA+0&W, ?WKVVVT( 3V2D80E("0 !P!CL/MC ' QG4FXLN$)#'+DGR)_L7
M.U5Y$ _J=L$#E^PQVZU$Y X'/MQ^OV_C^_6-0YI)+ER0/5P_0]@/2H<"!AF\
MP[S]O*ITK4  0.V#^F/Y]^/RU8**0 V(]H^F^:A\]_S\W^M1^GN>2?3D#)[^
MFI5@0Y.SEP3)@?SZ5=(1_J+>A('[_GK4FL;$G8P^9[^N8=ZH6<MAX\J:EOL_
M[_::4T#;MGH2W?H>X^AI35CL7!;H)G<]&..YI41W'YC^>H!;]MF(D%R._MG:
M@R&J9W ;42H)3@E2BHI 23]1R.>!G&,_J=646P9DAV:3]6,@/[XK*2G!+@R<
M8)..K&6=^YQ6C#Q@;H?&?G;G[IQ/")M%LM9VRNUT-Z71[PW,J46=<6Z*(, U
M2;)HD$RF!3F"AA<9#4SRTJ60%.)[C3NE9.&&<CKO[3[5T+%NVH#8XQ@>T]?2
M-J]CX*'Q*=Q/B*;2;J/;PVG1+6W3V*O2F6;<\ZV4NLT"Y&JW!ESX$^)'6XLP
MYL)VEU"--BI>EMI!8DMK2A:<YK*R0$JG?$DL3O. S0*PZFVE(<.%1/20')R)
MD"3(.U9[>+KP[,>(6S=OJ*Q1K?JE0M+=?;V\7%U]/2U&MNCW!&J-TPXBBLJ\
M^J4IM^,ZUEQJ:E986G"M9;B27:")'4R']G9C 8=VQ6E)*0HF&:'AQG:8!./.
MM7J? E\0&RZVQ2=J]_)-H;62-QGKOJ5JTN[FTOQ&)]UU&:VW0')\93%.I,:D
M/13.H+JW&J@MU:4!2D :UN6X%."&,F=^FS.W4C]MCGM<K,>;KRG#='+]7.V\
M"K\;]>&CXA%X;Q[QW)MEO^_;5HW'9UIT7:AINO1H%$L>NPY5BIEU6L6Z([DJ
MIRZ35*-<U7<;BJ;CW"Q5G*++=9;=:6U9EOGZP/O_ !L-A4!5L)9O,$3+NS;/
M!V]36/5P[ ?$ZO6Y]R8-G7Y6[5;H%KV':$25<^YCZ:)<53.U-GQ[D?MAN-3@
MXJ0U?J:O6G+D?=:$F6Q)IJHJ$.*<!KFQ'KT&3B8EG??-62NR)4#/1/<P0_F!
M]PT5=<?@_P#B85.G"0CQ 2ISU6I--I%X6\Q?ZJ33JM1H5(HT:7$H<EJF2%6]
M5JA4FJC*DU5M+I=8ZV"T#)!1/+<?]2=@99G\G$;MY/UGXE@8"SN"$OF!&2!C
MSJC["\#/Q(;%LVIVF]O>_+M6+;>V%N46RJ-?C=$I;UJ46304U^V*;654^74*
M!<#<6)6&'[H0PJ/6X4R6PXA+LILL@%N>8IRECS1WVCN6])>H4NT0"'#O_I;Z
M>O5X#F*VJ^"*W-R[ \/5D;6[I6J+;KVTU(H6VD*<U5V:RB]*?;%KT)AZ\&9#
M2E+9A5&L.5>'"3*<\]^+3$3G$-"4E.KI=G)VZR<PT>N[21BM:X.:$@ EQCJT
M8G:7W?H^7*%!><9R%!!&.>KN1R0, ?5U9Z<<@G4@ [C_ (S_ ,!SY5B^$1GZ
M?D3VJ(4@X^HC*ND93CZB">G.<$\%.!G*A@:OR'\,[]L?5I:6JI"06).?;L>_
ME[5.%(Z< '/<A0&4D@'I/?! P2.>^/34&VDR200)8G$MT[O#^6:<P3"<9G+^
MGE_Q4ASZ8S]]8RDF7(#;/Y/T;;&:J2Y<]&C\-$'_ ##W[8_3^LGTU=*4@9+Y
M.3&)_?$4<#8'W_.N(+]JF4H''2D<#&5#D?E@<<?UQC64%(=R8RPGI)W+M^"H
M+[?7S_COMTQ(4IY[G/<'. >.>#SG[_PXT-TAF B!UP.H/X*CD2V<[3^T=<_V
M'DRZ'2IJO,DT^*X\"2F2AH,RDDYY#[72[U<YSU@Z@W"Y9+."2#.=P=OW,1BA
M2&#*+LSAP1A_-ZZC=)JD(YI-P5*(D XCS%)J<0^R2V^4O=(' _YA7'&!J.6Q
M<'Z64'<,X&,.TN27^]9$WKR8"@0& >"0 P>#MG[YKTFJ]<\#_P"[I42KM)2D
M&13)/D2"4CO\E(!0#V.&E\'CD '6 Z8%1(,' )[O)CRS_%;"=7<=BD$,&8D%
MX[,D9F3YS7O1+[M]]Q,=]]^G2B!F/4HZXBL\9"77/[AP@^C;JB1S@:UUZ>XC
M(>6@CS_.NSUL6]?IUPZDD0>9) ?=C+A_>JM;?:=0'&UI6@_A4E04%?=)!((^
MX/OK$H%)8@O^9Z=/,BML*20X(]Q4WF)SCD<XYX_GW_345+RQ<0_U;:I]09!'
M4&IJEKP;#E&>!]#G.,X^E7./<>FBOTGR_/K6.X"P8/\ W]_M6E_Q+QU4O<?;
M&M='EH:NQ,%?( Z9J2G)QZ' SWQZXU>T#\,@YEAL#YEO?&(WKHV"3:9+O D[
ML8?<1,@^]9=[&2RS*6SD)4B6IOIYQ@N?3TGC_P Q.?L?3UK^DCL>IS@>8_-S
M6C>9*E(5D]('4>I^_2M@\58<CLK'JVGC[I'21S[$8SZ]_72@@ './;\>N?2I
MII2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2F
ME*:4II2FE*:4II2FE*:4J&>0,=_7C'Y=\_N&E*E6XA&.HX)) 'JH@9P/<XR?
MO@X['4@$XJI4!D^F^^WH:MU4KM<GON,6REF4AC#4BNOI<528CJ7%)<0PIE0<
MJSJ""VIN&L1VGDJ;??*@MI&S:L<P<@2H@!Y@.2V&'5QO(,5J7M2$E@2 TG9Y
M PY,PPSN"!7FL4AOSU3)SSU4J.1F3.6'$-*X)3$B@!B"@9)2A@!82KZG%*)U
ML\J$'!P^S=&[_3.,OH+N*7]I#@_5_8QUB/8 (.1C//(R#SW[E7;T.<^Y.I+.
MXCIA@?1^Q@0\F15';!8MF?;<G9B?<P:FU4M+8?\ )V>=R_2HIJ1EAOGL[[.,
M#S;8X=34 ]>X@9#=1W ]]P]*:C; [$Y.=BXVVW9C2FI<M!:7;TRY[8ES]U-2
M#B6EWW/GO@ENO=X4U#Y9GE@S=,3DSN>FX%*:D@M#L>A)&3'??&27>0*"2!UJ
M8H(]1Z^OM^FC!A(,$$3.[E@X:/09J6AW!\G_ (CU:H#N/SU&\;/TDDX!&=OJ
MS5 @@]*F40I)3TE61@# /5Z 8[9/;/IWX[!)\IVQ&"P\F+0&80PMS2,L/H^0
MXV[Y P(K3I\1?P3>,?Q:/U>7X:/'=7]@[318E4M2M[64NG/R+>N*LI0\9;M<
MN"DU5B33$3&5F!-S$DO1FCUK"TDMG7N)<@NWKWB"#VC#_7I:90 $3U(D >>W
M4=.K5K._X9C?&DM4/Q.>#^1M?:]JWKL?<L6Y+FW&L\U&<=S9,VMUFU:A-NF7
M*DSW'ZS3I=)"*.N(Y%AN4J6Z6X"5-.'2T3MZD!B"7?N._HP#U35ORDRSB.P(
MG&\8D--;Q?')5?$Y;E)VBN;PVL7=69=&O^6Y?MIV;2;;J50K]N*MFN-0H\YF
MYI<>&FFIN(4YE70EQ4<J$Q;#[3:D'.2H!R[1GN?^"_1Q6*PE*B$J P>P?>6P
M^,=F=CKJN;Q<_$PVY\/E\;R[OV=1=N3:=JT2+2J15;)M^7-K-UW-?;]&9J,V
M9!JDB)3%4&UF$S),>52FZ9)>EI>4TA"4L*QDJ<P&V?>6?9@(E\GIC94A&Q)E
MG#OU;?U'09.*X*UO?\4C=6T)E2V\C+-DS]IMEK\LJ^;%VXIM-N._I<FI;75>
M^)MN?VHJ]/-)F269^X%(?LFK4MOYRE1(Z8CS+DE$Z34DD/'1]W;^\;C?=\;)
M#0\$$'< D 0_GEO>LCO$7O%\2"W[POV#LEMX_4J'!N?;:#:]2E[=6]6:8NP*
MG;M(F79=SKK=VQ*[/O%JZWZG1JG:2J9%C46A1VZI% <>9>6=9A)#ALOT.6&=
MFZ^1-62$0_T,P8'MN3N>U6+MZ@_$GI]L[^5B0]NC2*](W2VHJ]IIC/T:JKDV
M.;A97N#"L^B5VMR66HS=->6I5-?D-3Q!85&:6I0452$WG(#3(G8N_5@S #N^
M[5//:2Q<=!YL&]7+X]:ZVU&X/Q?;(&R=AU>RT5^TWJG:BKMW"NFSZ97;D3#K
M-*MN94;9KB:==J'_ )>F./W3%F7BT2IJJPZ>7E.1RS'G/G1^IE>4MU<" 0<3
M&]#R*[,[-T?&)?+=:JW<GQ$?$_VHH6U%<J-@1K@IDK:NY[YWLN+^Q%KT^W+%
MJ;J*Z]2;5$.'6WJDJLVHB-1 _(C27X%P(F%U$1:2^AB251$RX<>0[G]]JJR"
M6EGA_7MN^^V^U5/X8?$QX]KWWVVBVXW>MJB4ZR-Q+5K>Z+U8JEFT>V+G8L.@
M1X$-1JM'HM9JL*DS+DK559?H:GGUR?V?3'.IAM]]0$!2G8@C<&7R>NVP),9V
MJJPD.Q+D '<>?:,G'E5[O I=GC-=O3<"R_$;9%:H^WU HD:HV'<=1C4]"#69
M5<J/S=)E5MZM5>JW+.^24S-;ELO)I<:)*C4L1&I=/DI.<$D$$D$9$$LP?RV>
M?1R"<*DIR^XR0W1P'[MYN\S6SP)*,I/3P> D@D @'"R#TE>22>E+8"2D! QD
MPK(;_:&@]\;]Y]ZUU@ @##9ZR9J.H]'[?DGT_:JTU8@!QB2^_0CH6S+'&\4I
MJ"&R6=G<N0&P6^D=':E-#Y #:)(V/K$GTWI34P' <N^W1WD'>'[3V"FJI<$Q
M))+ Y#OT.WN-Z5,$X&2,9QC!!()R.I)Z0<XYQC()[G&=9]IZ,VWEY4KHR8<2
M6V6I3+4ELY'0^E#B.3R5(<"^H\#L4\@:KS@Y8L_5V[%@WIF')K)_E)8I!R"0
MP#D8W.)P9\J\UN@K@K6]1Y\RD+4K/DQGE.P3QP'8,DO,*R3D^2&#CL0=0R"9
MY3E\$]@,-YER-JJE:TETDA]@3,N2<O.P8":[S%S7!35XK%+:JD5)!-0HR2B2
MD#DEZFO*4I:L8R8SY)QA#2E$ X%Z424$>15/0;EVZ/[!GV4:PLRPH_\ B"SO
M,$[=P'-5A2KHHE9"Q3YK;SS./F(A"FYT7.>),%Q*9;"L@@)<93D\ DZU3;4(
M@^1_/K6[;U"%LQ$[2XEL3Y='WJ:N>7)ISS8.0I!5@ J)00H=2 G(4$]U$$I1
MW64ZQ+"AD0#\P.89Q/YTK,% X?#[?S_;O6FKQE1E1F;?J@24BF7C1'0H@ @/
M**,CG_#GZCD=NQXQ>TH*=G\C]_S^*W+"_G0E)(<ANCCK_P %WGMD%LW,2*P%
M$_B^7?([#^_0PLD<CT:2?09)_/5;C?-/M,_\_@K7U27N@,(P_;'GF/>MD-+6
M'(,=0Y^CO^9ZO7GD$'GG2J='R>G5G_:O0TJ::4II2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2I%+Z<?2
M3G/8@8 QG\1 )Y[#DX.!QJ'P&,O]/-J5Y=3K,&E179<YT1V6T%74H K4<X ;
M0DJ6M2_PH0E/F+5A*4DD#61*"H^LN_KM[]*P+NA.8Z;GS[0\^QJWDE4ZY_JJ
M0?A4)0ZF:*EQ;$BHH)RERLNM$/-LGA;=.8>0E0(^>*\F,WMVT):>LX\C+B'=
MX;8/!K0NWU.PCMT\^I]B#]?7:;;:0VVVVVTAA(0PVRA"&VVPD("&FTI2B/A(
M RVD@CZ2D #.: 62(:7G<]26'5P^21M6MS$_J)@EF/5F[#$L[UR$Y[ # P !
MC]_N3ZG527+F/S^_8&H/8 >7W/4]34HSCGO_ %]AIL 3_8$.#O'4"3WAE1T(
M8=<O]7;R?(C!:":4T$$ D@/Y$,_>!,^O2E-2[=]]P&AMO0.(+$-2FC[ -M[Y
M<EV+.^''D!2FH@'MF-]L#[/$B'8*:.<=!(/H(WD9G$8 I34ENI#F?5H)>7$@
MGN^[*:B'#.2[3])!V[%L>LB"#T(KD*P01R/;^OYZ':2-F!PQ@%S\OJ[?0"0=
MSAOR8':>O8<>@$LQ=IA_H<>Y=QL2*BI5#J21@'(/"@"D_8@@@CWX/&@#$1]C
MV+=2^/L:5HJ\3_P,K,\0&[^XN[]D>,3Q2^'N9N]4UU;<JT-O;MD/V9<$V0RF
M-+<CTENIT'Y%#[ 4VJ/)<J<=(44MMMM*6VK$NT5%DL\P3VCJ#D1A@8K=M:I"
M  I*BT1R_N>F[O6:'@#^&SX=/AQ6%<EJ;(1:[5:Y>TR%5MP-QKWJ#=3NV[:C
M2FGFZ89;K$5N!3:5"$J8N+2:?#1&BKE27EB;,>,M-K:>0]68%LF&9X#Y8O/H
MQI>U N B1TY@&$O,F.TQ'>N]X[?$+O!X=Z-M)7-JK:H]PPJYN#+AW]"J2Y J
M+UH4>VJY<LZFT ?+2(4>I5A<!J$BL265-4Y;_DM-2 HD6*G_ -*HAGB&?K,$
M!C)!<"6M:3#);F,AW&\C#,Q<AHQEJQ.W*^*Y6+ 0Y1KJ\,WDUK^P]%N*50ZK
MN3&\ABM7#1*7<%-AJ4Q:4_\ ^F)S%5ATEN]%04T]%RAZFS(D>+'54&L94 2"
MDCS /D#.TX&3[91;61^L-+9W,D1!SU [Q7.U\5VZ958O6U;8\)]PSZI:U\T'
M;R"N1N#1Z/0JO5)=)NR96)[DMN@5)^-08/\ 9AZ3;M4^3EQ*_3I$6>U*@2OE
MJ<F8)$2)Q,PXGLQ@N(P:M\(@$_$!$[G:&9B>[%V(=SFN_NK\1/=K;K<VV*NC
M:JDU#9*\M@MG+ZH=)K5<5;%7BW?NQ(J]1?<O:\I],J%-M^GTBF6_+HS%)B0J
M@:I75PPI]@SV#%ERD0ES@,,=]F]-SZU3D!CG $P"0^ 1(,3F <L\5="#\16X
MG?"]=/B=JWAZK5"M^F7_ $ZT:';E8O.$Q7:I1GY##%7NNK1$4.7+HC%)?=4A
M%#A0JY5*DEI#T6.MIU2V@N7(/*7!A]NC[OD$QYS4"RDEN?9R3]0(/0/BL;%_
M%TO>TQ<C%\^'ZFU:J6W=-[Q!"LV^GXM>F6]3[GNBAVQ^RK<K%MM5NNU6.U;B
M*QN$N/)AQ+:MVJT6[T+?1/A45,%9,*! G;;>"P@-&/O5TZ<$'EN(!A^8GMDC
M(EOFR\'K46Z?Q?D;0UDVK?WAYJK%R'96F[HSJ?3;V?JM-H5:K4"/5Z795:K#
MEJPJ4N/*HTV(M-0HJJKT5 +@BA(=95*512PEOE47!=@S&(=WG+Y;/2K&R0(7
M;,EI42!B8)!\N_2K_>&3X@E0\0.]U*V?F; U6QGSMA"O>IW@;IH]=I$"94&V
MI+-%IBTTFERJ[2#&?9Z+@@M%M%12_!7$CN1UNFR5!18)7F<=>O,?3;(:L2T<
MH@I+/#%7G^H0W[O&:V9M(6H$JZ%*R/[P--@Y)RXZGCH\USE2N%A+A4CK6$]1
MV0&#,07)@[[ NV-]MYP=)9)5DL6=\EG<M SLP:>M<I!!^HDJ/)4<95Z!1Z0D
M9( S@=^W&JJDB&#-+ P_H'EO+L]07W+Y;.'(&:AJH#$'9PQZL9\ADR(;-131
MR?3J9R.[CT,3.32FI:1N8<"6&)C: 01/7HII!)+EL[ B>\=!&V^U*:AB(V</
M@%QT):=PVQ\Z4TRP9X</Y8@R6 &V,32F3[_;]/;4$K<RV6_4)V]!O@X84ITM
MGOU<]\>_.<<C[?QT;OL^SA_.#MW8XJ?EZGV'\_G9JD 6/4'^OR]=589Z8DQ]
M?I5F4?V#L^"Z7QZ8PVU<A#9 X5GW)S@>V,@*SV).._8XUE"_Q^FS-OMYL_2K
M6R)"CEL;MWZ#.?V\J?1:;45)7(CI+S2NJ-+94[$GQ%]^J-/BNMRF"% * CN,
M)4I(\U+@R#"B@DE0) (B&($M.QGKYBH,-R[8?Z.V&Z!@\D&N[2F*PA$J)-JG
M[4IXC@QC,C-?M-I: 3TN2XZ8[$A"0!Y;JXB)0[NONK'6K%?MH 2M((YF<,SN
MXF<0\88$/D;FGO+42DEVZL1'S;@=6G;M UH^-:D!VR+A>2E2E0'HE09 '*51
M9#2NHXYZDH*L 9 )[C&=:-L,LC =FEX#]^KR=L5VM./\RTN,@]\=QU'_ #7K
M;'U-$D6_*0I)^>HE'<*_\Y,1+:@2D?B#K2B><8/!)*@%T_JQ]NGD^?L)%6U
M>[SG&68N<]<#.3(D0P&T&VU%=)862%=7((SC\*,XSZ9^^/;[NFT MT<.U8"0
M3$=CV<?M]Z][2HII2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2FE*:4II2FE*:4II2H$X('OG^'^GW]./?4$L0&)?Z=_J*5X%
M=KL.C1!(DA3BW' S%BM)#LF7)6/[IF,V,J6XKGE((;3E:\(!(RHME1?89\WP
M?NQR,5@N70D>;A@<SM[?5N]4.Q%E3Y J=<2#,94?V?3PYYD6E#&/-0?_ ,TQ
M2#@OK"DMJZTM ?B.TE#,7,98@ ^_4#U;K7.7<+N<[3 'W?+&?**]< #.. >P
M' [?S)SD^IYXSC69H@0<.P)+Q@N8=@?K%8"7+_F!N\_A\HZ@-+$A\AF;J?(8
M;<XVJ*:J_OM@AOY].^:4U90(;+GRSV;H_I@12FHV&YA@P8#YNQ??IUEJ4T@@
M R8Q,-@"-\_O2FHP^VS=>H],]BU*:GOW^7:!+@98[-UZM2FA>''?N0^[OTAZ
M4U,$N5#ZP.T,?X<SLIJ&V(8^>>D#)>-V<](4TZ ,>AQ/EL>Y<X+]%-#N[!HZ
MDGO^_3SI31]V/9CT';H.C#.T4IH ^\B7,-/KN>WUI34?=_/^QI7#(2I;+B4J
M*5*3A)2DJ459'2E*4E)45'"0,@$G!XSJX/+)8L02&@3,X[''0&*,5 @9(+??
M;KCUWP<:_$AXD=G_  W6W;-S;OJ=-(NBZ:?:=+5&I\>IOM5"K!Q*9@BO.ID*
M@MI2ZF4]';6ZA"E)4GRPHZA=T,,AB,;Y ]^_<>>Q8LER09()WW)GT9C'GUK!
MS<[XI_A-H-"OPT.S*W?%Z4"#+C4ZUZE8S$1%RT:E3DPIU014YJ'$?V0ITM!^
M9EN-%EET)2W$43U)Q<_,1US]G[,7R&/9\[!MJ,$ACU9P=O?L.VYJNKJ^('L!
MMKN7>^W-Y6<F'=5&39)9J-!M1NJ4]J%7K=V^9I,^\JHU%0:7"AUW<^W+9AO)
M$GR69S#K+2"74ZM@OF,-B7W8$EAF&WDU)M*(S^$$>I:"9@022:DB?$L\*DMN
M%;E?I-7J%V*L/;"XZG1J+8DJM4(56^Z%;MR6U9%.J[L=J#(JZ6KH@3*5#><C
M*0Q)4ZRA*D.)U!6 7Z,-ND&8JHTZ@3S-).(P3/39BS_2*5IWQ/=FZW7:S;%T
M;/WC:U%@U2M4RF4RLVK%FU:\[RI%S1Z!3J=;-$94N#/FR9"W5.I?=8DPW6,^
M<I24JU7XH,"-I&6DSW(.,9.&J?@$""'ER[ #OV_G!:KZ;#>-/PP>)K<!=E[9
M4JH3J\JBW)<4"LU>PV(5,G*H\>TFKPA0:G(;<4_6J9#O6U6JS%!25M5&.PXM
M;:$H%TGXA\MRPS RQEAM&]8EVKGRLHCU@;>N3#B!64FY&RNUF\5K5>S]QK,H
M5T6_7X\:'48TN(&GW(D.4B7!BIJ4)46J,L0EMM+:89FMH\_K*<()1J>7E.'.
M82[YD@$P3UQVWHZDF2SG:2Y)D]F([/AJ]RQ=L-O=M*#0;8L.T:';5'M:EBB4
M")3H#:7J?1TN*>%-CU!\NU$1//6Y(+1DK0IY:G%@J4205/,$D'?Y"6[[CK#,
MQ.[U!N*+@GF9R88 X.7EIC[U7;1Z$].#Q@943U'_ -Q(RI7N??\ /5E76)<$
M&8>>O3?;_EL)'NY<'/\ ?SWFIUJZU9[:CF!A($0^[[^;OZYS@>SMW_M^/4NI
M8#((:&&\%R[_ -L"HIJ" \8&^7R?1\?7K2FA,J;W?O)&,QC:E-01GTZ 3(_X
MVI34J9X+^6.TN<"-NOFIH0T ^4,[MN^/I[TIHQ,F!N^V [;_ (]*:EF8 []"
MX?=LPSN,XQ2FH*2'Q ?TK(5]I:.Q8OO.S/WIHW< AX)&VS>?7T>L=-"(/_<"
M,=>K%@>@[=:D20.I%=^G*!>5_P"PHQ[G 'Z9/]9U%X_Y*8A/EL_TV &)?I67
M31=4=B ,L02-OH^_M6!?BOHXFV9>,<(R7*+42D$$DN(BN.(([GA: <#D8 &N
M?;FXJ6W;JXF']?3=J]#8+?"8[MY@N/\ BK">'&K"1;%A220":*8BP<$AV%,>
M9[@=^D@^A /.HN_ZO3]JM?F=X/U;S_!6W&S9 70F%'D)Z!D<Y*DI3@X[8("3
MG@8SVT&$G+I?[^?2M1V<]P,L[SOW)-5:% D =_4#G'&>=*D%_9_S^<':IM*F
MFE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:
M4II2FE*:4J!.,<#&>22  /\ 4GL!^\C2E>'7*U%HL-<N6%E/#3++(\V3+D.X
M0S$CM#EQ]Y?TI0DD!*5..%#25J3=">8^3;/'Y[U@O7/AI!DOS!AN1Z^?5O-J
MH2%%EORUUJL$*JKJ"AB,%=;-(C*)*&&>>D32CI$MU*0>M 2VI32BMS=0!^D8
MP6(DY?<%Q(EIV9ZYERXHF3\V#T&,;<T,6 (;H0:]@ #@#COD\J)/<D\9YR1P
M,9UD,0Q#OT_4&9F[AL#W>L1;9\DSF6R?-_*FJ@03F"&Z#+^G;<B<BHIJ.;YC
M&0'Z-AGR_ETW&%="IU2GT:G5"K564W!IM*A2JE4)CV?)B4^"PY)F2W>@+<\J
M,PTMUTI;40A)(RK"3=22 YZ!PPAV;'Y@2'JR$A99VEL=VZ]?VFM#ER_\27\,
M6V[]=LH7ENE6J=$J3E*G7[1=LJF_9L>0R\J.\^T])F1:Y+A,K2I3C\:AK664
M*=:9=RVES7-X<W*Q)P_U[EO;>,OM#1J+_. P?]/]_K6\';S<"S-V+%M+<S;J
MX:?=EBWW0J?<MIW)2GDOP*Q1*HRF1!FQU@E20ZRM)<:<"76'0XP\A+K2TC*D
M\P\VWW/67+2?/I(.O<1\-7*[]V;]S59J3TJ*<YQZ]M20Y+#T':##=>[00YBJ
M$,2.E2Z,1MUD,7)$#H1$^M14X1G!SW_G[=_Z_?A$.3[!]FW^_D.TL.I]@?WJ
M4C!(]CC3!.6#@R)SDL,^_26J"&)'0M4_1]_X?P[]_P"AJ8 S([!]P=WW_<1-
M6*0!GT8/[/UC^TUQZ0\PX;JWD9&"&Z"#_NJM-5G\ QW;RWG>*4U(&2KJQAY[
M[]9ABS4J/'//Y<=_]OOS^_1AUP[QW;=MFW@F-VF.OT_O[_OM#1V=L$]''4">
MA\NI!Q44T&,%Y(C./+&?R52K3U)*3V)&?R!!/;'/'!]#SI&\B7#PY'F20^3O
M@=WJ1(D9SMWJU6YNQVTN]$*BT_=:P;9OV';U6:KU%CW'36:BU2JRRA3::C3T
MOA7RDD)6M/6U@X40<\Y$(4"Z6$9(,^K;9?(!P(K);NK1/,?KT\XF=V^]MZQX
M+O"O<'1^V]BMNJDIM74AR3;L-;B<RG9JT%P)"UM/R7EO2FEJ4A]U16M)(3B.
M5'21@L/67;:-_.LGQU'=0\OIOTR"\UW=P/"9L3N(Q>[]6V^MN)<U]V^U;]6O
M.%2()N1#4#^SCU#EMS9++P<E6_4+0M6HTA3R5ICR[=I#B@LQ$DBGH0/*?.(<
ML-XZ$8J1J5@,Y9@ S>O=I($NV[N_C4?P4>&FF4*#1)FU=JUTQ+'LZPIE5K5.
M;EUBN4BQ:73J1;[]9F\*FU.%$I,'R:BM/SK:FPAMX,H:;;@6TO\ -(?+,Q;K
M,$8#^3B3;^I40J<!V+?,K]O.9C>O6D>#_P -,]NK(G;,6.^FLA2IGGT=E2GG
M?-8?6ZE\(!COJ?C,OE]+K+RWT>:7%+)RY&5" 02T02W4$/#[ ].E6M7BMRM8
MMI <J(Y@); (?;K[DOBYN;OKX"O!37VV:7;MLP]RH$>O0XEI;86[&FW'&_M(
MW:Z:O%FJI@$2D)K2+3M9N>B1(:DNQJ+ 28RD,)&O5\'\%\:XTCXVFTQM:9)2
M5WKA"$LLJD)405<H03T(8DD$5R]7QG36EJMINBZI)(^4A(<   F0,D9R,.:M
M9!\??BYW16Y)V-\&%8?HC_5\C5+[K+D N87]$AM@,4]/DN-J&$A12.A/3C)S
MZ%?@[@^ACB?']/86@_.A*1S%A^GE3<4J#CF+EV#L6YYXEKKD:;1*6XCYG>7<
M**.5]B [#HQ?GF^+;XBMDMN52]_!O0ZQ2FBE4D6W<:US([0_%Y3+,V>M:BD\
M)+([C\C1'A_PMJB+>G\0"V3"5&WS!9.(4I"AY.=I)@57K.)6DFY?T*DD93S
MCKE(/8.T#O5PMJ/BJ[%7568]G;M42Z-@[R=D,PC"ON&ZBWQ+>6&VF57 U'0U
M"2^LD,NU%B-'4O*/FBH'&MQ/_#[BNFLG5:%5KBFF8J"[:@E82Y_T\UQR!)$%
MMGBITW&;%]1%RW\ @LQ7S2&=PR5 =Y[D.'V;0:C JD)BHTR7'J$&6RB3"E0G
MVI4:9'6D+0\Q):6J.ZE:5!2"TZXA:?PK*B$GPMVVJPM2+J%65)A?.Z2E<PQ'
M-(:3RG9A-=NV$7$<Z;@)+\J ') #OD#K ?ZBNV@E0R1T@C*<^H_=QZ\<D$84
M <@42"020&R\*<=>H</T+[U4AF!<$C!#?O\ GVCJ'!_3(?=@(V\BV2W,PZ3'
MX::2\L)D;"26;IV&8W:E-0S[X\SZXP3ZA\4II'5^N=GZC_CR>E-21)C=F.=F
M9OIVP32FI=60<-T:>NW[ ]*5'&1QD_IQ^_)U#*))Y2V1+_0@=/L.E69/^[_^
M34-7Y5_[2S%I=A#>S/MM,51QU'O4X03CD<_GG]Q U!1DOB6 _DG^*FA1CUS_
M  X'/?GG^O0ZHY+^I/FTG\QF (L '=S$X$MTG_C>N>"KHDM^RG$9YQZCO^?/
M]9TN'FM\K,P,SW..L]?3KDL'EN B'4-R&>'!&P#9&YFL7O$)342Z75&EI)#\
M60TH>Z5LN-$X(P>#D]LCCCOKGG_+4#D$_<-B>E=RQ=^4'EFV< Y;)<#$SG?S
MK7MX9YCC5L4:,M6%4FXZ_3L'T'S3*D#GL,EP!)^^#W&EP'E*G=Q[.';?;^>]
M;5Q',GF=@0^'9B_K'2MP=G29+EJK,)]MF6EIIQM;J"ZR"EY!4AQL*25(<2E2
M5]*@0EPD<IYFTGG"0"$N>699AD_3HQ;<UR[MQ@N"6*3L')(!QMO/3!Q53T.Z
M?F9":758R:;6$M!TLES,26T3@2*=*4E"'V3QU1UA,MA7"V>CI<5D79*9=XZ2
M_1G?^/*32W>"B'#$.P<?P['[[358H="S@I*3@D=7^+! )3]AD9STJ&1E."#K
M!NS>N1]/IUGL^W!8B7KEU-*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2
MFE*:4II2FE*:4II2FE*:4II2FE*:4KI3Y+,..Y+?6EMF,A3KJU=D-(25.*.2
M ,)23D]B. 20-62.8M5%J !D=_(_O^-5MX_S-9F"OSPI#2$N)H-/7E)@170D
MF>\V1@5"8@-K"NI2F&4I0E?2ZZT=M"&!]"8<M,;!AN\,0 V_.OK);_M!9BS.
MTQN&?Z[FO32G&2223@DD=U>I')X).<')!*@%>6$(1E#AQN[.\[N(,XB#[M6F
M9_?O^>_HP$VG5B.K8+9;#;") (Z4IIEAN>YR_P"^XZL7S2GM_']QU4AE#J!U
M$%\]0_HS3FE>75Z53*[3JA1:U#9J%(J\&93*I!EM-O1)=/G1G(TV,^E]+K09
MD1G'&7 625!?TDJZ<9;A)#=A,LXP!AVW!V!-9++!0VDAH<N0^23U((&(>OD\
M_P"(,3X4-N?#KM'X$/#YL9MJGQ$;C[BVK,V]LC;.QZ Q==I4IF1.95-0[0H2
M*Q%G75-FQH$=AY]Z34PJ7,EA26F7UZ5W+#/3LQ.V>D^6PKJ6OU$EX2,D'I+P
M('W/6M_OPWO#W<_A4\#'AG\/E[26Y=X[:[<1J?=2F'OFF8MPU:IU*XJK2XS^
M2'HM(FU=ZF1W4%"%,Q4%MIM.&T[%H, &W!<3 PXVRS]ATC0U'S7#!&9S W.'
MV<_?;-M7?G'8=O3@<?IJY_47)B0P8R?MMYEYFL"Y43Y?85#5?<] _7\EF?K5
M:GZ^ ,=L=CCM_O\ [_I;!$=/(MG( (@'I)<]+ @;='G/T;;[[L1)J(.\D[QY
MEY^OLYBM3]?V_C^[TYQ]_7GVQ+9+$9+O&88GK@&<NW2SB8DEW><O$5)IT<=@
MV006Z2,#?L7BJTU#'(WWQ,P&;+='P,95!044J"5=*BDA*L=72H@X5TDC.#SC
M(SC&=)8EY#@@G,CH7R[G^]*)!"4A1"EA("E8"0H^I">>GUP,G'OGG48Z=Y??
MMY=]MZ=/KWJ.K>^>F#Z$21(CL^:4U&<O 8;#'5AM(?U+.:4TB=P!T;?WZ=]H
M#TIHX),9<YQN>GYUP5-1U^@]I]AYGJ9I31\[_A_GW;I2I@" % %6,JZ1@$A(
MYQD@<=_J('!R>V9#8+DPPR7(C]F&S-YY+:0743"!S*'8=<?O6DSX@'CQNN/<
MC_AL\.LY^+=TIY%,OB^8"^I^AB<D(_8E!?;2L1ZLXVZ%2JIU)=IH)0P X2Z/
MK/@/P8G6$<8XQ;"=!9'.E"V'.4N>92BS@@8D"#\VWDN.<;91TVG44N>52DD.
M20W*E+="7+@[.SUKUHEHUGPU738U=I=C4G=F]:[F;==>N>&JX54Z?)E)4N.V
M])><7'DQ$.NOB6]\ZX^^XZH>7C74X_K.+:W6_P!+P,KT_";:E6N6T.0*20E(
M*B D*PLAS\H<.<#P>KUE_0+L7B]TWE+5D@ 6^6 D!223SR6!W9\9X5/Q";^5
MM"6Z"\F@Q2VE3<6$R8;7 /2A'RZ6RK"TX472M.,!"&_J"J)\-:$6/C:D)7J!
M*A<"2YW;F*F8AC$D&:[0\7:ZWI0=-_E7&WDI D!N4.X)?<&6-6.VU\2WC<-Z
MW+$O%4I%MPEK_9C[D+R?,"'0$MMO)6E<L.('*E])'LKG/,T?!=)JM7\"]8LH
MLB I"4H(C_<A*7\Y\\/H:/QIQ4ZM*=>M5VRHLH$!@'+D?*=H;?$XKK>**]$;
MR[;2857VKH=7OQ<V/&BW'$I*?VO 0Z'0Y,94V8AG]*@42&93A8"%E?02D!73
MU-OB'AN];5PZ]?NZ9DE=DK4M <D%)#JCE"6'JX$5FXWQ72ZM87P]2DW D!13
M\KJ!)4"!D,6)9G;UMCX7?$SO7X&[HMFT-SY<^X=E:\W%=J=NN//U!5IHDE+2
M*K;+KY4*>Q#0&ESZ+%,: E(\Q"$/J4[KI<2\-Z3QGPB[Q.QIK6GXA804%*4I
M>XNV!<^9(%LGF^*S\JBR1N&&[P'BVKTU^W;U:U!*P%,I3I*3', 00%@I)!)!
M+&6%?3;;%TT6]*!1+GMN>S5Z'7J?&JM,J,1:7F9<*8RB0PXA0/25J2XE)3DJ
M#G4E2BL$J^#ZBU<TU]6CNI5:7;4I*^8?I*7'60<@G.0!@?2!=3?";MH\R2
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M09!'.6'"<IP.4E1!(/YC//O@XUSKLD;2VSN,&6VQMWKLV  % [,1N9SDE/G
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MJCO"*DPR%$1WC_AJD9*5!_\ PRT+9>:)PL#77:=+C(C'=7[ 'M-;EFZ4P7(
M(<[LS0(!EG\MJN P\ISJ"TA!&"D YR/4GVP2 4GD')[$'6K+D;".[QMM[UN@
MN =S^?GW-=C2III2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:
M4II2FE*:4J5:NE)5@D $G ). "3@#DD@8 'J1I3\/:J2N:KR8D5B'#"/VG5)
M"84%/*@T\IM;C\EP#DL0(R7)+ZDXSY0;!2M:1K);#JZC&P/WS$=^M:M^X0D
M03V;:9,P^1@^3UY$&(Q3XK,%A9*6DK+SA*BY(DND*D2'5J))6ZYEP<@)!"4C
MI3C6XD!.SOL6/O'G@OW:M!2@6<_IB)EI.-^K=NK]A73A/3@ #   & .P/ R<
MDG)Y.=7))#%Q.^[QT#00^Q$QO19!  :#MY?F\>]2ZC&('=LB>G0]W$;L,=-!
ML\"6A_VG(S2FD; Y!]&Z>Y=\;S*GK^__ $_VU!VAG#[8VQ^;TJ4I!(/^)/X5
M<Y3Z*QZ?4DE)R",>F1G3\\\_7TJX60&9QM^_YVJ=(4D$)!"2.>YSZ#OGMG@
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M3.LSGS ;OW:8.!(=W)DGKS8K"UMP0S%SZN&]_1SZ5)*L_P"++,VRIM8>W 5
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M1&CAT!TI4X \&O. 64(*DI<2DE",@](U5(90,DOV+.=G^E4N$W5)7<9:DX)
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MR8S4=EB*RRIEF*VVE$9MAMM#:&TL$*8" V@("?+ Z?I(QC';T""A2$E(0@J
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M$*6KZU/.3G)KV!G)Z0<J4 >#SQQK]9<&M"W;LV4L$(LI2TM( _9^Q.["O@O
MUW%:Z_<)<W;EPDMEB4OV\HZMO6CV..EM(  QVP ,<>GVY_+!UV+C)N)*=SOY
M_A\Z]N4BW"<%R7EX'4.W;;%=E:% K5T$J*E8YQQUGCV]O3@$#TU*E&SI[]Q7
M^=<4M90D!BGF)($,/E(8Y.YK%<'.NVC_ $<J>8 3^D,01L\1N:W\;1*\'5T?
M#QLS8)?C$LCP_P!VWY657;OBS-I<ZJ7!7)<:6L4^WYBQ$:\B'!###B66GWVW
M4+ 6@I[_  _B?_J1/B2_Q97A^_K;5FV$Z4!5M-M 93J )92BP))#QU->VTIT
M1T%FTI?(7?*W_2&)*&.S!RHO,&KT?&QVWVRB[#>&&Y(^\5*?N6Q[ IUOV!9R
M:8]\SN;;D]=$8J-T4YU*$_),4J-'C2EH<*%E#X0 0<'5_P ,^(ZI/&>(VKNF
M6C^JU6JO7E%(9%Q$IT;,0E1<D* $#NU9?$NG3<T]E06#R(2 )<AE$*,"'#2Y
M.7@U\SG^_OVSD^O/V^VOOJ4)"S<2%!;$2<QT+[-/N]>$4HI2 HN,GS=QZ3OV
M\J:JSN <8&?,#R/OWJU0/')]/O\ Z?R[ZD AB,N&+1N\YR):&]A(+$'H09QZ
MU%(' /;D9'V!Y^V?7[G&A"5.X(@'<=>\C [[ 551)4%2Y,G\P1+$=WJ1FI2J
M+4:=682@F53)L:?'7U8478JTK0DDYX4 6P"".E6,8SJJEKMH41!2'#CJ0/WA
MMZIJT(OZ>[;OIYT*M*! /*ICW!!R7G.>IK<1L>U6=T+OV_KMF0GI[\F"BKR%
MM-N/M1DQHJE2 \6$K*"I]KY<'I"4+"E*(2"=>;\?DGPU?M(3S+NI*$OA(4JV
MYEV!',V?4S7F/"MT<%X_H1<(3;LJN+0G=[J5B29.02[L_2OH#\-.YL*Y[[O&
MV7"(E9MLVS-DP7%(:D?+UR@1I2TNQG%"1YL.H(DLRG$-AIM?D)SEPZ_+O&.
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M+HU,->N&F6Y&B5R148@F$U4GE!+ .!!P6;H001 ;KAI?9MW;B_E#E@6!9O<
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M-X#1J7/U!\\H'I^ 4U>!C(9LN[DLS=&P,MD&J5.A()SZCL>>,Y]B,ZD0"7$
M,W5B)'7N:D8)[@06R#7::::F1Y=/?^IF;$?8=020%MNH4PXDJ&% D.XRDA0]
M#P-:]PDERQ8L^.A8^F_VK<LP2D%G'4^0Z[GT%<UD2GI5N4\R3F7&;<I\P\!1
ME4V0_ ?*@,!)6Y&+G2   O@8QK7N.X?\P^=W=_(8K=L_IR^!]ZJW6.LU-*4T
MI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI4JSA"CDC /([_II2J%K
M"OVI<E'I2BHL0FWJS,2.DI!:_N8:59YR7UK*><](R,8&,J0R7 ^8Q/<QW]AZ
MUI72570@N4 *YG9GRD]L9CWJ+RU*==/5A)4G#9[) R$X'/'!SGDY^YUN(2P#
M@3ZN?9G<-,-U%:5Q1"BQ [!HRP] W?%<9&.?_;_$$_E[Z&">S_Q^=JQD#E!W
M);[U#3J#NVX&Q;W!SUR:K30E\P68^8W.[G!^[.*5.D YR,XQZX_/4]\ NWNS
M=V![;XS4@ Y+?GY_;-04 #Q]^.?TSSZ]_3&I(+!F.?-A+D[!B[0S@34J #,7
MB?S]O>I=001#;P^?I'M^P:M-#&1E\MY?P7(DXW)5$$CL=2"9Q D'<89V] ]2
M"1 W\OSTIU'OGD^N!_7Z:@OS.TD1RF6: \X\NNU.8]<=A_'_ !6.WB)V(3OO
M1K&8AW=,L6[-L-R[:W6L2YX=-C5EFFW7;<:I08O[1H\Q34>?#F4JL5N&\@2(
MKR"XP[%DLO,K4JIF%3$=>^0^X<@_L:V;-THDGL8;??T)](8L:PWI7PVWZ!5Z
M]7J/OA/1<-6WNA[\MUJ59,)V<N[A$:@U*+4(YKAIKU*EL_,KC-1XL-Z*[)/4
M]+2VVD5Y$A@$_4D.?7OAFV\\JM0595V;Y<=BSDML[#;O=:V/!.BE>'BE>'FN
M[JU:OT"V=SK5W"H%<;MF#2:M%CVK?%/OUB@34(F2(\V*_58;L=Z>I3+S,-TA
MM@N("UN1(<- [D]8$O[9]*J+TN&W]XG'V=^DS2E[_#/V0W%W*NS<&Y)-3?BW
M[XAZ7XA+NMNGQQ2HUPS:1LG4-G%65,J%-FQZBN@5157K=UU5+3K?[0JE;K$1
M]MQJ9*=D/@AH'<EV,;'#Q/MD&K#4$&"YP[""<Y@0,D]N]41%^%U:U.MFOV;0
M]T9%N6W4][*CO50I%"LQF%=%G3JC5I50%)MJXVZ^E^D(I\:0FD0*G"B1Q^S
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M23DI)/X0"E.< C&N;Q3B5SB/$0OAKHLJ2HJ1; ((EY4DF0XSO#U1*4"TM=Q
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M)4EB2!(( V&P./WKYD?B_;#OT?;BXJDU")8H-QPKEH;P0 $0ZE*$27'+A(2
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MPS1,#(>MJ/AZ^,?XN]CVH=%KE;IV[EIQ$M,IIM]L27*BVRA2B6(UP1WFYZ,
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M].H.HI-Q:AS$J+K6JXHR8^918!@!"885J:F^F]=)&Y:!L&#%_KTWJTZ!AS(
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M);@0X,:"W+6WYWRD=AII/HI2O,*O8<#T=W0Z8IU)*U?,/F^9@\"7)@MF7+,
MU<S57PJ(;8@1ZX'YAZL=U=7?CIQCD]AP >" .2,>@SZ=^J@A2EE('Z3 '8R,
M3/08BM%"U  $EB"!)$-AL'+]VJ<=P,XY)!QV*L9//!SQU$>F >PU8X8B.CN.
MH! ;W,OUJ6&6#_CUU0</=@ %9."#U#/  XP3P1WSJS<R2D03L,@].KN#W^E9
M[:B)?KN[."&,OWEXBM@?@$IIF7+N>U])>%N4J2IM0^HH1.>.0/4@ J /?MC!
M(UH+"0H())"E\KCN"$@QAP-@(]_(^).9&D<05<Q[#YD.0V^V0[,[P=F-&JE4
MHUCWK8,E"W:97Y40QF%1%AYN0F9'GJ?6^0$MH"&5% ]<=([C7SO_ -+W#XOT
MW%4O\.U<N*=X9=JXG8G=09M\2[]$>*;*_!O_ $@E[B$H(!+MRW;:B 2\D)/J
M)=VK>E\/.TW;=\/D)YYHM+K54JE10">>C+<=*QSGI44<9X&,<>OR_P#Q+U0U
M'BFZES_DI2AH(#@P!UZMCL6%?0?\/M*;/ALWI(U-SG&V !VGRK-,X!0/8')]
MSQQ^@&?;VUXCE^7F??W?ZO!ZUZM:H3;+ H2T;EPY/=M_^*CJH>6#UBIJ#!20
MXEPX['_GZ3NKNT].939'=)*A^@(Q]P0H^NFH@$=7=CMV&!CHW[9]-*P0^Q[L
MQS/><U"U^EVL7M(XZ_V["ACCDLQ;?I"V\_;KE/8 X'/ZZU[]-H?]JE>JB']
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M@ R-QN9!B!N>];&E YO( ]=C_;!;;!KCLY17*O%P_P".[)2?S#%/IL4<X .
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M,-!W(,CMU%*AW^X.<\_O_KTU#S+Q.<F)Z=W8ON3D*CH/N&;S(#MM@;Y;:E1
MR0,COC22Y;)=O=L>H/UG$'!_M^\4("23C/XD@9^QQGT]>#[ZJL$)Y@XW[?J
M#?P7BJI+J$@G9P/-W<CMGS&];Q?AG4QIO9J[*@$$.3[RE-N.)(2IQ$&&U&4"
MHXR$)65'/^4C '?A<7N<UVR"72 "8!DEB7\T[$,)KR''U%-])!D L.DG8?\
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M4J!<N"X QWSBOF*L^C3'=ME0X"D0:Q5Z:Y/C*;=7Y32Y8*F2T[DM)66^5A(
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MZ@:C_IY=-I*+AYN1E,R4\W*(8%.U>%XW8X1Q[B]GBVIUERQ9T20Q4H)MI2D
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M]5KUIO7[BA_3@J!* 3 .Z6,.8 R0&K](#8[:>W-BMI=O=H;38#=!V]M2DVS
MPVAI#ZJ=&;:F35MMI2D/U"47ICJL84Z^LDE7?XEJ=2;EU:@DR2PY3 _TARX<
M LKN\17M4%K<B1!<_J.YEGP6B0(Z"["!U9SQW//'8#'?\OUQVUC43= >"EC/
M?+C 8 ]3Z@55"0%'HQ&8P7GI)WS34;PXF,@-ON.@W&):HIJ#AY5#/AOY[N!D
M8)I34 /O/K^>0WI34XR#Y3!F&@D,1O#]V*FHSL>WIG:?2=R]*:F!M)!!&&;)
M]1OM+]*4T/26+09)&0,1V#;NY%*:AGP-^\#O&W[',4IJ0SSOO(;OF>K?M2FF
M\]"^TL8\]AZ'-*:$0#^S>L9W[B,YI3(]]0/U)^_21G[OLU*B5#J5D>@^C_.5
M*" $_P"963GI3D_;68J (<@.S%V;+%\ 1E\MUJZ4%1*""(YF8R&.S3@>_=QJ
M@^*OXE4[(>'^[?V;.0Q7JK&;MN@-H)\YVNUSSXP4CI4%#Y&"B1.4I)R@M-]1
M'4G/TSP'P?\ JM9;U%Q*@/B.[%N5*07#I*2.<]=BU>!\1:U.IU2>%@@H0A*U
MEV 7SK!2H[*2E(@@%R(D$_$@ZXZXZZ])<6Y(==<>D.NJZENO/+*W'7%'DJ=<
M45D_XE*/OK]#*4C3VT6D$,  SA_/N._8F<UR[0^&/A_*R0X+@#R'MY]JR"\-
MWAKW&\4%_1[%L&%Y<6,&)5UW/*ZD4BUZ,IX^?)FK _OIDEH%,"GMDO2UM$*"
M64*6.-QGB5G06">= N  @!0*BI8<!A)=^H $D@ &M>]?Y$J)9PX P>YVB7&P
M$#(?/#XCGACVU\*>U.P-EV-$5(JM8KUSS[JN^<ADUJOSZ?2Z<TE<I;0 C4]I
MV7(,>"TI33*.A!4HA2E<3PYQ/5\1U=_XJBJRDVP  2A /Q'YEGJ&!,!TMT;#
MI%_%65$G>'AN8!F!(@ D>9+EZU&(.>"24C(3DY& >#[ 'N., $?GKW!Y$EDE
MT[$&"8,$%A/9QNPSM+!YE,VT0^)$?SB)Q4%%)4>GMDX_35<D$1B>Y.9DPV6F
M1O5A@/T_,5#27$/#@#9P"[# <Q@XG%334=6$C#$0TNX9V8]7?,2IH)$G[$]7
M;,$!\N'[TI_7O_7Y:L0SF<,"2TXC?WV$0:5#'!'OG^.H?>!@L[N/N&(P.W2E
M1]>.Y_?]M0=@V(ZN=R [>8[^RG23P!@DX&1CD^H]^_ZGC4Q\KM#O(P.KGMU9
ML=*@F"-V+#?TWHVGE60%'&<$@=0/8@G*>>0/<G SJ5$*'*)@P)QL0)$/N&W;
M;%(!)!R"_;/\201]*^AOX?5IRK=\--ORY;?E.W/6:Q<#3:TXZXLJ4ME"5$@?
M0XE""%$%/0>H'&#KR'$KP&I(2Z@@)"^4/R_J.PPRAS$X+G9SX[Q"%*U" D&2
M0DB7)(!'F&+!W\HKZ O"?MX+;L]^Z9["D56Y7?F(ZG$'S&J.V/+A@]0"FTOX
M4X<X"L(QGC'PWQSQ8ZW7ITMLI59T_P KI+I*S\V0X) ;!?+R(^J^">%_TF@3
MJ;J%)N+ ;F24D)@/+?J.-X/6LM<E1R<<?D/Y_P#4?;7AV^$(D*,LY,[03  W
M^KU[4?YAF&[;]0_WJ!43^_/W_7&,_NU3*BK!+Y?'2?88S0JCE&//\WWJ&K&
MWDQ/J8'3RZ=ZI4%#.!C/(S^6DX#GKF>GH-G\X=@KM/2D4ZCU:<2 (T.5)25X
M *V65N-@Y(P2M*0/=1&.XUAN$$ACU],9;ZUNV2 A3N'8#K&'VW!^A[^M:L)5
M/H-*A+&%QZ=";7P1EP,(\XX(')>\Q1^ZN=:R\C[;_AAJW;(9.[%B'?<2)[O5
M0ZI6:FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*@HX!.,X[#W/H
M!]R< ??2E43<;J(M?M&>3P)\ZG+.1TD3Z;*\L$GC*I#+*$#C*UI2.3@Y$@%*
M@?S#?;\S6I>(%RVL#FY7!8.64.4D]@#,P-WPEA*9#Y24GS%A0 ()Z<$@C&,@
M_D1C&#K<0W*)[]1W+.>Y;LV<:5Q@;LCYRDI[@';8^G[UUM6'MT):)[XSM[$S
M6O30F8EGR[QN?)OI(%*:!L%P'!#'MD^A&S]-Z4T?R+=3L2\AR[[@2&&]*:G,
M%XZ]<EY&?XD/*FH/DP+-T;?\WR=J4U+.'\VAA'E$[O$/S012FH]<OGS]AO.,
MA\LIJ1C!<$N1U&T#'J-^U*?;^N=5*G'(!D'#E_/=B7.W2&I7F5BG1*M E4VH
MP6*A3I\5^%.@RV6GXTV+(;6S*B/-/H6SY4R.\IAQQ:%'H!;"2A;BT60?@A*@
MX6DN"7 <?,"&EP9 ?K@@/<*@"3L&R7,C!Y007<Q'=Q\<_P 4#X,V_P#L[5[A
MWS\#$NNW1M8\W*J%R[)TP*FW-9:WG5NS)-CTUIA]FKVTD*+C5*!-1HZ"L0P\
MTTV1ZK3^/_$?#;%NSHKRQ9MAN5)60>=1!#!@"QG>2>U8KFAL7U?$4/\ ,0?U
M%IZ'<X:"P\S)^=3;NVIELUZ7<]_JD0JT[*>8J+=Q,/19M+?ZP)3E0CU)$>0)
M3;@""TM#:F025)2!KZUX!T&D3J%^*>(7K0UFI+\URX@'F6RCGYC[R1VKSW'+
M5_461I$)60Q0E@3AP,>S!R1.U71JET7=MEN QNI0ZM$%0ME'718$IOYF@S*<
M_%0E\%@94I4R/(4TVXA1#2D$)^I!U;_%;PPOC7#U\2N:WFM6ITZ0L*'PR"4\
MI<@@2(@L0'$UP=/X<TNITB^%7$!KR0G4+6EEA08+*' < LSARX<[U73^^E/\
M0J*;?^[].C4NH6B9)MJ+1RZW2F$H2A;BWQ*$QU]Y:DGJ>2E#2%?A0D#&O._X
M5^$>#<*TJ_$G$=4MM.RBA:D@.SM)#CF,2.AQ7G;/AO7^%=8O1<%7<5I+MQ2K
MANI5SAR1\O*  !&?*6KV=CML-W?&Y>Z;<V4VRK5UUR8Z*23&BJ51*/ "U)-3
MK=P+CF#1J<$_4XMQ06>P"5$ >VUWCKPWK-%J[J0A)05)0>=+J )'R_,2Q=X<
MNPWKZ+H]%>2$?%"E$A+@ DJ40YDCM(@0X+9^SCX6OPJ=O/AZV94K@JJX-[^(
M6^8D9-\W\B,Y\C0Z:M06+'L<26?-A4:(\D/5"HA:)E=E)1-GEGY:FQXOYRXK
MJ=)J=9>UMNRI/,6!"0"K<')8&>807$ABP[]KXB$\N# :09R[AG&7?E#L[S6W
MK6C #$^V';J\L\B/,L'BFA]0G=I'O@S'3&:4T8@]\O.9W[=2T]G-*:$8D-UF
M!/IL8=W?.RFDD!WD^[,(ZMW[S-*:>TD _0[O#[R[>ZIT$ G.!P1S[_PU8$!W
M=\,3+X,L",#=O459.^,0_5QW']LU*>Y]>3S[ZJTESU<]WC#P2TQN!4')WDSU
MJ&I?KMV#=V'E)$3T(#Q34/F8#"8]"&.6;TGI2FA[Y.Y>8](Z1ZQ2FG4B9.!
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M0#\10"E2&D$]2V',R G?+UKJNG_AW?!O=4)BDN7MOA3Z%$65T^CMW+3GVXJ
M<(95.D4M<UQII "6DK=6K '4HD$GLZWQ7Q_7\,'#[NJ(LH 0D$GFY$ADPTD
M#N! 8B*\MCG=-I*+B\K9@DR3S'L21W^E5_M5\ KP%[;);9J]"OW<B,TX'1 N
MZZY**<LIP2T_'I#4!3S*\%*D*>25=E#6MI?$G%]/PVYPE-X)L7 !<*@_,P C
M8'?S?UQ+TMDW@5*2MS*_3)/2-I\JVF;2[;;.;.4M>W.T6WEK[<46EI94BCVU
M2(5,CR"$I0'9*XZ/F*C(2V,&745S9'F $. \CSXO)MK%A*U7 742,)49)[2T
M!B=W%94:BT;BK0">=,!+[)<,'?T=\O5[RX HH(5@#!*O3&3P /\ #DXP?4C6
M0E15R\JN1OUL.3HPEOW:LJE %E)"2)Y3"F.[#KE_[O+JPE\L')'U9W,/B'DF
MM>FH(;+LP(G8]^LX;=\94TB'W&P#^?GMWW;-*:3#AQLP ?,1UWW'W4T(9GW=
M_*/KG!Z#>E-(DQ#'KT89&PG82P&ZF@)&P=LM.,^WTH ]1(([@C42&.-P_;^=
MNOH]2Q'Y^1WQ4-2(!RV#Y'+C(=@,YWJ*:$N7W+3N/L-L@/\ 44IH[!N62Q<_
MW'X.M*:"7@>3]>W4N&8,[-TI42"._KIOTVG]X8MELNSN7%&_/S[5!1(:7TC)
MQ@ >Y^WZ#T_74*E!8.K?<MN?S[FK?-RF/E)DMOT>J*OZ>*99U6DN**%?)%OZ
ML#I#KB6UGJ)P.E*^I6<X0E1SC74X+:-_7Z=)!(*TDP[$$9;9@3T$0\5S>/W?
M@\%U"@H"Z4J1;23\Q2H !A@.ZF;H^YK\][Q/;@R-T_$%N[?94M<2N7Q6V:4%
M*Z_*H]-E+IE+92H''0(D-M:,<$+R 3G/ZQX3:^!H])IU1;-I#$AGN-,%YASC
M.)%?.=,@ILVRL%)Y I1/^DJF9'D^0TE\YL_"N\)K6_6[-0W+NJ-YU@;./0*I
M(@O,+5&KES/K*J1"6X<-J13W4)GO-'JZ^AM*TE)UYOQ9QG_IY1PZVL"YJDEQ
MORC)&[C +P<5GU*+BM.JXA)^&ERJY(#$L0#N00YCJYKZJ&&@4(Z&PGZ4Y0E/
M2ELXY2$CA 21TA([ 8Y&OG=NXHA8,L0Q=X,D,<]3EW:37G.4*N*43D3D!Q
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MDJFUFK2TMJ3#IU/8?DNN 'I2@*4(*F$DS@N?)_4O!'2:V=/9%TEV8']GP_\
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MD[&H:D@<K[GKOL<>Y)'J7J*:!WR(;>/IEG;MM -*:-+#R&"-P[-(S+1G.58
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M=9;DI(!<NQVZ]C]O*M4 DP/SUJR=T6M)G3J[5%)<0A@(5%2D</@()44CCK
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M'8 !1[GL->CX+Q-5I7P;I(M$LG"F),,#(ENS/7E/$/"/B).JM)"KH2/B /\
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M,LNF1V"2K&KE"3<42Y( #S@3 S!V_BMJWSNFVD.&=1/=G!=I :=V+-)%=TZ
MQ3H[42,RB/&8:0RRRWGH;;: 0A(R23A  *CE2B.I9*B3K44KF+=G ^F?2M]"
M GL^1_'[]3Y"N_J*O32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E
M-*4TI34%VC-*:FE<;N"@@C.> ..20>#G@C&20>X!&I&>G?IWJJA![3EOSRJW
ME/0*'4Y=O/9,">'JA0E$@)3@A4VFHR1CY=U?G,')*F'%#"4,%1V4N4A3X@G)
M;+MC!=GQ [ZB@/F2690#1V+&>\%\YBNXM)05(((+:@.0>4+!*%'T'6!D)SU
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MC+7X#]KW(AYI*@TU)$V"YC",'/4E*O4CU'Y<X//(U-HV[@4X8-@EX)G?&_\
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MOYAZM/=&WK<M:YM&(8D**G'(Y^AIPGOC(/25?^D8))X!.O2<,XVJV!;O.JV
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MP!T&Y :M194Y=14>I\NC_OZU#/\ #C4+9?0 LSCHY]0,&?*2'K34  !@08
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M;1D_Y$)(]#P-4%U0PWM^8]NU;"=,D .22!O-5*B*VVE*&\(2D8 2E( 3_E2
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E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g373959page001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g373959page001.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( !\ KP,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /1_&OC'4/#FIP6UG#;NCP^83*"3G)&."/2NNA0C4C=G)7K2
MIRLC;\2:W<:/X9;4K>.-IODPKY*C<0.WUK*E34Y\K-:LW"',B/P=KMUX@T62
M[NXXDD29H\1@@$  ]R?6G7IJG*R"C4=2-V8OA/QKJ.NZ^]C=06Z1>6[@Q@@C
M!'J?>M:U"-.',C*C7E.?*SL=1U*RTFQDO=0N8[6UBQOEE;:JY.!D_4BN,ZR>
M*6.>%)H75XI%#(RG(8'D$4 5M,U;3M9MFN-,O8;N%',;/"X8!AU&1WH 1-7T
MY]7?24O86U"./S7MPX+JG]XCL.1^= #KK5+"QNK6UNKR&">[8I;QR. TK#J%
M'>@"W0!5M-3L;Z>Z@M;J*:6T?RYT1LF-O0^AH M4 4K?5].N]1NM.M[V&6\M
M<>?"C@O'GIN':@"/5->TG1/)&IZC;VAG;;$LL@4N?11WH 35O$.CZ#%%)JVI
M6]BDQ(C:>0(&(ZXS0!D_\+'\%_\ 0T:9_P"!"T :ND>(M&UZ.9])U.VO4A($
MA@D#!,],X^E &9_PL3P:./\ A)],_P# E?\ &@"U8>,_#&J72VMAK^GW%P_"
MQQW"EF^@SS0!JW=Y;:?:275Y<1V]O$,O+*X55'N30!S,/Q0\$3W @3Q-8[R<
M#<^T?F>* .JAFBGA26&19(G&5="""/4$4 >4_%/_ )#]K_UZ?^S-7I83X'ZG
MG8OXUZ'4^.O^1";_ +8_^A"N;#_Q?O.BO_"(OAC_ ,BO/_U]/_Z"M5BOC^0L
M+\'S.5^''_(XM_UQD_F*Z,3_  SGPW\0].U[2(=>\/ZAI,X'EW<#1$GMD<'\
M#@_A7F'I'E.C>-9]*^ ]_P">Q75])+Z4$S\WFYVI^0(_[Y- $GPQL9O 'BV\
M\)7\I\J]L(M1B9^ ) NV4?GG\%H U?A0IUO4?$WC:8<ZK>&&V)[01\+_ (?\
M!H X_7-.U7XH:QK_ (FTB>1+?0,0Z/L_Y;2QL&=A]<<?5?2@#U[P3XGA\7^$
MK'6(L+)(FV>,?\LY1PR_GT]B* .?^'O_ "-OCW_L*C_T 4 >@4 >#GQ5+X8^
M+_C5+#39=2U>_,$5E:QCAF" DL>R@$$_TZT ;WPIL++Q+<77BS6[I]0\40S-
M#-%.FT6!!.$1.W'?ZCKG( SXWRVL%WX-FOK8W-I'J)::%4WF1 !E0O?(XQ0!
M6M?$'PTN[R"V3X?W*O-(L8+Z.H4$G&2<\"@#U/3M!TC0K>X72=-MK%91F001
M!-Q XSCK0!\]_#_Q%\/-+\,_9O$VC)=ZCY\C&0V'G?*3P-V* +'B[4_ WBG2
MX]*\#^&I1XA>9/L\EM9^28L$9)([8_+KQB@#T'XJ>'M;U;PWH'DV;ZO'87,<
MNH64;[3<@#!QZ\Y]_FH QKGQ5X->Q^RZK\+]3M;=5PV=(4"/_@0P1]: .Y^'
M!\*_\(HJ^$)2^F^:[%69BZ.>2K!N1CC\,=>M '*?%/\ Y#]J/^G3_P!F:O2P
MGP/U/.Q?QKT.I\=?\B$W_;'_ -"%<V'_ (OWG17_ (1%\,?^17G_ .OI_P#T
M%:K%?'\A87X/F<K\.?\ D<6'_3"3^8KHQ/\ #.?#?Q#U^O,/2/%M4\!ZE/\
M&N-(X)CX;NYX]6N"$S%YT:L-I/J6YQZ-0!K_ !H\/ZM>Z9IVM>'X)Y=4LG>
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H*<8?"C3K,T"@ H * "@ H * "@ H * "@ H * "@ H * "@ H __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701428361360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ProKidney Corp.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001850270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">E9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701419788624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheet - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 51,889<span></span>
</td>
<td class="nump">$ 440,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">29,802,000<span></span>
</td>
<td class="nump">20,558,000<span></span>
</td>
<td class="nump">$ 4,578,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid assets</a></td>
<td class="nump">592,000<span></span>
</td>
<td class="nump">588,000<span></span>
</td>
<td class="nump">202,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_PrepaidClinicalCurrent', window );">Prepaid clinical</a></td>
<td class="nump">4,855,000<span></span>
</td>
<td class="nump">6,100,000<span></span>
</td>
<td class="nump">753,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">35,249,000<span></span>
</td>
<td class="nump">27,271,000<span></span>
</td>
<td class="nump">5,585,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_DeferredOfferingCost', window );">Deferred offering costs</a></td>
<td class="nump">5,108,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">11,103,000<span></span>
</td>
<td class="nump">11,358,000<span></span>
</td>
<td class="nump">8,914,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_RightOfUseAssetsOperatingAndFinanceLease', window );">Right of use assets, net</a></td>
<td class="nump">1,673,000<span></span>
</td>
<td class="nump">1,241,000<span></span>
</td>
<td class="nump">1,559,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">374,000<span></span>
</td>
<td class="nump">428,000<span></span>
</td>
<td class="nump">642,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">53,507,000<span></span>
</td>
<td class="nump">40,298,000<span></span>
</td>
<td class="nump">16,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable</a></td>
<td class="nump">2,509,000<span></span>
</td>
<td class="nump">2,834,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_AccruedExpensesAndOther', window );">Accrued expenses and other</a></td>
<td class="nump">8,117,000<span></span>
</td>
<td class="nump">9,213,000<span></span>
</td>
<td class="nump">4,496,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_CurrentAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,834,000<span></span>
</td>
<td class="nump">781,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_OperatingAndFinanceLeaseLiabilitiesCurrent', window );">Lease liabilities</a></td>
<td class="nump">328,000<span></span>
</td>
<td class="nump">267,000<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="nump">958,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent', window );">Related party notes payable</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">31,912,000<span></span>
</td>
<td class="nump">12,314,000<span></span>
</td>
<td class="nump">5,502,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">1,428,000<span></span>
</td>
<td class="nump">1,067,000<span></span>
</td>
<td class="nump">1,334,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 6)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersEquityAbstract', window );"><strong>Members' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(228,996,000)<span></span>
</td>
<td class="num">(161,510,000)<span></span>
</td>
<td class="num">(106,364,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapital', window );">Total members' equity</a></td>
<td class="nump">20,167,000<span></span>
</td>
<td class="nump">26,917,000<span></span>
</td>
<td class="nump">9,864,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">53,507,000<span></span>
</td>
<td class="nump">40,298,000<span></span>
</td>
<td class="nump">16,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember', window );">Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">51,889<span></span>
</td>
<td class="nump">440,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">543,088<span></span>
</td>
<td class="nump">504,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">594,977<span></span>
</td>
<td class="nump">944,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_PrepaidInsuranceNonCurrent', window );">Non-current prepaid insurance</a></td>
<td class="nump">123,750<span></span>
</td>
<td class="nump">247,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrustNoncurrent', window );">Marketable Securities held in Trust Account</a></td>
<td class="nump">250,033,500<span></span>
</td>
<td class="nump">250,008,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">250,752,227<span></span>
</td>
<td class="nump">251,200,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable</a></td>
<td class="nump">26,735<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_AccruedExpensesCurrent', window );">Accrued expenses</a></td>
<td class="nump">5,342,189<span></span>
</td>
<td class="nump">1,864,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Advances from related party</a></td>
<td class="nump">43,623<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,412,547<span></span>
</td>
<td class="nump">1,879,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_DeferredUnderwritingCommissions', window );">Deferred underwriting fee payable</a></td>
<td class="nump">7,700,000<span></span>
</td>
<td class="nump">7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">13,112,547<span></span>
</td>
<td class="nump">9,579,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Class A ordinary shares subject to possible redemption</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,008,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholder's Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preference shares, $0.0001 par value; 5,000,000 shares authorized; no&#160;shares issued and&#160;outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional&#160;paid-in&#160;capital</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Permanent Deficit</a></td>
<td class="num">(12,360,320)<span></span>
</td>
<td class="num">(8,387,619)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersEquityAbstract', window );"><strong>Members' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(12,361,009)<span></span>
</td>
<td class="num">(8,388,308)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">250,752,227<span></span>
</td>
<td class="nump">251,200,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassAMember', window );">Capital Unit, Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersEquityAbstract', window );"><strong>Members' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedPartnersContributedCapital', window );">Class Units</a></td>
<td class="nump">186,500,000<span></span>
</td>
<td class="nump">186,500,000<span></span>
</td>
<td class="nump">115,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassBMember', window );">Capital Unit, Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersEquityAbstract', window );"><strong>Members' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedPartnersContributedCapital', window );">Class Units</a></td>
<td class="nump">62,663,000<span></span>
</td>
<td class="nump">1,927,000<span></span>
</td>
<td class="nump">$ 1,228,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Class A ordinary shares subject to possible redemption</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,008,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholder's Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock value</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member] | Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholder's Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock value</a></td>
<td class="nump">$ 625<span></span>
</td>
<td class="nump">$ 625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_AccruedExpensesAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_AccruedExpensesAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_AccruedExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_AccruedExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_CurrentAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current accounts payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_CurrentAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_DeferredOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred offering cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_DeferredOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_DeferredUnderwritingCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred underwriting fee payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_DeferredUnderwritingCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_OperatingAndFinanceLeaseLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease liabilities current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_OperatingAndFinanceLeaseLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease liabilities non current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_PrepaidClinicalCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid clinical current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_PrepaidClinicalCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_PrepaidInsuranceNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid insurance non current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_PrepaidInsuranceNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_RightOfUseAssetsOperatingAndFinanceLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right of use assets operating and finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_RightOfUseAssetsOperatingAndFinanceLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrustNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldInTrustNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedPartnersContributedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of capital contributed by the limited partners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB TOPIC 4.F)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedPartnersContributedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MembersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MembersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnersCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of ownership interest of different classes of partners in limited partnership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnersCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701428320224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Balance Sheet (Parenthetical)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassAMember', window );">Capital Unit, Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedPartnersCapitalAccountUnitsIssued', window );">Limited partners capital account units issued</a></td>
<td class="nump">115,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding', window );">Limited partners capital account units outstanding</a></td>
<td class="nump">115,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassBMember', window );">Capital Unit, Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedPartnersCapitalAccountUnitsIssued', window );">Limited partners capital account units issued</a></td>
<td class="nump">7,767,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding', window );">Limited partners capital account units outstanding</a></td>
<td class="nump">7,767,122<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedPartnersCapitalAccountUnitsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of limited partner units issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedPartnersCapitalAccountUnitsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of limited partner units outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701420120432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,490,000<span></span>
</td>
<td class="nump">9,859,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,255,000<span></span>
</td>
<td class="nump">21,042,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,972,000<span></span>
</td>
<td class="nump">1,744,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,855,000<span></span>
</td>
<td class="nump">5,982,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating and formation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,462,000<span></span>
</td>
<td class="nump">11,603,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,110,000<span></span>
</td>
<td class="nump">27,024,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,462,000)<span></span>
</td>
<td class="num">(11,603,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,110,000)<span></span>
</td>
<td class="num">(27,024,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">43,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66,476,000)<span></span>
</td>
<td class="num">(11,603,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,108,000)<span></span>
</td>
<td class="num">(26,981,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,010,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,000<span></span>
</td>
<td class="num">(232,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67,486,000)<span></span>
</td>
<td class="num">(11,609,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,146,000)<span></span>
</td>
<td class="num">(26,749,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember', window );">Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating and formation costs</a></td>
<td class="nump">$ 5,182<span></span>
</td>
<td class="nump">4,006,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,332,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(5,182)<span></span>
</td>
<td class="num">(4,006,201)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,332,953)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest earned on marketable securities held in Trust Account</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,182)<span></span>
</td>
<td class="num">(3,981,025)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,324,629)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassAMember', window );">Capital Unit, Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (67,486)<span></span>
</td>
<td class="num">$ (11,609)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (55,146)<span></span>
</td>
<td class="num">$ (26,749)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Shares Outstanding, Basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,500,000<span></span>
</td>
<td class="nump">122,111,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,706,849<span></span>
</td>
<td class="nump">104,986,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Shares Outstanding, Diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,500,000<span></span>
</td>
<td class="nump">122,111,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,706,849<span></span>
</td>
<td class="nump">104,986,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per ordinary share , Basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per ordinary share , Diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (3,200,799)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,675,346)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Shares Outstanding, Basic</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,101,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Shares Outstanding, Diluted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,101,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per ordinary share , Basic</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per ordinary share , Diluted</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member] | Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,182)<span></span>
</td>
<td class="num">$ (780,226)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (649,283)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Shares Outstanding, Basic</a></td>
<td class="nump">5,500,000<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,852,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Shares Outstanding, Diluted</a></td>
<td class="nump">5,500,000<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,852,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per ordinary share , Basic</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per ordinary share , Diluted</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701414243776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Statements of Changes In Temporary Equity And Permanent Deficit - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Capital Unit, Class A [Member]</div></th>
<th class="th"><div>Social Capital Suvretta Holdings Corp. III [Member]</div></th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Social Capital Suvretta Holdings Corp. III [Member]</div>
</th>
<th class="th">
<div>Additional Paid-in Capital [Member] </div>
<div>Social Capital Suvretta Holdings Corp. III [Member]</div>
</th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th">
<div>Accumulated Deficit [Member] </div>
<div>Social Capital Suvretta Holdings Corp. III [Member]</div>
</th>
<th class="th">
<div>Member Units [Member] </div>
<div>Capital Unit, Class A [Member]</div>
</th>
<th class="th">
<div>Member Units [Member] </div>
<div>Capital Unit, Class B [Member]</div>
</th>
<th class="th">
<div>Common Class A [Member] </div>
<div>Social Capital Suvretta Holdings Corp. III [Member]</div>
</th>
<th class="th">
<div>Common Class A [Member] </div>
<div>Common Stock [Member] </div>
<div>Social Capital Suvretta Holdings Corp. III [Member]</div>
</th>
<th class="th">
<div>Common Class B [Member] </div>
<div>Social Capital Suvretta Holdings Corp. III [Member]</div>
</th>
<th class="th">
<div>Common Class B [Member] </div>
<div>Common Stock [Member] </div>
<div>Social Capital Suvretta Holdings Corp. III [Member]</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapital', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 15,883,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (79,615,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95,000,000<span></span>
</td>
<td class="nump">$ 498,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_PartnersCapitalOutstanding', window );">Units outstanding January&#160;1, 2020 at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Equity-based compensation</a></td>
<td class="nump">730,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">730,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountContributions', window );">Capital contribution(Value)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountUnitsContributed', window );">Capital contribution(Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(26,749,000)<span></span>
</td>
<td class="num">$ (26,749)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,749,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapital', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">9,864,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(106,364,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,000,000<span></span>
</td>
<td class="nump">1,228,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_PartnersCapitalOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Capital contribution(Value)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Capital contribution(Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Equity-based compensation</a></td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(11,609,000)<span></span>
</td>
<td class="num">(11,609)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,609,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,182)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 633<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,325,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapital', window );">Ending Balance at Mar. 31, 2021</a></td>
<td class="nump">18,430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(117,973,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000,000<span></span>
</td>
<td class="nump">1,403,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_PartnersCapitalOutstanding', window );">Ending Balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapital', window );">Beginning Balance at Dec. 31, 2020</a></td>
<td class="nump">9,864,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(106,364,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,000,000<span></span>
</td>
<td class="nump">1,228,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_PartnersCapitalOutstanding', window );">Units outstanding January&#160;1, 2020 at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Capital contribution(Value)</a></td>
<td class="nump">71,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Capital contribution(Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Equity-based compensation</a></td>
<td class="nump">699,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">699,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountUnitsContributed', window );">Capital contribution(Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(55,146,000)<span></span>
</td>
<td class="num">(55,146)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,146,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,387,619)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,388,308)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 625<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,008,324<span></span>
</td>
<td class="nump">$ 250,008,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,008,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapital', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="nump">26,917,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(161,510,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 186,500,000<span></span>
</td>
<td class="nump">1,927,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_PartnersCapitalOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Feb. 24, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Feb. 24, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of Class B ordinary shares to Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of Class B ordinary shares to Sponsor (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,325,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,182)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,182)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,182)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,182)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 633<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,325,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapital', window );">Ending Balance at Mar. 31, 2021</a></td>
<td class="nump">18,430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(117,973,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000,000<span></span>
</td>
<td class="nump">1,403,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_PartnersCapitalOutstanding', window );">Ending Balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Feb. 24, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Feb. 24, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of Class B ordinary shares to Sponsor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of Class B ordinary shares to Sponsor (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,325,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Sale of 25,000,000 Public Shares, net of underwriting discounts and offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 237,520,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Sale of 25,000,000 Public Shares, net of underwriting discounts and offering expenses (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity', window );">Remeasurement of Class A ordinary shares to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,487,990)<span></span>
</td>
<td class="nump">$ 12,487,990<span></span>
</td>
<td class="num">(6,424,311)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,063,679)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,487,990)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Capital contribution(Value)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,399,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Capital contribution(Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Equity-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Forfeiture of Founder Shares (share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,324,629)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,324,629)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,675,346)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(649,283)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,387,619)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,388,308)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 625<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,008,324<span></span>
</td>
<td class="nump">$ 250,008,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,008,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapital', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="nump">26,917,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(161,510,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 186,500,000<span></span>
</td>
<td class="nump">1,927,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_PartnersCapitalOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity', window );">Remeasurement of Class A ordinary shares to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,324<span></span>
</td>
<td class="num">$ (8,324)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited', window );">Equity-based compensation</a></td>
<td class="nump">55,186,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,186,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountContributions', window );">Capital contribution(Value)</a></td>
<td class="nump">5,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(67,486,000)<span></span>
</td>
<td class="num">$ (67,486)<span></span>
</td>
<td class="num">(3,981,025)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67,486,000)<span></span>
</td>
<td class="num">(3,981,025)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,200,799)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (780,226)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,360,320)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12,361,009)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 625<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending Balance at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending Balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapital', window );">Ending Balance at Mar. 31, 2022</a></td>
<td class="nump">$ 20,167,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (228,996,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 186,500,000<span></span>
</td>
<td class="nump">$ 62,663,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_PartnersCapitalOutstanding', window );">Ending Balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_PartnersCapitalOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Partners capital Outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_PartnersCapitalOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remeasurement of Class A ordinary shares to redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during period shares new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnersCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of ownership interest of different classes of partners in limited partnership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnersCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnersCapitalAccountContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total contributions made by each class of partners (i.e., general, limited and preferred partners).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 4.F)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnersCapitalAccountContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnersCapitalAccountUnitsContributed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Units contributed by each class of partners during the year. Units represent shares of ownership of the general, limited, and preferred partners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnersCapitalAccountUnitsContributed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph c(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701424387536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statements of Changes In Temporary Equity And Permanent Deficit (Parenthetical) - Social Capital Suvretta Holdings Corp. III [Member]<br></strong></div></th>
<th class="th" colspan="1">10 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_TemporaryEquityStockIssuedDuringThePeriodShares', window );">Temporary Equity Stock Issued During The Period Shares | shares</a></td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement</a></td>
<td class="nump">$ 6,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement</a></td>
<td class="nump">$ 640,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_TemporaryEquityStockIssuedDuringThePeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock issued during the period shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_TemporaryEquityStockIssuedDuringThePeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701420458112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Statement of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (67,486,000)<span></span>
</td>
<td class="num">$ (11,609,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (55,146,000)<span></span>
</td>
<td class="num">$ (26,749,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">710,000<span></span>
</td>
<td class="nump">361,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,984,000<span></span>
</td>
<td class="nump">964,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Equity-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,684,000<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">699,000<span></span>
</td>
<td class="nump">730,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,843,000)<span></span>
</td>
<td class="nump">249,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,704,000)<span></span>
</td>
<td class="num">(809,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,519,000<span></span>
</td>
<td class="nump">3,568,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,868,000<span></span>
</td>
<td class="nump">683,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">957,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,459,000)<span></span>
</td>
<td class="num">(7,256,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,299,000)<span></span>
</td>
<td class="num">(25,181,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Purchase of equipment and facility expansion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(839,000)<span></span>
</td>
<td class="num">(1,389,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,192,000)<span></span>
</td>
<td class="num">(5,456,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(839,000)<span></span>
</td>
<td class="num">(1,389,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,191,000)<span></span>
</td>
<td class="num">(5,456,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on finance leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
<td class="num">(7,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30,000)<span></span>
</td>
<td class="num">(11,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Borrowings under related party notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits', window );">Net cash contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,550,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,500,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows from financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,542,000<span></span>
</td>
<td class="nump">19,993,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,470,000<span></span>
</td>
<td class="nump">19,989,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,244,000<span></span>
</td>
<td class="nump">11,348,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,980,000<span></span>
</td>
<td class="num">(10,648,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,558,000<span></span>
</td>
<td class="nump">4,577,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,577,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents', window );">Cash, beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,558,000<span></span>
</td>
<td class="nump">4,578,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,578,000<span></span>
</td>
<td class="nump">15,226,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, end of period</a></td>
<td class="nump">$ 15,925,000<span></span>
</td>
<td class="nump">29,802,000<span></span>
</td>
<td class="nump">15,925,000<span></span>
</td>
<td class="nump">$ 20,558,000<span></span>
</td>
<td class="nump">20,558,000<span></span>
</td>
<td class="nump">4,577,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents', window );">Cash, end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,558,000<span></span>
</td>
<td class="nump">20,558,000<span></span>
</td>
<td class="nump">4,578,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>Supplemental disclosure of non-cash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_RightOfUseAssetsObtainedInExchangeForLeaseObligations', window );">Right of use assets obtained in exchange for lease obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">496,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Equipment and facility expansion included in accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">501,000<span></span>
</td>
<td class="nump">$ 910,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,295,000<span></span>
</td>
<td class="nump">$ 1,840,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember', window );">Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,182)<span></span>
</td>
<td class="num">(3,981,025)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,324,629)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_FormationCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares', window );">Formation costs paid by Sponsor in exchange for issuance of Founder Shares</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest earned on marketable securities held in Trust Account</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(25,176)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,324)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(751,689)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,864,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_IncreaseDecreaseOfAdvanceFromRelatedParty', window );">Advances from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">3,499,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(138)<span></span>
</td>
<td class="num">(388,599)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,209,846)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Investment of cash into Trust Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(250,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(250,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from sale of Public Shares, net of underwriting discounts paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from sale of Private Placement Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt', window );">Advances from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_RepaymentOfAdvancesFromRelatedParty', window );">Repayment of advances from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(87,319)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from promissory note&#8212;related party</a></td>
<td class="nump">255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_RepaymentOfPromissoryNoteRelatedParty', window );">Repayment of promissory note&#8212;related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of offering costs</a></td>
<td class="num">(117)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(359,666)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows from financing activities</a></td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">251,650,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(388,599)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, beginning of period</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">440,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, end of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">440,488<span></span>
</td>
<td class="nump">$ 440,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-Cash Investing and Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Offering costs paid by Sponsor in exchange for issuance of Founder Shares</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_RemeasurementOfClassAOrdinarySharesToRedemptionValue', window );">Remeasurement of Class A ordinary shares subject to possible redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,487,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_DeferredUnderwritingFeesAccruedButNotPaid', window );">Deferred underwriting fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_OfferingCostsIncludedInAccruedOfferingCosts', window );">Offering costs included in accrued offering costs.</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalent, restricted cash and restricted cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_DeferredUnderwritingFeesAccruedButNotPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred underwriting fees accrued but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_DeferredUnderwritingFeesAccruedButNotPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_FormationCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Formation costs paid by sponsor in exchange for issuance of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_FormationCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_IncreaseDecreaseOfAdvanceFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease of advance from related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_IncreaseDecreaseOfAdvanceFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_OfferingCostsIncludedInAccruedOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Offering costs included in accrued offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_OfferingCostsIncludedInAccruedOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_RemeasurementOfClassAOrdinarySharesToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remeasurement of class A ordinary shares to redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_RemeasurementOfClassAOrdinarySharesToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_RepaymentOfAdvancesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayment of advances from related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_RepaymentOfAdvancesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_RepaymentOfPromissoryNoteRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayment of Promissory Note Related Party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_RepaymentOfPromissoryNoteRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_RightOfUseAssetsObtainedInExchangeForLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right of use assets obtained in exchange for lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_RightOfUseAssetsObtainedInExchangeForLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common limited partners units during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701428496816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description Of Organization, Business Operations And Going Concern<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description Of Organization, Business Operations And Going Concern</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 1: The Company </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">ProKidney LLC was formed as a Bermuda limited liability company on December 12, 2018 and funded with $75,000,000 on December&#160;31, 2018. On January&#160;9, 2019 (the &#8220;Acquisition Date&#8221;), ProKidney LLC acquired all of the equity interests in inRegen and Twin City Bio LLC (&#8220;TC Bio&#8221;) for $62,000,000. inRegen was duly incorporated under the Cayman Islands Companies Act (as amended) on December&#160;21, 2015 as an exempted company. During 2020, inRegen&#8217;s name was changed to ProKidney (and is referred to herein as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;ProKidney-KY&#8221;),</div> and TC Bio&#8217;s name was changed to ProKidney, LLC (and is referred to herein as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;ProKidney-US&#8221;).</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> was formed as a limited liability company under the laws of Delaware on December&#160;18, 2015. In August 2021, ProKidney LP was organized as a limited partnership under the laws and regulations of Ireland, with ProKidney LLC becoming a wholly owned subsidiary of ProKidney LP (and is referred to herein as &#8220;ProKidney&#8221;). Following this reorganization on August&#160;5, 2021, and for the purposes of these financial statements, the term &#8220;ProKidney&#8221; as used herein, refers to ProKidney LP following this reorganization, and the financial information presented herein is that of ProKidney LP and its wholly owned subsidiaries. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">ProKidney acquired the equity interests in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> to develop its Renal Advanced Cell Therapy, which has the potential to stabilize or improve renal function in patients with chronic kidney disease or delay or eliminate the need for dialysis and organ transplantation. ProKidney acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> to provide contractual development and manufacturing services to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY,</div> which is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US&#8217;s</div> only customer. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because ProKidney is a limited partnership, the debts, obligations and liabilities of the Company (as defined below), whether arising in contract, tort or otherwise, are solely the debts, obligations and liabilities of the Company, and no holder of equity interests in ProKidney (&#8220;members&#8217; equity&#8221;) is obligated personally for any such debt, obligation or liability of the Company solely by reason of being a holder of members&#8217; equity. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On January&#160;18, 2022, the Company executed a definitive business combination agreement (the &#8220;Business Combination Agreement&#8221;), with Social Capital Suvretta Holdings Corp. III (&#8220;SCS&#8221;). Under the terms of the Business Combination Agreement, the Company will become a subsidiary of SCS and will be organized in an umbrella partnership corporation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;Up-C&#8221;)</div> structure, which provides potential future tax benefits for SCS when the equity holders ultimately exchange their pass-through interests for Class&#160;A ordinary shares in SCS. </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 1: The Company </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">ProKidney LLC was formed as a Bermuda limited liability company on December 12, 2018 and funded with $75,000,000 on December&#160;31, 2018. On January&#160;9, 2019 (the &#8220;Acquisition Date&#8221;), ProKidney LLC acquired all of the equity interests in inRegen and Twin City Bio LLC (&#8220;TC Bio&#8221;) for $62,000,000. inRegen was duly incorporated under the Cayman Islands Companies Act (as amended) on December&#160;21, 2015 as an exempted company. During 2020, inRegen&#8217;s name was changed to ProKidney (and is referred to herein as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;ProKidney-KY&#8221;),</div> and TC Bio&#8217;s name was changed to ProKidney, LLC (and is referred to herein as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;ProKidney-US&#8221;).</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> was formed as a limited liability company under the laws of Delaware on December&#160;18, 2015. In August 2021, ProKidney LP was organized as a limited partnership under the laws and regulations of Ireland, with ProKidney LLC becoming a wholly owned subsidiary of ProKidney LP (and is referred to herein as &#8220;ProKidney&#8221;). Following this reorganization on August&#160;5, 2021 and for the purposes of these financial statements, the term &#8220;ProKidney,&#8221; as used herein, refers to ProKidney LP following this reorganization, and the financial information presented herein is that of ProKidney LP and its wholly owned subsidiaries. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">ProKidney acquired the equity interests in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> to develop its Renal Advanced Cell Therapy, which has the potential to stabilize or improve renal function in patients with chronic kidney disease or delay or eliminate the need for dialysis and organ transplantation. ProKidney acquired <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> to provide contractual development and manufacturing services to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY,</div> which is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US&#8217;s</div> only customer. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Because ProKidney is a limited partnership, the debts, obligations and liabilities of the Company (as defined below), whether arising in contract, tort or otherwise, are solely the debts, obligations and liabilities of the Company, and no holder of equity interests in ProKidney (&#8220;members&#8217; equity&#8221;) is obligated personally for any such debt, obligation or liability of the Company solely by reason of being a holder of members&#8217; equity. </div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember', window );">Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description Of Organization, Business Operations And Going Concern</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 1. DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN </div></div></div></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Social Capital Suvretta Holdings Corp. III (the &#8220;Company&#8221;) is a blank check company incorporated as a Cayman Islands exempted company on&#160;February 25, 2021. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (a &#8220;Business Combination&#8221;). The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of Marc</div></div>h&#160;31, 2022, the Company had not commenced&#160;any operations. All activity for the period from February 25, 2021 (inception) through March&#160;31, 2022 relates to the Company&#8217;s formation, the initial public offering (the &#8220;Initial Public Offering&#8221;), described below, and, subsequent to the Initial Public Offering, identifying a target company for a Business Combination and activities in connection with the proposed acquisition of ProKidney LP (see Note 6). The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company generates <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> income in the form of interest income from the marketable securities held in the Trust Account (as defined below). </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The registration </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">statements for the Company&#8217;s Initial Public Offering became effective on June&#160;29, 2021 and June&#160;30, 2021. On July&#160;2, 2021, the Company consummated the Initial Public Offering of 25,000,000 Class&#160;A ordinary shares (the &#8220;Public Shares&#8221;), which includes the partial exercise by the underwriters of their over-allotment option in the amount of 3,000,000 Public Shares, at $10.00 per Public Share, generating gross proceeds of $250,000,000, which is described in Note 3. The fair value attributable to the unexercised portion of the over-allotment option was deemed to be immaterial to the condensed financial statements. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Substantially </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">concurrently with the closing of the Initial Public Offering, the Company consummated the sale of 640,000 Class&#160;A ordinary shares (the &#8220;Private Placement Shares&#8221;) at a price of $10.00 per Private Placement Share in a private placement to SCS Sponsor III LLC, a Cayman Islands limited liability company (the &#8220;Sponsor&#8221;), generating gross proceeds of $6,400,000, which is described in Note 4. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">costs amounted to $12,479,666, consisting of $4,400,000 of underwriting fees, $7,700,000 of deferred underwriting fees and $379,666 of other offering costs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In connection </div></div>with the closing of the Initial Public Offering on July&#160;2, 2021, an amount of $250,000,000 ($10.00 per Public Share) from the net proceeds of the sale of the Public Shares in the Initial Public Offering and the sale of the Private Placement Shares was placed in a trust account (the &#8220;Trust Account&#8221;), and invested in U.S. government treasury bills with a maturity of 185 days or less or in money market funds investing solely in U.S. Treasuries and meeting certain conditions of Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2a-7</div> of the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;). Except with respect to interest earned on the funds held in the Trust Account that may be released to the Company to pay its taxes, if any, the funds held in the Trust Account will not be released from the Trust Account until the earliest of: (a)&#160;the completion of a Business Combination, and then only in connection with those Public Shares that such shareholder properly elected to redeem, subject to certain limitations; (b)&#160;the redemption of any Public Shares properly submitted in connection with a shareholder vote to amend the Company&#8217;s Amended and Restated Memorandum and Articles of Association (i)&#160;to modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with the Business Combination or to redeem 100<div style="letter-spacing: 0px; top: 0px;;display:inline;">% of the Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (ii)&#160;with respect to any other material provisions relating to shareholders&#8217; rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-Business</div> Combination activity; and (c)&#160;the redemption of the Public Shares if the </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company has not completed a Business Combination within the Combination Period or during any applicable extension period. The proceeds deposited in the Trust Account could become subject to the claims of the Company&#8217;s creditors, if any, which could have priority over the claims of the holders of the Public Shares (the &#8220;Public Shareholders&#8221;). </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Shares, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. The Company must complete one or more Business Combinations having an aggregate fair market value of at least 80% of the value of the assets held in the Trust Account (excluding any deferred underwriting commissions and taxes payable on the income earned on the Trust Account) at the time of the Company signing a definitive agreement in connection with the Business Combination. However, the Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to complete a Business Combination successfully. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div>will provide the Public Shareholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of the Business Combination, either (a)&#160;in connection with a general meeting called to approve the Business Combination or (b)&#160;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company. The Public Shareholders will be entitled to redeem all or a portion of their Public Shares at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, calculated as of two business days prior to the consummation of the Business Combination, including interest (which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares, subject to the limitations described <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">below. </div></div></div><br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">with the Company&#8217;s Amended and Restated Memorandum and Articles of Association, in no event will the Company redeem the Public Shares in an amount that would cause the Company&#8217;s net tangible assets to be less than $5,000,001 following such redemptions. Redemptions of the Public Shares may also be subject to a higher net tangible asset test or cash requirement pursuant to an agreement relating to the Business Combination. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If a shareholder vote is not required in connection with a Business Combination and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (the &#8220;SEC&#8221;), and file tender offer documents with the SEC prior to completing a Business Combination. If, however, shareholder approval of the transaction is required by applicable law or stock exchange listing requirement, or the Company decides to obtain shareholder approval for business or other reasons, the Company will conduct the redemptions in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules and will file proxy materials with the SEC. If the Company seeks shareholder approval in connection with a Business Combination, the Company will complete such Business Combination only if the Company receives an ordinary resolution under Cayman Islands law, which requires the affirmative vote of holders of a majority of ordinary shares who attend and vote at a general meeting of the Company. The Public Shareholders may elect to redeem their Public Shares without voting and, if they do vote, irrespective of whether they vote for or against a Business Combination. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notwithstanding the foregoing redemption rights, if the Company seeks shareholder approval of the Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, the Company&#8217;s Amended and Restated Memorandum and Articles of Association provide that a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &#8220;group&#8221; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Exchange Act&#8221;)), will be restricted from redeeming its Public Shares with respect to more than an aggregate </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">of 15% of the Public Shares without the Company&#8217;s prior written consent. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsor and </div></div>the Company&#8217;s directors and officers have agreed to waive: (a)&#160;their redemption rights with respect to any Founder Shares, Private Placement Shares and Public Shares held by them, as applicable, in connection with the completion of a Business Combination; (b)&#160;their redemption rights with respect to any Founder Shares, Private Placement Shares and Public Shares held by them in connection with a shareholder vote to amend the Company&#8217;s Amended and Restated Memorandum and Articles of Association (i)&#160;to modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with the Business Combination or to redeem 100% of the Public Shares if the Company does not complete a Business Combination within the Combination Period, or (ii)&#160;with respect to any other material provisions relating to shareholders&#8217; rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-Business</div> Combination activity; and (c)&#160;their rights to liquidating distributions from the Trust Account with respect to any Founder Shares and Private Placement Shares they hold if the Company fails to complete a Business Combination within the Combination Period or during any applicable extension period (although such persons will be entitled to liquidating distributions from the Trust Account with respect to any Public Shares they hold if the Company fails to complete a Business Combination within the prescribed time frame). If the Company submits the Business Combination to the Public Shareholders for a vote, the Sponsor and the Company&#8217;s directors and officers have also agreed to vote any Founder Shares, Private Placement Shares and Public Shares held by them in favor of the Business Combination. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div>will have until July&#160;2, 2023 to complete a Business Combination (the &#8220;Combination Period&#8221;), or such longer period as a result of a shareholder vote to amend such time period pursuant to the Company&#8217;s Amended and Restated Memorandum and Articles of Association. However, if the Company has not completed a Business Combination within such Combination Period or during any applicable extension period, the Company will: (a)&#160;cease all operations except for the purpose of winding up; (b)&#160;as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less up to $100,000 of interest to pay dissolution expenses and which interest shall be net of taxes payable) divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish the Public Shareholders&#8217; rights as shareholders (including the right to receive further liquidating distributions, if any); and (c)&#160;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#8217;s remaining shareholders and its board of directors, liquidate and dissolve, subject in each case to the Company&#8217;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsor </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">has agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company&#8217;s independent auditors) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1) $10.00 per Public Share or (2)&#160;such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, due to reductions in the value of the trust assets, in each case net of the interest which may be withdrawn to pay taxes, except as to any claims by a third party that executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company&#8217;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company has not independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and believes that the Sponsor&#8217;s only assets are securities of the Company and, therefore, the Sponsor may not be able to satisfy those obligations. The Company has not asked the Sponsor to reserve for such obligations. None of the Company&#8217;s directors or officers will indemnify the Company for claims by third parties, including, without limitation, claims by vendors and prospective target </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">businesses.</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"/><br/></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Proposed ProKidney Business Combination</div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;18, 2022, the Company entered into a Business Combination Agreement (the &#8220;ProKidney Business Combination Agreement&#8221;) with ProKidney LP, a limited partnership registered under the laws of Ireland (&#8220;ProKidney&#8221;), acting through its general partner ProKidney GP Limited, a private limited company incorporated under the laws of Ireland (&#8220;Legacy GP&#8221;). </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The ProKidney </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Business Combination Agreement provides that, among other things and upon the terms and subject to the conditions thereof, prior to or at the closing of the ProKidney Business Combination Agreement (the &#8220;Closing&#8221;), the following transactions will occur (together with the other transactions contemplated by the ProKidney Business Combination Agreement, the &#8220;ProKidney Business Combination&#8221;): (1) ProKidney will issue to the Company a number of common units of ProKidney (&#8220;Post-Combination ProKidney Common Units&#8221;) equal to the number of fully diluted outstanding ordinary shares of the Company as of immediately prior to the Closing (but after giving effect to all redemptions of Public Shares and the purchase of Class&#160;A ordinary shares pursuant to one or more subscription agreements (the &#8220;PIPE Investment&#8221;)), in exchange for (a)&#160;(x) new Class&#160;B ordinary shares (&#8220;New ProKidney Class&#160;B ordinary shares&#8221;), which shares will have no economic rights but will entitle the holders thereof to vote on all matters on which shareholders of the Company are entitled to vote generally, and (y)&#160;restricted stock rights in respect of New ProKidney Class&#160;B ordinary shares (&#8220;New ProKidney Class&#160;B PMEL RSRs&#8221;), which restricted stock rights shall convert into New ProKidney Class&#160;B ordinary shares upon the vesting of the associated restricted common unit of ProKidney, (b)&#160;an amount in cash equal to the aggregate proceeds obtained by the Company in the PIPE Investment and (c)&#160;an amount in cash equal to the aggregate proceeds available for release to the Company from the Trust Account (after giving effect to all redemptions of Public Shares and after payment of any deferred underwriting commissions being held in the Trust Account and payment of certain transaction expenses); (2) Legacy GP will resign as the general partner of ProKidney and a private limited company incorporated under the laws of Ireland (&#8220;New GP&#8221;) will be admitted as the general partner of ProKidney; (3)&#160;ProKidney will distribute to the ProKidney unitholders the New ProKidney Class&#160;B ordinary shares and New ProKidney Class&#160;B PMEL RSRs received pursuant to clause (i)(a)&#160;(x) and (y) above; and (4)&#160;certain holders of ProKidney units will receive an aggregate of 17,500,000 restricted common units of ProKidney (&#8220;Earnout RCUs&#8221;) and 17,500,000 restricted stock rights of the Company (&#8220;Earnout RSRs&#8221; and, together with the Earnout RCUs, the &#8220;Earnout Rights&#8221;), which Earnout Rights will vest in three equal tranches upon the trading price of a Class&#160;A ordinary share reaching $15.00<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;per </div>share, $20.00<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;per </div>share and $25.00<div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;per </div>share, respectively, on the terms set forth in the ProKidney Business Combination Agreement, or upon certain change of control events. When vested, the Earnout RCUs will automatically convert into Post-Combination ProKidney Common Units and the associated Earnout RSRs will automatically convert into New ProKidney Class&#160;B ordinary shares, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;18, 2022, the Company entered into subscription agreements (the &#8220;Subscription Agreements&#8221;) with certain investors (&#8220;PIPE Investors&#8221;) pursuant to which the PIPE Investors have subscribed for an aggregate of 57,500,000 Class&#160;A ordinary shares for a price of $10.00 per share for an aggregate purchase price of $575,000,000, of which (1) $156,400,000 is committed by certain existing directors, officers and equityholders of, or investment funds managed by Suvretta Capital Management, LLC, the Company, the Sponsor and/or their respective affiliates participating in the PIPE Investment (collectively, the &#8220;Sponsor Related PIPE Investors&#8221;), and (2)&#160;at least $50,000,000 (which may, at the election of such investors, be increased to up to $100,000,000) is committed by certain existing directors, officers and unitholders of ProKidney and/or its affiliates participating in the PIPE Investment (the &#8220;ProKidney Related PIPE Investors&#8221;); provided that the ProKidney Related PIPE Investors may elect instead to purchase Post-Combination ProKidney Common Units, together with a corresponding number of Class&#160;B ordinary shares, in lieu of Class&#160;A ordinary shares. The Subscription Agreements are subject to certain conditions, including that there shall not be in force any injunction or order enjoining or prohibiting the issuance and sale of the shares under the Subscription Agreements; the terms of the ProKidney Business Combination Agreement shall not have been amended, and the minimum cash condition therein shall not have been waived, in a manner that is materially adverse to the investor party to the Subscription Agreement; and the representation and warranties of the parties to the Subscription Agreement shall be accurate (subject to agreed materiality </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">thresholds). </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Following the Closing, the combined company will be organized in an umbrella <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">partner</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ship-C</div> corporation (a so called <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Up-C&#8221;)</div> structure, and the Company&#8217;s direct assets will consist of ProKidney Common Units and equity interests of New GP, and substantially all of the operating assets and business of the Company will be held indirectly through ProKidney. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consummation of the proposed ProKidney Business Combination is subject to certain conditions as further described in the ProKidney Business Combination Agreement. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks and Uncertainties </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management </div></div>continues to evaluate the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and has concluded that while it is reasonably possible that the pandemic could have a negative effect on the Company&#8217;s business, financial position, results of operations and/or the search for a target company, the specific impact is not readily determinable as of the date of these condensed financial statements. The condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Going Concern </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31, 2022, the Company had $51,889 in its operating bank account and working capital deficit of $4,817,570. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Until the consummation of a Business Combination, the Company will be using the funds not held in the Trust Account for identifying and evaluating prospective acquisition candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to acquire, and structuring, negotiating and consummating the Business Combination. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may need to raise additional capital through loans or additional investments from its Sponsor, shareholders, officers, directors, or third parties. The Company&#8217;s officers, directors and Sponsor may, but are not obligated to (other than pursuant to the Promissory Note (as defined in Note 9)), loan the Company additional funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet the Company&#8217;s working capital needs. Accordingly, the Company may not be able to obtain such additional financing. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern for a reasonable period of time, which is considered to be one year from the issuance date of the condensed financial statements. These condensed financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">We have performed an assessment of going concern considerations in accordance with Financial Accounting Standard Board&#8217;s Accounting Standards Update (&#8220;ASU&#8221;) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2014-15,</div> &#8220;Disclosures of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern.&#8221; We have until July&#160;2, 2023 to consummate a Business Combination, which date may be extended pursuant to its Amended and Restated Memorandum and Articles of Association. It is uncertain that the Company will be able to consummate a Business Combination by July&#160;2, 2023. If a Business Combination is not consummated by this date and such date is not extended pursuant to the Company&#8217;s Amended and Restated Memorandum and Articles of Association, there will be a mandatory liquidation and subsequent dissolution of the Company. Management has determined that the mandatory liquidation, should a Business Combination not occur within the required time period, and potential subsequent dissolution raises substantial doubt about the Company&#8217;s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after July&#160;2, 2023. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <span></span>
</td>
<td class="text"><div id="fincov373959_6" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 1. DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN </div></div></div></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Social Capital Suvretta Holdings Corp. III (the &#8220;Company&#8221;) is a blank check company incorporated as a Cayman Islands exempted company on February&#160;25, 2021. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (a &#8220;Business Combination&#8221;). </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of December&#160;31, 2021, the Company had not commenced&#160;any operations. All activity for the period from February 25, 2021 (inception) through December&#160;31, 2021 relates to the Company&#8217;s formation, the initial public offering (the &#8220;Initial Public Offering&#8221;), described below, and, subsequent to the Initial Public Offering, identifying a target company for a Business Combination and activities in connection with the proposed acquisition of ProKidney LP (see Note 9). The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company generates <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-operating</div> income in the form of interest income from the marketable securities held in the Trust Account (as defined below). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The registration statements for the Company&#8217;s Initial Public Offering became effective on June&#160;29, 2021 and June&#160;30, 2021. On July&#160;2, 2021, the Company consummated the Initial Public Offering of 25,000,000 Class&#160;A ordinary shares (the &#8220;Public Shares&#8221;), which includes the partial exercise by the underwriters of their over-allotment option in the amount of 3,000,000 Public Shares, at $10.00 per Public Share, generating gross proceeds of $250,000,000, which is described in </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">Note 3. The fair value attributable to the unexercised portion of the over-allotment option was deemed to be immaterial to the financial statements.</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">Substantially concurrently with the closing of the Initial Public Offering<div style="letter-spacing: 0px; top: 0px;;display:inline;">, </div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the Company consummated the sale of 640,000 Class&#160;A ordinary shares (the &#8220;Private Placement Shares&#8221;) at a price of $10.00 per Private Placement Share in a private placement to SCS Sponsor III LLC, a Cayman Islands limited liability company (the &#8220;Sponsor&#8221;), generating gross proceeds of $6,400,000, which is described in Note 4. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Transaction costs amounted to $12,479,666, consisting of $4,400,000 of underwriting fees, $7,700,000 of deferred underwriting fees and $379,666 of other offering costs. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In connection with the closing of the Initial Public Offering on July&#160;2, 2021, an amount of $250,000,000 ($10.00 per Public Share) from the net proceeds of the sale of the Public Shares in the Initial Public Offering and the sale of the Private Placement Shares was placed in a trust account (the &#8220;Trust Account&#8221;), and invested in U.S. government treasury bills with a maturity of 185 days or less or in money market funds investing solely in U.S. Treasuries and meeting certain conditions of Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2a-7</div> of the Investment Company Act of 1940, as amended (the &#8220;Investment Company Act&#8221;). Except with respect to interest earned on the funds held in the Trust Account that may be released to the Company to pay its taxes, if any, the funds held in the Trust Account will not be released from the Trust Account until the earliest of: (a)&#160;the completion of a Business Combination, and then only in connection with those Public Shares that such shareholder properly elected to redeem, subject to certain limitations; (b)&#160;the redemption of any Public Shares properly submitted in connection with a shareholder vote to amend the Company&#8217;s Amended and Restated Memorandum and Articles of Association (i)&#160;to modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with the Business Combination or to redeem 100<div style="letter-spacing: 0px; top: 0px;;display:inline;">% of the Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (ii)&#160;with respect to any other material provisions relating to shareholders&#8217; rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-Business</div> Combination activity; and (c)&#160;the redemption of the Public Shares if the Company has not completed a Business Combination within the Combination Period or during any applicable extension period. The proceeds deposited in the Trust Account could become subject to the claims of the Company&#8217;s creditors, if any, which could have priority over the claims of the holders of the Public Shares (the &#8220;Public Shareholders&#8221;). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company&#8217;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Shares, although substantially </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">all of </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">the net proceeds are intended to be applied generally toward consummating a Business Combination. The Company must complete one or more Business Combinations having an aggregate fair market value of </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">at least 80% of the value of the assets held in the Trust Account (excluding any deferred underwriting commissions and taxes payable on the income earned on the Trust Account) at the time of the Company signing a definitive agreement in connection with the Business Combination. However, the Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to complete a Business Combination successfully. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company will provide the Public Shareholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of the Business Combination, either (a)&#160;in connection with a general meeting called to approve the Business Combination or (b)&#160;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company. The Public Shareholders will be entitled to redeem all or a portion of their Public Shares at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, calculated as of two business days prior to the consummation of the Business Combination, including interest (which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares, subject to the limitations described below. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In accordance with the Company&#8217;s Amended and Restated Memorandum and Articles of Association, in no event will the Company redeem the Public Shares in an amount that would cause the Company&#8217;s net tangible assets to be less than $5,000,001 following such redemptions. Redemptions of the Public Shares may also be subject to a higher net tangible asset test or cash requirement pursuant to an agreement relating to the Business Combination.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">If a shareholder vote is not required in connection with a Business Combination and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (the &#8220;SEC&#8221;), and file tender offer documents with the SEC prior to completing a Business Combination. If, however, shareholder approval of the transaction is required by applicable law or stock exchange listing requirement, or the Company decides to obtain shareholder approval for business or other reasons, the Company will conduct the redemptions in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules and will file proxy materials with the SEC. If the Company seeks shareholder approval in connection with a Business Combination, the Company will complete such Business Combination only if the Company receives an ordinary resolution under Cayman Islands law, which requires the affirmative vote of holders of a majority of ordinary shares who attend and vote at a general meeting of the Company. The Public Shareholders may elect to redeem their Public Shares without voting and, if they do vote, irrespective of whether they vote for or against a Business Combination. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Notwithstanding the foregoing redemption rights, if the Company seeks shareholder approval of the Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, the Company&#8217;s Amended and Restated Memorandum and Articles of Association provide that a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &#8220;group&#8221; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)), will be restricted from redeeming its Public Shares with respect to more than an aggregate of 15</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">% of the Public Shares without the Company&#8217;s prior written consent. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsor and the Company&#8217;s directors and officers have agreed to waive: (a)&#160;their redemption rights with respect to any Founder Shares, Private Placement Shares and Public Shares held by them, as applicable, in connection with the completion of a Business Combination; (b)&#160;their redemption rights with respect to any Founder Shares, Private Placement Shares and Public Shares held by them in connection with a shareholder vote </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">to amend the Company&#8217;s Amended and Restated Memorandum and Articles of Association (i)&#160;to modify the substance or timing of the Company&#8217;s obligation to allow redemption in connection with the Business Combination or to </div></div>redeem 100<div style="letter-spacing: 0px; top: 0px;;display:inline;">% of the Public Shares if the Company does not complete a Business Combination within the Combination Period, or (ii)&#160;with respect to any other material provisions relating to shareholders&#8217; rights or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">pre-Business</div> Combination activity; and (c)&#160;their rights to liquidating distributions from the Trust Account with respect to any Founder Shares and Private Placement Shares they hold if the Company fails to complete a Business Combination within the Combination Period or during any applicable extension period (although such persons will be entitled to liquidating distributions from the Trust Account with respect to any Public Shares they hold if the Company fails to complete a Business Combination within the prescribed time frame). If the Company submits the Business Combination to the Public Shareholders for a vote, the Sponsor and the Company&#8217;s directors and officers have also agreed to vote any Founder Shares, Private Placement Shares and Public Shares held by them in favor of the Business Combination. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company will have until July&#160;</div></div>2, 2023 to complete a Business Combination (the &#8220;Combination Period&#8221;), or such longer period as a result of a shareholder vote to amend such time period pursuant to the Company&#8217;s Amended and Restated Memorandum and Articles of Association. However, if the Company has not completed a Business Combination within such Combination Period or during any applicable extension period, the Company will: (a)&#160;cease all operations except for the purpose of winding up; (b)&#160;as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less up to $100,000 of interest to pay dissolution expenses and which interest shall be net of taxes payable) divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish the Public Shareholders&#8217; rights as shareholders (including the right to receive further liquidating distributions, if any); and (c)&#160;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#8217;s remaining shareholders and its board of directors, liquidate and dissolve, subject in each case to the Company&#8217;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company&#8217;s independent auditors) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1) $10.00</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>per Public Share or (2)&#160;such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, due to reductions in the value of the trust assets, in each case net of the interest which may be withdrawn to pay taxes, except as to any claims by a third party that executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company&#8217;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company has not independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and believes that the Sponsor&#8217;s only assets are securities of the Company and, therefore, the Sponsor may not be able to satisfy those obligations. The Company has not asked the Sponsor to reserve for such obligations. None of the Company&#8217;s directors or officers will indemnify the Company for claims by third parties, including, without limitation, claims by vendors and prospective target businesses. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Risks and Uncertainties </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Management continues to evaluate the impact of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">COVID-19</div> pandemic and has concluded that while it is reasonably possible that the pandemic could have a negative effect on the Company&#8217;s business, financial position, results of operations and/or the search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liquidity and Going Concern </div></div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, the Company had $440,488 in its operating bank accounts and working capital deficit of $935,119. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Until the consummation of a Business Combination, the Company will be using the funds not held in the Trust Account for identifying and evaluating prospective acquisition candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to acquire, and structuring, negotiating and consummating the Business Combination. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company may need to raise additional capital through loans or additional investments from its Sponsor, shareholders, officers, directors, or third parties. The Company&#8217;s officers, directors and Sponsor may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet the Company&#8217;s working capital needs. Accordingly, the Company may not be able to obtain additional financing. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. These conditions raise substantial doubt about the Company&#8217;s ability to continue as a going concern for a reasonable period of time, which is considered to be one year from the issuance date of the financial statements. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern. </div></div> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701424816064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 2: Significant Accounting Policies </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The condensed consolidated financial statements reflect the operations of ProKidney and its wholly-owned subsidiaries consisting of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> (together, the &#8220;Company&#8221;). All intercompany transactions and accounts have been eliminated. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair presentation of the Company&#8217;s financial information. These interim results and cash flows for any interim period are not necessarily indicative of the results to be expected for the full year. Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States of America (GAAP) as found in the Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB). These unaudited consolidated financial statements are presented in U.S. Dollars. </div></div>  <div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Going Concern </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company performed an analysis of its ability to continue as a going concern. As of March&#160;31, 2022, the Company had an accumulated deficit of $228,996,000. The Company has generated losses from operations for each year since its inception. The Company intends to continue to conduct significant additional research, development, and clinical study activities which, together with expenses incurred for general and administrative expenses, are expected to result in continuing operating losses for the foreseeable future. The amount of future losses and when, if ever, the Company will achieve profitability are uncertain. The Company&#8217;s ability to achieve profitability will depend, among other things, on successfully completing clinical studies, obtaining requisite regulatory approvals, establishing appropriate pricing for its product with payers, and raising sufficient funds to finance the Company&#8217;s activities. No assurance can be given that the Company&#8217;s clinical development efforts will be successful, that regulatory approvals will be obtained, or that the Company will be able to achieve appropriate pricing and market access or that profitability, if achieved, can be sustained. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These matters raise substantial doubt about the Company&#8217;s ability to continue as a going concern. As of March&#160;31, 2022, the Company has cash and cash equivalents of $29,802,000, and remaining availability of $80,000,000 under its two promissory note agreements with certain holders of its Class&#160;A Units (the &#8220;Promissory Notes&#8221;). The Company believes that these sources of liquidity will not be sufficient to fund its obligations for the next twelve months. The condensed consolidated financial statements do not include any adjustments related to the outcome of this uncertainty. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to execute our operating plan depends on our ability to obtain additional funding through equity offerings, debt financings or potential licensing and collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to us. Even if we raise additional capital, we may also be required to modify, delay or abandon some of our plans which could have a material adverse effect on our business, operating results and financial condition and our ability to achieve our intended business objectives. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of condensed consolidated financial statements, in accordance with GAAP, requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of expenses during the reported periods. Certain estimates in these condensed consolidated financial statements have been made in connection with the calculation of research and development expenses, equity-based compensation expense and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections, which management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all highly liquid investments with an original maturity of 90 days or less on the date of purchase to be cash equivalents. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concentrations of Credit Risk </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company&#8217;s cash and equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses as presented in the Condensed Consolidated Balance Sheets as of March&#160;31, 2022 and December&#160;31, 2021 consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">818</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,832</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinical study related costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">653</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,031</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued legal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,095</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">964</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Manufacturing improvement costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,137</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,164</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">414</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">222</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued expenses and other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,117</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,213</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>   <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development Costs </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries, benefits, third party license fees, and external costs of outside vendors engaged to conduct manufacturing and preclinical development activities and clinical trials. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records accruals based on estimates of services received, efforts expended, and amounts owed pursuant to contracts with numerous contract research organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company&#8217;s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company&#8217;s estimate of the degree of completion of the event or events specified in the specific clinical study. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Condensed Consolidated Statement of Operations and Comprehensive Loss as the Company receives the related goods or services. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Costs incurred in obtaining technology licenses are charged to research and development expense as purchased <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development if the technology licensed has not reached technological feasibility and has no alternative future use. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed Assets </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets are stated at cost, less accumulated depreciation. Generally, expenditures for maintenance and repairs are charged to expense and major improvements or replacements are capitalized. The Company computes depreciation and amortization using the straight-line method over the estimated useful life of the asset. Leasehold improvements are amortized over the lesser of, the life of the lease or the estimated useful life of the leasehold improvement. The estimated useful lives are as follows: </div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment and software</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-5</div> years</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-7</div> years</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">remainder of lease term</td></tr></table>  <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets consisted of the following (in thousands): </div></div></div><div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,220</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,180</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment and software</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">589</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">569</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,520</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,517</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Construction in progress</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">631</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">351</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: accumulated depreciation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,857</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,259</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total fixed assets, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,103</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,358</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation expense for the three months ended March&#160;31, 2022 and 2021 was $593,000 and $176,000, respectively. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible Assets </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets are comprised of acquired assembled workforce, which are accounted for in accordance with ASC 350&#8212;Intangibles&#8212;Goodwill and Other. The acquired assembled workforce is amortized on a straight-line basis over the useful life of five years. The following table summarizes information related to the Company&#8217;s assembled workforce intangible asset (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross carrying amount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,073</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,073</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">699</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">645</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net carrying amount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">374</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">428</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated amortization expense for the remaining nine months of 2022 is $154,000, $215,000 for the year ended December&#160;31, 2023 and $5,000 for the year ended December&#160;31, 2024. Amortization expense relating to the assembled workforce intangible asset was $54,000 for each of the three months ended March&#160;31, 2022 and 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairment of Long-Lived Assets </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-lived assets such as fixed assets and intangible assets subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. No impairment charges have been recorded for the three months ended March&#160;31, 2022 or 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company was organized as a limited liability company, is now a limited partnership and is classified as a partnership for U.S. income tax purposes, and as such, only records a provision for federal and state income taxes on its subsidiaries organized as C corporations or which have elected to be treated as corporations for U.S. federal income tax purposes. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> is a limited liability company and has elected to be treated as a C corporation. Therefore, a provision for federal and state taxes has been recorded. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> has been granted, by the Government in Council of the Cayman Islands, tax concessions under an undertaking certificate exempting it from any tax levied on profits, income, gains or appreciations in relation to its operations or in the nature of estate duty or inheritance tax for a period of twenty years from January&#160;20, 2016. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> elected to be treated as an entity disregarded from its owner for U.S. tax purposes, and as a result, it has not recorded an income tax provision. <br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company uses the liability method in accounting for income taxes as required by ASC Topic 740 &#8212; Income Taxes, under which deferred tax assets and liabilities are recorded for the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that such assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, available taxes in the carryback periods, projected future taxable income and tax planning strategies in making this assessment. Accordingly, the Company has provided a full valuation allowance to offset the net deferred tax assets at March&#160;31, 2022 and December&#160;31, 2021. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest and penalties related to income taxes are included in the benefit (provision) for income taxes in the Company&#8217;s Condensed Consolidated Statements of Operations and Comprehensive Loss. The Company has not incurred any significant interest or penalties related to income taxes in any of the periods presented. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">three-level</div> fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three&#160;levels of inputs used to measure fair value are as follows: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1 &#8211; Unadjusted quoted prices in active markets for identical assets or liabilities </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2 &#8211; Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable through correlation with market data </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3 &#8211; Unobservable inputs that are supported by little or no market data, which require the reporting entity to develop its own assumptions </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The carrying values of cash equivalents, accounts payable, and accrued liabilities approximate fair value due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">short-term</div> nature of these instruments. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leases </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company determines if an arrangement is a lease at inception.&#160;Balances recognized related to the Company&#8217;s operating and finance leases are included in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets, net and lease liabilities in the Condensed Consolidated Balance Sheets.&#160;Right of use assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date.&#160;Lease terms may include options to extend or terminate the lease if it is reasonably certain that the Company will exercise the option.&#160;As most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments.&#160;The right of use asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred.&#160;The Company has elected a practical expedient to not separate its lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components and instead account for them as a single lease component. Leases with a term of 12 months or less are not recorded on the balance sheet. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.&#160;Lease payments for short-term leases are recorded to operating expense on a straight-line basis and variable lease payments are recorded in the period in which the obligation for those payments is incurred. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent Liabilities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records reserves for contingent liabilities when it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements, and the amount of the loss can be reasonably estimated. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity-Based Compensation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Deed for the Establishment of a Limited Partnership of ProKidney LP, dated as of August&#160;5, 2021 (the &#8220;Limited Partnership Agreement&#8221;) which replaced the Amended and Restated Limited Liability Company Agreement of ProKidney LLC as the governing document of the parent entity in the Company, allows for the issuance of Profits Interests (as defined in the Limited Partnership Agreement) to employees, directors, other service providers of the Company and others denominated in the form of one or more Class&#160;B Units (as defined in the Limited Partnership Agreement). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On January&#160;17, 2022, the Company amended and restated its Limited Partnership Agreement (the &#8220;Amended and Restated Limited Partnership Agreement&#8221;) in part to authorize the issuance of up to 50,000,000 Class&#160;B Units (including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B-1</div> Units). The Amended and Restated Limited Partnership Agreement provides that certain qualified distribution events will result in holders of Profits Interests receiving disproportionate distributions from ProKidney until each such holder&#8217;s valuation threshold has been reduced to zero in order to &#8220;catch up&#8221; such holder&#8217;s distributions to its pro rata share of aggregate cumulative distributions, and once sufficient distributions to a holder of Profits Interests have been made in accordance with the foregoing, the associated Class&#160;B Units will automatically be converted into Class&#160;A Units. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures compensation expense for Profits Interests based on estimated fair values at the time of grant. The Company estimates the fair value of Profits Interests using generally accepted valuation procedures. The Company recognizes compensation expense, on a straight-line basis, for the portion of the Profits Interests&#8217; value that is expected to vest over the requisite service period. The Company records forfeitures of Profits Interests as they occur. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company operates in only one segment. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recently Adopted Accounting Pronouncements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In February 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-02,</div> Leases (Topic 842), which requires lessees to recognize a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset and a liability on the balance sheet for all leases, with the exception of short-term leases. The lease liability will be equal to the present value of lease payments, and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset will be based on the lease liability, subject to adjustment such as for initial direct costs. Leases will continue to be classified as either operating or finance leases in the income statement. The guidance is effective for annual periods beginning after December&#160;15, 2021, with early adoption permitted. The Company early adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-02,</div> Leases (Topic 842), as of January&#160;1, 2021. For additional detail, see Note 4, Leases. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsequent Events </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has evaluated subsequent events through June 10, 2022, which is the date the consolidated financial statements were available to be issued. See additional information in Note 9. </div></div> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 2: Significant Accounting Policies </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The consolidated financial statements reflect the operations of ProKidney and its wholly-owned subsidiaries consisting of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> (together, the &#8220;Company&#8221;). All intercompany transactions and accounts have been eliminated. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). These consolidated financial statements are presented in U.S. Dollars. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Going Concern </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company performed an analysis of its ability to continue as a going concern. As of December&#160;31, 2021, the Company had an accumulated deficit of $161,510,000. The Company has generated losses from operations for each year since its inception including losses from operations of $55,146,000 and $26,749,000 for the years ended December&#160;31, 2021 and 2020, respectively. The Company intends to continue to conduct significant </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">additional research, development, and clinical study activities which, together with expenses incurred for general and administrative expenses, are expected to result in continuing operating losses for the foreseeable future. The amount of future losses and when, if ever, the Company will achieve profitability are uncertain. The Company&#8217;s ability to achieve profitability will depend, among other things, on successfully completing clinical studies, obtaining requisite regulatory approvals, establishing appropriate pricing for its product with payers, and raising sufficient funds to finance the Company&#8217;s activities. No assurance can be given that the Company&#8217;s clinical development efforts will be successful, that regulatory approvals will be obtained, or that the Company will be able to achieve appropriate pricing and market access or that profitability, if achieved, can be sustained. These matters raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company believes that, based on its current business plan, its existing cash and cash equivalents of $20,558,000 at December&#160;31, 2021 will not be sufficient to fund its obligations for the next 12 months. The consolidated financial statements do not include any adjustments related to the outcome of this uncertainty. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to execute our operating plan depends on our ability to obtain additional funding through equity offerings, debt financings or potential licensing and collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to us. Even if we raise additional capital, we may also be required to modify, delay or abandon some of our plans which could have a material adverse effect on our business, operating results and financial condition and our ability to achieve our intended business objectives. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of consolidated financial statements, in accordance with GAAP, requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the amounts of expenses during the reported periods. Certain estimates in these consolidated financial statements have been made in connection with the calculation of research and development expenses, equity-based compensation expense and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections, which management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all highly liquid investments with an original maturity of 90 days or less on the date of purchase to be cash equivalents. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concentrations of Credit Risk </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company&#8217;s cash and equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses which have been presented on the consolidated balance sheets as of December&#160;31, 2021 and 2020 consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,832</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,085</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinical study related costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,031</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,154</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Facility expansion costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,709</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued legal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">964</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Manufacturing improvement costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,164</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">203</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">548</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued expenses and other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,213</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,496</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>   <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development Costs </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries, benefits, third party license fees, and external costs of outside vendors engaged to conduct manufacturing and preclinical development activities and clinical trials. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records accruals based on estimates of services received, efforts expended, and amounts owed pursuant to contracts with numerous contract research organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company&#8217;s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the company&#8217;s estimate of the degree of completion of the event or events specified in the specific clinical study. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Statement of Operations and Comprehensive Loss as the Company receives the related goods or services. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Costs incurred in obtaining technology licenses are charged to research and development expense as purchased <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development if the technology licensed has not reached technological feasibility and has no alternative future use. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed Assets </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets are stated at cost, less accumulated depreciation. Generally, expenditures for maintenance and repairs are charged to expense and major improvements or replacements are capitalized. The Company computes depreciation and amortization using the straight-line method over the estimated useful life of the asset. Leasehold improvements are amortized over the lesser of, the life of the lease or the estimated useful life of the leasehold improvement. The estimated useful lives are as follows: </div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 51%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 46%; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment and software</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5</div> years</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">7</div> years</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">remainder of lease term</td></tr></table>   <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,180</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,011</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment and software</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">569</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">130</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,517</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Construction in progress</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">351</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,854</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: accumulated depreciation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,259</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,157</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total fixed assets, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,358</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,914</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation expense for the years ended December&#160;31, 2021 and 2020 was $1,451,000 and $606,000, respectively. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible Assets </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets are comprised of acquired assembled workforce, which are accounted for in accordance with ASC 350&#8212;Intangibles&#8212;Goodwill and Other. The acquired assembled workforce is amortized on a straight-line basis over the useful life of five years. The following table summarizes information related to the Company&#8217;s assembled workforce intangible asset (in thousands): </div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross carrying amount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,073</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,073</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">645</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">431</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net carrying amount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">428</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">642</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated amortization expense for each of the years 2022 through 2023 is $215,000 and $5,000 for 2024. Amortization expense relating to the assembled workforce intangible asset was $214,000 for the year ended December&#160;31, 2021 and $215,000 for the year ended December&#160;31, 2020. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairment of Long-Lived Assets </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-lived assets such as fixed assets and intangible assets subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. No impairment charges have been recorded for the years ended December&#160;31, 2021 or 2020. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company was organized as a limited liability company, is now a limited partnership and is classified as a partnership for U.S. income tax purposes, and as such, only records a provision for federal and state income taxes on its subsidiaries organized as C corporations or which have elected to be treated as corporations for U.S. federal income tax purposes. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> is a limited liability company and has elected to be treated as a C&#160;corporation. Therefore, a provision for federal and state taxes has been recorded. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> has been granted, by the Government in Council of the Cayman Islands, tax concessions under an undertaking certificate exempting it from any tax levied on profits, income, gains or appreciations in relation to its operations or in the nature of estate duty or inheritance tax for a period of twenty years from January&#160;20, 2016. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> elected to be treated as an entity disregarded from its owner for U.S. tax purposes, and as a result, it has not recorded an income tax provision. </div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company uses the liability method in accounting for income taxes as required by ASC Topic 740&#160;&#8212; Income Taxes, under which deferred tax assets and liabilities are recorded for the future tax consequences attributable to the differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that such assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, available taxes in the carryback periods, projected future taxable income and tax planning strategies in making this assessment. Accordingly, the Company has provided a full valuation allowance to offset the net deferred tax assets at December&#160;31, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest and penalties related to income taxes are included in the benefit (provision) for income taxes in the Company&#8217;s Consolidated Statements of Operations. The Company has not incurred any significant interest or penalties related to income taxes in any of the periods presented. </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 9%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td style="width: 89%;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Level&#160;1&#160;&#8211;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Unadjusted quoted prices in active markets for identical assets or liabilities</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Level&#160;2&#160;&#8211;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable through correlation with market data</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Level&#160;3&#160;&#8211;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Unobservable inputs that are supported by little or no market data, which require the reporting entity to develop its own assumptions</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The carrying values of cash equivalents, accounts payable, and accrued liabilities approximate fair value due to the short-term nature of these instruments. There are no <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities included in cash and cash equivalents as of December&#160;31, 2021 and 2020. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leases </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company determines if an arrangement is a lease at inception. Balances recognized related to the Company&#8217;s operating and finance leases are included in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets, net and lease liabilities in the Consolidated Balance Sheets. Right of use assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Lease terms may include options to extend or terminate the lease if it is reasonably certain that the Company will exercise the option. As most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. The right of use asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company has elected a practical expedient to not separate its lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components and instead account for them as a single lease component. Leases with a term of 12 months or less are not recorded on the balance sheet. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Lease payments for short-term leases are recorded to operating expense on a straight-line basis and variable lease payments are recorded in the period in which the obligation for those payments is incurred. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>  <div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent Liabilities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records reserves for contingent liabilities when it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements, and the amount of the loss can be reasonably estimated. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity-Based Compensation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Deed for the Establishment of a Limited Partnership of ProKidney LP, dated as of August&#160;5, 2021 (the &#8220;Limited Partnership Agreement&#8221;) which replaced the Amended and Restated Limited Liability Company Agreement of ProKidney LLC as the governing document of the parent entity in the Company, allows for the issuance of Profits Interests (as defined in the Limited Partnership Agreement) to employees, directors, other service providers of the Company and others denominated in the form of one or more Class&#160;B Units (as defined in the Limited Partnership Agreement). The Company measures compensation expense for Profits Interests based on estimated fair values at the time of grant. The Company estimates the fair value of Profits Interests using generally accepted valuation procedures. The Company recognizes compensation expense, on a straight-line basis, for the portion of the Profits Interests&#8217; value that is expected to vest over the requisite service period. The Company records forfeitures of Profits Interests as they occur. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Defined Contribution Plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company sponsors a 401(k) plan for its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> employees and a defined contribution plan for its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> employees. Full-time employees are eligible to participate in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> plan. The Company matches 50% of participating <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> employees&#8217; contributions up to 8% of salary. The costs of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> plan were $161,000 and $119,000 for the years ended December&#160;31, 2021 and 2020, respectively. The Company contributes 7% of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> employee salaries to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> defined contribution plan. The costs of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> plan were $8,000 and $20,000 for the years ended December&#160;31, 2021 and 2020, respectively. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company operates in only one segment. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recently Adopted Accounting Pronouncements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In February 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-02,</div> Leases (Topic 842), which requires lessees to recognize a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset and a liability on the balance sheet for all leases, with the exception of short-term leases. The lease liability will be equal to the present value of lease payments, and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset will be based on the lease liability, subject to adjustment such as for initial direct costs. Leases will continue to be classified as either operating or finance leases in the income statement. The guidance is effective for annual periods beginning after December&#160;15, 2021, with early adoption permitted. The Company early adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-02,</div> Leases (Topic 842), as of January&#160;1, 2021. For additional detail, see Note 4, Leases. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsequent Events </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has evaluated subsequent events through April&#160;11, 2022, which is the date the consolidated financial statements were available to be issued. See additional information in Notes 5 and 8. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 3: Income Taxes </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company&#8217;s subsidiary, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US,</div> is treated as a C corporation, and therefore a provision for federal and state taxes has been recorded. </div> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember', window );">Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </div></div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The </div>accompanying unaudited condensed financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and in accordance with the instructions to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;10-Q</div> and Article&#160;8 of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Regulation&#160;S-X</div> of the SEC. Certain information or footnote disclosures normally included in condensed financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements contained in the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the period ended December&#160;31, 2021 filed with the SEC on March&#160;24, 2022. The interim results for the three months ended March&#160;31, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022 or for any future periods. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s condensed financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. <br/></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates</div></div></div></div><br/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Significant accounting estimates include the determination of the fair value of Class&#160;A ordinary shares subject to possible redemption and the fair value of Founder Shares transferred to directors. Accordingly, the actual results could differ significantly from those estimates.</div></div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of March&#160;31, 2022 and December&#160;31, 2021. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Marketable Securities Held in Trust Account </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At March&#160;31, 2022 and December&#160;31, 2021, substantially all of the assets held in the Trust Account were held in a money market fund which is invested primarily in U.S. Treasury securities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class&#160;A Ordinary Shares Subject to Possible Redemption </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its Class&#160;A ordinary shares subject to possible redemption in accordance with the guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 480, &#8220;Distinguishing Liabilities from Equity.&#8221; Class&#160;A ordinary shares subject to mandatory redemption are classified as a liability instrument and are measured at redemption value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) are classified as temporary equity. At all other times, ordinary shares are classified as permanent deficit. The Company&#8217;s Class&#160;A ordinary shares feature certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events. Accordingly, Class&#160;A ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the permanent deficit section of the Company&#8217;s condensed balance sheets. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying value of redeemable ordinary shares are affected by charges against additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital (to the extent available) and accumulated deficit. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At March&#160;31, 2022 and December&#160;31, 2021, the Class&#160;A ordinary shares subject to possible redemption reflected in the condensed balance sheets are reconciled in the following </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">table: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-size: 0px;">
<td style="width: 77%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares issuance costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,479,666</td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,487,990</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Class&#160;A ordinary shares subject to possible redemption, December&#160;31, <br/>2021</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">250,008,324</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr>
<td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"><br/></div></div> </td>
<td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;">&#160;</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Remeasurement of carrying value to redemption value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,324</td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares subject to possible redemption, March&#160;31, 2022</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">250,000,000</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr>
<td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"><br/></div></div> </td>
<td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;">&#160;</div></div></div> </td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Offering Costs </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div>complies with the requirements of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASC&#160;340-10-S99-1.&#160;Offering&#160;costs</div></div></div> consisted of legal, accounting, underwriting fees and other costs incurred through the Initial Public Offering that were directly related to the Initial Public Offering. The Company incurred offering costs amounting to $12,479,666 as a result of the Initial Public Offering, consisting of $4,400,000 of underwriting commissions, $7,700,000 of deferred underwriting commissions, and $379,666&#160;of other offering costs. <div style="letter-spacing: 0px; top: 0px;;display:inline;">As the shares sold in the IPO are redeemable, the offering costs were charged to temporary equity and additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital upon the completion of the Initial Public Offering. Immediately thereafter, temporary equity was remeasured and an adjustment was recognized through additional paid in capital and accumulated deficit to adjust temporary equity to the redemption value. </div><br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-Based Payment Arrangements </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">accounts for stock awards in accordance with ASC 718, &#8220;Compensation&#8212;Stock Compensation,&#8221; which requires that all equity awards be accounted for at their &#8220;fair value.&#8221; Fair value is measured on the grant date and is equal to the underlying value of the stock. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Costs equal </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">to these fair values are recognized ratably over the requisite service period based on the number of awards that are expected to vest, in the period of grant for awards that vest immediately and have no future service condition, or in the period the awards vest immediately after meeting a performance condition becomes probable (i.e., the occurrence of a Business Combination). For awards that vest over time, cumulative adjustments in later periods are recorded to the extent actual forfeitures differ from the Company&#8217;s initial estimates; previously recognized compensation cost is reversed if the service or performance conditions are not satisfied and the award is&#160;forfeited. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes under ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the condensed financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s condensed financial statements and prescribes a recognition threshold and measurement process for condensed financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> to be sustained upon examination by taxing authorities. The Company&#8217;s management has determined that the Cayman Islands is the Company&#8217;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of March&#160;31, 2022 and December&#160;31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has been subject to income tax examinations by major taxing authorities since inception. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is considered to be an exempted Cayman Islands company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#8217;s tax provision was zero for the periods presented. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Loss per Ordinary Share </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per ordinary share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding during the period. The Company has two classes of ordinary shares, which are referred to as </div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares and Class&#160;B ordinary shares. Losses are shared pro rata between the two classes of shares. Charges associated with the redeemable Class&#160;A ordinary shares are excluded from net loss per ordinary share as the redemption value approximates fair value. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31, 2022 and 2021, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted net loss per ordinary share is the same as basic net loss per ordinary share for the periods presented. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/>March&#160;31, 2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Period from<br/>February&#160;25, 2021<br/>(Inception) Through</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per ordinary share</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,200,799</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(780,226</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,182</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average shares outstanding</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,640,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per ordinary share</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.12</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.12</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:rgba(255, 255, 255, .0);;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution which, at times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on these </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:rgba(255, 255, 255, .0);;display:inline;">accounts. </div></div></div><br/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; (&#8220;ASC 820&#8221;), approximates the carrying amounts represented in the accompanying condensed balance sheet, primarily due to their short-term nature. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Standards </div></div></div><br/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2020, the FASB issued ASU No. 2020-06, &#8220;Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity&#8221; (&#8220;ASU 2020-06&#8221;), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. The Company adopted ASU 2020-06 effective as of January 1, 2021. The adoption of ASU 2020-06 did not have an impact on the Company&#8217;s condensed financial statements. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s condensed financial statements.</div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accrued Expenses </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At March&#160;31, 2022, accrued expenses includes $4,095,414 of&#160;legal expense, $283,348 of printing expense, $529,688 of due diligence expense, $363,740 of professional fee expense and $70,000 of&#160;regulatory fee expe<div style="background-color:rgba(255, 255, 255, .0);;display:inline;">nse</div></div><div style="background-color:rgba(255, 255, 255, .0);;display:inline;">, of which $2,500,000 of legal expense, $247,188 of consulting expense and $534,906 of other transactional related expenses incurred in connection with the Business Combination with ProKidney.</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2021, accrued expenses includes $1,506,528&#160;of legal expense, $5,000&#160;of printing expense, $282,500&#160;of due diligence expense, $70,000&#160;of regulatory filing fee and $770&#160;of accounting expense. </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the SEC. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Significant accounting estimates include the determination of the fair value of Class&#160;A ordinary shares subject to possible redemption and the fair value of Founder Shares transferred to directors. Accordingly, the actual results could differ significantly from those estimates. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of December&#160;31, 2021.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Marketable Securities Held in Trust Account </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2021, substantially all of the assets held in the Trust Account were held in money market funds which are invested primarily in U.S. Treasury securities. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class&#160;A Ordinary Shares Subject to Possible Redemption </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its Class&#160;A ordinary shares subject to possible redemption in accordance with the guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 480, &#8220;Distinguishing Liabilities from Equity.&#8221; Class&#160;A ordinary shares subject to mandatory redemption are classified as a liability instrument and are measured at redemption value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders&#8217; equity. The Company&#8217;s Class&#160;A ordinary shares feature certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events. Accordingly, Class&#160;A ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the permanent deficit section of the Company&#8217;s balance sheet. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying value of redeemable ordinary shares are affected by charges against additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital (to the extent available) and accumulated deficit. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2021, the Class&#160;A ordinary shares subject to possible redemption reflected in the balance sheet are reconciled in the following table: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"/><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size: 0px;">
<td style="width: 77%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size: 0px;">
<td style="width: 83%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares issuance costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,479,666</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Increase of carrying value to redemption value</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,487,990</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares subject to possible redemption</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">250,008,324</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/>    <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Offering Costs </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div>complies with the requirements of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASC&#160;340-</div></div></div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-S99-1.&#160;Offering&#160;costs</div></div></div> consisted of legal, accounting, underwriting fees and other costs incurred through the Initial Public Offering that were directly related to the Initial Public Offering. The Company incurred offering costs amounting to $12,479,666 as a result of the Initial Public Offering, consisting of $4,400,000 of underwriting commissions, $7,700,000 of deferred underwriting commissions, and $379,666<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>of other offering costs. The offering costs were charged to temporary equity and additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital upon the completion of the Initial Public Offering. Immediately thereafter, temporary equity was remeasured and an adjustment was recognized through additional paid in capital and accumulated deficit to adjust temporary equity to the redemption value. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-Based Payment Arrangements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for stock awards in accordance with ASC 718, &#8220;Compensation&#8212;Stock Compensation,&#8221; which requires that all equity awards be accounted for at their &#8220;fair value.&#8221; Fair value is measured on the grant date and is equal to the underlying value of the stock. </div><br/></div>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Costs equal to these fair values are recognized ratably over the requisite service period based on the number of awards that are expected to vest, in the period of grant for awards that vest immediately and have no future service condition, or in the period the awards vest immediately after meeting a performance condition becomes probable (i.e., the occurrence of a Business Combination). For awards that vest over time, cumulative adjustments in later periods are recorded to the extent actual forfeitures differ from the Company&#8217;s initial estimates; previously recognized compensation cost is reversed if the service or performance conditions are not satisfied and the award is forfeited.</div></div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes under ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> to be sustained upon examination by taxing authorities. The Company&#8217;s management has determined that the Cayman Islands is the Company&#8217;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">amounts accrued for interest and penalties as of December&#160;31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is considered to be an exempted Cayman Islands company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#8217;s tax provision was zero for the period presented. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Loss Per Ordinary Share </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per ordinary share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding during the period. The Company has two classes of shares, which are referred to as Class&#160;A </div></div></div>  <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ordinary shares and Class&#160;B ordinary shares. Losses are shared pro rata between the two classes of shares. Charges associated with the redeemable Class&#160;A ordinary shares are excluded from net loss per ordinary share as the redemption value approximates fair value. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted net loss per ordinary share is the same as basic net loss per ordinary share for the periods presented. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Period from</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">February&#160;25, 2021 (Inception)<br/>Through December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per ordinary share</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net loss</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right;">(1,675,346</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div><br/></td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom;"><div style="line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div><br/></div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right;">(649,283</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div><br/></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average shares outstanding</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">15,101,877</td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">5,852,751</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-indent: 0px;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per ordinary share</div></div></td>
<td style="vertical-align: bottom;;text-indent: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div><br/></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px; text-align: right;">(0.11</td>
<td style="vertical-align: bottom;;text-indent: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div><br/></div></td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-indent: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div><br/></div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px; text-align: right;">(0.11</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:center;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div><br/></div></td></tr></table>   <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution which, at times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on these accounts. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature.</div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Standards </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2020, the FASB issued ASU No. 2020-06, &#8220;Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity&#8221; (&#8220;ASU 2020-06&#8221;), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. We adopted ASU 2020-06 effective as of January 1, 2021. The adoption of ASU 2020-06 did not have an impact on our financial statements. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s financial statements. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accrued Expense </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses </div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">includes $1,506,528 of accrued legal expense, $5,000 of accrued printing expense, $282,500 of accrued due diligence expense, $70,000 of accrued regulatory filing fee and $770 of accrued accounting expense.</div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701414235376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Initial Public Offering<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember', window );">Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_InitialPublicOfferingDisclosureTextBlock', window );">Initial Public Offering</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 3. INITIAL PUBLIC OFFERING </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Initial Public Offering, the Company sold 25,000,000 Public Shares, which includes a partial exercise by the underwriters of their over-allotment option in the amount of 3,000,000 Public Shares, at a price of $10.00 per Public Share. Unlike some other initial public offerings of special purpose acquisition companies, investors in the Initial Public Offering did not receive any warrants (which would typically become exercisable following completion of the Business Combination). The fair value attributable to the unexercised portion of the over-allotment option was deemed to be immaterial to the condensed financial statements. </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 3. INITIAL PUBLIC OFFERING </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to the Initial Public Offering, the Company sold 25,000,000 Public Shares, which includes a partial exercise by the underwriters of their over-allotment option in the amount of 3,000,000 Public Shares, at a price of $10.00 per Public Share. Unlike some other initial public offerings of special purpose acquisition companies, investors in the Initial Public Offering did not receive any warrants (which would typically become exercisable following completion of the Business </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;">Combination). The fair value attributable to the unexercised portion of the over-allotment option was deemed to be immaterial to the financial statements.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_InitialPublicOfferingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial public offering disclosure [text block].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_InitialPublicOfferingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701428242128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 3: Income Taxes </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company&#8217;s subsidiary, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US,</div> is treated as a C corporation, and therefore a provision for federal and state taxes has been recorded. The Company&#8217;s income tax provision for the three months ended March&#160;31, 2022 and 2021 were $1,010,000 and $6,000, respectively. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, available taxes in the carryback periods, projected future taxable income and tax planning strategies in making this assessment. The difference between the Company&#8217;s effective tax rate of (1.5)% for the three months ended March&#160;31, 2022 and the U.S. statutory rate of 21% is primarily attributable to the Company and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> being treated as partnerships for income tax purposes. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For tax years beginning after December&#160;31, 2021, the Tax Cuts and Jobs Act of 2017 (the &#8220;TCJA&#8221;) requires specified research and development expenses to be capitalized and amortized ratably over a five-year period. The adoption of this provision of the TCJA is the primary driver of income tax expense recognized during the three months ended March&#160;31, 2022. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are no net unrecognized tax benefits as of March&#160;31, 2022 which, if recognized, would affect our effective tax rate. We expect none of the gross unrecognized tax benefits will decrease within the next year. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There have been no significant changes in the Company&#8217;s uncertain tax positions during the three months ended March&#160;31, 2022. </div></div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 3: Income Taxes </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company&#8217;s subsidiary, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US,</div> is treated as a C corporation, and therefore a provision for federal and state taxes has been recorded. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The provision for income tax expense consisted of the following for the year ended December&#160;31, 2021 and 2020 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 14%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 14%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(242</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(34</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current income tax expense (benefit)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(232</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred income tax expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense (benefit)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(232</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The difference between the statutory rate for federal income tax and the effective income tax rate was as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes at statutory rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State taxes, net of federal benefit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LLC flow-through structure</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal Credits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provision to return adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective income tax rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Components of the Company&#8217;s deferred tax assets and liabilities included in the consolidated balance sheet consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued bonus</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">376</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">243</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">108</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal credit carryforwards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">939</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">331</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Start-up</div> costs</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets before valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,382</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">730</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,237</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">560</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">145</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">170</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">90</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">148</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">47</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">145</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">170</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net deferred tax asset</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, available taxes in the carryback periods, projected future taxable income and tax planning strategies in making this assessment. Accordingly, the Company has provided a valuation allowance of $1,237,000 and $560,000 respectively for December&#160;31, 2021 and 2020, to offset the net deferred tax assets. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has $1,118,000 in Research Credit Carryforwards that begin to expire in 2040. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of the beginning and ending amount of total unrecognized tax benefits for the years ended December&#160;31, 2021 and 2020 consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrecognized tax benefits (gross):</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Benefits at the beginning of the year</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase related to prior year tax positions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decrease related to prior year tax positions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase related to current year tax positions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">86</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Benefits at the end of the year</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">180</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">There are no net unrecognized tax benefits as of December&#160;31, 2021 which, if recognized, would affect our effective tax rate. We expect none of the gross unrecognized tax benefits will decrease within the next year. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">In March 2020, the World Health Organization declared coronavirus <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(COVID-19)</div> a global pandemic. This contagious disease outbreak, which continued to spread, and the related adverse public health developments, have adversely affected work forces, economies and financial markets globally. As a result, governments around the world have enacted legislation to provide aid and stimulate economies. In the U.S., The Coronavirus, Aid, Relief and Economics Security Act (&#8220;CARES Act&#8221;), was enacted on March&#160;27, 2020, The Consolidated Appropriations Act, 2021 was enacted on December&#160;27, 2020, and the American Rescue Plan Act of 2021 was enacted on March&#160;11, 2021. All of these acts included both income tax and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-income</div> tax provisions to assist companies. No provisions in these acts had a material impact on the income tax provision or any other area of the Company&#8217;s financial statements. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Tax years 2018 through 2021 remain subject to examination by federal and state authorities. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701416536144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Private Placement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember', window );">Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_PrivatePlacementDisclosureTextBlock', window );">Private Placement</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 4. PRIVATE PLACEMENT </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Substantially concurrently with the closing of the Initial Public Offering, the Sponsor purchased 640,000 Private Placement Shares at a price of $10.00 per Private Placement Share, for an aggregate purchase price of&#160;$6,400,000. Each Private Placement Share is identical to the Class&#160;A ordinary shares sold in the Initial Public Offering, subject to certain limited exceptions as described in Note 7. A portion of the proceeds from the sale of the Private Placement Shares was added to the net proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period or during any applicable extension period, the proceeds from the sale of the Private Placement Shares held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Shares will be worthless. </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 4. PRIVATE PLACEMENT </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Substantially concurrently </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">with the closing of the Initial Public Offering, the Sponsor purchased 640,000 Private Placement Shares at a price of $10.00 per Private Placement Share, for an aggregate purchase price of&#160;$6,400,000. Each Private Placement Share is identical to the Class&#160;A ordinary shares sold in the Initial Public Offering, subject to certain limited exceptions as described in Note 7. A portion of the proceeds from the sale of the Private Placement Shares was added to the net proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period or during any applicable extension period, the proceeds from the sale of the Private Placement Shares held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Shares will be worthless. </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_PrivatePlacementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Private placement disclosure [text block].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_PrivatePlacementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701428242256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 4: Leases </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In February 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02:</div> Leases (Topic 842). This ASU requires a lessee to recognize a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset and a lease liability on its balance sheet for most operating leases. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02</div> is effective for annual and interim periods beginning after December&#160;15, 2018, including interim periods within those fiscal years. In July 2018, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-11,</div> Leases (Topic 842): Targeted Improvements, which provides companies with an additional optional transition method to apply the new standard to leases in effect at the adoption date through a cumulative effect adjustment. The Company adopted the new lease standard as of January&#160;1, 2021 using the modified retrospective transition method. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company elected the package of practical expedients referenced in ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02,</div> which permits companies to retain original lease identification and classification without reassessing initial direct costs for existing leases. The Company also elected the practical expedient that exempts leases with an initial lease term of twelve months or less, as well as the practical expedient that allows companies to select, by class of underlying asset, not to separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components. Adoption of this standard resulted in the recognition of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset and a lease liability on the Company&#8217;s January&#160;1, 2021 Consolidated Balance Sheet of $1,560,000 and $1,559,000 respectively. There was no material impact on the Company&#8217;s Condensed Consolidated Statement of Operations and Comprehensive Loss. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has operating leases for real estate (primarily office space) and certain equipment with various expiration dates. The Company also has one finance lease for certain equipment.&#160;&#160;&#160;&#160;Rent expense was $89,000 and $81,000, for the three months ended March&#160;31, 2022 and 2021, respectively. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the classification of operating and finance lease assets and obligations in the Company&#8217;s Condensed Consolidated Balance Sheets as of March&#160;31, 2022 and December&#160;31, 2021 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating leases:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Right of use assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,579</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,139</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities, current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">295</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">235</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities, noncurrent</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,354</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">985</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,649</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,220</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr>
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finance leases:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Right of use assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">102</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finance lease liabilities, current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finance lease liabilities, noncurrent</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">82</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total finance lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">107</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">114</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturities of lease liabilities for the Company&#8217;s operating and finance leases are as follows for the year ending March&#160;31, 2022 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating<br/>Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Finance<br/>Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022 (remaining nine months)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">315</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">345</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">428</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">468</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">440</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">480</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">440</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">447</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">355</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">355</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,993</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">117</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(344</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(354</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,649</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">107</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,756</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average remaining lease term for operating leases is 4.5 years, and 3.0 years for the finance lease. The weighted average discount rate is 8.5%. </div></div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 4: Leases </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In February 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02:</div> Leases (Topic 842). This ASU requires a lessee to recognize a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset and a lease liability on its balance sheet for most operating leases. ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02</div> is effective for annual and interim periods beginning after December&#160;15, 2018, including interim periods within those fiscal years. In July 2018, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2018-11,</div> Leases (Topic 842): Targeted Improvements, which provides companies with an additional optional transition method to apply the new standard to leases in effect at the adoption date through a cumulative effect adjustment. The Company adopted the new lease standard as of January&#160;1, 2021 using the modified retrospective transition method. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company elected the package of practical expedients referenced in ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02,</div> which permits companies to retain original lease identification and classification without reassessing initial direct costs for existing leases. The Company also elected the practical expedient that exempts leases with an initial lease term of 12 months or less, as well as the practical expedient that allows companies to select, by class of underlying asset, </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">not to separate lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components. Adoption of this standard resulted in the recognition of a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset and a lease liability on the Company&#8217;s January&#160;1, 2021 Consolidated Balance Sheet of $1,560,000 and $1,559,000 respectively. There was no material impact on the Company&#8217;s Consolidated Statement of Comprehensive Loss. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has operating leases for real estate (primarily office space) and certain equipment with various expiration dates. The Company also has one finance lease for certain equipment. Rent expense was $434,000 and $314,000, for the years ended December&#160;31, 2021 and 2020, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the classification of operating and finance lease assets and obligations in the Company&#8217;s Consolidated Balance Sheets as of December&#160;31, 2021 and December&#160;31, 2020 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating leases:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Right of use assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,139</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,415</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities, current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">235</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">195</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities, noncurrent</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">985</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,219</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,220</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,414</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr>
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finance leases:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Right of use assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">102</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">145</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finance lease liabilities, current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finance lease liabilities, noncurrent</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">82</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">115</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total finance lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">114</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">145</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturities of lease liabilities for the Company&#8217;s operating and finance leases are as follows for the year ending December&#160;31, 2021 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Finance</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">326</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">366</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">332</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">372</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">341</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">381</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">282</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">289</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">180</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">180</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,461</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">127</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,588</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(241</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(254</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,220</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">114</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,334</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average remaining lease term for operating leases is 4.4 years, and 3.3 years for the finance lease. The weighted average discount rate is 8.5%. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701424308160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 5: Related Party Debt </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;18, 2022, in connection with the Business Combination Agreement, the Company entered into the Promissory Notes. Through such promissory notes, the holders may fund up to $100,000,000 to support the operational financing needs of the Company prior to the closing of the Business Combination. These notes bear interest at a rate of 3% per annum and are due upon the earliest of either (i)&#160;the date on which the Business Combination closes or (ii)&#160;January 17, 2023. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Drawdowns on the Promissory Notes may be made in multiples of $10,000 unless otherwise agreed upon. Once an amount is drawn down under the Promissory Notes, it is no longer available for future drawdown requests even if prepaid. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three months ended March&#160;31, 2022, the Company borrowed $20,000,000 under this agreement, leaving remaining availability of $80,000,000 as of March&#160;31, 2022. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember', window );">Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 5. RELATED PARTY TRANSACTIONS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Founder Shares </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On March&#160;2, 2021, the Sponsor paid $25,000 to cover certain offering and formation costs of the Company in consideration for which the Sponsor received 5,750,000 Class&#160;B ordinary shares (the &#8220;Founder Shares&#8221;). On June&#160;29, 2021, the Company effected a share capitalization with respect to its Class&#160;B ordinary shares of 575,000 shares thereof, resulting in the Company&#8217;s initial shareholders holding an aggregate of 6,325,000 Founder Shares. All share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> amounts have been retroactively restated to reflect the share capitalization. The Founder Shares included an aggregate of up to&#160;825,000 shares that were subject to forfeiture depending on the extent to which the underwriters&#8217; over-allotment option was exercised. As a result of the underwriters&#8217; election to partially exercise their over-allotment option, a total of 750,000 Founder Shares are no longer subject to forfeiture and 75,000 Founder Shares were forfeited, resulting in an aggregate of&#160;6,250,000 Founder Shares outstanding. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2021, the Sponsor transferred 30,000 Founder Shares to Marc Semigran, an independent director of the Company. The sale of the Founders Shares to the Company&#8217;s director is in the scope of FASB ASC Topic 718, &#8220;Compensation-Stock Compensation&#8221; (&#8220;ASC 718&#8221;).&#160;Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date. The fair value of the 30,000 shares granted to the Company&#8217;s director was $214,160 or approximately $7.14 per share. The Founders Shares were effectively sold subject to a performance condition (i.e., the occurrence of a Business Combination). </div><br/></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation expense related to the Founders Shares is recognized only when the performance condition is probable of occurrence under the applicable accounting literature in this circumstance. As of March&#160;31, 2022, the Company determined that a Business Combination is not considered probable, and, therefore, no stock-based compensation expense has been recognized. Stock-based compensation would be recognized at the date a Business Combination is considered probable (i.e., upon consummation of a Business Combination) in an amount equal to the number of Founders Shares times the grant date fair value per share (unless subsequently modified) less the amount initially received for the purchase of the Founders Shares. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">The Sponsor and the Company&#8217;s&#160;directors and officers have agreed, subject to limited exceptions, not to transfer, assign or sell any of their Founder Shares until the earlier of: (A)&#160;one year after the completion of a Business Combination and (B)&#160;subsequent to a Business Combination, (x)&#160;if the last reported sale price of the Class&#160;A ordinary shares equals or exceeds $12.00 per share (as adjusted for share <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-divisions,</div> share dividends, rights issuances, consolidations, reorganizations, recapitalizations and other similar transactions) for any 20 trading days within any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-trading</div> day period commencing at least 150 days after a Business Combination, or (y)&#160;the date on which the Company completes a liquidation, merger, amalgamation, share exchange, reorganization or other similar transaction that results in all of the Public Shareholders having the right to exchange their Class&#160;A ordinary shares for cash, securities or other property. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Administrative Services Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company entered into an agreement in which it will pay an affiliate of the Sponsor $10,000 per month, commencing on June&#160;30, 2021, for office space, administrative and support services. Upon completion of a Business Combination or its liquidation, the Company will cease paying these monthly fees. For the three months ended March&#160;31, 2022, the Company incurred&#160;$30,000 in fees for these services, of which is included in due to related party in the accompanying condensed balance sheet. For the period from February&#160;25, 2021 (inception) through March&#160;31, 2021, the Company did not incur any fees for these services. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Due to&#160;Related Party </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2022, an affiliate of the Sponsor had advanced the Company $33,623 for working capital purposes, of which $0 was repaid during the three months ended March&#160;31, 2022. As of March&#160;31, 2022, and December&#160;31, 2021, the outstanding balance under the advances amounted to $43,623 and $10,000 respectively. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Promissory Note&#8212;Related Party </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On March&#160;2, 2021, the Company issued an unsecured promissory note to the Sponsor (the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#8220;Pre-IPO</div> Sponsor Promissory Note&#8221;), pursuant to which the Company could borrow up to an aggregate principal amount of $300,000. The <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-IPO</div> Sponsor Promissory Note was <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable on the earlier of December&#160;31, 2021 and the completion of the Initial Public Offering. The outstanding balance under the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-IPO</div> Sponsor Promissory Note of $300,000 was repaid at the closing of the Initial Public Offering on July&#160;2, 2021. Borrowings are no longer available under the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Pre-IPO</div> Sponsor Promissory Note. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Party Loans </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to fund working capital deficiencies or finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor or certain of the Company&#8217;s officers and directors may, but are not obligated to (other than pursuant to the Promissory Note (see Note 9)), loan the Company additional funds as may be required (&#8220;Working Capital Loans&#8221;). If the Company completes a Business Combination, it may repay such loaned amounts out of the proceeds of the Trust Account. In the event that the Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay such loaned amounts but no proceeds from the Trust Account would be used to repay such loaned amounts. As of March&#160;31, 2022 and December&#160;31, 2021, there were no outstanding amounts under the Working Capital Loans.</div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Subscription Agreements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concurrently with the execution of the ProKidney Business Combination Agreement, the Company entered into Subscription Agreements with the Sponsor Related PIPE Investors, pursuant to which the Sponsor Related PIPE Investors have subscribed for Class&#160;A ordinary shares. The Sponsor Related PIPE Investors are expected to fund $156,400,000 of the PIPE Investment, for which they will receive 15,640,000 Class&#160;A ordinary shares. Specifically, (i)&#160;SC Master Holdings, LLC, an entity affiliated with Mr.&#160;Palihapitiya, subscribed for 12,500,000 Class&#160;A ordinary shares and (ii)&#160;Averill Master Fund, Ltd., an entity affiliated with Mr.&#160;Mehta, subscribed for 3,140,000 Class&#160;A ordinary shares. The PIPE Investment will be consummated substantially concurrently with the Closing. </div></div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 5. RELATED PARTY TRANSACTIONS </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Founder Shares </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On March&#160;2, 2021, the Sponsor paid $25,000 to cover certain offering and formation costs of the Company in consideration for which the Sponsor received 5,750,000 Class&#160;B ordinary shares (the &#8220;Founder Shares&#8221;). On June&#160;29, 2021, the Company effected a share capitalization with respect to its Class&#160;B ordinary shares of 575,000 shares thereof, resulting in the Company&#8217;s initial shareholders holding an aggregate of 6,325,000 Founder Shares. All share and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">per-share</div> amounts have been retroactively restated to reflect the share capitalization. The Founder Shares included an aggregate of up to&#160;825,000 shares that were subject to forfeiture depending on the extent to which the underwriters&#8217; over-allotment option was exercised. As a result of the underwriters&#8217; election to partially exercise their over-allotment option, a total of 750,000 Founder Shares are no longer subject to forfeiture and 75,000 Founder Shares were forfeited, resulting in an aggregate of&#160;6,250,000 Founder Shares outstanding. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2021, the Sponsor transferred 30,000 Founder Shares to Marc Semigran, an independent director of the Company. The sale of the Founders Shares to the Company&#8217;s director is in the scope of FASB ASC Topic 718, &#8220;Compensation-Stock Compensation&#8221; (&#8220;ASC 718&#8221;).&#160;Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date. The fair value of the 30,000 shares granted to the Company&#8217;s director was $214,160 or approximately $7.14 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">per share. The Founders Shares were effectively sold subject to a performance condition (i.e., the occurrence of a Business Combination). Compensation expense related to the Founders Shares is recognized only when the performance condition is probable of occurrence. As of December&#160;31, 2021, the Company determined that a Business Combination is not considered probable, and, therefore, no stock-based compensation expense has been recognized. Stock-based compensation would be recognized at the date a Business Combination is considered probable (i.e., upon consummation of a Business Combination) in an amount equal to the number of Founders Shares times the grant date fair value per share (unless subsequently modified) less the amount initially received for the purchase of the Founders Shares. </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Sponsor and the Company&#8217;s directors and officers have agreed, subject to limited exceptions, not to transfer, assign or sell any of their Founder Shares until the earlier of: (A)&#160;one year after the completion of a Business Combination and (B)&#160;subsequent to a Business Combination, (x)&#160;if the last reported sale price of the Class&#160;A ordinary shares equals or exceeds </div></div>$12.00 per share (as adjusted for share <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-divisions,</div> share dividends, rights issuances, consolidations, reorganizations, recapitalizations and other similar transactions) for any 20 trading days within any <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">30-trading</div> day period commencing at least 150 days after a Business Combination, or (y)&#160;the date on which the Company completes a liquidation, merger, amalgamation, share exchange, reorganization or other similar transaction that results in all of the Public Shareholders having the right to exchange their Class&#160;A ordinary shares for cash, securities or other property.</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Administrative Services Agreement </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company entered into an agreement in which it will pay an affiliate of the Sponsor $10,000 per month, commencing on June&#160;30, 2021, for office space, administrative and support services. Upon completion of a Business Combination or its liquidation, the Company will cease paying these monthly fees. For the period from February&#160;25, 2021 (inception) through December&#160;31, 2021, the Company incurred&#160;$60,000 in fees for these services, of which such amount was recognized in Operating and Formation Costs in the accompanying statement of operations. </div><br/></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Advances from Related Party </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, the Sponsor had advanced the Company $97,319 for working capital purposes, inclusive of the administrative services agreement noted above, of which $87,319 was repaid during the period ended December&#160;31, 2021. As of December&#160;31, 2021, the outstanding balance was $10,000. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Promissory Note&#8212;Related Party </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On March&#160;2, 2021, the Sponsor issued an unsecured promissory note to the Company (the &#8220;Promissory Note&#8221;), pursuant to which the Company could borrow up to an aggregate principal amount of $300,000. The Promissory Note was <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing and payable on the earlier of December&#160;31, 2021 and the completion of the Initial Public Offering. The outstanding balance under the Promissory Note of $300,000 was repaid at the closing of the Initial Public Offering on July&#160;2, 2021. Borrowings are no longer available under the Promissory Note. </div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Related Party Loans </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In order to fund working capital deficiencies or finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor or certain of the Company&#8217;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#8220;Working Capital Loans&#8221;). If the Company completes a Business Combination, it may repay such loaned amounts out of the proceeds of the Trust Account. In the event that the Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay such loaned amounts but no proceeds from the Trust Account would be used to repay such loaned amounts. As of December&#160;31, 2021, there were no outstanding amounts under the Working Capital Loans. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701424300848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember', window );">Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 6. COMMITMENTS&#160;AND CONTINGENCIES </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Registration Rights </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to a registration rights agreement entered into on June&#160;29, 2021, the holders of the Founder Shares, Private Placement Shares and any Private Placement Shares that may be issued on conversion of Working Capital Loans (and any Class&#160;A ordinary shares issuable upon the conversion of the Founder Shares) are entitled to registration rights requiring the Company to register such securities for resale (in the case of the Founder Shares, only after conversion to the Class&#160;A ordinary shares). The holders of these securities will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent to the completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. The Company will bear the expenses incurred in connection with the filing of any such registration statements. At the closing of the ProKidney Business Combination, the Company will enter into the Registration Rights Agreement, with the Sponsor, the Company&#8217;s directors and the Closing ProKidney unitholders, which will replace the existing registration rights agreement. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain purported shareholders of the Company sent demand letters (the &#8220;Demands&#8221;) alleging deficiencies and/or omissions in the ProKidney Disclosure Statement filed by the Company with the SEC on February 14, 2022. The Demands seek additional disclosures to remedy these purported deficiencies. We believe that the allegations in the Demands are meritless. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Underwriting Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The underwriters are entitled to a deferred underwriting commission of $7,700,000 in the aggregate. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Unit Award </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September 2021, pursuant to a Director Restricted Stock Unit Award Agreement, dated September&#160;24, 2021, between the Company and Uma Sinha, Ph.D., the Company agreed to </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">grant&#160;30,000&#160;restricted stock units (&#8220;RSUs&#8221;) to Dr.&#160;Sinha, which grant is contingent on both the consummation of a Business Combination and a shareholder approved equity plan. The RSUs will vest upon the consummation of such Business Combination and represent&#160;30,000&#160;Class&#160;A ordinary shares of the Company that will settle on a date determined in the sole discretion of the Company that shall occur between the vesting date and March&#160;15 of the year following the year in which vesting occurs.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The RSUs granted by the Company are in the scope of ASC 718. Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date. The RSUs granted are subject to a performance condition (i.e., the occurrence of a Business Combination). Compensation expense related to the RSUs is recognized only when the performance condition is probable of occurrence under</div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">the</div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></div><div style="font-size: 10pt; letter-spacing: 0px; text-align: center; top: 0px;;display:inline;">applicable accounting literature in this circumstance. As of March&#160;31, 2022, the Company did not have a shareholder approved equity plan and also determined that a Business Combination is not considered probable, and, therefore, no stock-based compensation expense has been recognized. Stock-based compensation would be recognized at the date a Business Combination is considered probable (i.e., upon consummation of a Business Combination) in an amount equal to the number of RSUs times the grant date fair value per share (unless subsequently modified).</div></div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 6. COMMITMENTS AND CONTINGENCIES </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Registration Rights </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Pursuant to a registration rights agreement entered into on June&#160;29, 2021, the holders of the Founder Shares, Private Placement Shares and any Private Placement Shares that may be issued on conversion of Working Capital Loans (and any Class&#160;A ordinary shares issuable upon the conversion of the Founder Shares) are entitled </div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">to registration rights requiring the Company to register such securities for resale (in the case of the Founder Shares, only after conversion to the Class&#160;A ordinary shares). The holders of these securities will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent to the completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. The Company will bear the expenses incurred in connection with the filing of any such registration statements. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Underwriting Agreement </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The underwriters are entitled to a deferred underwriting commission of $7,700,000 in the aggregate. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Restricted Stock Unit Award </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September 2021, pursuant to a Director Restricted Stock Unit Award Agreement, dated September&#160;24, 2021, between the Company and Uma Sinha, Ph.D., the Company agreed to </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> grant&#160;</div></div>30,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;restricted stock units (&#8220;RSUs&#8221;) to Dr.&#160;Sinha, which grant is contingent on both the consummation of a Business Combination and a shareholder approved equity plan. The RSUs will vest upon the consummation of such Business Combination and represent&#160;</div>30,000<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;Class&#160;A ordinary shares of the Company that will settle on a date determined in the sole discretion of the Company that shall occur between the vesting date and March&#160;</div>15<div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> of the year following the year in which vesting occurs.</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The RSUs to be granted by the Company are in the scope of ASC 718.&#160;Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date. The RSUs to be granted are subject to a performance condition (i.e., the occurrence of a Business Combination). Compensation expense related to the RSUs is recognized only when the performance condition is probable of occurrence under the applicable accounting literature in this circumstance. As of December&#160;31, 2021, the Company did not have a shareholder approved equity plan and also determined that a Business Combination is not considered probable, therefore, no stock-based compensation expense has been recognized. Stock-based compensation would be recognized at the date a Business Combination is considered probable (i.e., upon consummation of a Business Combination) in an amount equal to the number of RSUs times the grant date fair value per share (unless subsequently modified).</div></div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701428313824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Members' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersEquityAbstract', window );"><strong>Members' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersEquityNotesDisclosureTextBlock', window );">Members' Equity</a></td>
<td class="text"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 6: Members&#8217; Equity </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Ownership interests in the Company are represented by two classes of units, Class&#160;A units and Class&#160;B units. The terms of the units are governed by the LLC Agreement. As of March&#160;31, 2022, there are 190,000,000 Class&#160;A and 50,000,000 Class&#160;B Units authorized (including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B-1</div> Units). </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holders of Class&#160;A units have voting rights and rights to profits and losses of the Company and distributions from the Company. No Class&#160;A units were issued during the three months ended March&#160;31, 2022. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">During the three months ended March&#160;31, 2022, the Company issued 6,098,901 of its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B-1</div> Units for total cash proceeds of $5,550,000. As these awards were issued for a price below their estimated fair value to employees, board members and other service providers, the provisions of ASC Topic 718 &#8211; Stock Compensation apply. Refer to Note 8 for further details. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Class&#160;B Units are reserved for issuance of Profits Interests and do not have voting rights. The Profits Interests are designed so that the holders of Profits Interests only participate in a qualified distribution event and only if its valuation threshold is attained in such a distribution event as set forth in the Limited Partnership Agreement; provided, however, that the Limited Partnership Agreement, as amended and restated in January 2022, provides that certain qualified distribution events will result in the holders of Profits Interests receiving disproportionate distributions from ProKidney until each such holder&#8217;s threshold value has been reduced to zero in order to &#8220;catch up&#8221; such holder&#8217;s distributions to its pro rata share of aggregate cumulative distributions, and once sufficient distributions to a holder of Profits Interests have been made in accordance with the foregoing, the associated Class&#160;B Units will automatically be converted into Class&#160;A Units. </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 5: Members&#8217; Equity </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Ownership interests in the Company are represented by two classes of units, Class&#160;A Units and Class&#160;B Units. The terms of the units are governed by the LLC Agreement. As of December&#160;31, 2021, there were 190,000,000 Class&#160;A and 10,000,000 Class&#160;B Units authorized. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holders of Class&#160;A Units have voting rights and rights to profits and losses of the Company and distributions from the Company. The following is a summary of the activity of the Class&#160;A Units: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 79%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Units outstanding January&#160;1, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">95,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issued 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Units outstanding December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">115,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issued 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">71,500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Units outstanding December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">186,500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Class&#160;B Units are reserved for issuance of Profits Interests and do not have voting rights. The Profits Interests are designed so that the holders of Profits Interests only participate in a qualified distribution event and only if its valuation threshold is attained in such a distribution event as set forth in the Limited Partnership Agreement; provided, however, that the Limited Partnership Agreement (as amended and restated on January&#160;17, 2022 as contemplated by Note 8 below) provides that certain qualified distribution events will result in the holders of Profits Interests receiving disproportionate distributions from ProKidney until each such holder&#8217;s threshold value has been reduced to zero in order to &#8220;catch up&#8221; such holder&#8217;s distributions to its pro rata share of aggregate cumulative distributions, and once sufficient distributions to a holder of Profits Interests have been made in accordance with the foregoing, the associated Class&#160;B Units will automatically be converted into Class&#160;A Units. </div></div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MembersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MembersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MembersEquityNotesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the formation, structure, control and ownership of a limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -URI https://asc.fasb.org/topic&amp;trid=2124037<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MembersEquityNotesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701423805232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Temporary Equity and Permanent Deficit<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember', window );">Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Temporary Equity and Permanent Equity</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 7. TEMPORARY EQUITY AND PERMANENT DEFICIT </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Preference Shares</div></div></div></div>&#8212;The Company is authorized to issue 5,000,000 preference shares, with a par value of $0.0001 per share. The Company&#8217;s board of directors will be authorized to fix the voting rights, if any, designations, powers, preferences, the relative, participating, optional or other special rights and any qualifications, limitations and restrictions thereof, applicable to the shares of each series. The Company&#8217;s board of directors will be able to, without shareholder approval, issue preference shares with voting and other rights that could adversely affect the voting power and other rights of the holders of the Company&#8217;s ordinary shares and could have anti-takeover effects. At March&#160;31, 2022 and December&#160;31, 2021, there were no preference shares issued or outstanding. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;A Ordinary Shares</div></div></div></div>&#8212;The Company is authorized to issue 500,000,000 Class&#160;A ordinary shares, with a par value of $0.0001 per share. At March&#160;31, 2022 and December&#160;31, 2021, there were 640,000 Class&#160;A ordinary shares issued and outstanding, excluding 25,000,000 Class&#160;A ordinary shares subject to possible redemption which are presented as temporary equity. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;B Ordinary Shares</div></div></div></div>&#8212;The Company is authorized to issue 50,000,000 Class&#160;B ordinary shares, with a par value of $0.0001 per share. At March&#160;31, 2022 and December&#160;31, 2021, there were 6,250,000 Class&#160;B ordinary shares issued and outstanding. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holders of record of Class&#160;A ordinary shares and Class&#160;B ordinary shares are entitled to one vote for each share held on all matters to be voted on by shareholders and vote together as a single class, except as required by law; provided that prior to a Business Combination, holders of Class&#160;B ordinary shares will have the right to appoint all of the Company&#8217;s directors and remove members of its board of directors for any reason, and holders of Class&#160;A ordinary shares will not be entitled to vote on the appointment of directors during such time. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Class&#160;B ordinary shares will automatically convert into Class&#160;A ordinary shares at the time of the Business Combination, or earlier at the option of the holder, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-for-one</div></div> basis, subject to adjustment for share <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-divisions,</div> share dividends, rights issuances, consolidations, reorganizations, recapitalizations and the like. Additionally, in the event that additional (in excess of the amounts issued in the Initial Public Offering) Class&#160;A ordinary shares, or equity-linked securities, are issued or deemed issued in connection with the closing of the Business Combination, the ratio at which the Class&#160;B ordinary shares will convert into Class&#160;A ordinary shares will be adjusted (unless the holders of a majority of the issued and outstanding Class&#160;B ordinary shares agree to waive such anti-dilution adjustment with respect to any such issuance or deemed issuance) so that the number of Class&#160;A ordinary shares issuable upon conversion of all Class&#160;B ordinary shares will equal, in the aggregate, 20% of the sum of the total number of Class&#160;A ordinary shares outstanding after such conversion (after giving effect to any redemptions of Class&#160;A ordinary shares by Public Shareholders, and excluding the Private Placement Shares), including any Class&#160;A ordinary shares issued or deemed issued, or issuable upon the conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with the Business Combination, excluding any Class&#160;A ordinary shares or equity-linked securities exercisable for or convertible into Class&#160;A ordinary shares issued, or to be issued, to any seller in the Business Combination and any private placement shares issued to the Sponsor or its affiliates upon conversion of Working Capital Loans; provided that such conversion of Class&#160;B ordinary shares will never occur on a less than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-for-one-basis.</div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Private </div></div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Placement Shares</div></div></div></div>&#8212;The Private Placement Shares are not transferable, assignable, or salable until 30 days after the completion of a Business Combination (except, among other limited exceptions, to the Company&#8217;s directors and officers and other persons or entities affiliated with the Sponsor). Holders of the Private Placement Shares are entitled to certain registration rights. If the Company does not complete a Business Combination within the Combination Period or during any applicable extension period, the proceeds from the sale of the Private Placement Shares held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Shares will be worthless. </div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 7. TEMPORARY EQUITY AND PERMANENT DEFICIT </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="null;text-indent: 0px;;font-style:italic;display:inline;">Preference Shares</div></div></div></div></div>&#8212;The Company is authorized to issue 5,000,000 preference shares, with a par value of $0.0001 per share. The Company&#8217;s board of directors will be authorized to fix the voting rights, if any, designations, powers, preferences, the relative, participating, optional or other special rights and any qualifications, limitations and restrictions thereof, applicable to the shares of each series. The Company&#8217;s board of directors will be able to, without shareholder approval, issue preference shares with voting and other rights that could adversely affect the voting power and other rights of the holders of the Company&#8217;s ordinary shares and could have anti-takeover effects. At December&#160;31, 2021, there were no preference shares issued or outstanding. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;A Ordinary Shares</div></div></div></div>&#8212;The Company is authorized to issue 500,000,000 Class&#160;A ordinary shares, with a par value of $0.0001 per share. At December&#160;31, 2021, there were 640,000 Class&#160;A ordinary shares issued and outstanding, excluding 25,000,000 Class&#160;A ordinary shares subject to possible redemption which are presented as temporary equity. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class</div></div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">&#160;B Ordinary Shares</div></div></div></div>&#8212;The Company is authorized to issue 50,000,000 Class&#160;B ordinary shares, with a par value of $0.0001 per share. At December&#160;31, 2021, there were 6,250,000 Class&#160;B ordinary shares issued and <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">outstanding. </div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holders of record</div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;of Class&#160;A ordinary shares and Class&#160;B ordinary shares are entitled to one vote for each share held on all matters to be voted on by shareholders and vote together as a single class, except as required by law; provided that prior to a Business Combination, holders of Class&#160;B ordinary shares will have the right to appoint all of the Company&#8217;s directors and remove members of its board of directors for any reason, and holders of Class&#160;A ordinary shares will not be entitled to vote on the appointment of directors during such time. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Class&#160;B ordinary shares will automatically convert into Class&#160;A ordinary shares at the time of the Business Combination, or earlier at the option of the holder, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-for-one</div></div> basis, subject to adjustment for share <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">sub-divisions,</div> share dividends, rights issuances, consolidations, reorganizations, recapitalizations and the like. Additionally, in the event that additional (in excess of the amounts issued in the Initial Public Offering) Class&#160;A ordinary shares, or equity-linked securities, are issued or deemed issued in connection with the closing of the Business Combination, the ratio at which the Class&#160;B ordinary shares will convert into Class&#160;A ordinary shares will be adjusted (unless the holders of a majority of the issued and outstanding Class&#160;B ordinary shares agree to waive such anti-dilution adjustment with respect to any such issuance or deemed issuance) so that the number of Class&#160;A ordinary shares issuable upon conversion of all Class&#160;B ordinary shares will equal, in the aggregate, 20% of the sum of the total number of Class&#160;A ordinary shares outstanding after such conversion (after giving effect to any redemptions of Class&#160;A ordinary shares by Public Shareholders, and excluding the Private Placement Shares), including any Class&#160;A ordinary shares issued or deemed issued, or issuable upon the conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with the Business Combination, excluding any Class&#160;A ordinary shares or equity-linked securities exercisable for or convertible into Class&#160;A ordinary shares issued, or to be issued, to any seller in the Business Combination and any private placement shares issued to the Sponsor or its affiliates upon conversion of Working Capital Loans; provided that such conversion of Class&#160;B ordinary shares will never occur on a less than <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">one-for-one-basis.</div></div></div> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Private Placement Shares</div></div></div></div>&#8212;The Private Placement Shares are not transferable, assignable, or salable until 30 days after the completion of a Business Combination (except, among other limited exceptions, to the Company&#8217;s directors and officers and other persons or entities affiliated with the Sponsor). Holders of the Private Placement Shares are entitled to certain registration rights. If the Company does not complete a Business Combination within the Combination Period or during any applicable extension period, the proceeds from the sale of the Private Placement Shares held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Shares will be worthless. </div> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701423567856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 7: Net Loss per Share </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic loss per share (&#8220;EPS&#8221;) was computed by dividing net loss by the number of weighted average units of Class&#160;A Units outstanding during the period. Diluted EPS was calculated to give effect to potentially issuable dilutive units of common units using the treasury method. For all periods presented, the vested Profits Interests have been excluded from the diluted EPS calculation as their effect would be anti-dilutive. The following table sets forth the calculation of basic and diluted earnings per share for the periods indicated based on the weighted average number of common shares outstanding: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss available to Class&#160;A Unit holders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(67,486</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,609</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average Class&#160;A Units outstanding, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">186,500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">122,111,111</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per Class&#160;A Unit</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per Class&#160;A Unit, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 6: Net Loss per Share </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic loss per share (&#8220;EPS&#8221;) was computed by dividing net loss by the number of weighted average units of Class&#160;A Units outstanding during the period. Diluted EPS was calculated to give effect to potentially issuable dilutive units of common units using the treasury method. For all periods presented, the vested Profits Interests have been excluded from the diluted EPS calculation as their effect would be anti-dilutive. The following table sets forth the calculation of basic and diluted earnings per share for the periods indicated based on the weighted average number of common shares outstanding: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss available to Class&#160;A Unit holders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(55,146</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(26,749</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average Class&#160;A Units outstanding, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150,706,849</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">104,986,301</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per Class&#160;A Unit</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per Class&#160;A Unit, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.37</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.25</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701423551344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember', window );">Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 8. FAIR VALUE MEASUREMENTS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company follows the guidance in ASC Topic 820 for its financial assets and liabilities that are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measured</div> and reported at fair value at each reporting period, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> assets and liabilities that are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measured</div> and reported at fair value at least annually. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s financial assets and liabilities reflects management&#8217;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">liabilities: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 8%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td style="width: 89%;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Observable inputs other than Level&#160;1 inputs. Examples of Level&#160;2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</div></td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt;">&#160;</td>
<td colspan="2" style="height: 6pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Unobservable inputs based on the Company&#8217;s assessment of the assumptions that market participants would use in pricing the asset or liability.</div></td></tr></table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">The</div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">following table presents information about the Company&#8217;s assets that are measured at fair value on a recurring basis at March&#160;31, 2022 and December&#160;31, 2021, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: </div><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 8%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/></tr></table> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31, 2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities held in Trust Account</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250,033,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250,008,324</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table>  <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 8. FAIR VALUE MEASUREMENTS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company follows the guidance in ASC Topic 820 for its financial assets and liabilities that are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measured</div> and reported at fair value at each reporting period, and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> assets and liabilities that are <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">re-measured</div> and reported at fair value at least annually. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s financial assets and liabilities reflects management&#8217;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: </div></div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="vertical-align: top;">
<td style="width: 20%; font-size: 10pt;"><div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 11%; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1: </div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="vertical-align: top;">
<td style="width: 20%; font-size: 10pt;"><div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 11%; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2: </div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">Observable inputs other than Level&#160;1 inputs. Examples of Level&#160;2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. </div></td></tr></table> <div style="clear: both; max-height: 0px; text-indent: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="vertical-align: top;">
<td style="width: 20%; font-size: 10pt;"><div style="text-indent: -2%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 11%; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3: </div></div></div></td>
<td><div style="letter-spacing: 0px; top: 0px;;display:inline;">Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability. </div></td></tr></table>  <div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">following table presents information about the Company&#8217;s assets that are measured at fair value on a recurring basis at December&#160;31, 2021, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities held in Trust Account</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250,008,324</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table>  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701429071504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Based Compensation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 8: Equity Based Compensation </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Profits Interests Awards </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The issuance of Profits Interests to employees, directors, and other service providers of the Company (&#8220;Plan Participants&#8221;) is administered at the discretion of ProKidney GP Limited, the general partner of ProKidney (the &#8220;General Partner&#8221;). Profits Interests allow the Plan Participants to participate in the residual profits of the Company after the distribution of proceeds reach a minimum threshold value. The threshold value is the amount of proceeds that must be distributed to the holders of Class&#160;A Units before the Plan Participants can participate in a distribution. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Limited Partnership Agreement, the General Partner determines the terms and conditions of the Profits Interests issued. The threshold value assigned to each grant shall not be less than the fair market value of the Company on the date of grant. Profits Interests awards vest at a rate of 25% on the latter of the first anniversary of employment and the first anniversary of the Acquisition Date with the remaining 75% to vest in increments of 25% on each anniversary following the first anniversary date, ratably over a three or four-year period from the date of grant, in annual installments of 33.3% over the three-year period from the date of grant, or in increments of 6.25% each calendar quarter following the first anniversary date. The Profits Interests are subject to a repurchase option should the plan participant no longer be employed by the Company. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The following table summarizes the activity for the three months ended March&#160;31, 2022, related to the Company&#8217;s Class&#160;B and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Units granted as equity awards to its employees, board members and service providers: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/>Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average&#160;Grant<br/>Date&#160;Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested awards outstanding at January&#160;1, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,460,617</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,498,488</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(449,486</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(29,070</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested awards outstanding at March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,480,549</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of March&#160;31, 2022, the unrecognized compensation expense related to these awards was $50,020,000. The current weighted average remaining period over which the unrecognized compensation expense is expected to be recognized is 3.6 years. The weighted average grant date fair value of the Profits Interests granted during the three months ended March&#160;31, 2022, was $6.03 per <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B-1</div> unit. There were no Profits Interests granted during the three months ended March&#160;31, 2021. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of March&#160;31, 2022, there remain 22,164,559 Class&#160;B Units available for issuance. Given that these instruments meet the criteria for being considered profits interests, the Company has recognized no tax benefit related to these awards.</div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Modification to Profits Interest Awards </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;17, 2022, the Limited Partnership Agreement was amended and restated to provide that certain qualified distribution events will result in the holders of Profits Interests receiving disproportionate distributions from ProKidney until each such holder&#8217;s threshold value has been reduced to zero in order to &#8220;catch up&#8221; such holder&#8217;s distributions to its pro rata share of aggregate cumulative distributions, and once sufficient distributions to a holder of Profits Interests have been made in accordance with the foregoing, the associated Class&#160;B Units will automatically be converted into Class&#160;A Units. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This amendment constitutes a modification to the Class&#160;B Units outstanding as of the date of the modification under the provisions of ASC Topic 718. In connection with the modification of its outstanding share-based compensation awards, the Company will recognize total additional compensation expense of $5,437,000 related to awards granted to its employees. The portion of this additional compensation expense attributable to vested awards of $3,715,000 was recognized immediately upon modification during the three months ended March&#160;31, 2022. </div></div>  <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Issuance of Profits Interests to Service Provider </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">During the three months ended March&#160;31, 2022, the Company issued 2,750,000 fully vested <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B-1</div> Units to a third party service provider as payment for research and development services provided in prior periods. The Company had previously recognized expense of $2,502,000 for these services based on the liability related to the services incurred. As the fair value of shares issued to satisfy that obligation was higher than the amount previously expensed, the Company recognized additional research and development expense of $14,080,000 during the three months ended March&#160;31, 2022. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Purchase of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B-1</div> Units </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">As discussed further in Note 6, certain of the Company&#8217;s employees, board members and service providers purchased 6,098,901 of its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B-1</div> Units for total cash proceeds of $5,550,000 during the three months ended March&#160;31, 2022. Since these <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B-1</div> Units were fully vested upon purchase and contain no service requirements, the Company immediately recognized the difference between the purchase price and the estimated fair value for these <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B-1</div> Units of $31,226,000 as equity-based compensation expense during the three months ended March&#160;31, 2022. </div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation Expense </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the three months ended March&#160;31, 2022 and 2021, the Company recognized equity-based compensation expense of $52,686,000 and $175,000, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Compensation expense related to the issuance and purchase of Class&#160;B and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Units is included in research and development and general and administrative expense as follows (in thousands): </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,367</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,319</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">175</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total equity-based compensation expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">52,686</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">175</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Estimate </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is privately held with no active public market for its equity instruments. Therefore, for financial reporting purposes, management may periodically determine the estimated per share fair value of the Company&#8217;s equity shares (including Profits Interests) using contemporaneous valuations. These contemporaneous valuations are done using methodologies consistent with the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, also known as the Practice Aid. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the Profits Interest Awards granted during the three months ended March&#160;31, 2022, the valuation approach utilized a hybrid method which consists of a combination of an Option Pricing Method (OPM) and a Probability Weighted Expected Return Method (PWERM) approach. Weighting allocations were assigned to the OPM and PWERM methods based upon the expected likelihood of possible future liquidity events, including the Business Combination. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the OPM approach, the fair value of the total equity of the Company within each scenario was first estimated using a back-solve method wherein the equity value is derived from a recent transaction in the Company&#8217;s own securities, and then the total equity value is allocated to the various components of the capital structure, including the Profits Interests, using an OPM or a waterfall approach based on the specific rights of </div></div>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">each of the equity classes. The OPM uses the fair value of the total equity of the Company within a scenario as a starting point and incorporates assumptions made regarding the expected returns and volatilities that are consistent with the expectations of market participants, and distribution of equity values is produced which cover the range of events that an informed market participant might expect. This process creates a range of equity values both between and within scenarios. The fair value measurement is sensitive to changes in the unobservable inputs. Changes in those inputs might result in a higher or lower fair value measurement. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The PWERM approach is a scenario-based analysis that estimates the value per share of common stock based on the probability-weighted present value of expected future equity values for the common stock, under various possible future liquidity event scenarios, including the proposed Business Combination, in light of the rights and preferences of each class and series of stock, including the Profits Interests, discounted for a lack of marketability. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In performing these valuations, management considered all objective and subjective factors that they believed to be relevant, including management&#8217;s best estimate of the Company&#8217;s business condition, prospects, and operating performance at each valuation date. Within the valuations performed, a range of factors, assumptions, and methodologies were used. The significant factors included trends within the industry, the prices at which the Company sold Class&#160;A units, the rights and preferences of the Class&#160;A units relative to the Class&#160;B units at the time of each measurement date, the results of operations, financial position, status of research and development efforts, stage of development and business strategy, the lack of an active public market for the units, and the likelihood of achieving an exit event in light of prevailing market conditions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following reflects the key assumptions used in each of the valuation scenarios: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">OPM</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">PWERM</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total equity value (in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">280,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,750,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility of total equity</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">95</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Discount for lack of market</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected time to exit event</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.7 years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.5 years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table>  <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 7: Equity Based Compensation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The issuance of Profits Interests to employees, directors, and other service providers of the Company (&#8220;Plan Participants&#8221;) is administered at the discretion of ProKidney GP Limited, the general partner of ProKidney (the &#8220;General Partner&#8221;). Profits Interests allow the Plan Participants to participate in the residual profits of the Company after the distribution of proceeds reach a minimum threshold value. The threshold value is the amount of proceeds that must be distributed to the holders of Class&#160;A Units before the Plan Participants can participate in a distribution. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Limited Partnership Agreement, the General Partner determines the terms and conditions of the Profits Interests issued. The threshold value assigned to each grant shall not be less than the fair market value of the Company on the date of grant. Profits Interests awards vest at a rate of 25% on the latter of the first anniversary of employment and the first anniversary of the Acquisition Date with the remaining 75% to vest in increments of 25% on each anniversary following the first anniversary date or in increments of 6.25% each calendar quarter following the first anniversary date. The Profits Interests are subject to a repurchase option should the plan participant no longer be employed by the Company. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Under the Limited Partnership Agreement (prior to its amendment and restatement on January&#160;17, 2022), there are 10,000,000 Class&#160;B Units authorized for issuance. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the activity related to the Company&#8217;s Profits Interest awards for the year ended December&#160;31, 2021: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/>Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average&#160;Grant<br/>Date&#160;Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Awards outstanding at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,402,398</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,941,781</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Awards outstanding at December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,460,617</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">No Class&#160;B Units were granted to employees during the year ended December&#160;31, 2021. As of December&#160;31, 2021, 2,232,878 Class&#160;B Units remained unissued. Given that these instruments meet the criteria for being considered profits interest, the Company has recognized no tax benefit related to these awards. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">During the years ended December&#160;31, 2021 and 2020, respectively, the Company recognized equity-based compensation expense of $699,000 and $730,000. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, the unrecognized compensation expense was $868,000. The current weighted average remaining period over which the unrecognized compensation expense is expected to be recognized is 1.4&#160;years. The weighted average grant date fair value of the Profits Interests granted during the year ended December&#160;31, 2020 was $0.36 per Class&#160;B unit. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Estimate </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is privately held with no active public market for its equity instruments. Therefore, for financial reporting purposes, management may periodically determine the estimated per share fair value of the Company&#8217;s equity shares (including Profits Interests) using contemporaneous valuations. These contemporaneous valuations are done using methodologies consistent with the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, also known as the Practice Aid. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The valuation approach utilized the Option Pricing Method (OPM), where the fair value of the total equity of the Company within each scenario is first estimated using a back-solve method wherein the equity value is derived from a recent transaction in the Company&#8217;s own securities, and then the total equity value is allocated to the various components of the capital structure, including the Profits Interests, using an OPM or a waterfall approach based on the specific rights of each of the equity classes. The OPM uses the fair value of the total equity of the Company within a scenario as a starting point and incorporates assumptions made regarding the expected returns and volatilities that are consistent with the expectations of market participants, and distribution of equity values is produced which cover the range of events that an informed market participant might expect. </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">This process creates a range of equity values both between and within scenarios. The fair value measurement is sensitive to changes in the unobservable inputs. Changes in those inputs might result in a higher or lower fair value measurement. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In performing these valuations, management considered all objective and subjective factors that they believed to be relevant, including management&#8217;s best estimate of the Company business condition, prospects, and operating performance at each valuation date. Within the valuations performed, a range of factors, assumptions, and methodologies were used. The significant factors included trends within the industry, the prices at which the Company sold Class&#160;A Units, the rights and preferences of the Class&#160;A Units relative to the Class&#160;B Units at the time of each measurement date, the results of operations, financial position, status of research and development efforts, stage of development and business strategy, the lack of an active public market for the units, and the likelihood of achieving an exit event in light of prevailing market conditions. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following reflects the key assumptions used in the OPM valuation: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total equity value (in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">78,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility of total equity</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Discount for lack of market</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected time to exit event</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3 years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table>  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701528794992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 9: Subsequent Events </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On June&#160;1, 2022, the Company issued Profits Interests to certain Plan Participants in the form of 1,478,590 Class&#160;B-1 Units. Additionally, the Company issued 549,451 of its Class&#160;B-1 Units for total value received by the Company (or its subsidiaries) of $500,000. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Note 8: Subsequent Events </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On January&#160;17, 2022, the Company amended and restated its Limited Partnership Agreement (the &#8220;Amended and Restated Limited Partnership Agreement&#8221;) in part to authorize the issuance of up to 50,000,000 Class&#160;B Units (including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B-1</div> Units). Upon authorization of these units, the Company issued Profits Interests to certain Plan Participants in the form of 8,498,488 <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B-1</div> Units. Additionally, the Company issued 8,848,901 of its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B-1</div> Units for total value received by the Company (or its subsidiaries) of $8,052,000. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Amended and Restated Limited Partnership Agreement provides that certain qualified distribution events will result in holders of Profits Interests receiving disproportionate distributions from ProKidney until each such holder&#8217;s valuation threshold has been reduced to zero in order to &#8220;catch up&#8221; such holder&#8217;s distributions to its pro rata share of aggregate cumulative distributions, and once sufficient distributions to a holder of Profits Interests have been made in accordance with the foregoing, the associated Class&#160;B Units will automatically be converted into Class&#160;A Units. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On January&#160;18, 2022, the Company executed a definitive business combination agreement (the &#8220;Business Combination Agreement&#8221;), with Social Capital Suvretta Holdings Corp. III (&#8220;SCS&#8221;). Under the terms of the Business Combination Agreement, the Company will become a subsidiary of SCS and will be organized in an umbrella partnership corporation <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">(&#8220;Up-C&#8221;)</div> structure, which provides potential future tax benefits for SCS when the equity holders ultimately exchange their pass-through interests for Class&#160;A ordinary shares in SCS. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;18, 2022, in connection with the Business Combination Agreement, the Company entered into two promissory note agreements with certain of its existing holders. Through such promissory notes, the existing holders may fund up to $100,000,000 to support the operational financing needs of the Company prior to the closing of the Business Combination. The Company has borrowed $20,000,000 against these promissory notes subsequent to December&#160;31, 2021. </div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember', window );">Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 9. SUBSEQUENT EVENTS </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed financial statements were issued. Based upon this review, other than as described below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the condensed financial statements. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On April&#160;20, 2022, the Company issued an unsecured promissory <div style="letter-spacing: 0px; top: 0px;;display:inline;">note </div>(the &#8220;Promissory Note&#8221;) to the Sponsor pursuant to which the Company may borrow up to an aggregate principal amount of $1,500,000.<div style="letter-spacing: 0px; top: 0px;;display:inline;"><br/></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Promissory Note is <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-interest</div> bearing, unsecured and payable upon the earlier of July&#160;2, 2023 and the effective date of the Company&#8217;s Business Combination. The Promissory Note is subject to customary events of default which could, subject to certain conditions, cause the Promissory Notes to become immediately due and payable. On April&#160;26, 2022, the Company drew $250,000 under the Promissory Note. </div></div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">NOTE 9. SUBSEQUENT EVENTS </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, other than as described below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements, except as follows: </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Proposed ProKidney Business Combination </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">18, 2022, the Company entered into a Business Combination Agreement (the &#8220;ProKidney Business Combination Agreement&#8221;) with ProKidney LP, a limited partnership registered under the laws of Ireland (&#8220;ProKidney&#8221;), acting through its general partner ProKidney GP Limited, a private limited company incorporated under the laws of Ireland (&#8220;Legacy GP&#8221;). </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The ProKidney Business Combination Agreement provides that, among other things and upon the terms and subject to the conditions thereof, prior to or at the closing of the ProKidney Business Combination Agreement (the &#8220;Closing&#8221;), the following transactions will occur (together with the other transactions contemplated by the ProKidney Business Combination Agreement, the &#8220;ProKidney Business Combination&#8221;): (1) ProKidney will issue to the Company a number of common units of ProKidney (&#8220;Post-Combination ProKidney Common Units&#8221;) equal to the number of fully diluted outstanding ordinary shares of the Company as of immediately prior to the Closing (but after giving effect to all redemptions of Public Shares and the purchase of Class A ordinary shares pursuant to one or more subscription agreements (the &#8220;PIPE Investment&#8221;)), in exchange for (a) (x) new Class B ordinary shares (&#8220;New ProKidney Class B ordinary shares&#8221;), which shares will have no economic rights but will entitle the holders thereof to vote on all matters on which shareholders of the Company are entitled to vote generally, and (y) restricted stock rights in respect of New ProKidney Class B ordinary shares (&#8220;New ProKidney Class B PMEL RSRs&#8221;), which restricted stock rights shall convert into New ProKidney Class B ordinary shares upon the vesting of the associated restricted common unit of ProKidney, (b) an amount in cash equal to the aggregate proceeds obtained by the Company in the PIPE Investment and (c) an amount in cash equal to the aggregate proceeds available for release to the Company from the Trust Account (after giving effect to all redemptions of Public Shares and after payment of any deferred underwriting commissions being held in the Trust Account and payment of certain transaction expenses); (2) Legacy GP will resign as the general partner of ProKidney and a private limited company incorporated under the laws of Ireland (&#8220;New GP&#8221;) will be admitted as the general partner of ProKidney; (3) ProKidney will distribute to the ProKidney unitholders the New ProKidney Class B ordinary shares and New ProKidney Class B PMEL RSRs received pursuant to clause (i)(a) (x) and (y) above; and (4)&#160;certain holders of ProKidney units will receive an aggregate of 17,500,000 restricted common units of ProKidney (&#8220;Earnout RCUs&#8221;) and 17,500,000 </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">restricted stock rights of the Company (&#8220;Earnout RSRs&#8221; and, together with the Earnout RCUs, the &#8220;Earnout Rights&#8221;), which Earnout Rights will vest in three equal </div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">tranches upon the trading price of a Class&#160;A ordinary share reaching </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;">$15.00/share, $20.00/share and $25.00/share, respectively, on the terms set forth in the ProKidney Business Combination Agreement, or upon certain change of control events. When vested, the Earnout RCUs will automatically convert into Post-Combination ProKidney Common Units and the associated Earnout RSRs will automatically convert into New ProKidney Class B ordinary shares, respectively. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January 18, 2022, the Company entered into subscription agreements (the &#8220;Subscription Agreements&#8221;) with certain investors (&#8220;PIPE Investors&#8221;) pursuant to which the PIPE Investors have subscribed for an aggregate of 57,500,000 Class A ordinary shares for a price of $10.00 per share for an aggregate purchase price of $575,000,000, of which (1) $156,400,000 is committed by certain existing directors, officers and equityholders of, or investment funds managed by Suvretta Capital Management, LLC, the Company, the Sponsor and/or their respective affiliates participating in the PIPE Investment, and (2) at least $50,000,000 (which may, at the election of such investors, be increased to up to $100,000,000) is committed by certain existing directors, officers and unitholders of ProKidney and/or its affiliates participating in the PIPE Investment (the &#8220;ProKidney Related PIPE Investors&#8221;); provided that the ProKidney Related PIPE Investors may elect instead to purchase Post-Combination ProKidney Common Units, together with a corresponding number of Class B ordinary shares, in lieu of Class A ordinary shares. The Subscription Agreements are subject to certain conditions, including that there shall not be in force any injunction or order enjoining or prohibiting the issuance and sale of the shares under the Subscription Agreements; the terms of the ProKidney Business Combination Agreement shall not have been amended, and the minimum cash condition therein shall not have been waived, in a manner that is materially adverse to the investor party to the Subscription Agreement; and the representation and warranties of the parties to the Subscription Agreement shall be accurate (subject to agreed materiality thresholds). </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Following the Closing, the combined company will be organized in an umbrella partnership-C corporation (a so called &#8220;Up-C&#8221;) structure, and the Company&#8217;s direct assets will consist of ProKidney Common Units and equity interests of New GP, and substantially all of the operating assets and business of the Company will be held indirectly through ProKidney. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The consummation of the proposed ProKidney Business Combination is subject to certain conditions as further described in the ProKidney Business Combination Agreement. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Legal Proceedings </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certain purported shareholders of the Company sent demand letters (the &#8220;Demands&#8221;) alleging deficiencies and/or omissions in the ProKidney Disclosure Statement filed by the Company with the SEC on February&#160;14, 2022. The Demands seek additional disclosures to remedy these purported deficiencies. We believe that the allegations in the Demands are meritless. </div></div></div> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701411924944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The condensed consolidated financial statements reflect the operations of ProKidney and its wholly-owned subsidiaries consisting of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> (together, the &#8220;Company&#8221;). All intercompany transactions and accounts have been eliminated. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair presentation of the Company&#8217;s financial information. These interim results and cash flows for any interim period are not necessarily indicative of the results to be expected for the full year. Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States of America (GAAP) as found in the Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB). These unaudited consolidated financial statements are presented in U.S. Dollars. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The consolidated financial statements reflect the operations of ProKidney and its wholly-owned subsidiaries consisting of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> (together, the &#8220;Company&#8221;). All intercompany transactions and accounts have been eliminated. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). These consolidated financial statements are presented in U.S. Dollars. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_GoingConcernPolicyTextBlock', window );">Going Concern</a></td>
<td class="text"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Going Concern </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company performed an analysis of its ability to continue as a going concern. As of March&#160;31, 2022, the Company had an accumulated deficit of $228,996,000. The Company has generated losses from operations for each year since its inception. The Company intends to continue to conduct significant additional research, development, and clinical study activities which, together with expenses incurred for general and administrative expenses, are expected to result in continuing operating losses for the foreseeable future. The amount of future losses and when, if ever, the Company will achieve profitability are uncertain. The Company&#8217;s ability to achieve profitability will depend, among other things, on successfully completing clinical studies, obtaining requisite regulatory approvals, establishing appropriate pricing for its product with payers, and raising sufficient funds to finance the Company&#8217;s activities. No assurance can be given that the Company&#8217;s clinical development efforts will be successful, that regulatory approvals will be obtained, or that the Company will be able to achieve appropriate pricing and market access or that profitability, if achieved, can be sustained. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These matters raise substantial doubt about the Company&#8217;s ability to continue as a going concern. As of March&#160;31, 2022, the Company has cash and cash equivalents of $29,802,000, and remaining availability of $80,000,000 under its two promissory note agreements with certain holders of its Class&#160;A Units (the &#8220;Promissory Notes&#8221;). The Company believes that these sources of liquidity will not be sufficient to fund its obligations for the next twelve months. The condensed consolidated financial statements do not include any adjustments related to the outcome of this uncertainty. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to execute our operating plan depends on our ability to obtain additional funding through equity offerings, debt financings or potential licensing and collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to us. Even if we raise additional capital, we may also be required to modify, delay or abandon some of our plans which could have a material adverse effect on our business, operating results and financial condition and our ability to achieve our intended business objectives. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Going Concern </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company performed an analysis of its ability to continue as a going concern. As of December&#160;31, 2021, the Company had an accumulated deficit of $161,510,000. The Company has generated losses from operations for each year since its inception including losses from operations of $55,146,000 and $26,749,000 for the years ended December&#160;31, 2021 and 2020, respectively. The Company intends to continue to conduct significant </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">additional research, development, and clinical study activities which, together with expenses incurred for general and administrative expenses, are expected to result in continuing operating losses for the foreseeable future. The amount of future losses and when, if ever, the Company will achieve profitability are uncertain. The Company&#8217;s ability to achieve profitability will depend, among other things, on successfully completing clinical studies, obtaining requisite regulatory approvals, establishing appropriate pricing for its product with payers, and raising sufficient funds to finance the Company&#8217;s activities. No assurance can be given that the Company&#8217;s clinical development efforts will be successful, that regulatory approvals will be obtained, or that the Company will be able to achieve appropriate pricing and market access or that profitability, if achieved, can be sustained. These matters raise substantial doubt about the Company&#8217;s ability to continue as a going concern. The Company believes that, based on its current business plan, its existing cash and cash equivalents of $20,558,000 at December&#160;31, 2021 will not be sufficient to fund its obligations for the next 12 months. The consolidated financial statements do not include any adjustments related to the outcome of this uncertainty. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our ability to execute our operating plan depends on our ability to obtain additional funding through equity offerings, debt financings or potential licensing and collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to us. Even if we raise additional capital, we may also be required to modify, delay or abandon some of our plans which could have a material adverse effect on our business, operating results and financial condition and our ability to achieve our intended business objectives. </div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of condensed consolidated financial statements, in accordance with GAAP, requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of expenses during the reported periods. Certain estimates in these condensed consolidated financial statements have been made in connection with the calculation of research and development expenses, equity-based compensation expense and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections, which management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of consolidated financial statements, in accordance with GAAP, requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the amounts of expenses during the reported periods. Certain estimates in these consolidated financial statements have been made in connection with the calculation of research and development expenses, equity-based compensation expense and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections, which management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all highly liquid investments with an original maturity of 90 days or less on the date of purchase to be cash equivalents. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all highly liquid investments with an original maturity of 90 days or less on the date of purchase to be cash equivalents. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concentrations of Credit Risk </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company&#8217;s cash and equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concentrations of Credit Risk </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company&#8217;s cash and equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_AccruedExpensesPolicyTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses as presented in the Condensed Consolidated Balance Sheets as of March&#160;31, 2022 and December&#160;31, 2021 consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">818</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,832</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinical study related costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">653</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,031</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued legal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,095</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">964</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Manufacturing improvement costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,137</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,164</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">414</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">222</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued expenses and other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,117</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,213</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued Expenses </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses which have been presented on the consolidated balance sheets as of December&#160;31, 2021 and 2020 consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,832</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,085</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinical study related costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,031</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,154</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Facility expansion costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,709</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued legal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">964</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Manufacturing improvement costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,164</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">203</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">548</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued expenses and other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,213</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,496</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development Costs </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries, benefits, third party license fees, and external costs of outside vendors engaged to conduct manufacturing and preclinical development activities and clinical trials. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records accruals based on estimates of services received, efforts expended, and amounts owed pursuant to contracts with numerous contract research organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company&#8217;s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company&#8217;s estimate of the degree of completion of the event or events specified in the specific clinical study. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Condensed Consolidated Statement of Operations and Comprehensive Loss as the Company receives the related goods or services. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Costs incurred in obtaining technology licenses are charged to research and development expense as purchased <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development if the technology licensed has not reached technological feasibility and has no alternative future use. </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development Costs </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries, benefits, third party license fees, and external costs of outside vendors engaged to conduct manufacturing and preclinical development activities and clinical trials. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records accruals based on estimates of services received, efforts expended, and amounts owed pursuant to contracts with numerous contract research organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company&#8217;s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the company&#8217;s estimate of the degree of completion of the event or events specified in the specific clinical study. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Statement of Operations and Comprehensive Loss as the Company receives the related goods or services. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Costs incurred in obtaining technology licenses are charged to research and development expense as purchased <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">in-process</div> research and development if the technology licensed has not reached technological feasibility and has no alternative future use. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Fixed Assets</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed Assets </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets are stated at cost, less accumulated depreciation. Generally, expenditures for maintenance and repairs are charged to expense and major improvements or replacements are capitalized. The Company computes depreciation and amortization using the straight-line method over the estimated useful life of the asset. Leasehold improvements are amortized over the lesser of, the life of the lease or the estimated useful life of the leasehold improvement. The estimated useful lives are as follows: </div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment and software</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-5</div> years</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-7</div> years</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">remainder of lease term</td></tr></table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets consisted of the following (in thousands): </div></div></div><div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,220</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,180</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment and software</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">589</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">569</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,520</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,517</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Construction in progress</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">631</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">351</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: accumulated depreciation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,857</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,259</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total fixed assets, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,103</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,358</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation expense for the three months ended March&#160;31, 2022 and 2021 was $593,000 and $176,000, respectively. </div></div> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed Assets </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets are stated at cost, less accumulated depreciation. Generally, expenditures for maintenance and repairs are charged to expense and major improvements or replacements are capitalized. The Company computes depreciation and amortization using the straight-line method over the estimated useful life of the asset. Leasehold improvements are amortized over the lesser of, the life of the lease or the estimated useful life of the leasehold improvement. The estimated useful lives are as follows: </div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 51%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 46%; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment and software</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5</div> years</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">7</div> years</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">remainder of lease term</td></tr></table>  <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,180</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,011</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment and software</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">569</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">130</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,517</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Construction in progress</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">351</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,854</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: accumulated depreciation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,259</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,157</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total fixed assets, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,358</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,914</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation expense for the years ended December&#160;31, 2021 and 2020 was $1,451,000 and $606,000, respectively. </div></div> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible Assets </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets are comprised of acquired assembled workforce, which are accounted for in accordance with ASC 350&#8212;Intangibles&#8212;Goodwill and Other. The acquired assembled workforce is amortized on a straight-line basis over the useful life of five years. The following table summarizes information related to the Company&#8217;s assembled workforce intangible asset (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross carrying amount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,073</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,073</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">699</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">645</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net carrying amount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">374</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">428</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated amortization expense for the remaining nine months of 2022 is $154,000, $215,000 for the year ended December&#160;31, 2023 and $5,000 for the year ended December&#160;31, 2024. Amortization expense relating to the assembled workforce intangible asset was $54,000 for each of the three months ended March&#160;31, 2022 and 2021. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible Assets </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets are comprised of acquired assembled workforce, which are accounted for in accordance with ASC 350&#8212;Intangibles&#8212;Goodwill and Other. The acquired assembled workforce is amortized on a straight-line basis over the useful life of five years. The following table summarizes information related to the Company&#8217;s assembled workforce intangible asset (in thousands): </div></div>  <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross carrying amount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,073</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,073</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">645</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">431</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net carrying amount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">428</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">642</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table>  <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Estimated amortization expense for each of the years 2022 through 2023 is $215,000 and $5,000 for 2024. Amortization expense relating to the assembled workforce intangible asset was $214,000 for the year ended December&#160;31, 2021 and $215,000 for the year ended December&#160;31, 2020. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairment of Long-Lived Assets </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-lived assets such as fixed assets and intangible assets subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. No impairment charges have been recorded for the three months ended March&#160;31, 2022 or 2021. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Impairment of Long-Lived Assets </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-lived assets such as fixed assets and intangible assets subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. No impairment charges have been recorded for the years ended December&#160;31, 2021 or 2020. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company was organized as a limited liability company, is now a limited partnership and is classified as a partnership for U.S. income tax purposes, and as such, only records a provision for federal and state income taxes on its subsidiaries organized as C corporations or which have elected to be treated as corporations for U.S. federal income tax purposes. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> is a limited liability company and has elected to be treated as a C corporation. Therefore, a provision for federal and state taxes has been recorded. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> has been granted, by the Government in Council of the Cayman Islands, tax concessions under an undertaking certificate exempting it from any tax levied on profits, income, gains or appreciations in relation to its operations or in the nature of estate duty or inheritance tax for a period of twenty years from January&#160;20, 2016. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> elected to be treated as an entity disregarded from its owner for U.S. tax purposes, and as a result, it has not recorded an income tax provision. <br/></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company uses the liability method in accounting for income taxes as required by ASC Topic 740 &#8212; Income Taxes, under which deferred tax assets and liabilities are recorded for the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that such assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, available taxes in the carryback periods, projected future taxable income and tax planning strategies in making this assessment. Accordingly, the Company has provided a full valuation allowance to offset the net deferred tax assets at March&#160;31, 2022 and December&#160;31, 2021. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest and penalties related to income taxes are included in the benefit (provision) for income taxes in the Company&#8217;s Condensed Consolidated Statements of Operations and Comprehensive Loss. The Company has not incurred any significant interest or penalties related to income taxes in any of the periods presented. </div></div> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company was organized as a limited liability company, is now a limited partnership and is classified as a partnership for U.S. income tax purposes, and as such, only records a provision for federal and state income taxes on its subsidiaries organized as C corporations or which have elected to be treated as corporations for U.S. federal income tax purposes. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> is a limited liability company and has elected to be treated as a C&#160;corporation. Therefore, a provision for federal and state taxes has been recorded. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> has been granted, by the Government in Council of the Cayman Islands, tax concessions under an undertaking certificate exempting it from any tax levied on profits, income, gains or appreciations in relation to its operations or in the nature of estate duty or inheritance tax for a period of twenty years from January&#160;20, 2016. <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> elected to be treated as an entity disregarded from its owner for U.S. tax purposes, and as a result, it has not recorded an income tax provision. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company uses the liability method in accounting for income taxes as required by ASC Topic 740&#160;&#8212; Income Taxes, under which deferred tax assets and liabilities are recorded for the future tax consequences attributable to the differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that such assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, available taxes in the carryback periods, projected future taxable income and tax planning strategies in making this assessment. Accordingly, the Company has provided a full valuation allowance to offset the net deferred tax assets at December&#160;31, 2021. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Interest and penalties related to income taxes are included in the benefit (provision) for income taxes in the Company&#8217;s Consolidated Statements of Operations. The Company has not incurred any significant interest or penalties related to income taxes in any of the periods presented. </div></div> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">three-level</div> fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three&#160;levels of inputs used to measure fair value are as follows: </div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;1 &#8211; Unadjusted quoted prices in active markets for identical assets or liabilities </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;2 &#8211; Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable through correlation with market data </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="page-break-inside: avoid;">
<td style="width: 5%;">&#160;</td>
<td style="width: 3%; vertical-align: top;;text-align:left;">&#8226;</td>
<td style="width: 1%; vertical-align: top;">&#160;</td>
<td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level&#160;3 &#8211; Unobservable inputs that are supported by little or no market data, which require the reporting entity to develop its own assumptions </div></div></td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The carrying values of cash equivalents, accounts payable, and accrued liabilities approximate fair value due to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">short-term</div> nature of these instruments. </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: </div></div> <div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 9%;"/>
<td style="width: 2%; vertical-align: bottom;"/>
<td style="width: 89%;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Level&#160;1&#160;&#8211;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Unadjusted quoted prices in active markets for identical assets or liabilities</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Level&#160;2&#160;&#8211;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable through correlation with market data</td></tr>
<tr style="font-size: 1pt;">
<td style="height: 6pt; font-size: 0px;">&#160;</td>
<td colspan="2" style="height: 6pt; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;">Level&#160;3&#160;&#8211;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: top;">Unobservable inputs that are supported by little or no market data, which require the reporting entity to develop its own assumptions</td></tr></table> <div style="clear: both; max-height: 0px;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The carrying values of cash equivalents, accounts payable, and accrued liabilities approximate fair value due to the short-term nature of these instruments. There are no <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> securities included in cash and cash equivalents as of December&#160;31, 2021 and 2020. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leases </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company determines if an arrangement is a lease at inception.&#160;Balances recognized related to the Company&#8217;s operating and finance leases are included in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets, net and lease liabilities in the Condensed Consolidated Balance Sheets.&#160;Right of use assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date.&#160;Lease terms may include options to extend or terminate the lease if it is reasonably certain that the Company will exercise the option.&#160;As most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments.&#160;The right of use asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred.&#160;The Company has elected a practical expedient to not separate its lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components and instead account for them as a single lease component. Leases with a term of 12 months or less are not recorded on the balance sheet. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.&#160;Lease payments for short-term leases are recorded to operating expense on a straight-line basis and variable lease payments are recorded in the period in which the obligation for those payments is incurred. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leases </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company determines if an arrangement is a lease at inception. Balances recognized related to the Company&#8217;s operating and finance leases are included in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> assets, net and lease liabilities in the Consolidated Balance Sheets. Right of use assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Lease terms may include options to extend or terminate the lease if it is reasonably certain that the Company will exercise the option. As most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. The right of use asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company has elected a practical expedient to not separate its lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components and instead account for them as a single lease component. Leases with a term of 12 months or less are not recorded on the balance sheet. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Lease payments for short-term leases are recorded to operating expense on a straight-line basis and variable lease payments are recorded in the period in which the obligation for those payments is incurred. </div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_ContingentLiabilitiesPolicyTextBlock', window );">Contingent Liabilities</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent Liabilities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records reserves for contingent liabilities when it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements, and the amount of the loss can be reasonably estimated. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Contingent Liabilities </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company records reserves for contingent liabilities when it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements, and the amount of the loss can be reasonably estimated. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Equity-Based Compensation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity-Based Compensation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Deed for the Establishment of a Limited Partnership of ProKidney LP, dated as of August&#160;5, 2021 (the &#8220;Limited Partnership Agreement&#8221;) which replaced the Amended and Restated Limited Liability Company Agreement of ProKidney LLC as the governing document of the parent entity in the Company, allows for the issuance of Profits Interests (as defined in the Limited Partnership Agreement) to employees, directors, other service providers of the Company and others denominated in the form of one or more Class&#160;B Units (as defined in the Limited Partnership Agreement). </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">On January&#160;17, 2022, the Company amended and restated its Limited Partnership Agreement (the &#8220;Amended and Restated Limited Partnership Agreement&#8221;) in part to authorize the issuance of up to 50,000,000 Class&#160;B Units (including <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;B-1</div> Units). The Amended and Restated Limited Partnership Agreement provides that certain qualified distribution events will result in holders of Profits Interests receiving disproportionate distributions from ProKidney until each such holder&#8217;s valuation threshold has been reduced to zero in order to &#8220;catch up&#8221; such holder&#8217;s distributions to its pro rata share of aggregate cumulative distributions, and once sufficient distributions to a holder of Profits Interests have been made in accordance with the foregoing, the associated Class&#160;B Units will automatically be converted into Class&#160;A Units. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company measures compensation expense for Profits Interests based on estimated fair values at the time of grant. The Company estimates the fair value of Profits Interests using generally accepted valuation procedures. The Company recognizes compensation expense, on a straight-line basis, for the portion of the Profits Interests&#8217; value that is expected to vest over the requisite service period. The Company records forfeitures of Profits Interests as they occur. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Equity-Based Compensation </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Deed for the Establishment of a Limited Partnership of ProKidney LP, dated as of August&#160;5, 2021 (the &#8220;Limited Partnership Agreement&#8221;) which replaced the Amended and Restated Limited Liability Company Agreement of ProKidney LLC as the governing document of the parent entity in the Company, allows for the issuance of Profits Interests (as defined in the Limited Partnership Agreement) to employees, directors, other service providers of the Company and others denominated in the form of one or more Class&#160;B Units (as defined in the Limited Partnership Agreement). The Company measures compensation expense for Profits Interests based on estimated fair values at the time of grant. The Company estimates the fair value of Profits Interests using generally accepted valuation procedures. The Company recognizes compensation expense, on a straight-line basis, for the portion of the Profits Interests&#8217; value that is expected to vest over the requisite service period. The Company records forfeitures of Profits Interests as they occur. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock', window );">Defined Contribution Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Defined Contribution Plan </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">The Company sponsors a 401(k) plan for its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> employees and a defined contribution plan for its <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> employees. Full-time employees are eligible to participate in the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> plan. The Company matches 50% of participating <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> employees&#8217; contributions up to 8% of salary. The costs of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-US</div> plan were $161,000 and $119,000 for the years ended December&#160;31, 2021 and 2020, respectively. The Company contributes 7% of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> employee salaries to the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> defined contribution plan. The costs of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ProKidney-KY</div> plan were $8,000 and $20,000 for the years ended December&#160;31, 2021 and 2020, respectively. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company operates in only one segment. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Segments </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company operates in only one segment. </div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recently Adopted Accounting Pronouncements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In February 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-02,</div> Leases (Topic 842), which requires lessees to recognize a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset and a liability on the balance sheet for all leases, with the exception of short-term leases. The lease liability will be equal to the present value of lease payments, and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset will be based on the lease liability, subject to adjustment such as for initial direct costs. Leases will continue to be classified as either operating or finance leases in the income statement. The guidance is effective for annual periods beginning after December&#160;15, 2021, with early adoption permitted. The Company early adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-02,</div> Leases (Topic 842), as of January&#160;1, 2021. For additional detail, see Note 4, Leases. </div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recently Adopted Accounting Pronouncements </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In February 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-02,</div> Leases (Topic 842), which requires lessees to recognize a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset and a liability on the balance sheet for all leases, with the exception of short-term leases. The lease liability will be equal to the present value of lease payments, and the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">right-of-use</div></div> asset will be based on the lease liability, subject to adjustment such as for initial direct costs. Leases will continue to be classified as either operating or finance leases in the income statement. The guidance is effective for annual periods beginning after December&#160;15, 2021, with early adoption permitted. The Company early adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No.&#160;2016-02,</div> Leases (Topic 842), as of January&#160;1, 2021. For additional detail, see Note 4, Leases. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsequent Events </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has evaluated subsequent events through June 10, 2022, which is the date the consolidated financial statements were available to be issued. See additional information in Note 9. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Subsequent Events </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has evaluated subsequent events through April&#160;11, 2022, which is the date the consolidated financial statements were available to be issued. See additional information in Notes 5 and 8. </div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember', window );">Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div></div> <div style="background: none;;font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The </div>accompanying unaudited condensed financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) for interim financial information and in accordance with the instructions to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Form&#160;10-Q</div> and Article&#160;8 of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Regulation&#160;S-X</div> of the SEC. Certain information or footnote disclosures normally included in condensed financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements contained in the Company&#8217;s Annual Report on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-K</div> for the period ended December&#160;31, 2021 filed with the SEC on March&#160;24, 2022. The interim results for the three months ended March&#160;31, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022 or for any future periods. </div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and pursuant to the rules and regulations of the SEC. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates</div></div></div></div><br/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Significant accounting estimates include the determination of the fair value of Class&#160;A ordinary shares subject to possible redemption and the fair value of Founder Shares transferred to directors. Accordingly, the actual results could differ significantly from those estimates.</div></div></div> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Significant accounting estimates include the determination of the fair value of Class&#160;A ordinary shares subject to possible redemption and the fair value of Founder Shares transferred to directors. Accordingly, the actual results could differ significantly from those estimates. </div></div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of March&#160;31, 2022 and December&#160;31, 2021. </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Cash and Cash Equivalents </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div><div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;">considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of December&#160;31, 2021.</div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_EmergingGrowthCompanyStatusPolicyTextBlock', window );">Emerging Growth Company</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s condensed financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. <br/></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Emerging Growth Company </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is an &#8220;emerging growth company,&#8221; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-emerging</div> growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#8217;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div></div> <div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:rgba(255, 255, 255, .0);;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution which, at times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on these </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color:rgba(255, 255, 255, .0);;display:inline;">accounts. </div></div></div><br/></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Concentration of Credit Risk </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution which, at times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on these accounts. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_AccruedExpensesPolicyTextBlock', window );">Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accrued Expense </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses </div></div><div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;">includes $1,506,528 of accrued legal expense, $5,000 of accrued printing expense, $282,500 of accrued due diligence expense, $70,000 of accrued regulatory filing fee and $770 of accrued accounting expense.</div> <div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"> </div></div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accrued Expenses </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At March&#160;31, 2022, accrued expenses includes $4,095,414 of&#160;legal expense, $283,348 of printing expense, $529,688 of due diligence expense, $363,740 of professional fee expense and $70,000 of&#160;regulatory fee expe<div style="background-color:rgba(255, 255, 255, .0);;display:inline;">nse</div></div><div style="background-color:rgba(255, 255, 255, .0);;display:inline;">, of which $2,500,000 of legal expense, $247,188 of consulting expense and $534,906 of other transactional related expenses incurred in connection with the Business Combination with ProKidney.</div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2021, accrued expenses includes $1,506,528&#160;of legal expense, $5,000&#160;of printing expense, $282,500&#160;of due diligence expense, $70,000&#160;of regulatory filing fee and $770&#160;of accounting expense. </div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes under ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the condensed financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s condensed financial statements and prescribes a recognition threshold and measurement process for condensed financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> to be sustained upon examination by taxing authorities. The Company&#8217;s management has determined that the Cayman Islands is the Company&#8217;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of March&#160;31, 2022 and December&#160;31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has been subject to income tax examinations by major taxing authorities since inception. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is considered to be an exempted Cayman Islands company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#8217;s tax provision was zero for the periods presented. </div></div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for income taxes under ASC 740, &#8220;Income Taxes&#8221; (&#8220;ASC 740&#8221;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> to be sustained upon examination by taxing authorities. The Company&#8217;s management has determined that the Cayman Islands is the Company&#8217;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">amounts accrued for interest and penalties as of December&#160;31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company is considered to be an exempted Cayman Islands company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#8217;s tax provision was zero for the period presented. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Equity-Based Compensation</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-Based Payment Arrangements </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">accounts for stock awards in accordance with ASC 718, &#8220;Compensation&#8212;Stock Compensation,&#8221; which requires that all equity awards be accounted for at their &#8220;fair value.&#8221; Fair value is measured on the grant date and is equal to the underlying value of the stock. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Costs equal </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">to these fair values are recognized ratably over the requisite service period based on the number of awards that are expected to vest, in the period of grant for awards that vest immediately and have no future service condition, or in the period the awards vest immediately after meeting a performance condition becomes probable (i.e., the occurrence of a Business Combination). For awards that vest over time, cumulative adjustments in later periods are recorded to the extent actual forfeitures differ from the Company&#8217;s initial estimates; previously recognized compensation cost is reversed if the service or performance conditions are not satisfied and the award is&#160;forfeited. </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Share-Based Payment Arrangements </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for stock awards in accordance with ASC 718, &#8220;Compensation&#8212;Stock Compensation,&#8221; which requires that all equity awards be accounted for at their &#8220;fair value.&#8221; Fair value is measured on the grant date and is equal to the underlying value of the stock. </div><br/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Costs equal to these fair values are recognized ratably over the requisite service period based on the number of awards that are expected to vest, in the period of grant for awards that vest immediately and have no future service condition, or in the period the awards vest immediately after meeting a performance condition becomes probable (i.e., the occurrence of a Business Combination). For awards that vest over time, cumulative adjustments in later periods are recorded to the extent actual forfeitures differ from the Company&#8217;s initial estimates; previously recognized compensation cost is reversed if the service or performance conditions are not satisfied and the award is forfeited.</div></div></div> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_TemporaryEquityPolicyTextBlock', window );">Class A Ordinary Shares Subject to Possible Redemption</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class&#160;A Ordinary Shares Subject to Possible Redemption </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its Class&#160;A ordinary shares subject to possible redemption in accordance with the guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 480, &#8220;Distinguishing Liabilities from Equity.&#8221; Class&#160;A ordinary shares subject to mandatory redemption are classified as a liability instrument and are measured at redemption value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) are classified as temporary equity. At all other times, ordinary shares are classified as permanent deficit. The Company&#8217;s Class&#160;A ordinary shares feature certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events. Accordingly, Class&#160;A ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the permanent deficit section of the Company&#8217;s condensed balance sheets. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying value of redeemable ordinary shares are affected by charges against additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital (to the extent available) and accumulated deficit. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At March&#160;31, 2022 and December&#160;31, 2021, the Class&#160;A ordinary shares subject to possible redemption reflected in the condensed balance sheets are reconciled in the following </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">table: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-size: 0px;">
<td style="width: 77%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares issuance costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,479,666</td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,487,990</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Class&#160;A ordinary shares subject to possible redemption, December&#160;31, <br/>2021</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">250,008,324</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr>
<td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"><br/></div></div> </td>
<td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;">&#160;</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Remeasurement of carrying value to redemption value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,324</td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares subject to possible redemption, March&#160;31, 2022</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">250,000,000</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr>
<td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"><br/></div></div> </td>
<td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;">&#160;</div></div></div> </td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Class&#160;A Ordinary Shares Subject to Possible Redemption </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for its Class&#160;A ordinary shares subject to possible redemption in accordance with the guidance in Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 480, &#8220;Distinguishing Liabilities from Equity.&#8221; Class&#160;A ordinary shares subject to mandatory redemption are classified as a liability instrument and are measured at redemption value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders&#8217; equity. The Company&#8217;s Class&#160;A ordinary shares feature certain redemption rights that are considered to be outside of the Company&#8217;s control and subject to occurrence of uncertain future events. Accordingly, Class&#160;A ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the permanent deficit section of the Company&#8217;s balance sheet. </div></div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying value of redeemable ordinary shares are affected by charges against additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital (to the extent available) and accumulated deficit. </div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2021, the Class&#160;A ordinary shares subject to possible redemption reflected in the balance sheet are reconciled in the following table: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"/><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size: 0px;">
<td style="width: 77%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size: 0px;">
<td style="width: 83%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares issuance costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,479,666</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Increase of carrying value to redemption value</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,487,990</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares subject to possible redemption</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">250,008,324</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/>  <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Marketable Securities Held in Trust Account</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Marketable Securities Held in Trust Account </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At March&#160;31, 2022 and December&#160;31, 2021, substantially all of the assets held in the Trust Account were held in a money market fund which is invested primarily in U.S. Treasury securities. </div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Marketable Securities Held in Trust Account </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2021, substantially all of the assets held in the Trust Account were held in money market funds which are invested primarily in U.S. Treasury securities. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_DeferredOfferingCostsPolicyTextBlock', window );">Offering Costs</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Offering Costs </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div>complies with the requirements of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASC&#160;340-10-S99-1.&#160;Offering&#160;costs</div></div></div> consisted of legal, accounting, underwriting fees and other costs incurred through the Initial Public Offering that were directly related to the Initial Public Offering. The Company incurred offering costs amounting to $12,479,666 as a result of the Initial Public Offering, consisting of $4,400,000 of underwriting commissions, $7,700,000 of deferred underwriting commissions, and $379,666&#160;of other offering costs. <div style="letter-spacing: 0px; top: 0px;;display:inline;">As the shares sold in the IPO are redeemable, the offering costs were charged to temporary equity and additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital upon the completion of the Initial Public Offering. Immediately thereafter, temporary equity was remeasured and an adjustment was recognized through additional paid in capital and accumulated deficit to adjust temporary equity to the redemption value. </div><br/></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Offering Costs </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company </div></div>complies with the requirements of the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">ASC&#160;340-</div></div></div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">10-S99-1.&#160;Offering&#160;costs</div></div></div> consisted of legal, accounting, underwriting fees and other costs incurred through the Initial Public Offering that were directly related to the Initial Public Offering. The Company incurred offering costs amounting to $12,479,666 as a result of the Initial Public Offering, consisting of $4,400,000 of underwriting commissions, $7,700,000 of deferred underwriting commissions, and $379,666<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div>of other offering costs. The offering costs were charged to temporary equity and additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">paid-in</div> capital upon the completion of the Initial Public Offering. Immediately thereafter, temporary equity was remeasured and an adjustment was recognized through additional paid in capital and accumulated deficit to adjust temporary equity to the redemption value. </div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Ordinary Share</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Loss per Ordinary Share </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per ordinary share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding during the period. The Company has two classes of ordinary shares, which are referred to as </div></div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares and Class&#160;B ordinary shares. Losses are shared pro rata between the two classes of shares. Charges associated with the redeemable Class&#160;A ordinary shares are excluded from net loss per ordinary share as the redemption value approximates fair value. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of </div></div><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">March&#160;31, 2022 and 2021, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted net loss per ordinary share is the same as basic net loss per ordinary share for the periods presented. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/>March&#160;31, 2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Period from<br/>February&#160;25, 2021<br/>(Inception) Through</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per ordinary share</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,200,799</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(780,226</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,182</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average shares outstanding</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,640,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per ordinary share</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.12</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.12</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Net Loss Per Ordinary Share </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per ordinary share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding during the period. The Company has two classes of shares, which are referred to as Class&#160;A </div></div></div> <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">ordinary shares and Class&#160;B ordinary shares. Losses are shared pro rata between the two classes of shares. Charges associated with the redeemable Class&#160;A ordinary shares are excluded from net loss per ordinary share as the redemption value approximates fair value. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of December&#160;31, 2021, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted net loss per ordinary share is the same as basic net loss per ordinary share for the periods presented. </div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Period from</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">February&#160;25, 2021 (Inception)<br/>Through December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per ordinary share</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net loss</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right;">(1,675,346</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div><br/></td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom;"><div style="line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div><br/></div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right;">(649,283</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div><br/></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average shares outstanding</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">15,101,877</td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">5,852,751</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-indent: 0px;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per ordinary share</div></div></td>
<td style="vertical-align: bottom;;text-indent: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div><br/></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px; text-align: right;">(0.11</td>
<td style="vertical-align: bottom;;text-indent: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div><br/></div></td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-indent: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div><br/></div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px; text-align: right;">(0.11</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:center;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div><br/></div></td></tr></table>  <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; (&#8220;ASC 820&#8221;), approximates the carrying amounts represented in the accompanying condensed balance sheet, primarily due to their short-term nature. </div></div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value of Financial Instruments </div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the Company&#8217;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#8220;Fair Value Measurement,&#8221; approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature.</div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Standards </div></div></div><br/></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2020, the FASB issued ASU No. 2020-06, &#8220;Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity&#8221; (&#8220;ASU 2020-06&#8221;), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. The Company adopted ASU 2020-06 effective as of January 1, 2021. The adoption of ASU 2020-06 did not have an impact on the Company&#8217;s condensed financial statements. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s condensed financial statements.</div></div></div><span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Recent Accounting Standards </div></div></div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In August 2020, the FASB issued ASU No. 2020-06, &#8220;Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity&#8221; (&#8220;ASU 2020-06&#8221;), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. We adopted ASU 2020-06 effective as of January 1, 2021. The adoption of ASU 2020-06 did not have an impact on our financial statements. </div></div></div> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#8217;s financial statements. </div></div></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_AccruedExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued expenses [Policy text block].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_AccruedExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_ContingentLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_ContingentLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_DeferredOfferingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs [policy text block].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_DeferredOfferingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_EmergingGrowthCompanyStatusPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Emerging growth company status [policy text block].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_EmergingGrowthCompanyStatusPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_GoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Going concern [Policy text block].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_GoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_TemporaryEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity [Policy text block].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_TemporaryEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy election to measure plan assets and benefit obligations as of the month-end that is closest to the fiscal year-end.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (u)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701414102736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of calculation of basic and diluted net income (loss) per ordinary share</a></td>
<td class="text">The following table sets forth the calculation of basic and diluted earnings per share for the periods indicated based on the weighted average number of common shares outstanding:
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss available to Class&#160;A Unit holders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(67,486</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,609</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average Class&#160;A Units outstanding, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">186,500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">122,111,111</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per Class&#160;A Unit</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per Class&#160;A Unit, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The following table sets forth the calculation of basic and diluted earnings per share for the periods indicated based on the weighted average number of common shares outstanding:
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss available to Class&#160;A Unit holders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(55,146</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(26,749</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average Class&#160;A Units outstanding, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150,706,849</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">104,986,301</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per Class&#160;A Unit</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per Class&#160;A Unit, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.37</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.25</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses as presented in the Condensed Consolidated Balance Sheets as of March&#160;31, 2022 and December&#160;31, 2021 consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">818</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,832</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinical study related costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">653</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,031</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued legal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,095</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">964</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Manufacturing improvement costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3,137</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,164</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">414</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">222</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued expenses and other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,117</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,213</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued expenses which have been presented on the consolidated balance sheets as of December&#160;31, 2021 and 2020 consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Compensation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,832</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,085</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Clinical study related costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,031</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,154</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Facility expansion costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">19</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,709</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued legal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">964</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Manufacturing improvement costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,164</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other accrued expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">203</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">548</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total accrued expenses and other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">9,213</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,496</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_DisclosureInTabularFormOfUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock', window );">Schedule of estimated useful lives</a></td>
<td class="text">The estimated useful lives are as follows: <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment and software</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-5</div> years</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-7</div> years</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">remainder of lease term</td></tr></table> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The estimated useful lives are as follows: <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 51%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 46%; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment and software</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">3-</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5</div> years</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">5-</div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">7</div> years</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-align:center;">remainder of lease term</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of fixed assets</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets consisted of the following (in thousands): </div></div></div><div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;">&#160;</div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,220</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,180</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment and software</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">589</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">569</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,520</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,517</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Construction in progress</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">631</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">351</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: accumulated depreciation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,857</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,259</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total fixed assets, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,103</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,358</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/> <div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 10%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and equipment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,180</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,011</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment and software</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">569</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">130</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,517</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">76</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Construction in progress</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">351</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7,854</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: accumulated depreciation</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(2,259</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,157</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total fixed assets, net</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">11,358</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,914</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible asset</a></td>
<td class="text">The following table summarizes information related to the Company&#8217;s assembled workforce intangible asset (in thousands):
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross carrying amount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,073</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,073</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">699</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">645</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net carrying amount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">374</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">428</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The following table summarizes information related to the Company&#8217;s assembled workforce intangible asset (in thousands): <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross carrying amount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,073</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,073</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accumulated amortization</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">645</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">431</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net carrying amount</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">428</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">642</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember', window );">Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of calculation of basic and diluted net income (loss) per ordinary share</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At March&#160;31, 2022 and December&#160;31, 2021, the Class&#160;A ordinary shares subject to possible redemption reflected in the condensed balance sheets are reconciled in the following </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">table: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-size: 0px;">
<td style="width: 77%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares issuance costs</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,479,666</td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accretion of carrying value to redemption value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,487,990</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;">Class&#160;A ordinary shares subject to possible redemption, December&#160;31, <br/>2021</div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">250,008,324</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr>
<td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"><br/></div></div> </td>
<td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;">&#160;</div></div></div> </td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Remeasurement of carrying value to redemption value</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(8,324</td>
<td style="vertical-align: bottom; white-space: nowrap;">)</td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: bottom; padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares subject to possible redemption, March&#160;31, 2022</div></div></div> </td>
<td style="vertical-align: bottom; padding-bottom: 0.375pt;">&#160;&#160;</td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">250,000,000</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td> </tr>
<tr>
<td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"><br/></div></div> </td>
<td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;">&#160;</div></div></div> </td>
<td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"> <div style="font-size: 1pt; line-height: 1pt;"><div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;">&#160;</div></div></div> </td> </tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div> </td>
<td>&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">At December&#160;31, 2021, the Class&#160;A ordinary shares subject to possible redemption reflected in the balance sheet are reconciled in the following table: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"/><br/></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 77%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size: 0px;">
<td style="width: 77%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-size: 0px;">
<td style="width: 83%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Gross proceeds</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares issuance costs</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(12,479,666</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Plus:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;">Increase of carrying value to redemption value</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">12,487,990</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Class&#160;A ordinary shares subject to possible redemption</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">250,008,324</div></div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <div style="clear:both;max-height:0pt;;text-indent: 0px;"/> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Schedule of Class A Ordinary shares reflected in the Balance Sheets</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 61%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended<br/>March&#160;31, 2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Period from<br/>February&#160;25, 2021<br/>(Inception) Through</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per ordinary share</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></div> </td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net loss</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(3,200,799</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(780,226</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(5,182</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average shares outstanding</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">25,640,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6,250,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">5,500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td> </tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per ordinary share</div></div> </td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.12</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.12</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.00</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td> </tr> </table> <span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts): </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For the Period from</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">February&#160;25, 2021 (Inception)<br/>Through December&#160;31, 2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per ordinary share</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Allocation of net loss</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right;">(1,675,346</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div><br/></td>
<td style="vertical-align: bottom; padding: 0px;">&#160;</td>
<td style="vertical-align: bottom;"><div style="line-height: normal;"><div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;">$</div><br/></div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-align: right;">(649,283</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="text-align: left; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div><br/></div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator:</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted weighted average shares outstanding</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">15,101,877</td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;">5,852,751</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;;text-indent: 0px;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic and diluted net loss per ordinary share</div></div></td>
<td style="vertical-align: bottom;;text-indent: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;">&#160;</div></td>
<td style="vertical-align: bottom;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div><br/></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px; text-align: right;">(0.11</td>
<td style="vertical-align: bottom;;text-indent: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div><br/></div></td>
<td style="vertical-align: bottom;;text-indent: 0px;">&#160;&#160;</td>
<td style="vertical-align: bottom;;text-indent: 0px;"><div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div><br/></div></td>
<td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px; text-align: right;">(0.11</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:center;"><div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">)</div><br/></div></td></tr></table> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_DisclosureInTabularFormOfUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure in tabular form of useful lives of property plant and equipment [Table Text Block].</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_DisclosureInTabularFormOfUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701420529024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The provision for income tax expense consisted of the following for the year ended December&#160;31, 2021 and 2020 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 65%;"/>
<td style="width: 14%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 14%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">72</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(242</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(34</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total current income tax expense (benefit)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(232</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred income tax expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income tax expense (benefit)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">38</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(232</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The difference between the statutory rate for federal income tax and the effective income tax rate was as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 12%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes at statutory rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">21.0</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">State taxes, net of federal benefit</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">LLC flow-through structure</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21.4</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(21.5</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal Credits</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1.8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Provision to return adjustment</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Change in valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.3</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Other</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.2</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Effective income tax rate</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.1</td>
<td style="vertical-align: bottom; white-space: nowrap;">)%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.9</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Components of the Company&#8217;s deferred tax assets and liabilities included in the consolidated balance sheet consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accrued bonus</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">376</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">243</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">108</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Federal credit carryforwards</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">939</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">331</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leases</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">28</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Start-up</div> costs</div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">39</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">48</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax assets before valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,382</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">730</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Valuation allowance</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,237</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">560</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">145</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">170</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Deferred tax liabilities:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">90</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">148</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fixed assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">47</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prepaid expenses</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">22</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total deferred tax liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">145</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">170</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net deferred tax asset</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Roll Forward</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A reconciliation of the beginning and ending amount of total unrecognized tax benefits for the years ended December&#160;31, 2021 and 2020 consisted of the following (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 13%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unrecognized tax benefits (gross):</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Benefits at the beginning of the year</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase related to prior year tax positions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Decrease related to prior year tax positions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Increase related to current year tax positions</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">86</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Benefits at the end of the year</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">180</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI https://asc.fasb.org/extlink&amp;oid=126976462&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701416569136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_LesseeOperatingAndFinanceLeaseTableTextBlock', window );">Schedule of the classification of operating and finance lease assets and obligations in the Company's Consolidated Balance Sheets</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the classification of operating and finance lease assets and obligations in the Company&#8217;s Condensed Consolidated Balance Sheets as of March&#160;31, 2022 and December&#160;31, 2021 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 70%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31,<br/>2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating leases:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Right of use assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,579</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,139</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities, current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">295</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">235</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities, noncurrent</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,354</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">985</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,649</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,220</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr>
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finance leases:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Right of use assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">102</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finance lease liabilities, current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">33</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finance lease liabilities, noncurrent</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">74</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">82</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total finance lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">107</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">114</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the classification of operating and finance lease assets and obligations in the Company&#8217;s Consolidated Balance Sheets as of December&#160;31, 2021 and December&#160;31, 2020 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/>2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating leases:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Right of use assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,139</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,415</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities, current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">235</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">195</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Operating lease liabilities, noncurrent</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">985</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,219</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,220</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,414</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr>
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td>
<td style="vertical-align: bottom; white-space: nowrap;"><div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finance leases:</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Right of use assets</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">102</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">145</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finance lease liabilities, current</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">32</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finance lease liabilities, noncurrent</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">82</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">115</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total finance lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">114</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">145</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Schedule of Maturities of lease liabilities for the Company's operating and finance leases</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturities of lease liabilities for the Company&#8217;s operating and finance leases are as follows for the year ending March&#160;31, 2022 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating<br/>Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Finance<br/>Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022 (remaining nine months)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">315</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">345</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">428</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">468</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">440</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">480</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">440</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">447</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">355</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">355</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,993</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">117</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,110</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(344</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(10</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(354</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,649</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">107</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,756</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Maturities of lease liabilities for the Company&#8217;s operating and finance leases are as follows for the year ending December&#160;31, 2021 (in thousands): </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 5%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Operating</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Finance</div></div><br/><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Leases</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">326</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">366</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">332</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">372</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">341</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">40</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">381</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2025</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">282</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">7</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">289</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2026</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">180</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">180</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease payments</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,461</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">127</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,588</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: imputed interest</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(241</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(13</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(254</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Present value of lease liabilities</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,220</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">114</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,334</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_LesseeOperatingAndFinanceLeaseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating and finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_LesseeOperatingAndFinanceLeaseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 303<br> -Paragraph (a)<br> -Subparagraph (5)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701427881648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Members' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersEquityAbstract', window );"><strong>Members' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_MembersEquityTableTextBlock', window );">Schedule Of Members Equity</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Holders of Class&#160;A Units have voting rights and rights to profits and losses of the Company and distributions from the Company. The following is a summary of the activity of the Class&#160;A Units: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 79%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Units outstanding January&#160;1, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">95,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issued 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">20,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Units outstanding December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">115,000,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Issued 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">71,500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Units outstanding December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">186,500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_MembersEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Members equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_MembersEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MembersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MembersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701423562240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of calculation of basic and diluted net income (loss) per ordinary share</a></td>
<td class="text">The following table sets forth the calculation of basic and diluted earnings per share for the periods indicated based on the weighted average number of common shares outstanding:
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss available to Class&#160;A Unit holders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(67,486</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(11,609</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average Class&#160;A Units outstanding, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">186,500,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">122,111,111</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per Class&#160;A Unit</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per Class&#160;A Unit, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.10</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table> <span></span>
</td>
<td class="text">The following table sets forth the calculation of basic and diluted earnings per share for the periods indicated based on the weighted average number of common shares outstanding:
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 60%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Years Ended December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Numerator</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss available to Class&#160;A Unit holders</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(55,146</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(26,749</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Denominator</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average Class&#160;A Units outstanding, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">150,706,849</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">104,986,301</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per Class&#160;A Unit</div></div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Net loss per Class&#160;A Unit, basic and diluted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.37</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(0.25</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701423600992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember', window );">Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of Assets that are Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 68%;"/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 3%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">March&#160;31, 2022</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities held in Trust Account</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250,033,500</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250,008,324</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The </div></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">following table presents information about the Company&#8217;s assets that are measured at fair value on a recurring basis at December&#160;31, 2021, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: </div></div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 8%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;">Description</div></div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Level</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,&#160;2021</div></div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top; font-size: 10pt;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets:</div></div></div></td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;&#160;</div></td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Marketable securities held in Trust Account</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">250,008,324</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701420495344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Summary of key assumptions used in the OPM valuation</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following reflects the key assumptions used in each of the valuation scenarios: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;">
<tr style="font-size: 0px;">
<td style="width: 69%;"/>
<td style="width: 7%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 6%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">OPM</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">PWERM</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total equity value (in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">280,400</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">1,750,000</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility of total equity</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">95</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">60</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Discount for lack of market</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">15</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected time to exit event</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3.7 years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.5 years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following reflects the key assumptions used in the OPM valuation: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 85%; font-family: &quot;Times New Roman&quot;;"/>
<td style="width: 8%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total equity value (in thousands)</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">78,100</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility of total equity</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">80</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Discount for lack of market</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">30</td>
<td style="vertical-align: bottom; white-space: nowrap;">%&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected time to exit event</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">3 years</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr></table> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Compensation Expense</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Compensation expense related to the issuance and purchase of Class&#160;B and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Units is included in research and development and general and administrative expense as follows (in thousands): </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 66%;"/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 11%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three&#160;Months&#160;Ended&#160;March&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">17,367</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">&#8212;&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">35,319</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">175</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total equity-based compensation expense</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">52,686</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">175</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of the activity related to the Company's Class B and B-1 Units granted</a></td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The following table summarizes the activity for the three months ended March&#160;31, 2022, related to the Company&#8217;s Class&#160;B and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">B-1</div> Units granted as equity awards to its employees, board members and service providers: </div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/>Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average&#160;Grant<br/>Date&#160;Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested awards outstanding at January&#160;1, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,460,617</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Granted</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">8,498,488</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(449,486</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Forfeited</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(29,070</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">6.03</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Unvested awards outstanding at March&#160;31, 2022</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">10,480,549</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4.94</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
<td class="text"><div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table summarizes the activity related to the Company&#8217;s Profits Interest awards for the year ended December&#160;31, 2021: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;">
<tr style="font-size: 0px;">
<td style="width: 64%;"/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/>
<td style="width: 9%; vertical-align: bottom;"/>
<td/>
<td/>
<td/></tr>
<tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/>Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/>Average&#160;Grant<br/>Date&#160;Fair&#160;Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Awards outstanding at December&#160;31, 2020</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">4,402,398</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">(1,941,781</td>
<td style="vertical-align: bottom; white-space: nowrap;">)&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr>
<tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);">
<td style="vertical-align: top;"><div style="text-indent: -1em; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Awards outstanding at December&#160;31, 2021</div></div></td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">2,460,617</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom; white-space: nowrap;">$</td>
<td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">0.36</td>
<td style="vertical-align: bottom; white-space: nowrap;">&#160;</td></tr>
<tr style="font-size: 1px;">
<td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; font-size: 0px;">&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td>
<td style="vertical-align: bottom;">&#160;&#160;</td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">&#160;</div></div></td>
<td>&#160;</td></tr></table> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701414603360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description Of Organization, Business Operations And Going Concern - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 18, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems', window );"><strong>Description Of Organization And Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Incorporation date of entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 12,  2018<span></span>
</td>
<td class="text">Feb. 25,  2021<span></span>
</td>
<td class="text">Feb. 25,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinimumNetWorthRequiredForCompliance', window );">Minimum net worth to consummate business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_PercentageOfPublicSharesThatCanBeTransferredWithoutAnyRestriction', window );">Percentage of public shares that can be transferred without any restriction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated', window );">Percentage of public shares to be redeemed in case business combination is not consummated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities', window );">Interest to pay dissolution expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_PerShareValueOfRestrictedAssets', window );">Per share value of restricted assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_PercentageOfPublicSharesRedemption', window );">Percentage of public shares redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,889<span></span>
</td>
<td class="nump">$ 440,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_WorkingCapital', window );">Working Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,817,570<span></span>
</td>
<td class="nump">$ 935,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_PipeInvestorsMember', window );">PIPE Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems', window );"><strong>Description Of Organization And Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="nump">57,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="nump">$ 575,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMember', window );">Existing Directors, Officers And Equityholders Of, Or Investment Funds Managed By Suvretta Capital Management, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems', window );"><strong>Description Of Organization And Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="nump">156,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember', window );">Existing Directors, Officers And Unitholders Of ProKidney [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems', window );"><strong>Description Of Organization And Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=prok_ProkidneyLpMember', window );">ProKidney LP [Member] | Restricted Stock Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems', window );"><strong>Description Of Organization And Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Business acquisition, equity interest issued or issuable, number of shares</a></td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=prok_ProkidneyLpMember', window );">ProKidney LP [Member] | Share Price One [Member] | Restricted Stock Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems', window );"><strong>Description Of Organization And Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, share price</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=prok_ProkidneyLpMember', window );">ProKidney LP [Member] | Share Price Two [Member] | Restricted Stock Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems', window );"><strong>Description Of Organization And Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, share price</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=prok_ProkidneyLpMember', window );">ProKidney LP [Member] | Share Price Three [Member] | Restricted Stock Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems', window );"><strong>Description Of Organization And Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, share price</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems', window );"><strong>Description Of Organization And Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_ProspectiveAssetsOfAcquireeAsAPercentageOfFairValueOfAssetsInTheTrustAccount', window );">Prospective assets of acquiree as a percentage of fair value of assets in the trust account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Existing Directors, Officers And Unitholders Of ProKidney [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems', window );"><strong>Description Of Organization And Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems', window );"><strong>Description Of Organization And Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems', window );"><strong>Description Of Organization And Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period new shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_TransactionCostsIncurredInConnectionWithInitialPublicOffering', window );">Transaction costs incurred inconnection with initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,479,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_UnderwritingFee', window );">Underwriting fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_DeferredUnderwritingFees', window );">Deferred underwriting fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">379,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockHeldInTrust', window );">Common stock held in trust account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems', window );"><strong>Description Of Organization And Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period new shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems', window );"><strong>Description Of Organization And Business Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period new shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement issue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_DeferredUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred underwriting fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_DeferredUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_DescriptionOfOrganizationAndBusinessOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_DescriptionOfOrganizationAndBusinessOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_PerShareValueOfRestrictedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share value of restricted assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_PerShareValueOfRestrictedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_PercentageOfPublicSharesRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of public shares redemption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_PercentageOfPublicSharesRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_PercentageOfPublicSharesThatCanBeTransferredWithoutAnyRestriction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of public shares that can be transferred without any restriction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_PercentageOfPublicSharesThatCanBeTransferredWithoutAnyRestriction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of public shares to be redeemed in case business combination is not consummated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_ProspectiveAssetsOfAcquireeAsAPercentageOfFairValueOfAssetsInTheTrustAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prospective assets of acquiree as a percentage of fair value of assets in the trust account.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_ProspectiveAssetsOfAcquireeAsAPercentageOfFairValueOfAssetsInTheTrustAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_TransactionCostsIncurredInConnectionWithInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction costs incurred in connection with initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_TransactionCostsIncurredInConnectionWithInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_UnderwritingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwriting fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_UnderwritingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Working capital .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockHeldInTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of common stock held in trust.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockHeldInTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of estimated accrued costs to dispose of assets or other items expected to be sold in liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=95464943&amp;loc=SL35686261-199414<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinimumNetWorthRequiredForCompliance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum net worth required for mortgage banking as defined by regulatory framework.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6490092&amp;loc=d3e47304-110998<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6490092&amp;loc=d3e47304-110998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6490092&amp;loc=d3e47080-110998<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 948<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6490092&amp;loc=d3e47304-110998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinimumNetWorthRequiredForCompliance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_PipeInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_PipeInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=prok_ProkidneyLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=prok_ProkidneyLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=prok_RestrictedStockRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=prok_RestrictedStockRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_SharePriceRangeAxis=prok_SharePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_SharePriceRangeAxis=prok_SharePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_SharePriceRangeAxis=prok_SharePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_SharePriceRangeAxis=prok_SharePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_SharePriceRangeAxis=prok_SharePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_SharePriceRangeAxis=prok_SharePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701416561472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The Company - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 09, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_NatureOfOperationsLineItems', window );"><strong>Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Incorporation date of entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 12,  2018<span></span>
</td>
<td class="text">Feb. 25,  2021<span></span>
</td>
<td class="text">Feb. 25,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_InitialCapital', window );">Initial capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=prok_RegenAndTwinCityBioLlcMember', window );">Regen And Twin City Bio LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_NatureOfOperationsLineItems', window );"><strong>Nature Of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business combination consideration transferred</a></td>
<td class="nump">$ 62,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_InitialCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_InitialCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_NatureOfOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nature of operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_NatureOfOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=prok_RegenAndTwinCityBioLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=prok_RegenAndTwinCityBioLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701413694336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">71 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 02, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 17, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents, at carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,802,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,558,000<span></span>
</td>
<td class="nump">$ 20,558,000<span></span>
</td>
<td class="nump">$ 4,578,000<span></span>
</td>
<td class="nump">$ 20,558,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(228,996,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(161,510,000)<span></span>
</td>
<td class="num">(161,510,000)<span></span>
</td>
<td class="num">(106,364,000)<span></span>
</td>
<td class="num">(161,510,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67,486,000)<span></span>
</td>
<td class="num">$ (11,609,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,146,000)<span></span>
</td>
<td class="num">(26,749,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">593,000<span></span>
</td>
<td class="nump">176,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,451,000<span></span>
</td>
<td class="nump">606,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,802,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,558,000<span></span>
</td>
<td class="nump">$ 20,558,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,558,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_UnsufficientToFundItsObligationsTerm', window );">Unsufficient to fund its obligations term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Finite lived intangible assets amortization expense next twelve months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,000<span></span>
</td>
<td class="nump">$ 215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Finite lived intangible assets amortization expense next two years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,000<span></span>
</td>
<td class="nump">215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Finite lived intangible assets amortization expense next three years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassAMember', window );">Capital Unit, Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (67,486)<span></span>
</td>
<td class="num">(11,609)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (55,146)<span></span>
</td>
<td class="num">(26,749)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized', window );">Limited Partners' Capital Account, Units Authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,000,000<span></span>
</td>
<td class="nump">190,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassBMember', window );">Capital Unit, Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized', window );">Limited Partners' Capital Account, Units Authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=prok_PromissoryNoteMember', window );">Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount', window );">Debt Instrument, Unused Borrowing Capacity, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=prok_PromissoryNoteMember', window );">Promissory Note [Member] | Capital Unit, Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount', window );">Debt Instrument, Unused Borrowing Capacity, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=prok_AcquiredAssemblyWorkforceMember', window );">Acquired Assembly Workforce [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite lived intangible assets useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Finite lived intangible assets amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,000<span></span>
</td>
<td class="nump">$ 54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 214,000<span></span>
</td>
<td class="nump">215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_KY', window );">CAYMAN ISLANDS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_PeriodForWhichTheProfitsEarnedAreExemptFromTax', window );">Periods for which the profits earned are exempt from tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_DefinedContributionPlanCosts', window );">Defined contribution plan costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_DefinedContributionPlanPercent', window );">Defined contribution plan employer matching contribution percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">UNITED STATES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_DefinedContributionPlanCosts', window );">Defined contribution plan costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,000<span></span>
</td>
<td class="nump">$ 119,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember', window );">Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents, at carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized tax benefits, accrued interests and penalities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash, FDIC insured amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_DeferredUnderwritingFees', window );">Deferred underwriting fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,700,000<span></span>
</td>
<td class="nump">7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_AccruedLegalExpense', window );">Accrued legal expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,095,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,506,528<span></span>
</td>
<td class="nump">1,506,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,506,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_AccruedPrintingExpense', window );">Accrued printing expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_AccruedDueDiligenceExpense', window );">Accrued due diligence expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">529,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">282,500<span></span>
</td>
<td class="nump">282,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">282,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_AccruedRegulatoryFilingFee', window );">Accrued regulatory filing fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">363,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_AccruedAccountingExpense', window );">Accrued accounting expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">770<span></span>
</td>
<td class="nump">770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_BusinessCombinationAccruedLegalExpense', window );">Business combination, accrued legal expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_BusinessCombinationAccruedConsultingExpense', window );">Business combination, accrued consulting expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">247,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_BusinessCombinationAccruedOtherTransactionalRelatedExpenses', window );">Business combination, Accrued other transactional related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">534,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,361,009)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,388,308)<span></span>
</td>
<td class="num">$ (8,388,308)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,388,308)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,182)<span></span>
</td>
<td class="num">(3,981,025)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,324,629)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (3,200,799)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,675,346)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">$ 379,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_TransactionCostsIncurredInConnectionWithInitialPublicOffering', window );">Transaction costs incurred inconnection with initial public offering</a></td>
<td class="nump">12,479,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_UnderwritingFee', window );">Underwriting fee</a></td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_DeferredUnderwritingFees', window );">Deferred underwriting fee</a></td>
<td class="nump">7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | IPO [Member] | Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">379,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_TransactionCostsIncurredInConnectionWithInitialPublicOffering', window );">Transaction costs incurred inconnection with initial public offering</a></td>
<td class="nump">12,479,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_UnderwritingFee', window );">Underwriting fee</a></td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_DeferredUnderwritingFees', window );">Deferred underwriting fee</a></td>
<td class="nump">$ 7,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_AccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_AccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_AccruedAccountingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued accounting expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_AccruedAccountingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_AccruedDueDiligenceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued due diligence expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_AccruedDueDiligenceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_AccruedLegalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued legal expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_AccruedLegalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_AccruedPrintingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued printing expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_AccruedPrintingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_AccruedRegulatoryFilingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued regulatory filing fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_AccruedRegulatoryFilingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_BusinessCombinationAccruedConsultingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination accrued consulting expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_BusinessCombinationAccruedConsultingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_BusinessCombinationAccruedLegalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination accrued legal expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_BusinessCombinationAccruedLegalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_BusinessCombinationAccruedOtherTransactionalRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination accrued other transactional related expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_BusinessCombinationAccruedOtherTransactionalRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_DeferredUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred underwriting fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_DeferredUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_DefinedContributionPlanCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_DefinedContributionPlanCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_DefinedContributionPlanPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_DefinedContributionPlanPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_PeriodForWhichTheProfitsEarnedAreExemptFromTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period for which the profits earned are exempt from tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_PeriodForWhichTheProfitsEarnedAreExemptFromTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_TransactionCostsIncurredInConnectionWithInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction costs incurred in connection with initial public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_TransactionCostsIncurredInConnectionWithInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_UnderwritingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwriting fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_UnderwritingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_UnsufficientToFundItsObligationsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unsufficient to fund its obligations term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_UnsufficientToFundItsObligationsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI https://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of limited partner units authorized to be issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=prok_PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=prok_PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=prok_AcquiredAssemblyWorkforceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=prok_AcquiredAssemblyWorkforceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_KY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_KY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701420392368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Class A Ordinary Shares Reflected in the Balance Sheets (Detail) - Social Capital Suvretta Holdings Corp. III [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 245,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity', window );">Accretion of carrying value to redemption value</a></td>
<td class="num">$ (8,324)<span></span>
</td>
<td class="nump">12,487,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Class A ordinary shares subject to possible redemption</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">250,008,324<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_TemporaryEquityIssaunceCosts', window );">Class&#160;A ordinary shares issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,479,666)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity', window );">Accretion of carrying value to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,487,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_IncreaseOfOrdinarySharesToRedemptionValueTemporaryEquity', window );">Increase of carrying value to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,487,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Class A ordinary shares subject to possible redemption</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">$ 250,008,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_RemeasurementOfCarryingValueToRedemptionValue', window );">Remeasurement Of Carrying Value To Redemption Value</a></td>
<td class="num">$ (8,324)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_IncreaseOfOrdinarySharesToRedemptionValueTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase of ordinary shares to redemption value temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_IncreaseOfOrdinarySharesToRedemptionValueTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_RemeasurementOfCarryingValueToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remeasurement of carrying value to redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_RemeasurementOfCarryingValueToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remeasurement of Class A ordinary shares to redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_TemporaryEquityIssaunceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity Issaunce Costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_TemporaryEquityIssaunceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701419883360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Calculation of Basic and Diluted Net Income (Loss) per Ordinary Share (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Allocation of net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (67,486,000)<span></span>
</td>
<td class="num">$ (11,609,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (55,146,000)<span></span>
</td>
<td class="num">$ (26,749,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember', window );">Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Allocation of net loss</a></td>
<td class="num">$ (5,182)<span></span>
</td>
<td class="num">(3,981,025)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,324,629)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Allocation of net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (3,200,799)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,675,346)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_BasicAndDilutedEarningsPerShareOtherDisclosuresAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Shares Outstanding, Basic</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,101,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Shares Outstanding, Diluted</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,101,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per ordinary share , Basic</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per ordinary share , Diluted</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B [Member] | Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Allocation of net loss</a></td>
<td class="num">$ (5,182)<span></span>
</td>
<td class="num">$ (780,226)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (649,283)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_BasicAndDilutedEarningsPerShareOtherDisclosuresAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Shares Outstanding, Basic</a></td>
<td class="nump">5,500,000<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,852,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Shares Outstanding, Diluted</a></td>
<td class="nump">5,500,000<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,852,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per ordinary share , Basic</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per ordinary share , Diluted</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_BasicAndDilutedEarningsPerShareOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basic and diluted earnings per share other disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_BasicAndDilutedEarningsPerShareOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701420504672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation</a></td>
<td class="nump">$ 818<span></span>
</td>
<td class="nump">$ 1,832<span></span>
</td>
<td class="nump">$ 1,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_AccruedClinicalStudyRelatedCostsCurrent', window );">Clinical study related costs</a></td>
<td class="nump">653<span></span>
</td>
<td class="nump">2,031<span></span>
</td>
<td class="nump">1,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_AccruedFacilityExpansionCostsCurrent', window );">Facility expansion costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">1,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal</a></td>
<td class="nump">3,095<span></span>
</td>
<td class="nump">964<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_AccruedManufacturingImprovementCosts', window );">Manufacturing improvement costs</a></td>
<td class="nump">3,137<span></span>
</td>
<td class="nump">4,164<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_OtherAccruedExpenses', window );">Other accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="nump">548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">414<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses and other</a></td>
<td class="nump">$ 8,117<span></span>
</td>
<td class="nump">$ 9,213<span></span>
</td>
<td class="nump">$ 4,496<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_AccruedClinicalStudyRelatedCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical study related costs current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_AccruedClinicalStudyRelatedCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_AccruedFacilityExpansionCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued facility expansion costs current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_AccruedFacilityExpansionCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_AccruedManufacturingImprovementCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued manufacturing improvement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_AccruedManufacturingImprovementCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_OtherAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_OtherAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701414094256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Estimated Useful Lives (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">remainder of lease term<span></span>
</td>
<td class="text">remainder of lease term<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905813&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701419725056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Fixed Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">$ (2,857)<span></span>
</td>
<td class="num">$ (2,259)<span></span>
</td>
<td class="num">$ (1,157)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total fixed assets, net</a></td>
<td class="nump">11,103<span></span>
</td>
<td class="nump">11,358<span></span>
</td>
<td class="nump">8,914<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">2,220<span></span>
</td>
<td class="nump">2,180<span></span>
</td>
<td class="nump">2,011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">589<span></span>
</td>
<td class="nump">569<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">10,520<span></span>
</td>
<td class="nump">10,517<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">$ 631<span></span>
</td>
<td class="nump">$ 351<span></span>
</td>
<td class="nump">$ 7,854<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701420401936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Fixed Assets (Parenthetical) (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 593,000<span></span>
</td>
<td class="nump">$ 176,000<span></span>
</td>
<td class="nump">$ 1,451,000<span></span>
</td>
<td class="nump">$ 606,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701411901200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Intangible Asset (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">$ 1,073<span></span>
</td>
<td class="nump">$ 1,073<span></span>
</td>
<td class="nump">$ 1,073<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">699<span></span>
</td>
<td class="nump">645<span></span>
</td>
<td class="nump">431<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net carrying amount</a></td>
<td class="nump">$ 374<span></span>
</td>
<td class="nump">$ 428<span></span>
</td>
<td class="nump">$ 642<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701414070608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Intangible Asset (Parenthetical) (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Finite lived intangible assets amortization expense next twelve months</a></td>
<td class="nump">$ 154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Finite lived intangible assets amortization expense next two years</a></td>
<td class="nump">215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Finite lived intangible assets amortization expense next three years</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=prok_AcquiredAssemblyWorkforceMember', window );">Acquired Assembly Workforce [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite lived intangible assets useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Finite lived intangible assets amortization expense</a></td>
<td class="nump">$ 54,000<span></span>
</td>
<td class="nump">$ 54,000<span></span>
</td>
<td class="nump">$ 214,000<span></span>
</td>
<td class="nump">$ 215,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=prok_AcquiredAssemblyWorkforceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=prok_AcquiredAssemblyWorkforceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701414064960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Initial Public Offering - Additional Information (Detail) - Common Class A [Member]<br></strong></div></th>
<th class="th">
<div>Jul. 02, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share | $ / shares</a></td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period new shares issued | shares</a></td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share | $ / shares</a></td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period new shares issued | shares</a></td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701427847712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,000<span></span>
</td>
<td class="num">$ (242,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(34,000)<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,000<span></span>
</td>
<td class="num">(232,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 1,010,000<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 38,000<span></span>
</td>
<td class="num">$ (232,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701411802848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income taxes at statutory rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_EffectiveIncomeTaxRateReconciliationLlcFlowThroughStructure', window );">LLC flow-through structure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21.40%)<span></span>
</td>
<td class="num">(21.50%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign', window );">Federal Credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Provision to return adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.30%)<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_EffectiveIncomeTaxRateReconciliationLlcFlowThroughStructure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation llc flow through structure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_EffectiveIncomeTaxRateReconciliationLlcFlowThroughStructure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701415068192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses', window );">Accrued bonus</a></td>
<td class="nump">$ 376,000<span></span>
</td>
<td class="nump">$ 243,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">108,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_DeferredTaxAssetsFederalCreditCarryForwards', window );">Federal credit carryforwards</a></td>
<td class="nump">939,000<span></span>
</td>
<td class="nump">331,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_DeferredTaxAssetsLeases', window );">Leases</a></td>
<td class="nump">28,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_DeferredTaxAssetsStartUpCosts', window );">Start-up&#160;costs</a></td>
<td class="nump">39,000<span></span>
</td>
<td class="nump">48,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets before valuation allowance</a></td>
<td class="nump">1,382,000<span></span>
</td>
<td class="nump">730,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">1,237,000<span></span>
</td>
<td class="nump">560,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">145,000<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">90,000<span></span>
</td>
<td class="nump">148,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">47,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">22,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">145,000<span></span>
</td>
<td class="nump">170,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_DeferredTaxAssetsFederalCreditCarryForwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets federal credit carry forwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_DeferredTaxAssetsFederalCreditCarryForwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_DeferredTaxAssetsLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_DeferredTaxAssetsLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_DeferredTaxAssetsStartUpCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets start up costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_DeferredTaxAssetsStartUpCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee bonuses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701424157312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward  (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_UnrecognizedTaxBenefitsGrossAbstract', window );"><strong>Unrecognized tax benefits (gross):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Benefits at the beginning of the year</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increase related to prior year tax positions</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decrease related to prior year tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increase related to current year tax positions</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Benefits at the end of the year</a></td>
<td class="nump">$ 180<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_UnrecognizedTaxBenefitsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized tax benefits (gross).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_UnrecognizedTaxBenefitsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701419729920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred Tax Assets, Valuation Allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,237,000<span></span>
</td>
<td class="nump">$ 560,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">$ 1,010,000<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 38,000<span></span>
</td>
<td class="num">$ (232,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Income Tax Rate Reconciliation, Percent</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_DeferredExpenseCapitalizedResearchAndDevelopmentCostsTerm', window );">Deferred Expense Capitalized Research and Development Costs term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,118,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_DeferredExpenseCapitalizedResearchAndDevelopmentCostsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred expense capitalized research and development costs term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_DeferredExpenseCapitalizedResearchAndDevelopmentCostsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701411901616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Private Placement - Additional Information (Detail) - Common Class A [Member]<br></strong></div></th>
<th class="th">
<div>Jul. 02, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share</a></td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period new shares issued | shares</a></td>
<td class="nump">640,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share</a></td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from private placement issue | $</a></td>
<td class="nump">$ 6,400,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701413683632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of the Classification of Operating and Finance Lease Assets and Obligations in the Company's Consolidated Balance Sheets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets</a></td>
<td class="nump">$ 1,579<span></span>
</td>
<td class="nump">$ 1,139<span></span>
</td>
<td class="nump">$ 1,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">295<span></span>
</td>
<td class="nump">235<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, noncurrent</a></td>
<td class="nump">1,354<span></span>
</td>
<td class="nump">985<span></span>
</td>
<td class="nump">1,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">1,649<span></span>
</td>
<td class="nump">1,220<span></span>
</td>
<td class="nump">1,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityAbstract', window );"><strong>Finance leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Right of use assets</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities, current</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, noncurrent</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total finance lease liabilities</a></td>
<td class="nump">$ 107<span></span>
</td>
<td class="nump">$ 114<span></span>
</td>
<td class="nump">$ 145<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701419877728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturities of Lease Liabilities for the Company's Operating and Finance Leases (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022 (remaining nine months)</a></td>
<td class="nump">$ 315<span></span>
</td>
<td class="nump">$ 326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">428<span></span>
</td>
<td class="nump">332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">440<span></span>
</td>
<td class="nump">341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">440<span></span>
</td>
<td class="nump">282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">355<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">1,993<span></span>
</td>
<td class="nump">1,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(344)<span></span>
</td>
<td class="num">(241)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">1,649<span></span>
</td>
<td class="nump">1,220<span></span>
</td>
<td class="nump">$ 1,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022 (remaining nine months)</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(10)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">$ 145<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022 (remaining nine months)</a></td>
<td class="nump">345<span></span>
</td>
<td class="nump">366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">468<span></span>
</td>
<td class="nump">372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">480<span></span>
</td>
<td class="nump">381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">447<span></span>
</td>
<td class="nump">289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">355<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">2,110<span></span>
</td>
<td class="nump">1,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(354)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_OperatingAndFinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 1,756<span></span>
</td>
<td class="nump">$ 1,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease and finance lease liability payments due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease and finance lease liability payments due after year five.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease and finance lease liability payments due next twelve months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease and finance lease liability payments due year five.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease and finance lease liability payments due year four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease and finance lease liability payments due year three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease and finance lease liability payments due year two.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease and finance lease liability undiscounted excess amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_OperatingAndFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_OperatingAndFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701424093184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_OperatingAndFinanceLeaseWeightedAverageDiscountRatePercent', window );">Operating And Finance Lease Weighted Average Discount Rate, Percent</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_RightOfUseAssetsOperatingAndFinanceLease', window );">Right Of Use Assets Operating And Finance Lease</a></td>
<td class="nump">$ 1,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,241<span></span>
</td>
<td class="nump">$ 1,559<span></span>
</td>
<td class="nump">$ 1,560,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_OperatingAndFinanceLeaseLiabilitiesCurrent', window );">Operating And Finance Lease Liabilities Current</a></td>
<td class="nump">328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="nump">$ 1,559,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_OperatingLeaseRentExpenses', window );">Operating Lease Rent Expenses</a></td>
<td class="nump">$ 89,000<span></span>
</td>
<td class="nump">$ 81,000<span></span>
</td>
<td class="nump">$ 434,000<span></span>
</td>
<td class="nump">$ 314,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_OperatingAndFinanceLeaseLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease liabilities current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_OperatingAndFinanceLeaseLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_OperatingAndFinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating and finance lease weighted average discount rate percent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_OperatingAndFinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_OperatingLeaseRentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease rent expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_OperatingLeaseRentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_RightOfUseAssetsOperatingAndFinanceLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right of use assets operating and finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_RightOfUseAssetsOperatingAndFinanceLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701413530464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 18, 2022</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 29, 2021</div></th>
<th class="th"><div>Mar. 02, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,498,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember', window );">Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock shares issued during the period for services value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_RepaymentOfAdvancesFromRelatedParty', window );">Repayment of advances from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_AdvancesPayableToRelatedPartyCurrent', window );">Advances from related party current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member] | Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue', window );">Fair value of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 214,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 214,160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_SponsorMember', window );">Sponsor [Member] | Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayments of related party debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_SponsorMember', window );">Sponsor [Member] | Founder Shares [Member] | Independent Directors [Member] | Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_PipeInvestorsMember', window );">PIPE Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="nump">$ 575,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="nump">57,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_PipeInvestorsMember', window );">PIPE Investors [Member] | Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="nump">$ 575,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="nump">57,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member] | Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Share based compensation shares forfeited during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member] | Founder [Member] | Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock shares issued during the period for services value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock shares issued during the period for services shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
<td class="nump">6,325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common stock, shares, subject to forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_SharesNoLongerSubjectToForfeiture', window );">Shares no longer subject to forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common stock, shares, subject to forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | PIPE Investors [Member] | Subscription Agreements [Member] | Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | SC Master Holdings, LLC | Subscription Agreements [Member] | Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Averill Master Fund, Ltd | Subscription Agreements [Member] | Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=prok_AdministrationAndSupportServicesMember', window );">Administration And Support Services [Member] | Sponsor [Member] | Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction fees payable per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty', window );">Selling general and administrative expenses from transactions with related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=prok_AdvanceFromRelatedPartyLoanMember', window );">Advance From Related Party Loan [Member] | Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_RepaymentOfAdvancesFromRelatedParty', window );">Repayment of advances from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,319<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=prok_AdvanceFromRelatedPartyLoanMember', window );">Advance From Related Party Loan [Member] | Sponsor [Member] | Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_RepaymentOfAdvancesFromRelatedParty', window );">Repayment of advances from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,319<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=prok_PromissoryNoteMember', window );">Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face value</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=prok_PromissoryNoteMember', window );">Promissory Note [Member] | Sponsor [Member] | Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Repayments of related party debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=prok_WorkingCapitalLoansMember', window );">Working Capital Loans [Member] | Sponsor [Member] | Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_BasisAxis=prok_RestrictionOnTransferOfSponsorSharesMember', window );">Restriction On Transfer Of Sponsor Shares [Member] | Common Class B [Member] | Founder [Member] | Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_NumberOfTradingDaysForDeterminingTheSharePrice', window );">Number of trading days for determining the share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice', window );">Number of consecutive trading days for determining the share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered', window );">Waiting period after which the share trading days are considered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">150 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">150 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_AdvancesPayableToRelatedPartyCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advances payable to related party current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_AdvancesPayableToRelatedPartyCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of consecutive trading days for determining the share price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_NumberOfTradingDaysForDeterminingTheSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of trading days for determining the share price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_NumberOfTradingDaysForDeterminingTheSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_RepaymentOfAdvancesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayment of advances from related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_RepaymentOfAdvancesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based Compensation Arrangement By Share based Payment Award Options Granted In Period Fair Value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_SharesNoLongerSubjectToForfeiture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares no longer subject to forfeiture.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_SharesNoLongerSubjectToForfeiture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Waiting period after which the share trading days are considered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=prok_FounderSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=prok_FounderSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=prok_IndependentDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=prok_IndependentDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_PipeInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_PipeInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_FounderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_FounderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_AgreementAxis=prok_SubscriptionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_AgreementAxis=prok_SubscriptionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_ScMasterHoldingsLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_ScMasterHoldingsLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_AverillMasterFundLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_AverillMasterFundLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=prok_AdministrationAndSupportServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=prok_AdministrationAndSupportServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=prok_AdvanceFromRelatedPartyLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=prok_AdvanceFromRelatedPartyLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=prok_PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=prok_PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=prok_WorkingCapitalLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=prok_WorkingCapitalLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_BasisAxis=prok_RestrictionOnTransferOfSponsorSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_BasisAxis=prok_RestrictionOnTransferOfSponsorSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701424086640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Related Party Debt - Additional Information (Detail) - Promissory Note [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Jan. 18, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face value</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
<td class="text">Jan. 17,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount', window );">Debt Instrument, Unused Borrowing Capacity, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Debt Instrument, Fee Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=prok_PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=prok_PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701420091008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) - Social Capital Suvretta Holdings Corp. III [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_DeferredUnderwritingFees', window );">Deferred underwriting fee</a></td>
<td class="nump">$ 7,700,000<span></span>
</td>
<td class="nump">$ 7,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_AgreementAxis=prok_DirectorRestrictedStockUnitAwardAgreementMember', window );">Director Restricted Stock Unit Award Agreement [Member] | Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_NumberOfSharesOfCommonStockCommittedToSettleOnADateFollowingTheYearBusinessCombinationOccurs', window );">Number of shares of common stock committed to settle on a date following the year Business combination occurs</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_AgreementAxis=prok_DirectorRestrictedStockUnitAwardAgreementMember', window );">Director Restricted Stock Unit Award Agreement [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of stock units granted</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_DeferredUnderwritingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred underwriting fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_DeferredUnderwritingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_NumberOfSharesOfCommonStockCommittedToSettleOnADateFollowingTheYearBusinessCombinationOccurs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock committed to settle on a date following the year Business combination occurs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_NumberOfSharesOfCommonStockCommittedToSettleOnADateFollowingTheYearBusinessCombinationOccurs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_AgreementAxis=prok_DirectorRestrictedStockUnitAwardAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_AgreementAxis=prok_DirectorRestrictedStockUnitAwardAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701428494800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Members' Equity -Schedule Of  Members Equity (Detail) - Capital Unit, Class A [Member] - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_MembersEquityLineItems', window );"><strong>Members Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding', window );">Units outstanding January&#160;1, 2020</a></td>
<td class="nump">115,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding', window );">Ending Balance (in shares)</a></td>
<td class="nump">186,500,000<span></span>
</td>
<td class="nump">115,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_MemberUnitsMember', window );">Member Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_MembersEquityLineItems', window );"><strong>Members Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding', window );">Units outstanding January&#160;1, 2020</a></td>
<td class="nump">115,000,000<span></span>
</td>
<td class="nump">95,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountUnitsContributed', window );">Issued 2020</a></td>
<td class="nump">71,500,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding', window );">Ending Balance (in shares)</a></td>
<td class="nump">186,500,000<span></span>
</td>
<td class="nump">115,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_MembersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Members equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_MembersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of limited partner units outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnersCapitalAccountUnitsContributed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Units contributed by each class of partners during the year. Units represent shares of ownership of the general, limited, and preferred partners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnersCapitalAccountUnitsContributed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_MemberUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_MemberUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701419732032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Members' Equity - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jan. 17, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassBMember', window );">Capital Unit, Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized', window );">Limited Partners' Capital Account, Units Authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedPartnersCapitalAccountUnitsIssued', window );">Limited partners capital account units issued</a></td>
<td class="nump">17,354,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,767,122<span></span>
</td>
<td class="nump">7,767,122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalUnitsByClassAxis=prok_CapitalUnitClassB1Member', window );">Capital Unit Class B1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedPartnersCapitalAccountUnitsIssued', window );">Limited partners capital account units issued</a></td>
<td class="nump">6,098,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_ProceedsFromLimitedPartnersCapitalAccountUnits', window );">Proceeds from Limited partners capital account units</a></td>
<td class="nump">$ 5,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassAMember', window );">Capital Unit, Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized', window );">Limited Partners' Capital Account, Units Authorized</a></td>
<td class="nump">190,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedPartnersCapitalAccountUnitsIssued', window );">Limited partners capital account units issued</a></td>
<td class="nump">186,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186,500,000<span></span>
</td>
<td class="nump">115,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_ProceedsFromLimitedPartnersCapitalAccountUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from limited partners capital account units</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_ProceedsFromLimitedPartnersCapitalAccountUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of limited partner units authorized to be issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedPartnersCapitalAccountUnitsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of limited partner units issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedPartnersCapitalAccountUnitsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsByClassAxis=prok_CapitalUnitClassB1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsByClassAxis=prok_CapitalUnitClassB1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701413572064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Temporary Equity and Permanent Deficit - Additional Information (Detail) - Social Capital Suvretta Holdings Corp. III [Member] - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">640,000<span></span>
</td>
<td class="nump">640,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding</a></td>
<td class="nump">640,000<span></span>
</td>
<td class="nump">640,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockOtherSharesOutstanding', window );">Common stock, shares, subject to forfeiture</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Common Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued</a></td>
<td class="nump">6,250,000<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding</a></td>
<td class="nump">6,250,000<span></span>
</td>
<td class="nump">6,250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_PercentOfFoundersSharesToCompanysIssuedAndOutstandingOrdinaryShares', window );">Percent of founders shares to company's issued and outstanding ordinary shares</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_PercentOfFoundersSharesToCompanysIssuedAndOutstandingOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of founders shares to Company's issued and outstanding ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_PercentOfFoundersSharesToCompanysIssuedAndOutstandingOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockOtherSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockOtherSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701428335184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share - Schedule of calculation of basic and diluted net income (loss) per ordinary share (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (67,486,000)<span></span>
</td>
<td class="num">$ (11,609,000)<span></span>
</td>
<td class="num">$ (55,146,000)<span></span>
</td>
<td class="num">$ (26,749,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassAMember', window );">Capital Unit, Class A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (67,486)<span></span>
</td>
<td class="num">$ (11,609)<span></span>
</td>
<td class="num">$ (55,146)<span></span>
</td>
<td class="num">$ (26,749)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average Class A Units outstanding , Basic</a></td>
<td class="nump">186,500,000<span></span>
</td>
<td class="nump">122,111,111<span></span>
</td>
<td class="nump">150,706,849<span></span>
</td>
<td class="nump">104,986,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average Class A Units outstanding , Diluted</a></td>
<td class="nump">186,500,000<span></span>
</td>
<td class="nump">122,111,111<span></span>
</td>
<td class="nump">150,706,849<span></span>
</td>
<td class="nump">104,986,301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_BasicAndDilutedNetIncomeLossPerShareAbstract', window );"><strong>Net loss per Class A Unit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per Class A Unit , Basic</a></td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per Class A Unit , Diluted</a></td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="num">$ (0.25)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_BasicAndDilutedNetIncomeLossPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Basic and diluted net income loss per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_BasicAndDilutedNetIncomeLossPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701424094048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Assets that are Measured at Fair Value on a Recurring Basis (Detail) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Social Capital Suvretta Holdings Corp. III [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_MarketableSecuritiesHeldToMaturityFairValueDisclosure', window );">Marketable securities held in Trust Account</a></td>
<td class="nump">$ 250,033,500<span></span>
</td>
<td class="nump">$ 250,008,324<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_MarketableSecuritiesHeldToMaturityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable securities held to maturity fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_MarketableSecuritiesHeldToMaturityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701414069856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Based Compensation - Summary of the Activity Related to Company's Class B and B-1 Units Granted (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Shares , Beginning Balance</a></td>
<td class="nump">2,460,617<span></span>
</td>
<td class="nump">4,402,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of Shares , Vested</a></td>
<td class="num">(449,486)<span></span>
</td>
<td class="num">(1,941,781)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares , Granted</a></td>
<td class="nump">8,498,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Number of shares , Forfeited</a></td>
<td class="num">(29,070)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Shares , Ending Balance</a></td>
<td class="nump">10,480,549<span></span>
</td>
<td class="nump">2,460,617<span></span>
</td>
<td class="nump">4,402,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value , Beginning Balance</a></td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value ,Vested</a></td>
<td class="nump">0.36<span></span>
</td>
<td class="nump">0.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value , Granted</a></td>
<td class="nump">6.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value , Forfeited</a></td>
<td class="nump">6.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value , Ending Balance</a></td>
<td class="nump">$ 4.94<span></span>
</td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="nump">$ 0.36<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701414393536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Based Compensation - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 17, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity-based compensation expense</a></td>
<td class="nump">$ 52,686,000<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="nump">$ 699,000,000<span></span>
</td>
<td class="nump">$ 730,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 50,020,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 868,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">weighted average grant date fair value of the Profits Interests granted during the year</a></td>
<td class="nump">$ 6.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">unrecognized compensation expense is expected to be recognized</a></td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountUnitsUnitbasedCompensation', window );">Partners' Capital Account, Unit-Based Payment Arrangement, Number of Units</a></td>
<td class="nump">2,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountUnitBasedCompensation', window );">Partners' Capital Account, Unit-Based Payment Arrangement, Amount</a></td>
<td class="nump">$ 2,502,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Research and Development in Process</a></td>
<td class="nump">14,080,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Compensation Expense</a></td>
<td class="nump">5,437,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Compensation expense attributable to vested awards</a></td>
<td class="nump">$ 3,715,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassBMember', window );">Capital Unit, Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized', window );">Limited Partners' Capital Account, Units Authorized</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of Shares Available for Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_NumberOfCommonUnitsUnissuedOfLimitedLiabilityCompany', window );">Number of common units unissued of limited liability company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,232,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prok_CommonUnitsUnissued', window );">Common Units Unissued</a></td>
<td class="nump">22,164,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalUnitsByClassAxis=prok_ClassB1unitsMember', window );">Class&#160;B-1&#160;Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized', window );">Limited Partners' Capital Account, Units Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Equity-based compensation expense</a></td>
<td class="nump">$ 31,226,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonUnitIssued', window );">Common Unit, Issued</a></td>
<td class="nump">6,098,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonUnitIssuanceValue', window );">Common Unit, Issuance Value</a></td>
<td class="nump">$ 5,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=prok_OnTheLatterOfTheFirstAnniversaryMember', window );">On The Latter Of The First Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vesting of award under share-based payment arrangement</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=prok_InFirstAnniversaryOfTheAcquisitionDateMember', window );">In First Anniversary Of The Acquisition Date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vesting of award under share-based payment arrangement</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=prok_OnEachEnniversaryMember', window );">On Each Enniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vesting of award under share-based payment arrangement</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=prok_EachCalendarQuarterMember', window );">Each Calendar Quarter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vesting of award under share-based payment arrangement</a></td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=prok_OverTheThreeYearPeriodFromTheDateOfGrantMember', window );">Over The Three Year Period From The Date Of Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vesting of award under share-based payment arrangement</a></td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_CommonUnitsUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common units unissued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_CommonUnitsUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_NumberOfCommonUnitsUnissuedOfLimitedLiabilityCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common units unissued of limited liability company</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_NumberOfCommonUnitsUnissuedOfLimitedLiabilityCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prok_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonUnitIssuanceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stated value of common units of ownership issued by a limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonUnitIssuanceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonUnitIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common units issued of limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonUnitIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of limited partner units authorized to be issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnersCapitalAccountUnitBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in partners' capital account for unit-based payment arrangement issued by partnership. Partner includes, but is not limited to, general, limited and preferred partners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnersCapitalAccountUnitBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnersCapitalAccountUnitsUnitbasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of units issued for unit-based payment arrangement issued by partnership. Partner includes, but is not limited to, general, limited and preferred partners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnersCapitalAccountUnitsUnitbasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsByClassAxis=prok_ClassB1unitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsByClassAxis=prok_ClassB1unitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=prok_OnTheLatterOfTheFirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=prok_OnTheLatterOfTheFirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=prok_InFirstAnniversaryOfTheAcquisitionDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=prok_InFirstAnniversaryOfTheAcquisitionDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=prok_OnEachEnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=prok_OnEachEnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=prok_EachCalendarQuarterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=prok_EachCalendarQuarterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=prok_OverTheThreeYearPeriodFromTheDateOfGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=prok_OverTheThreeYearPeriodFromTheDateOfGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701424073760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Based Compensation - Summary of Key Assumptions Used in the OPM Valuation (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersEquity', window );">Total equity value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility of total equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Discount for lack of market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected time to exit event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember', window );">Valuation Technique, Option Pricing Model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersEquity', window );">Total equity value</a></td>
<td class="nump">$ 280,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility of total equity</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Discount for lack of market</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected time to exit event</a></td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=prok_ValuationTechniqueProbabilityWeightedExpectedReturnMethodMember', window );">Valuation Technique, Probability Weighted Expected Return Method [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersEquity', window );">Total equity value</a></td>
<td class="nump">$ 1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility of total equity</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Discount for lack of market</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected time to exit event</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MembersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of ownership interest in limited liability company (LLC), attributable to the parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125520817&amp;loc=d3e70258-108054<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70434-108055<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=125520817&amp;loc=d3e70229-108054<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MembersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=prok_ValuationTechniqueProbabilityWeightedExpectedReturnMethodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=prok_ValuationTechniqueProbabilityWeightedExpectedReturnMethodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701424662896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Based Compensation - Summary of Compensation Expense (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation expense</a></td>
<td class="nump">$ 52,686,000<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="nump">$ 699,000,000<span></span>
</td>
<td class="nump">$ 730,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation expense</a></td>
<td class="nump">17,367,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity-based compensation expense</a></td>
<td class="nump">$ 35,319,000<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139701412981824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 26, 2022</div></th>
<th class="th"><div>Jan. 18, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 01, 2022</div></th>
<th class="th"><div>Apr. 20, 2022</div></th>
<th class="th"><div>Jan. 17, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 02, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Amount drew under the note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassBMember', window );">Capital Unit, Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized', window );">Limited Partners' Capital Account, Units Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedPartnersCapitalAccountUnitsIssued', window );">Limited Partners' Capital Account, Units Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,354,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,767,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,767,122<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=prok_PromissoryNoteMember', window );">Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_PipeInvestorsMember', window );">PIPE Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 575,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMember', window );">Existing Directors, Officers And Equityholders Of, Or Investment Funds Managed By Suvretta Capital Management, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember', window );">Existing Directors, Officers And Unitholders Of ProKidney [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember', window );">Existing Directors, Officers And Unitholders Of ProKidney [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Line of Credit Facility, Current Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Capital Unit, Class B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized', window );">Limited Partners' Capital Account, Units Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Capital Unit Class B 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedPartnersCapitalAccountUnitsIssued', window );">Limited Partners' Capital Account, Units Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">549,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,848,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalUnits', window );">Capital Units, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,052,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Capital Unit Class B 1 [Member] | Deferred Profit Sharing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LimitedPartnersCapitalAccountUnitsIssued', window );">Limited Partners' Capital Account, Units Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,478,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,498,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=prok_RestrictedStockRightsMember', window );">Restricted Stock Rights [Member] | ProKidney LP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Business acquisition, equity interest issued or issuable, number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=prok_RestrictedStockRightsMember', window );">Restricted Stock Rights [Member] | ProKidney LP [Member] | Share Price One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=prok_RestrictedStockRightsMember', window );">Restricted Stock Rights [Member] | ProKidney LP [Member] | Share Price Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=prok_RestrictedStockRightsMember', window );">Restricted Stock Rights [Member] | ProKidney LP [Member] | Share Price Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember', window );">Social Capital Suvretta Holdings Corp. III [Member] | PIPE Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 575,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember', window );">Social Capital Suvretta Holdings Corp. III [Member] | Existing Directors, Officers And Equityholders Of, Or Investment Funds Managed By Suvretta Capital Management, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember', window );">Social Capital Suvretta Holdings Corp. III [Member] | Existing Directors, Officers And Unitholders Of ProKidney [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember', window );">Social Capital Suvretta Holdings Corp. III [Member] | Existing Directors, Officers And Unitholders Of ProKidney [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember', window );">Social Capital Suvretta Holdings Corp. III [Member] | Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember', window );">Social Capital Suvretta Holdings Corp. III [Member] | Sponsor [Member] | Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember', window );">Social Capital Suvretta Holdings Corp. III [Member] | Subsequent Event [Member] | Sponsor [Member] | Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Amount drew under the note</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember', window );">Social Capital Suvretta Holdings Corp. III [Member] | Restricted Stock Rights [Member] | ProKidney LP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Business acquisition, equity interest issued or issuable, number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember', window );">Social Capital Suvretta Holdings Corp. III [Member] | Restricted Stock Rights [Member] | ProKidney LP [Member] | Share Price One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember', window );">Social Capital Suvretta Holdings Corp. III [Member] | Restricted Stock Rights [Member] | ProKidney LP [Member] | Share Price Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember', window );">Social Capital Suvretta Holdings Corp. III [Member] | Restricted Stock Rights [Member] | ProKidney LP [Member] | Share Price Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04.16(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of limited partner units authorized to be issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LimitedPartnersCapitalAccountUnitsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of limited partner units issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LimitedPartnersCapitalAccountUnitsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=prok_PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=prok_PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_PipeInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_PipeInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsByClassAxis=prok_CapitalUnitClassBOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsByClassAxis=prok_CapitalUnitClassBOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis=us-gaap_DeferredProfitSharingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis=us-gaap_DeferredProfitSharingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=prok_RestrictedStockRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityInterestIssuedOrIssuableByTypeAxis=prok_RestrictedStockRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=prok_ProkidneyLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=prok_ProkidneyLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_SharePriceRangeAxis=prok_SharePriceOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_SharePriceRangeAxis=prok_SharePriceOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_SharePriceRangeAxis=prok_SharePriceTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_SharePriceRangeAxis=prok_SharePriceTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prok_SharePriceRangeAxis=prok_SharePriceThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prok_SharePriceRangeAxis=prok_SharePriceThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=prok_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>d373959ds1_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:prok="http://www.businesswire.com/20220331"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="prok-20220331.xsd" xlink:type="simple"/>
    <context id="P01_01_2022To03_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="P02_25_2021To12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn07_02_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="P07_02_2021To07_02_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="P12_12_2018To12_31_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
        </entity>
        <period>
            <startDate>2018-12-12</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="PAsOn01_01_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RestrictionOnTransferOfSponsorSharesMemberPROKBasisAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:FounderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="prok:BasisAxis">prok:RestrictionOnTransferOfSponsorSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_DirectorMembersrtTitleOfIndividualAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WorkingCapitalLoansMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">prok:WorkingCapitalLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AdvanceFromRelatedPartyLoanMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">prok:AdvanceFromRelatedPartyLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ResearchMemberusgaapTaxCreditCarryforwardAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_25_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RestrictionOnTransferOfSponsorSharesMemberPROKBasisAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:FounderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="prok:BasisAxis">prok:RestrictionOnTransferOfSponsorSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_25_2021To12_31_2021_AdministrationAndSupportServicesMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">prok:AdministrationAndSupportServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_25_2021To12_31_2021_AdvanceFromRelatedPartyLoanMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">prok:AdvanceFromRelatedPartyLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_25_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_25_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_25_2021To12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_25_2021To12_31_2021_DirectorRestrictedStockUnitAwardAgreementMemberPROKAgreementAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="prok:AgreementAxis">prok:DirectorRestrictedStockUnitAwardAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_DirectorRestrictedStockUnitAwardAgreementMemberPROKAgreementAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="prok:AgreementAxis">prok:DirectorRestrictedStockUnitAwardAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P02_25_2021To12_31_2021_DirectorMembersrtTitleOfIndividualAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="P07_02_2021To07_02_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="P07_02_2021To07_02_2021_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">prok:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="PAsOn07_02_2021_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="P03_02_2021To03_02_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:FounderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-02</startDate>
            <endDate>2021-03-02</endDate>
        </period>
    </context>
    <context id="P06_29_2021To06_29_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:FounderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-29</startDate>
            <endDate>2021-06-29</endDate>
        </period>
    </context>
    <context id="P06_29_2021To06_29_2021_DirectorMembersrtTitleOfIndividualAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-29</startDate>
            <endDate>2021-06-29</endDate>
        </period>
    </context>
    <context id="PAsOn06_29_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:FounderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-29</instant>
        </period>
    </context>
    <context id="PAsOn06_30_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:FounderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="P07_01_2021To09_30_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="P02_25_2021To06_30_2021_FounderSharesMemberusgaapStatementEquityComponentsAxis_IndependentDirectorsMembersrtTitleOfIndividualAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">prok:IndependentDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">prok:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn03_02_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-02</instant>
        </period>
    </context>
    <context id="PAsOn03_02_2021_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">prok:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-02</instant>
        </period>
    </context>
    <context id="P06_30_2021To06_30_2021_AdministrationAndSupportServicesMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">prok:AdministrationAndSupportServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-30</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="PAsOn01_18_2022_PipeInvestorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:PipeInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-18</instant>
        </period>
    </context>
    <context id="PAsOn01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SharePriceThreeMemberPROKSharePriceRangeAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">prok:ProkidneyLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">prok:RestrictedStockRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="prok:SharePriceRangeAxis">prok:SharePriceThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-18</instant>
        </period>
    </context>
    <context id="PAsOn01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SharePriceTwoMemberPROKSharePriceRangeAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">prok:ProkidneyLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">prok:RestrictedStockRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="prok:SharePriceRangeAxis">prok:SharePriceTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-18</instant>
        </period>
    </context>
    <context id="PAsOn01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SharePriceOneMemberPROKSharePriceRangeAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">prok:ProkidneyLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">prok:RestrictedStockRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="prok:SharePriceRangeAxis">prok:SharePriceOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-18</instant>
        </period>
    </context>
    <context id="PAsOn01_18_2022_PipeInvestorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:PipeInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-18</instant>
        </period>
    </context>
    <context id="PAsOn01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SharePriceThreeMemberPROKSharePriceRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">prok:ProkidneyLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">prok:RestrictedStockRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="prok:SharePriceRangeAxis">prok:SharePriceThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-18</instant>
        </period>
    </context>
    <context id="PAsOn01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SharePriceTwoMemberPROKSharePriceRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">prok:ProkidneyLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">prok:RestrictedStockRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="prok:SharePriceRangeAxis">prok:SharePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-18</instant>
        </period>
    </context>
    <context id="PAsOn01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SharePriceOneMemberPROKSharePriceRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">prok:ProkidneyLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">prok:RestrictedStockRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="prok:SharePriceRangeAxis">prok:SharePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-18</instant>
        </period>
    </context>
    <context id="PAsOn01_18_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-18</instant>
        </period>
    </context>
    <context id="PAsOn01_18_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">prok:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-18</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_DirectorMembersrtTitleOfIndividualAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RestrictionOnTransferOfSponsorSharesMemberPROKBasisAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:FounderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="prok:BasisAxis">prok:RestrictionOnTransferOfSponsorSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AdvanceFromRelatedPartyLoanMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">prok:AdvanceFromRelatedPartyLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WorkingCapitalLoansMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">prok:WorkingCapitalLoansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CapitalUnitClassB1MemberusgaapCapitalUnitsByClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">prok:CapitalUnitClassB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">prok:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ValuationTechniqueProbabilityWeightedExpectedReturnMethodMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">prok:ValuationTechniqueProbabilityWeightedExpectedReturnMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_ClassB1unitsMemberusgaapCapitalUnitsByClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">prok:ClassB1unitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">prok:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="P01_18_2022To01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">prok:ProkidneyLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">prok:RestrictedStockRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-18</startDate>
            <endDate>2022-01-18</endDate>
        </period>
    </context>
    <context id="P01_18_2022To01_18_2022_PipeInvestorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:PipeInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-18</startDate>
            <endDate>2022-01-18</endDate>
        </period>
    </context>
    <context id="P01_18_2022To01_18_2022_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MaximumMembersrtRangeAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-18</startDate>
            <endDate>2022-01-18</endDate>
        </period>
    </context>
    <context id="P01_18_2022To01_18_2022_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-18</startDate>
            <endDate>2022-01-18</endDate>
        </period>
    </context>
    <context id="P01_18_2022To01_18_2022_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-18</startDate>
            <endDate>2022-01-18</endDate>
        </period>
    </context>
    <context id="P01_18_2022To01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">prok:ProkidneyLpMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquityInterestIssuedOrIssuableByTypeAxis">prok:RestrictedStockRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-18</startDate>
            <endDate>2022-01-18</endDate>
        </period>
    </context>
    <context id="P01_18_2022To01_18_2022_PipeInvestorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:PipeInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-18</startDate>
            <endDate>2022-01-18</endDate>
        </period>
    </context>
    <context id="P01_18_2022To01_18_2022_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-18</startDate>
            <endDate>2022-01-18</endDate>
        </period>
    </context>
    <context id="P01_18_2022To01_18_2022_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-18</startDate>
            <endDate>2022-01-18</endDate>
        </period>
    </context>
    <context id="P01_18_2022To01_18_2022_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-18</startDate>
            <endDate>2022-01-18</endDate>
        </period>
    </context>
    <context id="P01_18_2022To01_18_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">prok:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-18</startDate>
            <endDate>2022-01-18</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RestrictionOnTransferOfSponsorSharesMemberPROKBasisAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:FounderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="prok:BasisAxis">prok:RestrictionOnTransferOfSponsorSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_AdministrationAndSupportServicesMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">prok:AdministrationAndSupportServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_AdvanceFromRelatedPartyLoanMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">prok:AdvanceFromRelatedPartyLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_DirectorRestrictedStockUnitAwardAgreementMemberPROKAgreementAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="prok:AgreementAxis">prok:DirectorRestrictedStockUnitAwardAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_DirectorRestrictedStockUnitAwardAgreementMemberPROKAgreementAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="prok:AgreementAxis">prok:DirectorRestrictedStockUnitAwardAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_PipeInvestorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SubscriptionAgreementsMemberPROKAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:PipeInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="prok:AgreementAxis">prok:SubscriptionAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_AverillMasterFundLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SubscriptionAgreementsMemberPROKAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:AverillMasterFundLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="prok:AgreementAxis">prok:SubscriptionAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_ScMasterHoldingsLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SubscriptionAgreementsMemberPROKAgreementAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:ScMasterHoldingsLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="prok:AgreementAxis">prok:SubscriptionAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_OnTheLatterOfTheFirstAnniversaryMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">prok:OnTheLatterOfTheFirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_InFirstAnniversaryOfTheAcquisitionDateMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">prok:InFirstAnniversaryOfTheAcquisitionDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_OnEachEnniversaryMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">prok:OnEachEnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_EachCalendarQuarterMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">prok:EachCalendarQuarterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_OverTheThreeYearPeriodFromTheDateOfGrantMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">prok:OverTheThreeYearPeriodFromTheDateOfGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_ClassB1unitsMemberusgaapCapitalUnitsByClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">prok:ClassB1unitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_ValuationTechniqueProbabilityWeightedExpectedReturnMethodMemberusgaapValuationTechniqueAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">prok:ValuationTechniqueProbabilityWeightedExpectedReturnMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_AcquiredAssemblyWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">prok:AcquiredAssemblyWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To03_31_2022_CapitalUnitClassB1MemberusgaapCapitalUnitsByClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">prok:CapitalUnitClassB1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="P02_25_2021To03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P02_25_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P02_25_2021To03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P02_25_2021To03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P02_25_2021To03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P02_25_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-25</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn04_20_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">prok:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-20</instant>
        </period>
    </context>
    <context id="P06_01_2021To06_30_2021_FounderSharesMemberusgaapStatementEquityComponentsAxis_IndependentDirectorsMembersrtTitleOfIndividualAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">prok:IndependentDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">prok:FounderSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P06_01_2021To06_30_2021_DirectorMembersrtTitleOfIndividualAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="P04_26_2022To04_26_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">prok:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">prok:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-26</startDate>
            <endDate>2022-04-26</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_OnTheLatterOfTheFirstAnniversaryMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">prok:OnTheLatterOfTheFirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_InFirstAnniversaryOfTheAcquisitionDateMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">prok:InFirstAnniversaryOfTheAcquisitionDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_OnEachEnniversaryMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">prok:OnEachEnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_EachCalendarQuarterMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">prok:EachCalendarQuarterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_KYsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AcquiredAssemblyWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">prok:AcquiredAssemblyWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_KYsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_USsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AcquiredAssemblyWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">prok:AcquiredAssemblyWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To03_31_2021_AcquiredAssemblyWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">prok:AcquiredAssemblyWorkforceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="PAsOn01_17_2022_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-17</instant>
        </period>
    </context>
    <context id="PAsOn01_17_2022_CapitalUnitClassBOneMemberusgaapCapitalUnitsByClassAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">prok:CapitalUnitClassBOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-17</instant>
        </period>
    </context>
    <context id="PAsOn01_17_2022_CapitalUnitClassBOneMemberusgaapCapitalUnitsByClassAxis_DeferredProfitSharingMemberusgaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">prok:CapitalUnitClassBOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">us-gaap:DeferredProfitSharingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-17</instant>
        </period>
    </context>
    <context id="PAsOn01_17_2022_ClassB1unitsMemberusgaapCapitalUnitsByClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">prok:ClassB1unitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-17</instant>
        </period>
    </context>
    <context id="PAsOn01_17_2022_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-17</instant>
        </period>
    </context>
    <context id="PAsOn06_01_2022_CapitalUnitClassBOneMemberusgaapCapitalUnitsByClassAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">prok:CapitalUnitClassBOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="PAsOn06_01_2022_CapitalUnitClassBOneMemberusgaapCapitalUnitsByClassAxis_DeferredProfitSharingMemberusgaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">prok:CapitalUnitClassBOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis">us-gaap:DeferredProfitSharingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-01</instant>
        </period>
    </context>
    <context id="P01_20_2016To12_31_2021_KYsrtStatementGeographicalAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:KY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-20</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_09_2019To01_09_2019_RegenAndTwinCityBioLlcMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">prok:RegenAndTwinCityBioLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-09</startDate>
            <endDate>2019-01-09</endDate>
        </period>
    </context>
    <context id="PAsOn02_24_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-24</instant>
        </period>
    </context>
    <context id="PAsOn02_24_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-24</instant>
        </period>
    </context>
    <context id="PAsOn02_24_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-24</instant>
        </period>
    </context>
    <context id="PAsOn02_24_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-24</instant>
        </period>
    </context>
    <context id="PAsOn02_24_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-24</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">prok:SocialCapitalSuvrettaHoldingsCorp.IiiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2019_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:MemberUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001850270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Day">
        <measure>utr:Day</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_Month">
        <measure>utr:Month</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_segment">
        <measure>prok:segment</measure>
    </unit>
    <dei:AmendmentFlag contextRef="P01_01_2022To03_31_2022">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="P01_01_2022To03_31_2022">0001850270</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="P01_01_2022To03_31_2022">S-1</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="P01_01_2022To03_31_2022">ProKidney Corp.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P01_01_2022To03_31_2022">E9</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFilerCategory contextRef="P01_01_2022To03_31_2022">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2022To03_31_2022">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2022To03_31_2022">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="P01_01_2022To03_31_2022">false</dei:EntityExTransitionPeriod>
    <us-gaap:Cash
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">440488</us-gaap:Cash>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">504189</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">944677</us-gaap:AssetsCurrent>
    <prok:PrepaidInsuranceNonCurrent
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">247500</prok:PrepaidInsuranceNonCurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">250008324</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">251200501</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <prok:AccruedExpensesCurrent
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1864796</prok:AccruedExpensesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">10000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1879796</us-gaap:LiabilitiesCurrent>
    <prok:DeferredUnderwritingCommissions
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">7700000</prok:DeferredUnderwritingCommissions>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">9579796</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">25000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">250008324</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">640000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">640000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">25000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">64</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">6250000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">6250000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">625</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8388308</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8387619</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">251200501</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:OperatingExpenses
      contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">2332953</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-2332953</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">8324</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-2324629</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">15101877</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">15101877</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">5852751</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">5852751</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn02_24_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn02_24_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn02_24_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn02_24_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn02_24_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn02_24_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn02_24_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">6325000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">633</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="P02_25_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">24367</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">25000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <prok:TemporaryEquityStockIssuedDuringThePeriodShares
      contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">25000000</prok:TemporaryEquityStockIssuedDuringThePeriodShares>
    <prok:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="P02_25_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">25000000</prok:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="P02_25_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">237520334</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <prok:RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity
      contextRef="P02_25_2021To12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-12487990</prok:RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity>
    <prok:RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity
      contextRef="P02_25_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">6424311</prok:RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity>
    <prok:RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity
      contextRef="P02_25_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">6063679</prok:RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity>
    <prok:RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity
      contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">12487990</prok:RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P02_25_2021To12_31_2021_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">640000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">640000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">64</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P02_25_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">6399936</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">6400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">-75000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="P02_25_2021To12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">8</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:NetIncomeLoss
      contextRef="P02_25_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-2324629</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-2324629</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">25000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">250008324</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">640000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">64</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">6250000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">625</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8388308</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8387619</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-2324629</us-gaap:NetIncomeLoss>
    <prok:FormationCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares
      contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5000</prok:FormationCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">8324</us-gaap:InvestmentIncomeInterest>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">751689</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1864796</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-1209846</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">250000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-250000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">245600000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">6400000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt
      contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">97319</us-gaap:ProceedsFromRepaymentsOfRelatedPartyDebt>
    <prok:RepaymentOfAdvancesFromRelatedParty
      contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">87319</prok:RepaymentOfAdvancesFromRelatedParty>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">300000</us-gaap:ProceedsFromNotesPayable>
    <prok:RepaymentOfPromissoryNoteRelatedParty
      contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-300000</prok:RepaymentOfPromissoryNoteRelatedParty>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">359666</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">251650334</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">440488</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn02_24_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">440488</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:StockIssued1
      contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">20000</us-gaap:StockIssued1>
    <prok:RemeasurementOfClassAOrdinarySharesToRedemptionValue
      contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">12487990</prok:RemeasurementOfClassAOrdinarySharesToRedemptionValue>
    <prok:DeferredUnderwritingFeesAccruedButNotPaid
      contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">7700000</prok:DeferredUnderwritingFeesAccruedButNotPaid>
    <us-gaap:NatureOfOperations contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div id="fincov373959_6" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 1. DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Social Capital Suvretta Holdings Corp. III (the &#x201c;Company&#x201d;) is a blank check company incorporated as a Cayman Islands exempted company on February&#160;25, 2021. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (a &#x201c;Business Combination&#x201d;). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;As of December&#160;31, 2021, the Company had not commenced&#160;any operations. All activity for the period from February 25, 2021 (inception) through December&#160;31, 2021 relates to the Company&#x2019;s formation, the initial public offering (the &#x201c;Initial Public Offering&#x201d;), described below, and, subsequent to the Initial Public Offering, identifying a target company for a Business Combination and activities in connection with the proposed acquisition of ProKidney LP (see Note 9). The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company generates &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-operating&lt;/div&gt; income in the form of interest income from the marketable securities held in the Trust Account (as defined below). &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The registration statements for the Company&#x2019;s Initial Public Offering became effective on June&#160;29, 2021 and June&#160;30, 2021. On July&#160;2, 2021, the Company consummated the Initial Public Offering of 25,000,000 Class&#160;A ordinary shares (the &#x201c;Public Shares&#x201d;), which includes the partial exercise by the underwriters of their over-allotment option in the amount of 3,000,000 Public Shares, at $10.00 per Public Share, generating gross proceeds of $250,000,000, which is described in &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;Note 3. The fair value attributable to the unexercised portion of the over-allotment option was deemed to be immaterial to the financial statements.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;Substantially concurrently with the closing of the Initial Public Offering&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;, &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the Company consummated the sale of 640,000 Class&#160;A ordinary shares (the &#x201c;Private Placement Shares&#x201d;) at a price of $10.00 per Private Placement Share in a private placement to SCS Sponsor III LLC, a Cayman Islands limited liability company (the &#x201c;Sponsor&#x201d;), generating gross proceeds of $6,400,000, which is described in Note 4. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transaction costs amounted to $12,479,666, consisting of $4,400,000 of underwriting fees, $7,700,000 of deferred underwriting fees and $379,666 of other offering costs. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In connection with the closing of the Initial Public Offering on July&#160;2, 2021, an amount of $250,000,000 ($10.00 per Public Share) from the net proceeds of the sale of the Public Shares in the Initial Public Offering and the sale of the Private Placement Shares was placed in a trust account (the &#x201c;Trust Account&#x201d;), and invested in U.S. government treasury bills with a maturity of 185 days or less or in money market funds investing solely in U.S. Treasuries and meeting certain conditions of Rule &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2a-7&lt;/div&gt; of the Investment Company Act of 1940, as amended (the &#x201c;Investment Company Act&#x201d;). Except with respect to interest earned on the funds held in the Trust Account that may be released to the Company to pay its taxes, if any, the funds held in the Trust Account will not be released from the Trust Account until the earliest of: (a)&#160;the completion of a Business Combination, and then only in connection with those Public Shares that such shareholder properly elected to redeem, subject to certain limitations; (b)&#160;the redemption of any Public Shares properly submitted in connection with a shareholder vote to amend the Company&#x2019;s Amended and Restated Memorandum and Articles of Association (i)&#160;to modify the substance or timing of the Company&#x2019;s obligation to allow redemption in connection with the Business Combination or to redeem 100&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (ii)&#160;with respect to any other material provisions relating to shareholders&#x2019; rights or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-Business&lt;/div&gt; Combination activity; and (c)&#160;the redemption of the Public Shares if the Company has not completed a Business Combination within the Combination Period or during any applicable extension period. The proceeds deposited in the Trust Account could become subject to the claims of the Company&#x2019;s creditors, if any, which could have priority over the claims of the holders of the Public Shares (the &#x201c;Public Shareholders&#x201d;). &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Shares, although substantially &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;all of &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;the net proceeds are intended to be applied generally toward consummating a Business Combination. The Company must complete one or more Business Combinations having an aggregate fair market value of &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;at least 80% of the value of the assets held in the Trust Account (excluding any deferred underwriting commissions and taxes payable on the income earned on the Trust Account) at the time of the Company signing a definitive agreement in connection with the Business Combination. However, the Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to complete a Business Combination successfully. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company will provide the Public Shareholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of the Business Combination, either (a)&#160;in connection with a general meeting called to approve the Business Combination or (b)&#160;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company. The Public Shareholders will be entitled to redeem all or a portion of their Public Shares at a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per-share&lt;/div&gt; price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, calculated as of two business days prior to the consummation of the Business Combination, including interest (which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares, subject to the limitations described below. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In accordance with the Company&#x2019;s Amended and Restated Memorandum and Articles of Association, in no event will the Company redeem the Public Shares in an amount that would cause the Company&#x2019;s net tangible assets to be less than $5,000,001 following such redemptions. Redemptions of the Public Shares may also be subject to a higher net tangible asset test or cash requirement pursuant to an agreement relating to the Business Combination.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If a shareholder vote is not required in connection with a Business Combination and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;), and file tender offer documents with the SEC prior to completing a Business Combination. If, however, shareholder approval of the transaction is required by applicable law or stock exchange listing requirement, or the Company decides to obtain shareholder approval for business or other reasons, the Company will conduct the redemptions in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules and will file proxy materials with the SEC. If the Company seeks shareholder approval in connection with a Business Combination, the Company will complete such Business Combination only if the Company receives an ordinary resolution under Cayman Islands law, which requires the affirmative vote of holders of a majority of ordinary shares who attend and vote at a general meeting of the Company. The Public Shareholders may elect to redeem their Public Shares without voting and, if they do vote, irrespective of whether they vote for or against a Business Combination. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Notwithstanding the foregoing redemption rights, if the Company seeks shareholder approval of the Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, the Company&#x2019;s Amended and Restated Memorandum and Articles of Association provide that a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &#x201c;group&#x201d; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;)), will be restricted from redeeming its Public Shares with respect to more than an aggregate of 15&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the Public Shares without the Company&#x2019;s prior written consent. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Sponsor and the Company&#x2019;s directors and officers have agreed to waive: (a)&#160;their redemption rights with respect to any Founder Shares, Private Placement Shares and Public Shares held by them, as applicable, in connection with the completion of a Business Combination; (b)&#160;their redemption rights with respect to any Founder Shares, Private Placement Shares and Public Shares held by them in connection with a shareholder vote &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;to amend the Company&#x2019;s Amended and Restated Memorandum and Articles of Association (i)&#160;to modify the substance or timing of the Company&#x2019;s obligation to allow redemption in connection with the Business Combination or to &lt;/div&gt;&lt;/div&gt;redeem 100&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the Public Shares if the Company does not complete a Business Combination within the Combination Period, or (ii)&#160;with respect to any other material provisions relating to shareholders&#x2019; rights or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-Business&lt;/div&gt; Combination activity; and (c)&#160;their rights to liquidating distributions from the Trust Account with respect to any Founder Shares and Private Placement Shares they hold if the Company fails to complete a Business Combination within the Combination Period or during any applicable extension period (although such persons will be entitled to liquidating distributions from the Trust Account with respect to any Public Shares they hold if the Company fails to complete a Business Combination within the prescribed time frame). If the Company submits the Business Combination to the Public Shareholders for a vote, the Sponsor and the Company&#x2019;s directors and officers have also agreed to vote any Founder Shares, Private Placement Shares and Public Shares held by them in favor of the Business Combination. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company will have until July&#160;&lt;/div&gt;&lt;/div&gt;2, 2023 to complete a Business Combination (the &#x201c;Combination Period&#x201d;), or such longer period as a result of a shareholder vote to amend such time period pursuant to the Company&#x2019;s Amended and Restated Memorandum and Articles of Association. However, if the Company has not completed a Business Combination within such Combination Period or during any applicable extension period, the Company will: (a)&#160;cease all operations except for the purpose of winding up; (b)&#160;as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per-share&lt;/div&gt; price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less up to $100,000 of interest to pay dissolution expenses and which interest shall be net of taxes payable) divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish the Public Shareholders&#x2019; rights as shareholders (including the right to receive further liquidating distributions, if any); and (c)&#160;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#x2019;s remaining shareholders and its board of directors, liquidate and dissolve, subject in each case to the Company&#x2019;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Sponsor has agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company&#x2019;s independent auditors) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1) $10.00&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;per Public Share or (2)&#160;such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, due to reductions in the value of the trust assets, in each case net of the interest which may be withdrawn to pay taxes, except as to any claims by a third party that executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company&#x2019;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company has not independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and believes that the Sponsor&#x2019;s only assets are securities of the Company and, therefore, the Sponsor may not be able to satisfy those obligations. The Company has not asked the Sponsor to reserve for such obligations. None of the Company&#x2019;s directors or officers will indemnify the Company for claims by third parties, including, without limitation, claims by vendors and prospective target businesses. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risks and Uncertainties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management continues to evaluate the impact of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic and has concluded that while it is reasonably possible that the pandemic could have a negative effect on the Company&#x2019;s business, financial position, results of operations and/or the search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liquidity and Going Concern &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2021, the Company had $440,488 in its operating bank accounts and working capital deficit of $935,119. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Until the consummation of a Business Combination, the Company will be using the funds not held in the Trust Account for identifying and evaluating prospective acquisition candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to acquire, and structuring, negotiating and consummating the Business Combination. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company may need to raise additional capital through loans or additional investments from its Sponsor, shareholders, officers, directors, or third parties. The Company&#x2019;s officers, directors and Sponsor may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet the Company&#x2019;s working capital needs. Accordingly, the Company may not be able to obtain additional financing. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. These conditions raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for a reasonable period of time, which is considered to be one year from the issuance date of the financial statements. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern. &lt;/div&gt;&lt;/div&gt; </us-gaap:NatureOfOperations>
    <dei:EntityIncorporationDateOfIncorporation contextRef="P02_25_2021To12_31_2021">2021-02-25</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">25000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">3000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_USD">250000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">640000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_USD">6400000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <prok:TransactionCostsIncurredInConnectionWithInitialPublicOffering
      contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_USD">12479666</prok:TransactionCostsIncurredInConnectionWithInitialPublicOffering>
    <prok:UnderwritingFee
      contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_USD">4400000</prok:UnderwritingFee>
    <prok:DeferredUnderwritingFees
      contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_USD">7700000</prok:DeferredUnderwritingFees>
    <us-gaap:DeferredOfferingCosts
      contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_USD">379666</us-gaap:DeferredOfferingCosts>
    <us-gaap:CommonStockHeldInTrust
      contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_USD">250000000</us-gaap:CommonStockHeldInTrust>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</us-gaap:SaleOfStockPricePerShare>
    <prok:PercentageOfPublicSharesRedemption
      contextRef="P07_02_2021To07_02_2021"
      decimals="2"
      unitRef="Unit_pure">1</prok:PercentageOfPublicSharesRedemption>
    <prok:ProspectiveAssetsOfAcquireeAsAPercentageOfFairValueOfAssetsInTheTrustAccount
      contextRef="PAsOn07_02_2021_MinimumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.80</prok:ProspectiveAssetsOfAcquireeAsAPercentageOfFairValueOfAssetsInTheTrustAccount>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn07_02_2021_MinimumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:MinimumNetWorthRequiredForCompliance
      contextRef="PAsOn07_02_2021"
      decimals="0"
      unitRef="Unit_USD">5000001</us-gaap:MinimumNetWorthRequiredForCompliance>
    <prok:PercentageOfPublicSharesThatCanBeTransferredWithoutAnyRestriction
      contextRef="PAsOn07_02_2021"
      decimals="2"
      unitRef="Unit_pure">0.15</prok:PercentageOfPublicSharesThatCanBeTransferredWithoutAnyRestriction>
    <prok:PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated
      contextRef="PAsOn07_02_2021"
      decimals="2"
      unitRef="Unit_pure">1</prok:PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated>
    <us-gaap:LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities
      contextRef="PAsOn07_02_2021"
      decimals="0"
      unitRef="Unit_USD">100000</us-gaap:LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities>
    <prok:PerShareValueOfRestrictedAssets
      contextRef="PAsOn07_02_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</prok:PerShareValueOfRestrictedAssets>
    <us-gaap:Cash
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">440488</us-gaap:Cash>
    <prok:WorkingCapital
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">935119</prok:WorkingCapital>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and pursuant to the rules and regulations of the SEC. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Emerging Growth Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-emerging&lt;/div&gt; growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#x2019;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Significant accounting estimates include the determination of the fair value of Class&#160;A ordinary shares subject to possible redemption and the fair value of Founder Shares transferred to directors. Accordingly, the actual results could differ significantly from those estimates. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of December&#160;31, 2021.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Marketable Securities Held in Trust Account &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At December&#160;31, 2021, substantially all of the assets held in the Trust Account were held in money market funds which are invested primarily in U.S. Treasury securities. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Class&#160;A Ordinary Shares Subject to Possible Redemption &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for its Class&#160;A ordinary shares subject to possible redemption in accordance with the guidance in Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 480, &#x201c;Distinguishing Liabilities from Equity.&#x201d; Class&#160;A ordinary shares subject to mandatory redemption are classified as a liability instrument and are measured at redemption value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders&#x2019; equity. The Company&#x2019;s Class&#160;A ordinary shares feature certain redemption rights that are considered to be outside of the Company&#x2019;s control and subject to occurrence of uncertain future events. Accordingly, Class&#160;A ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the permanent deficit section of the Company&#x2019;s balance sheet. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying value of redeemable ordinary shares are affected by charges against additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital (to the extent available) and accumulated deficit. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At December&#160;31, 2021, the Class&#160;A ordinary shares subject to possible redemption reflected in the balance sheet are reconciled in the following table: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross proceeds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;250,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;A ordinary shares issuance costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,479,666&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Increase of carrying value to redemption value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,487,990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;250,008,324&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;    &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Offering Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company &lt;/div&gt;&lt;/div&gt;complies with the requirements of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ASC&#160;340-&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-S99-1.&#160;Offering&#160;costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; consisted of legal, accounting, underwriting fees and other costs incurred through the Initial Public Offering that were directly related to the Initial Public Offering. The Company incurred offering costs amounting to $12,479,666 as a result of the Initial Public Offering, consisting of $4,400,000 of underwriting commissions, $7,700,000 of deferred underwriting commissions, and $379,666&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;of other offering costs. The offering costs were charged to temporary equity and additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital upon the completion of the Initial Public Offering. Immediately thereafter, temporary equity was remeasured and an adjustment was recognized through additional paid in capital and accumulated deficit to adjust temporary equity to the redemption value. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Share-Based Payment Arrangements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for stock awards in accordance with ASC 718, &#x201c;Compensation&#x2014;Stock Compensation,&#x201d; which requires that all equity awards be accounted for at their &#x201c;fair value.&#x201d; Fair value is measured on the grant date and is equal to the underlying value of the stock. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Costs equal to these fair values are recognized ratably over the requisite service period based on the number of awards that are expected to vest, in the period of grant for awards that vest immediately and have no future service condition, or in the period the awards vest immediately after meeting a performance condition becomes probable (i.e., the occurrence of a Business Combination). For awards that vest over time, cumulative adjustments in later periods are recorded to the extent actual forfeitures differ from the Company&#x2019;s initial estimates; previously recognized compensation cost is reversed if the service or performance conditions are not satisfied and the award is forfeited.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for income taxes under ASC 740, &#x201c;Income Taxes&#x201d; (&#x201c;ASC 740&#x201d;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;more-likely-than-not&lt;/div&gt; to be sustained upon examination by taxing authorities. The Company&#x2019;s management has determined that the Cayman Islands is the Company&#x2019;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;amounts accrued for interest and penalties as of December&#160;31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is considered to be an exempted Cayman Islands company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#x2019;s tax provision was zero for the period presented. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net Loss Per Ordinary Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss per ordinary share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding during the period. The Company has two classes of shares, which are referred to as Class&#160;A &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ordinary shares and Class&#160;B ordinary shares. Losses are shared pro rata between the two classes of shares. Charges associated with the redeemable Class&#160;A ordinary shares are excluded from net loss per ordinary share as the redemption value approximates fair value. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2021, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted net loss per ordinary share is the same as basic net loss per ordinary share for the periods presented. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Period from&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;February&#160;25, 2021 (Inception)&lt;br/&gt;Through December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;A&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;B&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allocation of net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-align: right;"&gt;(1,675,346&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-align: right;"&gt;(649,283&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="text-align: left; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted weighted average shares outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;15,101,877&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;5,852,751&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;;text-indent: 0px;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px; text-align: right;"&gt;(0.11&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px; text-align: right;"&gt;(0.11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:center;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;   &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution which, at times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on these accounts. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#x201c;Fair Value Measurement,&#x201d; approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recent Accounting Standards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2020, the FASB issued ASU No. 2020-06, &#x201c;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&#x201d; (&#x201c;ASU 2020-06&#x201d;), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. We adopted ASU 2020-06 effective as of January 1, 2021. The adoption of ASU 2020-06 did not have an impact on our financial statements. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#x2019;s financial statements. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accrued Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued expenses &lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;includes $1,506,528 of accrued legal expense, $5,000 of accrued printing expense, $282,500 of accrued due diligence expense, $70,000 of accrued regulatory filing fee and $770 of accrued accounting expense.&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying financial statements are presented in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and pursuant to the rules and regulations of the SEC. &lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <prok:EmergingGrowthCompanyStatusPolicyTextBlock contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Emerging Growth Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-emerging&lt;/div&gt; growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#x2019;s financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.&lt;/div&gt;</prok:EmergingGrowthCompanyStatusPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Significant accounting estimates include the determination of the fair value of Class&#160;A ordinary shares subject to possible redemption and the fair value of Founder Shares transferred to directors. Accordingly, the actual results could differ significantly from those estimates. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company &lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; text-indent: 4%; letter-spacing: 0px; top: 0px;;display:inline;"&gt;considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of December&#160;31, 2021.&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Marketable Securities Held in Trust Account &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At December&#160;31, 2021, substantially all of the assets held in the Trust Account were held in money market funds which are invested primarily in U.S. Treasury securities. &lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <prok:TemporaryEquityPolicyTextBlock contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Class&#160;A Ordinary Shares Subject to Possible Redemption &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for its Class&#160;A ordinary shares subject to possible redemption in accordance with the guidance in Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 480, &#x201c;Distinguishing Liabilities from Equity.&#x201d; Class&#160;A ordinary shares subject to mandatory redemption are classified as a liability instrument and are measured at redemption value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control) are classified as temporary equity. At all other times, ordinary shares are classified as shareholders&#x2019; equity. The Company&#x2019;s Class&#160;A ordinary shares feature certain redemption rights that are considered to be outside of the Company&#x2019;s control and subject to occurrence of uncertain future events. Accordingly, Class&#160;A ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the permanent deficit section of the Company&#x2019;s balance sheet. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying value of redeemable ordinary shares are affected by charges against additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital (to the extent available) and accumulated deficit. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At December&#160;31, 2021, the Class&#160;A ordinary shares subject to possible redemption reflected in the balance sheet are reconciled in the following table: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross proceeds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;250,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;A ordinary shares issuance costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,479,666&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Increase of carrying value to redemption value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,487,990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;250,008,324&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt;  </prok:TemporaryEquityPolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At December&#160;31, 2021, the Class&#160;A ordinary shares subject to possible redemption reflected in the balance sheet are reconciled in the following table: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 83%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross proceeds&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;250,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;A ordinary shares issuance costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,479,666&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;Increase of carrying value to redemption value&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,487,990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;A ordinary shares subject to possible redemption&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;250,008,324&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear:both;max-height:0pt;;text-indent: 0px;"/&gt; </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">250000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <prok:TemporaryEquityIssaunceCosts
      contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-12479666</prok:TemporaryEquityIssaunceCosts>
    <prok:IncreaseOfOrdinarySharesToRedemptionValueTemporaryEquity
      contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">12487990</prok:IncreaseOfOrdinarySharesToRedemptionValueTemporaryEquity>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">250008324</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <prok:DeferredOfferingCostsPolicyTextBlock contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Offering Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company &lt;/div&gt;&lt;/div&gt;complies with the requirements of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ASC&#160;340-&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-S99-1.&#160;Offering&#160;costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; consisted of legal, accounting, underwriting fees and other costs incurred through the Initial Public Offering that were directly related to the Initial Public Offering. The Company incurred offering costs amounting to $12,479,666 as a result of the Initial Public Offering, consisting of $4,400,000 of underwriting commissions, $7,700,000 of deferred underwriting commissions, and $379,666&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;of other offering costs. The offering costs were charged to temporary equity and additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital upon the completion of the Initial Public Offering. Immediately thereafter, temporary equity was remeasured and an adjustment was recognized through additional paid in capital and accumulated deficit to adjust temporary equity to the redemption value. &lt;/div&gt;&lt;/div&gt;</prok:DeferredOfferingCostsPolicyTextBlock>
    <prok:TransactionCostsIncurredInConnectionWithInitialPublicOffering
      contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">12479666</prok:TransactionCostsIncurredInConnectionWithInitialPublicOffering>
    <prok:UnderwritingFee
      contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">4400000</prok:UnderwritingFee>
    <prok:DeferredUnderwritingFees
      contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">7700000</prok:DeferredUnderwritingFees>
    <us-gaap:DeferredOfferingCosts
      contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">379666</us-gaap:DeferredOfferingCosts>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Share-Based Payment Arrangements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for stock awards in accordance with ASC 718, &#x201c;Compensation&#x2014;Stock Compensation,&#x201d; which requires that all equity awards be accounted for at their &#x201c;fair value.&#x201d; Fair value is measured on the grant date and is equal to the underlying value of the stock. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Costs equal to these fair values are recognized ratably over the requisite service period based on the number of awards that are expected to vest, in the period of grant for awards that vest immediately and have no future service condition, or in the period the awards vest immediately after meeting a performance condition becomes probable (i.e., the occurrence of a Business Combination). For awards that vest over time, cumulative adjustments in later periods are recorded to the extent actual forfeitures differ from the Company&#x2019;s initial estimates; previously recognized compensation cost is reversed if the service or performance conditions are not satisfied and the award is forfeited.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for income taxes under ASC 740, &#x201c;Income Taxes&#x201d; (&#x201c;ASC 740&#x201d;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s financial statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;more-likely-than-not&lt;/div&gt; to be sustained upon examination by taxing authorities. The Company&#x2019;s management has determined that the Cayman Islands is the Company&#x2019;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;amounts accrued for interest and penalties as of December&#160;31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is considered to be an exempted Cayman Islands company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#x2019;s tax provision was zero for the period presented. &lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net Loss Per Ordinary Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss per ordinary share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding during the period. The Company has two classes of shares, which are referred to as Class&#160;A &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ordinary shares and Class&#160;B ordinary shares. Losses are shared pro rata between the two classes of shares. Charges associated with the redeemable Class&#160;A ordinary shares are excluded from net loss per ordinary share as the redemption value approximates fair value. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2021, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted net loss per ordinary share is the same as basic net loss per ordinary share for the periods presented. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Period from&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;February&#160;25, 2021 (Inception)&lt;br/&gt;Through December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;A&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;B&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allocation of net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-align: right;"&gt;(1,675,346&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-align: right;"&gt;(649,283&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="text-align: left; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted weighted average shares outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;15,101,877&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;5,852,751&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;;text-indent: 0px;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px; text-align: right;"&gt;(0.11&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px; text-align: right;"&gt;(0.11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:center;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  </us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:TemporaryEquityTableTextBlock contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Period from&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;February&#160;25, 2021 (Inception)&lt;br/&gt;Through December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;A&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;B&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allocation of net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-align: right;"&gt;(1,675,346&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="line-height: normal;"&gt;&lt;div style="text-indent: 0px; letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-align: right;"&gt;(649,283&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="text-align: left; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted weighted average shares outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;15,101,877&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;5,852,751&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:center;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0px; margin-bottom: 0px; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;;text-indent: 0px;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px; text-align: right;"&gt;(0.11&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-indent: 0px;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; text-indent: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; text-indent: 0px; text-align: right;"&gt;(0.11&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-indent: 0px;;text-align:center;"&gt;&lt;div style="margin-bottom: 0px; margin-top: 0px; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;)&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-1675346</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-649283</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">15101877</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">15101877</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">5852751</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">5852751</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution which, at times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on these accounts. &lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#x201c;Fair Value Measurement,&#x201d; approximates the carrying amounts represented in the accompanying balance sheet, primarily due to their short-term nature.&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recent Accounting Standards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2020, the FASB issued ASU No. 2020-06, &#x201c;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&#x201d; (&#x201c;ASU 2020-06&#x201d;), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. We adopted ASU 2020-06 effective as of January 1, 2021. The adoption of ASU 2020-06 did not have an impact on our financial statements. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#x2019;s financial statements. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <prok:AccruedExpensesPolicyTextBlock contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accrued Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued expenses &lt;/div&gt;&lt;/div&gt;&lt;div style="background-color: rgba(255, 255, 255, 0); letter-spacing: 0px; top: 0px;;display:inline;"&gt;includes $1,506,528 of accrued legal expense, $5,000 of accrued printing expense, $282,500 of accrued due diligence expense, $70,000 of accrued regulatory filing fee and $770 of accrued accounting expense.&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px; background: none;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</prok:AccruedExpensesPolicyTextBlock>
    <prok:AccruedLegalExpense
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1506528</prok:AccruedLegalExpense>
    <prok:AccruedPrintingExpense
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5000</prok:AccruedPrintingExpense>
    <prok:AccruedDueDiligenceExpense
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">282500</prok:AccruedDueDiligenceExpense>
    <prok:AccruedRegulatoryFilingFee
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">70000</prok:AccruedRegulatoryFilingFee>
    <prok:AccruedAccountingExpense
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">770</prok:AccruedAccountingExpense>
    <prok:InitialPublicOfferingDisclosureTextBlock contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 3. INITIAL PUBLIC OFFERING &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to the Initial Public Offering, the Company sold 25,000,000 Public Shares, which includes a partial exercise by the underwriters of their over-allotment option in the amount of 3,000,000 Public Shares, at a price of $10.00 per Public Share. Unlike some other initial public offerings of special purpose acquisition companies, investors in the Initial Public Offering did not receive any warrants (which would typically become exercisable following completion of the Business &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; text-indent: 0px;;display:inline;"&gt;Combination). The fair value attributable to the unexercised portion of the over-allotment option was deemed to be immaterial to the financial statements.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</prok:InitialPublicOfferingDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">25000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">3000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</us-gaap:SaleOfStockPricePerShare>
    <prok:PrivatePlacementDisclosureTextBlock contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 4. PRIVATE PLACEMENT &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Substantially concurrently &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;with the closing of the Initial Public Offering, the Sponsor purchased 640,000 Private Placement Shares at a price of $10.00 per Private Placement Share, for an aggregate purchase price of&#160;$6,400,000. Each Private Placement Share is identical to the Class&#160;A ordinary shares sold in the Initial Public Offering, subject to certain limited exceptions as described in Note 7. A portion of the proceeds from the sale of the Private Placement Shares was added to the net proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period or during any applicable extension period, the proceeds from the sale of the Private Placement Shares held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Shares will be worthless. &lt;/div&gt;&lt;/div&gt;</prok:PrivatePlacementDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">640000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_USD">6400000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 5. RELATED PARTY TRANSACTIONS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Founder Shares &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On March&#160;2, 2021, the Sponsor paid $25,000 to cover certain offering and formation costs of the Company in consideration for which the Sponsor received 5,750,000 Class&#160;B ordinary shares (the &#x201c;Founder Shares&#x201d;). On June&#160;29, 2021, the Company effected a share capitalization with respect to its Class&#160;B ordinary shares of 575,000 shares thereof, resulting in the Company&#x2019;s initial shareholders holding an aggregate of 6,325,000 Founder Shares. All share and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per-share&lt;/div&gt; amounts have been retroactively restated to reflect the share capitalization. The Founder Shares included an aggregate of up to&#160;825,000 shares that were subject to forfeiture depending on the extent to which the underwriters&#x2019; over-allotment option was exercised. As a result of the underwriters&#x2019; election to partially exercise their over-allotment option, a total of 750,000 Founder Shares are no longer subject to forfeiture and 75,000 Founder Shares were forfeited, resulting in an aggregate of&#160;6,250,000 Founder Shares outstanding. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June 2021, the Sponsor transferred 30,000 Founder Shares to Marc Semigran, an independent director of the Company. The sale of the Founders Shares to the Company&#x2019;s director is in the scope of FASB ASC Topic 718, &#x201c;Compensation-Stock Compensation&#x201d; (&#x201c;ASC 718&#x201d;).&#160;Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date. The fair value of the 30,000 shares granted to the Company&#x2019;s director was $214,160 or approximately $7.14 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per share. The Founders Shares were effectively sold subject to a performance condition (i.e., the occurrence of a Business Combination). Compensation expense related to the Founders Shares is recognized only when the performance condition is probable of occurrence. As of December&#160;31, 2021, the Company determined that a Business Combination is not considered probable, and, therefore, no stock-based compensation expense has been recognized. Stock-based compensation would be recognized at the date a Business Combination is considered probable (i.e., upon consummation of a Business Combination) in an amount equal to the number of Founders Shares times the grant date fair value per share (unless subsequently modified) less the amount initially received for the purchase of the Founders Shares. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Sponsor and the Company&#x2019;s directors and officers have agreed, subject to limited exceptions, not to transfer, assign or sell any of their Founder Shares until the earlier of: (A)&#160;one year after the completion of a Business Combination and (B)&#160;subsequent to a Business Combination, (x)&#160;if the last reported sale price of the Class&#160;A ordinary shares equals or exceeds &lt;/div&gt;&lt;/div&gt;$12.00 per share (as adjusted for share &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-divisions,&lt;/div&gt; share dividends, rights issuances, consolidations, reorganizations, recapitalizations and other similar transactions) for any 20 trading days within any &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30-trading&lt;/div&gt; day period commencing at least 150 days after a Business Combination, or (y)&#160;the date on which the Company completes a liquidation, merger, amalgamation, share exchange, reorganization or other similar transaction that results in all of the Public Shareholders having the right to exchange their Class&#160;A ordinary shares for cash, securities or other property.&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Administrative Services Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company entered into an agreement in which it will pay an affiliate of the Sponsor $10,000 per month, commencing on June&#160;30, 2021, for office space, administrative and support services. Upon completion of a Business Combination or its liquidation, the Company will cease paying these monthly fees. For the period from February&#160;25, 2021 (inception) through December&#160;31, 2021, the Company incurred&#160;$60,000 in fees for these services, of which such amount was recognized in Operating and Formation Costs in the accompanying statement of operations. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Advances from Related Party &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2021, the Sponsor had advanced the Company $97,319 for working capital purposes, inclusive of the administrative services agreement noted above, of which $87,319 was repaid during the period ended December&#160;31, 2021. As of December&#160;31, 2021, the outstanding balance was $10,000. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Promissory Note&#x2014;Related Party &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On March&#160;2, 2021, the Sponsor issued an unsecured promissory note to the Company (the &#x201c;Promissory Note&#x201d;), pursuant to which the Company could borrow up to an aggregate principal amount of $300,000. The Promissory Note was &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; bearing and payable on the earlier of December&#160;31, 2021 and the completion of the Initial Public Offering. The outstanding balance under the Promissory Note of $300,000 was repaid at the closing of the Initial Public Offering on July&#160;2, 2021. Borrowings are no longer available under the Promissory Note. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Related Party Loans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In order to fund working capital deficiencies or finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor or certain of the Company&#x2019;s officers and directors may, but are not obligated to, loan the Company funds as may be required (&#x201c;Working Capital Loans&#x201d;). If the Company completes a Business Combination, it may repay such loaned amounts out of the proceeds of the Trust Account. In the event that the Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay such loaned amounts but no proceeds from the Trust Account would be used to repay such loaned amounts. As of December&#160;31, 2021, there were no outstanding amounts under the Working Capital Loans. &lt;/div&gt;&lt;/div&gt; </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="P03_02_2021To03_02_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">25000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P03_02_2021To03_02_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">5750000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P06_29_2021To06_29_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">575000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn06_29_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">6325000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="PAsOn06_30_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">825000</us-gaap:CommonStockOtherSharesOutstanding>
    <prok:SharesNoLongerSubjectToForfeiture
      contextRef="PAsOn06_30_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">750000</prok:SharesNoLongerSubjectToForfeiture>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="P07_01_2021To09_30_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">75000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn06_30_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">6250000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P02_25_2021To06_30_2021_FounderSharesMemberusgaapStatementEquityComponentsAxis_IndependentDirectorsMembersrtTitleOfIndividualAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="INF"
      unitRef="Unit_shares">30000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P06_29_2021To06_29_2021_DirectorMembersrtTitleOfIndividualAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <prok:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue
      contextRef="P02_25_2021To12_31_2021_DirectorMembersrtTitleOfIndividualAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">214160</prok:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2021_DirectorMembersrtTitleOfIndividualAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">7.14</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RestrictionOnTransferOfSponsorSharesMemberPROKBasisAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">12</us-gaap:SharePrice>
    <prok:NumberOfTradingDaysForDeterminingTheSharePrice contextRef="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RestrictionOnTransferOfSponsorSharesMemberPROKBasisAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">P20D</prok:NumberOfTradingDaysForDeterminingTheSharePrice>
    <prok:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice contextRef="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RestrictionOnTransferOfSponsorSharesMemberPROKBasisAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">P30D</prok:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice>
    <prok:WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered contextRef="P02_25_2021To12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RestrictionOnTransferOfSponsorSharesMemberPROKBasisAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">P150D</prok:WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P06_30_2021To06_30_2021_AdministrationAndSupportServicesMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_USD">10000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="P02_25_2021To12_31_2021_AdministrationAndSupportServicesMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_USD">60000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2021_AdvanceFromRelatedPartyLoanMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_USD">97319</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <prok:RepaymentOfAdvancesFromRelatedParty
      contextRef="P02_25_2021To12_31_2021_AdvanceFromRelatedPartyLoanMemberusgaapRelatedPartyTransactionAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_USD">87319</prok:RepaymentOfAdvancesFromRelatedParty>
    <prok:AdvancesPayableToRelatedPartyCurrent
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">10000</prok:AdvancesPayableToRelatedPartyCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_02_2021_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_USD">300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="P07_02_2021To07_02_2021_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_USD">300000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WorkingCapitalLoansMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 6. COMMITMENTS AND CONTINGENCIES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Registration Rights &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to a registration rights agreement entered into on June&#160;29, 2021, the holders of the Founder Shares, Private Placement Shares and any Private Placement Shares that may be issued on conversion of Working Capital Loans (and any Class&#160;A ordinary shares issuable upon the conversion of the Founder Shares) are entitled &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;to registration rights requiring the Company to register such securities for resale (in the case of the Founder Shares, only after conversion to the Class&#160;A ordinary shares). The holders of these securities will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have certain &#x201c;piggy-back&#x201d; registration rights with respect to registration statements filed subsequent to the completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. The Company will bear the expenses incurred in connection with the filing of any such registration statements. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Underwriting Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The underwriters are entitled to a deferred underwriting commission of $7,700,000 in the aggregate. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restricted Stock Unit Award &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In September 2021, pursuant to a Director Restricted Stock Unit Award Agreement, dated September&#160;24, 2021, between the Company and Uma Sinha, Ph.D., the Company agreed to &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; grant&#160;&lt;/div&gt;&lt;/div&gt;30,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;restricted stock units (&#x201c;RSUs&#x201d;) to Dr.&#160;Sinha, which grant is contingent on both the consummation of a Business Combination and a shareholder approved equity plan. The RSUs will vest upon the consummation of such Business Combination and represent&#160;&lt;/div&gt;30,000&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;Class&#160;A ordinary shares of the Company that will settle on a date determined in the sole discretion of the Company that shall occur between the vesting date and March&#160;&lt;/div&gt;15&lt;div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; of the year following the year in which vesting occurs.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The RSUs to be granted by the Company are in the scope of ASC 718.&#160;Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date. The RSUs to be granted are subject to a performance condition (i.e., the occurrence of a Business Combination). Compensation expense related to the RSUs is recognized only when the performance condition is probable of occurrence under the applicable accounting literature in this circumstance. As of December&#160;31, 2021, the Company did not have a shareholder approved equity plan and also determined that a Business Combination is not considered probable, therefore, no stock-based compensation expense has been recognized. Stock-based compensation would be recognized at the date a Business Combination is considered probable (i.e., upon consummation of a Business Combination) in an amount equal to the number of RSUs times the grant date fair value per share (unless subsequently modified).&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <prok:DeferredUnderwritingFees
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">7700000</prok:DeferredUnderwritingFees>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P02_25_2021To12_31_2021_DirectorRestrictedStockUnitAwardAgreementMemberPROKAgreementAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <prok:NumberOfSharesOfCommonStockCommittedToSettleOnADateFollowingTheYearBusinessCombinationOccurs
      contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_DirectorRestrictedStockUnitAwardAgreementMemberPROKAgreementAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">30000</prok:NumberOfSharesOfCommonStockCommittedToSettleOnADateFollowingTheYearBusinessCombinationOccurs>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 7. TEMPORARY EQUITY AND PERMANENT DEFICIT &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="null;text-indent: 0px;;font-style:italic;display:inline;"&gt;Preference Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#x2014;The Company is authorized to issue 5,000,000 preference shares, with a par value of $0.0001 per share. The Company&#x2019;s board of directors will be authorized to fix the voting rights, if any, designations, powers, preferences, the relative, participating, optional or other special rights and any qualifications, limitations and restrictions thereof, applicable to the shares of each series. The Company&#x2019;s board of directors will be able to, without shareholder approval, issue preference shares with voting and other rights that could adversely affect the voting power and other rights of the holders of the Company&#x2019;s ordinary shares and could have anti-takeover effects. At December&#160;31, 2021, there were no preference shares issued or outstanding. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Class&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;A Ordinary Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#x2014;The Company is authorized to issue 500,000,000 Class&#160;A ordinary shares, with a par value of $0.0001 per share. At December&#160;31, 2021, there were 640,000 Class&#160;A ordinary shares issued and outstanding, excluding 25,000,000 Class&#160;A ordinary shares subject to possible redemption which are presented as temporary equity. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Class&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;B Ordinary Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#x2014;The Company is authorized to issue 50,000,000 Class&#160;B ordinary shares, with a par value of $0.0001 per share. At December&#160;31, 2021, there were 6,250,000 Class&#160;B ordinary shares issued and &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;outstanding. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Holders of record&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;of Class&#160;A ordinary shares and Class&#160;B ordinary shares are entitled to one vote for each share held on all matters to be voted on by shareholders and vote together as a single class, except as required by law; provided that prior to a Business Combination, holders of Class&#160;B ordinary shares will have the right to appoint all of the Company&#x2019;s directors and remove members of its board of directors for any reason, and holders of Class&#160;A ordinary shares will not be entitled to vote on the appointment of directors during such time. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Class&#160;B ordinary shares will automatically convert into Class&#160;A ordinary shares at the time of the Business Combination, or earlier at the option of the holder, on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-for-one&lt;/div&gt;&lt;/div&gt; basis, subject to adjustment for share &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-divisions,&lt;/div&gt; share dividends, rights issuances, consolidations, reorganizations, recapitalizations and the like. Additionally, in the event that additional (in excess of the amounts issued in the Initial Public Offering) Class&#160;A ordinary shares, or equity-linked securities, are issued or deemed issued in connection with the closing of the Business Combination, the ratio at which the Class&#160;B ordinary shares will convert into Class&#160;A ordinary shares will be adjusted (unless the holders of a majority of the issued and outstanding Class&#160;B ordinary shares agree to waive such anti-dilution adjustment with respect to any such issuance or deemed issuance) so that the number of Class&#160;A ordinary shares issuable upon conversion of all Class&#160;B ordinary shares will equal, in the aggregate, 20% of the sum of the total number of Class&#160;A ordinary shares outstanding after such conversion (after giving effect to any redemptions of Class&#160;A ordinary shares by Public Shareholders, and excluding the Private Placement Shares), including any Class&#160;A ordinary shares issued or deemed issued, or issuable upon the conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with the Business Combination, excluding any Class&#160;A ordinary shares or equity-linked securities exercisable for or convertible into Class&#160;A ordinary shares issued, or to be issued, to any seller in the Business Combination and any private placement shares issued to the Sponsor or its affiliates upon conversion of Working Capital Loans; provided that such conversion of Class&#160;B ordinary shares will never occur on a less than &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-for-one-basis.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Private Placement Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#x2014;The Private Placement Shares are not transferable, assignable, or salable until 30 days after the completion of a Business Combination (except, among other limited exceptions, to the Company&#x2019;s directors and officers and other persons or entities affiliated with the Sponsor). Holders of the Private Placement Shares are entitled to certain registration rights. If the Company does not complete a Business Combination within the Combination Period or during any applicable extension period, the proceeds from the sale of the Private Placement Shares held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Shares will be worthless. &lt;/div&gt; </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">640000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">640000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">25000000</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">6250000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">6250000</us-gaap:CommonStockSharesOutstanding>
    <prok:PercentOfFoundersSharesToCompanysIssuedAndOutstandingOrdinaryShares
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</prok:PercentOfFoundersSharesToCompanysIssuedAndOutstandingOrdinaryShares>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 8. FAIR VALUE MEASUREMENTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company follows the guidance in ASC Topic 820 for its financial assets and liabilities that are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-measured&lt;/div&gt; and reported at fair value at each reporting period, and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-financial&lt;/div&gt; assets and liabilities that are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-measured&lt;/div&gt; and reported at fair value at least annually. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Company&#x2019;s financial assets and liabilities reflects management&#x2019;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 20%; font-size: 10pt;"&gt;&lt;div style="text-indent: -2%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 11%; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 20%; font-size: 10pt;"&gt;&lt;div style="text-indent: -2%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 11%; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;2: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Observable inputs other than Level&#160;1 inputs. Examples of Level&#160;2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px; text-indent: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 20%; font-size: 10pt;"&gt;&lt;div style="text-indent: -2%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 1pt; margin-left: 11%; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;3: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;following table presents information about the Company&#x2019;s assets that are measured at fair value on a recurring basis at December&#160;31, 2021, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Description&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Marketable securities held in Trust Account&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;250,008,324&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  </us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="text-indent: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;following table presents information about the Company&#x2019;s assets that are measured at fair value on a recurring basis at December&#160;31, 2021, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 8%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid; white-space: nowrap;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 1pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Description&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Marketable securities held in Trust Account&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;250,008,324&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <prok:MarketableSecuritiesHeldToMaturityFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">250008324</prok:MarketableSecuritiesHeldToMaturityFairValueDisclosure>
    <us-gaap:SubsequentEventsTextBlock contextRef="P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 9. SUBSEQUENT EVENTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, other than as described below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements, except as follows: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Proposed ProKidney Business Combination &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January&#160;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;18, 2022, the Company entered into a Business Combination Agreement (the &#x201c;ProKidney Business Combination Agreement&#x201d;) with ProKidney LP, a limited partnership registered under the laws of Ireland (&#x201c;ProKidney&#x201d;), acting through its general partner ProKidney GP Limited, a private limited company incorporated under the laws of Ireland (&#x201c;Legacy GP&#x201d;). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The ProKidney Business Combination Agreement provides that, among other things and upon the terms and subject to the conditions thereof, prior to or at the closing of the ProKidney Business Combination Agreement (the &#x201c;Closing&#x201d;), the following transactions will occur (together with the other transactions contemplated by the ProKidney Business Combination Agreement, the &#x201c;ProKidney Business Combination&#x201d;): (1) ProKidney will issue to the Company a number of common units of ProKidney (&#x201c;Post-Combination ProKidney Common Units&#x201d;) equal to the number of fully diluted outstanding ordinary shares of the Company as of immediately prior to the Closing (but after giving effect to all redemptions of Public Shares and the purchase of Class A ordinary shares pursuant to one or more subscription agreements (the &#x201c;PIPE Investment&#x201d;)), in exchange for (a) (x) new Class B ordinary shares (&#x201c;New ProKidney Class B ordinary shares&#x201d;), which shares will have no economic rights but will entitle the holders thereof to vote on all matters on which shareholders of the Company are entitled to vote generally, and (y) restricted stock rights in respect of New ProKidney Class B ordinary shares (&#x201c;New ProKidney Class B PMEL RSRs&#x201d;), which restricted stock rights shall convert into New ProKidney Class B ordinary shares upon the vesting of the associated restricted common unit of ProKidney, (b) an amount in cash equal to the aggregate proceeds obtained by the Company in the PIPE Investment and (c) an amount in cash equal to the aggregate proceeds available for release to the Company from the Trust Account (after giving effect to all redemptions of Public Shares and after payment of any deferred underwriting commissions being held in the Trust Account and payment of certain transaction expenses); (2) Legacy GP will resign as the general partner of ProKidney and a private limited company incorporated under the laws of Ireland (&#x201c;New GP&#x201d;) will be admitted as the general partner of ProKidney; (3) ProKidney will distribute to the ProKidney unitholders the New ProKidney Class B ordinary shares and New ProKidney Class B PMEL RSRs received pursuant to clause (i)(a) (x) and (y) above; and (4)&#160;certain holders of ProKidney units will receive an aggregate of 17,500,000 restricted common units of ProKidney (&#x201c;Earnout RCUs&#x201d;) and 17,500,000 &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;restricted stock rights of the Company (&#x201c;Earnout RSRs&#x201d; and, together with the Earnout RCUs, the &#x201c;Earnout Rights&#x201d;), which Earnout Rights will vest in three equal &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;tranches upon the trading price of a Class&#160;A ordinary share reaching &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;$15.00/share, $20.00/share and $25.00/share, respectively, on the terms set forth in the ProKidney Business Combination Agreement, or upon certain change of control events. When vested, the Earnout RCUs will automatically convert into Post-Combination ProKidney Common Units and the associated Earnout RSRs will automatically convert into New ProKidney Class B ordinary shares, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January 18, 2022, the Company entered into subscription agreements (the &#x201c;Subscription Agreements&#x201d;) with certain investors (&#x201c;PIPE Investors&#x201d;) pursuant to which the PIPE Investors have subscribed for an aggregate of 57,500,000 Class A ordinary shares for a price of $10.00 per share for an aggregate purchase price of $575,000,000, of which (1) $156,400,000 is committed by certain existing directors, officers and equityholders of, or investment funds managed by Suvretta Capital Management, LLC, the Company, the Sponsor and/or their respective affiliates participating in the PIPE Investment, and (2) at least $50,000,000 (which may, at the election of such investors, be increased to up to $100,000,000) is committed by certain existing directors, officers and unitholders of ProKidney and/or its affiliates participating in the PIPE Investment (the &#x201c;ProKidney Related PIPE Investors&#x201d;); provided that the ProKidney Related PIPE Investors may elect instead to purchase Post-Combination ProKidney Common Units, together with a corresponding number of Class B ordinary shares, in lieu of Class A ordinary shares. The Subscription Agreements are subject to certain conditions, including that there shall not be in force any injunction or order enjoining or prohibiting the issuance and sale of the shares under the Subscription Agreements; the terms of the ProKidney Business Combination Agreement shall not have been amended, and the minimum cash condition therein shall not have been waived, in a manner that is materially adverse to the investor party to the Subscription Agreement; and the representation and warranties of the parties to the Subscription Agreement shall be accurate (subject to agreed materiality thresholds). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Following the Closing, the combined company will be organized in an umbrella partnership-C corporation (a so called &#x201c;Up-C&#x201d;) structure, and the Company&#x2019;s direct assets will consist of ProKidney Common Units and equity interests of New GP, and substantially all of the operating assets and business of the Company will be held indirectly through ProKidney. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consummation of the proposed ProKidney Business Combination is subject to certain conditions as further described in the ProKidney Business Combination Agreement. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Legal Proceedings &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certain purported shareholders of the Company sent demand letters (the &#x201c;Demands&#x201d;) alleging deficiencies and/or omissions in the ProKidney Disclosure Statement filed by the Company with the SEC on February&#160;14, 2022. The Demands seek additional disclosures to remedy these purported deficiencies. We believe that the allegations in the Demands are meritless. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="P01_18_2022To01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">17500000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="P01_18_2022To01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">17500000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="PAsOn01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SharePriceOneMemberPROKSharePriceRangeAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">15</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="PAsOn01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SharePriceTwoMemberPROKSharePriceRangeAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">20</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="PAsOn01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SharePriceThreeMemberPROKSharePriceRangeAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">25</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P01_18_2022To01_18_2022_PipeInvestorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">57500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn01_18_2022_PipeInvestorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">10</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P01_18_2022To01_18_2022_PipeInvestorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">575000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P01_18_2022To01_18_2022_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">156400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P01_18_2022To01_18_2022_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">50000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P01_18_2022To01_18_2022_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MaximumMembersrtRangeAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">100000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:Cash
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">51889</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">440488</us-gaap:Cash>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">543088</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">504189</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">594977</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">944677</us-gaap:AssetsCurrent>
    <prok:PrepaidInsuranceNonCurrent
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">123750</prok:PrepaidInsuranceNonCurrent>
    <prok:PrepaidInsuranceNonCurrent
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">247500</prok:PrepaidInsuranceNonCurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">250033500</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:AssetsHeldInTrustNoncurrent
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">250008324</us-gaap:AssetsHeldInTrustNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">250752227</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">251200501</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">26735</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <prok:AccruedExpensesCurrent
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5342189</prok:AccruedExpensesCurrent>
    <prok:AccruedExpensesCurrent
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1864796</prok:AccruedExpensesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">43623</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">10000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5412547</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1879796</us-gaap:LiabilitiesCurrent>
    <prok:DeferredUnderwritingCommissions
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">7700000</prok:DeferredUnderwritingCommissions>
    <prok:DeferredUnderwritingCommissions
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">7700000</prok:DeferredUnderwritingCommissions>
    <us-gaap:Liabilities
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">13112547</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">9579796</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">25000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">25000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">250000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">250008324</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">640000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">640000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">640000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">640000</us-gaap:CommonStockSharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">25000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">25000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">64</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">64</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="4"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">6250000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">6250000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">6250000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">6250000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">625</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">625</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-12361009</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8388308</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-12360320</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8387619</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">250752227</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">251200501</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">4006201</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P02_25_2021To03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5182</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-4006201</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P02_25_2021To03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-5182</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">25176</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P02_25_2021To03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-3981025</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P02_25_2021To03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-5182</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">25640000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">25640000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P02_25_2021To03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P02_25_2021To03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">-0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P02_25_2021To03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P02_25_2021To03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">6250000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">6250000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P02_25_2021To03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">5500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P02_25_2021To03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">5500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">-0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P02_25_2021To03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P02_25_2021To03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0</us-gaap:EarningsPerShareBasic>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">25000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2021_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">250008324</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">640000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">64</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">6250000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">625</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8388308</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8387619</us-gaap:StockholdersEquity>
    <prok:RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity
      contextRef="P01_01_2022To03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">8324</prok:RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity>
    <prok:RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity
      contextRef="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8324</prok:RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity>
    <prok:RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity
      contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8324</prok:RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-3981025</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-3981025</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">25000000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn03_31_2022_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">250000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">640000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">64</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">6250000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">625</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-12361009</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-12360320</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn02_24_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn02_24_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn02_24_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn02_24_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn02_24_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P02_25_2021To03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">6325000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="P02_25_2021To03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">633</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="P02_25_2021To03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">24367</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="P02_25_2021To03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">25000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:NetIncomeLoss
      contextRef="P02_25_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-5182</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P02_25_2021To03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-5182</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">6325000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">633</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2021_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">24367</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-5182</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">19818</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-3981025</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P02_25_2021To03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-5182</us-gaap:NetIncomeLoss>
    <prok:FormationCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares
      contextRef="P02_25_2021To03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5000</prok:FormationCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares>
    <us-gaap:InvestmentIncomeInterest
      contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">25176</us-gaap:InvestmentIncomeInterest>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-84851</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <prok:IncreaseDecreaseOfAdvanceFromRelatedParty
      contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">33623</prok:IncreaseDecreaseOfAdvanceFromRelatedParty>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">3499128</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P02_25_2021To03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">44</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-388599</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P02_25_2021To03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-138</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="P02_25_2021To03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">255</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P02_25_2021To03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">117</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P02_25_2021To03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">138</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-388599</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">440488</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">51889</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:StockIssued1
      contextRef="P02_25_2021To03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">20000</us-gaap:StockIssued1>
    <prok:OfferingCostsIncludedInAccruedOfferingCosts
      contextRef="P02_25_2021To03_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5000</prok:OfferingCostsIncludedInAccruedOfferingCosts>
    <us-gaap:NatureOfOperations contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 1. DESCRIPTION OF ORGANIZATION, BUSINESS OPERATIONS AND GOING CONCERN &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Social Capital Suvretta Holdings Corp. III (the &#x201c;Company&#x201d;) is a blank check company incorporated as a Cayman Islands exempted company on&#160;February 25, 2021. The Company was incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses (a &#x201c;Business Combination&#x201d;). The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of Marc&lt;/div&gt;&lt;/div&gt;h&#160;31, 2022, the Company had not commenced&#160;any operations. All activity for the period from February 25, 2021 (inception) through March&#160;31, 2022 relates to the Company&#x2019;s formation, the initial public offering (the &#x201c;Initial Public Offering&#x201d;), described below, and, subsequent to the Initial Public Offering, identifying a target company for a Business Combination and activities in connection with the proposed acquisition of ProKidney LP (see Note 6). The Company will not generate any operating revenues until after the completion of a Business Combination, at the earliest. The Company generates &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-operating&lt;/div&gt; income in the form of interest income from the marketable securities held in the Trust Account (as defined below). &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The registration &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;statements for the Company&#x2019;s Initial Public Offering became effective on June&#160;29, 2021 and June&#160;30, 2021. On July&#160;2, 2021, the Company consummated the Initial Public Offering of 25,000,000 Class&#160;A ordinary shares (the &#x201c;Public Shares&#x201d;), which includes the partial exercise by the underwriters of their over-allotment option in the amount of 3,000,000 Public Shares, at $10.00 per Public Share, generating gross proceeds of $250,000,000, which is described in Note 3. The fair value attributable to the unexercised portion of the over-allotment option was deemed to be immaterial to the condensed financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Substantially &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;concurrently with the closing of the Initial Public Offering, the Company consummated the sale of 640,000 Class&#160;A ordinary shares (the &#x201c;Private Placement Shares&#x201d;) at a price of $10.00 per Private Placement Share in a private placement to SCS Sponsor III LLC, a Cayman Islands limited liability company (the &#x201c;Sponsor&#x201d;), generating gross proceeds of $6,400,000, which is described in Note 4. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Transaction &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;costs amounted to $12,479,666, consisting of $4,400,000 of underwriting fees, $7,700,000 of deferred underwriting fees and $379,666 of other offering costs. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In connection &lt;/div&gt;&lt;/div&gt;with the closing of the Initial Public Offering on July&#160;2, 2021, an amount of $250,000,000 ($10.00 per Public Share) from the net proceeds of the sale of the Public Shares in the Initial Public Offering and the sale of the Private Placement Shares was placed in a trust account (the &#x201c;Trust Account&#x201d;), and invested in U.S. government treasury bills with a maturity of 185 days or less or in money market funds investing solely in U.S. Treasuries and meeting certain conditions of Rule &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2a-7&lt;/div&gt; of the Investment Company Act of 1940, as amended (the &#x201c;Investment Company Act&#x201d;). Except with respect to interest earned on the funds held in the Trust Account that may be released to the Company to pay its taxes, if any, the funds held in the Trust Account will not be released from the Trust Account until the earliest of: (a)&#160;the completion of a Business Combination, and then only in connection with those Public Shares that such shareholder properly elected to redeem, subject to certain limitations; (b)&#160;the redemption of any Public Shares properly submitted in connection with a shareholder vote to amend the Company&#x2019;s Amended and Restated Memorandum and Articles of Association (i)&#160;to modify the substance or timing of the Company&#x2019;s obligation to allow redemption in connection with the Business Combination or to redeem 100&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;% of the Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or (ii)&#160;with respect to any other material provisions relating to shareholders&#x2019; rights or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-Business&lt;/div&gt; Combination activity; and (c)&#160;the redemption of the Public Shares if the &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Company has not completed a Business Combination within the Combination Period or during any applicable extension period. The proceeds deposited in the Trust Account could become subject to the claims of the Company&#x2019;s creditors, if any, which could have priority over the claims of the holders of the Public Shares (the &#x201c;Public Shareholders&#x201d;). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company&#x2019;s &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Shares, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. The Company must complete one or more Business Combinations having an aggregate fair market value of at least 80% of the value of the assets held in the Trust Account (excluding any deferred underwriting commissions and taxes payable on the income earned on the Trust Account) at the time of the Company signing a definitive agreement in connection with the Business Combination. However, the Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the issued and outstanding voting securities of the target or otherwise acquires a controlling interest in the target business sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance that the Company will be able to complete a Business Combination successfully. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company &lt;/div&gt;&lt;/div&gt;will provide the Public Shareholders with the opportunity to redeem all or a portion of their Public Shares upon the completion of the Business Combination, either (a)&#160;in connection with a general meeting called to approve the Business Combination or (b)&#160;by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company. The Public Shareholders will be entitled to redeem all or a portion of their Public Shares at a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per-share&lt;/div&gt; price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, calculated as of two business days prior to the consummation of the Business Combination, including interest (which interest shall be net of taxes payable), divided by the number of then issued and outstanding Public Shares, subject to the limitations described &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;below. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In accordance &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;with the Company&#x2019;s Amended and Restated Memorandum and Articles of Association, in no event will the Company redeem the Public Shares in an amount that would cause the Company&#x2019;s net tangible assets to be less than $5,000,001 following such redemptions. Redemptions of the Public Shares may also be subject to a higher net tangible asset test or cash requirement pursuant to an agreement relating to the Business Combination. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;If a shareholder vote is not required in connection with a Business Combination and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to its Amended and Restated Memorandum and Articles of Association, conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;), and file tender offer documents with the SEC prior to completing a Business Combination. If, however, shareholder approval of the transaction is required by applicable law or stock exchange listing requirement, or the Company decides to obtain shareholder approval for business or other reasons, the Company will conduct the redemptions in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules and will file proxy materials with the SEC. If the Company seeks shareholder approval in connection with a Business Combination, the Company will complete such Business Combination only if the Company receives an ordinary resolution under Cayman Islands law, which requires the affirmative vote of holders of a majority of ordinary shares who attend and vote at a general meeting of the Company. The Public Shareholders may elect to redeem their Public Shares without voting and, if they do vote, irrespective of whether they vote for or against a Business Combination. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Notwithstanding the foregoing redemption rights, if the Company seeks shareholder approval of the Business Combination and the Company does not conduct redemptions pursuant to the tender offer rules, the Company&#x2019;s Amended and Restated Memorandum and Articles of Association provide that a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a &#x201c;group&#x201d; (as defined under Section&#160;13 of the Securities Exchange Act of 1934, as amended (the &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;Exchange Act&#x201d;)), will be restricted from redeeming its Public Shares with respect to more than an aggregate &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;of 15% of the Public Shares without the Company&#x2019;s prior written consent. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Sponsor and &lt;/div&gt;&lt;/div&gt;the Company&#x2019;s directors and officers have agreed to waive: (a)&#160;their redemption rights with respect to any Founder Shares, Private Placement Shares and Public Shares held by them, as applicable, in connection with the completion of a Business Combination; (b)&#160;their redemption rights with respect to any Founder Shares, Private Placement Shares and Public Shares held by them in connection with a shareholder vote to amend the Company&#x2019;s Amended and Restated Memorandum and Articles of Association (i)&#160;to modify the substance or timing of the Company&#x2019;s obligation to allow redemption in connection with the Business Combination or to redeem 100% of the Public Shares if the Company does not complete a Business Combination within the Combination Period, or (ii)&#160;with respect to any other material provisions relating to shareholders&#x2019; rights or &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;pre-Business&lt;/div&gt; Combination activity; and (c)&#160;their rights to liquidating distributions from the Trust Account with respect to any Founder Shares and Private Placement Shares they hold if the Company fails to complete a Business Combination within the Combination Period or during any applicable extension period (although such persons will be entitled to liquidating distributions from the Trust Account with respect to any Public Shares they hold if the Company fails to complete a Business Combination within the prescribed time frame). If the Company submits the Business Combination to the Public Shareholders for a vote, the Sponsor and the Company&#x2019;s directors and officers have also agreed to vote any Founder Shares, Private Placement Shares and Public Shares held by them in favor of the Business Combination. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company &lt;/div&gt;&lt;/div&gt;will have until July&#160;2, 2023 to complete a Business Combination (the &#x201c;Combination Period&#x201d;), or such longer period as a result of a shareholder vote to amend such time period pursuant to the Company&#x2019;s Amended and Restated Memorandum and Articles of Association. However, if the Company has not completed a Business Combination within such Combination Period or during any applicable extension period, the Company will: (a)&#160;cease all operations except for the purpose of winding up; (b)&#160;as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per-share&lt;/div&gt; price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest (less up to $100,000 of interest to pay dissolution expenses and which interest shall be net of taxes payable) divided by the number of then issued and outstanding Public Shares, which redemption will completely extinguish the Public Shareholders&#x2019; rights as shareholders (including the right to receive further liquidating distributions, if any); and (c)&#160;as promptly as reasonably possible following such redemption, subject to the approval of the Company&#x2019;s remaining shareholders and its board of directors, liquidate and dissolve, subject in each case to the Company&#x2019;s obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Sponsor &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;has agreed that it will be liable to the Company if and to the extent any claims by a third party (other than the Company&#x2019;s independent auditors) for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account to below (1) $10.00 per Public Share or (2)&#160;such lesser amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, due to reductions in the value of the trust assets, in each case net of the interest which may be withdrawn to pay taxes, except as to any claims by a third party that executed a waiver of any and all rights to seek access to the Trust Account and except as to any claims under the Company&#x2019;s indemnity of the underwriters of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;). In the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company has not independently verified whether the Sponsor has sufficient funds to satisfy its indemnity obligations and believes that the Sponsor&#x2019;s only assets are securities of the Company and, therefore, the Sponsor may not be able to satisfy those obligations. The Company has not asked the Sponsor to reserve for such obligations. None of the Company&#x2019;s directors or officers will indemnify the Company for claims by third parties, including, without limitation, claims by vendors and prospective target &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;businesses.&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;br/&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Proposed ProKidney Business Combination&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January&#160;18, 2022, the Company entered into a Business Combination Agreement (the &#x201c;ProKidney Business Combination Agreement&#x201d;) with ProKidney LP, a limited partnership registered under the laws of Ireland (&#x201c;ProKidney&#x201d;), acting through its general partner ProKidney GP Limited, a private limited company incorporated under the laws of Ireland (&#x201c;Legacy GP&#x201d;). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The ProKidney &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Business Combination Agreement provides that, among other things and upon the terms and subject to the conditions thereof, prior to or at the closing of the ProKidney Business Combination Agreement (the &#x201c;Closing&#x201d;), the following transactions will occur (together with the other transactions contemplated by the ProKidney Business Combination Agreement, the &#x201c;ProKidney Business Combination&#x201d;): (1) ProKidney will issue to the Company a number of common units of ProKidney (&#x201c;Post-Combination ProKidney Common Units&#x201d;) equal to the number of fully diluted outstanding ordinary shares of the Company as of immediately prior to the Closing (but after giving effect to all redemptions of Public Shares and the purchase of Class&#160;A ordinary shares pursuant to one or more subscription agreements (the &#x201c;PIPE Investment&#x201d;)), in exchange for (a)&#160;(x) new Class&#160;B ordinary shares (&#x201c;New ProKidney Class&#160;B ordinary shares&#x201d;), which shares will have no economic rights but will entitle the holders thereof to vote on all matters on which shareholders of the Company are entitled to vote generally, and (y)&#160;restricted stock rights in respect of New ProKidney Class&#160;B ordinary shares (&#x201c;New ProKidney Class&#160;B PMEL RSRs&#x201d;), which restricted stock rights shall convert into New ProKidney Class&#160;B ordinary shares upon the vesting of the associated restricted common unit of ProKidney, (b)&#160;an amount in cash equal to the aggregate proceeds obtained by the Company in the PIPE Investment and (c)&#160;an amount in cash equal to the aggregate proceeds available for release to the Company from the Trust Account (after giving effect to all redemptions of Public Shares and after payment of any deferred underwriting commissions being held in the Trust Account and payment of certain transaction expenses); (2) Legacy GP will resign as the general partner of ProKidney and a private limited company incorporated under the laws of Ireland (&#x201c;New GP&#x201d;) will be admitted as the general partner of ProKidney; (3)&#160;ProKidney will distribute to the ProKidney unitholders the New ProKidney Class&#160;B ordinary shares and New ProKidney Class&#160;B PMEL RSRs received pursuant to clause (i)(a)&#160;(x) and (y) above; and (4)&#160;certain holders of ProKidney units will receive an aggregate of 17,500,000 restricted common units of ProKidney (&#x201c;Earnout RCUs&#x201d;) and 17,500,000 restricted stock rights of the Company (&#x201c;Earnout RSRs&#x201d; and, together with the Earnout RCUs, the &#x201c;Earnout Rights&#x201d;), which Earnout Rights will vest in three equal tranches upon the trading price of a Class&#160;A ordinary share reaching $15.00&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;per &lt;/div&gt;share, $20.00&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;per &lt;/div&gt;share and $25.00&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;per &lt;/div&gt;share, respectively, on the terms set forth in the ProKidney Business Combination Agreement, or upon certain change of control events. When vested, the Earnout RCUs will automatically convert into Post-Combination ProKidney Common Units and the associated Earnout RSRs will automatically convert into New ProKidney Class&#160;B ordinary shares, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;18, 2022, the Company entered into subscription agreements (the &#x201c;Subscription Agreements&#x201d;) with certain investors (&#x201c;PIPE Investors&#x201d;) pursuant to which the PIPE Investors have subscribed for an aggregate of 57,500,000 Class&#160;A ordinary shares for a price of $10.00 per share for an aggregate purchase price of $575,000,000, of which (1) $156,400,000 is committed by certain existing directors, officers and equityholders of, or investment funds managed by Suvretta Capital Management, LLC, the Company, the Sponsor and/or their respective affiliates participating in the PIPE Investment (collectively, the &#x201c;Sponsor Related PIPE Investors&#x201d;), and (2)&#160;at least $50,000,000 (which may, at the election of such investors, be increased to up to $100,000,000) is committed by certain existing directors, officers and unitholders of ProKidney and/or its affiliates participating in the PIPE Investment (the &#x201c;ProKidney Related PIPE Investors&#x201d;); provided that the ProKidney Related PIPE Investors may elect instead to purchase Post-Combination ProKidney Common Units, together with a corresponding number of Class&#160;B ordinary shares, in lieu of Class&#160;A ordinary shares. The Subscription Agreements are subject to certain conditions, including that there shall not be in force any injunction or order enjoining or prohibiting the issuance and sale of the shares under the Subscription Agreements; the terms of the ProKidney Business Combination Agreement shall not have been amended, and the minimum cash condition therein shall not have been waived, in a manner that is materially adverse to the investor party to the Subscription Agreement; and the representation and warranties of the parties to the Subscription Agreement shall be accurate (subject to agreed materiality &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;thresholds). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Following the Closing, the combined company will be organized in an umbrella &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;partner&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ship-C&lt;/div&gt; corporation (a so called &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;Up-C&#x201d;)&lt;/div&gt; structure, and the Company&#x2019;s direct assets will consist of ProKidney Common Units and equity interests of New GP, and substantially all of the operating assets and business of the Company will be held indirectly through ProKidney. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The consummation of the proposed ProKidney Business Combination is subject to certain conditions as further described in the ProKidney Business Combination Agreement. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Risks and Uncertainties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management &lt;/div&gt;&lt;/div&gt;continues to evaluate the impact of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;COVID-19&lt;/div&gt; pandemic and has concluded that while it is reasonably possible that the pandemic could have a negative effect on the Company&#x2019;s business, financial position, results of operations and/or the search for a target company, the specific impact is not readily determinable as of the date of these condensed financial statements. The condensed financial statements do not include any adjustments that might result from the outcome of this uncertainty. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Liquidity and Going Concern &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;March&#160;31, 2022, the Company had $51,889 in its operating bank account and working capital deficit of $4,817,570. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Until the consummation of a Business Combination, the Company will be using the funds not held in the Trust Account for identifying and evaluating prospective acquisition candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to acquire, and structuring, negotiating and consummating the Business Combination. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company may need to raise additional capital through loans or additional investments from its Sponsor, shareholders, officers, directors, or third parties. The Company&#x2019;s officers, directors and Sponsor may, but are not obligated to (other than pursuant to the Promissory Note (as defined in Note 9)), loan the Company additional funds, from time to time or at any time, in whatever amount they deem reasonable in their sole discretion, to meet the Company&#x2019;s working capital needs. Accordingly, the Company may not be able to obtain such additional financing. If the Company is unable to raise additional capital, it may be required to take additional measures to conserve liquidity, which could include, but not necessarily be limited to, curtailing operations, suspending the pursuit of a potential transaction, and reducing overhead expenses. The Company cannot provide any assurance that new financing will be available to it on commercially acceptable terms, if at all. These conditions raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for a reasonable period of time, which is considered to be one year from the issuance date of the condensed financial statements. These condensed financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;We have performed an assessment of going concern considerations in accordance with Financial Accounting Standard Board&#x2019;s Accounting Standards Update (&#x201c;ASU&#x201d;) &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2014-15,&lt;/div&gt; &#x201c;Disclosures of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern.&#x201d; We have until July&#160;2, 2023 to consummate a Business Combination, which date may be extended pursuant to its Amended and Restated Memorandum and Articles of Association. It is uncertain that the Company will be able to consummate a Business Combination by July&#160;2, 2023. If a Business Combination is not consummated by this date and such date is not extended pursuant to the Company&#x2019;s Amended and Restated Memorandum and Articles of Association, there will be a mandatory liquidation and subsequent dissolution of the Company. Management has determined that the mandatory liquidation, should a Business Combination not occur within the required time period, and potential subsequent dissolution raises substantial doubt about the Company&#x2019;s ability to continue as a going concern. No adjustments have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after July&#160;2, 2023. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </us-gaap:NatureOfOperations>
    <dei:EntityIncorporationDateOfIncorporation contextRef="P01_01_2022To03_31_2022">2021-02-25</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">25000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">3000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_USD">250000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_shares">640000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_USD">6400000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <prok:TransactionCostsIncurredInConnectionWithInitialPublicOffering
      contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_USD">12479666</prok:TransactionCostsIncurredInConnectionWithInitialPublicOffering>
    <prok:UnderwritingFee
      contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_USD">4400000</prok:UnderwritingFee>
    <prok:DeferredUnderwritingFees
      contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_USD">7700000</prok:DeferredUnderwritingFees>
    <us-gaap:DeferredOfferingCosts
      contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_USD">379666</us-gaap:DeferredOfferingCosts>
    <us-gaap:CommonStockHeldInTrust
      contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_USD">250000000</us-gaap:CommonStockHeldInTrust>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</us-gaap:SaleOfStockPricePerShare>
    <prok:PercentageOfPublicSharesRedemption
      contextRef="P07_02_2021To07_02_2021"
      decimals="2"
      unitRef="Unit_pure">1</prok:PercentageOfPublicSharesRedemption>
    <prok:ProspectiveAssetsOfAcquireeAsAPercentageOfFairValueOfAssetsInTheTrustAccount
      contextRef="PAsOn07_02_2021_MinimumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.80</prok:ProspectiveAssetsOfAcquireeAsAPercentageOfFairValueOfAssetsInTheTrustAccount>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="PAsOn07_02_2021_MinimumMembersrtRangeAxis"
      decimals="2"
      unitRef="Unit_pure">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:MinimumNetWorthRequiredForCompliance
      contextRef="PAsOn07_02_2021"
      decimals="0"
      unitRef="Unit_USD">5000001</us-gaap:MinimumNetWorthRequiredForCompliance>
    <prok:PercentageOfPublicSharesThatCanBeTransferredWithoutAnyRestriction
      contextRef="PAsOn07_02_2021"
      decimals="2"
      unitRef="Unit_pure">0.15</prok:PercentageOfPublicSharesThatCanBeTransferredWithoutAnyRestriction>
    <prok:PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated
      contextRef="PAsOn07_02_2021"
      decimals="2"
      unitRef="Unit_pure">1</prok:PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated>
    <us-gaap:LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities
      contextRef="PAsOn07_02_2021"
      decimals="0"
      unitRef="Unit_USD">100000</us-gaap:LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities>
    <prok:PerShareValueOfRestrictedAssets
      contextRef="PAsOn07_02_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</prok:PerShareValueOfRestrictedAssets>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="P01_18_2022To01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">17500000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="P01_18_2022To01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis"
      decimals="0"
      unitRef="Unit_shares">17500000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="PAsOn01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SharePriceOneMemberPROKSharePriceRangeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">15</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="PAsOn01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SharePriceTwoMemberPROKSharePriceRangeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">20</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="PAsOn01_18_2022_ProkidneyLpMemberusgaapBusinessAcquisitionAxis_RestrictedStockRightsMemberusgaapEquityInterestIssuedOrIssuableByTypeAxis_SharePriceThreeMemberPROKSharePriceRangeAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">25</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P01_18_2022To01_18_2022_PipeInvestorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_shares">57500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn01_18_2022_PipeInvestorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P01_18_2022To01_18_2022_PipeInvestorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_USD">575000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P01_18_2022To01_18_2022_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_USD">156400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P01_18_2022To01_18_2022_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_USD">50000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P01_18_2022To01_18_2022_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_MaximumMembersrtRangeAxis"
      decimals="0"
      unitRef="Unit_USD">100000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:Cash
      contextRef="PAsOn03_31_2022"
      decimals="0"
      unitRef="Unit_USD">51889</us-gaap:Cash>
    <prok:WorkingCapital
      contextRef="PAsOn03_31_2022"
      decimals="0"
      unitRef="Unit_USD">4817570</prok:WorkingCapital>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The &lt;/div&gt;accompanying unaudited condensed financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for interim financial information and in accordance with the instructions to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Form&#160;10-Q&lt;/div&gt; and Article&#160;8 of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Regulation&#160;S-X&lt;/div&gt; of the SEC. Certain information or footnote disclosures normally included in condensed financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements contained in the Company&#x2019;s Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K&lt;/div&gt; for the period ended December&#160;31, 2021 filed with the SEC on March&#160;24, 2022. The interim results for the three months ended March&#160;31, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022 or for any future periods. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Emerging Growth Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-emerging&lt;/div&gt; growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#x2019;s condensed financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. &lt;br/&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of the condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Significant accounting estimates include the determination of the fair value of Class&#160;A ordinary shares subject to possible redemption and the fair value of Founder Shares transferred to directors. Accordingly, the actual results could differ significantly from those estimates.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of March&#160;31, 2022 and December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Marketable Securities Held in Trust Account &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At March&#160;31, 2022 and December&#160;31, 2021, substantially all of the assets held in the Trust Account were held in a money market fund which is invested primarily in U.S. Treasury securities. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Class&#160;A Ordinary Shares Subject to Possible Redemption &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for its Class&#160;A ordinary shares subject to possible redemption in accordance with the guidance in Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 480, &#x201c;Distinguishing Liabilities from Equity.&#x201d; Class&#160;A ordinary shares subject to mandatory redemption are classified as a liability instrument and are measured at redemption value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control) are classified as temporary equity. At all other times, ordinary shares are classified as permanent deficit. The Company&#x2019;s Class&#160;A ordinary shares feature certain redemption rights that are considered to be outside of the Company&#x2019;s control and subject to occurrence of uncertain future events. Accordingly, Class&#160;A ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the permanent deficit section of the Company&#x2019;s condensed balance sheets. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying value of redeemable ordinary shares are affected by charges against additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital (to the extent available) and accumulated deficit. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At March&#160;31, 2022 and December&#160;31, 2021, the Class&#160;A ordinary shares subject to possible redemption reflected in the condensed balance sheets are reconciled in the following &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;table: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross proceeds&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;250,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;A ordinary shares issuance costs&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,479,666&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accretion of carrying value to redemption value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,487,990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; padding-bottom: 0.375pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;A ordinary shares subject to possible redemption, December&#160;31, &lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;250,008,324&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt; &lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt; &lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt; &lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt; &lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Remeasurement of carrying value to redemption value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8,324&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;A ordinary shares subject to possible redemption, March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;250,000,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt; &lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt; &lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt; &lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt; &lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Offering Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company &lt;/div&gt;&lt;/div&gt;complies with the requirements of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ASC&#160;340-10-S99-1.&#160;Offering&#160;costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; consisted of legal, accounting, underwriting fees and other costs incurred through the Initial Public Offering that were directly related to the Initial Public Offering. The Company incurred offering costs amounting to $12,479,666 as a result of the Initial Public Offering, consisting of $4,400,000 of underwriting commissions, $7,700,000 of deferred underwriting commissions, and $379,666&#160;of other offering costs. &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;As the shares sold in the IPO are redeemable, the offering costs were charged to temporary equity and additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital upon the completion of the Initial Public Offering. Immediately thereafter, temporary equity was remeasured and an adjustment was recognized through additional paid in capital and accumulated deficit to adjust temporary equity to the redemption value. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Share-Based Payment Arrangements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;accounts for stock awards in accordance with ASC 718, &#x201c;Compensation&#x2014;Stock Compensation,&#x201d; which requires that all equity awards be accounted for at their &#x201c;fair value.&#x201d; Fair value is measured on the grant date and is equal to the underlying value of the stock. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Costs equal &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;to these fair values are recognized ratably over the requisite service period based on the number of awards that are expected to vest, in the period of grant for awards that vest immediately and have no future service condition, or in the period the awards vest immediately after meeting a performance condition becomes probable (i.e., the occurrence of a Business Combination). For awards that vest over time, cumulative adjustments in later periods are recorded to the extent actual forfeitures differ from the Company&#x2019;s initial estimates; previously recognized compensation cost is reversed if the service or performance conditions are not satisfied and the award is&#160;forfeited. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for income taxes under ASC 740, &#x201c;Income Taxes&#x201d; (&#x201c;ASC 740&#x201d;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the condensed financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s condensed financial statements and prescribes a recognition threshold and measurement process for condensed financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;more-likely-than-not&lt;/div&gt; to be sustained upon examination by taxing authorities. The Company&#x2019;s management has determined that the Cayman Islands is the Company&#x2019;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of March&#160;31, 2022 and December&#160;31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has been subject to income tax examinations by major taxing authorities since inception. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is considered to be an exempted Cayman Islands company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#x2019;s tax provision was zero for the periods presented. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net Loss per Ordinary Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss per ordinary share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding during the period. The Company has two classes of ordinary shares, which are referred to as &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;A ordinary shares and Class&#160;B ordinary shares. Losses are shared pro rata between the two classes of shares. Charges associated with the redeemable Class&#160;A ordinary shares are excluded from net loss per ordinary share as the redemption value approximates fair value. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;March&#160;31, 2022 and 2021, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted net loss per ordinary share is the same as basic net loss per ordinary share for the periods presented. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;br/&gt;March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Period from&lt;br/&gt;February&#160;25, 2021&lt;br/&gt;(Inception) Through&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;A&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;B&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;A&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;B&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allocation of net loss&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,200,799&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(780,226&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,182&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted weighted average shares outstanding&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,640,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,250,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,500,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per ordinary share&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color:rgba(255, 255, 255, .0);;display:inline;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution which, at times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on these &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color:rgba(255, 255, 255, .0);;display:inline;"&gt;accounts. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#x201c;Fair Value Measurement,&#x201d; (&#x201c;ASC 820&#x201d;), approximates the carrying amounts represented in the accompanying condensed balance sheet, primarily due to their short-term nature. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recent Accounting Standards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2020, the FASB issued ASU No. 2020-06, &#x201c;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&#x201d; (&#x201c;ASU 2020-06&#x201d;), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. The Company adopted ASU 2020-06 effective as of January 1, 2021. The adoption of ASU 2020-06 did not have an impact on the Company&#x2019;s condensed financial statements. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#x2019;s condensed financial statements.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accrued Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At March&#160;31, 2022, accrued expenses includes $4,095,414 of&#160;legal expense, $283,348 of printing expense, $529,688 of due diligence expense, $363,740 of professional fee expense and $70,000 of&#160;regulatory fee expe&lt;div style="background-color:rgba(255, 255, 255, .0);;display:inline;"&gt;nse&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color:rgba(255, 255, 255, .0);;display:inline;"&gt;, of which $2,500,000 of legal expense, $247,188 of consulting expense and $534,906 of other transactional related expenses incurred in connection with the Business Combination with ProKidney.&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At December&#160;31, 2021, accrued expenses includes $1,506,528&#160;of legal expense, $5,000&#160;of printing expense, $282,500&#160;of due diligence expense, $70,000&#160;of regulatory filing fee and $770&#160;of accounting expense. &lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="background: none;;font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px; background: none; text-decoration: none;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The &lt;/div&gt;accompanying unaudited condensed financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) for interim financial information and in accordance with the instructions to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Form&#160;10-Q&lt;/div&gt; and Article&#160;8 of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Regulation&#160;S-X&lt;/div&gt; of the SEC. Certain information or footnote disclosures normally included in condensed financial statements prepared in accordance with GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements contained in the Company&#x2019;s Annual Report on Form &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;10-K&lt;/div&gt; for the period ended December&#160;31, 2021 filed with the SEC on March&#160;24, 2022. The interim results for the three months ended March&#160;31, 2022 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2022 or for any future periods. &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <prok:EmergingGrowthCompanyStatusPolicyTextBlock contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Emerging Growth Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is an &#x201c;emerging growth company,&#x201d; as defined in Section&#160;2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the &#x201c;JOBS Act&#x201d;), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Further, Section&#160;102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-emerging&lt;/div&gt; growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company&#x2019;s condensed financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. &lt;br/&gt;&lt;/div&gt;</prok:EmergingGrowthCompanyStatusPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of the condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Significant accounting estimates include the determination of the fair value of Class&#160;A ordinary shares subject to possible redemption and the fair value of Founder Shares transferred to directors. Accordingly, the actual results could differ significantly from those estimates.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; </us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of March&#160;31, 2022 and December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Marketable Securities Held in Trust Account &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At March&#160;31, 2022 and December&#160;31, 2021, substantially all of the assets held in the Trust Account were held in a money market fund which is invested primarily in U.S. Treasury securities. &lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <prok:TemporaryEquityPolicyTextBlock contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Class&#160;A Ordinary Shares Subject to Possible Redemption &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for its Class&#160;A ordinary shares subject to possible redemption in accordance with the guidance in Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 480, &#x201c;Distinguishing Liabilities from Equity.&#x201d; Class&#160;A ordinary shares subject to mandatory redemption are classified as a liability instrument and are measured at redemption value. Conditionally redeemable ordinary shares (including ordinary shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s control) are classified as temporary equity. At all other times, ordinary shares are classified as permanent deficit. The Company&#x2019;s Class&#160;A ordinary shares feature certain redemption rights that are considered to be outside of the Company&#x2019;s control and subject to occurrence of uncertain future events. Accordingly, Class&#160;A ordinary shares subject to possible redemption are presented at redemption value as temporary equity, outside of the permanent deficit section of the Company&#x2019;s condensed balance sheets. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying value of redeemable ordinary shares are affected by charges against additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital (to the extent available) and accumulated deficit. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At March&#160;31, 2022 and December&#160;31, 2021, the Class&#160;A ordinary shares subject to possible redemption reflected in the condensed balance sheets are reconciled in the following &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;table: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross proceeds&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;250,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;A ordinary shares issuance costs&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,479,666&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accretion of carrying value to redemption value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,487,990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; padding-bottom: 0.375pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;A ordinary shares subject to possible redemption, December&#160;31, &lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;250,008,324&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt; &lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt; &lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt; &lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt; &lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Remeasurement of carrying value to redemption value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8,324&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;A ordinary shares subject to possible redemption, March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;250,000,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt; &lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt; &lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt; &lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt; &lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </prok:TemporaryEquityPolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At March&#160;31, 2022 and December&#160;31, 2021, the Class&#160;A ordinary shares subject to possible redemption reflected in the condensed balance sheets are reconciled in the following &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;table: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 77%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross proceeds&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;250,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;A ordinary shares issuance costs&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(12,479,666&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accretion of carrying value to redemption value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;12,487,990&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; padding-bottom: 0.375pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;A ordinary shares subject to possible redemption, December&#160;31, &lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;250,008,324&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt; &lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt; &lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt; &lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt; &lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Plus:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Remeasurement of carrying value to redemption value&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(8,324&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;A ordinary shares subject to possible redemption, March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.375pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;$&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black;;text-align:right;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;250,000,000&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.375pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 1pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt; &lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt; &lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; border-bottom: 0.75pt solid black; line-height: 1pt; font-size: 1pt;"&gt; &lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; line-height: 1pt; font-size: 1pt; padding-bottom: 0.375pt;"&gt; &lt;div style="font-size: 1pt; line-height: 1pt;"&gt;&lt;div style="font-size: 1pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="line-height: 1pt; font-size: 1pt;;font-weight:bold;display:inline;width:100%;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt; &lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">250000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <prok:TemporaryEquityIssaunceCosts
      contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-12479666</prok:TemporaryEquityIssaunceCosts>
    <prok:RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity
      contextRef="P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">12487990</prok:RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">250008324</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <prok:RemeasurementOfCarryingValueToRedemptionValue
      contextRef="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-8324</prok:RemeasurementOfCarryingValueToRedemptionValue>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">250000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <prok:DeferredOfferingCostsPolicyTextBlock contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Offering Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company &lt;/div&gt;&lt;/div&gt;complies with the requirements of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ASC&#160;340-10-S99-1.&#160;Offering&#160;costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; consisted of legal, accounting, underwriting fees and other costs incurred through the Initial Public Offering that were directly related to the Initial Public Offering. The Company incurred offering costs amounting to $12,479,666 as a result of the Initial Public Offering, consisting of $4,400,000 of underwriting commissions, $7,700,000 of deferred underwriting commissions, and $379,666&#160;of other offering costs. &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;As the shares sold in the IPO are redeemable, the offering costs were charged to temporary equity and additional &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;paid-in&lt;/div&gt; capital upon the completion of the Initial Public Offering. Immediately thereafter, temporary equity was remeasured and an adjustment was recognized through additional paid in capital and accumulated deficit to adjust temporary equity to the redemption value. &lt;/div&gt;&lt;br/&gt;&lt;/div&gt;</prok:DeferredOfferingCostsPolicyTextBlock>
    <prok:TransactionCostsIncurredInConnectionWithInitialPublicOffering
      contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">12479666</prok:TransactionCostsIncurredInConnectionWithInitialPublicOffering>
    <prok:UnderwritingFee
      contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">4400000</prok:UnderwritingFee>
    <prok:DeferredUnderwritingFees
      contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">7700000</prok:DeferredUnderwritingFees>
    <us-gaap:DeferredOfferingCosts
      contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">379666</us-gaap:DeferredOfferingCosts>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Share-Based Payment Arrangements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;accounts for stock awards in accordance with ASC 718, &#x201c;Compensation&#x2014;Stock Compensation,&#x201d; which requires that all equity awards be accounted for at their &#x201c;fair value.&#x201d; Fair value is measured on the grant date and is equal to the underlying value of the stock. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Costs equal &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;to these fair values are recognized ratably over the requisite service period based on the number of awards that are expected to vest, in the period of grant for awards that vest immediately and have no future service condition, or in the period the awards vest immediately after meeting a performance condition becomes probable (i.e., the occurrence of a Business Combination). For awards that vest over time, cumulative adjustments in later periods are recorded to the extent actual forfeitures differ from the Company&#x2019;s initial estimates; previously recognized compensation cost is reversed if the service or performance conditions are not satisfied and the award is&#160;forfeited. &lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company accounts for income taxes under ASC 740, &#x201c;Income Taxes&#x201d; (&#x201c;ASC 740&#x201d;). ASC 740 requires the recognition of deferred tax assets and liabilities for both the expected impact of differences between the condensed financial statement and tax basis of assets and liabilities and for the expected future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be established when it is more likely than not that all or a portion of deferred tax assets will not be realized. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;ASC 740 also clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s condensed financial statements and prescribes a recognition threshold and measurement process for condensed financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;more-likely-than-not&lt;/div&gt; to be sustained upon examination by taxing authorities. The Company&#x2019;s management has determined that the Cayman Islands is the Company&#x2019;s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of March&#160;31, 2022 and December&#160;31, 2021. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company has been subject to income tax examinations by major taxing authorities since inception. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is considered to be an exempted Cayman Islands company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As such, the Company&#x2019;s tax provision was zero for the periods presented. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Net Loss per Ordinary Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss per ordinary share is computed by dividing net loss by the weighted-average number of ordinary shares outstanding during the period. The Company has two classes of ordinary shares, which are referred to as &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;A ordinary shares and Class&#160;B ordinary shares. Losses are shared pro rata between the two classes of shares. Charges associated with the redeemable Class&#160;A ordinary shares are excluded from net loss per ordinary share as the redemption value approximates fair value. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;March&#160;31, 2022 and 2021, the Company did not have any dilutive securities or other contracts that could, potentially, be exercised or converted into ordinary shares and then share in the earnings of the Company. As a result, diluted net loss per ordinary share is the same as basic net loss per ordinary share for the periods presented. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;br/&gt;March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Period from&lt;br/&gt;February&#160;25, 2021&lt;br/&gt;(Inception) Through&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;A&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;B&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;A&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;B&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allocation of net loss&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,200,799&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(780,226&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,182&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted weighted average shares outstanding&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,640,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,250,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,500,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per ordinary share&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:TemporaryEquityTableTextBlock contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table reflects the calculation of basic and diluted net loss per ordinary share (in dollars, except per share amounts): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 61%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended&lt;br/&gt;March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For the Period from&lt;br/&gt;February&#160;25, 2021&lt;br/&gt;(Inception) Through&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;A&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;B&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;A&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Class&#160;B&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per ordinary share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Allocation of net loss&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(3,200,799&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(780,226&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(5,182&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted weighted average shares outstanding&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;25,640,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6,250,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;5,500,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt; &lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic and diluted net loss per ordinary share&lt;/div&gt;&lt;/div&gt; &lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.12&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.00&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; </us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-3200799</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-780226</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P02_25_2021To03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P02_25_2021To03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">-5182</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">25640000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">25640000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">6250000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">6250000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P02_25_2021To03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P02_25_2021To03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P02_25_2021To03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">5500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P02_25_2021To03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">5500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P02_25_2021To03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P02_25_2021To03_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD_per_Share">0</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P02_25_2021To03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P02_25_2021To03_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">0</us-gaap:EarningsPerShareBasic>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color:rgba(255, 255, 255, .0);;display:inline;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution which, at times may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. The Company has not experienced losses on these &lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color:rgba(255, 255, 255, .0);;display:inline;"&gt;accounts. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Company&#x2019;s assets and liabilities, which qualify as financial instruments under ASC Topic 820, &#x201c;Fair Value Measurement,&#x201d; (&#x201c;ASC 820&#x201d;), approximates the carrying amounts represented in the accompanying condensed balance sheet, primarily due to their short-term nature. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recent Accounting Standards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In August 2020, the FASB issued ASU No. 2020-06, &#x201c;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&#x201d; (&#x201c;ASU 2020-06&#x201d;), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. The Company adopted ASU 2020-06 effective as of January 1, 2021. The adoption of ASU 2020-06 did not have an impact on the Company&#x2019;s condensed financial statements. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company&#x2019;s condensed financial statements.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <prok:AccruedExpensesPolicyTextBlock contextRef="P01_01_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Accrued Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At March&#160;31, 2022, accrued expenses includes $4,095,414 of&#160;legal expense, $283,348 of printing expense, $529,688 of due diligence expense, $363,740 of professional fee expense and $70,000 of&#160;regulatory fee expe&lt;div style="background-color:rgba(255, 255, 255, .0);;display:inline;"&gt;nse&lt;/div&gt;&lt;/div&gt;&lt;div style="background-color:rgba(255, 255, 255, .0);;display:inline;"&gt;, of which $2,500,000 of legal expense, $247,188 of consulting expense and $534,906 of other transactional related expenses incurred in connection with the Business Combination with ProKidney.&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;At December&#160;31, 2021, accrued expenses includes $1,506,528&#160;of legal expense, $5,000&#160;of printing expense, $282,500&#160;of due diligence expense, $70,000&#160;of regulatory filing fee and $770&#160;of accounting expense. &lt;/div&gt;&lt;/div&gt;</prok:AccruedExpensesPolicyTextBlock>
    <prok:AccruedLegalExpense
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">4095414</prok:AccruedLegalExpense>
    <prok:AccruedPrintingExpense
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">283348</prok:AccruedPrintingExpense>
    <prok:AccruedDueDiligenceExpense
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">529688</prok:AccruedDueDiligenceExpense>
    <prok:AccruedRegulatoryFilingFee
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">363740</prok:AccruedRegulatoryFilingFee>
    <prok:AccruedAccountingExpense
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">70000</prok:AccruedAccountingExpense>
    <prok:BusinessCombinationAccruedLegalExpense
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">2500000</prok:BusinessCombinationAccruedLegalExpense>
    <prok:BusinessCombinationAccruedConsultingExpense
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">247188</prok:BusinessCombinationAccruedConsultingExpense>
    <prok:BusinessCombinationAccruedOtherTransactionalRelatedExpenses
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">534906</prok:BusinessCombinationAccruedOtherTransactionalRelatedExpenses>
    <prok:AccruedLegalExpense
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">1506528</prok:AccruedLegalExpense>
    <prok:AccruedPrintingExpense
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">5000</prok:AccruedPrintingExpense>
    <prok:AccruedDueDiligenceExpense
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">282500</prok:AccruedDueDiligenceExpense>
    <prok:AccruedRegulatoryFilingFee
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">70000</prok:AccruedRegulatoryFilingFee>
    <prok:AccruedAccountingExpense
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">770</prok:AccruedAccountingExpense>
    <prok:InitialPublicOfferingDisclosureTextBlock contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 3. INITIAL PUBLIC OFFERING &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to the Initial Public Offering, the Company sold 25,000,000 Public Shares, which includes a partial exercise by the underwriters of their over-allotment option in the amount of 3,000,000 Public Shares, at a price of $10.00 per Public Share. Unlike some other initial public offerings of special purpose acquisition companies, investors in the Initial Public Offering did not receive any warrants (which would typically become exercisable following completion of the Business Combination). The fair value attributable to the unexercised portion of the over-allotment option was deemed to be immaterial to the condensed financial statements. &lt;/div&gt;&lt;/div&gt;</prok:InitialPublicOfferingDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">25000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_OverAllotmentOptionMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">3000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_IPOMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</us-gaap:SaleOfStockPricePerShare>
    <prok:PrivatePlacementDisclosureTextBlock contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 4. PRIVATE PLACEMENT &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Substantially concurrently with the closing of the Initial Public Offering, the Sponsor purchased 640,000 Private Placement Shares at a price of $10.00 per Private Placement Share, for an aggregate purchase price of&#160;$6,400,000. Each Private Placement Share is identical to the Class&#160;A ordinary shares sold in the Initial Public Offering, subject to certain limited exceptions as described in Note 7. A portion of the proceeds from the sale of the Private Placement Shares was added to the net proceeds from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination within the Combination Period or during any applicable extension period, the proceeds from the sale of the Private Placement Shares held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Shares will be worthless. &lt;/div&gt;&lt;/div&gt;</prok:PrivatePlacementDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="INF"
      unitRef="Unit_shares">640000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">10</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P07_02_2021To07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="0"
      unitRef="Unit_USD">6400000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 5. RELATED PARTY TRANSACTIONS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Founder Shares &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On March&#160;2, 2021, the Sponsor paid $25,000 to cover certain offering and formation costs of the Company in consideration for which the Sponsor received 5,750,000 Class&#160;B ordinary shares (the &#x201c;Founder Shares&#x201d;). On June&#160;29, 2021, the Company effected a share capitalization with respect to its Class&#160;B ordinary shares of 575,000 shares thereof, resulting in the Company&#x2019;s initial shareholders holding an aggregate of 6,325,000 Founder Shares. All share and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;per-share&lt;/div&gt; amounts have been retroactively restated to reflect the share capitalization. The Founder Shares included an aggregate of up to&#160;825,000 shares that were subject to forfeiture depending on the extent to which the underwriters&#x2019; over-allotment option was exercised. As a result of the underwriters&#x2019; election to partially exercise their over-allotment option, a total of 750,000 Founder Shares are no longer subject to forfeiture and 75,000 Founder Shares were forfeited, resulting in an aggregate of&#160;6,250,000 Founder Shares outstanding. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In June 2021, the Sponsor transferred 30,000 Founder Shares to Marc Semigran, an independent director of the Company. The sale of the Founders Shares to the Company&#x2019;s director is in the scope of FASB ASC Topic 718, &#x201c;Compensation-Stock Compensation&#x201d; (&#x201c;ASC 718&#x201d;).&#160;Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date. The fair value of the 30,000 shares granted to the Company&#x2019;s director was $214,160 or approximately $7.14 per share. The Founders Shares were effectively sold subject to a performance condition (i.e., the occurrence of a Business Combination). &lt;/div&gt;&lt;br/&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compensation expense related to the Founders Shares is recognized only when the performance condition is probable of occurrence under the applicable accounting literature in this circumstance. As of March&#160;31, 2022, the Company determined that a Business Combination is not considered probable, and, therefore, no stock-based compensation expense has been recognized. Stock-based compensation would be recognized at the date a Business Combination is considered probable (i.e., upon consummation of a Business Combination) in an amount equal to the number of Founders Shares times the grant date fair value per share (unless subsequently modified) less the amount initially received for the purchase of the Founders Shares. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;The Sponsor and the Company&#x2019;s&#160;directors and officers have agreed, subject to limited exceptions, not to transfer, assign or sell any of their Founder Shares until the earlier of: (A)&#160;one year after the completion of a Business Combination and (B)&#160;subsequent to a Business Combination, (x)&#160;if the last reported sale price of the Class&#160;A ordinary shares equals or exceeds $12.00 per share (as adjusted for share &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-divisions,&lt;/div&gt; share dividends, rights issuances, consolidations, reorganizations, recapitalizations and other similar transactions) for any 20 trading days within any &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;30-trading&lt;/div&gt; day period commencing at least 150 days after a Business Combination, or (y)&#160;the date on which the Company completes a liquidation, merger, amalgamation, share exchange, reorganization or other similar transaction that results in all of the Public Shareholders having the right to exchange their Class&#160;A ordinary shares for cash, securities or other property. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Administrative Services Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company entered into an agreement in which it will pay an affiliate of the Sponsor $10,000 per month, commencing on June&#160;30, 2021, for office space, administrative and support services. Upon completion of a Business Combination or its liquidation, the Company will cease paying these monthly fees. For the three months ended March&#160;31, 2022, the Company incurred&#160;$30,000 in fees for these services, of which is included in due to related party in the accompanying condensed balance sheet. For the period from February&#160;25, 2021 (inception) through March&#160;31, 2021, the Company did not incur any fees for these services. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Due to&#160;Related Party &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March&#160;31, 2022, an affiliate of the Sponsor had advanced the Company $33,623 for working capital purposes, of which $0 was repaid during the three months ended March&#160;31, 2022. As of March&#160;31, 2022, and December&#160;31, 2021, the outstanding balance under the advances amounted to $43,623 and $10,000 respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Promissory Note&#x2014;Related Party &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On March&#160;2, 2021, the Company issued an unsecured promissory note to the Sponsor (the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;Pre-IPO&lt;/div&gt; Sponsor Promissory Note&#x201d;), pursuant to which the Company could borrow up to an aggregate principal amount of $300,000. The &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-IPO&lt;/div&gt; Sponsor Promissory Note was &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; bearing and payable on the earlier of December&#160;31, 2021 and the completion of the Initial Public Offering. The outstanding balance under the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-IPO&lt;/div&gt; Sponsor Promissory Note of $300,000 was repaid at the closing of the Initial Public Offering on July&#160;2, 2021. Borrowings are no longer available under the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pre-IPO&lt;/div&gt; Sponsor Promissory Note. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Related Party Loans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In order to fund working capital deficiencies or finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor or certain of the Company&#x2019;s officers and directors may, but are not obligated to (other than pursuant to the Promissory Note (see Note 9)), loan the Company additional funds as may be required (&#x201c;Working Capital Loans&#x201d;). If the Company completes a Business Combination, it may repay such loaned amounts out of the proceeds of the Trust Account. In the event that the Business Combination does not close, the Company may use a portion of the working capital held outside the Trust Account to repay such loaned amounts but no proceeds from the Trust Account would be used to repay such loaned amounts. As of March&#160;31, 2022 and December&#160;31, 2021, there were no outstanding amounts under the Working Capital Loans.&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Subscription Agreements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Concurrently with the execution of the ProKidney Business Combination Agreement, the Company entered into Subscription Agreements with the Sponsor Related PIPE Investors, pursuant to which the Sponsor Related PIPE Investors have subscribed for Class&#160;A ordinary shares. The Sponsor Related PIPE Investors are expected to fund $156,400,000 of the PIPE Investment, for which they will receive 15,640,000 Class&#160;A ordinary shares. Specifically, (i)&#160;SC Master Holdings, LLC, an entity affiliated with Mr.&#160;Palihapitiya, subscribed for 12,500,000 Class&#160;A ordinary shares and (ii)&#160;Averill Master Fund, Ltd., an entity affiliated with Mr.&#160;Mehta, subscribed for 3,140,000 Class&#160;A ordinary shares. The PIPE Investment will be consummated substantially concurrently with the Closing. &lt;/div&gt;&lt;/div&gt; </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="P03_02_2021To03_02_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">25000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="P03_02_2021To03_02_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">5750000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P06_29_2021To06_29_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">575000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn06_29_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">6325000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="PAsOn06_30_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">825000</us-gaap:CommonStockOtherSharesOutstanding>
    <prok:SharesNoLongerSubjectToForfeiture
      contextRef="PAsOn06_30_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_shares">750000</prok:SharesNoLongerSubjectToForfeiture>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="P07_01_2021To09_30_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">75000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn06_30_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">6250000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P06_01_2021To06_30_2021_FounderSharesMemberusgaapStatementEquityComponentsAxis_IndependentDirectorsMembersrtTitleOfIndividualAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="INF"
      unitRef="Unit_shares">30000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P06_01_2021To06_30_2021_DirectorMembersrtTitleOfIndividualAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <prok:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue
      contextRef="P06_01_2021To06_30_2021_DirectorMembersrtTitleOfIndividualAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">214160</prok:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue>
    <us-gaap:SharePrice
      contextRef="PAsOn03_31_2022_DirectorMembersrtTitleOfIndividualAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">7.14</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="PAsOn03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RestrictionOnTransferOfSponsorSharesMemberPROKBasisAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">12</us-gaap:SharePrice>
    <prok:NumberOfTradingDaysForDeterminingTheSharePrice contextRef="P01_01_2022To03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RestrictionOnTransferOfSponsorSharesMemberPROKBasisAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">P20D</prok:NumberOfTradingDaysForDeterminingTheSharePrice>
    <prok:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice contextRef="P01_01_2022To03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RestrictionOnTransferOfSponsorSharesMemberPROKBasisAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">P30D</prok:NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice>
    <prok:WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered contextRef="P01_01_2022To03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_FounderMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_RestrictionOnTransferOfSponsorSharesMemberPROKBasisAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">P150D</prok:WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="P06_30_2021To06_30_2021_AdministrationAndSupportServicesMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_USD">10000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty
      contextRef="P01_01_2022To03_31_2022_AdministrationAndSupportServicesMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_USD">30000</us-gaap:RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="PAsOn03_31_2022_AdvanceFromRelatedPartyLoanMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_USD">33623</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <prok:RepaymentOfAdvancesFromRelatedParty
      contextRef="P01_01_2022To03_31_2022_AdvanceFromRelatedPartyLoanMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_USD">0</prok:RepaymentOfAdvancesFromRelatedParty>
    <prok:AdvancesPayableToRelatedPartyCurrent
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">43623</prok:AdvancesPayableToRelatedPartyCurrent>
    <prok:AdvancesPayableToRelatedPartyCurrent
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">10000</prok:AdvancesPayableToRelatedPartyCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn03_02_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_USD">300000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="P07_02_2021To07_02_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis"
      decimals="0"
      unitRef="Unit_USD">300000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WorkingCapitalLoansMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_WorkingCapitalLoansMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_PipeInvestorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SubscriptionAgreementsMemberPROKAgreementAxis"
      decimals="0"
      unitRef="Unit_USD">156400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_PipeInvestorsMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SubscriptionAgreementsMemberPROKAgreementAxis"
      decimals="0"
      unitRef="Unit_shares">15640000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_ScMasterHoldingsLlcMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SubscriptionAgreementsMemberPROKAgreementAxis"
      decimals="0"
      unitRef="Unit_shares">12500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P01_01_2022To03_31_2022_AverillMasterFundLtdMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SubscriptionAgreementsMemberPROKAgreementAxis"
      decimals="0"
      unitRef="Unit_shares">3140000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 6. COMMITMENTS&#160;AND CONTINGENCIES &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Registration Rights &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Pursuant to a registration rights agreement entered into on June&#160;29, 2021, the holders of the Founder Shares, Private Placement Shares and any Private Placement Shares that may be issued on conversion of Working Capital Loans (and any Class&#160;A ordinary shares issuable upon the conversion of the Founder Shares) are entitled to registration rights requiring the Company to register such securities for resale (in the case of the Founder Shares, only after conversion to the Class&#160;A ordinary shares). The holders of these securities will be entitled to make up to three demands, excluding short form registration demands, that the Company register such securities. In addition, the holders have certain &#x201c;piggy-back&#x201d; registration rights with respect to registration statements filed subsequent to the completion of a Business Combination and rights to require the Company to register for resale such securities pursuant to Rule 415 under the Securities Act. The Company will bear the expenses incurred in connection with the filing of any such registration statements. At the closing of the ProKidney Business Combination, the Company will enter into the Registration Rights Agreement, with the Sponsor, the Company&#x2019;s directors and the Closing ProKidney unitholders, which will replace the existing registration rights agreement. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Certain purported shareholders of the Company sent demand letters (the &#x201c;Demands&#x201d;) alleging deficiencies and/or omissions in the ProKidney Disclosure Statement filed by the Company with the SEC on February 14, 2022. The Demands seek additional disclosures to remedy these purported deficiencies. We believe that the allegations in the Demands are meritless. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Underwriting Agreement &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The underwriters are entitled to a deferred underwriting commission of $7,700,000 in the aggregate. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Restricted Stock Unit Award &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In September 2021, pursuant to a Director Restricted Stock Unit Award Agreement, dated September&#160;24, 2021, between the Company and Uma Sinha, Ph.D., the Company agreed to &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;grant&#160;30,000&#160;restricted stock units (&#x201c;RSUs&#x201d;) to Dr.&#160;Sinha, which grant is contingent on both the consummation of a Business Combination and a shareholder approved equity plan. The RSUs will vest upon the consummation of such Business Combination and represent&#160;30,000&#160;Class&#160;A ordinary shares of the Company that will settle on a date determined in the sole discretion of the Company that shall occur between the vesting date and March&#160;15 of the year following the year in which vesting occurs.&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The RSUs granted by the Company are in the scope of ASC 718. Under ASC 718, stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date. The RSUs granted are subject to a performance condition (i.e., the occurrence of a Business Combination). Compensation expense related to the RSUs is recognized only when the performance condition is probable of occurrence under&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;the&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size: 10pt; letter-spacing: 0px; text-align: center; top: 0px;;display:inline;"&gt;applicable accounting literature in this circumstance. As of March&#160;31, 2022, the Company did not have a shareholder approved equity plan and also determined that a Business Combination is not considered probable, and, therefore, no stock-based compensation expense has been recognized. Stock-based compensation would be recognized at the date a Business Combination is considered probable (i.e., upon consummation of a Business Combination) in an amount equal to the number of RSUs times the grant date fair value per share (unless subsequently modified).&lt;/div&gt;&lt;/div&gt; </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <prok:DeferredUnderwritingFees
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">7700000</prok:DeferredUnderwritingFees>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2022To03_31_2022_DirectorRestrictedStockUnitAwardAgreementMemberPROKAgreementAxis_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">30000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <prok:NumberOfSharesOfCommonStockCommittedToSettleOnADateFollowingTheYearBusinessCombinationOccurs
      contextRef="P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_DirectorRestrictedStockUnitAwardAgreementMemberPROKAgreementAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">30000</prok:NumberOfSharesOfCommonStockCommittedToSettleOnADateFollowingTheYearBusinessCombinationOccurs>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 7. TEMPORARY EQUITY AND PERMANENT DEFICIT &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Preference Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#x2014;The Company is authorized to issue 5,000,000 preference shares, with a par value of $0.0001 per share. The Company&#x2019;s board of directors will be authorized to fix the voting rights, if any, designations, powers, preferences, the relative, participating, optional or other special rights and any qualifications, limitations and restrictions thereof, applicable to the shares of each series. The Company&#x2019;s board of directors will be able to, without shareholder approval, issue preference shares with voting and other rights that could adversely affect the voting power and other rights of the holders of the Company&#x2019;s ordinary shares and could have anti-takeover effects. At March&#160;31, 2022 and December&#160;31, 2021, there were no preference shares issued or outstanding. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Class&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;A Ordinary Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#x2014;The Company is authorized to issue 500,000,000 Class&#160;A ordinary shares, with a par value of $0.0001 per share. At March&#160;31, 2022 and December&#160;31, 2021, there were 640,000 Class&#160;A ordinary shares issued and outstanding, excluding 25,000,000 Class&#160;A ordinary shares subject to possible redemption which are presented as temporary equity. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Class&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;B Ordinary Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#x2014;The Company is authorized to issue 50,000,000 Class&#160;B ordinary shares, with a par value of $0.0001 per share. At March&#160;31, 2022 and December&#160;31, 2021, there were 6,250,000 Class&#160;B ordinary shares issued and outstanding. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Holders of record of Class&#160;A ordinary shares and Class&#160;B ordinary shares are entitled to one vote for each share held on all matters to be voted on by shareholders and vote together as a single class, except as required by law; provided that prior to a Business Combination, holders of Class&#160;B ordinary shares will have the right to appoint all of the Company&#x2019;s directors and remove members of its board of directors for any reason, and holders of Class&#160;A ordinary shares will not be entitled to vote on the appointment of directors during such time. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Class&#160;B ordinary shares will automatically convert into Class&#160;A ordinary shares at the time of the Business Combination, or earlier at the option of the holder, on a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-for-one&lt;/div&gt;&lt;/div&gt; basis, subject to adjustment for share &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;sub-divisions,&lt;/div&gt; share dividends, rights issuances, consolidations, reorganizations, recapitalizations and the like. Additionally, in the event that additional (in excess of the amounts issued in the Initial Public Offering) Class&#160;A ordinary shares, or equity-linked securities, are issued or deemed issued in connection with the closing of the Business Combination, the ratio at which the Class&#160;B ordinary shares will convert into Class&#160;A ordinary shares will be adjusted (unless the holders of a majority of the issued and outstanding Class&#160;B ordinary shares agree to waive such anti-dilution adjustment with respect to any such issuance or deemed issuance) so that the number of Class&#160;A ordinary shares issuable upon conversion of all Class&#160;B ordinary shares will equal, in the aggregate, 20% of the sum of the total number of Class&#160;A ordinary shares outstanding after such conversion (after giving effect to any redemptions of Class&#160;A ordinary shares by Public Shareholders, and excluding the Private Placement Shares), including any Class&#160;A ordinary shares issued or deemed issued, or issuable upon the conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with the Business Combination, excluding any Class&#160;A ordinary shares or equity-linked securities exercisable for or convertible into Class&#160;A ordinary shares issued, or to be issued, to any seller in the Business Combination and any private placement shares issued to the Sponsor or its affiliates upon conversion of Working Capital Loans; provided that such conversion of Class&#160;B ordinary shares will never occur on a less than &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;one-for-one-basis.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Private &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Placement Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&#x2014;The Private Placement Shares are not transferable, assignable, or salable until 30 days after the completion of a Business Combination (except, among other limited exceptions, to the Company&#x2019;s directors and officers and other persons or entities affiliated with the Sponsor). Holders of the Private Placement Shares are entitled to certain registration rights. If the Company does not complete a Business Combination within the Combination Period or during any applicable extension period, the proceeds from the sale of the Private Placement Shares held in the Trust Account will be used to fund the redemption of the Public Shares (subject to the requirements of applicable law) and the Private Placement Shares will be worthless. &lt;/div&gt; </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">640000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">640000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">640000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">640000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockOtherSharesOutstanding
      contextRef="PAsOn03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">25000000</us-gaap:CommonStockOtherSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">50000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">6250000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">6250000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">6250000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2021_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="INF"
      unitRef="Unit_shares">6250000</us-gaap:CommonStockSharesOutstanding>
    <prok:PercentOfFoundersSharesToCompanysIssuedAndOutstandingOrdinaryShares
      contextRef="PAsOn03_31_2022_CommonClassBMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="2"
      unitRef="Unit_pure">0.20</prok:PercentOfFoundersSharesToCompanysIssuedAndOutstandingOrdinaryShares>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 8. FAIR VALUE MEASUREMENTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company follows the guidance in ASC Topic 820 for its financial assets and liabilities that are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-measured&lt;/div&gt; and reported at fair value at each reporting period, and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-financial&lt;/div&gt; assets and liabilities that are &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;re-measured&lt;/div&gt; and reported at fair value at least annually. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The fair value of the Company&#x2019;s financial assets and liabilities reflects management&#x2019;s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and &lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;liabilities: &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 8%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td style="width: 89%;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height: 6pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;2:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Observable inputs other than Level&#160;1 inputs. Examples of Level&#160;2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height: 6pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top; font-size: 10pt;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;3:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unobservable inputs based on the Company&#x2019;s assessment of the assumptions that market participants would use in pricing the asset or liability.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;The&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;following table presents information about the Company&#x2019;s assets that are measured at fair value on a recurring basis at March&#160;31, 2022 and December&#160;31, 2021, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: &lt;/div&gt;&lt;br/&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 8%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Description&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Marketable securities held in Trust Account&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;250,033,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;250,008,324&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  </us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 68%;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 3%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Description&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Level&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&#160;2021&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Marketable securities held in Trust Account&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;250,033,500&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;250,008,324&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <prok:MarketableSecuritiesHeldToMaturityFairValueDisclosure
      contextRef="PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">250033500</prok:MarketableSecuritiesHeldToMaturityFairValueDisclosure>
    <prok:MarketableSecuritiesHeldToMaturityFairValueDisclosure
      contextRef="PAsOn12_31_2021_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis"
      decimals="0"
      unitRef="Unit_USD">250008324</prok:MarketableSecuritiesHeldToMaturityFairValueDisclosure>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt; text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;NOTE 9. SUBSEQUENT EVENTS &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed financial statements were issued. Based upon this review, other than as described below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the condensed financial statements. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On April&#160;20, 2022, the Company issued an unsecured promissory &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;note &lt;/div&gt;(the &#x201c;Promissory Note&#x201d;) to the Sponsor pursuant to which the Company may borrow up to an aggregate principal amount of $1,500,000.&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;br/&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Promissory Note is &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-interest&lt;/div&gt; bearing, unsecured and payable upon the earlier of July&#160;2, 2023 and the effective date of the Company&#x2019;s Business Combination. The Promissory Note is subject to customary events of default which could, subject to certain conditions, cause the Promissory Notes to become immediately due and payable. On April&#160;26, 2022, the Company drew $250,000 under the Promissory Note. &lt;/div&gt;&lt;/div&gt; </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn04_20_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_USD">1500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P04_26_2022To04_26_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis_SponsorMemberusgaapRelatedPartyTransactionsByRelatedPartyAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_USD">250000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">20558000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4578000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">588000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">202000</us-gaap:PrepaidExpenseCurrent>
    <prok:PrepaidClinicalCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">6100000</prok:PrepaidClinicalCurrent>
    <prok:PrepaidClinicalCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">753000</prok:PrepaidClinicalCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">25000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">52000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">27271000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">5585000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">11358000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">8914000</us-gaap:PropertyPlantAndEquipmentNet>
    <prok:RightOfUseAssetsOperatingAndFinanceLease
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1241000</prok:RightOfUseAssetsOperatingAndFinanceLease>
    <prok:RightOfUseAssetsOperatingAndFinanceLease
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1559000</prok:RightOfUseAssetsOperatingAndFinanceLease>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">428000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">642000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">40298000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">16700000</us-gaap:Assets>
    <prok:CurrentAccountsPayable
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2834000</prok:CurrentAccountsPayable>
    <prok:CurrentAccountsPayable
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">781000</prok:CurrentAccountsPayable>
    <prok:OperatingAndFinanceLeaseLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">267000</prok:OperatingAndFinanceLeaseLiabilitiesCurrent>
    <prok:OperatingAndFinanceLeaseLiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">225000</prok:OperatingAndFinanceLeaseLiabilitiesCurrent>
    <prok:AccruedExpensesAndOther
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">9213000</prok:AccruedExpensesAndOther>
    <prok:AccruedExpensesAndOther
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4496000</prok:AccruedExpensesAndOther>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">12314000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">5502000</us-gaap:LiabilitiesCurrent>
    <prok:OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1067000</prok:OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion>
    <prok:OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1334000</prok:OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2021"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2020"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:LimitedPartnersCapitalAccountUnitsIssued
      contextRef="PAsOn12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="INF"
      unitRef="Unit_shares">186500000</us-gaap:LimitedPartnersCapitalAccountUnitsIssued>
    <us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding
      contextRef="PAsOn12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="INF"
      unitRef="Unit_shares">186500000</us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding>
    <us-gaap:LimitedPartnersCapitalAccountUnitsIssued
      contextRef="PAsOn12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="INF"
      unitRef="Unit_shares">115000000</us-gaap:LimitedPartnersCapitalAccountUnitsIssued>
    <us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding
      contextRef="PAsOn12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="INF"
      unitRef="Unit_shares">115000000</us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding>
    <us-gaap:LimitedPartnersContributedCapital
      contextRef="PAsOn12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="-3"
      unitRef="Unit_USD">186500000</us-gaap:LimitedPartnersContributedCapital>
    <us-gaap:LimitedPartnersContributedCapital
      contextRef="PAsOn12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="-3"
      unitRef="Unit_USD">115000000</us-gaap:LimitedPartnersContributedCapital>
    <us-gaap:LimitedPartnersCapitalAccountUnitsIssued
      contextRef="PAsOn12_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis"
      decimals="INF"
      unitRef="Unit_shares">7767122</us-gaap:LimitedPartnersCapitalAccountUnitsIssued>
    <us-gaap:LimitedPartnersCapitalAccountUnitsIssued
      contextRef="PAsOn12_31_2020_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis"
      decimals="INF"
      unitRef="Unit_shares">7767122</us-gaap:LimitedPartnersCapitalAccountUnitsIssued>
    <us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding
      contextRef="PAsOn12_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis"
      decimals="INF"
      unitRef="Unit_shares">7767122</us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding>
    <us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding
      contextRef="PAsOn12_31_2020_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis"
      decimals="INF"
      unitRef="Unit_shares">7767122</us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding>
    <us-gaap:LimitedPartnersContributedCapital
      contextRef="PAsOn12_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis"
      decimals="-3"
      unitRef="Unit_USD">1927000</us-gaap:LimitedPartnersContributedCapital>
    <us-gaap:LimitedPartnersContributedCapital
      contextRef="PAsOn12_31_2020_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis"
      decimals="-3"
      unitRef="Unit_USD">1228000</us-gaap:LimitedPartnersContributedCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-161510000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-106364000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:PartnersCapital
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">26917000</us-gaap:PartnersCapital>
    <us-gaap:PartnersCapital
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">9864000</us-gaap:PartnersCapital>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">40298000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">16700000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">46255000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">21042000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8855000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">5982000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">55110000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">27024000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-55110000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-27024000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">43000</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-55108000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-26981000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">38000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-232000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-55146000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-26749000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2021To12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="0"
      unitRef="Unit_shares">150706849</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2021To12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="0"
      unitRef="Unit_shares">150706849</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2020To12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="0"
      unitRef="Unit_shares">104986301</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2020To12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="0"
      unitRef="Unit_shares">104986301</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2021To12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2021To12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2020To12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2020To12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.25</us-gaap:EarningsPerShareDiluted>
    <prok:PartnersCapitalOutstanding
      contextRef="PAsOn12_31_2019_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">95000000</prok:PartnersCapitalOutstanding>
    <us-gaap:PartnersCapital
      contextRef="PAsOn12_31_2019_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">95000000</us-gaap:PartnersCapital>
    <us-gaap:PartnersCapital
      contextRef="PAsOn12_31_2019_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">498000</us-gaap:PartnersCapital>
    <us-gaap:PartnersCapital
      contextRef="PAsOn12_31_2019_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-79615000</us-gaap:PartnersCapital>
    <us-gaap:PartnersCapital
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">15883000</us-gaap:PartnersCapital>
    <us-gaap:PartnersCapitalAccountUnitsContributed
      contextRef="P01_01_2020To12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">20000000</us-gaap:PartnersCapitalAccountUnitsContributed>
    <us-gaap:PartnersCapitalAccountContributions
      contextRef="P01_01_2020To12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">20000000</us-gaap:PartnersCapitalAccountContributions>
    <us-gaap:PartnersCapitalAccountContributions
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">20000000</us-gaap:PartnersCapitalAccountContributions>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="P01_01_2020To12_31_2020_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">730000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">730000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-26749000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-26749000</us-gaap:NetIncomeLoss>
    <prok:PartnersCapitalOutstanding
      contextRef="PAsOn12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">115000000</prok:PartnersCapitalOutstanding>
    <us-gaap:PartnersCapital
      contextRef="PAsOn12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">115000000</us-gaap:PartnersCapital>
    <us-gaap:PartnersCapital
      contextRef="PAsOn12_31_2020_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1228000</us-gaap:PartnersCapital>
    <us-gaap:PartnersCapital
      contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-106364000</us-gaap:PartnersCapital>
    <us-gaap:PartnersCapital
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">9864000</us-gaap:PartnersCapital>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2021To12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_shares">71500000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2021To12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">71500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">71500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="P01_01_2021To12_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">699000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">699000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-55146000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-55146000</us-gaap:NetIncomeLoss>
    <prok:PartnersCapitalOutstanding
      contextRef="PAsOn12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">186500000</prok:PartnersCapitalOutstanding>
    <us-gaap:PartnersCapital
      contextRef="PAsOn12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">186500000</us-gaap:PartnersCapital>
    <us-gaap:PartnersCapital
      contextRef="PAsOn12_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1927000</us-gaap:PartnersCapital>
    <us-gaap:PartnersCapital
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-161510000</us-gaap:PartnersCapital>
    <us-gaap:PartnersCapital
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">26917000</us-gaap:PartnersCapital>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-55146000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-26749000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1984000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">964000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">699000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">730000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5704000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">809000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">7868000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">683000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-50299000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-25181000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">5192000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">5456000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-5191000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-5456000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">30000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">11000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">71500000</us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits>
    <us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">20000000</us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">71470000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">19989000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">15980000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-10648000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <prok:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4578000</prok:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents>
    <prok:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">15226000</prok:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents>
    <prok:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">20558000</prok:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents>
    <prok:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4578000</prok:CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1295000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1840000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:NatureOfOperations contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 1: The Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;ProKidney LLC was formed as a Bermuda limited liability company on December 12, 2018 and funded with $75,000,000 on December&#160;31, 2018. On January&#160;9, 2019 (the &#x201c;Acquisition Date&#x201d;), ProKidney LLC acquired all of the equity interests in inRegen and Twin City Bio LLC (&#x201c;TC Bio&#x201d;) for $62,000,000. inRegen was duly incorporated under the Cayman Islands Companies Act (as amended) on December&#160;21, 2015 as an exempted company. During 2020, inRegen&#x2019;s name was changed to ProKidney (and is referred to herein as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;ProKidney-KY&#x201d;),&lt;/div&gt; and TC Bio&#x2019;s name was changed to ProKidney, LLC (and is referred to herein as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;ProKidney-US&#x201d;).&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-US&lt;/div&gt; was formed as a limited liability company under the laws of Delaware on December&#160;18, 2015. In August 2021, ProKidney LP was organized as a limited partnership under the laws and regulations of Ireland, with ProKidney LLC becoming a wholly owned subsidiary of ProKidney LP (and is referred to herein as &#x201c;ProKidney&#x201d;). Following this reorganization on August&#160;5, 2021 and for the purposes of these financial statements, the term &#x201c;ProKidney,&#x201d; as used herein, refers to ProKidney LP following this reorganization, and the financial information presented herein is that of ProKidney LP and its wholly owned subsidiaries. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;ProKidney acquired the equity interests in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-KY&lt;/div&gt; to develop its Renal Advanced Cell Therapy, which has the potential to stabilize or improve renal function in patients with chronic kidney disease or delay or eliminate the need for dialysis and organ transplantation. ProKidney acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-US&lt;/div&gt; to provide contractual development and manufacturing services to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-KY,&lt;/div&gt; which is &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-US&#x2019;s&lt;/div&gt; only customer. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Because ProKidney is a limited partnership, the debts, obligations and liabilities of the Company (as defined below), whether arising in contract, tort or otherwise, are solely the debts, obligations and liabilities of the Company, and no holder of equity interests in ProKidney (&#x201c;members&#x2019; equity&#x201d;) is obligated personally for any such debt, obligation or liability of the Company solely by reason of being a holder of members&#x2019; equity. &lt;/div&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
    <dei:EntityIncorporationDateOfIncorporation contextRef="P12_12_2018To12_31_2018">2018-12-12</dei:EntityIncorporationDateOfIncorporation>
    <prok:InitialCapital
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">75000000000</prok:InitialCapital>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="P01_09_2019To01_09_2019_RegenAndTwinCityBioLlcMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">62000000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 2: Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The consolidated financial statements reflect the operations of ProKidney and its wholly-owned subsidiaries consisting of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-KY&lt;/div&gt; and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-US&lt;/div&gt; (together, the &#x201c;Company&#x201d;). All intercompany transactions and accounts have been eliminated. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). These consolidated financial statements are presented in U.S. Dollars. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Going Concern &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company performed an analysis of its ability to continue as a going concern. As of December&#160;31, 2021, the Company had an accumulated deficit of $161,510,000. The Company has generated losses from operations for each year since its inception including losses from operations of $55,146,000 and $26,749,000 for the years ended December&#160;31, 2021 and 2020, respectively. The Company intends to continue to conduct significant &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;additional research, development, and clinical study activities which, together with expenses incurred for general and administrative expenses, are expected to result in continuing operating losses for the foreseeable future. The amount of future losses and when, if ever, the Company will achieve profitability are uncertain. The Company&#x2019;s ability to achieve profitability will depend, among other things, on successfully completing clinical studies, obtaining requisite regulatory approvals, establishing appropriate pricing for its product with payers, and raising sufficient funds to finance the Company&#x2019;s activities. No assurance can be given that the Company&#x2019;s clinical development efforts will be successful, that regulatory approvals will be obtained, or that the Company will be able to achieve appropriate pricing and market access or that profitability, if achieved, can be sustained. These matters raise substantial doubt about the Company&#x2019;s ability to continue as a going concern. The Company believes that, based on its current business plan, its existing cash and cash equivalents of $20,558,000 at December&#160;31, 2021 will not be sufficient to fund its obligations for the next 12 months. The consolidated financial statements do not include any adjustments related to the outcome of this uncertainty. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our ability to execute our operating plan depends on our ability to obtain additional funding through equity offerings, debt financings or potential licensing and collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to us. Even if we raise additional capital, we may also be required to modify, delay or abandon some of our plans which could have a material adverse effect on our business, operating results and financial condition and our ability to achieve our intended business objectives. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of consolidated financial statements, in accordance with GAAP, requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the amounts of expenses during the reported periods. Certain estimates in these consolidated financial statements have been made in connection with the calculation of research and development expenses, equity-based compensation expense and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections, which management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company considers all highly liquid investments with an original maturity of 90 days or less on the date of purchase to be cash equivalents. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Concentrations of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company&#x2019;s cash and equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued expenses which have been presented on the consolidated balance sheets as of December&#160;31, 2021 and 2020 consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,832&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,085&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Clinical study related costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,031&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,154&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Facility expansion costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,709&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued legal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;964&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Manufacturing improvement costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,164&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other accrued expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;203&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;548&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total accrued expenses and other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,213&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,496&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;   &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and Development Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries, benefits, third party license fees, and external costs of outside vendors engaged to conduct manufacturing and preclinical development activities and clinical trials. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company records accruals based on estimates of services received, efforts expended, and amounts owed pursuant to contracts with numerous contract research organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company&#x2019;s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the company&#x2019;s estimate of the degree of completion of the event or events specified in the specific clinical study. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Statement of Operations and Comprehensive Loss as the Company receives the related goods or services. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Costs incurred in obtaining technology licenses are charged to research and development expense as purchased &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development if the technology licensed has not reached technological feasibility and has no alternative future use. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fixed Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fixed assets are stated at cost, less accumulated depreciation. Generally, expenditures for maintenance and repairs are charged to expense and major improvements or replacements are capitalized. The Company computes depreciation and amortization using the straight-line method over the estimated useful life of the asset. Leasehold improvements are amortized over the lesser of, the life of the lease or the estimated useful life of the leasehold improvement. The estimated useful lives are as follows: &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 51%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 46%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer equipment and software&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture and equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5-&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;remainder of lease term&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;   &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fixed assets consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture and equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,180&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,011&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer equipment and software&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;569&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;130&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,517&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Construction in progress&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;351&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,854&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: accumulated depreciation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,259&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,157&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total fixed assets, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,358&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,914&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation expense for the years ended December&#160;31, 2021 and 2020 was $1,451,000 and $606,000, respectively. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets are comprised of acquired assembled workforce, which are accounted for in accordance with ASC 350&#x2014;Intangibles&#x2014;Goodwill and Other. The acquired assembled workforce is amortized on a straight-line basis over the useful life of five years. The following table summarizes information related to the Company&#x2019;s assembled workforce intangible asset (in thousands): &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross carrying amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,073&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,073&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;645&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;431&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net carrying amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;428&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;642&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated amortization expense for each of the years 2022 through 2023 is $215,000 and $5,000 for 2024. Amortization expense relating to the assembled workforce intangible asset was $214,000 for the year ended December&#160;31, 2021 and $215,000 for the year ended December&#160;31, 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairment of Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-lived assets such as fixed assets and intangible assets subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. No impairment charges have been recorded for the years ended December&#160;31, 2021 or 2020. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company was organized as a limited liability company, is now a limited partnership and is classified as a partnership for U.S. income tax purposes, and as such, only records a provision for federal and state income taxes on its subsidiaries organized as C corporations or which have elected to be treated as corporations for U.S. federal income tax purposes. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-US&lt;/div&gt; is a limited liability company and has elected to be treated as a C&#160;corporation. Therefore, a provision for federal and state taxes has been recorded. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-KY&lt;/div&gt; has been granted, by the Government in Council of the Cayman Islands, tax concessions under an undertaking certificate exempting it from any tax levied on profits, income, gains or appreciations in relation to its operations or in the nature of estate duty or inheritance tax for a period of twenty years from January&#160;20, 2016. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-KY&lt;/div&gt; elected to be treated as an entity disregarded from its owner for U.S. tax purposes, and as a result, it has not recorded an income tax provision. &lt;/div&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company uses the liability method in accounting for income taxes as required by ASC Topic 740&#160;&#x2014; Income Taxes, under which deferred tax assets and liabilities are recorded for the future tax consequences attributable to the differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that such assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, available taxes in the carryback periods, projected future taxable income and tax planning strategies in making this assessment. Accordingly, the Company has provided a full valuation allowance to offset the net deferred tax assets at December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest and penalties related to income taxes are included in the benefit (provision) for income taxes in the Company&#x2019;s Consolidated Statements of Operations. The Company has not incurred any significant interest or penalties related to income taxes in any of the periods presented. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 9%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td style="width: 89%;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;Level&#160;1&#160;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;Unadjusted quoted prices in active markets for identical assets or liabilities&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height: 6pt; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;Level&#160;2&#160;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable through correlation with market data&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height: 6pt; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;Level&#160;3&#160;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;Unobservable inputs that are supported by little or no market data, which require the reporting entity to develop its own assumptions&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The carrying values of cash equivalents, accounts payable, and accrued liabilities approximate fair value due to the short-term nature of these instruments. There are no &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities included in cash and cash equivalents as of December&#160;31, 2021 and 2020. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company determines if an arrangement is a lease at inception. Balances recognized related to the Company&#x2019;s operating and finance leases are included in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets, net and lease liabilities in the Consolidated Balance Sheets. Right of use assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Lease terms may include options to extend or terminate the lease if it is reasonably certain that the Company will exercise the option. As most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. The right of use asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company has elected a practical expedient to not separate its lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components and instead account for them as a single lease component. Leases with a term of 12 months or less are not recorded on the balance sheet. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Lease payments for short-term leases are recorded to operating expense on a straight-line basis and variable lease payments are recorded in the period in which the obligation for those payments is incurred. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;  &lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company records reserves for contingent liabilities when it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements, and the amount of the loss can be reasonably estimated. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Deed for the Establishment of a Limited Partnership of ProKidney LP, dated as of August&#160;5, 2021 (the &#x201c;Limited Partnership Agreement&#x201d;) which replaced the Amended and Restated Limited Liability Company Agreement of ProKidney LLC as the governing document of the parent entity in the Company, allows for the issuance of Profits Interests (as defined in the Limited Partnership Agreement) to employees, directors, other service providers of the Company and others denominated in the form of one or more Class&#160;B Units (as defined in the Limited Partnership Agreement). The Company measures compensation expense for Profits Interests based on estimated fair values at the time of grant. The Company estimates the fair value of Profits Interests using generally accepted valuation procedures. The Company recognizes compensation expense, on a straight-line basis, for the portion of the Profits Interests&#x2019; value that is expected to vest over the requisite service period. The Company records forfeitures of Profits Interests as they occur. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Defined Contribution Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company sponsors a 401(k) plan for its &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-US&lt;/div&gt; employees and a defined contribution plan for its &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-KY&lt;/div&gt; employees. Full-time employees are eligible to participate in the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-US&lt;/div&gt; plan. The Company matches 50% of participating &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-US&lt;/div&gt; employees&#x2019; contributions up to 8% of salary. The costs of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-US&lt;/div&gt; plan were $161,000 and $119,000 for the years ended December&#160;31, 2021 and 2020, respectively. The Company contributes 7% of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-KY&lt;/div&gt; employee salaries to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-KY&lt;/div&gt; defined contribution plan. The costs of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-KY&lt;/div&gt; plan were $8,000 and $20,000 for the years ended December&#160;31, 2021 and 2020, respectively. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company operates in only one segment. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recently Adopted Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In February 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-02,&lt;/div&gt; Leases (Topic 842), which requires lessees to recognize a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset and a liability on the balance sheet for all leases, with the exception of short-term leases. The lease liability will be equal to the present value of lease payments, and the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset will be based on the lease liability, subject to adjustment such as for initial direct costs. Leases will continue to be classified as either operating or finance leases in the income statement. The guidance is effective for annual periods beginning after December&#160;15, 2021, with early adoption permitted. The Company early adopted ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-02,&lt;/div&gt; Leases (Topic 842), as of January&#160;1, 2021. For additional detail, see Note 4, Leases. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subsequent Events &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has evaluated subsequent events through April&#160;11, 2022, which is the date the consolidated financial statements were available to be issued. See additional information in Notes 5 and 8. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 3: Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company&#x2019;s subsidiary, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-US,&lt;/div&gt; is treated as a C corporation, and therefore a provision for federal and state taxes has been recorded. &lt;/div&gt; </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The consolidated financial statements reflect the operations of ProKidney and its wholly-owned subsidiaries consisting of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-KY&lt;/div&gt; and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-US&lt;/div&gt; (together, the &#x201c;Company&#x201d;). All intercompany transactions and accounts have been eliminated. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). These consolidated financial statements are presented in U.S. Dollars. &lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <prok:GoingConcernPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Going Concern &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company performed an analysis of its ability to continue as a going concern. As of December&#160;31, 2021, the Company had an accumulated deficit of $161,510,000. The Company has generated losses from operations for each year since its inception including losses from operations of $55,146,000 and $26,749,000 for the years ended December&#160;31, 2021 and 2020, respectively. The Company intends to continue to conduct significant &lt;/div&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;additional research, development, and clinical study activities which, together with expenses incurred for general and administrative expenses, are expected to result in continuing operating losses for the foreseeable future. The amount of future losses and when, if ever, the Company will achieve profitability are uncertain. The Company&#x2019;s ability to achieve profitability will depend, among other things, on successfully completing clinical studies, obtaining requisite regulatory approvals, establishing appropriate pricing for its product with payers, and raising sufficient funds to finance the Company&#x2019;s activities. No assurance can be given that the Company&#x2019;s clinical development efforts will be successful, that regulatory approvals will be obtained, or that the Company will be able to achieve appropriate pricing and market access or that profitability, if achieved, can be sustained. These matters raise substantial doubt about the Company&#x2019;s ability to continue as a going concern. The Company believes that, based on its current business plan, its existing cash and cash equivalents of $20,558,000 at December&#160;31, 2021 will not be sufficient to fund its obligations for the next 12 months. The consolidated financial statements do not include any adjustments related to the outcome of this uncertainty. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our ability to execute our operating plan depends on our ability to obtain additional funding through equity offerings, debt financings or potential licensing and collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to us. Even if we raise additional capital, we may also be required to modify, delay or abandon some of our plans which could have a material adverse effect on our business, operating results and financial condition and our ability to achieve our intended business objectives. &lt;/div&gt;&lt;/div&gt; </prok:GoingConcernPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">-161510000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">-55146000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">-26749000</us-gaap:NetIncomeLoss>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">20558000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <prok:UnsufficientToFundItsObligationsTerm contextRef="P01_01_2021To12_31_2021">P12M</prok:UnsufficientToFundItsObligationsTerm>
    <us-gaap:UseOfEstimates contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of consolidated financial statements, in accordance with GAAP, requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the amounts of expenses during the reported periods. Certain estimates in these consolidated financial statements have been made in connection with the calculation of research and development expenses, equity-based compensation expense and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections, which management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known. &lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company considers all highly liquid investments with an original maturity of 90 days or less on the date of purchase to be cash equivalents. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items. &lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Concentrations of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company&#x2019;s cash and equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. &lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <prok:AccruedExpensesPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued expenses which have been presented on the consolidated balance sheets as of December&#160;31, 2021 and 2020 consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,832&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,085&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Clinical study related costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,031&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,154&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Facility expansion costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,709&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued legal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;964&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Manufacturing improvement costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,164&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other accrued expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;203&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;548&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total accrued expenses and other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,213&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,496&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  </prok:AccruedExpensesPolicyTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued expenses which have been presented on the consolidated balance sheets as of December&#160;31, 2021 and 2020 consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,832&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,085&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Clinical study related costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,031&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,154&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Facility expansion costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;19&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,709&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued legal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;964&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Manufacturing improvement costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,164&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other accrued expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;203&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;548&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total accrued expenses and other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,213&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,496&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1832000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1085000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <prok:AccruedClinicalStudyRelatedCostsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2031000</prok:AccruedClinicalStudyRelatedCostsCurrent>
    <prok:AccruedClinicalStudyRelatedCostsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1154000</prok:AccruedClinicalStudyRelatedCostsCurrent>
    <prok:AccruedFacilityExpansionCostsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">19000</prok:AccruedFacilityExpansionCostsCurrent>
    <prok:AccruedFacilityExpansionCostsCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1709000</prok:AccruedFacilityExpansionCostsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">964000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:AccruedProfessionalFeesCurrent>
    <prok:AccruedManufacturingImprovementCosts
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4164000</prok:AccruedManufacturingImprovementCosts>
    <prok:AccruedManufacturingImprovementCosts
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</prok:AccruedManufacturingImprovementCosts>
    <prok:OtherAccruedExpenses
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">203000</prok:OtherAccruedExpenses>
    <prok:OtherAccruedExpenses
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">548000</prok:OtherAccruedExpenses>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">9213000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4496000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and Development Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries, benefits, third party license fees, and external costs of outside vendors engaged to conduct manufacturing and preclinical development activities and clinical trials. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company records accruals based on estimates of services received, efforts expended, and amounts owed pursuant to contracts with numerous contract research organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company&#x2019;s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the company&#x2019;s estimate of the degree of completion of the event or events specified in the specific clinical study. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Statement of Operations and Comprehensive Loss as the Company receives the related goods or services. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Costs incurred in obtaining technology licenses are charged to research and development expense as purchased &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development if the technology licensed has not reached technological feasibility and has no alternative future use. &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fixed Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fixed assets are stated at cost, less accumulated depreciation. Generally, expenditures for maintenance and repairs are charged to expense and major improvements or replacements are capitalized. The Company computes depreciation and amortization using the straight-line method over the estimated useful life of the asset. Leasehold improvements are amortized over the lesser of, the life of the lease or the estimated useful life of the leasehold improvement. The estimated useful lives are as follows: &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 51%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 46%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer equipment and software&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture and equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5-&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;remainder of lease term&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fixed assets consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture and equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,180&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,011&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer equipment and software&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;569&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;130&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,517&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Construction in progress&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;351&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,854&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: accumulated depreciation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,259&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,157&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total fixed assets, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,358&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,914&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation expense for the years ended December&#160;31, 2021 and 2020 was $1,451,000 and $606,000, respectively. &lt;/div&gt;&lt;/div&gt; </us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <prok:DisclosureInTabularFormOfUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock contextRef="P01_01_2021To12_31_2021">The estimated useful lives are as follows: &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 51%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 3%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 46%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer equipment and software&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture and equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5-&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;7&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;remainder of lease term&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </prok:DisclosureInTabularFormOfUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2021To12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2021To12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2021To12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2021To12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="P01_01_2021To12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">remainder of lease term</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fixed assets consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 10%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture and equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,180&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,011&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer equipment and software&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;569&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;130&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,517&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;76&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Construction in progress&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;351&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7,854&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: accumulated depreciation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,259&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,157&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total fixed assets, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,358&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,914&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">2180000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">2011000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">569000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">130000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">10517000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">76000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">351000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2020_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">7854000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2259000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1157000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">11358000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">8914000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">1451000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">606000</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets are comprised of acquired assembled workforce, which are accounted for in accordance with ASC 350&#x2014;Intangibles&#x2014;Goodwill and Other. The acquired assembled workforce is amortized on a straight-line basis over the useful life of five years. The following table summarizes information related to the Company&#x2019;s assembled workforce intangible asset (in thousands): &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross carrying amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,073&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,073&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;645&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;431&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net carrying amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;428&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;642&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated amortization expense for each of the years 2022 through 2023 is $215,000 and $5,000 for 2024. Amortization expense relating to the assembled workforce intangible asset was $214,000 for the year ended December&#160;31, 2021 and $215,000 for the year ended December&#160;31, 2020. &lt;/div&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2021To12_31_2021_AcquiredAssemblyWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="P01_01_2021To12_31_2021">The following table summarizes information related to the Company&#x2019;s assembled workforce intangible asset (in thousands): &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross carrying amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,073&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,073&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;645&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;431&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net carrying amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;428&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;642&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1073000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1073000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">645000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">431000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">428000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">642000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">215000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">215000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">5000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2021To12_31_2021_AcquiredAssemblyWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="0"
      unitRef="Unit_USD">214000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2020To12_31_2020_AcquiredAssemblyWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="0"
      unitRef="Unit_USD">215000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairment of Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-lived assets such as fixed assets and intangible assets subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. No impairment charges have been recorded for the years ended December&#160;31, 2021 or 2020. &lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company was organized as a limited liability company, is now a limited partnership and is classified as a partnership for U.S. income tax purposes, and as such, only records a provision for federal and state income taxes on its subsidiaries organized as C corporations or which have elected to be treated as corporations for U.S. federal income tax purposes. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-US&lt;/div&gt; is a limited liability company and has elected to be treated as a C&#160;corporation. Therefore, a provision for federal and state taxes has been recorded. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-KY&lt;/div&gt; has been granted, by the Government in Council of the Cayman Islands, tax concessions under an undertaking certificate exempting it from any tax levied on profits, income, gains or appreciations in relation to its operations or in the nature of estate duty or inheritance tax for a period of twenty years from January&#160;20, 2016. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-KY&lt;/div&gt; elected to be treated as an entity disregarded from its owner for U.S. tax purposes, and as a result, it has not recorded an income tax provision. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company uses the liability method in accounting for income taxes as required by ASC Topic 740&#160;&#x2014; Income Taxes, under which deferred tax assets and liabilities are recorded for the future tax consequences attributable to the differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that such assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, available taxes in the carryback periods, projected future taxable income and tax planning strategies in making this assessment. Accordingly, the Company has provided a full valuation allowance to offset the net deferred tax assets at December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest and penalties related to income taxes are included in the benefit (provision) for income taxes in the Company&#x2019;s Consolidated Statements of Operations. The Company has not incurred any significant interest or penalties related to income taxes in any of the periods presented. &lt;/div&gt;&lt;/div&gt; </us-gaap:IncomeTaxPolicyTextBlock>
    <prok:PeriodForWhichTheProfitsEarnedAreExemptFromTax contextRef="P01_20_2016To12_31_2021_KYsrtStatementGeographicalAxis">P20Y</prok:PeriodForWhichTheProfitsEarnedAreExemptFromTax>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 9%;"/&gt;
&lt;td style="width: 2%; vertical-align: bottom;"/&gt;
&lt;td style="width: 89%;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;Level&#160;1&#160;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;Unadjusted quoted prices in active markets for identical assets or liabilities&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height: 6pt; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;Level&#160;2&#160;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable through correlation with market data&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1pt;"&gt;
&lt;td style="height: 6pt; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="height: 6pt; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;Level&#160;3&#160;&#x2013;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;"&gt;Unobservable inputs that are supported by little or no market data, which require the reporting entity to develop its own assumptions&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The carrying values of cash equivalents, accounts payable, and accrued liabilities approximate fair value due to the short-term nature of these instruments. There are no &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities included in cash and cash equivalents as of December&#160;31, 2021 and 2020. &lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company determines if an arrangement is a lease at inception. Balances recognized related to the Company&#x2019;s operating and finance leases are included in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets, net and lease liabilities in the Consolidated Balance Sheets. Right of use assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Lease terms may include options to extend or terminate the lease if it is reasonably certain that the Company will exercise the option. As most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. The right of use asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred. The Company has elected a practical expedient to not separate its lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components and instead account for them as a single lease component. Leases with a term of 12 months or less are not recorded on the balance sheet. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Lease payments for short-term leases are recorded to operating expense on a straight-line basis and variable lease payments are recorded in the period in which the obligation for those payments is incurred. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <prok:ContingentLiabilitiesPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company records reserves for contingent liabilities when it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements, and the amount of the loss can be reasonably estimated. &lt;/div&gt;&lt;/div&gt;</prok:ContingentLiabilitiesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Deed for the Establishment of a Limited Partnership of ProKidney LP, dated as of August&#160;5, 2021 (the &#x201c;Limited Partnership Agreement&#x201d;) which replaced the Amended and Restated Limited Liability Company Agreement of ProKidney LLC as the governing document of the parent entity in the Company, allows for the issuance of Profits Interests (as defined in the Limited Partnership Agreement) to employees, directors, other service providers of the Company and others denominated in the form of one or more Class&#160;B Units (as defined in the Limited Partnership Agreement). The Company measures compensation expense for Profits Interests based on estimated fair values at the time of grant. The Company estimates the fair value of Profits Interests using generally accepted valuation procedures. The Company recognizes compensation expense, on a straight-line basis, for the portion of the Profits Interests&#x2019; value that is expected to vest over the requisite service period. The Company records forfeitures of Profits Interests as they occur. &lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Defined Contribution Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company sponsors a 401(k) plan for its &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-US&lt;/div&gt; employees and a defined contribution plan for its &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-KY&lt;/div&gt; employees. Full-time employees are eligible to participate in the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-US&lt;/div&gt; plan. The Company matches 50% of participating &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-US&lt;/div&gt; employees&#x2019; contributions up to 8% of salary. The costs of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-US&lt;/div&gt; plan were $161,000 and $119,000 for the years ended December&#160;31, 2021 and 2020, respectively. The Company contributes 7% of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-KY&lt;/div&gt; employee salaries to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-KY&lt;/div&gt; defined contribution plan. The costs of the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-KY&lt;/div&gt; plan were $8,000 and $20,000 for the years ended December&#160;31, 2021 and 2020, respectively. &lt;/div&gt;</us-gaap:DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock>
    <prok:DefinedContributionPlanCosts
      contextRef="P01_01_2021To12_31_2021_USsrtStatementGeographicalAxis"
      decimals="0"
      unitRef="Unit_USD">161000</prok:DefinedContributionPlanCosts>
    <prok:DefinedContributionPlanCosts
      contextRef="P01_01_2020To12_31_2020_USsrtStatementGeographicalAxis"
      decimals="0"
      unitRef="Unit_USD">119000</prok:DefinedContributionPlanCosts>
    <prok:DefinedContributionPlanPercent
      contextRef="P01_01_2021To12_31_2021_KYsrtStatementGeographicalAxis"
      decimals="2"
      unitRef="Unit_pure">0.07</prok:DefinedContributionPlanPercent>
    <prok:DefinedContributionPlanPercent
      contextRef="P01_01_2020To12_31_2020_KYsrtStatementGeographicalAxis"
      decimals="2"
      unitRef="Unit_pure">0.07</prok:DefinedContributionPlanPercent>
    <prok:DefinedContributionPlanCosts
      contextRef="P01_01_2021To12_31_2021_KYsrtStatementGeographicalAxis"
      decimals="0"
      unitRef="Unit_USD">8000</prok:DefinedContributionPlanCosts>
    <prok:DefinedContributionPlanCosts
      contextRef="P01_01_2020To12_31_2020_KYsrtStatementGeographicalAxis"
      decimals="0"
      unitRef="Unit_USD">20000</prok:DefinedContributionPlanCosts>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company operates in only one segment. &lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recently Adopted Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In February 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-02,&lt;/div&gt; Leases (Topic 842), which requires lessees to recognize a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset and a liability on the balance sheet for all leases, with the exception of short-term leases. The lease liability will be equal to the present value of lease payments, and the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset will be based on the lease liability, subject to adjustment such as for initial direct costs. Leases will continue to be classified as either operating or finance leases in the income statement. The guidance is effective for annual periods beginning after December&#160;15, 2021, with early adoption permitted. The Company early adopted ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-02,&lt;/div&gt; Leases (Topic 842), as of January&#160;1, 2021. For additional detail, see Note 4, Leases. &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subsequent Events &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has evaluated subsequent events through April&#160;11, 2022, which is the date the consolidated financial statements were available to be issued. See additional information in Notes 5 and 8. &lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 3: Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company&#x2019;s subsidiary, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-US,&lt;/div&gt; is treated as a C corporation, and therefore a provision for federal and state taxes has been recorded. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The provision for income tax expense consisted of the following for the year ended December&#160;31, 2021 and 2020 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 14%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 14%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;72&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(242&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(34&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total current income tax expense (benefit)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(232&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred income tax expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax expense (benefit)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(232&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The difference between the statutory rate for federal income tax and the effective income tax rate was as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income taxes at statutory rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State taxes, net of federal benefit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;LLC flow-through structure&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(21.4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(21.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal Credits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provision to return adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effective income tax rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Components of the Company&#x2019;s deferred tax assets and liabilities included in the consolidated balance sheet consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued bonus&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;376&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;243&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fixed assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;108&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal credit carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;939&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;331&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Start-up&lt;/div&gt; costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;39&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets before valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,382&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;730&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,237&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;560&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;145&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;170&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;90&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;148&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fixed assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;47&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prepaid expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred tax liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;145&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;170&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net deferred tax asset&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, available taxes in the carryback periods, projected future taxable income and tax planning strategies in making this assessment. Accordingly, the Company has provided a valuation allowance of $1,237,000 and $560,000 respectively for December&#160;31, 2021 and 2020, to offset the net deferred tax assets. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has $1,118,000 in Research Credit Carryforwards that begin to expire in 2040. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A reconciliation of the beginning and ending amount of total unrecognized tax benefits for the years ended December&#160;31, 2021 and 2020 consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unrecognized tax benefits (gross):&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Benefits at the beginning of the year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Increase related to prior year tax positions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Decrease related to prior year tax positions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Increase related to current year tax positions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;86&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Benefits at the end of the year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;180&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There are no net unrecognized tax benefits as of December&#160;31, 2021 which, if recognized, would affect our effective tax rate. We expect none of the gross unrecognized tax benefits will decrease within the next year. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;In March 2020, the World Health Organization declared coronavirus &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(COVID-19)&lt;/div&gt; a global pandemic. This contagious disease outbreak, which continued to spread, and the related adverse public health developments, have adversely affected work forces, economies and financial markets globally. As a result, governments around the world have enacted legislation to provide aid and stimulate economies. In the U.S., The Coronavirus, Aid, Relief and Economics Security Act (&#x201c;CARES Act&#x201d;), was enacted on March&#160;27, 2020, The Consolidated Appropriations Act, 2021 was enacted on December&#160;27, 2020, and the American Rescue Plan Act of 2021 was enacted on March&#160;11, 2021. All of these acts included both income tax and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-income&lt;/div&gt; tax provisions to assist companies. No provisions in these acts had a material impact on the income tax provision or any other area of the Company&#x2019;s financial statements. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Tax years 2018 through 2021 remain subject to examination by federal and state authorities. &lt;/div&gt;&lt;/div&gt; </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The provision for income tax expense consisted of the following for the year ended December&#160;31, 2021 and 2020 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 65%;"/&gt;
&lt;td style="width: 14%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 14%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;72&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(242&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(34&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total current income tax expense (benefit)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(232&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred income tax expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income tax expense (benefit)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;38&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(232&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">72000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-242000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-34000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">10000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">38000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-232000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">38000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">-232000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The difference between the statutory rate for federal income tax and the effective income tax rate was as follows: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 12%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Current:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income taxes at statutory rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;21.0&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;State taxes, net of federal benefit&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;LLC flow-through structure&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(21.4&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(21.5&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal Credits&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1.8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Provision to return adjustment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1.3&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.2&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Effective income tax rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.1&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.9&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <prok:EffectiveIncomeTaxRateReconciliationLlcFlowThroughStructure
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">-0.214</prok:EffectiveIncomeTaxRateReconciliationLlcFlowThroughStructure>
    <prok:EffectiveIncomeTaxRateReconciliationLlcFlowThroughStructure
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">-0.215</prok:EffectiveIncomeTaxRateReconciliationLlcFlowThroughStructure>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.018</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.023</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">-0.013</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2021To12_31_2021"
      decimals="3"
      unitRef="Unit_pure">-0.001</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2020To12_31_2020"
      decimals="3"
      unitRef="Unit_pure">0.009</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Components of the Company&#x2019;s deferred tax assets and liabilities included in the consolidated balance sheet consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued bonus&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;376&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;243&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fixed assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;108&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Federal credit carryforwards&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;939&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;331&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;28&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Start-up&lt;/div&gt; costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;39&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;48&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax assets before valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,382&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;730&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Valuation allowance&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,237&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;560&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;145&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;170&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Deferred tax liabilities:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;90&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;148&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fixed assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;47&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Prepaid expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;22&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total deferred tax liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;145&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;170&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net deferred tax asset&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">376000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">243000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">108000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <prok:DeferredTaxAssetsFederalCreditCarryForwards
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">939000</prok:DeferredTaxAssetsFederalCreditCarryForwards>
    <prok:DeferredTaxAssetsFederalCreditCarryForwards
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">331000</prok:DeferredTaxAssetsFederalCreditCarryForwards>
    <prok:DeferredTaxAssetsLeases
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">28000</prok:DeferredTaxAssetsLeases>
    <prok:DeferredTaxAssetsLeases
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</prok:DeferredTaxAssetsLeases>
    <prok:DeferredTaxAssetsStartUpCosts
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">39000</prok:DeferredTaxAssetsStartUpCosts>
    <prok:DeferredTaxAssetsStartUpCosts
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">48000</prok:DeferredTaxAssetsStartUpCosts>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1382000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">730000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1237000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">560000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">145000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">170000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">90000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">148000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">47000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">8000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">22000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">145000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">170000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2021"
      decimals="0"
      unitRef="Unit_USD">1237000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2020"
      decimals="0"
      unitRef="Unit_USD">560000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2021_ResearchMemberusgaapTaxCreditCarryforwardAxis"
      decimals="0"
      unitRef="Unit_USD">1118000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;A reconciliation of the beginning and ending amount of total unrecognized tax benefits for the years ended December&#160;31, 2021 and 2020 consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 13%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unrecognized tax benefits (gross):&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Benefits at the beginning of the year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Increase related to prior year tax positions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Decrease related to prior year tax positions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Increase related to current year tax positions&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;86&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Benefits at the end of the year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;180&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2019"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">94000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">86000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">180000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="PAsOn12_31_2021_ResearchMemberusgaapTaxCreditCarryforwardAxis"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 4: Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In February 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-02:&lt;/div&gt; Leases (Topic 842). This ASU requires a lessee to recognize a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset and a lease liability on its balance sheet for most operating leases. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-02&lt;/div&gt; is effective for annual and interim periods beginning after December&#160;15, 2018, including interim periods within those fiscal years. In July 2018, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-11,&lt;/div&gt; Leases (Topic 842): Targeted Improvements, which provides companies with an additional optional transition method to apply the new standard to leases in effect at the adoption date through a cumulative effect adjustment. The Company adopted the new lease standard as of January&#160;1, 2021 using the modified retrospective transition method. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company elected the package of practical expedients referenced in ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-02,&lt;/div&gt; which permits companies to retain original lease identification and classification without reassessing initial direct costs for existing leases. The Company also elected the practical expedient that exempts leases with an initial lease term of 12 months or less, as well as the practical expedient that allows companies to select, by class of underlying asset, &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;not to separate lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components. Adoption of this standard resulted in the recognition of a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset and a lease liability on the Company&#x2019;s January&#160;1, 2021 Consolidated Balance Sheet of $1,560,000 and $1,559,000 respectively. There was no material impact on the Company&#x2019;s Consolidated Statement of Comprehensive Loss. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has operating leases for real estate (primarily office space) and certain equipment with various expiration dates. The Company also has one finance lease for certain equipment. Rent expense was $434,000 and $314,000, for the years ended December&#160;31, 2021 and 2020, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the classification of operating and finance lease assets and obligations in the Company&#x2019;s Consolidated Balance Sheets as of December&#160;31, 2021 and December&#160;31, 2020 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating leases:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right of use assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,139&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,415&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities, current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;235&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;195&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities, noncurrent&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;985&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,219&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,220&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,414&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finance leases:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right of use assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;102&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;145&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finance lease liabilities, current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finance lease liabilities, noncurrent&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;82&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;115&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total finance lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;114&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;145&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Maturities of lease liabilities for the Company&#x2019;s operating and finance leases are as follows for the year ending December&#160;31, 2021 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Operating&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Finance&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;326&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;366&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;332&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;372&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;341&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;381&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;282&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;289&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;180&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;180&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,461&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;127&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,588&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: imputed interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(241&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(254&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Present value of lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,220&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;114&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,334&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The weighted average remaining lease term for operating leases is 4.4 years, and 3.3 years for the finance lease. The weighted average discount rate is 8.5%. &lt;/div&gt;&lt;/div&gt; </us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="PAsOn12_31_2021">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <prok:RightOfUseAssetsOperatingAndFinanceLease
      contextRef="PAsOn01_01_2021"
      decimals="-3"
      unitRef="Unit_USD">1560000000</prok:RightOfUseAssetsOperatingAndFinanceLease>
    <prok:OperatingAndFinanceLeaseLiabilitiesCurrent
      contextRef="PAsOn01_01_2021"
      decimals="-3"
      unitRef="Unit_USD">1559000000</prok:OperatingAndFinanceLeaseLiabilitiesCurrent>
    <prok:OperatingLeaseRentExpenses
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">434000000</prok:OperatingLeaseRentExpenses>
    <prok:OperatingLeaseRentExpenses
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">314000000</prok:OperatingLeaseRentExpenses>
    <prok:LesseeOperatingAndFinanceLeaseTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the classification of operating and finance lease assets and obligations in the Company&#x2019;s Consolidated Balance Sheets as of December&#160;31, 2021 and December&#160;31, 2020 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating leases:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right of use assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,139&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,415&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities, current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;235&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;195&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities, noncurrent&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;985&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,219&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,220&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,414&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finance leases:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right of use assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;102&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;145&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finance lease liabilities, current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finance lease liabilities, noncurrent&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;82&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;115&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total finance lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;114&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;145&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </prok:LesseeOperatingAndFinanceLeaseTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1139000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1415000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">235000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">195000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">985000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1219000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1220000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">1414000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">102000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">145000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">32000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">30000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">82000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">115000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiability
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">114000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">145000</us-gaap:FinanceLeaseLiability>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Maturities of lease liabilities for the Company&#x2019;s operating and finance leases are as follows for the year ending December&#160;31, 2021 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Operating&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Finance&lt;/div&gt;&lt;/div&gt;&lt;br/&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;326&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;366&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;332&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;372&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;341&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;381&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;282&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;289&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;180&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;180&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,461&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;127&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,588&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: imputed interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(241&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(13&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(254&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Present value of lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,220&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;114&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,334&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">326000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">40000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">366000</prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">332000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">40000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">372000</prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">341000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">40000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">381000</prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">282000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">7000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">289000</prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">180000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">180000</prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1461000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">127000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1588000</prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">241000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">13000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-254000</prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1220000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">114000</us-gaap:FinanceLeaseLiability>
    <prok:OperatingAndFinanceLeaseLiability
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1334000</prok:OperatingAndFinanceLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2021">P4Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2021">P3Y3M18D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <prok:OperatingAndFinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2021"
      decimals="3"
      unitRef="Unit_pure">0.085</prok:OperatingAndFinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:MembersEquityNotesDisclosureTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 5: Members&#x2019; Equity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Ownership interests in the Company are represented by two classes of units, Class&#160;A Units and Class&#160;B Units. The terms of the units are governed by the LLC Agreement. As of December&#160;31, 2021, there were 190,000,000 Class&#160;A and 10,000,000 Class&#160;B Units authorized. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Holders of Class&#160;A Units have voting rights and rights to profits and losses of the Company and distributions from the Company. The following is a summary of the activity of the Class&#160;A Units: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 79%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Units outstanding January&#160;1, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;95,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Issued 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Units outstanding December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;115,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Issued 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;71,500,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Units outstanding December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;186,500,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Class&#160;B Units are reserved for issuance of Profits Interests and do not have voting rights. The Profits Interests are designed so that the holders of Profits Interests only participate in a qualified distribution event and only if its valuation threshold is attained in such a distribution event as set forth in the Limited Partnership Agreement; provided, however, that the Limited Partnership Agreement (as amended and restated on January&#160;17, 2022 as contemplated by Note 8 below) provides that certain qualified distribution events will result in the holders of Profits Interests receiving disproportionate distributions from ProKidney until each such holder&#x2019;s threshold value has been reduced to zero in order to &#x201c;catch up&#x201d; such holder&#x2019;s distributions to its pro rata share of aggregate cumulative distributions, and once sufficient distributions to a holder of Profits Interests have been made in accordance with the foregoing, the associated Class&#160;B Units will automatically be converted into Class&#160;A Units. &lt;/div&gt;&lt;/div&gt; </us-gaap:MembersEquityNotesDisclosureTextBlock>
    <us-gaap:LimitedPartnersCapitalAccountUnitsAuthorized
      contextRef="PAsOn12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="0"
      unitRef="Unit_shares">190000000</us-gaap:LimitedPartnersCapitalAccountUnitsAuthorized>
    <us-gaap:LimitedPartnersCapitalAccountUnitsAuthorized
      contextRef="PAsOn12_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis"
      decimals="0"
      unitRef="Unit_shares">10000000</us-gaap:LimitedPartnersCapitalAccountUnitsAuthorized>
    <prok:MembersEquityTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Holders of Class&#160;A Units have voting rights and rights to profits and losses of the Company and distributions from the Company. The following is a summary of the activity of the Class&#160;A Units: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 79%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Units outstanding January&#160;1, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;95,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Issued 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;20,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Units outstanding December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;115,000,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Issued 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;71,500,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Units outstanding December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;186,500,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </prok:MembersEquityTableTextBlock>
    <us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding
      contextRef="PAsOn12_31_2019_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">95000000</us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding>
    <us-gaap:PartnersCapitalAccountUnitsContributed
      contextRef="P01_01_2020To12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">20000000</us-gaap:PartnersCapitalAccountUnitsContributed>
    <us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding
      contextRef="PAsOn12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">115000000</us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding>
    <us-gaap:PartnersCapitalAccountUnitsContributed
      contextRef="P01_01_2021To12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">71500000</us-gaap:PartnersCapitalAccountUnitsContributed>
    <us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding
      contextRef="PAsOn12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">186500000</us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 6: Net Loss per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic loss per share (&#x201c;EPS&#x201d;) was computed by dividing net loss by the number of weighted average units of Class&#160;A Units outstanding during the period. Diluted EPS was calculated to give effect to potentially issuable dilutive units of common units using the treasury method. For all periods presented, the vested Profits Interests have been excluded from the diluted EPS calculation as their effect would be anti-dilutive. The following table sets forth the calculation of basic and diluted earnings per share for the periods indicated based on the weighted average number of common shares outstanding: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss available to Class&#160;A Unit holders&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(55,146&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(26,749&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average Class&#160;A Units outstanding, basic and diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;150,706,849&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;104,986,301&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss per Class&#160;A Unit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss per Class&#160;A Unit, basic and diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.37&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P01_01_2021To12_31_2021">The following table sets forth the calculation of basic and diluted earnings per share for the periods indicated based on the weighted average number of common shares outstanding:
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years Ended December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss available to Class&#160;A Unit holders&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(55,146&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(26,749&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average Class&#160;A Units outstanding, basic and diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;150,706,849&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;104,986,301&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss per Class&#160;A Unit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss per Class&#160;A Unit, basic and diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.37&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.25&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="0"
      unitRef="Unit_USD">-55146</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="0"
      unitRef="Unit_USD">-26749</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2021To12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="0"
      unitRef="Unit_shares">150706849</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2021To12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="0"
      unitRef="Unit_shares">150706849</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2020To12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="0"
      unitRef="Unit_shares">104986301</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2020To12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="0"
      unitRef="Unit_shares">104986301</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2021To12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2021To12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.37</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2020To12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2020To12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 7: Equity Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The issuance of Profits Interests to employees, directors, and other service providers of the Company (&#x201c;Plan Participants&#x201d;) is administered at the discretion of ProKidney GP Limited, the general partner of ProKidney (the &#x201c;General Partner&#x201d;). Profits Interests allow the Plan Participants to participate in the residual profits of the Company after the distribution of proceeds reach a minimum threshold value. The threshold value is the amount of proceeds that must be distributed to the holders of Class&#160;A Units before the Plan Participants can participate in a distribution. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under the Limited Partnership Agreement, the General Partner determines the terms and conditions of the Profits Interests issued. The threshold value assigned to each grant shall not be less than the fair market value of the Company on the date of grant. Profits Interests awards vest at a rate of 25% on the latter of the first anniversary of employment and the first anniversary of the Acquisition Date with the remaining 75% to vest in increments of 25% on each anniversary following the first anniversary date or in increments of 6.25% each calendar quarter following the first anniversary date. The Profits Interests are subject to a repurchase option should the plan participant no longer be employed by the Company. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under the Limited Partnership Agreement (prior to its amendment and restatement on January&#160;17, 2022), there are 10,000,000 Class&#160;B Units authorized for issuance. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the activity related to the Company&#x2019;s Profits Interest awards for the year ended December&#160;31, 2021: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt;Average&#160;Grant&lt;br/&gt;Date&#160;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Awards outstanding at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,402,398&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vested&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,941,781&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Awards outstanding at December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,460,617&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No Class&#160;B Units were granted to employees during the year ended December&#160;31, 2021. As of December&#160;31, 2021, 2,232,878 Class&#160;B Units remained unissued. Given that these instruments meet the criteria for being considered profits interest, the Company has recognized no tax benefit related to these awards. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the years ended December&#160;31, 2021 and 2020, respectively, the Company recognized equity-based compensation expense of $699,000 and $730,000. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of December&#160;31, 2021, the unrecognized compensation expense was $868,000. The current weighted average remaining period over which the unrecognized compensation expense is expected to be recognized is 1.4&#160;years. The weighted average grant date fair value of the Profits Interests granted during the year ended December&#160;31, 2020 was $0.36 per Class&#160;B unit. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair Value Estimate &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is privately held with no active public market for its equity instruments. Therefore, for financial reporting purposes, management may periodically determine the estimated per share fair value of the Company&#x2019;s equity shares (including Profits Interests) using contemporaneous valuations. These contemporaneous valuations are done using methodologies consistent with the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, also known as the Practice Aid. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The valuation approach utilized the Option Pricing Method (OPM), where the fair value of the total equity of the Company within each scenario is first estimated using a back-solve method wherein the equity value is derived from a recent transaction in the Company&#x2019;s own securities, and then the total equity value is allocated to the various components of the capital structure, including the Profits Interests, using an OPM or a waterfall approach based on the specific rights of each of the equity classes. The OPM uses the fair value of the total equity of the Company within a scenario as a starting point and incorporates assumptions made regarding the expected returns and volatilities that are consistent with the expectations of market participants, and distribution of equity values is produced which cover the range of events that an informed market participant might expect. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;This process creates a range of equity values both between and within scenarios. The fair value measurement is sensitive to changes in the unobservable inputs. Changes in those inputs might result in a higher or lower fair value measurement. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In performing these valuations, management considered all objective and subjective factors that they believed to be relevant, including management&#x2019;s best estimate of the Company business condition, prospects, and operating performance at each valuation date. Within the valuations performed, a range of factors, assumptions, and methodologies were used. The significant factors included trends within the industry, the prices at which the Company sold Class&#160;A Units, the rights and preferences of the Class&#160;A Units relative to the Class&#160;B Units at the time of each measurement date, the results of operations, financial position, status of research and development efforts, stage of development and business strategy, the lack of an active public market for the units, and the likelihood of achieving an exit event in light of prevailing market conditions. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following reflects the key assumptions used in the OPM valuation: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total equity value (in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;78,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected volatility of total equity&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Discount for lack of market&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected time to exit event&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3 years&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P01_01_2021To12_31_2021_OnTheLatterOfTheFirstAnniversaryMemberusgaapVestingAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P01_01_2021To12_31_2021_InFirstAnniversaryOfTheAcquisitionDateMemberusgaapVestingAxis"
      decimals="2"
      unitRef="Unit_pure">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P01_01_2021To12_31_2021_OnEachEnniversaryMemberusgaapVestingAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P01_01_2021To12_31_2021_EachCalendarQuarterMemberusgaapVestingAxis"
      decimals="4"
      unitRef="Unit_pure">0.0625</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:LimitedPartnersCapitalAccountUnitsAuthorized
      contextRef="PAsOn01_17_2022_ClassB1unitsMemberusgaapCapitalUnitsByClassAxis"
      decimals="0"
      unitRef="Unit_shares">10000000</us-gaap:LimitedPartnersCapitalAccountUnitsAuthorized>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the activity related to the Company&#x2019;s Profits Interest awards for the year ended December&#160;31, 2021: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt;Average&#160;Grant&lt;br/&gt;Date&#160;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Awards outstanding at December&#160;31, 2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,402,398&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vested&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(1,941,781&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Awards outstanding at December&#160;31, 2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,460,617&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="PAsOn12_31_2020"
      decimals="INF"
      unitRef="Unit_shares">4402398</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.36</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="P01_01_2021To12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">1941781</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.36</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">2460617</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.36</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="PAsOn12_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis"
      decimals="INF"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <prok:NumberOfCommonUnitsUnissuedOfLimitedLiabilityCompany
      contextRef="PAsOn12_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis"
      decimals="INF"
      unitRef="Unit_shares">2232878</prok:NumberOfCommonUnitsUnissuedOfLimitedLiabilityCompany>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">699000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">730000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">868000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2021To12_31_2021">P1Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2020To12_31_2020"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following reflects the key assumptions used in the OPM valuation: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 85%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 8%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total equity value (in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;78,100&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected volatility of total equity&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;80&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Discount for lack of market&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected time to exit event&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3 years&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:MembersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">78100000</us-gaap:MembersEquity>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_pure">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions
      contextRef="P01_01_2021To12_31_2021"
      decimals="2"
      unitRef="Unit_pure">0.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2021To12_31_2021">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2021To12_31_2021">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 8: Subsequent Events &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;On January&#160;17, 2022, the Company amended and restated its Limited Partnership Agreement (the &#x201c;Amended and Restated Limited Partnership Agreement&#x201d;) in part to authorize the issuance of up to 50,000,000 Class&#160;B Units (including &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;B-1&lt;/div&gt; Units). Upon authorization of these units, the Company issued Profits Interests to certain Plan Participants in the form of 8,498,488 &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;B-1&lt;/div&gt; Units. Additionally, the Company issued 8,848,901 of its &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;B-1&lt;/div&gt; Units for total value received by the Company (or its subsidiaries) of $8,052,000. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Amended and Restated Limited Partnership Agreement provides that certain qualified distribution events will result in holders of Profits Interests receiving disproportionate distributions from ProKidney until each such holder&#x2019;s valuation threshold has been reduced to zero in order to &#x201c;catch up&#x201d; such holder&#x2019;s distributions to its pro rata share of aggregate cumulative distributions, and once sufficient distributions to a holder of Profits Interests have been made in accordance with the foregoing, the associated Class&#160;B Units will automatically be converted into Class&#160;A Units. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On January&#160;18, 2022, the Company executed a definitive business combination agreement (the &#x201c;Business Combination Agreement&#x201d;), with Social Capital Suvretta Holdings Corp. III (&#x201c;SCS&#x201d;). Under the terms of the Business Combination Agreement, the Company will become a subsidiary of SCS and will be organized in an umbrella partnership corporation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;Up-C&#x201d;)&lt;/div&gt; structure, which provides potential future tax benefits for SCS when the equity holders ultimately exchange their pass-through interests for Class&#160;A ordinary shares in SCS. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January&#160;18, 2022, in connection with the Business Combination Agreement, the Company entered into two promissory note agreements with certain of its existing holders. Through such promissory notes, the existing holders may fund up to $100,000,000 to support the operational financing needs of the Company prior to the closing of the Business Combination. The Company has borrowed $20,000,000 against these promissory notes subsequent to December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:LimitedPartnersCapitalAccountUnitsAuthorized
      contextRef="PAsOn01_17_2022_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">50000000</us-gaap:LimitedPartnersCapitalAccountUnitsAuthorized>
    <us-gaap:LimitedPartnersCapitalAccountUnitsIssued
      contextRef="PAsOn01_17_2022_CapitalUnitClassBOneMemberusgaapCapitalUnitsByClassAxis_DeferredProfitSharingMemberusgaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      unitRef="Unit_shares">8498488</us-gaap:LimitedPartnersCapitalAccountUnitsIssued>
    <us-gaap:LimitedPartnersCapitalAccountUnitsIssued
      contextRef="PAsOn01_17_2022_CapitalUnitClassBOneMemberusgaapCapitalUnitsByClassAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">8848901</us-gaap:LimitedPartnersCapitalAccountUnitsIssued>
    <us-gaap:CapitalUnits
      contextRef="PAsOn01_17_2022_CapitalUnitClassBOneMemberusgaapCapitalUnitsByClassAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">8052000000</us-gaap:CapitalUnits>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="PAsOn01_18_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">100000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="PAsOn12_31_2021_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">20000000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">29802000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">20558000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">592000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">588000</us-gaap:PrepaidExpenseCurrent>
    <prok:PrepaidClinicalCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">4855000</prok:PrepaidClinicalCurrent>
    <prok:PrepaidClinicalCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">6100000</prok:PrepaidClinicalCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">25000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">35249000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">27271000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">11103000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">11358000</us-gaap:PropertyPlantAndEquipmentNet>
    <prok:RightOfUseAssetsOperatingAndFinanceLease
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1673000</prok:RightOfUseAssetsOperatingAndFinanceLease>
    <prok:RightOfUseAssetsOperatingAndFinanceLease
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1241000</prok:RightOfUseAssetsOperatingAndFinanceLease>
    <prok:DeferredOfferingCost
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">5108000</prok:DeferredOfferingCost>
    <prok:DeferredOfferingCost
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</prok:DeferredOfferingCost>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">374000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">428000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Assets
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">53507000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">40298000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2509000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2834000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <prok:OperatingAndFinanceLeaseLiabilitiesCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">328000</prok:OperatingAndFinanceLeaseLiabilitiesCurrent>
    <prok:OperatingAndFinanceLeaseLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">267000</prok:OperatingAndFinanceLeaseLiabilitiesCurrent>
    <prok:AccruedExpensesAndOther
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">8117000</prok:AccruedExpensesAndOther>
    <prok:AccruedExpensesAndOther
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">9213000</prok:AccruedExpensesAndOther>
    <us-gaap:TaxesPayableCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">958000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:TaxesPayableCurrent>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">20000000</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">31912000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">12314000</us-gaap:LiabilitiesCurrent>
    <prok:OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1428000</prok:OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion>
    <prok:OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1067000</prok:OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion>
    <us-gaap:LimitedPartnersCapitalAccountUnitsIssued
      contextRef="PAsOn03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="INF"
      unitRef="Unit_shares">186500000</us-gaap:LimitedPartnersCapitalAccountUnitsIssued>
    <us-gaap:LimitedPartnersCapitalAccountUnitsIssued
      contextRef="PAsOn12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="INF"
      unitRef="Unit_shares">186500000</us-gaap:LimitedPartnersCapitalAccountUnitsIssued>
    <us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding
      contextRef="PAsOn03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="INF"
      unitRef="Unit_shares">186500000</us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding>
    <us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding
      contextRef="PAsOn12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="INF"
      unitRef="Unit_shares">186500000</us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding>
    <us-gaap:LimitedPartnersContributedCapital
      contextRef="PAsOn03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="-3"
      unitRef="Unit_USD">186500000</us-gaap:LimitedPartnersContributedCapital>
    <us-gaap:LimitedPartnersContributedCapital
      contextRef="PAsOn12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="-3"
      unitRef="Unit_USD">186500000</us-gaap:LimitedPartnersContributedCapital>
    <us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding
      contextRef="PAsOn03_31_2022_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis"
      decimals="INF"
      unitRef="Unit_shares">17354894</us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding>
    <us-gaap:LimitedPartnersCapitalAccountUnitsIssued
      contextRef="PAsOn03_31_2022_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis"
      decimals="INF"
      unitRef="Unit_shares">17354894</us-gaap:LimitedPartnersCapitalAccountUnitsIssued>
    <us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding
      contextRef="PAsOn12_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis"
      decimals="INF"
      unitRef="Unit_shares">7767122</us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding>
    <us-gaap:LimitedPartnersCapitalAccountUnitsIssued
      contextRef="PAsOn12_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis"
      decimals="INF"
      unitRef="Unit_shares">7767122</us-gaap:LimitedPartnersCapitalAccountUnitsIssued>
    <us-gaap:LimitedPartnersContributedCapital
      contextRef="PAsOn03_31_2022_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis"
      decimals="-3"
      unitRef="Unit_USD">62663000</us-gaap:LimitedPartnersContributedCapital>
    <us-gaap:LimitedPartnersContributedCapital
      contextRef="PAsOn12_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis"
      decimals="-3"
      unitRef="Unit_USD">1927000</us-gaap:LimitedPartnersContributedCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-228996000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-161510000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:PartnersCapital
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">20167000</us-gaap:PartnersCapital>
    <us-gaap:PartnersCapital
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">26917000</us-gaap:PartnersCapital>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">53507000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">40298000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">28490000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">9859000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">37972000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1744000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">66462000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">11603000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-66462000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-11603000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">14000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-66476000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-11603000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1010000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">6000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-67486000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-11609000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="0"
      unitRef="Unit_shares">186500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="0"
      unitRef="Unit_shares">186500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2021To03_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="0"
      unitRef="Unit_shares">122111111</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2021To03_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="0"
      unitRef="Unit_shares">122111111</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2021To03_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.1</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2021To03_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.1</us-gaap:EarningsPerShareDiluted>
    <prok:PartnersCapitalOutstanding
      contextRef="PAsOn12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">186500000</prok:PartnersCapitalOutstanding>
    <us-gaap:PartnersCapital
      contextRef="PAsOn12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">186500000</us-gaap:PartnersCapital>
    <us-gaap:PartnersCapital
      contextRef="PAsOn12_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1927000</us-gaap:PartnersCapital>
    <us-gaap:PartnersCapital
      contextRef="PAsOn12_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-161510000</us-gaap:PartnersCapital>
    <us-gaap:PartnersCapital
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">26917000</us-gaap:PartnersCapital>
    <us-gaap:PartnersCapitalAccountContributions
      contextRef="P01_01_2022To03_31_2022_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">5550000</us-gaap:PartnersCapitalAccountContributions>
    <us-gaap:PartnersCapitalAccountContributions
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">5550000</us-gaap:PartnersCapitalAccountContributions>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="P01_01_2022To03_31_2022_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">55186000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">55186000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-67486000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-67486000</us-gaap:NetIncomeLoss>
    <prok:PartnersCapitalOutstanding
      contextRef="PAsOn03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">186500000</prok:PartnersCapitalOutstanding>
    <us-gaap:PartnersCapital
      contextRef="PAsOn03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">186500000</us-gaap:PartnersCapital>
    <us-gaap:PartnersCapital
      contextRef="PAsOn03_31_2022_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">62663000</us-gaap:PartnersCapital>
    <us-gaap:PartnersCapital
      contextRef="PAsOn03_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-228996000</us-gaap:PartnersCapital>
    <us-gaap:PartnersCapital
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">20167000</us-gaap:PartnersCapital>
    <prok:PartnersCapitalOutstanding
      contextRef="PAsOn12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">115000000</prok:PartnersCapitalOutstanding>
    <us-gaap:PartnersCapital
      contextRef="PAsOn12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">115000000</us-gaap:PartnersCapital>
    <us-gaap:PartnersCapital
      contextRef="PAsOn12_31_2020_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1228000</us-gaap:PartnersCapital>
    <us-gaap:PartnersCapital
      contextRef="PAsOn12_31_2020_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-106364000</us-gaap:PartnersCapital>
    <us-gaap:PartnersCapital
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">9864000</us-gaap:PartnersCapital>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2021To03_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">20000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2021To03_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">20000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">20000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="P01_01_2021To03_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">175000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">175000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationForfeited>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-11609000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-11609000</us-gaap:NetIncomeLoss>
    <prok:PartnersCapitalOutstanding
      contextRef="PAsOn03_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      unitRef="Unit_shares">135000000</prok:PartnersCapitalOutstanding>
    <us-gaap:PartnersCapital
      contextRef="PAsOn03_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">135000000</us-gaap:PartnersCapital>
    <us-gaap:PartnersCapital
      contextRef="PAsOn03_31_2021_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis_MemberUnitsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">1403000</us-gaap:PartnersCapital>
    <us-gaap:PartnersCapital
      contextRef="PAsOn03_31_2021_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      unitRef="Unit_USD">-117973000</us-gaap:PartnersCapital>
    <us-gaap:PartnersCapital
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">18430000</us-gaap:PartnersCapital>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-67486000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-11609000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">710000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">361000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">52684000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">175000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3843000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-249000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1519000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">3568000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">957000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-15459000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-7256000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">839000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1389000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-839000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">-1389000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">8000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">7000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">20000000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">5550000</us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits>
    <us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">20000000</us-gaap:ProceedsFromIssuanceOfCommonLimitedPartnersUnits>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">25542000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">19993000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">9244000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">11348000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">20558000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">4577000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">29802000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">15925000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <prok:RightOfUseAssetsObtainedInExchangeForLeaseObligations
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">496000</prok:RightOfUseAssetsObtainedInExchangeForLeaseObligations>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">501000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">910000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:NatureOfOperations contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 1: The Company &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;ProKidney LLC was formed as a Bermuda limited liability company on December 12, 2018 and funded with $75,000,000 on December&#160;31, 2018. On January&#160;9, 2019 (the &#x201c;Acquisition Date&#x201d;), ProKidney LLC acquired all of the equity interests in inRegen and Twin City Bio LLC (&#x201c;TC Bio&#x201d;) for $62,000,000. inRegen was duly incorporated under the Cayman Islands Companies Act (as amended) on December&#160;21, 2015 as an exempted company. During 2020, inRegen&#x2019;s name was changed to ProKidney (and is referred to herein as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;ProKidney-KY&#x201d;),&lt;/div&gt; and TC Bio&#x2019;s name was changed to ProKidney, LLC (and is referred to herein as &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#x201c;ProKidney-US&#x201d;).&lt;/div&gt; &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-US&lt;/div&gt; was formed as a limited liability company under the laws of Delaware on December&#160;18, 2015. In August 2021, ProKidney LP was organized as a limited partnership under the laws and regulations of Ireland, with ProKidney LLC becoming a wholly owned subsidiary of ProKidney LP (and is referred to herein as &#x201c;ProKidney&#x201d;). Following this reorganization on August&#160;5, 2021, and for the purposes of these financial statements, the term &#x201c;ProKidney&#x201d; as used herein, refers to ProKidney LP following this reorganization, and the financial information presented herein is that of ProKidney LP and its wholly owned subsidiaries. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;ProKidney acquired the equity interests in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-KY&lt;/div&gt; to develop its Renal Advanced Cell Therapy, which has the potential to stabilize or improve renal function in patients with chronic kidney disease or delay or eliminate the need for dialysis and organ transplantation. ProKidney acquired &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-US&lt;/div&gt; to provide contractual development and manufacturing services to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-KY,&lt;/div&gt; which is &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-US&#x2019;s&lt;/div&gt; only customer. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Because ProKidney is a limited partnership, the debts, obligations and liabilities of the Company (as defined below), whether arising in contract, tort or otherwise, are solely the debts, obligations and liabilities of the Company, and no holder of equity interests in ProKidney (&#x201c;members&#x2019; equity&#x201d;) is obligated personally for any such debt, obligation or liability of the Company solely by reason of being a holder of members&#x2019; equity. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On January&#160;18, 2022, the Company executed a definitive business combination agreement (the &#x201c;Business Combination Agreement&#x201d;), with Social Capital Suvretta Holdings Corp. III (&#x201c;SCS&#x201d;). Under the terms of the Business Combination Agreement, the Company will become a subsidiary of SCS and will be organized in an umbrella partnership corporation &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;(&#x201c;Up-C&#x201d;)&lt;/div&gt; structure, which provides potential future tax benefits for SCS when the equity holders ultimately exchange their pass-through interests for Class&#160;A ordinary shares in SCS. &lt;/div&gt;</us-gaap:NatureOfOperations>
    <dei:EntityIncorporationDateOfIncorporation contextRef="P12_12_2018To12_31_2018">2018-12-12</dei:EntityIncorporationDateOfIncorporation>
    <prok:InitialCapital
      contextRef="PAsOn12_31_2018"
      decimals="-3"
      unitRef="Unit_USD">75000000000</prok:InitialCapital>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="P01_09_2019To01_09_2019_RegenAndTwinCityBioLlcMemberusgaapBusinessAcquisitionAxis"
      decimals="-3"
      unitRef="Unit_USD">62000000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 2: Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The condensed consolidated financial statements reflect the operations of ProKidney and its wholly-owned subsidiaries consisting of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-KY&lt;/div&gt; and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-US&lt;/div&gt; (together, the &#x201c;Company&#x201d;). All intercompany transactions and accounts have been eliminated. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company&#x2019;s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair presentation of the Company&#x2019;s financial information. These interim results and cash flows for any interim period are not necessarily indicative of the results to be expected for the full year. Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States of America (GAAP) as found in the Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB). These unaudited consolidated financial statements are presented in U.S. Dollars. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Going Concern &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company performed an analysis of its ability to continue as a going concern. As of March&#160;31, 2022, the Company had an accumulated deficit of $228,996,000. The Company has generated losses from operations for each year since its inception. The Company intends to continue to conduct significant additional research, development, and clinical study activities which, together with expenses incurred for general and administrative expenses, are expected to result in continuing operating losses for the foreseeable future. The amount of future losses and when, if ever, the Company will achieve profitability are uncertain. The Company&#x2019;s ability to achieve profitability will depend, among other things, on successfully completing clinical studies, obtaining requisite regulatory approvals, establishing appropriate pricing for its product with payers, and raising sufficient funds to finance the Company&#x2019;s activities. No assurance can be given that the Company&#x2019;s clinical development efforts will be successful, that regulatory approvals will be obtained, or that the Company will be able to achieve appropriate pricing and market access or that profitability, if achieved, can be sustained. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These matters raise substantial doubt about the Company&#x2019;s ability to continue as a going concern. As of March&#160;31, 2022, the Company has cash and cash equivalents of $29,802,000, and remaining availability of $80,000,000 under its two promissory note agreements with certain holders of its Class&#160;A Units (the &#x201c;Promissory Notes&#x201d;). The Company believes that these sources of liquidity will not be sufficient to fund its obligations for the next twelve months. The condensed consolidated financial statements do not include any adjustments related to the outcome of this uncertainty. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our ability to execute our operating plan depends on our ability to obtain additional funding through equity offerings, debt financings or potential licensing and collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to us. Even if we raise additional capital, we may also be required to modify, delay or abandon some of our plans which could have a material adverse effect on our business, operating results and financial condition and our ability to achieve our intended business objectives. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of condensed consolidated financial statements, in accordance with GAAP, requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of expenses during the reported periods. Certain estimates in these condensed consolidated financial statements have been made in connection with the calculation of research and development expenses, equity-based compensation expense and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections, which management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company considers all highly liquid investments with an original maturity of 90 days or less on the date of purchase to be cash equivalents. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Concentrations of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company&#x2019;s cash and equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued expenses as presented in the Condensed Consolidated Balance Sheets as of March&#160;31, 2022 and December&#160;31, 2021 consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;818&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,832&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Clinical study related costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;653&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,031&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued legal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,095&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;964&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Manufacturing improvement costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,137&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,164&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other accrued expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;414&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;222&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total accrued expenses and other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,117&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,213&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;   &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and Development Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries, benefits, third party license fees, and external costs of outside vendors engaged to conduct manufacturing and preclinical development activities and clinical trials. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company records accruals based on estimates of services received, efforts expended, and amounts owed pursuant to contracts with numerous contract research organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company&#x2019;s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company&#x2019;s estimate of the degree of completion of the event or events specified in the specific clinical study. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Condensed Consolidated Statement of Operations and Comprehensive Loss as the Company receives the related goods or services. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Costs incurred in obtaining technology licenses are charged to research and development expense as purchased &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development if the technology licensed has not reached technological feasibility and has no alternative future use. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fixed Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fixed assets are stated at cost, less accumulated depreciation. Generally, expenditures for maintenance and repairs are charged to expense and major improvements or replacements are capitalized. The Company computes depreciation and amortization using the straight-line method over the estimated useful life of the asset. Leasehold improvements are amortized over the lesser of, the life of the lease or the estimated useful life of the leasehold improvement. The estimated useful lives are as follows: &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer equipment and software&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-5&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture and equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5-7&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;remainder of lease term&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fixed assets consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture and equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,220&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,180&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer equipment and software&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;589&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;569&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,520&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,517&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Construction in progress&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;631&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;351&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: accumulated depreciation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,857&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,259&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total fixed assets, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,103&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,358&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation expense for the three months ended March&#160;31, 2022 and 2021 was $593,000 and $176,000, respectively. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets are comprised of acquired assembled workforce, which are accounted for in accordance with ASC 350&#x2014;Intangibles&#x2014;Goodwill and Other. The acquired assembled workforce is amortized on a straight-line basis over the useful life of five years. The following table summarizes information related to the Company&#x2019;s assembled workforce intangible asset (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross carrying amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,073&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,073&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;699&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;645&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net carrying amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;374&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;428&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated amortization expense for the remaining nine months of 2022 is $154,000, $215,000 for the year ended December&#160;31, 2023 and $5,000 for the year ended December&#160;31, 2024. Amortization expense relating to the assembled workforce intangible asset was $54,000 for each of the three months ended March&#160;31, 2022 and 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairment of Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-lived assets such as fixed assets and intangible assets subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. No impairment charges have been recorded for the three months ended March&#160;31, 2022 or 2021. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company was organized as a limited liability company, is now a limited partnership and is classified as a partnership for U.S. income tax purposes, and as such, only records a provision for federal and state income taxes on its subsidiaries organized as C corporations or which have elected to be treated as corporations for U.S. federal income tax purposes. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-US&lt;/div&gt; is a limited liability company and has elected to be treated as a C corporation. Therefore, a provision for federal and state taxes has been recorded. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-KY&lt;/div&gt; has been granted, by the Government in Council of the Cayman Islands, tax concessions under an undertaking certificate exempting it from any tax levied on profits, income, gains or appreciations in relation to its operations or in the nature of estate duty or inheritance tax for a period of twenty years from January&#160;20, 2016. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-KY&lt;/div&gt; elected to be treated as an entity disregarded from its owner for U.S. tax purposes, and as a result, it has not recorded an income tax provision. &lt;br/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company uses the liability method in accounting for income taxes as required by ASC Topic 740 &#x2014; Income Taxes, under which deferred tax assets and liabilities are recorded for the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that such assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, available taxes in the carryback periods, projected future taxable income and tax planning strategies in making this assessment. Accordingly, the Company has provided a full valuation allowance to offset the net deferred tax assets at March&#160;31, 2022 and December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest and penalties related to income taxes are included in the benefit (provision) for income taxes in the Company&#x2019;s Condensed Consolidated Statements of Operations and Comprehensive Loss. The Company has not incurred any significant interest or penalties related to income taxes in any of the periods presented. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;three-level&lt;/div&gt; fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three&#160;levels of inputs used to measure fair value are as follows: &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1 &#x2013; Unadjusted quoted prices in active markets for identical assets or liabilities &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;2 &#x2013; Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable through correlation with market data &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;3 &#x2013; Unobservable inputs that are supported by little or no market data, which require the reporting entity to develop its own assumptions &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The carrying values of cash equivalents, accounts payable, and accrued liabilities approximate fair value due to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;short-term&lt;/div&gt; nature of these instruments. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company determines if an arrangement is a lease at inception.&#160;Balances recognized related to the Company&#x2019;s operating and finance leases are included in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets, net and lease liabilities in the Condensed Consolidated Balance Sheets.&#160;Right of use assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date.&#160;Lease terms may include options to extend or terminate the lease if it is reasonably certain that the Company will exercise the option.&#160;As most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments.&#160;The right of use asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred.&#160;The Company has elected a practical expedient to not separate its lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components and instead account for them as a single lease component. Leases with a term of 12 months or less are not recorded on the balance sheet. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.&#160;Lease payments for short-term leases are recorded to operating expense on a straight-line basis and variable lease payments are recorded in the period in which the obligation for those payments is incurred. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company records reserves for contingent liabilities when it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements, and the amount of the loss can be reasonably estimated. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Deed for the Establishment of a Limited Partnership of ProKidney LP, dated as of August&#160;5, 2021 (the &#x201c;Limited Partnership Agreement&#x201d;) which replaced the Amended and Restated Limited Liability Company Agreement of ProKidney LLC as the governing document of the parent entity in the Company, allows for the issuance of Profits Interests (as defined in the Limited Partnership Agreement) to employees, directors, other service providers of the Company and others denominated in the form of one or more Class&#160;B Units (as defined in the Limited Partnership Agreement). &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On January&#160;17, 2022, the Company amended and restated its Limited Partnership Agreement (the &#x201c;Amended and Restated Limited Partnership Agreement&#x201d;) in part to authorize the issuance of up to 50,000,000 Class&#160;B Units (including &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;B-1&lt;/div&gt; Units). The Amended and Restated Limited Partnership Agreement provides that certain qualified distribution events will result in holders of Profits Interests receiving disproportionate distributions from ProKidney until each such holder&#x2019;s valuation threshold has been reduced to zero in order to &#x201c;catch up&#x201d; such holder&#x2019;s distributions to its pro rata share of aggregate cumulative distributions, and once sufficient distributions to a holder of Profits Interests have been made in accordance with the foregoing, the associated Class&#160;B Units will automatically be converted into Class&#160;A Units. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company measures compensation expense for Profits Interests based on estimated fair values at the time of grant. The Company estimates the fair value of Profits Interests using generally accepted valuation procedures. The Company recognizes compensation expense, on a straight-line basis, for the portion of the Profits Interests&#x2019; value that is expected to vest over the requisite service period. The Company records forfeitures of Profits Interests as they occur. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company operates in only one segment. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recently Adopted Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In February 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-02,&lt;/div&gt; Leases (Topic 842), which requires lessees to recognize a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset and a liability on the balance sheet for all leases, with the exception of short-term leases. The lease liability will be equal to the present value of lease payments, and the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset will be based on the lease liability, subject to adjustment such as for initial direct costs. Leases will continue to be classified as either operating or finance leases in the income statement. The guidance is effective for annual periods beginning after December&#160;15, 2021, with early adoption permitted. The Company early adopted ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-02,&lt;/div&gt; Leases (Topic 842), as of January&#160;1, 2021. For additional detail, see Note 4, Leases. &lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subsequent Events &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has evaluated subsequent events through June 10, 2022, which is the date the consolidated financial statements were available to be issued. See additional information in Note 9. &lt;/div&gt;&lt;/div&gt; </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basis of Presentation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The condensed consolidated financial statements reflect the operations of ProKidney and its wholly-owned subsidiaries consisting of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-KY&lt;/div&gt; and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-US&lt;/div&gt; (together, the &#x201c;Company&#x201d;). All intercompany transactions and accounts have been eliminated. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These unaudited condensed consolidated financial statements have been prepared on the same basis as the Company&#x2019;s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair presentation of the Company&#x2019;s financial information. These interim results and cash flows for any interim period are not necessarily indicative of the results to be expected for the full year. Any reference in these notes to applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States of America (GAAP) as found in the Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB). These unaudited consolidated financial statements are presented in U.S. Dollars. &lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <prok:GoingConcernPolicyTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Going Concern &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company performed an analysis of its ability to continue as a going concern. As of March&#160;31, 2022, the Company had an accumulated deficit of $228,996,000. The Company has generated losses from operations for each year since its inception. The Company intends to continue to conduct significant additional research, development, and clinical study activities which, together with expenses incurred for general and administrative expenses, are expected to result in continuing operating losses for the foreseeable future. The amount of future losses and when, if ever, the Company will achieve profitability are uncertain. The Company&#x2019;s ability to achieve profitability will depend, among other things, on successfully completing clinical studies, obtaining requisite regulatory approvals, establishing appropriate pricing for its product with payers, and raising sufficient funds to finance the Company&#x2019;s activities. No assurance can be given that the Company&#x2019;s clinical development efforts will be successful, that regulatory approvals will be obtained, or that the Company will be able to achieve appropriate pricing and market access or that profitability, if achieved, can be sustained. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;These matters raise substantial doubt about the Company&#x2019;s ability to continue as a going concern. As of March&#160;31, 2022, the Company has cash and cash equivalents of $29,802,000, and remaining availability of $80,000,000 under its two promissory note agreements with certain holders of its Class&#160;A Units (the &#x201c;Promissory Notes&#x201d;). The Company believes that these sources of liquidity will not be sufficient to fund its obligations for the next twelve months. The condensed consolidated financial statements do not include any adjustments related to the outcome of this uncertainty. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Our ability to execute our operating plan depends on our ability to obtain additional funding through equity offerings, debt financings or potential licensing and collaboration arrangements. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to us. Even if we raise additional capital, we may also be required to modify, delay or abandon some of our plans which could have a material adverse effect on our business, operating results and financial condition and our ability to achieve our intended business objectives. &lt;/div&gt;&lt;/div&gt;</prok:GoingConcernPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn03_31_2022"
      decimals="0"
      unitRef="Unit_USD">-228996000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn03_31_2022"
      decimals="0"
      unitRef="Unit_USD">29802000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount
      contextRef="PAsOn03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      unitRef="Unit_USD">80000000</us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount>
    <us-gaap:UseOfEstimates contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The preparation of condensed consolidated financial statements, in accordance with GAAP, requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the amounts of expenses during the reported periods. Certain estimates in these condensed consolidated financial statements have been made in connection with the calculation of research and development expenses, equity-based compensation expense and the provision for or benefit from income taxes. The Company bases its estimates on historical experience and various other assumptions, including in certain circumstances future projections, which management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known. &lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company considers all highly liquid investments with an original maturity of 90 days or less on the date of purchase to be cash equivalents. The carrying value of cash and cash equivalents approximates fair value due to the short-term nature of these items. &lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Concentrations of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Cash and equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company&#x2019;s cash and equivalents are deposited in accounts at large financial institutions, and amounts may exceed federally insured limits. &lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <prok:AccruedExpensesPolicyTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued expenses as presented in the Condensed Consolidated Balance Sheets as of March&#160;31, 2022 and December&#160;31, 2021 consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;818&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,832&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Clinical study related costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;653&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,031&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued legal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,095&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;964&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Manufacturing improvement costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,137&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,164&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other accrued expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;414&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;222&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total accrued expenses and other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,117&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,213&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  </prok:AccruedExpensesPolicyTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued expenses as presented in the Condensed Consolidated Balance Sheets as of March&#160;31, 2022 and December&#160;31, 2021 consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Compensation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;818&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,832&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Clinical study related costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;653&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,031&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accrued legal&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,095&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;964&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Manufacturing improvement costs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3,137&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4,164&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Other accrued expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;414&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;222&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total accrued expenses and other&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,117&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;9,213&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">818000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1832000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <prok:AccruedClinicalStudyRelatedCostsCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">653000</prok:AccruedClinicalStudyRelatedCostsCurrent>
    <prok:AccruedClinicalStudyRelatedCostsCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2031000</prok:AccruedClinicalStudyRelatedCostsCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3095000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">964000</us-gaap:AccruedProfessionalFeesCurrent>
    <prok:AccruedManufacturingImprovementCosts
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">3137000</prok:AccruedManufacturingImprovementCosts>
    <prok:AccruedManufacturingImprovementCosts
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">4164000</prok:AccruedManufacturingImprovementCosts>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">414000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">222000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">8117000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">9213000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and Development Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development costs are expensed as incurred. Research and development expenses are comprised of costs incurred in performing research and development activities, including salaries, benefits, third party license fees, and external costs of outside vendors engaged to conduct manufacturing and preclinical development activities and clinical trials. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company records accruals based on estimates of services received, efforts expended, and amounts owed pursuant to contracts with numerous contract research organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company&#x2019;s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company&#x2019;s estimate of the degree of completion of the event or events specified in the specific clinical study. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expense in the Condensed Consolidated Statement of Operations and Comprehensive Loss as the Company receives the related goods or services. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Costs incurred in obtaining technology licenses are charged to research and development expense as purchased &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;in-process&lt;/div&gt; research and development if the technology licensed has not reached technological feasibility and has no alternative future use. &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fixed Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fixed assets are stated at cost, less accumulated depreciation. Generally, expenditures for maintenance and repairs are charged to expense and major improvements or replacements are capitalized. The Company computes depreciation and amortization using the straight-line method over the estimated useful life of the asset. Leasehold improvements are amortized over the lesser of, the life of the lease or the estimated useful life of the leasehold improvement. The estimated useful lives are as follows: &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer equipment and software&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-5&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture and equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5-7&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;remainder of lease term&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fixed assets consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture and equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,220&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,180&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer equipment and software&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;589&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;569&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,520&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,517&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Construction in progress&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;631&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;351&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: accumulated depreciation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,857&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,259&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total fixed assets, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,103&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,358&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Depreciation expense for the three months ended March&#160;31, 2022 and 2021 was $593,000 and $176,000, respectively. &lt;/div&gt;&lt;/div&gt; </us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <prok:DisclosureInTabularFormOfUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock contextRef="P01_01_2022To03_31_2022">The estimated useful lives are as follows: &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="width: 4%; vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;
&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;;"/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer equipment and software&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;3-5&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture and equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;5-7&lt;/div&gt; years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;;text-align:center;"&gt;remainder of lease term&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </prok:DisclosureInTabularFormOfUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2022To03_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2022To03_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2022To03_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="P01_01_2022To03_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MinimumMembersrtRangeAxis">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="P01_01_2022To03_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">remainder of lease term</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fixed assets consisted of the following (in thousands): &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-block: 0em; margin-bottom: 0px; margin-top: 0px;"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Furniture and equipment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,220&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,180&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Computer equipment and software&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;589&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;569&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leasehold improvements&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,520&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,517&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Construction in progress&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;631&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;351&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: accumulated depreciation&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,857&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(2,259&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total fixed assets, net&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,103&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;11,358&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn03_31_2022_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">2220000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">2180000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn03_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">589000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">569000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn03_31_2022_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">10520000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">10517000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn03_31_2022_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">631000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2021_ConstructionInProgressMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">351000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2857000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">2259000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">11103000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">11358000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="P01_01_2022To03_31_2022"
      decimals="0"
      unitRef="Unit_USD">593000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="P01_01_2021To03_31_2021"
      decimals="0"
      unitRef="Unit_USD">176000</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Intangible assets are comprised of acquired assembled workforce, which are accounted for in accordance with ASC 350&#x2014;Intangibles&#x2014;Goodwill and Other. The acquired assembled workforce is amortized on a straight-line basis over the useful life of five years. The following table summarizes information related to the Company&#x2019;s assembled workforce intangible asset (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross carrying amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,073&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,073&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;699&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;645&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net carrying amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;374&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;428&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Estimated amortization expense for the remaining nine months of 2022 is $154,000, $215,000 for the year ended December&#160;31, 2023 and $5,000 for the year ended December&#160;31, 2024. Amortization expense relating to the assembled workforce intangible asset was $54,000 for each of the three months ended March&#160;31, 2022 and 2021. &lt;/div&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="P01_01_2022To03_31_2022_AcquiredAssemblyWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="P01_01_2022To03_31_2022">The following table summarizes information related to the Company&#x2019;s assembled workforce intangible asset (in thousands):
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Gross carrying amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,073&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,073&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Accumulated amortization&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;699&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;645&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net carrying amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;374&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;428&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1073000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1073000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">699000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">645000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">374000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">428000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="PAsOn03_31_2022"
      decimals="0"
      unitRef="Unit_USD">154000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="PAsOn03_31_2022"
      decimals="0"
      unitRef="Unit_USD">215000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="PAsOn03_31_2022"
      decimals="0"
      unitRef="Unit_USD">5000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2021To03_31_2021_AcquiredAssemblyWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="0"
      unitRef="Unit_USD">54000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="P01_01_2022To03_31_2022_AcquiredAssemblyWorkforceMemberusgaapFiniteLivedIntangibleAssetsByMajorClassAxis"
      decimals="0"
      unitRef="Unit_USD">54000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Impairment of Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Long-lived assets such as fixed assets and intangible assets subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. No impairment charges have been recorded for the three months ended March&#160;31, 2022 or 2021. &lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="P01_01_2021To03_31_2021"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="P01_01_2022To03_31_2022"
      decimals="0"
      unitRef="Unit_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company was organized as a limited liability company, is now a limited partnership and is classified as a partnership for U.S. income tax purposes, and as such, only records a provision for federal and state income taxes on its subsidiaries organized as C corporations or which have elected to be treated as corporations for U.S. federal income tax purposes. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-US&lt;/div&gt; is a limited liability company and has elected to be treated as a C corporation. Therefore, a provision for federal and state taxes has been recorded. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-KY&lt;/div&gt; has been granted, by the Government in Council of the Cayman Islands, tax concessions under an undertaking certificate exempting it from any tax levied on profits, income, gains or appreciations in relation to its operations or in the nature of estate duty or inheritance tax for a period of twenty years from January&#160;20, 2016. &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-KY&lt;/div&gt; elected to be treated as an entity disregarded from its owner for U.S. tax purposes, and as a result, it has not recorded an income tax provision. &lt;br/&gt;&lt;/div&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company uses the liability method in accounting for income taxes as required by ASC Topic 740 &#x2014; Income Taxes, under which deferred tax assets and liabilities are recorded for the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is recorded to reduce the carrying amounts of deferred tax assets unless it is more likely than not that such assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, available taxes in the carryback periods, projected future taxable income and tax planning strategies in making this assessment. Accordingly, the Company has provided a full valuation allowance to offset the net deferred tax assets at March&#160;31, 2022 and December&#160;31, 2021. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt; &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Interest and penalties related to income taxes are included in the benefit (provision) for income taxes in the Company&#x2019;s Condensed Consolidated Statements of Operations and Comprehensive Loss. The Company has not incurred any significant interest or penalties related to income taxes in any of the periods presented. &lt;/div&gt;&lt;/div&gt; </us-gaap:IncomeTaxPolicyTextBlock>
    <prok:PeriodForWhichTheProfitsEarnedAreExemptFromTax contextRef="P01_20_2016To12_31_2021_KYsrtStatementGeographicalAxis">P20Y</prok:PeriodForWhichTheProfitsEarnedAreExemptFromTax>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;three-level&lt;/div&gt; fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three&#160;levels of inputs used to measure fair value are as follows: &lt;/div&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;1 &#x2013; Unadjusted quoted prices in active markets for identical assets or liabilities &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;2 &#x2013; Inputs other than quoted prices included within Level&#160;1 that are either directly or indirectly observable through correlation with market data &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="page-break-inside: avoid;"&gt;
&lt;td style="width: 5%;"&gt;&#160;&lt;/td&gt;
&lt;td style="width: 3%; vertical-align: top;;text-align:left;"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width: 1%; vertical-align: top;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: top;;text-align:left;"&gt;&lt;div style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Level&#160;3 &#x2013; Unobservable inputs that are supported by little or no market data, which require the reporting entity to develop its own assumptions &lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; &lt;div style="clear: both; max-height: 0px;"/&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The carrying values of cash equivalents, accounts payable, and accrued liabilities approximate fair value due to the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;short-term&lt;/div&gt; nature of these instruments. &lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company determines if an arrangement is a lease at inception.&#160;Balances recognized related to the Company&#x2019;s operating and finance leases are included in &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets, net and lease liabilities in the Condensed Consolidated Balance Sheets.&#160;Right of use assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date.&#160;Lease terms may include options to extend or terminate the lease if it is reasonably certain that the Company will exercise the option.&#160;As most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments.&#160;The right of use asset also includes any lease payments made and excludes lease incentives and initial direct costs incurred.&#160;The Company has elected a practical expedient to not separate its lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components and instead account for them as a single lease component. Leases with a term of 12 months or less are not recorded on the balance sheet. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.&#160;Lease payments for short-term leases are recorded to operating expense on a straight-line basis and variable lease payments are recorded in the period in which the obligation for those payments is incurred. &lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <prok:ContingentLiabilitiesPolicyTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Contingent Liabilities &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company records reserves for contingent liabilities when it is probable that an asset has been impaired or a liability has been incurred at the date of the financial statements, and the amount of the loss can be reasonably estimated. &lt;/div&gt;&lt;/div&gt;</prok:ContingentLiabilitiesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Equity-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Deed for the Establishment of a Limited Partnership of ProKidney LP, dated as of August&#160;5, 2021 (the &#x201c;Limited Partnership Agreement&#x201d;) which replaced the Amended and Restated Limited Liability Company Agreement of ProKidney LLC as the governing document of the parent entity in the Company, allows for the issuance of Profits Interests (as defined in the Limited Partnership Agreement) to employees, directors, other service providers of the Company and others denominated in the form of one or more Class&#160;B Units (as defined in the Limited Partnership Agreement). &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;On January&#160;17, 2022, the Company amended and restated its Limited Partnership Agreement (the &#x201c;Amended and Restated Limited Partnership Agreement&#x201d;) in part to authorize the issuance of up to 50,000,000 Class&#160;B Units (including &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;B-1&lt;/div&gt; Units). The Amended and Restated Limited Partnership Agreement provides that certain qualified distribution events will result in holders of Profits Interests receiving disproportionate distributions from ProKidney until each such holder&#x2019;s valuation threshold has been reduced to zero in order to &#x201c;catch up&#x201d; such holder&#x2019;s distributions to its pro rata share of aggregate cumulative distributions, and once sufficient distributions to a holder of Profits Interests have been made in accordance with the foregoing, the associated Class&#160;B Units will automatically be converted into Class&#160;A Units. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company measures compensation expense for Profits Interests based on estimated fair values at the time of grant. The Company estimates the fair value of Profits Interests using generally accepted valuation procedures. The Company recognizes compensation expense, on a straight-line basis, for the portion of the Profits Interests&#x2019; value that is expected to vest over the requisite service period. The Company records forfeitures of Profits Interests as they occur. &lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:LimitedPartnersCapitalAccountUnitsAuthorized
      contextRef="PAsOn01_17_2022_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis"
      decimals="INF"
      unitRef="Unit_shares">50000000</us-gaap:LimitedPartnersCapitalAccountUnitsAuthorized>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Segments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company operates in only one segment. &lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="P01_01_2022To03_31_2022"
      decimals="0"
      unitRef="Unit_segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Recently Adopted Accounting Pronouncements &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In February 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-02,&lt;/div&gt; Leases (Topic 842), which requires lessees to recognize a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset and a liability on the balance sheet for all leases, with the exception of short-term leases. The lease liability will be equal to the present value of lease payments, and the &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset will be based on the lease liability, subject to adjustment such as for initial direct costs. Leases will continue to be classified as either operating or finance leases in the income statement. The guidance is effective for annual periods beginning after December&#160;15, 2021, with early adoption permitted. The Company early adopted ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;No.&#160;2016-02,&lt;/div&gt; Leases (Topic 842), as of January&#160;1, 2021. For additional detail, see Note 4, Leases. &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Subsequent Events &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has evaluated subsequent events through June 10, 2022, which is the date the consolidated financial statements were available to be issued. See additional information in Note 9. &lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 3: Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;The Company&#x2019;s subsidiary, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-US,&lt;/div&gt; is treated as a C corporation, and therefore a provision for federal and state taxes has been recorded. The Company&#x2019;s income tax provision for the three months ended March&#160;31, 2022 and 2021 were $1,010,000 and $6,000, respectively. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, available taxes in the carryback periods, projected future taxable income and tax planning strategies in making this assessment. The difference between the Company&#x2019;s effective tax rate of (1.5)% for the three months ended March&#160;31, 2022 and the U.S. statutory rate of 21% is primarily attributable to the Company and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;ProKidney-KY&lt;/div&gt; being treated as partnerships for income tax purposes. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For tax years beginning after December&#160;31, 2021, the Tax Cuts and Jobs Act of 2017 (the &#x201c;TCJA&#x201d;) requires specified research and development expenses to be capitalized and amortized ratably over a five-year period. The adoption of this provision of the TCJA is the primary driver of income tax expense recognized during the three months ended March&#160;31, 2022. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There are no net unrecognized tax benefits as of March&#160;31, 2022 which, if recognized, would affect our effective tax rate. We expect none of the gross unrecognized tax benefits will decrease within the next year. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;There have been no significant changes in the Company&#x2019;s uncertain tax positions during the three months ended March&#160;31, 2022. &lt;/div&gt;&lt;/div&gt; </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2022To03_31_2022"
      decimals="0"
      unitRef="Unit_USD">1010000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="P01_01_2021To03_31_2021"
      decimals="0"
      unitRef="Unit_USD">6000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2022To03_31_2022"
      decimals="3"
      unitRef="Unit_pure">0.015</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2022To03_31_2022"
      decimals="0"
      unitRef="Unit_USD">21</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <prok:DeferredExpenseCapitalizedResearchAndDevelopmentCostsTerm contextRef="P01_01_2022To03_31_2022">P5Y</prok:DeferredExpenseCapitalizedResearchAndDevelopmentCostsTerm>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 4: Leases &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;In February 2016, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-02:&lt;/div&gt; Leases (Topic 842). This ASU requires a lessee to recognize a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset and a lease liability on its balance sheet for most operating leases. ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-02&lt;/div&gt; is effective for annual and interim periods beginning after December&#160;15, 2018, including interim periods within those fiscal years. In July 2018, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2018-11,&lt;/div&gt; Leases (Topic 842): Targeted Improvements, which provides companies with an additional optional transition method to apply the new standard to leases in effect at the adoption date through a cumulative effect adjustment. The Company adopted the new lease standard as of January&#160;1, 2021 using the modified retrospective transition method. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The Company elected the package of practical expedients referenced in ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2016-02,&lt;/div&gt; which permits companies to retain original lease identification and classification without reassessing initial direct costs for existing leases. The Company also elected the practical expedient that exempts leases with an initial lease term of twelve months or less, as well as the practical expedient that allows companies to select, by class of underlying asset, not to separate lease and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-lease&lt;/div&gt; components. Adoption of this standard resulted in the recognition of a &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; asset and a lease liability on the Company&#x2019;s January&#160;1, 2021 Consolidated Balance Sheet of $1,560,000 and $1,559,000 respectively. There was no material impact on the Company&#x2019;s Condensed Consolidated Statement of Operations and Comprehensive Loss. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company has operating leases for real estate (primarily office space) and certain equipment with various expiration dates. The Company also has one finance lease for certain equipment.&#160;&#160;&#160;&#160;Rent expense was $89,000 and $81,000, for the three months ended March&#160;31, 2022 and 2021, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the classification of operating and finance lease assets and obligations in the Company&#x2019;s Condensed Consolidated Balance Sheets as of March&#160;31, 2022 and December&#160;31, 2021 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating leases:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right of use assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,579&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,139&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities, current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;295&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;235&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities, noncurrent&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,354&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;985&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,649&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,220&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finance leases:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right of use assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;102&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finance lease liabilities, current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finance lease liabilities, noncurrent&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;74&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;82&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total finance lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;107&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;114&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Maturities of lease liabilities for the Company&#x2019;s operating and finance leases are as follows for the year ending March&#160;31, 2022 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Operating&lt;br/&gt;Leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Finance&lt;br/&gt;Leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022 (remaining nine months)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;315&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;345&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;428&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;468&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;440&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;480&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;440&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;447&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;355&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;355&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,993&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;117&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,110&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: imputed interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(344&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(354&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Present value of lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,649&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;107&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,756&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The weighted average remaining lease term for operating leases is 4.5 years, and 3.0 years for the finance lease. The weighted average discount rate is 8.5%. &lt;/div&gt;&lt;/div&gt; </us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="PAsOn03_31_2022">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <prok:RightOfUseAssetsOperatingAndFinanceLease
      contextRef="PAsOn01_01_2021"
      decimals="-3"
      unitRef="Unit_USD">1560000000</prok:RightOfUseAssetsOperatingAndFinanceLease>
    <prok:OperatingAndFinanceLeaseLiabilitiesCurrent
      contextRef="PAsOn01_01_2021"
      decimals="-3"
      unitRef="Unit_USD">1559000000</prok:OperatingAndFinanceLeaseLiabilitiesCurrent>
    <prok:OperatingLeaseRentExpenses
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">89000000</prok:OperatingLeaseRentExpenses>
    <prok:OperatingLeaseRentExpenses
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">81000000</prok:OperatingLeaseRentExpenses>
    <prok:LesseeOperatingAndFinanceLeaseTableTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following table summarizes the classification of operating and finance lease assets and obligations in the Company&#x2019;s Condensed Consolidated Balance Sheets as of March&#160;31, 2022 and December&#160;31, 2021 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 70%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;March&#160;31,&lt;br/&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating leases:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right of use assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,579&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,139&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities, current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;295&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;235&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Operating lease liabilities, noncurrent&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,354&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;985&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total operating lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,649&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,220&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; border-bottom: 2pt double black;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; line-height: 1pt;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finance leases:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Right of use assets&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;102&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finance lease liabilities, current&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;33&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;32&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Finance lease liabilities, noncurrent&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;74&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;82&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total finance lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;107&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;114&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </prok:LesseeOperatingAndFinanceLeaseTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1579000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1139000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">295000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">235000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1354000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">985000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1649000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">1220000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">94000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">102000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">33000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">32000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">74000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">82000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiability
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">107000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="PAsOn12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">114000</us-gaap:FinanceLeaseLiability>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Maturities of lease liabilities for the Company&#x2019;s operating and finance leases are as follows for the year ending March&#160;31, 2022 (in thousands): &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 5%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Operating&lt;br/&gt;Leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Finance&lt;br/&gt;Leases&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2022 (remaining nine months)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;315&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;345&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;428&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;468&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;440&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;40&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;480&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2025&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;440&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;7&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;447&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;2026&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;355&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;355&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Thereafter&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total lease payments&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,993&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;117&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,110&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Less: imputed interest&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(344&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(354&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Present value of lease liabilities&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,649&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;107&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,756&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">315000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">30000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">345000</prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">428000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">40000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">468000</prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">440000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">40000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">480000</prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">440000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">7000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">447000</prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">355000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">355000</prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">15000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">0</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">15000</prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1993000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">117000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">2110000</prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">344000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">10000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">-354000</prok:LesseeOperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1649000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">107000</us-gaap:FinanceLeaseLiability>
    <prok:OperatingAndFinanceLeaseLiability
      contextRef="PAsOn03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">1756000</prok:OperatingAndFinanceLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn03_31_2022">P4Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn03_31_2022">P3Y</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <prok:OperatingAndFinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn03_31_2022"
      decimals="3"
      unitRef="Unit_pure">0.085</prok:OperatingAndFinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 5: Related Party Debt &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January&#160;18, 2022, in connection with the Business Combination Agreement, the Company entered into the Promissory Notes. Through such promissory notes, the holders may fund up to $100,000,000 to support the operational financing needs of the Company prior to the closing of the Business Combination. These notes bear interest at a rate of 3% per annum and are due upon the earliest of either (i)&#160;the date on which the Business Combination closes or (ii)&#160;January 17, 2023. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Drawdowns on the Promissory Notes may be made in multiples of $10,000 unless otherwise agreed upon. Once an amount is drawn down under the Promissory Notes, it is no longer available for future drawdown requests even if prepaid. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the three months ended March&#160;31, 2022, the Company borrowed $20,000,000 under this agreement, leaving remaining availability of $80,000,000 as of March&#160;31, 2022. &lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn01_18_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      unitRef="Unit_USD">100000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn01_18_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis"
      decimals="2"
      unitRef="Unit_pure">0.03</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="P01_18_2022To01_18_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis">2023-01-17</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="PAsOn03_31_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      unitRef="Unit_USD">10000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="PAsOn03_31_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      unitRef="Unit_USD">20000000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount
      contextRef="PAsOn03_31_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis"
      decimals="0"
      unitRef="Unit_USD">80000000</us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount>
    <us-gaap:MembersEquityNotesDisclosureTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt;&lt;/div&gt; &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 6: Members&#x2019; Equity &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;Ownership interests in the Company are represented by two classes of units, Class&#160;A units and Class&#160;B units. The terms of the units are governed by the LLC Agreement. As of March&#160;31, 2022, there are 190,000,000 Class&#160;A and 50,000,000 Class&#160;B Units authorized (including &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;B-1&lt;/div&gt; Units). &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Holders of Class&#160;A units have voting rights and rights to profits and losses of the Company and distributions from the Company. No Class&#160;A units were issued during the three months ended March&#160;31, 2022. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;During the three months ended March&#160;31, 2022, the Company issued 6,098,901 of its &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;B-1&lt;/div&gt; Units for total cash proceeds of $5,550,000. As these awards were issued for a price below their estimated fair value to employees, board members and other service providers, the provisions of ASC Topic 718 &#x2013; Stock Compensation apply. Refer to Note 8 for further details. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Class&#160;B Units are reserved for issuance of Profits Interests and do not have voting rights. The Profits Interests are designed so that the holders of Profits Interests only participate in a qualified distribution event and only if its valuation threshold is attained in such a distribution event as set forth in the Limited Partnership Agreement; provided, however, that the Limited Partnership Agreement, as amended and restated in January 2022, provides that certain qualified distribution events will result in the holders of Profits Interests receiving disproportionate distributions from ProKidney until each such holder&#x2019;s threshold value has been reduced to zero in order to &#x201c;catch up&#x201d; such holder&#x2019;s distributions to its pro rata share of aggregate cumulative distributions, and once sufficient distributions to a holder of Profits Interests have been made in accordance with the foregoing, the associated Class&#160;B Units will automatically be converted into Class&#160;A Units. &lt;/div&gt;&lt;/div&gt;</us-gaap:MembersEquityNotesDisclosureTextBlock>
    <us-gaap:LimitedPartnersCapitalAccountUnitsAuthorized
      contextRef="PAsOn03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="0"
      unitRef="Unit_shares">190000000</us-gaap:LimitedPartnersCapitalAccountUnitsAuthorized>
    <us-gaap:LimitedPartnersCapitalAccountUnitsAuthorized
      contextRef="PAsOn03_31_2022_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis"
      decimals="0"
      unitRef="Unit_shares">50000000</us-gaap:LimitedPartnersCapitalAccountUnitsAuthorized>
    <us-gaap:LimitedPartnersCapitalAccountUnitsIssued
      contextRef="PAsOn03_31_2022_CapitalUnitClassB1MemberusgaapCapitalUnitsByClassAxis"
      decimals="0"
      unitRef="Unit_shares">6098901</us-gaap:LimitedPartnersCapitalAccountUnitsIssued>
    <prok:ProceedsFromLimitedPartnersCapitalAccountUnits
      contextRef="P01_01_2022To03_31_2022_CapitalUnitClassB1MemberusgaapCapitalUnitsByClassAxis"
      decimals="0"
      unitRef="Unit_USD">5550000</prok:ProceedsFromLimitedPartnersCapitalAccountUnits>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 7: Net Loss per Share &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Basic loss per share (&#x201c;EPS&#x201d;) was computed by dividing net loss by the number of weighted average units of Class&#160;A Units outstanding during the period. Diluted EPS was calculated to give effect to potentially issuable dilutive units of common units using the treasury method. For all periods presented, the vested Profits Interests have been excluded from the diluted EPS calculation as their effect would be anti-dilutive. The following table sets forth the calculation of basic and diluted earnings per share for the periods indicated based on the weighted average number of common shares outstanding: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss available to Class&#160;A Unit holders&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(67,486&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11,609&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average Class&#160;A Units outstanding, basic and diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;186,500,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;122,111,111&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss per Class&#160;A Unit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss per Class&#160;A Unit, basic and diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="P01_01_2022To03_31_2022">The following table sets forth the calculation of basic and diluted earnings per share for the periods indicated based on the weighted average number of common shares outstanding:
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 60%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three Months Ended March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Numerator&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss available to Class&#160;A Unit holders&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(67,486&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(11,609&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Denominator&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Weighted average Class&#160;A Units outstanding, basic and diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;186,500,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;122,111,111&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss per Class&#160;A Unit&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Net loss per Class&#160;A Unit, basic and diluted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(0.10&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="0"
      unitRef="Unit_USD">-67486</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To03_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="0"
      unitRef="Unit_USD">-11609</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2022To03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="0"
      unitRef="Unit_shares">186500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2022To03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="0"
      unitRef="Unit_shares">186500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2021To03_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="0"
      unitRef="Unit_shares">122111111</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2021To03_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="0"
      unitRef="Unit_shares">122111111</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2022To03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2022To03_31_2022_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2021To03_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.1</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2021To03_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis"
      decimals="2"
      unitRef="Unit_USD_per_Share">-0.1</us-gaap:EarningsPerShareBasic>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 8: Equity Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Profits Interests Awards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The issuance of Profits Interests to employees, directors, and other service providers of the Company (&#x201c;Plan Participants&#x201d;) is administered at the discretion of ProKidney GP Limited, the general partner of ProKidney (the &#x201c;General Partner&#x201d;). Profits Interests allow the Plan Participants to participate in the residual profits of the Company after the distribution of proceeds reach a minimum threshold value. The threshold value is the amount of proceeds that must be distributed to the holders of Class&#160;A Units before the Plan Participants can participate in a distribution. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under the Limited Partnership Agreement, the General Partner determines the terms and conditions of the Profits Interests issued. The threshold value assigned to each grant shall not be less than the fair market value of the Company on the date of grant. Profits Interests awards vest at a rate of 25% on the latter of the first anniversary of employment and the first anniversary of the Acquisition Date with the remaining 75% to vest in increments of 25% on each anniversary following the first anniversary date, ratably over a three or four-year period from the date of grant, in annual installments of 33.3% over the three-year period from the date of grant, or in increments of 6.25% each calendar quarter following the first anniversary date. The Profits Interests are subject to a repurchase option should the plan participant no longer be employed by the Company. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The following table summarizes the activity for the three months ended March&#160;31, 2022, related to the Company&#x2019;s Class&#160;B and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-1&lt;/div&gt; Units granted as equity awards to its employees, board members and service providers: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt;Average&#160;Grant&lt;br/&gt;Date&#160;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unvested awards outstanding at January&#160;1, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,460,617&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,498,488&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vested&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(449,486&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(29,070&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unvested awards outstanding at March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,480,549&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;As of March&#160;31, 2022, the unrecognized compensation expense related to these awards was $50,020,000. The current weighted average remaining period over which the unrecognized compensation expense is expected to be recognized is 3.6 years. The weighted average grant date fair value of the Profits Interests granted during the three months ended March&#160;31, 2022, was $6.03 per &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;B-1&lt;/div&gt; unit. There were no Profits Interests granted during the three months ended March&#160;31, 2021. &lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;As of March&#160;31, 2022, there remain 22,164,559 Class&#160;B Units available for issuance. Given that these instruments meet the criteria for being considered profits interests, the Company has recognized no tax benefit related to these awards.&lt;/div&gt;&lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Modification to Profits Interest Awards &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On January&#160;17, 2022, the Limited Partnership Agreement was amended and restated to provide that certain qualified distribution events will result in the holders of Profits Interests receiving disproportionate distributions from ProKidney until each such holder&#x2019;s threshold value has been reduced to zero in order to &#x201c;catch up&#x201d; such holder&#x2019;s distributions to its pro rata share of aggregate cumulative distributions, and once sufficient distributions to a holder of Profits Interests have been made in accordance with the foregoing, the associated Class&#160;B Units will automatically be converted into Class&#160;A Units. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;This amendment constitutes a modification to the Class&#160;B Units outstanding as of the date of the modification under the provisions of ASC Topic 718. In connection with the modification of its outstanding share-based compensation awards, the Company will recognize total additional compensation expense of $5,437,000 related to awards granted to its employees. The portion of this additional compensation expense attributable to vested awards of $3,715,000 was recognized immediately upon modification during the three months ended March&#160;31, 2022. &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Issuance of Profits Interests to Service Provider &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;During the three months ended March&#160;31, 2022, the Company issued 2,750,000 fully vested &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;B-1&lt;/div&gt; Units to a third party service provider as payment for research and development services provided in prior periods. The Company had previously recognized expense of $2,502,000 for these services based on the liability related to the services incurred. As the fair value of shares issued to satisfy that obligation was higher than the amount previously expensed, the Company recognized additional research and development expense of $14,080,000 during the three months ended March&#160;31, 2022. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Purchase of &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;B-1&lt;/div&gt; Units &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;As discussed further in Note 6, certain of the Company&#x2019;s employees, board members and service providers purchased 6,098,901 of its &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;B-1&lt;/div&gt; Units for total cash proceeds of $5,550,000 during the three months ended March&#160;31, 2022. Since these &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;B-1&lt;/div&gt; Units were fully vested upon purchase and contain no service requirements, the Company immediately recognized the difference between the purchase price and the estimated fair value for these &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Class&#160;B-1&lt;/div&gt; Units of $31,226,000 as equity-based compensation expense during the three months ended March&#160;31, 2022. &lt;/div&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Compensation Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;During the three months ended March&#160;31, 2022 and 2021, the Company recognized equity-based compensation expense of $52,686,000 and $175,000, respectively. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Compensation expense related to the issuance and purchase of Class&#160;B and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-1&lt;/div&gt; Units is included in research and development and general and administrative expense as follows (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,367&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,319&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;175&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total equity-based compensation expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;52,686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;175&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Fair Value Estimate &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The Company is privately held with no active public market for its equity instruments. Therefore, for financial reporting purposes, management may periodically determine the estimated per share fair value of the Company&#x2019;s equity shares (including Profits Interests) using contemporaneous valuations. These contemporaneous valuations are done using methodologies consistent with the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, also known as the Practice Aid. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;For the Profits Interest Awards granted during the three months ended March&#160;31, 2022, the valuation approach utilized a hybrid method which consists of a combination of an Option Pricing Method (OPM) and a Probability Weighted Expected Return Method (PWERM) approach. Weighting allocations were assigned to the OPM and PWERM methods based upon the expected likelihood of possible future liquidity events, including the Business Combination. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Under the OPM approach, the fair value of the total equity of the Company within each scenario was first estimated using a back-solve method wherein the equity value is derived from a recent transaction in the Company&#x2019;s own securities, and then the total equity value is allocated to the various components of the capital structure, including the Profits Interests, using an OPM or a waterfall approach based on the specific rights of &lt;/div&gt;&lt;/div&gt;  &lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"/&gt; &lt;div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;each of the equity classes. The OPM uses the fair value of the total equity of the Company within a scenario as a starting point and incorporates assumptions made regarding the expected returns and volatilities that are consistent with the expectations of market participants, and distribution of equity values is produced which cover the range of events that an informed market participant might expect. This process creates a range of equity values both between and within scenarios. The fair value measurement is sensitive to changes in the unobservable inputs. Changes in those inputs might result in a higher or lower fair value measurement. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The PWERM approach is a scenario-based analysis that estimates the value per share of common stock based on the probability-weighted present value of expected future equity values for the common stock, under various possible future liquidity event scenarios, including the proposed Business Combination, in light of the rights and preferences of each class and series of stock, including the Profits Interests, discounted for a lack of marketability. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;In performing these valuations, management considered all objective and subjective factors that they believed to be relevant, including management&#x2019;s best estimate of the Company&#x2019;s business condition, prospects, and operating performance at each valuation date. Within the valuations performed, a range of factors, assumptions, and methodologies were used. The significant factors included trends within the industry, the prices at which the Company sold Class&#160;A units, the rights and preferences of the Class&#160;A units relative to the Class&#160;B units at the time of each measurement date, the results of operations, financial position, status of research and development efforts, stage of development and business strategy, the lack of an active public market for the units, and the likelihood of achieving an exit event in light of prevailing market conditions. &lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following reflects the key assumptions used in each of the valuation scenarios: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;OPM&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;PWERM&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total equity value (in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;280,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,750,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected volatility of total equity&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;60&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Discount for lack of market&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected time to exit event&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.7 years&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.5 years&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;  </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P01_01_2022To03_31_2022_OnTheLatterOfTheFirstAnniversaryMemberusgaapVestingAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P01_01_2022To03_31_2022_InFirstAnniversaryOfTheAcquisitionDateMemberusgaapVestingAxis"
      decimals="2"
      unitRef="Unit_pure">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P01_01_2022To03_31_2022_OnEachEnniversaryMemberusgaapVestingAxis"
      decimals="2"
      unitRef="Unit_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P01_01_2022To03_31_2022_OverTheThreeYearPeriodFromTheDateOfGrantMemberusgaapVestingAxis"
      decimals="3"
      unitRef="Unit_pure">0.333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P01_01_2022To03_31_2022_EachCalendarQuarterMemberusgaapVestingAxis"
      decimals="4"
      unitRef="Unit_pure">0.0625</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;The following table summarizes the activity for the three months ended March&#160;31, 2022, related to the Company&#x2019;s Class&#160;B and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-1&lt;/div&gt; Units granted as equity awards to its employees, board members and service providers: &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 64%;"/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 9%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number of&lt;br/&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt;Average&#160;Grant&lt;br/&gt;Date&#160;Fair&#160;Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unvested awards outstanding at January&#160;1, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;2,460,617&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;8,498,488&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Vested&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(449,486&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.36&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;(29,070&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;6.03&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Unvested awards outstanding at March&#160;31, 2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;10,480,549&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;4.94&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="PAsOn12_31_2021"
      decimals="INF"
      unitRef="Unit_shares">2460617</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2021"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.36</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2022To03_31_2022"
      decimals="INF"
      unitRef="Unit_shares">8498488</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2022To03_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">6.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="P01_01_2022To03_31_2022"
      decimals="INF"
      unitRef="Unit_shares">449486</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="P01_01_2022To03_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">0.36</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="P01_01_2022To03_31_2022"
      decimals="INF"
      unitRef="Unit_shares">29070</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="P01_01_2022To03_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">6.03</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="PAsOn03_31_2022"
      decimals="INF"
      unitRef="Unit_shares">10480549</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn03_31_2022"
      decimals="2"
      unitRef="Unit_USD_per_Share">4.94</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn03_31_2022"
      decimals="0"
      unitRef="Unit_USD">50020000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="P01_01_2022To03_31_2022">P3Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2022To03_31_2022"
      decimals="INF"
      unitRef="Unit_USD_per_Share">6.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <prok:CommonUnitsUnissued
      contextRef="PAsOn03_31_2022_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis"
      decimals="INF"
      unitRef="Unit_shares">22164559</prok:CommonUnitsUnissued>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_USD">5437000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="P01_01_2022To03_31_2022_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="0"
      unitRef="Unit_USD">3715000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:PartnersCapitalAccountUnitsUnitbasedCompensation
      contextRef="P01_01_2022To03_31_2022"
      decimals="INF"
      unitRef="Unit_shares">2750000</us-gaap:PartnersCapitalAccountUnitsUnitbasedCompensation>
    <us-gaap:PartnersCapitalAccountUnitBasedCompensation
      contextRef="P01_01_2022To03_31_2022"
      decimals="0"
      unitRef="Unit_USD">2502000</us-gaap:PartnersCapitalAccountUnitBasedCompensation>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="P01_01_2022To03_31_2022"
      decimals="0"
      unitRef="Unit_USD">14080000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:CommonUnitIssued
      contextRef="PAsOn03_31_2022_ClassB1unitsMemberusgaapCapitalUnitsByClassAxis"
      decimals="INF"
      unitRef="Unit_shares">6098901</us-gaap:CommonUnitIssued>
    <us-gaap:CommonUnitIssuanceValue
      contextRef="PAsOn03_31_2022_ClassB1unitsMemberusgaapCapitalUnitsByClassAxis"
      decimals="0"
      unitRef="Unit_USD">5550000</us-gaap:CommonUnitIssuanceValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To03_31_2022_ClassB1unitsMemberusgaapCapitalUnitsByClassAxis"
      decimals="0"
      unitRef="Unit_USD">31226000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To03_31_2022"
      decimals="0"
      unitRef="Unit_USD">52686000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To03_31_2021"
      decimals="0"
      unitRef="Unit_USD">175000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;Compensation expense related to the issuance and purchase of Class&#160;B and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;B-1&lt;/div&gt; Units is included in research and development and general and administrative expense as follows (in thousands): &lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 66%;"/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 11%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Three&#160;Months&#160;Ended&#160;March&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&#160;&#160;&#160;2021&#160;&#160;&#160;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;17,367&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;General and administrative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;35,319&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;175&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total equity-based compensation expense&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;52,686&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;175&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size: 1px;"&gt;
&lt;td style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 0px;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To03_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">17367000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To03_31_2022_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">35319000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To03_31_2021_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      unitRef="Unit_USD">175000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2022To03_31_2022"
      decimals="-3"
      unitRef="Unit_USD">52686000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2021To03_31_2021"
      decimals="-3"
      unitRef="Unit_USD">175000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;The following reflects the key assumptions used in each of the valuation scenarios: &lt;/div&gt;&lt;/div&gt; &lt;div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;;text-indent: 0px;"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width: 69%;"/&gt;
&lt;td style="width: 7%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td style="width: 6%; vertical-align: bottom;"/&gt;
&lt;td/&gt;
&lt;td/&gt;
&lt;td/&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;OPM&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;PWERM&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Total equity value (in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;280,400&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;$&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;1,750,000&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected volatility of total equity&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;95&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;60&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Discount for lack of market&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;30&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;15&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"&gt;
&lt;td style="vertical-align: top;"&gt;&lt;div style="text-indent: -1em; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Expected time to exit event&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;3.7 years&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"&gt;0.5 years&lt;/td&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt; </us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:MembersEquity
      contextRef="PAsOn03_31_2022_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="-3"
      unitRef="Unit_USD">280400000</us-gaap:MembersEquity>
    <us-gaap:MembersEquity
      contextRef="PAsOn03_31_2022_ValuationTechniqueProbabilityWeightedExpectedReturnMethodMemberusgaapValuationTechniqueAxis"
      decimals="-3"
      unitRef="Unit_USD">1750000000</us-gaap:MembersEquity>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2022To03_31_2022_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      unitRef="Unit_pure">0.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2022To03_31_2022_ValuationTechniqueProbabilityWeightedExpectedReturnMethodMemberusgaapValuationTechniqueAxis"
      decimals="2"
      unitRef="Unit_pure">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions
      contextRef="P01_01_2022To03_31_2022_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis"
      decimals="2"
      unitRef="Unit_pure">0.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions
      contextRef="P01_01_2022To03_31_2022_ValuationTechniqueProbabilityWeightedExpectedReturnMethodMemberusgaapValuationTechniqueAxis"
      decimals="2"
      unitRef="Unit_pure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2022To03_31_2022_ValuationTechniqueOptionPricingModelMemberusgaapValuationTechniqueAxis">P3Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2022To03_31_2022_ValuationTechniqueProbabilityWeightedExpectedReturnMethodMemberusgaapValuationTechniqueAxis">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2022To03_31_2022">&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;;text-indent: 0px;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Note 9: Subsequent Events &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style="text-indent: 4%; font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"&gt;&lt;div style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"&gt;On June&#160;1, 2022, the Company issued Profits Interests to certain Plan Participants in the form of 1,478,590 Class&#160;B-1 Units. Additionally, the Company issued 549,451 of its Class&#160;B-1 Units for total value received by the Company (or its subsidiaries) of $500,000. &lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:LimitedPartnersCapitalAccountUnitsIssued
      contextRef="PAsOn06_01_2022_CapitalUnitClassBOneMemberusgaapCapitalUnitsByClassAxis_DeferredProfitSharingMemberusgaapDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">1478590</us-gaap:LimitedPartnersCapitalAccountUnitsIssued>
    <us-gaap:LimitedPartnersCapitalAccountUnitsIssued
      contextRef="PAsOn06_01_2022_CapitalUnitClassBOneMemberusgaapCapitalUnitsByClassAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      unitRef="Unit_shares">549451</us-gaap:LimitedPartnersCapitalAccountUnitsIssued>
    <us-gaap:CapitalUnits
      contextRef="PAsOn06_01_2022_CapitalUnitClassBOneMemberusgaapCapitalUnitsByClassAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="-3"
      unitRef="Unit_USD">500000000</us-gaap:CapitalUnits>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>92
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( !6?"%4'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  5GPA5MP1]M^\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9)-
M:L,P$$:O4K2WQY9I*,+Q)B6K% H-M'0GI$DB:OT@3;%S^\INXE#: Q2TT<RG
M-V] K0I"^8C/T0>,9##=C;9W2:BP9B>B( "2.J&5J<P)EYL''ZVD?(U'"%)]
MR","KZH56"2I)4F8@$58B*QKM1(JHB0?+WBM%GSXC/T,TPJP1XN.$M1E#:R;
M)H;SV+=P TPPPFC3=P'U0IRK?V+G#K!+<DQF20W#4 [-G,L[U/#VM'N9URV,
M2R2=POPJ&4'G@&MVG?S:;![W6];QBO.B>LAGSQMQOQ*\>9]<?_C=A*W7YF#^
ML?%5L&OAU[_HO@!02P,$%     @ %9\(59E<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M"  5GPA5'<*SU_D"  !'"0  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;(V66V_:,!3'OXJ527MJR85K.T JM-U0UPJ5;GN8]N FAV#5L3/;*?#M=YQ
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MYX@=YSZ*[:THRA_K+)#\]A8,FE.6<^HM<N6M'3[-<F20Y?;;?3.9KL5=LDK
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M*];O4)8W]3E\E91E13IJY#<?YWM92O5.30%@VTP 47C,.W(437$TW"(:C=D
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M_7(C8M5_*@/U_5V>R^<WU<^M''^/Y^K_4$L#!!0    ( !6?"%7='OL"4@(
M +4&   8    >&PO=V]R:W-H965T<R]S:&5E=#,N>&ULO95M;],P$,>_BA4D
M!-+4/*Q-T$@CK9T02$RJ-@U>(%ZXR;6QYMC!OK3CVW-VLJB(KF((Z(O&9]_]
M_3N?<\GWVMS;&@#90R.5G0<U8GL1AK:LH>%VHEM0M++1IN%(IMF&MC7 *Q_4
MR#")HC1LN%!!D?NYE2ERW:$4"E:&V:YIN/F^ *GW\R .'B=NQ+9&-Q$6><NW
M< MXUZX,6>&H4HD&E!5:,0.;>7 97RPRY^\=/@G8VX,Q<YFLM;YWQH=J'D0.
M""24Z!0X/7:P!"F=$&%\&S2#<4L7>#A^5'_G<Z=<UMS"4LO/HL)Z'KP)6 4;
MWDF\T?OW,.0S<WJEEM;_LWWO.Z,=R\ZB;H9@LANA^B=_&,[A("!Y*B 9 A+/
MW6_D*:\X\B(W>L^,\R8U-_"I^FB"$\H5Y18-K0J*PV*I545'#!5;<,E5">S6
MWX57*VY 80TH2BY?YR'29BXD+ ?A12^</"%\!>6$G<=G+(F2B-F:Y.S/*B&A
MCKS)R)MXV>E3O+P5R"6[4P+/V%)R:]DE^W(-S1K,UV.8)_7<G;^P+2]A'M"E
MMF!V$!0O7\1I]/8$[?E(>WZ2]J-H!-+9MMR@ F-9.>#SLM2=0M91&I8):SNH
MCL'W\JF7=^_7KHCC6>1_>;@[0C8=R:9_@XQ>8XM<54)MC^%-GXLW&_%FSR[S
MXF293^K]89G3D3;]MV5.?SG'+$NS.$F.GV(V<F7_H<C9;\*%!UW(-?1K;K9"
M629A0Y'1)*,2F;Y)]@;JUC>FM49J<WY8TW<%C'.@]8W6^&BX7C=^J8H?4$L#
M!!0    ( !6?"%5,&H\7M0D  ,Y6   8    >&PO=V]R:W-H965T<R]S:&5E
M=#0N>&ULM5QM;^.X$?XKA%L45V W%JE7ITF Q'JY -V[Q:;;^U#T@V(SL;"V
MY)-H9P_HCS]*5BQ3'-'V>IH/B>W,/#/2,R0UCRG=O!7EMVK!N2#?5\N\NATM
MA%A?C\?5;,%7:755K'DN__-2E*M4R+?EZ[A:ESR=-TZKY9A9EC=>I5D^NKMI
M/OM<WMT4&[',<OZY)-5FM4K+/Q[XLGB['='1^P=?LM>%J#\8W]VLTU?^Q,77
M]>=2OAOO4>;9BN=55N2DY"^WHWMZG3AN[=!8_#OC;]7!:U(?RG-1?*O?/,YO
M1U:=$5_RF:@A4OEGRZ=\N:R19!Z_MZ"C?<S:\?#U.WK<'+P\F.>TXM-B^5LV
M%XO;43 B<_Z2;I;B2_'V,V\/J$EP5BRKYC=YV]GZTGBVJ42Q:IUE!JLLW_U-
MO[<GXL!!XL .K'5@ISK8K8/==W &')S6P>D[> ,.;NO@GNK@M0[>J2GYK8/?
MD+4[NPTU82K2NYNR>"-E;2W1ZA<-OXVW9"3+ZU)\$J7\;R;]Q-VTR.>RL/B<
M/(E4<%EDHB+%"_EUS<NT+I:*?"1?GT+RTU__?C,6,F+M-YZUZ \[=#: 3LFG
M(A>+BD0RRASPGYK][6/^T9'XUC& ^ @ ,P",Y;G>GW#V?L(?F!'Q4UI>$9M^
M(,QB%#HCI[LSP#V\+'ID=@_YS.@>7^:>G.YN&:BP][5O-WC. -X7ON7YAD-E
M;72LEX?K:IW.^.U(SO\5+[=\=/>WOU#/^@?$Z [,;<#JI6%[)[/?'I)VU"+"
M3"@^&BXQ62CGVMF?:Z=QL0?.=3N?Y*^$?U_7$TX%G78'\[1C@H688!$F6(P)
MEB"!*27B[DO$/3(<*YZ6LP5)\[F\FMC*RZ1UO1Y!A6)$.K=0=F#>0;&SP)E8
M\J<W3'7#2>!.-+L(,[M8#^IXS'6UJ EP&-1RV*&APHNWY\4S\I+P7([=94-+
M.I?7(%DEZK&\!6=.(]:YS'C:(=G^Q&<Z,[HA]1U'9P8SNU@/&@00,;J=.PF&
M>?'WO/A&7KHIM69FUY745_>SHA+@[&J$.Y<:7SLHSY.%J5.C&U*):>O<8*87
MZU%=EU)]3">Z(?,MY@RR$^S9"8SL_+.H*O)2%BM2["^E(5*,*.>2$F@'\W&
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M=3(CU.1B(*8-L:.;?63V<"M!.WF&&EO[_2 ">4"595HT=<#X3@ -&,"T'C!
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M-I#_?RD*\?ZF#K!_A.W=GU!+ P04    "  5GPA5!SB)8)P2  "H$0$ &
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MBMWC&RT,0U6(>V'0Q693];C;LKC[_8S1F&A/'?UAN5P=&FP5\&FQ6EZOMN=
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M;HS2$I26HK2,HC5;1FT$ZFHE<) 6<&(U+B7'HJHV4V<.[@2H"HC2/)3FH[0
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M^OU]490OW]Q4_&_%[O=CQOO_ E!+ P04    "  5GPA5H=8[G+8"  !H!@
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M@1NJ*Q94M!Q07Z2GA)DA8!WV9 19!U/&0,IQ!5)OJ116J%E8.?66HLHHJ+0
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MS <6<C8#;P9/2/8MD^4W@)K-'!P#E'0* 5\M3@^=$G!?DH5&7Q,65.D H^Z
M7PJ^@16 ?O4$H&>ZJES$7,OOP$@+>4^24O"ZZ!JCMR1+5 U%SV9D5"BEJ#.U
M$L+J6<[X]+*C;2)4!VK/F<]^W/]:+-4=NMXKZ<@B3^\?5(!&<8* UWN] US,
ML,Q)09E<2R5.D R&M.9\@+<&E1.@K6AJY$1"]EU!F*T4^ 1!ZJ&6$#6$B8QV
M?<GYCB)-.?W!20A+63/5A0A5,P6QTX@^='UU30J3F;M4-CU4&'\9\RKD]^O\
M#A8EK-N#MGFUR_9+B]BSN"9V1PE"G8Q,UX Y!<^AGAN*=W+"PKIF#Y$"8HH8
MGDT;$+]0ID K[W'81%:(#*,$/BL3VMEQ2%>#G7'>CPARH\A=2\0G!22#)TU&
MS\_ /XQ3ILF9"5(H3@-$P_F M^#X=!3_;(!-8-8^0TPI;>,L$TJ6I,LYA=8'
M)*HFX)291C09&6:ZI8@A6",7VS9 & %UP7M=$C]AZ@@!R<B+!7_AIOW0;P\R
MB5JQHM7]:$W,P0 #U5=A$34R'7!4+*NYY21B"8A@JT;FQOI[XNL;^V&YO9QB
MH: U1B@EAJGJEF-[5,$ ]UB+L>(")6"1$F) W*AO4Q08)TA6&$UVK5I5+%%P
M=%W_G7R&D443L^AXU PVX=I,GE@?491-VJJ1VU:QX$X7)ON 0!M5'KK5%^>M
M2TVE!)UVED^*N.$XVLD6S&)?Q!/E=3;Q<AH!PHUN]E$.IA8<0^E,<^UYXY0R
M-Z2?!"Y:*I>4&JF+^)O+KT#\P+ZYQY>1""-_0W^2J6)22^"H7FB>R 2#9&..
M_:W) Y:%3;Y3ZA9T=,T,VZ4O#V'"<BJZ?@P/N,H:49$7L2YX2#Z2N< ,*_6M
MZL?&H^6N%S-&SY."ZA56,LV=F*54L0(_@,R2BV9!:15I0W/8+G4#2;FT/K/A
M 4Y\2+"&V R&C@7).#";YRE+0-%OQJV>KL3.RWF!>07 -6&7YE.(;+Q#D2E5
M>X'\N:T8?>DH7+LCJEUJ<&,+;$V'+COJ&?$,CH-U&"C9QEA"?4: P(/2^-R4
MI9JZ0@F-<OH,/949,'M5#THHA,.XH7-3\"@P5<T*%BG+TR8ZB[H$6\,^ZRK(
M@XK:2M33E&#4:U3_#HW,<6MB'!K90U"L/\T8Z2P9&$T"PZ68W\35B/%]Q)AB
M#^L4K@+Q5&"U;'4XYF0YL\QR&"LN=U%RVVCQ65DT"Z/'@T"=Y>36B.[HJ,=*
M. N!!5+X>O3BZ)C2NJ90&I@+?["U&]1YP-X=.J6ECBE'7L)AF+T)=C ?J_SM
M1XSD.Y.#$X0_"-')0*+#BD@?T=D\82 #;$*1&]@#EDJ;DD*Z!RF&?C?3GX*Q
M+SDW"7.$KMW9,7W5IAU=)GS*/,Y/*;=0$_E-X(Z&#;[2)==.[\5.8018YKWG
MTD"3!1(&UVDX8\#E<BS6:'": :E(=95P"J5 .:K0W"0=X,@ZDCER*J0;21B^
M1)7JGPK1@,%_4V$25&$X8N(2]!]](R[;%A& J(E5)W^,G0M5?X1*?B^XMV)G
MM#N42Z84U'B7I09=9%0\O/C*T.%86#KO*3$LAW^G&FQ($F0M@FF12!IEE'@3
M.X._$HK7-(F=>8HDE,2LCJPX$V'#11O3,;;12DPXFDE*N<QQ'XB[.0*/T.E1
M"P+<I-N&V(FXU.M 6DI]QT5A4\&AQ(A)N6%"#O0XAE,4;11]N,+ZS,#N7A=&
M#]=FN5? [BDZ#.=_C.U"S8<NFU>WCTR) X?YY?P6$D_3M0KN:%#!A</;G-@E
M$Y8C0#8&>8M7@U7=J1PTN<I!,F-%FJ$UP1Z!V&)9]4*Z!,T?ZU)\JCVE8M2'
M(5Z;+R?I;TA&8>$]ICS3)(R=;>[44R+@>P'H>HH)+\]["#2>GT\@>45& <&H
MIO>DV#WJ=EHL0("UNB,_S"0$O#P^<09Y?R;2I;:-E<2(!9X\((1/H6,2(@[%
MQ>#-:F$+()@(+-&V@/6C1%;?3%7%KDF2317P%L'!,I\IH=>?S4W ^XQ1-U/X
M@.A#1B?Z&FQ-[X/3X1:M$+<<$C)YY&P>54ULU.CF 7LFN"F;MD&]CI74Z[+
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MZ.PJRQ+ IV?4B(V+=VU\H(+I&+^7>4>N;&U[6QY+,DQ8)(\!",YSM&)B$FR
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M]#Z0$;O3C6*'OI\)C,LRWFW[9;;;YE*QXU)MD0UCW)L';.+>\5M$K:!YC$5
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MQ$?Q\[S>Y2(X"9 ."UJ@MN#<>-68+%"C,/&C(;2(*4^P-D\<87A%G>H%)=3
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MALLR44^DX,[I#*]AL:&/L7[, ]!1X1L/-6:2"( J*#LP3;QN?I$4S:3&+,)
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MFY[8G]H3NZX3]E^__[7O-X9^H(]T^#>&#KQ?_:7V2?SU9*06:"3^ 6#WU/U
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MU6&A?R2!'#S ;%:MJI3(!H83B.<26SX<#";AQ<59V._WF]-;*LNRV"3-@03
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MF8(_15('#INIC=9=<T 3H]:*&4;%K?AA@].#'OD)?LSZ.O@#C.OI_.O[1^7
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MNT7C#6B]T-KM!C[ OE^>_@502P,$%     @ %9\(5:)R4-TV"   OA@  !D
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MPW#BS,'!]\UD[K<$-GW4:%R1NM,"60,#,=>35!2, P3!C:9%@K3P=@6WCA<
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M1V#HX![KZ?'<RN4J7;-CAMG]@-!+7=:BN@??2Q!.ZM"&3]BU0$^AIG2IB2A
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M0-VY*3(GM!4)3LT$G8NML%WCR? P7IP9D9IL2JI:2IW*<:H$,A!,[0K26)
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MJL!@#/A+59 8_CF0YT"X.8DY\DS&"CWUEU]T!9X;,9Y+Q/9 W!FUD([$78:
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M<A9, LBQ8+6PG]3V5VSU#!U?IH3Q_[!MUO;C ++:6%6U8/*@XK)YLOLV#GN
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MZ'TZ?JG,FO_^$9FX,@5_7"F4+DL+\'QA3!6_T '-7]"^^C]02P,$%     @
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M,&K=QZ;NHC(K_OQR9BJ =?ZY1!E6EE[ \[DQ5;B@#>(7OR__"U!+ P04
M"  5GPA5_T@.>]8M   X  $ &0   'AL+W=O<FMS:&5E=',O<VAE970R,BYX
M;6SM?6ESVT:VZ'?]"I2OZY94!<D$%RW.4B5+=L8S3NQGQ7>I5^\#2#1)Q"#
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MXL1)L4^TB'-V^I,*0I>^KW>W<&*AM-'A9V6.Z,I,@ZP-H.S5FJ4'DQKO(IO
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MO7J"?\L;,6#B;@6?%7')CA]4LX"\!N9B<M_;YF F:B9!YPZ;UEL_U/V2;4[
M+:Q@S[ SC8<U+$N1+@6[ \OT*-@] ^X9\"_&@/UG8&:^!W2B[?4<]#=[?LL%
M3+]B 5.K MRA3ZH+L^;20E-!(K\<_@DYPUG9 K5['2OS<8]26(Y]!D.\0"_%
M,EXS<V)H%Y#,T3 "YSZ"Z*1FE[9("^,RZZS0,?I0!_JH#[()DS=JOB0MFUTM
MZ%*L57WI1@BU/JVU15[!DN"M)N$\=U-A5>+R0YDKMOV*^ABS%#V7EB6=U%O
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M,/MKWKG:!_>QMNWNG_9CM_M/AX0ZJ=@N$</^+A$WU933\DJZF+"#(G8H&=\
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MN6X[=UM@F5;WPI495CD3A7Z+^J'4'RFL0F,A)OL6)=8JP7(6<N,D:.41N&9
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MN8[6*_#YW!C:"/Z"[I_"Y!=02P,$%     @ %9\(5719/-.V!   > T  !D
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M[3*+2F I+.>I5#?.I.:%N3.3N""9*+?ZO&F ]L%:EZZJC_94W^W9R.(H$L9
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M>#T-I/7Z1%Z_BAX2OF\(&AO%OO7GF*T_>S4["PZU_J TAJ+I@BOKSSTRF^M
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M$UT<HC !^OF*<[5KF 15N1G^!E!+ P04    "  5GPA5T#Y32S02  !+Z
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M%C2(V^Q%T1>T=+:Y4J1*4G;S[7>D9-E>9"U&/;^PGN[^O!\IGNZ&&ZF^ZA6
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M-J+?E-NO=\[/\*6+%>=]?!E4V\Q;?+7K_9YFRRC-4<R>9"KCPI'Z9M5&\NI
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M7+VDV.:%Q)[D,1CR&,RI9VM1FB-'3+&P9:UC1RW;U+ICEGC)TCV>)V.*\9+
M?PK:6$ XB0;0D^##(?AP/GB8@"O&D=)-\0#EDA,-MR@72ELO2*<6G\401\'(
MS!3CX\ ;F9F"/"\*[6:BP4PT:^8]R1EG^@'1^YIT]?^BD5FEGSW+T=1,.O)K
M@2QP:O<;#W[C6;^/-8_3/>$VD_'DI0%.H]%V34%I'(ZBGV*P/?3%$/IB-O1/
MI&IV4&<::>H/*VLICA0^VOKRCBVF9KQ@,3(S!87>Q,T4=,%-,KA)9MW\J0]4
M0J/0;0?M/T$V$[,Z/WOL$MM%&WF=8J(PL;M-![?I"[E-+;LQVHSU%./[X\HW
M&\__+.\>_J\/P;-^OP@-!7+L%T$/@81)A;61P):J[XU/JP65^MYX"RVH,$SC
MT2:Z9YV6Z8NA6=FS2D%QV $-7RV +[M6LQMH4;?-UYW0T,JUCP=HSZDT %C?
M":$?!Z:?&QK^[ =02P,$%     @ %9\(5>Y&]TF8 P  01,  !D   !X;"]W
M;W)K<VAE971S+W-H965T,S8N>&ULM5C1:MLP%/T5X<'8H*MC.TVZ+@FT:<L*
M+825;0]C#ZI]G8A9DB?)30O[^$FR:\?@*,OJO"22K'.D>W0LKN]DS<4ON0)0
MZ(EF3$Z]E5+YF>_+> 44RV.> ]-/4BXH5KHKEK[,!>#$@FCFAX/!R*>8,&\V
ML6,+,9OP0F6$P4(@65"*Q?,%9'P]]0+O9> +6:Z4&?!GDQPOX1[4UWPA=,^O
M61)"@4G"&1*03KWSX&P>C W SOA&8"TWVLB$\L#Y+].Y2:;>P.P(,HB5H<#Z
M[Q'FD&6&2>_C=T7JU6L:X&;[A?W:!J^#>< 2YCS[3A*UFGJG'DH@Q46FOO#U
M9Z@".C%\,<^D_47K<NY83XX+J3BMP'H'E+#R'S]50FP PN$60%@!PG\%1!4@
MLH&6.[-A76*%9Q/!UTB8V9K--*PV%JVC(<P<X[T2^BG1.#6[)TM&4A)CIM!Y
M'/."*<*6:,$S$A.0Z .ZU\Y)B@P03]&55$1+!PGZ*B$M,G2KST"B=Y>@,,G>
M3WREMV2(_;A:_J)</MRR?(3N.%,KB:Y8 DD'?N[&!Z&#P-=:U(*$+X)<A$[&
M.RR.410<H7 0AET;<L,O(:[A@6,[47T^D>4;;N&;<YH7"@2Z^EV07+\_"OVX
M _H XB?Z@^[P$Z$%K8>Z#L#);VZ),YGC&*:>O@8DB$?P9F_?!*/!IZ[@>R)K
M23&LI1A:]FB+% NA+R^AGH_0(C-VQ2S95.563T<W"JCLE&'8IPP]D;5D.*EE
M.'$ZPBG#4?-BIM E@YO[!#T#%K(KY/\ ML(;U>&-7F-XPG8:WLF_[TGW1-:2
M8EQ+,3Z@X<=]RM 364N&TUJ&TP,:WLT=;3?\?P!;X7VLP_OH9+HN!".J$& #
MNR9/IBWWO>6=:^Q[VCV1M>0(!DU&,CB@[2ORGI3HBZTMQ49R%AS0^CO('9?]
M#N1XI_F#L DQ?*W]_^'.=R^R]ZGWQ-:6I$GY@NB0+T"O"5]?;&TIFI0O<*92
MKWT!W.2=-J["=B-WISM!D\X%[M3I%O17Z(IG";JAN>"/8$*3;K<[&?<^XI[8
MVO$W^5XP.J3;>\WV^F)K2]'D>X$SC]KE]NZO[TY5W.L(, 6>1"?9^IL^,_Y#
M.N.FG8KTP%2JX6\4*2B(I:W=2&1+#F6]HAZMZT/GMBKB-]/+XI+^1E\2)O6"
MJ88.CL?:P:*LUY0=Q7-;\GC@2G%JFRO >IMF@GZ><JY>.F:!NFHV^PM02P,$
M%     @ %9\(5:7"30O^ P  OA0  !D   !X;"]W;W)K<VAE971S+W-H965T
M,S<N>&ULM5A=CYLX%/TK%ENM6FDZ8 @DF4TB3</.;J56BII^/*SVP0,WB57
MU#;)]-^O31@2$@\[4SDO$S[N.?B<\3$73W:,?Q<; (D>\JP04V<C97GCNB+9
M0$[$-2NA4'=6C.=$JE.^=D7)@:0U*,]<W_,B-R>T<&:3^MJ"SR:LDADM8,&1
MJ/*<\)_O(&.[J8.=QPN?Z'HC]05W-BG)&I8@OY0+KL[<EB6E.12"L@)Q6$V=
M6WP3XT@#ZHJO%';BZ!AI*?>,?=<G[].IX^D100:)U!1$_6QA#EFFF=0X?C2D
M3OM,#3P^?F2_J\4K,?=$P)QEWV@J-U-GY* 45J3*Y">V^QL:0:'F2U@FZK]H
MU]1Z#DHJ(5G>@-4(<EKL?\E#8\01  ^> /@-P'\N(&@ P7,!@P8PJ)W92ZE]
MB(DDLPEG.\1UM6+3![69-5K)IX7^OR\E5W>IPLG9DJX+NJ()*22Z31)6%9(6
M:[1@&4TH"/06+=542ZL,$%NA._H *;H5 J1 KV.0A&9O5,V798Q>OWJ#7B%:
MH,\;5@E2I&+B2C5"_1PW:4;S;C\:_XG1?"3\&@7X"OF>[QO@\WYX#$D+QP9X
M_'RXUX6[RM;66[_UUJ_Y@B?X%ES%D\N?5VB1:7^5)^C/'Q4M56XD^N>#*D?O
M)>3B7Y-3>^Z!F5LO!S>B) E,'95W 7P+SNSWWW#D_6'RS299;(FLXVG0>AKT
ML<\^@! W:K5(JKS*B%2S,07UF(02O8R8?-SSA36?7@6WL[?^*!Q.W.VQ0:8J
M/QQWJV)#%<9'7!U)@U;2H%?29R9)AE9UM$@=K2M4@#1IV1-%1\_'&'O!B193
M51".3K2<5XW&>&"6$K92PEXI=Q4OJ*PXU',='N>Z24HOT4NGMTVRV!)9Q\"H
M-3"ZX)(1V?34)EELB:SCZ;#U=-@[*7L]O4)_<2:,KZKA64!\7[\7.EDS%.'1
M25%L*/(P-D=MU*H:]:J:L[RL)/!#RFIA@JWDCG P">HE?.GTL$D66R+K&#EN
MC1Q?,')CFY[:)(LMD74\Q=ZAK?0N$KJ&]C@KX>CD-3PW%46G[VI#$0X\<^CP
M4;N,_Z?_4!\9&Y:EB.8E9UO0>LQ*>HE>.C6LLL6VV+HF'OIB?,G&&%OMC*VR
MQ;;8NL8>FF/<WQW_<NJ"\ZQXX=G+SER&AZ?).R\;1D\$[] DX_XN><X*(7FU
MWRU07YDJ?&MEH5E.+]6+9XA-MM@66]?&0X..PTM&SVK7;I4MML76-?;0N./>
M'O;7HQ>=?5-& 3X-WGE1$.+3V)T7#4?AZ1>=>[17I'?V/A*^IH5 &:P4S+L>
M*CS?;Y;M3R0KZ^VC>R8ER^O##9 4N"Y0]U>,R<<3O2/5;EG._@-02P,$%
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M/<%V5G6?__BJ%^(ONF)<D0)RW,J[N45G9=5?JHD6&UM ET)C.;;#-;9DD,8
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MA*'O%6\D9KF,7:6K-'NY65?155M1\$I%7[$X1:'_ 05>$ S K_?#4\AZN#\
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MOD5KO0@S&V6FA'Y*-$Z-9F3)R(*DF"DT3E->,$78$DTY)2D!B2[13._-K*"
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M9H)^ON!</7>,@?K#R.A?4$L#!!0    ( !6?"%4/V08&M@(  -((   9
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M-739#NKM1HO&C:YKH<T@[)8[\W(#T@+,_8T0^F5CI^'^=2G_'U!+ P04
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M1I>LK 3J^(IS^;Q1O85K7]/._@=02P,$%     @ %9\(5<=XY#DG!   "Q,
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M ZMGH11F>)6+1[KY"^H.A8HOH3DO_Z--91M)XV3%!2UJL(R@R$CUBU_K1.P
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M$VA\K>C"+#OV!J\^V,+?4$L#!!0    ( !6?"%777Y^E?@,  #$,   9
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M3*FG1V4-:#^1TCQ-[ N:?PFSGU!+ P04    "  5GPA5PCHC'?P"  "V"@
M&0   'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6RU5FU/VS 0_BM6)FT@ 7GI
M.VLCT0(:T] 0B.T#XH.;7!L+QPZVT\*_G^VDH:5IQ*:N'QJ_W#WW/!>?<\,E
M%T\R 5#H):5,CIQ$J>S4=6640(KE"<^ Z9T9%RE6>BKFKLP$X-@ZI=0-/*_K
MII@P)QS:M1L1#GFN*&%P(Y#,TQ2+US%0OAPYOK-:N"7S1)D%-QQF> YWH.ZS
M&Z%G;H42DQ28))PA ;.1<^:?3GS/.%B+7P26<FV,C)0IYT]F<A6/',\P @J1
M,A!8/Q8P 4H-DN;Q7((Z54SCN#Y>H5]:\5K,%$N8</J;Q"H9.7T'Q3##.56W
M?/D-2D$=@Q=Q*NT_6I:VGH.B7"J>ELZ:04I8\<0O92+6'/SN#H>@= C>.[1W
M.+1*AY856C"SLLZQPN%0\"42QEJCF8'-C?76:@@SK_%.";U+M)\*KR&=@I!?
MT,5S3M0K.K[3!R7.*:"?,X3*W=7FP3DH3.@A.D83G!&%*;IG1!VA"<52HC/T
M4#@\:@.98 %RZ"I-TH1RHY+0N" 4["#D!^B:,Y7HH"R&>!/ U>HJB<%*XCAH
M1#R'Z 2U_",4>(%?0VCR<7>O@4ZKRGC+XK6:,[[*Z<,/O8^N%*3RL2Y;!5B[
M'LP4^:G,< 0C1U>Q!+$ )_S\R>]Z7^N4[@EL0W>[TMUN0@_-29%(WR128183
M-D??,<OUU5%$J$UPD8("MVMQS;6T"'V_X]G?T%VLZVMD\(_Z.I6^3J.^BT+4
M&%/,(D 'A)4U<%BGJ;.MJ=_MU&FJL=Q2OT&X6Q'N-A(N#B(JWLNJ<NNX-L+\
M[1'<$]B&XEZEN+?/TNOM4_>>P#9T]RO=_?]4>OT/E]ZVY:#QE XJ[H-&[E=2
MYA#O)#C8"MOS:\MHVS#PFOCYWML7U-MCX9=@'ZG\.M,=I>^N=0 IB+EMC"2*
M>,Y4\:6L5JOFZ\RV'._6QZ8ILYW%&TS1T5UC,2=,(@HS#>F=]/3%)(HFJ9@H
MGMD^8\J5[EKL,-&-)0ACH/=GG*O5Q 2H6M7P#U!+ P04    "  5GPA54\X9
M+)<#  "X$0  &0   'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6R]6.]OTSH4
M_5>L@!X@P?*C3=+NM96Z)@@0DRJFP0?T/GC);6N1Q,%V5N"OQW;2T'192%%X
M^[#&R3WG7I_CWL:>[2G[PG<  GU+DXS/C9T0^:5I\F@'*>87-(=,/ME0EF(A
MAVQK\IP!CC4H34S'LCPSQ20S%C-];\T6,UJ(A&2P9H@7:8K9]RM(Z'YNV,;A
MQ@>RW0EUPUS,<KR%&Q"W^9K)D5FSQ"2%C!.:(0:;N;&T+T-; W3$1P)[?G2-
MU%3N*/VB!F_CN6&IBB"!2"@*+#_N805)HIAD'5\K4J/.J8#'UP?VUWKR<C)W
MF,.*)I](+'9S8V*@&#:X2,0'NG\#U81<Q1?1A.O_:%_&>I:!HH(+FE9@64%*
MLO(3?ZN$. )(GG: 4P&<4\#X$<"H HSZ L858-P7X%8 /76SG+L6+L "+V:,
M[A%3T9)-76CU-5KJ13*U4&X$DT^)Q(G%-:1WP/@S%'XMB/B.7J%E'!/E(4[0
MVZQ<B<K1YP$(3)(7,N+V)D#/G[Z8F4(6H&C,J$IV529S'DDV0M<T$SN.PBR&
MN(DW9>%U]<ZA^BNGD_ :LPLTLE\BQW*<EGI6W?!W.+M MO\H/.B&!Q#5V>T6
M>-@?;G6(,:JM'&F^\2-\*YP3(5V[S8AXB58)YAQ=H<^EP_^UN=7)IUK4)<]Q
M!'-#]B .[!Z,Q3]/;,_ZMTWJ(<F"(<G"@<@:IHQK4\:=IKPG*1$0HS5F(M-?
MM(--RRBB12:=4GYQM"S$CC+RX_1[43I5)O%T$M7[[Q>N5?[-S/MC%_H&!@\#
M[=; L'-^?ZB>6ZOG]E(OK]1#424>+L5#A=:.<%ZTZ^8^G*4_<L>3Z?A$M\XZ
MSEV]#[/ZON?;JL<TI/U]7$,UKU;-Z]T(#GW [FP$G7SG-H(AR8(AR<*!R!JF
M^+4I_M]=ROZ#Q>)9T\G4LD]6<F<9Y\H_)%DX$%E#_DDM_Z13_C6C$4#,T8;1
M%/4SH\V%,HM[W%]=MZ4/=U9SK@M#DH4#D35<F-8N3,]^15EV=J9.OG,[TY!D
MP9!DX4!D#5-LZ]<>P/H_7E*J+(U?VVG[:TIW0>=:T3]Q.%3BIM)'NRW[[_X*
M5/R-J4X\MU7CSE+.UKAWXK MU'9/["@%-(]VKBFPK3XRD*HH+<I-;'VW/I98
MZLVX^2N\/-.0>\$MR3A*8".AUH4OFS0KCPG*@:"YW@??42%WU?IR!S@&I@+D
M\PVEXC!0">K#FL5/4$L#!!0    ( !6?"%4)+Z3(#00  &\2   9    >&PO
M=V]R:W-H965T<R]S:&5E=#4V+GAM;*U8:X^C-A3]*Q:M^I"V 9/'9*9)I)E,
MJXW4E:)-'Q]6^\&!F\0=P*QMDIW^^MI  $\(CU7FP_"Z]^2<"S[7]NS$^(LX
M $CT-0PB,;<.4L8/MBV\ X1$#%@,D7JR8SPD4EWRO2UB#L1/D\+ =AUG8H>$
M1M9BEMY;\\6,)3*@$:PY$DD8$O[Z! $[S2ULG6]\I/N#U#?LQ2PF>]B _"M>
M<W5E%R@^#2$2E$6(PVYN/>*'I>OHA#3B;PHG43E'6LJ6L1=]L?+GEJ,900">
MU!!$'8ZPA"#02(K'EQS4*GY3)U;/S^B_I^*5F"T1L&3!/]27A[DUM9 /.Y($
M\B,[O8=<T%CC>2P0Z7]TRF,="WF)D"S,DQ6#D$;9D7S-"U%)P*,K"6Z>X'9-
M&.8)PU1HQBR5]4PD6<PX.R&NHQ6:/DEKDV8K-332KW$CN7I*59Y<_ EAS+AZ
M@>BW+PF5KXA$/EJ#*E $D43/L*,>E>@7].C[5!>>!&@599^/?@T_/8,D-/A9
M16R81]73)8FI5,=-<N0@)4'O6>#3:"_0DO%X@%:K%?KT <(M\,\JZWMD(W$@
M',3,EDJ0IF5[.?FGC+Q[A?P'P@=HB-\AUW'=FO1E<_HS>$4Z-M-M5<:BEFY1
M2S?%&U[!6P9$",1V:".9]X(^_:&>HY6$4'RNTY:!C>K!]/!]$#'Q8&ZI\2F
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M)0O3TP,0I5$'J.<[QN3Y0N\Y%'M,B_\!4$L#!!0    ( !6?"%57#=&4% 0
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M;&7N9@0HV);*YHS7]7;W/P_FUJ/7_QC<SP-+?Z;OB\R5Q#M]<]FDCKFKB@I
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M2)0O8"L_R'QC7ABVR*7,4[.YYDP-)%U ?;_*<_GR00?8OP9O]B=02P,$%
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M/L [/?,V8*F@B2\&ME1YZ]5MK\CQ,L_1/9)C"Z8LD8& Z\1'OR9^8HXGK@'
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MAHP^YU65+]9?WJ3)+"V:!]2_O\KSZN&;9H*[O/AE?7BG_P]02P,$%     @
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M8;3SN<[4N<WJ4IFJBZ-310-H_%*O_$ 86:KQX,RNE1,3N5#-3<&G7.7=#59
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M;',O=V]R:V)O;VLN>&UL+G)E;'/-V3MNVT 4A>&M"%R 1_<UM@/+51JW@3=
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M2P$"% ,4    "  5GPA5!T%-8H$   "Q    $               @ $
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( !6?"%6W!'VW[P   "L"   1
M              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M !6?"%697)PC$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ %9\(51W"L]?Y @  1PD  !@
M     ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M !6?"%7^G+V=<0H  )M'   8              " @3T+  !X;"]W;W)K<VAE
M971S+W-H965T,BYX;6Q02P$"% ,4    "  5GPA5W1[[ E("  "U!@  &
M            @('D%0  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#
M%     @ %9\(54P:CQ>U"0  SE8  !@              ("!;!@  'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( !6?"%4'.(E@G!(  *@1
M 0 8              " @5<B  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q0
M2P$"% ,4    "  5GPA5H=8[G+8"  !H!@  &               @($I-0
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ %9\(51:!CPC:
M#0  BGP  !@              ("!%3@  'AL+W=O<FMS:&5E=',O<VAE970W
M+GAM;%!+ 0(4 Q0    ( !6?"%49W%^&OQH  ,)Z   8              "
M@25&  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  5GPA5
M&S/&\J<I    W0  &               @($:80  >&PO=V]R:W-H965T<R]S
M:&5E=#DN>&UL4$L! A0#%     @ %9\(54SR&CF? P  .PL  !D
M     ("!]XH  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !6?"%6&L&3;, @  "XA   9              "
M@;"M  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ %9\(
M54U/&%!;!0  WQ(  !D              ("!%[8  'AL+W=O<FMS:&5E=',O
M<VAE970Q-BYX;6Q02P$"% ,4    "  5GPA5*1'8U/T#   E#0  &0
M        @(&INP  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0
M   ( !6?"%6:;3"Z(00  $L-   9              " @=V_  !X;"]W;W)K
M<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ %9\(58X,?J9\!0  +Q8
M !D              ("!-<0  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q0
M2P$"% ,4    "  5GPA50/.HJ$@/  !-.P  &0              @('HR0
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( !6?"%7P++8V
M@0T  /TK   9              " @6?9  !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&UL4$L! A0#%     @ %9\(5?](#GO6+0  .  ! !D
M ("!'^<  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  5
MGPA5/>(U;ID(  #&(@  &0              @($L%0$ >&PO=V]R:W-H965T
M<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( !6?"%4E\5Z5204  '\.   9
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M970R."YX;6Q02P$"% ,4    "  5GPA5=%D\T[8$  !X#0  &0
M    @(%',@$ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (
M !6?"%485!6CV L  .=Y   9              " @30W 0!X;"]W;W)K<VAE
M971S+W-H965T,S N>&UL4$L! A0#%     @ %9\(53;!WEE@ P  >@X  !D
M             ("!0T,! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"
M% ,4    "  5GPA5T#Y32S02  !+Z   &0              @(':1@$ >&PO
M=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( !6?"%59XFC5[P,
M "T/   9              " @459 0!X;"]W;W)K<VAE971S+W-H965T,S,N
M>&UL4$L! A0#%     @ %9\(5: @;3$8!@  VB\  !D              ("!
M:UT! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    "  5GPA5
M1?>O\&8#  #\"P  &0              @(&Z8P$ >&PO=V]R:W-H965T<R]S
M:&5E=#,U+GAM;%!+ 0(4 Q0    ( !6?"%7N1O=)F ,  $$3   9
M      " @5=G 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%
M  @ %9\(5:7"30O^ P  OA0  !D              ("!)FL! 'AL+W=O<FMS
M:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    "  5GPA5.K@62:P"  #P!P
M&0              @(%;;P$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+
M 0(4 Q0    ( !6?"%5<L43DGP(  )4'   9              " @3YR 0!X
M;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ %9\(57^#*].D
M P  )!$  !D              ("!%'4! 'AL+W=O<FMS:&5E=',O<VAE970T
M,"YX;6Q02P$"% ,4    "  5GPA5#]D&!K8"  #2"   &0
M@('O> $ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( !6?
M"%6=9LF\=P,  *X0   9              " @=Q[ 0!X;"]W;W)K<VAE971S
M+W-H965T-#(N>&UL4$L! A0#%     @ %9\(5:&>:P>O P  %0X  !D
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M=#0W+GAM;%!+ 0(4 Q0    ( !6?"%6.GS%(;P,  #H-   9
M  " @:R1 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @
M%9\(5;K3V7@K!0  LAT  !D              ("!4I4! 'AL+W=O<FMS:&5E
M=',O<VAE970T.2YX;6Q02P$"% ,4    "  5GPA5QWCD.2<$   +$P  &0
M            @(&TF@$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4
M Q0    ( !6?"%4P"*=N&1,  "8U 0 9              " @1*? 0!X;"]W
M;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ %9\(59=:+^?[ @
MO D  !D              ("!8K(! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX
M;6Q02P$"% ,4    "  5GPA5UU^?I7X#   Q#   &0              @(&4
MM0$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( !6?"%7"
M.B,=_ (  +8*   9              " @4FY 0!X;"]W;W)K<VAE971S+W-H
M965T-30N>&UL4$L! A0#%     @ %9\(55/.&2R7 P  N!$  !D
M     ("!?+P! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4
M"  5GPA5"2^DR T$  !O$@  &0              @(%*P $ >&PO=V]R:W-H
M965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( !6?"%57#=&4% 0  %$3   9
M              " @8[$ 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L!
M A0#%     @ %9\(55L _:62 @  ?08  !D              ("!V<@! 'AL
M+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4    "  5GPA5B-85 P$$
M  #L$   &0              @(&BRP$ >&PO=V]R:W-H965T<R]S:&5E=#4Y
M+GAM;%!+ 0(4 Q0    ( !6?"%7$C<=Y[P@  !)/   9              "
M@=K/ 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ %9\(
M5;#%&'D]!   6!0  !D              ("! -D! 'AL+W=O<FMS:&5E=',O
M<VAE970V,2YX;6Q02P$"% ,4    "  5GPA5Y&YU_)H#  #,$0  &0
M        @(%TW0$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0
M   ( !6?"%4_3TX T1   !D2 0 9              " @47A 0!X;"]W;W)K
M<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ %9\(555TZ'4Z P  [A,
M  T              ( !3?(! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  5
MGPA5EXJ[',     3 @  "P              @ &R]0$ 7W)E;',O+G)E;'-0
M2P$"% ,4    "  5GPA5]4TEX>D$  #:*0  #P              @ &;]@$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ %9\(52=EU:4, @  A"4  !H
M             ( !L?L! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ %9\(5>[5[1CF 0  ]20  !,              ( !]?T! %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&     $< 1P!H$P  #  "

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>231</ContextCount>
  <ElementCount>363</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>62</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Condensed Balance Sheet</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/CondensedBalanceSheet</Role>
      <ShortName>Condensed Balance Sheet</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Condensed Balance Sheet (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/CondensedBalanceSheetParenthetical</Role>
      <ShortName>Condensed Balance Sheet (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Condensed Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/CondensedStatementsOfOperations</Role>
      <ShortName>Condensed Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Condensed Statements of Changes In Temporary Equity And Permanent Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit</Role>
      <ShortName>Condensed Statements of Changes In Temporary Equity And Permanent Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Condensed Statements of Changes In Temporary Equity And Permanent Deficit (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficitParenthetical</Role>
      <ShortName>Condensed Statements of Changes In Temporary Equity And Permanent Deficit (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Statement - Condensed Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/CondensedStatementOfCashFlows</Role>
      <ShortName>Condensed Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Description Of Organization, Business Operations And Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcern</Role>
      <ShortName>Description Of Organization, Business Operations And Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Initial Public Offering</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/InitialPublicOffering</Role>
      <ShortName>Initial Public Offering</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Private Placement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/PrivatePlacement</Role>
      <ShortName>Private Placement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Members' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/MembersEquity</Role>
      <ShortName>Members' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Temporary Equity and Permanent Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficit</Role>
      <ShortName>Temporary Equity and Permanent Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Net Loss per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Equity Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/EquityBasedCompensation</Role>
      <ShortName>Equity Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.businesswire.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.businesswire.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.businesswire.com/role/IncomeTaxes</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.businesswire.com/role/Leases</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Members' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/MembersEquityTables</Role>
      <ShortName>Members' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.businesswire.com/role/MembersEquity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Net Loss per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.businesswire.com/role/NetLossPerShare</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.businesswire.com/role/FairValueMeasurements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Equity Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/EquityBasedCompensationTables</Role>
      <ShortName>Equity Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.businesswire.com/role/EquityBasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Description Of Organization, Business Operations And Going Concern - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail</Role>
      <ShortName>Description Of Organization, Business Operations And Going Concern - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - The Company - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/TheCompanyAdditionalInformationDetail</Role>
      <ShortName>The Company - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Significant Accounting Policies - Schedule of Class A Ordinary Shares Reflected in the Balance Sheets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfClassAOrdinarySharesReflectedInTheBalanceSheetsDetail</Role>
      <ShortName>Significant Accounting Policies - Schedule of Class A Ordinary Shares Reflected in the Balance Sheets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Significant Accounting Policies - Schedule of Calculation of Basic and Diluted Net Income (Loss) per Ordinary Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail</Role>
      <ShortName>Significant Accounting Policies - Schedule of Calculation of Basic and Diluted Net Income (Loss) per Ordinary Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Significant Accounting Policies - Schedule of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfAccruedExpensesDetail</Role>
      <ShortName>Significant Accounting Policies - Schedule of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Significant Accounting Policies - Schedule of Estimated Useful Lives (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail</Role>
      <ShortName>Significant Accounting Policies - Schedule of Estimated Useful Lives (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Significant Accounting Policies - Schedule of Fixed Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfFixedAssetsDetail</Role>
      <ShortName>Significant Accounting Policies - Schedule of Fixed Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Significant Accounting Policies - Schedule of Fixed Assets (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfFixedAssetsParentheticalDetail</Role>
      <ShortName>Significant Accounting Policies - Schedule of Fixed Assets (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Significant Accounting Policies - Schedule of Intangible Asset (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetDetail</Role>
      <ShortName>Significant Accounting Policies - Schedule of Intangible Asset (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Significant Accounting Policies - Schedule of Intangible Asset (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetParentheticalDetail</Role>
      <ShortName>Significant Accounting Policies - Schedule of Intangible Asset (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Initial Public Offering - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/InitialPublicOfferingAdditionalInformationDetail</Role>
      <ShortName>Initial Public Offering - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail</Role>
      <ShortName>Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward  (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetail</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward  (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Private Placement - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/PrivatePlacementAdditionalInformationDetail</Role>
      <ShortName>Private Placement - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Leases - Schedule of the Classification of Operating and Finance Lease Assets and Obligations in the Company's Consolidated Balance Sheets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/LeasesScheduleOfTheClassificationOfOperatingAndFinanceLeaseAssetsAndObligationsInTheCompanySConsolidatedBalanceSheetsDetail</Role>
      <ShortName>Leases - Schedule of the Classification of Operating and Finance Lease Assets and Obligations in the Company's Consolidated Balance Sheets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities for the Company's Operating and Finance Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail</Role>
      <ShortName>Leases - Schedule of Maturities of Lease Liabilities for the Company's Operating and Finance Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Leases - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/LeasesAdditionalInformationDetail</Role>
      <ShortName>Leases - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - Related Party Transactions - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail</Role>
      <ShortName>Related Party Transactions - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - Related Party Debt - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/RelatedPartyDebtAdditionalInformationDetail</Role>
      <ShortName>Related Party Debt - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/CommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - Members' Equity -Schedule Of  Members Equity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/MembersEquityScheduleOfMembersEquityDetail</Role>
      <ShortName>Members' Equity -Schedule Of  Members Equity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure - Members' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/MembersEquityAdditionalInformationDetail</Role>
      <ShortName>Members' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure - Temporary Equity and Permanent Deficit - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficitAdditionalInformationDetail</Role>
      <ShortName>Temporary Equity and Permanent Deficit - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure - Net Loss per Share - Schedule of calculation of basic and diluted net income (loss) per ordinary share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/NetLossPerShareScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail</Role>
      <ShortName>Net Loss per Share - Schedule of calculation of basic and diluted net income (loss) per ordinary share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure - Fair Value Measurements - Summary of Assets that are Measured at Fair Value on a Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/FairValueMeasurementsSummaryOfAssetsThatAreMeasuredAtFairValueOnARecurringBasisDetail</Role>
      <ShortName>Fair Value Measurements - Summary of Assets that are Measured at Fair Value on a Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure - Equity Based Compensation - Summary of the Activity Related to Company's Class B and B-1 Units Granted (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/EquityBasedCompensationSummaryOfTheActivityRelatedToCompanySClassBAndB1UnitsGrantedDetail</Role>
      <ShortName>Equity Based Compensation - Summary of the Activity Related to Company's Class B and B-1 Units Granted (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure - Equity Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Equity Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure - Equity Based Compensation - Summary of Key Assumptions Used in the OPM Valuation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/EquityBasedCompensationSummaryOfKeyAssumptionsUsedInTheOpmValuationDetail</Role>
      <ShortName>Equity Based Compensation - Summary of Key Assumptions Used in the OPM Valuation (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure - Equity Based Compensation - Summary of Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/EquityBasedCompensationSummaryOfCompensationExpenseDetail</Role>
      <ShortName>Equity Based Compensation - Summary of Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="d373959ds1.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1063 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="S-1" original="d373959ds1.htm">d373959ds1.htm</File>
    <File>d373959dex1013.htm</File>
    <File>d373959dex1014.htm</File>
    <File>d373959dex1015.htm</File>
    <File>d373959dex1016.htm</File>
    <File>d373959dex1017.htm</File>
    <File>d373959dex1018.htm</File>
    <File>d373959dex1019.htm</File>
    <File>d373959dex1020.htm</File>
    <File>d373959dex1021.htm</File>
    <File>d373959dex1022.htm</File>
    <File>d373959dex231.htm</File>
    <File>d373959dex232.htm</File>
    <File>d373959dex51.htm</File>
    <File>d373959dexfilingfees.htm</File>
    <File>prok-20220331.xsd</File>
    <File>prok-20220331_cal.xml</File>
    <File>prok-20220331_def.xml</File>
    <File>prok-20220331_lab.xml</File>
    <File>prok-20220331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g373959g10a01.jpg</File>
    <File>g373959g10b02.jpg</File>
    <File>g373959g97s11.jpg</File>
    <File>g373959g99d44.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="1108">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="13">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>97
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d373959ds1.htm": {
   "axisCustom": 3,
   "axisStandard": 22,
   "contextCount": 231,
   "dts": {
    "calculationLink": {
     "local": [
      "prok-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "prok-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "d373959ds1.htm"
     ]
    },
    "labelLink": {
     "local": [
      "prok-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "prok-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "prok-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/currency/2022/currency-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/exch/2022/exch-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 568,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 91,
   "keyStandard": 272,
   "memberCustom": 33,
   "memberStandard": 29,
   "nsprefix": "prok",
   "nsuri": "http://www.businesswire.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "1001 - Document - Cover Page",
     "role": "http://www.businesswire.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "prok:InitialPublicOfferingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1010 - Disclosure - Initial Public Offering",
     "role": "http://www.businesswire.com/role/InitialPublicOffering",
     "shortName": "Initial Public Offering",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "prok:InitialPublicOfferingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1011 - Disclosure - Income Taxes",
     "role": "http://www.businesswire.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "prok:PrivatePlacementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1012 - Disclosure - Private Placement",
     "role": "http://www.businesswire.com/role/PrivatePlacement",
     "shortName": "Private Placement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "prok:PrivatePlacementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1013 - Disclosure - Leases",
     "role": "http://www.businesswire.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1014 - Disclosure - Related Party Transactions",
     "role": "http://www.businesswire.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1015 - Disclosure - Commitments and Contingencies",
     "role": "http://www.businesswire.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MembersEquityNotesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1016 - Disclosure - Members' Equity",
     "role": "http://www.businesswire.com/role/MembersEquity",
     "shortName": "Members' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MembersEquityNotesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1017 - Disclosure - Temporary Equity and Permanent Deficit",
     "role": "http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficit",
     "shortName": "Temporary Equity and Permanent Deficit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1018 - Disclosure - Net Loss per Share",
     "role": "http://www.businesswire.com/role/NetLossPerShare",
     "shortName": "Net Loss per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1019 - Disclosure - Fair Value Measurements",
     "role": "http://www.businesswire.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002 - Statement - Condensed Balance Sheet",
     "role": "http://www.businesswire.com/role/CondensedBalanceSheet",
     "shortName": "Condensed Balance Sheet",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1020 - Disclosure - Equity Based Compensation",
     "role": "http://www.businesswire.com/role/EquityBasedCompensation",
     "shortName": "Equity Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1021 - Disclosure - Subsequent Events",
     "role": "http://www.businesswire.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1022 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1023 - Disclosure - Significant Accounting Policies (Tables)",
     "role": "http://www.businesswire.com/role/SignificantAccountingPoliciesTables",
     "shortName": "Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "prok:AccruedExpensesPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1024 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.businesswire.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "prok:LesseeOperatingAndFinanceLeaseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1025 - Disclosure - Leases (Tables)",
     "role": "http://www.businesswire.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "prok:LesseeOperatingAndFinanceLeaseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "prok:MembersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1026 - Disclosure - Members' Equity (Tables)",
     "role": "http://www.businesswire.com/role/MembersEquityTables",
     "shortName": "Members' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "prok:MembersEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1027 - Disclosure - Net Loss per Share (Tables)",
     "role": "http://www.businesswire.com/role/NetLossPerShareTables",
     "shortName": "Net Loss per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1028 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.businesswire.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1029 - Disclosure - Equity Based Compensation (Tables)",
     "role": "http://www.businesswire.com/role/EquityBasedCompensationTables",
     "shortName": "Equity Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LimitedPartnersCapitalAccountUnitsIssued",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003 - Statement - Condensed Balance Sheet (Parenthetical)",
     "role": "http://www.businesswire.com/role/CondensedBalanceSheetParenthetical",
     "shortName": "Condensed Balance Sheet (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding",
       "us-gaap:LimitedPartnersCapitalAccountUnitsIssued",
       "us-gaap:LimitedPartnersCapitalAccountUnitsIssued",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn12_31_2020_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P12_12_2018To12_31_2018",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1030 - Disclosure - Description Of Organization, Business Operations And Going Concern - Additional Information (Detail)",
     "role": "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
     "shortName": "Description Of Organization, Business Operations And Going Concern - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn07_02_2021",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:MinimumNetWorthRequiredForCompliance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P12_12_2018To12_31_2018",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityIncorporationDateOfIncorporation",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1031 - Disclosure - The Company - Additional Information (Detail)",
     "role": "http://www.businesswire.com/role/TheCompanyAdditionalInformationDetail",
     "shortName": "The Company - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn12_31_2018",
      "decimals": "-3",
      "lang": null,
      "name": "prok:InitialCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1032 - Disclosure - Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "div",
       "div",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1033 - Disclosure - Significant Accounting Policies - Schedule of Class A Ordinary Shares Reflected in the Balance Sheets (Detail)",
     "role": "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfClassAOrdinarySharesReflectedInTheBalanceSheetsDetail",
     "shortName": "Significant Accounting Policies - Schedule of Class A Ordinary Shares Reflected in the Balance Sheets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "prok:TemporaryEquityPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P02_25_2021To12_31_2021_CommonClassAMemberusgaapStatementClassOfStockAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1034 - Disclosure - Significant Accounting Policies - Schedule of Calculation of Basic and Diluted Net Income (Loss) per Ordinary Share (Detail)",
     "role": "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail",
     "shortName": "Significant Accounting Policies - Schedule of Calculation of Basic and Diluted Net Income (Loss) per Ordinary Share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "prok:AccruedExpensesPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1035 - Disclosure - Significant Accounting Policies - Schedule of Accrued Expenses (Detail)",
     "role": "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfAccruedExpensesDetail",
     "shortName": "Significant Accounting Policies - Schedule of Accrued Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "prok:AccruedExpensesPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1036 - Disclosure - Significant Accounting Policies - Schedule of Estimated Useful Lives (Detail)",
     "role": "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail",
     "shortName": "Significant Accounting Policies - Schedule of Estimated Useful Lives (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022_ComputerEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis_MaximumMembersrtRangeAxis",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1037 - Disclosure - Significant Accounting Policies - Schedule of Fixed Assets (Detail)",
     "role": "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfFixedAssetsDetail",
     "shortName": "Significant Accounting Policies - Schedule of Fixed Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1038 - Disclosure - Significant Accounting Policies - Schedule of Fixed Assets (Parenthetical) (Detail)",
     "role": "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfFixedAssetsParentheticalDetail",
     "shortName": "Significant Accounting Policies - Schedule of Fixed Assets (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1039 - Disclosure - Significant Accounting Policies - Schedule of Intangible Asset (Detail)",
     "role": "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetDetail",
     "shortName": "Significant Accounting Policies - Schedule of Intangible Asset (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004 - Statement - Condensed Statements of Operations",
     "role": "http://www.businesswire.com/role/CondensedStatementsOfOperations",
     "shortName": "Condensed Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1040 - Disclosure - Significant Accounting Policies - Schedule of Intangible Asset (Parenthetical) (Detail)",
     "role": "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetParentheticalDetail",
     "shortName": "Significant Accounting Policies - Schedule of Intangible Asset (Parenthetical) (Detail)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "prok:InitialPublicOfferingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SaleOfStockPricePerShare",
      "reportCount": 1,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1041 - Disclosure - Initial Public Offering - Additional Information (Detail)",
     "role": "http://www.businesswire.com/role/InitialPublicOfferingAdditionalInformationDetail",
     "shortName": "Initial Public Offering - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1042 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Detail)",
     "role": "http://www.businesswire.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail",
     "shortName": "Income Taxes - Schedule of Components of Income Tax Expense (Benefit) (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1043 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)",
     "role": "http://www.businesswire.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1044 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail)",
     "role": "http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn12_31_2020",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1045 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward  (Detail)",
     "role": "http://www.businesswire.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetail",
     "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits Roll Forward  (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2021To12_31_2021",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1046 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://www.businesswire.com/role/IncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "prok:InitialPublicOfferingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn07_02_2021_CommonClassAMemberusgaapStatementClassOfStockAxis",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:SaleOfStockPricePerShare",
      "reportCount": 1,
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1047 - Disclosure - Private Placement - Additional Information (Detail)",
     "role": "http://www.businesswire.com/role/PrivatePlacementAdditionalInformationDetail",
     "shortName": "Private Placement - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "prok:LesseeOperatingAndFinanceLeaseTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1048 - Disclosure - Leases - Schedule of the Classification of Operating and Finance Lease Assets and Obligations in the Company's Consolidated Balance Sheets (Detail)",
     "role": "http://www.businesswire.com/role/LeasesScheduleOfTheClassificationOfOperatingAndFinanceLeaseAssetsAndObligationsInTheCompanySConsolidatedBalanceSheetsDetail",
     "shortName": "Leases - Schedule of the Classification of Operating and Finance Lease Assets and Obligations in the Company's Consolidated Balance Sheets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "prok:LesseeOperatingAndFinanceLeaseTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1049 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities for the Company's Operating and Finance Leases (Detail)",
     "role": "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail",
     "shortName": "Leases - Schedule of Maturities of Lease Liabilities for the Company's Operating and Finance Leases (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PartnersCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005 - Statement - Condensed Statements of Changes In Temporary Equity And Permanent Deficit",
     "role": "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit",
     "shortName": "Condensed Statements of Changes In Temporary Equity And Permanent Deficit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn12_31_2019",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PartnersCapital",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1050 - Disclosure - Leases - Additional Information (Detail)",
     "role": "http://www.businesswire.com/role/LeasesAdditionalInformationDetail",
     "shortName": "Leases - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1051 - Disclosure - Related Party Transactions - Additional Information (Detail)",
     "role": "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
     "shortName": "Related Party Transactions - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis",
      "decimals": "0",
      "lang": null,
      "name": "prok:AdvancesPayableToRelatedPartyCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn01_18_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1052 - Disclosure - Related Party Debt - Additional Information (Detail)",
     "role": "http://www.businesswire.com/role/RelatedPartyDebtAdditionalInformationDetail",
     "shortName": "Related Party Debt - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn01_18_2022_PromissoryNoteMemberusgaapRelatedPartyTransactionAxis",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_pure",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "prok:DeferredUnderwritingFees",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1053 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://www.businesswire.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_DirectorRestrictedStockUnitAwardAgreementMemberPROKAgreementAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis",
      "decimals": "INF",
      "lang": null,
      "name": "prok:NumberOfSharesOfCommonStockCommittedToSettleOnADateFollowingTheYearBusinessCombinationOccurs",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LimitedPartnersCapitalAccountUnitsIssued",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn12_31_2020_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1054 - Disclosure - Members' Equity -Schedule Of  Members Equity (Detail)",
     "role": "http://www.businesswire.com/role/MembersEquityScheduleOfMembersEquityDetail",
     "shortName": "Members' Equity -Schedule Of  Members Equity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LimitedPartnersCapitalAccountUnitsIssued",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn12_31_2021_CapitalUnitClassAMemberusgaapCapitalUnitsByClassAxis",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:LimitedPartnersCapitalAccountUnitsOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:MembersEquityNotesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn03_31_2022_CapitalUnitClassBMemberusgaapCapitalUnitsByClassAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LimitedPartnersCapitalAccountUnitsAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1055 - Disclosure - Members' Equity - Additional Information (Detail)",
     "role": "http://www.businesswire.com/role/MembersEquityAdditionalInformationDetail",
     "shortName": "Members' Equity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:MembersEquityNotesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn03_31_2022_CapitalUnitClassB1MemberusgaapCapitalUnitsByClassAxis",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:LimitedPartnersCapitalAccountUnitsIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1056 - Disclosure - Temporary Equity and Permanent Deficit - Additional Information (Detail)",
     "role": "http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficitAdditionalInformationDetail",
     "shortName": "Temporary Equity and Permanent Deficit - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn03_31_2022_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1057 - Disclosure - Net Loss per Share - Schedule of calculation of basic and diluted net income (loss) per ordinary share (Detail)",
     "role": "http://www.businesswire.com/role/NetLossPerShareScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail",
     "shortName": "Net Loss per Share - Schedule of calculation of basic and diluted net income (loss) per ordinary share (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "prok:MarketableSecuritiesHeldToMaturityFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1058 - Disclosure - Fair Value Measurements - Summary of Assets that are Measured at Fair Value on a Recurring Basis (Detail)",
     "role": "http://www.businesswire.com/role/FairValueMeasurementsSummaryOfAssetsThatAreMeasuredAtFairValueOnARecurringBasisDetail",
     "shortName": "Fair Value Measurements - Summary of Assets that are Measured at Fair Value on a Recurring Basis (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn03_31_2022_FairValueInputsLevel1MemberusgaapFairValueByFairValueHierarchyLevelAxis_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "prok:MarketableSecuritiesHeldToMaturityFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1059 - Disclosure - Equity Based Compensation - Summary of the Activity Related to Company's Class B and B-1 Units Granted (Detail)",
     "role": "http://www.businesswire.com/role/EquityBasedCompensationSummaryOfTheActivityRelatedToCompanySClassBAndB1UnitsGrantedDetail",
     "shortName": "Equity Based Compensation - Summary of the Activity Related to Company's Class B and B-1 Units Granted (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "prok:TemporaryEquityStockIssuedDuringThePeriodShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006 - Statement - Condensed Statements of Changes In Temporary Equity And Permanent Deficit (Parenthetical)",
     "role": "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficitParenthetical",
     "shortName": "Condensed Statements of Changes In Temporary Equity And Permanent Deficit (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P02_25_2021To12_31_2021_SocialCapitalSuvrettaHoldingsCorp.IiiMemberdeiLegalEntityAxis",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "prok:TemporaryEquityStockIssuedDuringThePeriodShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1060 - Disclosure - Equity Based Compensation - Additional Information (Detail)",
     "role": "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail",
     "shortName": "Equity Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn03_31_2022",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:MembersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1061 - Disclosure - Equity Based Compensation - Summary of Key Assumptions Used in the OPM Valuation (Detail)",
     "role": "http://www.businesswire.com/role/EquityBasedCompensationSummaryOfKeyAssumptionsUsedInTheOpmValuationDetail",
     "shortName": "Equity Based Compensation - Summary of Key Assumptions Used in the OPM Valuation (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn12_31_2021",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:MembersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1062 - Disclosure - Equity Based Compensation - Summary of Compensation Expense (Detail)",
     "role": "http://www.businesswire.com/role/EquityBasedCompensationSummaryOfCompensationExpenseDetail",
     "shortName": "Equity Based Compensation - Summary of Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromRelatedPartyDebt",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1063 - Disclosure - Subsequent Events - Additional Information (Detail)",
     "role": "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail",
     "shortName": "Subsequent Events - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "PAsOn01_18_2022_SubsequentEventMemberusgaapSubsequentEventTypeAxis",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007 - Statement - Condensed Statement of Cash Flows",
     "role": "http://www.businesswire.com/role/CondensedStatementOfCashFlows",
     "shortName": "Condensed Statement of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1008 - Disclosure - Description Of Organization, Business Operations And Going Concern",
     "role": "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcern",
     "shortName": "Description Of Organization, Business Operations And Going Concern",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "1009 - Disclosure - Significant Accounting Policies",
     "role": "http://www.businesswire.com/role/SignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d373959ds1.htm",
      "contextRef": "P01_01_2022To03_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 62,
   "tag": {
    "country_KY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CAYMAN ISLANDS"
       }
      }
     },
     "localname": "KY",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.businesswire.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.businesswire.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.businesswire.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.businesswire.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.businesswire.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.businesswire.com/role/CommitmentsAndContingencies",
      "http://www.businesswire.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/CondensedBalanceSheet",
      "http://www.businesswire.com/role/CondensedBalanceSheetParenthetical",
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows",
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit",
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficitParenthetical",
      "http://www.businesswire.com/role/CondensedStatementsOfOperations",
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcern",
      "http://www.businesswire.com/role/FairValueMeasurements",
      "http://www.businesswire.com/role/FairValueMeasurementsSummaryOfAssetsThatAreMeasuredAtFairValueOnARecurringBasisDetail",
      "http://www.businesswire.com/role/FairValueMeasurementsTables",
      "http://www.businesswire.com/role/InitialPublicOffering",
      "http://www.businesswire.com/role/PrivatePlacement",
      "http://www.businesswire.com/role/RelatedPartyTransactions",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPolicies",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfClassAOrdinarySharesReflectedInTheBalanceSheetsDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesTables",
      "http://www.businesswire.com/role/SubsequentEvents",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail",
      "http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficit",
      "http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.businesswire.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.businesswire.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.businesswire.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when an entity was incorporated",
        "label": "Entity Incorporation, Date of Incorporation",
        "terseLabel": "Incorporation date of entity"
       }
      }
     },
     "localname": "EntityIncorporationDateOfIncorporation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/TheCompanyAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.businesswire.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.businesswire.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.businesswire.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.businesswire.com/role/CommitmentsAndContingencies",
      "http://www.businesswire.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/CondensedBalanceSheet",
      "http://www.businesswire.com/role/CondensedBalanceSheetParenthetical",
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows",
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit",
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficitParenthetical",
      "http://www.businesswire.com/role/CondensedStatementsOfOperations",
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcern",
      "http://www.businesswire.com/role/FairValueMeasurements",
      "http://www.businesswire.com/role/FairValueMeasurementsSummaryOfAssetsThatAreMeasuredAtFairValueOnARecurringBasisDetail",
      "http://www.businesswire.com/role/FairValueMeasurementsTables",
      "http://www.businesswire.com/role/InitialPublicOffering",
      "http://www.businesswire.com/role/PrivatePlacement",
      "http://www.businesswire.com/role/RelatedPartyTransactions",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPolicies",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfClassAOrdinarySharesReflectedInTheBalanceSheetsDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesTables",
      "http://www.businesswire.com/role/SubsequentEvents",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail",
      "http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficit",
      "http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "prok_AccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "AccountingPoliciesLineItems",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "prok_AccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Table]"
       }
      }
     },
     "localname": "AccountingPoliciesTable",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "prok_AccruedAccountingExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued accounting expense.",
        "label": "Accrued Accounting Expense",
        "terseLabel": "Accrued accounting expense"
       }
      }
     },
     "localname": "AccruedAccountingExpense",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_AccruedClinicalStudyRelatedCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfAccruedExpensesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical study related costs current.",
        "label": "Accrued Clinical Study Related Costs Current",
        "terseLabel": "Clinical study related costs"
       }
      }
     },
     "localname": "AccruedClinicalStudyRelatedCostsCurrent",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_AccruedDueDiligenceExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued due diligence expense.",
        "label": "Accrued Due Diligence Expense",
        "terseLabel": "Accrued due diligence expense"
       }
      }
     },
     "localname": "AccruedDueDiligenceExpense",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_AccruedExpensesAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 17.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses and other.",
        "label": "Accrued Expenses And Other",
        "verboseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "AccruedExpensesAndOther",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_AccruedExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 20.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses current.",
        "label": "Accrued Expenses Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedExpensesCurrent",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_AccruedExpensesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued expenses [Policy text block].",
        "label": "Accrued Expenses [Policy Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccruedExpensesPolicyTextBlock",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "prok_AccruedFacilityExpansionCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfAccruedExpensesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued facility expansion costs current.",
        "label": "Accrued Facility Expansion Costs Current",
        "terseLabel": "Facility expansion costs"
       }
      }
     },
     "localname": "AccruedFacilityExpansionCostsCurrent",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_AccruedLegalExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued legal expense.",
        "label": "Accrued Legal Expense",
        "terseLabel": "Accrued legal expense"
       }
      }
     },
     "localname": "AccruedLegalExpense",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_AccruedManufacturingImprovementCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfAccruedExpensesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued manufacturing improvement costs.",
        "label": "Accrued Manufacturing Improvement Costs",
        "terseLabel": "Manufacturing improvement costs"
       }
      }
     },
     "localname": "AccruedManufacturingImprovementCosts",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_AccruedPrintingExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued printing expense.",
        "label": "Accrued Printing Expense",
        "terseLabel": "Accrued printing expense"
       }
      }
     },
     "localname": "AccruedPrintingExpense",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_AccruedRegulatoryFilingFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued regulatory filing fee.",
        "label": "Accrued Regulatory Filing Fee",
        "terseLabel": "Accrued regulatory filing fee"
       }
      }
     },
     "localname": "AccruedRegulatoryFilingFee",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_AcquiredAssemblyWorkforceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acquired Assembly Workforce.",
        "label": "Acquired Assembly Workforce [Member]"
       }
      }
     },
     "localname": "AcquiredAssemblyWorkforceMember",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_AdministrationAndSupportServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Administration And Support Services [Member]"
       }
      }
     },
     "localname": "AdministrationAndSupportServicesMember",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_AdvanceFromRelatedPartyLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advance From Related Party Loan [Member]"
       }
      }
     },
     "localname": "AdvanceFromRelatedPartyLoanMember",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_AdvancesPayableToRelatedPartyCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advances payable to related party current.",
        "label": "Advances Payable To Related Party Current",
        "terseLabel": "Advances from related party current"
       }
      }
     },
     "localname": "AdvancesPayableToRelatedPartyCurrent",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_AgreementAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement .",
        "label": "Agreement [Axis]",
        "terseLabel": "Agreement [Axis]"
       }
      }
     },
     "localname": "AgreementAxis",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "prok_AgreementDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement .",
        "label": "Agreement [Domain]",
        "terseLabel": "Agreement [Domain]"
       }
      }
     },
     "localname": "AgreementDomain",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_AverillMasterFundLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Averill Master Fund, Ltd.",
        "label": "Averill Master Fund, Ltd [Member]",
        "terseLabel": "Averill Master Fund, Ltd"
       }
      }
     },
     "localname": "AverillMasterFundLtdMember",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_BasicAndDilutedEarningsPerShareOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basic and diluted earnings per share other disclosures.",
        "label": "Basic And Diluted Earnings Per Share Other Disclosures [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "BasicAndDilutedEarningsPerShareOtherDisclosuresAbstract",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "prok_BasicAndDilutedNetIncomeLossPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basic and diluted net income loss per share.",
        "label": "Basic And Diluted Net Income Loss Per Share [Abstract]",
        "terseLabel": "Net loss per Class A Unit"
       }
      }
     },
     "localname": "BasicAndDilutedNetIncomeLossPerShareAbstract",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/NetLossPerShareScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "prok_BasisAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis [Axis]"
       }
      }
     },
     "localname": "BasisAxis",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "prok_BasisDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis [Domain]"
       }
      }
     },
     "localname": "BasisDomain",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_BusinessCombinationAccruedConsultingExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination accrued consulting expense.",
        "label": "Business Combination Accrued Consulting Expense",
        "terseLabel": "Business combination, accrued consulting expense"
       }
      }
     },
     "localname": "BusinessCombinationAccruedConsultingExpense",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_BusinessCombinationAccruedLegalExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination accrued legal expense.",
        "label": "Business Combination Accrued legal Expense",
        "terseLabel": "Business combination, accrued legal expense"
       }
      }
     },
     "localname": "BusinessCombinationAccruedLegalExpense",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_BusinessCombinationAccruedOtherTransactionalRelatedExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination accrued other transactional related expenses.",
        "label": "Business Combination Accrued Other Transactional Related Expenses",
        "terseLabel": "Business combination, Accrued other transactional related expenses"
       }
      }
     },
     "localname": "BusinessCombinationAccruedOtherTransactionalRelatedExpenses",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_CapitalUnitClassB1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital unit class B-1",
        "label": "Capital Unit Class B1 [Member]"
       }
      }
     },
     "localname": "CapitalUnitClassB1Member",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/MembersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_CapitalUnitClassBOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capital unit classB1member.",
        "label": "Capital Unit Class B One [Member]",
        "terseLabel": "Capital Unit Class B 1 [Member]"
       }
      }
     },
     "localname": "CapitalUnitClassBOneMember",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, cash equivalent, restricted cash and restricted cash equivalents.",
        "label": "Cash, Cash Equivalent, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, end of period",
        "periodStartLabel": "Cash, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_ClassB1unitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class\u00a0B-1\u00a0Units.",
        "label": "Class B1Units [Member]",
        "terseLabel": "Class\u00a0B-1\u00a0Units [Member]"
       }
      }
     },
     "localname": "ClassB1unitsMember",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_CommonUnitsUnissued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common units unissued.",
        "label": "Common Units Unissued"
       }
      }
     },
     "localname": "CommonUnitsUnissued",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "prok_ContingentLiabilitiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent liabilities.",
        "label": "Contingent Liabilities [Policy Text Block]",
        "terseLabel": "Contingent Liabilities"
       }
      }
     },
     "localname": "ContingentLiabilitiesPolicyTextBlock",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "prok_CurrentAccountsPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 21.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current accounts payable.",
        "label": "Current Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "CurrentAccountsPayable",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_DeferredExpenseCapitalizedResearchAndDevelopmentCostsTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred expense capitalized research and development costs term.",
        "label": "Deferred Expense Capitalized Research and Development Costs term",
        "terseLabel": "Deferred Expense Capitalized Research and Development Costs term"
       }
      }
     },
     "localname": "DeferredExpenseCapitalizedResearchAndDevelopmentCostsTerm",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "prok_DeferredOfferingCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred offering cost.",
        "label": "Deferred Offering Cost",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredOfferingCost",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_DeferredOfferingCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred offering costs [policy text block].",
        "label": "Deferred Offering Costs [Policy Text Block]",
        "terseLabel": "Offering Costs"
       }
      }
     },
     "localname": "DeferredOfferingCostsPolicyTextBlock",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "prok_DeferredTaxAssetsFederalCreditCarryForwards": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets federal credit carry forwards.",
        "label": "Deferred Tax Assets Federal Credit Carry forwards",
        "verboseLabel": "Federal credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsFederalCreditCarryForwards",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_DeferredTaxAssetsLeases": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets leases.",
        "label": "Deferred Tax Assets Leases",
        "verboseLabel": "Leases"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeases",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_DeferredTaxAssetsStartUpCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets start up costs.",
        "label": "Deferred Tax Assets Start Up Costs",
        "verboseLabel": "Start-up\u00a0costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsStartUpCosts",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_DeferredUnderwritingCommissions": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 15.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred underwriting fee payable.",
        "label": "Deferred Underwriting Commissions",
        "terseLabel": "Deferred underwriting fee payable"
       }
      }
     },
     "localname": "DeferredUnderwritingCommissions",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_DeferredUnderwritingFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred underwriting fee.",
        "label": "Deferred Underwriting Fees",
        "terseLabel": "Deferred underwriting fee"
       }
      }
     },
     "localname": "DeferredUnderwritingFees",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_DeferredUnderwritingFeesAccruedButNotPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred underwriting fees accrued but not paid.",
        "label": "Deferred Underwriting Fees Accrued But Not Paid",
        "terseLabel": "Deferred underwriting fee payable"
       }
      }
     },
     "localname": "DeferredUnderwritingFeesAccruedButNotPaid",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_DefinedContributionPlanCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution plan costs.",
        "label": "Defined Contribution Plan Costs",
        "terseLabel": "Defined contribution plan costs"
       }
      }
     },
     "localname": "DefinedContributionPlanCosts",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_DefinedContributionPlanPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution plan percent.",
        "label": "Defined Contribution Plan Percent",
        "terseLabel": "Defined contribution plan employer matching contribution percent"
       }
      }
     },
     "localname": "DefinedContributionPlanPercent",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "prok_DescriptionOfOrganizationAndBusinessOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description Of Organization And Business Operations [Line Items]"
       }
      }
     },
     "localname": "DescriptionOfOrganizationAndBusinessOperationsLineItems",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "prok_DescriptionOfOrganizationAndBusinessOperationsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description Of Organization And Business Operations [Table]"
       }
      }
     },
     "localname": "DescriptionOfOrganizationAndBusinessOperationsTable",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "prok_DirectorRestrictedStockUnitAwardAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Director restricted stock unit award agreement .",
        "label": "Director Restricted Stock Unit Award Agreement [Member]"
       }
      }
     },
     "localname": "DirectorRestrictedStockUnitAwardAgreementMember",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_DisclosureInTabularFormOfUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure in tabular form of useful lives of property plant and equipment [Table Text Block].",
        "label": "Disclosure In Tabular Form Of Useful Lives Of Property Plant And Equipment [Table Text Block]",
        "terseLabel": "Schedule of estimated useful lives"
       }
      }
     },
     "localname": "DisclosureInTabularFormOfUsefulLivesOfPropertyPlantAndEquipmentTableTextBlock",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "prok_EachCalendarQuarterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "each calendar quarter",
        "label": "Each Calendar Quarter [Member]"
       }
      }
     },
     "localname": "EachCalendarQuarterMember",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_EarningsPerShareBasicAndDilutedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings per share basic and diluted [Line items].",
        "label": "Earnings Per Share Basic And Diluted [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedLineItems",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "prok_EarningsPerShareBasicAndDilutedTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings per share basic and diluted [Table].",
        "label": "Earnings Per Share Basic And Diluted [Table]"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedTable",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "prok_EarnoutSharesTrancheAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnout Shares Tranche [Axis].",
        "label": "Earnout Shares Tranche [Axis]",
        "terseLabel": "Earnout Shares Tranche [Axis]"
       }
      }
     },
     "localname": "EarnoutSharesTrancheAxis",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "prok_EarnoutSharesTrancheDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnout Shares Tranche",
        "label": "Earnout Shares Tranche [Domain]",
        "terseLabel": "Earnout Shares Tranche [Domain]"
       }
      }
     },
     "localname": "EarnoutSharesTrancheDomain",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_EffectiveIncomeTaxRateReconciliationLlcFlowThroughStructure": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation llc flow through structure.",
        "label": "Effective Income Tax Rate Reconciliation LLC Flow Through Structure",
        "terseLabel": "LLC flow-through structure"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationLlcFlowThroughStructure",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "prok_EmergingGrowthCompanyStatusPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Emerging growth company status [policy text block].",
        "label": "Emerging Growth Company Status [Policy Text Block]",
        "verboseLabel": "Emerging Growth Company"
       }
      }
     },
     "localname": "EmergingGrowthCompanyStatusPolicyTextBlock",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "prok_ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Existing Directors, Officers And Equityholders Of, Or Investment Funds Managed By Suvretta Capital Management, LLC [Member]"
       }
      }
     },
     "localname": "ExistingDirectorsOfficersAndEquityholdersOfOrInvestmentFundsManagedBySuvrettaCapitalManagementLlcMember",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Existing Directors, Officers And Unitholders Of ProKidney [Member]"
       }
      }
     },
     "localname": "ExistingDirectorsOfficersAndUnitholdersOfProkidneyMember",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_FormationCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows": {
       "order": 46.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Formation costs paid by sponsor in exchange for issuance of ordinary shares.",
        "label": "Formation Costs Paid By Sponsor In Exchange For Issuance Of Ordinary Shares",
        "terseLabel": "Formation costs paid by Sponsor in exchange for issuance of Founder Shares"
       }
      }
     },
     "localname": "FormationCostsPaidBySponsorInExchangeForIssuanceOfOrdinaryShares",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_FounderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Founder [Member]"
       }
      }
     },
     "localname": "FounderMember",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_FounderSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Founder Shares [Member]"
       }
      }
     },
     "localname": "FounderSharesMember",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_GoingConcernPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Going concern [Policy text block].",
        "label": "Going Concern [Policy Text Block]",
        "terseLabel": "Going Concern"
       }
      }
     },
     "localname": "GoingConcernPolicyTextBlock",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "prok_InFirstAnniversaryOfTheAcquisitionDateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In first anniversary of the acquisition date",
        "label": "In First Anniversary Of The Acquisition Date [Member]"
       }
      }
     },
     "localname": "InFirstAnniversaryOfTheAcquisitionDateMember",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_IncomeTaxActAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax act.",
        "label": "Income Tax Act [Axis]"
       }
      }
     },
     "localname": "IncomeTaxActAxis",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "prok_IncomeTaxActDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax act.",
        "label": "Income Tax Act [Domain]"
       }
      }
     },
     "localname": "IncomeTaxActDomain",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_IncomeTaxDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureLineItems",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "prok_IncomeTaxDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax disclosure.",
        "label": "Income Tax Disclosure [Table]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTable",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "prok_IncreaseDecreaseOfAdvanceFromRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows": {
       "order": 53.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease of advance from related party.",
        "label": "Increase Decrease of Advance From Related Party",
        "verboseLabel": "Advances from related party"
       }
      }
     },
     "localname": "IncreaseDecreaseOfAdvanceFromRelatedParty",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_IncreaseOfOrdinarySharesToRedemptionValueTemporaryEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase of ordinary shares to redemption value temporary equity.",
        "label": "Increase of Ordinary Shares to Redemption Value Temporary Equity",
        "terseLabel": "Increase of carrying value to redemption value"
       }
      }
     },
     "localname": "IncreaseOfOrdinarySharesToRedemptionValueTemporaryEquity",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfClassAOrdinarySharesReflectedInTheBalanceSheetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_IndependentDirectorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Independent Directors [Member]"
       }
      }
     },
     "localname": "IndependentDirectorsMember",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_InitialCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial capital.",
        "label": "Initial Capital",
        "terseLabel": "Initial capital"
       }
      }
     },
     "localname": "InitialCapital",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/TheCompanyAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_InitialPublicOfferingDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial public offering disclosure [text block].",
        "label": "Initial Public Offering Disclosure [Text Block]",
        "terseLabel": "Initial Public Offering"
       }
      }
     },
     "localname": "InitialPublicOfferingDisclosureTextBlock",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/InitialPublicOffering"
     ],
     "xbrltype": "textBlockItemType"
    },
    "prok_LesseeOperatingAndFinanceLeaseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating and finance lease.",
        "label": "Lessee operating and finance lease [Table Text Block]",
        "terseLabel": "Schedule of the classification of operating and finance lease assets and obligations in the Company's Consolidated Balance Sheets"
       }
      }
     },
     "localname": "LesseeOperatingAndFinanceLeaseTableTextBlock",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail": {
       "order": 13.0,
       "parentTag": "prok_OperatingAndFinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease and finance lease liability payments due.",
        "label": "Lessee Operating Lease And Finance Lease Liability Payments Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail": {
       "order": 19.0,
       "parentTag": "prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease and finance lease liability payments due after year five.",
        "label": "Lessee Operating Lease And Finance Lease Liability Payments Due After Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail": {
       "order": 14.0,
       "parentTag": "prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease and finance lease liability payments due next twelve months.",
        "label": "Lessee Operating Lease And Finance Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2022 (remaining nine months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail": {
       "order": 18.0,
       "parentTag": "prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease and finance lease liability payments due year five.",
        "label": "Lessee Operating Lease And Finance Lease Liability Payments Due Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail": {
       "order": 17.0,
       "parentTag": "prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease and finance lease liability payments due year four.",
        "label": "Lessee Operating Lease And Finance Lease Liability Payments Due Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail": {
       "order": 16.0,
       "parentTag": "prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease and finance lease liability payments due year three.",
        "label": "Lessee Operating Lease And Finance Lease Liability Payments Due Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail": {
       "order": 15.0,
       "parentTag": "prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease and finance lease liability payments due year two.",
        "label": "Lessee Operating Lease And Finance Lease Liability Payments Due Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAndFinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_LesseeOperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail": {
       "order": 20.0,
       "parentTag": "prok_OperatingAndFinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease and finance lease liability undiscounted excess amount.",
        "label": "Lessee Operating Lease And Finance Lease Liability Undiscounted Excess Amount",
        "terseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAndFinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_MarketableSecuritiesHeldToMaturityFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities held to maturity fair value disclosure.",
        "label": "Marketable Securities Held To Maturity Fair Value Disclosure",
        "terseLabel": "Marketable securities held in Trust Account"
       }
      }
     },
     "localname": "MarketableSecuritiesHeldToMaturityFairValueDisclosure",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/FairValueMeasurementsSummaryOfAssetsThatAreMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_MembersEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Members equity",
        "label": "Members Equity [Line Items]"
       }
      }
     },
     "localname": "MembersEquityLineItems",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/MembersEquityScheduleOfMembersEquityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "prok_MembersEquityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Members equity",
        "label": "Members Equity [Table]"
       }
      }
     },
     "localname": "MembersEquityTable",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/MembersEquityScheduleOfMembersEquityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "prok_MembersEquityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Members equity",
        "label": "Members Equity [Table Text Block]",
        "terseLabel": "Schedule Of Members Equity"
       }
      }
     },
     "localname": "MembersEquityTableTextBlock",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/MembersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "prok_NatureOfOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of operations.",
        "label": "Nature Of Operations [Line Items]"
       }
      }
     },
     "localname": "NatureOfOperationsLineItems",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/TheCompanyAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "prok_NatureOfOperationsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature of operations.",
        "label": "Nature Of Operations [Table]"
       }
      }
     },
     "localname": "NatureOfOperationsTable",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/TheCompanyAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "prok_NumberOfCommonUnitsUnissuedOfLimitedLiabilityCompany": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common units unissued of limited liability company",
        "label": "Number of common units unissued of limited liability company",
        "terseLabel": "Number of common units unissued of limited liability company"
       }
      }
     },
     "localname": "NumberOfCommonUnitsUnissuedOfLimitedLiabilityCompany",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "prok_NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of consecutive trading days for determining the share price.",
        "label": "Number Of Consecutive Trading Days For Determining The Share Price",
        "terseLabel": "Number of consecutive trading days for determining the share price"
       }
      }
     },
     "localname": "NumberOfConsecutiveTradingDaysForDeterminingTheSharePrice",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "prok_NumberOfSharesOfCommonStockCommittedToSettleOnADateFollowingTheYearBusinessCombinationOccurs": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock committed to settle on a date following the year Business combination occurs.",
        "label": "Number of Shares Of Common Stock Committed To Settle On A Date Following The Year Business Combination Occurs",
        "terseLabel": "Number of shares of common stock committed to settle on a date following the year Business combination occurs"
       }
      }
     },
     "localname": "NumberOfSharesOfCommonStockCommittedToSettleOnADateFollowingTheYearBusinessCombinationOccurs",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "prok_NumberOfTradingDaysForDeterminingTheSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of trading days for determining the share price.",
        "label": "Number Of Trading Days For Determining The Share Price",
        "terseLabel": "Number of trading days for determining the share price"
       }
      }
     },
     "localname": "NumberOfTradingDaysForDeterminingTheSharePrice",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "prok_OfferingCostsIncludedInAccruedOfferingCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Offering costs included in accrued offering costs.",
        "label": "Offering Costs Included In Accrued Offering Costs",
        "terseLabel": "Offering costs included in accrued offering costs."
       }
      }
     },
     "localname": "OfferingCostsIncludedInAccruedOfferingCosts",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_OnEachEnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "on each anniversary",
        "label": "On Each Enniversary [Member]"
       }
      }
     },
     "localname": "OnEachEnniversaryMember",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_OnTheLatterOfTheFirstAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "on the latter of the first anniversary",
        "label": "On The Latter Of The First Anniversary [Member]"
       }
      }
     },
     "localname": "OnTheLatterOfTheFirstAnniversaryMember",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_OperatingAndFinanceLeaseLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 22.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating and finance lease liabilities current.",
        "label": "Operating And Finance Lease Liabilities Current",
        "terseLabel": "Lease liabilities",
        "verboseLabel": "Operating And Finance Lease Liabilities Current"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiabilitiesCurrent",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet",
      "http://www.businesswire.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 30.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating and finance lease liabilities non current portion.",
        "label": "Operating And Finance Lease Liabilities Non Current Portion",
        "terseLabel": "Lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiabilitiesNonCurrentPortion",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_OperatingAndFinanceLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating and finance lease liability.",
        "label": "Operating And Finance Lease Liability",
        "totalLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseLiability",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_OperatingAndFinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating and finance lease weighted average discount rate percent.",
        "label": "Operating And Finance Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Operating And Finance Lease Weighted Average Discount Rate, Percent"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "prok_OperatingLeaseRentExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease rent expenses.",
        "label": "Operating Lease Rent Expenses",
        "terseLabel": "Operating Lease Rent Expenses"
       }
      }
     },
     "localname": "OperatingLeaseRentExpenses",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_OtherAccruedExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfAccruedExpensesDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other accrued expenses.",
        "label": "Other Accrued Expenses",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedExpenses",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_OverTheThreeYearPeriodFromTheDateOfGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Over the three - year period from the date of grant",
        "label": "Over The Three Year Period From The Date Of Grant [Member]"
       }
      }
     },
     "localname": "OverTheThreeYearPeriodFromTheDateOfGrantMember",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_PartnersCapitalOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Partners capital Outstanding.",
        "label": "Partners Capital Outstanding",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Units outstanding January\u00a01, 2020"
       }
      }
     },
     "localname": "PartnersCapitalOutstanding",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "prok_PerShareValueOfRestrictedAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share value of restricted assets.",
        "label": "Per Share Value Of Restricted Assets",
        "terseLabel": "Per share value of restricted assets"
       }
      }
     },
     "localname": "PerShareValueOfRestrictedAssets",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "prok_PercentOfFoundersSharesToCompanysIssuedAndOutstandingOrdinaryShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percent of founders shares to Company's issued and outstanding ordinary shares.",
        "label": "Percent Of Founders Shares To Companys Issued And Outstanding Ordinary Shares",
        "terseLabel": "Percent of founders shares to company's issued and outstanding ordinary shares"
       }
      }
     },
     "localname": "PercentOfFoundersSharesToCompanysIssuedAndOutstandingOrdinaryShares",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "prok_PercentageOfPublicSharesRedemption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of public shares redemption.",
        "label": "Percentage Of Public Shares Redemption",
        "terseLabel": "Percentage of public shares redemption"
       }
      }
     },
     "localname": "PercentageOfPublicSharesRedemption",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "prok_PercentageOfPublicSharesThatCanBeTransferredWithoutAnyRestriction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of public shares that can be transferred without any restriction.",
        "label": "Percentage Of Public Shares That Can Be Transferred Without Any Restriction",
        "terseLabel": "Percentage of public shares that can be transferred without any restriction"
       }
      }
     },
     "localname": "PercentageOfPublicSharesThatCanBeTransferredWithoutAnyRestriction",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "prok_PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of public shares to be redeemed in case business combination is not consummated.",
        "label": "Percentage Of Public Shares To Be Redeemed In Case Business Combination Is Not Consummated",
        "terseLabel": "Percentage of public shares to be redeemed in case business combination is not consummated"
       }
      }
     },
     "localname": "PercentageOfPublicSharesToBeRedeemedInCaseBusinessCombinationIsNotConsummated",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "prok_PeriodForWhichTheProfitsEarnedAreExemptFromTax": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period for which the profits earned are exempt from tax.",
        "label": "Period For Which The Profits Earned Are Exempt From Tax",
        "terseLabel": "Periods for which the profits earned are exempt from tax"
       }
      }
     },
     "localname": "PeriodForWhichTheProfitsEarnedAreExemptFromTax",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "prok_PipeInvestorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PIPE Investors [Member]"
       }
      }
     },
     "localname": "PipeInvestorsMember",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_PrepaidClinicalCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid clinical current.",
        "label": "Prepaid Clinical Current",
        "terseLabel": "Prepaid clinical"
       }
      }
     },
     "localname": "PrepaidClinicalCurrent",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_PrepaidInsuranceNonCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 9.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid insurance non current.",
        "label": "Prepaid Insurance Non Current",
        "verboseLabel": "Non-current prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsuranceNonCurrent",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_PrivatePlacementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Abstract]"
       }
      }
     },
     "localname": "PrivatePlacementAbstract",
     "nsuri": "http://www.businesswire.com/20220331",
     "xbrltype": "stringItemType"
    },
    "prok_PrivatePlacementDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private placement disclosure [text block].",
        "label": "Private Placement Disclosure [Text Block]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementDisclosureTextBlock",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/PrivatePlacement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "prok_ProceedsFromLimitedPartnersCapitalAccountUnits": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from limited partners capital account units",
        "label": "Proceeds from Limited partners capital account units",
        "terseLabel": "Proceeds from Limited partners capital account units"
       }
      }
     },
     "localname": "ProceedsFromLimitedPartnersCapitalAccountUnits",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/MembersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_ProkidneyLpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ProKidney LP [Member]"
       }
      }
     },
     "localname": "ProkidneyLpMember",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_PromissoryNoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Note [Member]"
       }
      }
     },
     "localname": "PromissoryNoteMember",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyDebtAdditionalInformationDetail",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_ProspectiveAssetsOfAcquireeAsAPercentageOfFairValueOfAssetsInTheTrustAccount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prospective assets of acquiree as a percentage of fair value of assets in the trust account.",
        "label": "Prospective Assets Of Acquiree As A Percentage Of Fair Value Of Assets In The Trust Account",
        "terseLabel": "Prospective assets of acquiree as a percentage of fair value of assets in the trust account"
       }
      }
     },
     "localname": "ProspectiveAssetsOfAcquireeAsAPercentageOfFairValueOfAssetsInTheTrustAccount",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "prok_RegenAndTwinCityBioLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regen and twin city bio LLC.",
        "label": "Regen And Twin City Bio LLC [Member]"
       }
      }
     },
     "localname": "RegenAndTwinCityBioLlcMember",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/TheCompanyAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_RemeasurementOfCarryingValueToRedemptionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remeasurement of carrying value to redemption value.",
        "label": "Remeasurement Of Carrying Value To Redemption Value"
       }
      }
     },
     "localname": "RemeasurementOfCarryingValueToRedemptionValue",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfClassAOrdinarySharesReflectedInTheBalanceSheetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_RemeasurementOfClassAOrdinarySharesToRedemptionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remeasurement of class A ordinary shares to redemption value.",
        "label": "Remeasurement Of Class A Ordinary Shares To Redemption Value",
        "terseLabel": "Remeasurement of Class A ordinary shares subject to possible redemption"
       }
      }
     },
     "localname": "RemeasurementOfClassAOrdinarySharesToRedemptionValue",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remeasurement of Class A ordinary shares to redemption value.",
        "label": "Remeasurement of Ordinary Shares to Redemption Value Temporary Equity",
        "negatedLabel": "Remeasurement of Class A ordinary shares to redemption value",
        "terseLabel": "Accretion of carrying value to redemption value"
       }
      }
     },
     "localname": "RemeasurementOfOrdinarySharesToRedemptionValueTemporaryEquity",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfClassAOrdinarySharesReflectedInTheBalanceSheetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_RepaymentOfAdvancesFromRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows": {
       "order": 39.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayment of advances from related party.",
        "label": "Repayment Of Advances From Related Party",
        "negatedLabel": "Repayment of advances from related party",
        "terseLabel": "Repayment of advances from related party"
       }
      }
     },
     "localname": "RepaymentOfAdvancesFromRelatedParty",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_RepaymentOfPromissoryNoteRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows": {
       "order": 40.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayment of Promissory Note Related Party.",
        "label": "Repayment of Promissory Note Related Party",
        "terseLabel": "Repayment of promissory note\u2014related party"
       }
      }
     },
     "localname": "RepaymentOfPromissoryNoteRelatedParty",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_RestrictedStockRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock rights[Member].",
        "label": "Restricted Stock Rights [Member]"
       }
      }
     },
     "localname": "RestrictedStockRightsMember",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_RestrictionOnTransferOfSponsorSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restriction On Transfer Of Sponsor Shares [Member]"
       }
      }
     },
     "localname": "RestrictionOnTransferOfSponsorSharesMember",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_RightOfUseAssetsObtainedInExchangeForLeaseObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of use assets obtained in exchange for lease obligations.",
        "label": "Right Of Use Assets Obtained In Exchange For Lease Obligations",
        "verboseLabel": "Right of use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetsObtainedInExchangeForLeaseObligations",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_RightOfUseAssetsOperatingAndFinanceLease": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 12.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right of use assets operating and finance lease.",
        "label": "Right Of Use Assets Operating And Finance Lease",
        "terseLabel": "Right of use assets, net",
        "verboseLabel": "Right Of Use Assets Operating And Finance Lease"
       }
      }
     },
     "localname": "RightOfUseAssetsOperatingAndFinanceLease",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet",
      "http://www.businesswire.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_ScMasterHoldingsLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SC master holdings, llc.",
        "label": "SC Master Holdings, LLC [Member]",
        "terseLabel": "SC Master Holdings, LLC"
       }
      }
     },
     "localname": "ScMasterHoldingsLlcMember",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based Compensation Arrangement By Share based Payment Award Options Granted In Period Fair Value.",
        "label": "Share based Compensation Arrangement By Share based Payment Award Options Granted In Period Fair Value",
        "terseLabel": "Fair value of shares granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedInPeriodFairValue",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_SharePriceOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price One [Member]"
       }
      }
     },
     "localname": "SharePriceOneMember",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_SharePriceRangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price Range [Axis]"
       }
      }
     },
     "localname": "SharePriceRangeAxis",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "prok_SharePriceRangeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price Range [Domain]"
       }
      }
     },
     "localname": "SharePriceRangeDomain",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_SharePriceThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price Three [Member]"
       }
      }
     },
     "localname": "SharePriceThreeMember",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_SharePriceTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price Two [Member]"
       }
      }
     },
     "localname": "SharePriceTwoMember",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_SharesNoLongerSubjectToForfeiture": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares no longer subject to forfeiture.",
        "label": "Shares No Longer Subject To Forfeiture",
        "terseLabel": "Shares no longer subject to forfeiture"
       }
      }
     },
     "localname": "SharesNoLongerSubjectToForfeiture",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "prok_SocialCapitalSuvrettaHoldingsCorp.IiiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Social capital suvretta holdings corp. III.",
        "label": "Social Capital Suvretta Holdings Corp. III [Member]"
       }
      }
     },
     "localname": "SocialCapitalSuvrettaHoldingsCorp.IiiMember",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/CommitmentsAndContingencies",
      "http://www.businesswire.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/CondensedBalanceSheet",
      "http://www.businesswire.com/role/CondensedBalanceSheetParenthetical",
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows",
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit",
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficitParenthetical",
      "http://www.businesswire.com/role/CondensedStatementsOfOperations",
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcern",
      "http://www.businesswire.com/role/FairValueMeasurements",
      "http://www.businesswire.com/role/FairValueMeasurementsSummaryOfAssetsThatAreMeasuredAtFairValueOnARecurringBasisDetail",
      "http://www.businesswire.com/role/FairValueMeasurementsTables",
      "http://www.businesswire.com/role/InitialPublicOffering",
      "http://www.businesswire.com/role/PrivatePlacement",
      "http://www.businesswire.com/role/RelatedPartyTransactions",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPolicies",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfClassAOrdinarySharesReflectedInTheBalanceSheetsDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesTables",
      "http://www.businesswire.com/role/SubsequentEvents",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail",
      "http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficit",
      "http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_SponsorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sponsor [Member]"
       }
      }
     },
     "localname": "SponsorMember",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_SubscriptionAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subscription Agreements",
        "label": "Subscription Agreements [Member]"
       }
      }
     },
     "localname": "SubscriptionAgreementsMember",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_TemporaryEquityIssaunceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity Issaunce Costs.",
        "label": "Temporary Equity Issaunce Costs",
        "terseLabel": "Class\u00a0A ordinary shares issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityIssaunceCosts",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfClassAOrdinarySharesReflectedInTheBalanceSheetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_TemporaryEquityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity [Policy text block].",
        "label": "Temporary Equity [Policy Text Block]",
        "terseLabel": "Class A Ordinary Shares Subject to Possible Redemption"
       }
      }
     },
     "localname": "TemporaryEquityPolicyTextBlock",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "prok_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during period shares new issues.",
        "label": "Temporary Equity Stock Issued During Period Shares New Issues",
        "verboseLabel": "Sale of 25,000,000 Public Shares, net of underwriting discounts and offering expenses (shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "prok_TemporaryEquityStockIssuedDuringThePeriodShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock issued during the period shares.",
        "label": "Temporary Equity Stock Issued During The Period Shares",
        "terseLabel": "Temporary Equity Stock Issued During The Period Shares"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringThePeriodShares",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficitParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "prok_TransactionCostsIncurredInConnectionWithInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction costs incurred in connection with initial public offering.",
        "label": "Transaction Costs Incurred In Connection With Initial Public Offering",
        "terseLabel": "Transaction costs incurred inconnection with initial public offering"
       }
      }
     },
     "localname": "TransactionCostsIncurredInConnectionWithInitialPublicOffering",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_UnderwritingFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting fee.",
        "label": "Underwriting Fee",
        "terseLabel": "Underwriting fee"
       }
      }
     },
     "localname": "UnderwritingFee",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_UnrecognizedTaxBenefitsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized tax benefits (gross).",
        "label": "Unrecognized Tax Benefits (Gross) [Abstract]",
        "verboseLabel": "Unrecognized tax benefits (gross):"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsGrossAbstract",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "prok_UnsufficientToFundItsObligationsTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsufficient to fund its obligations term.",
        "label": "Unsufficient To Fund Its Obligations Term",
        "terseLabel": "Unsufficient to fund its obligations term"
       }
      }
     },
     "localname": "UnsufficientToFundItsObligationsTerm",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "prok_ValuationTechniqueProbabilityWeightedExpectedReturnMethodMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation technique, probability weighted expected return method.",
        "label": "Valuation Technique, Probability Weighted Expected Return Method [Member]"
       }
      }
     },
     "localname": "ValuationTechniqueProbabilityWeightedExpectedReturnMethodMember",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationSummaryOfKeyAssumptionsUsedInTheOpmValuationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "prok_WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Waiting period after which the share trading days are considered.",
        "label": "Waiting Period After Which The Share Trading Days Are Considered",
        "terseLabel": "Waiting period after which the share trading days are considered"
       }
      }
     },
     "localname": "WaitingPeriodAfterWhichTheShareTradingDaysAreConsidered",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "prok_WorkingCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Working capital .",
        "label": "Working Capital"
       }
      }
     },
     "localname": "WorkingCapital",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prok_WorkingCapitalLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working Capital Loans [Member]"
       }
      }
     },
     "localname": "WorkingCapitalLoansMember",
     "nsuri": "http://www.businesswire.com/20220331",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "auth_ref": [
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.",
        "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Schedule of Maturities of lease liabilities for the Company's operating and finance leases"
       }
      }
     },
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.businesswire.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person serving on board of directors.",
        "label": "Director [Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r186",
      "r188",
      "r189",
      "r190",
      "r209",
      "r219",
      "r261",
      "r263",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r477",
      "r479",
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r186",
      "r188",
      "r189",
      "r190",
      "r209",
      "r219",
      "r261",
      "r263",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r477",
      "r479",
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r179",
      "r186",
      "r188",
      "r189",
      "r190",
      "r209",
      "r219",
      "r249",
      "r261",
      "r263",
      "r294",
      "r295",
      "r296",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r477",
      "r479",
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r179",
      "r186",
      "r188",
      "r189",
      "r190",
      "r209",
      "r219",
      "r249",
      "r261",
      "r263",
      "r294",
      "r295",
      "r296",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r477",
      "r479",
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r152",
      "r153",
      "r245",
      "r246",
      "r478",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r513",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r152",
      "r153",
      "r245",
      "r246",
      "r478",
      "r494",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r513",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r155",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 19.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfAccruedExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "totalLabel": "Total accrued expenses and other"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfAccruedExpensesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued legal"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r10",
      "r175"
     ],
     "calculation": {
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfFixedAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfFixedAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r18",
      "r419"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 34.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional\u00a0paid-in\u00a0capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r306",
      "r307",
      "r308",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r299"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "presentationGuidance": "Total equity-based compensation expense",
        "verboseLabel": "Equity-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail",
      "http://www.businesswire.com/role/EquityBasedCompensationSummaryOfCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r63",
      "r163",
      "r168"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Finite lived intangible assets amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetParentheticalDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r12",
      "r76",
      "r134",
      "r143",
      "r149",
      "r158",
      "r194",
      "r195",
      "r196",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r364",
      "r366",
      "r379",
      "r417",
      "r419",
      "r454",
      "r467"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r25",
      "r76",
      "r158",
      "r194",
      "r195",
      "r196",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r364",
      "r366",
      "r379",
      "r417",
      "r419"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/FairValueMeasurementsSummaryOfAssetsThatAreMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsHeldInTrustNoncurrent": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 10.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash, securities, or other assets held by a third-party trustee pursuant to the terms of an agreement which assets are available to be used by beneficiaries to that agreement only within the specific terms thereof and which agreement is expected to terminate more than one year from the balance sheet date (or operating cycle, if longer) at which time the assets held-in-trust will be released or forfeited.",
        "label": "Assets Held-in-trust, Noncurrent",
        "verboseLabel": "Marketable Securities held in Trust Account"
       }
      }
     },
     "localname": "AssetsHeldInTrustNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r260",
      "r262",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail",
      "http://www.businesswire.com/role/TheCompanyAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r260",
      "r262",
      "r354",
      "r355",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail",
      "http://www.businesswire.com/role/TheCompanyAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Business acquisition, equity interest issued or issuable, number of shares"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Business acquisition, share price"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r357",
      "r358",
      "r359"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Business combination consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/TheCompanyAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r67",
      "r68",
      "r69"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "verboseLabel": "Equipment and facility expansion included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalUnitClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class A of capital units, which are a type of ownership interest in a corporation.",
        "label": "Capital Unit, Class A [Member]",
        "terseLabel": "Capital Unit, Class A [Member]"
       }
      }
     },
     "localname": "CapitalUnitClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet",
      "http://www.businesswire.com/role/CondensedBalanceSheetParenthetical",
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit",
      "http://www.businesswire.com/role/CondensedStatementsOfOperations",
      "http://www.businesswire.com/role/MembersEquityAdditionalInformationDetail",
      "http://www.businesswire.com/role/MembersEquityScheduleOfMembersEquityDetail",
      "http://www.businesswire.com/role/NetLossPerShareScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalUnitClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class B of capital units, which are a type of ownership interest in a corporation.",
        "label": "Capital Unit, Class B [Member]",
        "terseLabel": "Capital Unit, Class B [Member]"
       }
      }
     },
     "localname": "CapitalUnitClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet",
      "http://www.businesswire.com/role/CondensedBalanceSheetParenthetical",
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit",
      "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail",
      "http://www.businesswire.com/role/MembersEquityAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalUnitClassDomain": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type or class of capital units or capital shares.",
        "label": "Capital Unit, Class [Domain]"
       }
      }
     },
     "localname": "CapitalUnitClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet",
      "http://www.businesswire.com/role/CondensedBalanceSheetParenthetical",
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit",
      "http://www.businesswire.com/role/CondensedStatementsOfOperations",
      "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail",
      "http://www.businesswire.com/role/MembersEquityAdditionalInformationDetail",
      "http://www.businesswire.com/role/MembersEquityScheduleOfMembersEquityDetail",
      "http://www.businesswire.com/role/NetLossPerShareScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalUnits": {
     "auth_ref": [
      "r488"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.",
        "label": "Capital Units, Value",
        "terseLabel": "Capital Units, Value"
       }
      }
     },
     "localname": "CapitalUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalUnitsByClassAxis": {
     "auth_ref": [
      "r485",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of the entity's capital units.",
        "label": "Capital Units by Class [Axis]"
       }
      }
     },
     "localname": "CapitalUnitsByClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet",
      "http://www.businesswire.com/role/CondensedBalanceSheetParenthetical",
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit",
      "http://www.businesswire.com/role/CondensedStatementsOfOperations",
      "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail",
      "http://www.businesswire.com/role/MembersEquityAdditionalInformationDetail",
      "http://www.businesswire.com/role/MembersEquityScheduleOfMembersEquityDetail",
      "http://www.businesswire.com/role/NetLossPerShareScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r8",
      "r419",
      "r486",
      "r487"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet",
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r8",
      "r65"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r66",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities Held in Trust Account"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r60",
      "r65",
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, end of period",
        "periodStartLabel": "Cash, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r60",
      "r383"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r8"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash equivalents, at carrying value",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFDICInsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, FDIC Insured Amount",
        "terseLabel": "Cash, FDIC insured amount"
       }
      }
     },
     "localname": "CashFDICInsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r74",
      "r76",
      "r97",
      "r98",
      "r99",
      "r101",
      "r103",
      "r111",
      "r113",
      "r115",
      "r158",
      "r194",
      "r199",
      "r200",
      "r201",
      "r205",
      "r206",
      "r217",
      "r218",
      "r222",
      "r226",
      "r233",
      "r379",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CommitmentsAndContingencies",
      "http://www.businesswire.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/CondensedBalanceSheet",
      "http://www.businesswire.com/role/CondensedBalanceSheetParenthetical",
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit",
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficitParenthetical",
      "http://www.businesswire.com/role/CondensedStatementsOfOperations",
      "http://www.businesswire.com/role/CoverPage",
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/FairValueMeasurements",
      "http://www.businesswire.com/role/FairValueMeasurementsTables",
      "http://www.businesswire.com/role/InitialPublicOffering",
      "http://www.businesswire.com/role/InitialPublicOfferingAdditionalInformationDetail",
      "http://www.businesswire.com/role/MembersEquityAdditionalInformationDetail",
      "http://www.businesswire.com/role/PrivatePlacement",
      "http://www.businesswire.com/role/PrivatePlacementAdditionalInformationDetail",
      "http://www.businesswire.com/role/RelatedPartyTransactions",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfClassAOrdinarySharesReflectedInTheBalanceSheetsDetail",
      "http://www.businesswire.com/role/SubsequentEvents",
      "http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficit",
      "http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/InitialPublicOfferingAdditionalInformationDetail",
      "http://www.businesswire.com/role/PrivatePlacementAdditionalInformationDetail",
      "http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r36",
      "r458",
      "r471"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 29.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and Contingencies (Note 6)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r181",
      "r182",
      "r183",
      "r191",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Common Class A [Member]"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/CondensedBalanceSheet",
      "http://www.businesswire.com/role/CondensedBalanceSheetParenthetical",
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit",
      "http://www.businesswire.com/role/CondensedStatementsOfOperations",
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/InitialPublicOfferingAdditionalInformationDetail",
      "http://www.businesswire.com/role/PrivatePlacementAdditionalInformationDetail",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfClassAOrdinarySharesReflectedInTheBalanceSheetsDetail",
      "http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonClassBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation.",
        "label": "Common Class B [Member]",
        "terseLabel": "Class B [Member]"
       }
      }
     },
     "localname": "CommonClassBMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet",
      "http://www.businesswire.com/role/CondensedBalanceSheetParenthetical",
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit",
      "http://www.businesswire.com/role/CondensedStatementsOfOperations",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail",
      "http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockHeldInTrust": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of common stock held in trust.",
        "label": "Common Stock Held in Trust",
        "terseLabel": "Common stock held in trust account"
       }
      }
     },
     "localname": "CommonStockHeldInTrust",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r82",
      "r83",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockOtherSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares of other common stock instruments held by shareholders, such as exchangeable shares. May be all or portion of the number of common shares authorized.",
        "label": "Common Stock, Other Shares, Outstanding",
        "verboseLabel": "Common stock, shares, subject to forfeiture"
       }
      }
     },
     "localname": "CommonStockOtherSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheetParenthetical",
      "http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheetParenthetical",
      "http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheetParenthetical",
      "http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock shares outstanding",
        "verboseLabel": "Common stock shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheetParenthetical",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17",
      "r419"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 33.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock value"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonUnitIssuanceValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stated value of common units of ownership issued by a limited liability company (LLC).",
        "label": "Common Unit, Issuance Value"
       }
      }
     },
     "localname": "CommonUnitIssuanceValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonUnitIssued": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common units issued of limited liability company (LLC).",
        "label": "Common Unit, Issued"
       }
      }
     },
     "localname": "CommonUnitIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfFixedAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r120",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfFixedAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r77",
      "r337",
      "r345"
     ],
     "calculation": {
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "verboseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r77",
      "r337",
      "r345",
      "r347"
     ],
     "calculation": {
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current income tax expense (benefit)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "verboseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r77",
      "r337",
      "r345"
     ],
     "calculation": {
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "verboseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r207",
      "r211",
      "r212",
      "r392",
      "r394",
      "r395"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument face value"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyDebtAdditionalInformationDetail",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument, Fee Amount"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyDebtAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r33",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyDebtAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r34",
      "r209",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date",
        "terseLabel": "Debt Instrument, Maturity Date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyDebtAdditionalInformationDetail"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.",
        "label": "Debt Instrument, Unused Borrowing Capacity, Amount",
        "terseLabel": "Debt Instrument, Unused Borrowing Capacity, Amount"
       }
      }
     },
     "localname": "DebtInstrumentUnusedBorrowingCapacityAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyDebtAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain": {
     "auth_ref": [
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes equity-based compensation plans, defined benefit pension plans and defined benefit other postretirement benefit plans.",
        "label": "Deferred Bonus and Profit Sharing Arrangement, Individual Contract, Type of Deferred Compensation [Domain]"
       }
      }
     },
     "localname": "DeferredBonusAndProfitSharingArrangementIndividualContractTypeOfDeferredCompensationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis": {
     "auth_ref": [
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes equity-based compensation plans, defined benefit pension plans and defined benefit other postretirement benefit plans.",
        "label": "Deferred Bonus and Profit Sharing Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTypeOfDeferredCompensationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r77",
      "r338",
      "r345"
     ],
     "calculation": {
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "verboseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r63",
      "r77",
      "r338",
      "r345",
      "r346",
      "r347"
     ],
     "calculation": {
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred income tax expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "verboseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r13",
      "r14",
      "r327",
      "r455",
      "r466"
     ],
     "calculation": {
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredProfitSharingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a share in the profits, as defined in the agreement, of the entity or portion thereof. Employer contributions may be discretionary or may be based on a fixed formula related to profits, compensation, or other factors. It is a form of incentive compensation to employees in addition to their regular salary and bonuses.",
        "label": "Deferred Profit Sharing [Member]"
       }
      }
     },
     "localname": "DeferredProfitSharingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r77",
      "r338",
      "r345"
     ],
     "calculation": {
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "verboseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r328"
     ],
     "calculation": {
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Deferred tax assets before valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]",
        "verboseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "verboseLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses": {
     "auth_ref": [
      "r335",
      "r336"
     ],
     "calculation": {
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee bonuses.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Bonuses",
        "verboseLabel": "Accrued bonus"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r329"
     ],
     "calculation": {
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "terseLabel": "Deferred Tax Assets, Valuation Allowance",
        "verboseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "verboseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r335",
      "r336"
     ],
     "calculation": {
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 12.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "verboseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r335",
      "r336"
     ],
     "calculation": {
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail": {
       "order": 11.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "verboseLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy election to measure plan assets and benefit obligations as of the month-end that is closest to the fiscal year-end.",
        "label": "Defined Benefit Plan, Plan Assets, Accounting Policy Election, Measurement Date [Policy Text Block]",
        "terseLabel": "Defined Contribution Plan"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccountingPolicyElectionMeasurementDatePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r63",
      "r173"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfFixedAssetsParentheticalDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r63",
      "r132"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows": {
       "order": 48.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r267",
      "r268",
      "r300",
      "r301",
      "r303",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Equity Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r266",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "terseLabel": "Summary of key assumptions used in the OPM valuation"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r27",
      "r80",
      "r197",
      "r199",
      "r200",
      "r204",
      "r205",
      "r206",
      "r411"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 18.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Advances from related party"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r80",
      "r197",
      "r199",
      "r200",
      "r204",
      "r205",
      "r206",
      "r411",
      "r457",
      "r472"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyDebtAdditionalInformationDetail",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r48",
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r95",
      "r97",
      "r101",
      "r102",
      "r103",
      "r107",
      "r108",
      "r370",
      "r371",
      "r461",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per Class A Unit , Basic",
        "verboseLabel": "Net loss per ordinary share , Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfOperations",
      "http://www.businesswire.com/role/NetLossPerShareScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareBasicLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/NetLossPerShareScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r48",
      "r87",
      "r88",
      "r89",
      "r90",
      "r91",
      "r97",
      "r101",
      "r102",
      "r103",
      "r107",
      "r108",
      "r370",
      "r371",
      "r461",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per Class A Unit , Diluted",
        "verboseLabel": "Net loss per ordinary share , Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfOperations",
      "http://www.businesswire.com/role/NetLossPerShareScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r104",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "verboseLabel": "Net Loss Per Ordinary Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Percent",
        "verboseLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r78",
      "r317",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Income taxes at statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r317",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "verboseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r317",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "verboseLabel": "Provision to return adjustment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r317",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "verboseLabel": "State taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign": {
     "auth_ref": [
      "r317",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent",
        "verboseLabel": "Federal Credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for employee benefit and equity-based compensation.",
        "label": "Employee Benefits and Share-Based Compensation",
        "terseLabel": "Compensation Expense"
       }
      }
     },
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfAccruedExpensesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationSummaryOfCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r302"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "unrecognized compensation expense is expected to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r41",
      "r42",
      "r43",
      "r82",
      "r83",
      "r84",
      "r86",
      "r92",
      "r94",
      "r110",
      "r159",
      "r233",
      "r241",
      "r306",
      "r307",
      "r308",
      "r341",
      "r342",
      "r369",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r407",
      "r480",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit",
      "http://www.businesswire.com/role/MembersEquityScheduleOfMembersEquityDetail",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityInterestIssuedOrIssuableByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of equity interests that are issued or issuable in a business combination.",
        "label": "Equity Interest Type [Axis]",
        "terseLabel": "Equity Interest Type [Axis]"
       }
      }
     },
     "localname": "EquityInterestIssuedOrIssuableByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityInterestIssuedOrIssuableTypeDomain": {
     "auth_ref": [
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of equity interest issued or issuable to acquire an entity in a business combination.",
        "label": "Equity Interest Issued or Issuable, Type [Domain]",
        "terseLabel": "Equity Interest Issued or Issuable, Type [Domain]"
       }
      }
     },
     "localname": "EquityInterestIssuedOrIssuableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method investment ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Assets that are Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r259",
      "r373",
      "r423",
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/FairValueMeasurementsSummaryOfAssetsThatAreMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r210",
      "r250",
      "r251",
      "r256",
      "r259",
      "r373",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/FairValueMeasurementsSummaryOfAssetsThatAreMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r259",
      "r423",
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/FairValueMeasurementsSummaryOfAssetsThatAreMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r377",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueOptionQuantitativeDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Option, Quantitative Disclosures [Line Items]"
       }
      }
     },
     "localname": "FairValueOptionQuantitativeDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/FairValueMeasurementsSummaryOfAssetsThatAreMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueOptionQuantitativeDisclosuresTable": {
     "auth_ref": [
      "r380",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value under fair value option.",
        "label": "Fair Value Option, Disclosures [Table]"
       }
      }
     },
     "localname": "FairValueOptionQuantitativeDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/FairValueMeasurementsSummaryOfAssetsThatAreMeasuredAtFairValueOnARecurringBasisDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r397",
      "r404"
     ],
     "calculation": {
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetailAlternate1": {
       "order": 24.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Total finance lease liabilities",
        "verboseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail",
      "http://www.businesswire.com/role/LeasesScheduleOfTheClassificationOfOperatingAndFinanceLeaseAssetsAndObligationsInTheCompanySConsolidatedBalanceSheetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability [Abstract]",
        "terseLabel": "Finance leases:"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfTheClassificationOfOperatingAndFinanceLeaseAssetsAndObligationsInTheCompanySConsolidatedBalanceSheetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance lease liabilities, current"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfTheClassificationOfOperatingAndFinanceLeaseAssetsAndObligationsInTheCompanySConsolidatedBalanceSheetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Finance lease liabilities, noncurrent"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfTheClassificationOfOperatingAndFinanceLeaseAssetsAndObligationsInTheCompanySConsolidatedBalanceSheetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetailAlternate1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail": {
       "order": 12.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022 (remaining nine months)"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail": {
       "order": 11.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail": {
       "order": 10.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail": {
       "order": 9.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetailAlternate1": {
       "order": 23.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r398",
      "r402"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows": {
       "order": 41.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payments on finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r396"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Right of use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfTheClassificationOfOperatingAndFinanceLeaseAssetsAndObligationsInTheCompanySConsolidatedBalanceSheetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r403",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance Lease, Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite lived intangible assets useful lives"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetParentheticalDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r11",
      "r167"
     ],
     "calculation": {
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r169"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Finite lived intangible assets amortization expense next twelve months"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetParentheticalDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r169"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Finite lived intangible assets amortization expense next three years"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetParentheticalDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r169"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Finite lived intangible assets amortization expense next two years"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetParentheticalDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r164",
      "r165",
      "r167",
      "r170",
      "r438",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r167",
      "r439"
     ],
     "calculation": {
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Gross carrying amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r164",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetParentheticalDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r167",
      "r438"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 13.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Net carrying amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfFixedAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementsOfOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationSummaryOfCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/InitialPublicOfferingAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r63",
      "r172",
      "r177"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment of long lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r46",
      "r134",
      "r142",
      "r145",
      "r148",
      "r150",
      "r452",
      "r459",
      "r463",
      "r475"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Net loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r178",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationSummaryOfCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationSummaryOfCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r78",
      "r318",
      "r325",
      "r332",
      "r343",
      "r349",
      "r351",
      "r352",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Tax"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r79",
      "r93",
      "r94",
      "r133",
      "r316",
      "r344",
      "r350",
      "r476"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementsOfOperations": {
       "order": 10.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "presentationGuidance": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense (benefit)",
        "totalLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfOperations",
      "http://www.businesswire.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfComponentsOfIncomeTaxExpenseBenefitDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r40",
      "r314",
      "r315",
      "r325",
      "r326",
      "r331",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Statutory income tax rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows": {
       "order": 54.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows": {
       "order": 52.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows": {
       "order": 56.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "verboseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows": {
       "order": 51.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows": {
       "order": 55.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows": {
       "order": 50.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r72",
      "r166",
      "r434",
      "r435",
      "r436",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r44",
      "r131",
      "r391",
      "r393",
      "r462"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementsOfOperations": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r51",
      "r130"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows": {
       "order": 47.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.businesswire.com/role/CondensedStatementsOfOperations": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedLabel": "Interest earned on marketable securities held in Trust Account",
        "terseLabel": "Interest earned on marketable securities held in Trust Account"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows",
      "http://www.businesswire.com/role/CondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNonoperating": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementsOfOperations": {
       "order": 9.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.",
        "label": "Investment Income, Nonoperating",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfFixedAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetailAlternate1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022 (remaining nine months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetailAlternate1": {
       "order": 21.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lessee, Operating Lease, Term of Contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r30",
      "r76",
      "r144",
      "r158",
      "r194",
      "r195",
      "r196",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r365",
      "r366",
      "r367",
      "r379",
      "r417",
      "r418"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 14.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r22",
      "r76",
      "r158",
      "r379",
      "r419",
      "r456",
      "r469"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r32",
      "r76",
      "r158",
      "r194",
      "r195",
      "r196",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r365",
      "r366",
      "r367",
      "r379",
      "r417",
      "r418",
      "r419"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 16.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LimitedPartnersCapitalAccountUnitsAuthorized": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of limited partner units authorized to be issued.",
        "label": "Limited Partners' Capital Account, Units Authorized",
        "terseLabel": "Limited Partners' Capital Account, Units Authorized",
        "verboseLabel": "Limited Partners' Capital Account, Units Authorized"
       }
      }
     },
     "localname": "LimitedPartnersCapitalAccountUnitsAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail",
      "http://www.businesswire.com/role/MembersEquityAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_LimitedPartnersCapitalAccountUnitsIssued": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of limited partner units issued.",
        "label": "Limited Partners' Capital Account, Units Issued",
        "terseLabel": "Limited partners capital account units issued",
        "verboseLabel": "Limited Partners' Capital Account, Units Issued"
       }
      }
     },
     "localname": "LimitedPartnersCapitalAccountUnitsIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheetParenthetical",
      "http://www.businesswire.com/role/MembersEquityAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_LimitedPartnersCapitalAccountUnitsOutstanding": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of limited partner units outstanding.",
        "label": "Limited Partners' Capital Account, Units Outstanding",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Units outstanding January\u00a01, 2020",
        "terseLabel": "Limited partners capital account units outstanding"
       }
      }
     },
     "localname": "LimitedPartnersCapitalAccountUnitsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheetParenthetical",
      "http://www.businesswire.com/role/MembersEquityScheduleOfMembersEquityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_LimitedPartnersContributedCapital": {
     "auth_ref": [
      "r242"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 26.0,
       "parentTag": "us-gaap_PartnersCapital",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of capital contributed by the limited partners.",
        "label": "Limited Partners' Contributed Capital",
        "terseLabel": "Class Units"
       }
      }
     },
     "localname": "LimitedPartnersContributedCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "auth_ref": [
      "r28"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Current Borrowing Capacity",
        "terseLabel": "Line of Credit Facility, Current Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r28"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities": {
     "auth_ref": [
      "r2"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of estimated accrued costs to dispose of assets or other items expected to be sold in liquidation.",
        "label": "Liquidation Basis of Accounting, Accrued Costs to Dispose of Assets and Liabilities",
        "terseLabel": "Interest to pay dissolution expenses"
       }
      }
     },
     "localname": "LiquidationBasisOfAccountingAccruedCostsToDisposeOfAssetsAndLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r192",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MemberUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest in limited liability company (LLC).",
        "label": "Member Units [Member]",
        "terseLabel": "Member Units [Member]"
       }
      }
     },
     "localname": "MemberUnitsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit",
      "http://www.businesswire.com/role/MembersEquityScheduleOfMembersEquityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MembersEquity": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r115",
      "r241"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of ownership interest in limited liability company (LLC), attributable to the parent entity.",
        "label": "Members' Equity",
        "terseLabel": "Total equity value"
       }
      }
     },
     "localname": "MembersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationSummaryOfKeyAssumptionsUsedInTheOpmValuationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MembersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Members' Equity [Abstract]",
        "terseLabel": "Members' equity:"
       }
      }
     },
     "localname": "MembersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MembersEquityNotesDisclosureTextBlock": {
     "auth_ref": [
      "r114",
      "r115",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the formation, structure, control and ownership of a limited liability company (LLC).",
        "label": "Members' Equity Notes Disclosure [Text Block]",
        "terseLabel": "Members' Equity"
       }
      }
     },
     "localname": "MembersEquityNotesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/MembersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinimumNetWorthRequiredForCompliance": {
     "auth_ref": [
      "r490",
      "r491",
      "r492",
      "r493"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum net worth required for mortgage banking as defined by regulatory framework.",
        "label": "Banking Regulation, Mortgage Banking, Net Worth, Minimum",
        "terseLabel": "Minimum net worth to consummate business combination"
       }
      }
     },
     "localname": "MinimumNetWorthRequiredForCompliance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r117",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "verboseLabel": "Description Of Organization, Business Operations And Going Concern"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcern"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows": {
       "order": 33.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash Flows from Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows": {
       "order": 29.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r60",
      "r61",
      "r64"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows": {
       "order": 44.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r38",
      "r39",
      "r43",
      "r47",
      "r64",
      "r76",
      "r85",
      "r87",
      "r88",
      "r89",
      "r90",
      "r93",
      "r94",
      "r100",
      "r134",
      "r142",
      "r145",
      "r148",
      "r150",
      "r158",
      "r194",
      "r195",
      "r196",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r371",
      "r379",
      "r460",
      "r473"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows": {
       "order": 45.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.businesswire.com/role/CondensedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "positiveLabel": "Net income loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Allocation of net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows",
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit",
      "http://www.businesswire.com/role/CondensedStatementsOfOperations",
      "http://www.businesswire.com/role/NetLossPerShareScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/NetLossPerShareScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Non-Cash Investing and Financing Activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": {
     "auth_ref": [
      "r26",
      "r80",
      "r412"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 24.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Notes Payable, Related Parties, Current",
        "terseLabel": "Related party notes payable"
       }
      }
     },
     "localname": "NotesPayableRelatedPartiesClassifiedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of Operating Segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Operating and formation costs"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r134",
      "r142",
      "r145",
      "r148",
      "r150"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r397"
     ],
     "calculation": {
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetailAlternate1": {
       "order": 22.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total operating lease liabilities",
        "verboseLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfMaturitiesOfLeaseLiabilitiesForTheCompanySOperatingAndFinanceLeasesDetail",
      "http://www.businesswire.com/role/LeasesScheduleOfTheClassificationOfOperatingAndFinanceLeaseAssetsAndObligationsInTheCompanySConsolidatedBalanceSheetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability [Abstract]",
        "terseLabel": "Operating leases:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfTheClassificationOfOperatingAndFinanceLeaseAssetsAndObligationsInTheCompanySConsolidatedBalanceSheetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfTheClassificationOfOperatingAndFinanceLeaseAssetsAndObligationsInTheCompanySConsolidatedBalanceSheetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r397"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfTheClassificationOfOperatingAndFinanceLeaseAssetsAndObligationsInTheCompanySConsolidatedBalanceSheetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r396"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/LeasesScheduleOfTheClassificationOfOperatingAndFinanceLeaseAssetsAndObligationsInTheCompanySConsolidatedBalanceSheetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r403",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/LeasesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfAccruedExpensesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r24",
      "r419"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income:"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r23",
      "r161"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/InitialPublicOfferingAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PartnersCapital": {
     "auth_ref": [
      "r241"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 25.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of ownership interest of different classes of partners in limited partnership.",
        "label": "Partners' Capital",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total members' equity"
       }
      }
     },
     "localname": "PartnersCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet",
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PartnersCapitalAccountContributions": {
     "auth_ref": [
      "r240",
      "r241"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Capital contribution(Value)",
        "documentation": "Total contributions made by each class of partners (i.e., general, limited and preferred partners).",
        "label": "Partners' Capital Account, Contributions"
       }
      }
     },
     "localname": "PartnersCapitalAccountContributions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PartnersCapitalAccountUnitBasedCompensation": {
     "auth_ref": [
      "r241",
      "r243"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in partners' capital account for unit-based payment arrangement issued by partnership. Partner includes, but is not limited to, general, limited and preferred partners.",
        "label": "Partners' Capital Account, Unit-Based Payment Arrangement, Amount"
       }
      }
     },
     "localname": "PartnersCapitalAccountUnitBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PartnersCapitalAccountUnitsContributed": {
     "auth_ref": [
      "r241",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Capital contribution(Shares)",
        "documentation": "Units contributed by each class of partners during the year. Units represent shares of ownership of the general, limited, and preferred partners.",
        "label": "Partners' Capital Account, Units, Contributed",
        "terseLabel": "Issued 2020"
       }
      }
     },
     "localname": "PartnersCapitalAccountUnitsContributed",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit",
      "http://www.businesswire.com/role/MembersEquityScheduleOfMembersEquityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PartnersCapitalAccountUnitsUnitbasedCompensation": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of units issued for unit-based payment arrangement issued by partnership. Partner includes, but is not limited to, general, limited and preferred partners.",
        "label": "Partners' Capital Account, Unit-Based Payment Arrangement, Number of Units"
       }
      }
     },
     "localname": "PartnersCapitalAccountUnitsUnitbasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows": {
       "order": 36.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows": {
       "order": 30.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Investment of cash into Trust Account"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r54",
      "r361",
      "r362",
      "r363"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows": {
       "order": 32.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Purchase of equipment and facility expansion"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheetParenthetical",
      "http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheetParenthetical",
      "http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r16",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheetParenthetical",
      "http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheetParenthetical",
      "http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r16",
      "r419"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 32.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preference shares, $0.0001 par value; 5,000,000 shares authorized; no\u00a0shares issued and\u00a0outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r4",
      "r23",
      "r160",
      "r161"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid assets"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficitParenthetical",
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/PrivatePlacementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows": {
       "order": 37.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Proceeds from initial public offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Gross proceeds",
        "verboseLabel": "Proceeds from sale of Public Shares, net of underwriting discounts paid"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows",
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfClassAOrdinarySharesReflectedInTheBalanceSheetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonLimitedPartnersUnits": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows": {
       "order": 42.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common limited partners units during the period.",
        "label": "Proceeds from Issuance of Common Limited Partners Units",
        "verboseLabel": "Net cash contribution"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonLimitedPartnersUnits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows": {
       "order": 38.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "disclosureGuidance": "Proceeds from sale of Private Placement Shares",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from private placement issue",
        "verboseLabel": "Proceeds from Issuance of Private Placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows",
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficitParenthetical",
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/PrivatePlacementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows": {
       "order": 35.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Notes Payable",
        "terseLabel": "Proceeds from promissory note\u2014related party"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows": {
       "order": 43.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.",
        "label": "Proceeds from Related Party Debt",
        "terseLabel": "Amount drew under the note",
        "verboseLabel": "Borrowings under related party notes payable"
       }
      }
     },
     "localname": "ProceedsFromRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfRelatedPartyDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows": {
       "order": 34.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from long-term debt by a related party. Related parties, include, but are not limited to, affiliates, owners or officers and their immediate families, and pension trusts.",
        "label": "Proceeds from (Repayments of) Related Party Debt",
        "verboseLabel": "Advances from related party"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows": {
       "order": 31.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "verboseLabel": "Proceeds from sale of equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfFixedAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r9",
      "r174"
     ],
     "calculation": {
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfFixedAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfFixedAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfFixedAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r176",
      "r419",
      "r464",
      "r470"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 11.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfFixedAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Fixed assets, net",
        "totalLabel": "Total fixed assets, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfFixedAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r176",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Fixed Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of fixed assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfFixedAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r257",
      "r410",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "auth_ref": [
      "r410",
      "r414"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transactions with related party during the financial reporting period.",
        "label": "Related Party Transaction, Amounts of Transaction",
        "terseLabel": "Related party transaction fees payable per month"
       }
      }
     },
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r257",
      "r410",
      "r411",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyDebtAdditionalInformationDetail",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyDebtAdditionalInformationDetail",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyDebtAdditionalInformationDetail",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of selling, general and administrative expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.",
        "label": "Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party",
        "terseLabel": "Selling general and administrative expenses from transactions with related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r257",
      "r410",
      "r414",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r408",
      "r409",
      "r411",
      "r415",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "auth_ref": [
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.",
        "label": "Repayments of Related Party Debt",
        "terseLabel": "Repayments of related party debt"
       }
      }
     },
     "localname": "RepaymentsOfRelatedPartyDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r312",
      "r433",
      "r509"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationSummaryOfCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r19",
      "r241",
      "r419",
      "r468",
      "r483",
      "r484"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 27.0,
       "parentTag": "us-gaap_PartnersCapital",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "verboseLabel": "Retained earnings accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r82",
      "r83",
      "r84",
      "r86",
      "r92",
      "r94",
      "r159",
      "r306",
      "r307",
      "r308",
      "r341",
      "r342",
      "r369",
      "r480",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "verboseLabel": "Accumulated Deficit [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r45",
      "r76",
      "r128",
      "r129",
      "r141",
      "r146",
      "r147",
      "r151",
      "r152",
      "r154",
      "r158",
      "r194",
      "r195",
      "r196",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r379",
      "r463"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementsOfOperations": {
       "order": 6.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Sale of stock, consideration received on transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficitParenthetical",
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/InitialPublicOfferingAdditionalInformationDetail",
      "http://www.businesswire.com/role/PrivatePlacementAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, number of shares issued in transaction"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/InitialPublicOfferingAdditionalInformationDetail",
      "http://www.businesswire.com/role/PrivatePlacementAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "verboseLabel": "Schedule of Components of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "verboseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of calculation of basic and diluted net income (loss) per ordinary share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/NetLossPerShareTables",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "auth_ref": [
      "r97",
      "r98",
      "r101",
      "r103",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/NetLossPerShareScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "verboseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r298",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationSummaryOfCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r164",
      "r166",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfIntangibleAssetParentheticalDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r164",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of intangible asset"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfEstimatedUsefulLivesDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfFixedAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r412",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyDebtAdditionalInformationDetail",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r264",
      "r265",
      "r268",
      "r269",
      "r270",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail",
      "http://www.businesswire.com/role/EquityBasedCompensationSummaryOfKeyAssumptionsUsedInTheOpmValuationDetail",
      "http://www.businesswire.com/role/EquityBasedCompensationSummaryOfTheActivityRelatedToCompanySClassBAndB1UnitsGrantedDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of the activity related to the Company's Class B and B-1 Units granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r74",
      "r111",
      "r113",
      "r213",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r222",
      "r226",
      "r231",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/InitialPublicOfferingAdditionalInformationDetail",
      "http://www.businesswire.com/role/PrivatePlacementAdditionalInformationDetail",
      "http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r324",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "verboseLabel": "Schedule of Unrecognized Tax Benefits Roll Forward"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Disclosure [Abstract]"
       }
      }
     },
     "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows": {
       "order": 49.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Equity-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Recognized Amount [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of stock units granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CommitmentsAndContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Discount for Postvesting Restrictions",
        "terseLabel": "Discount for lack of market"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationSummaryOfKeyAssumptionsUsedInTheOpmValuationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility of total equity"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationSummaryOfKeyAssumptionsUsedInTheOpmValuationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail",
      "http://www.businesswire.com/role/EquityBasedCompensationSummaryOfKeyAssumptionsUsedInTheOpmValuationDetail",
      "http://www.businesswire.com/role/EquityBasedCompensationSummaryOfTheActivityRelatedToCompanySClassBAndB1UnitsGrantedDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of Shares Available for Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of shares granted",
        "verboseLabel": "Number of shares , Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationSummaryOfTheActivityRelatedToCompanySClassBAndB1UnitsGrantedDetail",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "weighted average grant date fair value of the Profits Interests granted during the year",
        "verboseLabel": "Weighted Average Grant Date Fair Value , Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail",
      "http://www.businesswire.com/role/EquityBasedCompensationSummaryOfTheActivityRelatedToCompanySClassBAndB1UnitsGrantedDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r271",
      "r291",
      "r292",
      "r293",
      "r294",
      "r297",
      "r309",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Equity-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Percentage of vesting of award under share-based payment arrangement"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected time to exit event"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationSummaryOfKeyAssumptionsUsedInTheOpmValuationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Number of Shares , Ending Balance",
        "periodStartLabel": "Number of Shares , Beginning Balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationSummaryOfTheActivityRelatedToCompanySClassBAndB1UnitsGrantedDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options forfeited.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "negatedLabel": "Number of shares , Forfeited"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationSummaryOfTheActivityRelatedToCompanySClassBAndB1UnitsGrantedDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted Average Grant Date Fair Value , Forfeited"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationSummaryOfTheActivityRelatedToCompanySClassBAndB1UnitsGrantedDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Grant Date Fair Value , Ending Balance",
        "periodStartLabel": "Weighted Average Grant Date Fair Value , Beginning Balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationSummaryOfTheActivityRelatedToCompanySClassBAndB1UnitsGrantedDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r288"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Compensation expense attributable to vested awards"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "negatedLabel": "Number of Shares , Vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationSummaryOfTheActivityRelatedToCompanySClassBAndB1UnitsGrantedDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value ,Vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationSummaryOfTheActivityRelatedToCompanySClassBAndB1UnitsGrantedDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r71",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r74",
      "r76",
      "r97",
      "r98",
      "r99",
      "r101",
      "r103",
      "r111",
      "r113",
      "r115",
      "r158",
      "r194",
      "r199",
      "r200",
      "r201",
      "r205",
      "r206",
      "r217",
      "r218",
      "r222",
      "r226",
      "r233",
      "r379",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CommitmentsAndContingencies",
      "http://www.businesswire.com/role/CommitmentsAndContingenciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/CondensedBalanceSheet",
      "http://www.businesswire.com/role/CondensedBalanceSheetParenthetical",
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit",
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficitParenthetical",
      "http://www.businesswire.com/role/CondensedStatementsOfOperations",
      "http://www.businesswire.com/role/CoverPage",
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/FairValueMeasurements",
      "http://www.businesswire.com/role/FairValueMeasurementsTables",
      "http://www.businesswire.com/role/InitialPublicOffering",
      "http://www.businesswire.com/role/InitialPublicOfferingAdditionalInformationDetail",
      "http://www.businesswire.com/role/MembersEquityAdditionalInformationDetail",
      "http://www.businesswire.com/role/PrivatePlacement",
      "http://www.businesswire.com/role/PrivatePlacementAdditionalInformationDetail",
      "http://www.businesswire.com/role/RelatedPartyTransactions",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfClassAOrdinarySharesReflectedInTheBalanceSheetsDetail",
      "http://www.businesswire.com/role/SubsequentEvents",
      "http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficit",
      "http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficitAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r37",
      "r41",
      "r42",
      "r43",
      "r82",
      "r83",
      "r84",
      "r86",
      "r92",
      "r94",
      "r110",
      "r159",
      "r233",
      "r241",
      "r306",
      "r307",
      "r308",
      "r341",
      "r342",
      "r369",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r407",
      "r480",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit",
      "http://www.businesswire.com/role/MembersEquityScheduleOfMembersEquityDetail",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CommitmentsAndContingencies",
      "http://www.businesswire.com/role/CondensedBalanceSheet",
      "http://www.businesswire.com/role/CondensedBalanceSheetParenthetical",
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows",
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit",
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficitParenthetical",
      "http://www.businesswire.com/role/CondensedStatementsOfOperations",
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcern",
      "http://www.businesswire.com/role/FairValueMeasurements",
      "http://www.businesswire.com/role/FairValueMeasurementsTables",
      "http://www.businesswire.com/role/InitialPublicOffering",
      "http://www.businesswire.com/role/MembersEquityAdditionalInformationDetail",
      "http://www.businesswire.com/role/PrivatePlacement",
      "http://www.businesswire.com/role/RelatedPartyTransactions",
      "http://www.businesswire.com/role/SignificantAccountingPolicies",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesTables",
      "http://www.businesswire.com/role/SubsequentEvents",
      "http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r82",
      "r83",
      "r84",
      "r110",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CommitmentsAndContingencies",
      "http://www.businesswire.com/role/CondensedBalanceSheet",
      "http://www.businesswire.com/role/CondensedBalanceSheetParenthetical",
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows",
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit",
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficitParenthetical",
      "http://www.businesswire.com/role/CondensedStatementsOfOperations",
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcern",
      "http://www.businesswire.com/role/FairValueMeasurements",
      "http://www.businesswire.com/role/FairValueMeasurementsTables",
      "http://www.businesswire.com/role/InitialPublicOffering",
      "http://www.businesswire.com/role/MembersEquityAdditionalInformationDetail",
      "http://www.businesswire.com/role/PrivatePlacement",
      "http://www.businesswire.com/role/RelatedPartyTransactions",
      "http://www.businesswire.com/role/SignificantAccountingPolicies",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesTables",
      "http://www.businesswire.com/role/SubsequentEvents",
      "http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r67",
      "r68",
      "r69"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "Offering costs paid by Sponsor in exchange for issuance of Founder Shares"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of Class B ordinary shares to Sponsor (in shares)",
        "verboseLabel": "Stock shares issued during the period for services shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r233",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "presentationGuidance": "Capital contribution(Shares)",
        "terseLabel": "Stock issued during period new shares issued",
        "verboseLabel": "Stock issued during period, shares, new issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit",
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/InitialPublicOfferingAdditionalInformationDetail",
      "http://www.businesswire.com/role/PrivatePlacementAdditionalInformationDetail",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares (or other type of equity) forfeited during the period.",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, Forfeited",
        "terseLabel": "Forfeiture of Founder Shares (share)",
        "verboseLabel": "Share based compensation shares forfeited during the period"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Issuance of Class B ordinary shares to Sponsor",
        "verboseLabel": "Stock shares issued during the period for services value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r233",
      "r241"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Capital contribution(Value)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationForfeited": {
     "auth_ref": [
      "r304"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of forfeited shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, Forfeited",
        "verboseLabel": "Equity-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensationForfeited",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r20",
      "r21",
      "r76",
      "r156",
      "r158",
      "r379",
      "r419"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 31.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total Permanent Deficit"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet",
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Shareholder's Equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r75",
      "r218",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r241",
      "r244",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Temporary Equity and Permanent Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/TemporaryEquityAndPermanentDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r390",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r390",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r390",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/InitialPublicOfferingAdditionalInformationDetail",
      "http://www.businesswire.com/role/PrivatePlacementAdditionalInformationDetail",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r390",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/InitialPublicOfferingAdditionalInformationDetail",
      "http://www.businesswire.com/role/PrivatePlacementAdditionalInformationDetail",
      "http://www.businesswire.com/role/RelatedPartyTransactionsAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Event [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reporting subsequent events.",
        "label": "Subsequent Events, Policy [Policy Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r420",
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficitParenthetical",
      "http://www.businesswire.com/role/DescriptionOfOrganizationBusinessOperationsAndGoingConcernAdditionalInformationDetail",
      "http://www.businesswire.com/role/InitialPublicOfferingAdditionalInformationDetail",
      "http://www.businesswire.com/role/PrivatePlacementAdditionalInformationDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.businesswire.com/role/SubsequentEventsAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Elements [Abstract]",
        "verboseLabel": "Supplemental disclosure of non-cash investing activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r333"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "verboseLabel": "Tax Credit Carryforward, Amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 23.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r7",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]",
        "terseLabel": "Temporary Equity, by Class of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfClassAOrdinarySharesReflectedInTheBalanceSheetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r194",
      "r199",
      "r200",
      "r201",
      "r205",
      "r206"
     ],
     "calculation": {
      "http://www.businesswire.com/role/CondensedBalanceSheet": {
       "order": 28.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Class A ordinary shares subject to possible redemption"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheet",
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfClassAOrdinarySharesReflectedInTheBalanceSheetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity Disclosure [Abstract]",
        "terseLabel": "Temporary Equity Disclosure [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfClassAOrdinarySharesReflectedInTheBalanceSheetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Temporary Equity, Shares Outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedBalanceSheetParenthetical",
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Sale of 25,000,000 Public Shares, net of underwriting discounts and offering expenses"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfChangesInTemporaryEquityAndPermanentDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "auth_ref": [
      "r7",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity [Table Text Block]",
        "terseLabel": "Schedule of Class A Ordinary shares reflected in the Balance Sheets"
       }
      }
     },
     "localname": "TemporaryEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r313",
      "r320"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Benefits at the end of the year",
        "periodStartLabel": "Benefits at the beginning of the year",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r321"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "verboseLabel": "Decrease related to prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r319"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Unrecognized tax benefits, accrued interests and penalities"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r322"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "verboseLabel": "Increase related to current year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r321"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "verboseLabel": "Increase related to prior year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesScheduleOfUnrecognizedTaxBenefitsRollForwardDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "verboseLabel": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r118",
      "r119",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationSummaryOfKeyAssumptionsUsedInTheOpmValuationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationSummaryOfKeyAssumptionsUsedInTheOpmValuationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationTechniqueOptionPricingModelMember": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation technique calculating price of option.",
        "label": "Valuation Technique, Option Pricing Model [Member]"
       }
      }
     },
     "localname": "ValuationTechniqueOptionPricingModelMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationSummaryOfKeyAssumptionsUsedInTheOpmValuationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r268",
      "r269",
      "r270",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/EquityBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r96",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average Class A Units outstanding , Diluted",
        "verboseLabel": "Weighted Average Shares Outstanding, Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfOperations",
      "http://www.businesswire.com/role/NetLossPerShareScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r95",
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average Class A Units outstanding , Basic",
        "verboseLabel": "Weighted Average Shares Outstanding, Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/CondensedStatementsOfOperations",
      "http://www.businesswire.com/role/NetLossPerShareScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail",
      "http://www.businesswire.com/role/SignificantAccountingPoliciesScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.businesswire.com/role/NetLossPerShareScheduleOfCalculationOfBasicAndDilutedNetIncomeLossPerOrdinaryShareDetail"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70258-108054"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "272",
   "URI": "https://asc.fasb.org/topic&trid=2124037"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=95464943&loc=SL35686261-199414"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.F)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.F)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.F)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187171-122770"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(u)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "c(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14172-108612"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14210-108612"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14217-108612"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "https://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=25866437&loc=d3e10246-115837"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04.16(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04.16)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=6490092&loc=d3e47080-110998"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=6490092&loc=d3e47304-110998"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=6490092&loc=d3e47304-110998"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=6490092&loc=d3e47304-110998"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r510": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r511": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r512": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "303",
   "Subparagraph": "(5)"
  },
  "r513": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r514": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29"
  },
  "r515": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column B",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r516": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column C",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r517": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column D",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r518": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column E",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r519": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column F",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r520": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column G",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r521": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column H",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r522": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column I",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28"
  },
  "r523": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(b))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>98
<FILENAME>0001193125-22-215250-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-22-215250-xbrl.zip
M4$L#!!0    ( !6?"%6J6OKKI4,  "AW @ 2    9#,W,SDU.61E>#$P,3,N
M:'1M[7UK<]/(MO9W5_D_=+'??2I4F9 + 28PU'$N@/?D5DG8<WB_M:6VW8,L
M>>N2X//KS[IT2RU9#@D8T&"=.C6;R%*K):U>O2[/>M;K]]>G)V]>OS_N'[WI
M=EY?#ZY/CM\<_\^3[:W-[=W73_EO^.&I.4.\/C@_^B@.WAV>GYQ?_O[HS_>#
MZ^-';T2W R<=JC!5\9O71X-_BZOKCR?'OS^ZU7XZV7^YN:?#1T(&>AS^_BA0
MH_01C75A3YO*>*S#)VDTV]^:I:^$^7L8I6DTY4.C*$R?)/I_U?YV\?=(3G4P
MW[_64Y6(,W4K+J.IA#OU3P;OSGY_%.OQ!&[U^N#-\>>)'NI4T'.)UT\/WKQ^
M>H$/ED_!&7\'QJ_,:&%"C][\5SA,9J]PF.4/LGB9G9I'[PI? [VZP>D[<75Y
M^/NC\>Z+W=_V?AMOO=S:VWJYL[VW^VSO^>9?LS%>>?W[HY/S=^?\\LHW_H;I
MO^:YN*,%.E1/)@I?W_[SS:TO#8AW'$:QKV)[9'MS"TX3211H7_QCB_[O%0O#
MSO8_2W=_:F[O?@SG;O0XJQ((^]9!(EY?G?9/3MZ<]J^NCR]?/^6_A#EZ=7SY
M[\'A\57U>/_=Y?'QZ?'9=?'#:D5I#;_%P?'UG\?'9U6!_@$B\.[X_/+=L3@\
M&9P-#OLGXN+Z8[=S,C@%E7:4?]COKZ7LC/H'9V)W5VS]]E)LOWPF]G9>BJID
M?>^7TC\[^@G?X?+XW?'9*;SSC</^Q]/^V6-Q<GW4ZW;\I\.G4EQ<GO\Q.#H[
M_NBNM:>PQ\"_#ZVX"OK_US.1I/- E6>MI@N3QD,S.59/AK&2GYX,U2B*U;X,
M;N4\0>WZ^OVEN!K\?WC\W4=V2-KQ]O_Q&_W?(_'GX.CZ_>^/MK>V_ID_TR%H
MAN/+QFV'^(Y9SPFKV$2NR<3&Z57_<:T><Z;Q?$73N'X_<.^-=]4)#.PK$86L
MB.[_W^T]_M^W:AAG,IZ+G:V=[;O6S*J>PJBL_3HE48SU_*%F!!I@_8.38SO4
MP?GET?'E$Q"\D_[%U?&^_<>=$ZP^S2/!P_S^:.N1.#P^.;GH'QT-SM[E?U]=
M] _MWZY0\WPN6?S%[^*1LV!TF&@?%LQ-I'USXI&]> _6P[_-@H#GSA<'R_GV
M)EB51_82]Z?21>X;%>67*+[U$[X2E3G5;P6HA/#[BHU%Q?Q81"-QHFY4P)]O
MKR>VQ1\Z'(NK-%8J[>'=TN@VA']<_0ER^6Q']#]<75_"??O=S@;>447Q6(E#
MV-ZU)P.\T^-70H:^X)T87A+\YQ+_@S+1BMB]16RG@2)VJ<8J/%4^;'%R#B?
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MZ8K^"2+S</P2C-:E1!J].'A(DS]3_D^Q,8R7XDRZJCWP4Y4-6',9+4G2)6[
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M:FEG<91&7A14-5JO.H2;5.\7AT_D;9G<SY([<.R"SG'+ MIM]-L%N(';:)T
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MJ#L3 -U^QH!*3A0YPF*%B$JVP/Z:(FBC)Q8Z><9JA'S\[JU SKC4 LVU/!>
MRBQF&PXTU>%$(A2-FP+ X$B1M#$X/ 0["P7<O3X(4$][48BQW66*&L8_/!2G
M^667&5;NFJ9"B()F'DQ,EE=?"SU!C$5C>.<@\@SQ,$(RD2BJF$LRD3P9?.L?
MP=GI=3L?-J\V^YL]4,<]9NZ:9NP+&;"K+( D1?\GC5Y997 3+2J>\T;')N\)
M3WP<C@.=3#8%4I?I2F]A2W$E\KYP3OF<<X<<#@#WR4PO+ZL1W)=B4XIPJ']T
MV/+DKT)%-+%9T?U4Q,YV7E7 1%&L"ZQ,Y_)5HQSLN=T.F#2>4I@/3YA2;DZ,
M4RE3W4]GBGJ;_05BF_C::PV8%4G=7@.E[D-(@'Z#"_(8V6$ZX14-41<['CVL
MMKC;<6KK?97,=*I,&SV=I,K@^[]H![68Z'7 1&^WF.A?7!?BA]UM;NQI<'9T
M?'HVN+/[0+OQW7OCVVUD\ F^\RD[!QJVJ6E(N*F6LV ]P>,.<\H&*@"6""[/
MI</,%6TD)>^XZY"4]<CZZ8]&.M#$Y&H:I.E87*H96/'8XA?CC& +;9 Q)4/A
MW HAV<6=>N"I8M,&[IGC=A$/H@2\5;C'4&.+\)Z%QG*_1[B@1'J-=SB!*WCZ
M<,>%VX'C.QIAAV@BT?)UC*'.HNE]R4;KE0LRXU(QW")LA[K\4.DH&H">)"=W
M.!>+;]="'-WV1V4^)KA9J,#I'BMSZUL=C+) 3'5B?'2\:G'DGB6>XZ9A" WB
MYH6):[A6VW2=4#=-M'&35*<95<^:5V/A).7&[1Q2J=Z\]=77$%./82N[HU"P
M"-:M',=R-L'$)3^I#:/%"B07ZYSC:!;%'(P+YI46X[9)G;MV3?]8NV[LTL#&
M>KA8J+\WAZ/P5I6%0JA+/<P,(QX.C0+?NOCKAT"_+HN5Z^"/M8E#+NHU4U55
MI1! #QXC28'44]BA/BD6Y4!)[E@ >P#]A+'<8H7DM1\@I<$\[SWOQI(7)T 8
M&MAOJ:<]+*/2!FO!!TBT#OK;:&FZCPSA.]M863[95O+7#]A>(U3((TJ<1)C2
MI;P)B0NCI]2(+ ^4HD2E:5!(D1%XK/+AF#Z%_>_0UG;9H'E!"CXR0W)$ER6R
M'Y@$#?4NJ5ND<BY40*T[HAQ(;Z=IH\,T,U@H*AAATH4"=+=A;C/BG)F7@XAN
MDJA7M]CPO821:_$@CZH]CW(>>%M_<9+(EF&Z24>F: #Y/=HUMYX8_[.%E 3J
M^$D4L#*7,PP\R\!*;_TZR\*B'TR;+U]#0/\2>X5Z"7%'HH+/*U4S<O2FFNP
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M]M8:*;0^JOYE8U7](2(;58QAKZ0AJKXFK$Y4<J:C)O(]B3";#C%:-F)HIGT
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MHF0X+$U51??1$<<6$FY'EJB.FM4XR;*H;];72C,R90FDJHLHS8?I;3J<P=^
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M[/;94$&?HO8C_\X&5/XQ34H_%.GR7A!;<HH1='&I2Q%1%<'?R4KL)L#77\\
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M1NE'O$,J3M0B_#8/79CEL\WC4^N0 ?R X[NLSN8,;;#M,7J^'%3""FX(R-8
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MFG(&OO*<IUI3 20A/XQ27KQ7J9YS7KM7K3]D!#<FC8<ZXB4)4N<=.ZC#91*
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M^<% %5NQ]@W2+DS^0YB'PD%P;"]6E*YEE/PB&)TC_Q,Z0*!$H5(B'=JH\\A
MO*G4\0(GCP417".D+E=56A6-W_-I+KDA3T0A\L#>L#3:H+>3="H9:<ZSS:64
MD#&C1 VJ;&,MRJ'"V'HKFS:9>\(:SN*0DXLQ-,]*9G'G6CC&VMW+:NRC6<Y9
MM^%F(?FKJF&/AEV V%6L"?(=95>!SM=P=;=*(;5$%U/G5Y %?<!ED2<Y*]HP
M2]';[H/5CK0'] BU\XTG@:AWWDIOXY2-70\KQ 3T 0XV*H:+8%\_CD(-K1R
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M>I2)SK("#13V8<_:% 'YMZG1X8I\V%*UAW!C<,]<(32:9]=X>^:BGV#755V
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M_ A%N45.FZ25J[I%/J/VX[Y8E3=KV[=[DI;O<]J[3+(&&AD5"^ !Q:!#<IL
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ML/+,\RCA"K]EY>:A]+$EQ;:Q*B,L:QFVR;=FN59;#5U#.<TLLJOB&X&$F*N
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M!\@BKR\NCWN7]+',BC_9 KXZ/7QWU7NN/RQ=89,<R#G,^]>7K^2'8QWXV7^
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M,:G#.:B*'+Z80Q- DABC8<%SA[XJ(,2D-$>2KXY+IT .3CERC%UZ=Z4/$/:
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MFE:V\VC.\-+%$E[IT%#,-HO(L^J?1Z_*KKY";ZPOP\WJ) L/M-)J@N)/[W1
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M;TME$;RK.DIX@F%7N1JEK3J75 3/I&<O(+'!14::J &1;0@'5^@%5?#4B]E
M,LX_Z8N%<C8E$W"D\UT2MRY]8H@;W@11(S!2(31DC,*E\VXP4XD0@QO$9 -I
M7;\'\QU+P908B%F5:BHGH:<8.HO!S9E)G4!(D[IR/L'$=!5I^:B</!87(+\"
MI2AF:/,ATE .W]6QTFT*UK46Z]O^*+?]]>K>]L-)(9SX!*LO_!IA\!!=M$%.
M89\>$.>R6X\7H2X;M']R6*>B<$Q@RG!C* R(4FLC"?!>4CT;$[OT02>P;OR
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M.1UEL+T=!D\>PO]_#/__*2N+1]L[+^FI[>L,9W,,IB4'5V;P8@@)-5[2)3@
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M33\9)[D.?IB*;M@->7J.MO%9C;0C)0?T**?'HV#S/9I@^)"V/CF-M%TRLO/
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MGMT_R5.P!/@)NFH!UN\ G.-\J:C$_RTC!V#B[Z.+E00"V[!Z2<2NY.Y#21'
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M)XV ;,O8[16S7F6(3G60#Z.&?_8-L[>@HK9^23YX_BI#&PX,S$?7VNIT>#,
MNL,>PZ+P2P.YWSC/PC=,_39+/R\R?&>[CQWVL<,^=OA+QPXO[8_[M,/]<8\/
M/AT?G( .V#T]_'AT0OUQ_]H]/MX].CT\N&I?W/_X3.KW&7Y/1]UUL7<M;I.#
M?->V_6[B7#48;@=&ZJ.2!4B*Q6T14ML0MXNEI?"Y*]!*TNP5+OB)P=H>SIRY
M,A(FP-*!:C!.=/]9L'F8*(8O\HA]/ 2H0#&,/Q=?VN"9 :ZF3R"94&/R_-!)
M$^Y<0PJ*C.9<8&L^DVN$@ED04A*@,%ZI0*<^9\2,1'9K&;S!F"LN[WY1SX)=
M*7\L!+#OH,GW=QT0E4.AP6YBCDT\F3JH6F[P%WNM\4U:H[O>XK'R?0\4I;]X
MPS40W?T!<^OYR:?=[("I)<"H9IT=*TQ>S6$)DN#9 8'B49OM8WH(%7;8TKS5
M'!(AN.8^.,[G=!%M:#MP.HP\I#RYM0(G)%"_,2>MD,ZT\0DY&34\%AP6\DO:
M*>M0X$J/=$-D%$H**_2Z)+LD(_SLT7!=9\%^1]W8CNI@V<VE.PK-FTSL#XH:
M42$7&1L96AM1^<72<[C [4PX$:12@MC",;V(.W-],83PW.F@,DS!;!]ZNL>_
MY$>76^)=2&QH@+A-+L,4C#%*;LJVLR1!ED2ZU<+"W_OCP%VL22=R"T?M-]4=
M;*HN5G9<95,E57 F'68WULPVJUA=[P+93U;=BPFR ;<6@4FB<#72O'5QIFB+
M6X!'^WBP. _VIRT"<9AN='T%97^X2^$]RV7IS#=5,V1KXZ<88Y_!%_D%$P)1
M,([IWYJ8'F+0Y<HL/,:D= VQ\L3%BSMXG0L672'*WL/ ;W_3=K"LX[)-FU0Z
M(\'X*'VND+0S[90^2>8Y>,8Y^>H(R]$EI</!!LC/-$_3_,+AWTE552'DJ[24
M>,$I"?=)4JURSZT44K"A*/AT2X0,_U@SO&\9G&["H+%(*TW1KG4"]CG@;W/J
M'_W$3KV6V]ZIOP/%V\E6<[:\;(.U)"5K)4(Y4W%"A%A3K  3.2VPVKQ17F.L
MA^% QT2QPS#:[V[?85U/KPT65OCR "+S;N7K;NEQW""+G:H8F]>$;$EE4258
M3:09I!A!FJ/QLN+3A!LI5C6:\PHVS5H]_#-FR'?Z#'F?(>\SY+]TAOQ[#[H.
MQMKT03=EF.:EX0$Z?1B9=1XE*1TD?D<!,;_=1B@VC38<6-<:,;WGB#4S%.EP
M[,V*:"Y4);INVF"2#;RS-;9'))W,=>KQ=K554;!3T BVZVN\X@3=P\7-!$K*
M\9JX_=XX_*8]T\%0FNP9PQ>;IVYY,8F,I@5V^JY$S>2]L[^66#5"3 @-Z*$Q
M#4/L1=(0V'PAYAABG(N"PDG%Y8YSH>Z+^1@ZG$B%FM92MQ7-L0*G!!L$#C*F
M$8:'+_*B:O&F^<LIZ(*2^0]XXK!+D1P!;53A>>NK7.["[7[<6;=[7XVC@AR"
M/2Q1F(J*[9WLN]"CC[OL9$]8'I2?A& F->P_@X)C?6</E/WHX5.MD-ZP.TN8
MGY  /VQ&[.7E7%587K([J<)@9SOX/#H9[8$Z(L#/TV<O40(?/7H2;44$_=D:
M:[)X/OHQN0['/4KN&H]XY+>,\6*?U)U,E68684M45+*"VI)QLH*]B7$'6Z/#
M9GEC:V0Y58>=)W'--5W2A\]2-YECV4:"<#/11LH+ [[S]]1P</5-Y>VIP-M2
M 6\GW$H!["6SB6!#!3>ZETRC/[J24(&ETZ2S.I,)ZO 35_^NKAM6%ZY?N)O9
MJ7U2X0:MFR>=M6Z.P >N2Z0A$ESNP==)6M,?5!ZD-]([%:756;"' OQ)W-T?
M5?5KF2"N @HPY[%A3A"N4X4SI>8N):T _S/*2*,0HM<AM\",?9$0'RR735'%
M5[+@@C;P?B0JC5W\:*6(@DX'!C3V -5-N!&'%@8?J $;E[GROY-XY ;"W/^N
MZAQ=\7Q%G9,P:2N_<KT2\F]9"KZ2IV_DHCG_X4 6(+A\_DZ7F35M4Z4VN*FE
M>IUT@SKI:9=UTD<2 R>[^6-4C4-/*4UF+^R0F!32S\ENZG:*&P(^31-5T^&.
MW;9HFLX]A>.8M0]U+\5:]&;WPE[X+ZWY>M;AFJ_#H_V##T>';P[WJ.B+:KX.
MCTX^'^\>[1WT<86[4'_/.ESR=0B6R#RS@28G5]#+QJT[UB 978PY:0D@ S81
M"5F&2,"KA#"9N'ZQ?7F*S#.F52):>"Y!C?1'2!![#3*FBA(IKS *GQ?8]3&:
M<6='0P(>"FS5]!XP/7ISI/?F5K998(K21'XKI=S:-,T@1<AS3;1&71GA\=$<
MGHKT,DDTAH%6U'9RDI=BUVN>U)!)JO@X741+Z4'Y=QW/Y)]3IER9<D-9E8$I
MFBB'L&8"ZS-CFAZ'=\P0LOY"N(Y'/:ZCQW7TN(Y?&M>Q\[#UG%M_8H%VAP4J
M,K4T/:\,7H^49K UR:FDCAKBB$Y_3VI:*W)#7<B! -OK!@E"ZU*0VR9R4-9)
MQ1 )82I$TJMQ(L7,I*0I%$+I6NJ+FE%K8CIRF =U$I4*K:"(J_F0,A'# W+R
MV(-G#X?1=N;8$ZF5OE^@'?^+864F-77(V%;Q%FM)BJ24VS[-]$AR.V.X,-YS
MHEO312EAHVK=,(!>Y,47ZL.!Q5]KP)BAOUSEFH8H:-X\&CF >[>'="-*3)5=
M%#-:T%K9J!&^=%KM8,M'SA/Q9)2D-;.IS7#"%.Z1:TW\K5#@VI[;CD02BEIA
M.\=2-PLKT/V%!*NCOG(Y9C)%E$&$S+0)U=7 "H-1  ^4;FWCY3T;_I,F1(VW
MVM@8&A[;AE] Z2B4P4*@G4)@AC/X2XI\I*NTA/2G3);+ZT;+08MG7P-"A6Q$
M35$\S;VT+J5_+W$"^Z:89I(SZ0;3KYBM)LLFQ6M.28-+5MW#<F#\H:_?N3UO
MHX-IO,\D!%D>3))B4L^YNT'I=$&GC61)06A3:N-]J<UT/X*.=(:@:))26?51
M(DZ(A7,M YMQ9+@.S8W@UYD#KL,;83U=0[DQ3X=E-";?(XDU@R3M1MEF?;':
M[0M[!V%QGFLMDB4:D9&8*^XVT;:VNMN>F\LGI'=6H5H'36W/ +!'D(@THDY
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MQWD(;S3/-<6K;4;SQYN/1Z>P,W5<^PQ>VOUR$4W4BRR_*"+8EAEX\\Z\_GB
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M.EXZ@&VF;A$1#6D5C/8- &4I/-:_N)2B^Z6%S@T'/I;UFL/4CT2W4@?].()
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M"#DEM0[IVZ#]\M<T>S>P48PD2*0'IABF?+"-@DG]9:5<C88#'MN8MK#7J'0
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M'6X&^$R3XBQ!GC>I;_OQ:_PU_%1?\OX,#^IX^!Y^,SS>'^)Q'AW!:H*/A^=
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MNK@ G&LHQ(O$* TJRG.+@H8N=51X7A9U%<7Y!<^,:-Q)I%GD]VH,8DX)IXR
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MCW@3ULQPJH7H=>$H9UF5X(J&!9@9XP15.WIBH*U9F_.U. S4W+E692C&7&U
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M[Q= 0L@HS[.XBDHCRG9M0'G 8M#H8"KX"'R5::CIE7EOLLRRQ$4EC;$JQOP
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MO:'.O7B 3?%\K3=%S>*ECKTBDDZQDUBUT^FQ\VKLVJ(,<S@)%W3FP;IB?&>
MKH6YP"]>RB0L![*(U2.4U\/>X5_RH%N=#QK)%HS$$GX;%B3[.(=W]H@'PS2M
MR)*?2*L\VE=MD8'V<0J=R(":R<SA.57NZ!7MHR7P_VG[#'VQ%/P3A%D30>HH
MC=7G;?9DY/)"'!'J<HE>@@E8X-BOF3]5:ARX R"I'*N\N *@._SN?9^_6.M]
M[CO68E[%NJ#4#H-$2/RQ0!%I]IFC4T1IT,)_350X+ALNY3K87M7>8Y47BY4V
M%,$6;]8+ -<B7^<^";?K6" !9Z[$+6P%&NB .6\)>*94\+;> R^!^Z#U:,A5
M:*BL^SA@UYV+#[!?7J[U?AE-FI3V-0(K,;L:"5:BO[YFZX]MKRMFZ78-B2U'
M<0-0Q;E8#F03\\\DL3V,/4P6D_VBGC?9XDZQWSO0X,E:2RIE0/W"6I/_]R(%
M0BAB?6<;$+8%CM2!$^]$X$%E2B,(J'OFLI*$'*P!H=I QLVL#8>8&V'26K[?
MYCNQJ3(5@DVNK8ZGW$GF#IO<A%?E#Y:WNM/:][\9O@/8#9SB%$>Z ?_.A@)W
MY2-W?$ =O\'6F:@8R44"SBXJ/4V#(DRX70H6&I;8]!BT-W@-VOY*J'\!MUL(
M2_AY('@"3N[#!P%WK@>+?\$%4?SML/ @,=ODK/A% M1FV21[)$!!) XQ,Z-[
M^]R4)L/S*DL>8?8181C=1NHZQ=T)0O'9^B(4ST;G!\&O(_BG:Q;W$.KQV9J#
M$GUW2+K#V3(=[GF[P6:K4Y)C13AKI"_3V$_&U21M$IZ0>[34RY007J'FFL*-
M& BJ&;X<924^52]P43JN2XZ>(DU.ZG\HE"&H]*2QA/W3A"QTC)!*I"9%2#9H
M2PR88E)CAOD(U'S9&-6S-&+-LRE7[31QVTT,F2[*F@N,;)V(V*PH/$MA)5J&
MHB-:>( MMMYXQ%K$80G ZTF1:W?F;\ BF&*=&.-IB;7,V;V3,,)R;JHA$T&W
MY.XL?[0C$=3@?=MG6V"3(<\6N5;$V:D=U8*WL]MC+]02BDI_X'E_XJX!,SBP
MJR$;L=EZQFQ@?TZ&LQ_SC9Q=*;*$MB_H#T,?P4]H[]568O+%1'_=R,)B)>U$
M6UVGU+"SY+YH*1O_^P Q7G1 C.])F]ZL,)^OKWGJE=Z/CLY.#O:PL\P95=(,
M/^W?;+1V3OV=':G/Q6J5?BSK*"GMY7^&<CU2FNC-0V,D4K(P#$Y=S>NP K\X
M1T@\&[BQAJ^5U 0Q82A/)O1@MH><*1STGT"'B#S$]A %7SZY-AF1)F,IAQ&N
MI =:\Z^N,;!_YPTD-_E,D /\!O:\V12<@>DM0_7M> !2[:+)W_"M=1IXS+^(
MN_'N+0C*G!HQR]]IXOZPA(32JQEV;,)*0G!8N)-DA;%"5AZEE.AM>Q/;P8?L
M"I.^ P:<RHHLV4R:"Y>8R3LW07'AR:^!'&I,L54R0:[8%M*J!<(G2\Q5<<-J
MCI2V#%%WJ*&'T#[K;=#720<;FXXRCTZ,T%JN$$2-3=;;U8_K0N44!F@=,5BM
M-A&2;DD]K;Y?)Y_W+Y_K72MC?1_GI@T"ZQY^I70VJ$G<88CZDDX=::B JE_5
MW2D0;),>-=YBKH104-)&H'S'RGX]MF=3VU@<S28':WSZ6&$ M)&;+O_S8)MA
MO8ME1I.&2BZLU-LF.2!WBRHOJC"51C>.H(X7YCE+KU\I/=%B3%'QL=ERF$5%
M1GJ!(#.EDC7&5G3/:6E"SRH?.9MX.PAPS#:.SZY2IE'A#H&$Y*2<$>XO2Y1'
M0\C)0**[2!O>E29,MRWN<%NL=SW#B*"74L?/I?44E\>]PD>"%T23,Z#@/+OU
MCMACJ%-B(1T9U0;G7J'P7(':CHM:P_KR[A,/!(>D,"0VC\LYH^MFH0N)$&(G
M+@%22^2R*(MZA%/HNPS5@2%;N#E.*SY)OV==2<H,V-\,E1BN<8P%>HG--$0S
M>,M>.8.IYN 68(5 \9!]05*WYHLWOX/ O@*:8QLQ=)?RO9.8VHOUC:GM'1^]
M'^T?')V/AH?!Z.C]\>G'KF'S@QT$+]8\ >S%D)IIG94!'-$]^R[>(T$BC\R1
MRG0E,T/%]38UT_;5SFF]?SE<[Z#*;^+:P9'Z!]@?U I$PHA\?)^("'%CA5,R
MQ=$-=7(Y(/82*;8F^FG#B4(GGK/2Q=X83B8ZT63-")+V!NZVNE3?MC5N\3\[
ML;X[L5[O6$R+>LVXJ.I+Q*@1@3<I=LEKDQ_*46^BD*VU>,6O7X77+AQ.07,M
MS%LKFBX8UW)%ZGX@*!W;>S[T,3?85RK&K 9V-P1'M):?X-UCPT0W3SZEVB9,
MWBAVI#$!@ 68&I,P&0ZSWU/@6V?7BF!!L)'!08&?V-;.\,>F=<Y( )TC0I+7
M\Q+MY&G(EVLAN: VH5>SC%SI1$V)[VR<(;:8BH^58#9N @IXV8AEGMXZ:N#O
MQ-;PL@,)_#!:=[V#?J<JT@M-C&5^#-S19]=B9)P87,H+MI<Q:"$A)$<?T=]>
MX[RO-9@[\^#^!76]PW!'68FG-1V=)L5R:RESFJ5;<I)6N3+US+[H8BA/PW%M
M]P$&X[PP&IQ%W(N^V8_%8-DTV@+VN+X!%B<!*_69+ ^.,MNAH4/H%P@-707#
M87A%<7C3$!E^C.<Z!0LFY^A?48T7F4I#@@;FL!-?6]+/ ?9C89@ ^:JVK93%
M/KHA^!.W]"6VGY73$V+\(*^#3BOI*54SC]!^^*)7 TIAU3N1+@,,5C9]L7P:
MU%7K[/,\<DFL>P4N>3;&HE<+WW K.V6N"*?/&F^;VOB8KEIN37CEIO@VEEQ]
MS^X+8_:J!$[BFDG71(&)WTVJO%%INWS_#2+J*I?^8&*ODO/81%%VU_1[]8LF
M:'H)S-MP#+0-C"Z@UA"&JZ8T]UB63%Y.RU5OT9YP$]N_8H5]?>,AT4R%$@+%
MO(N5+Z\#F#_ (;+>+#:8N/ U3;NG44--XS74'I/Z97$6D2N2J7I>2"M09.$9
M!0+L^KV-YYL^*/"=K.BU"O,"/PF8%)]4U(W=M,0,:ZK!E1O#] "C)+_FHM 0
M>:!BY,Z.<F6V1_U\,>S5M7G74>I%D&3HSQ:L%?P1]'O^$)A/D;%C6!5845_Q
M^B Z:^[^-^)Z,^=\U 4UGLS]\^4VM5]3\YA"C$*\B<YSM0AS$N99F,^I,_+2
M,8EF#4C@ORLX5"GYR;W\\$MPWWF6JNL@#N?P<HKM8 DNRPE%J@4GSC>LQ#!V
M81Y<ZBRI;^&Z0N$<;MP<$F\W*CFA!*6>SOC<5>H"U,X?51K1,4HVV,0 2\58
MF4A^ETQ6O^-Y'?MCXD(+AD!@@":-;2%8\ZI8P4+0\6V3J'9-NH8<?SWW^7)]
M<Y^CHW-8D8.]\T_#P^#D]/CDX/3\]^!T],N'KI3@873VR^^CE ";Z[T+HXMI
M3J'>T4D]F2G6 [NZX(@5J,&:24V!]U\16%(;;):$G) >P&!*;/>*Y:9:V#O.
MUZ-A1.XS0W]1E9)Y)TR82-Y9&_-RVJ S2NY?P'>_!P&_N0JUF61%Z<=FV529
M"38U^MHUCI>E%"KXH6=TQ$YUA&A+.O9-&2CYLX82B3ML\>:B'A7^=D Y_W>5
ME=8VJD,CO7VXJMH33:@Q=0!?*B4U?'G2!.1JQJV'*:1;S(1-#(&@@KI$7C+3
M]Y+!4IVS??_;:;T3NOX^8H9,LG1UF5CNKWVP;"\5F>Y\AH34IP(L="3P0O/3
MRJZH])(#MMO!F>7"[/=./^X=FBB3L-"1U=Y.@63#BPY-S,WMN<V2.SLDWK4T
MT";T4$XN4@_@1P0;.[9A^,(>>0+#,)O.MAWP-VZ6H&LR(>RH!?6C6L'DJM>9
MLM\S!+QU+";.#.Y'5?"%M]6)L _,>HT [D&09]=A4EYO39"_4%06;?8I'*Y3
MLOUAYNA:G5T7I9H'^P@6@3<15Q&/6+J'N.6C3/$2$(04 A^Q_IUN5I>H>;0C
MD-,%)Y"$V$HSR<4,#O*I538NPL@3,"45,(6_4]9XYTF7-OYA=/MZIXU7E&$X
MU$I-15)1+AI!:38'I:<V2=&.4@RO8!QV>UD18_LL!P/BC[_HKJR^!W+.,/@'
MQ$\5I:?2R6:QS_>\EYAS3&%4>F587@JFE@U'5 P-R-U)+*XTG*L&P&UIM$AX
MWL#)D^>#&K&+MMQ%M&7GR?J&6TX//A[LCPZ8L.%P]'%TSDCSX_?PV_#=Z'!T
M_GL7=GD(50M2LMZX\V7N!LNDJ_(<NZTXZXET%O*L4W]R-IYK6-U66D<L0>(,
M$%.)%G4SCH"12!O$]%UDZE6IM!X?LS6_HB86_N(H!AP%6*FD:Y-IA>X,Y$'3
MJ"/"(I>T\WL];;!M"9/F)?)3>S4X82T<O[.S:2'*_9YGQ[9HY$ E2J+J\%RE
M\7FO'(PB5PN#<HP5)@4IV-5F"H=-GC=;F/@:E]5B"H2<M7'2.=)N)JTTS2IN
M?FA7O/@0RF.]BP4.V#>=D+<5CC7A*[@Z%V.O3/:":2$+<CHSQ;\O4#!?!K5O
M>L6_2/=2VU5+.[?,2BRWLU]N^LTVJI3:+C&XS4"0-QR&)U53V-2*2A<Q,%7:
MQDJ\AS7R-@>1SJ-JCN P:K3GFE+P&*@MA^5[]7>6V4GUYLFA\"Z:AAN2UNOW
MK,[LHL4/L+76.[YUE&&/ANER:H(3'S'3'B=ZKCENY>T$D"<^2PPG$544N[]'
M8<KX0Z)*MASC+HC#F JP [ +,-PM":\ZB7P B7SZ/20POH7.MU!O#&XFVIB%
M356+CSW,BL+P;(ERA8]?=>)[J_B^O$E\;W:'P61=/WE-,F80!C]EHN'LSQ8+
M./VQM]OUP!(0#U :D2*>)&RC47W$%H1PFWDD INOR:OI9.H^96J\AC+%%#8L
M! ,F.T)^:P23#4"58??@2X4Y&ZR*"SF_0GT['=:)U%]64']#[+")2I/]YLP8
MJRFK0>1UH@K".C*AD[K[E+IH+:4N9K547B\H\DNJK2X\R\! -"A<M32"AQG%
MN,R@W#AX=W>7P<+;P7FMPJ2&5O!Z@'$PR#D\U$I&CF@'4F@R+5%:;NEHQWV%
MV,IPW@;1H;@ZF@3XB#E:'POX:I2$>E[X?3=JT(AN[]R[$;O>A5YUN:M;E,:$
M1.*P*D<U3@%0A!&KA$NX1;Z;+'R84J:LC_DJ>%:-[Q:.V): Q?5NT>.JK-NZ
M#39+K^\RUL#,80V\ZAYZ@B2?#-&8_:L,"8="8^H\N0?8!.M=J%+?! 2<2;-Z
M*,UWJ_"T&8CY,A!I@X]O+<+C"^!PN:6$DM$OUX_QERA+)"8NM7NVA$_*V4+L
M@5883BTZ"+"G9%ABVX]:LB+S><V$Q,0G'F#\6UAOW%ZWP!R%PW($S^UB(06C
M065S713,;CCI]Y8?R5-UK:BPZU28YQI.\ V,;#Y_C4Q1_ G^_N(UOK#-[:"M
M0A7Q%-,,?ALTZC^91UEFEF )3LLKQ^O'*E43;;QD*1*@6!"<N=?>?=C(H&0W
MUQ-QP4*<S9&\(<*',,0JO>[WBFI>$/6+,3F$]5OFY8P2BIG6'?GMX+U)2>#.
M-!0P<5:-P?9U]V#D3KT4Z:P:FU"O%WPU:*8VH^9O!-_9Z> [W]/Y<LL1LK.^
MX(+1T?[!QZ/1.>(+NM9E#V!.[*PYA, 'B0K024U4&F.Q?*SFJ9X@61@<#L2W
MA$5T"<*^?; XTXXR-3 <31XCF#0.TGF_YUW0RC1DF8CX))H22F'CC;-W?LFS
M:D'GJ0M34[RX)7R]AXZD];'I8\NZBF=6%U'^\2+*8 X5&3?*_:-BE%Y(EIV.
M] )S&*81-'7R7<$^6[<;SQ'E]U$0-Z^[ ,6/%U)NP!H$5:4^JZ@R\-''QI)=
M1EP9LKA;^)(ZR?H!P\8M+0VI++Y>,@*R5:L_$2"Q%-##D"X4LU@;/IDQ V&(
MWIH"L^#G%D46Z;#A,I,6=![YZ^[$O%<1C-=4!!W&*C#P3 D@S'4AG1\:</95
MHM)A"^](5M2:RDK-'#)*"SV&2974 'IPRA7A1 E;CD?+Y0@J"!LEK%VFP*QT
M4<Y^CW)%2&>*\:U%E@8M"M.EKU9T&^"/45T._/[Q VI-C^X)@JK&E6GS4].G
M+<^3819&N[8>YA1][3;(?6Z0R9IN$)U.L'^40 &J- FO<&OX/#<YZM5PP=S!
MEC@&JT4IO#L CZ6D;]>8F\SFPN9[;16R5!K@Q[+'AGS.*_QN,3-,8."6'KXW
MMN6Y7=:]I7^V(K@J'^%2OGKYCZ\+MKZUI?'<]U"R?10[0(2_C16LJ&>@\$%C
MC;[D6"1JG]0'Z&-6P3W;[X9B$<L2<N%O63$@4O6"E9 DUG'AQ6.M14AN:<*T
ML^,"^+FR5;MA:L:HF;@ZRWUF2G@ZAJIAY[;("S>P+/18NFA3[-Y-$UD[8L5D
M9O*P%J*BP.<ILLVAI GV%S%&PFJI,$$SV&2=8A7I0E0WW7$L[:8*598)XQ#&
MJKQ2\I80<&M[4W:&[1V&0->[$**>7EL*?[9$/WW=:"*@;6%/+RS:[[6$/9G=
MQD8^-_"^-I%H'D#;VDLG_JGP9]CDJG50'.?D#0*)57RIU6^_]^:3U;)O'G]Z
M6].T_=XA(>:LLF7TD[+*=N!IVP$/UUO@PBW 7]&\3B,UZ5H\?2B*3. D?UF3
M<LN6FU2I+TBU:=ZL5!4Q)ZZM5NWW5JK5OTF^=K?+U_XXI]=ZUQH-4W-4E4I@
ME](YTYQ@.F++G=W1IA*K'SHC\QT5>SS0YN3QR*Q-SU@AK&YIPKZQ=-/K&@.U
MN2DY)^S.&S^F4;27Z O%I%/T:#H\*'UC^CA/.$OCSW;@J"?"2:ER86.PLY-!
MCE6$*)@@O HMS2@8Z>%<,7_.\M"=U@^1&3N6:D*O0 ''1FM-K4=-,6Y*;A7E
M4@>V>A!Q3O7WL?WS@(D^49FB7D=EGB,RB<])K\J1*#]IW7#^0O#;>.=(P'<9
M:M+@+6#C#E7[$ KDNR@-&TUJ6\03^+ HJKDJ&I+LQ&^P8F\AGY5-L):*#"+3
M0I=N0L$#PV!5P2>)28D5IK@^$ I[_- RH*P>ZH3Z@2*6W6Y^&OS2V&7C2")W
M>>PK<?GP-F^:+Y&043RRI@'0!9:'IZ Z0(-,6!F4PN];7-2Z$&<K9TAKQBQ^
MMGD ]R7UOE]8@]<\EGGQ_3+GY7MWI  /H0S6&V)?8Q0A-^E/*X4T\\XNPOQZ
M#H+?X(*WHK#?S3&L^<4MZI<VH>&K-]?52@60ZZ[6,F.FDMC"_%7<<2O="?QQ
M=YWACV>?3H='>P<=^/$AM-WNFH,?ZR&@0D6FEXWM0;.RQ8?AF2QOZ7A*A[_C
MAH/%KG+I!X^HC2F7] D=J1_Q%X]J.=IF0D2F"GH[V -#@TU^9#BYI.Z6MC&[
M>R+5)AD5Z[R"";5J#VVO$;)>C+XU'I8KLNBLA(?8-^L=,6^PRH+OS+RRW#58
M4NP29JVU3'5TBG:'F<X;8 ;H%&0X"4HB,".>QZ7$?]L&:G9M!1^X*DHLU)%F
MJH7I].IX<IT=7>]W\V"[24A>/"IPL[^^RB7OK)!5>^BG];5"/GSZ.#P*WHV.
M#X]_&>T-#X.SX<>3PQLK,CKM>G?:]:<UMTI^(\HG/S545*BDX+L?WIUY?.6#
MVD6>XJ4F/D8IHQ9^U<7Y?KR*!SS=4&!$>MKQ:%0.BT<Y5I6.,6<'9R[:P;&<
MYI=:77&&4<$W(VP@-Z>Z4C:'S<W[/8]'WUC-2^=M>FVY_!OG+GWN$86><LO3
M.<DS5>Y0X2P;Q9\XV("3X[0S_@U^*B5HB(?PK((U,8'VPE1W8)P130/X=I9K
M6.T.K?H#EFV@)*#P[&<IB7Y!B:54<&X@[7L</GK-B?).0'ZTZHLEU>F4VZM@
M0PLCKX0L/R$&N<D6^AHN:UQ'I6.<FT"O(HBQXP4G12AY*-"-N<J)<LKX/K&Z
M5$FVF%MYA!N;.U^AI6 5M@F;@N_A!1(0\9'2'0UA@&A1NP/^5M",GSIHQG>C
M-OZR(;_>89*EVFJ/'YSB A(/&%B5$ 9^8R P>]0E M":YU)0$D5=J5YSF,1R
MA*M4VG%?L_HR4(5;L5ZQVC)M=!#")[0M.0%#?GX=9;&*I5B"P=]BC(7.B%ME
MN['"*SEF"J9A+ !F[F7>VMW;4TSOT8R,48W!W\8:2=L=ZQCBS (AG<%BMDD
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MN4>B R%$T\#5 ]=Q3ZR]<G*@1"/3L</'='M"T:NF;<-%=:)X[Z*X]E;M3=#
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MT;W#L^_V-'KQ>/?EXY5GT/?H$N]\B4L,"NQX_W?X\,/YQ\.W_Q]02P,$%
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M1_C'??"GC(N&3_6ZH(I$C'*F,P1UP7M5*TR3I)C%<[LV8]<,<P\LL_;6T9C
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M<-'4# 5(D(#'2*ZLY/*P*U*Q[+P/!]@ ?Q$F0BE8U[&FL0$EWH4E0J"_Y,
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M3Q@G8@R,KK#49Y@5.?\H.F(D5\4?G:BJQ'!"?9+L/8W),+D'=F&\Y8*&9.O
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M/#^V12,'*E&21X?K*HW7>^Z $[E:&5QCK+ ,2%FN-E<X;%*ZV5;$%_A8+8I
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MAP&B,^%ZHQ$JS)C%=:+DANU]]&@=&KP3G-7Z26I(!6_4%R>"7+!#$V/$2CN
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M]XM$>[3[.3D&T.E'^[_#A^_.WA^\^O]02P,$%     @ %9\(56E$#2"]6
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MC.P= 2<6E9ZE01$FW'T$"_E*[/H+VAN\!FU_)<"_X-HM>B7\,A H >?UX8.
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MMA5!9V+PS/-S0]B('YM#8=GF\7+^?'V_I[Y0UVG+T+)4),FGRSP3SDG\*+[
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M#C92?I7@MU0%IKDN?GFV2PL6]GLG914S9Y;T6[CN^Z;P?(X$I<K^S:'E),-
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M0"2OYP6>D)%"[=XI8=\T_9 C;(ZP!5*E8'<0W2BH8X5&1)Z!!N9R?1N#\O\
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M0$+% 0EEDV,7GR)@">,UJP@!H@@UIC"*\>4M]@,A0(@S*=G3O4T2$+'?&0A
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MSR87K2JNSL#XK_$+K'[DF/D54D*JQ/BC&(TO$#<WYG0\T2!(J8O[B/O *A7
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M:0QE\&_'OO!J<.QP @61ZNC33[#/DMARTQF&40T67G-NV2,?005S;FU)4T5
MST-*8DO<8#Z!M=RR;.%XE\':\V+]%;7VXK,:GASG31:\P]HT)LBS0)O";QJ'
M!<?NJR"!4YNN'T;*TTZ2BJ\6#QR6FQ"O_DV'[1N/5&+B\H''3)S*-FFPC#O[
M.E3,Q!9@YNU.*(V]'>7*&M,X)&6%%)SUC"XOK.N$Z-5(JXO>BL8(A"&"%6Q
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MQEHPED37HSFWZ55T?6$[$&?ENC3"ORKQ&%!^G-539&5C#\Y6"U%;UH*B[-P
M<2D907HUCG8WSS"&A*3EZ"-G$I:'A=UA2W(YB3US)(SX;=M>8QTS#-4C)"VX
MTHZUE=3/B75@I\C]2Y="6;9PO-T<WGH]8;E8]TNI'=;>&#9!ZU>ORIU=2&+W
MIAF3[TKQ PED375!:%NC>*6TGQ*TR!X0='"]1/EA+Y597=!P7DX# V 9/=(
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M[X"O=M3?.3DXNK=(^PO0-,U2NQ![\;JG8D15H)2+RO.2I(-$[:3QH?3V9-"
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M'0U(SS1.NU57MFXGL5@Y*:TWCY0+)P74'P@Y\SGZ4^/?!A=T6X:": RPL#2
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M\N86H1:8[\'N'_#+3R>?]W[]_U!+ P04    "  5GPA5.FH'H4X#  #^!P
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MYR &L3C5?6Q9_3E9W7N!K'YT4']]_ !.![8&]E6L8$IX> /Z70"S 9_3M U
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M,S<S.34Y9&5X9FEL:6YG9F5E<RYH=&WM6FUSVC@0_LX,_V&'IITP8Q(,2>"
M,$/ )-R1P(#;7C\*6X"F?CM;)*&__E:6C0TE29/0IB_)3!)DK:1G5\^N5FL:
M%_IEO]FXT%J=9C;3T'MZ7VMJ_Q:ZO7[OZARZFC9N',JGV'T8R4'C;-#Y!&?G
M[4%_,#K-?;SHZ5JN"=D,"K6IPZG?;'1Z'V"L?^IKI[D;9O)YK7IPS)P<$(O-
MG-.<1:<\%\XUC,5LXL^84^"N5RMZO Y1>^)R[MKRT=1U>"%@7VA-3=I38C-K
M6=.930.XHC<P<FV"*[7ZO?.KTYS/9G-<JG'6U&[G;,(XJ,4*- [/FHW#H5!K
M&P"UM$,$1FB2$$*;6,;"(IRY#KA3Z#*+.3/H4@HZF5CTI6 UWC<;W<&5OMJQ
M.>.T$'C$H#7'O?&)EVMV7=]^YTP"KSXNJ(U#(=Y$O#CR?LR[W,L8\KX  _K2
MHWD02V]GT7>TUM!W_V&F0Y?0=GWO0#A'8HCOS^F5';1;8G"X(C85=!K1&0NX
M3QP.)("Q1PTV9=0$Y@#C ;3GQ,=ATF0_E&'OFY+>:DU(6<L(*?41W)@:"Y]Q
MAC-((ZX9,+6L0+9ASZ]PYIJ2HN$L(J*USOH:M+5^?SQLM3&FG>:*N; ];'4Z
M<?MCKZ-?G.8J)V]S<#88=;11^#B"()\4,-CU6\.Q5HL_W&N#M,$JB&O3)")6
MA@!'S>A#)X91KKQ%DQWJG:3G0S1:*KH"K,:"ZQ.HQ\^=X.BY$U2?.T$I?HY_
M1K)SM(438L>CD1=:[_Q"QZ&;&]?7NCI*WD+@6LR$-\7PIQ[M=$$?#+?U>L0T
M,387Q$%5JZ:9E8!-+8FD0(:A?J5=+/^ZV$X66_6.Q (/@-E"-(_,:&'B4_*Y
MP)R F;1&KET<_BC/;][A .L!(5E2TBX*:4APJ#]@@:^9BF>4SK@5G@D:,>;0
MMD@02%WQ411QE\!=F-!4+)8'6+(QFY CC' OH&T[_'3=<T\^32M/.-E;MKO
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M,DG."N,;2'.OGGA/+3W=V*<25!G2B@DDOI)$NBII^J]&J).YU+3#M9SA)=W
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M93=[3MOO#P1&>V[F1OTP^6]%DNL9O_-#];D1]?3'4Q['OE!_? NB._%S*/\
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M>!RP'O^(*:[(#],HA:F8@.<&:2Q2#$:$YZY3@-+[VJ&3PJHEI(R<M+I+D*<
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M]'/53)CG<0&W\]@=."G=8ZE8>[1T.FS+JUP^EMWG\D]U52]OCS..F-;V-16
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M;NR/U:>5)>=6 :!R;8\'Z.4?K9.+YE^ IM=79>QI.9"LC?&UU8%D[4D<\_L
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M?>EHTU2<Q.C1F^CN&(+#G%$,[U7[HGZ!#K;2C;I[C@$!;'_(A$BQ&3>^_S%
MH/8FKIMB^QRU FS,(OMSY)TT:5[\\ID==);256^Y+8M.L?5RUD@X2A.\[@C&
MWT,?SZV-?6Z$"9!/V(NQQ^XX'8V'. 9 !<A30TZ Y#V=FVQ%+4^$6D52/Z38
M&41"\*Q/CF>T-BQMF2+[G/XGC7WA^;)+XSUB"9PK_=&E-ICPUD$:P]0<CSSF
M?Z=^S+U"NU35::FP+8EHLJNH? 1)0V(74D8LN.RQ10TFJ=DG$%5'\%@U@HTY
M+I]6HGK)$Q2BD6WK-J$S=CNK,=W'>46 B7TG/CZ%'3V^+=USR.(1>WH9;NR/
M]%NTW7)&NN6L=#L<P^UCV^+,Q/72!A,K>"F^($A:2JK0S?D^O4PC[*.)<%B-
MWL1U;'^+<AU<;=><NN%Y,YHGO>CZKLVFV]>RHW==]_ V%ZJ;-F*+;4&W=-G6
MG*GS50I"[C_38"COS%I-MZSM#&5/XGX$XL!5'/WA>R$?RE:V[0%(#U%<R7J-
M9[^3M*+[5VLA0LHT Q93VT'\@R,;?#W"7 V$_'I6GWRL7WVX+F]]5SAGOHLM
M#IVZ;(".QVEA]S5BL3>=*#HX1+9KC[DKM85NCJD6AE]3 1^$P$ZA'3]DH\W:
M-4BI@ZO0C3B!HX2"*04"55G>AVE5LU<<4#9MSG@LV*?#9P9.ZV==XUDV@:FS
M,&6QYNL?)5_7;+W#DWLTL;0;;?H[9^!G5_:(&FP(NW!:(@#8T$$-6(AW5]V=
M<4"%H<X;[)PK[^:WVIA4G/NS!7;C:_-Z,E ;I.V0T22_$IMW+$@5\DN1A[/8
M[5E8NM_.KR;#4C7+=&ZCR(-=A&D7^'A*]IY!C"S=Y<+"L-$#097'T^E<<+CZ
M/$W<A(6Q%KS[O!_!)>FE?2E!H]LBX-*6*T3D^BRWIFF. 5S9BP;J%D7CFL\"
MG#$*E.DM=&HUDM.)C=M3:OQQ,@71>W$4^J[S4UYI\#!GV+QUZX$61" _W$Y'
M;5<.TOA9)JY82"I(EBN^D^'[QG\KY3&$;+G2_,;P %R=-\_>$A-YXQ>>A.^=
MJT@DNZ8,:<QB#ZB!;6:G2FHD6 B2+,ZY!YIUS)7;G?4'G]5WON>T>7QG;T8<
MSK^=3I'4$*AP!?I]N@1O@ZC/XS1@(+OY@39#H5O3PK%Y/L7P@V!LIG$T@+\D
M$B+[!061AZXU6GQI/KC &6_Y;%6LS4'>]<GD:#Z$]UKM^.!]Q<F5,PO6'$+S
M&2*X'C_)^##+HMQNM"L%JT-F+9YZM=J3.FW,8!Y=#H "[>&4!0*AR?P^62,L
MZ$X;5S-@1\F[IU',_=L0!-XX3@<)(*+2C2T4"8HG\P$QDFKQ29S>.G6O[X>9
M-\K"\/2F,1V&IXJ(;V+FD8V@[U,$D@7=MWI]BHF+N6Z4AHDT:?FAZP_0\@*R
M$T(S&.+OG,PL9<%5>''506H%N=_"^5OC:HHB^PW)NP%#,2(WYY"E8+/Q8*\=
M#V8#PM8U(&P)G&<R>JX(XYG"WG.= (2SP9[S[<HY\_O(PBN8!^#VG)C#;"ZP
M]#-^R]PACF#R2E67 ,6AP*=", #J'^E !78K!<1> 0"[)\=9?+-NY"^_MZ[J
M,V3EWSD+DI[3"D4:L]#ESE44)ZSC!WXBM>6Z%&CT5YD!X_C(PO?WUDVS\?N<
M ,[S+VZXVPO1E3PDXV_3C<*H[[L$[DRD4<]9C0^&*U9J,-^ B8)P^,H+E/)=
MG:3Y*4(KXD.*0\9XO\<%7-':?J6@3KLL3*VG&Z2Q2%F8Z)@H8RYY&SE7\I(1
M/7]@8Y_6#I.^/A:3?LZ-25\M)BT2D^83%DTQD:%AX [SZ0(%85=%8/BA"T)E
M%-/AI0#'F(XD8/=TS"W,E@HS01,T7GG&\\B6\$K,^HJL?%EZAD\7,[,I+#2O
M&*4#ME IY6**_P;S'\>"!TS-JM]7T00D$M'P(L/6K"R*/7@^'CJBQV*>44;,
M85NWG.(8M*.(]&L4MR9.5Q^9SHDD_;E,]!Q,=KQC 4:O4?Z )$_YKTY"</W8
M3?LB03E:)A^(M/,?P!4DO&Q0%'J^#%X>Y;WC/C"+5%>MJR:@%*;;SG8* D !
M@H+L*!A8/.5PZ7S>P0G/AXCCA]5..\*-_4$Q>MKZ!T=/S*GW47^<?G#L%@!X
MBW?B;1P)D1\DW%LNIAJ[W+^3L8EE >/:F#[R:GL6!D"B:6%A20_SP#6+RK/;
M99HX!9#Z V:X+48/V5+'8TZD31QH\G',Y%V:/B:=1\6A(@7Z^N(ZEC(GFFLN
M<V:*&"*SZ^9EB6^R2Y;*83"XVV)8W0!ON/#6"=-^1XJB(_L9O;?AM7[783*]
M#*[IM\7]!3Y/Y^+HE@M,P+GSYMD\6LHY"]DM$:K3!'$G =9ZUD"%Y2N/^ZG'
M,H4E\+4Y4*DN%L84$=M\\ 6Y?G^?%8>K6>T 1J$H>-^+*!ZLSY%FI%8/,U:<
M'@\PC %P6ZH=\$&*UQK;E0(RKN'+1^'&I*59!7#BJ4V+8YXNMI0>.IWC/0\"
MI9O[L;+)<&1T2@&!__0C4#'P-10KH/  OD=;L+3?&,B1BT#S,F<4;7%YUXWO
MJ'$Y'=YC03>[",I6[DCU).2J: PR=1N!/Q5W$+K3<>1:U;N!HRN>CVFA*37:
M92^89*MKRQR@TN1[:\>;]QCGHZ>20W[EA1="*J;Z%\I-PL;F7AK!;$#.JP?D
MV(@<&Y&S-A$Y&:^9DMB6A@&**)2\=N]C5;L0\Z<2S'PGFU$W4?Z4,G&F@LZ7
M("59#/EGR/J@.4MK+!5R;$>4$=M@ URDTT[O8M@S(]$)'A(J'JC5:B'SU#=X
M,5JHHI>,B1^9MFNOX!Q,2M&<1UE5JNE$E726-TWKM"#SGH!L3::*_2J6J9!.
M!#]+5\>H793!,7PWNL>RF2+M"-_ST?1@*[J4G^1J^M7';$9S8!I^7?OP64RU
M/5702NI@50CN_%+=JU:K-53?Y*\6+U8=+\8LDD_$BQ++IL6+M<8+J82WKTLQ
M(HJ=%8'CM%66VB+:(./^U%7YYM 631S/WJ;?(&L88XEA7X@4+5<CBJ0MR34O
M'33[@R :<JX.Z$H[0J\"5EH;S3!&CH2F3YO)0CR'5BM$K<V_X]KI\7A04V&S
MTGDLH N*\")Z-&3 W_WCK\*%,55=>(/AUSP&$?XGO#A$UG;-;WEX#MSJC2R)
M]M8Y2[P]YXWWKO,.]0+Z_>U;U#)<%94->V6WZ"@/ JHL@<HF&_ TP:)@,Q2/
M:37=X(S=%-V=*@,DB3F3CG5@S;J8$.@BH'FJ6D(RD]U5)=@[9D@K:#2J]!XJ
M-,<6!><T5<Y(B/5CD92;0J?.2C%GK'1,@P5!T9)Z-:V"XH?2.@8W40 X"(R'
M5:1.C.:J. J0_X, RF(T6V *K[1<H$C:WJOOT5=[_]HS" -=YK$ O(6Q\-_B
M." #NO;QQ3;FL0RUY@H$QA/.C18# QFB^!;8P7^G1?Y:<.> G%M?&[FO9T0$
M3AX^IMK9T\CA!)^P/D $P+F(DEG'D=Q3,QW]1(A/.&0YIX ?T!D*]]G9%5Z+
MI=5D*^BOSLUTF<>:/W W-8L<3E= *O+)Z<7$39U&F@A%"O],J#R.4U/ODRZ0
MLY,.\.,OM6JU4I7_U^$;>>0C#!#I .0&V; G&G!9K +8-R)F%U8=NA17!3./
M9Q#9 (_I*%H>\#8[0H?K((DL[+^"76I\5Q>83XUC'ST4%6.,'@4&SP0^57F8
M-ZK2'M\CJQNB]"V#9BAFA@*@RO/M_'Z?>W@:P#4*E /\1*3]/IO%/.S9+%&Q
M^]Z>6[$CH;=,N[NY!Z)JH![^U8]P$"ER)\ %[C&W8[+?2%*G[/4F"\QC<1&0
M@^]X$ U(I$>R+Y8O%K)&(PG[ Q /^@")E+H%RFKG/MQQ<%FXF=)G*'RH3>YV
M*-I5ZI-^)HN@60V=A:5ZGHQ[MZJ>.?RZ66_<3$:;:U*AZVF"V==1BM6]@\"Y
M(:BKUB(!9QX>OY?"H;MP#+[L?6?]?":8RX/:UCE(:E+J[(2MVI"I;0N9NK,1
M4S9B:ETBIB9X^B;?C''^@* '8ND:! D#4WJX+/MB+2-S@O^\/D4*B;E,UR=G
M45]56':8=X>)PUH('+[V'LK9W<N?Z*L' A!"M5G<8: $[EX^!'PX1_'GL?%(
M/_O5ZKZM^VP.;S>FE,F?/^@2=;L1!QM_X/V!65Y#JWR=S.#[ANQX%2,V5!G.
M*AC^EZF2(^[>M_;4LE3,E8O8>42$WSRYI+(0A*L04":AVIBN^7!C_M Z.7+L
M5,8>M:?R]%-ISBCX3$6SC98%J+EF!4EL_6<#DL_7\*>?Q+367F6>XZP#PJA!
M0X>RW^-OY%?CW2Y*\EFE4;P: 5S6UCW[S#5=/*;M1][MX\!*?05XRO[-4R0_
MN$34(,JI4=D>(R*>K4<P"\+E;L\RN.=-=N?V?'**<\Q]GZKJ2%84!EW? ATE
M[%;5[M$"O);H\XH3*GB)+G*CP[?VH,H\>F6)0+7Y">[4T7HE<DZ0$0")\"EJ
M+ Q X%Q8$?]+^WJ*P"!XP,E6)&,2T8-E(3:AYM&,R]Y\*+O)Q\-ARGHFC]5K
MLF=PPQZ Y6&I#+)%SREQ37KJ*2VE:+[K.C&D(5:#!Z8%4TEC'_9C]GC7#W,F
M->G=;VT_JCF/O.?'4LX>CG+\Z9$BH]=#'SO=X($Z$Z:,8@OM*=!>1J4_3223
MWVJ/9"*VSHW^(&!AO)0O,!8S[Q'+G*E2)$I[>5M8-JNXW&=B:-M^6/^*2*2>
M\V(ZP2!2N'J^8TAXPGZ2:5K>2:>\$QL!L>_UC:2YV-+2 )AS#IJ!R[!6E$QS
M =%ES\8LK&#,@@U96->0!=_[;2>.^@<?#HX/CW_L[\R-L8]#J"=BKX(I@70V
M0WP97&_4O]^T+B_JUW\Y%Y<W3>>Z^:U^?=*Z^.:<7E[_"1]WSRXO_\"_VS?U
MF^9Y\^*F72"/%?)POPS$0&X0&.E(-I54J HX%)L:W[/8VPVBZ"<%MZ+M6:JE
M*+NA3P:N(:GSZ&;QZ(ZM.%$:._"2$#Y2KTU^JUT)^CWP"VR^YW2TG=G(;6#!
M'L9B@C!HO!$]/3(X5MFL.SSP>5<^R(1(^P-931V(N)^9D_:<>@ J4GJ+UF_Y
M"*A?9"DRUN@3S=/39,]ZP!4R^04P"67C !D4)!V1WMZ"'"-%TX16.05.N&K@
ME"(*D<%4<!%P8Z)TA4N&'X=1JM/FG7L?BT6Z/5ICA&8NH/#_<O66\;5&<6&I
MU#!VVD+\$"O64X:,49 ^]L5/F#<-E1DA\_H80-USONG.E15S5EHY3HT[ C0"
M\8YBG3$@6IBUE(QG,%.'QR%5NP3)WR?&&\NW 52[:8)P851[$K%$(TB.2!4'
M !3*VI8@TZ2!C.',,F6P]&8\[5A*T*O/AH >@)Z@>'ATN!68( BB>WG29-$D
MNB#DNX]B+PL-56@ELKI.ZGO=A'[\AP=) B-? VW\I^Q[O&-=)L9_@$6/?H4X
M-/J=  ((O+%O.?\YO@1"LM&1;H][:<#'IL!T4VEKS>)@\U(8A*B>^8/P@9TQ
M0EHX-C$39S'FGN4VDE(NA0B2HZ!V!"11 4U9)TJ!<T_D[P8+/7JV@'JT( 'U
M?_^O7Q.22M"J.F >TM%O.]4=^EM-3'^K)70 )7E,+] 5JTC"^NP41+!G7"SR
M#;LP:\ & K[6G[*?"OO=D7O()$%#;O1#X7LH-]Y%OJ<'>B,BU.$_#, D7OF@
M ]@2Z"F48J$%(H#SY\^&A$2"EU+\CJ;,59LPUY15S/GJB3*DE F7++DYB&2[
M6O96"NZKB1MD_0ES)TT';I:N"L.?Y7G.-!<\"/@WIG^12HH@=@/.XD\H8 "/
M?-!;5V1KZ=_2OZ7_5Z-_E+NUFQ[$SSZ*G$S9=P/E:49I#H9-C<Q3:L %$Q[[
MV_ DQS]YXKQ10HC\5<D@;RT;L6S$LI$-92.H\A/7N(VC^Z2G8MS\.QX,+=U;
MNK=TOQET+X-E7!<T!*SZ(F06?@**?RXWZ+3M0JX^\@(*Q[3<P'(#RPTVAQL,
M(K*(8XF-)(G]3IHH [9I63#90E;- 0W%,$XVG8NC.VS+; RTG,)R"LLI-H13
MC.L+JFP/=ZA8C*3\\JHOE@]8/F#YP$;R@:A#QD=9R4M9(F-^FP8LP9J44BY
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MP.2+_W*EQI%Z&'/@-Z17RA=4\I53WC8!2IV:@JZRD1"$/?480(Y>BN]D^9*
M.B(ANV670[U]W9!VT'XJ"W>"TAL9,^A3C[D?_D???##".%2 /G/Z@'I]6AA<
M!4P@2D5IHMZ(L[G<0RL9S8=MLLD6-N#RG6A5PQX&@'UXO4@[J;D?[+T=D@KN
M&<<_<WL$5Q18@00BO$'D=A/)=_%.INPW2G[+IR58^_U^&D98G(RP@[+LD2+H
MZI*%/60[4V7/\U1%L[%EP!7,$R!]M">&^>\.]M:$:7%["I!$DMAS4MF]6"C=
MC5X$0H_<"HD.T2T/.1!9/G[/44P@+W"B"BO)-5WU %6<@Y&"2#).2).N'+,_
MN6C2.#[V(P\O/RXK$=PA4)$<Z?C(0.'YK,,Q,[$/Q.VC.!11\!%L@'(188>
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M];3NMZJG!EJ*20N<<'AG0%;N"'_%UTO+\_BO7]6OA>.BJ)<2 !<H-P__F \
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M+6= >T2$49\((BS=ERX<ZF W8I!$4$N-,6&<>5Z,QAT%WFP)F8:K36DJ^F>
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M5!2]P#I=9L PG:K((]B5M'?/*UK84]^D8O0;. ,S,\I(WF@40P[IC3CY:+B
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MCO!RYU2>QF$EE)N3@.%F1#2(/[$6'T[E07UF.RG-X@ZG(WD;(A'X&X4$A:S
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M=2,":?!)\-!]>W #[R$&P@/7$BD?MST*''<.2^C'\S?F#D !"TAKA]'2,8<
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M2V^;B;SO'NG.[#UD.Y+MR%78D2"H67&S"Z0Z VI@V%?=5H(),$W=727D)M'
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M6+T:P,JZ/?FFA"^_>_'*NA)FTY1-4S9-UV&:TD;&48&(&Y0%BV5EH1A5D.U
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M-."?'1 ?\Q.M'6T0W.BNI+V+C<EJ3!)I'^#]Q&5?>JA!_!-ZAYV9 =_3..D
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MT<&!Q8\JHINN/(YT2VQS>K1%VF&B=RK,YD<)ZOXQ[=PLT)1\_!\&P#R.:_H
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M(Z4]&DM-89HEE.:E<&%A\0W%FI:B#L=&,Z9A,.?>]]XA6TH7\;$%ZP1;0XU
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M\3/Z%-YSD(10"O7=2;=I1<[@XPT]<CV<PIJV<3RTV]*CAO&GG<A00:S'Z_6
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MF8L102!5<WMJ.195&RYF['_H+9B,G'H,[P03NZ.5VMX_&8\&BJ73N-VR#L)
M%X,^Q5?_0IN@&?8!,A\)U_#N>^M/U39/L +TF>XJ^@$*.N9^L)Q:Y/.>,?OE
M:D_'')K_H7HUU["P_>=J79436B3M<M<UVM-\<OG^2#%XJQS)Z:'!SL(?D&B0
M;1H479;VUG>JKJ2>J!W[EVVF'\$SYU)A0H:\7;P7>$HD8E,6IC1DO.P8WBSE
M6K.PPTRBQC!>"#3<9C0+SK)\2G2/A%.7W%60;_OQ>&R[0:5\^4LJ;Y(%&BZ.
M<SE3GRDAJT67/P![?[_G$Y][F)MN,9\MYP=<G/I=7=Y[R9_'WCOPRMD-H"N6
MK)Q+ 5I5+S"=X"3?0\55CV\6>+3NA?6)PS%V<N'-XP,29@7UZ]A%NBOIDNH1
MX'OES@VL7>E@$<K-R0\ Q;#WCBP1;(7C!XR5&[R5FX,)]% CV^0Z*- N"$W8
M-3?"Q9#7-!(HS@/CC2$4.L\7HT_*^]00+=G+%6&VTR #%XHD!>P^J4J;/P'Y
M^-CQ*81#J*03<JI"X:TB!]C;EJ?S-1V)?B7!Q,\\UZ!4I0*W=&D*G07;U?3H
M4BDJR[Z?C)\4?@69JY!9GJ]*_%%UOM_0H?O0;M&'2OV(-U9X,003-2D[B_(N
M""/(84J+ ?O..$\4"/#65ZO@I\;8B*+$Y:T/JQ7O'=L-6ST+$VOJ"C+U"J5Y
MPSD.<LTF:V&X'!-TK 9K?]2S,9QS*]4-8%$O23G-)=#:CI7!>&E+B]58ZD$E
M)QX_R.P35GUYVSG+UE@60VVNH@0XRJ11/8*R9>:7E9.9A_6X/J^3[%$BO'_A
M ;4+[8+PHTLUR!8,)H]^N1NXF?5=Y>[-'<#7JJV'26C;:SH&*@0XC5Q,;!D3
M9E?'ZJY%KC&9GOETI*_\.]^8QJJU%;3X6GBDG;N7E@8<;(<H+7C&YKQCY,AF
MF^=^"UY<&#D16^$48ZN2 2&H$T1)#W&U(_WO2=@^BUHCOVL!8L?8R^+V7NIS
M4Y?5H??B3O@MNH?=F\)6X[#KL8E8VZZO_"WE# T:*G]<(CKIUO"0\EK&K7Q
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MX3CPK/4=#;[C)6TFTW+3(D_6UUO6<3HQYSPUC"1.5#T?!X52X5$!PD/"!?3
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MQG'19" 5>3@KXSS<8>8!4E+N\0)1U%UN$9)U!J79;2GT':KPN(HY'^@$_QE
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MR#-.,\]&1D8/FBAII $>?:A(8ONNK/HMW5@/SE<?VN96G*@E;?VP),4W&#_
M(%2VJ)(R9,70PDE%&U_JPF7R/LVR.7+&%:?9IHZJ(Q'];Q*2Z]6+HFWH_@7Z
M%@V=)B,  .W'[75SE*8#C&==A@O9G%>!OGA-,OX&E*AEM=N7"C@ICA JHN(3
M%YV I17<]LGX1]TJG$J !;/_JR0ROK&?7A&M]3;TYD35VD8M4+;K U4;&6?A
M4[+N3)MO1+(8]/2Q/X*6+TAVP2ZR9'6DL6&H+2Y&1TE*K>RKIMFQMN!B,/ET
M5=-!4R1IX%_W[*(:2(]7*)S09AT8MQ\AN D QT*WH75%1MJVP*IOJ(US*?9
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M>83QV>=7?#@L!$,7$!#I)/"]8>^YN"%S:3UE=YT8TK%_:6XYE%PK/&P)T>;
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MGV@YY_GW7[_N8CE'9XI8!.X0&IF'%1-"1D"(CI%@>B]I+WI]>HA@><3"H'_
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M]M6+Y]^^3,!=_R#KTW*'[/.,C6FMS:B[41EGS>/_-ZZOO$1-PG1YH_F$Q()
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M%EU(P_*ZX[=9I/8PT@T0+Q?M#K-Z.EE'CUXJ)2=/EP]"%\&H2^MY<8M.PS(
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M)(5ZSA2 V[V9R%CN-INZ9E*HTGLKB@,?24/*-M=7JOP"Z<T]#'\_\_[_6B2
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M#>7RC&@DDV<&\ K5_LKWH,0M'><"S&ZI3:=W80'F1A3U.>CX%YJ#D\HERX0
M!45)#AQ-:W<;1;X#_).L+,H&MU=J<X'!X)A,$!O6JQ=D'.B*=4D:H>BT%.Q_
M^X+VC(_SZG5;WA3;LT.3^4,6JK]X\=K%ZCKP@[)?S16]B,FB:"K</?JIO8>$
MOCQRI+I);H4,LKB06WT,.1G\R:C>48=TP?O>R!YK-WJDIH[$OI-.&2<A(A@R
MV&K^290OR0[PRZT.C'KDU\8 8#J%9&+4)WGDU/(CTZ/HH),P? X;<<UA/_>[
M^3;O61!%/A91*UMOR8X'?2OX9.F3HJ>N9<+KPGWAWG66 L%+QMW ,@*%.F$S
M\N\296:FKG77N%&0EP N76J<Q+9R\85<>T-1Z11=0N+$N#GNHRMN1CUH*^T/
MUZ4&<[!3.H3#3A\#[G 1WFZFIBU$Q;S4^!YKI>1WGRTUOE_V3.U3DL:)VY=W
M0OWEU>OGS_/Y&OAQ$Q<VZ:9;\CO[H(U8T*\.)M(4_1B6P_?^?N^_EX!SI>D9
M/@=? /X-1F$U@\H..>?<4C6$0_Z\"38SAS.63U%F[QS6?42%!SB?.<S#?-]+
M<@CR]CSOQ:?4"M98D)1D<$Q3-W!0!/Q%HXN$GIB9X1&2S-CP:_HOM59G 9=E
M3T>X2:,X@O_\\N5SU_8U#M"<:QP3:IFK)=6R+)?)6;.!RQJ\UR*)?]8Q@2_Y
MJPZ]\-OXO?7JDY=__S5[A[__C]__YQ]7GZAW^.<O7W]KWB%  (_6;0T N7KU
M=6$ >P"9^^P/:W6="LV%S4=\'#X4AXNA7YH$N"OL2V6I^ ?=20L[#.HZ52A3
MW^[+Y[HX](H:BK [M&D;.JVQ0*-%FQR_N$Z.ZAA'A*_FGVR$O9WD\;JX4>#:
M0KHY.W."[(5G/3]_"3BQY;[4JF=Z11W&Q6)BA 4!LK^,G]&@E<A*?,W<Z1/_
M4A"2V&OMY'/2PYKN/$$7=[LW\F=UJ])!ZYB(#7(EV_=_V7O7WKBM+%WX^P'.
M?R@$IP$;H#UVTG&ZVV<:<)SD3'HZ;2-V=]ZO5!5+8LPBU;Q(KOGU[U[/NNRU
M259)3F1+M@G,="RIBI=]67M=GO4\$>NI.BR3>C.>XO),%..3Y2%XQO#H;XKB
M_.!XP@P4F4Z'YECTL<?5>J20&<A+N<RSQGH8YLT$MZWHN+H'UQ"<UD?1]4*L
M2A6$3B,.B4DF&)*#P4A;D" 5YEN-F_GN9:VIOW249+8C'L".GG&Z*>IHXX#1
MO)%[)U3AF[+N_4A&>OEMN0:9HVM'&7](3EC7(V<14]-N'LA,^GTKAV'G4Z&5
M0"$L_L$BX< V]OCKQA5[P'TUDM&^\<IDG<@)9-9?JYM.  +;U7!.3QM6QU=/
M_OCT\:/LT2/\/Q"6^-.7?U#'HV\H3W#9M-6&RMC$!4$0C'#4U.#?0"0HO@K7
MYS3?OBMKLK!A"L.^XHZ?Y+Y?SMSWC]>]KYS4U(4(&!525M2#HS#\KN#ZL=[?
M32=PHF%];)$Q.!B:-G(*)MD\3370ZFG6BC?O"5:U.96^-4J9=9J:/J>T6#?"
MM&3<J6 TFV2Z-Z7BN:3ZB-V"VHS%R3L 4SE+A FE*DJ,N=5TT5M.RY&VEHF?
MM!LUQ87;4:/P ]8MDUTKQOUS%%JPIJX$,L2@!H]&F$7/K9A(VI].C#.&L2>5
M TYK]&-HR:!\A'+"(Z%Q@IB ,\'H=$B>*#JL."]@ES;%10F"Q%;.+%[V#+VC
MPW13;H&[",O]I)(D2G<(GQ(6:V.);BFQ*O5GDM+-P_.7:!)@?\.5#IPW]"SL
M/@1"9:^GIW2PV7'H' L:-RK/4L<N']CV/HJ/X%8K*OEVH[&APW"2_84?# NA
M^(JQ;,2TU]:F%Y=ELA]7H=;QW*S"A?IB=$K@Y8.-VI9%M<D0IRG-1'PJEVQG
M2Y5". UG1ZV^G00TX4H7Q6QG#V/\6@+7"-(BC/>W;?&V[#/4_SG%OTER_#!8
M[%K1-\:G9G3_1Z&3/"(,3FP^0@<G-W507SYRC:E5P6-1T4=7Z0BUJDU2<N."
MB"$N5Y'P-?TTO14E(F8A_[<=B=Y>;UP:/L[%AN:<:QU^Y/)PV1Y]T:6+_6,F
MH-1X@5?ER/,3NZ%FD DV$"FX'3]E2F3[)\$NMQ]%V! V("7!*Y LQ5VT*PA(
M4W8[50K:AK6#^@HYOC4 %BZW;Y'C.)XBZZ0FEZN6#GWJ\!3/#UP+W2CD4#2H
M=&)DPQP_0*=BA[*.C(=RAOO: ],\;Z ,;7D?V"6F'I#2$ZO]),DA*P1J?*P$
M$PWW+U.U7LFYY1&[-RLO8)-F/2)FV\%,8]Y=W68'6T6U?::X28]IN]+GL$8\
MTMH<Z1N^MC3+WE+EXFRS5L$1) )P(^Z$X_/5GL/G-UQ/)L40):"S4:TH1#9$
M&W&:&S'K.%4R#6$,]887B&.I&1_3W:)ZHP3/>I>22;G")+?D\H4[7GD_QVO,
M'>Q60TP[UZW1+P5$U).V]+YO$2=%ME@JK043H@?E#"HLV/\:'J,@2.!K.U:#
M$"4*L(PB2:)\Y=J]4T+V[TK>//FZ#^Q@O^!6L>.W3UC9PK\'361&WCGC>(C)
M36P&TEN&G7"DLP:&%&ZW>V%( &7VQQVGW^Y/0U*W_M@;V0C(:T>O:KQ-1V85
MRA7!\I_3-!@]FSQ,6+QC[#3[_Z]H15UON&RFA#2!?I)6S@N!2TMQKO'V,PP1
M^[1]T\!NH1&T6?KF[FX5X^LOEYK:4E.[*ZOQ9&B#ZTU8<;8;B!O#X>TZP1/N
M^P:>"1T$-$7BL+8,E1;>)XI.*7IIXO$&5T!Q/6+*PU=.&\[ZTHGI2#LF>$&G
MS9<YW4SRJDNKXO!!P:H\!Z"%"][T,-[T[S3QF>-'!YQ).W^\[^=+$S1+*>>
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M+&4F.<]%=!LA8?%6LT I;8"IN0AA!$#/I,TW,/C=B+N7XOJ[D#GE;8+K5$.
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M4Q.@TT#M'>^#_H^\#IX4HV#=VWZ) &&<TQL;).%*(IRJ#Q X% $N'HT.P;0
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M5/ +@%43:8A_OGKY^H719,"V4IJ6:M?46W@I$(WQ7$4B8!MB:2(:D=#+E,F
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M&)TK<VIZ24I3'+H"^K[>2Q.UCW6\'MFU[R%PZOV\;!VNV>_/60<+QPY@TD@
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M4LPH>+,Q]BE>%="MT[K\GYPK;>C/H!H-8IQX'YY3N(_;V8$*<7D),.4[]?V
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M-,VE^?*]/!V=2!%78LB)4SCRP:(1ETC;#[5 L!Q1F":??V5SW?FPP1GB8"E
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M2#KCO\/D;IH=#W?Z.^F!$75&3$7X[C__F]:&@B,Z\&I537W:">GU*M\Q1!E
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M-1W$^)S:7.P2#NMS/0#_D:#Y!8+(>.2PSWGU,V:>"!KV*R]!-Q&'/-P413J
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MWR@M()Z2'U$T8);$LE=U?9P&[T1WT#B7%XA346V1SGAW<9Y69,#\<1!:/91
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M, +)$G; @#C349^FV.3Y8*GFF%1GKK9UY@;#IM>9HZ%WM? >567+:5_0$0;
M\GMJ[*IW:3TZOM*4+2R42&?8Q#.\#RT_LC#\!T_QS+9!2H+H9OR859G'S_M7
M4,ZY?T!'W)PCAB.C\VK.>7&RBC9=O'#G,I2'BH76*DFE?OG3YT*A@_X7+%ZU
M#L8K,&PK&9-MFH5@3#!NPRP$8X)QW6>AS-IZ9]:>6]$$K?0V_ %=CA\M3SC
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M(T=+&RPT]T%L>0;[.W'CYY:;9B@6K,S\T#&[QT.R/I2:JX_7K&F3H%*/69J
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M?-Z_"F)F] _HB)MSQ'!D=%[-.2].5L=@+<4+=QY,1_QKIY4'N-7548!@&_)
MKV<LM( ]&>S[C/D16[62-;G>ZN=Z:]/N"<9MF85@3#!NPRP$8^I#UN;&)[<L
M8E9H3]"_Y+!'Y@4SL&!L6U#<7OQUJWJ>;"2%YL0\.FUP\S%"FJ8QB?K,4FLD
M;,[%;!%&U%H$:JTMK7Z"DK2E!3Y*2FASQD]V$*W<(*[NE8N.S$[GN ETIV4-
MK0A*Q,.:,TO],;$Q=*Q%6%%K^8DDHS5(1O]@/A>-/)2++&?J^FX4@ZCTR%HN
M%C64L6T92OVA>3KL$6#:@CX-X1KUF:7^F-B<*]HBM-B<8%3SJB]4:+#5VVQ
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MFC++>P<^<<%#?UES.HV2V'!4(^#@R4=45SUB&'\GF+JVWOA[SF.ZL.V8:IF
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M$$#RTU;2=?*2\>2'7]Z;;+3+[G-29ZPEJCE/B[."OW7&&+9-#:.)%]8U%K*
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MJKZF4S:2%+FK2ZF7)\.2[>5QDN1<83TGU:A56%&[,D,$,GSLW%*X WTY50"
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M&'KTCD5AS5D\BG>G37?:=*=-=]KT4[7I&Y*SX@T!;B\^B,&"4!$+>=542_2
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MK.Q<KY;=)VO[XPF1/20B'B\C37B(5O?$XQ.\,E>K&X=)[:;:H,RNQ5>(D&"
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M?'3?$$U\G&YI&(=/XB+?<)YO?!Q/[\<0Z@@IK\ENR:'S*-=22Q'9"JY43W$
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M_YGCHZ/#W<]^ZLR#@]_XAE8/@NZ$'E[I\9I*L.H\4* (J0VL=_\B'AR'_N
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MK)FM(,%ZC9EH\['F,65([_I?#*CJLHR@#P2F-*[S,^X1,*OJXM\!NN!;9ZU
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MV(]'%5GH=6&WTTI,<HUKI:1UL#6L79&J"$;6E UDK>\H1+J**7@*>(;X:T0
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MT_?AF"AIR3#6IL9"8Y@(D5A3M$H/RL^@@EH,)[$T-DX.J\5@2][_0GGE5:Q
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ML]+(MX3-#G%#'S\P6,N04I5_GF:0K*57_A$FZZBV;O+$6@G1Y^JG][0BK\2
MUGNA3# O016YORX:!QFQQ,%1*;OJ]:#VQ,<'WA/[BT3;%6)*X]%AJN$QY9YV
MOK;48H18/UHH/ZY>J1X?G!';2#<OFA2%R?:CS"Y&;T ROENXU[S/#Y?O_C*Z
M:F/FAQ=9%C5-Z/JH+G,AW]"N\#E6Q'2TT1BYR:H6OT!:=]LJN0[^, -2EQ:
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MS/>6#W%!==.Z[:+>+G,DWE6U@5&@Y/'=PN@I[+Z-I[X2DM7;RGRSSFU%"F)
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M@M^05([/7A/O# !*A8ETZR-PHRJ5D,05X$R!(0ZDT; #Y/1@U6Z[@EN+VNP
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MT/>N*:6?T0&CCY@,QL3T/3(IQ4I'#M9OG.V/O[T4'53>17'>0T-+DWQX:O%
MO==@@'1K='2#TP:X0T)>E)8ADJ0MK8\PG#,J-$JMT/U55T#?2>OO'DQ1OP3<
MZXH9QY1_6V^;*>>WP\)9GMS6S3*W*\:<-DA;FSI<610_I:.Q?2:.*?!5\F1+
M(J' A@K.WHK+6,RK&$S%,QQ(R7 X80C1@HA$V]BJN0+5[&#;\1:"&."F_8S*
MB) B[_9,>O/MF1V[9L#(P[+!%)+81!J2UAFV)#<49;-N*!RX1<.6 @)3ZKYR
MA4^MA-0RZ;>,W1F#'5*>2,RQ!PSU%Z3AR1?1%;6'M<>FK"D$Z](>'G%+(8^U
MY"4D'L&JS:M:H%%Z1 '[P'IDNB%X#T=&07-<3D?7>VXKIU$P-EM.("+4,1,"
M* 'K9'2[=*3>FN2]G034>"0'N[Z$1^48!R)_R:YQ@OH>U[$R:;C/Z^E6"'"*
M:D''44=]R[>%6UYR23WYF[JWJ/7PWV["M\3T^;?=VY0$> @E<Y/&'SHVNKNV
M$TUZ5Y%E$4P*+]ML9)*%/4>LKY044] ;FU[75#VV_J4%Q:C6I&H5:'#+(*+G
M)ETE@:WV-__ U8]<071QQ]K#!#V>:@B-2?"+R%:^#HX^Q,U&+Y@#E^)X"Q]R
M$5A13KX'%QJ_$&[;:/13419/E\"AD2L(I2<(!59-#W:CEXT)#.>-1P0(W4ON
M'(G!NM>"+6?9"WS!U\=<+<DC_&0=$M)(@"'T*ON2-E+ET_/[(]6^N]?#% T(
MBO<(4_I$E;%C<3S-]@RYN\$N+V[##!SKX$GNTE(S#+RTTG'9'#QU<#@".'@@
MBQ!V816YF1CI)$Z>B]!\TDD56"%Q$#/P)FHJB0=$L<-1C<\+V:[S0-^Z ^HV
MZB= -XFI2?A-ECVAV392XB3!_['6^+D6=\[.OS[6&H^UQMYR5)^$DF*<C"^T
MKA43.#%A(^F4@UFK;JYJH.3&;?7#9@NQ"/G2PT&U8,JC-]5_\BI--\7,2_(:
MHH<0[&\+KC%*<I4L&UBE%RP;3AHC'QA\IDF9EQQZKTBN" #)SZ1G]M7KU\,]
MLW;N?&SVDC</EQMH>K,<I 0NS!4WG=9;H60C 4$6T6@R_B\#@V\H63VU5I44
M)8,J)L?&@CD-!RDYI4@RA4&K.//GA;TO]LH:'P P9Y[Z)/-Y #I-.1(;<IN8
M"9:382Y ZYZ,82SH[6<[[6,%0%N6+,;88O7]0ZQ+-3:'19V#G6B=:K)27>?<
M"JSJ*N=4NCN%KD07*7<P(0HX%>A:,9O9"M[\9HO48.K7[W6-D/TGM+/>*408
M45NMDP!\0%'F2\6+;QN6NZ!%.# )XV$+S-E&6GR-@S![)1\Q:"+U&\:< M3U
M@IK*5N'0'D=).NZPML4G7S0S07P^X7PZ9-J%BTP*C)N65+@RNY#/>MM9<-U[
M)ZBV25>D-\@(M,,_RN7.XF[*E^7+'1OIWFZ!H/#'C+_D:VV0),?E?.]"H?$\
M#JY-^:#E3- &YK][$^-FK&-ET[J>=H<X@7LD$(?621OA.(=?O.7)HNMK*Z$<
M"7BH.!NQRX]LS:&J3#R,!X;/YE$ '7X"DN72&S-8*D0E,Z8D[=F-E"(A<Y\6
MUJLD*AEXN(^=@O0US4X<*,.ETWO_Y8Q[Q),/GYF2:J#V[!H07-KD0JI+]:4-
MVH8BO3F\@FVC;-B:3*>.J5JYGZI(PBT),*'XY%D59!.UYYA!<XB C^U05;C"
MDK4MRO6\?07-OI&II]/P%FJNF/[8U)8&AXKV)5HB,3I&=XBZ:R\IE@B")7AX
MWC%)SI\0_@7W\$PI"]]T!AQY:)/XQ61%$Q!S]&C#*6^X;38O1)T[NL/JJ 2G
M(^D$%]Y9FTN97V/#\JWQU,*SP2)%47+(M_**DEG2RFO/9V?-<3ONW8Y1^99H
M#>9"")+UU+TC7TA*WH+-&4):+E(107/:/YU4C)/2LG'$[/>3=3E'\H6>&W'1
M2CLP"!2&]%>3-%?9RAG1$2DJYW6#[I>T]\R5K'QYOTM:D&I":F]BKV ^L(IE
M1 :L3,^6$)2V7&Y9L5IF()JY]$[&8L*U=G^7&'L,64 ?80AE:F=([-)<H\Y(
M0\!B+.+'U69P;Y?\9(8Y6R(N6=4JD2#=B.W(B?IZXF&6.7'^5[1[A5+L;O8N
M=L&>=3KR&(B@ZE2&-3W6%.Y,R[4?&W.L*+S.2A!JBDZ=5=2[U.B.PV7&.,HQ
M0NR" _YES0P0%'-+T<!SU-O9"?.1<IT/BH$2_W,UY=*^5+'))U$=D%26MF*2
MY*C*D @M.!Z1I*&VM\^*YB8#8;/J))355@@FE98S;C]G68>%EQSHB$>#X$S"
MS\Z4E\(&TQ3*CB4"Y>1LQ$#*]1+8.^H;M.2?Z1V21FS?@,WZ\4L0VH@ CI@T
M:0X.M]R4;;?;]\%Z(UV!A;3?7XMND[[R@W$4V%+KB&_LD;SB6%KD3>)]HRAR
MEXQ%F%?K9IY52C<-?K<F!(A5L:3 N5SF"%52;940+H2+B9JR*M2SU$3PHZS)
MVXXV9MLE#QR;8EE3?-+V] 6T%U;51<9.F!WFP;K.[0.+>ID/+=U$Y#E^7."
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MI;&?%V^O6B.=?NQ)1LTX93M)$; =%7F!E?CBO4J::;'9_>EWE.*0%'E2.A^
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MK96L%_%SA)!VRVIP'1'F_0.H.JFB.2=DR&$U3!>TFM E3@O*%%M<_W?R4+2
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M2SE(TTV?5"Y[*0/GKY-UV!"0B W$3E(*T8Z)7>D>TL-GM-?+5=,-B!,9O'B
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M=.(-#L:H=PU(?\.8\TCD>E<BU^?$GWM%R:LIES6OB["[:*4<^5IC(4)"V?%
MV1*+DYWMB,J/P]GJ<(9=9#(?$2@.,FOE,G9_&)MWR/ZYEZ_ARBCB%ZI=.CM(
MYZG*31/]6$DV):N*>MM2CF>SV+9B0*99SYCQAGZP+K[T-Q(UQHHY[8.S_<.K
M=R\N?[A+@T0(SHIJ'B9%$E;A, K_:5.S[%O0W$(9VRH1IYT958S[(^:4*1P
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M&^_^< @H,B/%**R6%.R?=]YO)ITD)MUKZT?LMC#"BPO#CLGIZ)=%N2S\%,?
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MRY ]D "VJWB7^6TO:W&Y[ _\L OE]AL/JG4?IT/^O9(D<R"";\3DO$P&\\S
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M>-\9%E(^YB?LL8K;YC;.+($$)UR&9,"N,!*:@RZ%J)F+TN<MN@01H8=DR:(
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MES!TF</&8BLQ9)-ERL*!6-!!U%4K20WRN&UHDCN;T>).N=7E2B:.^KA#<E7
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M-3RO2EQ55X8@[:L<XX[XI! -(?&#D4Q@67(^DO["VEWON? V>L &>QALL).
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M+F"?E3G[Q]U3['F[ -&#\B#1PUK>!G- IX4ED DX2KC1EQRS @/)*0ES4)I
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MPF!W/HM]U$W(H4V3Z%&FZ)<@7=#ODL"HWXXI%[[4,!DDIMRML'C68Q=*'Y)
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MYTV9L#T99B!O6:K4'&^F4C/!1#8"4EX&*[89*LU=> %>Q4?/GV^[,G,7$S,
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M^)S-,#^^IH(#@:?4NN)R#*2=P# ?IYI2:/2+)/FY02\RI7K]]P!QOV9"K6V
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M(="&=$K49YEWCWMCO^<AQ5%51&.$[*T$*\/UBCLJ=7%%FT.5%7,<.-9!J]J
M@0DL=+N*WKH2:@^<SJ?R<6I.?\ )AN'M"?$$]-9TQS=O2P&.-UN0Z,3,'K0X
M>UB".+<O%?1^BPTH60=XH6L46AW\8F%/*\%J0?('!SJ&3E0;J!)<( FI2(U]
M^XWN!>UW\\HX9#?W,T32Y.AY,03A9P'2+%10,_4J\.W/+,PC(F;E1MM)'"Q"
MD2>&?@VK]K60R[I)L4VQSBXSFBP[!Q3XL[\QQ9AC/DH,XCS"?(M+7B &R+,
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MZZ!TR9M!OU-[>Q[>COUUL^B=_=&1SWG!$RO[NZ*UG)#*IN#W-*T&OACE(_Z
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MPYSV6]DTT..MPVCS=%9Z<Z':@/?_N<+.6O+JHO[3S\OO7US];92R.W<'0+&
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M["IT+Z&_A9.P$K>VK:TG,51^)"DQN@[(*[0!2N1$XY(=OJNM#]AF8PKX)'2
MBF#@,(><"?=OZK"_+7@L>NX2_2,@9$8#^,9=>%32$IY.'O_))]P5Y!/.?O[A
M'60^G 6270TT3;PL01)2HG,F+T'\EI&IN .!AE+-6K_ %K#'I1&JI5NT&00Z
MQMP0?882ZSVXO[4C54Y2^;Y2D#'9#R"GCP2HGENPQK H4PBT:]]R!]VC$UA
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M]N^D?K"N\MEY%Z8^VM^Q"957U_BV(8TAC2&-(8TAC2F?;<IGF_+9\D]3/KL
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M@_U]Q(6O=Z U-^O.T?F7Q\UZ*.S0A[ZPS!QNGK@@^SPU)IA>BN7;< &CHK+
M0ER$OOI2MNH.5.DW"Y?-"66%>RVE%OD*.\(2F;*^O%?*V1$ 5+',/%9A/RKU
M2KH$O;S-=<"PV#UT0]JV+4)7#EW*@6PQ6M(+D">^NAQWK]PV2%( :J2#JS;D
MT$$W[(,>CEK"TOK0KJP8+U^&79AM-"YMNQX<\AAP_+I 9/%4X4;@D.-HI^#
MEF*0A?-U&XI!EHWSDGKV&*5ELT2R,^Y[\IIC%,BDUB0SX!,I*Z6ND+(AVL"#
MY'"33-#BOA^R/>8"31E(>76K ]8KDE<9T.D,%<P@M ,?40^[1?[&BNMS%$=)
M#0L(PD6VO)JP1D>X+UQM\=()T%)_!"+LS][)[^33U:==.:)+YMD_HD\OKS^K
M3^\HWL9PB_IK$$W05(=>?4JO51VZ9JI#;UEUZ.?KL(W;AG.2;XAZ <;W@P4@
M/"(AEX(IRZ53)+0)\V;!&/"W /R-TZ0(G09>."(G4X_])#ML*O ;V*)#NCLO
MM+-J:CYM5M]OZ)*> '07(#3SR WS8TAV"4C$XXCB;ZC_@ZAKN^0M00Q;C<OW
M=K 2K7SC1@I[<I((^^B04%=-/YZ8A)KR187>[Q_JUUXW:COI1E.C&Q&V#:T(
M@%2#6^ZC5=.E+L#(2(I/6'3K4=0@P%HT9&PU=/@K-FYF<F06.6-NND,-SK'8
M-!I(\HXD#EN$S=,=8"?CMS&,!*+:"E=?ZM_AF<Z8321E(F)%5,=W]&T)+H[*
MSGM0PDZ<R#G@7Z#3N0O+%H0*.=XD\X FCIDSYI9ZL'1_\>/"8<F\L_.;!2?E
MR'+PY"./D6\<SGS:^'M@5R?^E\@O ),"GHC1G<.DI'(8'42%OM.25QI;DZDC
M<6(LH^*AQA+(2P;B!X"&F6(7"L!4"6WT2PC/&8#:8U9D%C-O*(FC!%BJ#=!M
M8[RH3#H?<I97(N=J8QER1D ,3:FR4T%:OD$?((80KM^RV"B.U8D5^6@4<-:X
M&/I;90&PK_\):826058S5 $I%X2UZ"=KSOG)*@>'*5_68G]GCNB#]$IUVQX.
M0;S[F>XO$V@O1^*+O@-FM^[_4PA3AJZD/S$SF,-HHGA73>A(2QIW!PIPV8&4
MX6I*Z+.B04KNZW=P.95RFY]LN8X=7E+95\6:*S;_D/6!._/TN!WON,[1R77:
M32$5'9IC6H?*]4^&>N115^D*;$@9:NE'+:V6_)QY6F0'F)K\@'_<R.&8M)!^
M#]0END8&R;N[B@P)+U8.#II9_V:Y7B(?F?)I.,(=[:&0P2DE6A9O#H16I2\$
M%9IT!HDIXY3L@/;=U5Y&] LI)>K+=5.NO2 U0!H-,(@&N,!?<_JV)U7G)7""
M+4FJ%GRFIH67(9P +Z(OQ]6NF@ZZ@T9*U=-%Y0OB819AA.EXYN/6D6U] =X4
M[H*_Y]WX:N9+8VR$:HU]>O&HEGEK,H4BHB@,7BZA0C"+#6$<0"%.?:T%-'<F
MA;.#H3/7![R).T][47+B.&/I*P<9!:),:0*0$QWJT(''07K?YVF]..KMIC1B
M&BPO3,9:+O[QQBV!ZBZC?I5C-/JFQVQ/^OLEE_>A91DK@.V$?=@46,=3 Q]S
M$+-GPAMDS9AKALLLB0'"HRR;=]":P+?@RT'Z82 10TD_]=!_+Y6KEGD492L.
MV@=.5KH5FKFSI"(&EK4#T!XR/@&29&81)L]BRPG!8[+7D5X>%#/,DV$W$,]\
M)(%!"501#DK'4Z(1,"MG[?6R52,%[I+O"!74A9I$7J"B(#BT"YVPOT(U7HHR
M$MW6\'NU;I&6'%:S!L, (]N7EB'L/#Z%EX X7Z;0SY@!+WAI&G5$R2*=\Z,.
M^8Z0!+>80B@7TB#X07IWU'65T.]].\(5C AV<=%1OJQ>B"2(1GP--IS<IUWJ
M!7AK:6IKJ6@.<)[T><FIS%"_R1<LXE,G"KH <)*J#-:HGS:@K(5 D'2D:V,P
M96@IJ(4+C-D+>4P'&R$=.L.[8ET5EU#:V N&PN%".P?E#KO@*1.Z2Z4;?8I"
M3#VD8F!*;P%F"U*-J'FHL;],J!)HL(?SUS@YVB=Y,X_5&LRY70([4D*]L7 Q
MST,JH(\4S'!O$"DP#,1\0N45FX>I( 2"8.:Z_LP!?0I:^ (XI&>/A5 X"0^/
M';75F]!<..G#,_$%.NK!=Z/8EM6DV0@%%X.?:&Q+%=Q<A9:-,Q+O&V4;Q**3
MKT3],5/Q@-6" .?_\^V\37X#4P/4!L<W(E4OC8IR"U99@#A!=G.#3.@AIG!"
MG_E\ CUZ*[)S/H)9BD/"P+T]L\%8[=$A>M> #O_%.YTOX %]2;24RLKVY#;I
M =?I6ZQ44/$V,;&4&1+!"B5['S&8R\@+J9UET9A4X$.1/YUO)@<0!X-D<D-Z
M./OQ /*2&)8-0O?9'@'T'J&ZO68H>"._5QNE>A!CZU0R12T]>PSD/Z'S:)9Z
M$'-=E _F\C=J<2=MWQ>VO)@\:B+J+&.:JCR#=(NI;1OECRSLQ+RMAL[*A:[2
M"Z6G$->I#F",XR%'AO@-V@M',:7QE'V<Z_(%&E+K5VXD5BWN_GR!DF2!H'M"
MA_=CO2YN^8@[<5 ][0A1UKUV3$BWQY #S (M'OL^0$:&TJI*G" EV( 8YE=7
MLL/X\/YZ.X:DDM7SR&6B<9L6!JFTZB8:9Z)Q;[T-48X><[04P')%;U2.5 W(
M%9V..]230NX:[!J@ED6N.MKO"/*QJ?+'T!L]H3]0BJ-@0OD]42EX<C:<>DK>
MR>LMQV 9,A=OK!Q2]%SU9["/ >7#8I,0X*$W$MC00(^N1'J(:&"WH*T8^:\B
MKQ6*UZX_ P">.+&.PQ\+"4:R^D.$_><?T$ _4H1 (=4I9F4Y$AE0HF&$/5/6
M+! ;#=G8XZR<8T.&%VQ*] )/N6PZ]O0P@X5.(WIWY/;-TS/2@7@JFUP:E<14
MJ%0W:J:)5IY_+?+EH;DC?76@ OT5XUZ;>-C@E2-F]YTC>!>)\(LWVVR6T:?'
MEK;YA)LN@Y6Q !=..,2XEL8W^$;OGW55$XMF8HIU<[J/79"+=Z@ $[ZH/:GM
MR!?.*?_\I^YG/E&_<J 21+/K@)Y8$*(Q.>>3XJL$<T>=%0A,'5^D75]S20Q]
MV3S\D=S%_+($CPFQ(_/@UMT1>@>JY<.<_B0AY=>5P]W<\Q(]^5DZ--BR[MVU
M>K'R:7C%?IY/)F#9S7OAKT[^<[XDWSGEU,S)\*8ZJYE.IYZ@8,D"JN#8A8BR
M( >@?D<87H!O!-BZ3$6EX<T !(+4T?(%%KDX&.(*->PH#CX,73N*>%/89"/F
M[DEO+K CN5%71N?LM7E&EN<- OE2BI-O,(=3N(HB$3RJZ_3Z.MA]Z$J/ H'0
MUES46;N;Y6FU)/*0BFCT/1&"8E1Y4SA4'0 /DGATDD4E^X<=9*.!.2.8) 4O
M8YP1Z%)-#ABD,@-R)GX7,=E\CN=\0@'8MURNAR:N5.&Q/SL>%;"!P](T0->_
M#,0D%Z0#4.H.0?Y[T=:2&:?=TQ/85[T)8,C/R Z@@V _P1"[63^ZDM\8Q 0V
ML8-LE.",3M"VZ.CM%S5]IB.ZE8/]AEHN';^5TT>,&N+1#2U<=. ZZSD^=V!0
M@NON*;GE& 1'QZ':*GX0O7=%=00D3DF2'/6142<8E^8V$5!+MB8<3(*'=>R,
MZ12W48OTJ?O#"Z<!2-(I"Y170&8S)8D']9P5S82"CTO?2I<+8/H;P[0V%[N[
M3(/;3.)5'(_'\$$*>9^+NR4)_DA,)4WL.,L?&DKUEC0EXV+[.>./HQ9_85X$
ML!Y5'L% ZX&,KM>I!$S'YF*WXF).]EA2WU9VCG*]2*!P)[,D?-D Y@K <FCH
MO) NT]>A@'<3 YBK![L1*#".$27#NC]Q4NT3Q;./P7LY':T <N+S<-7*(L:Q
MYE&G&N%KP)7T-+.']&(P'$4/TWL?[8!).*"YN"^'0ESEV8#^0AL_-ZUU*4R^
M%C-Y?DZ)>S)U[ 1T7'>O_R-!!Z:_#)P9&7GB#H5O$JJ,$ ?V*=S8*G80.<"*
M#*2B0@CAX'G"*,< U1[S)>C1@D(FO%D+V7B8 90[Y1R4*I=\;AOFHZR<.<_%
M?LI+.[TOG:X?<F<0A17BB.]B;R72UOYFZF#8)W])Z?JWJ"WV]";1&U0Z*W!8
M/X"]= (S!O>[N.I1HB,>VN0#M5T&K!\06P>U96",+2QM).=C@)7=C#0AC=+\
MUASUR_F[?+Z5-$.?3/G?L\D":C[I_N^EW,##$ @M?4LCQ+:PTY*\C,><EU0'
M!AW4O\F!039%O,L0)@9)'IR:4R:89M8]L^Z/7O8,!L$,3V1&5S.UQ("@Z/X4
MW@_2M@&43"2"C,\P+PC3AI5M[L:#"3"F183]@Z'/$8:9PEMSI]5:.ADEMQ65
MVC29,M>78,K*VB+G+NP>764C:YHD^?WQQ#X*7Y$>4Q5[*DV&]$(0LMXL9V(K
MB<RT(2H[.O(P:3.9[2$ 1YA*B+5P8/.HL>Z<>D#.\>\QS(X>DGRFOES_!G:%
MNP?;<<@#O8&CS*EA,K)$U^C]Z0?A8*8S:U1NT(3;GM@3WHBZW)_ AH>.&!AN
MVKRXI;8\^'N(YQ3=5(!:&Q3X5.2@UL8&6'L!5RG2N#0IPVP(F%4^(X^9<[2\
MM:W(P&9+%CY);Z)\XBOS7!Z33X-G?):,5&39AP[886*.4=SOM\P-@96\B9 (
M&PCM*GH1M+%"3PXUSA.3(8,(HLNS^)@& #O0#<:8,,WE-E2MK8HXTJJWC?'?
MORE0$%[<+Q\B4<B4>B!;P(BA8#M8+R'F%G:)6NF_<_8'<\=XJ%^[+_[2R> P
M=$5THDT6<H&G52,GOXRG2*$HHR@BX[ V@>"-B<!56@T3"#:!X'@;2H,H$:81
MKM&' 6V!%15"D N)8!93S! *79TBJ9R\'-U_B;Z9<PJ5+=*^[+6EFM4]#)2U
MT"B706B/!1A%Z":1,OZ2_9110QQ:1L:XL5Q9.FKTR4C51ON>H(-E EKJ>JI&
MG#TB<8FE'W!2E,=N%A>HG!SF0UVF/&?D1&7A7L=J2BDSZ$#58!FHS'/I#R_C
M[R#G X7W8G^Q5LA:M@*31DG*$X!IZ)J&"<*(0+RN72=TOGP[/]X#[*U50@ZM
MYDYQM$NIBAOG"M7RO&.0$5(:4$!S0%I!]1)221)<84$Z\ES&=\QF=SAH6%68
M9G$4R<G;C!--&<HZ-7W./O&D8<DUU$QE&$=F>I[-+36[MFPRKC@, DC''RX$
MM7] (Z$\>I9^$9VCB1T$)H$NCI-8"T#$29*1,.=-E#&K'QQ/[<:.Q7G+7?F,
ML@$G":[?C0-P_I::S?( JB$ML\J4'VAU-Y]J[2XGR/B$:.:\YTL/)/&KK5VZ
M?/YS3XYN29PV<YI'394KP6@+X#8\YZ!/HP&;1;;#@-URY-?$0Q$AV"2Q$22M
M=$!IJ9'C>4].KR7AP3F-HBWVZ+"("Z X\-@41#&8<U82.;+2]4_LY+BC.IFJ
M''DRK).U]Q-W8]HTN!*WHA-"[Q=\(@_J)2'.;YUK%>*<=\T(U\[&-Q,5%'J>
MS)U..VENP@F>)HV*/)UBAJHOC2)V%]=^00WG"X<#@>3C-E(+E.N.#@:_L0R(
MR)1F^B@.;<5N"'TN-D]D+HDO1]3WH[ UF(9H,:K07 Z3]S%_-N6Z27O=OI\>
MDV] ?FAPOD0<N56?QSZC(>P \A)N]]BW-;"R7*CSH^^I:9@O?%:HCA$G]&E6
M5950Z<@5ODPD5X=ZDV)'L4,G#MCA$LTGT5_(@UEQ6KH-("DZ\:O#J <RZ@T_
M#P!2R)#OO;6&\J>*L!"[_QZ=,<\&S/$H()X/V_O.^EA^3/M45]]C]]0^RCJY
M5(JU](RM0//Y#>6'?1@TIQD/Q8)R6CE[Y01SR@5INWRBLO=!2EJ92/G)1?M*
MRB?MAU&!3WET7[VDX6W&S\"UEV_1=QS'[J-$'KF3X!4\4A^%_P,48I&7"KL:
M @+4_:DWI_(T7ES1[I8ZH8+O^"1#IRX\0<2=*W^_C8+"F)QH8<VW'PSS/^67
M<B Z^5'2[0Z^8I&T2=+XJ^5'[(9+X%+OE@("";VE9TRO3JZ_/;F:7U[MK_@L
M.S*]I"%:L)XL_.C=8KT"?P:;6V9R"$]-?]%AW\H6!IO;98_=85^F ;\"WIJ?
M_)?NC=I7#T\U3N8-M.D%%A/# _D@>)AV18,9$I"=DZL;=?@2,X(]4)W1V4H_
M\+.U#50F37IUU4[X7ZSOXV=9X']O>KOI"$%VX\=6188#_' :G;9! QKF J@R
M*A\-U.)>'.)G>64?&IE#.,T%9I\OG"BMT:A^D';^R[X6[+=+ZOO4'@-Q QC8
MLDHV48;&94F:AIGCCPO'%%-VWB+NT\:0)LMB5L4@E)8R=A91)(6QY-Y.X;QH
M7(#^46M 8_F)%'&$(B<7X]V85.FJ_AMA3F4&]'AC*ETMP-?[;*ZEV*[.K_V,
M8##4\2=0^8K-%R5]!CQQ5>;%RO:9]'<9@<3D6-SZ_3EB#X_6)7%,5:XT\M!_
M3#9Y4E9 A=MB)CK23@R%TK"< ![,3^JP1$5?&O."41?W3==I4?5)HA=6IXP\
MM@"2WK=QM6% 8&2ESX)J[]T+'(M=(&"VTO,R.BVBZ/R9ZOH/BQ-.K4Q.'U@>
M!R0YZ04HST$/S!60>/AM^%6&GO1&P#5/=GU;G=RW\EZ.OXO/=LSW;D6^T,[R
M_KM>B(]B9]\6)JQW&AZH21Y+E4H YHLVZV".HV/GI%1NRC$ILV;2I875,=N4
M8G-AB8+D4$J. S+=QPJZJ<]L"HI2'8%^N*K4@KY9\"#&)S$CGXTV-!%:H/,"
M<1F.)>O#5! #2::+=",/IIR0$L+&!YOA%]>G,C%Y>?J@B=.]89RN:>)T)DZW
M,2 Q[WXU]4ERR=I&H,<WXM?8I,FCR[,B K%?;*4HP+WIOBD#\8%A9A!R;G)L
M6]Y3<.[V0\^/LG'3=V]$II5J(@4,4FV<>>%41%"$>2)JSB*]]A$H=-(I?2M)
M\U]5YH_,?G7R0]:RU>2+8L8]D X_8,#VF+JCV#^3C*OV  E6.8B$ASR8CX"L
MG1FC]NY&@Y180D?^?#*@@;SBP\;4)UW<A=NQ5:_]U0=)$8A,?"1OJ$F^FG__
M>,^<F2W\F9L>Y(-GHV(7G#KO QV$+O\KE&_**ST >80C!#C#*!:JR@0"L_UX
M8.29H'*? LP'O1([,Y, ,[.%*R91,>!A^I(85697>24$NB1@)M!/O78XPLAR
M&SZ%5P6NSZ7J'R/.]P2;<\89!9#4)2U1/"K&<7H\UD+66[338S?.'+5C>/>,
ML/#]4>#WX;AH._)X/;D0P2U>3+%YQ:#4R)X;$)YOKL@1X7M(MW!%TYP9C,Z*
M;[W8' 6C,7+-PL<9UZSVR?IQ;:?8.[OHYZXF:<S9DHW0%9J\6"MO+O5YSC.$
M#H'Y::TV)2F JH<W:*JE[AU<F*<.%64]-/MS97EU9&*%_GKQQ5'ZG.,LZC.>
M\$(QK&JJ)N]^_C(FSMA%>W@:==1G+L/,W%14/8HZ=X\NX]/&4BK.WV\U2T7M
M%ZX)FR/9XI)$D<?4AI*9NTL!T'GGR_5)RI.!.^P2!NV@6-)=]:+859)5Y,KB
MDO=M#EE&31]130H;:TH!%5(NZOE7<QS^F8*YJH@PZ,899K2+'ZF,=DM[\M51
MR_@0IGKCZ]6?Y%C<N>HBI&ARD><AW4@2$F@G#:4KF46UQ.)ZAJDC!&<>'82R
MV&E<&J7M:3T:]9;1X?/S?UPDP80'5K+\EMQ;OUFJ-AG>VM1MJLEYE9NK;B/<
M?H^JC3)&,KK[M35N8E_D354?7Y!1<9FR<'F9JLEN82X+B>].BQ(/IJI>K:Q[
M=]WY&&6^Q'5LK=2SD0,3GPT<+)BHOI G2%)'\I/'KF^^IPQ(78$\DI"IYXX<
M:O_ &^-8UG%O@5P$S0R34<E1<V[7(=@OR^ZY2A$FJ[/CU&%;:HADW"(J ;A8
MT@4/?[@S)Z^ @(HD:TVGGXJU71P.;U]<_;F;V,/.3-;ZQ5CWLF2 I&96>ELR
M5UJ)Z"1(+F6LZC($K?SISYTHG:;!D!ZP;JMR<* O>"Q7[R4EIH<0-XQX(75:
M7A41S53EU\N-ZC3IW$IYM+7%FLEWD%;5)<?*7RX/E] =";H\FT*6;[ZA/]B
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M%9-PIUI %Z""C$VXHU)%T15]6_&@/-FM%:<YCML"-]RDR9T ,PSA,HK[&$6
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M@4._WQWZ91_Z*?1HW:'O#OT:'/HWW:%_HD/?0K?XP"/?\+;7=.8[EI>Z#T?
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MT(8#]TB6>]O-]GC3,HN,X$5?J^=QM>C-*/>H:O+]*IKFGY45;+KS*"<('QB
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M[OL%+MZ&@9#VK*7WC&NS?CE7[!4P ?IJ4&@WEWN?\'4;QF*MD&%'B+#XN[L
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MQ@1YD?W/)KA0(LMI4TPGS&8YR,N>[NH(JYE5&NG$_%R&E,T48*R#3'D_(::
M4I-3E(S22&OY,O+K>YI5*QN;9PL5Q7)"V7%P#WO,.\T0)S2KYO^ P8?J9RA.
M9IM/9\D>0W.V)@E,OA'$_00+)HU8U#\(N9REW%D"Q3%3E(:LI!94&M2/@G"<
M.8F$_9R,T$1"L[J^,B0X9S@*U$3@OAZ?EK<_YYC:XTB)"US%4!E(.9V/CH?=
M '4@KG[L7:.V'(CVO!:2]>LDB2U@PPQ<%??$!X-DPL!(&!R'LV*JJB8\UMR.
M53:Z9&TJKAS3X6)C;TW<>9R4YY$CZACU+A=H8V9GD%M1D RG= .1Q==$(6S?
M%TU*(1;UN0/Q7=V*LULYMY7N'5/Y[.:ED/$K8J24QWH7X(63F:P#PIFG5!^$
M1R.];^3B>FNE\3:)$"]&>[;(OPW;A9T$/^\R931YNM!9@*_?_47O+9W(W'@'
MY G6? >9WB?6=9[?V5KD@3<,LSX\2*X(0S\K)=_Q??7DC8*!#_]GQTDI$KH^
MF=,\Y-\(7)*&E K)F?GKNFV:MLI8P2[Y=4:4X>T/>.2=-RPARO"__]?_X3K5
MOHJB"89_XIO_^&GG)_I;7DQ_2Q=Z23I0*37@"9(,.<D_>"4O^@](?VYA"T/H
MP22#C_6_S%>E\?[$8S#.?,?U'Q)'R:^PVY-PH!\<5+S@![\X$Y,/FA_:AR'!
MD<$\KDC[RF&>/WQPG.?D.Y<0_-LI[]IM>=>47LS9=&L8@-WZ*R[P\W"3;>GP
MB9S')],)4 +)!70W HT8E?14@SY0_1+<;<9/;I5P<;Z34!;\\;J$-(H?JFEM
M#QEE[D,UM(7K"_^?TO]CJ^65ZT<@44'#RD<?QL%W/:,B#3JQTHF53JRLCUCQ
MOL4(2>I"14C]" H6]JEA>C%1,)!J-D[8)(Y!@;HE@8-16F_CX)?-1C >RD?M
M)$@G03H)LE0)@D<Y'(_5 ".P'C?O(%^*N<86<JIN$K*0Z>AGVF%$NCX]V1^%
M$<)3Y6HB_P0+CISV^)'Y]R0I,BR$"'L19;.O?Y7QF%RB6YCZ$=SYK;Z2]>S\
M,'C&G1\$!58=/]?N]U)WYY0ZC_?9VO<_HWJCQNZ[L&I^W67.9>;+N/I]@3\P
M.H>;&(E8<'' [B<=<MBD'VJS9H32!M-."-VN<,#L6GJ]C#[;\.&2M927S0-H
MM4?TD;5Y8@<J@WN32PG&81R.H45X& ,E(?-?#>&'#!9IZ0TD.B$@+%C&'T2$
M=1;F5"Y-GC@*#!'BALU*HDRB1$?/V.D[24.F;ZBYAV%,6-7A8!B"LD,>XED]
M)+<T]D1]AU-7QQJIPE:[54M4Q<<!)_&4%H,PI^PY](HKFD\I&<3:@5""0%0=
M2?YLXZ_FHH&2N[I#'%O?E.'#+F7XF:8,AX/_^ G.^/Z[_?<'[__?[N%/<V_:
MI\<E.SZYO#XZ_>)]/KH^N3P].F/PAJ,OGY:OTWPY_[*%;Y<5._UR?/[YQ+L^
M^F_O^/S+U>FGD\NCZU/X5\NF>G?09AQ66OI@?W2X#9OXI_][V% W^(HNX^M2
M6)2"?WBY%5)8;8&'3*2J#<$# [O(%A/WE2FK)72M3(J&2<^BJ"'G6< =Q5\9
M1&+ZW2QN"JS&LCV$OS39J@.M-*V/ALM=T$_*>J#I^E3  W2(45IV'-)=KYD.
M^.>D?TXG=@LS@]]$LT&JZ\QFF;]5D*HI:JF3]_&G:*)+G>D5)]4(QOG>WJX9
M53)0]4F$5Q5C#1##B,R9X>C,F'JTY/:3LL&93!#D+W#GW))_8$*0QC+B1#[G
M*:UG,?)!*FE[E2TS>Y4DQJPWQ "=6%.S3%[Z60\Q(#^FA.509^T4F)4Q!7&(
MMIU,M\XYIPT,>C'5JQ;&242OM\G1G*69X,+IO4YZ\ 3)4P3V#!84740&YSQ/
MDX"!)1ABHO'$!V8421PQ9M8@$31U#2+H\"+7Q9/1PGNH+$?J5@[F?5(P]0AB
MB,&/[[$ @1,4"M@Z7C],^\48"T_Z*G-+!1#& EMW9!')OPB&B_DL,!XR8HHQ
M=H:U]\]J -=5RMUS@*)BA9 8AN5$5L.4.M!<"F96PX@PP'>/Z!<XEDJZ.G$M
M(T14$9G33H\[HC._GT@2F&4?FC;.7^<R'#IG^]HXVW=WYO&V[W7>]F<6KQO"
MW1?W.9?(T(=DC(VCOP$-Y39$<4$U"Z'J O:=!.@DP$N1 +TT^0;/H\]3=;DX
MW='NCO:+.=HW6*\1"SL6X@=CN3Q1G=!MGQ)Q5B 5' *NUPF 3@!T N"%" "!
M+:"R-^,:P *%(.[4^.ZH=T?])1UUL-2Y[-<]['#)9WEWTKN3WIWTEW+2U?=)
MD*><@(1^.NB.2KTHB6^V"'@R5;@YA!$7G?\(K@0J $%1=Z*@$P6=*'@IHD#2
M[24H1_1MC A/9.!IH1&6L0*GE)T*CU#>ZD;OGIFNX8/;("H4Y:QB_%+7UG32
MHI,6G;1XB=)"* SQL$]-B'%SD)!I\#OR@3#"H$ZK%ZS01!/;-1 O5!X-8Y1#
M))*B@ ..E*YSAV\.LA*66">$.B'4":$7(H0LME3GA^S.=W>^5W:^):"/-RN1
M*Z:E-,O@&508(D8R#'V+L9)+QV>L\E%"97M!OX_ 3YAF6*5#F:79:+G329Q.
MXG02Y]EJ%-JLP;( !IF<8= $#%7*=<H"FX:,;8-!I'P-4^9Z4*BBP/=&:G #
M_X%O$ 93* 2YR  SU&]2BK3"9UD(XPY2MU2RTW$ZB=-)G!<B<:CN13-9(O67
M)OKJJ2BYV\1"KPQQ>N.^\#_P;NY;*NR1<HN+.N'0"8=..+P0X>!0V&=(TFNJ
M)B@%TV5%Z*.2PF2^@45/I]\9Q6("CVSEHS0I;D;V35CIV%9\-RG2"8@?8<7&
M6LK&:E4J-W7;[(10)X0Z(;1*(;0<NBTX:^J[&D\T76RU**L[N=W)[4[NLU4?
MA)L(F:$09 >F 382W.B"/B%T;=U-W9WW[KR_A/.."CZZ&/5A;RK4J&*/=,"!
MBU"2#84N1.,(;5A@BD!X^.XKMIF7P\',V2XK_[AFF!7Z#?/99.BDSF:ZJ'T#
M0$(=81(59QR^P>%-2^1T#C)E&-=,/(:V$;JG"&$.)RH6*!?"S<F#O#!9PW,W
M):B"Z"DW7%#."PQVD\8*&2B'IT]P@H)\L39A%]RJ:-L[M8@EBTQ.4MT3<\<.
M=&M%>B/@4<A,%.4,^H(K%@QNPXP8;S0O8B.8S,)85[.Z-@6@2 MTE.@EX3<7
M,N.><]OQ9UL.AM^.[^'_-JN/Z#;Q=):_H4[]ZF5)1+>=V]%.4?AQ16$!%6!E
MN'@O4D'X<OWIUQ5@&":QBV&(<L+BQ K8G :8)?RS*.D33FP!PB1:&9BP,W$=
M?.O3P+>^[^!;GRE\ZPKTZO;]V8!T9X@U-7BCX*0/$$T.,QTX\3I-8I B?<U_
M_#?HQ*0C#50_9!I._!7B0$7(K3Q&)T1ZKR&W4:$=>->PHT!2(90UE9KSS\K0
M?PPLH>'^JF3HA/?G0/HALF0)T@]&$PK2.S^<<2;ZO27[0[Y TJQRC:'7@CG(
M8'>$$=BLEFD@P 'U.HSK2((&,Q!TBQ3I)[$G 2>=85P%J^Q\D=*K /*/:Q>&
M,%\*A6+)!H%O4=>TH/C6*('/-\A"@-6Z"8?,D2T%Q/3U9B/1]<LV%O^E&.P=
MUS?#F%ON"U D?:2^Z]S"3*EO/F[4(C+0\2:J?QH3@&/D78*5$A=(T4P(:MX&
M/B(91Z>75Y)KM(E+(%MZ#IS<QCVJ/'@?[6X8$]$-6])U9_/R#WQ#V5RRQ32V
M93$9J4BP5D'/2/-M[S-<& @FXS-,C->'K=3#:2(46,[GIK*289$COGVD;L(L
MDHWIB :_*H1X_C*N68.F'.%#UBH?-,RWPCHVY^0&?=#6@[[AH*&-RW%50K8M
M'=IM[Z^Y[;9J%JG#?Z=-L>H18\!31@(M(7^"]5;(), 2WX$%0AX%9-BK"AY-
M0E#$ Z491>\R3110E2K:6_1W 3\#L9W3(*=C:BZ!!WF!\SH5(_SZC],K[]/I
MU?'7JZO3\R\>_'7^Y>PO[\B[^OKY\]'E7][Y;YX&$J?9_NT$T;S/VC&^O:.K
MJ_/CTZ/KDT_>OTZO__"N_SCQCH[_Z^OIU2D^X'OG__IR<GGUQ^D%@9%#ZQ?G
M_!4V=O[UTCL^@W= '\XO/YU^P4Y<_7%T>0*-GQP=_^%=7)Y?79P<7Y_^>0*]
M^//DZOK\$OXQ[9<XKJ^7OT./KL^INU_/KKW3ZROL"@WAZ-.?IU?P&NHP_ #?
MC\]BWR^.+J]/C[^>'5V:T9[\U]>3+\?P7GCDZBOTR?0#1K"T\?HXR6=?X;/?
M^:47%V>GQT<?3\].K_^B=YW\]AMV%%YS].6O\OJL!..=%UT(?KRK:UADWSL[
M/SXZ\Q\%6![G_^SH7U?/F6E<O"Z/1 -<RI!S)^U10+3;R<2?%$-;RB'I,E'Z
MOG!!ETTVLC-]VSHA^<AS/F4\ZR:_YDP/)J+0$U ZW-:H5\_CM^[@FI^9$["+
M%K[,:"%9<-!T."C@I K#*FCI80XOI7H$C?[2@;]TLJ"3!2]:%KB)091IS'X>
MB4>C8PBW/=._V"<W04K<!#$TC*B0*#+J)F=-</C6"M5 L9ZPK7PBUA=V?ATG
M43'NA4$G9SHYT\F9ER)G8N,6'BEM'1C7>YAIHA?<^R!0;M(DR_1C\Q@7DBD1
MH2]="%,SL&+ZJB-V[P1))TA>D"!A-%H?71X;X29/K8087$JZDN9!!@Z>ACRQ
MT%.3-"0BKZR88&2%:[%O18EQ(PR6\XV:IKA'$BN#?U=N2E>2NR6=H8VB;G)L
M*"CR49(*1:ZD:Q-O&$8A\X!Y?&T8H]0^M+L1ZJ&'.7'O!HB\%PX\%8F#")ID
M&C/1S$R,]=*)L7)B2"E/L6DP*TX=7;?  H9YLE%21(-R@ <!$)T@#VZII.!
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MG,JPH8;PH1N8W*B,42>9%96.=;0AG1#KA-C+$6*8J .;67R7*!]*"3LZ1HB
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M/?<^<F(@/D= 5@11U80)&4-%OB\$XY!9/F5?#THBIGA<I>*;5H637M_D* Q
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M7$UT%Z$B(F+9//%;6:&9+DN.V547)<2S"QL9#$ @D-Z+'V;Y#:0"HY8#W[S
M/\8C?(!?R&WG&$K(EUPRL\(-Y0?(.":.UA ]L+@R1;,MDOY?RO0+8$E.%I<(
M01/3,ZCJ&]]J'9SH<&M#PZWY&52M SV#:BJZ?[WZO?/5^-9Y>+BZNW_GPZ<L
MC]R&'R^L-WCN)^/KUUO0^D )!.8/$H2B<\C0GP&3@*.GR7D3I0,*!.6"+^/B
MHS)&2O<.L>4U[Z;$UY4.N9]LQ&A!LG5!<JH%R6X(DD,M2*:B^]7_O;VZ>WCG
M(@0]^EE>1NJN(.Y]?W&/#@?X[9+9U$2/,\CVH6FT#EJ'Q.W38 ,?9DN!H6O6
M#Q,0&/SRUK&X_*/KVXSB1Y_2@%C%D[E'C=?55KLUK,2AAGX@B+Y9H9T,40":
MZN _->+%G:!RMA-:; ,W'%)*>N:/Y@$PLJ5P[@*W?\AW.QHQBV+OS(O8"WYL
M<-N(.V%Y_^-LU2$#:P^[J9,0)@^.>.0CV&>^M,& B)^"4(AFN@H7A6MBKP#2
M.)*]V<62Z56X;?CCW3H$'[B-BA-W'++JJS X\Q2 8F3%*;89.12&7P[,%)EI
MOJ/0D^*70 QF%H%1@>7<L3#V-!5+).+>YI6CG/_A/O4.EN+T58@>Y_^TAJ//
MQK\  1[7AM[&1^Z;!*"BRR'BP5Y,&+?B !0_;)+]&%JC)YE8SF,;BI< @!M:
MZ%B,DCZ< 2P #L,)DGZ,E2")</9P#PEF@1R>?H:WD(_\C4?F<<T)]W :CX%X
M@<U"/U\S CNX"6)FM!1GQ61$^-0PVM5Z\-;UX#.M!^^&'MS2>O!T+\(?5W=7
MQK]ZWXV+SHUQW;VY-+[UX)/NS77O[ENG1C.^92!PX'KHUZ\,M?G&=0",>.59
M=?=[AZ;8?1;R9:]/( _CR*P,]"*9')ZWVR2+14JR63IV>G9/"^;BY-5B)X ;
M, 5,"'$*% H]QO4'& H3LWY4U;HJ7KF/(#0&2<@3&Y3[1SPL0<D6&"'E^0^)
M.F3#--Z"!$L'$@^+#08LS:2M.#'Y" G+]YFFF*7[O7 <![CXB>69F%47PM.\
M-QX/$].QN4X"T 8L>'U355\E)44YN33M\?[J8M_H ;SA%WP1]>)!)6@LQ4PH
ME93D_\+Z$1 10,TE!%-2;>$Q7F"3!H8I/B\O^X ,^X_!\[X!-$LU!_(NY4'B
M4EC]3U+2]^U@B'C-+4/$!W$E 82RX](%XE1Y1@+(!E)YQ,KBE<(*M>: _YO&
M^S'7&'/5>&*D-8@YM;\1Z!A6%X2!CZ7D<"5G40AQJF\&0O+=Z(F23\SL#!X*
MM"E(%]-]?)-WG;/BM #4Q@0ARJ,B")DJB# ]"XF?\@=P8+G(L,3/@.*#$+;/
MD]Q]OH)9:W!5Q%Y>'3U<ASZJ%>:M*\SG6F&>K##+%_F)YWW.23+>9Z/.^C2L
M7^C31\W3IPL&03O=P-Q)0708H!U?_5_CH6=<]&[N>U^[EYV'JTM4FCLW%]W.
MUTJEN1+;6LOSU-:*6-:\[6KX(GF[&HY'M6]@HSQ/^;K81>:\_3<Z\*HN,ZV2
M+C/\J/*W3?F=MRH97]\L4H'$U,SM>"H6:XA#SO!L_W@4S],L9[8'C3\.3@W.
MR?_[AXRA5#U:'"O_<T]AZ0>F@?]]*EXB44U!%_&-2 LD=V&NQT_*25426SIK
M<")SNNW\?I6WJE<$[.5QBU/:PLC%^RU5FVY[)/?7+"OR(HW>.&,+I3JZ:#HB
M*'"A^KJO4U_W?6;-8 3C/J!/+ZP19JP:]\ES".^SC#]@2V3J78 YL&]TN]TR
MM\[,>%A-W5/P=R' <7:]>V_1A*H2:GL.0MT,Z65J_ #MZ&>A2!Y^^,<=#PF!
MSMY5(G)W643NECM/.ED$Z-H-AYEBOSF**_-^+B#ERQZCBE&R*0I'M1+'Z_7]
M7FMN,3E]TYKV&DE[K0__^&)Y%*"]?V(,?7@3LE0TO2U$;VU-;YK>.+VU/_SC
M/I=6TQLQ'L)1:LU7E/XE[M%TNRC='FFZU70KO+4*W9)KF0J-*2OI@0TQ(!2^
M&5?_3C"#"<-%MPRVX>/%EVS@VFX\&W5G)#M'AJ>F[H6H^UA3MZ9N3MW'1:E\
M845/QK47O&BI7#NZ/=%TJ^F6T^W)AW]@ C,UC2ASX6H*6XC"3C=(80(K*.B2
M?U>:?K!_BC&953FATW#9T8>UO4FSDUV*&'WW+1TSTC&C]T"JC9'\IQ_^ <3H
M\):?10]V3"6,3SDKN65\3.GX$YGHVIA>94CI0&OEFC8Y;9ZIM#G5VPV&,F/&
M$-;R%(EBT#+J74%]]/AC#U6FH"E_,<H_U)2O*9]3_GDUY2_N,-<,HN$,0J>;
M: 8A4[T.)G"(<9^[)OV&D[[.?-&D+TG_4''69SR@U(NF*6]IRMMD[HKVX>\\
MFVFZ#W^^JH]\KRO0+NZ3/AR@:X4NB[33?NMOT;393!6@557I0>09A#I@OV""
M^;G6LS61"2)K?_C'1/F5EX'CL;/2N-B!#IFM/+M<A\PTT4JB/9J+:"N#:M1O
M/AB.0O8$YC4.+_D:1)D_C?=?S7=<U62^9C+7\3%-YI+,CY<@<R6"]HW(,Q+-
M?V4835/Y%JE<![DTE4LJ/UF,RBN"8)J<MT#..G"ER5F2\ZE*SF.TK,:T)KN6
M-2TN1HLZE*7=Y3J4M7 YB@YFU?LMFCJ;J1:<+>EGK\IDTXK\"I6'8UTMKBE6
M4NSY1ISL<R2MZC33U1#Y)@O6-9'7FLA;!YMPL6L:WSB-GVD:US2>CF1>I8-=
M$_/&B5GGJVEBSN9*ZKJ0S35/6U_2&?S$B3=Y,K ]9H6_P:.>/@^M5XF+!^1?
MU^/'YMG39H@44.10SQ]K\,#>PF2%F?%V]?*H(>&4NZO;WMV#T;LV<![9[17\
MN'DP[JY^[]X_7-U=71JWW[]\[5X8G8N+WO>;A^[-[\9U]^[;M#&^2S"%^@U4
M?> 33.]QDNX3'!X8QJ0.?PFLT*%Q 6[(;"S@P#_6 9/:,<K9F[S-"(_%"3 W
M2[2!%-@;N3Y.; WX$.52S6^#0[-/ZH9J<E2W#/LBD"S;#H8CRW_#43A]$5N*
M,+:$%#@'<G[$IZ&7JW7P^8(_DOXZ_/QIXB@04\R@]LC$CG)NM"#UE9LX4EBZ
MU.*T[PO+^KZ,TKXOCNC[0J.&T4H?K*7_LE@]OD7=@4\FR$<<@0B<S'UFWAL?
MMQW2H&&$A0*I08JCV<XEV "N/HT3#CA><TB5W6&,0A;AU@>6&WIOIB$FC0_A
M@A O%2/-H^(C1D%$TZWE3')Q<%,.+-MRE'C\I%S\)Q_9P(_6#WZ7!C3CM&9$
M!)JF;66SG48A/,H=>7 BC\R'Y>$8:)S9/(JS8>O??3?U[M!F.D-8HVU-&\"L
M&>[5*_SM6R"OWXQ;*[0>P:1[(D]WZ_/O 1X *+8V"_UWS78?BFRVE(2),_<9
M\Y&81Q9R"RN*DB'>0!/'5?I\<8&Z<3"YZR<,J=4R'@G>-H?WOM&)#%B(G=!P
M<D!T](P8AW*$?-D*3/4-(EP1&?TD@EU$P&+@I'%X>59K*\0L;@Q (KB(E=T!
M7_3A/7QTNV 9Q<<3@\ O7X+P)VU B)I)'(AFN^,0]2@9(*O'Q<#&Q$(8<1Y<
M+LYLQ]GPS\#C6$23W2-<K^^XG$V%E@L?1$D?H "PA-<Z0=('R=$/DKATO5;?
M]9#1T.LF@/\;D,4CP36]%5<4<0X5LD?4=_EAP J 3\>D"L.^+"\* ,B1';I]
M]>CX8/I2U'$".5+>2QQX C)PYZ\DBOG7?%X]<@_!L3GSQ>W!-@%JC+-_.-P$
MEX_3[N,WS?VFT?47*W*Y7).*YSOG<E$%?B):"WUA!&3G"AK*ZQPIG0Q3TMDW
M>J#]%.YRR;_+7E'E045#:D>2'14?5[JBOH5L,>#J%:G#^P9HQT1_QHB/B%34
MB($;#I%HY1!)(F)\F9@F*=FR,E6R]PP$333';=N/.2WC4TY=OKWH]+YDRC)P
M0UQ(B,JM4!K[P-24+@>"B9!.)UFZ7 .J?K",T"%-/EWI]_W[?6/ '-2!C(C9
M24A,T?"LERCESM9H!-LAIU28H-*$7\"^$T_H=>+([K/[\8JK5ZZ<XQJ&;A2I
M#)_V-H&7K)(FZN?O^).+F\3&HT]QK>J,4 HY@"PIG 7P'IZ"2/U68 9G["^,
MBV9A Z$FS,^2W@3($?21H<--5A3X=+:H5X3T:B[H7IX8W!%6FQ>(C@.,;<*Z
M4IL"3UI>8J;/<$ @(GV&(?!%^&\0PD*X[$HQ-")QI>(W*C\F!I9@._ NV!/S
M'X$+T)=B5VAWB%T)@\-%]Z-O<4TH##PC *)3=A!2BQ X*%*'0*>B.]-C,/$]
M14H3T()7)3ZZIQ#H2,_XREE?!RI03%M,;9XD'.$1PD,$X\*KQGD7&PRXS4CZ
M4P5_G&?7A&3P*]J$"%3!-?T E![[2;[^W9)G3Z%(TIU2$N+&8V S)PEY1!&(
M!D%'<LR-?D:5M"#/K5S'GD@GIDK%Q24@L7-9*#1'Q"A:RKYQCZ>I7)QNA[T"
M('UXE(DX9AD@>V*4?BXLA3V[<*XV$^HH-S2 (H8HPSAG1Q/""R+QS,IM<4'-
M(4GZ:_;^9\M+K#A]=JEIGJ PQM>!P/1=T.A!&3=@H>Z0+/*A!4IM_TU1#$S4
MN5^81V9"X15(#>C[$"X12W5OE*_]3[2[/)<]"XZ:\6F *,((]7N%??93O4]Q
MSLRJ+C>=9'Z-?J6DEF1H?/UZ^TXVO;T-2Y=MQ,)G\@B46Z6\ZQ70#Y(S9?DK
M*YL[OV(NXVN_-,B[JYB 3_Q7$/XTC9M_O8_XE)+!UFJ+#+;)&]=I%UM-NR@>
MCTZ[**1=R!?YB>=]SBFXO)JN,5D9K6UF991!;G-29UO!^MY%M_/5N.C<=A_@
MW_OO_[R[>GCH&'_TOEYV;WZ_-RYZ=[?CP?K%V9$^M]6X:CM?.S<75\;]'U=7
M#_IHZG0TEU<75]^^7-T50CR-.J.)BE!.B=WN^:L+6EZQ$MO&W%^2F#88Y"/+
M04?"WS\<?*"_Q>/I[YS:0:\1(J\?A X+^2=V$H:P?5(7/ALY?6*)D^5OV,.D
M#&L4P<?RM_2K'!S*#J*RQX?RM5,4_*=_*^\!(+YOP:XJ<\N5VZ;\OL:"!:-O
MV3\?PR#QG3U%A6L=' &=ML_@Q_'QIR:6-<S8O&,G66[G_O[JX;Z:P\Y1 +$,
MK/+%$\Y<Q03S5TLL>\>6JX+&'O=.Z6DS%'+!I9#1B2(6+]O;1M.(%D1-JJ_#
MRM9Z5,3]LHYB./?U-S_PKT/,# M\P[>&\-0DVGNTK-%ON/</%%F%.^_0973;
MB7K^8>M'^_ '&B8_>$JTR(B6"=$R'YK2H;NNRXO^'>9^98^6=^7';OS6>76C
M#T;BN_RYF _RX_O]Y0?#8;8+!QYQ)1FVQN@WC %:\=\_N*_Q;WXRW'.">$]<
M^N$?1T<'YM'9V7_]FM^-+H1]3X1ZBXFB+@9Y1UCK&M6#:-=7QCJ1<GL85A<0
MN>( $5*\"?1\#'+L\.Q\._0L>U6.V[%KZ%6WJ(8Q_WV5P8Y*>A>^ !YF&+T:
MU/J!](P#T\#_/JU#QRT+6;V[;6H]<H/=2#=5[(F)_-6FU+L341P$#9)*YT='
MYLGIJ=8RZTG&.>)4;SD\/)[#7VZ*+R,6N@.YE;D38P)_3_CN>0&3B[4K(L^X
MF(KP/LA^% 8_?Q,::5>" N#4( ;0.CHUCP\.&LL M+3?9)[83\8#@4IYR!/S
MJ(;M(4RB6-;':"4@^@/@TO4)*L 1[ 9QA.,#\^#@S&SC8'!MK&IC51NKV]-?
MR\':)-E4Q_#X0P]S^ZJ"Y!L06)M,0?@EO\-9ESBMS>":\R9FD+#-$*:'9NO@
M %3LPQ)ANLBY5 C6S1U-69J8%N=SRKDVR#GL1(%UV+LLSVNS3VV/OG.9_[7;
M^=+]VGWH7MV;QL/5M]O>7>?N7\;5__N]^_ OHW-S:=Q>W7WKW&!+Q\NKZ^Y%
M]Z%Q$Z_>P[NT,[G>7B(9#?)<WDG)W7S60@.Q>D<H:&>E7_U2@X2G%;N>O*%/
MMAXNU\WG\TDXW'(P='P'/@D3YGS-&%"#XC''YL$&HS&%9XK:'D YU\_^WS]H
MN?[GSX47EA!I6O>3W7EP<#B*X9?6"=;'EA%0GHXOX.']T$T#EI8?[>6BEN-)
M\A.#IAN-D K$D]EZTRA20CL'; !3 ="3++%Q6#<.R#E\'85L;[&!%65I]!KP
M&P/\ED"NEH=R<=&T4YC;5U>=B"#8CTB-;9+0.S3/3H[,T_.3B3Y23<K;(N5M
M5\;-:E5HBV&B>N(\8WY2Q)L#RV[VV#3Q;4'C8=:#6:&),=\K-_*R^6V6RX0]
M!'?\ &X!_LTR40X/UF&C+'*P-0@Y52W[^)A6O#@^SO7<=3U]-Y(Y-#!*@+$
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MIGA:^<+W3TY+UBX^_JSF5!B45)$_DO'SLHRG$)6\_X@#^X.\S$\\[W,)]WQ
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MP5SA:P\K\.6[;-@?7$J5$OC0%SXH3H(G,VR)SPI86223Q5!#;$5#_)._#H=
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MY^S((<$F7RF<%<V806N,ADG"8SB[(@6 9B(+KCJV-*4V)$?Q*<N+D.>E+*C
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MVG0OZTJF-CS#6;1BW?"5%>6WAA,A!P/L/_K,Q#@8U(B--W@J3BP"[/%)O-$
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M+^S(:)M@N.80'RNW;#P!T9Z5QM3<P;T4N9AO2=?B%A0OJAJCW@[*A8FB-"S
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M&P[!'/=%!LM\\AF&-14K;K9RLD:F"Q[7(HI40U<;I-L@A$+'H0+"J-<Q%:K
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MJS^$K_A>^#0JE.6P>5/^H%!G;,YV]YB#('^_,A?G= %[)A64Q #&?EJ52?X
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M94):IY=%Q+,<E6HY9GZR3$,?O]LZ?N] @NT@0$1O1%<1$]Q*?@P7:/@7@_#
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M@:.3GWQL@5/9I'&,LPB;%_#/Z>GAHH,:XX!+1?LHL;EAAS 5[L,G[DVXCX<
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MZ;A Q93OCN("5VS(?)P^3Z/27[$_W'TRAHR5*PVXB\B@),V#0IE+[QG'R.-
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M4J7KG?:AZ;H[9KXY(:@E=R!RU)ABM[P (VEO3/RLM3[I;UN'58B(TOXQQ@1
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MWRDRCK^+V_,TH.H1T6.$1<=C0OP3*_1]D KR73X;">?F3;SZ20DZP4T=<QS
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M)K[]&%(M==^[,[$,NNPB_-"[4N7W> GI1=&]J#4;)UI\JRZ^[^K4?=,QN\R
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M<W"&FL\VQ6?O!1"SVG96^?FH D"-E62@=\ Z[X\!-AC'*1*AR5GA1L(VLYW
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M[TM9A!4\\2O1LW%;I#QOI6Z-E??WC29*L<<N5FH)6+5,);S[ 0:E(DBIY]4
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M)+@7G*GD?:/P//J>.3#@*N"XV$51K%URA^ 7>P@L(B1#-12S(COK"-R A^N
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M#+F/3O$3 M/F!2[!D?$'E@CS^8NUF9.&'QB86T*L)8M _A-N8<%82Q2O4'Q
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M9OK62.2<1+N]I8:&,09L#V%Q@KC1S#-S8&-' <,0@>URJ(@L0)* MY1@@>U
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M>^FXKQ6W(L6-U]R 11>UDK;>0E1,Z8@HS?5C22DZ38LYZ8NA%!2M !0^JXI
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MX/F)T<TK5V.YLL8 EI:^"2TWN<55*I%0^[)LFY4O?!(Q!Z?;*E-%AR*=Z6.
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MOC931,Z%"]H"WO..'$17<A/3#0O&P-&OB.?J)86$*4R21/:4+;?SA86,2GO
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MN?<YR58\R76%3]\WR0XZ @N=@06(W2DCA3(Y3N*$C"VM8/*<JV59PMU;P5U
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MYW!"V *J6V$YSQ(OD;+P;,?E.AL:0^>Q'A-$0\5A.6+C5Q^-T$^!D=);*DL
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M^B/XW@\FQGN\=IZ?H(8<89>8/=1J?+I/6_\&3]"WS4\?\^A:XSA @$""+M"
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M>;E?+N]31G2MEQ!%PQ<!G] ',\5OS0OFMQ/CUC.Z\5,<1J2@9(3-/77N!T_
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M9&]B()X /CP HO'1G8Z]<%0G.9LZ9_C-]'T\.$^>,W#Z6)Z1LXF@RWO?=?I
MRT?8 )]=O__K+?X0>L7Q8F%WP3+ IAZ$*TCX_NRTSQH7C8MF[30I<YJT?C>T
MI3'2M3'4XBSMYOILP1EU-\@M\X3_?==2KV,5RWTW.[&(1&S6!4E/9 %0"=_7
MXR(!8M29<;>2C/(3QVA6N\VJML?3JBWUXW .]CH2O@M42!S3)C2KH\A_HJ.,
M3T=Y:DAIGEI%7=?EDT99DJ09LOLC5/F:G,0YM$!+[0GAI7JF?8!ZR52ZPWQ>
MS1VE*2'!2 ,]AI-EH1FTWO#H)7W?2D7JF*'?79C/DP"EAXYR^%V0GPC>Q=;1
M"P9_42R'NNR2D+42C>&OW>Z]MO#>A.U.@>43N W0MCP5*K+&8Y"[%&)]BF%R
M]%0(!SR*>_B=WL4/V+<51T,_<%"*P-2P(X-<%[&7#$\[(6"(GFT%Y":SZ00A
MX:/&V7VX2O089,#"-W^,D=[:.S^2=R2UT_!680.???A/\OY-]^%S2IM'(L7\
M=47E+[6S8:(_3AY.C"\@;*P@?(O60\[MO_HPTBL?"!YX*SC\YNHYEV>7M9Y3
ML-%I'0RY$-4X&G='Y!7(.-CBEO'DR_>)J#W40I2KA%A[!#V3!!JB1\1R$__<
M "0*5OXED1#"E^% ABC@)]V^DO*&L]^@T3C@4MH]&4<XR43[0'-0'E8,ETA'
M"3R.>H,RA4#*J4W$CM#,+$"62H]K4=C7S(E^[JC?CT?H(X5^T0+M.^27FQ-]
M^2XB"XW5:RM %*RPF[;RA1MYSSW\1A(P:2R,X';6-#O-LM#)8V;>ZN@B_[4?
MHA^50'PUW0V-4V$!)V#4$(9 1P[9OWC2I9=+D/8E3<PGXC<189QS)+Y""ZNX
M6_$&NG4Z9O/TK#B2B.R]BBDL<XO@#5-HG9GGIY?%4U .\PGE1(A%<B+0!QZ.
M!57X=B=9WD'U%&-J^B[DSU@2G,:KS-#9)^[4%W4Z:77.&$PG/2U*)YW.0EI1
M,NG[<TFWEUJXF03-3/<@(/I'QZ<P_K/G%^/_,^#3Y9\_%N6/KRR+D_^%72OW
M/:L"F%99XJZ;H>MVQW@=*WGT9_/#PBVO4D%>.AF_)"MW3W:]9=N4T0&:&MI1
M5M ?FGKTA]WC?7@:;Z'  &-[HMV69\T1'?/LZV#+6=TL176!KMW1B20M9_9I
MV"-H,8P"-EC5"^S.Q[\0 (>MW#!V(Q4% $8A3Q'K&YH6(@\\%#.A$,31@QB3
M]O@DLT9H?R*3\[?J/1S*RU!XIN$,#)ATD%467QP7AML?.O 3ALD&3J0T4AQG
MC-HG:H29XS+)JM"4U^(VJ'E;X+8P<8@X,R)B-$3MTD2%/8S[?="9!S%Z'-
M@ 4FU5=?$4=0R .'@K\%@A-UA$H$\(,)NA,"_QFT#1.L4[Q@XX1#"A[@]^/
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M[K6T02MJ=>PX1(LDLJ&HO/0%E8?^4-BQ*^B."C;U-?6<T 9?W8KMM:K4S2%
M)U=EM911F5,M+9:,,ZAGN>1C"X>"7%@SDB]3S!UYT4/8RJV57JX^(O>"'X>(
MW/#Q]_)(D#[QUKN5%&YB!5H* EG2\=(7KCO&T(+W1,%&_%LVS&%(_?BF#J0\
M9&A._D;&6^G<_61(Z7IVD6?!Y3A$8G]2)&<<PM?J4_)3A@ ?_E*&(9S^:N<.
M@#-0'3XPG''1S\TVS* 4S31];>['-;1+N*-O@[PG37<&XOU"8,N29U*V/>D0
MXVK8J"MH9ZHUX %8=>^_/K0^S&M9,@G_J9<F29%CLX^HU=&83_XBP5%)G&3
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MC>6@PJQCU*!D192<$4Y4T/6[WPD:#D%#!EWS$(.H>2KIEGC++,_&1Y__S<P
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MW 8VEE<1Q*%K+X8MZ,T83[-=24D3!CZ\ _A!XL5Z%E/RI.0E!NR=M _8 A.
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MW@ F)Q*U'A)I<?!#G&RB?7[0-2O**X%?^N%+R .ASG:D^_0$!T>70:OQ(6O
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MU,-;.>YGN^"VU^^"VVJ>YU^8Y+?".>>18'VIF[_*6%<Z:.UY_..TL8NNN2S
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MY\B:FXU"4V>5YEQEIBMSW$U*Z]5,P_<G0"QOAF\='Q.F:A9SQU."2"0^WR"
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MANUVH8A4QE^MJK<?Q28512B*4!2A*&(C$_"OB]M8+#*^#JYWQ-.0::(<,;/
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M78_4VY2B5^%^@94[N'\#N@' $8[FE88AF!K:JT=&'I&VT"/DQ\#3 /B#2+L
MM5IJ(2F=!7Z!60/??@X1GV#B^-XH^8C0041O09P(#!E#X^$(P#2)1D.!\8H:
M8C3ZW%I5:\&,UH+=7N5;"UY>;;+$)4T(+Q:W]=MM_/J\K&(9:A_+(/BN%P8\
M,$1CU?\S0#;Z$\% A'G5J$ \PYZ2T5::1?=3T"VQBYI76UF+/\0S]'7R\<?
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M1%9#=I1CTARS0A__@Z/!HFS/.M<^V@[-#$L22S$<,Q3<&X[C"W(7-A@P,Z"
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M/I"L=R#$*6[T+<K[D/?*$8<"AD71?0X2AXC[Q,=L'W;-^1FP$B]\&<:U%L2
MJ0/@8:(#@E1F;P'P8,(C%#>+CR" !%B(*R*HIYQI$T*F*/>( 05O'N)_!*JM
M!X!WT=,1GU<1P1C++:G",5 S*!)3(A[C(05JB<_/C"8-O=F7*/EO$,*9$4;_
M"E7K,^SN?G #R[:#6P BWNQ],7YAT_1KS_<IU N8 _R2>:6/JEA/J&+[5*F:
MC276.P"!AV.4X 2P., 23Z,(L 3HN=3G?29\-NYU1[E4CD>944LXG A@358Y
M>288LI45)[+0<"-"Q=9!0Z( S3[1T%J"!>/%P-Q6Z:F8I65B^](#"/!>5.@G
M[15<4G-*I2]5('VIH]*7MF@-OXPH\K_@RTI!FO>]EYAC56#Z%+:T6N\HSG27
MSPO78E#,UQI@;NIK^[)]U;D""?INCQ10DZNBJ8W]^8%,@L>$4VFMZR(%UBPO
MGX?'!Z/UX1,54">S^]IPR$)_'#*VYFV< F^6M9@*"EX%Q^/-@!"BNLP4"&UY
M#H26E;MPV8L;M6;^WEG94E5+=$]=_KF8H2E (F/K>;1LU=:*X5BC"60> \T/
MIUI^?L%LP=BD(G4(+?>Y0*E*(5*A,!7>.FL81UB<[S^1'_#WSC0V)ZH\V,">
M47WRW35""^_ YI.)"H;:=O#:=;Y=R"RG\/OEJQ8!N8N]Y16/R*VB?MSGG 4\
M2RW.X:BO8'U;;7.N6<91SU7MU=5QK@*9X(&SMY+\);)>LC''N!3+JL5<U5Y=
M'>=2>MLA-.R^,;BH)&3B!XQ >34<<8%2+H];5LQ@^Q$VSYI$@'R:@J$?W!B^
M/P%8+NI UVC+2_A6CC?J5WJOT<K.;]P%G"5PS=KBL8@R%:V&WNG,Q]_GBD>E
M.E:;PS[X;&S8UIY4QWSX0$YG4H)"-M*1.G5)++5S=4C\M.((+(*7=C(2F>K"
M2)5"6SJ[->%O!-Y1,ESJ<B@A<2,!42Z[O=![G8YBN.4@L)!&>HL+K-6 X2I6
MFD?61(#%P<V]NCXK<1HC]8< (NZN"N6F _L7L\XP&Q"WVFLU6Q_F3N)>X5E7
MMKH1(@MQ"!0L$Q>Q5,D&,F+<*N"1WI8YS##PC?NK SA$>,\>VJMOQ#L/8YLE
M<)E# =61;%.9WSOJC)W*Z8RB0K;2&:=-Q8M7%^=+8W;TUL65LKZ+QETA&N*E
MWKJ<K_>C#.\CBC:Z1?M/,D]=<],UC(^.@S[XF+L?3+!>7=!W+;S5I9Y&7UE9
M#+79U)N-MF*H):.R"/X*J&S7^$K^8%79ZG'A;U';LI"SHV?&="%!$+D??.=,
M:$;W41-!.,JW5%.%?68&+RM*JJEW+Q53WAM*"^'.8+@HY?>HV6Y43Q<X+WS
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M;&,8#!N-<7!YEL^UCZ&/=C8F:NK1@BBFX/(#)P31ZD0\B(5"?THT)T@!-M=
MS2:LX*]#H!.\J>'YQS)*PHKG/_O[OV)2EKR42#(FO-5;T 7)[GD?WQ^C?9QG
MR(1<YDQ.)N>8Y?N+^?V4$!WCC2-K^,C@$SIEYNBMV1/T=J[=N5H_? EY0'I)
MBMD\T.2>_P)4_-_9^<>RCN?0'L_.C'CRV4OH"$4%5W*'1<!=2Q=L/<W0GAGL
M@()=M;>AY\#Y\MXP'(Q'1L $1TBM:SDIS&(N1IMV"\-3;7)8++TN-T<+12@)
M4 @8=70)$I)*GMC@.(2#SQF7G)>S3%^63L\"ZD>+%H/KI+9I8MFZV I/GUS8
MZ6#9BL72<*KI(FQ7,#K<T!B$ 6KIT2P(LF!H!'/P)'""V,B&/["P\RQ?09YJ
MT!(M<KK26/0MDGD%'LB__TM" #!DL5?F>&,"V3?F M3[UBO6N@4+BX%4!E42
M9@.V!6LPA]K0X()V//19())@#" 6/+__A</I:_8(:_8Q0"\.!AJ0$+RPHS%@
MD@PS.CCFT/=<4.1^"GC <D6(I ]+@G7C!X8'%,0RHRE=Q@3M AZ=";?%X20:
MT@(4U+!=-R!J.=<R %T&AP-@R(J%HEPVR-T00^X%D..@ Z"A<("_D2#DS'^U
M36'?%HKU2&8)5-H%")I9"8/R4$[JN7 :3>!('BC(^SR#^^HEP4P#(X6GE&DO
MD$&"XUKL&9EO(F282">2E7;,MV-+#]4RBPTH_O@9Z.WM%$\M@T=\#3@?1UK#
MFF22,&$:#^\T?,W#1][@ .IT[<$]AP&NMEJ$8.,NB#"PBV%>V<I]EKDE-#HI
M5$8DT;DD&OE2K,O;/%H#@@J>\X"YP!J1'>#6>0@$C8M-KA6W-E4M9H E-_D\
MT; V%#X\ * )T3U=>^:JSK52K.DE)#QK@PD5J-724UL$S=L,$6"&( L;&XEK
MS]+^0%TK,GHTX\5G).Y39EQDJF@)^TCK1X].C3KBYX\>R6QIPVJ/X:L/)\30
M_@; I XJ-V!G@(YV=Q?C_/%FJH9JWV/%"W6-F*Z6KR&]X3<;!!:I8 SVG-:Y
M8"XB3?E,0A5$1<O5PM$SZ'6.D5(&$_Z#_'EE!(7OX[.;" R2I'C@AR@=6"1V
MI5#A";D["/$!+3!^P79<P&] RC5M%$Z]FU0L!$&#EN8$8",&2/AQ=@(\9ONP
M:\[/ A#)X<LP<51QP!L'?A-TU@>P 3(1I'P(K(+.,DPX/1$S3I"E?L!'^\6U
M![8)4KLOPNP ;@^>8YO 5Y[@)%T[GOES&]\@O6*[(;/Z8"7C4(_,8:2(_.BT
MNXU>HW=1C .Q=P .Q-9[+8$:;8H;+4+.QB[?:P/TM?O!#)HGXM^=4%T$%A?[
M,6N!1 *VL(O(9I+\JPI^X"<1/6%AV*RU.HX"+4D\M\3+O/BZ(&WSI0V^LWF#
MC^:Q11)J$1FO&885KJD,>^,D\%Y(P1."4$H4*0^GLK7O.(*I1_X5LI>$4Y!'
M(<TBSGEHH([ 0'[$UI=UA-KZ$_E#POBV<1.BG8)P[#-0)^ Y3XACCI[!9SJ>
MTHY.H(I\AX;KHL&8.2XYG6Q7'@;0YX36"MLV7J0V%)T7]*<;UK_!VI(^G.01
M0$,,WA,!5O *AO:2XIM\0>@=: ZX#&Q3CC*?M&UM8*"^D&0M:=4ZWDNF(^=<
M$Z E<K1',#T'K81/BR3+ELY2L8\>$V6)Q'J\(%Z331YL"P05Z;9R(=&88$^#
MIH=1^F; IGZO00C0P9L<.!CN1'BK&/93%;#E3(: P>O&> P2BB(U7D+ .3W%
MP2Q P0B_T[OX <<UPF#H^78@UF),Q>98M+%T8,P74-5\,EW@=T9^<8E1]/K#
M7W1_31RN3X+4T$[^Z/<?3C7RG89N_'Q"+,,[KF7XY*>W2&P36D[ZCS>G!-C,
M9[^/D8;QJ>^G$>2F]^B9KUQ[\!_MY+;_>'T:(3)U1E:<#$3?U)$'&_E^#KKC
M1^#;AL_/9T34K"HY]X4*IZL.O[Q]/.LVLL+IY@,O<@JFVSV6;G^A5>4$J*6F
M-PW'/#F[@/5W7]^T/VOPZ>JWTZSXV=RBV,2_<&JE-2:X$H:5+;#(EIAM_3$F
MH\2/_FB^6V!QT'WZ'QX0+:S(9+Y;B(U11;5_>:SQT4<U$4UHDBBJ80WM3[=-
M1[SOKMP:VHLG1R+PDHX;*9%TX$9CAQ0;H9\!Z_QOK#O*VAFHJ'#XD@]DK ;\
ME'0T2[U'JJV@G?B<.$_DT#Q/A3V!PAA=-:-_3]X8P>-H*D8^85#<(I8C;H13
MNP#UD-[("'Y+^QV'AIC%-,-1*!I$H\/5M.EV<D4,RC<F:F!\,GRL \_[TU$^
MBD%VJ2O9B,-&\!/(J_]]=[:JOF2KIU]==1<$D#RE]ATIM'2+[W&\3![XWBAI
MJZ/6S0P@ ]2X80FD0M,M .J_D440CXD*/T:<)%$C/ELA&#8\X9C"KCHX !DQ
MG"&6].15F[B+,('J,0<(B#BT)HDJ5((Z\19$F-#"C1WE].+Z*.61-B#5=F$J
M6V 6@RWE"ST_>D'<G<3&!AD':(9$5RZP$[*^!&3@4P2OR"KQ<!.,Y*GP[0K
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M6N(TDIYA"!WIAK+_X$0!GW&KS[FJLH9=Y"'AA-$T".LK0E_,>N2^$X3"XOZ
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M$@VS<B2)VY?&Z15IK?LAA_<H>M_A:!2D$CQW.3KU<GV[K38%KXPI35 &)BG
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M_5-R71C>INFKA'P2:D/F-HN$:*X0,;FX<ARL^K1T?JRPWK(T(T^]:"8%#BB
M-!I[P81C KB,1@0A_%7>SZ)<Q8P^%<T)12'X0_2AG^+ ?B#C3\G@&*NAI#&?
MR]P]\-P(%$E%/2V$>'C&M(L)K9MW\&_\?$UKZU0FD>?#6RS#1:'F(ESQS.7E
M.'@F(\YF:R E)C12-4H,WF^H$_2R3!2/\?O9Z!YJ.#W:)1N[$?,N9&B'MO!"
MO]\I@V-K_:-U*H&UU*/X#/'!ARR@5N9+\6%2"9XE4+.)+"C(]==/BR-H'2&"
M5CF:6QEKNAJH:O4AM.QPAZH#F1SV0"9*+K_W^J"J6TX=Z?U7#)X#(3O )&0!
M%J'02> A"OO*XA[DF2'H4G72IR6,3.8E,0;+"0.Z" THZ)Q]M9!UU*DDQ/HT
M3R*2406.'"2)':>U')@<*O#;+#0!%@-1!.G?/,3PJ\SEQ0_4*;%9!"^-QXKW
M2\?(ST^5[,,2,,K,+.(JTD*# 1:#PX)40P[,7,L]*\VY@ *-<;_OVA1_G7H]
M4Q,H)V2*,T,1XY(NODJ \D$ Y&[HW.8  0C0KICF5=G2%YP^C(_#:0!3LH?A
M51^3"4BTPJPRSUW(YUYAG#3K1*A,8T%QZ,12R\90IS<ON9+(8$PE%]A)YCA\
M11Q%&!?Y^@_]7!E(U/1PLMY05I7AK@*G\#$.FAX;X&,X(KB._$!)E+=\?8W*
M"&PC,3G4$=>:?VIZZH"I!<@"P'PMY",5LNA8,F52")!AJ75!P=OIB:-O![/H
M<S>B'2HECK2O)E9@@U/V(H^)#U"$WNGD#E/BLL83J(AM8AF:W^7=B+S-)@BE
MV289L##833?]&WVEH@GZ+) U(1]^%M :V/;3EI1ZX4N.(Y#[(BELAV/O(Q:0
MC*>8D[E&IKSC&!D"!KQP E(RZ2Y8^6VHQ]F]]JU/O!>B*V8AJI"TE#Y=W'\@
M/P<7</]M]<;[UZ"IT8Q:)X='[88B@+K"?BM1%LZ.VP>%#$)!5]A<5E@EZAF4
M\*[GZ,@\OTR\M.Q27J)<@9TJKX@;J:F+J)EC;6A,W25+XR"?GC-)"O@Y.C@Z
M46HJP2-_?9P&8W>>X'KYN0R9 HT:.6Q:JM A1S$!MZ7,^>EDE$PR!@RB@6@4
M_D0>*E#EXJ>W^X@WE\]'<W7V#A4M)Y%QN:N#V'4T"(3$KT"7BQC%]W%C=4%S
MC\/QIQ@:ZP,="\7Z+14 5#S%&19[,D>F,.$[P&^.>,',S/RJ#I)"1C7SD24-
M0? )">(X+OG;'N8U,=>#[>7<^AJ -7W<4*]\7N+J?=R3,"W1U:-1LNLV?Q-B
M6Y+:]="E-;"#*=%-^K5P($5*)Q6LTO4\O\?@J;:.=-15JEA7I/=Q,B$PDPA:
M=C-G/7&L*DYQ3TB\2;NA:=W#T<J<N&SN(0@T.G3GS\@=6@CY]Z,K;"_ R,1Z
MT7_/SD[,"2V5VK"[G7=6K5& D]AF@I@+^GZMT+5:>>%)JT2B34PLB4;[$C#:
MLL66@6HN"]*M&UU( 3"GFTIR*%7OF0\236:=>.8EC84:1ZV*>XL%FNLLN815
M0,B7=)FNZ(R4PK)YDVKCQ:1<UD=C8\IEUZ1<[AP*:@U@3C-FQQ9P0*]]!3BG
MRT$4R%_:$J4$,*X![RJ!V'L:<G)\YT(.HK8JW**4P=(9.,*:P1$^Y,!)<]BD
M19LDC5MH$$U<V]O92OE*/Y1HYSMX4"9]QC"C%%3N6:;&&"B15=1IK]_#]CQC
MH]F=TM,'/SW'R,*?$X Z&GH@$X%_-'46M%BP:Q%V 9# ^Q6&S$7T21J5]WJ8
M'$TW:ZJU6U/$^TDFGL+WH8L!IQ(8W&Q*U2: \7N<F#ZUXC,-/W1<L*PSQFM+
M%L"X&Y) 0O;.CD%JP%!Y"0',9UUJB+3?@YZP+NQ(]CMMG>:RO!XN?[](\K:2
MBP*TBF64%4/:>,#H30IJ@"2LNL?7+;QLF4(EVZ7X23M6? .+*+F8KN'9C/1^
MC8:LSM=E^L8[-8D+W_F83N$2H\4//!PM>,9F-9+H@RP\1#I/6?_9%($DIDNZ
MU!49+U!I5R2G#@;)0P=:*W0?93).AJW3/IQ),5Q&$RXFYK:?C+B]L%W(52TF
ME6?'?H:.!+ MA;-0<>TR'4$F1@/KE--G&PH\DBDPZS@LT:]-ZP^-BPWC^TD"
M_B#$K/KJJ9"5!:(ZI'L2!3(DT8)_1'3(7_F&IIEIL*U93-I,=\(R$PCOA55A
M.2J,0+@R%>[%!VK)$*I$X$@2(^2=R%J#J.='K3,31*T*HAZ_TU==M0B?;BE?
M0%W^O:N\_%.0K#AX8@ PE2NPKZD"A>M\U?YM.F% PDXD]\LZ)6"=&Y7&N4NO
MI%4;6! _HZ6NIUMG#2M-*2^^(=%&Z'#W770WI-G9M(!M?X^]B7K%IECV[+#5
MJKZOAD.)33/1?;@>H1&FR]UDW"#)19<=[=P$V<'/WJI)6P[3-Q"7F3[5O4W2
M-AJDGI_0A_0=%M(W:6:!ZGFALFX3ZU#= LKK0I;-YM8/)-D0^9P G0V@1Y5L
MFHQ=?4>O$G4)-3IPM.4>@4&2=!TIKG&;_E0N#T)W2:.")/L[&Y!!50(T@C4
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MQY/SF:"/W?6 /M;WM2]P> V6Y"ZC$":U%H0^*-L\&2#)G=I"Y3Z:#=S5#:2
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MV8%K]0:4X/<1D5+*<9#N&]B3H@)H+ZX IK,Z?[* ^*"SX:>DN;$ODQ-S8,S
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MPM 1<Q'.#2-1*5X)1:J2LF@9/);@'51*'@O$B+.&[)%;?D""8AB$$M#.GR!
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MJ1]U%\]# &&P[YD(F[42]<'+LFTS]7W6D!OP*NO\MWUNYQ3ZKZ2X?WVU_7J
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M</B<K+!I;'M2P^")PTG,SXG,73_(T!N3;JC*8H;;G>%:>H&;,N=L?SU]N:.
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MC*2TP)L]U*?RGA%A,1U$/5)GN*'[!N 1Z$\D&(IJ*H,U. ,:@FYQ=VR#YPE
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M3S]Q$$[.J%,2'/QKXG AJ$3^@WO9ZFS9^P?_$NQT<?L;^VPVW?BN=UK.4CN
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M:QX!(*>HM:4H)S^/J)4PKQ /CZ"0U0^@7XS] ^C[/1Z6D%_ZG,8"0H&!1'A
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M5_[/2(KGC_$4I"WRJPK%U=9RH[7ZVBLR'BG&796C!C)5ZNR[1;,N3$[?CI*
M#1-FW&A'6$AWFSRB !!S?A H4:0:Y0^ME=ARVLV#A^K-F4VL<;$DS#_>IN 5
MTP/F&J'#WA-Y,,L7BY:FO/O\AJ^L]SHU%</PE*GQ!?'"W(B9A](#[PS)LJF]
M"48:&SPKEB7LL $?!=9K@3GVCP9#M@)WEZ["5BLEA#N+.">2)0_2Y%2Y@.5P
M56;7:MGV_*S1VZZV5H);WC(<;%P4,MD9KE'MY2K8D$B&/9"@WGTL^H=:/M*5
M&"SZ4>KB3)^;QSC!.]_*C+?B-DCCS59$CM.7OZA9!(5;H)OI'?O/ <OY@NQ7
MJPI<R8;X+H>^5$W*?Y1-,;+_R#0&R[*8@:K#Q=N^K#LO ^^^K1(]MF8.E7F0
MWX>/I =//[]I'FI,63@DQ7FP$O]XS)+YE2I'];+-E&&JN<1\"&5JH+U<CT.M
M#.3)>JW<QP8SL*.G<5%^9NB8U/M:HJ1R4]N&JJ7'F;D(\8=7OT#]K+;-1LCH
M*)GJ.2_ 9KW,OR(MO;ARVS1JWN.UTX'(&LRSYRE=;/2[+)13^8)\CA#(BBV.
M#2V/W$GY9MZ'#)D.X:;Z%9SEP3 J[=N'X.$WS:0,F$RS;!Y^[;6*KK9MU0Y3
M!HMUACH+;%U--X:-^R3H!G.10-+G'.6JKM?O3J9H$+?74/'FL<6D75Y+OK3I
MLED87PCVH1>F+4S:%,YYY>$R&TDO*)OH35C,15UVDT WFGA2@U__\B2(O=$S
M:^%]IS[%6Z);-8<;',-F(B.^!,;IN7Q,YD96CF^L/"6RIWIB%9,CQJ?;RUO"
M4R(7<9]NKB^"R&**[W2G0V93$J9L'&,2V%:6$G*#[\7DX+((O\8R:*RV%9+=
M NZV.G]M^:R-L"IE)M-ZSSHBS*O(_BB??$ORR0SP@-(_1V09G*(KVU;Q(O\)
MLQX^"3\#H<T+Z*V\.-8@*R8Z>PJM27F'C$+0?N JDW?1PSU[P8 !57WV;Z62
MS#'\G6;)KC7"@[L0)ZI.\9N67&M@07V3Q_8*&3W#AY>9>_N(G80J7BXU7.OF
M24 Z18Q9\=EE=Y5Z-HBBYWQDDUM:FZK!_+ ;7B>#SZH9WO4B6/O3D&C.D>E=
MG;)K.RLQ XD/@-AMPVIRG34W"8N>XBV[,7;DILV!)YYO@B9H:HU,DNW>Q)N$
M.VWE&VAN.,WD)G,B73MSIQS\N)4K9W5'/89S%NC>46-JOL7:!4I[X?6]IJ4V
MIX=SVYB>  @I7#7"INQ'<U4"M&JLNH0#97+:I_O>\ZXW$$'L7%2S6(*/D)#)
MWKN\WD*E/>PJ2N5^>&H%U(:$K\<CJ_OT,#D.BU*]-,0M%QO-'FU@442OQ7L5
MC!XSVB.L+OI-I6"JK@<XXE:QI[@*#ASK\3/H]=5./C!^P3?I'>Y"/#C9$'2@
M4BJ2V[N\LQ#^=)(DB 9N" W+URS$U5-A,\]<C2>4[O+.?\-1#,/&'[$_B%JG
M"BG=J< GC1E?$XPP5\FO$ERD*:\8V?AJI?7"P":*18[3$-;:6[A]8;V:(5[6
MB+*(N7>9;%3PX_YMAK#"Z")K4&\*DK?>N&;Q>2<7]]N5]M*JM=:;X<M3,?EB
M64+^FJS#4>JZIJ\(GY? 'KPK[+#JBN-<]X+<CZ&&F1$%? +6\:EH >E7^QR9
M6?,KZDLJ=V48 (5XF 29=$O#UQ4CKG=ZEYES57[5KA('V8V)L@5*/C1=:&3R
MS1.V>WG7H*JPL8T?MZF['$>FI\"P,S=QL2!RKT9GU)R^^#[5!]CM8AU.2)6>
M_DC?3&,3/-3/J"^0Z=Z%)66ZWGP_7H2&HT74S8L!LH?P8'U<\14#:Q/PJSND
M??D5PTWVFQ&2M [V27RI@<TA8:J*-_1U.*^:JB[I"J'37=V RC?-,'K6#+Q^
MAD;W3E!Y"6%_R;;"A7MJ?_$5Q7 __TU/+,)\A*NG>O+F85?5Q3QH-W8?K#@R
M-^9JE0_^Q22P,VU&";+'A>O.[00+V L?CB+#T9=,+B$CSCT)40U3;!B/D581
M=V/;]!BZA*ZV37DO$(_(C8HW&>P97'"49-_KEJNBQ8OW]&; M\REU'$LW#=L
M-2@4C7< QPC;#SE6Z/94Z?D+<&B.,P]Q?(9IYQ(_T#/8&_MD%RM7E378#-?^
M)+[(8]TZE*K?]Q7^QE8H:GI09N<(Z,^N7O[-+BJO-C%71%S1V*Y_P#"S(BQ:
MV+J+R44W-$LMJHS %:YCGE(0SZDJ>^W#<%#M;6[C*JZ$3P\92PSDJ U8:H!H
MEF^&VB@,2Y,TY^Q;;?+(C-1+5N7"YQ0S!;,K*S"GUL/$1B]IM#$X6/&Z21C)
M/8IB,-U7L"09PRL89"*<M>>+K_S:8LZ\I>-7,) 6]KXR>-PT:&I_"RM'=,0$
MR[G9H\!HF54MZ&7#T 0/"66D=<7<6KPB"W&Z2V)'=Z5GTHVXB!8/FR35#C7.
MQ0B6 1Y:(CT!YA0,2M+5DB62Q-3"O4QN\:^JWAJ?[_9L\YOA#T'JZ*N#D-Z/
MWHH,M,R6W/6L+[>>5B^*_!96 =0VF1LN[VXI>"<T:S::XZF=FJGJ$2E/A=TO
M_OM=VG_&('RZX6-U;X^Q;-SJ%MU]*=W\N.M[AA,0SYU@V'Z:XE@!^:?/-X85
M,ALH6L2>48$W'I@W]QE&8$?NO[X9%E>QC5;'J2%V4*&M6AWMZ@Y)3:F^;Z:R
M'CP+26)[P*L9YV_Y<?:*>H=+ [10.L4\05[_8T%JE45N AF)>J$EX:33FX:^
M>8YJW!<R%['1"NIW2QT&^$+OIG(-YZTP#'Z3:$]+"U!2@:=UKM&DS$VA[;W0
M9F9#BWZ@ E,-7*J. ^S$?RS-W\YJ9^"[JOEZEG+/RU:;;?VYBV#]8A!)QL=K
M1]RIRCGWB.>S+\E317$HL"&1-R9)TBRURFXQL#H\=KXO9J9DD!D=-BAM\Y("
MBSYB*4(>R-IM6TG^F@8*4N J>#LM>-4><".1@I0PFUD\?NQ!0= DC@=U%A+]
M(C:!.M#O]7J<>B+Y>AY&^TAPQ6P';TV%>8Y7M(&T81M29\BXTBB8A$1&2F"U
M8IFC6F=9W;&!;;(KVMUS?^W)_LYG^M>F%]EU">& =NIDLSO+)"&BDFF0R7U^
MDDC=0C/3:2.NGG2^1NV,A(S;E?%ZS,\^ASE^<1*IRRGI)LXA)H' ! &87+;A
MVZOW=_N7"8,;C9#].M1(+=Q!$K:L8OAL=,&US]F5IJ&R2J:M2O:R]*RFV3D?
M9)^6/<!](NU6)U":_V2BJ,/RS@02TN=%V6] [0=^F''C1>[S[@V&ON;/UY3U
M7)C%01)61"MBHM:B-P E]Z:]!R$'I=+4&TCJX)>\QSEZ=JV8 =:4_BYY]9W%
ME[DOU54ETS3[Q/8ER$?H:$CG %\^T&3(S.#2;P]\RY,4NI[)5$9OFD. ?K5Q
M1L\^KJ3263.=_<.<?5!0R<V"]CLCGQ$UWBD).$.FN6G$MN0U6$Q1PQL=K'P,
M'2^<:!XDF5J+,73IJN#H:%W#2^ZS(G!^\C!Z:;[8^%WH3-5*W%7.$2^=:L'B
M82T'YQ, #O0=A2MGD6%>X&>&4/44N<:!RIGU?1$$6V .^<VNSB616*8&./--
M,WH\K-BY6&WM>6N_^% (GD,<;F&.WM670#%[X6H3Z8*O!$T+YD<*'%P[FPXZ
M)H.7PQ3+V%>)N E&5.'B^DE3BU64%1%"P0I=E=@%*CJ9 HM<,BI.[?1L&H32
MRN-L!H]['\I8RQ<%X:[.Q'2RDPK%'BGN7>H@=<AL-+"8MSX&OZS0'K.XH[7-
M>U>Y/: 8O58OUF0F?X GW0\W[T)C*8]9J'@#_1<7D*Q=F_ =)_,6_5WEEJ@R
M\T5B,X.#M,]60[,.NU?N93UO_U"BO-,FF[CB&>%BH1C(*XG%>F\0>##:P$@:
M/9\+?VD^-S.VN%>QT+CY@JO+\]GK/@ZA./P,&5IY[ZW\X >)9KBA7%#RF+BX
MFE#OJ!JI]F6F:+72T72\@R1XX5Y/3US<X*MNGHVF==?BZC=<!:^Y))8@>C6P
ME[EC)AF/T]8/J577<*&[@( TS.=AFG:=M'-$KNL&?-7F$<^(M6^2I@V64"D0
M.>3.37A+]JYWE0GU[A/)\GI,(5G[X6C#J\Y0&*2($YJMF&T%(7\ER$3^H:<)
M^7F)HR@1VX)8(DJ$7NZ-FOOT#(WN"-JU/#L9A+^><S.M<7D*-YGIY2.*+KZO
M/E^^ZN=*?-Q_^2S"YE:#/GLP)(89_6Z @DD4Z\1+P2^9]Q\UC9>9TNUYM?$^
M*B.TZB BRW9D'P[^<'T@+&\"PEIY1ZG4YZZI>1))Z).7LOFIE]4C<!JLV.<_
MQ2\J/<0HBCX<P4TSFK_(<IW^"RN9/5_.2+=K$.#Y[EU?VD[>K_K13;2=#Z<-
MEW2-7[SP4XB]**,&9)?IT+[ZL=4J\1T2O(*C-6M2EE7CT.FC15TARMW &O/Y
MNFKX1=PKHVKJ1"&YKB(?WVLJZ]_4>D\,53'T7F'-SJ6T*-4IO5$PVJ[#CHAZ
M&7<UJW-Q8WQ@X6%G85A:3HBF%%=2A]G3G6$:7G6*\,?/[+0B"W'CNC!Q8ZNC
M;LB^6_[(P5)00T^7M843BLGF,51P4?""![XE^[QVNPC=6FZZGDR,D9&?9<U^
M#-7E?K^+%#E!I#I,([<YE"([2*<\:EH?B&4W!EVMTZ2!([]*7QK:+XDNU1_K
MDV4*C+<KR>Z!<R(^8M<D6S_>-%2MZ%A=[GO<+U^Y9VW=\PBSFXF79FP:=E.C
MP%% ,YT3!X>:02S5T+/PGAHV-L%-_'><4NU%5MT!9H&+)#OTRO*Q(L[YZPN*
M(;8S^F]K[CPG7!#J@R<%^Q/R33MR>S52@MFQ;U,S<H&*<JZFL":0&(;57Z.@
MTV':5*'T$/FX'B.3L&H_2UR).Z/]IE"E0I]MSCC%N&^'A*:3T]XX5C<'&G2-
M>-!'4B^22D)H^$A!BW+X0H<C(W3A;O)E^S2XDFJ!SS>ZQIG'ZI@A1%^R>VAD
MMPO46^-*P*;T#C,2".6B<@.Q-UL%):5Y)0%Z6NA,9F9W$7)EI7XDCS7G.^YX
M0'@IKR.$^ETUI[0)IM4R<&@+'XHYW\O;>.]3H35/^M\YS_Y'C$R+0;UWL0;D
M6S-"FX7<#L7VG/3B :P-<;60F]= \EL5'V8CUY.N7TL5$G_J'.Q1FR*E4/CX
M(Y//"U]LJ4<&QMX'^CD^JDM$!5K>% /*?>F/;"(UZ4<&[T2IP!Q*:_R'JA<C
M]+6N9UXV=WPJ6ZC\.5C"\[7\A0+LR2<?2S8OR"A6DK7?C'QWOY(Y'Z@%@ZP'
M:<<148U\K4T3O 8/-Q2TT7FX.- =C2<1ZW'#($&,O[A^"G?J#F2]MRSO$WC7
M74J"LB%Y'5:3)0"Z]LH)+_%*X MSXH0P<YTU"1\-6F''0M7(J6LJ+/Q.-]2A
MQVHW6?$+%WK7NYE=IF^RLY:QKFGC1G\VG+8D%G69WPB79U?.BI6&4;%A?9DY
ME'X;=FM/\I7*]MX1::H..)M<7>^>931M77FY"4*TY/4+F(X5TVT/?5(AUWGM
M-ZDW<I[FD<;&)XO[87(5O9XNJ7G'2+">7OF^7;\<G!20 GZLM^&A7M26=/G#
M83I+8V&ZMTD^>8 /6?2@LJGHY?S%CX4;[* J[>Q"3L<9H1(@_TJ.TY.Y/+&Z
M!!-IZQR_QH?!U>JZ7"\K!L,V,W=@[ ]NAA/1];%(IJ3,OFL(M'@(,M)7WS8*
MJKJOYD77ELY[Q$Y6Z!+\\.TBN\E,_1HX9]2#'7*=\DWSDT_JIH=&JVND*1;
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MS4'QN%ZA:0F])0N/ I67DE"3ZO57B0']/9GK\ATT8E4%0JMZ>2TU6O=U013
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M;96L_^I^(&H<#RSZU(@;3TZ^&P7)4:6I(YCY_.O98R]MG:'H)WK7 0NT!U^
MSMKS$A=G!ZVBUBO3#8DND=%9K<JR!'<O]R'7LWM]M8I9$R:!(<L"[88H_?'#
M@G$NW<-#.K:Q;U";*]=AJ;-:HH *;$Y/*1(_*8GBJL^_40.[/A9F:SL#Q)A,
M)45>6AQX.@8;:,9,[ <?6-ZC =))T'76(A4;"H,%VBB9.CZ#V+WPNR%B, Q-
MY :+5P"1(M:9TAAT/E(_+F&<QJ-KJV3+:JEC+:/CZ1HS=*" B>1IR+22,=U
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M)TOZ=,Y4/\#9=J(D:6-R']>V\)SR;H[+D';:,^G=U"S,N3#BV YU[$'=-R9
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M7*A <PD(D-,\IT//<LI&D]A+S0E2TQB#6,KIM,:9R$_*R>.2]B >9"A>9/*
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M((GS\U_.8A:J:8R41J1.D3-!26F"Z[P"V'UY';2XNBD+P[QKG!UDP[9L#Y%
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M.HU5Y[7WB. Q&SU%K-V!FEP*NHJ"@)0-C>.0Z0 <,=MI"A">\U?FZX"/3O\
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M6S!IX5OL."0WZ$0M63*S$Q5''Z0'+4$N:BC29;99QB<W,47.9INFVG#V0Q8
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MS[W?XXFPN3O_91W'6)-EM<Y\#U?U5HIX AZ!L> (:8VRZ3E.=\0?R@J?W!3
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M3)#%7@D$ZI"%*$RBGV'V^';-.8FLGC$8L$7C-ER$;B&]_!Y$#5PU,&%E,'U
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M7PM7Y2LLEY5B-<=OI#0<907F8J=IU)2^8$E-A<J]CH*&.*^V89NJ/>)2EKW
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M@IQ7/EPGUJ?HI7KR'9E3'1UIM%FZW=5,3/D)3AZ[;M055KFT#U6_VM+CAF-
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M%(CT?K\6+/IA?@%D1K@>?8^57"T.W5037NR)"[2^K5P!@P5O1V=FMS+>#)W
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MOZ'?S+\'XO+3$9<)'8"P1@<3YI#6_(@J4N73"FF@)Z=>EBS]YZIC5(I*#]^
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M8<BW'Y_/H#VV=>'?'L@K^/6PI1>XY_Z*TBM\>3KJ88XO964K./LF7FD]@Y@
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MEF6!V@7)+]56HT>K[02$!>P4D'828'4=TR0MZ8ZW'DW^EVX!)^H<3YRB@R\
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MH\ZJO M] G*OMKYBN<'A_DAB7J1WGN2:DCQ"1.HGY6!7C(;%;-=:?1-!O\5
M>^<3$>'=Q:,)R*&<_A,[1")K23^8>HO !T>?-%!BB'\^ %",1:*.T9"X[-W?
MJP2@;>*@:ZSTE6]XG:4J\R:  &@/BY'1VJQ7.I/Q?*XV:2A[.2^$F+;D)%:S
M3KI")]Z%)%$OM3VPV(NUA]ZG':\?EV!5L=J&^!OS,P<:1V9V8K8-$+\@FEYI
M %4C]8!(7E/IOE#SBI]E2&W9WZ2L!MEWP<0<9]&/S>Z[T\=[,97;*91%+%1'
M'--WY/VL)*,.0S5R6!"\>=%%A6ZS/G]&E6A8%6G)BMNZI9II?F^W2^<NZK8-
M<TO[Q$5V9I_>)V!J</)R0D8XXY]F(VD>_#_,I;S(K3G!P*VM$?O*$Q&O)R;7
M0%>G1XB,_77TW7-%P*Q)U/9)X/OKP]:*?S>GUA#-NU?D6<W;7@]?3RR8*1^:
M>-2YT%&"Z'Z]W73BQ,^1[_7W!;]/"J-SKQ%X/V-0'[)AT8B?DG0^>>EV=4H\
M[\VY@SI&::W2]7/+[KG;Y_A>V E2GGJJ[_1.'5_P)X,]QC@GW/4A':>DN:W)
MC9K:8N>#CJH["Q?UWGA&XY&F?#U0PM+?Z^/@./ C;>H38+;>KBJZT@"S(>\I
M2B.G_PD0]'=YMU\C>ZT-$FCZUOMTD21HB 8S04PY^/\N[4P0C?J2? )^U5Z(
M\"J<WL,L>1T?#^,2R^5*2>T.O#VU^$J<:S&.WN$2G#ZTMM[?">C8<$?K@O#+
M:K@*)NS*>XDSG-T93PVT@=]Q7ZRCCBD5FMWHK$=<R4O],F]2FR>@6Q;(L&*Y
M_.Q*[9.O?2><9MG[\.KXA;F'@7VV'U*$.+$L\J"/? =PUVB!'_/UZW+/-,2Y
MZE7AFL.S^)?Q"*?4E,YH] 16&$LIC>9B,YJF*V;Z22=]"<7.)N4.: A/HK\Z
MTEU+$ PR,9U1X-\[0Q=.T_"W3]D22E6GHF_K,Z4___TCUZVCE9VD(,Z6X">!
MJ_E0XBONL=_O*LR2D&Y&J6*I5UZ)<Y;3R6 =;=3=?/P^3S=N'1D>.Z\&W[4X
MA^\TZ_H=F6/TVL]R7@JQ CE:I]3H"X+..$*E'R3HI!_$_1;RR W5.*[<B\L=
MMN18%==D2N N!H7B9CD-W*9 JBZ; 8!P\0_C/:,)FF_B2*HGY#_ES.5W9CDT
MNCK3%0N+;0=I9GBFE"@0X]1_*4@+7PS)4=JSP/_&S!;?9#QF)7RY_T)=+KN7
MVC9T]VX.JG#N8!X4)>&W?\$/_0X-WTSD50<IOBZI;'P5V*L#1;RNM6D$4BA
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M&JMV=UL;J_^ :*4XLMP8 P89WB]= ;+6TSKI8S5EEH^+U@@C^\W+)IY4;9^
MYB1):Q4=4":!8^>%L="WL_8F4)4[5>^)2;+RK7ED@G8$H'U=$>MU0NV0U/1?
MW'U@R$4$PY,?GCDIFU\()K006D7P:=DM;_*3T<"=X<''[A?G=]4MS7FK8IX9
M\>5<1F-_?+\U73$9*8(5K-B3D_:+BG1"M:SG=DD\W/$54S3\0;8<0(^XA4XK
MHW-R(O7KV)B&#LF 85>B(4IWZI*!@$-3.B$#^W<$@51\&KFSI[X)-VJ7WEU7
MP'/"TUU#<"96&9ZG9<E:5B91 E[C<#22.%8P4*8?Y:,NU\@R=A7VG* N>+7B
MKSDHK%VJJ[1*<;T!F8;<J6&7ZI<7L6YC2'Y:D;9->36V:#+=:GHAR4X#0,/(
M_K'#&C?QPID,(4O\YMG*,Z01(E<!1XX5&TQH+8RCQU&J;F->C?+;0UI%P:%!
M1Y$^\<Q737>@U<\W#EZ0@CN5TB8>/AM6P::APD0[<H%$3W8.1UZR3<UY"_>]
M5Y$WJ<@=4'AIR?$0!"#'DE3O1"@-;#Y*1%G- _,>J;.7X>B(:X?#+='C'N*]
MU)[H=*CL0XD@/+T4U&^B#4U36:WT37D^!Q4L/&@OJG OJ)%S*K$S\5L6+D2<
M7(Z-+MM O&.LX14X%+!!T H'?-9RE!%G+@:!<S4D*LOPFU!B+IKG-V>TT&J:
M@GZ/Q\,B62WA"E<K'S]4VS S!]85R#K6Q/VVR19'J![29%\#VI/NCQM[*\X0
M_IB__!Q5S>LHL'62;/Z78)N%P-5-0$S2_$2D]@G ?,I,6M.!^<BWVOT$7-YM
M?@(.-V?1FWFK'W,X@TY GX V.H__# 9C_PG8%>VP@[%1E7MZ)+U<]']Q>>_P
MWCI<=/4EG5H#QX2\Y\H$!"3_FQ?*J[G^YT1?A(V8H7L#[NB!BY K.Q#VNU_[
MR%D)^C#U(6L)O*"#^"L//H]#?=3VAV:32ZM?HAWBK-BMK7\"J..?;8]]<\X)
MW1IU#L2:U%S:CW^?(!*A!YYN@<<"C_P)[:<JOA(:2)?9&/0;1,_!2_BUF+LV
MEG%>G*T;:,K=4@N4!7C(#_PE-XX04X4XL_SZ4D8@XZ[3*R6[!KVLYC61Q+$.
M2Y?E_X9$[0';(0]P>T$;/5,I^3ZXO@_)P-A^U&2.D/*IU5"GBO*>$;DLV3PZ
M-Q80K6F-*4=]+2,=)Z_21E/"8?X=D\# 4W-H]C!)NI69EZ@3C]VHV4;UZM2N
MT6=JM42:<SGZ]4:O]2#?$V([!&VMDZF^2<-S)?]B2_<C)H9#B/9/".!]#CE-
MW?9(O[I:W2U[U,_)(HFIZH2SQ]CG\F6%0:0[?_/EY^V'PD/G)\!"^"!3I(;E
MER'[Q;78IG?KV#:&9^GR9+RXKJ"$Z"<@$36&B(EU&.I^/:"^[7(1'*16]J'@
M/1Q8^OWY0-0=F&M)P(&35'WN:<FN\'C+,[]#"U.UP3A*"CCS)C!EEM@ \#%T
MJ-]]N/1%BT8_=&,VY(D4M\^H_.3QWYP-R' T;,,HB4L.HIXA9\K38,3#/Q)I
M%S!E>;H0A2 XKWN^O'60%8LT%!QQB=U/<S_XQGK$=$8?-YW_9RG0KEI/B,!S
M:<"X_)..32(<U&FZ93^&G.JC\6;29'N%,]V-7-O7=SB'UT6&KO?Y_2I#F8TA
MLK-NC4_ 70*F[(TMT;!5*Q849S']ZNX$<@:V96X-OI[FDSA"^K;1F=S81P,1
MZ883Y+\=S_YQ'>_/05%H,5<.SH-(#P$B&.5I6(Q^Y?^XNHH1HJ47U_-'N=0&
M#BIW7"V@*BT2[YB6VG$:5,3N8KG'166Y6O/W?W$:=V9@I/ Q3_B-8"GT\0DX
MKBLP-V86%OXQ5(&L0",Z!Z_%7(A+K"-2)DGU:!*UEC(.6<<Z6RQ=5:8=)']_
MSHU RO[*N,,,.M;]T:[(O_FXL9=942CV]GQ_@5"Q.[(;QESA;9!NH$_R[Y]Z
M]2B8=RN">RB789\+5P62M9!06*EJCR%HD)<PNIK\>(+X5CHL%OC8%_G^"4 C
M^5-2VXKK]2<7UQ*U'>')XRX_G(MJKQ;I%.,#N?FB8$T_[!/0HU__"?@$\+QM
MF+O2!5D#^S*U0D?$3/O!/IR?@$DN#W]6XQTJQ>;I\5<LOL77XF$^,=$5_Z#"
M?#8WL:IXL_JS3T"*RP5)4-WH?*+:OQ*1NV*KML&?45]%ND/>NV$"_WU\;)A>
M\IAJ.PN4?4<'FX,WL@2>%W^?8\LM]%QS[M(OR*XJ1P<MX['*0SW\I_51"C@\
M&!1:YM2 T$Y")(K_,A0M_GY H$L6JRU'IPL_3FQ2TO8O+\H>7B'DXEJRZ(-X
MVI MS>I<2O43P!&^4\N?$J61M,1;BIHQT2)AWQI:BDMG7M_3#[JYWP*3V:Y"
M.]X<P,PS'=3<U@85O#>SBU2T W><:@B8-10TOT3W(5@<+R:NWD8@0!T7#3#_
MORE: H8O%DM Q#V-=2^Z@,AWO)0T"A-!9@Q-;]%<]2'![R"%2@-/BQU]N>1
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MPXC(>(G5N+&FAP.,-8K:Q8$42Q?BL*%\L"'M9UL![_[7UJ 8_0@HMJ%58"R
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M@"OVKTQU#!,<=:TRR3<.L8@ORGK$#U93^"^E&LN&NX05>HIUTL$TFDB/C&/
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MD4D)D2:DH;M/0)2:V>'QR(8>]YOTC^=2MP?+A PD)8*O'R4!#" #NL[3C4^
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M6FJ.=82RR.A,1*<;_$4*&3/@J4,\<BDCDUV3?$*]B^K8(&TO)<-Y:;&+H5V
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ML/(@\@8#5) \.[=##OHK.=Q["#>0^&>'O/..L#E.BK'5>P^<7D7>;?C>BL
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M[=5-; $35(LX@0+)R1%]1BOPGQ8;M?A'T#*;["2FCM[OZE%L+B^7'?,'4*O
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MJ:>)J^,1/FF_8AJ>-"MSEJ0."_^B"NWB8?N\MK2J2U[+\DO^$W$1@97:QQ;
MMX8Z+'FOF'5)CJIUUO!8#1'4RYIPR-=GDC +'UYF=HRNZ(]2\XPV=BEQS4H:
MQ1.<>%_?"HQ&[3RZ4M$,RA!%YXR"(U$C5A5(*)])B"&#)!/O4WQQJR/0]->)
M=T?3)^0!N"@U!+BQ8S[XL8EF<&S<\*D^I!I)A24,Q35&DY15WQ<"Y<]Y5W#X
MD 4B 1, !35!W'<*>3A181R#P^D9 [C%^0E1)7(HQJQE<H-$:9Y3:RLAJTH*
MHG_204&4(91TB^\GTLCE]^D+-4(J%&GC0S ?;UWJB[,P<*W)Q[0V"@$@ <HO
M)3M&-YC/:+/M=IPUF072&J%W1RNE2[;"+RQ/O_C:OW4:D@[35@>^VPVAR;I;
M4,,U&QID@,M(+4;G"5TON=8P5^8>QE7_@U<P=:E5.,KDS ;2$)W/%$5D 76^
M>S,WHJ)/4:'%#R1$,=G#XE5E%.XVV39'(X !,JW(4?)[LRT UG36<#EJ$'JV
M#YNW/3N*C@[VI&B-F447=D)I"W+0"2\$9Y6LY/4S2*SF7]K^:3A*+D29KU]"
MAXO\DJG$F=V,90 LG)952TR2:U/_)A94PQNR!Q_IV_7G/#5!!Z$+R#SY 48A
M@/0S0IQ,SBAB=!\'FOA<QU&&=@\I@SZ1HUV2[!KG^*X&#-!;'A\8%^ (,D(%
MW#A]U$?=WULO+L8(U-!_7TG>">!>.B'R_EU9CB5/5 IB]RR/\&^PSJVL!Q7?
MD"V8)*R@JM&U4 A@(J:0=9 \1@<&XN-[XBN&/X;\Y 9\\FGWB@G.,JI'"DV+
M#\^C;&DF25%.38&;RK?L%! _+/90(^V_IW%/!+LNS(>'2"E2&6:81H@1B(^#
MN !>2B5:HA;!H;L)O*UF\OMYGY,;WJ!_U6_0_,*2<LV-V.C8RKM1)(4;@X/5
MY/NWF(H;"3T*9'34#^SY(S<5M*775:F-*1*ZC@;N:\HTZ,=,1ITOPK_7/T8<
MJ.\[,E$Q^=C+,M)8+[89;DQ,LL1_Q4V%GRK[\QF",FBYZR&*H)(XYL2*BRLZ
M!TIJKI!'<;7;0]&91%5 2]IR%&*58[8:#%90GXUCVVW&'2OZ3(97%M7J^J-?
MC).R0)2YD%^B6'2I4?U$U$"5 T[T>ALDM_Z^]PBYKD+2"U(/B2E)0VE4R*=B
MP&Y>0HCUP\#XE0(GH4L7>,DB2.A.+8!9DK!"\B&/ZUFR[<D34C99][T5*D4;
MY)]A*""KL2'!Q)AMT<.%B&*KY>]<@8G=4L-'HIJ:VX5P4'U+\GSCO.(!.0?W
M?9S&@0MLJ%]8Q8F51GQ9M"@\1-):GI/I2P8;%*Z>59>4B!X83J!/,L@1_!&G
MJ>/["B>4"R[K,XG-PU(>07U8<0H1FO](K<OGP1?K'7+!%1.=U\DX+&"7:%?Y
MO$&SW9B;Q$>3^$#H"=XR"/) <41?J:"S9Z8,V@OU:D^70=$@D)#&S*G.T/YF
M@93Q#=.N=K6&:#^:-/CY2CK(5BS=04)Q;]HD/^]S:"NHA '0NJUSD#.-'X(E
M0Z>+#4='6;R(_ADQ:J[T+R2$T%I?\C,5BIH\TGA7=&7<^ZI-SNONPKJA.'O1
M)NJN(%ZAQTKB9,()3;9AV_6X?,:($T=;5DZU;3 #&9K*))/8!RC]&;R\U2D=
M*,&KC#(8CO:]"T+@SU!BV:4^<SU^O3PE7C->TAI*!GC11\/LS=R;K;^+.6I@
MX!8VYPK<["XAHN>3#_CMJD^ECSUH/%;TBKH)<^Z&F7.QG OA4_PY3?UI&1[I
M[Y^T_1GX2G!(<.54AP/B+2944%:[0#(>=';DVM'KX$E@FCCYT>/9@^.LM2L'
M\G9Z/<J#1";!+%'%[SNRB+9%WJ]5K_BA86$ZT@0R",5BH3WJ,$ CN:7@1=\>
M9MZM'/2':]"O]-!-)@_:99Z_I&(H6#,K::]$-F)OV6*7K@6.&&*A-1H44'-K
M?U]@)0G7_"Y?(KC.:5WYJ4_ T7Z@&\KR(F9.<9J.!+QV6:T[/4CZ7H!IN/A^
MP>Z35=\R9:-(W&OTKL?3K9"3J.&0\ (M:-$A18-]0++$_#6O@>+>.-OJ)5OX
M=QMR:7T$#(#N6^P) Q22FR-/61*2/..]]1W=G0HZ"5URI98L\B>.JLO];&JE
M[MMO1V!?W]H5JWK_L:62-OZ9:M^X_RAAU?>B=[T1V7A4>1I,D68"[Q-ZHK83
MBMM)/&$RLZ+[BF?3=ZOGSZA(0*HE\V18F9E:PS^5I^.?5BGMUX<BA<U,V6BP
M*G67D>C#@"6G!K<IC005.@WQ0/388&-Y219R5F!RRE_8L!@!"XF9O4B9B6FM
M+I "#RVEZ5'0Z;<J##"IA]X(6Z0=)\M]$D@KX&AH6O;(A. NA+#;';#+\G?4
MAK,9D01^UZ35$=]?_1#[RM_$-MJ4DJH)G4JA4JY5+8X@,US$@P%&R,UY1::E
MK(&Y$NO^0\_>981^XZP:*KZ7#N.Q0!L'WE5>%_)T?@NFZC9_')2@Q1QUD3ML
M+O#;Q<J]R$NO_P__(<=V#/V\M4;./@W&6@GN/IM3T_,? CNA81MT1P8]E#SV
M6H$PP#_R3I:!;:<!%[+] /?GB[:"PPM7I$D2-I63A"/LIGO<\.,N?G4HBP@7
MZ"!7?^C18!&A]SDT_15UC*73 _+:=WGV@HS7G;X0+ !:)-()7WU!4;]3SO$8
M3&!4X*Y3-H.R' .EH)3[8G$2EJ(_W'&Q57,A7@&E7LE:@;Y/U=C_&86G*PQP
M/ 0#H(VZ854?^^Y+V1H$I56T_(Y+R=\EM),,] _U4"@&Q3Y%".<[\9(X=PB,
M1WZF#8[8VB<<\T&HZK8;/GT-;U_3M5P]A'_@Y.<,8ZWT'A[/.TXM:<BV<FC(
MVSMM9B_E3<WLK5? 23@\#+I I%_(+7/S%W)MP_OH5I<S_M4[*_4&($MD=1\P
MR*O$^&6\*1]#J.*#=7H3)4;-7.*W?\:@!#Y*3[5"G*]>P\M@ .,'Y^4K4EOB
M9.M3A+0QMYV2)1&*IOM/8MK]DOAO!YC=@LB_%:C"+]LJ13O#,RBD7O^L/?O>
MIK0%%#EEW0/<=_"$5]. /5PB3,BA-%2K+T0OM=._H2-X+0%'HCSAERV5XG<+
MPC.]NZ1A4P\4USD/X).^F>4PZ!+W]EIAPFJ:=Y[-*777IQD88"ATC.U0L(20
MZI^.PTV?J:R%/(4L"87('BZ:7OQ@@+R38;RI6QNT3O5G+! \<M,](0S M0H#
M/!8_>D.U9!__>67;*TX3#0RP2<+QPIO\ @-X?2"U/>/HVTZ_E8X0$C(W]S1"
M^'+N,JI-9M% HM,BXU908A">@5/1((%,W409+U(;\@$11T(H&-N-?[7)8N8N
M$@$H$'9N_YG.6!BICM2_I-Y!JNF^D=<X^_TG*O6?E%2?2ZEPD-]E?KNZ+RL;
MVOP<(_\0M>&S]E$WUV"=C7$T[1UG]#1!RO=.?#Z%Z6/$<ZP=U_N<H!^1\A58
M3MK>"W8/\3<'K58@S]P-2I+&V"I\0"#UAVIX;"_BWO:S>.'/" S_0]**A1-7
M/:ND>P]V68M81UB EWCLQ(PWGG%L6_?:812%=LO,CS^9),; _L%_MT4A2+ZD
M,/5Q]]L=F[V4VI3MQ?%'>QYDYDFW:DV\T>K56CL9?Z1LJ".S=QUUZCS;J-/X
MDCGS^J"!OL<WN3L.('RETTI91_O5MW2OFJ-\FR)3V6^KSM:_-T:DMN@!]=V.
M\SQ<C=_43]/$*-OBO8R-@;RTZ)F3+!4'%[OS*U]L.PAZW_ZJF?V>7</)Y[]M
MQ6U$3\Q<H2]!R99V.:,:,TA((R-AR3@C.5Y='7FKDH-<O>4.Q4SB+N)Y5YUD
M@:N_#;[</'?;OX*_@O78,^10&T$M[7S"$9SXA,7%7J8,JS1EWQ]<#\>P/1@)
M*-G[R7NCS81^<^9+!5C.KK!Y26O'PWN0F$ U+-::,@9BS:K*)ZVM,@]B8A2:
MB+F:(6@#E%MI2=QIC'%@#RPA3_#-5G^W<C&SKC7;'X4J8SL-A9F,V,W)SQM,
MQ76O I1H9:D-BR%TDLJXAIV=(>43(._;[_VICN492Z'4RYI&XS:[+M^-2E-B
MTN@58WO2-'4J!2EW4][O:JE/Q\:OMN^6516MZ#1PI'S K,M D=BI0R;"5Y#N
M3U!G-O=+RR#]-;RATX,;'/T7B8N9Y$$.V!)?Y=^647_J2RA^TC;[;^7I;/P(
MYIY7[NI)0?ET3[]?7L@]AI;BIN(05RWQP4:9NI2/)+%-AM[_+=_YY-@+O"OH
M :[&DBLJO"(Z#L\RX*)Z3^"ET]PY/]"9WGA'[MCBB9JI-_LTWA4:O:%4IF4-
M/?K6& \OE:!D/4&*)8<;;=9\S<ADD("/M<5T,,H5C%C;?\/DU^[*'7,Y50!7
MGF'XZ;+P>SS]I;__E46,NM::':N*+)=ZL>Z24G.%MO!J.A(A"6_PS]/UEF&=
MI0]>O-5C:?8V(.V:E9NUIHAVAR^8M"R7YLHQ\@PRP2'UOS5EB&SDCI&Q O/'
MLY.=M:2;=3X#\4W8*,V>1%69T4/+/=R]5AT=W7G,?3 )S@UVLPW5W$[=EK+E
MS1K>!>-7FQ<FEJN.>CRAM%BUC..B2ZR['*P!"FBT_Y9Q* ":Y:;&0Q2J4JQ(
MN>H[=:LM_;&N;.H,@LH?"?.L]+[P3G!EI-X3K"J[HS,HLZ/U[TX)Q&9'C?<:
M7M(*LS0\'V/SEPI=DV8^&2QVR1T2/Q:@Z!9BNHWA=GM$;OSM^BF^RV&^:;1#
MN&M"+ZQT-.V8NNUV>,9%S/NTF8^B239\GI%H'!=6UA35$C\=_^%P+!QNK&&)
ME'6,K8=^ZKLEOFNEGX-/&0-:T@ ZM"5P:% \%$]G^\,P5Z>,2M;P:(229#1#
M<>L V[72U,IDT^#'UI$+([?] AI-&Z7X3T8H#"$1H/@=O1II&R---XC=7T2J
MZQMIB\T='IW^G[550YQ%T5V#XB$ N4D5&U8\AAE?DKKGA]23X?L4.U%L;5/Y
MV*49W M[NS-[OU6U8XY)-/!CW6]TJ[7J4NV::()9T%'J+V_6SJT#]M9EDYE-
MW#8ZA5I5 \!Q'_]^MB+;)18!0,:*DH<%C>=[[/-Q3<2JE1#Y3^<UP3O(PMDK
MJ=<4&M*L*1L3>^I/5J;P^$UL-6.4Q\QNOJ->B'&OK-DM)/_BI.UTB__+!SKA
M&PXZ)/$#&\"!UR(A:W>)%>\T+M\K6COHN?PUB_CZXD;(74RTK(SX+RZ<PH52
M9O=:_=2/R08""6RS"UU\;4]6[YMDM3MG$S<,3=VBG?::5I"I&6\S^HB>;P$T
M[H&IS$17'VUPL%?:,M-RI*W2,-IFW%<[Y)UBK<@'X>(R'5XVQG*>UE09QEJM
MF* 4)+2%4FT[+35;O;W+G7*#-(^:YZQX:\TZ-S1VZK6)BF&9%/@T3&GAV(F)
M*6LM_>8$+4=K7;'[&/G/K"PKB9@96,*I:!G(PAA&FI^Q.ZWAH]1:N)$TUZ]0
M08%CE4A(%3]*M8UVJ!]7-DP^-*5@!:EN6UY<?R#[! X0$84!)/I41]YF9=_@
M)=\8EY/IW)W4[_)6?KQR]//Q6[QM>5]^\Y G<:PG P*\H+R0@[92*%!447U^
M8\?>+?[\Y\/5YJ/E-\02G%WB[&-J25]GB/^;*4=?F?(#N.!D?J_MPQ1Q& K2
M;TYM7\Z8&SWXOQT:#LR9--JS>TG26!N=O@&0A(O'9PI5%9[GNZO'D1F37@J4
M<.RL@R/TH3FK(REI(-;0Q=T%#- 'A,Q3#;/V%TBV K-0?ET:7J'ATX%W]Q%?
M(>'.)P\P .^ZQ<G6!]_'7V-W+_,OXQ13WN)\TL=%$*)7G0/%&^W;#?TP>"!%
M8Y,&K]"Y8"P,@ 5UA*/+1L?1N64=R#8%>8/5Z)U/=[)7CO/>BK0+'LDP ^OA
MR-H00&](\I"+%80[^LL=K1_>>=-*8_UN[VQEW.%I7QZ_<%!TO9*)7IT<O0A>
MV?7XH8IS/C%)%[I?P<G/[$=CP@# 9]DRR*O$L>&&:O7R7#7NDJH!?;%<^-U;
MW_+%MDQXV=WM!70GBO3I$LN<D-Q($>5"%[-T4+3W>0 &N"N*[YL%&K<KFM )
M-OG6\2_'Y$SS3['+2Y#+7\IV>N"?Y5J3X%U"?M, -0\0^DS*VFZNFO"N-"\H
MBQ O@?*D_IEXEH.4!.=WY>EED]GZLHXS,]]? X"S_,NN^=/;*>/!QA\;-D5/
M-H35;;-2%K<IV"! R*.O[RW4DR;X9IO(L [KX["*$9JMY<ZHG'/OR^O+\RO$
M:];S8L65>FCY5:SM^?G*GWVDPSKH\==M]I--4NH6PGR^6,0K## MNQQTW5:+
M_2=?^.(DVL/[5(9^TZQJ&5(8\(2)U=?TK$K"J_4\3=B>;O]ZXC;!WR4'W'HQ
MR-S:QJ=X_H[<86=7_E%TSWUYN__J_3J&6[)3;F%/_!'%_LY9%_(-+J9P7+?!
MYOLWK_O)^]I-R)GWZ%L1T3+9G_W_Z?9UEQ 7!3DMKR3)"$U[9!"N)^4]0MT%
MA4JW%:-\4.%[O1%@I__W\EBQL:L)C((,[0PR IX[KU[^%EWCQ8'6X!+N+98:
MUT^M+P$6_H0I^*%(N!*0^!]81BSR=)!*@$)BJIPHDEYHG)L-J%R@46]>3&YX
MIP6MD\#!^FM_+#D&PU1!Q!75B#6MWAEO .%JW)@4*Z63IR1.XB&RBF#]-#DQ
MO'RP!YT6VN,C'4T>KOP5G)I110-#L<YI:/2FT"'#C<&QZ@BO@C@3_6,QH&X[
M"152VG^.LL4]5RZT.!VAK08>J2&>#!<N$9?BK+E;CK;_" .X%5<N_:$-=5N9
M0@#]G&R:),%=9=I']G"095AYWX#@K/G.5J@^&6E#H9W1=92S(TQO7C@]2JYG
M7LQUFW16AJ%Q55= 0:.F%7WW>Q:([E<(@5L*X:"1"R*NAO#P+<GM<D]X=Q5[
M)E,5ZTCH(ZTY%K50J);TPSIZ'%H=V6P@O-J<."*65DW#9?$]$JUODB>X@C:N
MVYJ#MKF?&E">PXERG.C?$0W_GHNIKVA=Q):H!.ND&EC&Q[(8C*OE^T[CQ[6'
M4-7)"'%Z4I)(A1HFW.%$H-7O(H?&J;AA@S&*7&-WO2HLT^C"-]$0'%_,>_#+
M\O>CY8"0N"(G'N<Q,9SOZ77YPC2LJZD%@5_&6GH]BWX!Y!B%V$O_ND-<>[?H
M/9_C(FFQ0DKH'>=X>TZKU.RTX5I;_W(U*P^EWQE*ES0G3H[5P_OPHI"XD;V1
MUSAH>-'&%:4G_^+:2N-2L#?;93SL-E[MXXN,Q ]["I=,@N<[:H568?US;EZX
M55M$_^.GQ'[5$'B6\F;4W3O?( L$EE^UU_@-HG(_!?5D"/B7A#>N&T&:RS0T
MQAH,L1/FW%EP:I',F<R:]./[TJH_-(H90?@EHZV&03*4J"]EE!,_F0KX "%'
M6YBKIRI6$\QE@IG8Q+6TO')JD@+)?YA05';\.]KH"K] BP*RR'JEPNYQ4/*I
MH^JD+[\7?AD(F^DN1Y'D^>U#:5++("]T[6>(?P/7V4KKCG8]OH>&6(Q0SR3D
M];==9LDHNT0S+"K[CUF[3!15A_7VIM_?5(#&4BH8W51&4+LIY/XQ94Q'E0KS
M5'Y/7 & 2N)JE8>F(4?EW7AY97\7W:X<B1'PH/C,CG=:+XBEFD$"[8VD:+N_
M:NI-6+)5F&7>K<5+,64(DV'C?E@]U5B,A$_B>P1AO?KB+=<>O$#4YV<O^F9*
M'[/UK<5\=?,13>\(29-X,JQM,!7QMRGXVSB#1=<,?.8O!RN/.@Z8C"UUYQ1T
M D41'=9Z+9U\K\+(:8NN %ZE%C  !W[YN^X=U)+L%!X9E,.%W5Z' O/UO6^(
M"1H"7@  7H?0#0%9OP@6^!EAU(R?BX-3["XM7S44GM:L*_K0KQ .([B%CF.V
MA=R\N )%(VXH+</P&I1/ZY9RCILS>GS./ZT>SH1J ])C1"(O?&N.*4[R/Y*&
M>'D[<Q2P?TWSE(E5NZK?%FNH$Y**HVOYI/()1-DVUD@$TJ)D*5'%"2D861A
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M@ZEV.J6<4>_^8%C>93]3@OMFDB/](;B 3Q(>MT3/(\(I7O9?B.YK!#J/\+[
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MC*O!<;X++>0G'[A\PB(R';$U=@F!WTFY6NC)4E"+C\C/"V50D$#V#]QAK[8
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M\_]YVUDM<']4]&R:H\M_?_VP7?ZC3M_;M*='& I_1'\FZ',H7>:9SA$@"!
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M=HCV?1?")#]KG0XHQEG[M#^ PN5'P>ZA7H&HPP4 8!<U*2CT -0 M)/7)SL
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M.<=2@1(RDZ^-QOMY-]-TP%/6YJ\[6^YM\U4?S!V]/?JL_\0]0#UW_5W#^M2
M?>+GQ\ZZQ^V'(D^I(':D9HRUM%XAWN)BTY][C1X:VYHB>?"U+4>O*P0M'I,H
M8%4V(?U=98O?5)8]<ST!X+@%;I#NM$96B%CFAO?3=D+!Y4Y2=$_\CXX?K]4-
M-05^L7B\38ASZPEM,0[V+1YHW/S:LROIGR+U.KMJ>Z:.79!1V=6\6!U*4V^\
M]S/=<H^6:,O5J(Z> ,[E7,[E7,[E7,[E7,[E7,[E7,[E7,[E_Y]RLJB@Z(1
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M-O)JC&WB]'[P[.-/*9E?;G8^/-J2V<?A7"9*N!Z5]6EO/N.(($ZR5.$37A.
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M^ /$"*E!O7$RO\K@ ^OS7.^T\1BO[ML3!?@4O>NP"U%?<8,@@,GCRV] '*%
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M9YJ^UU/,Z!J3'-*.IE$2'UNYZFF&$*#]9S&2L"J%YM<9QO,^$P^690$?KS\
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MS 9^.0CNV/E)P#J50\9%T=?U_*L4KD-#<0MO<9PI$=M@!X"G2,80"#=9'C'
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MJ!:F49_2-9W70&;.E5%27YC1:!6I>\AOI(Z\1/;K$,7!"69S7Q)>#Y$X\X"
M3/OB%NM3W[*DU%XNRN@CB*(: QX!_??WEMG:F[<3M6,$1E/:N",\1AKEU:K
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M,"#&Y$DBE:!X.;LSQ.^U6@CXY^@+U8U]8>GE,Q%Z.=J>^]1:E,J,WDRE*(5
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MK]/N+7?\P%BRL\0H6!)4LIN_/1XZ+!X],X@G$0[2UQAA4J8-OL:7//M6;33
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MI99#W,Q;7>!10%\7 VW<KBEE=K8R%5,FWB+AE]<0(>>ZGL[9!1+;@4N/2/.
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MTJ_MDM[UFR[(;!/$2[''-V8^&%K[OE[HA8J6?VS)]_.C74E+F0A"Y*0\MDA
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M+0S(8:@^$=:F&CXC,]'1*G4K?F'^Z:K%-T2(1CE-K1QQSCV7X!*BU,?OC?C
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MCO_@\1?3'^3'FX47G_ZUYOI_6N2.E\[^E]^ ?<U_S6OR0ZRZJ^17[N:7LO_
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MUB$ZRD$5?6V2O:AG\3Q3HMYL,=5K!;L@'".Z;$,=*N,<MT'.LR[\H5&S+YI
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M5%" W=4A@WA=#NF:EX_;RZ7IZN3J%%4M,J_1Y(>Z3<K*TF=O$ WI97:"U&!
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M#*LJXZ5O2K+#YBH 97.5O(0/#TN<3Y-JE@)8RZT9A.!DVE9ZX6BP3://QPU
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M5@8DOY-?S%P8<_6&JRN<ESZMJ4[_<EX?^RGJ#Y%Z-_2J&K;QI*3@RNBMZ>S
MMROSCY\__"$J69.\GAT\89_2OZZ:0!$<?E[7?/99?S7EG?N2X!B2[EKY<M8%
M%RCVZS?N:ZO/L]V6L6>!XHJ:3<;_457VX1EDYVU[#CL7GG^MF?F[M>ZK9\TO
M1-CN70I_,UC1_0N2_AB?<EE7\>PMOIOI[JUKQI^51Q6:">=)P8<:$>;&#R<.
M;2GB_Z^%OII"]?U_CB*;]1>DR4FJWO_>J?\_FX*VK&H1K HTKU*/NS*O;6,4
MOY9[L/_WC[IO+U[MHYL?^KG;-M][]4KO?T2CGLZZ0/0/T<Q.\:H<5GI!5:]G
M&?>\4Y/HAD*O;X>>*LWYY>WQPE+ 2VG/_B!%H]_F/O=EQQ?83O5_4:D5SJ2V
MF'P=_W#D_R;\9]2.7"UO!ZN0 /8<5T@0GR?W$N8Y0V:*9EDZOP51N>*><(/N
M<;>UC6X5E=W.8W?4Z1TMV^ASO]QD@J/K"BVGJXF.@F!+[*,#XK+MA:M,;[X*
M?^R[,\2JBNB%ZU.,L(E)IBYR'>JJZ'D!4 H.W*B5FIK'+BVY%E/,N;<*C9C3
MC'%1+$H+<6#;^(NEH !-UTK1641:+\,8&BMS=V?%$IM5863D+#V#%JKMCS7<
M,UKN0]Q RK &^2#+JR4$8T6!D&^Q&E_XZX8R7NONY6D%9L^D:AJ[2>^$>*)'
M6VB7#5CZ1Q!1!VO8$UM-7HJL!*F8?5I,<7X]$[UO]BHX:1S\R!UY0_9F4R-\
MF4I@&+8 ?-"A4IIH8]%\VU&H]W:46+<S&8?2JG#NBM"VI/NW/FW.[^)FE$W/
M]9PP[.EO_0J79W X.\=D*JN 3AQ;-\JA_&X/'07\.R\_L1*I3N9^[^<Z=4S\
M@'5-KZ-P]%.!]^D&@[H.%Z,?]Z; L]_-AO?F$M\S)42R&OM8D<SN2=S&F?;H
MZ4]OG,$X4QCB2)OL0DAT14ZK4BFX3KO#9<><^6JTS8?,WIJ,^>&15;Y [L<2
M*BQ.W]&8'-_0"D# K7E3"NOJ&;>85%.*\&]/V'_@/_-K:@VB"X;0*\YB*^2/
M181OM%+S/>>UK*P%G?8"[C!%#@@A+RA(U(5Z\T+A6Y:#26G4+[\E[2<PPI7B
MA"BKG#;O<V@#.%(3G-2="GE:PA&T3<&UXP/"VV3AHNTNTAJ5%+6#U7N+5/HZ
MA$"JVSQM2[V9FY9?G-19!:_*M9#[AHV9JCK:0*^@ (O>UCT&\0ZV+/85[Z4Z
MC\4UQH]C-B:<(.>VW%/R8JW9:IXY($5FD+,)K"0C)N&RS4FXJ=Z=:CJ6)[AU
M/:8)^BAZE34T]I.OR-2X2#&AE306,5D'SN9=Z%E8ZWC\/;F1)E!8-CKKEG/<
ML'VK#7?FZIDIJ X_H2,OAT6VXD8]C^BO%TMLEW=T'P\O H.$Z7?G1D'-VM^Y
MYH13,V6,&5-7R0I=&7KC:+P]\?63XE$ #'C@;EDY(P/4>?KX>:\&H]M"AGZ.
MUPXV$CUQLP>;V# ;>'1ACD06FUD,D%@9>-Z)@2%*TRZ'K>1:8P%ETB\7T*97
MY35_-['C=I7I;G7.V+E?L5!P7_O&G$1#NX),J6[7:7WY\A1WB*6>C('TZ("!
MV=UOG7.ZH&I'W7CL'$T$;@^;-#76B1;&H<>65)Q,": E3)Q&()@I2:,U(]K,
ML=FTJ15Z9&=R%S?@3:<7D.I70]4TJ8H/:_RX[^,5XF+RF;<Z2KA]*5,#N2,)
M%WO0.=XC> Y<.,(S#[+L0%G(\3H)(#UMMNAW!F*F?MQW,VOD!S1([JFH56 Q
M];7@.\&@)L/$1P$[/,)6^:,#GPA8+;B"U,=:U330KLDG5N'2'@!*]H>9ZS&Z
M0/F7'>U/USC6*'9;QA5:4VH%Q)M^U%0;4BO<KU/L:Q65H';EBD81>VV3'2!]
M3L/VP/4@V%:F73FW5,U3\:ZW<*"ZOC$G(B,3(?50#Y0I!18<GE\$2(E+U?.Y
M]Q]M-POI9E?/E/A9% ]&3^<!JJ44+/!&.3F>I8E'#6].I 9A:*Y4K1M!.<)2
MC':I?72+]TV=0C>JD_5:,TOLN";\L.?Y+S@%TYAS*7+D-U P="=F@:379Z]J
MJ=M0*/MJK>,!4VA3;P(S2D"Z*%3*!#U\!_;*#^\2"II;]G<2G5[O#K7*=W-"
MT+J=9^4(5/!4^#% +DRGNZMT2Z"&ZX'NINZ1_8;8!@,%'_@QP&S>LDF&KC=*
M2?JDIVS$9]HWAR$?DATVQ61+_EPR>B:>+=B;S35%UI3=9'K49_"8%M&Z+^5N
MH:M\_S&3):1ZP_7@$(RA6B\]8B!QGV<"MLZ9<ZMN1D@OCQC"MQ\'\P\$D]U*
M"OSP<68(/P%]"&' G!?[O>5(Z]-=-NH7Y%=6\RR?%6^>[N7QA])GR-S50LI:
MGE@7<S.E./?[E7T]J=*FE_3K/ZP'W*.4GM'^]"E0,6@O.A:VG=;O>HG[3";I
M*L6J'?8)0<&Q,]7*!-<?8-AW>UKN75\ U6'&%WKD+-,)^G'OB<<X35VPM_RL
M5A4;9N"2Z\M=[+KH$@CZPLE^3^[1:/$=)ZU,P;D?<SA<A\*33^1CK:9"^=Y+
MPF>[HVK%8!!P_UI<G!#66CSK6<>N5,<EK>[.)>ELT*MQTCD&B#(MC>/3&^L=
MS]Y8CYZC4G$Q)!T]I^MCTT=]X[YGX0$QFUI2>K=0'MC,UYD;Q6USEMOJ>5B>
MNK=7\T+J17--;H7)\K<$$=?"UZA$W6GMN'%".3$IP!3!)2?=5P4!4N'Z14C-
MWIW'+?@JBO.'VQ#YQ %CQ*)8M4B]UK7VJ?>3@'*;!Y'?K9V6IRQO[M-G>P-5
M'_2"OI:*:O'DQ3JNDYFDYFO49R/7>1>$'AQ^ZEJJ]$K:GK5T2=M\AU588I(/
MVS8AJ_;&?EBNT"&VU@T=RN.I.D)(C^[^1GR>SO90<JSG?B:;OSXY^?GU:E.P
M--)/34%ON<#0XNCU #G<_T%3QM!L7!S_W.HO=JPDPDN8<84SVV"N#XZ/:VEM
M-_<:\TCFTCDAW6?@;(7OJG0;PM!)EOEDGY1#>((2>CBE4O! EP!IYO!;OC6K
M?X@6U@J\;CY5+4FRP#_Q#A(NMRA)KYHM<RLX*A&.$&J;4OPV(\4L$BFR!<>J
M"Z>ZP=CRG?M_>OM^3&<9<H%6J?;Q.$JWH/W>,9?P53"G.\'PG!9"7O$I#0&I
M@<[G26$SB?;MA?T[G-4)7H?P6X6RV\Q@&"4A]H?A]Z3-^/C8/&82]C]$5Q<.
M1M\T5>-[&[[1O7DQ,+:#%M50&@BYIGX9>_^[^=DQ$='*Z<_ @>R[?XBT+\G[
M(NRV%,ZK$ZO_3Y=+_]UL/FG2G&ILN/=C[?2*V>!T<VOCCEG/YW^MPH\&O=]%
MO.UN7S*Z$&B*?_^^_I7I_[-N$MQ46H^=XG?/0[QI9FY\P.%FS,Q?-B'O/ZK[
M C/!EU+"S0>8UB5Z:/G<?U@^\B/B7 6Q(X,I7L#AO[@]0#\X:LXK6A2XPV]*
MI=Y0Z6=K/75P:W1C.%5;A#39?^8C-V;0*$Z+-D>,"%PLP]=6F25VAC>K='%W
M?3>^;:7-Y?/=3_S-,H!VL/(5;U:18_"IUR%/KM]@4;'IK6$B.'&_>'C:O::'
MTE2R03P* G>;?I[E(9[)$ZRU4S2J*DUMY87F5%,K6+3L*UW$ZL+>&8X+I0R!
MFILC83%\H K=? I^.?&AR1]+VD)LF!Q&L+/YP=%]H.R-T* 48L '@0[>>_!B
M$[X%]V3!OON&9 YIO+VM]^B%')-X#!?$^K<+B%DE&"=HQB("O>W?8OIL.6'8
M-JT3,!;I "UOP86K&DO=D=-UXIZ2D"M"X)O,\JG<],_/5$/A2+H2_L^3326Z
M:7>VY<FJ2VOCG-;!R5H[S]W"9@"=3QRRQ!B%.;0N/QH@:60_^8C<&/[*V4M,
M*%5/Y=HWC]'(OA/K'\V@07>F?WM+;+CTP#0([,Y85HMP<T$5%U" >"0]I<@F
MSY8^66HX;V841E7+WV+!Z8 @,#ZME+.$9 &3H7&=7+\DI.-6"ES*\Y'6-S(*
MR3INN#)I\:H=]PV-E\1<LG3+SY-/B'U%20/3WV Z;S>D9*JYPL(F;_0>LFJS
M?,;0X&]3\"GR5B>(/K%T*%!?J#MHPHWM6KJ5O'4S0S9ILT(@MN>)E>S4,BV/
MGHAGWC8J]4%G5NJFTF9JI6OEP[?XY0:GLTTPX\JJ0E3F6F#+0#[>4+5#N19_
MB7'&SVJIO.;]8!!AVS0SD<&+]]-O>7U>^TX"DJ2PF+Y$C9N"A4M(&4:C9:(A
MJMP?Z2/?QX*!L3T/)_/JYW6Z+/"Q//C07N<0Z.L7&FJS,]7T2<(]>CXIR3F'
M<,O)W6A>K=IP]Z<"!?W1T2UF^1;^14M>"VBC#!>M'2%,3/DA#!=9I+D(B22R
M3J# ;08%\WK0'FD)'8T]2;M(Z/[E9 0,_" AP&\"4AY:-PM4'5.U<WAQ??-<
M4D&,-+,_O])MM.FL1[AZKZGO4'9&(.@&<[D7K"P.=*-S)W?0 U90878*T])-
M)$:WWD;JS^B-W:TLI1T-PXR#<W(GX:-[OJQBO_1#<A5&!A>BR8'5/:=E01ZQ
MV.*/@]8_[A<[[I_;9S%> /,;2)@8D1G19&'[$*A$'RF//+',\TV,1T)<9M7N
M-$V%W0OI2GM]Y(41@'H$5'A;B1!;5H(:HO!\H=#FF;^/D2/W>=LV&*KSTM%@
M#-\^EUW/6EM;04_8=$KS.1GHMQA@_8K4&I(3A,LF2XL'H6M%"IPT#8<D<K@U
M IV0*G%/Y<1?8 F+4\DDO:S^*:]#"Q0>KN0RQ6DXWZR7DBUU?"%=SJ&LH#X#
M76&:E1!TLDS=.US(G3._U<*CNM<O<H&08R^:8V8QU,&)*^G:\IK8[.ILJ&LA
MYD3*93T=[R18'F9S?F50Y?4J</+I-.8BS6Q'186K5DM&0+1&*>M%+#VZ;63I
M3G]\HH[#RZ22$S9?-FRF4F)\C2N#I*[$AO5]GP / \J^Q'W+?9#VS(UQ)LT?
M"GJ3*<#*E.WT2I*P-,NIKR(Q597?.P  -.TPB(GK6(!/TA)[<)DQ WVL/JR*
MQ:ZY+JDY\H6T4UV]A\R/ODIB&'I@0[7XM8Q"F>7N:]>;:G&TZZ&0K(.OB10G
MOD)BE*&LO_J#Q*]$G07];!P0MO)?XL#5+4X9AZ(3XED"+P/=Y\?[.T_J>G&>
M=/6!@1 %Z,QH4J"7UQT73@<D*G_1VD##T,2'%(I<KVIY22?>,32'()S,,2'-
M]\E8D\#D0HXO^:7GM^=4#JR-',S%'[-4)=WVJ8?WA.5!7%LUB+4XC&&T/C/#
M"G0KB/) NB=VU0U#>M;Z<@*AE:A85F7C6[.Z(OMOLW! :W#A*)K'W]T/;"(O
M-XO*XC3103P^$ERE$G>Y&5]5Z("3#(&5ID=+AM N3BL$6ZRN*OA"V82B11@3
MA4T]<;?7J8F)C*A-[TLA-JDA0J;MO<*<<, $DZ5^\)MN*ZQ,AHB&]H1C1H/G
MHH_2BV'#,:-2(W' X4<_S](%<DE#KLK*,J.2[(\UH3PYG/(F,_Q-B;VA9:,2
M%'*TC*N<2H.X@%@Y$*IWN+>\,WE[0JIKM!ZAM&S@[^*BD%^( 5H\^)$K*0AK
M?N_!&$I.F9[AH\_"=U22$#EN+J8>ZL^F5KV>M$-X).L%D,*EV[MC:J4DI* 2
M.C]K6/R>Y[ZMX<7?0.:6.^0ZC:SP,L;WU,:.=2!W"+N;,M!J (_55I?%UG>4
MKC0G+B"!IC2FC&^7RS%IL51#O24-Q^6DA;#DQB8I/*?C3V\L^?3I?['VUG%Q
M-=NV:"/!78([!"?!W0GN[B%8(\%=&W=M)#C!W=T")+@&=W=WEWY\^SNRSS[W
MOO?.>_>O[O7K6C6K2\8<8]9<M;J@HTQKVA(#*<N#A/&!+L9D%9;-<TSVFYJ6
MN"$(<3>A'W>T7('&$$#MN=-T$D6I58(55N^TG$^V)1=OEBG>5%S6W6BK@H%\
M_<^CM-EYZVSR\Y,M(F7%JJQ40H_(H.EKB^E\;X0@.@;F=%BF,T<87T:F=[]3
M$UDIS($I:#4+APH%%[S4V8Q1YLKVN^\:7(GE>SB2:WIAJBG2Z, ?/M @JO=:
MSD<<Y^N[Q17;DO#8>"C+QB6?>Y>?]5*HM4/C3!&QF8ILWVE5ZB)BCSA,8:2@
M[<JF3)F#9<RSOA+GS=2'#>-'.3A4FQ]6Z'[JH5/6"Z 9P[$OWBX+)H*283HS
M[2?]0D 5HW^>;#P"IV>OG7Q9ZQXC4ZKT"KLZX(:L(A=[/]-$!0%,F]R&,/'M
M9D#UC"ARD:BW/33)V^V5]F4Z(USBI;SJOMR<<K!'B\/TQ^8*8?@4'7SX&;JV
MEB2O\#_@+4D/^-^" 2-&P]1^;'ZC'-UTYE\!@#FH>$P 8"R7G*B'XNQ.'0A2
M$1HSS1)!Q[*B$2C936D!)LHGLG/X<^1]LLQ0H$-G,"SW,^4\#!NX<7\2O0G@
M/E\3*,DZE?K][>GL2\8P0K*''+8LXFZ:);1,-%BGSX-Z[P-81\)#38$IZZ>E
M"*_J (40+U6<VZ5 )+"+?H/ZP9\<F*Q(?[P++W3)!I\?E>&T-!4[GV?*)R//
M8 ED\1"SI 4;I>GLI+ S32JPF/WU_@.,%%@1=X2S4 ]8H\!8D'#8:4G5Y(=_
M_J/66Q:Q>4!CBE?N+NX7^2)B9]MG3)+7YZ:[T_'P;IS_B/@2'9,!(8#*QFF?
MH0KXG4M\U4:8?ZNBHN#'PUJ]+P10\OJXN@F_Z%LGV^+ \7?EJG:<.WB*+3#\
M+UJ*;'RCBC\U)AO;!!NYJ]*2"\T_TTBI0G^V"A?0UC9WM$W:6(M?1*W[*(F,
M@\4@L]/%B_4)MIRA@IXH;&:^E "=&NUW,#(&2:.JHN4:_EF:. [53QVQNI0M
MXI5?C+P:P^]@X_V_"/(Z%#/\2F!ISR]CT"W*&9.ML=0(?"?RYT(>/[K5*=)>
M@^K*LQ?5B5:4SP6+F0<7T1)(?J"44L/BJZA&G=P3&;8*C<-[)!J+T(4+8OH(
M[@I ZXJ1F&5E&Q,)#LIOB4(8\!Y 1Q3])<V"UBNI:)WSK>/6XT3&8J$R&/JX
M>CL1? ENU)A^"DA0T:K-RPI7UZ$G1OO4<_/5EKEOJF^0:9(?O!ZTS4ZJVC.5
M;J(W%K7_1[X*9]2.LMZV@%8Z"QC<#1.B'D%O:OJ-+5^UAIBU!G-6RL^SY[>D
MN7A?LWM0&6(\ FTXWYQT\QSC+)]4%A>REC0G@#2EM.Z_35X#DTDW3ANT<!UB
M:0MWU=7JD"(-.J@9?NOPDA%FPJNE=ZKD]O24X9$"/6(U= R)-=3J6-A7X-_0
MZG[N,K . $12[T^,31F8FPCE<<5F+ 73&#KB]LDDZUQ$!!?=%8I%WHL36-&Q
M"F[>[:>' R59>J>9'!J=)40*E8,&WJG:9L6,:26YWX42<HGHCNS1DE)JIPO4
M3F9L^'1G%QU4;.%_"'+KPIA.CLA_8E+*M72,H7>:/]43Z<BZ+AW8J6*1+, M
M*)%VK_S:G.1$''S/*+91A,%"=!&HTFQL(M[+(.5C%2>2RS7R?NHW\^]0%W<)
M>U^NSR*&;6D5=Y9'J?6?K7K%9K0"EO5*(\(Y'BUW+A<TF#@X^:6B$67:"WT0
M5P\*\5R/,AHW[[H5*KX*KC!_6QSRS&M;54S%,JNU+E?I+UKFZ%M60OT]\,Q6
M/L43<B=G[>4.^ZU[LZ7:YK,I:_D%X\7[WAZ5'KOXE.7%<M%F,W&\;6-.-KU#
M.8ZK[\30TG;O!WZ9LL)@1">UMD0*GLT_[JX2^H^5Y52]HW7PJISOE9T>8,%5
M'"F)]S\HZ0Z.AM&%C39O*I*??-P,%TABEEQ5RZN=;@ ?KA0X,-.G$OKW+17_
M8!UF,N?)CSDK Z^%$PPOW]RAQ/.1(E).)5'5QO6@P*:PF#C.Q1(K_\@?P'V<
M+PADK;9,][?)$"%5K!$9W7)8D1CQW U.YE6O1SG)K!DM._BO2,>PN(J3E+OT
MQ1#;CFQ:C?/'%$OA5)5T*D+Q]WP'Q627=[++8X4>:F6.&O3F5+9[!<JZ+D/8
MI:E8Y]0J=+D'JXP>.Q*6ACRF\91BXK+[P<GDZGC/)H"?DM0"VM%)S=H&WXKO
M,,JCRHB&"=D;D?HJNU&"6)'#+O5#*/!1>#<^-&S)S^K)<!H:I*^4;MGQ-Q#R
M"^MUMZH;,[H92J\&%!-9:T_CCKJI\S=-VC*=-8CBBJ),M[:9JIS<-+>76@B6
M%+^*#FJY[1TS.DP".N3$6D-^S&+U:<PRJEO3'9^L!_& G9N!K6#^,-@5W3*7
M'U)D)(XJMH3CXL973"?6EDLJMY8LQ,NNH:F_7N\.)WE@>NVQ(Z1H" A%LR(*
M7!;A.JMNL\!!+>FR2TB:8+/,TPP5_06&28D;Y#RJ6!?-4?.@89 ,>U;/;(CI
M]-([[C6U'0V'C 0Z[>N%98)=>^?2=R&+JY-Z838?,SDE-.OEBI,]C#>G*3XI
MT670:KEQ-!82@#\TU#?61^B8;[93<!FT+NQ&\PULI2L&!W?+]+P?6WL_9AK#
ML\5.D-L8<&&;E,4[.OI<\QF1RX*1E4N]>8ZET:IJ@:4#67M2(QA/IY72R:F$
MAD-[;9J_N:4Y)2M$R'4;MJ2 _E=7<M\[A!%G&A=N3J'#@C$W*5H<.KJ6 (3<
M)G?:&#.*=1H9+-G;870]]XN:(TJYEH+$?NQ<!!0[.S(='-91:BFF48&)8<38
M"\TY:2EX:)I%?IH<.@/4W@R'7 .V@9=O57/Q1+(F\C71?//_ C[E7Q<;AUL-
MC]Q[>GY]K9W&F9FMT[C2<9I6'+&!2Y PX!/++?Z\P^XQF>^3V*H"<WVBH(2H
M^0.O^INFCLPR=IXA^(GW7<=-Q3#F;^0L@>*X4E;5$\)&D73$F?+ X%GZ#R(;
M9BY6E9CF=9U-1DH6M1W!\-LAS>"A34;#&G^U&9J1>-DN<,YFC%B,R>=ROD:<
MP>0JB\Q<VSQ<46.L!%?<2J8O9"R9+1XERYG+AP_J7.J4FS$Q15:%AZJ1^=OQ
M?&46-RH"R2VCE.I,50@#2NPM2]KF$QM3$V8A&LDRN<@VK#'T^82)<^Q#N<K?
M?2H/-Z=[NJG<)RK=(^@1'%SAE:T;>W[TXCA*S>82A6W$2C<T1GS8^##ZH[&I
MTSHP/*_E>UWC))Y5W>V9R5#F15:%[(G[R<M >XZ7-;*_]*SZ.R"#$U)AI0^)
MM0Y+M+5:+;U/B0$VB^Z6N&LD--R[<,DL_4WU8$9",X<H&7/+&6;G?>,Z=_#B
MG'(#&#DZUR)XM<.I2.0RG^XR/<6%.^!2#-&B\G%0=?.Q^R.JS'M;3D12HQ,'
M%S,/3/F0&/?-*9/X+;'CFH*R1>H_O;\D0F9RM.2LZVS;U!8&?^[5+RRR%I[7
M31[C+HEQ1C/J%"\@LF3: +^Y&$8D2?OE'^FK)<).;K,G.\C,9JF'#AG!3J+)
M)6B>2N^TIFFG9IJYQM7M10^W50-''(S%@N6[U4IU1B*1.2@(*AIUJ(*IXNA8
M\RUXD'$OC:--UYGD\!\W:%4G25LJ'I,S-4TH(S<(;WS^R8WIWB]2[2_,1[H]
MG^T5S0^!O"X>23LUUUQ]T_Y+Q.CU[XC1,\9_GIRD)R=ZU6GQ @&HO=QT]* 9
M-CZ.,NST_+V]G13&73E<@^LP>_)Q118Z+BMJ8>Q6.<GKQD!VZ':UHN36DR'?
MPJ/<HR ,U3VOV/3:3"1GT._F,U*^79F99 GQ5''*2J0E"576(HW)XDZ]F81Q
M457$+CQ+@:(F, 8GA%>$&1.S&77FG'!/>EL:V:]P=:/(4AK%,^MWL1Y^M?0E
MS&IJ*EOI!@E^P$9(G?*J3R+N,02@H2T5W5F>CJS@HJ:9%"UY)NTF:NW'6%K&
M9I5:_+I0MN<FE).G693IY2/O\WGIXYG,3 !!,LX"?;C"H9*E!U,RF#EH6[L;
M5IFZ0T<&Q7@_.0F#SK!2QB8_J$^<X*M'P0C8IK )$TJ(Q42RS2/-->P3'2DC
M3[\YDQ*,K'$K6YF9B5S89J _)4'5"4E4KAW-SQR\;_'U+C4E+(+Q.38O1)HK
M5@Y8!9*"6CA/J)PRM56.MIQ4@7K0SN\W4U2'9JVX&F)BUC*12)52%3AF:_4K
MSVRQ'B^MPSZ$\!\$Y<)3_ K'.JL?ZJHEH,92P.Y%:E>VUS^T/^]K*O_-$S!L
MB0-MUFQM44DIPY,I83$56::M064FBI\F4YB42=+S1T<V9\2VH34QN)B>P3@I
MFZ'@<Q%U X,9'6*26#ARLEIL8ER:$8.:/&(4=("E7W4*-6(0#&M/7!Y_RG2^
MV7SN^TVZ('"I]GJ-BI^V?P;P9V,>6DU?+0_X\V<L'N6<93J4#<DA@EIWR=\\
MN->2N)G_0OW5;DQ,TE<8U=C96M-ZSL^4VALY.L ?AISXTVYWZ#'XDECA<-P)
M5XLGDY*ITU1R>,EI4JGO4]A48>C-4&"@U2^-T&2S68D( Q!A80)$ ??$WWPT
M<I7NV;RHITR2%N1;=#9)9EN-20VLR_?X#GD/]F/.^CQM^S=3G-:"P]X8]DT6
MD#K&,&T/6>X'@#O&>[M9(,2#.]ILM;>-Y,2N[F425%ZUNHCK.I$8F DXD.>:
MX(1>G%#E:HVWD9)MHRJ- .>5D&)")S)'5:&R*:JJSD#9 6%#!^3[!VPS3U8R
M>V1(.J)<1VKA67+8U!FALV19>JIYQS_QGD16G.R%#\O83P8T;_#VR9!J)?;;
MPPDXI"W<R]%9 : *.0"HW"_-NYH[\O]*-]6CN_*QE@G1&G]\9U)?#6G*+^7[
M;'PMHEPAEIP/U![),1;ATQG$E0G7XQWL6J"E4P K.NH4#* YM$1/?G[.=W'(
MV&(01],6Z'> RPG%JLV21[B-T@R# )X$7:GL3Y"]:N)?JB2/,LZ>]]:.@@0"
M^ZFR'@YP]G@; UW-=Y_>4V<][C[KD*Y%?X?!7W8:D]G9^NET-VMQ+#[?V;B$
MMBQ;NCGQ76A#B_&PE>F06<W&2 TG#(N:]R+SUFPPN 1)+5B;=$2%'$Z)54QE
M3Y[M\H$=+OBUA/E9!OLW(0.KP^\$L#@**=7 1<T5V&FLJJE.SI6I\BQIX[<)
M !JA"V9$$+\B _8'01< Z M#T&4D"$4\@HZT_-_26A@^H/CM$QP%"UZMZ6H8
MS.//A_<ZSKU#N_N#KE\C-O70>IL1]]-#I2X#R$W^)R$*#-LGCR7++D_! I!P
MP3]AZ?0N!>@Y^?'V+<P;F89S"RZ<C[O.Y%RX_-QC0P&[?D,S/?[D-6I:.-@1
MA9K>R-ZBZ*8Z\;$EHA2HRSL6JJIAHLXAT!#(7M<&,UDR+!N08LZG\:,RPRXQ
M;U>#URR. 1F+-F4!R*A[IM[2$?69+ER9)RYLYCL+#$!1>P]JB0@X),3YC<N^
MZ]FRM_>7UA#YL;O3,N]YI;<]/#FC\3U@&8 Y5E$J]K_0DBS^YYT'9V9" DOW
MGI3"P,[.J:&D:O>T_^5SZW14?IC[LSA5XYD?[T3;^$/=\D":K\7 M;7# B<H
MQ$"*[66*,S0X<@Q)T8$"/;U_0O9=F!-AG=[_1/8_&HEU[QSDU.LUU)?U>C]J
M?Q*8G*&2Z2LF+Y)$\F^1D_OM4)3/RU<KI[M<(6LY*OLC^-V0Q9AH+R'6.(OT
M"5%^F+L!@0&^"<.0./T:E3'4LG%.(EO2U[BN$E+R*,PC7'^R<[E; >'#<07;
M_MJV^#;>Q[J8T+['[_=JS_-/-1  S.A9@NY*Q-)V9Q7MD:;\O,'W;RPCS W(
MG\.:%&8O&LOT@X=R9)?WE'D'MAL:> =5Z+C<[MQ,9%/Y7.#QF$J*J%L"'+"I
MLXP2Q34W3S>/R_1ES>C:&:15_!M79:,NB3+2&NE,@G##W:%XJ:BWMPB6LPX[
M:ZHT_[<GR___NOSWE*C0^]6[@\37Z+7 *,'7*E#92$7@K[\R7U;BUHR>A'U<
M&O-.%:R1-+N^RMYGY"N;>&Y.^D7D8='%?X+RD[ZZPA4H,-J@.V>\$OU^)4J^
M_O%&3"5E&Y4;Z0QV&!].,D(4G[D+.9%"U!>1AVV>V$?O_%4+QB1HCT #S&63
MR/=>0, +CN#2L5T/1!ON-!SF1&JFQT^\9,FQ^,@047C@<A*&;RLH<OOKLXP+
M'=8I#:O]EV(YXN!."[[#RL:3:1]6>[,?9;J21WBRQ?0)O]@.50LL!"]*K'_-
MD4[7SE %''TVRL X.,%1X=JHJ)]W$21U:VJ.9:=N#3[-M"S665:"UT'4\B<8
M;.E(NJ5-E"&MY9E9?%S<^17,0*364GT@V*I@34]BJNN3M)N3LRH*9,M#_-J>
MB#E_/1]:)-8E9N!,?&WBYWPT4R4A?6VRMC:786KK(OCR@FMS C_VDG?WHG0W
M>P=UFUT^6:G_/PE&_;^YK$IR[*D8F*G2_1%D$5<HJ-M@%1T7-*A:R&*22*_L
M42>K0XVAGI#F4*C %/R=>FK\DRPT11"86F60*0J+9R+?S1A7!5..G9TDH#1
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M%$Z2L#3>Y:[V"VK1K+QC4[ARMPLD.7;2W2XUB?Y/1I16#+U]32+'(Q_0?D,
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MKX4]LLNI:DTE:# +.C0_ Z7W=J)$O=+.7CTD:%S?JL6^G"UIOZ(>"+_D>1-
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M"^% 0KN#55+0Z<2;QCCIGXA(.,^;%(Z;=#UO:'OZ>&FY-CSW@FS;>8O$ 8
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M[ *C=),\=G%X(THJOF;?]ODD:Z-,"4MAMX\OJDPB_Y*V/M(FCIS4-\#B)"-
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MBFGW1-!USF4=I]0<["ET^8[BM3=30.(*C,H@4!/(1M'34E?P%CQ73V_D2D!
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M4T<G=KA+<\<T2C]9VP\P>4,?JA"V-*KN\"B^]AC0NG,_WP 0[5TVE2GJ%L>
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M<F(7)UC(E05/27>NOYT<7>+(L]048F__^;>]]XI70=2A@?(<E9LY 9N1"GZ
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MB/%\!7]&DZ-<P1TI#P"6BRLH")/@9#9OW>$KN'CLMVH.;(6JL+C,":*1BVF
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M"1CSD8L$OL'H4.[?.<T+;!!.V<2RAH^V[@N;]T-OI@BJB,PDPEEN$2$ +E#
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MPD__[R.?560NZ$03C(2I&!>@M.#F44)3E7I [-$-!Z!R&L>>;#HFB-A5Y3(
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M:#!DY/KF1.C4CP23K@[SKE1HWR*Q"^(9L.C%Y&0&?$[$!,DQ!U'\L&"B7^G
MQ-,*D1R@^8JI&'3[:7$B1O)0!\]CFOKR'TF)PJ,!GW=TZMC2Y$E*FQN]MXT-
M/\U54_$5*]N4/JK58U@+%DDS E<Y7DU(WBI?X1)82R86W@[E"?V\'?J%\M94
M%X8#B9&KNIY32*^W(>%IV=A08/)*F.B(MD6XZ KF;4 .YNV]FO5?"#HT$-)M
M/%$;DK]QC+@D/V5>WX+?HMI?//R"]B\G6T"3V8[7$@K<L(%M]Q=SR(!HWO^
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M[G4#%D0R(FQ(PU(G5C&'B,)^D6"QC+0>^CAY!6]&.TQE.K9J7["J(:;BSZ)
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M%Q^,/V$_,?Z_??'@G[/_ E!+ P04    "  5GPA57"A>CHX% 0"K60$ $0
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MV^3?H6[D+D@N+4Q<M#(3:1ARPS+\:P!G(^:_7DQ^W=;JL''[ET2]_*0D('8
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MY_+E>MS;4B/8-:[;=XH\Z_.JA+_6'@!6SUPM@32%)WH^-BB0>?$L659FMMY
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MJ:G'=)6!(@W??!FVFLI6V'&/-V?^V2?&VGWN+:*6^Y+#=M+73NGR7"V39KE
MO$BEE8=RY(=MAYJZ3]-U$4[^,>J:P;&00=BW;*'Z0FNUX=(>8I7DXMFR1SV?
M+\9[.AIW?'Q!KW>"M)C[G;+%\CO-^/K^RZM*1.BV2_Y* XM6)%\K<U0O!=^,
M^6J('&*AN$;5Q9Y\ !@HXEUX_S:3^9D12<\Y\B7LUZWSB2U57YL<@<WK'^/L
M'0X :QM7PB68OLZ% ]A#HXJ=M*[<8$X"O^M,V;V@G5?UWNA%U2@?;'_N,G=Z
M<U^0_SU2DP<N NKK$8(U=($P_SA!QXBIF1K(*L.R'_Y-C*>7#\$"I49%:E49
MHW%!<J) 9?6IV.6MR.S<F.Z30BO/3])U4@.:966*Z-CL9V6D5&LC)MU7;3F(
MR#OD$(&S+0,)SCN2/E0%RYQ7ISSU5B3A# 7CGONIWN7DG@&Y5%!1Q=BLL8@R
ME?R2I0IU!PF5*O:<X&+;IK!'DV2&\52Z*4VG11W#WY@]C"[OI+[O$-69$#1(
M0M=%6JE>,?A$[&%BQF4G%8P*4*S;MU#7HC_Q !"Q5+O6+]6#9@8F0(F\JNK.
MD*M+2\F],;AY=Z<2-<5A=EY7C&E /Z(]>4HWE267SJ_*@:C(8+W4C!8DY2,:
MYIZLF 3%TK6_WEZ^3H*)R8WJ2N<TBH1^">7WA%X72N8W-#;HRG-1"=6M(5 1
M9 _6OO_E:4"J,/PQ(U%\U2T/4#/-AH*TG)@_TN*%IW)6UF(N[<SCYXWM%:!<
M7A[CW<B"I':6G(*M0#X* VJE,M:L\YS7B0 -5IWK/GC=7;WS$Z0D._#UP&2!
M+'LG,J$O;:JKVSJ\EWNRZ9VUI28@<2@%TM(75>5/9MX-T U51UQ=I3/]&MW2
M5S3*.(LT,]#,DU]?5?-54Z<4JN)JY'C[>7?5(UFG"EI:+=NO4 %H$YR/%PA[
M)LO'8<D8E^GCS9_Y%##S]9&:$W&(MDK3S2L3O5/R-[3JHV@5]2**<N/8H<K3
MUI^^U]2]]NG> X  I+9_60E#'GC)O0AP;6_T !!20W'MS_K;/Y*]U/ZH!R<+
M7J>D.@ TP?!:3LT+]="/'0#BZZZ?B'K+>'?SR[3RFK?(I:KT*+&7\QZK;UY\
MB<=5-OLE[Z[YI<]7G0.SE0U'"KX@E_>OJ=J]N/'(LO?)RMGHAT(,\'>/.<5O
MAO+:9BL\#AY \7ZPT;CEU21I^9Y!*T,=+R6M"G_M:8%M5FW16L4@1/XM$])_
MC-6D?SGK(4%,-\#CH?_V1/9,V4;&@P9:=M(P\IW]<VM1A>9O6$ &&RMQA#HD
M:L"W%=F+<;WHO;I71%\VJL4_R%<1GP&<^=1B2M3QY%G/B]M[FTV/UGU_^&7W
MJ*V.P\<V6!)#RGS":C--P\RS'NHY9<UZ>@?<K)RG5+X"$2PR+G4] ##V5IF6
MK$/>J<HT"*?RO>J((!D_RRAISV[3*KRZVYOT4*57LGTC81G1R+8MGQ>WL39
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MH!P\5PWPDJ;,VH'#YENNH-W5B1)SI$"NZ>9T@%1)KI-D$JJ/XK8_ \Z2NL@
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M2Y35F48KOEO-R]KREJF2C0CA^84C#V32D?M.IT7P(N>.)>';H(NM5MU@8S=
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M HOJ&09AV+B;W:LS,L\80T/;6,\,?]SB066O,"?90X7?MJ%NP[L8P5E69 O
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M-- TM4GJE5R+\FH=_98AJ<IFC([Z!:J!B_#4B54:Q6>1H,*1Q%.R]?O_BKJ
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ME3LX!Z4K90G5&>SB\U6V1BUHW#;B9!RAK6.>Q4S+"N1.5.TV0VWBU<MJ PW
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M>W-B<333/-V*$5KXD($8]_EV(7!D(:*J1"/?5;D9&,M&B3&YOXUGJRR]?59
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MYSA\9U/>*H6(!1'WSH*H[V(I2[YD^CCUB75C9!YWFXGR?I;;4I)0(@MGAN:
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M4898KY5NONPK#"1YV!U-#=H3ARZ36,3.O(2)WV6T3X =,1U@"WOE[)=?]RU
M5INKB=P*<YK^J*I2:[A+MA]82[346!E-%+)&U6=:U6=SHGYI!CT,&S!+<O0
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MU4;_UKL[*Z(\*Q]RR',4?C( Z:D'<!WDM0)IY'4:.H^=/3W="=W /<2%>$(
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M&((AQ)ECREBU)5RO?B!1+*DIN;E05^+<S)QQD6G"CGD^IWO[I"H5'<K#DB]
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M8GX!L:1V"H :&))L@DD--TN%.=H22ZPC&B8#L*@-0(9-6^I50I\#VXK5,,#
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ML&C.B=5QIN<*%I(J@P?PC"VX#9'HA\NJV@*%1<M"%L+7I[6Y-.>;$10JS0"
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MY W^F>Q)J'<V4D^"TH*&E!*+% IPW#^>?L.'JP59?_Z<[NR41WPCO*;=SJE
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M9'IA'+4U;FI7IY$HT\?2E\E1 *G-6"&+V#C:3.7@O[$%98^>+H$&2O9%[@Z
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M?Y%4G*6R8* ,7T.ON-"-Z&79BUCLGE(Y97'MG_$0PCN""/JI<VBM)X ,"NY
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M]0J(//3J.N81>GH\[D=!OCIZGDGA3HCH"%=;N3_^>76\<@=EA]PU.UACF+W
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M5@5=\__[D*W_/SYT7W_^'U!+ P04    "  5GPA5YINK##NH 0#;_ $ $0
M &<S-S,Y-3EG.3ED-#0N:G!G[+P'5!-;M#<>>I/>!.G2,?0N'6E!>@]%*0$#
M)(20T!1$I(@H(E($I/>N J&#*(B H%*5@#01 6E2!8%_0+W7>Z_W_=_[WEMO
M?=]:["$S<_8^>__VWJ?,G!G6'+P]F #0@+3UM %X>'B >-P&.%@\N6)\R0OE
MY7/)"\$E)2H.D-?0,R D!.#HY$"SL^6?18 )&SX @/MCPS<&D"*14I+RLM(2
M;/A$ 'D#J#/2R\?+%<5EY85TX0)R&2.]]*$N<$@ [ES;"PGC,@-*<!E X:A
MKG-(1UP]>5%I44G)[V!\1]9IDEF;Y]?SVSN@QE>_^HYE;QW)%(]D,X=RW _O
MJ$2!0.(L&:%1"#0*5R0ZY!G[H,R<O+P\CVKHP5$0"!P-^WE^>-3T1!Z6J8]T
MS:#^AS4TH*A#G3]M0I"&CC"(N9:U^1]@WQ5P\7BYFD%0:(21D[LSCGT"8 Q
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M7LA?DDO[74%#YP_!H1N&7O##(QG*"X&[)/E ?DT<N2<ND?_@GG ZFO;^P:=
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MPE/IY^%5C)EX&[MT<S * 6L'.TO>%1ZJ>Y\'*G[J*]RMWB\<KIAGD,P^2-C
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MXC6;/TL!'=N8X%O=E#05TYFEY+'X\)\8?AQ9 1R<"&'N\*?,;]NAF"! NC$
MT^"8#GS);2 SP(B%)>&[(.!KO8DMLG%^@D3FQ_[?*5%927:#@:WV^-0P)@/4
M9U'^BU3A!&JCSJ-Y':"H?\SEIQ-PP)0V$^NVZ#%F$]GQ8^AYSS>,KC4%H/Y4
MA<9KV47K,*+TSCK&?G<YL;=_G())VE)]J(CWBHLO$ A&]]7.\X1/HFJZL\$"
M_-F<C4$VPXW,;*$>BSZ3@^=6BIGIPZ?IFPC"<J_SR*%&YG##!G_ Q<5%]((W
MJR3>^<OT".6CR\OF.W5D'NA_&Q99$AB6*(D<5+F2_/)BGUQ<Q%]J3\7#-6PM
M?% ;R%01D0T3@\@*AS#1N5(%E%7'\4]/*<GP,,8@E-, Z ![^K\_KNUKX:ZO
M_]=?%6,GXM#%CET)L)3MEV/WE;C35]JOW9XH^$2.#B#12@0(!_=^\HX=5,;:
M2:'*Q\ZFG=PN>Y47EY>T&9"]A@4R[,3^,< EH\D>743JEM#9ZXY1Y:V2$-4.
M)D'L)P/LZ>'M2B0.TR!ZMIN]S!-U<1J>&"XYQ /FX7A1D+OJ+1F>2L4<;DHP
M-\45RKYY["SB?(W$$^LF^+VYY,V9JODE,?+\Y=L+D=[2X?1V#_>09P#'9)P^
M8?U5@8#'(^&I,B?M-H5?G-L[HW;XW#. =$?9(.L)M,WPT*4VZ$%K[5Q0/O[?
MZ@%XE2;GD%^ DQSH ?N)$7KT#&!3JDPUW$GG'*.=%5D(0[\G/KI_I8:1(2$J
M(JK(8@G#IMJ9LU)YC+@]>C@Z@-Z&[N,RXPG[KV;T^XK:BM-9M(_S(S%7:@R?
M;-5,+<AWVD151),H$O(D2_D9A"(>:$3U3"XFXGAECT_R6 OOS:S[$F9^ G\Z
MD#KA=J+)YKK<;3'S4VV^I"K8IAH+036D_?/TF";E;X-BLQ]3+YUN4;]]-"9J
M ?Z(4KTH*$Q'9(QO,&04TS10P47.V7:$?3V<4L6H ?BC1Y5[X^[)FU:QO'P0
M*"0L%@H8#.F;DF7AN^1GCK0%,V[&0$FP4.WEFW?IM8.B7W?:MWV#ZU$48;6R
M$+7_"76_Y?[..59&AWPE92<)W0[1K'[:RVGUI\B'ZB-4NP%G&/.EN]-]XU78
ME,;BAXEZ2;<]'&K&J=W+FMPGXG,V698]\CY5H&GD;"/VAT<\VA3[5T?U<7;5
M\]H! ,N0MVXVG/[QJ1J+5SJJ/AAH4A8#Y->#_GT'?66%=$3_Y,ZYP(^5.IB-
MB$?4*"N=2[$:Y/\O8 (QJ:9NG5?8<^D=9WS, C 2+%]A>(&*</M7 MEMSNB[
MWY+U!L8^?_(;ILXMJ2$:@%$'4KD^;'JZZ-OHZZ-B)B:%SA5*;WEUR 3U$*]A
MESMAJ9KSIV]0]*FIL$-:8;P/,,L#V !8!PR),NZ2/$.?R(3FWNJ+ZQ$15.4H
MN]L/!N@VB5\QOMK3.9BQ.GHJ3EM$+WP&7&*VZK3P&$0O0V,4LC6+0,=Q%-_S
MJTK2.9J:H_0Z5W<R[S=6N%Q8F7=NC1UT# B^FG,(!V$Z K\,[GN)*\=&B?F<
MI_UT?>.D'Q%0>'6HU?46+T,'_%48UYA*-D5#./#V" 7$SY$WHI]V*P;$>8MC
M+EUU'O'XZS1O$_D9/.[#]P"YY%:H').B]RMEEV^848[5SX!HQ?3S]-4$FO18
M$@YLMHVCWZ_,AV@LO%.9;<\8Z+:*J4=D:I/>E&*0D.1<T+?T/OY43.D<>UK?
M_:/LTI,[J=/GM=IOK8H]=QYQ<\P#JC0T6W3SLN>2T0^>+_ST#>/<H*ZR 0?$
MR(L&3POI<>!7+!&137-=Q,!X!OPI<L85?@:<T7\6OP^G5?UM@.A3374J=/&.
ML&B>HIS-5G##TLUBF-K(34ZX^GCH4K3=N(A-]PQXB)(1OQC4Q:--W#D6W!LR
ME3/V<"KRE(>E7(?SFS0'7_5=%8:]:OQO7\ .1H2TN=B3%O\3]K4U?^DSX 8Q
M;^Z_Q7V;[-<<X/.N)6<9^T15_>4BE=X;44;'>SM-?H9T6%9&'>?UH53D#WE*
M*[G%LXVY-@_7K$:7P"?CUKY_OAZQ*KG$/_3<!)2IGF9<91G2A\2Q3_JV?NLB
MY@E(TOT#17R/WW_5<\$L"M@:ER^5/D.S6P+<1=0\_H2!F5+JMB&M MM<ZXX=
M# 0<%3[+.2MM.6NH3C&&NJ=G .KX^HM=C9[*77W.+!=H]@4$L[FI)EOT?"&_
M'WRY*4@:D2U&WBO&B!'@0E8RUH_1=^X_X<WR<@E,>]_W#/CENNL3)_C[*S]F
M<<D_&6"8-.=4N'>R41SA5X]F*EH%58V/AS$G<]=7#U:*CZ;/@'1_PG/=]QY>
M!<)*1ZJ$*R' L!$2";]>@QR1O\RIOJLP+$__&S%:;[')!7+PW:M+AI,CM=/+
M -_"&N0SX+00:RS#!NU 2OUDFQ3VX&GGP+?WDE\$/0A;6%X[!9$MNR:'2X=X
M'1TBX$F?VPC'S+LBDK(Y&A?6%RB5^UFT<)_[D5!%3D2Q38OB,/NPB23GG+=0
M1\(/ZR6<=3/WZ=TK%C:A  X.O.E4A%P?Q^="IC\3*S<QQUTMDDHL&[H.LO2'
M_!.TQ=P9;M9;;\9BG446&QF<;_YBL4FA'6-RP>KE&/_+N80B#53681-$B[D?
M7+?1W0:.<>WMZI4:WY.Q,S;[]4@1BI-;7?.L?'-D^QR;;::X[[3(D*N.G!8P
M).\ E-E\. )N$A%JD^/=-0CTEC*=_N [&/83*7J[7%6@7Y"@_8H]KL$_>O#>
M;EJELZ&0ASO,U3A%6++)6,%8H@_PA!5?ZW'ORU B,]UQ_!-K*%SCCRN9)J@A
M3EZRD=]OU!O3H[.;M2KXH&]OE/_>;?KM[\A:TVWPHD??<CXCP2;AV-V]-8N>
MZ]C&K5L/&C *A]&-?-/'9%)%CISG,Y!&)O=--"3B?[*<8LEF3J\[Z!3@&=#1
MR4SE+4\=*>3P_>&11]TGRG<"1T1K/K6!&=6O3AMGIX4^R4_9M5&P-JFM?!A)
M[ ;S27U?:<F[[^2X(XAK*29$/ A-Q^V\^\YH>,!BAF=,^41=+9SX.7D7MZIM
MST%@K.X9T%F:;2-UUA"-790D*RR))BZ&'\'=.>:U<;00:I_(-U;I\)C*W^LU
M4(K9)40D=T>[(6A>U0RI_9SW_P>.";J0)E@F0DYN#(#4]Q,.Y9^(ZWSOQ6=;
MN@>E,,I_!E"6E7ZPY3N)*_3O*Q>H@,3Y*:IJ$OGM_W=U;K1)1>_U;]&^L?W-
M5B[[5!C)2VEIE\[7@5<XA-\EM]]/3\@VO D ]]81YS9DDDIB"/XW[!LMKTL%
MDU%@-7J];I?NXTWB&4_R<O)YMSAI .[G(?><)RP*>*W*'G-LF4)<3\1DXFIL
M/2<&!A[4N?2'3E7 /IJLQ=4"MEN@,"MT.WM_Z8,+QCB_,15A8N/^:EMO$Z36
M9%1%W?'N9^=8TJ1F^D.BCQ$_BS0]JW74@K=*-#82 R D!C3=E'S-"("!S3^B
M=:!+$JZ\>DNS'O)")Q9 RZGJA6T[-Q3@^_B+_SI;_"=:Q92<XUH>/4.VH%SX
MP!\Q:D4.>7<:OZP.85P^@=<5N'"[2,HV[/$&E*,V- 5\&XK'B ,2K#1)&$B(
MF2ZN#)!E,CS_0^W8[M/M:G))TVZK5<HH^8I@#\MMP6/,@EO+#W&,T0$,?KD_
M$CE?Y"0#H$DU818)9KP[(_S'-\,4I1U!6ZK/B!_U(LCAT;?N'M84,-KI)ZQ%
M')ZAS.L]E#PI0?[0C_'$G$-0I4M:X*U)6OA$/%5&D@Z^ IP7,[[IQ7^"[T%[
M3<@+;TNCRDLN"H0A&'L @FQ8B0G 30AM[GI&F@TT8.^+.E_. T$K:,_/]V:R
M$RBT07@8;_$V4ETN<\\'(+UX.&MZ?N"I+7:,0&H:W5$N+1FK0?=&N?2,TQUJ
MN,<YBWH1#\,@#TN>2-H.Z(/I:!(-B[ZC6!3*7#+DA7.   G$OU?&52(S9EP>
MH>33^N4.?5NZ]HV5'>(9T .G5PZ$&7$AS]\IAM66XL:02')IZ: <:M:)SEF@
M9/F+F 3 PM@/1"U$KM":,C206S13\^^,)X')->1\@5'CP5%@+5Q6PA^DI0HD
MB#W+F0YWR:6*<G*G,F.AGG#94KX?\THX5-AJN5Z<7"O/=[RX6'KP%X3EV?Z\
M<'U-97J1BZ0S))[*N@AP\A"G*\SSYM_5H/JO_'I4"B^.+:Z%'T_Q3F%$H]IH
MR1^""T&]$Z1YA9ET( @+& VD[$JBA"ZV4QB%TSF*,WR6&W->7/Q:UC+X1%B_
M")WT*^&.<F\9%K-XW,NF'^#H+0GWS'-H3A.J<LE6G G/:GNJ;ND%!%%S:ZT)
M)80ZI;L:3!QFZXUJ?>Z;T:\K?F$:H#3RNZG]JL=)/(7 RSQ?/':X/S*+G9.%
MM;0__%Y>3M>.ZUQ:SK&>*+>T-DN:@!ZL X/FQKA\_)S^@TRP?:4EZ40EEY,[
M^!5*Q%O2YN1=XR"E)F,N\:Y$*(/0VO?^>_^5]OSRT[>=J'Z7+N7*@^GB_AB$
M2/DF%<']'4RH[@PB1W[UAWN ;U!MFV9E70L,)$A[V8<O'^YWPZ4?"N"6LB=8
MRZ7'9VK)>KB^YK=G^;>-<B'?A^:K6CE-[;#H3NU^M=!PSN!C+A<*P O6>@:0
MC $D[+#-.+%, V,:V,4.;R^+D/@BLO\IVOY))=H=XL514%DRFQRQ&.F\ZZ!X
M/TB1JU7=Z(<IG"@U_E+T)#)VYT%[0U.E1IXHR(LXR00(P/H*_[U/TAR*&9NI
MU<_]>RAASEAHNYFMUDU&1YU@WW%F'.>L^',(R>#]&DLTQI7>CP"QN[!E.AIQ
MNNV@D9_*@UNK)M6&,L<"_,4%JH5R#"DI#C T_L5&88<=?-8J=M9>&A'S:*4B
M0\3Z7MSK/AT$ET<,63:E+78!K829 !AXB;]J(N#)?4[[))B*;?=HXEX2J.U%
M._'EXPXU^;]'@-L*SZ[,(@Y^1'*I0*D,O3Y_ MK.NYT(J880#PH20B\AM=3S
M$F:9:A!]9(YG1D-I[+>H#N3$VEQ S@7AY>,^TM])91^,]1I*FD?$%9]A4\P\
MF5-<+'35Z[,PJUX<RD@:-39I/SRSP$,6C_%14!!^\+7#M0H-;_6*F<XB790S
MPE5&F)69R^/);>] C<E2<PVJ)!R1A7K"O5<OL@4I_@_$.\\^%_LV. [%6JA/
MD$;-R_!1I48!3B)GH;I1S>@K'4;UFR)S=H*!U<HYSP#KB>/MNB+-D&\"VLJ3
ML#P-Y" S-:LC ,2&^,Y(("/#?](Y7=I8EWT+?-5HV]Z0=E!@^<KJHSPGEQ*&
MJ'O0B3"K(24F]]-7%G%:B4<E]X&WF\^ /;KKCOYC)TLN68N]!7!D/>1O\T_W
MB%OA=JP;GE1<?HARD_CC!M0P&1=PB9X_D9\,_?]&KEH(>$]UA[S/.<*[&2Z4
M2MB6U>7?^)\%]K".%6J :NK4WWGE;WR.ODGE8Q$)L14-G27,IGP!C1 #!O[*
MPU,UY'X0-M;?U/4Q-A0BB)/L;]R?YBF%R5D&$ALRO8:D6!-\_$"(3';O&B3O
M1UL?5.+*Y.*L21.0^+H-?O<BHA?GY'Y8X^>(\8"0G],S8 GS&O/C/]1L<C+0
MG47^,HF$E0N:W=8X!,VA=]_H]PL\0T)D,4;D\^B\63HHYC!!=K#FMPYCS,PM
MER<\9=GLZ!HYHR6A]&QH]1S8U^6V=>-^K^9!;R6@Z&( !RQ!PCH.; SRJ91?
M[$11?>S@,^;[-X+J[D2$^_!.C(1#3E2IU"8!MLBB3[O]QOWE;\ED,+M>E+">
MJ.0<(208'8N\I:OEL:7(I50,('84>&=R>[UQ-AT0)O8RY"HR_[;0Z_KA8>5
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M0H0W1<'6"@'5]%C#D?]8) $3U_P@+HQC# 9J?M+L=9F)+[9J8D<R1L;^" 8
M<*.X9)PXMDM-:6E]V-VD[<!S*UBO@W<C+[U^0^]+&@&-/Q])* TYE941&]9O
MY53E=I65N)QW-5>/";,BF/LNKL@"S[- 5#W!>UN*/2P$_+\2# ]UT[_'-VU:
MU4!T0V[3MA8_Y,1=T0D2A!NDV_^R#RE%H.+D5SI;"2HAEGE0Z7K'4F>&&M$W
ML4/<%J76("'&*L'(_K\TM/_J"G]Y^!*],/T#LSW'C F!1F5M[EB]Q]0L6==
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MI*^:EQOUH/WR@V>>3<-?/@;LP!@40X3@0;KOD H_\+'+V$/3J6<EED:[SH%
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M%<N'/\EYL+VSU=\W=5-1^<G]&K,N18E2J2>S VOQS2L, MXA4:.)SSRT/%U
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MB%4'O5=S]G"8\F1CBS9O]]F[^FI'>@4Y#2F(A-A\02X\"0Z34H %OTESY?=
M@RMF[Y76\(I0]X]IF ,QTE'Y5+U_Q&05MG[IX&M+P7R'86GHODGDQ2QEP=-2
M&C79%IC9N3_+=Z88I,4O/VE_D8XOUIH'XA!"OT-[AE1F"^D.I!834IGQ#MEP
M6%G%&''*K.ALV?Z(AO_7.K.W8.C*8))M4=2<]<T@OF8]F''5MVZ%>>VODW!&
M54AMZ6L&M^P0#3ERWJML<RHFEA;J!N;UCH[-3^<.:]NF[>MC_P VQ]E^[DXM
MOGNX6T(]0SZTB1.!QFD5,WWZ-1@GLV+&'4XPLB=/3)/(W][WIS2C90R?C+EZ
ME)^>K)JT<KN&5>ZZ/CF/'D]3+6@HB.8+1N]'.F2?<B]4C )2TNB*2P]1OIN0
M^6*T69Y\B((0&U5/SWIVR">.$._3]%0>*81!T"VQ&\>YB+TMV: EFWN$&C@2
M:$(7^;MQZ6U[+P,CA DG>-DWE7B=V+6F_[3B$DA*VXCSYS:G-/5L@E8C#'YF
M?O,X<CT>TCX#T0KW "(%8>1(9L@VD)60-?F &*>&'Z:V^C*82I"0A1>FFD_R
M%\5$50XK9MW":*.U6L[=V[]B J0\)V:\1W_.OVNIQ*69E'9J,0J^,//J%4-1
MC*EVGP6G) XX\QY.B[4]>7!X$8E]"KZ9SII#?'CU'O,%!HLWNE]+"_7C "VB
M&#Q"A;_'\NUFG]9B;]7_RL:<Z([&KPDL%80/((<#+''8>"/Z3V&"&_:E8HR"
MS+(RI<UH^RS[3+D0!&^B(3D2$ZXQH2.1FW@TO8/A5S$*2<JU"%+5J%?99VC
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M[FT@A2=WB9_(Q/"9OFM4!N_T$BC[KH10ZZ>R]$[/1?TT)=@N'L55I5)8M&#
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M]=>A4IJ#_ *+04I-%^6\#"!&>PDR:43#]JOCS%PJ3W!71IU>J9*>8;O=[&3
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M0>@!/>,M4.W+$A"%KUDN[@1VGOKC[N5ED#J=(.[RO>IXCQ4VQ5<#\R_3:U[
M&A<O:S[?D9?GR/-D'. _0&09R((!%["U"?@'D.0OUY=MT4EMXB6-/DQ:=5QH
MK(B5H5)Y>YF&N6S&D"MW4Y'@+^POJW<]^9@@'?%-F\PN];*(7E$4S*V+CF*M
M$2 H !<N4J>N&292)ISDN)0DNOB?1KW%?Z0RLKM ZCF@]"+Y&5RZ2/EH>JB(
M1M$&J+1_2K)$"3N58/SM8'=89KY,Y4<PQ.7G98#7T V@V![77X]VEF[G%@_:
MAU3?".XZ7N&%>XAV\Q9*"'I$'RMY:G7#1+]E4&8F:VK_WK8@0'V<2-_C_ <X
MD,*P'R_\K5<<66&*G]'-:"HM7@ &U$*C71EEB!F^&R-OK?L-Y=U3Y^?"DI6!
M;J5#;W XL43;(SCM]YQ>JDQ'J>>2#Z>%%X."$_$M7BR3A\@\W=]6QM&R3QN*
M0%,!_FCH('%/_W'[_<P90EG'/\J1:/T/7?[4#M,RL C=/1<Q%V)&U]6Y58.*
MJMRE:&5]QYPSL7&AH-\H]ROL"5:&O"!M_>"X"(>V%LZQW]5\"U@H[0+&[/OX
M@5S^/'-^% FN*X#?TQSD>6*GB'L"I!P46+0M*E)*U_AR8.6@-.\)3*1<*M$F
M I5\E$X\X4LFER#&,+S!!8]0<M[NO;]WOJX8X8'*6--K)!ZV7%*,64!]=5LT
M^-0M^QV'_7NZM.!JB8_8PT%=$*.DV!Q& /HM=7_#B5CD8\^NM_<Y=<625/';
MX)O2IO>' O_W5T9H71CK5AS&X.F]+;3 'N\)Y::U#V7GE'4\&.V-3TXT?-YY
MJ9OK9FHX[#.A/-B/Q8?@,R;^UGO#NSKO.PN?U/5@;)'&V_&R'M9PL)(X>,L%
M]9R:"8.S$.8.83 )TYUUC_N(/.0X,7%B!$M6!F0LO^OQI$"ZRK/68%3;C!!+
MKYP96WS*>^KL?7'GMV>6._$8Z%5N0:3I#>ZX(A0-;7/"ZOO1/6&<6?$.?('Y
M[>[K^(E+X-$&7%1:9'"<]S!A0GL5T.97YVWFYQPW'42D$ACXQ6&:'" ><+M[
M.2'YXXD7Q5AM)7+QD5N].[:>/UB '<!/%?WX]./ 1 8HYTR<A_ +["Y3(["P
M//]CVNT&VG33)5$^\F3,Z,7%=HWPNB2&X9((G3]>%FN=YFI48E_=V^%?B$%(
MARTS,<;%6X_5/\W11Y[] U#$_WGMQ21VJECS+=);M<9IK'JYS=ZS7"677E#
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MNPM-A)'X0SI]B_,'#T0%NTG;IPW61A]E%H+_[ 1',Y>D);>#6\IW.#TX).Y
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M"J.B*=8:=N78U]_?33CG8QG!RL4_HIYK9^ VY/EE)8UDB9TYPTIW\3QKX>\
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M>2BL%W-<DP7A<+[B2$5'#50?3I89%^-1WX<,[& 1T_\#<-_--LLZAH7)ZAT
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M/DB4Q@671]172%_?.\=L0:-766^E5GV)BGC5JT))3_)%WHOCW/(F49:(I>$
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M@I57<Y1)Q9I:WA^!_N7X2<P=M/^!CP%12<QBR.^$KQ4S9%\ELA&<VSUY&6\
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MS<9(&<N-^S;L#?<]24W/X&@7%+5U,;Q7S?2)W-U-&-O;83,')--6D T<$TI
ML%0L=O%X_HB=+)>B_RKT;X8D=NA$O;LKT.'0=F)2+B--GM6-IYPYSO@B6%9G
MP=1"N#$4M-K8O.]3Y$9E)18)[>BK,>JY=O\N9)P-?J\Y(>:0'MR3^@['7+<>
M,#\Q;X =;A=.=!1X'U9).S^_#LLR25QR1-H($&2D"Q;+?BAC@&C)TA?UT$9'
MRU]31$Y+S0%04X"!(&FC7\[/*Z6T/9."(!HWMB$E$9J+.9D2I&->D]"W0L*P
M/$+JU?&;<J,4@KN;>0P"-P":Z4;P'$\/2C1)+^U5)3\WY#/)KQ%1H?;@]4.M
MD[((O_9V 8;H;D^/R"7Z (A5NO.IMP'80R>IG,U.&L'R>1\F<0-$SB/P6^IE
MU,;!PL8$Q15?MIQBRG*%H1@RKH_<):93R1"J3W@3I.-+.S1)UPOW+L=0E:L5
M?OM7%<R$XY9ND$PX9*1"3F<O92Z34[IPC\2>QY!,2J#[';9M(/P*F/E'$'6]
MJO[Q_$2WI=3#;*4E.V)-,M-'KONS1\G8$_4K0);IE($%2'PR[K82CMH1EXA@
M6JOT,B 05H"[]^\PYU@VM,U#RU4DF'.BFVG?T^P7?Z&Q"(QV.KI\!5Q\5..E
M8VU+%=\I9K$$"G!BZ%?!!G_X8CR)S62*4?,7Q2A,.C4!:$O'ZN4W2 D,G7VG
M:/P"+.!P?<;4W3W?YW7$N==BI78^WSAR2(.]KJ HW/^N#)&_&[S 9HU+&K>E
M*W#LOW\H7-FNI&C&)_,](?\!F>L?*LO#85F C*:;L!L%Q<%ZD^^GGX2/=,?#
M/']=E!L?]'[JSP@</;=C4VPG3.CXQ35=W1XEW0(V7!Z.])_YPIXK-"O"_26F
M=1X\]7;%U.)? <-IR(\MC+1L#0O8*__WJ8PI291%K.W9LI#$HR6:0^DGWU>
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MO0)P[L31%%.&B;K+4%0O8@;S4K#,/@ EG"Y#$I90&T)K2+:JR O#X7QQLI)
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M8@;1),9VO@*4,\,QD8GCHD=W90'N1'./%BD21+7VT:0SNGQWU_8S2(%G.:\
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MF?3<1:J+H.Q>W#EB/NF5*(^'"=IHG*PG"=>-#5)!6E(I JL6$5I_OC%G(V\
M DBQ(U-HT(GU'@)0$P#HC6<&.Y ("WQ [ZE;A-,O0FYZ$3'&'(K;Q;Z<N6.\
M5)//:I%5QITN4VW5]R.F"Y57A]=M+F#=X@9 C)+5LC.N!SNK C<LA(SE!ZNN
M$KZ3J '1_/I=!5M=HBT B45"G.@^Q2L4M>=[\]?^(H-!+15F#P][0\K MP"0
M9\+ND4JXX$8"E)LD,3[ 0ZR';CL:(+-?X^A)K,4T6XN.%8Q*3K(\=,S3\,LS
MZ7>#]-9G?X&(0<DO3#*E38KB"IH@(HJ<G3W3?K.2KS=& <_B7,HSNM+] 7R.
M.+]Z7"@$LM1F5>9#HKD(9TXIEV,U?0;*\^*9CY4T;7N1+C<?9W(7NV_NK0=X
MTON1Y109_7U#)(NE:8C.<K?+?#<,Z]MC6XPYA;\7RRS"]O\]-V(8+L&JW8'"
MGK"7L>^)/12@#5.31(3HXTMIC+Q/]9\S1I3*G#6MVIF\-$:W#_S7?V-*DTW1
M:"Q0 ^<(C+'&/'<(G!UYRE6P:0H,>[)L)>()6NS@ME D$$W0<_T3&-7W_8'#
MYHW56+//)_CE;O.NL,N"S1L4A2J!HR@VZ+*4FBR]=(04I@J:*$89C>'1B-/[
M'FM9N3(@Z&.2^$>$,"YW&)< AYO+=H<4:944LF2"E&PJ*$ FS;AW?>S] 4Z?
MWU\<^RF_PYR^>/56O?MPA!/&A#5LZ7(S> XY4^Y.-4P NX\KA^M\G>;"I&JQ
M5,ZV6./[*^!]41MDZG?<1APUVN4E(Z(+:]-_QI*DO.W'NZT>>].DN#0"]@<8
M?_!"W2*3##.-G_1_*73.MW$3OHD95_AA9_*//(#_H=-;Y<4HS1Y^0_"OC(SD
M\>K?LU/TRXDJ&UOOQ]1A\"W%;^S")).I*U\$56W 7WFE\L#9\5*O8DEI 8HI
M1O&4Q(#]:HO2O.6GS:7W#==%JF4W5@,!C-+)3$P>@*H4C6W#G6CBAB("5R+8
M]C=[0EF3Q5E*ARK[92"#XN82?FT8W-$OK+O*ND]=+!@24OMCN%3*SH<H%07S
M"H9)D]HQ2-_6NE!W*09_H;!>JZ,4KC6F_4?,W#XO7:%A;07YWQ$$0Q*8%"9P
M.<!8S4+Z-Y/\>=6^@-UO.D<)V0?A/"D#)CFLZ_@%WF:+&V>1V'ZO#144$"1&
M@@0^]?MV\VBGAK]A_XEOKXD6G**\"[H%3/2LG:<0IQ,D)>5R&4D@8QWV J--
M@"^?32B$5J6=(\[FW#_LM]K_SK+2-;0?N1^#> >X+3WXW2S,AS5+:3-W\337
M\FA?_TF/L!COL/?)/ 1",]!['6D(AYN4\JG%%0X5Z$>:56L_,HQW;<@:_4>\
M$V]@G<[Z7_TC"-BL"1*1?T\W/ZTS6ZM")^E_YX=X?CZ](/B-"LV(U>WR>0Z]
MB@X;9RVGZ'64BY^S0Z$K])LKA3_LJ[,YC:!+]J=>K46X-,M::Z9_*_U<*9&L
M4-9KG*^82W:GFC=N5KJM$,706,_&^%OL1_VN/.PRS6DP7R:/O ]"OC5M2A]$
MG+=IQ8'E2./3$YJ*+N'7 A3MR\,21A]U8<1((M2;D'&GIWD%D!($\[T"CD_T
M-]?%48B/FK\NB*Q6_!BO^]Y3WLR;TIRM4P]:NEY(\\WH;(@KV%;+4_@*"ZK%
M%9E5B$<TO(A?T./5VD]&7@YF&K5"-23W55 Y#7$H_X)/OE5;VAIH#BB_ K@P
M;LASPEQ"@_HG1N_GX.W69O7ZJ2[KB'CLAN/2M+)F)\YKK8;FAYZD72E1,-$.
MED(+,HZ<M+4IL5I28$V5!X9DD6*^'^O6FRH\\Z)NWO%PC'3;PMRTQU':RBFG
M<<T;\J_Q6%JXRBFHFSW#]1@@Q?GOUJE?UIIT H80RHAI-*EE&3URU)(7\V#N
MK"<UIO-OE-!D;I$?G^#A*GBLJ,P(R?GN00?<CS&.-Q?O,_[::)0JQOW*/Q]A
M$BD> <J&?Y!PXNV=O7.1*Y_Y^$-7PF84:X[=RNP'.@Z+(PWRQ.9XF/#\]Y<'
MU2>I@DS_TV<A7HY\R_1W*U$R',T0(Y;_NK!.'#)LX&D-1GBR2LMJ;DI)#'6<
MW6ENTN'U-51>,!/-LS<<%_PH!PH+@_$%HV4/G/3=ID)O7L@6/G[IU732EFLF
MK0Q%J$_2Q%]>!@"(<EFM;]V$;?G=AW9/,UW,^,8:71??";&"AB*+55C.D><2
M5:M6<6"&T^6]XJI13I(6O[!4 -YV[K ._I_3UJ=%#$QH8,E]N3)DF?$KXL&_
M-.UX1P=MHF0[(3[*Q<3$&\B0).ETQH9PPHTFOTDQ\F[L[(X[K^7D]T$5+?S=
MX3I[(--U_DM&P<M/0M9SY!^\:< 6OW]\#;^4GL<.UWZG:<9$8I'BIYU)]W&?
MXWWYS'_>M+'IN%QD,! +4.GH_(URCU!7UKB_VV:+0:2%DTHRJSW4*=5/^?B,
MM[G*L@=7J8FVK:-^)):[=RN#7CE[1:8+=UC>/&DZ7/3R*GV]&3J[_)LUGR)N
MS1SUP=9H;5V8M2B.=N>Q'A.Q]C@QD^$-!CSCGQ%TM'M7?"?$FL1 =3E[XC64
M<'?O)_D8_ &S9ZWSBY;P-N&SKCL]G)?UU-=3Y!%1Q32E*?J7\UQ.WAY-<O2O
M_$V9M4'U6K"[T2[H\S501%7Y/@WWG2BF28H#^!!BZ;USJF\R(R3S$YKA^M9T
M0R+B<KDYPK*85RP G9$I:OO7>%B$1Z1R@,0_#,'KX77EFMD 9HJ$4WI1X3"[
M@,J0-L_N4Q,!O$2T@*-]71+06T;KI+J<4!VG>=9O2&+:/CV24^ #D9\[&T0Y
M^'5O_W0H!] D WGDXY[[.^@Y--PK_G:>"YX)8DJ1>[8SH;;'QR9UR]L94*Y3
MZ1VD^]R%%IZL:HWKT0T5=NJ4#4G_D']9;RD6^/:1.[F<HYJ=[,,]$AC'9D^M
M]OH#T8-![RJGE8!^QAT8]>G7Z0A$56"L-0JV9%Z3]/$54+9@W?A.87R<E3U.
M0K446-2"+&NTJ^T@Y]"QI4K;*/(X)DU$925FG+(]+F=I,HZDR*J87(J*#*V+
M$SP[.7T2#^B4@F<#DHD= 1,OJ<LP+AXM65;4S;3Q4$47YG'A#?2:7]V +JK#
M+EH^[,42826[]K_G$>2(K@JTHB?XO':(6XX]DJ="\<+6C!9NGSEW[%V.#XC8
M]5*,JUKH1&\\\?R/'Q5T)TQBERU(DAEX#*!\UR(TCFAULK)PS Y!IC&T_=R-
M<';LL<G<AH41X?2/(Y#8*UQ/?S1GA52I6-&R_\ GE=@PN4"],1$YFKZCWJ/:
M(6'B"R>:T%WCQ!WHVL9 ;Z/AXMP!/)TT". R YH4IWBTT6QROF(=[!?K+XDX
MK;H\[+C4>(\I(\N:'^5.5=I+:SSTO"'E_]YRBE%:;=H:J/R/ME4L[:6[FAN_
MFK*)JQ4PSH4:AN@S\1'*G4*YO'EIMSIJM37)/X(5&4H'0V!Y]K*.W":"[$ W
MO'JO"IKG[M3'_3OK#=QZ/)C>-JY_E^Q!Z?E3I^_54-A'@8\?X"=$0%M%N4XV
M <&SW.:C9X)_\X8\W2H=1-,;I]+TMA6&R::^;$!",$H 3XYO .W5@3A7_@<L
MEX9H"9]XZF;I7X;66!1.7?ZPY#="ZK,_<"W0P&C?I@[C?'V?15VQXH&UN+L!
M]M4T=#W[?]1PS+&6(E#C)I:=/AX(1:MO+'5FMKB/.U<]=S<7=E!DLZ8>7<'?
MZWSR]DUN?M0PJ8"0S10$E6S=E+.JCF$I*F%(:Y4KIHPMD">5,R1 0LKB>CFD
MAY"H-;HJ$';:+=6&F]@,#$7_*(/3$V>Z&F])S(W52E8RW:7"359N)UBXBCO@
MUECFZ6@I,T5Q(=?Y]T;X-VC?<WDE M1K,NXRHUX!,PTV;:1X)Q*JS!FZ"2B"
MSL2D*&$!YT,M(AC2[@,T7U@-N)J--Z%=T$V&40'B#0''G<"ETW>X7UFG320B
M9[1B:4.7S)IFB.%V,E+:<E98?5*<2>RB]^^'!!=['?3UX#]LO$.W4B#!+=SE
M;T%?)PVE-==.=*B\I?J@Q"'Y (#36#\Z.$#^5*Y^T?U;,%VPTUDPX[KP5DG&
M]T/!*X<A4/\QI8)H^X[(I!=?/R>2I=IH+XANP/\MP8/UH2&I(S\G^C.6[<O&
M!,1?^>KIY;DR:$_"#X\M=(G.S*T47SB"DGFG@)V7<IFF9MPIO( ;)B15U)1,
MM)"%(+DBI@STS>!^]*29TCX@E"*.HZD$8:$(2[S%M!NZKPR:\5+.HL/^BI%'
MJ4+Q3!;[Q^9;ZCM]G;L'#80TB&"RN]/9FFWN_SXC_?FOTQS+5VM"$83\F)T"
M*+8OC7O%2ZK^N(1X2\TW]K0--[ ^M_GV8:%XHP@.#1#I*<*E26$>L;#\VUH2
M4D64:XL,__D#K125+H\T ?-42,EO:;BZJ:HL#$60OMN^W=Z7UZ'XSP\FC@U!
M!Y68VR%^WOTCUH]BCO2562W4:7XWY2J '/02)3>7#U\-*C'6"8_E&F51MR=#
MB%8M!Q*V;7MN1C Z[O\$4?X;8J,*P'0<XF%HMCB)\$C<)9V.&+@=,9R86JJW
M6"N')H,(L7I%&S^ 05S&GVM?X-TR@VQ,8 S4Z!V">;VPH\-"%L!&PV943+^]
MQ4\4Z@S[22%3-?^:5:>GH?RG.AQQ&;SPLX,>XQ"BW%&'E72Z;=@KP Y%R;=3
M<N)ZU2M#S3DG:S_KXM]3I_ABC#QJR[..ZY0T_GH,)(F%92/Q:!3UG.=)&)&7
M'$?^.SNO6;_SK5!&BGE\;7#L&904A/;=]$<E!A(3!FM?6UQ>=5%\+]!$A%X/
MHH5:')10"AP0_R!\>[)0K0M"+1_KSUYJ1<:E>V[3(/2(O7.\$[C0CB X>S>J
MPVL]44!\,BW%S2Z7_@T!3=F%!K7 9+4FI?;X&7\K(\F@Z%AMZ2I@?JG4'F\Z
MT1$YE.':Q<AS-URBL$Z"_Q<.)5BA5)*B<D83(UCK'[41;?Z;:^<.KE+&";LG
M7:0/I%^29P].5AOVX9$!CJ'J0E_8772MB@ I"<T:/Y'F"B29ZZLN#.@7SWO[
M3Q'A=0&$<>"]'5G3?C  ?T/"^&U'D^ :7T)4U-ARD'SBA#>QC'^QYJ/Z.?;Y
MFZ91NXQ.[.?5\-\"M(0<1]40UG'67G9QNK@Y-)&Q<V@1ZTZRF_)"4^I EH%2
MO[UCTE^L6D<DQS)Q'@"CH?N5OZ[<S#)_(#2AF;M;/G&&+Y=MQ7SFI&G2=I?=
MVZ5!Q]/F9) \)44M4K11]H=\+#"D&&GY/2PVK6Q$S@1=[XN+J6< X89(K-C'
M=RN#(56:2*[$G,F4S T-Z,SN9,E445^WJ@ YWWODCE-Q:9]I+V^\QP-8\GX8
MXA+7R)N> UX!^(J<OK(+4FKJXV/57Y]M!84X4YY7ZLHER*%2LCFJV";M^*W^
MIY>(/H,/-/$W%BX$X9[O&@_+&.J.>R*6_AT)V*U3JLJ&K=JBW-^?K+O]9BWJ
M#Z/F1+HB6O0=7E/ -/==>RH\RJ(+]E*5320<KOE*28VU)(?4EH'\M1?.+C#5
M/!,@^CE(.(B7F&+;\;D[N^U!5([H_I[V0GDN'(,]>,=YFV$)=]\KTE(N=;7A
M5*S?-N 5H *Q/*9.D7LCONJ'WU 2I(^1>',RUV*.>[S&J@*$O;0YS%H];T:9
MU1V?ZJITBXO-HQ%3&<B.#@'H]D\>")06E<LE#1'KSO#<J=9*G]42,:AITS-=
M6>6#1XG6O!4'2[X!2.?AEY!T-5-C3H&C$+2KV$) 2LTEQE6 O=#?H!2,&M20
MB#] E+(<*(HJ/>CB\;P>W.N*C8U\"(FW ST-L@'0*? 1Y@>/&4__.I3L<6-F
M+]#:FY>AB\2M/AK+Q6CO:\8*9\TXTN7,V#!HD4%\"]&.4I=(@E-'="0V&Y;7
M&:Y?ZJUP92U:9M'V:+8%X@T$9X$EO^M^03V1DY0>("6FGF+28)^]J;[V/AN=
MFW9>O/&V0L\%]$E1Y/*W.!/L*I6I/$=L15(Z87CEI/^4T\\^>;4]4$-FH*Y[
M3UI#_H>[-$(K/:T58*=NEE'JEIZ/&&2YT*C(V8HM8C\JW8J=@(%:P*DDODEE
MQD.949XR++3/+VD72PFB([#+P!B"&C]#+(P$^]KE;K\5_HU[@,L]&,0UI9KJ
MEJCODL2VE:3X>0>#$' XGQ^Z7$7OXU1.I O'2_A9/A#A6-,V@'EPDG9E^6*S
MDX5?G4@&RG&*<XGQ%D>N:O2*0[)74YP4'/ ,!TB:Z.D1*N\:&K(@A7]/?8XR
MM+"^[XO,BQ\%9!EI3:$^X*\U7@\&@7DZ) ]C)7QE/.'::L5C^G0BH4K-VXMO
MVW,G7@&BZFOGAE-%,FE98>P=(P%(H12'T,  C%]#>>EXZ4>MS+6K_"LEA64D
M)#OWZ].EY2Z1JJI99JN<MNBP.Q"!7V3 X[^YQ/D,8/U$MTP:B+_\;=*8K^SS
M=E/E!$[<&@#WZS+\\=I(69903L:'GFV'S0$55".N:0:0R6,603DZ$'UN-'\O
M!T+^%H"$H$!/]02TC(BIH8T3GQ'2"QIKHYM3>&7 [9LN3]:HV^)-OEV7DWG=
MF*O:<?8)C3'FVV!ZF<XW!;T=B.1N)6B?29G)+0LJ"BXMG]?Y%?2CBA5*K$N.
MC@$^BWZV=N4_.3S^P2[)F!P($E3;',_EG#I]!<CKDXFPP/_25GV[IC)6=3;X
MQSQ>L->J0H-1*@<--,]44EHHNU[*EFS@7D;K6T_K>/" ,0RH.K*=S/L(DZ\9
M".X2O@*$!J+KS;*PWG54%ZJ4SZTK9&*]YP^'>/I9[(U0VR(8QH-(R#JJDN @
MNQND8C%JYU8US%35[\P(*9^ZE (^ISBXD:2<B)$GS<[V)AUP6_.NNE5C1&5V
M63N(>5>9J=]H UE\KZMULPL31E:H\"<IYLLYF6O GH2QIQF<HVI#[,:;9A?<
M,X1A>[OQ\K+=;'M[N\$RH@A@_RB8:\'UI%FHEN"5*^ZR(&H:7F;9$^X4Y@/0
M-RCA^U<Q*TO)^*?E%N$(<CVP^D]B^P7VG\47H4C"R!0-%H*<+LWMV'[SX[3=
MO-? %SJU&A_\]7P1^N:F[]]VI?(#L5"X+?R/,9+U_^Q]LXO*56)+H.JVU2,N
M86!0/E!@2R<L0L[-]<$H[> $B.(5ERU3(H&5)Q4;X,G8J*&,OI._5QVX1!E+
MF QC"H2.3<]$LXN,*Y,LF(, $ !&DU@!X+&(D-2W9Z%K?W;QJN1O8QT*0.QF
MM+S\_V/U=3*$^YU$.E$/-FC8-1D--UH@ 2;S7_RH9+PA,*C]Z2[#C7GT1)?\
MY<]?;KLEVY_E4-9LM66,UJOR714-]:S+DCCX\LGS!B QOBI)*A3D\.3J[S6C
M4S$.V 6)2X]9%"+1&S5B!]Q<3QW"M6:PN%;%EM;+CIZ//N_<9V2#4"8S[PEE
M<]K[I9OX!D8D?7A<TWL=#*PCPX$N"6)+<Q'N":#O 3*U'S9X<MD2])[Z/>6:
M9POG,F!G6:$,N2-;* \"[RH5Y-(LE[B XUP6ZTM9,S]37@%W$<L..'!7C37?
MF^ZJYZZZ<CR!5#;741;I^IWBXHY(=;JLA/+&C(:&IJ+^4M4E/[EJ@!<TH!B3
MS0@TB9/+?/,1]7O&\NSR&[";H;]%_RN SC7V+[H?0PY]%X-&XS^/.U^]E1,"
M!_L0;=?4TS%D%@)AP8.8*=BQP)Y:*DWTL:9R0\M^"D)#;65%$H4[,ZN_"8N2
M\)GA:O=,I:S^/#W#U)U#B$^<2ZO<27=AMU FW5'/%2%:ZS!34*$ :7=2VYPN
M^\/(5S*S$Y$,B9K.&S!EW;ML7K?U]3S&(JP=TZ&__+HO'O,-P(84?-WC":^6
M1- (:[+CMTNUL1)6X]@W0EHLU?G$S+.U\J<BOA7/,:*1/@T(7O\K^I(T E43
M6:!Q^B4Y%EI)B'6++F16YQ3K41EE(TPWPXA8]G"4/%+5.%*S,4]4KM'E%?C$
MQO2.JH(,TJ@M_?W!3@B;%'E7/IU)81@VQDVZM>K$T)!4;LH$?D<KX NGO@Y#
MB!7\M".*\Y;-?FRP]\[2+)JVNV88(J6S&BBV:ULZLK(KIS/62"YEA9+_0%[I
MQ701D%01F![6WYR<O8<7R_2+GX@_A7CV(ZV=#WL=M;][3S 4_=1R4:3 44)"
MT!:JEZ(EZ;1)5HJM"6P(T-A/2KZWVO68"\+?)NCP'%#=_!"&C%-_.\E/6Z\7
ME/4*B$;&A"00S/T@+'S>DF'99$,M Y *@;$9F&B]S_Z9G^TJ!74%KU\MM"5#
M?K,%0S*UJM6,I@^N6YRMR:BJ%*65K<X-)2W;.6Q;ZZ+D96(H\S0>JUN2/L6I
MU0G.7<5MO#$GI+]]N?$/T58]6E^#-WXO>\/4[@9-J]$A&U/O_9RF3\0V9S6-
M^'2(+CPI$T>53C3\S64D;O:GD/(FIF<IE0:-G94<Q_W4CC_9%QW;()X6SO,>
M9(MV8X5O477E;U.]1K*)K.7#I_AT#E4.H% D%D=<5V2L:\;%;.>SA,RG):3Q
M7-'<EH<X+CH+K;*7W' T)GE=V]X1= G_C<?(3KZ34?SMF*L/E?D[^&'IO0AS
M14$ 86X>L5A-GTOO(IB_M2J.0,HMW =9]DST8=%!P9<J$W9<U!<X\D&6,8\]
MUV=>47#'V^+ZJ1TQ<0=?_YU[(.R9-3?K-]RUON*\Y@2Q]I6FS0Z<4%(LD0Y=
M29IUQJ2E'3%_X#-JCE25I^EV?LF3']:-5)4,0FT-D#T>GK0H<Q]D,XW#9(8"
MG$"VM%%\DO&T:19_I5'$[A_<AZODBY$Y!5\!2IL/?FV) 92C0Q,T]02><.>A
MG[*VK3< K@",Q&?IWTZ( GZ+X!;VN;2U*($P8SQHAKT<"3Z];_#-/XKB3X<-
MZ0(/UZDH""N%=WIM)**22WP&2[?%B@78JK!MP;/C+/_J8H5T9WXX7O>OA,'1
M<A#GPR/2;+/?S5!!7I",[:6OOWO-38PF"BX_\[HP+OWZ)Y<QN/A\J3][Z4RM
MQ1#3&=W@4G9O2Y'P+L^7NE.ARJA1V:OEXC%S9*F 345%'19;9[6NI&ABWJ,G
MAI(W+<DEA/8@_&.IU":()$^+UU4.<XMB#/G,3J\&/"[=,S'^@Y,!4B-$)%1;
M9Y)ONZZH\K=+&0O9N.MDL6?P:EM=0.*-0 '$*_&&?O;V%-Y86D?JI\,W-IH&
ME.!\*WQZLU-5M-J2:=K,#4V*%G2FH/EL]O?=^Q."S</-^%P",6QV:Y^1T3=F
MUP-V VU_H5)Z'Q>V9=Q(94BQV^*QL8R*2G]N)!,%UTQV.$3GL&Y%I:I_S]0@
M;6?!+_F>C.DC=H>8%LM4R>-K88<; 7_";,,LH\\"117!O/'30]2; J)ZH"Q7
MEN"@8J1A%5#B%&A?SY0<->Y/@J_,R7/E/@!,?^^90",H"L:WV8=OESI5-7AX
M->BP';HI'#J)K6L0=[-F?!%,(#J:OL*_?F$RL^[I8=8_ZDGY^U)L;<6 \@J8
M8X=ZM:6)E[RO+93C\@&E<X-!O@EBC5?G2R/8 $#.-F,TC4D" <60?TY72MX8
MD"+E@\GAOX<.^SC/UK!JKE-@<Z&F$;#,%&4=X]B#XGD'SQ@8]/FVGY#:@6$_
MW&M /C5F?_'NT],CC&!/0'Q82DFU]6#R]ZT;7?10TAQM8'A:3C!(_-^G,E-_
MO6Z_GP,4SHR<-#TQ 4!I83?K,%J93IG_Q]A;!L7A1,^B"XL'W0#!)2S!"2SN
M;DNP18*[.R2XN[N[!+= <(?@$B"X^^(>7._OU?ORJMZM^[_5WZ>F^ISIZ5,U
M4TTD&'<W=/,&T'=!L@ C$ > ^*^%@Z4_M2+87J! VS%!BC[L@4J^@!L1'Q/Q
M=YYUMNCI82*Z&/Y\N1 VK6&!6[S9+_ODR][H*=8APDGRP3?2I1II%,@03(VQ
M1+J)Y".M*!"_*+5]U]'4BA4Q4N71(TRV>FQD)M8Y?\3,(?AY8HEW W5X>AOF
MKZ:&@" )KWV!S-0-^'"ZTU_$R5]L&7%HMRQ&";C:WSN5K#;2<H9E_Y#T%6!M
MME4U!>?6CCBVJ\8O'2>Q73-_E[*L[+UD\;OACTJ#MMJ&<*1C6#&RG>C +:F4
M'&AJYAE?YG2HD@L>@)19^?UE[62[%G3?!7 :H,$E#O*I5 ^E6:K)FDJTO+$K
MP<;RP[22LLKD"B%@!@:Z)NDNN>T\W&>7'(K4K7LKP6:H'%D?B_\+FC.9/,DC
M:K @?S6_2,U\P6QW[F\-!#@?1F#^1UCZ)Z>/O^"HZ+N8I70!T=B]?,"Z$>'.
MUGU]LKP;CA-%GK5]D?:%*3$D@#S"ROWQDZQG<G:BWT\[$Q%VYT4Z[WK?"YPT
M:*5%\QXC"<ZT6#291?[QM=&\E0(HUW@MSR3.V\($FD-7E#!I:^@9+T.Q= V<
MO8#(DM0*!K<:G0OGY!6A+H,1Y0'[Q>*E'+=<[(=V=#7?UMBWV! 8/;\$DEC1
M'V*@%EMC,TU18X#]T7E9=9EBNEX=#@2^*-AIR_0I\3Q&(\R2U?6=Y^X;Z</K
MY14^I?=#Y..:4AAUCIZ5QIVDG"D8!2NKK8481Y"I $[5-I&,$)]/[$_=R1WS
M+T7^[$)>K6MAYH^$%5&:;P#A-\" ^?_LSDJ2RS4@*9@6-,! CVM!3^!$$>'G
MZ8HJ,KN<[$:=17+\]LQR11<I=J;HDE(\)/I@15-"BP*&0YJG78_/V9B )3HZ
M'4P/Q)EXS5]--!X4H3[2G %0C2(B#*3A$7( UKIGY(E@<,%<<W2\HD^@9W+R
M2RQ4S1$BVDN%#,X9<\/M'9,,Y3-\XCY[FH^9I2?@0!\[?4_NY3>)2P<V(?KO
M6#C,W+G.XPH;ZZ.Q'% _P7^L6/>9>_IYQM:LZ8VP28CX3M8"AB,CK;J A'2X
MIW/;/FY]L$R?*/2<)H?GB-,.N&; #O!WR6_WM'ICQ0WR[A)[RI=DT;9SG4]I
M6DE"W]/3.#36I 6M@X\XK;#ZJSY"-#3&"(AF-"6VWME#UJ!.4K58K^4QA8IL
M$@YG@Z[7E?1?1;_$3V)JF[7'%6F$^6TYFZ5R5PYF6YYR][N_TJS%]KLJIR[%
M+EN98;&MR$)A8Y;B;,&WZ$ &:7%I)J:'=%$WEID.SM<^KOHJ.9B8K.,2,X_/
M9*7/TO$!<%"Z7\U;X=YU52^^8)7ME#_G&#L'*RO2&2Q D1ZNKNT#E8BM(RT?
MX$\U*1NTL^TDA\D;0):S$)JYSPJLJ;]H%4KO)K!]V1.[=IWZ5514!\$9)XK)
M*EA$P1QLS%SX?==OA[>BGV'K7N :)]; '-/7<#B[+#7CL\(@I7_8?MR,:3/=
M*%THRF:/,6>-;"PH4(1J-V\B5SR8!Y4,)<-+7V!0B1_%%&,%>*3U"WL^1*Y!
M3U$QP$KB>L7M)N_7ELM7*K>,MMOJE?$]'2*U$5V7VIF<6%1LYRMTLKY6* :X
MJS+B;:K:)#$Z'^UURY7,F4I4-.]50(P;>L)G+?KL1E6WJNJ0U]:& ^7QIC@>
M,JP9X8FZ FR418$ZQL3_6BP%[.)7UC95^S6V] 5B#!KO,F?Q=4KV5QX'2-(<
M]=KW)9PJ]9=7'NW*.:R/#!8K [FX(RRF6=VMUKSL*^U^1SCJ\D@60%OU%+B6
M5 EWE3\A##V&]L:J4R'J@JAL3ZPN61# X6\ XWQ"]JM].W]WYQOSL[P0UWMU
MYC%9B4N63_974S4Q?>6S/-;-W\\T*^6+])H:=#PS*P2_JQ671*D%T_"WLB^:
M+6)A!*>!*J*&H1O>M*YNI+$O=RN?EXNLE=\!=AS2A!7)X^S6K9_N'2ZDMFDL
MW*37.EB[<2$U-M)Y]3.N?U<@>O"6M!_7[4WRN.-Z?R+4V[0"%,OF:6B;K<IC
M^ /04RW_%O*1CB2W!BSMZGY@VSA"(F:=62MR=6:XG/953OT6F(3MG8\R=N.D
M^:!V;W2?VYK>8*+N+3LC8CY]V_906T/B GE8YV'X2COGW/Q=.J&-ZTC=5<JE
M/;?>FTLO"..A\8-RL]V3'B=]X6J2NH>^?EWQNSTJ8VF]I=U6(Q2.64(",UU)
MT-:N6%\[IANYC%Q5Z@7-II?',YT^#_-3MTOUV.!(I39E77G3VB>I)94O&-MG
M;3'N<PQUQR4Y* $*:@R]$5-4A3ISQ!FYY5AM*26*KC!)?_* H3S]%1\;O:^X
MA::UKLRZ=^:GK&(W525="#Q<8G**J)EH=&"\F8 AI.AH5Z0+69+=XY1_B$F+
MO<180%0_]GU]CG"J2LUBW!&,I @*U;65]XTN=LLAL A!M0(NZH-34$2$U3L=
M&S,PR( *-Y"/P7&3@DV1+^L#NFR&-^X4&SQ:R=6=($FZLD]]TFPVOE=3EC?P
MY).QWK8-;;E+>DIXC%SDGO(9CAPR:_%OX9*%>-29(QFD6_[#E984(@'[)/++
MNYOTG_)__J33_-G3EE%:B_[Z\_;N#;"C\8TH;*7JP0M#.=K1A<UMT=?3Q&@!
M5!)3.RX@>\*3ME%.@U\2,P/8#5AI)SP\#C/C9'9TUG3I<5!H>ZB'929MN T;
MGVX8GT^A8\HC<^$(A*ZXF2.2+F!2?F.TE)8'LG2 +MA.X?!.AK(XH:L)B(%/
MU,MC>3EEL%E;1#0WCVUM,:=%7\MAS#B:Q60[)H8JC.=(ECQJDX/0-KQ?$A8)
M1Q9Q%'UY^,\,'_.'4*8$[_"R+1H!?9Z/?L.D-[N+<-8;*R^A(<+%6VUVW8 6
MD89&DN_H\,*?YPRUZWKB:A:>8J-J__ ( 4B5!?U7^ BWN9@=4?P[$UJB(/\)
M^)=^/(2@P NQ:,)-I^,/K,M*?4J\#G?.J7+@P'<B]B_+759-DWUZ^F^ #:R:
MNK\X?\Q;/?[2*.)P;O>&CN\53[A*(\A"-25>D&6*J,PT&:A\_"*=QCSM\2I<
M&OL,@WU+]HR)!XD^.$NTRW\%RI7L=QHE,6CNAU)/9KBQ;>+*!2KXU/GV1?_!
MH.W&2^90"/IBG$10]#TV/=[DHZ#IM:.8'18UX'OR!=J.08YTL80R:Z#OQY\$
M5</H&*J)]Q9T;A#,R#N22L33PN TL<;1>VI1C@^I2 !\G[LJ\P2\8<BNI >C
M^*)[DW@M-@(M&.3HG.M9/Y.GY_-9Z;M>0Y9_(+Z_;E \41_BQ(7IH'Z72-7T
M3X6R=LMHAC< 3.GX(:A.R(O['7LUSK.C:TVE[LI+V=K1%_%G 5"=>G.-!>Y*
M; WSNPQVLN(_*K:4M*$5RE&T4"5H\OT)BLNI(%:%.)=;-8.M!D8\:<JHG/@T
M/'W4B\U1RO[P'9MOOT#>'9"B:+R'MNY? #&RH7-NH6<@J*;8;1 4-Z@F,@B
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MGA$VUI"QA !86J(5.5'?K0:[_:N7MG0>%%^M#)FJJ'4(!MP$H=\27&LUM4-
M)YYSTT.8H;NBQ13*R[]5=UNIZZYOFN*342(]26SQ"_B(*$EV<L'W6]H^_!B@
MP)__$*@'T4$3DF/P#:X308$MEP+"\TLJ_+K1(EI%.>KA??_>GK"A&;JI&94,
MNQ+<U!51:BH$?Y'A;%=%H2=*!??I1GU&1G *PU5_SD@&!#S(;?U(PK(\LX(N
MBIN(1)F,8BB %G!38[Z*1/;H%9WK]6_R8K^K%@2K$1V7.V_@^![VJ%94+%H>
M-&&.:CMX"9\2O1/)F,KF9+-]F%CR+)C<W__7B= [$;8N8.%M^G37:VB1K32+
M)^ZLM/JJ]P8(VR^1QQ%[6%32!LF=UKYZW7QJ);%MV5;FF,569&-#=<81XGT#
ML._,4+2%T.<3C@2M^,0Y2,"_BB-0F3Y!VLDDH^\&OG]J9RRG6KYNUMB86CYN
M1!%.PJ I+7?"W;^WAF4=VC4$[4'&2F0,$ZNLX>@\^/*) !S>]T VUU<FZPV!
MDF6)4)?W:]D?K!!*79FGI=P4_0?X!51H(.&7Z5:8O\8\#NR:_,5!$#E>44 9
M'$I3;EJ65"W%E-YL 3S,@VZ((WH)RUP^W0B+MS]&=OZ?(RC^7W A+W- K:UT
M[3?S SER 3N)8IO[@>R)8F<() FY.8]N%65BIWP.DXS-R=<8Y(IZ';=?T+>.
M0M E_9,W0Q1*?H!-X&L&V;TCC$8#F+28!.3)K;*JV^@CMNTFR$N7P*Y"_X=$
MK62@C/&@5Z_W'E-+0S(!5> [:V"\AW@OO<HUN:$IG9 H9AD=%=EFJ*.YJ9)Q
M/Y$)Q3\6;1Y<&,(5<%3Q7\OPTP*A_VX[^8_+;F3CDNH,M6OLR1,11UUNX^2I
M.HB0X]9X/>KP@;ST21E>-C;[1D*NC+T 7K8I65QS1VE*^&=  T>I-\7/A4,0
MO@0W^!7K9>=C<-5.\J9A=" ^SL\M:L;>9V(BQ6 :YZ'ZNL.Y0F?=N3_3$JA$
M'GW?CS=P.C5QWF=5?K=-'=/WRK-8^O7S\;1JCA'*$AZMMB>?(9^@$8%=3\M^
MR"*;0^MH%3>:O>H>S7*'J9^ZXD3O]*E"2PXNZXC#=LCJ(^W\KLM40YX>NIHX
M+;%;E^%3-T..; VZO<^\+\C#^#YFTY<SB?R=Y)3BIY1Y@K5!'.->L[KG:NIV
M@6[L;)E=IH +B8)PAIHD41UE=@F8U3#]-^K8#XR:,E$Q[X8ZG^%U&4-^E]5[
MC73_#F#B^(DBSLRK]8DM3W^2!P_=0$S>5NS+<CM*;\XG9+NG&MO,ZEZ,'WP'
M4Z9SA\HGZ03!;#?2N@<L[+3*\%]/$[WV/N("Q5C%=>@=]:^AV'M4>%T?B3MO
MK<MKX]$QD"\0!'I.F[MS-#1PXGQ>5WT:+S\X_7T6D"M>:]?K>#)H\G)3;#MP
M:VQ%>?YASS(IE:_.RI_#K69QS-[]"VNXO%O7-_7X<N<3T-H#5\R]Q)=V1#!:
MK_^+L&NB'[*Z!NQT'%ML2!0MM@<[(0.E^F7N\M,EN:4^CQVH=,OW!_=RHSWC
M::M*->R -(Y;"OU(LK1\UF"9NH)T7#W)>T2"2\?E\7WBMF1A5_*DP;C+9Z6H
M;WO?<;>-.DJ)6$T]9S9+7_IJG>!-I/:=C--:N8+/7GR.->J]#6Q,214I!"O)
M*Y):S7"4*.M6M78#>P+8:>(:WPAD0;&@(&W[3TE'J%YD;6L$Y'V,3+\.JKR(
M+1'FJQ(VVY]&8<#G?YA=BTM9?S.&BJ+_7!CL?/7J^'+6>6AA3QD&/R6HMUUL
M8$K-4RZO@1NWLU:KAM@('T=%J10-E(X4S<8X%_ZAO;]:*5==*J!]_T/P.DPM
MNLQY0"S"6!_-)SV#7.S(\4:^'(XK1MU#);92;XS&CD50OQ6-G8V_$\@1R-Y+
MW'LZ/'G$Y?+ASN\+WYDA*D*GC0I=<MI5'/MU9,H@[,G:3A2_'$,\ !4#&B G
MS0OD$[SRN!&,8'@G@?-QY_SL:98>7!3R <PI"Z=.'S?68;V);KS'6;[[2&'%
MB,4%5@C<8XLFNZ%EO*&9]=7=_#<\N\Q]ALQKN$B[F;%!^@;@_><9ZT.[J8)9
M8QK_!BC>0?2!H!HS45L2E,T=V1 0.N)?'OK$YFOT=3XWJZ]^GL7$=?3]Z1L3
M%:[IZ".+M=%R6H][<\C"\F%F/"6%=OC!+*66QF+%?,/Z=G[:C\+166E/)O_)
M3S\;3E4>9?OGG*-13PZJ*#<FLT&:]T,M,QP'B7=51+]ZQ7:;(S8SU$/8W9OM
MBB_M'U\*9Q*+D)]OS.PF3UMF;D&?H N?16_L4WU_".>Z(TZ74"ZE4?@ 0YGQ
M!4?XI,9+NULQ%VVGV>K)TX0)IL%$\E3@%+^QTE>LO2%;"\Z20N#Y5+N,QL09
MW8F5@I()H'9E*H.((IWV3A4F@%?7M_.BU'1YF*EZ/7G^!A#G,A27^$#$>R2
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M+OL@1].EB3#/WDXR5J#?_=7GC+!I*X-*S/$W@ XH[)#9K0*,M.3%6( 7H>C
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M%(SN-VO:3N;#C7RIS@7Y&X0\PP7GXR\[H'"1-OIG  9Y:LN]GH8.RLC;4=,
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M^P'V7E\L?DSCG\4[2]H';AC)X?RFN 045+#X!!HV(\Z<?3R>Y(^2]WP6Z:#
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M_YQ\'2.H(8C6I!*)*E&6EW#GS<@2::P-[=7OGAKI&[##O.JA4"'U'._GZ7V
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MD&HUB1ZK #H(($<D7-&/->AO0DKQV7@4MC[9=(GK[F-]DP,#XU.+A638+96
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M!4;N.A@?B)<L0N[5;];QXQ.GA7NLU <"9OS8;U21_?A]*JB?P5YH>ECAGVM
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M[H2A#<([X<)IP\_W%_1) A%(4 8F "9%M1*7FF[H#@=C,D[GZ^/!CO"UID%
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M_L<3+)X229/J+Z7Z,?333Y\^G>C2M"H 8C6@6:RA;'U/I0VRE;\[B0HW5-3
M_>4Z0T0HC^>$K-+J,R*GNFI<H 675':#D"NQSI,@J?MN'CR=Q(7Y!J$0T"]-
M+>+27!./LNK:4)"K2%_<175-+,E5Y82YLKJN+LI5ELRMK@H%N8H@(;5>45DI
M.UV2AZM6P@ 82@HR6 GJXI@UJO'3"1&N"'P*6%UU3%]6/N%$!6)]";]3G$*5
MJ8./><*$,C&2%N7)4Z+0($<=%)]@,;9Y?_S^]/C#Z1'. X3S0!&<4/2OU8KQ
M68!_XJ#XC+Q,H)6#?SS>7]4/9\WY>0 SX!V9PPAA(*G-SQ2H1V$:8QKE*8QN
MF+,RLYVN[V"#'T^*M1, H:3>F/]9_PTZD=!2<X!#*&X55ZEJL0'8K+Y+?#?T
MS0A.<I+J)SKN40Z SXB/<\S#@E*5B+&JR"#2#R#'!Q )364:-W;BUHYN?A"P
M%L,=@?E.+:AB0$B-M//U#*+_V$STSC<Y:'_<8U6DTI+CV7B%1A$:-P4]&"H9
ME/"M40D;.$XP<S:0#O+7HCU?$#ZG\HI/Z'(5""+67W\+F5J/N'='Q9)PJ ;V
M'G-9<5KJ"L6@P>\::C!&!7:SDR)S(FP.H'-2?$Z,\*#HMBJJFQX' 6GH M^_
M5A<XS+UE_8'ZB%Q<^L&S<>;-5C&H[$_;5:8U!G <#6C_1']!I2O8"C'!2B;F
MA+/?-=ZSN/IF38+.^U/ ^!RDZ%+!([WT:&]0V@]H?S/I^H$,!<4?&Q3.&!;)
M#))_=Q(TF;53CS*-R8E1[9]:']B<,YA="%<C5_O<((Z[P(?YAL8CJKZ*03F?
MBLK)0'$V8)P$SOY)_@K)(OY=. 4)C&<S*D >D<2KBZHE??J^*.FXM1,U=Y+V
M^RAA^)-.R$O2D[,?#-(\+4L3VSBZT?Z)\$ZP)U@ [WSBZE4PDF/IJT&8'XK"
MC!LZ:<O]D^@U)3+IC_'?!NE]+$HOJKY_(KNG/@8OP?A5ZXD@7!(WXVH;2PUB
M_;8HUAB HR$X61#[)^KS8+ED2KLH8!R!582+-.4;8Z"N@D'@WQ4%GH'A$##!
M<E#V3^8W=#FE0D:>7R3E_">#7+\ORC5N]8?8B=P_238-_G0.[YS^J2CSDN=.
M#L$;5,4M5=>!E"")AP41\99*\:-!R"7'#MHYV- !U\W13?=/H)>$B;\1/Z0W
M8 6 6/3T&8FUNL@@W))CAJT=W=S)MM\_"4<#^ QL+%C7EBL*9@!BC61L*JR6
M\H>24Q;/#AJ DX6P?W)^"*>2_A8".U^?-IVX]-4@V9*#MFGH1"WW4*)U$9H6
MP9PM09T/)7]N2U#'^2;Y:P]CU;62GI"IWT@E<46#0DHNXE:%1/#V4!V9V$]6
M^.7/!E&7W,9L8&B/Y1H%);(BS7TQ2+/D$T:-]EB..9<O*\ZJ H-4MWF$>RS>
M@NN1%7!UD4'$)0>P[)OLL90K/9&LK.LJ&"1>\@8-#LL>B]W@G&0%7U_%(/J2
MKVCT8O98^-TWMD>>ISDB_A6?!6*I*UU019C?=\^\#G2ULC^67-;^V^D 9$.(
MDZ'$^2:B90^[RV1!<> 0OMZJ_F95#>HL^<D S8G!'?32TEW;JJK.K0W::^UI
M'S3:3J-X*L<+?3J>G?M$RM%8>(P3L=86G+RG,Y^ZBGI7'(9--I=:-M9Z7PR&
MGM':Y8<:,24ZA0UI<49.0DUDLDHGI<=AW%$P5>2RON6A&VU5\H:@\0P,).;"
M<GC!_!!D"CY"%"V(_8Q<5^C2H7KB,G2M4HBC9=?:4(4_-5UZ.RRF3+M*<=3D
M&Z3NC]IGRO?$0T?;IGPH$R'UOKZ@\4V[S$?5$ R=HA2I:=<I8EQ.@NR@WVW:
M^2H56V)"RJ.DL]"_9D^=E%P#QJ#I4O2HG:93A$Z$T=$H#_K>IJA+]D*]D93=
M;(MR:X-V2X&K=MK5>)P(T4&G+;22.[+13\%5H S:+@7-^F@[?^KDH/UM*KL"
M=OF<37VJ)=A!Z=40#+INFVI?T/4&5Z3P@WY;:J?O"&\ KEKSWY9"=GTU?QCI
M=8<SMD:!6K<RZ+7B$$+ED8Y#U*=VGS_C, ?+5<"CXYYIA=@E.:,<F%%Y/?:"
M8=!J*::7RR H^-(ILFB@)A43/\KY)D:YWX.T0DU?86RX"ER/M/0>G))[Z@;<
M93ZK&+/]@!B470K3U2@[Q995-")T\A@/JLYKZ8+"-"BH!Y\C4W7$O6M&IB O
MQ?).<X_V!@77YP/E%9P@THJ-K6H,C&60'72;U\TC%]#WP9KY7>LGGNWD?>#[
MEX%X)L+;JM[&( P:+D6^:C2<Q:6UG&!S$)T3XW,.6D;9-;"C&M4UZ*T4QRKH
M[6 R;3GDN54_;1H8E%0*1Y6.AAXT94JVW$QQF"& &WK:YXNV@^)\#/ [N'?)
M..[AZ5;I"C<&%V(>96SHO<<X)^#A/, ;&IF'(5SCCN<N"3#TI%*H*TXES4_0
MN*69IS1SCQ)X4K@<Q]1& ++K=(;B9'LT)OH/TLF2?=@U-?74&Z)"H2V=\4R7
M96P?6!TSW<#4?VK[X7#@#;VL%&2K[&4;,O!7U(^R1A[,887>4],##]UGZT*T
MO5JU.K\K1<Y2=1[6G(:G[[<JITM#@[I* 3'SF?V#"NM5>$&GVPV\-@T,*BM%
MN_(J0Z@'5;6Z@&&KUCJV-2BP%,&JO;;AH,LM1WHRMDKV<U9_+>H;=%8*2A4/
M !VGULIXYB2EZ>F@@Z;T=1#;QEGCV@8ME0)+)2T=QE+[JSVVI]/W F'092G8
MU.Q"D(.*MQ[1&SBU]M6@&SI&DX.">>?1S>?/3M/\62_.G^4 @<7YLWZ:/QLD
M^;-RS_-G*\\6/H3+)0AG/(O".9,%42.1U/!&*FTTYJ-[BD](@$F#O2 7;G@=
MT(:>T_C (]Y]H4G0B;91N$H!%0[V@X0.!WYG $#?(DY*C4[2WN<X@^%89*K:
MR8*.<&L6*L7^RR1(XY483CR#R>+L]!&XDS^!%PH5LOWF]< ;^DZ+$YNYWH-!
MJ822U%-303;,J0^.G.D)Z>SXU-$T.3%1AQY45/%6:Z1#NVJ=?]_\KJ&#U=%^
M!O@/NH:I-5SJ<[#R4<8GML:K)4ZH3=7: 9Q!VZ506,,1#HB=#&9,TD_/>HWO
M;IP4_:$O&)67_1@G8K71O;FY0=>E&%I#7>=*THRQO55K\6JQ[:=Y6S0PJ*Y\
M3+-X3=EA,K:X:SCR%14<K)K35]X_S" R](SB&S\V-Q*=E#SG])^\=^$_^%+B
M/9TY^AW$SPJ*OQQ)MESY^,BA_K80=/;E"-]S/$Z>;/P[L/3N9>DG51!RS?.&
MNE\6I1 C3D#$;^?5O],(0 +0$:KO)"'^R#D9@"&0>%N&\DIZ6^SX9-J6'6A"
M_;?'"73MMIP41L/ _)QDGDD\R3^@R#!LJ1Q>^:"JZ271Z"W6ZR#*J*EI@K^.
MDW;'^.GX],/QQ]-W+]*+:6M!P(:K=@0D[5H24/TT:D/420/$^5T3;(8G4ZO0
MR82XRC8GU%<R^:([96-FJQ]AK26AJDGRHR/R_'NNS;!GVZ2_NN'/O/O:"'=:
M7__5#6?V_=A&2#<-HC^[H=V\1=L(:5(=_^B(</-&;3.,27W]5V.<Y6=N]23+
MZ1P#7,W&L"]$KA4.Y$\X>9Q^WXN$AE-(!KWJC;K^D=^FY&2A?-T :4F=X37F
M1MTAJ8Y_-.X,IO>4>\RL&DQ[ HKO(#>C('EH.<*>PNB$OB?B3N.OZB%G(P7;
M6NK?,D-#_+"[)@)OSHM.W"0G)<\#"1T\LMOT0^F?EP$,*"+65^"(H6-QY)"I
M5 *Z])>C&?'U$^RZ(IA2+/ FNFEDP0 DSGP?+SS\<J1$&+]N@+;?WZL12W#^
M%5,A\OB3",)50@4#[ FB:90[_.7(HU-\J:*"K3M!5X1Y5UR& NO>!OQ<KW%V
MF*M#/S"+YV"KX2'D';!70CT4:_=LOE#CV6.2"V\*)5AAMCDQ0[%?N'8(3P*H
M!156N#7B;L><"R.[&7<V^ZT)]6"\Q1#C&P7D'5DC'59X,Z$>C#=3O\]$VVSJ
ML@TY@\D@6;0>N4?%,\8=<>%:+IF43+^S9G'A--)@4^.;A>T.#!N&C\"\#=U7
M$#:87!X"E\&J1U9,$?\A?!)4*?+7P/> (GD>B-6[*\:B5,5$'&"814;H9R]8
M$L:K!!(Q69:'%T;W!M<(I!5%6^10M1[#CS2=!B]8SE[0.0GNJ4>CW5*=.E-(
M'QR@1S200$\2!^L;F+3/J9"Q+L:APL[LZ1=KLW+0.6AR:+NL!GE[K1>$]* "
M]]<K*6$!O0C18K_3M$42OJ7/NDCVYK*!KCL2-KP$)@N:Q?46>"^1U&6TK\@Z
M&D8C[PE[O+P4P3)[U,76F&Y R& C-X/M#K# <AJ(]6V MYGLD/$Z4@9SM_)S
M9]4MS*49=">S>D/*7M7<NZ3@%45^Q%FH0"EWX G;D48+<H:S 3/A&7G%73_T
M,!,K1IDKM2.$5@0--SD4@P!3!58<(O[ZXBX(G]/+0&@;-',$WM(8Z4;:8**Y
M3-)QM,RQ^YVM'U9XUE_D2,!5"H$5C3,[4NI/Y5"S+?19@=JXH-'_T\5M-XML
M"W*&DL YD0O\#TV8)^)#P3T%5AC>JH_?P:O+?]A4M.-B]R-PN(["RI<D;E+E
M)O1%G?E@_I5]3)44#=]9FI+4WNPLW9434URPJA6B'-A]-J/NS\9N%=:(FO9,
M5FW>1(^BKG?!93-RVK/Y=4G%'.!![6>U2!(;%5'A#IEM0U1OEW=W;&XCI#UK
MA>C_[EC;1DA[UK(OFNV.KUHJVC.57IN@,G'=W7'7C)P.<VDZ)5_A*X.A3P0:
MJ]JB3]ZCT'$ 3%5<PTP.ZQ/W<%2L$(I^3G GD^ZP=+<7W#4%?X>:]@)V)I=V
M9+5GN_S,[2ZXK*6BBT%A>, 1CW66WG"<E'=57\4N[$25@7E/?5X 7N&&4WHU
MC!BNX3>"*@:>=R^*#&5=+.A KJ)[GN.(QFSD0C\3%'Z/[D"$>,)@CD]^I ?'
MXZ/E^HC@1(0RV0<OCXA5U'[PC)@A:6XOLT)(T$[HH(1T*,_7%.C<V?YZA'RP
MS*U,=XA<Z3B4O2#JG/ SJJ]IBZCXF:E%$,+*N4XB#IE-]E?OU?T)[3#\34B#
M,XJA?JCK7?%S6$N3>0=\H"DLL8CB2MX&"B\:Q3.>.G-YQY+J1G0GJ6F,\=2R
M"4]%DTRE''2#X0513T<'EW1S:6$2],?,#I1GP#G5!=C[*H-3=F;"GB2^]L2R
MV2$;9CPT"3PU(*5]5_@Y$+^BCQGE-UA9#HHHA\L4 >C,XW1]O;*:*U2!MTN.
M0#*N=0:"WH.25MFHI:##_,E6X,>"RZH"89>12LP=8I4O3"H=C1<PWP HF%Z8
M"RY:['2K]2+PP:*1:+Y'^+#U9<@]>4,X#%3<$8M3Q^+>'GW':M>^:U4HUK@9
M5M!XUT]*6#K0WHSDZLEK+PH]I=_!**3WN'TZ M067-%*K&:OVV- ,:;&&KWN
M L +K19;F9O5N/OH8LRIW>33*LQ]&)@LP&W>$0LYW+V8> YVQ<(&<WL&;O$^
M#9H^3F$QV&;$W">@=D_G%$-4DV?&S_'.(1;87LKJ21A"0S;C@+78VS,3.T0V
M#?HBRB$/-A6>+K4U=(R8^PR=,E";_:P6>^>]7Y@?-<QXZ]7FH;,2ZJ$/U%V$
M](+Y#*^9ISO@KQ+]T#S"7(IWON!!?, U5*B[,8^5Z(?F\9K.B;\#!>;Q#L95
M1;QS5XPV)65HC6[FLAVHM0*Y!=WJ:+9OF^56] P7R-,T7@;BYP5S%W@ 1P3X
MHN57(CC(7\!TB"%/S*>=D)>\()*5\!7"KZUHZI0"B%GFF!4CV%0WQ!P/BR<!
MZBD8<"^R"DL<W[863]]&1GL%F@>+/O&?V=(@?IP'GF2L[7@P-Z!OL,']"/,&
M!M 8IBP%&%^\PB,6Z4&*"15+.T.Z&25=3&.=IZ WZ)93?XT;'K, NI55+WDK
M%9WR2#)'YVSOL52@[IV->R4E":''6IQDZRD8^DS,VSQ;WIVZ 0^GY@]"$B'6
M8,Q$6-_&V<PM) TF"C1A\%J#)-.@\!*-K9A+,S+Z!&"V8+ 9C6E.2@<[) ^K
MB$HO]IM<8VGQ6%!GRCK'IY(;M1Y4Z"4/G>BI=@>W)&VG96@_^9*XF%:_!C..
MZ!V[7;&^A9#A#E=C#RJ<!K%S@4XEXJ'U>4-XB%=?ZHLIKI: ^4G7&LI\::S/
M+80,MS3-9E$.</06&GC6]P0O;7 #CATJNJS:=R_]X'FR $3SQ0,0C'11:XYD
M+QJ[GQ0$/%$&X"48!H+XYUJ*VFBX#,0S$9[=[-Y&] R=SYPBC5X;V W#">Y7
M8^X!N%"/*WNC? L%0S'ZR 6,DCEGOVM49Y33F7YN+) VK9)F9'39BHWG@\P9
M84NVM!EU'_LYA3IRE:74I#+*/GE)66A6DY*J$ _2H6SZ+/7HNZ]DL;T4YP_@
M*+RGDA+AXK40%_2)^L$J-2[LA0=[D-?[Z*5>4@QW,:[OHJNLY$5(;^F+FCQ3
M_XG>!%PM[*P.@]$ZF)G8D:+_ BU.GH.W++24Q+<@JTLP<M^ZL"(:=RVMT4Q1
M\<\@L@*ANY;;6Q;5CJ3SR#U8;C'C )<B%UJ.EMF#N&]&5&9"K=V?/,3V1?_+
MDH?<INBS;&#B]9OK)=5$O@5Y70:AG1<!>M/XZN/I9XJ'OZ@W>H+R.;V(QS7&
MM09-T^@^UII0V-X*S^OD'@H&#"(WN8JS!O]009>?B3Z '^4SZ>4_R6C2>S 3
M0?!ZZPNREB-!,<N+>510SX[/U9FXC@=+Y&UP'? Y%0_A]!_4Q3200,PHRP:0
M8X_Z-:X7;T!#A^,,(29'X)O/T''<$"/3&;D![ L*<ETR'EUNO3GF8D?%/<CK
ML L8WW(=/]Z!N^B;^S>M[H,U(F2PB3T1\EM4_.MI.]E)SS^"/A("#P)BO;/U
MIDJ\LHYP9V(<O4S_$U14>,= G.R97"QC9_)_/>J'2T\FDDE+D=\,KCXA7PW&
M:JPWA['[10#08,R3ZV#&L_AJY6C%V,F] $T(ZC!F(S!V3W;F<;8G&LQPO,O(
M*M$%G!W60C"5 ?@-D3#C8K;KM?+L9J36$-"AX[@1H.11'MNG4&OP][V&Y3J
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M8=B[41O<Z<QS159TUQ/;^@4UVF*G%X@N?NVIS_-Y#>C7GBP,?OH_4$L#!!0
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M7<(8'UZ5K GE\+)G32H[.'SI]!T<.Z]X1LE10QX97]GA.>\R:.J@V=#-9^[
M(G.'^/530L)=$LT![AX\,^Z<M8>_IY3S.6SSUO0%*Z<D\F >%R6)+GB,EM R
MYCTZ[M@Y:JWP&P3 9_N%=;;?8/)SXFB>HA__@=9"OA\].^Y8.E'M,9Z'@,_Y
M2^N<)]Z1G(2ST> %<@K=$#M-OK[)IN+U+QPY[ERV32IR/'P975F7T5V<H/P&
M$S3/<O&W<?#DN-=IFPQ.Z0=4LC/K3']98DUUDW(H9/K!D^.>';79(M-/Z0>8
M7E\15F7ZER7*YW$Z_SW/OI<+YN$0,I\[8MQKW6$,XP"$45_K51;&#YK40+GW
MA/(XFXHE<?+XN->ZHQD  <A@\ZG_=FC2M&7DY-5L\F"8$AD^X8?'_?KZ42-R
M(=LG_\%QO^O.["GAEL1"MJ/WW\;.RE1BY^A5LG:*I*-KZ 1/X'99.ON6#F$3
MID[0_@S@^ S&SGZ_!=9./<'8LW?6$E"V7&9IE:OR]>!RPA/0R</C@9VC1W)=
MDJQ\0!I\ZDT;1AM*8:@CA>$&AQ>MN:D4]JEW;SQ]0/,HJ6[0P.G->6K<&5ST
M>A=V%KW90UM(O2^C*7@&'#_"2+5DD9,>QT+F08K8,>6^[*/:3/9]QAK@MNQ4
MU;)XGH8ADM^,7[))'"4WT7M<1LG+ZB-'91G]+4M(7>WB)LO??[V/8W#[UIVB
M0G9Y[LL<P5_3A]*HC\FXC;36L5O13--SK]?5F216Y( 1%%>W:\<];$>7DR(Q
M;E!M*"%*HER'X ZH4/4LN9>5E3LISZ6BXF(R;FT-0%*^CR2K(I,=5AW'2OH1
ML0J*('\$P^=7)91\+&KR.@$$",JQLGY$I8*NR!_!</G5&HT(Z@00("BW^CS+
M#WLCH2J34B"?PP?'?2^WO5HF?0[E .NUE'C@ZKW)[]T4Z[O)"AY;P6?' Z^<
MY3"+<Y$&"0<86U]=K[^F_X824@,E7Q7E8Y:2NC^5MT:\P+FCQIW. .L47F(/
ME 6CA0.04WV-O[Z<I"(9#RY:Q'A*+<!>$ZK]4X[>HQC+MECEQ%&-I7L#KFW)
M"+8>O!ZN:AN."@; J^=64:_@,-J4C]6CY\?]-JUX'O& +%RKY,5">.,L%N-!
M )LZCX'0G9*1#/#7K2(]*A<H9U\FRQB'MR+YH/' 2UQ975E(@  2<JLO'V!2
MW87& R^!977E<$H[P'K7&G"Q(*5;/J*$UGLK;Z(\7^.[,JU%*=F6X(%4?>RT
M;]=2003(S:U"K+N?\7< BLF2\]62E"1  .&84)G9FV_PDZ0PA=IU]NAI1F@K
M3A E& "_W6K2](Q3/41.'Z[0^'$,-CK6 12 3-QJS7>$AX@T)YD>%;(I'I%(
M/N*!%<JKL'5!72B P.HG%=4[4;)WE)?KIX14ZDFGY"A\)\9+L;A$P]B2])(%
MIBTL-2! #*B6]@Z<+\_Q?%&.9M\VU="@FE[0B:,ZGH'QDGJM9T[11P2(QZU"
MOU>E#1-*H_@663+=-4"0VUM4IQCWO7Y<6@X.+4R (-U:#O8H5I,5L?)U+RZ]
M*J9:;)9*:H<(D(A;2\$>9>K&2WC0N.]U%S0K*AXV0&AN;0RW*_2:[347VM$J
M$!H\:'SNI:J%(L?Y8I*@ <2D95( ;A5'I3))B56B.D"7".#Q\<#K.:/%<RD.
M@-OU8^/-[&1:.]CXW*O5IM9' *  Q.'8&5^5)BV>HC6)\\3KA:T@+3EIS,(<
M@EZ-#K6D6 LC(&,MDX3:!B<QR_&?'G=Z?3QO>X2AA 5@N@GW_H;"P[4 ,9W_
M-+-_M.Q@D6$!<A!-& @@]5=IB]*<H8K_._-J9],73AU\@,#<F@QH9PJVEN3'
M#.=IBN>BUYZ/20D+(!NW5H#'K-Q2>'2%9]T-T%0N,XU9*OR6:E#8E&4MC(",
MO=D5N)IX U/=^/P3V1A@A( 8W2?? SU_1:$,\*CQN=<0!@/"DX$#Y&;"]+ )
MO_Z6XCF_DT8F) 0;DU.05"&>1%2&54K%55MMK'H0 >FX-574\F (F#((Q7Y7
M]YN28 .$YMB@L>W<^40CDEF>C\AXP1\Q/O><0R/D-6"C$$ !I.,V.D+KAL$[
M<3V[_6K(!$ !B,-U[ /;D"F1LM!'SM/C<Z\A7;4$ L$ ZO<XKB1 J]HHB>/X
MT?&YU[M!+5EP,0""<&R90$M2#SE?5U@V,;'#)3%_#<LRC]]6)5'X7K.J;Y?(
M;J$[%[T(7?JI8F_POM  -[ &M"P@]<V)N_REIRPO]^IDU# LGLS%3'"AF*QJ
M7>2;X0:$Z];T<=# 7.%BSWV^PN2G"K_!#U6"#9"76QO'0XSU^<JPEF):B49/
M]P\TE5_QI6,95J\W?HD0(!N5,C) BF[S-YY)6\L43;]$>4K*.@TGD]5R14VF
MMYCIDUCT"<H',[1>\S-KR5$'&B!(M\:1[8J3?GQ'3[**-U[O-K5$!.( Y+%9
MA/X*I!\TE&U1M?0+YSEE>PKARP)SK;@OBA7BU?R7#QI?>EW; #]5=.$3%"&4
M2=]3$?%Z'N44WY1JBT\HIR2K*<G0Z/&E5X^CEKQ4X8100KUN$P)+>9FZ30A@
M(7#H-=B$P*T69+8)P45X30A.*[^JP0BBIGK#HO>V\FT--"&XT*EU#R?<.JZN
MWE@>H52C-"88605*MTI)T_+W%UX- ,#*%]T$3J@W78_=1RN("Z_J>UTI[%/O
MOF![_28$?4MN!K.'MI!Z7[TI]>KC]SN6HHIK-R&@S#OE,Y]R;\THM;GL^Y U
MP&YI86<M'3R<-@3]CA==&U[5'-]6+4RAE4XWT8; 4ADK.]J<%$F0%=(;%;>W
M59#/3!N" :Q(2# %62*]H:1\GTE6128]K1RKZ6:KV_NMMRC[6-3D=0+(1(GU
MT/I%^"W-;D90)X""*-F^YW90=(\!(\:7GN-%Z_E:3B $4:#]A,#1JBS**"47
M51W1[ T;^ZWATTP^QSA,E'DW[%RNX<%4FV!LJ\.A=:>S$%$01>-Y3G*U3TTR
M<NRWMG_C2(%C*$&4E3^.B*L.6%:W@-Y[U62G-4]U7OLMT*0ESIKH@BAL?[+Q
M#U?E(LOC?^G=2':CQGY[QS0[]8Y@!%'87KZZI!=(U2G83;D]IY\^L" *YA_E
M<NB<@K*A5=9'KSV:@3J@4&KFGQS=2ENF>.#XPFN!A\:WER,DD@KZ;J-XM^"*
MT8SEVI#* >T)X27E4R^=)Q?7"SBL:+5S!="-.MSRC;^.(<H-QA^ZO:V;C3^L
M^&'G(&GBMMK)22Q5&% ( ;U-P]\J,)8,3 9B$K?,!F[> D0AA/(:$D\HGBH+
M<I+YJ=P7;6H2K%B!"BUB<?M)B-17/HX@0GP;QBY68$(+8%07R@F.(,)ZS<:U
M6"J]:O&"((431-BOR8B)*TNZI9G8EBNX[)P$D^G(X  $%<J%P8K$9%<&M\Y$
MLY$M/;]ECF6?BIJX3@!YB%-N$'Q_9N>J8.$L$D(P$:7L(CC<5M6=^B'X9R>M
M#F'*C0<96^.R[S/! +NE08U:VGU (?@]+V9[>%4?BJ,^IB#"AFFWG<<LS38%
MLN[32;9$K%>%0IDIM0DJ#U-P3? DUFM=;$%$$]^G'ZB@A:0K:N_3$N7X-P(9
M0D,8,J]N,UT9\"4I1QA$@/$QF?NX->2W/ZRZG_H-8[4C0S[*(.*/M^4&-SU_
M1!OH\;-CORU?:VR37 1!A!R/#E?<0U8HB6+W]/@JM!@Y56$<80@BN/@9?:!T
M)?P<-H^P&+Z6?0JGU <1$7SRA:I<[* Q;*]MZW<!PPDB'/@9%0@S8S%,I[=X
M,249[6W.B!9^-X)Q#*/7NF$* H"^*25D083Z_HY2C#(AS1:G2\QC@K",/Y!<
M?I*1#*?7N-_:$E3&%D0P\",JE6X+!\^-KT)+C9#LAZ?4!Q&VNZ/I#H.LVB"M
M\)+;!15>HUF6H^HYVI3NRP^\G#"U<1KE:XH=:P8DL@PS,*$7(04%V-I;V>(.
M+4U-LCJ<,"2(8.,M K897>.]:B:LZ@R,8+@\-^&I)V@!&$F8L1LA;:I,;W+M
M%*ZOT!"&K&662#D:0$YN[1Y_H'B^*-%T^(&WB3EZ7!$^C&:W<4(JO.OD8&C.
MQ+RP7G42N8SXLJT-%1"Y6PO+,>KKJ(@G&M\E?9YA\GJ%JBL^"2! 2&[M+L<T
MLK6E(28V@N'RJH:8$M0))" HVJVI!M@-3K8!V7>F-0]CG5=CF^'M4P84$+9;
M8\_F3BPW#QP]6;5E'G@UZ-2Y; (@ &%LX/G+9;M91.D<%??I40KE,)WB=;J,
M4OS8I@],BY+=SMP>/S2TN\H2OEWE^%O$O(LS=K79')IH>I,MR;J@^N5=EL]0
M+#ZCFDQ+EFJ_[[?#+209_L=C!FT0.70:>@ W5[E%0N.3'T)V7-/6MIU.: GP
MLH^'0W\(>7#'V?G\[YS6&GI$W^E?1/M]G>FJT(OPX@Y@@39#&4(ZG7 _5Q&T
MV@05:$LI1.X/.@ZN$-+P1.NO^C4^BU]0_A%/ZLB4/P]F07#69FVQBJ"%D,OG
MO:]R_\I/ +21?5D'8@@Y@9:K!O6O^BW2.-01A9 E*-I?C.N8*K-62I??Z&ES
M6[0R6 -YAT#RR3-&$A6KG (:S4;,UURMR]?L&4WQ@B7OI00?K5Z.C)M/2E /
M+H(K9<H1L4FLQC,6W??S[;7I0@P"L-AKY>B=XB-0,H(2/ C/Y0Y\)2I @FB?
MPB_)N&VI3BNP*7\6O-$,;XM.,"U00718$=35W)(M+GJH-$&%^BHXAY&N*&%<
M)M(I@<U0S=@DM]S4GXQ9.UJ@/)C &$0>I9!H S8=8"+,!:_5F S:Z@!L061:
MUJZ]>6;'ZZ%==U,DDU.*3=;;K&^1L5J9Q))EI5%EDK.3HG]"\HVG3%JJE]$/
MKC%H7[%391\NN!-<^]5^N(U!U=DMJTJBEP@94%62OI>K-+RJ.;>P6IB"2((T
M6T#Q_-S.?F7X:%"&$D2FH\FB?.?GECXF(]43*<^EHN)B"B*?T;"D?!]*5D4F
M/:[\-G5M5C_Q_-QKW+[L8U&3UPF@(+((S78&/3\/M3.HAJ!.  6126BX?\.9
MG5A42S<+"9 @4@@;=P4XL_3MF&C8< :7- >0!)'C9T FH=P:# I'>E=P7&O9
M2'L&K[X^Z", I"+ $$0J7_/>#%[]/;6E<4!_$'EVVZ^>125FR_>,I&[)K K"
M<9@; 1;#5CC]83"2/#PWPCHB3WK@<)_'>'R5SM;@-U]0 D" @-P:%(P)*+A+
M@3%)R>X&/;=VA.%T&E<4/$7Q]#YENIKT4!*.P_N[UW 2P6?"EY8"&D!:;HT)
M%4'4L"65T,FSE;X]\!I#H"T9 0I (FZM!L^HQ C0=%.C0"H6_@"\QOQ6SM"5
MBP@&(!C'UH)==W'%&_;>LQB'WXHSNN( $ "2""?]HD$V(R^#\ZK] 5(0+$"4
M;BT)]0I@=CHM"/ 6D [D!&]4\%;4(*E2ZA:HC"<80XL*DOCR NA&_W7MG-_:
MT7]=T [#H]AD]%^;O35=.[&;C>PUW3I=MKN?I<-V-^#NVEVMCLW=S])5N]N&
MCMJZL@FKD_;+ZJV(IS%)O8P2I+BM06/&G5[W[,S2AV1K:Y.#":*JQXZXQVB)
M?WS-H[2()H0HZ;<E'\S >O=7RX4!2%$#80BE/!R),YCMT[Y<9=NJ6V/04QY_
MX!WH*8DF=!N26H3X Q@XOT8&C4^++T09-M,E.ZSF]O1:<;H)R3?=CMM2TDG/
MUVDD9-XIG_F4>^BE79/+O@\) ^R6-APV48?"2\-A+UL_O*H/Q5$?DXFB%34S
MY%\7:#\S&!*5YC2TZ%"O&UQ]BM-3N1FZ, I5Y-D$H2EM"$2HCM()OI<<7S.$
MMRV5":@OY,IOIH*>Q547EZ10A2='PVAV$Q6+NR3[7K3)<4!*(0W<6F\>44E8
MA<7^$6/.7Z^_83[>IW=QBB5/:AWB6_H'EI92ETW]R? 5/KC"RQLI@,ZV6A@-
M>"# 2G+OT;I:]</I!_E@Z=?[C!*,;4HJSPCJQ4F'THV[<^%5@:S+<\ZQI84X
M!*^$.G8C'^:XT_?Z09H1=5W<(?@\]D_@QZQ$Q5.TECAVH2$8E->@1K/"%*,,
MP16R3^%VHRE&L_W=Y1:]J=XK15-@T%[#O>R)5HXZ!&_*TY;&K>9##I.;K"C%
M=0KA81B<5T7!L$BE2 UX4>0W(HQF&1=%EJ_)EJ%Y)X('5_5C_;:-MW,K4L$<
MAG_$H0;OM^.QO;U6!7<(Y=!Y--\3.43)T^HMB2>CV0SEXI+VRG,PZ)]I+]:'
M;MK#4T?J%5KT@*("X?6)@;^3;)?J7!%(6CBNJK$Z^$0?M"+<, J=<S>?*A7@
M(5[&[*PAI7)I HWV_@U/Q3CAM1B)BYU<A0,F?%R&M:6:&M*Q?H 17O4^P;5,
M#VT0%=P):O(_XA#ZB!*R^SPCC#">8*+)'X;I]/ 7>T^*XCJ;S(M5C>#:2HD-
MS ;@!N%B>\S2"2;N/OW Q))UGTZWWP!EA(I#074._ D%UTA3XD?0@V:Q(/Q1
M(Y6J!HFDG0JL/.O/1>WM9^=>'=^:TN"JT$V0AU8DOB/X*/<?JWPE@_;*3@S*
M1'5WX*N[15CERM'T6XKG_)['A/([A"\%DTF.B;A>E8]925+[H4]->8*JL]G
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M0DF^&+3D<JN.!A" EO+?^+IT'15Q,9H=A2UH>';5)L"*=,NLV#JX "^NVQ*
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M[JA'E\DEI:JO'8(*H762]=SMGK4J]R;2\"M!J,L/@!="=R0GDO0=ZN9*I-(
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MX.\QR:9]Z%8Y[/L2UX354M>N@=K-$IY_C7[$R]52R/6#9QCM7FHB@2OVE-L
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MKPM$"<&@IOC/M]&Z&.:DP$41XU?O=LMCC:/F='CA>BT^5D>.S?$&$>ZZC?N
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M(77K,7]<Z4!)(3H>P.;3@(KN)M, "1  ?TJ+ZON=<P9>M#C>Q71K![87%T#
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M?V'"84OU'A/H9\/.@B-H4*"^]H;Z.@"HK[W L@X,ZG/U'A/J:S^HKQ&@WDX
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M;'!VY>NJ.HO/IKQ)A;DG;_7>94M.:HI -N0N(K1\BT@K >I&M@\DZSZVCZ)
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M])C'VYA?A6!04B4&;5%\/0UD!-_0<UU>C?+,!R/W,*HQ=Z]!SQML6.F=-=B
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MG4[+3F^&.@UZVFA"R,!+BWIX@ !:YI-_I,5SRA3JA>8RN/LE8=/T'!_K)<X
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MD+0XDK*\>LDSJ/#5I!%HA;/*(4C%$!2M(<C4$%#-$ 00X')6 <> %RS^)P;
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M#F8^FZ>Q<#N89PG>[QOC\H7A[?GX1[ N7EI$>\<5S:GW#YQAS[L3)U'BN"F
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MD%_'T6.\CXN8^I1%U1'B ']8!J,*-$B4ZQ?6Z;ZG2%P']C5)* ?Z!G 9=,*
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M*@2DJCE@J:LX#D":H6Y/608S.L9%M.?+_1W-*9/N>9UL+^@+W:?B0I"H9_)
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M_)*B>,ER]4S<^'+4[X5'W2X"X(Y]X"=7C[,H29:/&91<;7PYZB,:0>IRM8L
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M$V3E+^" ?FBCV-&A+_$0=C-4@B)8HYC\=&YWAS?N0\C+%\>?A$>(>6N P<?
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M2Z=2XI S8WO@:+7" 4/<8S;^,-\O<YS_/4LF5 >+RRQ_^_TFCC4EQ,R[$')
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M^O!9S?-UQ"P<Y8*NAU%:Q**BKAG)RK8"/5*V.S<,&P(,^_WSJOQD-J5[*L?
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M5)BOVMH[FQ\*Y,B!),;TR-F%(&&5F]3ML(-Q":R[TN\8H*/> :99SW:MU>#
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M,3,N:'1M4$L! A0#%     @ %9\(5?,[F$Y 3@  DG$! !(
M ( !U4,  &0S-S,Y-3ED97@Q,#$T+FAT;5!+ 0(4 Q0    ( !6?"%6 HO46
M-4@  &F. 0 2              "  462  !D,S<S.34Y9&5X,3 Q-2YH=&U0
M2P$"% ,4    "  5GPA5;F!U'7UN   =&P, $@              @ &JV@
M9#,W,SDU.61E>#$P,38N:'1M4$L! A0#%     @ %9\(52",JGI^8@  <]0!
M !(              ( !5TD! &0S-S,Y-3ED97@Q,#$W+FAT;5!+ 0(4 Q0
M   ( !6?"%4YNK'/\"<  *FY   2              "  06L 0!D,S<S.34Y
M9&5X,3 Q."YH=&U02P$"% ,4    "  5GPA5/F(JD;%8   V40( $@
M        @ $EU $ 9#,W,SDU.61E>#$P,3DN:'1M4$L! A0#%     @ %9\(
M5;!(W,>S6   "E(" !(              ( !!BT" &0S-S,Y-3ED97@Q,#(P
M+FAT;5!+ 0(4 Q0    ( !6?"%5I1 T@O5@  /92 @ 2              "
M >F% @!D,S<S.34Y9&5X,3 R,2YH=&U02P$"% ,4    "  5GPA57\X'S1M,
M   J=0$ $@              @ '6W@( 9#,W,SDU.61E>#$P,C(N:'1M4$L!
M A0#%     @ %9\(53IJ!Z%. P  _@<  !$              ( !(2L# &0S
M-S,Y-3ED97@R,S$N:'1M4$L! A0#%     @ %9\(52:1OG;D @  PP8  !$
M             ( !GBX# &0S-S,Y-3ED97@R,S(N:'1M4$L! A0#%     @
M%9\(50V[)G-C#P  I58  !               ( !L3$# &0S-S,Y-3ED97@U
M,2YH=&U02P$"% ,4    "  5GPA5V0M#[]$&  "?)   &
M@ %"00, 9#,W,SDU.61E>&9I;&EN9V9E97,N:'1M4$L! A0#%     @ %9\(
M5>VT<2K@U08 M<M*  X              ( !24@# &0S-S,Y-3ED<S$N:'1M
M4$L! A0#%     @ %9\(56\T,C8)F0$ :? ! !$              ( !51X*
M &<S-S,Y-3EG,3!A,#$N:G!G4$L! A0#%     @ %9\(52W+M9FLEP$ &/D!
M !$              ( !C;<+ &<S-S,Y-3EG,3!B,#(N:G!G4$L! A0#%
M  @ %9\(55PH7HZ.!0$ JUD! !$              ( !:$\- &<S-S,Y-3EG
M.3=S,3$N:G!G4$L! A0#%     @ %9\(5>:;JPP[J $ V_P! !$
M     ( !)54. &<S-S,Y-3EG.3ED-#0N:G!G4$L! A0#%     @ %9\(5<Y-
MKU5)&   I0H! !$              ( !C_T/ '!R;VLM,C R,C S,S$N>'-D
M4$L! A0#%     @ %9\(5?F/*&(N$0  V3$! !4              ( !!Q80
M '!R;VLM,C R,C S,S%?8V%L+GAM;%!+ 0(4 Q0    ( !6?"%7I\-#;16<
M %&7!@ 5              "  6@G$ !P<F]K+3(P,C(P,S,Q7V1E9BYX;6Q0
M2P$"% ,4    "  5GPA5>>W?GW"   "D: < %0              @ '@CA
M<')O:RTR,#(R,#,S,5]L86(N>&UL4$L! A0#%     @ %9\(58H+]$%,=0
ML^,' !4              ( !@P\1 '!R;VLM,C R,C S,S%?<')E+GAM;%!+
4!08     &  8  4&   "A1$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
